<SEC-DOCUMENT>0001213900-25-116002.txt : 20251128
<SEC-HEADER>0001213900-25-116002.hdr.sgml : 20251128
<ACCEPTANCE-DATETIME>20251128141500
ACCESSION NUMBER:		0001213900-25-116002
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		123
FILED AS OF DATE:		20251128
DATE AS OF CHANGE:		20251128

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Abpro Holdings, Inc.
		CENTRAL INDEX KEY:			0001893219
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				871013956
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-291347
		FILM NUMBER:		251534935

	BUSINESS ADDRESS:	
		STREET 1:		6 ST JOHNS LANE, FLOOR 5
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013
		BUSINESS PHONE:		248-890-7200

	MAIL ADDRESS:	
		STREET 1:		6 ST JOHNS LANE, FLOOR 5
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10013

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Atlantic Coastal Acquisition Corp. II
		DATE OF NAME CHANGE:	20211110
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>ea0266502-s1a1_abpro.htm
<DESCRIPTION>AMENDMENT NO. 1 TO FORM S-1
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 28 18:01:33 UTC 2025 -->
<html xmlns:abp="http://www.abpro.com/20250930" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml">
<head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type"/>
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">As filed with the U.S. Securities and Exchange
Commission on November 28, 2025</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><b style="-keep: true">Registration No. 333-291347</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES<br/>
SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Washington, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true"><ix:nonNumeric contextRef="c0" name="dei:AmendmentDescription" id="ixv-42258">AMENDMENT NO. 1</ix:nonNumeric> TO</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <span style="-sec-ix-hidden: hidden-fact-0">S-1</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>REGISTRATION STATEMENT<br/>
UNDER<br/>
THE SECURITIES ACT OF 1933</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName" id="ixv-48"><b>Abpro Holdings, Inc.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in its Charter)</p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="ixv-58"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Delaware</b></span></ix:nonNumeric></td> <td style="text-align: center; width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2834</b></span></td> <td style="text-align: center; width: 2%">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>87-1013956</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of <br/>
incorporation or organization)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary Standard Industrial <br/>
Classification Code Number)</span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S. Employer <br/>
Identification No.)</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>100 Summit Drive</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Burlington, MA 01803</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b style="-keep: true">Tel: (339) 227-5961</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address, Including Zip Code, and Telephone Number,
Including Area Code, of Registrant&#8217;s Principal Executive Offices)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Miles Suk<br/>
Chief Executive Officer<br/>
100 Summit Drive</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Burlington, MA 01803</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true"></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Tel: (339) 227-5961 </b></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true"></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Name, Address, Including Zip Code, and Telephone
Number, Including Area Code, of Agent for Service)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Copies to:</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Jonathan H. Talcott</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>E. Peter Strand</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Michael K. Bradshaw, Jr.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Nelson Mullins Riley &amp; Scarborough LLP</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>101 Constitution Ave NW, Suite 900</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, DC 20001</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Telephone: (202) 689-2800</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Approximate date of commencement of proposed sale
to public: From time to time after the effective date hereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered on this
Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.
&#9746;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional securities
for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment filed
pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer &#9744;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer &#9744;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="ixv-42259">Non-accelerated filer</ix:nonNumeric> &#9746;</span></td> <td style="text-indent: 0.75pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="ixv-42260">&#9746;</ix:nonNumeric></span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="ixv-42261">&#9746;</ix:nonNumeric></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. <ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="ixv-42262">&#9744;</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>The registrant hereby amends this registration
statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which
specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities
Act or until the registration statement shall become effective on such date as the SEC, acting pursuant to Section 8(a) of the Securities
Act, may determine.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="color: Red">The information contained
in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement
filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities
and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 33%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">PRELIMINARY
    PROSPECTUS</span></td>
    <td style="width: 34%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Red">SUBJECT
    TO COMPLETION</span></td>
    <td style="width: 33%; text-align: center"><span style="color: Red">DATED NOVEMBER 28, 2025</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Abpro Holdings, Inc.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>9,775,017 shares of Common Stock </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">This
prospectus relates to the offer and resale from time to time, up to 9,775,017 </span>shares of Common Stock, par value $0.0001 per share
(the &#8220;<b>Common Stock</b>&#8221;), of Abpro Holdings, Inc. (the &#8220;<b>Company</b>&#8221; or &#8220;<b>New Abpro</b>&#8221;),
<span style="background-color: white">issuable pursuant to the Standby Equity Purchase Agreement (the &#8220;<b>SEPA</b>&#8221;) with
YA II PN, Ltd. (&#8220;<b>YA</b>&#8221; or &#8220;<b>Selling Securityholder</b>&#8221;), in which YA has committed to purchase from us,
at our direction, up to $50,000,000 of shares of Common Stock, subject to terms and conditions specified in the SEPA. </span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">Our
registration of the securities covered by this prospectus does not mean that YA will offer or sell any of the shares of Common Stock.
YA may offer, sell or distribute all or a portion of their Common Stock publicly or through private transactions at prevailing market
prices or at negotiated prices. We will not receive any proceeds from the sale of the Common Stock by YA pursuant to this prospectus.
However, we may receive up to $50,000,000 in aggregate gross proceeds from sales of the Common Stock to YA that we may, in our discretion,
elect to make, from time to time after the date of this prospectus, pursuant to the SEPA. The sale of the Common Stock being offered by
YA pursuant to this prospectus, or the perception that these sales could occur, could result in a decline in the public trading price
of our Common Stock. Though we have been advised by YA and YA represents in the SEPA, that YA is purchasing the Common Stock for its own
account, for investment purposes in which it takes investment risk (including, without limitation, the risk of loss), and without any
view or intention to distribute such shares in violation of the Securities Act of 1933, as amended (the &#8220;<b>Securities Act</b>&#8221;)
or any other applicable securities laws, the Securities and Exchange Commission (the &#8220;<b>SEC</b>&#8221;) may take the position that
YA may be deemed an &#8220;underwriter&#8221; within the meaning of Section 2(a)(11) of the Securities Act and any profits on the sales
of shares of our Common Stock by YA and any discounts, commissions or concessions received by YA are deemed to be underwriting discounts
and commissions under the Securities Act.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YA is an &#8220;underwriter&#8221;
within the meaning of Section 2(a)(11) of the Securities Act, and any profits on the sales of shares of our Common Stock by YA and any
discounts, commissions, or concessions received by YA are deemed to be underwriting discounts and commissions under the Securities Act.
If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price,
fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth,
in any applicable prospectus supplement. See the section of this prospectus titled &#8220;<i>Plan of Distribution</i>&#8221; for more
information. No securities may be sold without delivery of this prospectus and any applicable prospectus supplement describing the method
and terms of the offering of such securities. You should carefully read this prospectus and any applicable prospectus supplement before
you invest in our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Our Common Stock and our
Public Warrants are listed on the Nasdaq Global Market under the symbols &#8220;ABP&#8221; and &#8220;ABPWW,&#8221; respectively. On
November 26, 2025, the closing price of our Common Stock was $6.81 and the closing price for our Public Warrants was $0.0133.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>We are an &#8220;emerging
growth company&#8221; as defined under the federal securities laws and, as such, have elected to comply with certain reduced public company
reporting requirements.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Investing in our Common
Stock and Warrants is highly speculative and involves a high degree of risk. See the section entitled <i>&#8220;Risk Factors</i>&#8221;
beginning on page 7 of this prospectus.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy
or adequacy of this prospectus. Any representation to the contrary is a criminal offense.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;,
2025</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; width: 91%; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</span></a></td>
    <td style="width: 1%">&#160;</td>
    <td style="vertical-align: bottom; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FREQUENTLY USED TERMS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">iii</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">v</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUMMARY</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">THE OFFERING</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">COMMITTED EQUITY FINANCING</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND POLICY</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">57</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF ABPRO</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">58</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF NEW ABPRO&#8217;S BUSINESS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">68</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_012"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DIRECTORS AND EXECUTIVE OFFICERS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">111</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_013"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXECUTIVE COMPENSATION</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">119</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_014"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PRINCIPAL STOCKHOLDERS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">129</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_015"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">130</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_016"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">136</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_017"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SELLING STOCKHOLDERS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">144</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_018"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">145</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_019"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">147</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_020"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_021"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">152</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_022"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">153</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#a_023"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">INDEX TO FINANCIAL STATEMENTS</span></a></td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-1</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABOUT THIS PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus is part of
a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the &#8220;<b>SEC</b>&#8221;) using the
&#8220;shelf&#8221; registration process. Under this shelf registration process, the Selling Securityholders may, from time to time, sell
the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such Selling Securityholders
of the securities offered by them described in this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also file a prospectus
supplement or post-effective amendment to the registration statement of which this prospectus forms a part that may contain material information
relating to these offerings. The prospectus supplement or post-effective amendment, as the case may be, may add, update or change information
contained in this prospectus with respect to such offering. If there is any inconsistency between the information in this prospectus and
the applicable prospectus supplement or post-effective amendment, you should rely on the prospectus supplement or post-effective amendment,
as applicable. Before purchasing any of the Common Stock or Warrants, you should carefully read this prospectus and any prospectus supplement
and/or post-effective amendment, as applicable, together with the additional information described under &#8220;<i>Where You Can Find
More Information</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Neither we nor the Selling
Securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in
this prospectus and any prospectus supplement and/or post-effective amendment, as applicable, prepared by or on behalf of us or to which
we have referred you. We and the Selling Securityholders take no responsibility for, and can provide no assurance as to the reliability
of, any other information that others may give you. We and the Selling Securityholders will not make an offer to sell the Common Stock
or Warrants in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus
and any prospectus supplement and/or post-effective amendment, as applicable, is accurate only as of the date on the respective cover.
Our business, prospects, financial condition or results of operations may have changed since those dates. This prospectus contains, and
any prospectus supplement or post-effective amendment may contain, market data and industry statistics and forecasts that are based on
independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not
guarantee the accuracy or completeness of this information, and we have not independently verified this information. In addition, the
market and industry data and forecasts that may be included in this prospectus and any prospectus supplement and/or post-effective amendment,
as applicable, may involve estimates, assumptions and other risks and uncertainties and are subject to change based on various factors,
including those discussed under &#8220;<i>Risk Factors</i>&#8221; in this prospectus and any prospectus supplement and/or post-effective
amendment, as applicable. Accordingly, investors should not place undue reliance on this information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 13, 2024, Atlantic
Coastal Acquisition Corp. II (&#8220;<b>ACAB</b>&#8221;) completed a series of transactions that resulted in the combination (the &#8220;<b>Business
Combination</b>&#8221;) of ACAB with Abpro Corporation pursuant to the previously announced Business Combination Agreement, dated December
11, 2023, amended by an amendment dated September 4, 2024 (the &#8220;<b>BCA</b>&#8221;), by and among ACAB, Abpro Merger Sub Corp., a
Delaware corporation and a wholly owned subsidiary of ACAB (&#8220;<b>Merger Sub</b>&#8221;), and Abpro Corporation (the &#8220;<b>Closing</b>&#8221;),
following the approval at the special meeting of the shareholders of ACAB held on November 7, 2024 (the &#8220;<b>Special Meeting</b>&#8221;).
On November 12, 2024, pursuant to the BCA, and as described in greater detail in the Company&#8217;s final prospectus and definitive proxy
statement, which was filed with the SEC on October 18, 2024 (the &#8220;<b>Proxy Statement/Prospectus</b>&#8221;), Merger Sub merged with
and into Abpro Corporation, with Abpro Corporation surviving the merger as a wholly owned subsidiary of ACAB, and ACAB changed its name
to Abpro Holdings, Inc. As consideration for the Business Combination, New Abpro issued to or reserved for Abpro Corporation shareholders
an aggregate of approximately 1,666,667 shares of Common Stock, consisting of 1,304,107 shares of Common Stock issued to Abpro Corporation
shareholders, and 362,413 shares of Common Stock reserved for issuance in connection with certain Abpro Corporation rollover RSUs and
stock options (collectively, the &#8220;<b>Merger Consideration</b>&#8221;). In addition, New Abpro issued an aggregate of 112,247 shares
of Common Stock to the PIPE investors in connection with a private investment in public equity (the &#8220;<b>PIPE Financing</b>&#8221;),
an aggregate of 42,762 shares of Common Stock to various vendors in connection with the Closing (the &#8220;<b>Vendor Shares</b>&#8221;),
and Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company (the &#8220;<b>Sponsor</b>&#8221;) forfeited
and New Abpro cancelled 32,215 shares of Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of the Effective Date,
as defined in the SEPA, there were 1,684,509 shares of Common Stock outstanding, and therefore the Exchange Cap would have been 336,733
shares of Common Stock. Thus, we previously registered the maximum amount that we could register without obtaining approval of stockholders
in accordance with Nasdaq&#8217;s &#8220;minimum price rule.&#8221; However, pursuant to the SEPA, if the Company desires to issue more
than 336,733 shares of Common Stock at an average price per share that does not equal or exceed $129.30 (which represents the lower of
(i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding the Effective Date; or (ii) the average Nasdaq
Official Closing Price for the five trading days immediately preceding the Effective Date), it would be required to obtain stockholder
approval under the Nasdaq listing rules (the &#8220;Stockholder Approval&#8221;). On April 8, 2025, the Company held a special meeting
of stockholders and obtained the Stockholder Approval for the issuance of shares pursuant to the SEPA, which may represent more than
20% of the Company&#8217;s issued and outstanding Common Stock as of the date of the SEPA. All of the shares registered previously under
a registration statement which was declared effective by the SEC on June 12, 2025 (Registration Statement No. 333-287492) have been sold.
In order to continue to access the SEPA, the Company needs to register additional shares to be offered and sold to the Selling Stockholder
pursuant to the terms of the SEPA.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1-for-30 Reverse Stock Split</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 31, 2025, we effected
a 1-for-30 reverse stock split with respect to our Common Stock. Unless we indicate otherwise or the context otherwise requires, all information
in this prospectus gives effect to this reverse stock split.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FREQUENTLY USED TERMS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Unless otherwise stated
in this prospectus, the terms &#8220;<b><i>we</i></b>,&#8221; &#8220;<b><i>us</i></b>,&#8221; &#8220;<b><i>our</i></b>,&#8221; or &#8220;<b><i>New
Abpro</i></b>,&#8221; or the &#8220;<b><i>Company</i></b>&#8221; refer to Abpro Holdings, Inc., a Delaware corporation, and its consolidated
subsidiaries. In addition, in this prospectus, unless otherwise noted or the context otherwise requires, references to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>ACAB</b>&#8221;
are to Atlantic Coastal Acquisition Corp. II, a Delaware corporation;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>ACAB IPO</b>&#8221;
are to the initial public offering by ACAB which closed on January 19, 2022;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Abpro</b>&#8221;
are to Abpro Corporation, a Delaware corporation;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Additional Sponsor
Shares</b>&#8221; are to the 20,020 shares of Common Stock issued to the Sponsor at the Closing;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>BCA</b>&#8221; or
&#8220;<b>Business Combination Agreement</b>&#8221; are to the Business Combination Agreement, dated as of December 11, 2023, by and among
ACAB, Merger Sub and Abpro, as amended;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Board</b>&#8221;
are to the board of directors of New Abpro;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#8220;Business Combination&#8221;</b>
are to the transactions contemplated by the BCA;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Bylaws</b>&#8221;
are to the amended and restated bylaws of New Abpro, dated November 12, 2024;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Closing</b>&#8221;
are to the closing of the Business Combination, which was completed on November 13, 2024;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Closing Date</b>&#8221;
are to November 13, 2024;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Code</b>&#8221;
are to the Internal Revenue Code of 1986, as amended;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Continental</b>&#8221;
means Continental Stock Transfer &amp; Trust Company, the transfer agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>ACAB Common Stock</b>&#8221;
are to Series A common stock and Series B common stock of ACAB;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Company Owners</b>&#8221;
are to the stockholders of Abpro prior to the Closing;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>DGCL</b>&#8221;
are to the Delaware General Corporation Law, as amended;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Exchange Act</b>&#8221;
are to the Securities Exchange Act of 1934, as amended;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Charter</b>&#8221;
are to the second amended and restated certificate of incorporation of New Abpro, dated November 12, 2024, and, as further amended on
October 16, 2025, for the Reverse Stock Split;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#8220;<b>Founder Shares</b>&#8221;
are to (i) the one (1) share (pre-split) of ACAB&#8217;s Series B common stock held by the Sponsor; (ii) the 7,499,999 shares (pre-split)
of ACAB&#8217;s Series B common stock that were converted by the Initial Stockholders into ACAB&#8217;s Series A common stock on April
18, 2023; and (iii) ACAB&#8217;s Series A common stock issued upon the automatic conversion of the one (1) share (pre-split) of ACAB&#8217;s
Series B common stock at the time of the Business Combination.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>GAAP</b>&#8221;
are to generally accepted accounting principles in the United States, as applied on a consistent basis;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Initial Stockholders</b>&#8221;
are to the Sponsor, Apeiron Investment Group and certain directors of ACAB who hold Founder Shares as of the date of this prospectus;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Merger Sub</b>&#8221;
are to Abpro Merger Sub Corp., a Delaware corporation;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>New Abpro Incentive
Plan</b>&#8221; are to the Abpro Holdings, Inc. 2024 Equity Incentive Plan;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>PIPE Financing</b>&#8221;
are to the issuance and sale to the Subscribers, on the Closing Date, of the PIPE Shares at an effective purchase price of $99.90 per
share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>PIPE Shares</b>&#8221;
are to the 112,247 shares of Common Stock (including the Incentive Shares) issued to the Subscribers pursuant to the Subscription Agreements
in the PIPE Financing;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Placement Warrants</b>&#8221;
are to ACAB&#8217;s warrants issued to the Sponsor in a private placement simultaneously with the closing of the ACAB IPO;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Public Shares</b>&#8221;
are to shares of ACAB&#8217;s Series A common stock sold as part of the units in the ACAB IPO (whether they were purchased in the ACAB
IPO or thereafter in the open market);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>public stockholders</b>&#8221;
are to the holders of ACAB&#8217;s Public Shares, including the Sponsor and ACAB&#8217;s directors and officers to the extent the Sponsor
and ACAB&#8217;s directors or officers purchase Public Shares; provided, that each of their status as a &#8220;public stockholder&#8221;
shall only exist with respect to such Public Shares;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Public Warrants</b>&#8221;
are to ACAB&#8217;s warrants sold as part of the units in the ACAB IPO (whether they were purchased in the ACAB IPO or thereafter in the
open market);</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Reverse Stock Split</b>&#8221;
are to the one-for-thirty (1:30) reverse stock split of the shares of Common Stock, which became effective at 5:01 p.m. on October 31,
2025 as approved by the Company&#8217;s stockholders at the 2025 annual meeting of the stockholders;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>SEC</b>&#8221; are
to the Securities and Exchange Commission;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Securities Act</b>&#8221;
are to the Securities Act of 1933, as amended;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Series A common
stock</b>&#8221; are to the Series A common stock, par value $0.0001 per share, of ACAB;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Series B common
stock</b>&#8221; are to the Series B common stock, par value $0.0001 per share, of ACAB;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Sponsor</b>&#8221;
are to Atlantic Coastal Acquisition Management II LLC, a Delaware limited liability company;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Sponsor Letter Agreement</b>&#8221;
are to the Amended Sponsor Letter Agreement, dated January 18, 2024, among Abpro, ACAB, the Sponsor and Abpro Bio International, Inc.;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Subscription Agreements</b>&#8221;
are to the Subscription Agreements, dated as of August 22, 2024, by and between ACAB and each of the subscribers, pursuant to which each
such Subscriber agreed to purchase PIPE Shares;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>VWAP</b>&#8221;
are to volume weighted average price; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Warrants</b>&#8221;
are to the Public Warrants and the Placement Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;<b>Yorkville</b>&#8221;
and &#8220;<b>YA</b>&#8221; are to YA II PN, Ltd.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless specified otherwise,
amounts in this proxy statement/prospectus are presented in United States (&#8220;U.S.&#8221;) dollars.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Defined terms in the financial
statements contained in this proxy statement/prospectus have the meanings ascribed to them in the financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">This prospectus contains
forward-looking statements, including statements about the anticipated benefits of the Business Combination, and the financial conditions,
results of operations, earnings outlook and prospects of New Abpro and other statements about the period following the consummation of
the Business Combination. Forward-looking statements appear in a number of places in this prospectus including, without limitation, in
the sections titled &#8220;<i>Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations of New Abpro</i>&#8221;
and &#8220;<i>Business of New Abpro</i>.&#8221; In addition, any statements that refer to projections, forecasts or other characterizations
of future events or circumstances, including any underlying assumptions, are forward-looking statements. Forward-looking statements are
typically identified by words such as &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221;
&#8220;outlook,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;project,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221;
&#8220;may,&#8221; &#8220;might,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221;
&#8220;would&#8221; and other similar words and expressions, but the absence of these words does not mean that a statement is not forward-looking.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The forward-looking statements
are based on the current expectations of the management of New Abpro and are inherently subject to uncertainties and changes in circumstances
and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be
those that have been anticipated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All subsequent written and
oral forward-looking statements concerning the Business Combination or other matters addressed in this prospectus and attributable to
New Abpro or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements contained or referred
to in this prospectus. Except to the extent required by applicable law or regulation, New Abpro undertakes no obligation to update these
forward-looking statements to reflect events or circumstances after the date of this prospectus or to reflect the occurrence of unanticipated
events.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 7 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<a id="a_004"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PROSPECTUS SUMMARY</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>This summary highlights
certain information appearing elsewhere in this prospectus. Because it is only a summary, it does not contain all of the information that
you should consider before investing in our Securities and it is qualified in its entirety by, and should be read in conjunction with,
the more detailed information appearing elsewhere in this prospectus. Before you decide to invest in our Securities, you should read the
entire prospectus carefully, including &#8220;Risk Factors&#8221; and the financial statements of New Abpro and related notes thereto
included elsewhere in this prospectus.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New Abpro is a biotechnology
company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and
life-threatening diseases. New Abpro is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its
proprietary DiversImmune&#174; and MultiMab<sup>TM</sup> antibody discovery and engineering platforms, New Abpro is developing a pipeline
of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Background</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 13, 2024, ACAB
completed a series of transactions that resulted in the combination (the &#8220;<b>Business Combination</b>&#8221;) of ACAB with Abpro
Corporation pursuant to the previously announced Business Combination Agreement, dated December 11, 2023, amended by an amendment dated
September 4, 2024 (the &#8220;<b>BCA</b>&#8221;), by and among ACAB, Abpro Merger Sub Corp., a Delaware corporation and a wholly owned
subsidiary of ACAB (&#8220;<b>Merger Sub</b>&#8221;), and Abpro Corporation (the &#8220;<b>Closing</b>&#8221;), following the approval
at the special meeting of the shareholders of ACAB held on November 7, 2024 (the &#8220;<b>Special Meeting</b>&#8221;). On November 12,
2024, pursuant to the BCA, and as described in greater detail in the Company&#8217;s final prospectus and definitive proxy statement,
which was filed with the U.S. Securities and Exchange Commission (the &#8220;<b>SEC</b>&#8221;) on October 18, 2024 (the &#8220;<b>Proxy
Statement/Prospectus</b>&#8221;), Merger Sub merged with and into Abpro Corporation, with Abpro Corporation surviving the merger as a
wholly owned subsidiary of ACAB, and ACAB changed its name to Abpro Holdings, Inc. As consideration for the Business Combination, New
Abpro issued to or reserved for Abpro Corporation shareholders an aggregate of approximately 1,666,667 shares of Common Stock, consisting
of 1,304,107 shares of Common Stock issued to Abpro Corporation shareholders, and 362,413 shares of Common Stock reserved for issuance
in connection with certain Abpro Corporation rollover RSUs and stock options. In addition, New Abpro issued an aggregate of 112,247 shares
of Common Stock to the PIPE investors in connection with the PIPE Financing, an aggregate of 42,762 shares of Common Stock to various
vendors in connection with the Closing, and the Sponsor forfeited and New Abpro cancelled 32,215 shares of Common Stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Simultaneous with the Closing,
New Abpro also completed its previously announced private investment in public equity, issuing 37,416 shares of Common Stock and 74,831
Incentive Shares in the PIPE Financing, which raised $7.0 million in gross proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Our Common Stock and our
Public Warrants are listed on the Nasdaq Global Market under the symbols &#8220;ABP&#8221; and &#8220;ABPWW,&#8221; respectively. On
November 26, 2025, the closing price of our Common Stock was $6.81 and the closing price for our Public Warrants was $0.0133.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
the holders of the Warrants will elect to exercise any or all of the Warrants, which could impact our liquidity position. To the extent
that the Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of the Warrants
will decrease. We believe the likelihood that Warrant holders will exercise their Warrants, and therefore the amount of cash proceeds
that we would receive is, among other things, dependent upon the market price of our Common Stock. If the market price for our Common
Stock is less than the applicable exercise price of $114.90, subject to adjustment as described herein, we believe such holders will be
unlikely to exercise their Warrants. Based on our current operating plan, our existing cash and cash equivalents will be insufficient
to meet our anticipated cash needs for working capital, financial liabilities and capital expenditures for the next 12 months from the
date of this filing. To finance our operations beyond that point, we would need to raise additional capital, which cannot be assured.
The Company does not believe this offering will have a significant impact on our ability to raise additional financing, although it may
impact the per share price and shares issued in future capital raise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Common Stock being
registered for resale in this prospectus represent a substantial percentage of our public float and of our outstanding Common Stock.
The number of shares being registered in this prospectus represents approximately 360% of the total Common Stock outstanding as of November
28, 2025, which was 2,716,278 shares of Common Stock. The sale of the securities being registered in this prospectus, or the perception
in the market that such sales may occur, could result in a significant decline in the public trading price of our Common Stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The rights of holders of
our Common Stock and Warrants are governed by our second amended and restated certificate of incorporation (the &#8220;<b>Charter</b>&#8221;)
and our amended and restated bylaws (the &#8220;<b>Bylaws</b>&#8221;) and the General Corporation Law of the State of Delaware (the &#8220;<b>DGCL</b>&#8221;),
and in the case of the Warrants, the Public Warrant Agreement, dated January 13, 2022, by and between ACAB and Continental Stock Transfer
&amp; Trust Company (the &#8220;<b>Public Warrant Agreement</b>&#8221;) and the Private Warrant Agreement, dated January 13, 2022, by
and between ACAB and Continental Stock Transfer &amp; Trust Company (the &#8220;<b>Private Warrant Agreement</b>&#8221; and, together
with the Public Warrant Agreement, the &#8220;<b>Warrant Agreements</b>&#8221;). See the section entitled &#8220;<i>Description of Capital
Stock</i>.&#8221;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Implications of Being an Emerging Growth Company</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company&#8221; as defined in Section 2(a) of the Securities Act of 1933, as amended (the &#8220;<b>Securities Act</b>&#8221;),
as modified by the Jumpstart Our Business Startups Act of 2012 (the &#8220;<b>JOBS Act</b>&#8221;). As an emerging growth company, we
may benefit from specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. These
provisions include:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">presentation
of only two years of audited financial statements and only two years of related management&#8217;s discussion and analysis of financial
condition and results of operations in this prospectus;</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure about
    our executive compensation arrangements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">no non-binding stockholder
    advisory votes on executive compensation or golden parachute arrangements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption from any requirement
    of the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report
    providing additional information about the audit and the financial statements (i.e., an auditor discussion and analysis); and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemption from the auditor
    attestation requirement in the assessment of our internal control over financial reporting.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may benefit from these
exemptions until we cease to be an emerging growth company. We will cease to be an emerging growth company upon the earliest of: (a)
the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (b) the last day of the fiscal
year following the fifth anniversary of the date of the completion of the ACAB IPO; (c) the date on which we have issued more than $1
billion in nonconvertible debt during the previous three years; or (d) the date on which we are deemed to be a &#8220;large accelerated&#8221;
filer under the Securities Exchange Act of 1934, as amended (the &#8220;<b>Exchange Act</b>&#8221;). We may choose to benefit from some
but not all of these reduced disclosure obligations in future filings. If we do, the information that we provide stockholders may be
different than you might get from other public companies in which you hold stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><b>Summary Risk Factors</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should consider all the
information contained in this prospectus before making a decision to invest in our Securities. In particular, you should consider the
risk factors described under &#8220;<i>Risk Factors</i>&#8221; beginning on page 7. Such risks include, but are not limited to,
the following risks with respect to the Company subsequent to the Business Combination:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risks Related to Our Business
and Industry</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our management has concluded
    that uncertainties around our ability to raise additional capital raise substantial doubt about our ability to continue as a going
    concern, including drug development;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drug development is a highly
    uncertain undertaking and involves a substantial degree of risk;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our product candidates
    are in early stages of development and have never been tested in a human subject;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market may not be receptive
    to our product candidates based on our novel therapeutic modality, and we may not generate any revenue from the sale or licensing
    of product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We will need substantial
    additional funds to advance development of our product candidates, and we cannot guarantee that we will have sufficient funds available
    in the future to develop and commercialize our current or future product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through our AbMed subsidiary,
    we have in-licensed certain intellectual property rights relating to ABP-201 from MedImmune Limited, or MedImmune (now AstraZeneca),
    and are in breach of the terms of our license agreement with MedImmune/AstraZeneca;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have entered, and may
    in the future seek to enter, into collaborations with third parties for the development and commercialization of our product candidates.
    If such collaborations are not successful, we may not be able to capitalize on the market potential of our product candidates;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If our partners cease development
    efforts under our existing or future collaborations, or if any of those agreements is terminated, these collaborations may fail to
    lead to commercial products, and we may never receive milestone payments or future royalties under these agreements;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If third parties on which
    we intend to rely on to conduct certain preclinical studies, or any future clinical trials, do not perform as contractually required,
    fail to satisfy regulatory or legal requirements or miss expected deadlines, our development program could be delayed with material
    and adverse effects on our business, financial condition, results of operations and prospects;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because we may rely on
    third-party manufacturing and supply partners for preclinical and clinical development materials, our supply may become limited or
    interrupted or may not be of satisfactory quantity or quality;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We face competition from
    entities that have developed or may develop product candidates for the treatment of the diseases that we are initially targeting,
    including companies developing novel treatments and technology platforms;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any inability to attract
    and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Litigation and legal proceedings
    may substantially increase our costs and harm our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risks Related to Intellectual
Property</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to obtain
    or protect intellectual property rights related to our technology and current or future product candidates, or if our intellectual
    property rights are inadequate, we may not be able to compete effectively;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we fail to comply with
    our obligations under any license, collaboration or other intellectual property related agreements, we may be required to pay damages
    and could lose intellectual property rights that are necessary for developing, commercializing and protecting our current or future
    technologies or product candidates or we could lose certain rights to grant sublicenses;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Patent terms may be inadequate
    to protect our competitive position on our current or future technologies or product candidates for an adequate amount of time;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may not be able to protect
    our intellectual property rights throughout the world, which could negatively impact our business; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we are unable to protect
    the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risks Related to Government
Regulation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical development involves
    a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future
    trial results;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may be unable to obtain
    U.S. or foreign regulatory approval and, as a result, be unable to commercialize our product candidates, resulting in substantial
    harm to our business;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may in the future conduct
    clinical trials for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory
    authorities may not accept data from such trials;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even if we receive regulatory
    approval for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review,
    which may result in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling
    and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements
    or experience unanticipated problems with our products;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Healthcare legislative
    reform measures may have a material adverse effect on our business and results of operations;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If we or existing or future
    partners, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to
    enforcement actions, which could affect our ability to develop, market and sell our products and may harm our reputation; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We are subject to U.S.
    and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject
    us to criminal and/or civil liability and harm our business.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risks Related to Our Organization
and Structure</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Charter and the Bylaws
    provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between
    us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with
    us or our directors, officers, or employees;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anti-takeover provisions
    in our governing documents and under Delaware law could make an acquisition of us more difficult, limit attempts by our stockholders
    to replace or remove our current management and limit the market price of our Common Stock;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Abpro&#8217;s management
    team may not successfully or efficiently manage its transition to being a public company; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We have identified material
    weaknesses in our internal control over financial reporting, which could affect our ability to ensure timely and reliable financial
    reports and weaken investor confidence in our financial reporting;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restatement of prior
    period financial statements may affect investor confidence and raise reputational issues; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Abpro is an &#8220;emerging
    growth company,&#8221; and its reduced SEC reporting requirements may make its shares less attractive to investors.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Risks Related to an Investment
in Our Securities</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">An active market for New
    Abpro&#8217;s securities may not develop, which would adversely affect the liquidity and price of New Abpro&#8217;s securities;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our failure to meet Nasdaq&#8217;s
    continued listing requirements could result in a delisting of New Abpro&#8217;s Common Stock and Public Warrants;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The market price for our
    Common Stock may decline;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Common Stock price
    may fluctuate, and you could lose all or part of your investment as a result;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">New Abpro stockholders
    may experience dilution in the future;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There is no guarantee that
    the Warrants will ever be in the money; they may expire worthless, or the terms of Warrants may be amended; </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There may be sales of a
    substantial amount of our Common Stock by current stockholders, and these sales could cause the price of our Common Stock to fall;
    and</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">It is not possible to predict
    the actual number of shares we will sell under the SEPA, or the actual gross proceeds resulting from those sales. Further, we may
    not have access to any or the full amount available under the SEPA.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Corporate Information</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">New Abpro&#8217;s principal
executive offices are located at 100 Summit Drive, Burlington, MA 01803, and New Abpro&#8217;s telephone number is (339) 227-5961.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><div style="padding-right: 5.4pt; padding-left: 5.4pt; border: Black 1.5pt solid">

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<a id="a_005"></a><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>THE OFFERING</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 28%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Issuer</b></span></td>
    <td style="white-space: nowrap; width: 1%; text-align: justify">&#160;</td>
    <td style="width: 71%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Abpro Holdings,
    Inc.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock Offered by the Selling Securityholders</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up to 9,775,017 shares
    of Common Stock.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares Outstanding after the Offering</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12,491,295 shares.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of proceeds</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We may receive up to $50,000,000
    in aggregate gross proceeds from the sale of Common Stock under the SEPA. We intend to use the net proceeds from this offering for
    working capital and general corporate purposes. See &#8220;<i>Use of Proceeds</i>.&#8221;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Common Stock and Public Warrants</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Common Stock and our
    Public Warrants are listed on the Nasdaq Global Market under the symbols &#8220;ABP&#8221; and &#8220;ABPWW,&#8221; respectively.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk factors</span></td>
    <td style="white-space: nowrap; text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any investment in the securities
    offered hereby is speculative and involves a high degree of risk. You should carefully consider the information set forth under &#8220;<i>Risk
    Factors</i>&#8221; and elsewhere in this prospectus.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In this prospectus, unless
otherwise indicated, the number of shares of Common Stock outstanding as of November 28, 2025, and the other information based thereon:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Gives effect to the Reverse Stock Split;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>



<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not reflect 8,080 shares of Common Stock issuable upon the exercise of stock options and 16,667 shares of Common Stock issuable upon
    the vesting of Restricted Stock Units, under our New Abpro Incentive Plan, as of November 28, 2025;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
    not reflect 214,487 shares of Common Stock issuable upon the exercise of rollover stock options as of November 28, 2025, originally
    issued by Abpro Corporation with a weighted-average exercise price of $51.81 per share;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Does not reflect the exercise of Warrants to purchase up to
961,667 shares of Common Stock with a weighted-average exercise price of $114.90 per share; and</td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Does
not reflect the exercise of the Ian Chan Warrants (defined below) to purchase up to 28,333 shares of Common Stock with a weighted-average
exercise price of $99.90 per share.</span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

</div><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>You should carefully consider
all the following risk factors, together with all of the other information included or incorporated by reference in this prospectus,
including the consolidated financial statements and the accompanying notes and matters addressed in the section titled &#8220;Cautionary
Note Regarding Forward-Looking Statements,&#8221; in evaluating an investment in the Common Stock or Warrants. The following risk factors
apply to the business and operations of New Abpro and its consolidated subsidiaries. The occurrence of one or more of the events or circumstances
described in these risk factors, alone or in combination with other events or circumstances, may adversely affect the ability to realize
the anticipated benefits of the Business Combination and may have an adverse effect on the business, cash flows, financial condition
and results of operations of New Abpro following the consummation of the Business Combination. We may face additional risks and uncertainties
that are not presently known to us or that we currently deem immaterial, which may also impair our business, cash flows, financial condition
and results of operations. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Business and Industry</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our management has concluded that uncertainties
around our ability to raise additional capital raise substantial doubt about our ability to continue as a going concern, including drug
development. We will require additional financing to fund our future operations. Any failure to obtain additional capital when needed
on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have concluded that we
do not have sufficient cash to fund our operations and drug development and to meet our obligations as they become due within one year
from the date that our consolidated financial statements were issued and as a result, there is substantial doubt about our ability to
continue as a going concern. Our ability to continue as a going concern is an issue raised as a result of ongoing operating losses and
a lack of financing commitments to meet cash requirements, and is subject to our ability to generate a profit or obtain appropriate financing
from outside sources, including obtaining additional funding from the sale of our securities or obtaining loans from third parties where
possible. We will need to raise additional capital to fund our operations and drug development. We cannot assure you that we will be
able to raise additional capital on commercially reasonable terms or at all. The perception that we may not be able to continue as a
going concern may materially limit our ability to raise additional funds through the issuance of new debt or equity securities or otherwise
and no assurance can be given that sufficient funding will be available when needed to allow us to continue as a going concern. This
perception may also make it more difficult to operate our business due to concerns about our ability to meet our contractual obligations.
If we cannot continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets
are carried on our financial statements, and it is likely that our stockholders may lose some or all of their investment in us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Drug development is a highly uncertain
undertaking and involves a substantial degree of risk. We are a preclinical stage biopharmaceutical company with a history of losses,
expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability, which could
result in a decline in the market value of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Pharmaceutical and biopharmaceutical
product development is a highly speculative undertaking and involves a substantial degree of risk. We are a preclinical stage biopharmaceutical
company with a history of losses. Since our inception, we have devoted our resources to the development of antibody product candidates,
our technologies and our <i>DiversImmune<sup>&#174;</sup></i> and <i>MultiMab<sup>TM</sup></i> platforms. We are not profitable and have
had significant operating losses since our inception. As of September 30, 2025, we had an accumulated deficit of $124.6 million. For
the nine months ended September 30, 2025 and the year ended December 31, 2024, our net loss was $8.5 million and $7.2 million, respectively.
Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from
general and administrative costs associated with our operations. We continue to incur significant research and development (&#8220;<b>R&amp;D</b>&#8221;)
and other expenses related to ongoing operations and expect to incur losses for the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical studies and clinical
trials are long, expensive and unpredictable processes that can be subject to extensive delays. We cannot guarantee that any clinical
trials will be conducted as planned or completed on schedule, if at all. It may take several years and require significant expenditures
to complete the preclinical studies and clinical trials necessary to commercialize a product candidate, and delays or failure are inherently
unpredictable and can occur at any stage. We may also be required to conduct additional clinical trials or other testing of our product
candidates beyond the trials and testing that we contemplate, which may lead to us incurring additional unplanned costs or result in
delays in clinical development. In addition, we may be required to redesign or otherwise modify our plans with respect to an ongoing
or planned clinical trial, and changing the design of a clinical trial can be expensive and time consuming. An unfavorable outcome in
one or more trials would be a major setback for our product candidates and for us. An unfavorable outcome in one or more trials may require
us to delay, reduce the scope of or eliminate one or more product development programs, which could have a material adverse effect on
our business, financial position, results of operations and future growth prospects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates are
in early stages of development, and we are subject to the risks of failure inherent in the development of product candidates based on
novel technologies. We believe that we are at a sufficiently mature development stage with both lead candidates that given adequate funding
and, in the case of ABP-102, continued successful collaboration with Celltrion, these programs would be able to enter clinical trials
in 2026 (in the case of ABP-102 and ABP-201). However, there can be no guarantee that both or either will do so, and to date, we have
not yet had any discussions with the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) regarding the clinical trial design for
our lead product candidates. We have never generated any revenue from product sales, and have not obtained regulatory approval for any
of our product candidates. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays, and difficulties
frequently encountered by preclinical stage biopharmaceutical companies such as ours. We currently do not expect to generate any near-term
revenue other than from certain milestone payments under the collaboration agreements relating to our two lead antibodies. We do not
expect to generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating
losses for the foreseeable future due to the cost of research and development, preclinical studies and clinical trials, and the regulatory
approval process for our product candidates. We expect our net losses to increase substantially as we enter into clinical development
of our lead programs. However, the amount of our future losses is uncertain. Our ability to achieve profitability, if ever, will depend
on, among other things, our, and our existing or future partners, successfully developing product candidates, obtaining regulatory approvals
to market and commercialize product candidates, achieving contractual milestones under our collaboration agreements, manufacturing any
approved products on commercially reasonable terms, realizing royalties on any approved products under our collaboration agreements,
establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient
funds to finance business activities. If we, and our existing or future partners, are unable to develop our technologies and commercialize
one or more of our product candidates or if sales revenue from any product candidate that receives approval is insufficient, we will
not achieve profitability, which will have a material and adverse effect on our business, financial condition, results of operations
and prospects. Any predictions you make about our future success or viability may not be as accurate as they could be if we had a history
of successfully developing and commercializing pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our product candidates are in early stages
of development and have never been tested in a human subject. Our product candidates may fail in development or suffer delays that materially
and adversely affect their commercial viability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no products on the
market and all of our product candidates, including ABP-102, for the potential treatment of breast and gastric cancers, and ABP-201,
for the potential treatment of wet age-related macular degeneration (Wet AMD) and diabetic macular edema (DME), have not yet entered
clinical trials. In particular, none of our product candidates has ever been tested in a human subject. Our ability to achieve and sustain
profitability depends on obtaining regulatory approvals for and successfully commercializing our product candidates, either alone or
with third parties. Before obtaining regulatory approval for the commercial distribution of our product candidates, we or an existing
or future partner must conduct extensive preclinical studies and clinical trials to demonstrate the safety and efficacy in humans of
our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not have the financial
resources to continue development of, or to modify existing or enter into new collaborations for, a product candidate if we experience
any issues that delay or prevent regulatory approval of, or our ability to commercialize, product candidates, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">negative
or inconclusive results from our clinical trials or the clinical trials of others for product candidates similar to ours, leading to
a decision or requirement to conduct additional preclinical studies or clinical trials or abandon a program;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product-related
side effects experienced by participants in our clinical trials or by individuals using drugs or therapeutic antibodies similar to our
product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
in submitting investigational new drug applications (each an &#8220;IND&#8221;) or comparable foreign applications or delays or failure
in obtaining the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial
once commenced;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conditions
imposed by the FDA, or comparable foreign authorities regarding the scope or design of our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
in enrolling research subjects in clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">high
drop-out rates of research subjects;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">inadequate
supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">greater
than anticipated clinical trial costs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">poor
effectiveness of our product candidates during clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">unfavorable
FDA or other regulatory agency inspection and review of a clinical trial site;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">failure
of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations
in a timely manner, or at all;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delays
and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory oversight around clinical
testing generally or with respect to our technology in particular; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">varying
interpretations of data by the FDA and similar foreign regulatory agencies.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our approach to the discovery and development
of our antibodies using our DiversImmune<sup>&#174;</sup> and MultiMab<sup>TM</sup> may not result in a marketable therapeutic antibody
product.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The scientific research that
forms the basis of our efforts to discover product candidates based on our <i>DiversImmune<sup>&#174;</sup></i> and <i>MultiMab<sup>TM</sup></i>
platforms is ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic antibodies based on our platforms
is both preliminary and limited. We may not be correct in our assumptions about the superiority of our platforms to competing technologies.
If our <i>DiversImmune<sup>&#174;</sup></i> and <i>MultiMab<sup>TM</sup></i> platforms are not able to develop next-generation approved
antibody constructs that are effective against clinically validated targets at the necessary speed or scale, it could have a material
and adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our next-generation bispecific antibodies
may not demonstrate the therapeutic effects of, or benefits at least comparable to, monospecific antibodies that we anticipate once tested
in humans.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our product candidates
have been tested in humans. We may ultimately discover that our product candidates do not possess certain properties that we believe
are helpful for therapeutic effectiveness, including strong binding for increased efficacy and increased binding sites for increased
potency, and safety, including reduced immunogenicity and optimized binding domain position, or dosing, including a longer circulating
half-life resulting in reduced dosing required. For example, when administered in a human, we may find that our product candidates perform
differently than in preclinical studies. We currently have only limited preclinical data, and no conclusive evidence, to suggest that
we can introduce these favorable properties into any of our product candidates. We may spend substantial funds attempting to introduce
these properties and may never succeed in doing so. In addition, certain of our product candidates may demonstrate different chemical
and pharmacological properties in patients than they do in laboratory studies. Although certain of our product candidates have successful
results in animal studies, they may not demonstrate the same chemical and pharmacological properties in humans and may interact with
human biological systems in unforeseen, ineffective or harmful ways. As a result, we may never succeed in developing a marketable product,
we may not become profitable and the value of our Common Stock will decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, we are aware of
only nine bispecific antibodies that have been approved by the FDA. As such, we believe the FDA has limited early experience with bispecific
antibody-based therapeutics, which may increase the complexity, uncertainty and length of the regulatory approval process for our product
candidates. For example, the FDA may require us to provide additional data to support our regulatory applications. We and our existing
or future partners may never receive approval to market and commercialize any product candidate. Even if we or an existing or future
partner obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad
as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or
an existing or future partner may be subject to post-marketing testing requirements to maintain regulatory approval. If any of our product
candidates prove to be ineffective, unsafe or commercially unviable, our entire pipeline could have little, if any, value, which could
require us to change our focus, approach to antibody development and reengineer the antibody. Any of these events could have a material
and adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market may not be receptive to our
product candidates based on our novel therapeutic modality, and we may not generate any revenue from the sale or licensing of product
candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if regulatory approval
is obtained for a product candidate, we may not generate or sustain revenue from sales of the product due to factors such as whether
the product can be sold at a competitive cost and otherwise accepted in the market. The antibodies we are developing use relatively new
technologies. Market participants with significant influence over acceptance of new treatments, such as physicians and third-party payors,
may not adopt a product or treatment based on our platforms and technologies, and we may not be able to convince the medical community
and third-party payors to accept and use, or to provide favorable reimbursement for, any product candidates developed by us or our existing
or future partners. Market acceptance of our product candidates will depend on, among other factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
timing of our receipt of any marketing and commercialization approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
terms of any approvals and the countries in which approvals are obtained;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
safety and efficacy of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
prevalence and severity of any adverse side effects associated with our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
relative convenience and ease of administration of our product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
willingness of patients to accept any new methods of administration;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
success of our physician education programs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
availability of adequate government and third-party payor reimbursement;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
pricing of our products, particularly as compared to alternative treatments; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative
risks, benefits and costs of those treatments.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any product candidate
we commercialize fails to achieve market acceptance, it could have a material and adverse effect on our business, financial condition,
results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need substantial additional funds
to advance development of our product candidates, and we cannot guarantee that we will have sufficient funds available in the future
to develop and commercialize our current or future product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development of biopharmaceutical
product candidates is capital-intensive. If our product candidates enter and advance through preclinical studies and clinical trials,
we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing and sales capabilities. We
have used substantial funds to develop our technology and product candidates and will require significant additional funds to conduct
further research and development and preclinical testing and clinical trials of our product candidates, to seek regulatory approvals
for our product candidates and to manufacture and market products, if any, that are approved for commercial sale. In addition, we expect
to incur additional costs associated with operating as a public company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the length of time
and activities associated with successful research and development of our product candidates is highly uncertain, we are unable to estimate
the actual funds we will require for development and any approved marketing and commercialization activities. The timing and amount of
our operating expenditures will depend largely on:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
timing and progress of preclinical and clinical development activities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
number and scope of preclinical and clinical programs we decide to pursue;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
progress of the development efforts of parties with whom we have entered or may in the future enter into collaboration and research and
development agreements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
timing and amount of milestone or royalty payments we may receive under collaboration agreements;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
ability to maintain our current licenses and research and development programs and to establish new collaborations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
cost and timing of regulatory approvals; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
efforts to enhance operational systems and hire additional personnel, including personnel to support development of our product candidates
and satisfy our obligations as a public company.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to obtain
funding on a timely basis or on acceptable terms, we may have to delay, reduce or terminate our research and development programs and
preclinical studies or clinical trials, if any, limit strategic opportunities or undergo reductions in our workforce or other corporate
restructuring activities. We also could be required to seek funds through arrangements with partners or others that may require us to
relinquish rights to some of our technologies or product candidates that we would otherwise pursue on our own. We do not expect to realize
revenue from sales of products or royalties from licensed products in the foreseeable future, if at all, and unless and until our product
candidates are clinically tested, approved for commercialization and successfully marketed. To date, we have primarily financed our operations
through the sale of debt and equity securities and payments received under our collaboration agreements. We will be required to seek
additional funding in the future and currently intend to do so through additional collaborations, public or private equity offerings
or debt financings, credit or loan facilities or a combination of one or more of these funding sources. Our ability to raise additional
funds will depend on financial, economic and other factors, many of which are beyond our control. Additional funds may not be available
to us on acceptable terms or at all. If we raise additional funds by issuing equity securities, our stockholders will suffer dilution,
and the terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional
funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available,
is likely to involve restrictive covenants limiting our flexibility in conducting future business activities, and, in the event of insolvency,
debt holders would be repaid before holders of our equity securities received any distribution of our corporate assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may expend our limited resources to
pursue a particular product candidate and fail to capitalize on product candidates that may be more profitable or for which there is
a greater likelihood of success.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we have limited financial
and managerial resources, we focus on specific product candidates. As a result, we may forgo or delay pursuit of opportunities with other
product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize
on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs
and product candidates for specific indications may not yield any commercially viable product candidates. If we do not accurately evaluate
the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate
through partnership, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain
sole development and commercialization rights to such product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Through our AbMed subsidiary, we have in-licensed
certain intellectual property rights relating to ABP-201 from MedImmune Limited, or MedImmune (now AstraZeneca), and are in breach of
the terms of our license agreement with MedImmune/AstraZeneca.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The license agreement
with MedImmune/AstraZeneca provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement
(December 2022), These target dates were not met, which gives MedImmune/AstraZeneca a termination right. We communicated with MedImmune/AstraZeneca
in September 2021 regarding the development timeline, but no further discussion has been held.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not expect a material
impact on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with
the development of ABP-200, which we are no longer developing. We believe that we do not need the intellectual property licensed under
that agreement for the development and eventual commercialization of ABP-201 or any of our other programs. The risks described elsewhere
pertaining to our patents and other intellectual property rights also apply to the intellectual property rights that we license from
third parties, and any failure by us or our licensors to obtain, maintain, defend and enforce these rights could have a material adverse
effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have entered, and may in the future
seek to enter, into collaborations with third parties for the development and commercialization of our product candidates. If such collaborations
are not successful, we may not be able to capitalize on the market potential of our product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-102 is being developed
and commercialized through a worldwide strategic partnership with Celltrion Inc. (&#8220;<b>Celltrion</b>&#8221;) (KRX:068270), a leading
Korean biopharmaceutical company headquartered in Incheon, South Korea. ABP-201 is being developed and commercialized through a territorial
partnership with Abpro Bio International, Inc. (&#8220;<b>Abpro Bio</b>&#8221; or &#8220;<b>ABI</b>&#8221;), a subsidiary of Abpro Bio
Co. Ltd (KOSDAQ:195990), a company headquartered in Daegu, South Korea. ABP-150 is being developed under a collaboration agreement with
Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd (&#8220;<b>NJCTTQ</b>&#8221;), headquartered in Nanjing, China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will continue to explore
strategic and geographic-oriented partnerships that provide us with near-term economic benefits where we retain product rights to key
strategic markets. More generally, we may also seek out third-party partners, such as biotech companies, pharmaceutical companies and
distributors, for marketing, distribution, development, licensing or broader arrangements to complement our own capabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to generate revenues
from our existing collaborations for licensing and co-development of our product candidates and any future similar arrangements, will
depend on our ability to successfully develop the product candidates and receive necessary product approvals for commercialization in
the agreed territories. We have limited ability to control the actions of our joint development and any other third-party partners, and
successful product development will depend to some extent on such third parties to perform the functions assigned to them in our contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Collaborations involving
our product candidates currently pose, and will continue to pose, the following risks to us:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
parties have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
parties may not pursue development and commercialization of our product candidates or may elect not to continue or renew development
or commercialization programs based on preclinical study or clinical trial results, changes in strategic focus or available funding,
or external factors such as an acquisition that diverts resources or creates competing priorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
parties may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product
candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
parties could independently develop, or develop with other third parties, products that compete directly or indirectly with our product
candidate if the partners believe that competitive products are more likely to be successfully developed or can be commercialized under
terms that are more economically attractive than ours;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
parties with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution
of such product or products;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
parties may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in such
a way as to invite litigation or other legal proceedings that could jeopardize, invalidate or render unenforceable our intellectual property
or proprietary information or expose us to litigation, other legal proceedings or potential liability;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
parties may infringe, misappropriate or violate the intellectual property rights of others, which may expose us to litigation, other
legal proceedings and potential liability;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">third
parties may engage in misconduct, including non-compliance with regulatory requirements, that may result in governmental investigations
or other actions or lawsuits against us or the third party;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disputes
may arise between our third-party collaborators and our company that result in the delay or termination of the research, development
or commercialization of our product candidate or that result in costly litigation or arbitration that diverts management attention and
resources; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">collaborations
may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization
of the applicable product candidates.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Collaboration agreements
may not lead to development or commercialization of our product candidates in the most efficient manner or at all. If a partner of ours
were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program
could be delayed, diminished or terminated. Any failure of our existing and any future collaborations would negatively affect our business
plans and strategy for our product candidate pipeline, which could have a material and adverse effect on our business, financial condition,
results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our partners cease development efforts
under our existing or future collaborations, or if any of those agreements is terminated, these collaborations may fail to lead to commercial
products, and we may never receive milestone payments or future royalties under these agreements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A portion of our future revenue
and cash resources is expected to be derived from our license and collaboration agreements. Revenue from these collaborations depends
upon continuation of the collaborations, reimbursement of development costs, the achievement of milestones and royalties, if any, derived
from future products developed from our research. If we are unable to successfully advance the development of our product candidates
or achieve milestones, revenue and cash resources from milestone payments under our collaboration agreements will be substantially less
than expected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, to the extent
that any of our existing or future partners were to terminate a collaboration agreement, we may be forced to independently develop these
product candidates, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and maintaining,
enforcing and defending intellectual property rights, or, in certain instances, abandon product candidates altogether, any of which could
result in a change to our business plan and a material and adverse effect on our business, financial condition, results of operations
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not successfully engage in strategic
transactions, including any additional collaborations we seek, which could adversely affect our ability to develop and commercialize
product candidates, impact our cash position, increase our expense, and present significant distractions to our management.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
consider strategic transactions, such as additional collaborations, acquisitions of companies, asset purchases, joint ventures and out-
or in-licensing of product candidates or technologies. In particular, we will evaluate and, if strategically attractive, seek to enter
into additional collaborations, including with major biotechnology or biopharmaceutical companies or hospitals. The competition for partners
is intense, and the negotiation process is time-consuming and complex. Any new collaboration may be on terms that are not optimal for
us, and we may not be able to maintain any new collaboration if, for example, development or approval of a product candidate is delayed,
sales of an approved product candidate do not meet expectations or the partner terminates the collaboration. Any such collaboration,
or other strategic transaction, may require us to incur non-recurring or other charges, increase our near- and long-term expenditures
and pose significant integration or implementation challenges or disrupt our management or business. These transactions would entail
numerous operational and financial risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">exposure
to unknown liabilities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">disruption
of our business and diversion of our management&#8217;s time and attention in order to manage a collaboration or develop acquired products,
product candidates or technologies;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">incurrence
of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">higher
than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization
expenses;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">difficulty
and cost in facilitating the collaboration or combining the operations and personnel of any acquired business;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">impairment
of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
inability to retain key employees of any acquired business.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, although there
can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions
that we do complete may be subject to the foregoing or other risks and have a material and adverse effect on our business, financial
condition, results of operations and prospects. Conversely, any failure to enter any additional collaboration or other strategic transaction
that would be beneficial to us could delay the development and potential commercialization of our product candidates and have a negative
impact on the competitiveness of any product candidate that reaches market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may acquire assets or form strategic
alliances in the future, and we may not realize the benefits of such acquisitions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may acquire additional
technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment
our existing business. If we acquire assets with promising markets or technologies, we may not be able to realize the benefit of acquiring
such assets if we are unable to successfully integrate them with our existing technologies. We may encounter numerous difficulties in
developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us
from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will
achieve the expected synergies to justify the transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If third parties on which we intend to
rely on to conduct certain preclinical studies, or any future clinical trials, do not perform as contractually required, fail to satisfy
regulatory or legal requirements or miss expected deadlines, our development program could be delayed with material and adverse effects
on our business, financial condition, results of operations and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to rely on third-party
clinical investigators, contract research organizations (&#8220;<b>CROs</b>&#8221;), clinical data management organizations and consultants
to design, conduct, supervise and monitor certain preclinical studies of our product candidates and will do the same for any clinical
trials. Because we intend to rely on these third parties and will not have the ability to conduct certain preclinical studies or clinical
trials independently, we will have less control over the timing, quality and other aspects of such preclinical studies and clinical trials
than we would have had we conducted them on our own. These investigators, CROs and consultants will not be our employees, and we will
have limited control over the amount of time and resources that they dedicate to our programs. These third parties may have contractual
relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third
parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials,
resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we cannot contract with
acceptable third parties on commercially reasonable terms, or at all, or if these third parties do not carry out their contractual duties,
satisfy legal and regulatory requirements for the conduct of preclinical studies or clinical trials or meet expected deadlines, our clinical
development programs could be delayed and otherwise adversely affected. In all events, we will be responsible for ensuring that each
of our preclinical studies and clinical trials are conducted in accordance with the general investigational plan and protocols for the
trial. The FDA requires preclinical studies to be conducted in accordance with good laboratory practices, or GLPs, and clinical trials
to be conducted in accordance with good clinical practices (&#8220;<b>GCPs</b>&#8221;), including for designing, conducting, recording
and reporting the results of preclinical studies and clinical trials to ensure that data and reported results are credible and accurate
and that the rights, integrity and confidentiality of clinical trial participants are protected. Our reliance on third parties that we
do not control will not relieve us of these responsibilities and requirements. Any adverse development or delay in our clinical trials
could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because we may rely on third-party manufacturing
and supply partners for preclinical and clinical development materials, our supply may become limited or interrupted or may not be of
satisfactory quantity or quality.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We produce only small-scale
quantities of our antibodies and reagents for characterization, in vivo and in vitro assessment. We may rely on third-party contract
manufacturers to manufacture our preclinical and clinical trial product supplies. We do not currently own manufacturing facilities for
producing such supplies. There can be no assurance that our preclinical or clinical development product supplies will not be limited
or interrupted, or will be of satisfactory quality or continue to be available at acceptable prices. In particular, any replacement of
our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacturing process
for a product candidate is subject to FDA and foreign regulatory authority review. Suppliers and manufacturers must meet applicable manufacturing
requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory
standards, such as current Good Manufacturing Practices (&#8220;<b>cGMPs</b>&#8221;). In the event that any of our manufacturers fails
to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of
components or other materials becomes limited or interrupted for other reasons, we may be forced to manufacture the materials ourselves,
for which we currently do not have the capabilities or resources, or enter into an agreement with another third party, which we may not
be able to do on reasonable terms, if at all. In some cases, the technical skills or technology required to manufacture our product candidates
may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another
third party and a feasible alternative may not exist. These factors would increase our reliance on such manufacturer or require us to
obtain a license from such manufacturer in order to have another third party manufacture our product candidates. If we are required to
change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that
comply with quality standards and with all applicable regulations and guidelines. The delays associated with the verification of a new
manufacturer could negatively affect our ability to develop product candidates in a timely manner or within budget.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to rely on third-party
manufacturers if we receive regulatory approval for any product candidate. To the extent that we have existing, or enter into future,
manufacturing arrangements with third parties, we will depend on these third parties to perform their obligations in a timely manner
consistent with contractual and regulatory requirements, including those related to quality control and assurance. If we are unable to
obtain or maintain third-party manufacturing for product candidates, or to do so on commercially reasonable terms, we may not be able
to develop and commercialize our product candidates successfully. Our or a third party&#8217;s failure to execute on our manufacturing
requirements and comply with cGMPs could adversely affect our business in a number of ways, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
inability to initiate or continue clinical trials of product candidates under development;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">delay
in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">loss
of the cooperation of an existing or future partner;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">subjecting
third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">requirements
to cease distribution or to recall batches of our product candidates; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in
the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our third-party manufacturers may be unable
to successfully scale manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from
developing our product candidates and commercializing approved products, if any.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to conduct clinical
trials, we will need to manufacture large quantities of our product candidates. We may use third parties for our manufacturing needs.
Our manufacturing partners may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely
or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities. If our manufacturing partners
are unable to successfully scale the manufacture of our product candidates in sufficient quality and quantity, the development, testing,
and clinical trials of that product candidate may be delayed or infeasible, and regulatory approval or commercial launch of any resulting
product may be delayed or not obtained, which could significantly harm our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If the market opportunities for our product
candidates are smaller than we believe they are, our future product revenues may be adversely affected and our business may suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our understanding of both
the number of people who suffer from HER2+ breast and gastric cancers or other tumors that can be treated with VEGF inhibitors, is based
on estimates. These estimates may prove to be incorrect and new studies may reduce the estimated incidence or prevalence of these diseases.
The number of patients in the United States, Europe, or elsewhere may turn out to be lower than expected, may not be otherwise amenable
to treatment with our product candidates or patients may become increasingly difficult to identify and access, all of which would adversely
affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, there are several
factors that could contribute to making the actual number of patients who receive our potential product candidates less than the potentially
addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped
markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We face competition from entities that
have developed or may develop product candidates for the treatment of the diseases that we are initially targeting, including companies
developing novel treatments and technology platforms. If these companies develop technologies or product candidates more rapidly than
we do or their technologies are more effective, our ability to develop and successfully commercialize product candidates may be adversely
affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development and commercialization
of drugs and therapeutic biologics is highly competitive. We compete with a variety of multinational biopharmaceutical companies and
specialized biotechnology companies, as well as technology being developed at universities and other research institutions. Our competitors
are often larger and better funded. Our competitors have developed, are developing or will develop product candidates and processes competitive
with our product candidates and processes. Competitive therapeutic treatments include those that have already been approved and accepted
by the medical community and any new treatments that are currently in development or that enter the market. We believe that a significant
number of products are currently under development, and may become commercially available in the future, for the treatment of conditions
for which we may try to develop product candidates. There is intense and rapidly evolving competition in the biotechnology, biopharmaceutical
and antibody and immunoregulatory therapeutics fields. We believe that while our <i>DiversImmune<sup>&#174;</sup></i> and <i>MultiMab<sup>TM</sup></i>
platforms, their associated intellectual property, the characteristics of our antibody product candidates in development, and our scientific
and technical know-how give us a competitive advantage in this space, competition from many sources remains. Given the number of competitors,
we strive to differentiate ourselves from them and contrast the perceived advantages of our technologies and product candidates. There
is a risk that some of our competitors will take issue with our positioning and make allegations regarding our company or our business
practices. Any such allegations could divert management&#8217;s attention, which could have an adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are aware of several companies
that are developing antibodies for the treatment of cancer and autoimmune diseases. Many of these companies are well-capitalized and,
in contrast to us, have significant clinical experience, and may include our existing or future partners. In addition, these companies
compete with us in recruiting scientific and managerial talent. Our success will partially depend on our ability to develop and protect
antibodies that are safer and more effective than competing products. Our commercial opportunity and success will be reduced or eliminated
if competing products that are safer, more effective, or less expensive than the antibodies we develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to compete with
antibody developers, such as AnaptysBio, Inc., Bristol-Myers Squibb Company, Genmab A/S, Ichnos Glenmark Innovation, Janux Therapeutics,
Regeneron Pharmaceuticals, Inc., Roche AG, Vir Bio, and Xencor Inc. If our lead product candidates are approved, they will compete with
a range of treatments that are either in development or currently marketed. For example, some of our product candidates will compete
against traditional cancer therapies, such as chemotherapy, as well as immune-based treatments for cancer, such as CAR T and TCR therapies,
developed or currently marketed by Bellicum Pharmaceuticals, Inc., Bluebird bio, Inc., Bristol-Myers Squibb Company, Cellectis S.A.,
Gilead Sciences, Inc., Novartis AG, Precigen, Inc., AstraZeneca and Genentech, Inc. (a member of the Roche Group, or Genentech/Roche).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors have
significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully
obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness
of our products, the ease with which our products can be administered and the extent to which patients accept relatively new routes of
administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing
and sales capabilities, price, reimbursement coverage and patent position. Competing products could present superior treatment alternatives,
including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive
products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing
our product candidates. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our
ability to execute our business plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Any inability to attract and retain qualified
key management, technical personnel and employees would impair our ability to implement our business plan.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success largely depends
on the continued service of key management, advisors and other specialized personnel. The loss of one or more members of our executive
team, management team or other key employees or advisors could delay our research and development programs and have a material and adverse
effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The relationships that our
key managers have cultivated within our industry make us particularly dependent upon their continued employment with us. We are dependent
on the continued service of our technical personnel because of the highly technical nature of our product candidates and technologies
and the specialized nature of the regulatory approval process. Because our management team and key employees are not obligated to provide
us with continued service, they could terminate their employment with us at any time without penalty. Our future success will depend
in large part on our continued ability to attract and retain other highly qualified scientific, technical and management personnel, as
well as personnel with expertise in clinical testing, manufacturing, governmental regulation and commercialization. We face competition
for personnel from other companies, universities, public and private research institutions, government entities and other organizations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of November 28, 2025,
we had four full-time employees (with one employee being furloughed) and two part-time employees. Our focus on the development of our
product candidates will require adequate staffing. We may need to hire and retain new employees to execute our future clinical development
and manufacturing plans. We cannot provide assurance that we will be able to hire and/or retain adequate staffing levels to develop our
product candidates or run our operations and/ or to accomplish all of our objectives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may experience difficulties in managing
our growth and expanding our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have limited experience
in product development and have not begun clinical trials for any of our product candidates. As our product candidates enter and advance
through preclinical studies and any clinical trials, we will need to expand our development, regulatory and manufacturing capabilities
or contract with other organizations to provide these capabilities for us. We may also experience difficulties in the discovery and development
of new antibody product candidates using our <i>DiversImmune<sup>&#174;</sup></i> and <i>MultiMab<sup>TM</sup></i> platforms if we are
unable to meet demand as we grow our operations. In the future, we also expect to have to manage additional relationships with collaborators,
suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our
operational, financial and management controls, reporting systems and procedures. We may not be able to implement improvements to our
management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If any of our product candidates is approved
for marketing and commercialization and we are unable to develop sales, marketing and distribution capabilities on our own or enter into
agreements with third parties to perform these functions on acceptable terms, we will be unable to commercialize successfully any such
future products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently have no sales,
marketing or distribution capabilities or experience. If any of our product candidates is approved, we will need to develop internal
sales, marketing and distribution capabilities to commercialize such products, which would be expensive and time-consuming, or enter
into partnerships with third parties to perform these services. If we decide to market our products directly, we will need to commit
significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution,
administration and compliance capabilities. If we rely on third parties with such capabilities to market our products or decide to co-promote
products with partners, we will need to establish and maintain marketing and distribution arrangements with third parties, and there
can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party
marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and there can be no
assurance that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance
of any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through
third parties, our business, financial condition, results of operations and prospects could be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our future growth may depend, in part,
on our ability to operate in foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future growth may depend,
in part, on our ability to develop and commercialize our product candidates in foreign markets for which we may rely on partnership with
third parties. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the
applicable regulatory authority in that foreign market, and we may never receive such regulatory approval for any of our product candidates.
To obtain separate regulatory approval in many other countries, we must comply with numerous and varying regulatory requirements of such
countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution
of our product candidates, and we cannot predict success in these jurisdictions. If we obtain approval of our product candidates and
ultimately commercialize our product candidates in foreign markets, we would be subject to the risks and uncertainties, including the
burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements and the reduced protection of
intellectual property rights in some foreign countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Price controls imposed in foreign markets
may adversely affect our future profitability.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some countries, particularly
member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing
negotiations with governmental authorities can take considerable time after receipt of marketing approval for a product. In addition,
there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost
containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations
may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution,
or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we or future partners may
be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our antibody product candidates to other
available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors
or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.
If reimbursement of any product candidate approved for marketing is unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, our business, financial condition, results of operations or prospects could be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If any of our product candidates receives
marketing approval and we or others later identify undesirable side effects caused by the product candidate, our ability to market and
derive revenue from the product candidates could be compromised.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects
caused by our product candidates could cause regulatory authorities to interrupt, delay or halt clinical trials and could result in a
more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. While we have not yet
initiated clinical trials for any of our product candidates, it is likely that there may be side effects associated with their use. Results
of our trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our trials
could be suspended or terminated, and the FDA or comparable foreign regulatory authorities could order us to cease further development
of or deny approval of our product candidates for any or all targeted indications. Such side effects could also affect patient recruitment
or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may
materially and adversely affect our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, clinical trials
by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure,
rare and severe side effects of our product candidates may only be uncovered with a significantly larger number of patients exposed to
the product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event that any of
our product candidates receive regulatory approval and we or others identify undesirable side effects caused by one of our products,
any of the following adverse events could occur, which could result in the loss of significant revenue to us and materially and adversely
affect our results of operations and business:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
authorities may withdraw their approval of the product or seize the product;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be required to recall the product or change the way the product is administered to patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional
restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component
thereof;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">regulatory
authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
could be sued and held liable for harm caused to patients;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
product may become less competitive; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
reputation may suffer.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Litigation and legal proceedings may substantially
increase our costs and harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have been, are, and may
in the future become, party to lawsuits and legal proceedings including, without limitation, actions and proceedings in the ordinary
course of business relating to our collaboration partners, directors, officers, stockholders, intellectual property rights, employment
matters and the safety or efficacy of our products, which will cause us to incur legal fees and other costs related thereto, including
potential expenses for the reimbursement of legal fees of officers and directors under indemnification obligations. See &#8220;<i>Legal
Proceedings</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The expense of defending
against such litigation and legal proceedings may be significant and there can be no assurance that we will be successful in any defense.
Further, the amount of time that may be required to resolve such lawsuits or legal proceedings is unpredictable, and these actions may
divert management&#8217;s attention from the day-to-day operations of our business, which could adversely affect our business, results
of operations, and cash flows. Our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our
policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards
could have a material adverse effect on our consolidated operations, cash flows and financial position. Additionally, any such claims,
whether or not successful, could damage our reputation and business. Litigation and legal proceedings are subject to inherent uncertainties,
and an adverse result in such matters that may arise from time to time could have a material adverse effect on our business, results
of operations, and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our business entails a significant risk
of product liability and our ability to obtain sufficient insurance coverage could have a material and adverse effect on our business,
financial condition, results of operations and prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we move into conducting
clinical trials of our product candidates, we will be exposed to significant product liability risks inherent in the development, testing,
manufacturing and marketing of antibody treatments. Product liability claims could delay or prevent completion of our development programs.
If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products,
our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement
action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the
merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to
defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants
or patients and a decline in our stock price. We currently do not have product liability insurance and will need to obtain such insurance
prior to marketing any of our product candidates. Any insurance we have or may obtain may not provide sufficient coverage against potential
liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, our partners
or we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims
that could have a material and adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our employees, principal investigators,
consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards
and requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to the risk
of fraud, waste, abuse or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct
by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with
manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial
information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in
the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other wasteful
or abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion,
sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of
information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation.
It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and
we are not successful in defending ourselves or asserting our rights, those actions could have a material and adverse effect on our business,
financial condition, results of operations and prospects, including the imposition of significant criminal, civil, and administrative
fines or other sanctions, such as monetary penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation
in government funded healthcare programs, such as Medicare and Medicaid, integrity obligations, reputational harm, and the curtailment
or restructuring of our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our internal computer systems, or those
of CROs or other contractors or consultants we currently use or may use in the future, may fail or suffer security breaches, which could
result in a material disruption of our product development programs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our internal computer systems
and those of CROs and other contractors and consultants we use or may use in the future, may be vulnerable to damage from computer viruses,
unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such events could cause interruptions
of our operations. For instance, the loss of preclinical data or data from any future clinical trial involving our product candidates
could result in delays in our development and regulatory filing efforts and significantly increase our costs. To the extent that any
disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary
information, we could incur liability, and the development of our product candidates could be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our information technology systems could
face serious disruptions that could adversely affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our information technology
and other internal infrastructure systems, including corporate firewalls, servers, leased lines and connection to the Internet, face
the risk of systemic failure that could disrupt our operations. A significant disruption in the availability of our information technology
and other internal infrastructure systems could cause interruptions and delays in our research and development work.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, any significant
breach, breakdown, destruction or interruption of these systems by employees, others with authorized access to our systems or unauthorized
persons has the potential to negatively affect our operations. There is also a risk that we could experience a business interruption,
theft of information or reputational damage as a result of a cyberattack, such as the infiltration of a data center, denial-of-service
attacks, viruses, malicious software, phishing attacks, security breaches or data leakage of confidential information either internally
or at our third-party providers. Although we have invested in the protection of our data and information technology to reduce these risks,
there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could have a material adverse effect
on our financial condition, results of operations and liquidity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we do not comply with laws regulating
the protection of the environment and health and human safety, our business could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research, development
and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic
chemicals in our facilities that are required for our research, development and manufacturing activities. We are subject to federal,
state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We
believe our procedures for storing, handling and disposing these materials in our facilities comply with the relevant guidelines of the
Commonwealth of Massachusetts and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe
that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations,
the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable
for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and
regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous
materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries
to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities.
We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our
storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations
may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of
these laws or regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We or the third parties upon whom we depend
may be adversely affected by natural disasters and we may not be adequately protected from a serious disaster.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current operations are
located outside of Boston, Massachusetts. Any unplanned event, such as flood, fire, explosion, extreme weather condition, medical epidemics,
power shortage, telecommunication failure or other natural or manmade accidents or incidents that result in us being unable to fully
utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material and adverse effect
on our ability to operate our business, particularly on a daily basis, and have significant negative consequences on our financial and
operating conditions. Loss of access to this facility may result in increased costs, delays in the development of our product candidates
or interruption of our business operations. Natural disasters such as snowstorms or hurricanes could further disrupt our operations,
and have a material and adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster,
power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical
infrastructure, such as our research facility or the manufacturing facilities of our third-party contract manufacturers, or that otherwise
disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period
of time. We do not currently have disaster recovery and business continuity plans in place, and this may have adverse consequences in
the event of a serious disaster or similar event. As a result, we may incur substantial expenses, which could have a material adverse
effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate
for our business. However, in the event of an accident or incident at this facility, we cannot assure you that the amounts of insurance
will be sufficient to satisfy any damages and losses. If our facility, or the manufacturing facilities of our third-party contract manufacturers,
are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our
research and development programs may be harmed. Any business interruption may have a material and adverse effect on our business, financial
condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to obtain or protect intellectual
property rights related to our technology and current or future product candidates, or if our intellectual property rights are inadequate,
we may not be able to compete effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends in part
on our ability to obtain and maintain protection with respect to our owned and in-licensed intellectual property and proprietary technology.
We rely on patents and other forms of intellectual property rights, including in-licenses of intellectual property rights of others,
to protect our current or future platforms, product candidates, methods used to manufacture our current or future product candidates
and methods for treating patients using our current or future product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot predict whether
any future patent applications will result in the issuance of patents that effectively protect any of our product candidates or will
effectively prevent others from commercializing competitive products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also rely on our ability
to preserve our trade secrets, to prevent third parties from infringing, misappropriating or violating our proprietary rights and to
operate without infringing, misappropriating or violating the proprietary rights of others. The patent prosecution process is expensive,
complex and time-consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents
and patent applications at a reasonable cost or in a timely manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that
we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.
The patent applications that we own or in-license may fail to result in issued patents, and, even if they do issue as patents, such patents
may not cover our current or future technologies or product candidates in the United States or in other countries or provide sufficient
protection from competitors. In addition, the coverage claimed in a patent application can be significantly reduced before the patent
is issued and its scope can be reinterpreted after issuance. There is no assurance that all of the potentially relevant prior art relating
to our owned or in-licensed patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing
from a pending application. Even if patents do successfully issue and even if such patents cover our current or any future technologies
or product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed,
invalidated or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive
us of rights necessary for the successful commercialization of any current or future technologies or product candidates that we may develop.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If patent applications we
own or have in-licensed with respect to our development programs and current or future technologies or product candidates fail to issue,
if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity, it could dissuade companies
from collaborating with us to develop current or future technologies or product candidates, and threaten our ability to commercialize
current or future products. Any such outcome could have a material adverse effect on our business, financial condition, results of operations
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent positions of biopharmaceutical
companies are generally uncertain because they involve complex legal and factual considerations and have, in recent years, been the subject
of much legislation and litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights
are highly uncertain. The standards applied by the United States Patent and Trademark Office, or USPTO, and foreign patent offices in
granting patents are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable
subject matter or the scope of claims allowable in patents. In addition, changes in either the patent laws or interpretation of the patent
laws in the United States and other countries may diminish the value of our owned or in-licensed patents or narrow the scope of our patent
protection. Publications of discoveries in scientific literature often lag behind the actual discoveries and patent applications in the
United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore,
we cannot know with certainty whether we or our licensors were the first to make the inventions claimed in our owned or in-licensed patents
or pending applications, or that we or our licensors were the first to file for patent protection of such inventions. There is no assurance
that all potentially relevant prior art relating to our owned or in-licensed patents and patent applications has been found. We may be
unaware of prior art that could be used to invalidate an issued patent or prevent our owned or in-licensed pending patent applications
from issuing as patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The filing of a patent application
or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability, validity, or enforceability, and
patents and patent applications may be challenged in the courts in the patent office in the Unites States and abroad. For example, we
or our licensors may be subject to a third-party pre-issuance submission of prior art to the USPTO or become involved in opposition,
derivation, reexamination, inter partes review, post-grant review, or interference proceedings, declaratory judgment actions or counterclaims
challenging our owned or in-licensed patent rights or the rights of others. An adverse determination in any such submission, proceeding,
or litigation could prevent the issuance of, reduce the scope of, invalidate, or render unenforceable our owned or in-licensed patent
rights, limit our ability to stop others from using or commercializing similar or identical platforms and products, allow third parties
to compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing
third-party patent rights. In addition, if the breadth or strength of protection provided by our owned or in-licensed patents and patent
applications is threatened, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future
platforms or product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results
of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any failure to obtain or
any loss of patent protection could have a material adverse impact on our business, financial condition, results of operations and prospects.
We may be unable to prevent competitors from entering the market with a product that is similar to or the same as our current or future
product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, some of our owned
and in-licensed patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive
license to any such third-party co-owners&#8217; interest in such patents or patent application, such co-owners may be able to license
their rights to other third parties, including our competitors, and our competitors could market competing products and technology. In
addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and
such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business,
financial conditions, results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, our owned and
in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, we in-license certain patent
rights covering ABP-110 from the National Cancer Institute, or NCI, a division of the National Institutes of Health, or NIH. As a result,
the U.S. government may have certain rights, including so-called march-in rights, to such patent rights and any products or technology
developed from such patent rights. When new technologies are developed with U.S. government funding, the U.S. government generally obtains
certain rights in any resulting patents, including a non-exclusive license authorizing the U.S. government to use the invention for non-commercial
purposes. These rights may permit the U.S. government to disclose our confidential information to third parties and to exercise march-in
rights to use or allow third parties to use our licensed technology. The U.S. government can exercise its march-in rights if it determines
that action is necessary because we fail to achieve the practical application of government-funded technology, because action is necessary
to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition,
our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United
States. Any exercise by the U.S. government of such rights could harm our competitive position, business, financial condition, results
of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with our obligations
under any license, collaboration or other intellectual property related agreements, we may be required to pay damages and could lose
intellectual property rights that are necessary for developing, commercializing and protecting our current or future technologies or
product candidates or we could lose certain rights to grant sublicenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are heavily reliant upon
licenses to certain patent rights and proprietary technology from third parties that are important or necessary to the development of
our technologies and product candidates. Our current license agreements impose, and any future license agreements we enter into are likely
to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution
and enforcement and/or other obligations on us. We previously were party to an Exclusive License Agreement with Memorial Sloan Kettering
Cancer Center (&#8220;MSK&#8221;), which was terminated by MSK in September 2023 for our failure to fulfil our payment obligations to
MSK. MSK has demanded payments totaling approximately $1.2 million. We have contacted MSK about possible settlement and have responded
to a counterproposal received from MSK in February 2024, and are continuing discussions. See &#8220;<i>Legal Proceedings</i>&#8221; for
more information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are in breach of our obligations
under our license agreement with MedImmune/AstraZeneca. See  &#8220;- <i>Through our AbMed subsidiary, we have in-licensed certain intellectual
property rights relating to ABP-201 from MedImmune Limited, or MedImmune (now AstraZeneca), and are in breach of the terms of our license
agreement with MedImmune/AstraZeneca</i>.&#8221; Our breach of this license agreement or breach of any other license agreement, or the
use of intellectual property licensed to us in an unauthorized manner, may require us to pay damages and the licensor may have the right
to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed
technology or enable a competitor to gain access to the licensed technology. In certain circumstances, our licensed patent rights are
subject to our reimbursing our licensors for their patent prosecution and maintenance costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we may not have
the right to control the preparation, filing, prosecution, maintenance, enforcement, and defense of patents and patent applications that
we license from third parties. For example, pursuant to each of our intellectual property licenses with MedImmune, and the National Cancer
Institute (&#8220;NCI&#8221;), our licensors retain control of preparation, filing, prosecution, and maintenance, and, in certain circumstances,
enforcement and defense of the patents and patent applications. Therefore, we cannot be certain that these patents and patent applications
will be prepared, filed, prosecuted, maintained, enforced, and defended in a manner consistent with the best interests of our business.
If our licensors fail to prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications,
the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products or product candidates
that are subject of such licensed rights could be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, our licensors may
own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their
merit, that we are infringing, misappropriating or otherwise violating the licensor&#8217;s intellectual property rights. In addition,
while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products, if
any, the amounts may be significant. The amount of our future royalty obligations will depend on the technology and intellectual property
we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize
products, we may be unable to achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the agreements
under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow
what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be
our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business,
financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have licensed prevent
or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully
develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial conditions,
results of operations, and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Patent terms may be inadequate to protect
our competitive position on our current or future technologies or product candidates for an adequate amount of time.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patents have a limited lifespan.
In the United States, the standard expiration of a patent is generally 20 years after it is filed. Various extensions may be available.
However, the life of a patent and the protection it affords is limited. As a result, our owned and in-licensed patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. For example, given the
large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting
such candidates might expire before or shortly after such candidates are commercialized. In the United States, the Drug Price Competition
and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent,
which is limited to the approved indication (or any additional indications approved during the period of extension). Additionally, a
patent term extension cannot extend the remaining term of a patent beyond 14 years from the date of product approval, only one patent
may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended.
However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in
other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our
patents, or may grant more limited extensions than we request. An extension may not be granted or may be limited because of, for example
a failure to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines,
failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. If this occurs, our
competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical
data and launch their product earlier than might otherwise be the case, which could have a material adverse effect on our business, financial
condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in U.S. patent law or the patent
law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our
current or any future technologies or product candidates.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in either the patent
laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution
of patent applications and the enforcement or defense of issued patents. The United States has recently enacted and implemented wide-ranging
patent reform legislation. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law, which
could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement
or defense of our owned or in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law.
These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and
switch the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a first-to-file
system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be
entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. These provisions also allow
third-party submission of prior art to the USPTO during patent prosecution and set forth additional procedures to challenge the validity
of a patent by the USPTO administered post grant proceedings, including derivation, reexamination, inter partes review, post-grant review,
and interference proceedings. The USPTO developed additional regulations and procedures to govern administration of the Leahy-Smith Act,
and many of the substantive changes to patent law associated with the Leahy-Smith Act, and, in particular, the first-to-file provisions,
only became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation
of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of
our owned or in-licensed patent applications and the enforcement or defense of our issued owned or in-licensed patents, all of which
could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. Supreme Court has
ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or
weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our and our licensors&#8217;
ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once
obtained. The recent decision by the Supreme Court in <i>Association for Molecular Pathology v. Myriad Genetics, Inc</i>. precludes claims
directed to a nucleic acid having a stated nucleotide sequence that is identical to a sequence found in nature and that is unmodified.
This decision has yet to be clearly interpreted by other courts and by the USPTO. We cannot assure you that the interpretations of this
decision or that subsequent rulings will not adversely impact our owned or in-licensed patents or patent applications. Depending on decisions
by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways
that would weaken our and our licensors&#8217; ability to obtain new patents or to enforce our existing owned or in-licensed patents
and patents that we might obtain or in-license in the future. Similarly, changes in patent law and regulations in other countries or
jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces
patent laws or regulations may have a material adverse effect on our and our licensors&#8217; ability to obtain new patents or to protect
and enforce our owned or in-licensed patents or that we may obtain or in-license in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Other companies or organizations may challenge
our or our licensors&#8217; patent rights or may assert patent rights that prevent us from developing and commercializing our current
or future products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bispecific antibodies are
a relatively new scientific field. As the field of antibody and immunoregulatory therapeutics matures, patent applications are being
processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, as to when,
to whom, and with what claims. In addition, third parties may attempt to invalidate our or our licensors&#8217; intellectual property
rights. Even if such rights are not directly challenged, disputes could lead to the weakening of our or our licensors&#8217; intellectual
property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could
be costly to us, could require significant time and attention of our management and could have a material and adverse effect on our business,
financial condition, results of operations and prospects or our ability to successfully compete.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are many issued and
pending patents that claim aspects of our current or future product candidates and modifications that we may need to apply to our current
or future product candidates. There are also many issued patents that claim antibodies or portions of antibodies that may be relevant
for products we wish to develop. Thus, it is possible that one or more third parties will hold patent rights to which we will need a
license, which may not be available on reasonable terms or at all. If those third parties refuse to grant us a license to such patent
rights on reasonable terms or at all, we may be required to expend significant time and resources to redesign our technology, product
candidates, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on
a technical or commercial basis. If we are unable to do so, we may not be able to market such technology or product candidates or perform
research and development or other activities covered by these patents, which could have a material adverse effect on our business, financial
condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may not be able to protect our intellectual
property rights throughout the world, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting and defending
patents on current or future technologies or product candidates in all countries throughout the world would be prohibitively expensive.
Competitors or other third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop
their own products and, further, may export otherwise infringing products to territories where we have patent protection or licenses
but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other
intellectual property rights may not be effective or sufficient to prevent them from competing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the laws of
some foreign jurisdictions do not protect intellectual property rights to the same extent as the laws in the United States, and many
companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems
of certain countries, including certain developing countries, do not favor the enforcement of patents and other intellectual property
protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of our owned
and in-licensed patents or the marketing of competing products in violation of our intellectual property and proprietary rights generally.
Proceedings to enforce our owned or in-licensed intellectual property and proprietary rights in foreign jurisdictions could result in
substantial costs and divert our efforts and attention from other aspects of our business, could put our owned or in-licensed patents
at risk of being invalidated or interpreted narrowly, could put our owned or in-licensed patent applications at risk of not issuing,
and could provoke third parties to assert claims against us or our licensors. We or our licensors may not prevail in any lawsuits that
we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our
and our licensors&#8217; efforts to enforce such intellectual property and proprietary rights around the world may be inadequate to obtain
a significant commercial advantage from the intellectual property that we develop or in-license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many countries have compulsory
licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the
enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited
remedies, which could materially diminish the value of its patents. If we or any of our licensors are forced to grant a license to third
parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and
our business, financial condition, results of operations and prospects may be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Third parties may initiate legal proceedings
alleging that we are infringing, misappropriating or violating their intellectual property rights, the outcome of which would be uncertain
and could have a material adverse impact on the success of our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success depends,
in part, upon our ability and the ability of our current or future collaborators to develop, manufacture, market and sell our current
or any future product candidates and use our proprietary technologies without infringing, misappropriating or violating the proprietary
and intellectual property rights of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and
complex litigation regarding patents and other intellectual property rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We or our licensors, or any
future strategic partners may be party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property
rights with respect to our current or any future product candidates and technologies, including derivation, reexamination, inter partes
review, post-grant review, or interference proceedings before the USPTO and similar proceedings in jurisdictions outside of the United
States such as opposition proceedings. In some instances, we may be required to indemnify our licensors for the costs associated with
any such adversarial proceedings or litigation. For example, our majority-owned subsidiary, AbMed Corporation, is obligated under the
Collaboration and License Agreement with MedImmune to indemnify and hold harmless MedImmune for damages arising from intellectual property
infringement by us resulting from exercise of the license from MedImmune. Third parties may assert infringement claims against us, our
licensors or our strategic partners based on existing patents or patents that may be granted in the future, regardless of their merit.
There is a risk that third parties may choose to engage in litigation with us, our licensors or our strategic partners to enforce or
to otherwise assert their patent rights. Even if we believe such claims are without merit, a court of competent jurisdiction could hold
that these third-party patents are valid, enforceable and infringed, which could have a material adverse impact on our ability to commercialize
our current or any future platforms or product candidates. In order to successfully challenge the validity of any such U.S. patent in
federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing
evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate
the claims of any such U.S. patent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or our licensors, or
any future strategic partners are found to infringe, misappropriate or violate a third-party patent or other intellectual property rights,
we could be required to pay damages, including treble damages and attorney&#8217;s fees, if we are found to have willfully infringed.
In addition, we or our licensors, or any future strategic partners may choose to seek, or be required to seek, a license from a third
party, which may not be available on commercially reasonable terms, if at all. Even if a license can be obtained on commercially reasonable
terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights
licensed to us, and it could require us to make substantial licensing and royalty payments. We also could be forced, including by court
order, to cease developing, manufacturing and commercializing the infringing platforms or product candidates. Any of the foregoing could
have a material adverse effect on our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue
sufficient to sustain our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we or our licensors
may find it necessary to pursue claims or initiate lawsuits to protect or enforce our owned or in-licensed patent or other intellectual
property rights. The cost to us in defending or initiating any litigation or other proceeding relating to our owned or in-licensed patent
or other intellectual property rights, even if resolved in our favor, could be substantial, and any litigation or other proceeding would
divert our management&#8217;s attention. Such litigation or proceedings could materially increase our operating losses and reduce the
resources available for development activities or any future sales, marketing or distribution activities. Some of our competitors may
be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.
Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development
efforts and materially limit our ability to continue our operations. Furthermore, because of the substantial amount of discovery required
in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by
disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other
interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a material
adverse effect on the price of our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or our licensors were
to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technology, the
defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of
several statutory requirements, for example, lack of novelty, indefiniteness, lack of written description, obviousness or non-enablement.
Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant
information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity
and unenforceability during patent litigation is unpredictable. With respect to the validity question, for example, we cannot be certain
that there is no invalidating prior art, of which we or our licensors and the patent examiner were unaware during prosecution. If a defendant
were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection
on one or more of our product candidates or certain aspects of our platform technology. Such a loss of patent protection could have a
material adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property
rights also will not protect our product candidates and technologies if competitors or third parties design around such product candidates
and technologies without legally infringing, misappropriating or violating our owned or in-licensed patents or other intellectual property
rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights of third parties
could adversely affect our ability to commercialize our current or future technologies or product candidates, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our current or future technologies or product candidates,
which may not be available on commercially reasonable terms or at all.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the antibody landscape
is still evolving, it is difficult to conclusively assess our freedom to operate without infringing, misappropriating or violating third-party
rights. There are numerous companies that have pending patent applications and issued patents broadly covering antibodies generally or
covering antibodies directed against the same targets as, or targets similar to, those we are pursuing. Our competitive position may
materially suffer if patents issued to third parties or other third-party intellectual property rights cover our current or future technologies
or product candidates or elements thereof, or our manufacture or uses relevant to our development plans. In such cases, we may not be
in a position to develop or commercialize current or future technologies or product candidates unless we successfully pursue litigation
to nullify or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual
property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by
third parties that, if found to be valid and enforceable, could be alleged to be infringed by our current or future technologies or product
candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be
alleged to be infringed by our current or future technologies or product candidates. If such an infringement claim should be brought
and be successful, we may be required to pay substantial damages, be forced to abandon our current or future technologies or product
candidates or seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable
terms, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that
we have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before November 29, 2000
and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until patents issue.
Patent applications in the United States and elsewhere are published approximately 18 months after the earliest filing for which priority
is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our
product candidates or platform technologies could have been filed by others without our knowledge. Additionally, pending patent applications
that have been published can, subject to certain limitations, be later amended in a manner that could cover our platforms, our product
candidates or the use of our technologies. Third-party intellectual property right holders may also actively bring infringement, misappropriation
or violation claims against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such claims. If
we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue costly, unpredictable
and time-consuming litigation and may be prevented from or experience substantial delays in marketing our product candidates. If we fail
in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing
any of our current or future technologies or product candidates that are held to be infringing, misappropriating or violating. We might,
if possible, also be forced to redesign current or future technologies or product candidates so that we no longer infringe, misappropriate
or violate the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us
to divert substantial financial and management resources that we would otherwise be able to devote to our business, which could have
a material adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we are unable to protect the confidentiality
of our trade secrets, our business and competitive position would be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to seeking patent
protection for certain aspects of our current or future technologies and product candidates, we also consider trade secrets, including
confidential and unpatented know-how, important to the maintenance of our competitive position. However, trade secrets and know-how can
be difficult to protect. We protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure
and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside
scientific collaborators, CROs, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality
and invention or patent assignment agreements with our employees and consultants that obligate them to maintain confidentiality and assign
their inventions to us. Despite these efforts, any of these parties may breach such agreements and disclose our proprietary information,
including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. We may also become involved in inventorship
disputes relating to inventions and patents developed by our employees or consultants under such agreements. Enforcing a claim that a
party illegally disclosed or misappropriated a trade secret, or securing title to an employee-or consultant-developed invention if a
dispute arises, is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United
States and certain foreign jurisdictions are less willing or unwilling to protect trade secrets. If any of our trade secrets were to
be lawfully obtained or independently developed by a competitor, we would have no right to prevent them from using that technology or
information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive
position would be materially and adversely harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be subject to claims that we or
our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of our employees&#8217;
or consultants&#8217; former employers or their clients.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our employees were
previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors.
We may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary
information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims,
in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or may be enjoined from using
such intellectual property, and would likely divert significant resources from our core business, including distracting our technical
and management personnel from their normal responsibilities. A loss of key research personnel or their work product could limit our ability
to commercialize, or prevent us from commercializing, our current or future technologies or product candidates, which could materially
harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a
distraction to management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Obtaining and maintaining our patent protection
depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies,
and our patent protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance fees,
renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid to the USPTO and various
government patent agencies outside of the United States over the lifetime of our owned and in-licensed patents and/or applications and
any patent rights we may own or in-license in the future. The USPTO and various non-U.S. government patent agencies require compliance
with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable
law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply
with these requirements with respect to our in-licensed intellectual property. In many cases, an inadvertent lapse can be cured by payment
of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result
in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
In such an event, potential competitors might be able to enter the market with similar or identical products or platforms, which could
have a material adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If our trademarks and trade names are not
adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely
affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our trademarks or trade names
may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect
our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential
partners or customers in our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names,
we may not be able to compete effectively and our business may be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Intellectual property rights do not necessarily
address all potential threats to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future protection
afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business. The following examples are illustrative:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may be able to make compounds or formulations that are similar to our product candidates, but that are not covered by the claims of any
patents, should they issue, that we own, license or control;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent applications
that we own, license or control;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
or our licensors might not have been the first to file patent applications covering certain of our owned and in-licensed inventions;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">others
may independently develop similar or alternative technologies or duplicate any of our technologies without infringing, misappropriating
or violating our owned or in-licensed intellectual property rights;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">it
is possible that our owned or in-licensed pending patent applications will not lead to issued patents;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issued
patents that we own, in-license or control may not provide us with any competitive advantages, or may be narrowed or held invalid or
unenforceable, including as a result of legal challenges;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from
patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights
and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may not develop additional proprietary platforms that are patentable;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we
may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent
covering such trade secrets or know-how; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
patents of others may have an adverse effect on our business.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should any of these events
occur, they could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Clinical development involves a lengthy
and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of our product candidates
are in preclinical development and their risk of failure is high. It is impossible to predict when or if any of our product candidates
will prove effective and safe in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities
for the sale of any product candidate, we must complete preclinical studies and then conduct extensive clinical trials to demonstrate
the safety and efficacy of our product candidates in humans. Clinical testing is expensive and can take many years to complete, and its
outcome is inherently uncertain. Failure can occur at any time during the development process. The results of preclinical studies and
early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates
in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical
studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced
clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">We
                                            expect to commence clinical trials of our two lead product candidates, ABP-102 for the treatment
                                            of breast and gastric cancers, and ABP-201 for the treatment of wet age-related macular degeneration
                                            (Wet AMD) and diabetic macular edema (DME) in the first half of 2026. Commencing these clinical
                                            trials is subject to finalizing the trial design and filing an IND or similar filing with
                                            the FDA or similar foreign regulatory authority. Even after we file our IND or comparable
                                            submissions in other jurisdictions, the FDA or other regulatory authorities could disagree
                                            that we have satisfied their requirements to commence our clinical trials or disagree with
                                            our study design, which may require us to complete additional preclinical studies or amend
                                            our protocols or impose stricter conditions on the commencement of clinical trials.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may experience delays
in completing our preclinical studies and initiating or completing clinical trials of our product candidates. We do not know whether
planned preclinical studies and clinical trials will be completed on schedule or at all, or whether planned clinical trials will begin
on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Our development programs may be delayed
for a variety of reasons, including delays related to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
FDA or other regulatory authorities requiring us to submit additional data or imposing other requirements before permitting us to initiate
a clinical trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
regulatory approval to commence a clinical trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reaching
agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation
and may vary significantly among different CROs and clinical trial sites;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">obtaining
institutional review board, or IRB, approval at each clinical trial site;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recruiting
suitable patients to participate in a clinical trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">having
patients complete a clinical trial or return for post-treatment follow-up;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">clinical
trial sites deviating from trial protocol or dropping out of a trial;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">adding
new clinical trial sites; or</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacturing
sufficient quantities of our product candidates for use in clinical trials.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patient enrollment, a significant
factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity
of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, the severity of the disease
under investigation, our payments for conducting clinical trials, competing clinical trials and clinicians&#8217; and patients&#8217;
perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including
any new drugs or therapeutic biologics that may be approved for the indications we are investigating. Especially because our product
candidates may initially target indications that may be characterized as orphan markets, the clinical trial timeline for the regulatory
process could be prolonged if sufficient patients cannot be enrolled in a timely manner. Furthermore, we expect to rely on our partners,
CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we expect to enter into agreements
governing their committed activities, we have limited influence over their actual performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We could encounter delays
if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates
in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended
or terminated by us, our partners, the IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring
Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical
trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site
by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects,
failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions
or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of, or termination of, any clinical
trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product
revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase
our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenues.
Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.
In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately
lead to the denial of regulatory approval of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may be unable to obtain U.S. or foreign
regulatory approval and, as a result, be unable to commercialize our product candidates, resulting in substantial harm to our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot commercialize a
product until the appropriate regulatory authorities have reviewed and approved the product candidate. Our product candidates are subject
to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy,
approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs
and therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required
to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed.
Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. It
is possible that none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our existing
or future partners to begin selling them. We have very limited experience in conducting and managing the clinical trials necessary to
obtain regulatory approvals, including approval by the FDA. The time required to obtain FDA and other approvals is unpredictable but
typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product
candidate. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes
it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities
is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We
may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative
action, or from changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. It is impossible
to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed,
or what the impact of such changes, if any, may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the FDA has limited
early experience with bispecific antibody-based therapeutics, which may increase the complexity, uncertainty and length of the regulatory
approval process for our product candidates. For example, the FDA may require us to provide additional data to support our regulatory
applications, including Biologics License Applications (&#8220;<b>BLAs</b>&#8221;). In addition, because there may be approved treatments
for some of the diseases for which we may seek approval, in order to receive regulatory approval, we may need to demonstrate through
clinical trials that the product candidates we develop to treat these diseases, if any, are not only safe and effective, but safer or
more effective than existing products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any delay or failure in obtaining
required approvals could have a material and adverse effect on our ability to generate revenues from the particular product candidate
for which we are seeking approval. Furthermore, any regulatory approval to market a product may be subject to limitations on the approved
uses for which we may market the product or the labeling or other restrictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject to numerous
foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization,
pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks
associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions.
Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. Approval by the FDA does not ensure
approval by regulatory authorities outside the United States and vice versa.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may in the future conduct clinical trials
for current or future product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not
accept data from such trials.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may in the future choose
to conduct one or more clinical trials outside the United States. The acceptance of study data from clinical trials conducted outside
the United States or another jurisdiction by the FDA or comparable foreign regulatory authority may be subject to certain conditions
or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing
approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data
are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized
competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by
the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection
or other appropriate means. In addition, even where the foreign study data are not intended to serve as the sole basis for approval,
the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted
in accordance with GCP and the FDA is able to validate the data from the study through an onsite inspection, if deemed necessary. Many
foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable
local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign
regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or
any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which could
be costly and time-consuming, and which may result in current or future product candidates that we may develop not receiving approval
for commercialization in the applicable jurisdiction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, conducting clinical
trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical
trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences
in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as
well as political and economic risks relevant to such foreign countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we receive regulatory approval
for any of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result
in significant additional expense. Additionally, our product candidates, if approved, could be subject to labeling and other restrictions
and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated
problems with our products.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any regulatory approvals
that we or our existing or future partners obtain for our product candidates may also be subject to limitations on the approved indicated
uses for which a product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing
testing, including &#8220;Phase 4&#8221; clinical trials, and surveillance to monitor the safety and efficacy of the product candidate.
In addition, if the FDA or a comparable foreign regulatory authority approves any of our product candidates, the manufacturing processes,
labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for the
product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other
post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that
we conduct post-approval. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity
or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may
result in, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">restrictions
on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fines,
warning letters or holds on clinical trials;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal
by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic partners;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">suspension
or revocation of product license approvals;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product
seizure or detention or refusal to permit the import or export of products; and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions
or the imposition of civil or criminal penalties.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&#8217;s policies
may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product
candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative
action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption
of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we
may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may fail to obtain and maintain orphan
drug designation from the FDA for our current and future product candidates, as applicable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our strategy may include
filing for orphan drug designation if and where available for our product candidates. Under the Orphan Drug Act, the FDA may grant orphan
drug designation to a drug or biologic intended to treat a rare disease or condition, which is defined as one occurring in a patient
population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there
is no reasonable expectation that the cost of developing the drug or biologic will be recovered from sales in the United States. In the
United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages and user-fee exemptions. In addition, if a product that has orphan drug designation subsequently receives
the first FDA approval for the disease for which it has such designation, the product is entitled to orphan drug exclusivity, which means
that the FDA may not approve any other applications, including a full NDA or BLA, to market the same drug or biologic for the same indication
for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity
or where the original manufacturer is unable to assure sufficient product quantity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may pursue orphan designations
for our lead product candidates ABP-102 and ABP-201. However, while we may seek orphan drug designations for our product candidates,
we may never receive such designations. In addition, orphan drug designation neither shortens the development time or regulatory review
time of a drug, nor gives the drug any advantage in the regulatory review or approval process. Even if we obtain such designations, we
may not be the first to obtain regulatory approval of a product candidate for the orphan-designated indication due to the uncertainties
associated with developing pharmaceutical products. We may also fail to meet requirements to maintain orphan drug designation while developing
ABP-102 and ABP-201. In addition, exclusive marketing rights in the United States may be limited if we decide to seek approval for an
indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation
was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the orphan-designated
disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect
the product from competition because different drugs with different active moieties may receive and be approved for the same condition,
and only the first applicant to receive approval will receive the benefits of marketing exclusivity. Even after an orphan-designated
product is approved, the FDA can subsequently approve a later drug with the same active moiety for the same condition if the FDA concludes
that the later drug is clinically superior if it is shown to be safer, more effective or makes a major contribution to patient care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may attempt to secure approval from
the FDA through the use of accelerated approval pathways. If unable to obtain approval under an accelerated pathway, we may be required
to conduct additional preclinical studies or clinical trials which could increase the expense of obtaining, reduce the likelihood of
obtaining and/or delay the timing of obtaining, necessary marketing approvals. Even if we receive accelerated approval from the FDA,
if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA
may seek to withdraw accelerated approval.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek an accelerated
approval development pathway for our product candidates, including ABP-102 and ABP-201. Under the accelerated approval provisions of
the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), and the FDA&#8217;s implementing regulations, the FDA may grant accelerated
approval to a product designed to treat a serious or life-threatening condition that provides meaningful therapeutic advantage over available
therapies and demonstrates an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical
benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given
disease. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image,
physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate
clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably
likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval development pathway
may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a
clinically important improvement from a patient and public health perspective. If granted, accelerated approval is contingent on the
sponsor&#8217;s agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the
drug&#8217;s clinical profile or risks and benefits for accelerated approval. The FDA may require that any such confirmatory study be
initiated or substantially underway prior to the submission of an application for accelerated approval. If such post-approval studies
fail to confirm the drug&#8217;s clinical profile or risks and benefits, the FDA may withdraw its approval of the drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we choose to pursue accelerated
approval, we intend to seek feedback from the FDA or will otherwise evaluate our ability to seek and receive such accelerated approval.
There can be no assurance that, after our evaluation of the feedback from the FDA or other factors, we will decide to pursue or submit
a BLA for accelerated approval or any other form of expedited development, review or approval. Furthermore, if we submit an application
for accelerated approval, there can be no assurance that such application will be accepted or that approval will be granted on a timely
basis, or at all. The FDA also could require us to conduct further studies or trials prior to considering our application or granting
approval of any type. We might not be able to fulfill the FDA&#8217;s requirements in a timely manner, which would cause delays, or approval
might not be granted because our submission is deemed incomplete by the FDA. A failure to obtain accelerated approval or any other form
of expedited development, review or approval for a product candidate would result in a longer time period to commercialize such product
candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive accelerated
approval from the FDA, we will be subject to rigorous post-marketing requirements, including the completion of confirmatory post-market
clinical trial(s) to verify the clinical benefit of the product, and submission to the FDA of all promotional materials prior to their
dissemination. The FDA could seek to withdraw accelerated approval for multiple reasons, including if we fail to conduct any required
post-market study with due diligence, a post-market study does not confirm the predicted clinical benefit, other evidence shows that
the product is not safe or effective under the conditions of use, or we disseminate promotional materials that are found by the FDA to
be false and misleading.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Healthcare legislative reform measures
may have a material adverse effect on our business and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our products
profitably. In particular, in 2010, the Patient Protection and Affordable Care Act, or the ACA, was enacted, which, among other things,
addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that
are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid
Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed
care organizations; subjected manufacturers to new annual fees and taxes for certain branded prescription drugs; created a new Medicare
Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget
Act of 2018, effective as of January 1, 2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries
during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and
provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since its enactment, there
have been judicial, Congressional and executive challenges to certain aspects of the ACA. On June 17, 2021, the U.S. Supreme Court dismissed
the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA.
Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special enrollment period from February
15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order
also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare,
including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies
that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other
healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact
our business. Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. The Budget Control
Act of 2011 and subsequent legislation, among other things, created measures for spending reductions that resulted in aggregate reductions
of Medicare payments to providers up to 2% per fiscal year, which, due to subsequent legislative amendments, will remain in effect through
2030 unless additional Congressional action is taken.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2022, the Inflation
Reduction Act of 2022, or the IRA, was signed into law. The IRA includes several provisions that may impact our business, depending on
how various aspects of the IRA are implemented. Provisions that may impact our business include a $2,000 out-of-pocket cap for Medicare
Part D beneficiaries, the imposition of new manufacturer financial liability on most drugs in Medicare Part D, permitting the U.S. government
to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition,
requiring companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delaying the rebate rule that
would require pass through of pharmacy benefit manager rebates to beneficiaries. In August 2023, the government selected the first 10
drugs to be put through the Medicare drug price negotiation program, which is currently subject to several constitutional challenges.
The outcomes of these challenges on the IRA, and the effect of the IRA on our business and the healthcare industry in general, are not
yet known.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There has been increasing
legislative and enforcement interest in the United States with respect to product pricing practices. Specifically, there have been several
recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency
to product pricing, reduce the cost of products under Medicare, review the relationship between pricing and manufacturer patient programs,
and reform government program reimbursement methodologies for drugs. The U.S. Department of Health and Human Services (&#8220;HHS&#8221;)
has already started the process of soliciting feedback on some of these measures and, at the same time, is immediately implementing others
under its existing authority. It is unclear what effect such legislative and enforcement interest may have on prescription devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that these and
other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward
pressure on the price that we receive for any marketed product, which could have an adverse effect on patients for our product candidates.
Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private
payers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been, and likely
will continue to be, legislative and regulatory proposals at the foreign, federal and state levels in the U.S. directed at broadening
the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or
other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Such
reforms could have an adverse effect on anticipated revenue from products that we may successfully develop and for which we may obtain
regulatory marketing authorization and may affect our overall financial condition and ability to develop product candidates. If we or
any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or
policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future product candidates
we may develop may lose any regulatory marketing authorization that may have been obtained and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, there
have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the ACA was
enacted, which substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted
the U.S. pharmaceutical industry. The ACA, among other things, subjected therapeutic biologics to potential competition by lower-cost
biosimilars, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated
for drugs and therapeutic biologics that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates
owed by manufacturers under the Medicaid Drug Rebate Program, extended the rebate program to individuals enrolled in Medicaid managed
care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs and therapeutic biologics
and added a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts
off negotiated prices of applicable brand drugs and therapeutic biologics to eligible beneficiaries during their coverage gap period
as a condition for the manufacturer&#8217;s outpatient drugs and therapeutic biologics to be covered under Medicare Part D.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">However, some provisions
of the ACA have yet to be fully implemented, and certain provisions have been subject to judicial and Congressional challenges, as well
as efforts by the Trump Administration to repeal or replace certain aspects of the ACA. For example, since January 2017, President Trump
has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA.
Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. On December 20, 2017,
Congress passed The Tax Cuts and Jobs Act, which includes a provision repealing the individual mandate under the ACA, effective January
1, 2019. We continue to evaluate how the ACA and recent efforts to repeal and replace or limit the implementation of the ACA will impact
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted in the United States since the ACA was enacted. On August 2, 2011, the Budget Control Act of 2011
among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with
recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals,
thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of
Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative
amendments to the statute, will remain in effect through 2024 unless additional Congressional action is taken. On January 2, 2013, the
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types
of providers. Additionally, there has been heightened governmental scrutiny recently over the manner in which manufacturers set prices
for their marketed products. For example, there have been several recent Congressional inquiries and proposed and enacted federal and
state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and
manufacturer patient programs, and reform government program reimbursement methodologies for drug products. These new laws and initiatives
may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our future
customers and accordingly, our financial operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, on December 13,
2016, President Obama signed the 21st Century Cures Act (the &#8220;<b>Cures Act</b>&#8221;), into law. Among other provisions, the Cures
Act reauthorized the existing priority review voucher program for certain drugs intended to treat rare pediatric diseases until 2020;
created a new priority review voucher program for drug applications determined to be material national security threat medical countermeasure
applications; revised the FDCA to streamline review of combination product applications; required FDA to evaluate the potential use of
&#8220;real world evidence&#8221; to help support approval of new indications for approved drugs; provided a new &#8220;limited population&#8221;
approval pathway for antibiotic and antifungal drugs intended to treat serious or life-threatening infections; and authorized FDA to
designate a drug as a &#8220;regenerative advanced therapy,&#8221; thereby making it eligible for certain expedited review and approval
designations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that additional
state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state
governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional
pricing pressures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we or existing or future partners, manufacturers
or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could
affect our ability to develop, market and sell our products and may harm our reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare providers, physicians
and third-party payors, among others, will play a primary role in the prescription and recommendation of any product candidates for which
we obtain marketing approval. Our future arrangements with third-party payors and customers, among others, may expose us to broadly applicable
fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships
through which we market, sell and distribute our product candidates for which we obtain marketing approval. Restrictions under applicable
federal and state healthcare laws and regulations, include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal Anti-Kickback Statute, which prohibits, among other things, a person or entity from knowingly and willfully soliciting, offering,
paying, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an
individual for, or the purchase, lease order, arranging for or recommendation of, any good, facility, item or service, for which payment
may be made, in whole or in part, by a federal healthcare program, such as Medicare or Medicaid. A person or entity does not need to
have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violation of the federal
Anti-Kickback Statue carries criminal penalties and fines as well as administrative sanctions under the Civil Money Penalties Law. In
addition, a violation of the Anti-Kickback Statute can form the basis for a violation of the federal False Claims Act;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal civil and criminal false claims laws, including the federal False Claims Act, and civil monetary penalties laws that impose criminal
and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting,
or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to
avoid, decrease or conceal an obligation to pay money to the federal government. In addition, the government may assert that a claim
including items and services resulting from a referral made in violation of the federal Anti-Kickback Statute constitutes a false or
fraudulent claim for purposes of the federal False Claims Act;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
U.S. federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which imposes criminal and civil liability
for executing a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a
material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or
services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific
intent to violate it in order to have committed a violation;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and its implementing
regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare
providers, health plans, and healthcare clearinghouse as well as their business associates that perform certain services involving the
use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding
the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals
and regulatory authorities of certain breaches of security of individually identifiable health information;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal false statements statute, which prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making
any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
federal transparency requirements known as the federal Physician Payments Sunshine Act, created as part of ACA, which requires certain
manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicare or the Children&#8217;s
Health Insurance Program to report annually to CMS information related to payments and other transfers of value made by that entity to
physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;
and</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
analogous local, state and foreign laws and regulations, such as state anti-kickback and false claims laws that may apply to healthcare
items or services reimbursed by third-party payors, including private insurers; local, state and foreign transparency laws that require
manufacturers to report information related to payments and transfers of value to other health care providers and health care entities,
or marketing expenditures; state laws that require pharmaceutical companies to register certain employees engaged in marketing activities
in the location and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government; and state and foreign laws governing the privacy and security of health information in certain
circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance
efforts.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Ensuring that our future business
arrangements with third parties comply with applicable healthcare laws and regulations could involve substantial costs. If our operations
are found to be in violation of any such requirements, we may be subject to penalties, including criminal and significant civil monetary
penalties, damages, fines, individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation
in government healthcare programs, integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production,
denial or withdrawal of pre-marketing product approvals, private qui tam actions brought by individual whistleblowers in the name of the
government, refusal to allow us to enter into supply contracts, including government contracts, and the curtailment or restructuring of
our operations, any of which could adversely affect our ability to operate our business and our results of operations. Although effective
compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely
eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert
our management&#8217;s attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining
compliance with applicable laws and regulations may be costly to us in terms of money, time and resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If we fail to comply with U.S. and foreign
regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and
subject us to other penalties that could materially harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive marketing
and commercialization approval of a product candidate, we will be subject to continuing regulatory requirements, including in relation
to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available,
both in the United States and any foreign jurisdiction in which we seek regulatory approval. The FDA has significant post-market authority,
including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials
to evaluate safety risks related to the use of a product or to require withdrawal of the product from the market. The FDA also has the
authority to require a Risk Evaluation and Mitigation Strategy (a &#8220;<b>REMS</b>&#8221;), after approval, which may impose further
requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing
facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory
agencies, including for continued compliance with cGMP requirements. The discovery of any new or previously unknown problems with our
third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product, manufacturer or facility,
including withdrawal of the product from the market. We intend to rely on third-party manufacturers, and we will not have control over
compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to
regulatory requirements and continuing regulatory review. If we or our existing or future partners, manufacturers or service providers
fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our
products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal
by the FDA to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product
recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions,
injunction, civil penalties and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Even if we are able to commercialize any
product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement
policies, which would harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ability to commercialize
any products successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related
treatments will be available from third-party payors, such as government authorities, private health insurers, and health maintenance
organizations. Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse
all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs,
such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use our future
product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product
candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Cost-containment is a
priority in the U.S. healthcare industry and elsewhere. As a result, government authorities and other third-party payors have
attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly,
third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging
the prices charged for medical products. Third-party payors also may request additional clinical evidence beyond the data required
to obtain marketing approval, requiring a company to conduct expensive pharmacoeconomic studies in order to demonstrate the medical
necessity and cost-effectiveness of its product. We cannot be sure that coverage and adequate reimbursement will be available for
any product that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Coverage and
reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage
and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize any
product candidate for which we obtain marketing approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, the regulations
that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country.
Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the
pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains
subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for
a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly
for lengthy time periods and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse
pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates
obtain regulatory approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are subject to U.S. and foreign anti-corruption
and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal and/or civil
liability and harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the U.S.
Foreign Corrupt Practices Act of 1977, as amended (the &#8220;<b>FCPA</b>&#8221;), the U.S. domestic bribery statute contained in 18 U.S.C.
&#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws
in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees,
agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly
or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of<b>&#160;</b>government
agencies and government-affiliated hospitals, universities, and other organizations. In addition, we may engage third-party intermediaries
to promote our clinical research activities abroad and/or to obtain necessary permits, licenses, and other regulatory approvals. We can
be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors,
partners, and agents, even if we do not explicitly authorize or have actual knowledge of such activities. We have adopted a Code of Business
Conduct and Ethics, which was effective upon the Closing of the Business Combination, and expect to prepare and implement policies and
procedures to ensure compliance with such code. The Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption
laws applicable to our business throughout the world. However, we cannot assure you that our employees and third-party intermediaries
will comply with this code or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject
us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits,
significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain
persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. If any subpoenas,
investigations, or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in
any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In
addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources
and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us
to appoint an independent compliance monitor which can result in added costs and administrative burdens.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Comprehensive tax reform bills could adversely affect our business
and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. government is
in the process of enacting comprehensive tax legislation that includes significant changes to the taxation of business entities.
These changes include, among others, (i) a permanent reduction to the corporate income tax rate, (ii) a partial limitation on the
deductibility of business interest expense, (iii) a shift of the U.S. taxation of multinational corporations from a tax on worldwide
income to a territorial system (along with certain rules designed to prevent erosion of the U.S. income tax base) and (iv) a
one-time tax on accumulated offshore earnings held in cash and illiquid assets, with the latter taxed at a lower rate.
Notwithstanding the reduction in the corporate income tax rate, the overall impact of this tax reform is uncertain, and our business
and financial condition could be adversely affected. This prospectus does not discuss any such tax legislation or the manner in
which it might affect purchasers of our Common Stock. We urge our stockholders to consult with their legal and tax advisors with
respect to any such legislation and the potential tax consequences of investing in our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our ability to utilize our net operating
loss carryforwards and certain other tax attributes may be limited.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Sections 382 and 383
of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a
greater than 50 percentage points change (by value) in the ownership of its equity over a rolling three-year period), the corporation&#8217;s
ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income
and taxes may be limited.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">We may have experienced
such ownership changes in the past, and we may experience ownership changes in the future, some of which are outside of our control.
As of December 31, 2024, we had federal net operating loss carryforwards of approximately $85.9 million, and our ability to utilize those
net operating loss carryforwards could be limited by an &#8220;ownership change&#8221; as described above, which could result in increased
tax liability to our company.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Organization and Structure</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Charter and the Bylaws provide that
the Court of Chancery of the State of Delaware is the sole and exclusive forum for substantially all disputes between us and our stockholders,
which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers,
or employees.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter and the Bylaws
provide that, unless we consent in writing to the selection of an alternative forum, the (a) Court of Chancery (the &#8220;<b>Chancery
Court</b>&#8221;) of the State of Delaware (or, in the event that the Chancery Court does not have jurisdiction, the federal district
court for the District of Delaware or other state courts of the State of Delaware) shall, to the fullest extent permitted by law, be the
sole and exclusive forum for: (i) any derivative action, suit or proceeding brought on our behalf; (ii) any action, suit or proceeding
asserting a claim of breach of fiduciary duty owed by any of our directors, officers, or stockholders to us or to our stockholders; (iii)
any action, suit or proceeding asserting a claim arising pursuant to the DGCL, the Charter or the Bylaws; or (iv) any action, suit or
proceeding asserting a claim governed by the internal affairs doctrine, and (b) subject to the foregoing, the federal district courts
of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under
the Securities Act. Notwithstanding the foregoing, such forum selection provisions shall not apply to suits brought to enforce any liability
or duty created by the Exchange Act or any other claim for which the federal courts of the United States have exclusive jurisdiction.
The exclusive forum provision may increase the costs for a stockholder to bring a claim or limit a stockholder&#8217;s ability to bring
a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage
such lawsuits against us and our directors, officers, and other employees. Alternatively, if a court were to find the choice of forum
provision contained in the Charter to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving
such action in other jurisdictions, which could harm our business, results of operations, and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, Section 22 of
the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder. As noted above, our Charter and the Bylaws provide that the federal
district courts of the United States of America shall have jurisdiction over any action arising under the Securities Act. Accordingly,
there is uncertainty as to whether a court would enforce such provision. Our stockholders will not be deemed to have waived our compliance
with the federal securities laws and the rules and regulations thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Anti-takeover provisions in our governing
documents and under Delaware law could make an acquisition of us more difficult, limit attempts by our stockholders to replace or remove
our current management and limit the market price of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Charter, the Bylaws and
Delaware law contain provisions that could have the effect of rendering more difficult, delaying, or preventing an acquisition deemed
undesirable by our Board. Among other things, the Charter and/or Bylaws include the following provisions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">&#160;</td>
    <td style="width: 0.25in; font-size: 10pt">&#9679;</td>
    <td style="text-align: justify; font-size: 10pt">a staggered board, which means that our Board is classified into three classes of directors with staggered three-year terms and directors are only able to be removed from office for cause;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">limitations on convening special stockholder meetings, which could make it difficult for our stockholders to adopt desired governance changes;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">a prohibition on stockholder action by written consent, which means that our stockholders will only be able to take action at a meeting of stockholders and will not be able to take action by written consent for any matter;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">a forum selection clause, which means certain litigation against us can only be brought in Delaware;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">the authorization of undesignated preferred stock, the terms of which may be established and shares of which may be issued without further action by our stockholders; and</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="text-align: justify; width: 0.5in">&#160;</td>
    <td style="text-align: justify; width: 0.25in">&#9679;</td>
    <td style="text-align: justify">advance notice procedures, which apply for stockholders to nominate candidates for election as directors or to bring matters before an annual meeting of stockholders.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These provisions, alone or
together, could delay or prevent hostile takeovers and changes in control or changes in our management. As a Delaware corporation, we
are also subject to provisions of Delaware law, including Section 203 of the DGCL, which prevents interested stockholders, such as certain
stockholders holding more than 15% of our outstanding Common Stock, from engaging in certain business combinations unless (i) prior to
the time such stockholder became an interested stockholder, the board of directors approved the transaction that resulted in such stockholder
becoming an interested stockholder, (ii) upon consummation of the transaction that resulted in such stockholder becoming an interested
stockholder, the interested stockholder owned at least 85% of the Common Stock, or (iii) following board approval, such business combination
receives the approval of the holders of at least two-thirds of our outstanding Common Stock not held by such interested stockholder at
an annual or special meeting of stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any provision of the Charter,
the Bylaws or Delaware law that has the effect of delaying, preventing or deterring a change in control could limit the opportunity for
our stockholders to receive a premium for their shares of our Common Stock and could also affect the price that some investors are willing
to pay for our Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our management team may not successfully or efficiently manage
its transition to being a public company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company, we have
incurred new obligations relating to our reporting, procedures, and internal controls. These new obligations and attendant scrutiny will
require investments of significant time and energy from our executives and could divert their attention away from the day-to-day management
of our business, which in turn could adversely affect our financial condition or operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of our management
team have limited experience managing a publicly traded company, interacting with public company investors, and complying with the increasingly
complex laws, rules and regulations that specifically govern public companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will incur significant increased expenses
and administrative burdens as a public company, which could have an adverse effect on its business, financial condition and results of
operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the
consummation of the Business Combination, we face increased legal, accounting, administrative and other costs and expenses as a
public company that we did not incur as a private company. The Sarbanes-Oxley Act of 2002 (the &#8220;<b>Sarbanes-Oxley
Act</b>&#8221;), including the requirements of Section 404, as well as rules and regulations subsequently implemented by the SEC,
the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the rules and regulations promulgated and to be
promulgated thereunder, Public Company Accounting Oversight Board (the &#8220;<b>PCAOB</b>&#8221;) and the securities exchanges,
impose additional reporting and other obligations on public companies. Compliance with public company requirements will increase
costs and make certain activities more time-consuming. A number of those requirements have and will require us to carry out
activities we have not done previously. For example, we have created new Board committees and will adopt new internal controls and
disclosure controls and procedures. In addition, expenses associated with SEC reporting requirements will be incurred. Furthermore,
if any issues in complying with those requirements are identified, we could incur additional costs rectifying those issues, and the
existence of those issues could adversely affect our reputation or investor perceptions of us. It may also be more expensive to
obtain director and officer liability insurance. Risks associated with our status as a public company may make it more difficult to
attract and retain qualified persons to serve on the Board or as executive officers. The additional reporting and other obligations
imposed by these rules and regulations will increase legal and financial compliance costs and the costs of related legal, accounting
and administrative activities. These increased costs will require us to divert a significant amount of money that could otherwise be
used to expand the business and achieve strategic objectives. Advocacy efforts by stockholders and third parties may also prompt
additional changes in governance and reporting requirements, which could further increase costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the need to establish
the corporate infrastructure demanded of a public company may also divert management&#8217;s attention from implementing our business
strategy, which could prevent us from improving our business, results of operations and financial condition. We have made, and will continue
to make, changes to our internal control over financial reporting, including IT controls, and procedures for financial reporting and accounting
systems to meet our reporting obligations as a public company. However, the measures we take may not be sufficient to satisfy our obligations
as a public company. If we do not continue to develop and implement the right processes and tools to manage our changing enterprise and
maintain our culture, our ability to compete successfully and achieve our business objectives could be impaired, which could negatively
impact our business, financial condition and results of operations. In addition, we cannot predict or estimate the amount of additional
costs we may incur to comply with these requirements. We anticipate that these costs will materially increase our general and administrative
expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">We also spent considerable
management time in connection with our restatement of previously issued financial statements as of the periods ended September 30, 2024,
December 31, 2023 and December 31, 2022 for Abpro Corporation. This was due to prior period accounting errors resulting from the understatement
of liabilities under one of the Company&#8217;s license agreements, as disclosed in Item 9A of the Company&#8217;s Annual Report on Form
10-K for the year ended December 31, 2024, filed with the SEC on April 15, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We have identified material weakness in
our internal control over financial reporting, which could affect our ability to ensure timely and reliable financial reports and weaken
investor confidence in our financial reporting.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Under the supervision
and with the participation of our management, including our principal executive officer and principal financial officer, we conducted
an evaluation of the effectiveness of our disclosure controls and procedures as of September 30, 2025. Based on such evaluation, our
principal executive officer and principal financial officer has concluded that our disclosure controls and procedures contained material
weaknesses as of September 30, 2025, due to the Company having inadequate segregation of duties over internal wire transfer authorization
and access to bank accounts, inadequate existing control to ensure timely identification and evaluation of contractual obligations such
as license agreements, and failing to design and maintain formal written policies and procedures regarding internal controls over financial
reporting. We may also identify material weaknesses or other deficiencies in our disclosure controls and procedures in the future.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A material weakness in internal
control over financial reporting is a deficiency, or a combination of deficiencies, such that there is a reasonable possibility that a
material misstatement of our annual or interim financial statements will not be prevented, or detected and corrected on a timely basis.
Material weaknesses in internal control over financial reporting could limit our ability to prevent or detect a misstatement of our accounts
or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable
to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange
listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. We cannot
assure you that the measures we have taken to date, or any measures we may take in the future, will be sufficient to avoid potential future
material weaknesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To address these material
weaknesses, management has devoted and continues to devote significant effort and resources to the remediation and improvement of its
internal controls over financial reporting by enhancing its authorization procedures and access controls with respect to wire transfers
and bank account access, implementing and improving controls to ensure timely accounting review of significant contractual obligations
such as license agreements and designing and maintaining formal written policies and procedures regarding internal controls over financial
reporting. These material weaknesses will not be considered remediated until our controls are effectively designed and operational for
a sufficient period of time, tested, and management concludes that these controls are operating effectively. Failing to develop or maintain
effective internal control over financial reporting may result in a misstatement of our financial statements or cause investors to lose
confidence in us, which could have a material adverse effect on our business, financial condition or results of operations. These remediation
measures may be time consuming and costly, and we can offer no assurance that these initiatives will ultimately have the intended effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We reached a determination to restate certain
of our previously issued consolidated financial statements as a result of the identification of errors in previously issued consolidated
financial statements, which resulted in unanticipated costs and may affect investor confidence and raise reputational issues.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As discussed in the Explanatory
Note, in Note 2 of our consolidated financial statements for the years ended December 31, 2024 and 2023, Summary of Significant Accounting
Policies included in this prospectus, we reached a determination to restate certain of our historical consolidated financial statements
and related disclosures for the Non-Reliance Periods disclosed in that note after identifying accounting errors resulting from the understatement
of liabilities under one of its license agreements. As a result, we have incurred unanticipated costs for accounting and legal fees in
connection with or related to the restatement, and have become subject to a number of additional risks and uncertainties, which may affect
investor confidence in the accuracy of our financial disclosures and may raise reputational risks for our business, both of which could
harm our business and financial results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our disclosure controls and procedures may
not prevent or detect all errors or acts of fraud.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We must design our disclosure
controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is
accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the
rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how
well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple
error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people
or by an unauthorized override of the controls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Changes in accounting rules and regulations,
or interpretations thereof, could result in unfavorable accounting charges or require us to change our compensation policies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accounting methods and policies
for public companies are subject to review, interpretation and guidance from our independent registered accounting firm and relevant accounting
authorities, including the SEC. Changes to accounting methods or policies, or interpretations thereof, may require us to reclassify, restate
or otherwise change or revise our consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We will need to improve our operational
and financial systems to support our expected growth, increasingly complex business arrangements, and rules governing revenue and expense
recognition and any inability to do so will adversely affect our billing and reporting.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To manage the expected
growth of our operations and increasing complexity, we will need to improve our operational and financial systems, procedures, and
controls and continue to increase systems automation to reduce reliance on manual operations. Any inability to do so will affect our
manufacturing operations, customer billing and reporting. Our current and planned systems, procedures and controls may not be
adequate to support our complex arrangements and the rules governing revenue and expense recognition for our future operations and
expected growth. Delays or problems associated with any improvement or expansion of our operational and financial systems and
controls could adversely affect our relationships with our customers, cause harm to our reputation and brand and could also result
in errors in our financial and other reporting. We expect that complying with these rules and regulations will substantially
increase our legal and financial compliance costs and will make some activities more time-consuming and costly. These increased
costs will increase our net loss and we cannot predict or estimate the amount or timing of additional costs we may incur to respond
to these requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our management has limited experience in
operating a U.S.-listed public company.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management has limited
experience in the management of a U.S.-listed public company. Our management team may not successfully or effectively manage our transition
to a U.S.-listed public company that will be subject to significant regulatory oversight and reporting obligations under federal securities
laws. Their limited experience in dealing with the increasingly complex laws pertaining to public companies could be a significant disadvantage
in that it is likely that an increasing amount of their time may be devoted to these activities which will result in less time being devoted
to the management and growth of the combined company. We may not have adequate personnel with the appropriate level of knowledge, experience,
and training in the accounting policies, practices or internal controls over financial reporting required of U.S.-listed public companies.
The development and implementation of the standards and controls necessary for the combined company to achieve the level of accounting
standards required of a public company listed on a public exchange in the United States may require costs greater than expected. It is
possible that we will be required to expand our employee base and hire additional employees to support our operations as a public company,
which will increase our operating costs in future periods.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We are an &#8220;emerging growth company,&#8221;
and our reduced SEC reporting requirements may make our shares less attractive to investors.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &#8220;emerging
growth company&#8221; as defined in the JOBS Act. We will remain an &#8220;emerging growth company&#8221; until the earliest to occur
of (i) the last day of the fiscal year (a) following the fifth anniversary of the of the date of the completion of the ACAB IPO, (b) in
which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which
means the market value of our Common Stock held by non-affiliates exceeds $700 million as of the last business day of our prior second
fiscal quarter, and (ii) the date on which we issued more than $1.0 billion in non-convertible debt during the prior three-year period.
We intend to take advantage of exemptions from various reporting requirements that are applicable to most other public companies, such
as an exemption from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring our independent registered public accounting
firm provide an attestation report on the effectiveness of our internal control over financial reporting and reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We cannot predict
if investors will find our shares less attractive because we intend to rely on certain of these exemptions and benefits under the JOBS
Act. If some investors find our shares less attractive as a result, there may be a less active, liquid and/or orderly trading market for
our shares and the market price and trading volume of our shares may be more volatile and decline significantly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to an Investment in of Our Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>An active market for our securities may not develop, which would
adversely affect the liquidity and price of our securities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The price of our securities
may vary significantly due to factors specific to us as well as to general market or economic conditions. Furthermore, an active trading
market for our securities may never develop or, if developed, it may not be sustained. You may be unable to sell your securities unless
a market can be established and sustained.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our failure to meet Nasdaq&#8217;s continued listing requirements
could result in a delisting of our shares.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 2, 2025, the
Company received written notice (the &#8220;<b>Notice</b>&#8221;) from the Listing Qualifications Department Staff of Nasdaq (the
&#8220;<b>Staff</b>&#8221;) notifying the Company that, based on the closing bid price of the Company&#8217;s Common Stock for the
last 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on
The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per
share (the &#8220;<b>Minimum Bid Price Requirement</b>&#8221;), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to
meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business days. Pursuant to
the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain compliance with
the Minimum Bid Price Requirement. The letter stated that the Company had 180 calendar days, or until September 29, 2025, to regain
compliance. To regain compliance, the closing bid price of the Company&#8217;s Common Stock had to be at least $1.00 per share for a
minimum of 10 consecutive business days prior to September 29, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On April 10, 2025, the
Company received two letters from the Staff of Nasdaq. One letter (the &#8220;<b>MVPHS Notice</b>&#8221;) indicated that based upon Nasdaq&#8217;s
review of the Company&#8217;s Market Value of Publicly Held Shares (&#8220;<b>MVPHS</b>&#8221;) for the last 30 consecutive business
days prior to the date of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which
requires listed securities to maintain a minimum MVPHS of $15,000,000 (the &#8220;<b>MVPHS Requirement</b>&#8221;). The second letter
notified the Company that from February 20, 2025, to April 9, 2025, the Company&#8217;s Market Value of Listed Securities (&#8220;MVLS&#8221;)
was below the minimum of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A)
(the &#8220;<b>MVLS Requirement</b>&#8221;). Each letter stated that the Company had 180 calendar days, or until October 7, 2025, to
regain compliance.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 30, 2025, the
Company received a letter from Nasdaq notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement
during the compliance period. Accordingly, the Company timely requested a hearing before the appeal panel (the &#8220;<b>Panel</b>&#8221;),
which stayed the suspension of the Company&#8217;s securities with Nasdaq pending the Panel&#8217;s decision or any extension of time
provided by the Panel to regain compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 14, 2025, the Company
received a letter (the &#8220;<b>Notice</b>&#8221;) from Nasdaq notifying the Company that it had not regained compliance with either
the MVPHS Requirement or the MVLS Requirement during the compliance period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Hearing was held on
October 30, 2025. During the Hearing, the Company presented its plans to regain compliance with the Minimum Bid Price Requirement, the
MVPHS Requirement and the MVLS Requirement. On November 10, 2025, the Company received a decision letter from the Panel granting the
Company&#8217;s request for continued listing on The Nasdaq Stock Market, subject to the Company&#8217;s strict adherence to certain
interim deadlines and conditions. The Panel will maintain jurisdiction over the Company&#8217;s listing through March 30, 2026, and may
reconsider the terms of the exception or delist the Company if it fails to meet any of the imposed deadlines or becomes deficient with
any listing rule during this period. There can be no assurance that the Company will be able to meet the conditions imposed by the Panel
or regain and maintain compliance with Nasdaq&#8217;s listing requirements. Failure to do so may result in the delisting of the Company&#8217;s
securities from Nasdaq.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">If we are unable to regain
compliance with the Minimum Bid Price Rule, MVPHS Requirement and MVLS Requirement, and maintain compliance with other continued listing
requirements, Nasdaq may take steps to delist our shares. Such a delisting would likely have a negative effect on the price of our shares
and would impair your ability to sell or purchase our shares when you wish to do so. In the event of a delisting, we can provide no assurance
that any action taken by us to restore compliance with listing requirements would allow our shares to become listed again, stabilize
the market price or improve the liquidity of our shares, prevent our shares from dropping below Nasdaq&#8217;s Minimum Bid Price Requirement
or prevent future non-compliance with Nasdaq&#8217;s listing requirements.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If Nasdaq delists our securities
from trading on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities
could be quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a limited availability of market quotations for our securities;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">reduced liquidity for our securities;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a determination that our Common Stock is &#8220;penny stock&#8221;
which will require brokers trading in the Common Stock to adhere to more stringent rules and possibly result in a reduced level of trading
activity in the secondary trading market for our securities;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a limited amount of news and analyst coverage; and</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a decreased ability to issue additional securities or obtain
additional financing in the future.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Reverse Stock Split may decrease the
liquidity of the shares of our Common Stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective October 31, 2025,
we effected a reverse stock split of our Common Stock at a 1-for-30 ratio to regain compliance with Nasdaq&#8217;s Bid Price Rule. The
liquidity of the shares of our Common Stock may be affected adversely by the Reverse Stock Split given the reduced number of shares that
are outstanding following the Reverse Stock Split. In addition, the Reverse Stock Split increased the number of stockholders who own odd
lots (less than 100 shares) of our Common Stock, creating the potential for such stockholders to experience an increase in the cost of
selling their shares and greater difficulty effecting such sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Following a reverse stock split, the resulting
market price of our Common Stock may not attract new investors, including institutional investors, and may not satisfy the investing requirements
of those investors. Consequently, the trading liquidity of our Common Stock may not improve. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe that a
higher market price of our Common Stock may help generate greater or broader investor interest, there can be no assurance that a reverse
stock split, including the Reverse Stock Split, will result in a share price that will attract new investors, including institutional
investors. In addition, there can be no assurance that the market price of our Common Stock will satisfy the investing requirements of
those investors. As a result, the trading liquidity of our Common Stock may not necessarily improve.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The Common Stock being registered in this
prospectus represent a substantial percentage of our public float and of our outstanding Common Stock, and the sale of such shares could
cause the market price of Common Stock to decline significantly.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="background-color: white">This
prospectus relates to the offer and resale from time to time by the Selling Securityholders of up to 9,775,017 shares of Common Stock
issuable pursuant to the SEPA with YA.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Common Stock being
registered for resale in this prospectus represent a substantial percentage of our public float and of our outstanding Common Stock.
The number of shares being registered in this prospectus represents approximately 360% of the total Common Stock outstanding as of November
28, 2025, which was 2,716,278 shares of Common Stock. The sale of the securities being registered in this prospectus, or the perception
in the market that such sales may occur, could result in a significant decline in the public trading price of our Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>The market price of our Common Stock may
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price of our Common
Stock may decline for a number of reasons including if:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investors react negatively to the prospects of our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of the Business Combination on our business and prospects is not consistent with the expectations of financial or industry analysts; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we do not achieve the perceived benefits of the Business Combination as rapidly or to the extent anticipated by financial or industry analysts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or reports about our business or publish negative reports about our business, our share price and trading volume could
decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for
our shares will depend on the research and reports that securities or industry analysts publish about us or our business. Currently,
we do not have any analyst coverage and may not obtain analyst coverage in the future. In the event we obtain analyst coverage, we
will not have any control over such analysts. If one or more of the analysts who cover us downgrade our shares or change their
opinion of our shares, the share price would likely decline. If one or more of these analysts cease coverage of us or we or fail to
regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading
volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Our Common Stock price may decline and
you could lose all or part of your investment as a result.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading price of our Common
Stock is likely to be volatile. The stock market recently has experienced extreme volatility. This volatility often has been unrelated
or disproportionate to the operating performance of particular companies. You may not be able to resell your Common Stock at an attractive
price due to a number of factors such as those listed in &#8220;- <i>Risks Related to Our Business and Industry</i>&#8221; and the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results of operations that vary from the expectations of securities analysts and investors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">results of operations that vary from our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in expectations as to our future financial performance, including financial estimates and investment recommendations by securities analysts and investors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">declines in the market prices of stocks generally;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">strategic actions by us or our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements by us or our competitors of significant contracts, acquisitions, joint ventures, other strategic relationships or capital commitments;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">announcements of estimates by third parties of actual or anticipated changes in the size of our customer base or the level of customer engagement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in general economic or market conditions or trends in our industry or markets;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in business or regulatory conditions, including new laws or regulations or new interpretations of existing laws or regulations applicable to our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">additional securities being sold or issued into the market by us or any of the existing shareholders or the anticipation of such sales, including if we issue shares to satisfy restricted stock unit related tax obligations or if existing shareholders sell shares into the market when applicable &#8220;lock-up&#8221; periods end;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">investor perceptions of the investment opportunity associated with our Common Stock relative to other investment alternatives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the public&#8217;s response to press releases or other public announcements by us or third parties, including our filings with the SEC;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">litigation involving us, our industry, or both, or investigations by regulators into our operations or those of our competitors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">guidance, if any, that we provide to the public, any changes in this guidance or our failure to meet this guidance;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the development and sustainability of an active trading market for our Common Stock;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the market&#8217;s reaction to our reduced disclosure and other requirements as a result of being an &#8220;emerging growth company&#8221; under the JOBS Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the size of our public float;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">actions by institutional or activist shareholders;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developments in new legislation and pending lawsuits or regulatory actions, including interim or final rulings by judicial or regulatory bodies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in senior management or key personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">changes in accounting standards, policies, guidelines, interpretations or principles; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">other events or factors, including those resulting from pandemics, natural disasters, war, acts of terrorism or responses to these events.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These broad market and industry
fluctuations may adversely affect the market price of our Common Stock, regardless of our actual operating performance. In addition, price
volatility may be greater if the public float and trading volume of our Common Stock is low. In the past, following periods of market
volatility, shareholders have instituted securities class action litigation. If we are involved in securities litigation, it could have
a substantial cost and divert resources and the attention of executive management from our business regardless of the outcome of such
litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Concentration of ownership among existing
executive officers, directors and their affiliates, including the investment funds they represent, may prevent new investors from influencing
significant corporate decisions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of November 28, 2025,
our executive officers, directors and their affiliates, including the investment funds they represent, as a group beneficially own approximately
12.6% of our Common Stock. As a result, these stockholders will be able to exercise a significant level of control over all matters requiring
stockholder approval, including the election of directors, amendment of the Charter and approval of significant corporate transactions.
This control could have the effect of delaying or preventing a change of control of our company or changes in management and will make
the approval of certain transactions difficult or impossible without the support of these stockholders.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Because there are no current plans to pay
cash dividends on our Common Stock for the foreseeable future, you may not receive any return on investment unless you sell your Common
Stock at a price greater than what you paid for it.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to retain future
earnings, if any, for future operations, expansion and debt repayment, and there are no current plans to pay any cash dividends for the
foreseeable future. The declaration, amount and payment of any future dividends on our Common Stock will be at the sole discretion of
our Board. Our Board may take into account general and economic conditions, our financial condition and results of operations, our available
cash and current and anticipated cash needs, capital requirements, contractual, legal, tax and regulatory restrictions, implications of
the payment of dividends by us to our shareholders or by our subsidiaries to us and such other factors as our Board may deem relevant.
As a result, you may not receive any return on an investment in our Common Stock unless you sell your Common Stock for a price greater
than that which you paid for it.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our shareholders may experience dilution in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The percentage of our Common
Stock owned by current shareholders may be diluted in the future because of equity issuances for acquisitions, capital market transactions
or otherwise, including, without limitation, equity awards that we may grant to our directors, officers and employees, exercise of our
warrants. Such issuances may have a dilutive effect on our earnings per share, which could adversely affect the market price of our Common
Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>If securities or industry analysts do not
publish research or reports about our business, if they change their recommendations regarding our Common Stock or if our operating results
do not meet their expectations, our Common Stock price and trading volume could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market for our
Common Stock will depend in part on the research and reports that securities or industry analysts publish about us or our businesses.
If no securities or industry analysts commence coverage of us, the trading price for our Common Stock could be negatively impacted. In
the event securities or industry analysts initiate coverage, if one or more of the analysts who cover us downgrade our securities or publish
unfavorable research about its businesses, or if our operating results do not meet analyst expectations, the trading price of our Common
Stock would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, demand for
our Common Stock could decrease, which might cause our Common Share price and trading volume to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Future sales, or the perception of future
sales, by us or our shareholders in the public market could cause the market price for our Common Stock to decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The sale of our Common Stock
in the public market, or the perception that such sales could occur, could harm the prevailing market price of our Common Stock. These
sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future
at a time and at a price that it deems appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The sale of the securities
being registered pursuant to the registration statement of which this prospectus forms a part, or the perception in the market that such
sales may occur, could result in a significant decline in the market price of shares of our Common Stock. These factors could also make
it more difficult for us to raise additional funds through future offerings of our shares of Common Stock or other securities.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the shares of
our Common Stock reserved for future issuance under the New Abpro Incentive Plan will become eligible for sale in the public market once
those shares are issued, subject to provisions relating to various vesting agreements, lock-up agreements and, in some cases, limitations
on volume and manner of sale applicable to affiliates under Rule 144, as applicable. The number of shares reserved for future issuance
under the New Abpro Incentive Plan is 208,026 shares of Common Stock. In addition, the New Abpro Incentive Plan includes an evergreen
feature that will allow our Board, in its sole discretion, to reserve additional shares of Common Stock for future issuance under the
New Abpro Incentive Plan each calendar year, Beginning January 1, 2026 and ending on and including January 1, 2034 equal to the lesser
of 5% of the shares of Common Stock outstanding on the final day of the immediately preceding calendar year and a smaller number of shares
determined by the Board. We have filed a registration statement on Form S-8 under the Securities Act to register shares of our Common
Stock or securities convertible into or exchangeable for shares of our Common Stock issued pursuant to the New Abpro Incentive Plan. Accordingly,
shares registered under such registration statement will be available for sale in the open market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the future, we may also
issue securities in connection with investments or acquisitions. The amount of Common Stock issued in connection with an investment or
acquisition could constitute a material portion of the then-outstanding Common Stock. Any issuance of additional securities in connection
with investments or acquisitions may result in additional dilution to our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Sales of our Common Stock, or the perception
of such sales, pursuant to the registration statement of which this prospectus forms a part may have negative pressure on the public trading
price of our Common Stock. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Selling Securityholders
will determine the timing, pricing and rate at which they sell the shares being registered for resale on the registration statement of
which this prospectus forms a part into the public market. Significant sales of Common Stock pursuant to the registration statement of
which this prospectus forms a part may have negative pressure on the public trading price of our Common Stock. The number of shares being
registered in this prospectus represents approximately 360% of the total Common Stock outstanding as of November 28, 2025, which was
2,716,278 shares of Common Stock. Also, even though the current trading price is significantly below the Company&#8217;s initial public
offering price, based on the closing price of our Common Stock on November 28, 2025, certain private investors may have an incentive
to sell their shares, because they will still profit on sales due to the lower prices at which they purchased their shares as compared
to the public investors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On November 26, 2025,
the closing price of the Common Stock was $6.81 per share. The initial public offering price of our units was $300.00 per unit (post-split),
with each unit consisting of one Common Share and one half of one Public Warrant to purchase one Common Share at an exercise price of
$114.90 per share (post-split).</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There is no guarantee that the warrants
will ever be in the money; they may expire worthless or the terms of warrants may be amended.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price for the
warrants is $114.90 per share of Common Stock. There is no guarantee that the Public Warrants will ever be in the money prior to their
expiration, and as such, the warrants may expire worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our warrants
were issued in registered form under a warrant agreement between Continental Stock Transfer &amp; Trust Company, as warrant agent, and
ACAB. The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity
or correct any defective provision, but requires the approval by the holders of at least 50% of the then-outstanding Public Warrants to
make any change that adversely affects the interests of the registered holders of Public Warrants. Accordingly, we may amend the terms
of the Public Warrants in a manner adverse to a holder if holders of at least 50% of the then-outstanding Public Warrants approve of such
amendment. Although our ability to amend the terms of the Public Warrants with the consent of at least 50% of the then-outstanding Public
Warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants,
convert the warrants into cash or stock (at a ratio different than initially provided), shorten the exercise period or decrease the number
of shares of our Common Stock purchasable upon exercise of a warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our Warrant Agreement designates the courts
of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for
certain types of actions and proceedings that may be initiated by holders of our warrants, which could limit the ability of warrant holders
to obtain a favorable judicial forum for disputes with us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Warrant Agreement provides
that, subject to applicable law, (i) any action, proceeding or claim against ACAB arising out of or relating in any way to the warrant
agreement, including under the Securities Act, will be brought and enforced in the courts of the State of New York or the United States
District Court for the Southern District of New York, and (ii) that we irrevocably submit to such jurisdiction, which jurisdiction shall
be the exclusive forum for any such action, proceeding or claim. We will waive any objection to such exclusive jurisdiction and that such
courts represent an inconvenient forum.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the
foregoing, these provisions of the warrant agreement will not apply to suits brought to enforce any liability or duty created by the
Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive
forum. Any person or entity purchasing or otherwise acquiring any interest in any of our warrants shall be deemed to have notice of
and to have consented to the forum provisions in our warrant agreement. If any action, the subject matter of which is within the
scope the forum provisions of the warrant agreement, is filed in a court other than a court of the State of New York or the United
States District Court for the Southern District of New York (a &#8220;<b>foreign action</b>&#8221;) in the name of any holder of our
warrants, such holder shall be deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located in
the State of New York in connection with any action brought in any such court to enforce the forum provisions (an
&#8220;<b>enforcement action</b>&#8221;), and (y) having service of process made upon such warrant holder in any such enforcement
action by service upon such warrant holder&#8217;s counsel in the foreign action as agent for such warrant holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This choice-of-forum provision
may limit a warrant holder&#8217;s ability to bring a claim in a judicial forum that we find favorable for disputes with us, which may
discourage such lawsuits. Alternatively, if a court were to find this provision of our warrant agreement inapplicable or unenforceable
with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving
such matters in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations
and result in a diversion of the time and resources of our management and Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may redeem unexpired warrants prior to
their exercise at a time that is disadvantageous to warrantholders, thereby making their warrants worthless.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have the ability to redeem
outstanding warrants at any time after they become exercisable and prior to their expiration, at a price of $0.30 per warrant, provided
that the last sales price of the Common Stock has been at least $179.70 per share (as adjusted for stock splits, stock dividends, reorganizations,
recapitalizations and the like) for any 20 trading days within the 30 trading-day period ending on the third business day prior to the
date on which we give notice of such redemption and provided certain other conditions are met. Redemption of the outstanding warrants
could force warrantholders (i) to exercise their warrants and pay the exercise price therefor at a time when it may be disadvantageous
for them to do so, (ii) to sell their warrants at the then-current market price when they might otherwise wish to hold their warrants
or (iii) to accept the nominal redemption price which, at the time the outstanding warrants are called for redemption, is likely to be
substantially less than the market value of their warrants. None of the Placement Warrants will be redeemable by us so long as they are
held by the Sponsor or its permitted transferees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>There may be sales of a substantial amount
of our Common Stock by current stockholders, and these sales could cause the price of our Common Stock to fall.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Future sales of the Common
Stock may cause the market price of our securities to drop significantly, even if our business is doing well. Upon the effectiveness
of this registration statement, the Selling Securityholder may sell large amounts of our Common Stock in the open market or in privately
negotiated transactions, which could have the effect of increasing the volatility in our Common Stock share price or putting significant
downward pressure on the price of our Common Stock.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of substantial amounts
of our Common Stock in the public, or the perception that such sales will occur, could adversely affect the market price of our Common
Stock and make it difficult for us to raise funds through securities offerings in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our Warrants may not be exercised at all or may be exercised
on a cashless basis and we may not receive any cash proceeds from the exercise of the Warrants.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The exercise price of the
Warrants may be higher than the prevailing market price of the underlying Common Stock. The exercise price of the Warrants is subject
to market conditions and may not be advantageous if the prevailing market price of the underlying Common Stock is lower than the exercise
price. The cash proceeds associated with the exercise of Warrants to purchase our Common Stock are contingent upon our stock price. The
value of our Common Stock will fluctuate and may not align with the exercise price of the warrants at any given time. If the Warrants
are &#8220;out of the money,&#8221; meaning the exercise price is higher than the market price of our Common Stock, there is a high likelihood
that Warrant holders may choose not to exercise their Warrants. As a result, we may not receive any proceeds from the exercise of the
Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, with regard to
the Warrants, it is possible that we may not receive cash upon their exercise since the Warrants may be exercised on a cashless basis.
A cashless exercise allows warrant holders to convert the warrants into shares of our Common Stock without the need for a cash payment.
Instead of paying cash upon exercise, the Warrant holder would receive a reduced number of shares based on a predetermined formula. As
a result, the number of shares issued through a cashless exercise will be lower than if the Warrants were exercised on a cash basis, which
could impact the cash proceeds we receive from the exercise of such warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Warrants may only be exercised
for cash provided there is then an effective registration statement registering the Common Stock issuable upon the exercise of such Warrants.
If there is not a then-effective registration statement, then such warrants may be exercised on a &#8220;cashless basis,&#8221; pursuant
to an available exemption from registration under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>We may from time to time need additional
financing to fund operations and to expand our business, including to pursue acquisitions and other strategic opportunities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to fund our
current working capital needs in the ordinary course of business and to continue to expand our business with our existing cash and
cash equivalents, and cash flows from operating activities. However, we may from time to time need additional financing to fund
operations and to expand our business. We may, from time to time, explore additional financing sources to lower our cost of capital,
which could include equity, equity-linked and debt financing. In addition, from time to time, we may evaluate acquisitions and other
strategic opportunities. If we elect to pursue any such investments, we may fund them with internally generated funds, bank
financing, the issuance of other debt or equity or a combination thereof. There is no assurance that any such financing or funding
would be available to us on acceptable terms or at all. Sales of securities registered under the registration statement to which
this prospectus forms a part could lower the market price of our Common Stock and warrants. We do not believe this would harm our
chances of raising capital, but could affect the sale price and number of securities we need to issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is no assurance that
the holders of the Warrants will elect to exercise any or all of the Warrants, which could impact our liquidity position. To the extent
that the Warrants are exercised on a &#8220;cashless basis,&#8221; the amount of cash we would receive from the exercise of the Warrants
will decrease. We believe the likelihood that Warrant holders will exercise their Warrants, and therefore the amount of cash proceeds
that we would receive is, among other things, dependent upon the market price of our Common Stock. If the market price for our Common
Stock is less than the applicable exercise price of $114.90, subject to adjustment as described herein, we believe such holders will be
unlikely to exercise their Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>It is not possible to predict the actual
number of shares we will sell under the SEPA, or the actual gross proceeds resulting from those sales. Further, we may not have access
to any or the full amount available under the SEPA.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 30, 2024, we entered
into the SEPA with YA, pursuant to which YA has committed to purchase up to $50 million of our Common Stock, pursuant to Advance Notices
delivered by the Company any time during the commitment period terminating on the 36-month anniversary of the SEPA; provided that any
Advance Notice may only be made if (x) no amount remains outstanding under a Promissory Note, (y) there is an effective Resale Registration
Statement filed with the SEC for the resale under the Securities Act of the shares of Common Stock to be issued pursuant to such Advance
Notice, and (z) other customary conditions precedent. Additionally, at any time during the commitment period, provided there is a balance
remaining outstanding under a YA Promissory Note, YA may deliver an Investor Notice, causing an Advance Notice to be deemed delivered
to YA, subject to certain conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Save for the issuance of shares
of Common Stock following receipt of an Investor Notice (as defined in the SEPA) or pursuant to conversion of a Promissory Note, we generally
have the right to control the timing and amount of any sales of shares of Common Stock to YA under the SEPA. Sales of Common Stock, if
any, to YA under the SEPA will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell
to YA all, some or none of the shares of Common Stock that may be available for us to sell to YA pursuant to the SEPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the purchase price
per share to be paid by YA for the shares of Common Stock that we may elect to sell to YA under the SEPA, if any, will fluctuate based
on the market prices of Common Stock prior to each sale made pursuant to the SEPA, if any, it is not possible for us to predict, as of
the date of this prospectus and prior to any such sales, the number of shares of Common Stock that we will sell to YA under the SEPA,
the purchase price per share that YA will pay for shares purchased from us under the SEPA, or the aggregate gross proceeds that we will
receive from those purchases by YA under the SEPA, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are filing the prospectus
which is part of this registration statement on Form S-1 to register under the Securities Act the resale by YA such shares of Common Stock
we seek to issue from time to time under the SEPA, which the SEC must declare effective. At the special meeting of stockholders held on
April 8, 2025, the Company obtained stockholder approval for the issuance of shares over 20% of the Company&#8217;s outstanding shares
pursuant to Nasdaq Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEPA does not obligate
YA to subscribe for or acquire any shares of Common Stock under the SEPA if those shares of Common Stock, when aggregated with all other
shares of Common Stock acquired by YA under the SEPA, would result in YA beneficially owning more than 4.99% of the then outstanding shares
of Common Stock. YA has agreed not to engage in &#8220;short sales&#8221; of our stock during the term of the SEPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, it is not possible
to predict the actual number of shares we will sell under the SEPA, or the actual gross proceeds resulting from those sales, if any. Accordingly,
we may not have access to any or the full amount available under the SEPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Our management team will have broad discretion
over the use of the net proceeds from our sale of shares of Common Stock to YA, if any, and you may not agree with how we use the proceeds
and the proceeds may not be invested successfully. </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management team will have
broad discretion as to the use of the net proceeds from our sale of shares of Common Stock to YA, if any, and we could use such proceeds
for purposes other than those contemplated at the time of commencement of this offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, you will be relying
on the judgment of our management team with regard to the use of those net proceeds, and you will not have the opportunity, as part of
your investment decision, to assess whether the proceeds are being used appropriately. It is possible that, pending their use, we may
invest those net proceeds in a way that does not yield a favorable, or any, return for us. The failure of our management team to use such
funds effectively could have a material adverse effect on our business, financial condition, operating results and cash flows.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>COMMITTED EQUITY FINANCING </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 30, 2024, we entered
into the Standby Equity Purchase Agreement (&#8220;SEPA&#8221;) with YA pursuant to which we have the right to sell to YA up to $50,000,000
shares of Common Stock, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term of the
SEPA. Sales of shares of Common Stock to YA under the SEPA, and the timing of any such sales, are at our option, and we are under no obligation
to sell any securities to YA under the SEPA. In accordance with our obligations under the SEPA, we have filed the registration statement
that includes this prospectus with the SEC to register under the Securities Act the resale by YA of 9,775,017 shares of Common Stock that
we may elect, in our sole discretion, to issue and sell to YA, under the SEPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have the right to
commence any sales of our Shares to YA under the SEPA until the date on which all of the conditions to YA&#8217;s purchase obligation
set forth in the SEPA have been satisfied, including that the registration statement of which this prospectus forms a part be declared
effective by the SEC and the final form of this prospectus is filed with the SEC. Upon the satisfaction of the conditions to YA&#8217;s
purchase obligation set forth in the SEPA, we will have the right, but not the obligation, from time to time at our discretion until the
first day of the month following the 24-month period after the date of the SEPA, to direct YA to purchase a specified amount of Shares
(each such sale, an &#8220;Advance&#8221;) by delivering written notice to YA (each, an &#8220;Advance Notice&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The per share subscription
price YA will pay for the shares of Common Stock will be 97% of the market price during a one- or three-day pricing period elected by
New Abpro. The &#8220;Market Price&#8221; is defined in the SEPA as the lowest daily VWAP (as defined below) during the one trading day,
in the case of a one-day pricing period, or of the three consecutive trading days, in the case of a three-day pricing period, commencing
on the trading day on which New Abpro delivers an Advance Notice to YA. &#8220;VWAP&#8221; means, for any trading day, the daily volume
weighted average price of our Common Stock for such date on NASDAQ as reported by Bloomberg L.P. during regular trading hours. There is
no upper limit on the subscription price per share that YA could be obligated to pay for the Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will control the timing
and amount of any sales of Shares to YA. Actual sales of Shares to YA under the SEPA will depend on a variety of factors to be determined
by us from time to time, which may include, among other things, market conditions, the trading price of our Common Stock and determinations
by us as to the appropriate sources of funding for our business and its operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YA will not be obligated to
subscribe to any Shares under the SEPA which, when aggregated with all other shares of Common Stock then beneficially owned by YA and
its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act, and Rule 13d-3 promulgated thereunder), would result in the
beneficial ownership by YA and its affiliates to exceed 4.99% of the outstanding voting power or number of Common Stock (the &#8220;Beneficial
Ownership Limitation&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The net proceeds under the
SEPA to us will depend on the frequency and prices at which we sell our Shares to YA. We expect that any proceeds received by us from
such sales to YA will be used for working capital and general corporate purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As consideration for YA&#8217;s
commitment to purchase shares of Common Stock at our direction upon the terms and subject to the conditions set forth in the SEPA, we
paid YA, (i) a commitment fee in the amount of $35,000 and (ii) a commitment fee in the form of 9,905 Commitment Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The SEPA contains customary
representations, warranties, conditions and indemnification obligations of the parties. The representations, warranties and covenants
contained in such agreements were made only for purposes of such agreements and as of specific dates, were solely for the benefit of the
parties to such agreements and may be subject to limitations agreed upon by the contracting parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the Effective
Date, as defined in the SEPA, there were 1,684,509 shares of Common Stock outstanding, and therefore the Exchange Cap would have
been 336,733 shares of Common Stock. Thus, we previously registered the maximum amount that we could register without obtaining
approval of stockholders in accordance with Nasdaq&#8217;s &#8220;minimum price rule.&#8221; However, pursuant to the SEPA, if the
Company desires to issue more than 336,733 shares of Common Stock at an average price per share that does not equal or exceed
$129.30 (which represents the lower of (i) the Nasdaq Official Closing Price (as reflected on Nasdaq.com) immediately preceding the
Effective Date; or (ii) the average Nasdaq Official Closing Price for the five trading days immediately preceding the Effective
Date), it would be required to obtain stockholder approval under the Nasdaq listing rules (the &#8220;Stockholder Approval&#8221;).
On April 8, 2025, the Company held a special meeting of stockholders and obtained the Stockholder Approval for the issuance of
shares over 20% of the Company&#8217;s outstanding shares pursuant to Nasdaq Rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares registered for resale under
this prospectus with the SEC is based on the remaining aggregate gross proceeds equal to the approximately $44 million available to us
under the SEPA and the Floor Price. The number of shares ultimately offered for resale by YA is dependent upon the number of shares we
may elect to sell to YA under the SEPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not know what the subscription
price for the Shares will be and therefore cannot be certain as to the number of Shares we might issue to YA under the SEPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are substantial risks
to our stockholders as a result of the sale and issuance of Shares to YA under the SEPA. These risks include the potential for substantial
dilution and significant declines in the share price of our securities. See the section entitled &#8220;<i>Risk Factors</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The below summary is qualified
in its entirety by reference to the SEPA, a copy of which is filed as exhibit 10.28.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Advances of Shares Under the SEPA </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Advances </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have the right, but not
the obligation, from time to time at our discretion, until the first day of the month following the 24-month period after the date of
the SEPA, and up to an aggregate subscription amount of $50,000,000, to direct YA to Advance a specified maximum amount of Shares as set
forth in the SEPA (each, an &#8220;Advance&#8221;) by delivering an Advance Notice on any trading day (each, an &#8220;Advance Notice
Date&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Conditions to Each Advance </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YA&#8217;s obligation to accept
Advance Notices that are timely delivered by us under the SEPA and to purchase shares of Common Stock in Advances under the SEPA, is subject
to the satisfaction, at the applicable Advance Notice Date, of certain conditions, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the accuracy in all material respects of the representations
and warranties of the Company included in the SEPA;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the registration statement that includes this prospectus (and
any one or more additional registration statements filed with the SEC that include Shares that may be issued and sold by the Company
to YA under the SEPA) having been declared effective under the Securities Act by the SEC, and we shall have filed with the SEC in a timely
manner all reports, notices and other documents required under the Exchange Act and applicable SEC regulations during the twelve-month
period immediately preceding the applicable Condition Satisfaction Date;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">New Abpro having performed, satisfied and complied in all
material respects with all covenants, agreements and conditions required by the SEPA to be performed, satisfied or complied with by the
Company;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">New Abpro shall have obtained all permits and qualifications
required by any applicable state for the offer and issuance of all the Shares issuable pursuant to such Advance Notice or shall have
the availability of exemptions therefrom. The issuance of such Shares shall be legally permitted by all laws and regulations to which
New Abpro is subject;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">no condition, occurrence, state of facts or event constituting
a Material Outside Event (as such term is defined in the SEPA) shall have occurred and be continuing;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">no statute, rule, regulation, executive order, decree, ruling
or injunction shall have been enacted, entered, promulgated or endorsed by any court or governmental authority of competent jurisdiction
that prohibits or directly, materially and adversely affects any of the transactions contemplated by the SEPA;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the shares of Common Stock are quoted for trading on the Nasdaq
(or the New York Stock Exchange, NYSE American, the Nasdaq Global Market, or the Nasdaq Capital Market) and all the shares of Common
Stock issuable pursuant to such Advance Notice will be approved for trading on the Principal Market. The issuance of Shares with respect
to the applicable Advance Notice will not violate the shareholder approval requirements of the exchange. New Abpro shall not have received
any written notice that is then still pending threatening the continued quotation of the Shares on the stock exchange;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">There shall be a sufficient number of authorized but unissued
and otherwise unreserved shares of Common Stock for the issuance of all of the shares issuable pursuant to such Advance Notice; and</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Except with respect to the first Advance Notice, New Abpro
shall have delivered all Shares relating to all prior Advances, and at least 5 Trading Days shall have elapsed from the immediately preceding
Advance Date.</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Termination of the SEPA </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless earlier terminated
as provided in the SEPA, the SEPA will terminate automatically on the earliest to occur of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the first day of the month next following the 24-month anniversary
of the date of the SEPA; and</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the date on which YA shall have purchased Shares under the
SEPA for an aggregate gross purchase price equal to $50,000,000;</td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also have the right to
terminate the SEPA at any time, at no cost or penalty, upon five (5) trading days&#8217; prior written notice to YA, provided that there
are no outstanding Advance Notices under which we are yet to issue Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also agree with YA
to terminate the SEPA by mutual written consent. Neither we nor YA may assign or transfer their respective rights and obligations under
the SEPA, and no provision of the SEPA may be modified or waived by the YA or us other than by an instrument in writing signed by both
parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>No Short-Selling by YA </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YA has agreed that it and
its affiliates will not engage in any short sales during the term of the SEPA and will not enter into any transaction that establishes
a net short position with respect to the shares of Common Stock. The SEPA stipulates that YA may sell our Shares to be issued pursuant
to an Advance Notice, following receipt of the Advance Notice, but prior to receiving such shares and may sell other shares of Common
Stock acquired pursuant to the SEPA that YA has continuously held from a prior date of acquisition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Effect of Sales of our shares of Common Stock under the SEPA
on our Stockholders </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All shares of Common
Stock that may be issued or sold by us to YA under the SEPA that are being registered under the Securities Act for resale by YA in
this offering are expected to be freely tradable. The shares of Common Stock being registered for resale in this offering may be
issued and sold by us to YA from time to time at our discretion over the term of the SEPA. The resale by YA of a significant amount
of shares of Common Stock registered for resale in this offering at any given time, or the perception that these sales may occur,
could cause the market price of our Common Stock to decline and to be highly volatile. Sales of our Shares, if any, to YA under the
SEPA will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to YA all, some
or none of the Shares that may be available for us to sell to YA pursuant to the SEPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If and when we do elect to
sell shares of Common Stock to YA pursuant to the SEPA, YA may resell all, some or none of such shares in its discretion and at different
prices subject to the terms of the SEPA. As a result, investors who purchase Shares from YA in this offering at different times will likely
pay different prices for those shares of Common Stock, and so may experience different levels of dilution and in some cases substantial
dilution and different outcomes in their investment results. Investors may experience a decline in the value of the Shares they purchase
from YA in this offering as a result of future sales made by us to YA at prices lower than the prices such investors paid for their Shares
in this offering. In addition, if we sell a substantial number of Shares to YA under the SEPA, or if investors expect that we will do
so, the actual sales of Shares or the mere existence of our arrangement with YA may make it more difficult for us to sell equity or equity-related
securities in the future at a desirable time and price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the purchase price
per share to be paid by YA for the shares of Common Stock that we may elect to sell to YA under the SEPA, if any, will fluctuate based
on the market prices of our Common Stock during the applicable Pricing Period (as defined in the SEPA), as of the date of this prospectus
we cannot reliably predict the number of Shares that we will sell to YA under the SEPA, the actual purchase price per share to be paid
by YA for those shares, or the actual gross proceeds to be raised by us from those sales, if any.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The issuance, if any, of Shares
to YA pursuant to the SEPA will not affect the rights or privileges of our existing stockholders, except that the economic and voting
interests of each of our existing stockholders would be diluted. Although the number of Shares that our existing stockholders own would
not decrease as a result of sales, if any, under the SEPA, the shares of Common Stock owned by our existing stockholders would represent
a smaller percentage of our total outstanding Common Stock after any such issuance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>USE OF PROCEEDS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All of the Common Stock offered
by YA pursuant to this prospectus will be sold by YA for its own account. We will not receive any of the direct proceeds from these sales.
However, we may receive up to $50.0 million aggregate gross proceeds from any sales we make to YA pursuant to the SEPA. The net proceeds
from sales, if any, under the SEPA, will depend on the frequency and prices at which we sell Shares to Yorkville after the date of this
prospectus. See the section titled &#8220;<i>Plan of Distribution</i>&#8221; elsewhere in this prospectus for more information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to use any proceeds
that we receive under the SEPA for working capital and general corporate purposes. As of the date of this prospectus, we cannot specify
with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive.
Accordingly, we will retain broad discretion over the use of these proceeds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MARKET INFORMATION FOR COMMON STOCK AND DIVIDEND
POLICY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Our Common Stock and our
Public Warrants are listed on the Nasdaq Global Market under the symbols &#8220;ABP&#8221; and &#8220;ABPWW,&#8221; respectively. As
of November 28, 2025, there were 75 holders of record of our Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Dividend Policy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not paid any cash
dividends on our Common Stock to date. The payment of cash dividends by us in the future will be dependent upon our revenues and earnings,
if any, capital requirements and general financial condition. The payment of any dividends will be within the discretion of our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF
FINANCIAL CONDITION AND RESULTS OF<br/>
OPERATIONS OF NEW ABPRO</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
and analysis summarizes the significant factors affecting the consolidated operating results, financial condition, liquidity, and cash
flows of our company as of and for the periods presented below. The following discussion and analysis of our financial condition and results
of operations should be read together with our consolidated financial statements and the related notes and other financial information
included elsewhere in this prospectus. The discussion and analysis should also be read together with the section of this prospectus entitled
&#8220;Description of New Abpro&#8217;s Business.&#8221; The discussion contains forward- looking statements that are based on the beliefs
of management, as well as assumptions made by, and information currently available to, our management. Actual results and timing of selected
events could differ materially from those discussed or implied by the forward-looking statements as a result of various factors, including
those discussed below and detailed elsewhere in this proxy statement/prospectus, particularly in the sections entitled &#8220;Risk Factors&#8221;
and &#8220;Forward-Looking Statements; Summary Risk Factors; Market, Ranking and Other Industry Data.&#8221;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Unless otherwise indicated
or the context otherwise requires, references in this section to &#8220;New Abpro,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221;
the &#8220;Company,&#8221; and other similar terms refer to Abpro Holdings, Inc. and its subsidiaries.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In our Annual Report on
Form 10-K for the year ended December 31, 2024 (the &#8220;<b>Annual Report</b>&#8221;), we restated our previously issued consolidated
financial statements for the years ended December 31, 2023 and 2022, and Abpro Corporation&#8217;s interim reporting period for the nine
months ended September 30, 2024. See the &#8220;Explanatory Note&#8221; in this prospectus and the section entitled &#8220;<i>Risk Factors
- Risks Related to Our Organization and Structure - We reached a determination to restate certain of our previously issued consolidated
financial statements as a result of the identification of errors in previously issued consolidated financial statements, which resulted
in unanticipated costs and may affect investor confidence and raise reputational issues&#8221; </i>for background on the restatement,
the fiscal periods impacted, control considerations, and other information. As a result, we have also restated our previously issued
financial information as of and for the year ended December 31, 2023 in this &#8220;Management&#8217;s Discussion and Analysis of Financial
Condition and Results of Operations&#8221;, to conform the discussion with the appropriate restated amounts. See Note 2 to our Consolidated
Financial Statements included in this prospectus for additional information related to the restatement including descriptions of the
errors and the impact to our consolidated financial statements. As a result of the restatement, it was determined that the Company&#8217;s
disclosure controls and procedures were not effective as of December 31, 2024, and that the Company had identified material weaknesses
in its internal controls over financial reporting, as referenced in Item 9A of the Annual Report.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not amended and do
not plan to amend our previously filed reports for the periods affected by the restatement. The information that has been previously filed
or otherwise reported for these periods is superseded by the information in the Annual Report. Accordingly, the consolidated financial
statements and related financial information contained in such previously filed or furnished reports should no longer be relied upon.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Overview</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abpro Holdings, Inc. and its
subsidiaries, (the &#8220;<b>Company</b>&#8221;) is a biotechnology company headquartered in Burlington, Massachusetts, dedicated to developing
next-generation antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. The Company is focused
on the development of novel antibodies using its proprietary discovery and engineering platforms, primarily in the areas of immuno-oncology,
ophthalmology and infectious disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By leveraging our proprietary
DiversImmune&#174; and MultiMabTM antibody discovery and engineering platforms, we are developing a pipeline of antibodies, both independently
and through collaborations with global pharmaceutical and research institutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our two lead product
candidates, ABP-102 and ABP-201, feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to
two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient&#8217;s immune system to
fight cancer by engaging T cells through co-targeting human epidermal growth factor receptor 2, or HER2, and cluster of
differentiation 3, or CD3, T-cell co-receptor. We plan initially to develop ABP-102 for difficult to treat HER2+ solid tumors,
focusing on orphan indications. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through
co-targeting vascular endothelial growth factor, or VEGF, and angiopoietin-2, or ANG-2. We plan to develop ABP-201 to treat vascular
disease of the eye, focusing on wet age-related macular degeneration (Wet AMD). We intend to follow these two lead product
candidates with a broad pipeline of CD3-targeting T-cell engagers based on the differentiated format of ABP-102. We expect to
initiate clinical trials for ABP-102 in the first half of 2026. The initiation of clinical trials for ABP-201 may depend on future
funding availability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Merger</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the Closing Date, ACAB
consummated the Business Combination pursuant to the terms of the Business Combination Agreement by and among Abpro Corporation, ACAB,
and Merger Sub. Pursuant to the Business Combination Agreement, on the Closing Date, (i) ACAB changed its name to &#8220;Abpro Holdings,
Inc.&#8221;, and (ii) Merger Sub merged with and into Legacy Abpro, with Legacy Abpro as the surviving company in the merger (such transaction,
the &#8220;<b>Merger</b>,&#8221; and, collectively with the other transactions described in the Business Combination Agreement, the &#8220;<b>Reverse
Recapitalization</b>&#8221;). After giving effect to the Merger, Legacy Abpro became a wholly owned subsidiary of the Company. Shares
of the New Abpro commenced trading on the Nasdaq Global Market on November 14, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, certain investors
purchased an aggregate of 112,247 shares of Common Stock in the PIPE Financing that closed concurrently with the Closing for an aggregate
purchase price of $11.2 million. Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related
price information to give effect to the Exchange Ratio as set forth in the Business Combination Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Recent Developments</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On October 16, 2025, the
Company filed with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the
&#8220;Certificate of Amendment&#8221;), which became effective at 5:01 p.m. on October 31, 2025, to effect a one-for-thirty (1:30) reverse
stock split (the &#8220;Reverse Stock Split&#8221;), of the shares of the Company&#8217;s Common Stock. The Reverse Stock Split was approved
by the Company&#8217;s stockholders at the 2025 annual meeting of the stockholders on October 10, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the Reverse
Stock Split, every 30 shares of issued and outstanding Common Stock were automatically combined into one (1) issued and outstanding share
of Common Stock, without any change in the par value per share. No fractional shares were issued as a result of the Reverse Stock Split.
Instead, stockholders who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly
divisible by the Reverse Stock Split ratio were entitled to receive an additional fraction of a share of Common Stock to round up to the
next whole share.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Following the Reverse
Stock Split, the number of shares of Common Stock outstanding were proportionally reduced from 81,150,000 shares to approximately 2,705,061
shares. The shares of Common Stock underlying the Company&#8217;s outstanding stock options and warrants were similarly adjusted along
with corresponding adjustments to their exercise prices. Unless we indicate otherwise or the context otherwise requires, all information
in this section gives effect to this reverse stock split.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Common Stock began trading
on a reverse stock split-adjusted basis upon market open on November 3, 2025. The ticker symbol for the Common Stock remains &#8220;ABP.&#8221;
The new CUSIP number for the Common Stock following the Reverse Stock Split is 000847202.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Results of Operations for the Nine Months
Ended September 30, 2025 and 2024</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The following is a comparative discussion of our results of operations
for the nine months ended September 30, 2025 and 2024 (in thousands):</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Nine Months <br/>
Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Change</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Revenue:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">Research and development services</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">183</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(183</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-100</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Total revenue</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">183</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(183</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-100</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Operating expenses:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Research and development</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">881</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,469</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(1,588</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-64</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"><span style="-keep: true">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">5,674</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">4,864</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">810</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">17</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt"><span style="-keep: true">Total operating expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">6,555</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">7,333</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(778</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-11</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Loss from operations</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(6,555</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(7,150</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">595</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-8</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Other (expense) income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(1,973</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">3,253</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(5,226</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">-161</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Net loss</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(8,528</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(3,897</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(4,631</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">-119</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Our research and development
services revenue decreased by $0.2 million during the nine months ended September 30, 2025 as compared to the nine months ended September
30, 2024, due to the revenue earned from the research and development services performed for Celltrion related to ABP-102 development.
No such research and development services revenue was earned during the nine months ended September 30, 2025. Our ability to generate
product revenues in the future will depend almost entirely on our ability to successfully develop, obtain regulatory approval for, and
then successfully commercialize a drug candidate, or enter into collaborations that provide for payments to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Research and Development Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">The following table summarizes our research and development expenses
by product candidate and program for the nine months ended September 30, 2025 and 2024 (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Nine Months <br/>
    Ended<br/> September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid"><span style="-keep: true">Research and development expenses</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold"><span style="-keep: true">ABP-110</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">28</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">96</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="-keep: true">ABP-102</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">180</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">710</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-keep: true">ABP-150</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">14</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">19</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="-keep: true">ABP-201</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">37</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">21</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-keep: true">ABP-100</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">SARS-CoV-2 neutralizing antibody program</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Unallocated research and development expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">622</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">1,603</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">881</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true">2,469</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Research and development
expenses decreased by $1.6 million for the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024,
primarily due to the majority of the personnel being on furlough since October 2024. The overall decrease in expenses was a result of
the decrease in research and development activities while raising additional capital necessary to restart our research and development
programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">General and Administrative Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">General and administrative
expenses increased by $0.8 million for the nine months ended September 30, 2025, as compared to the nine months ended September 30, 2024,
primarily due to an increase of approximately $2.4 million in costs of operating as a public company, including legal, accounting, and
insurance expenses, partially offset by a decrease in payroll and related expenses of approximately $1.6 million as a result of the progressive
reduction in employee headcount between the closing date of the Merger through September 30, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Other Income (Expense), Net</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The net balance in other
income (expense) decreased by $5.2 million for the nine months ended September 30, 2025, as compared to the nine months ended September
30, 2024. This change is primarily due to other income recognized during the nine months ended September 30, 2024 of approximately $3.5
million related to the reversal of the liability to one of the Company&#8217;s research and development providers, as this provider informed
the Company they were not pursuing collection on this liability. The remaining decrease is related to the increase in interest expense
of approximately $0.8 million, primarily related to the fair value of the warrants issued under the promissory note with an executive,
the loss of approximately $0.8 million for the change in fair value of embedded derivative liabilities, and $0.4 million loss on the
settlement of the convertible notes during the nine months ended September 30, 2025.&#160;&#160;</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Results of Operations for the Years Ended
December 31, 2024 and 2023</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a comparative
discussion of our results of operations for the years ended December 31, 2024 and 2023 (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended December
    31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 9pt">Research and development services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">183</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Collaboration revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(99</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9pt">Royalty</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">23</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(23</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-100</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">183</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">122</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">61</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">50</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,983</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,266</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,283</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-30</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,121</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">7,602</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(481</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-6</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,104</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,868</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,764</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-15</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss from operations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(9,921</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(11,746</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,825</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-16</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,689</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,649</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6623</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Net loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,232</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,706</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">4,474</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">-38</td><td style="padding-bottom: 2.5pt; text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We did not generate any material
revenues during the years ended December 31, 2024 and 2023. Our research and development services revenue increased by $0.2 million during
the year ended December 31, 2024 as compared to the year ended December 31, 2023, due to the revenue earned from the research and development
services performed for Celltrion related to ABP-102 development.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The collaboration revenue
of $0.1 million was recognized during the year ended December 31, 2023 under the collaboration agreement with Celltrion related to ABP-102
entered into during 2022 with no further revenues in 2024. Our ability to generate product revenues in the future will depend almost
entirely on our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize a drug candidate,
or enter into collaborations that provide for payments to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and Development Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation for those individuals involved in research
and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies and clinical
materials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our research and development expenses by product candidate and program for the year ended December 31, 2024 and 2023 (in thousands):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Research and development expenses</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; font-weight: bold">ABP-110</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">110</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">344</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">ABP-102</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">801</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">311</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ABP-150</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">283</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold">ABP-201</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">217</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ABP-100</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">137</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SARS-CoV-2 neutralizing antibody program</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,066</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Unallocated research and development expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,985</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,908</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; padding-bottom: 4pt">Total</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">2,983</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">4,266</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unallocated research and development
expenses include engineering platform-related expenses that are not allocable to a specific product candidate or program, as well as stock-based
compensation, other employee-related expenses that are not related to a specific product candidate or program, and facilities and depreciation
expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
decreased by $1.3 million for the year ended December 31, 2024, as compared to the year ended December 31, 2023 primarily due to a decrease
in expenses associated with the SARS-CoV-2 neutralizing antibody program, partially offset by increased expenses associated with the development
of ABP-102. The overall decrease in expenses attributable to specific product candidates or programs was a result of the decrease in research
and development activities while raising additional capital necessary to restart our research and development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative Expenses</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of compensation and benefits to our personnel, including the costs related to our management services agreements,
directors, and senior advisors; professional service fees, including accounting, legal, and other consulting services. General and administrative
expenses decreased by $0.5 million for the year ended December 31, 2024, as compared to the year ended December 31, 2023, primarily due
to the cancellation of the accrued bonuses related to prior years during the fourth quarter of 2024 of $0.9 million, offset by the bonuses
approved during the year ended December 31, 2024 of $0.6 million. The remaining decrease in payroll and benefits expenses was due to the
reduction in employee headcount.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Other Income, Net</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other income, net increased
to $2.7 million for the year ended December 31, 2024, from $40 thousand in other income for the year ended December 31, 2023. This change
is primarily due to the reversal of the approximately $3.5 million liability to one of the Company&#8217;s research and development providers
as this provider informed the Company they are not pursuing collection on this liability. This increase in other income was partially
offset by $0.3 million loss on the change in the fair value of the SEPA put rights asset (as defined in the notes to the consolidated
financial statements), $0.3 million loss on the change in the fair value of the Forward Purchase Agreement asset related to the financing
arrangements entered into in November 2024, and $0.4 million increase in interest expense due to the promissory notes which were issued
in October 2023, December 2023, and April 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Liquidity, Capital Resources and Going Concern</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">To date, we have financed
our operations primarily through the sale of equity securities and convertible debt, proceeds from the Merger and related PIPE Financing,
borrowings under loan facilities and, to a lesser extent, through payments received in connection with collaboration and license agreements.
Since our inception, we incurred significant recurring losses, including a net loss of $8.5 million and $3.9 million for the nine months
ended September 30, 2025, and 2024, respectively. As of September 30, 2025, we had an accumulated deficit of $124.6 million. We expect
to incur operating losses in the foreseeable future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 2, 2025, the Company received written
notice (the &#8220;Notice&#8221;) from the Listing Qualifications Department staff (the &#8220;Staff&#8221;) of the Nasdaq Stock Market
(&#8220;Nasdaq&#8221;) notifying the Company that, based on the closing bid price of the Company&#8217;s common stock for the last 30
consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq Stock
Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the &#8220;Minimum
Bid Price Requirement&#8221;), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement
exists if the deficiency continues for a period of 30 consecutive business days. &#160;Pursuant to the Nasdaq Listing Rules, the Company
has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. The letter
stated that the Company had 180 calendar days, or until September 29, 2025, to regain compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On April 10, 2025, the
Company received two letters from the Staff of Nasdaq. One letter (the &#8220;MVPHS Notice&#8221;) indicated that based upon Nasdaq&#8217;s
review of the Company&#8217;s Market Value of Publicly Held Shares (&#8220;MVPHS&#8221;) for the last 30 consecutive business days prior
to the date of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed
securities to maintain a minimum MVPHS of $15 million (the &#8220;MVPHS Requirement&#8221;). The second letter notified the Company that
from February 20, 2025 to April 9, 2025, the Company&#8217;s Market Value of Listed Securities (&#8220;MVLS&#8221;) was below the minimum
of $50 million required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the &#8220;MVLS
Requirement&#8221;). Each letter stated that the Company had 180 calendar days, or until October 7, 2025, to regain compliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On September 30, 2025,
the Company received a letter from Nasdaq notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement
during the compliance period. Accordingly, the Company timely requested a hearing before the appeal panel (the &#8220;Panel&#8221;),
which stayed the suspension of the Company&#8217;s securities with Nasdaq pending the Panel&#8217;s decision or any extension of time
provided by the Panel to regain compliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On October 14, 2025, the
Company received a letter (the &#8220;Notice&#8221;) from Nasdaq notifying the Company that it had not regained compliance with either
the MVPHS Requirement or the MVLS Requirement during the compliance period.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The Hearing was held on
October 30, 2025. During the Hearing, the Company presented its plans to regain compliance with the Minimum Bid Price Requirement, the
MVPHS Requirement and the MVLS Requirement. On November 10, 2025, the Company received a decision letter from the Panel granting the
Company&#8217;s request for continued listing on The Nasdaq Stock Market, subject to the Company&#8217;s strict adherence to certain
interim deadlines and conditions. The Panel will maintain jurisdiction over the Company&#8217;s listing through March 30, 2026, and may
reconsider the terms of the exception or delist the Company if it fails to meet any of the imposed deadlines or becomes deficient with
any listing rule during this period. There can be no assurance that the Company will be able to meet the conditions imposed by the Panel
or regain and maintain compliance with Nasdaq&#8217;s listing requirements. Failure to do so may result in the delisting of the Company&#8217;s
securities from Nasdaq.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of September 30, 2025,
the Company had cash of $328. Due to its current liabilities, the cash available to the Company will not be sufficient to allow the Company
to operate for at least 12 months from the date these financial statements are available for issuance. The future viability of the Company
is largely dependent on its ability to raise additional capital to finance its operations. The Company expects to seek additional funding
through equity and debt financings, collaboration agreements and research grants. Although the Company has been successful in raising
capital in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the
Company, if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research
and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accordingly, based on the
considerations discussed above, management has concluded there is substantial doubt as to the Company&#8217;s ability to continue as a
going concern within one year after the date the condensed consolidated financial statements are issued. The Company plans to continue
to fundraise, as well as seek alternate revenues from collaboration and license agreements. If adequate funds are not available, the Company
may be required to initiate steps to slow cash burn, extending the cash runway until financing can be secured. The unaudited condensed
consolidated financial statements included elsewhere in this filing do not include any adjustments with respect to the carrying amounts
of assets and liabilities and their classification that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Future Funding Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">We expect our expenses
to increase in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our
product candidates. In addition, subsequent to the Closing of the Merger, we expect to incur additional costs associated with operating
as a public company. The timing and amount of our operating expenditures will depend largely on:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the scope, number, initiation, progress, timing, costs, design, duration, any potential delays, and results of clinical trials and nonclinical studies for our current or future product candidates, particularly the planned Phase 1/2 clinical trial for ABP-102, focusing on HER2+ breast and gastric cancers, as well as Phase 1 clinical trials for ABP-201 for the treatment of Wet AMD;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the clinical development plans we establish for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number and characteristics of product candidates and programs that we develop or may in-license;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the outcome, timing and cost of regulatory reviews, approvals or other actions to meet regulatory requirements established by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies for our product candidates than those that we currently expect;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain marketing approval for our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of filing, prosecuting, defending and enforcing our patent claims and other intellectual property rights covering our product candidates, including any such patent claims and intellectual property rights that we have licensed pursuant to the terms of its license agreement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to maintain, expand and defend the scope of its intellectual property portfolio, including the cost of defending intellectual property disputes, including patent infringement actions brought by third parties against us or our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost and timing of completion of commercial-scale outsourced manufacturing activities with respect to our product candidates;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to establish and maintain licensing, collaboration or similar arrangements on favorable terms and whether and to what extent we retain development or commercialization responsibilities under any new licensing, collaboration or similar arrangement;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the cost of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize its products on our own;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of any other business, product or technology that we acquire or in which we invest;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs of acquiring, licensing or investing in businesses, product candidates and technologies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">our need and ability to hire additional management and scientific and medical personnel;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the costs to operate as a public company in the United States, including the need to implement additional financial and reporting systems and other internal systems and infrastructure for our business;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">market acceptance of our product candidates, to the extent any are approved for commercial sale; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the effect of competing technological and market developments.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until such time, if ever,
as we can generate substantial product revenue, we expect to finance our cash needs through a combination of equity offerings, debt financings,
collaborations, strategic alliances, and marketing, distribution or licensing arrangements with third parties. To the extent that we raise
additional capital through the sale of equity or convertible debt securities, our ownership interest may be materially diluted, and the
terms of such securities could include liquidation or other preferences that adversely affect the rights of our stockholders and the rights
of the stockholders of the combined organization following the Closing of the merger. Debt financing and preferred equity financing, if
available, may involve agreements that include restrictive covenants that limit our ability to take specified actions, such as incurring
additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, strategic alliances or
marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future
revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable
to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, scale back
or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses
or acquisitions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The following table summarizes
our cash flows for the nine months ended September 30, 2025 and 2024 (in thousands):</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">For the Nine Months<br/>
    Ended<br/> September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">Change</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">%</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-keep: true">Net cash used in operating activities</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(5,386</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(5,215</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(171</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">3</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Net cash provided by investing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">26</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">26</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">100</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Net cash provided by financing activities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">2,711</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">4,495</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(1,784</span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-40</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Net cash used in operating
activities for the nine months ended September 30, 2025, increased by $0.2 million as compared to the nine months ended September 30,
2024. The increase in cash used in operating activity is primarily due to the timing of payments of operating expense, with approximately
$0.2 million increase in prepaid expenses for the nine months ended September 30, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Net
                                            cash provided by financing activities decreased by $1.8 million for the nine months ended
                                            September 30, 2025, as compared to the nine months ended September 30, 2024. During the nine
                                            months ended September 30, 2025, the Company received net proceeds of $1.9 million from the
                                            issuance of debt and proceeds of $0.1 million from the settlement of the Forward Purchase
                                            Agreement and proceeds of $0.7 million from the issuance of Advance Shares. During the nine
                                            months ended September 30, 2024, the Company received proceeds of $4.9 million from the issuance
                                            of notes payable to related parties, which were partially offset by the payments of $0.4
                                            million in offering costs and a less than $0.1 million remaining payment on finance lease
                                            liabilities.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
our cash flows for the years ended December 31, 2024 and 2023:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/>
 December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="text-align: center; padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Net cash used in operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(9,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,402</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,628</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">22</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Net cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(48</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">48</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-100</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">11,161</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">849</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">10,312</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1215</td><td style="text-align: left">%</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating
activities for the year ended December 31, 2024, increased by $1.6 million as compared to the year ended December 31, 2023. The increase
in net cash used for operating activities was primarily due to cash collections of $1.9 million during the year ended December 31, 2023
related to revenue recognized in 2022 but collected during the year ended December 31, 2023 under the collaboration agreement with Celltrion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities decreased by $48 thousand for the year ended December 31, 2024, as compared to the year ended December 31, 2023. The Company
purchased laboratory equipment during the year ended December 31, 2023. No property or equipment was purchased during the year ended December
31, 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities increased by $10.3 million for the year ended December 31, 2024, as compared to the year ended December 31, 2023. During the
year ended December 31, 2024, the Company received gross proceeds of $10.4 million from the PIPE Financing, $2.8 million in proceeds from
the Convertible Note, and $0.5 million from the Merger (which includes $2.4 million proceeds from the trust account, less $1.9 million
used to settle the ACAB liabilities at the closing of the Merger). These proceeds were partially offset by the payments of $1.4 million
in offering costs and $1.1 million cash transferred into escrow pursuant to the Forward Purchase Agreement. During the year ended December
31, 2023, the Company received proceeds of $1.4 million from the issuance of notes payable to related parties, which were partially offset
by the payments of $0.4 million in offering costs and $0.2 million remaining payment on finance lease liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Critical Accounting Policies and Estimates</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion and analysis
of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance
with US GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the
reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial
statements, as well as the reported expenses and net loss incurred during the reporting periods. Our estimates are based on our historical
experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making
judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ
from these estimates under different assumptions or conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Recent Accounting Pronouncements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See Note 2<i>, Summary of
Significant Accounting Policies</i> of the Notes to the Financial Statements for a discussion of recent accounting pronouncements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DESCRIPTION OF NEW ABPRO&#8217;S BUSINESS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>The following discussion
contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this section,
the terms &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;objective,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221;
&#8220;could,&#8221; &#8220;can,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221;
&#8220;potential,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;seek,&#8221; &#8220;future,&#8221; &#8220;strategy,&#8221;
&#8220;likely,&#8221; or the negative of these terms, and similar expressions are intended to identify forward-looking statements. These
forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance
or achievements to be materially different from any future results, performance or achievements expressed or implied by these or any other
forward-looking statements. These risks and uncertainties include, but are not limited to, those risks set forth under &#8220;Risk Factors.&#8221;
Readers are cautioned not to place undue reliance on these forward-looking statements, which are based on current expectations and reflect
management&#8217;s opinions only as of the date hereof. These forward-looking statements speak only as of the date of hereof. Abpro expressly
disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein
to reflect any change in our expectations with regard thereto or any changes in events, conditions or circumstances on which any such
statement is based.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Unless otherwise indicated
or the context otherwise requires, references in this section to &#8220;Abpro,&#8221; &#8220;Legacy Abpro,&#8221; &#8220;we,&#8221; &#8220;us,&#8221;
&#8220;our&#8221; and other similar terms refer to Abpro Corporation prior to the Business Combination and to New Abpro and its consolidated
subsidiaries or the &#8220;Company&#8221; after giving effect to the Business Combination on November 13, 2024.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Merger </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On November 13, 2024,
ACAB and Legacy Abpro completed the closing of the Business Combination between ACAB and Abpro Corporation, pursuant to the Business
Combination Agreement, dated December 11, 2023, amended by an amendment dated September 4, 2024, by and among ACAB, Abpro Merger Sub
Corp. (the &#8220;<b>Merger Sub</b>&#8221;), a Delaware corporation and a wholly owned subsidiary of ACAB, and Abpro Corporation, following
the approval at the special meeting of the shareholders of ACAB held on November 7, 2024. On November 13, 2024, pursuant to the Business
Combination Agreement, and as described in greater detail in the Company&#8217;s final prospectus and definitive proxy statement, which
was filed with the SEC on October 18, 2024, Merger Sub merged with and into Abpro Corporation (the &#8220;<b>Merger</b>&#8221;), with
Abpro Corporation surviving the Merger as a wholly owned subsidiary of ACAB, and ACAB changed its name to Abpro Holdings, Inc. At the
effective date of the Merger, New Abpro issued to or reserved for Abpro Corporation shareholders an aggregate of approximately 1,666,667
shares of Common Stock, consisting of 1,304,107 shares of Common Stock issued to Abpro Corporation shareholders, and 362,413 shares of
Common Stock reserved for issuance in connection with certain Abpro Corporation rollover RSUs and stock options (the Merger, collectively
with the other transactions described in the Business Combination Agreement, the &#8220;<b>Reverse Recapitalization</b>&#8221;). In addition,
New Abpro issued an aggregate of 112,247 shares of Common Stock to the PIPE investors (as described below), an aggregate of 42,762 shares
of Common Stock to vendors in connection with the Closing, and the Sponsor forfeited and New Abpro cancelled 32,215 shares of Common
Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After giving effect to the
Merger, Legacy Abpro became a wholly owned subsidiary of the Company. The Business Combination is accounted for as a reverse recapitalization
in accordance with U.S. GAAP, and under this method of accounting, ACAB is treated as the acquired company for financial reporting purposes
and Legacy Abpro is treated as the acquirer. Operations prior to the Business Combination are those of Legacy Abpro. The &#8220;Company&#8221;
refers to Abpro Holdings, Inc. and its subsidiaries, including Abpro Corporation, prior to and subsequent to the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Under the Second Amended
Articles of Incorporation of ACAB dated November 12, 2024, each of the outstanding shares of ACAB Series A Common Stock and the outstanding
share of ACAB Series B Common Stock was exchanged into one share (pre-split) of Common Stock.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 30, 2024,
ACAB entered into a Standby Equity Purchase Agreement (the &#8220;<b>SEPA</b>&#8221;) with YA II PN, Ltd. (&#8220;<b>YA</b>&#8221;).
Under the SEPA, YA agreed to advance up to $5 million to the Company upon the occurrence of certain events in exchange for one or
more promissory notes (each a &#8220;<b>Promissory Note</b>&#8221;) maturing in one-year, subject to acceleration. In addition,
after the Closing of the Business Combination, if certain conditions are met, the Company may issue shares to YA with YA relaying
cash to the Company in an amount specified in the SEPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ACAB, Abpro and YA also entered
into a registration rights agreement (the &#8220;<b>Registration Rights Agreement</b>&#8221;), dated October 30, 2024, pursuant to which
New Abpro agreed to file with the Securities and Exchange Commission a registration statement covering the resale of the applicable registrable
securities under the Registration Rights Agreement, including shares of Common Stock issuable to YA under the SEPA. The SEPA, Registration
Rights Agreement, and the Promissory Note, and the documents executed in connection therewith, are referred to herein collectively as
the &#8220;Financing Agreements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 12.5pt; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On November 7, 2024, ACAB
and Abpro entered into a Confirmation of an OTC Equity Prepaid Forward Transaction (the &#8220;<b>Forward Purchase Agreement</b>&#8221;)
with YA (the &#8220;<b>Seller</b>&#8221;) to which a maximum of up to 16,667 shares of Common Stock (the &#8220;<b>Maximum Number of
Shares</b>&#8221;) will be subject. At the Closing Date, the Seller purchased 3,333 shares of Common Stock from third parties (&#8220;<b>Recycled
Shares</b>&#8221;), pursuant to the pricing date notice dated November 12, 2024, and paid approximately $1.1 million (the &#8220;<b>Prepayment
Amount</b>&#8221;) equal to $340.80 per Recycled Share (the &#8220;<b>Initial Price</b>&#8221;) to the redeeming shareholders. Pursuant
to the terms of the Forward Purchase Agreement, at the Closing, the Company remitted the Prepayment Amount into an escrow account for
the benefit of the Seller. On January 28, 2025, YA elected to effect an Optional Early Termination with respect to all 3,333 shares of
Common Stock subject to the Forward Purchase Agreement which terminated the agreement as a whole. YA paid the Company the Early Termination
Obligation in the aggregate amount of approximately $0.1 million, based on the Reset Price of $39.51 in effect on January 28, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On November 14, 2024,
pursuant to the previously disclosed SEPA, New Abpro entered into a Convertible Promissory Note (&#8220;<b>Convertible Note</b>&#8221;)
for $3,000,000, issued with an 8% original issue discount, and received net proceeds of $2,755,000. On June 23, 2025, the Company entered
into an additional Convertible Promissory Note (the &#8220;<b>Second Convertible Note</b>&#8221; and together with the First Convertible
Note, the &#8220;<b>Convertible Notes</b>&#8221;) for $2,000,000, issued with an 8% original issue discount, and received net proceeds
of $1,840,000. The Convertible Notes had a maturity of November 13, 2025, incurred interest at a rate of 0% (or 18% upon the occurrence
of an uncured Event of Default), and were redeemable at the option of New Abpro if the VWAP of New Abpro&#8217;s Common Stock is less
than $345.00. YA had a right to convert any portion of the Convertible Notes at any time at a conversion price per share equal to the
lower of (i) 94% of the lowest daily VWAP during the previous 5 consecutive trading days and (ii) $345.00, which may be adjusted downward
upon payment of stock dividend, stock split or reclassification, or if New Abpro issues Common Stock for no consideration or at a price
lower than the then-effective Fixed Price (as defined in the Convertible Notes). As of the date of this prospectus, YA exercised its
conversion option for the total principal amount of $5,000,000 of the Convertible Notes. As a result of the exercises, the Company issued
to YA 881,472 shares of common stock based on the average conversion price of approximately $5.67.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a biotechnology company
dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening
diseases. We are focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging our proprietary <i>DiversImmune<sup>&#174;
</sup></i>and <i>MultiMab<sup>TM</sup>&#160;</i>antibody discovery and engineering platforms, we are developing a pipeline of next-generation
antibodies, both independently and through collaborations with global pharmaceutical and research institutions. Our two lead product candidates,
ABP-102 and ABP-201, feature our next generation tetravalent antibody format, or TetraBi antibody format, which binds to two different
targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient&#8217;s immune system to fight cancer by
engaging T cells through co-targeting human epidermal growth factor receptor 2, or HER2, and cluster of differentiation 3, or CD3, T-cell
co-receptor. We plan initially to develop ABP-102 for difficult to treat HER2+ solid tumors, focusing on orphan indications. ABP-201 is
designed to block blood vessel formation and normalize damaged vessels through co-targeting vascular endothelial growth factor, or VEGF,
and angiopoietin-2, or ANG-2. We plan to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration
(Wet AMD). We intend to follow these two lead product candidates with a broad pipeline of CD3-targeting T-cell engagers based on the differentiated
format of ABP-102. We expect to initiate clinical trials for ABP-102 in the first half of 2026 and in the second half of 2026 for ABP-201.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-102 is being
developed and commercialized through a worldwide strategic partnership with Celltrion Inc. (&#8220;<b>Celltrion</b>&#8221;)
(KRX:068270), a leading Korean biopharmaceutical company headquartered in Incheon, South Korea, under a Collaboration Agreement
entered into in September 2022 and amended in October 2024. We received an initial milestone payment of $2.0 million from Celltrion
in connection with this agreement. In addition, we are eligible for net sales milestone payments of up to $1.75 billion and
development milestone payments of up to $4.0 million under that agreement. In 2022, we also received an equity investment in our
Series F preferred stock of $2.0 million from Celltrion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-201 is being developed
and commercialized through a territorial partnership with Abpro Bio, a subsidiary of Abpro Bio Co. Ltd (KOSDAQ:195990), a company formerly
named Ugint Co Ltd with diversified holdings in precision machine tools, equipment and biotechnology headquartered in Daegu, South Korea,
under a collaboration and license agreement entered into in January 2020 that granted Abpro Bio exclusive development and commercialization
rights in the People&#8217;s Republic of China, Japan, South Korea, Southeast Asia (which for the purposes hereof means Philippines, Indonesia,
Taiwan, Pakistan, India, Vietnam, Laos, Cambodia, Thailand, Myanmar and West Malaysia), the Middle East (which for the purposes hereof
means Bahrain, Cyprus, Egypt, Iraq, Israel, Jordan, Kuwait, Lebanon, Northern Cyprus, Oman, Palestine, Qatar, Saudi Arabia, Syria, Turkey,
United Arab Emirates and Yemen), and the Commonwealth of Independent States (CIS) (which for the purposes hereof means Armenia, Azerbaijan,
Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan).
We received an initial $30 million equity investment in our Series E preferred stock from Abpro Bio in connection with that agreement,
and we are potentially eligible for net sales milestones of up to $485 million and development milestones of up to $56.5 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>DiversImmune<sup>&#174;</sup></i>
is our antibody discovery platform that rapidly generates a diverse collection of proprietary antibodies against both clinically validated
and novel targets that have been traditionally difficult to access. This provides us with high affinity and high specificity antibody
building blocks with drug-like properties that we then use to engineer novel therapeutics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>MultiMab<sup>TM</sup></i>
is our engineering platform that provides us with the flexibility to combine these antibody building blocks in different combinations
and orientations to rapidly create &#8220;fit for purpose&#8221; novel full-length multi-specific antibody constructs. Our antibody constructs,
including our TetraBi antibody format, can potentially benefit patients with the goal of improved efficacy, better safety profiles, and
more convenient dosing regimens relative to current standard-of-care therapies. Furthermore, in contrast to single-format bispecific antibody
platforms that are only able to provide a single solution to different biological problems, our platform enables us to design a diverse
suite of full-length multi-specific antibody formats to address new problems in medicine. Our approach is designed to result in therapeutic
candidates with differentiated characteristics, including potentially stronger binding affinity, improved safety, more convenient dosing
regimens and streamlined manufacturing processes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ABP-102: Next generation T-cell engager targeting HER2 and CD3 for
HER2+ solid tumors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>ABP-102</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_001.jpg" style="height: 128px; width: 122px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Key Characteristics of ABP-102</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual-arm affinity-tuned construct for selective killing and cytokine release on HER2-high target cells, with reduced killing and cytokine release on HER2-low target cells to reduce &#8220;on-target, off-tumor&#8221; toxicity</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bivalent HER2 binding to promote more selective HER2-high target cell engagement</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TetraBiTM IgG-[L]-scFv format with functionally monovalent CD3 binding at the hinge region to prevent T cell activation in the absence of tumor cells</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-reactivity to human and cynomolgus CD3 for toxicity assessment</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engineered for reduced Fc receptor engagement</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symmetrical structure with natural antibody features for efficient manufacturing and a potentially improved dosing profile</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead product candidate,
ABP-102, is a next generation immuno-oncology TetraBi antibody targeting HER2 and CD3 being developed for the treatment of HER2+ solid
tumors, including breast and gastric cancers. ABP-102 features bivalent HER2 binding sites and is engineered through affinity tuning to
selectively target tumor cells expressing high and intermediate levels of HER2, with reduced activity on cells expressing low-to-negative
levels of HER2. ABP-102 also features an affinity-tuned CD3 binding domain to provide enhanced potential for safety. ABP-102 harnesses
the power of the immune system by redirecting and activating cytotoxic T cells to attack tumor tissue. ABP-102 may provide an improved
therapeutic window to attack tumor cells while reducing systemic toxicity by promoting &#8220;on-target, on-tumor&#8221; effects, with
reduced potential for &#8220;on-target, off-tumor&#8221; toxicity toward endogenous tissues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical in vitro studies,
ABP-102 has demonstrated selectivity in both cytokine secretion and cytotoxicity with HER2-high and intermediate breast, ovarian, and
gastric cancer cell lines, including those that are resistant to Herceptin (trastuzumab), with reduced activity on HER2-low and negligible
activity on HER2-negative cell lines. We plan to initiate a Phase 1/2 clinical trial of ABP-102 with our partner Celltrion in the first
half of 2026, focusing on HER2+ breast and gastric cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe ABP-102 is an improvement
over currently approved HER2-targeting agents such as Herceptin, Perjeta (pertuzumab), and Kadcyla (T-DM1), as well as other HER2-targeting
agents currently in development, because it relies on the redirection of cytotoxic T cells to selectively target and eliminate tumor cells,
while sparing endogenous HER2-expressing cells. Current HER2-directed therapies, which are designed either to block HER2 function or deliver
toxic payloads to the tumor, are only effective in a subset of HER2+ patients, cause undesirable side effects, and are limited by the
onset of drug resistance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">It is management&#8217;s
belief that ABP-102 has the potential to provide longer lasting or even curative results in a broader set of patients than are currently
addressed by HER2-directed therapies. The global HER2+ market is forecast to grow to $12.1 billion by 2030, at a CAGR of 1.5%, according
to Research and Markets.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the TetraBi antibody
format of ABP-102 provides a potentially transformative approach to immuno-oncology. The TetraBi antibody format features two affinity-tuned
binding sites, and thus bivalent binding for the tumor antigen, creating a stronger connection to the tumor cell compared to monovalent
binding. In addition, the placement of the CD3 binding domain in the middle, or hinge region, of the TetraBi antibody format results in
a therapeutic candidate that, in preclinical studies, selectively activates T cells only in the presence of tumor cells. We have designed
ABP-102 with the goal of a favorable safety profile and potential for an enhanced therapeutic window.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are leveraging the TetraBi
antibody format of ABP-102 to pursue a broad pipeline of immuno-oncology agents that target highly expressed antigens on a diverse range
of tumor types, as depicted in the following chart. Our platform of T cell engagers has the potential to translate into an industry-leading
pipeline of therapeutic agents with the goal of improving the treatment of patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>TetraBi series of CD3-targeting T-cell engagers</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_002.jpg" style="height: 269px; width: 537px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ABP-201: Ligand trap targeting VEGF and ANG-2 for vascular diseases
of the eye</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>ABP-201</i></b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i><img alt="" src="image_003.jpg" style="height: 123px; width: 88px"/></i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Key characteristics of ABP-201</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual inhibition of VEGF and ANG-2 to block angiogenesis</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Four high-affinity binding sites for increased potential potency</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dual targeting in single molecule</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Natural antibody structure for potentially improved dosing</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Symmetrical structure for efficient manufacturing</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-201 is a different
TetraBi antibody format, designed to simultaneously inhibit VEGF and ANG-2 for the potential treatment of vascular diseases of the
eye, including diabetic macular edema, or DME, and wet age-related macular degeneration, or Wet AMD. In both DME and Wet AMD, blood
vessels form abnormally and leak fluid, resulting in vision loss. Whereas VEGF drives new blood vessel formation, ANG-2 acts to
destabilize blood vessels and contributes to vessel leakage. The current standard of care for DME and Wet AMD includes intravitreal
injections of VEGF-targeted agents, including Eylea (aflibercept), Lucentis (ranibizumab), and Avastin (bevacizumab, used
off-label). However, these drugs require eye injections every one to two months and are only effective in a subset of patients, many
of whom eventually develop resistance. Because ABP-201 has a high binding capacity, with a total of four binding sites per molecule,
we believe ABP-201 could be administered less frequently than current agents. Recently, the VEGF and ANG-2 co-targeting agent
Vabysmo (faricimab), was approved by the FDA, and clinical trial results showed a dose-dependent improvement in best-corrected
visual acuity relative to Lucentis, providing strong support for this approach. In 2022, the combined worldwide sales of Eylea and
Lucentis exceeded $10.5 billion according to company filings. Through our AbMed subsidiary, we have in-licensed certain intellectual
property rights relating to ABP-201 from MedImmune (now AstraZeneca), and are in breach of the terms of our license agreement with
MedImmune/AstraZeneca.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Clinical Development Plan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to conduct a Phase
1, multiple-ascending dose evaluation of the safety and initial efficacy of ABP-201 in patients with wet age-related macular degeneration
(Wet AMD). Following the identification of the maximum tolerated dose (MTD) or the safety and tolerability of the maximum administered
dose (MAD), a larger randomized phase 2 study is planned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have an experienced leadership
team with significant industry know-how and deep experience in antibody discovery and development, biomarker discovery and validation,
clinical development and regulatory approval, partnerships, operations, and corporate finance. Our leadership team has broad industry
experience from working at pharmaceutical and Biotech companies, including Celgene, Gan &amp; Lee, LG Chem, and Moderna. We also have
a group of scientific advisors comprised of leaders in our industry across various disciplines, including Robert Langer, PhD, David H.
Koch, Professor at MIT and a co-founder of Moderna; Laurie Glimcher, MD, President and CEO of the Dana-Farber Cancer Institute; Ron Levy,
MD, Professor and Chief, Division of Oncology, Stanford School of Medicine; George Tsokos, MD, Professor of Medicine, Beth Israel Deaconess
Medical Center; Dr. Shiv Pillai, PhD, Professor of Medicine, Harvard Medical School and Massachusetts General Hospital and Steven Schnittman,
MD, PhD, who previously served as Medical Branch Chief of the AIDS division at the National Institutes of Health and Vice President, Global
Clinical Research at Bristol Myers Squibb.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Pipeline</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our <i>DiversImmune<sup>&#174;</sup>&#160;</i>and
<i>MultiMab<sup>TM</sup></i> platforms and licensing strategy have generated a pipeline of next-generation antibody product candidates,
as reflected in the following table:&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_004.jpg" style="height: 203px; width: 537px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-201 is held through our
majority-owned subsidiary AbMed Corporation, or AbMed. AstraZeneca (formerly MedImmune) owns a minority stake in AbMed and, with respect
to Asia, the Middle East and certain other countries, ABP-201 is being developed and commercialized through a territorial partnership
with Abpro Bio, with our company retaining rights in the rest of the world. ABP-102 is being developed and commercialized through our
world-wide strategic partnership with Celltrion. We hold world-wide exclusive rights to ABP-110 under a patent license granted by the
National Cancer Institute, or NCI, a division of the NIH. ABP-150 is being developed under a collaboration agreement with Nanjing Chia
Tai Tianqing Pharmaceutical Co., Ltd (&#8220;NJCTTQ&#8221;), pursuant to which NJCTTQ has exclusive commercialization rights in China
and Thailand and we retain commercialization rights in the rest of the world.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our mission is to develop
next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. Traditionally,
creating antibodies against targets and validating them as potential therapies has been time consuming and labor-intensive. We believe
that our proprietary antibody platforms and approach overcome these limitations, however, we have yet to (i) produce antibodies on a scale
needed for clinical trials or commercialization or (ii) evaluate any of our product candidates in a patient. By leveraging the speed,
quality, and target-access of our <i>DiversImmune</i><sup>&#174;</sup> platform, we have generated a proprietary collection of antibody
building blocks that enable us to establish our own pipeline of next-generation antibody product candidates. We believe our ability to
leverage our <i>MultiMab<sup>TM</sup></i> platform to design novel bi-and multi-specific antibody constructs with natural, antibody-like
structures presents a significant opportunity to unleash the immune system&#8217;s natural ability to fight disease and to elicit responses
from broader patient populations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our key strategies to achieve
this mission are:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Aggressively advance our lead product candidates, ABP-102 and ABP-201, into the clinic</b>. We plan to initiate a Phase 1/2 clinical trial of ABP-102 in the first half of 2026, focusing on HER2+ breast and gastric cancers. Additionally, we are planning to advance ABP-201 into Phase 1 clinical trials also in the second half of 2026 for the treatment of Wet AMD. We believe that the development of our lead antibody product candidates, if successful, will generate substantial value and provide us with differentiated products to pursue in large markets with significant unmet medical needs. IND-enabling studies are underway for both lead product candidates in preparation for final GLP toxicity studies and GMP manufacturing for filing the IND and we will request Pre-IND meetings beforehand with the FDA when appropriate.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Rapidly follow ABP-102 with a broad pipeline of CD3-targeting T-cell engagers and leverage this approach to other immune cell targets in multiple indications and disease areas</b>. We are building on the optimized format of ABP-102 to aggressively develop a suite of immuno-oncology agents that redirect T cells to a diverse range of liquid and solid tumors. ABP-110, targeting GPC3 on hepatocellular carcinoma, and ABP-150, targeting Claudin 18.2 on gastric cancer, are currently in preclinical development. We may also use this &#8220;pipeline in a format&#8221; strategy with other immune cell targets, including CD137 and CD47.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leverage our <i>DiversImmune</i><sup>&#174;</sup> and <i>MultiMab</i></b><i><sup>TM</sup></i> <b>platforms to grow our pipeline of antibody product candidates</b>. We plan to continue investing in our <i>DiversImmune<sup>&#174;</sup></i> and <i>MultiMab<sup>TM</sup></i> platforms to maintain our competitive advantage. We will continue to expand our collection of high affinity and high specificity antibody building blocks against both clinically validated and novel therapeutic targets, and apply our &#8220;fit for purpose&#8221; antibody engineering approach to construct novel multi-valent, multi-specific therapeutic product candidates. We will continue to build on the success of existing immuno-oncology or cell therapies that use the power of T cells to fight cancer, such as chimeric antigen receptor T-cell, or CAR T, therapy, but will focus on simpler, more accessible, and less expensive approaches that provide a universal solution for large populations of cancer patients.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Continue to explore and execute strategic collaborations</b>. In addition to the development and commercialization collaborations we have entered into with Celltrion and Abpro Bio, we entered into a collaboration agreement in January 2019 with NJCTTQ, a pharmaceutical company specializing in research and development, production and commercialization of drugs for cardiovascular diseases, tumors, perioperative care, gastrointestinal disorders and urologic diseases headquartered in Nanjing, China, for the development of novel bispecific antibody therapies for immuno-oncology, including potentially best in class T-cell engagers. Under that agreement, we are jointly developing ABP-150, a T-cell engager designed to fight cancer through co-targeting CD3 and Claudin 18.2. NJCTTQ has exclusive commercialization rights in China and Thailand and we retain commercialization rights in the rest of the world. We will continue to explore strategic and geographic-oriented partnerships that provide us with near-term economic benefits where we retain product rights to key strategic markets.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Build a leading fully integrated discovery-to-commercial antibody therapeutics company</b>. We have assembled an experienced scientific and business team, and have built robust discovery and antibody engineering platforms that allow us to create a broad pipeline of novel product candidates. As we advance our product candidates into clinical development, we intend to complement our discovery and development strengths with clinical expertise and commercial capabilities to build a fully integrated company.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Introduction to Monoclonal and Dual-Targeting Antibodies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Antibodies are large and diversified
proteins produced by B cell immune responses to counter threats including infectious entities such as viruses, bacteria, and fungi. Antibodies
can be raised against antigens seen by the immune system as &#8220;non-self,&#8221; and therefore antibodies against human proteins are
often raised using a variety of immunization strategies in mice or other animals. The resulting antibodies can then be used as building
blocks to develop therapeutics for molecular targets, including proteins overexpressed on the surface of cancer cells. Because they recognize
their target antigens with high affinity and high specificity, and because they are natural elements of the immune system, antibodies
have been used effectively as drugs for over 30 years. Monoclonal antibodies are the largest and most rapidly growing class of therapeutic
proteins and have become a mainstay of therapeutic options for patients with cancer, autoimmune disorders, and other diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An immunoglobulin G, or IgG,
is the most common type of antibody and comprises two identical heavy chains and two identical light chains, which assemble to form a
Y-shaped molecule, as depicted in the following graphic. The bottom tail of the &#8220;Y&#8221; is called the fragment crystallizable,
or Fc, region, and is structurally constant across entire classes of antibodies. The Fc region of an antibody interacts with a variety
of receptors on immune cells and is also responsible for the long circulating half-life of an antibody. The tips of the &#8220;Y&#8221;
are called the fragment variable, or Fv, regions, and contain the antigen-binding sites. A natural antibody recognizes a single target
antigen and is therefore &#8220;monospecific.&#8221; Because it features two identical binding sites, however, it is &#8220;bivalent&#8221;
for that target. Bivalency is a critical feature of natural antibodies. Just as it is much easier to hang from a bar with two arms rather
than one, bivalent binding has been shown in preclinical studies to provide a much stronger connection to the target antigen than would
be possible with monovalent binding.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_005.jpg" style="height: 226px; width: 210px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although natural antibodies
recognize a single target, they can be engineered in different ways to bind two or more targets, resulting in a bispecific or multispecific
antibody. While there are many different types of dual-targeting antibodies, several mechanisms of action can be implemented for a bispecific
construct, including dual binding, cross-linking, and cell-cell bridging, as depicted in the following graphics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Two antibodies in one</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><img alt="" src="image_006.jpg" style="height: 169px; width: 149px"/>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Replaces a combination of two monospecific antibodies</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Simplifies the regulatory process, decreases manufacturing costs, and provides more favorable reimbursement conditions</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensures both targets are engaged in the same place at the same time</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Cross-linking</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;<img alt="" src="image_007.jpg" style="height: 231px; width: 182px"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cross-links two targets on the same cell</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Physically connects two proteins and can be used to activate pathways that are otherwise inactive or more potently inhibit pathways that are already active</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Can produce a synergistic effect, where the dual-targeting antibody out-performs the corresponding combination of two single-targeting antibodies</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Cell-bridging</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><img alt="" src="image_008.jpg" style="height: 222px; width: 198px"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bridges two cells, physically bringing them into close proximity</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Promote immune cell activation to kill the tumor cells to which they are attached</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Platforms</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our approach consists of two
technology platforms: our <i>DiversImmune<sup>&#174;</sup></i> platform, which we use to generate therapeutic &#8220;building blocks,&#8221;
which are high affinity and high specificity antibodies with functional activity against therapeutic targets; and our <i>MultiMab<sup>TM</sup></i>
platform, which we use to construct therapeutic product candidates by assembling the building blocks into different combinations of bi-
and multi-specific antibodies. Together, these platforms support our strategy of building a broad pipeline of next generation antibody
therapeutics that are designed to address a wide range of human diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>DiversImmune<sup>&#174;</sup></i>: Our antibody discovery platform</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our <i>DiversImmune<sup>&#174;</sup></i>
platform was built to address a key bottleneck in the antibody therapeutics industry: the ability to rapidly generate high affinity and
high specificity antibodies against virtually any target of interest. Although <i>in vitro</i> methods, such as phage and yeast display,
have been developed to mimic the immune system, these methods typically rely on collections of antibodies from unimmunized donors and
as a result generally yield relatively low affinity antibodies. Improving these antibodies through affinity maturation (<i>i.e.</i>, mutation
and selection) is often a lengthy process and is not always successful. In contrast, the adaptive immune system of a mouse has a built-in
mechanism called somatic hypermutation that improves the affinity of antibodies up to one thousand times, yielding high affinity and high
specificity antibodies suitable for therapeutic development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The greatest challenge with
mouse-based methods, however, lies in generating a strong and diverse immune response to the target of interest. The mammalian immune
system has a mechanism called tolerance that prevents it from making antibodies against proteins that are perceived as &#8220;self.&#8221;
Thus, to generate a strong immune response against a target that is difficult to access, either because the target is not particularly
immunogenic, or capable of producing an immune response, or because the target, a human protein, is very similar to the corresponding
mouse protein, it is necessary to &#8220;break tolerance.&#8221; A key component of our <i>DiversImmune<sup>&#174;</sup></i> platform is
our genetically engineered hyperimmune mouse which seeks to solve this problem in two ways. First, the mouse has been genetically engineered
so that more of its antibody-generating B cells survive and proliferate than in a non-engineered mouse. This results in a larger and more
diverse collection of high affinity antibodies. Second, the mouse has a hyperactive immune system in which its tolerance to self-antigens
has been &#8220;broken.&#8221; This enables us to generate a diverse array of antibodies against a wide range of targets, including targets
that are very similar between mouse and human.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The <i>DiversImmune<sup>&#174;</sup></i>
platform comprises three key steps, all focused on generating a diverse collection of high quality antibodies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Immunization</i>. We have developed an integrated collection of immunization methods, termed Raptor, which includes purified proteins, engineered cells, viral-like particles, and DNA. These methods all work in concert with the goal to elicit a strong and diverse immune response.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Diversification</i>. We have developed a hyperimmune mouse, combined with a variety of co-stimulation methods, to optimize the immune response to each target and yield a diverse collection of antibodies that recognize different epitopes, or binding regions, on the same target protein. This is a critical component of our discovery process as we believe it greatly increases the probability of identifying antibodies with the desired functional properties necessary for therapeutic development.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Optimization</i>. We have streamlined the processes of humanization and optimization so that we can rapidly advance antibodies with the desired functional properties to fully developed building blocks. These building blocks can then be assembled into novel therapeutic product candidates using our <i>MultiMab<sup>TM</sup></i> platform.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_009.jpg" style="height: 226px; width: 537px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, our <i>DiversImmune<sup>&#174;</sup></i>
platform has been used to generate antibodies for pharmaceutical and biotechnology companies. We are now using this platform internally
to create what management believe to be an industry-leading collection of building blocks to support a growing pipeline of therapeutic
product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>MultiMab</i></b><i><sup>TM</sup></i><b>: Our antibody engineering
platform</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our <i>MultiMab<sup>TM</sup></i>
platform enables us to build a diverse array of bi-and multi-specific antibody formats, allowing us to optimize the format of our product
candidates. Because biology is diverse and complex, there is no &#8220;one size fits all&#8221; solution to engineering multi-specific
antibodies. Instead, different problems call for different solutions. We draw from a suite of different antibody formats to choose the
one that we believe best suits the disease and mechanism we are targeting. Despite having multiple formats from which to choose, our formats
typically contain two key features:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bivalent binding</i>. Bivalent binding, or binding with two points of contact, takes advantage of the concept of avidity, specifically that multipoint connections are much stronger than single point connections. In order to maximize efficacy, we build bivalent binding into our therapeutic product candidates where increased strength of binding is desirable. For example, ABP-102 features two identical binding sites for HER2, rather than one. This enables the molecule to bind tightly to HER2+ tumor cells, forming a strong immunological synapse, or cell-to-cell interaction, between the tumor cell and the cytotoxic T cell. We believe this is critical to generating a strong and sustained immune response and differentiates ABP-102 from other T-cell engaging bispecific antibodies that only feature a single binding site for the tumor-specific antigen.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Fc region</i>. The Fc region of an antibody interacts with various receptors on immune cells to control both the immune response to antibody binding and the circulating half-life of an antibody. To take advantage of these natural functions, we build Fc regions into all our therapeutic product candidates. For example, ABP-102 features a human IgG1 Fc region that promotes a long circulating half-life, and has been further engineered to reduce or eliminate antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) to reduce potentially harmful side-effects associated with inflammation and cytokine release. Similarly, ABP-201 features an Fc region that results in greater stability and, due to its size, a longer ocular half-life, potentially enabling more convenient dosing for patients.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Both of our lead product candidates,
ABP-102 and ABP-201, are TetraBi antibodies that feature two high affinity binding sites for each of their targets and Fc regions for
longer half-lives. In addition, both product candidates are symmetrical, with two identical heavy chains and two identical light chains.
Many bispecific antibody formats are asymmetrical, featuring two different heavy chains. This creates the possibility of chain mispairing,
which complicates the manufacturing process as it is necessary to rigorously characterize each batch and minimize the presence of mispaired
species. With our TetraBi antibody format, this allows for straightforward manufacturing, as there is no possibility of chain mispairing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>MultiMab<sup>TM</sup></i> antibody engineering
platform</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_010.jpg" style="height: 249px; width: 538px"/>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Key advantages of our antibody technology platforms</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our <i>DiversImmune<sup>&#174;</sup></i>
and <i>MultiMab<sup>TM</sup></i> platforms overcome several significant limitations associated with competing antibody technologies and
have the following key competitive advantages:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Superior target access</i>. By breaking immune tolerance, our <i>DiversImmune</i><sup>&#174;</sup> platform enables us to generate high quality antibodies against traditionally difficult-to-target proteins, providing access to new therapeutic targets.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Superior speed of antibody discovery</i>. By generating a wide diversity of high quality antibodies against a single target, our <i>DiversImmune</i><sup>&#174;</sup> platform accelerates the discovery phase by increasing the probability of identifying high quality antibodies with the appropriate function. This speed allows us to rapidly scale and build a broad portfolio of functional building blocks to address disease-specific challenges that are not currently met by existing therapeutics or products. However, any product candidate developed with our platforms will still be subject to clinical trial requirements prior to approval, and we cannot accelerate clinical trials.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Superior flexibility in engineering novel therapeutics</i>. By providing access to a diverse array of bi- and multi-specific antibody formats, our <i>MultiMab<sup>TM</sup></i> platform enables us to rapidly test a broad range of solutions, shortening the timeline for lead selection and increasing the chance of finding an optimal format that meets key performance specifications.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>B cell cloning platform</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to our <i>MultiMab<sup>TM</sup></i>
platform we have developed a B cell cloning platform that enables us to isolate potently neutralizing antibodies to SARS-CoV-2, RSV, and
other viruses recognizing conserved viral epitopes resistant to mutational escape.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Immuno-Oncology Strategy For T Cell Engagement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the most promising
strategies in cancer therapy is to direct cytotoxic T cells to kill tumor cells. This can be achieved using dual-targeting antibodies,
which bind simultaneously to a tumor-specific antigen on a tumor cell and to CD3 on a T cell, bringing these cells into close proximity
and causing the T cell to kill the tumor cell. First-generation bispecific antibodies were called Bispecific T-cell Engagers, or BiTEs,
and contained two Fv regions, one for the tumor antigen and one for CD3. Because they do not contain an Fc region, BiTEs have very short
circulating half-lives, requiring patients to wear an infusion pump for continuous intravenous administration. Second-generation bispecific
antibodies contain an Fc region, but typically have only one binding site for the tumor antigen. This results in weaker binding to the
tumor cell than could be achieved with the corresponding bivalent antibody.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Key features of the TetraBi antibody format for T-cell engagement</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_011.jpg" style="height: 397px; width: 537px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abpro&#8217;s TetraBi
antibody format improves upon both first-and second-generation bispecific T-cell engaging antibodies, as summarized in the following
table. First, unlike first-generation bispecific antibodies, our TetraBi antibodies contain an Fc region, which provides enhanced
stability and a longer circulating half-life for potentially more convenient dosing. Second, unlike second-generation antibodies,
our TetraBi antibodies have two binding sites for the tumor antigen, rather than one. Bivalent binding promotes maximal efficacy via
an avidity-based binding effect for the tumor associated antigen, allowing for the establishment of strong connections between the T
cell and the tumor cell, leading to sustained activation through clustering of the T cell receptor complex in the presence of high
antigen densities. By placing the CD3-binding domain in the hinge region of the molecule, the TetraBi antibody format has been shown
in preclinical studies to exhibit monovalent-like interaction with CD3. This is important in preventing TetraBi antibodies from
activating T cells in the absence of tumor cells, which could lead to undesirable toxicities such as cytokine release syndrome, or
CRS, a potentially life-threatening toxicity associated with T cell targeted therapies. Finally, unlike second-generation
antibodies, our TetraBi antibodies contain two identical heavy chains and two identical light chains. This allows for easy
manufacturing, as there is no possibility of mispairing between two different heavy chains.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Key advantages of our TetraBi antibody format</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_012.jpg" style="height: 226px; width: 538px"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead product candidate,
ABP-102, illustrates the key advantages of this format. ABP-102 is bivalent for HER2, providing stronger binding to tumor cells than could
be achieved with first- and second-generation formats that are monovalent for HER2. ABP-102 has been shown in preclinical mouse studies
not to activate T cells in the absence of tumor cells, but induce T cells to kill tumor cells in a HER2-dependent manner.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the TetraBi antibody
format of our ABP-102 product candidate offers several significant competitive advantages over other bispecific antibody formats and other
approaches to T-cell-based therapy leading to a potentially superior therapeutic window:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Bivalent binding</i>. By including two binding sites for the tumor antigen, our antibodies are designed to form a much stronger connection to tumor cells than competitor molecules that feature only a single binding site.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Potentially better dosing through inclusion of an Fc region</i>. By including an Fc region, our TetraBi antibodies are designed to have long circulating half-lives, enabling potentially more convenient dosing for patients.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Controlled immune effector function through Fc engineering</i>. By introducing defined mutations into the Fc region, we are potentially able to diminish or eliminate Fc-mediated interactions that can contribute to unwanted side effects such as CRS.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Lower immunogenicity</i>. By closely resembling human antibodies with natural amino acid sequences, our TetraBi antibodies may have a reduced risk of being immunogenic, or capable of producing an undesirable immune response, which could otherwise lead to decreased efficacy.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Streamlined manufacturing</i>. By building symmetrical molecules with two identical heavy chains and two identical light chains, our molecules are designed to eliminate complications arising from potential chain mispairing.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Advantages of TetraBi antibodies over CAR T
therapy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">T cells can also be directed
to kill tumor cells by genetically modifying them to express a chimeric antigen receptor, or CAR. A CAR is a synthetic receptor in which
an Fv domain of an antibody that recognizes a tumor-specific antigen is linked to a portion of the T-cell receptor, typically CD3-zeta,
as well as one or more costimulatory domains. T cells expressing a CAR, or CAR T cells, bind to and subsequently kill tumor cells expressing
the appropriate antigen. CAR T therapy has demonstrated efficacy in liquid tumors garnering FDA approval, including agents targeting hematological
malignancies such as lymphomas, leukemias, and multiple myeloma. However, there are currently no approvals in solid tumor indications.
Unlike antibody therapy, CAR T therapy is a complex, multi-step process. After a patient&#8217;s white blood cells are collected, T cells
are isolated and activated. They are then genetically engineered to express the CAR. The CAR T cells then need to be grown for several
weeks before being infused back into the patient. Prior to infusion, however, patients have to undergo chemotherapy to deplete immune
cells, providing an opportunity for the CAR T cells to engraft in the patient. Despite the effectiveness of this approach, there are several
challenges to the widespread adoption of CAR T therapy. The process of engineering CAR T cells is technically challenging, time-consuming,
and expensive. In addition, there are significant toxicities associated with CAR T therapy, including CRS. Although patients receiving
CAR T therapy are often treated for CRS while undergoing therapy, treatments for CRS, namely administration of immuno-suppressive agents,
can also reduce the efficacy of the therapy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we have yet to observe
any advantages of TetraBi antibodies in a clinical trial, and TetraBi antibodies have not yest received marketing approval, we believe
our next-generation CD3-targeted T-cell engagers have several advantages over CAR T therapies. Like CAR T therapy, we are redirecting
cytotoxic T cells to fight cancer. Unlike CAR T therapy, however, potential treatment with our TetraBi antibodies should be straightforward
and convenient for patients. They will not be required to travel large distances to state-of-the-art cancer centers, but may instead be
treated by simple intravenous infusion in local clinics. They will not be required to wait weeks for their T cells to undergo a lengthy
and complex modification process, and they will not need to undergo chemotherapy to deplete their immune cells. It will also be potentially
much easier to manage toxicities by altering the dose of the antibody. Finally, our TetraBi antibody therapy is expected to be less expensive,
reducing obstacles associated with payment and reimbursement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Target Markets</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead product candidates
are currently targeting the therapeutic areas of cancer and ophthalmology. The global breast cancer monoclonal antibodies market size
is estimated to grow by USD 15 billion at a CAGR of 12.5% between 2022 and 2027, according to Technavio. North America is estimated to
contribute 42% to the growth of the global market during the forecast period, according to the same source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Immuno-oncology / oncology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Oncology therapeutics accounted
for $143 billion in branded pharmaceutical sales in 2019-approximately 20% of global pharmaceutical sales. Analyst consensus figures indicate
a 12% CAGR, and global oncology therapeutics sales are forecasted to hit $250 billion by 2024, according to McKinsey &amp; Co. In 2022,
global sales of Rituxan/MabThera (rituximab), Avastin, and Herceptin combined for $11.55 billion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Ophthalmology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The global ophthalmology
market is expected to experience growth in the forecast period of 2023 to 2030. Data from Bridge Market Research analyzes that the
market is growing with a CAGR of 6.4% in the forecast period of 2023 to 2030 and is expected to reach $84 billion by 2030, from $51
billion in 2022. The global wet age-related macular degeneration (AMD) market, estimated at $6.9 billion in 2018, is projected to
reach $10.4 billion by 2024, registering a CAGR of 7.1% during the forecast period. The market is predominantly driven by the
increase in prevalence of AMD, lack of availability of specific treatment, and surge in geriatric population, according to P&amp;S
intelligence (Prescient &amp; Strategic Intelligence).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Product Candidates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ABP-102 for HER2+ breast and gastric cancers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our lead product candidate,
ABP-102, is a TetraBi antibody targeting HER2 and CD3. It is an affinity-tuned, Fc engineered dual-targeting antibody with a human IgG1-like
structure. ABP-102 features two binding sites for bivalent binding to cells expressing HER2, and two binding sites for CD3 in a format
that promotes functional monovalency during cell binding. We believe this structure provides greater potential for clinical applications
compared with other HER2-directed T-cell-engaging bispecific antibodies that have only one binding site for the tumor-specific antigen
(<i>i.e.</i>, HER2), allowing for an avidity-enhanced effect. ABP-102 is designed to redirect T cells to tumor cells that are overexpressing
HER2 at high or intermediate levels. In preclinical studies, we have shown that ABP-102 selectivity promotes T cell activation, cytokine
release and cytotoxicity in the presence of HER2-high and intermediate expressing cells, including HER2+ breast, ovarian, and gastric
cancer cell lines. We have also observed reduced or no cytotoxic activity against cell lines expressing low/endogenous levels of HER2.
This feature provides the opportunity for an improved therapeutic window to attack tumor cells while reducing systemic toxicity by promoting
&#8220;on-target, on-tumor&#8221; effects, with reduced potential for &#8220;on-target, off-tumor&#8221; toxicity toward endogenous tissues.
We plan to initiate clinical trials of ABP-102 in the first half of 2026 with our partner Celltrion, focusing on HER2+ breast and gastric
cancers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background and market opportunity for HER2+ breast and gastric cancers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Breast cancer is the most
common cancer in women in the United States, except for skin cancers. It is about 30% (or 1 in 3) of all new female cancers each year.
The American Cancer Society&#8217;s estimates for breast cancer in the United States for 2023 are: About 297,790 new cases of invasive
breast cancer will be diagnosed in women. About 55,720 new cases of ductal carcinoma in situ (DCIS) will be diagnosed. About 43,700 women
will die from breast cancer. Breast cancer is the second leading cause of cancer death in women (only lung cancer kills more women each
year). The chance that a woman will die from breast cancer is about 1 in 39 (about 2.5%). The American Cancer Society&#8217;s estimates
for stomach cancer (also known as gastric cancer) in the United States for 2023 are approximately 26,500 new cases (15,930 in men and
10,570 in women) and approximately 11,130 deaths (6,690 men and 4,440 women). Stomach cancer accounts for about 1.5% of all new cancers
diagnosed in the United States each year, according to the American Cancer Society.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, HER2 directed therapies
generated approximately $10.3 billion in full year sales. The four drugs that made up this number include PERJETA (approximately $4.6
billion), KADCYLAZ (approximately $2.3 billion), HERCEPTIN (approximately $2.2 billion), and ENHERTU (approximately $1.2 billion), according
to public disclosures made by Genentech/Roche and Daiichi Sankyo/AstraZeneca.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cancer type</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incidence<br/>
of high<br/>
HER2 <br/>
expression</b></span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Breast</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">~20 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Endometrial</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8-35 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gastroesophageal</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4-22 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pancreatic</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2-29 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cervical</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1-21 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bladder</span></td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5-15 </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Source: Cancer Treatment Reviews</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Potential competitive advantages of ABP-102 versus approved anti-HER2
therapies</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Current HER2-directed therapies
have demonstrated increased chemical off target toxicity (e.g., TKIs and ADCs) and/or reduced efficacy from drug resistance or limited
potency requiring combination with chemotherapy (i.e., mAbs), especially in the relapsed and refractory disease population. ABP-102 seeks
to overcome these challenges as a single-agent therapy that potently engages the patient&#8217;s natural immune system without toxic chemicals
to directly target and destroy the tumor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Potential benefits of ABP-102 in immuno-oncology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-102 is a TetraBi antibody
that is designed to bind simultaneously to HER2 overexpressed on a tumor cell and CD3 on a T cell, thereby bringing the two cells into
close proximity and promoting T-cell activation that leads to killing of the tumor cell. ABP-102 is a differentiated therapeutic in that
it is able to selectively target HER2-high and intermediate expressing cells, with reduced activity on HER2-low or negative cells, an
engineered design feature to promote safety for endogenous HER2-expressing tissues. The TetraBi antibody format of ABP-102 is intended
to improve on the clinical efficacy of HER2 targeted therapy by inducing infiltration of T cells into HER2+ tumors. In addition to HER2+
breast cancer, ABP-102 can potentially target any solid tumor in which HER2 is overexpressed, including HER2+ gastric, esophageal, endometrial,
ovarian, colorectal, lung, pancreatic, cervical, gallbladder, and bladder cancers, as well as HER2+ pediatric indications including osteosarcoma.
By targeting both HER2 and CD3, ABP-102 may overcome many of the limitations of single-targeting agents. For instance, agents targeting
HER2 alone, such as Herceptin, face problems with drug resistance, often caused by alterations in the HER2 signaling pathway or other
related pro-proliferative pathways.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-102 works by a different
mechanism, engaging cytotoxic T cells to kill the tumor cells rather than blocking the function of HER2. As such, we believe that ABP-102
could lead to more durable responses in patients, with reduced risk of drug resistance. Furthermore, ABP-102 possesses an advanced TetraBi
antibody format, unlike that of competing agents that only feature a single binding site for HER2. Having two binding sites for HER2 enables
higher binding potential and selectivity for tumor cells, which may result in greater potency and an improved therapeutic index. In addition,
this dual binding may provide access to a broader patient population, including patients that express intermediate levels of HER2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABP-102</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>immune-mediated</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>HER2+ tumor cell death</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;<img alt="" src="image_013.jpg" style="height: 492px; width: 537px"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Preclinical data</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For ABP-102 to be both safe
and effective, it must only activate T cells when HER2+ tumor cells are present. The key safety risk for T-cell engaging therapies is
CRS, in which T cells and other white blood cells become activated, leading to the over-production of pro-inflammatory cytokines. This
can cause high fever, swelling, redness, extreme fatigue, nausea, and, in rare cases, death. The ABP-102 Fc region is engineered to have
reduced binding to Fc receptors and C1q, thereby making T cell engagement the definitive mechanism of action. By positioning the CD3-binding
domain near the hinge region of the molecule, it selectively activates T cells only in the presence of HER2+ tumor cells. Thus, when ABP-102
is added to T cells or PBMCs alone, the T cells do not release pro-inflammatory cytokines like TNFa, IL-6, IL-2and IFNg. When HER2+ tumor
cells are introduced, however, ABP-102 causes potent activation of the T cells, along with cytokine release reflecting T cell activation.
This strong dependency on HER2 for T cell engagement may result in a beneficial therapeutic index for ABP-102, enabling a dose to be found
that is both safe and effective. In addition, HER2 is expressed at lower levels in some tissues of the human body, including heart and
lung tissues. Therefore, we have engineered ABP-102 to promote selectivity for T cell activation and killing of HER2-high and intermediate
target cells, which is a key differentiating feature.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical in vitro studies,
ABP-102 has shown strong antitumor activity that is dependent on the presence of CD3-positive T cells, a key component of cellular immunity
within human peripheral blood mononuclear cells, or PBMCs. PBMCs consist of monocytes and lymphocytes, which are white blood cells made
up of T cells, B cells, and natural killer, or NK cells.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have tested ABP-102
for cytotoxicity on a wide variety of cell lines with a broad range of HER2 surface expression levels, from high to intermediate to
low, as determined by flow cytometry with trastuzumab biosimilar antibody (Figure 1). These cell lines include HER2-high expressing
cell lines such as SKBR-3, BT-474, and NCI-N87, and also HCC1954 breast cancer cells, which are HER2+, but resistant to Herceptin.
ABP-102a, b, and c lead candidate affinity-tuned constructs were all able to kill all cell lines expressing high-to-intermediate
HER2 levels at a similar dose range for maximum cytotoxicity to the parental HER2 x CD3 TetraBi construct with unmodified HER2 and
CD3 affinity. MDA-MB-453 cells are reported to be HER2 intermediate in the literature, and this was similar in our flow cytometry
assessment; ABP-102 similarly shows killing of that cell line as well. However, in contrast to the HER2 x CD3 parental TetraBi
antibody, ABP-102a, b, and c have reduced activity on HER2 low-to-negative cells, including the ZR-75-1, MCF-7, HT55, JIMT-1 cell
lines, in which erbb2/HER2 gene expression is not amplified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In these studies, ABP-102a,
b and c exhibited selective cytotoxicity in the presence of human PBMCs that was dependent on HER2 expression level, with preferential
killing of HER2-high expressing cell lines and reduced activity on HER2-low cell lines. This selectivity for targeting of HER2-high expressing
cells may help to widen the therapeutic window of a T cell engager with less potential for toxicity toward tissues expressing endogenous
levels of HER2.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Figure 1. ABP-102 is effective in vitro against
a range of cancer cell lines expressing high and intermediate HER2 levels, but shows reduced activity on HER2 low to negative cell lines.</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;<img alt="" src="image_014.jpg" style="height: 246px; width: 605px"/></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Figure 1 legend</b>:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Cell lines were harvested
with Accutase followed by staining with 1 ug/mL trastuzumab biosimilar antibody, followed by staining with anti-human IgG-PE secondary
antibody. Flow cytometry data were collected using a BD FACSCelesta and analyzed in FlowJo software as quantified by median fluorescence
intensity (MFI). For cytotoxicity analysis, PBMCs were added at a 10:1 E:T ratio (100,000 PBMCs: 10,000 seeded target cells) and incubated
with antibodies for 42 hours, at which time cytotoxicity was quantified using the CellTiterGlo2.0 protocol for each cell line. Lead clones
ABP-102a, b, and c are shown as compared to a positive control (non-affinity tuned CD3 x HER2 parental TetraBi), as well as a comparator
molecule (HER2 x CD3 monovalent heterodimer). An isotype control bispecific antibody with an intact CD3 binding arm was used as a negative
control.&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To determine whether T cell
activation differences account for the observed differential activity on HER2-high and intermediate cells, we assessed culture supernatants
for cytokine release (Figure 2). Similar cytotoxicity is observed with ABP-102a, b, and c on the HER2-high (SKBR-3) cell line, with a
modest reduction in cytokine release compared to the HER2 x CD3 parental control TetraBi molecule. However, when using cell lines with
HER2-low expression (MCF-7) as target cells, we observe less cytotoxicity with ABP-102a, b, and c as compared to the HER2 x CD3 parental
control TetraBi molecule. On HER2-low expressing cells, we also observe a markedly reduced cytokine release profile, reflecting reduced
activation of T cells as compared to the HER2 x CD3 parental control TetraBi molecule.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This data demonstrates the
selectivity of our ABP-102 candidate lead molecules, a feature which should help to promote cytotoxicity for HER2 overexpressing cells
while potentiating an environment for durable T cell responses, while also mitigating risks to endogenous HER2-expressing tissues including
the heart and lungs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Figure 2. ABP-102 exhibits selectivity for
HER2 overexpressing cells through differential activation of T cell cytotoxicity and cytokine release against HER2-high (SKBR-3) and HER2-low
(MCF-7) cell lines.</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_015.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_016.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Figure 2 legend:</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>PBMCs were added at a 10:1
E:T ratio and incubated for 42 hours, at which time cytotoxicity was quantified using the CellTiterGlo2.0 protocol. Cytokine release was
detected in supernatants diluted 1:5 in assay buffer before addition to a sensitive multiplexed bead-based assay for quantification of
IL-2, IFNg, TNFa, and IL-6 (R&amp;D Systems/Biotechne), with detection and quantification on a MagPix system (Luminex).</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-102 lead candidates are
currently under evaluation with HER2-high and HER2-low expressing cell line xenograft tumor models in mice, with human PBMCs as effector
cells. Final selection of a lead molecule will be based on cumulative in vitro data and anti-tumor efficacy in the HER2 tumor in vivo
models. Expression cell lines are currently in development for production of ABP-102a, b, and c, with plans in place for CMC activities
ahead of GLP toxicology studies and clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Clinical development of ABP-102</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In collaboration with Celltrion,
we plan to initiate first-in-human Phase 1/2 clinical trials with ABP-102 in the first half of 2026 in HER2+ solid tumors, including breast
and gastric cancer as well as orphan drug indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ABP-201 for DME and Wet AMD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our second lead product candidate,
ABP-201, is a different TetraBi antibody that simultaneously targets VEGF and ANG-2. ABP-201 binds with very high, or subnanomolar, affinity
to ANG-2 and most of the major isoforms of VEGF, including VEGF165, VEGF189, and VEGF121. Due to its TetraBi antibody format, ABP-201
features two binding sites for each of VEGF and ANG-2, which distinguishes it from bispecific antibodies that feature only a single binding
site for each target. ABP-201 is formulated for intravitreal injection and is designed to function as a &#8220;ligand trap,&#8221; removing
both VEGF and ANG-2 from the eye.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through our majority-owned
subsidiary, AbMed Corporation, we are developing ABP-201 for potential indications in ophthalmology, including DME and Wet AMD. DME is
an eye condition brought on by diabetes in which blood vessels form abnormally and leak fluid into the macula of the eye, resulting in
blurred vision and, in extreme cases, blindness. Wet AMD is similarly a severe eye condition caused by the growth and leakage of abnormal
blood vessels under the retina and macula of the eye, causing the macula to bulge or lift up from its normally flat position, thus distorting
or destroying central vision. VEGF is a clinically validated target in both DME and Wet AMD, where Eylea and Lucentis are approved and
in widespread use. As depicted in the following chart, VEGF and ANG-2 act in concert to promote angiogenesis. In normal blood vessel development,
ANG-2 plays a role in destabilizing mature blood vessels, creating an environment in which vessel branching can occur. VEGF then promotes
the sprouting of new blood vessels. In DME and Wet AMD, however, excessive destabilization of blood vessels by ANG-2 contributes to vessel
leakage, or edema. In addition, upregulation of ANG-2 is the primary mechanism of resistance to VEGF inhibition. We believe that effective
control of angiogenesis and inhibition of vessel leakage requires simultaneous inhibition of both pathways.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_017.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Current treatment options for DME</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although the underlying molecular
cause of DME and Wet AMD is not completely understood, both VEGF and ANG-2 play central roles in new blood vessel growth-a hallmark common
to both ocular diseases. Several biological therapies have been developed to inhibit VEGF by binding to and sequestering the protein.
The current standard-of-care includes Lucentis, a recombinant humanized monoclonal antibody fragment that binds VEGF, and Eylea, a recombinant
fusion protein containing portions of the human VEGF receptor. Another VEGF antibody is Avastin, a recombinant human monoclonal antibody
which is approved for the treatment of several cancer indications and is used off-label for the treatment of DME and wet AMD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before the approval of Lucentis
for the treatment of DME in 2012, the use of intravitreal injections was less common in North America and laser photocoagulation, or the
use of light to coagulate tissue, was the primary treatment. Prior to the Lucentis DME approval, several treatments including Avastin
and Macugen (pegaptanib sodium injection) were used off-label. Macugen received FDA-approval for the treatment of Wet AMD in 2004.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional products were approved
and launched in 2014, namely Eylea, Ozurdex (dexamethasone intravitreal implant), and Iluvien (fluocinolone acetonide intravitreal implant),
as well as the approval in 2022 of Vabysmo. According to estimates by Future Market Insights, intravitreal injections control a large
market share of the treatment used in DME patients. In 2021, over 94% of DME patients were utilizing anti-VEGF intravitreal injections
and implants, according to the same source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Current treatment options for Wet AMD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lucentis, Eylea, and Vabysmo
were initially FDA-approved for the treatment of Wet AMD and DME. Avastin is used off-label for the treatment of Wet AMD. Because anti-VEGF
treatments do not appear to cause regression of new blood vessels, current therapies require regular intraocular injections, typically
as often as seven times per year, and real-world studies indicate that less than 20% of patients treated with anti-VEGF biologics improve
their visual acuity by 15 or more letters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to frequent injections,
anti-VEGF treatments have been associated with subretinal fibrosis, or the formation of excess connective tissue under the retina, as
well as retinal scarring in some patients. We believe a more effective therapy that requires less frequent dosing would address the deficiencies
of current therapy and be rapidly adopted as the new standard of care for the treatment of the disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background and market opportunity for DME and Wet AMD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">DME is a leading cause of
blindness among the working age population in most developed countries. DME is one of the major complications of diabetes and studies
show that DME patients utilize significantly higher healthcare resources than non-DME diabetic patients. The growing incidences of diabetes
across the globe should further increase the burden of DME. As of 2022, nearly 422 million people worldwide have diabetes, and the number
is expected to grow to 592 million within the next 20 years, according to Future Market Insights. North America is projected to be the
largest market in terms of value and accounted for over 60% of total market revenue in 2021, according to the same source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">AMD is a progressive disease
that results in a gradual loss of vision as people age. Approximately up to 10% of total cases of AMD represent an advanced form of the
disease called Wet AMD, which is a severe eye condition that results in blurred vision and can lead to significant vision loss or blindness
due to abnormal blood vessel formation in the eye. Although Wet AMD represents only 10% of AMD, it is responsible for 90% of AMD-related
severe vision loss. Wet AMD is a leading cause of vision loss, with approximately 200,000 cases of Wet AMD diagnosed per year in North
America, according to ResearchAndMarkets.com.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, Eylea and Lucentis,
the leading approved biologics for the treatment of DME and Wet AMD accounted for over $10.4 billion in worldwide sales according to company
filings. It is important to note that the first biosimilar for Lucentis was approved in the third quarter of 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Potential ABP-201 Competitive Advantages</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unlike Eylea and Lucentis,
ABP-201 seeks to inhibit both VEGF and ANG-2. Unlike Vabysmo, ABP-201 has two binding sites for VEGF and ANG-2, designed to more effectively
trap each ligand. ABP-201 also has a longer half-life in the eye than Eylea, which contributes to pharmacological durability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Clinical Development Plan for Wet AMD</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to conduct a Phase
1, multiple-ascending dose evaluation of the safety and initial efficacy of ABP-201 in patients with wet age-related macular degeneration
(Wet AMD). Following the identification of the maximum tolerated dose (MTD) or the safety and tolerability of the maximum administered
dose (MAD), a larger randomized phase 2 study is planned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Potential benefits of ABP-201 in ophthalmology</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One way to co-inhibit VEGF
and ANG-2 is to add an ANG-2 inhibitor to an approved VEGF inhibitor. The shortcoming of this approach is that the two agents are not
physically linked and as a result will accumulate differently and be cleared from the eye at different rates. It is therefore difficult
to ensure that both targets are inhibited in the same place at the same time. In contrast to this dual agent approach, other investigational
agents, including ABP-201, use a single-agent dual-targeting antibody to ensure that both targets are engaged at the same time. Clinical
trial results with Vabysmo, a bispecific antibody co-targeting VEGF and ANG-2, showed a dose-dependent improvement in best-corrected visual
acuity relative to Lucentis, providing strong support for this approach. Importantly, our single agent approach may have regulatory advantages
over the dual agent approach given that the necessary efficacy endpoints for approval could include non-inferiority in contrast with superiority
to current standard-of-care. The dosing regimens of current DME and AMD drugs, specifically Lucentis and Eylea, are characterized by relatively
frequent injections, initially every month followed by every other month. The frequency of injection is determined by a combination of
the potency of the drug and its clearance rate from the eye. Large molecules generally clear slower than smaller molecules, and ABP-201
is approximately twice the size of Eylea and approximately four times the size of Lucentis. ABP-201 also has a higher binding capacity
than either Eylea or Lucentis, with two binding sites for VEGF and two binding sites for ANG-2. As such, we believe that ABP-201 will
require less frequent dosing, providing a significant advantage in the commercial setting. In addition, as increased signaling by ANG-2
in response to anti-VEGF therapy is one of the primary mechanisms of resistance to VEGF inhibitors, we anticipate that ABP-201 will not
suffer from drug resistance to the same extent as drugs that target VEGF alone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a rat laser-induced choroidal
neovascularization model, ABP-201 administered intravitreally resulted in comparable reductions in vascular leakage and vascular lesion
volume as Eylea. In this model, a laser is used to ablate blood vessels in the choroid (the vascular layer underlying the retina). The
area ablated then heals (becomes revascularized) spontaneously by the formation of neovascular &#8220;lesions.&#8221; Anti-angiogenic
agents can then be assessed by how much they can delay this healing, as measured by how well they can reduce vascular leakage and neovascular
lesion size.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_018.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Source: Ora, Inc., CNV Study with Intravitreally-injected Abpro
Test Article ABP201 in Brown Norway Rats, December 20, 2023.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pharmacological durability
is desired in agents administered intravitreally injection given the risk of injection-associated inflammation and the uncomfortable nature
of the injection. A major contributing factor to pharmacological durability is half-life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Administration of ABP-201
resulted in significantly reduced vascular leakage and neovascular lesion volume compared to a vehicle control and comparable to Eylea.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A major concern for all intravitreally-administered
agents is the potential for inflammation, either caused by the agent or the injection procedure. Given that intravitreal injection itself
is associated with the potential for ocular inflammation among other toxicities, increasing the pharmacological durability of such agents
is critical in minimizing the potential for such toxicities. As such, ABP-201 is engineered to both maximize half-life in the eye and
to reduce any Fc receptor-mediated inflammatory responses. In preclinical PK models, ABP-201 displays a favorable ocular half-life compared
to Faricimab (RG7716/Vabysmo) or Eylea (aflibercept). In addition, ABP-201 is well tolerated in rabbit toxicity studies.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_019.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_020.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Source: PoweredResearch, Safety, Tolerability,
and Pharmacokineti C Study Following Intravitreal (IVT) Delivery of a Novel Compound in Rabbit, April 27, 2021.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Administration of ABP-201
results in intraocular pressure (IOP) increases comparable to vehicle control (left panel above). Additionally, ocular examinations (OE)
to evaluate ocular surface morphology, anterior segment and posterior segment inflammation, cataract formation, and retinal changes were
performed. The OE scores can range from 0, indicating no abnormalities, to 48, indicating a maximum number of maximally severe abnormalities.
Other than a mild increase in OE score of 5 at day 1 post-injection, which returned to 0 for the duration of the study, the OE scores
were identical to that of the vehicle control. Taken together, the lack of increases in IOP and OE scores suggests that ABP-201 is well-tolerated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The vitreous humor in the
human eye is approximately 4 ml. Given the small volume of the vitreous humor, agents injected intravitreally must be able to be sufficiently
concentrated so as to be injected in small enough volumes to not produce significant increases in IOP. Excessive increases in IOP resulting
in ocular hypertension is associated with a variety of adverse events such as ocular inflammation, glaucoma, and retinal detachment. As
such, ABP-201 formulation efforts have achieved a 100 mg/ml concentration with acceptable biophysical characteristics, especially viscosity.
We believe that this concentration will allow us to administer efficacious dose levels of ABP-201 in small enough volumes to avoid toxic
increases in IOP. Even so, preliminary evidence suggests that higher concentrations are achievable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Other programs</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Additional TetraBi antibody T-cell engagers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Building on the CD3-directed
TetraBi antibody format of ABP-102, we are using our <i>DiversImmune<sup>&#174;</sup></i> and <i>MultiMab<sup>TM</sup></i> platforms to
develop a broad pipeline of immuno-oncology agents that target highly expressed antigens on a diverse range of tumor types.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ABP-110</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-110 is a TetraBi antibody
targeting GPC3 and CD3 for the potential treatment of hepatocellular carcinoma, or HCC, the major form of liver cancer. ABP-110 is designed
to bind bivalently to GPC3 on HCC cells and CD3 on cytotoxic T cells, bringing these two cell types into close proximity and triggering
sustained T-cell activation and tumor cell killing. GPC3 is an onco-fetal antigen that is only expressed during fetal development and
on HCC cells, making it an ideal tumor antigen target. GPC3 expression is also prognostic of poor overall survival in HCC, suggesting
that ABP-110 may be most effective in the patients at highest risk and most in need of novel therapeutic interventions. Targeting this
patient population may provide for a relatively rapid path to approval given the unmet medical need in HCC.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_021.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Source: Abpro internal data.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have generated three lead
candidates that have displayed potent T cell-mediated killing of GPC3-positive tumor cells. The next steps are to assess the pharmacokinetics
and in vivo efficacy in preclinical GPC3-positive tumor models. We expect to initiate clinical trials for ABP-110 in the first half of
2027. According to SNS Insider, the global liver cancer therapeutics market is projected to reach $12.9 billion by 2030.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ABP-150</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-150 is a TetraBi antibody
targeting claudin 18.2 and CD3 for the potential treatment of gastric cancers. Like our other T cell engagers, ABP-150 is designed to
bind bivalently to claudin 18.2 on gastric cancer cells and to CD3 on cytotoxic T cells, leading to T cell-mediated killing of gastric
tumor cells. Claudin 18.2 is exclusively expressed on gastric tissue, a tissue with a high physiological turnover rate, making it tolerant
of even moderate acute toxicity without unacceptable or chronic toxic effects.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><img alt="" src="image_022.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Source: Abpro internal data.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><img alt="" src="image_023.jpg"/></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Source: Abpro internal data.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinically, ABP-150 shows
potent killing in in vitro T cell-mediated killing assays. In both mouse syngeneic tumor models using human CD3-transgenic mice and human
tumor xenograft models using human peripheral blood mononuclear cells as a source of T cells, ABP-150 shows potent efficacy. As ABP-150
cross-reacts with mouse claudin 18.2, but not mouse CD3, we demonstrated in a human CD3-transgenic mouse toxicity model that ABP-150 is
well tolerated, with little impact on body weight, appetite (food consumption) or body temperature. IL-6, a key cytokine for the initiation
of cytokine release syndrome, saw little increase over vehicle (placebo) control. The next steps are to evaluate toxicity in a non-human
primate model. We expect to initiate clinical trials for ABP-150 in the first half of 2027. According to Data Bridge Market Research,
the global gastric cancer market is projected to reach $13.1 billion by 2029.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>SARS-CoV-2 neutralizing antibody program</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of October 2023, according
to data published by the Word Health Organization, the COVID pandemic has resulted in over 771 million confirmed cases and over 6 million
deaths have been reported globally. While vaccination efforts have made tremendous strides in bringing the pandemic under control, vaccination
is contraindicated in some individuals, such as the immunocompromised. For these patients, there are no currently available prophylactic
therapies. The only therapies available are Nirmatrelvir/ritonavir, molnupiravir, and remdesivir. While these are effective therapies,
their toxicities preclude them from being used as prophylactics. Monoclonal antibodies are ideal molecules to serve as prophylactic therapies
as they can effectively neutralize the SARS-CoV-2 virus and have a proven safety profile and can be engineered to extend their half-lives.
However, all antibody therapies and prophylactics to date have become ineffective due to SARS-CoV-2 viral mutation. In response to the
global pandemic, Abpro sought to develop COVID antibodies targeting highly conserved (resistant to mutation) areas of the virus with highly
potent neutralizing antibodies engineered to have extended half-lives to allow for dosing intervals of greater than six months, through
collaborations with third parties in the form of in-license agreements. Several candidate molecules were evaluated through different stages
of development. The most advanced molecule was developed through GMP manufacturing and evaluated in a clinical trial. Although the clinical
trial was not successful, Abpro has developed significant capabilities in the infectious disease area and may leverage such capabilities
into novel therapeutics.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Collaborations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing next generation
antibodies both independently and in collaboration with leading global biopharmaceutical companies and non-profit and government research
institutions. We in-license some of the technology that we use in the ABP-110 and ABP-201 molecules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>In-licensing agreements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We in-license rights to intellectual
property relevant or potentially relevant to our development and commercialization plans in the ordinary course of business. We have in-licensed
rights to certain intellectual property from the National Institutes of Health, or NIH, and from AstraZeneca (formerly Medimmune).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>National Institutes of Health-ABP-110</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2017 we entered
into a patent license agreement effective as of August 1, 2017 with the National Cancer Institute, or NCI, a division of the NIH, pursuant
to which we received an exclusive, worldwide license, with the right to sublicense (subject to certain conditions), under certain patent
rights to make, have made, use, have used, sell, have sold, offer to sell and import products covered by the licensed patents in the field
of using certain monoclonal antibodies as monospecific or bispecific antibodies for the treatment of liver cancer. The license was amended
in May 2020 and October 2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the
treatment of GPC-3 expressing liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization
was extended. We agreed to pay NCI a $25,000 issuance fee in connection with the October 2023 amendment to the patent license agreement.
Under the amended patent license agreement, we will be obligated to pay a $25,000 minimum annual royalty, creditable against any earned
royalties, and to pay royalties of a single digit percentage based on net sales of licensed products. We also agreed to pay up to an aggregate
of approximately $16.0 million of benchmark royalties, which are payable upon achieving certain clinical, regulatory and commercial milestones.
We also agreed to pay sublicense royalties ranging from a mid-single digit percentage to a low-double digit percentage based on the fair
value of the consideration we receive from any sublicensees. The royalty term expires on a licensed patent-to-licensed patent and country-by-country
basis upon the earlier of (i) the date an application in the licensed patents has been abandoned, (ii) the date a licensed patent expires
or (iii) the date a licensed patent has been held invalid or unenforceable by a court of competent jurisdiction or administrative agency.
Unless earlier terminated, our agreement with NCI will expire upon expiration of all licensed patent rights. NCI may terminate our agreement
upon the occurrence of specified bankruptcy events for us or if we are in material default or breach of the agreement and do not cure
within a specified notice and cure period. NCI may terminate the agreement if necessary to meet the public use requirement specified by
federal regulations and we are not reasonably satisfying such requirements. We may also terminate the agreement as to any licenses in
any country or territory upon 60 days written notice. Upon expiration or termination of the agreement, we are required to return to NCI
or destroy all licensed products and other materials in the licensed patents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our license is subject to
the reserved rights of NCI and the U.S. government. Additionally, all licensed products used or sold in the United States are required
to be manufactured substantially within the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>AstraZeneca</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2016, we entered
into a collaboration and license agreement through our majority-owned subsidiary, AbMed Corporation, or AbMed, and MedImmune (now AstraZeneca),
pursuant to which MedImmune granted AbMed an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license
under specified patent rights and know-how to make, use, sell certain of its proprietary ANG-2/VEGF-H1RK bispecific antibodies. We hold
82% of the capital stock of AbMed, and MedImmune (now AstraZeneca) holds the remainder. We are responsible for the operational activities
of AbMed, and bear all costs necessary to operate AbMed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the agreement, AbMed
agreed to pay milestone and royalty payments, including up to $244.0 million in milestone payments, which are comprised of $14.0 million
upon meeting certain clinical development milestones, $80.0 million upon achieving certain regulatory events and $150.0 million upon meeting
certain worldwide commercial sales thresholds; and tiered high-single digit to low double-digit percentage royalties based on annualized
net sales of each product commercialized from our collaboration on a country-by-country basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless earlier terminated
in accordance with its terms, the agreement with AbMed and AstraZeneca remains in effect on a country-by-country basis until the later
of (i) the expiration of patent claims that cover the licensed product in a country, (ii) 10 years after the first commercial sale of
a licensed product in a country, and (iii) the expiration of regulatory exclusivity for a licensed product in a country. AbMed could be
required to redeem AstraZeneca&#8217;s equity stake in certain circumstances. We are in breach of the terms of our license agreement with
AstraZeneca. See &#8220;Risk Factors - Risks Relating to Abpro&#8217;s Business and Industry - Through our AbMed subsidiary, we have in-licensed
certain intellectual property rights relating to ABP-201 from MedImmune Limited, or MedImmune (now AstraZeneca), and are in breach of
the terms of our license agreement with MedImmune/AstraZeneca.&#8221; AstraZeneca may terminate our agreement on the basis of this breach,
or upon the occurrence of specified bankruptcy events for us or if we are in material default or breach of the agreement and do not cure
within a specified notice and cure period. We may also terminate the agreement upon 90 days written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In November 2016, we entered
into an amendment to this agreement pursuant to which MedImmune granted us a non-exclusive sublicense to certain additional intellectual
property rights held by MedImmune under an agreement with EMD Millipore Corporation and the know-how included under the agreement was
amended. In August 2017, we entered into a side letter with MedImmune to clarify our agreement regarding the timing of our required contribution
to AbMed and the issuance of MedImmune&#8217;s equity stake. The agreement was further amended in November 2017, March 2018 and December
2019 to modify the dates for the achievement of certain development and commercialization milestones and AbMed agreed to use commercially
reasonable efforts to reach these development and commercialization milestones within specified timeframes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Partnerships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Celltrion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-102 is being developed
and commercialized through a worldwide strategic partnership with Celltrion, a leading Korean and global biopharmaceutical company headquartered
in Incheon, South Korea, under a Collaboration Agreement entered into in September 2022 and amended in October 2024. We received an initial
milestone payment of $2.0 million from Celltrion in connection with this agreement. We also received an equity investment in our Series
F preferred stock of $2.0 million from Celltrion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to form a joint
steering committee to oversee the collaboration that includes representatives from both our company and Celltrion. Celltrion agreed to
use commercially reasonable efforts to develop and commercialize a licensed product, including the achievement of certain milestones by
certain dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Collaboration Agreement,
our company is responsible for certain in vitro pre-clinical work, and Celltrion is responsible for in vivo preclinical work, CMC, clinical
development and commercialization on a worldwide basis. All costs and expenses for future development and commercialization of the molecule
are required to be paid initially by Celltrion. The proceeds from commercialization are subject to a 50/50 profit split. Amounts that
may be paid by third party collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization
partners, are also subject to a 50/50 split. Following commercial approval of ABP-102, we have agreed to reimburse Celltrion 250% of its
direct and certain indirect costs and expenses incurred through first commercial sale. Celltrion is entitled to offset amounts otherwise
due to us under the agreement until our share of these costs has been paid back; provided that we are entitled to a minimum 50% of profit
from commercial sales and from third party collaborators regardless of the amount of unreimbursed development costs outstanding (and then
50% once the reimbursement has been made in full). In addition, we are entitled to up to over $1.75 billion in development and sales milestones.
We are responsible for world-wide patent prosecution, with Celltrion reimbursing 50% of our out-of-pocket costs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless earlier terminated,
our agreement with Celltrion will remain in effect so long as ABP-102 is being developed or commercialized anywhere in the world. Either
party may terminate our agreement upon the occurrence of specified bankruptcy events relating to the other party. We may terminate the
agreement if Celltrion is in material default or breach of the agreement and does not cure within a specified notice and cure period.
Celltrion may also terminate the agreement upon 180 days written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Abpro Bio</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ABP-201 is being developed
and commercialized through a territorial partnership with Abpro Bio, a subsidiary of Abpro Bio Co. Ltd (KOSDAQ:195990), a company formerly
named Ugint Co Ltd. with diversified holdings in precision machine tools, equipment and biotechnology headquartered in Daegu, South Korea
granting Abpro Bio exclusive development and commercialization rights under a Collaboration and License agreement entered into in January
2020, in the People&#8217;s Republic of China, Japan, South Korea, Southeast Asia (which for the purposes hereof means Philippines, Indonesia,
Taiwan, Pakistan, India, Vietnam, Laos, Cambodia, Thailand, Myanmar and West Malaysia), the Middle East (which for the purposes hereof
means Bahrain, Cyprus, Egypt, Iraq, Israel, Jordan, Kuwait, Lebanon, Northern Cyprus, Oman, Palestine, Qatar, Saudi Arabia, Syria, Turkey,
United Arab Emirates and Yemen), and the Commonwealth of Independent States (CIS) (which for the purposes hereof means Armenia, Azerbaijan,
Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abpro Corporation, through
its majority owned subsidiary, AbMed Corporation, received an initial equity investment in our Series E preferred stock of $30 million
from Abpro Bio in connection with this agreement. Under the Collaboration and License Agreement, we granted Abpro Bio an exclusive, royalty-bearing
sublicenseable (subject to certain restrictions) license under specified patent rights and know-how to make, use, sell certain proprietary
ANG-2/VEGF-H1RK bispecific antibodies in China, Japan, South Korea and certain other countries in South East Asia, the Middle East and
the Commonwealth of Independent States (CIS).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to form a joint
steering committee to oversee the collaboration that includes representatives from both AbMed Corporation and Abpro Bio. Abpro Bio agreed
to use commercially reasonable efforts to develop and commercialize a licensed product, including the achievement of certain milestones
by certain dates. Under the agreement, Abpro Bio agreed to pay us a double-digit percentage royalty in the low teens, tiered based on
cumulative net sales by Abpro Bio, its affiliates or sublicensees beginning with the first commercial sale of a licensed product in its
territory. We are also entitled to payments totaling approximately $540 million subject to the satisfaction of certain development and
sales milestones. We are responsible for patent prosecution and Abpro Bio has agreed to reimburse us for patent costs in its licensed
territory. Unless earlier terminated in accordance with its terms, the agreement with Abpro Bio remains in effect on a country-by-country
basis until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) 10 years after the first
commercial sale of a licensed product in a country, and (iii) the expiration of regulatory exclusivity for a licensed product in a country.
We may terminate the agreement upon the occurrence of specified bankruptcy events relating to Abpro Bio or if Abpro Bio is in material
default or breach of the agreement and does not cure within a specified notice and cure period. Abpro Bio may also terminate the agreement
upon 90 days written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NJCTTQ</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We entered into a collaboration
agreement in January 2019 with NJCTTQ, a pharmaceutical company specializing in research and development, production and commercialization
of drugs for cardiovascular diseases, tumors, perioperative care, gastrointestinal disorders and urologic diseases headquartered in Nanjing,
China.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to form a joint
steering committee to oversee the collaboration that includes representatives from both our company and NJCTTQ. NJCTTQ paid a technology
access fee to us and agreed to reimburse our preclinical research and development costs for the selected program up to CMC stage. Under
the agreement, CMC development costs and GLP toxicology costs are shared equally, with each party thereafter being responsible for its
own development and commercialization costs in its territory, with the NJCTTQ territory being China and Thailand and our company retaining
rights to the rest of the world. The parties agreed to pay reciprocal royalties, with each of them paying the other party low single-digit
royalties, tiered based on net sales per calendar year in its territory. In addition, NJCTTQ agreed to pay us milestones based on commercial
approval and sales in its territory of up to $405 million and we agreed to pay NJCTTQ a milestone based on commercial approval in our
territory of $5 million. ABP-150 is being developed under this agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless earlier terminated
in accordance with its terms, the initial term of this agreement is five years from its effective date, with automatic renewals for an
additional five years unless objected to in writing by a party at least six months prior to expiration of the initial term. If no joint
development program gets to clinical stage within the first five years of the collaboration, then the agreement by its terms will not
be renewed after expiration. Either party has the right to terminate in the case of material default or breach of the agreement by the
other party not cured within a specified period, in which case the parties&#8217; rights and obligations under the agreement are terminated,
except for rights accrued prior to termination and customary survival clauses. If the agreement is terminated other than for cause, the
territorial rights and payment obligations of each party relating to the development and commercialization of a licensed product in its
territory survive such termination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The agreement remains unrenewed
at this time after the expiration of its initial term. However, notwithstanding the agreement&#8217;s expiration, the low single-digit
royalties and the $5 million milestone payable to NJCTTQ based on commercial approval in our territory, as described above, will continue
to apply.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not have, and we do
not currently plan to acquire or develop, the infrastructure, facilities or capabilities to manufacture current Good Manufacturing Practices,
or cGMP, bulk drug substance or filled drug product for use in human clinical trials. We intend to utilize third-party manufacturers such
as contract manufacturing organizations, or CMOs, to produce, test and release cGMP bulk drug substance and drug product for our planned
clinical trials. We expect to continue to rely on such third parties to manufacture clinical trial material for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The biotechnology and biopharmaceutical
industries, and the immuno-oncology and ophthalmology subsectors, are characterized by rapid evolution of technologies, fierce competition
and strong defense of intellectual property. Any product candidates that we successfully develop and commercialize will have to compete
with existing therapies and new therapies that may become available in the future. While we believe that our proprietary <i>DiversImmune<sup>&#174;</sup></i>
and <i>MultiMab<sup>TM</sup></i> platforms, along with our scientific expertise in the field of biologics and immuno-oncology, provide
us with competitive advantages, a wide variety of institutions, including large biopharmaceutical companies, specialty biotechnology companies,
academic research departments and public and private research institutions, are actively developing potentially competitive products and
technologies. Our competitors generally fall within the following categories:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Immune-based treatments for cancer, such as T-cell engager, CAR T and TCR therapies</i>. Such as Amgen, Bristol-Myers Squibb Company, Janux, J&amp;J, Genentech, Inc. (a member of the Roche Group, or Genentech/Roche), Vir Bio and Xencor.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Treatments for Ophthalmology related indications</i>. Such as Allergan plc, Genentech/Roche, Novartis International AG, and Regeneron Pharmaceuticals, Inc.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our competitors, either
alone or with strategic partners, have substantially greater financial, technical and human resources than we do. Accordingly, our competitors
may be more successful than us in obtaining approval for treatments and achieving widespread market acceptance, rendering our treatments
obsolete or non-competitive.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Accelerated merger and acquisition
activity in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number
of our competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing
clinical study sites and patient registration for clinical studies and acquiring technologies complementary to, or necessary for, our
programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial opportunity
could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, less
toxic, more convenient or less expensive than our comparable products. Competitors may also obtain regulatory approvals before us, resulting
in our competitors building a strong market position in advance of our products&#8217; entry, if any. We believe the factors determining
the success of our product pipeline will be the efficacy, safety and convenience of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success will
depend significantly on our and our licensors&#8217; ability to obtain and maintain patent and other proprietary protection for our product
candidates and the other technology, inventions and improvements we consider important to our business, defend any patents we obtain or
in-license, preserve the confidentiality of our trade secrets and operate without infringing the patents and proprietary rights of third
parties. Our policy is to seek to protect our proprietary and intellectual property position by, among other methods, filing and in-licensing
U.S., international (under Patent Cooperation Treaty, or PCT) and foreign patent applications related to our product candidates and other
proprietary technology, inventions and improvements that we consider are important to the development and implementation of our business.
We also rely on trade secrets, know-how and continuing technological innovation to develop and maintain our proprietary and intellectual
property position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>ABP-102</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As
                                            of September 30, 2025, we own two patent families that cover compositions of matter, methods
                                            of use, and methods of manufacture for our ABP-102 product candidate, a bispecific HER2 and
                                            CD3 binding antibody. The first and second families each consist of pending patent applications
                                            in Australia, Canada, China, Europe, Hong Kong, Japan, South Korea, and the United States.
                                            Any patents resulting from these applications would be expected to expire in 2042, excluding
                                            any patent term adjustments and/or extensions.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>ABP-110</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As
                                            of September 30, 2025, we have licensed one patent family from the US Department of Health
                                            and Human Services that covers compositions of matter, methods of use, and methods of manufacture
                                            related to our ABP-110 product candidate, a tetravalent bispecific glypican-3 (GPC3) and
                                            CD3 binding antibody. This family includes one issued patent in the United States and issued
                                            patents in China, Japan, South Korea, and Singapore. The patents in this family are expected
                                            to expire in 2033, excluding any patent term adjustments and/or extensions.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>ABP-150</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of September 30, 2025,
we own one patent family that covers compositions of matter, methods of use, and methods of manufacture for our ABP-150 product candidate,
a bispecific Claudin18.2 and CD3 binding antibody. This family includes applications that are currently pending in the United States,
China, Europe, Hong Kong, Japan, South Korea, and Thailand. The patents in this family are expected to expire in 2041, excluding any
patent term adjustments and/or extensions.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>ABP-201</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of September 30, 2025,
we own one patent family that covers compositions of matter, methods of use, and methods of manufacture for our ABP-201 product candidate,
which binds to both angiopoietin-2, or ANG-2, and vascular endothelial growth factor, or VEGF. This family includes pending applications
in the United States, China, Europe, Hong Kong, Japan, and South Korea. Any patents resulting from that application would be expected
to expire in 2042, excluding any patent term adjustments and/or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Through our majority-owned
subsidiary AbMed Corporation, we have also exclusively licensed from MedImmune/AstraZeneca certain intellectual property originally entered
in connection with ABP-200, which we are no longer developing. As of September 30, 2025, we have licensed three patent families from
MedImmune/AstraZeneca comprised of pending and/or issued U.S. and foreign patents and applications. The patents in these families are
not expected to cover ABP-201 and/or are expected to expire before commercialization of ABP-201, excluding any patent term adjustments
and/or extensions. We believe that we do not need the intellectual property licensed under this agreement for the development and eventual
commercialization of ABP-201 or any of our other programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of September 30, 2025,
one of these licensed patent families includes three issued U.S. patents, and issued patents in Australia, Brazil, China, Hong Kong,
Japan, Mexico, Russia, South Korea, as well as pending applications in Europe and India. The patents in this family are expected to expire
in 2025, excluding any patent term adjustments and/or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of September 30, 2025,
the second family of these licensed patent families includes two issued patents in the United States and issued patents in Australia,
China, Hong Kong, Japan, and South Korea, as well as pending applications in Canada, Europe, Hong Kong, and Israel. Any patents resulting
from that application would be expected to expire in 2037, excluding any patent term adjustments and/or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of September 30, 2025,
the third family of these licensed patents includes two issued patents in the United States, and issued patents in Australia, China,
Europe, Hong Kong, Japan, and South Korea, as well as pending applications in Canada, Europe, Hong Kong, and Israel. Any patents resulting
from that application would be expected to expire in 2037, excluding any patent term adjustments and/or extensions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Regulatory framework</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of individual patents
depends upon the legal term for patents in the countries in which they are obtained. In most countries, including the United States, the
patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, a patent&#8217;s
term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the USPTO in examining and
granting a patent, or may be shortened if a patent is terminally disclaimed over an earlier filed co-owned patent. The term of a patent
that covers a drug or biological product may also be eligible for patent term extension when FDA approval is granted, provided statutory
and regulatory requirements are met. However, as to the FDA component, the restoration period cannot be longer than five years and the
total patent term including the restoration period must not exceed 14 years following the FDA approval. Additionally, only one patent
may be extended, and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended.
The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the
earliest effective filing date. In the future, if and when our product candidates receive approval by the FDA or foreign regulatory authorities,
we expect to apply for patent term extensions on issued patents covering those products, depending upon the length of the clinical studies
for each product and other factors. There can be no assurance that any of our pending patent applications will issue or that we will benefit
from any patent term extension or favorable adjustments to the terms of any of our patents. The FDA and the USPTO in the United States,
and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available,
and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. An extension may also not be
granted because of, for example, a failure to exercise due diligence during the testing phase or regulatory review process, failing to
apply within applicable deadlines, failing to apply prior to the expiration of relevant patents, or otherwise failing to satisfy applicable
requirements. The actual protection afforded by a patent varies on a product-by-product basis, from country-to-country, and depends upon
many factors, including the type of patent, the scope of its coverage, the availability of regulatory-related extensions, the availability
of legal remedies in a particular country, and the validity and enforceability of the patent. In addition to patents, we rely upon unpatented
trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect
our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and non-competition,
non-solicitation, confidentiality and invention assignment agreements with our employees and consultants. We also have or intend to implement
executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. These confidentiality agreements
are designed to protect our proprietary information and, in the case of invention assignment agreements, to grant us ownership of technologies
that are developed through a relationship with a third party. However, these agreements may be breached, and we may not have adequate
remedies for any breach, with a third party. In addition, our trade secrets may otherwise become known or be independently discovered
by competitors. To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by
others in their work for use, disputes may arise as to the rights in related or resulting know-how and inventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also seek to preserve the
integrity and confidentiality of our proprietary technology and processes by maintaining physical security of our premises and physical
and electronic security of our information technology systems. Although we have confidence in these individuals, organizations, and systems,
agreements or security measures may be breached and we may not have adequate remedies for any breach. To the extent that our employees,
contractors, consultants, collaborators, and advisors use intellectual property owned by others in their work for us, disputes may arise
as to the rights in related or resulting know-how and inventions. For more information regarding the risks related to our intellectual
property, proprietary technology, inventions, improvements, platforms and product candidates, please see the section entitled &#8220;<i>Risk
Factors - Risks Related to Intellectual Property.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Government regulation and product approval</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Governmental authorities in
the United States, at the federal, state, and local level, and other countries extensively regulate, among other things, the research,
development, testing, manufacture, labeling, packaging, promotion, storage, advertising, distribution, marketing, and export and import
of products such as those we are developing. Our therapeutic product candidates must be approved by the FDA through the Biologics License
Application, or BLA, process before they may be legally marketed in the United States and will be subject to similar requirements in other
countries prior to marketing in those countries. The process of obtaining regulatory approvals and the subsequent compliance with applicable
federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>U.S. Government regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and, in the case of therapeutic biologics, the Public Health
Service Act, or PHSA, and implementing regulations of each. Failure to comply with the applicable U.S. requirements at any time during
the product development or approval process, or after approval, may subject an applicant to administrative or judicial sanctions, any
of which could have a material adverse effect on us. These sanctions could include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">refusal to approve pending applications;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">withdrawal of an approval;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">imposition of a clinical hold;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">warning or untitled letters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">seizures or administrative detention of product;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">total or partial suspension of production or distribution; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">injunctions, fines, disgorgement, or civil or criminal penalties.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>BLA approval process</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process required by the
FDA before a therapeutic biologic may be marketed in the United States generally involves the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion of nonclinical laboratory tests, animal studies and formulation studies conducted according to Good Laboratory Practices, or GLPs, and other applicable regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin, and applicable institutional review boards (IRBs)/ ethics committee approvals;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance of adequate and well-controlled human clinical trials according to Good Clinical Practices, or GCPs, to establish the safety and efficacy of the product candidate for its intended use;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission to the FDA of a BLA;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product candidate is produced to assess readiness for commercial manufacturing and conformance to the manufacturing-related elements of the application, to conduct a data integrity audit, and to assess compliance with cGMPs to assure that the facilities, methods, and controls are adequate to preserve the product candidate&#8217;s identity, strength, quality, and purity;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">satisfactory completion of an FDA inspection at selected clinical research sites, the contract research organization if the monitoring of the study was outsourced, and/or inspection of the Sponsor organization to assess GCP compliance may also be required; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">FDA review and approval of the BLA.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once a biopharmaceutical candidate
is identified for development, it enters the preclinical or nonclinical testing stage. Nonclinical tests include laboratory evaluations
of product chemistry, toxicity, and formulation, as well as animal studies. An IND sponsor must submit the results of the nonclinical
tests, together with manufacturing information and analytical data, to the FDA as part of the IND. Some nonclinical testing may continue
even after the IND is submitted. In addition to including the results of the nonclinical studies, the IND will also include a protocol
detailing, among other things, the objectives of the clinical trial, the parameters to be used in monitoring safety, and the effectiveness
criteria to be evaluated if the first phase lends itself to an efficacy determination. The IND automatically becomes effective 30 days
after receipt by the FDA, unless the FDA, within the 30-day time period, places the IND on clinical hold. In such a case, the IND sponsor
and the FDA must resolve any outstanding concerns before clinical trials can begin. A clinical hold may occur at any time during the life
of an IND and may affect one or more specific studies or all studies conducted under the IND.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All clinical trials must be
conducted under the supervision of one or more qualified investigators in accordance with GCPs. They must be conducted under protocols
detailing the objectives of the trial, dosing procedures, research subject selection and exclusion criteria, and the safety and effectiveness
criteria to be evaluated. Each protocol, and any subsequent material amendment to the protocol, must be submitted to the FDA as part of
the IND, and progress reports detailing the status of the clinical trials must be submitted to the FDA annually. Sponsors also must report
to the FDA serious and unexpected suspected adverse reactions in a timely manner, any clinically important increase in the rate of a serious
suspected adverse reaction over that listed in the protocol or investigation brochure or any findings from other studies or animal or
<i>in vitro</i> testing that suggest a significant risk in humans exposed to the product candidate. An IRB at each institution participating
in the clinical trial must review and approve the protocol before a clinical trial commences at that institution and must also approve
the information regarding the trial and the informed consent form that must be provided to each research subject or the subject&#8217;s
legal representative, monitor the study until completed and otherwise comply with IRB regulations. There are also requirements governing
the reporting of ongoing clinical trials and completed clinical trial results to public registries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials are
typically conducted in three sequential phases that may overlap or be combined.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase 1</i></b>-The product candidate is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, and elimination. In the case of some therapeutic candidates for severe or life-threatening diseases, such as cancer, especially when the product candidate may be inherently too toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase 2</i></b>-Clinical trials are performed on a limited patient population intended to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Phase 3</i></b>-Clinical trials are undertaken to further evaluate dosage, clinical efficacy, and safety in an expanded patient population at geographically dispersed clinical study sites. These studies are intended to establish the overall risk-benefit ratio of the product and provide an adequate basis for product labeling.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A pivotal study is a clinical
study that adequately meets regulatory agency requirements for the evaluation of a product candidate&#8217;s efficacy and safety such
that it can be used to justify the approval of the product. Generally, pivotal studies are also Phase 3 studies but may be Phase 2 studies
if the trial design provides a reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need.
Human clinical trials are inherently uncertain, and Phase 1, Phase 2, and Phase 3 testing may not be successfully completed. The FDA or
the sponsor may suspend a clinical trial at any time for a variety of reasons, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution
if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated
with unexpected serious harm to patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the development of
a new product candidate, sponsors are given opportunities to meet with the FDA at certain points; specifically, prior to the submission
of an IND, at the end of Phase 2 and before a BLA or New Drug Application, or NDA, is submitted. Meetings at other times may be requested.
These meetings can provide an opportunity for the sponsor to share information about the data gathered to date and for the FDA to provide
advice on the next phase of development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-approval trials, sometimes
referred to as &#8220;Phase 4&#8221; clinical trials, may be conducted after initial marketing approval. These trials are used to gain
additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, FDA may mandate the
performance of such &#8220;Phase 4&#8221; clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrent with clinical trials,
sponsors usually complete additional animal safety studies, develop additional information about the chemistry and physical characteristics
of the product candidate, and finalize a process for manufacturing commercial quantities of the product candidate in accordance with cGMP
requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and the manufacturer
must develop methods for testing the quality, purity, and potency of the product candidate. To help reduce the risk of the introduction
of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose
attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product
candidate and, among other criteria, the sponsor must develop methods for testing the identity, strength, quality, potency, and purity
of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted
to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life. Additionally, appropriate
packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo
unacceptable deterioration over its proposed shelf-life.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of product development,
nonclinical studies, and clinical trials, along with descriptions of the manufacturing process, analytical tests and other control mechanisms,
proposed labeling, and other relevant information are submitted to the FDA as part of a BLA requesting approval to market the product.
Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts
the PDUFA user fees on an annual basis. PDUFA also imposes an annual product fee for products and an annual establishment fee on facilities
used to manufacture prescription biological or drug products. Fee waivers or reductions are available in certain circumstances, such as
where a waiver is necessary to protect the public health, where the fee would present a significant barrier to innovation, or where the
applicant is a small business submitting its first human therapeutic application for review.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Within 60 days following submission
of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing.
The FDA may refuse to accept for filing any BLA that it deems incomplete or not properly reviewable at the time of submission, and may
request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application
also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth
substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent,
and/or effective for its intended use, and has an acceptable purity profile and whether the product is being manufactured in accordance
with cGMP. The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an
advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether
the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but
it considers such recommendations carefully when making decisions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the product approval
process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy, or REMS, plan is necessary to assure the safe
use of the product. If the FDA concludes a REMS plan is needed, the sponsor of the BLA must submit a proposed REMS plan. The FDA will
not approve a BLA without a REMS plan, if required. The FDA has authority to require a REMS plan to ensure that the benefits of a drug
or therapeutic biologic outweigh the risks. Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured.
The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP
requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving
a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with
IND trial requirements and GCP requirements. To assure cGMP and GCP compliance, an applicant must incur significant expenditure of time,
money, and effort in the areas of training, record keeping, production, and quality control. Notwithstanding the submission of relevant
data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval.
Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data.
If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of
the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling
changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended
actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the
applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even
if a product receives regulatory approval, the approval may be significantly limited to specific indications and dosages or the indications
for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain
contraindications, warnings, or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product
distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Post-approval requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once an approval is granted,
the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product
candidate reaches the market. Later discovery of previously unknown problems with a product candidate may result in restrictions on the
product candidate or even complete withdrawal of the product candidate from the market. After approval, some types of changes to the approved
product candidate, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further FDA review
and approval. In addition, the FDA may under some circumstances require testing and surveillance programs to monitor the effect of approved
therapeutic candidates that have been commercialized, and the FDA under some circumstances has the power to prevent or limit further marketing
of a product candidate based on the results of these post-marketing programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any therapeutic candidates
manufactured or distributed by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">record-keeping requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reporting of adverse experiences with the product candidate;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">providing the FDA with updated safety and efficacy information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">product sampling and distribution requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">notifying the FDA and gaining its approval of specified manufacturing or labeling changes; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">complying with FDA promotion and advertising requirements, which include, among other things, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therapeutic manufacturers
and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments
with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance
with cGMPs and other laws. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive
procedural, substantive, and record-keeping requirements. In addition, changes to the manufacturing process are strictly regulated, and,
depending on the significance of the change, may require FDA approval before being implemented. FDA regulations would also require investigation
and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers
that we may decide to use if our product candidates are approved. Accordingly, manufacturers must continue to expend time, money, and
effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Orphan Drug Act</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug Act,
the FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition - generally a disease or condition that
affects fewer than 200,000 individuals in the United States. Orphan Drug Designation must be requested before submitting a BLA. After
the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA.
Orphan Drug Designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The
first BLA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug Designation
is entitled to a seven-year exclusive marketing period in the United States for that product, for that indication. During the seven-year
exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances,
such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent the FDA
from approving a different drug for the same disease or condition, or the same drug for a different disease or condition. Among the other
benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the BLA application user fee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>New legislation and regulations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is drafted, introduced, and passed in Congress that could significantly change the statutory provisions governing the testing, approval,
manufacturing, and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations, guidance documents, and
policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible
to predict whether further new legislation will be enacted or FDA regulations, guidance documents, policies, or interpretations changed
or what the effect of such changes, if any, may be.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Review and approval of drug products outside the United States</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to market any drug
product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries
and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization,
commercial sales, and distribution of drug products. Whether or not it obtains FDA approval for a product, the company would need to obtain
the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the product
in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional
product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions
might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not
ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively
impact the regulatory process in others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pharmaceutical coverage, pricing and reimbursement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States and markets
in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally
rely on third-party payors to reimburse all or part of the associated healthcare costs. Significant uncertainty exists as to the coverage
and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved,
sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United
States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage, and establish adequate
reimbursement levels for, the product. The process for determining whether a payor will provide coverage for a product may be separate
from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party
payors are increasingly challenging the prices charged, examining the medical necessity, and reviewing the cost-effectiveness of medical
products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved
list, also known as a formulary, which might not include all of the approved products for a particular indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to secure coverage
and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in
order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other
comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision
by a third-party payor not to cover a product candidate could reduce physician utilization once the product is approved and have a material
adverse effect on sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for
a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage
for a drug product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage
and reimbursement can differ significantly from payor to payor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The containment of healthcare
costs also has become a priority of federal, state and foreign governments and other third-party payors, and the prices of drugs have
been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls,
restrictions on reimbursement, and requirements for substitution of generic products. Adoption of price controls and cost-containment
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s
revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time.
Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive
marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Outside the United States,
ensuring adequate coverage and payment for a product also involves challenges. Pricing of prescription pharmaceuticals is subject to governmental
control in many countries. Pricing negotiations with governmental authorities can extend well beyond the receipt of regulatory marketing
approval for a product and may require a clinical trial that compares the cost effectiveness of a product to other available therapies.
The conduct of such a clinical trial could be expensive and result in delays in commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Healthcare law and regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare providers and third-party
payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with
providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims
laws, reporting of payments to physicians and teaching physicians, patient privacy laws and regulations, and other healthcare laws and
regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws
and regulations include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Anti-Kickback Statute, which prohibits, among other things, a person or entity from knowingly and willfully soliciting, offering, paying, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, arrange for or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, by a federal healthcare program such as Medicare or Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violation of the federal Anti-Kickback Statue carries criminal penalties and fines as well as administrative sanctions under the Civil Money Penalties Law. In addition, a violation of the Anti-Kickback Statute can form the basis for a violation of the federal False Claims Act;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws, which prohibit an individual or entity from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false, fictitious, or fraudulent or knowingly making, using, or causing to made or used a false record or statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program, or knowingly and willingly falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their respective implementing regulations, including the Final Omnibus Rule published in January 2013, which impose obligations on certain covered entity healthcare providers, health plans, and healthcare clearinghouses as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information, and require notification to affected individuals and regulatory authorities of certain breaches of security of individually identifiable health information;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal false statements statute, which prohibits knowingly and willfully falsifying, concealing, or covering up a material fact, or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items, or services;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the federal transparency requirements known as the federal Physician Payments Sunshine Act, created by the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the ACA, which requires certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, information related to payments and other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">analogous local, state, and foreign laws and regulations, such as state anti-kickback and false claims laws that may apply to healthcare items or services that are reimbursed by third-party payors, including private insurers; local, state, and foreign transparency laws that require manufacturers to report information related to payments and transfers of value to other health care providers and health care entities, or marketing expenditures; state laws that require pharmaceutical companies to register certain employees engaged in marketing activities in the locale and comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines or relevant compliance guidance promulgated by the federal government; and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any such requirements, we may be subject to sanctions, including criminal fines, significant civil monetary penalties,
individual imprisonment, disgorgement, contractual damages, reputational harm, exclusion from participation in government healthcare programs,
integrity obligations, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of
pre-marketing product approvals, private qui tam actions brought by individual whistleblowers in the name of the government, refusal to
allow us to enter into supply contracts, including government contracts, and the curtailment or restructuring of our operations, any of
which could adversely affect our ability to operate our business and our results of operations. Although effective compliance programs
can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely eliminated. Any action
against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s
attention from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with
applicable laws and regulations may be costly to us in terms of money, time and resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Healthcare reform</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In both the United States
and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could
impact our ability to sell our products profitably. In particular, in 2010, the ACA was enacted, which, among other things, addressed
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs and biologics;
increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate
program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new
annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers
must agree to offer 50% (increased to 70% as of January 1, 2019 and further revised, effective January 1, 2025 under the IRA), point-of-sale
discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for
the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and provided incentives to programs that increase the federal
government&#8217;s comparative effectiveness research. Effective January 1, 2025, certain provisions of the Inflation Reduction Act of
2022 will reduce Medicare Part D beneficiaries&#8217; annual out-of-pocket maximum from $7,050 to $2,000, thereby effectively eliminating
the coverage gap.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since its enactment, there
have been numerous judicial, administrative, executive and legislative challenges to certain aspects of the ACA. On June 17, 2021, the
U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the
constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, President Biden issued an executive order to initiate a special
enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace.
The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit
access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements,
and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear
how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will
impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other legislative changes
have been proposed and adopted in the United States since the ACA was enacted:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2011, the Budget Control Act of 2011 and subsequent legislation, among other things, created measures for spending reductions by Congress, including a reduction of Medicare payments to providers up to 2% per fiscal year, and, due to subsequent legislative amendments, this will remain in effect through 2030 unless additional Congressional action is taken.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The U.S. American Taxpayer Relief Act of 2012 was signed into law in 2013, which among other things, further reduced Medicare payments to several types of providers.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Further Consolidated Appropriations Act, signed into law in 2019, repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax. It is impossible to determine whether similar taxes could be instituted in the future.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There has been increasing
legislative and enforcement interest in the United States with respect to product pricing practices. Specifically, there have been several
recent U.S. Congressional inquiries and proposed federal and state legislation designed to, among other things, bring more transparency
to drug pricing, reduce the cost of therapies under Medicare, review the relationship between pricing and manufacturer patient programs,
and reform government program reimbursement methodologies for drug products. The HHS has already started the process of soliciting feedback
on some of these measures and, at the same time, is immediately implementing others under its existing authority. It is unclear what effect
such legislative and enforcement interest may have on our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, on December 13, 2016,
President Obama signed the 21st Century Cures Act, or Cures Act, into law. Among other provisions, the Cures Act reauthorized the existing
priority review voucher program for certain drugs intended to treat rare pediatric diseases until 2020; created a new priority review
voucher program for drug applications determined to be material national security threat medical countermeasure applications; revised
the FDCA to streamline review of combination product applications; required the FDA to evaluate the potential use of &#8220;real world
evidence&#8221; to help support approval of new indications for approved drugs; provided a new &#8220;limited population&#8221; approval
pathway for antibiotic and antifungal drugs intended to treat serious or life-threatening infections; and authorized the FDA to designate
a drug as a &#8220;regenerative advanced therapy,&#8221; thereby making it eligible for certain expedited review and approval designations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that these and other
healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward
pressure on the price that we receive for any approved product, which could have an adverse effect on customers for our product candidates.
Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been, and likely
will continue to be, legislative and regulatory proposals at the foreign, federal and state levels in the U.S. directed at broadening
the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other
healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. Such reforms
could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain
regulatory approval and may affect our overall financial condition and ability to develop products. If we, or any third parties we may
engage, are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such
third parties are not able to maintain regulatory compliance, our current or any future product candidates we may develop may lose any
regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">As of November 28, 2025,
we had four full-time employees (with one employee being furloughed), and two part-time employees. None of our employees are represented
by a labor union or covered by a collective bargaining agreement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We occupy shared office space
in Burlington, Massachusetts, under a lease that expires in November 2025, which we use for our corporate headquarters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, we may
become involved in litigation relating to claims arising from the ordinary course of business. Our management believes that there are
currently no claims or actions pending against us, the ultimate disposition of which would have a material adverse effect on our results
of operations, financial condition or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2023, we entered
into a settlement agreement with Parexel International (IRL) Limited relating to payment obligations arising out of a clinical trial performed
by Parexel, which was co-financed by the Company and Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062), a biopharmaceutical company
headquartered in Shanghai, China (&#8220;<b>Mabwell</b>&#8221;). The Company made some but not all installment payments due under the
settlement agreement and Parexel filed a complaint in Superior Court in Middlesex County, Massachusetts in April 2023. Parexel subsequently
amended the complaint twice and filed a motion for default judgment in September 2023 seeking contractual damages of approximately $640,000
plus additional damages under Massachusetts Chapter 93A for deceptive business practices. A hearing on the motion was held on January
9, 2024. The court asked for additional submissions by January 16, 2024 and indicated that a ruling would follow thereafter. On January
26, 2024, the court entered a judgment in the case awarding Parexel a total of approximately $700,000 and rejecting Parexel&#8217;s claim
under Chapter 93A.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2017, we entered
into an Exclusive License Agreement with Memorial Sloan Kettering Cancer Center (&#8220;<b>MSK</b>&#8221;), which was subsequently amended
by Amendment No. 1 to Exclusive License Agreement dated March 31, 2017, Amendment No. 2 to Exclusive License Agreement dated March 31,
2018, and Amendment No. 3 to Exclusive License Agreement dated December 31, 2019 (collectively, the &#8220;<b>Exclusive MSK License Agreement</b>&#8221;).
In June 2023, we received a notice of breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded
payments totaling at least $1,060,405 in principal and $169,173 in interest. We do not dispute the payment obligations under the Exclusive
MSK License Agreement and have not made the payment to preserve cash. We are working to finalize a settlement agreement including a cash
component significantly less than the face amount of the obligation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 12, 2024, our landlord
filed a Summary Process (Eviction) Summons and Complaint with the District Court in Woburn, Massachusetts relating to our Cummings Park
premises. On November 20, 2024 the Company made late rent payments to the landlord, and on November 25, 2024, the Summons was dismissed
by the landlord.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are unable to predict the
ultimate outcome of these matters, the timing of any final decisions of various agencies or courts, or the impact on our results of operations,
financial condition or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DIRECTORS AND EXECUTIVE OFFICERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Executive Officers and Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
the names, ages and positions of the directors and executive officers of Abpro Holdings, Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 29%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 61%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: top; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Executive Officers</i></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">J. Wook (Miles) Suk<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">56</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, Director and Chairman of the Board</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Non-Employee Directors</i></b></span></td>
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony D. Eisenberg<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soo Young Lee<sup>(2)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">53</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian McDonald<sup>(1)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">37</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian Chan<sup>(3)</sup></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">52</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(1)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(2)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class II Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><sup>(3)</sup></span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class III Director</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Background of Directors and Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Executive Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Jin Wook (Miles) Suk
</i></b>has served as our Chief Executive Officer since March 2025 and as a member of the Board of New Abpro since the Business Combination.
He previously served as Co-Chief Executive Officer since September 2024 and as a member of Abpro&#8217;s board of directors since January
2020. From September 2011 to September 2019, Mr. Suk served on the board of directors, and as a senior director and advisor, of Gan &amp;
Lee Pharmaceuticals Co., Ltd., a public pharmaceutical company specializing in the development, production, and commercialization of insulin
analogs and medical devices. Mr. Suk co-founded Bio CND Inc., a pharmaceutical company, which was later acquired. Mr. Suk also has extensive
experience in licensing, strategic alliance, and co-development deals at LG Life Sciences, Ltd., a company engaged in manufacturing, supply,
and distribution of pharmaceutical products, animal health products and specialty chemicals. Mr. Suk earned a B.S. in Microbiology from
Michigan State University. We believe that Mr. Suk&#8217;s business experience, and his previous service on the board of directors of
a public company in the industry, qualify him to serve as a member of the board of directors.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Employee Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Anthony D. Eisenberg
</i></b>has served as a director of New Abpro since the Business Combination. Prior to the Business Combination, Mr. Eisenberg served
as ACAB&#8217;s Chief Strategy Officer and served as a director of ACAB since January 2022. Mr. Eisenberg also served as Chief Strategy
Officer and a director of ACA I from February 2021 to October 2023. Since 2013, Mr. Eisenberg has managed Tappan Street, a multi-strategy
family office with expertise in environmental, social and corporate governance principles and private market investments. Since March
2020, Mr. Eisenberg has also served on the board of advisors of Komma, a mobility company targeting the urban mobility vehicle market.
From 2013 to 2019, Mr. Eisenberg served on the board of advisors of Michigan Income Principal-Protected Growth Fund, an impact investing
fund in partnership with the State of Michigan and the US Department of Treasury and led the firm&#8217;s development activities. Mr.
Eisenberg began his career in politics working in the Office of U.S. Senator Debbie Stabenow, Patton Boggs and the D.C. based research
group Marwood Group, prior to his principal investing career, which began at the hedge fund Christofferson Robb &amp; Company. Mr. Eisenberg
holds an M.B.A. in Finance from Georgetown University-The McDonough School of Business, a J.D. from the University of Michigan Law School
and a B.B.A. in Finance and Political Science from the University of Miami. We believe Mr. Eisenberg&#8217;s experience in public policy
and expertise in private market investments makes him well-qualified to serve on our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Soo Young Lee </i></b>has
served as a director of New Abpro since the Business Combination. Mr. Lee has also served as a senior vice president and head of the new
drug division of Celltrion Inc., a leading Korean biopharmaceutical company, since April 2022. From January 2019 to March 2022, Mr. Lee
served as a vice president and head of the vaccine and non-clinical department of Celltrion Inc. Mr. Lee has also served on the board
of directors of A&amp;G Pharmaceuticals, Inc., a pharmaceutical company specializing in the development of products that improve cancer
detection, diagnosis, and treatment, since April 2022. Mr. Lee earned a master&#8217;s degree from Hanyang University in biochemical engineering,
and he earned a Ph.D. from Inha University in biochemical engineering. We believe that Mr. Lee&#8217;s experience in drug development,
and his previous service on the board of directors of a pharmaceutical company, qualify him to serve as a member of the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Ian McDonald </i></b>has
served as a director of New Abpro since the Business Combination. Mr. McDonald has also served as the Chief Executive Officer and as a
director of Bright Minds Biosciences Inc. since 2017. Previously, he served on the management team at a TSX-listed gold mining company,
Avnel Gold, from August 2016 to September 2017. In that capacity, Mr. McDonald developed and implemented the corporate strategy as it
relates to M&amp;A and capital markets resulting in a $160 million sale within one year. Previously, he worked in a senior role at a Canadian
Investment Bank and in private equity in Vancouver, London and Toronto. Under McDonald&#8217;s guidance, clients raised hundreds of millions
of dollars in capital. Mr. McDonald has served as a member of the Board of Directors of several TSX Venture Exchange, Canadian Securities
Exchange-listed and private companies. Mr. McDonald has a B.A. in Business from Arizona State University. We believe Mr. McDonald&#8217;s
experience as an executive and board member of a publicly traded company and in the bioscience industry makes him well-qualified to serve
on our board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Ian Chan</i></b> has
served as a member of the Board of New Abpro since the Business Combination, previously served as the Chief Executive Officer of New Abpro
from the Business Combination until March 2025, previously served as Abpro Corporation&#8217;s Chief Executive Officer from January 2020
to March 2025 and served on its board of directors since co-founding Abpro Corporation in 2004 until March 2025. Mr. Chan previously served
as Abpro&#8217;s Chief Executive Officer from 2004 to 2018 and Chairman of its board of directors from 2004 to January 2020. Mr. Chan
served as co-Chief Executive Officer and as a director of Abpro Bio. Co. Ltd. (KOSDAQ: 195990) from August 2019 to president. Mr. Chan
earned an A.B. in Biology and Economics from Brown University and an M.B.A. from the Harvard Business School. We believe Mr. Chan&#8217;s
experience on Abpro&#8217;s board of directors and as Abpro&#8217;s chief executive officer, as well as his experience in the industry,
qualifies him to serve on the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Family Relationships</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no family relationships
among any of our directors or executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Composition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and affairs are
organized under the direction of our Board. The Board consists of five members upon consummation of the Business Combination. The primary
responsibilities of the Board is to provide oversight, strategic guidance, counseling, and direction to our management. The Board will
meet on a regular basis and additionally as required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with our Charter,
our Board is divided into three classes, Class I, Class II and Class III, with members of each class serving staggered three-year terms.
The directors are assigned to the following classes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class I consists of Mr. McDonald, whose term will expire at our 2028 annual meeting of stockholders;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class II consists of Mr. Eisenberg and Mr. Lee, whose terms will expire at our 2026 annual meeting of stockholders; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class III consists of Mr. Chan and Mr. Suk, whose terms will expire at our 2027 annual meeting of stockholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At each annual meeting of
stockholders to be held after the initial classification, the successors to directors whose terms then expire will be elected to serve
from the time of election and qualification until the third annual meeting following their election and until their successors are duly
elected and qualified. This classification of our Board may have the effect of delaying or preventing changes in our control or management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Director Independence</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of our Common
Stock being listed on the Nasdaq, we adhere to the listing rules of the Nasdaq in affirmatively determining whether a director is independent.
Our Board has consulted, and will consult, with its counsel to ensure that the Board&#8217;s determinations are consistent with those
rules and all relevant securities and other laws and regulations regarding the independence of directors. The Nasdaq listing standards
generally define an &#8220;independent director&#8221; as a person, other than an executive officer of a company or any other individual
having a relationship which, in the opinion of the issuer&#8217;s board of directors, would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the directors other
than Mr. Chan and Mr. Suk qualify as independent directors as defined under the listing rules of the Nasdaq, and our board consists of
a majority of independent directors, as defined under the rules of the SEC and Nasdaq Listing Rules relating to director independence
requirements. In addition, we are subject to the rules of the SEC and Nasdaq relating to the membership, qualifications, and operations
of the audit committee, the compensation committee, and the nominating and corporate governance committee, as discussed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Board Oversight of Risk</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">One of the key functions of
our Board will be informed oversight of its risk management process. The Board does not anticipate having a standing risk management committee,
but rather anticipates administering this oversight function directly through the Board as a whole, as well as through various standing
committees of the Board that address risks inherent in their respective areas of oversight. In particular, our Board will be responsible
for monitoring and assessing strategic risk exposure and our audit committee will have the responsibility to consider and discuss the
combined company&#8217;s major financial risk exposures and the steps its management will take to monitor and control such exposures,
including guidelines and policies to govern the process by which risk assessment and management is undertaken. The audit committee will
also monitor compliance with legal and regulatory requirements. Our compensation committee will also assess and monitor whether our compensation
plans, policies and programs comply with applicable legal and regulatory requirements. Our nominating and corporate governance committee
will monitor the effectiveness of our governance guidelines and provide oversight with respect to corporate governance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Committees of the Board</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board established an audit
committee, a compensation committee and a nominating and corporate governance committee. Our Board adopted a written charter for each
of these committees, which complies with the applicable requirements of current Nasdaq Listing Rules. Copies of the charters for each
committee are available on the investor relations portion of New Abpro&#8217;s website at www.abpro.co. The composition and function of
each committee will comply with all applicable requirements of the Sarbanes-Oxley Act and all applicable SEC rules and regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of the audit committee
are Mr. Eisenberg, Mr. McDonald, and Mr. Lee, with Mr. Eisenberg serving as chair. Our Board has determined that each of the members of
the audit committee will be an &#8220;independent director&#8221; as defined by, and meet the other requirements of the Nasdaq Listing
Rules applicable to members of an audit committee and Rule 10A-3(b)(i) under the Exchange Act, including that each member of the audit
committee can read and understand fundamental financial statements in accordance with Nasdaq audit committee requirements. In arriving
at this determination, the Board examined each audit committee member&#8217;s scope of experience and the nature of their prior and current
employment. The audit committee will meet on at least a quarterly basis. Both the combined company&#8217;s independent registered public
accounting firm and management intend to periodically meet privately with our audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The primary purpose of the
audit committee is to discharge the responsibilities of the Board with respect to our accounting, financial, and other reporting and internal
control practices and to oversee our independent registered accounting firm. Specific responsibilities of our audit committee include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting the Board in the oversight of (i) accounting and financial reporting processes of New Abpro and the audits of the financial statements of New Abpro, (ii) preparation and integrity of the financial statements of New Abpro, (iii) compliance by New Abpro with financial statement and regulatory requirements, (iv) performance of New Abpro&#8217;s internal finance and accounting personnel and its independent registered public accounting firms, and (v) qualifications and independence of New Abpro&#8217;s independent registered public accounting firms;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing with each of the internal and independent registered public accounting firms the overall scope and plans for audits, including authority and organizational reporting lines and adequacy of staffing and compensation;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing with management and internal auditors New Abpro&#8217;s system of internal control and discussing with the independent registered public accounting firm any significant matters regarding internal controls over financial reporting that have come to its attention during the conduct of its audit;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing with management, internal auditors and independent registered public accounting firm New Abpro&#8217;s financial and critical accounting practices, and policies relating to risk assessment and management;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">receiving and reviewing reports of the independent registered public accounting firm discussing (i) all critical accounting matters in the firm&#8217;s audit of New Abpro&#8217;s financial statements, (ii) all alternative treatments of financial information within U.S. GAAP that have been discussed with management, ramifications of the use of such alternative disclosures and treatments, and the treatment preferred by the independent registered public accounting firm, and (iii) other material written communications between the independent registered public accounting firm and management, such as any management letter or schedule of unadjusted differences;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing with management and the independent registered public accounting firm the annual and quarterly financial statements and section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of New Abpro prior to the filing of New Abpro&#8217;s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing, or establishing, standards for the type of information and the type of presentation of such information to be included in, earnings press releases and earnings guidance provided to analysts and rating agencies;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discussing with management and the independent registered public accounting firm any changes in New Abpro&#8217;s critical accounting principles and the effects of alternative U.S. GAAP methods, off-balance sheet structures and regulatory and accounting initiatives;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing material pending legal proceedings involving New Abpro and other contingent liabilities;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">meeting periodically with the Chief Executive Officer, Chief Financial Officer, the senior internal auditing executive and the independent registered public accounting firm in separate executive sessions to discuss results of examinations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving all transactions between New Abpro and related parties or affiliates of the officers of New Abpro requiring disclosure under Item 404 of Regulation S-K prior to New Abpro entering into such;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing procedures for the receipt, retention and treatment of complaints received by New Abpro regarding accounting, internal accounting controls or auditing matters, and the confidential, anonymous submissions by employees or contractors of concerns regarding questionable accounting or accounting matters;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing periodically with New Abpro&#8217;s management, the independent registered public accounting firm and outside legal counsel (i) legal and regulatory matters which may have a material effect on the financial statements, and (ii) corporate compliance policies or codes of conduct, including any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues regarding New Abpro&#8217;s financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities; and;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">establishing policies for the hiring of employees and former employees of the independent registered public accounting firm.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Audit Committee Financial
Expert</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board has determined that
Mr. Eisenberg qualifies as an &#8220;audit committee financial expert&#8221; as such term is defined in Item 407(d)(5) of Regulation S-K
and meets the financial sophistication requirements of the Nasdaq Listing Rules. In making this determination, our Board considered Mr.
Eisenberg&#8217;s formal education, training, and previous experience in financial roles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of the compensation
committee are Mr. Eisenberg, Mr. McDonald, and Mr. Lee, with Mr. Eisenberg serving as chair. Our Board has determined that each of the
members will be an &#8220;independent director&#8221; as defined by the Nasdaq Listing Rules applicable to members of a compensation committee.
The Board has determined that each of the members of the compensation committee is a non-employee director, as defined in Rule 16b-3 promulgated
under the Exchange Act and satisfy the independence requirements of the Nasdaq. The compensation committee will meet from time to time
to consider matters for which approval by the committee is desirable or is required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Specific responsibilities
of our compensation committee include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing the performance of the Chief Executive Officer and executive management;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting the Board in developing and evaluating potential candidates for executive positions (including Chief Executive Officer);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving goals and objectives relevant to the Chief Executive Officer and other executive officer compensation, evaluating the Chief Executive Officer&#8217;s and other executive officers&#8217; performance in light of these corporate goals and objectives, and setting Chief Executive Officer and other executive officer compensation levels consistent with its evaluation and New Abpro&#8217;s philosophy;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving the salaries, bonuses and other compensation for all executive officers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving compensation packages for new corporate officers and termination packages for corporate officers as requested by management;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and discussing with the Board and senior officers plans for officer development and corporate succession plans for the Chief Executive Officer and other senior officers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and making recommendations concerning executive compensation policies and plans;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the Board the adoption of or changes to the compensation of New Abpro&#8217;s directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the awards made under any executive officer bonus plan, and providing an appropriate report to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and making recommendations concerning long-term incentive compensation plans, including the use of stock options and other equity-based plans, and, except as otherwise delegated by the Board, acting as the &#8220;Plan Administrator&#8221; for equity-based and employee benefit plans;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for New Abpro&#8217;s executive officers and employees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and making recommendations concerning executive compensation policies and plans;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and recommending to the Board the adoption of or changes to the compensation of New Abpro&#8217;s directors;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and approving the awards made under any executive officer bonus plan, and providing an appropriate report to the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing and making recommendations concerning long-term incentive compensation plans, including the use of stock options and other equity-based plans, and, except as otherwise delegated by the Board, acting as the &#8220;Plan Administrator&#8221; for equity-based and employee benefit plans;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">approving all special perquisites, special cash payments and other special compensation and benefit arrangements for New Abpro&#8217;s executive officers and employees;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing periodic reports from management on matters relating to New Abpro&#8217;s personnel appointments and practices;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">assisting management in complying with the Company&#8217;s proxy statement and annual report disclosure requirements;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">issuing an annual Report of the Compensation Committee on Executive Compensation for New Abpro&#8217;s annual proxy statement in compliance with applicable SEC rules and regulations;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">annually evaluating the committee&#8217;s performance and the committee&#8217;s charter and recommending to the Board any proposed changes to the charter or the committee; and;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">undertaking all further actions and discharging all further responsibilities imposed upon the committee from time to time by the Board, the federal securities laws or the rules and regulations of the SEC.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Nominating and Corporate
Governance Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The members of the nominating
and corporate governance committee are Mr. Eisenberg, Mr. McDonald, and Mr. Lee, with Mr. Eisenberg serving as chair. The Board determined
that each of the members will be an &#8220;independent director&#8221; as defined by the Nasdaq Listing Rules applicable to members of
a nominating committee. The nominating and corporate governance committee will meet from time to time to consider matters for which approval
by the committee is desirable or is required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Specific responsibilities of our nominating and
corporate governance committee include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">developing and recommending to the Board the criteria for appointment as a director;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">identifying, considering, recruiting and recommending candidates to fill new positions on the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">reviewing candidates recommended by stockholders;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">conducting the appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">recommending director nominees for approval by the Board and election by the stockholders at the next annual meeting.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The nominating and corporate
governance committee will recommend to the board of directors candidates for nomination for election at the annual meeting of the stockholders.
In identifying and evaluating potential candidates, the nominating and corporate governance committee will consider several factors, including,
without limitation, high personal and professional integrity, strong ethics and values, the ability to make mature business judgments,
experience in corporate management such as serving as an officer or former officer of a publicly held company, experience as a board member
of another publicly held company, professional and academic experience relevant to our business, leadership skills, experience in finance
and accounting, or executive compensation practices, whether candidate has the time required for preparation, participation and attendance
at board of directors meetings and committee meetings, if applicable, independence, and the ability to represent the best interests of
New Abpro&#8217;s stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Code of Ethics</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a code of
ethics that applies to all of our directors, officers and employees in accordance with applicable federal securities laws. A copy of our
code of ethics is available on our website at www.abpro.co. We also intend to post on our website all disclosures that are required by
law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code of ethics rather than
by filing a Current Report on Form 8-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Clawback Policy</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective October 2023 ACAB
adopted a Clawback Policy (the &#8220;<b>Clawback Policy</b>&#8221;). Under the policy, in the event New Abpro is required to prepare
an accounting restatement due to material noncompliance of New Abpro with any financial reporting requirement under the U.S. federal securities
laws, the Board will take, in its discretion, such action it deems necessary to recover from its executive officers who received incentive-based
compensation, based on performance in a year for which New Abpro is required to prepare restated financial statements, the excess of what
would have been paid to the executive officer under the accounting restatement. This applies during a lookback period of three years,
and the amounts to be reclaimed are as determined by the Board in its sole discretion. For purposes of the Clawback Policy, an executive
officer is any of New Abpro&#8217;s officers who are required, or who have been required during the immediately preceding three calendar
years, to file reports pursuant to Section 16 of the Exchange Act as well as New Abpro&#8217;s Chief Legal Officer, if not included. This
policy may, in certain circumstances, be applied to other current or former employees whose actions or omissions contributed to the circumstances
requiring the restatement and also involved willful misconduct or a willful violation of any of New Abpro&#8217;s rules. Additionally,
if the Board determines that detrimental conduct has occurred that results in a material adverse impact, any incentive compensation paid
during the prior year may be subject to clawback. Incentive compensation excludes base salary and other compensation but includes equity
compensation and bonuses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2022, the SEC adopted
new Rule 10D-1 under the Exchange Act, which requires national securities exchanges, including Nasdaq, to establish listing standards
relating to executive officer incentive compensation clawback and disclosure rules. In February 2023, Nasdaq released its final version
of the proposed listing standards, which require listed companies to adopt, no later than December 1, 2023, clawback policies providing
for the recovery of erroneously awarded incentive-based compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Compensation Committee
Interlocks and Insider Participation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our executive officers
currently serves, and in the past year has not served, as a member of the compensation committee of any entity that has one or more executive
officers serving on our Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Shareholder and Interested
Party Communications</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders and interested
parties may communicate with our Board, any committee chairperson or the non-management directors as a group by writing to the board or
committee chairperson in care of Abpro Holdings, Inc., 100 Summit Drive, Burlington, MA 01803. Each communication will be forwarded, depending
on the subject matter, to the Board, the appropriate committee chairperson or all non-management directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><b><i>Limitations of Liability
and Indemnification of Directors and Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter limits a directors&#8217;
liability to the fullest extent permitted under the DGCL. The DGCL provides that directors of a corporation will not be personally liable
for monetary damages for breach of their fiduciary duties as directors, except for liability:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for any transaction from which the director derives an improper personal benefit;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for any unlawful payment of dividends or redemption of shares; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">for any breach of a director&#8217;s duty of loyalty to the corporation or its stockholders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the DGCL is amended to
authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the directors will
be eliminated or limited to the fullest extent permitted by the DGCL, as so amended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delaware law and the Bylaws
provide that New Abpro will, in certain situations, indemnify its directors and officers and may indemnify other employees and other agents,
to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to advancement, direct
payment, or reimbursement of reasonable expenses (including attorneys&#8217; fees and disbursements) in advance of the final disposition
of the proceeding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, New Abpro will
enter into separate indemnification agreements with its directors and officers. These agreements, among other things, require New Abpro
to indemnify its directors and officers for certain expenses, including attorneys&#8217; fees, judgments, fines, and settlement amounts
incurred by a director or officer in any action or proceeding arising out of their services as one of its directors or officers or any
other company or enterprise to which the person provides services at its request.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New Abpro plans to maintain
a directors&#8217; and officers&#8217; insurance policy pursuant to which its directors and officers are insured against liability for
actions taken in their capacities as directors and officers. We believe these provisions in the Charter and the Bylaws and these indemnification
agreements are necessary to attract and retain qualified persons as directors and officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers, or control persons, in the opinion of the SEC,
such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXECUTIVE COMPENSATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>References to the &#8220;Company,&#8221;
&#8220;New Abpro,&#8221; &#8220;our,&#8221; &#8220;us&#8221; or &#8220;we&#8221; in the following section refer to Abpro prior to the
Business Combination.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Executive Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently considered
an &#8220;emerging growth company&#8221; within the meaning of the Securities Act for purposes of the SEC&#8217;s executive compensation
disclosure rules. Accordingly, we are required to provide a Summary Compensation Table, as well as limited narrative disclosures regarding
executive compensation for our last two completed fiscal years and an Outstanding Equity Awards at Fiscal Year End Table for our last
completed fiscal year. These reporting obligations extend only to the following &#8220;named executive officers,&#8221; who are the individuals
who served as our principal executive officer and the next two most highly compensated executive officers at the end of the fiscal year
2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This section discusses material
components of the executive compensation programs for New Abpro&#8217;s executive officers who area named in the &#8220;Summary Compensation
Table&#8221; below. In 2024, New Abpro&#8217;s &#8220;named executive officers&#8221; and their positions were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miles Suk, Chief Executive Officer and Chairman of the Board;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian Chan, the former Chief Executive Officer; </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Robert Markelewicz, the former Chief Medical Officer; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; text-align: justify">&#160;</td>
    <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christian Zapf, the former Senior Vice President Corporate Development and former General Counsel of Abpro.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This discussion may contain
forward-looking statements that are based on New Abpro&#8217;s current plans, considerations, expectations, and determinations regarding
future compensation programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Summary Compensation Table</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table contains
information pertaining to the compensation of New Abpro&#8217;s named executives for the years ending December 31, 2024 and 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name and Principal Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Salary<br/> ($)<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Bonus<br/> ($)<sup>(2)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Option<br/> awards<br/> ($)<sup>(3)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Miles Suk</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;<sup>(5)</sup></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief Executive Officer and Chairman<sup>(4)</sup></i></span></td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 42%; text-align: left">Ian Chan</td><td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: center">2024</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">521,754</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#8212;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">521,754</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Former Chief Executive Officer<sup>(6)</sup></i></span></td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">502,917</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">772,917</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Markelewicz</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">483,577</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">483,577</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-style: italic; text-align: left; padding-left: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Former Chief Medical Officer<sup>(7)</sup></i></span></td><td>&#160;</td>
    <td style="text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">466,118</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">80,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">546,118</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Christian Zapf</td><td>&#160;</td>
    <td style="text-align: center">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">258,433</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">258,433</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left; text-indent: 0in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Former Senior Vice President of Corporate Development and Former General Counsel of Abpro Corporation<sup>(8)</sup></i></span></td><td>&#160;</td>
    <td style="vertical-align: top; text-align: center">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">338,337</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="vertical-align: top; text-align: right">338,337</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amounts in this column represent the amount of base salary earned for service during 2023 and 2024. The following base salary amounts for 2023 were accrued but unpaid as of December 31, 2023: $9,925 for Mr. Chan, $9,198 for Dr. Markelewicz and $6,677 for Mr. Zapf. The following base salary amounts for 2024 were accrued but unpaid as of December 31, 2024: $4,253 for Mr. Chan, $3,942 for Dr. Markelewicz and $0 for Mr. Zapf.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The amounts in this column represent the amount of bonus earned for service during 2023 and 2024. The bonus amounts for 2023 were accrued but unpaid in 2024. No bonus was declared yet in 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">No stock options were awarded to the named executive officers in 2023 and 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive compensation information for the year ended December 31, 2023, is not provided, as the individual was not a named executive officer for that period.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the Closing of the Business Combination in October 2024, Abpro Corporation&#8217;s board of directors approved and recommended the grant of 8,667 RSUs with standard vesting to Miles Suk, to be issued by New Abpro upon the satisfaction of any required action by the compensation committee of New Abpro and filing of a Form S-8 covering the subject RSUs. New Abpro&#8217;s compensation committee has not yet approved such grant.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">(6)</td>
    <td style="font-size: 10pt">On March 3, 2025, the Board removed Mr. Chan as Chief Executive Officer of the Company for cause, and Mr. Suk was appointed as Chief Executive Officer of the Company.</td></tr>
  </table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in; font-size: 10pt">(7)</td>
    <td style="font-size: 10pt">On September 30, 2025, the Company furloughed Dr. Markelewicz, the Company&#8217;s Chief Medical Officer, effective September 30, 2025 until November 30, 2025. During the furlough period, Dr. Markelewicz will not perform any duties or responsibilities associated with his role. Dr. Markelewicz&#8217;s employment will be terminated effective November 30, 2025.</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr. Zapf resigned from his position as SVP of Corporate Development and General Counsel of Abpro effective September 23, 2024, prior to the Closing of the Business Combination.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>Narrative Disclosure to the Summary Compensation
Table</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Elements of Compensation</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation of our NEOs
generally consists of base salary, annual cash bonus opportunities, long term incentive compensation in the form of equity awards and
other benefits, as described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Base Salary</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The base salary payable to
each NEO is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role, responsibilities,
and contributions. Each NEO&#8217;s initial base compensation was specified in their employment agreement, as described below, and is
reviewed (and, if applicable, adjusted) from time to time by Abpro&#8217;s board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Bonus</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NEOs are eligible for
a performance-based cash bonus opportunity. Each executive&#8217;s target bonus is set annually by Abpro&#8217;s compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Long Term Equity Incentives</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abpro&#8217;s equity-based
incentive awards are designed to align their interests and the interests of their stockholders with those of their employees and consultants,
including the NEOs. The Abpro board of directors or compensation committee approves equity grants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Compensation Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abpro entered into an employment
offer letter with Dr. Markelewicz, the material terms of which are summarized below. The Company did not have a formal executive compensation
arrangement with Mr. Suk in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Robert Markelewicz Jr.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 11, 2018, Abpro Corporation
provided Robert Markelewicz Jr. with an offer letter setting forth the terms and conditions of his employment as Senior Vice President,
Head of Clinical Research and Development, which provides for a base salary of $420,000, a discretionary bonus with a specified annual
target amount of 40% of his annual base salary, a $35,000 signing bonus, and eligibility to participate in employee benefit programs established
by Abpro Corporation. Pursuant to the offer letter, Dr. Markelewicz was also granted 7,783 stock options that vest in full upon a change
in control. The offer letter also provides that in the event Dr. Markelewicz is terminated without cause (as defined below), that he is
eligible to receive severance consisting of six months of continued base compensation, provided that he sign a separation agreement and
release prepared by Abpro Corporation, and provided that he sign a confidentiality, non-compete and non-solicitation agreement, which
contains (i) customary confidentiality provisions, (ii) a non-compete covenant for one year post-termination of employment, and (iii)
non-solicit covenants relating to employees and customers for 24 months and 18 months post-termination of employment, respectively. The
offer letter defines &#8220;cause&#8221; as (i) poor work performance, as determined by Abpro Corporation, (ii) misconduct, as determined
by Abpro Corporation, or (iii) any conduct that Abpro Corporation deems materially harmful to its business, interests, or reputation.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 30, 2025, the
Company furloughed Robert J. Markelewicz, Jr., M.D., M.M.Sc., the Company&#8217;s Chief Medical Officer, effective September 30, 2025
until November 30, 2025. During the furlough period, Dr. Markelewicz will not perform any duties or responsibilities associated with his
role. Dr. Markelewicz&#8217;s employment will be terminated effective November 30, 2025.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Outstanding Equity
Awards at Fiscal Year-End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table summarizes
the number of shares of Common Stock underlying outstanding option and restricted stock unit awards for each named executive officer as
of December 31, 2024. All awards were granted pursuant to the 2014 Stock Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Grant<br/> Date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options (#)<br/> Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Securities<br/> Underlying<br/> Unexercised<br/> Options (#)<br/> Unexercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> Exercise<br/> Price<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option<br/> Expiration<br/> Date</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares or <br/> Units of<br/> Stock<br/> That Have<br/> Not Vested<br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Market<br/> Value of<br/> Shares or<br/> Units That<br/> Have Not<br/> Vested<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity<br/> Incentive<br/> Plan<br/> Awards:<br/> Number of<br/> Unearned<br/> Shares,<br/> Units or<br/> Other<br/> Rights<br/> That<br/> Have Not<br/> Vested<br/> (#)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity<br/> Incentive<br/> Plan<br/> Awards:<br/> Market or <br/> Payout<br/> Value of<br/> Unearned<br/> Shares,<br/> Units or<br/> Other<br/> Rights<br/> That<br/> Have Not<br/> Vested<br/> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 14%; text-align: left">Ian Chan</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 9%; text-align: center">3/21/2019</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">19,250</td><td style="width: 0.5%; text-align: left"><sup>(1)</sup></td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 0.5%; text-align: left">&#160;&#160;<sup>(1)</sup></td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">51.90</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3/21/2029</span></td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 0.5%">&#160;</td>
    <td style="width: 0.5%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">&#8212;</td><td style="width: 0.5%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">6/19/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">25,903</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;&#160;<sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/19/2030</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/14/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,057</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,187</td><td style="text-align: left">&#160;&#160;<sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/14/2031</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/18/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,587</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,655</td><td style="text-align: left">&#160;&#160;<sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/18/2032</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Miles Suk</td><td>&#160;</td>
    <td style="text-align: center">2/18/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20,450</td><td style="text-align: left"><sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;&#160;<sup>(5)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/18/2032</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/14/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">214</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,501</td><td style="text-align: left">&#160;<sup>(6)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Robert Markelewicz</td><td>&#160;</td>
    <td style="text-align: center">9/28/2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">17,953</td><td style="text-align: left"><sup>(7)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/28/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">12/19/2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,297</td><td style="text-align: left"><sup>(8)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12/19/2028</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">6/19/2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,360</td><td style="text-align: left"><sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;&#160;<sup>(2)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">50.10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6/19/2030</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">4/14/2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,183</td><td style="text-align: left"><sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">199</td><td style="text-align: left">&#160;&#160;<sup>(3)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/14/2031</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">2/18/2022</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240</td><td style="text-align: left"><sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99</td><td style="text-align: left">&#160;&#160;<sup>(4)</sup></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">48.90</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2/18/2032</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This option became fully vested and exercisable on April 6, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This option became fully vested and exercisable on June 19, 2024.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This option vests as follows: 25% vested on April 14, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This option vests as follows: 25% vested on April 14, 2022 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify">This option became fully vested and exercisable on June 18, 2022. Options
are held by BioCelsus International Co Ltd., an entity controlled by Mr. Suk.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Calculated in accordance with Instruction 3 to Regulation S-K Item 402(p)(2). The closing market price of the Company&#8217;s Common Stock on December 31, 2024, was $53.70 per share.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(7)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This option became fully vested and exercisable on August 27, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8)</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This option became fully vested and exercisable on December 12, 2022.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Non-Employee Director Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of ACAB&#8217;s directors
received compensation for services rendered to ACAB during the year ended December 31, 2024. ACAB provided reimbursement to its non-employee
directors for their reasonable expenses incurred in attending meetings of the ACAB board of directors and its committees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the Business Combination,
the non-employee directors of New Abpro are Anthony D. Eisenberg, Soo Young Lee, and Ian McDonald. None of New Abpro&#8217;s non-employee
directors received compensation for services rendered to New Abpro during the year ended December 31, 2024. New Abpro intends to approve
and implement a compensation program for our non-employee directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Summary of the New Abpro Incentive Plan</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>General</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the New Abpro
Incentive Plan is to enhance New Abpro&#8217;s ability to attract, retain and motivate persons who make (or are expected to make) important
contributions by providing these individuals with equity ownership opportunities and/or equity-linked compensatory opportunities. Equity
awards and equity-linked compensatory opportunities are intended to motivate high levels of performance and align the interests of directors,
employees and consultants with those of stockholders by giving directors, employees and consultants the perspective of an owner with an
equity or equity-linked stake in our company and providing a means of recognizing their contributions to New Abpro&#8217;s success. Our
Board believes that equity ownership opportunities and/or equity-linked compensatory opportunities are necessary to remain competitive
in its industry and are essential to recruiting and retaining the highly qualified employees who help us meet our goals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 129; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Shares of Common Stock Available for Issuance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The New Abpro Incentive Plan
provides for an aggregate of 208,026 shares of Common Stock to be reserved for future issuance (the &#8220;<b>Initial Share Limit</b>&#8221;)
plus shares subject to outstanding equity awards granted under Abpro&#8217;s prior incentive plan that were converted into equity awards
denominated in shares of New Abpro Common Stock under the New Abpro Incentive Plan immediately prior to, the consummation of the Business
Combination, plus an annual increase on the first day of each fiscal year beginning in 2026 and ending in 2034, equal to the lesser of
(A) five (5%) percent of the shares outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of
shares as determined by the Board or the Committee (as defined below). Shares subject to an award under the New Abpro Incentive Plan that
are forfeited, cancelled, expired, unexercised or are settled in cash under the New Abpro Incentive Plan will again become available for
awards under the New Abpro Incentive Plan. Shares of Common Stock that are tendered or exchanged by a participant or withheld by New Abpro
as payment in connection with any award under the New Abpro Incentive Plan, as well as any shares exchanged by a participant or withheld
by New Abpro or any subsidiary thereof to satisfy tax withholding obligations related to any full value award, will become available for
subsequent awards under the New Abpro Incentive Plan. Shares, if any, that are tendered or exchanged by a participant or withheld by New
Abpro as full or partial payment in connection with the exercise of any option or SAR under the New Abpro Incentive Plan or the payment
of any tax withholding obligation related thereto or not issued by New Abpro in connection with the stock settlement of any SAR will be
added to the aggregate number of shares available for awards under the New Abpro Incentive Plan. Shares, if any, underlying awards that
are granted in assumption of, or in substitution for, outstanding awards previously granted by an entity acquired by New Abpro or with
which New Abpro combines will not be counted against the aggregate number of shares available for awards under the New Abpro Incentive
Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Annual Director Limits</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-employee director of
New Abpro may not be granted awards in respect of such service as a non-employee director under the New Abpro Incentive Plan during any
calendar year that, when aggregated with such non-employee director&#8217;s cash fees received with respect to such calendar year, exceed
$750,000 in total value; provided, however, that the non-employee directors who are considered independent (under the rules of the Nasdaq
or other securities exchange on which Common Stock is traded) may make exceptions to this limit for a non-executive chair of the Board,
if any, in which case the non-employee director receiving such additional compensation may not participate in the decision to award such
compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Administration</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The New Abpro Incentive Plan
will be administered by a committee of at least two people as the Board may appoint, or if no such committee has been appointed by the
Board (the &#8220;<b>Committee</b>&#8221;). The Committee may interpret the New Abpro Incentive Plan and may prescribe, amend and rescind
rules and make all other determinations necessary or desirable for the administration of the New Abpro Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The New Abpro Incentive Plan
permits the Committee to select the eligible recipients who will receive awards, to determine the terms and conditions of those awards,
including but not limited to the exercise price or other purchase price of an award, the number of shares of Common Stock or cash or other
property subject to an award, the term of an award and the vesting schedule applicable to an award, and to amend the terms and conditions
of outstanding awards. All decisions made by the Committee pursuant to the provisions of the New Abpro Incentive Plan will be final, conclusive
and binding on all persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Eligible Participants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each of the directors, officers,
employees, consultants, and advisors (or prospective directors, officers, employees, consultants and advisors) of Board or any of its
affiliates are eligible to participate in the New Abpro Incentive Plan, provided that they have been selected by the Committee to receive
awards under the New Abpro Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Types of Awards</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The New Abpro Incentive Plan
provides for the issuance of stock options (including non-statutory stock options and incentive stock options), stock appreciation rights
(referred to as &#8220;<b>SARs</b>&#8221;), restricted stock, restricted stock units (referred to as &#8220;<b>RSUs</b>&#8221;), stock
bonuses, and performance compensation awards to directors, officers, employees, consultants, and advisors of New Abpro or its affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>RSUs and Restricted Stock</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">RSUs and restricted stock
in respect of Common Stock may be granted under the New Abpro Incentive Plan. The Committee will determine the purchase price, vesting
schedule and performance objectives, if any, applicable to the grant of RSUs and restricted stock. If the restrictions, performance objectives
or other conditions determined by the Committee are not satisfied, the RSUs and restricted stock will be forfeited. Subject to the provisions
of the New Abpro Incentive Plan and the applicable individual award agreement, the Committee may provide for the lapse of restrictions
in installments or the acceleration or waiver of restrictions (in whole or part) under certain circumstances as set forth in the applicable
individual award agreement, including the attainment of certain performance goals, a participant&#8217;s termination of employment or
service under certain circumstances or a participant&#8217;s death or disability. The rights of holders of RSUs and restricted stock upon
a termination of employment or service will be set forth in individual award agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless the applicable award
agreement provides otherwise, participants with restricted stock will generally have all of the rights of a stockholder during the restricted
period, including the right to vote and receive dividends declared with respect to such restricted stock, provided, that any dividends
declared during the restricted period with respect to such restricted stock will only become payable if the underlying restricted stock
vests. During the restricted period, participants with RSUs will generally not have any rights of a stockholder, but, if the applicable
individual award agreement so provides, may be credited with dividend equivalent rights that will be paid at the time that shares in respect
of the related RSUs are delivered to the participant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Options</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Options to acquire Common
Stock may be granted under the New Abpro Incentive Plan. Options may be in the form of non-qualified options or &#8220;incentive stock
options&#8221; within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended, as set forth in the applicable individual
option award agreement. The maximum number of shares that may be granted pursuant to options intended to be incentive stock options under
the New Abpro Incentive Plan is equal to the Initial Share Limit (subject to adjustment in accordance with the terms of the New Abpro
Incentive Plan). The exercise price of all options granted under the New Abpro Incentive Plan will be determined by the Committee, but
in no event may the exercise price be less than 100% of the fair market value of the underlying shares of Common Stock on the date of
grant (other than options granted in substitution or previously granted awards, as defined in the New Abpro Incentive Plan). The maximum
term of all options granted under the New Abpro Incentive Plan will be determined by the Committee, but may not exceed 10 years. Each
option will vest and become exercisable (including in the event of the optionee&#8217;s termination of employment or service) at such
time and subject to such terms and conditions as determined by the Committee and set forth in the applicable individual option agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Appreciation Rights</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">SARs may be granted under
the New Abpro Incentive Plan either alone or in conjunction with all or part of any option granted under the New Abpro Incentive Plan.
A SAR granted under the New Abpro Incentive Plan entitles its holder to receive, at the time of exercise, an amount per share equal to
the excess of the fair market value (at the date of exercise) of a share of Common Stock over the base price of the SAR. A SAR granted
in conjunction with all or part of an option under the New Abpro Incentive Plan entitles its holder to receive, at the time of exercise
of the SAR and surrender of the related option, an amount per share equal to the excess of the fair market value (at the date of exercise)
of a share of Common Stock over the exercise price of the related option. Each SAR will be granted with a base price that is not less
than 100% of the fair market value of the related shares of Common Stock on the date of grant (other than SARs granted in substitution
of previously granted awards). The maximum term of all SARs granted under the New Abpro Incentive Plan will be determined by the Committee,
but may not exceed 10 years. The Committee may determine to settle the exercise of a SAR in Common Stock, cash, or any combination thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each SAR will vest and become
exercisable (including in the event of the SAR holder&#8217;s termination of employment or service under certain circumstances) at such
time and subject to such terms and conditions as determined by the Committee and set forth in in the applicable individual SAR agreement.
SARs granted in conjunction with all or part of an option will be exercisable at such times and subject to all of the terms and conditions
applicable to the related option.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Stock Bonuses and Cash Awards</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may issue unrestricted
shares of Common Stock or other awards denominated in Common Stock, either alone or in tandem with other awards, in such amounts as the
Committee may determine in its sole discretion from time to time. Each stock bonus award will be evidenced by an award agreement setting
forth the terms and conditions of such awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Performance Goals</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Committee may grant equity-based
awards and incentives under the New Abpro Incentive Plan that are subject to the achievement of performance objectives selected by the
Committee in its sole discretion, including, without limitation, one or more of the following business criteria: (i) net earnings or net
income (before or after taxes); (ii) basic or diluted earnings per share (before or after taxes); (iii) revenue or revenue growth (measured
on a net or gross basis); (iv) gross profit or gross profit growth; (v) operating profit (before or after taxes); (vi) return measures
(including, but not limited to, return on assets, capital, invested capital, equity, or sales); (vii) cash flow (including, but not limited
to, operating cash flow, free cash flow, net cash provided by operations and cash flow return on capital); (viii) financing and other
capital raising transactions (including, but not limited to, sales of New Abpro&#8217;s equity or debt securities); (ix) earnings before
or after taxes, interest, depreciation and/or amortization; (x) gross or operating margins; (xi) productivity ratios; (xii) share price
(including, but not limited to, growth measures and total stockholder return); (xiii) expense targets; (xiv) margins; (xv) productivity
and operating efficiencies; (xvi) customer satisfaction; (xvii) customer growth; (xviii) working capital targets; (xix) measures of economic
value added; (xx) inventory control; (xxi) enterprise value; (xxii) sales; (xxiii) debt levels and net debt; (xxiv) combined ratio; (xxv)
timely launch of new facilities; (xxvi) client retention; (xxvii) employee retention; (xxviii) timely completion of new product rollouts;
(xxix) cost targets; (xxx) reductions and savings; (xxxi) productivity and efficiencies; (xxxii) strategic partnerships or transactions;
and (xxxiii) personal targets, goals or completion of projects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any one (1) or more of the
performance criteria may be used on an absolute or relative basis to measure the performance of New Abpro and/or one or more affiliates
as a whole or any business unit(s) of New Abpro and/or one or more affiliates or any combination thereof, as the Committee may deem appropriate,
or any of the above performance criteria may be compared to the performance of a selected group of comparison or peer companies, or a
published or special index that the Board, in its sole discretion, deems appropriate, or as compared to various stock market indices.
The Committee also has the authority to provide for accelerated vesting of any award based on the achievement of performance goals pursuant
to the performance criteria. Any performance criteria that are financial metrics, may be determined in accordance with GAAP or may be
adjusted when established to include or exclude any items otherwise includable or excludable under GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Equitable Adjustments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of (i) any dividend
(other than ordinary cash dividends) or other distribution (whether in the form of cash, Common Stock, other securities or other property),
recapitalization, stock split, reverse stock split, reorganization, merger, amalgamation, consolidation, spin-off, split-up, split-off,
combination, repurchase or exchange of shares of Common Stock or other securities of New Abpro, issuance of warrants or other rights to
acquire Common Stock or other securities of New Abpro, or other similar corporate transaction or event (including, without limitation,
a change in control (as defined below)) that affects Common Stock, or (ii) unusual or infrequently occurring events (including, without
limitation, a change in control) affecting New Abpro, any affiliate, or the financial statements of New Abpro or any affiliate, or changes
in applicable rules, rulings, regulations or other requirements of any governmental body or securities exchange or inter-dealer quotation
system, accounting principles or law, such that in either case an adjustment is determined by the Committee in its sole discretion to
be necessary or appropriate to prevent the dilution or enlargement of the benefits intended to be made available under the New Abpro Incentive
Plan, then the Committee shall make any such adjustments in such manner as it may deem equitable, including without limitation any or
all of the following: (a) adjusting any or all of (A) the number of shares of Common Stock or other securities of New Abpro (or number
and kind of other securities or other property) that may be delivered in respect of awards or with respect to which awards may be granted
under the New Abpro Incentive Plan, and (B) the terms of any outstanding award, including, without limitation, (1) the number of shares
of Common Stock or other securities of New Abpro (or number and kind of other securities or other property) subject to outstanding awards
or to which outstanding awards relate, (2) the exercise price with respect to any award or (3) any applicable performance measures (including,
without limitation, performance criteria and performance goals); (b) providing for a substitution or assumption of awards in a manner
that substantially preserves the applicable terms of such awards; (c) accelerating the exercisability or vesting of, lapse of restrictions
on, or termination of, awards or providing for a period of time for exercise prior to the occurrence of such event; (d) modifying the
terms of awards to add events, conditions or circumstances (including termination of employment within a specified period after a change
in control) upon which the exercisability or vesting of or lapse of restrictions thereon will accelerate; (e) deeming any performance
measures (including, without limitation, performance criteria and performance goals) satisfied at target, maximum or actual performance
through closing or such other level determined by the Committee in its sole discretion, or providing for the performance measures to continue
(as is or as adjusted by the Committee) after closing; (f) providing that for a period prior to the change in control determined by the
Committee in its sole discretion, any options or SARs that would not otherwise become exercisable prior to the change in control will
be exercisable as to all shares of Common Stock subject thereto (but any such exercise will be contingent upon and subject to the occurrence
of the change in control and if the change in control does not take place after giving such notice for any reason whatsoever, the exercise
will be null and void) and that any options or SARs not exercised prior to the consummation of the change in control will terminate and
be of no further force and effect as of the consummation of the change in control; and (g) canceling any one or more outstanding awards
and causing to be paid to the holders thereof, in cash, Common Stock, other securities or other property, or any combination thereof,
the value of such awards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Change in Control</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the New Abpro
Incentive Plan, a &#8220;change in control&#8221; means, in summary, the first to occur of any of the following events: (i) one person
or group of persons becomes the beneficial owner, directly or indirectly, of more than 50% of the combined voting power of the then issued
and outstanding securities of New Abpro, whether pursuant to a sale of securities, merger or otherwise, (ii) during any period of not
more than two (2) consecutive years, individuals who constitute the Board as of the beginning of the period cease for any reason to constitute
at least a majority of the Board or (iii) the consummation of a sale, transfer or other disposition of all or substantially all of the
business and assets of New Abpro, whether by sale of assets, merger or otherwise (determined on a consolidated basis), to one person or
group of persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Tax Withholding</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each participant will be required
to make arrangements satisfactory to the Committee regarding payment of an amount up to the maximum statutory rates in the participant&#8217;s
applicable jurisdictions with respect to any award granted under the New Abpro Incentive Plan, as determined by New Abpro. New Abpro has
the right, to the extent permitted by law, to deduct any such taxes from any payment of any kind otherwise due to the participant. With
the approval of the Committee, the participant may satisfy the foregoing requirement by either electing to have New Abpro withhold from
delivery of shares of Common Stock, cash or other property, as applicable, or by delivering already owned unrestricted shares of Common
Stock, in each case, having a value not exceeding the applicable taxes to be withheld and applied to the tax obligations. New Abpro may
also use any other method of obtaining the necessary payment or proceeds, as permitted by law, to satisfy its withholding obligation with
respect to any award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Amendment and Termination of the Plan</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The New Abpro Incentive Plan
provides the Board with authority to amend, alter or terminate the New Abpro Incentive Plan, but no such action may impair the rights
of any participant with respect to outstanding awards without the participant&#8217;s consent. The Committee may amend an award, prospectively
or retroactively, but no such amendment may materially impair the rights of any participant without the participant&#8217;s consent. Stockholder
approval of any such action will be obtained if required to comply with applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Plan Term</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The New Abpro Incentive Plan
will terminate on November 7, 2034, although awards granted before that time will remain outstanding in accordance with their terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Material U.S. Federal Income Tax Consequences</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a general
summary under current law of the principal United States federal income tax consequences related to awards under the New Abpro Incentive
Plan. This summary deals with the general federal income tax principles that apply and is provided only for general information. Some
kinds of taxes, such as state, local and foreign income taxes, and federal employment taxes, are not discussed. This summary is not intended
as tax advice to participants, who should consult their own tax advisors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Non-Qualified Stock Options</i>.
If an optionee is granted an NSO under the New Abpro Incentive Plan, the optionee should not have taxable income on the grant of the option.
Generally, the optionee should recognize ordinary income at the time of exercise in an amount equal to the fair market value of the shares
acquired on the date of exercise, less the exercise price paid for the shares. The optionee&#8217;s basis in our Common Stock for purposes
of determining gain or loss on a subsequent sale or disposition of such shares generally will be the fair market value of our Common Stock
on the date the optionee exercises such option. Any subsequent gain or loss will be taxable as a long-term or short-term capital gain
or loss. We or our subsidiaries or affiliates generally should be entitled to a federal income tax deduction at the time and for the same
amount as the optionee recognizes ordinary income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Incentive Stock Options</i>.
A participant receiving ISOs should not recognize taxable income upon grant or at the time of exercise. However, the excess of the fair
market value of the shares of our common stock received over the option exercise price is an item of tax preference income potentially
subject to the alternative minimum tax. If stock acquired upon exercise of an ISO is held for a minimum of two years from the date of
grant and one year from the date of exercise and otherwise satisfies the ISO requirements, the gain or loss (in an amount equal to the
difference between the fair market value on the date of disposition and the exercise price) upon disposition of the stock will be treated
as a long-term capital gain or loss, and we will not be entitled to any deduction. If the holding period requirements are not met, the
ISO will be treated as one that does not meet the requirements of the Code for ISOs and the participant will recognize ordinary income
at the time of the disposition equal to the excess of the amount realized over the exercise price, but not more than the excess of the
fair market value of the shares on the date the ISO is exercised over the exercise price, with any remaining gain or loss being treated
as capital gain or capital loss. We and our subsidiaries or affiliates generally are not entitled to a federal income tax deduction upon
either the exercise of an ISO or upon disposition of the shares acquired pursuant to such exercise, except to the extent that the participant
recognizes ordinary income on disposition of the shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Other Awards</i>. The current
federal income tax consequences of other awards authorized under the New Abpro Incentive Plan generally follow certain basic patterns:
SARs are taxed and deductible in substantially the same manner as NSOs; nontransferable restricted stock subject to a substantial risk
of forfeiture results in income recognition equal to the excess of the fair market value over the price paid, if any, only at the time
the restrictions lapse (unless the recipient elects to accelerate recognition as of the date of grant through a Section 83(b) election
under the Code); RSUs, dividend equivalents and other stock or cash based awards are generally subject to tax at the time of (unless the
recipient elects to accelerate recognition as of the date of grant through a Section 83(b) election under the Code); RSUs, dividend equivalents
and other stock or cash based awards are generally subject to tax at the time of payment. We and our subsidiaries or affiliates generally
should be entitled to a federal income tax deduction at the time and for the same amount as the optionee recognizes ordinary income.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Section 409A of the Code</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain types of awards under
the New Abpro Incentive Plan may constitute, or provide for, a deferral of compensation subject to Section 409A of the Code. Unless certain
requirements set forth in Section 409A of the Code are complied with, holders of such awards may be taxed earlier than would otherwise
be the case (e.g., at the time of vesting instead of the time of payment) and may be subject to an additional 20% penalty tax (and, potentially,
certain interest, penalties and additional state taxes). To the extent applicable, the New Abpro Incentive Plan and awards granted under
the New Abpro Incentive Plan are intended to be structured and interpreted in a manner intended to either comply with or be exempt from
Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance that may be issued under Section 409A
of the Code. To the extent determined necessary or appropriate by the plan administrator, the New Abpro Incentive Plan and applicable
award agreements may be amended to further comply with Section 409A of the Code or to exempt the applicable awards from Section 409A of
the Code.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>New Plan Benefits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The benefits or amounts that
may be received or allocated to participants under the New Abpro Incentive Plan will be determined at the discretion of the plan administrator
and are not currently determinable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Form S-8</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form S-8 covering the Common Stock of New Abpro issuable under the New Abpro Incentive Plan.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PRINCIPAL STOCKHOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding the beneficial ownership of shares of our Common Stock upon the completion of the Business Combination by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each person known by us to be the beneficial owner of more than 5% of New Abpro&#8217;s Common Stock;</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each director of New Abpro</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our named executive officers; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each of our officers and directors as a group.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beneficial ownership is determined
according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses
sole or shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable
within 60 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The beneficial ownership
of Common Stock in the table below is based on 2,716,278 shares Common Stock issued and outstanding as of November 28, 2025. The issued
and outstanding shares of Common Stock does not include 362,413 shares that made up the Business Combination Consideration and are reserved
for future issuance pursuant to rollover RSUs and options of Abpro Corporation and 208,025 shares of Common Stock reserved for future
issuance under the New Abpro Incentive Plan. The below table excludes the Common Stock underlying the Warrants, because these securities
are not exercisable until registered, which may or may not occur within sixty (60) days.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
New Abpro believes that all persons named in the table have sole voting and investment power with respect to all common shares beneficially
owned by them. Unless otherwise noted, the business address of each of the following entities or individuals is 100 Summit Drive, Burlington,
MA 01803.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold"><span style="-keep: true">Name and Address of Beneficial Owner</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span style="-keep: true">Number of<br/>
    Shares<br/>
    Beneficially<br/>
    Owned</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif">%
    <b>of<br/>
    Class</b></span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic"><span style="-keep: true">Directors and Named Executive Officers</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">J. Wook
    (Miles) Suk<sup>(1)</sup></span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-keep: true">27,731</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 7%; text-align: right"><span style="-keep: true">1.0</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Ian Chan<sup>(2)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">291,700</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10.7</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Robert Markelewicz<sup>(3)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">25,328</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">0.9</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Anthony D. Eisenberg <sup>(6)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,020</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Soo Young Lee <sup>(6)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,020</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Ian McDonald <sup>(6)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">2,020</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Christian Zapf</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">-</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">All executive officers and directors as a group (6 individuals)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">350,819</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">12.6</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; font-style: italic; text-align: left"><span style="-keep: true">Greater than Five Percent Holders:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Abpro Bio International,
    Inc.<sup>(4)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">550,244</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">20.3</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Ian Chan<sup>(2)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">291,700</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">10.7</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Atlantic Coastal
    Acquisition Management II LLC<sup>(5)</sup></span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">577,742</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">18.2</span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consists
    of (1) 7,072 shares of Common Stock held by Mr. Suk, (2) 210 shares of Common Stock underlying vested rollover RSUs held by Mr. Suk,
    and (3) 20,449 shares underlying rollover stock options that are currently exercisable and held by BioCelsus International Co Ltd.,
    an entity controlled by Mr. Suk (does not include 16,667 Restricted Stock Units which are not vested within 60 days of the date of
    November 28, 2025).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Includes
    the issuance of 14,167 shares of Common Stock exercisable upon the exercise of Warrants at an exercise price of $99.90 per share
    and the issuance of 2,020 shares of Common Stock exercisable upon the exercise of Common Stock Options at an exercise price of $9.46
    per share (does not include the exercise of an additional 14,167 Warrants which are not exercisable within 60 days of the date of
    November 28, 2025).</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Includes 25,328
                                            shares of Common Stock issuable pursuant to rollover options, which are exercisable within
                                            60 days of November 28, 2025. Excludes 21 shares of Common Stock issuable pursuant to rollover
                                            options, which are not exercisable within 60 days of November 28, 2025.</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The business address for Abpro Bio International, Inc. is 139, Techno jungang-daero, Yuga-myeon, Dalseong-gun, Daegu, Republic of Korea. Abpro Bio International, Inc. is a subsidiary of Abpro Bio Co. Ltd, a publicly traded company listed on the KOSDAQ market of the Korea Exchange (KOSDAQ: 195990).</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Atlantic
    Coastal Acquisition Management II LLC, or the Sponsor, is the record holder of the shares reported herein. Shahraab Ahmad is the
    manager and the majority owner of the Sponsor. Accordingly, Mr. Ahmad may be deemed to beneficially own all of the shares held by
    the Sponsor. Mr. Ahmad disclaims beneficial ownership of any securities held by the Sponsor except to the extent of his pecuniary
    interest therein. Includes 461,667 shares of Common Stock underlying 461,667 warrants, at an exercise price of $114.90 per share,
    held by the Sponsor, which are exercisable within 60 days of the date of November 28, 2025.</span></td></tr>
  </table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)</span></td>
    <td style="text-align: justify; font-size: 10pt"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">Includes 2,020
                                            shares of Common Stock issuable pursuant to options, which are exercisable within 60 days
                                            of&#160;November 28, 2025.</span></p></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Pre-Closing Related Person Transactions-ACAB</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Founder Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, the Sponsor
purchased 7,187,500 Founder Shares (pre-split) for an aggregate purchase price of $25,000, or approximately $0.0035 per share (pre-split).
Due to the underwriters&#8217; election to partially exercise their overallotment option, 3,750 shares were forfeited. In October 2021,
the Sponsor transferred 50,000 Founder Shares (pre-split) to each of Ms. Lord, Mr. Kahlon, Mr. Stanwood, Mr. Dove and Mr. Schiano, ACAB&#8217;s
independent directors. The number of Founder Shares issued was determined based on the expectation that such Founder Shares would represent
approximately 20% of the outstanding shares upon completion of the ACAB IPO. On January 13, 2022, ACAB effectuated a 1.044-for-1 stock
split, resulting in an aggregate of 7,503,750 founder shares (pre-split) outstanding and held by the Initial Stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 18, 2023, the Sponsor,
ACAB&#8217;s independent directors, and Apeiron Investment Group Ltd (collectively, the &#8220;<b>Series B Holders</b>&#8221;) voluntarily
converted 7,499,999 shares (pre-split) of Series B common stock of ACAB they held as of such date into 7,499,999 shares (pre-split) of
Series A common stock of the Company (the &#8220;<b>Conversion</b>&#8221;) in accordance with the charter amendment. With respect to shares
of Series A common stock that they received as result of the Conversion, the Series B Holders (i) agreed that they would not vote such
stock until after the closing of a business combination and (ii) acknowledged that such stock would not be entitled to any distribution
from ACAB&#8217;s trust account. On December 15, 2023, ACAB held a special meeting of stockholders to approve a charter amendment proposal
to further extend the date by which ACAB must consummate a business combination to September 19, 2024 (subject to additional approval
by the ACAB Board (as defined below)). On December 13, 2023, holders of an aggregate of 2,768,301 shares (pre-split) of Series A common
stock exercised, and did not reverse, their right to redeem their shares, and as a result, such holders received a payment of approximately
$10.68 per share redeemed (pre-split). On September 19, 2024, at a special meeting of the stockholders, the stockholders approved a proposal
to amend ACAB&#8217;s Certificate of Incorporation to extend the date by which ACAB must complete its initial business combination from
September 19, 2024 to October 19, 2024 and to allow ACAB, without another stockholder vote, to elect to extend the October 19, 2024 termination
date by resolution of ACAB&#8217;s board of directors, if requested by the Sponsor, until November 19, 2024, unless the Closing shall
have occurred prior thereto.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 19, 2024, holders
of an aggregate of 126,122 shares (pre-split) of Series A common stock exercised, and did not reverse, their right to redeem their shares,
and as a result, such holders received a payment of approximately $11.29 per share redeemed (pre-split). As a result of the conversion
and the results of the stockholder meetings described above, ACAB has an aggregate of 8,041,268 shares (pre-split) of Series A common
stock outstanding and one (1) share (pre-split) of Series B common stock (held by the Sponsor) outstanding prior to the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->130<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Private Placement Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Sponsor purchased an aggregate
of 461,667 Placement Warrants at a price of $30.00 per warrant ($13,850,000 in the aggregate) in a private placement that occurred simultaneously
with the closing of the ACAB IPO. Each Placement Warrant entitled the holder thereof to purchase one share of ACAB&#8217;s Series A common
stock at a price of $345.00 per share. On March 6, 2025, the Company issued a warrant adjustment notice to the holders of its Warrants
notifying holders that effective after the close of trading on March 5, 2025, (i) the exercise price of the Warrants was reduced from
$345.00 per share to $114.90 per share and (ii) the $540.00 per share redemption trigger price was reduced to $179.70 per share (the &#8220;<b>Warrant
Adjustments</b>&#8221;). The Warrant Adjustments were required pursuant to Section 4.3.2 of the Warrant Agreements. The Placement Warrants
(including the Series A common stock issuable upon exercise thereof) may not, subject to certain limited exceptions, be transferred, assigned
or sold by the holder.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Registration Rights</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Founder Shares
and Placement Warrants are entitled to registration rights pursuant to a Registration Rights Agreement dated January 13, 2022, by and
among ACAB, the Sponsor and certain other securityholders of ACAB. The holders of a majority of these securities are entitled to make
up to three demands that we register such securities. The holders of a majority of the units issued in payment of working capital loans
made to us (or underlying securities) can elect to exercise these registration rights at any time after we consummate a business combination.
In addition, the holders have certain &#8220;piggy-back&#8221; registration rights with respect to registration statements filed subsequent
to our consummation of a business combination. We will bear the expenses incurred in connection with the filing of any such registration
statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Director and Officer Reimbursement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No compensation of any kind,
including any finder&#8217;s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, was paid by ACAB to the
Sponsor, officers and directors, or any of their respective affiliates, prior to, or in connection with any services rendered in order
to effectuate, the consummation of the Business Combination, other than the repayment of any loans from the Sponsor, officers and directors
for working capital purposes and reimbursement of any out-of-pocket expenses incurred in connection with activities on ACAB&#8217;s behalf
such as identifying potential target businesses and performing due diligence on suitable business combinations. ACAB did not have a policy
that prohibited the Sponsor, executive officers or directors, or any of their respective affiliates, from negotiating for the reimbursement
of out-of-pocket expenses by a target business. ACAB&#8217;s audit committee reviewed on a quarterly basis all payments that were made
to the Sponsor, officers, directors or ACAB or their respective affiliates and determined which expenses and the amount of expenses that
would be reimbursed. There was no cap or ceiling on the reimbursement of out-of-pocket expenses incurred by such persons in connection
with activities on ACAB&#8217;s behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Related Party Notes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, the Sponsor
agreed to loan ACAB an aggregate of up to $250,000 to cover expenses related to the ACAB IPO pursuant to a promissory note (the &#8220;<b>2021
Note</b>&#8221;). The 2021 Note was non-interest bearing and payable upon the completion of the ACAB IPO. The outstanding borrowings under
the 2021 Note in the amount of $149,539 were repaid on February 22, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 14, 2023 and November
14, 2023, ACAB issued unsecured promissory notes (the &#8220;<b>Extension Promissory Notes</b>&#8221;) to the Sponsor in the aggregate
principal amounts of $80,000 and $80,000, respectively, in connection with monthly extensions of the deadline to consummate an initial
business combination. These loans were consolidated under the Expense Advance Agreement described below and repaid in connection with
the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->131<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Expense Advance Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 30, 2024, ACAB and
the Sponsor entered into an expense advancement agreement, pursuant to which the Sponsor agreed to advance to ACAB up to $600,000 in the
aggregate, including previous amounts advanced from the Sponsor to ACAB, on an interest-free basis as may be necessary to cover working
capital expenses, fund certain redemptions of the ACAB&#8217;s common stock and cover costs and expenses in connection with the consummation
of ACAB&#8217;s proposed business combination. This agreement replaced the previous Extension Promissory Notes in the aggregate amount
of $160,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the Business Combination
date, the Sponsor advanced to ACAB $2,270,051. The advances from the Sponsor did not accrue interest. At the Business Combination date,
$2,000,000 of advances were converted into 20,020 shares of Common Stock of New Abpro and the remaining balance was repaid in cash.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Promissory Note Issued to Shahraab Ahmad, CEO of ACAB</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For more information about
the Ahmad Promissory Note, see the subsection entitled &#8220;<i>Certain Relationships and Related Party Transactions - Pre-Closing Related
Person Transactions - Abpro Corporation - Promissory Note for Bridge Loan with Shahraab Ahmad, Chief Executive Officer of ACAB.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Sponsor Letter Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">In
                                            connection with the execution of the Business Combination Agreement, the Sponsor entered
                                            into an agreement with ACAB, the Company and Abpro Bio International, Inc. (the &#8220;<b>Sponsor
                                            Letter Agreement</b>&#8221;), whereby the Sponsor agreed to (i) retain 2.95 million shares
                                            (pre-split) of ACAB Series A common stock held by it, (ii) divide 2,458,333 shares (pre-split)
                                            of ACAB Series A common stock held by it among the Sponsor, who will be entitled to 491,667
                                            of the shares, Abpro, who will be entitled to 983,333 of the shares (pre-split), and Abpro
                                            Bio who will be entitled to 983,333 of the shares (pre-split), for such party to use to obtain
                                            non-redemption commitments from ACAB stockholders or other capital for ACAB or the surviving
                                            company (with any shares unused for such purpose to be retained by such party) and (iii)
                                            forfeit the remainder of any ACAB Series A common stock and ACAB Series B common stock held
                                            by it. At Closing, the Sponsor forfeited 966,442 shares (pre-split) of Common Stock pursuant
                                            to the Sponsor Letter Agreement.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Deferred Underwriting Fee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 8, 2024, ACAB and
Cantor entered into the Fee Reduction Agreement, pursuant to which Cantor has agreed to settle $10,290,000 of the deferred underwriting
fees payable, resulting in a remainder of $6,000,000 of deferred underwriting fees payable (the &#8220;<b>Reduced Deferred Fee</b>&#8221;)
by the Company to Cantor upon the Closing. The Reduced Deferred Fee was paid at Closing to Cantor in the form of 20,000 shares of Common
Stock. The Fee Reduction Agreement only applied to the consummation of the Business Combination with Abpro.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Polar Subscription Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 10, 2024, ACAB, Polar
Multi-Strategy Master Fund (&#8220;<b>Pola</b>r&#8221;), and the Sponsor entered into a subscription agreement (the &#8220;<b>Polar Subscription
Agreement</b>&#8221;) pursuant to which Polar agreed to provide a capital contribution to the Sponsor in an aggregate amount of up to
$360,000 (the &#8220;<b>Capital Contribution</b>&#8221;) in exchange for 1 share (pre-split) of ACAB&#8217;s Series A common stock held
by the Sponsor for each $1 invested by Polar as of the closing of ACAB&#8217;s initial business combination, provided that the obligation
to make capital contributions would terminate on November 19, 2024 (the date by which ACAB must consummate its initial business combination).
Funds invested by Polar pursuant to the Polar Subscription Agreement would in turn will be loaned by the Sponsor to ACAB on an interest-free
basis (the &#8220;<b>SPAC Loan</b>&#8221;) in order to fund ACAB&#8217;s working capital needs and other expenses in connection with the
Business Combination. As of June 30, 2024, Polar funded $345,051 of the Capital Contribution to the Sponsor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the consummation of the
Business Combination, ACAB paid to the Sponsor the principal amount outstanding under the SPAC Loan. In addition, Polar received from
the Sponsor 12,000 shares of Common Stock, an amount equal to the Capital Contribution, which represented 1 share (pre-split) of Common
Stock for each $10 invested by Polar as of the Closing of the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->132<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Abpro Corporation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Director and Executive Officer Compensation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abpro has granted stock options
to its directors and executive officers, as more fully described in the section &#8220;<i>Executive Compensation.</i>&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Abpro Bio International, Inc.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abpro Bio owns approximately
20.3% of New Abpro.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Abpro Bio Collaboration Agreement</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abpro entered into a Collaboration
and License Agreement (the &#8220;<b>Abpro Bio Collaboration Agreement</b>&#8221;) in January 2020 with AbMed Corporation and Abpro Bio
to develop and commercialize ABP-201 through a territorial partnership that granted Abpro Bio exclusive development and commercialization
rights in the People&#8217;s Republic of China, Japan, South Korea, Southeast Asia (which for the purposes hereof means Philippines, Indonesia,
Taiwan, Pakistan, India, Vietnam, Laos, Cambodia, Thailand, Myanmar and West Malaysia), the Middle East (which for the purposes hereof
means Bahrain, Cyprus, Egypt, Iraq, Israel, Jordan, Kuwait, Lebanon, Northern Cyprus, Oman, Palestine, Qatar, Saudi Arabia, Syria, Turkey,
United Arab Emirates and Yemen), and the Commonwealth of Independent States (CIS) (which for the purposes hereof means Armenia, Azerbaijan,
Belarus, Estonia, Georgia, Kazakhstan, Kyrgyzstan, Latvia, Lithuania, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Abpro agreed to form a joint
steering committee to oversee the collaboration that includes representatives from both Abpro and Abpro Bio. Abpro Bio agreed to use commercially
reasonable efforts to develop and commercialize a licensed product, including the achievement of certain milestones by certain dates.
Under the Collaboration Agreement, Abpro Bio agreed to pay Abpro a double-digit percentage royalty in the low teens, tiered based on cumulative
net sales by Abpro Bio, its affiliates or sublicensees beginning with the first commercial sale of a licensed product in its territory.
Abpro is also entitled to payments totaling approximately $540 million, subject to the satisfaction of certain development and sales milestones.
Abpro is responsible for patent prosecution and Abpro Bio has agreed to reimburse Abpro for patent costs in its licensed territory. Unless
earlier terminated in accordance with its terms, the agreement with Abpro Bio remains in effect on a country-by-country basis until the
later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) 10 years after the first commercial sale
of a licensed product in a country, and (iii) the expiration of regulatory exclusivity for a licensed product in a country. Abpro may
terminate the agreement upon the occurrence of specified bankruptcy events relating to Abpro Bio or if Abpro Bio is in material default
or breach of the agreement and does not cure within a specified notice and cure period. Abpro Bio may also terminate the agreement upon
ninety (90) days&#8217; written notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with entering
into the Abpro Bio Collaboration Agreement, Abpro Bio made a $30 million equity investment in Abpro.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">Series E and Series F Preferred Stock Offerings</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2020, Abpro issued and
sold to Abpro Bio in a private placement an aggregate of 3,303,966 shares (pre-split), or 100%, of Abpro&#8217;s Series E Redeemable Convertible
Preferred Stock at a purchase price of $9.08 per share (pre-split) for an aggregate purchase price of approximately $30.0 million. Each
share of Series E Redeemable Convertible Preferred Stock was automatically converted into one share of Common Stock upon closing of the
Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2022, Abpro issued and
sold to Abpro Bio in a private placement an aggregate of 444,444 shares (pre-split), or 80%, of Abpro&#8217;s Series F Redeemable Convertible
Preferred Stock at a purchase price of $18.00 per share (pre-split) for an aggregate purchase price of approximately $8.0 million. Each
share of Series F Redeemable Convertible Preferred Stock was automatically converted into one share of Common Stock upon closing of the
Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->133<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i><span style="text-decoration:underline">2023 Promissory Note</span></i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 18, 2023, Abpro
issued a Promissory Note for the benefit of Abpro Bio in the principal amount of up to $6 million for expenses incurred in connection
with the Business Combination and for Abpro operating expenses. Amounts borrowed under the Promissory Note plus accrued interest were
due and payable on the earlier of (i) the closing of the Business Combination and (ii) April 18, 2025. The Promissory Note accrued interest
at 5% per annum until the maturity date and 7% thereafter. At the Closing in connection with the PIPE Financing, the outstanding $4.2
million on the Promissory Note was cancelled, and Abpro Bio invested an addition $2.0 million in cash, resulting in a total of 62,247
shares of Common Stock being issued to Abpro Bio (including Incentive Shares).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Related Party Promissory Notes</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On December 29, 2023,
Abpro issued a Promissory Note for the benefit of Ian Chan in the principal amount of $176,625. Amounts borrowed under the Promissory
Note plus accrued interest were due and payable on the earlier of (i) the closing of the Business Combination and (ii) June 29, 2025.
The Promissory Note accrues interest at 5% per annum until the maturity date and 7% thereafter. As of both September 30, 2025 and December
31, 2024, $23,584 of principal was outstanding.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">On December 29, 2023,
Abpro issued a Promissory Note for the benefit of Eugene Chan in the principal amount of $123,638. Amounts borrowed under the Promissory
Note plus accrued interest were due and payable on the earlier of (i) the closing of the Business Combination and (ii) June 29, 2025.
The Promissory Note accrues interest at 5% per annum until the maturity date and 7% thereafter. The principal amount of this Promissory
Note was outstanding at September 30, 2025 and December 31, 2024.</span></p><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Consulting Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 1, 2023, Abpro
entered into a consulting agreement with NEM LLC, whose sole member is Eugene Chan, Abpro&#8217;s Chairman. The Consulting Agreement provides
for annual payment of $250,000 paid monthly, and a possible performance bonus of up to 50%. The Consulting Agreement has a term of twelve
(12) months, and automatically renews for additional 12-month terms thereafter unless cancelled by either party. Either party may terminate
the agreement with sixty (60) days&#8217; notice to the other party. This agreement was terminated during the year ended December 31,
2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Promissory Note Agreement with Executive</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 18, 2024, the Company
entered into a promissory note agreement with one of its executives to receive up to $2,158,000 in funding. Between April and the Closing,
the Company received $1,997,000 in advances from the executive. These advances accrue interest at 7.5% per annum through the maturity
date and at 9.5% per annum after the maturity date if any amounts then remain outstanding. All advances, plus accrued interest, were due
and payable on the earlier of (i) the closing of the Business Combination and (ii) November 19, 2024. This promissory note agreement included
early repayment provisions which state that if in any calendar month prior to the closing of the Business Combination, the Company receives
capital or cash flows from another party, then the executive will be paid 10% of such proceeds prior to any other obligations that the
Company may have until the principal and interest have been repaid. At the closing of the Business Combination, the Company issued 20,000
shares of Common Stock to Ian Chan in satisfaction of the promissory note. Pursuant to the terms of the promissory note, Abpro Corporation
agreed to cause to be issued to Ian Chan a number of New Abpro stock options or warrants in an amount equal to the outstanding principal
amount of such promissory note. On February 7, 2025, the Company issued warrants to purchase 28,333 shares of Common Stock (the &#8220;<b>Ian
Chan Warrants</b>&#8221;) in full satisfaction of such agreement to issue stock options or warrants. The Ian Chan Warrants are exercisable
for $99.90 per share on or before the tenth anniversary of the issuance. Of the Ian Chan Warrants, 14,167 were exercisable upon issuance,
6,666 are exercisable upon the first anniversary of issuance, and the final 7,500 are exercisable on the second anniversary of issuance.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->134<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Promissory Note for Bridge Loan with Shahraab Ahmad, Chief Executive
Officer of ACAB</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2024, Abpro
issued a Promissory Note to Shahraab Ahmad, Chief Executive Officer of ACAB, pursuant to which Abpro received a bridge loan in the principal
amount of $103,000 from Mr. Ahmad (the &#8220;<b>Bridge Loan</b>&#8221;). The Bridge Loan matured on the earlier of (i) November 20, 2024
and (ii) the successful closing of the de-SPAC transaction contemplated by the Business Combination Agreement (the &#8220;<b>Ahmad Note
Maturity Date</b>&#8221;). On the Ahmad Note Maturity Date, the sum of $206,000, including $103,000 principal, will be payable by Abpro
to Mr. Ahmad. On the Closing Date, the Bridge Loan was cancelled and replaced with a promissory note to ACAB providing for the payment
of $103,000 principal on the Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification of Our Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Charter provides that
we must indemnify and advance expenses to our directors and officers to the full extent authorized by the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concurrently with the Closing,
New Abpro entered into indemnification agreements with each of its directors and executive officers. Such agreements may require New Abpro,
among other things, to advance expenses and otherwise indemnify its executive officers and directors against certain liabilities that
may arise by reason of their status or service as executive officers or directors, to the fullest extent permitted by law. New Abpro intends
to enter into indemnification agreements with any new directors and executive officers in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The indemnification rights
set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute,
any provision of our Charter, our Bylaws, agreement, vote of stockholders or disinterested directors or otherwise. Notwithstanding the
foregoing, we shall not be obligated to indemnify a director or officer in respect of a proceeding (or part thereof) instituted by such
director or officer, unless such proceeding (or part thereof) has been authorized by the Board pursuant to the applicable procedure outlined
in our restated certificate of incorporation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Post-Closing Related Party Transactions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Severance Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 21, 2024, we entered
into a severance agreement with an executive (the &#8220;<b>Severance Agreement</b>&#8221;). Pursuant to the terms of the Severance Agreement,
we made a severance payment of $221,000 upon execution of the agreement. The Severance Agreement supersedes and extinguishes all other
agreements between the executive and the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Payment to Sponsor </i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 24, 2024, we made
a payment of $574,000 to the Sponsor in accordance with the terms of the Business Combination Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Other Material Interests Relating to the Business Combination</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ACAB&#8217;s directors and
officers will be eligible for continued indemnification and continued coverage under ACAB&#8217;s directors&#8217; and officers&#8217;
liability insurance for six years after the Closing Date pursuant to the Business Combination Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;<b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Procedures with Respect to Review and Approval of Related Person
Transactions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Code of Business Conduct
and Ethics requires us to avoid, wherever possible, all related party transactions that could result in actual or potential conflicts
of interests, except under guidelines approved by the Board (or the audit committee). Related-party transactions are defined as transactions
in which (1) the aggregate amount involved will or may be expected to exceed $120,000 in any calendar year, (2) we or any of our subsidiaries
is a participant, and (3) any (a) executive officer, director or nominee for election as a director, (b) greater than 5% beneficial owner
of our shares of Common Stock, or (c) immediate family member of the persons referred to in clauses (a) and (b), has or will have a direct
or indirect material interest (other than solely as a result of being a director or a less than 10% beneficial owner of another entity).
A conflict of interest situation can arise when a person takes actions or has interests that may make it difficult to perform his or her
work objectively and effectively. Conflicts of interest may also arise if a person, or a member of his or her family, receives improper
personal benefits as a result of his or her position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->135<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee, pursuant
to its written charter, is responsible for reviewing and approving related-party transactions to the extent we enter into such transactions.
The audit committee will consider all relevant factors when determining whether to approve a related party transaction, including whether
the related party transaction is on terms no less favorable to us than terms generally available from an unaffiliated third-party under
the same or similar circumstances and the extent of the related party&#8217;s interest in the transaction. No director may participate
in the approval of any transaction in which he is a related party, but that director is required to provide the audit committee with all
material information concerning the transaction. We also require each of our directors and executive officers to complete a directors&#8217;
and officers&#8217; questionnaire that elicits information about related party transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These procedures are intended
to determine whether any such related party transaction impairs the independence of a director or presents a conflict of interest on the
part of a director, employee or officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To further minimize conflicts
of interest, we have agreed not to consummate an initial business combination with an entity that is affiliated with any of the Sponsor
or our officers or directors including (i) an entity that is either a portfolio company of, or has otherwise received a material financial
investment from, any private equity fund or investment company (or an affiliate thereof) that is affiliated with any of the foregoing,
(ii) an entity in which any of the foregoing or their affiliates are currently passive investors, (iii) an entity in which any of the
foregoing or their affiliates are currently officers or directors, or (iv) an entity in which any of the foregoing or their affiliates
are currently invested through an investment vehicle controlled by them, unless we have obtained an opinion from an independent investment
banking firm, or another independent entity that commonly renders valuation opinions on the type of target business we are seeking to
acquire, and the approval of a majority of our disinterested independent directors that the business combination is fair to our unaffiliated
stockholders from a financial point of view. Furthermore, no finder&#8217;s fees, reimbursements, consulting fee, monies in respect of
any payment of a loan or other compensation will be paid by us to the Sponsor, our officers or directors, or any of their respective affiliates,
for services rendered to us prior to, or in connection with any services rendered in order to effectuate, the consummation of our initial
business combination (regardless of the type of transaction that it is), other than the repayment of any loans from the Sponsor, officers
and directors for working capital purposes and reimbursement of any out-of-pocket expenses incurred in connection with activities on our
behalf such as identifying potential target businesses and performing due diligence on suitable business combinations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>DESCRIPTION OF CAPITAL STOCK</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summary is not
intended to be a complete summary of the rights and preferences of such securities, and is qualified by reference to the Charter and Bylaws,
copies of which are filed as exhibits to the registration statement of which this prospectus forms a part. We urge you to read the Charter
and Bylaws in their entirety for a complete description of the rights and preferences of our securities following the consummation of
the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Authorized Capitalization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">New Abpro&#8217;s authorized
capital stock consists of 110,000,000 shares of Common Stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par
value $0.0001 per share. As of November 28, 2025, there were 2,716,278 shares of Common Stock issued and outstanding. No shares of preferred
stock are issued and outstanding. Unless the Board determines otherwise, New Abpro will issue all shares of its capital stock in uncertificated
form.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Common Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Voting rights. </i></b>Holders
of shares of Common Stock are entitled to one (1) vote for each share of Common Stock held as of the record date on all matters submitted
to a vote of stockholders, provided, however, that, except as otherwise required in the Charter or by applicable law, the holders of Common
Stock will not be entitled to vote on any amendment to our Charter that relates solely to the terms of one or more outstanding series
of preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more
other such series, to vote thereon pursuant to our Charter (including any certificate of designation relating to any series of preferred
stock) or pursuant to the DGCL.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->136<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Dividend rights. </i></b>Subject
to applicable law and the rights and preferences of the holders of any outstanding series of New Abpro preferred stock, and to the other
provisions of the Charter, the holders of Common Stock shall be entitled to the payment of dividends on the Common Stock in cash, in property
or in shares of New Abpro when, as and if declared thereon by the Board from time to time out of assets or funds of New Abpro legally
available therefor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Rights upon liquidation.
</i></b>Subject to the rights of holders of preferred stock, upon New Abpro&#8217;s liquidation, dissolution or winding up and after payment
in full of all amounts required to be paid to creditors and to any future holders of preferred stock having liquidation preferences, if
any, the holders of Common Stock will be entitled to receive pro rata New Abpro&#8217;s remaining assets available for distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Post-Combination Company Preferred Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terms of the Charter,
the Board is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. The Board
has the discretion to determine the rights, powers, preferences, privileges and restrictions, including voting rights, dividend rights,
conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of authorizing
the Board to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote
on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings
and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third
party from seeking to acquire, a majority of the outstanding voting stock. Additionally, the issuance of preferred stock may adversely
affect the holders of Common Stock by restricting dividends on the Common Stock, diluting the voting power of the Common Stock or subordinating
the liquidation rights of the Common Stock. As a result of these or other factors, the issuance of preferred stock could have an adverse
impact on the market price of the Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Warrants</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 6, 2025, the Company
issued a warrant adjustment notice to the holders of its Warrants notifying holders that effective after the close of trading on March
5, 2025, (i) the exercise price of the Warrants was reduced from $345 per share to $114.90 per share and (ii) the $540.00 per share redemption
trigger price was reduced to $179.70 per share. The Warrant Adjustments were required pursuant to Section 4.3.2 of the Warrant Agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Public Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is currently outstanding
an aggregate of 500,000 Public Warrants, which entitle the holder to acquire Common Stock. Each whole warrant will entitle the registered
holder to purchase one share of Common Stock at an exercise price of $114.90 per share. A holder may exercise its warrants only for a
whole number of shares of Common Stock. This means only a whole warrant may be exercised at a given time by a warrant holder. The warrants
will expire at 5:00 p.m., New York City time, on the earlier to occur of five (5) years after the completion of the Business Combination
or redemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New Abpro will not be obligated
to deliver any shares of Common Stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such warrant
exercise unless a registration statement under the Securities Act covering the issuance of the shares of Common Stock issuable upon exercise
of the Public Warrants is then effective and a current prospectus relating thereto is available, subject to New Abpro satisfying its obligations
described below with respect to registration, or a valid exemption from registration is available, including in connection with a cashless
exercise. No Public Warrant will be exercisable for cash or on a cashless basis, and New Abpro will not be obligated to issue any shares
to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the
securities laws of the state of the exercising holder, or an exemption from registration is available. In the event that the conditions
in the two immediately preceding sentences are not satisfied with respect to a Public Warrant, the holder of such warrant will not be
entitled to exercise such warrant and such warrant may have no value and expire worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->137<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As soon as practicable, but
in no event later than twenty (20) business days after the Closing, New Abpro will use its commercially reasonable efforts to file with
the SEC a registration statement covering the issuance, under the Securities Act, of the shares of Common Stock issuable upon exercise
of the Public Warrants, and will use commercially reasonable efforts to cause the same to become effective within sixty (60) business
days after the Closing and to maintain the effectiveness of such registration statement, and a current prospectus relating thereto, until
the expiration of the Public Warrants in accordance with the provisions of the Warrant Agreement. Notwithstanding the above, if shares
of Common Stock are, at the time of any exercise of a Public Warrant, not listed on a national securities exchange such that they satisfy
the definition of a &#8220;covered security&#8221; under Section 18(b)(1) of the Securities Act, New Abpro may, at its option, require
holders of Public Warrants who exercise their warrants to do so on a &#8220;cashless basis&#8221; in accordance with Section 3(a)(9) of
the Securities Act and, in the event New Abpro so elects, it will not be required to file or maintain in effect a registration statement,
but will use its commercially reasonable efforts to register or qualify the shares under applicable blue sky laws to the extent an exemption
is not available. In such event, each holder would pay the exercise price by surrendering the Public Warrants for that number of shares
of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying the Public
Warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the Public Warrants
by (y) the fair market value. The &#8220;fair market value&#8221; means the volume weighted average price of the shares of Common Stock
for the 10 trading days ending on the trading day prior to the date on which the notice of exercise is received by the warrant agent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Redemption of Public Warrants</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once the warrants become exercisable,
New Abpro may redeem the outstanding warrants (except as described herein with respect to the Placement Warrants):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; font-size: 10pt">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in whole and not in part;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a price of $0.30 per warrant;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon not less than 30 days&#8217; prior written notice of redemption (the &#8220;<b>30-day redemption period</b>&#8221;) to each warrant holder; and</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="background-color: white; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if, and only if, the last reported sale price of the Common Stock equals or <span style="background-color: white">exceeds $179.70 per</span> share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending three business days before New Abpro sends the notice of redemption to the warrant holders.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New Abpro will not redeem
the Public Warrants as described above unless a registration statement under the Securities Act covering the issuance of the shares of
Common Stock issuable upon exercise of the Public Warrants is then effective and a current prospectus relating to those shares of Common
Stock is available throughout the 30-day redemption period. If and when the Public Warrants become redeemable, New Abpro may exercise
its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities
laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The redemption criterion discussed
above was established to prevent a redemption call unless there is at the time of the call a significant premium to the Public Warrant
exercise price. If the foregoing conditions are satisfied and New Abpro issues a notice of redemption of the Public Warrants, each warrant
holder will be entitled to exercise his, her or its warrant prior to the scheduled redemption date. However, the price of shares of New
Abpro Common Stock may fall below the $179.70 redemption trigger price (as adjusted for stock splits, stock capitalizations, reorganizations,
recapitalizations and the like) as well as the $114.90 Public Warrant exercise price after the redemption notice is issued.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->138<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If New Abpro calls the Public
Warrants for redemption as described above, its management will have the option to require any holder that wishes to exercise its Public
Warrant to do so on a &#8220;cashless basis.&#8221; In determining whether to require all holders to exercise their warrants on a &#8220;cashless
basis,&#8221; New Abpro&#8217;s management will consider, among other factors, New Abpro&#8217;s cash position, the number of warrants
that are outstanding and the dilutive effect on New Abpro&#8217;s stockholders of issuing the maximum number of shares of Common Stock
issuable upon the exercise of its Public Warrants. If New Abpro&#8217;s management takes advantage of this option, all holders of Public
Warrants would pay the exercise price by surrendering their warrants for that number of shares of Common Stock equal to the quotient obtained
by dividing (x) the product of the number of shares of Common Stock underlying the Public Warrants, multiplied by the excess of the &#8220;fair
market value&#8221; of Common Stock over the exercise price of the Public Warrants by (y) the fair market value. The &#8220;fair market
value&#8221; will mean the average last reported sale price of shares of Common Stock for the ten trading days ending on the third trading
day prior to the date on which the notice of redemption is sent to the holders of warrants. If New Abpro&#8217;s management takes advantage
of this option, the notice of redemption will contain the information necessary to calculate the number of shares of Common Stock to be
received upon exercise of the Public Warrants, including the &#8220;fair market value&#8221; in such case. Requiring a cashless exercise
in this manner will reduce the number of shares to be issued and thereby lessen the dilutive effect of a warrant redemption. If New Abpro
calls the Public Warrants for redemption and management does not take advantage of this option, the Sponsor and its permitted transferees
would still be entitled to exercise their Placement Warrants for cash or on a cashless basis using the same formula described above that
other warrant holders would have been required to use had all warrant holders been required to exercise their warrants on a cashless basis,
as described in more detail below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A holder of a warrant may
notify New Abpro in writing in the event it elects to be subject to a requirement that such holder will not have the right to exercise
such warrant, to the extent that after giving effect to such exercise, such person (together with such person&#8217;s affiliates), to
the warrant agent&#8217;s actual knowledge, would beneficially own in excess of 9.8% (or such other amount as a holder may specify) of
Common Stock outstanding immediately after giving effect to such exercise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i>&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Anti-Dilution Adjustments</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the number of outstanding
shares of Common Stock is increased by a share capitalization payable in shares of Common Stock, or by a split-up of Common Stock or other
similar event, then, on the effective date of such share capitalization, split-up or similar event, the number of shares of Common Stock
issuable on exercise of each warrant will be increased in proportion to such increase in the outstanding shares of Common Stock. A rights
offering to holders of Common Stock entitling holders to purchase Common Stock at a price less than the fair market value will be deemed
a share capitalization of a number of shares of Common Stock equal to the product of&#8201; (i) the number of shares of Common Stock
actually sold in such rights offering (or issuable under any other equity securities sold in such rights offering that are convertible
into or exercisable for Common Stock) and (ii) the quotient of&#8201; (x) the price per share of Common Stock paid in such rights offering
and (y) the fair market value. For these purposes (i) if the rights offering is for securities convertible into or exercisable for shares
of Common Stock, in determining the price payable for Common Stock, there will be taken into account any consideration received for such
rights, as well as any additional amount payable upon exercise or conversion and (ii) fair market value means the VWAP of shares of Common
Stock as reported during the ten (10) trading day period ending on the trading day prior to the first date on which the Common Stock trades
on the applicable exchange or in the applicable market, regular way, without the right to receive such rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if New Abpro,
at any time while the warrants are outstanding and unexpired, pays a dividend or makes a distribution in cash, securities or other assets
to the holders of Common Stock on account of such Common Stock (or other securities into which the warrants are convertible), other than
(a) as described above, or (b) certain ordinary cash dividends.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the number of outstanding
shares of Common Stock is decreased by a consolidation, combination, reverse share split or reclassification of Common Stock or other
similar event, then, on the effective date of such consolidation, combination, reverse share split, reclassification or similar event,
the number of shares of Common Stock issuable on exercise of each warrant will be decreased in proportion to such decrease in outstanding
share of Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->139<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Whenever the number of shares
of Common Stock purchasable upon the exercise of the warrants is adjusted, as described above, the warrant exercise price will be adjusted
by multiplying the warrant exercise price immediately prior to such adjustment by a fraction (x) the numerator of which will be the number
of shares of Common Stock purchasable upon the exercise of the warrants immediately prior to such adjustment, and (y) the denominator
of which will be the number of shares of Common Stock so purchasable immediately thereafter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the case of any reclassification
or reorganization of the outstanding Common Stock (other than those described above or that solely affects the par value of such Common
Stock), or in the case of any merger or consolidation of New Abpro with or into another corporation (other than a consolidation or merger
in which New Abpro is the continuing corporation and that does not result in any reclassification or reorganization of the outstanding
Common Stock), or in the case of any sale or conveyance to another corporation or entity of the assets or other property of New Abpro
as an entirety or substantially as an entirety in connection with which New Abpro is dissolved, the holders of the warrants will thereafter
have the right to purchase and receive, upon the basis and upon the terms and conditions specified in the warrants and in lieu of Common
Stock immediately theretofore purchasable and receivable upon the exercise of the rights represented thereby, the kind and amount of shares
of Common Stock or other securities or property (including cash) receivable upon such reclassification, reorganization, merger or consolidation,
or upon a dissolution following any such sale or transfer, that the holder of the warrants would have received if such holder had exercised
their warrants immediately prior to such event. If less than 70% of the consideration receivable by the holders of Common Stock in such
a transaction is payable in the form of Common Stock in the successor entity that is listed for trading on a national securities exchange
or is quoted in an established over-the-counter market, or is to be so listed for trading or quoted immediately following such event,
and if the registered holder of the warrant properly exercises the warrant within thirty days following public disclosure of such transaction,
the warrant exercise price will be reduced as specified in the warrant agreement based on the Black-Scholes value (as defined in the warrant
agreement) of the warrant. The purpose of such exercise price reduction is to provide additional value to holders of the warrants when
an extraordinary transaction occurs during the exercise period of the warrants pursuant to which the holders of the warrants otherwise
do not receive the full potential value of the warrants in order to determine and realize the option value component of the warrant. This
formula is to compensate the warrant holder for the loss of the option value portion of the warrant due to the requirement that the warrant
holder exercise the warrant within 30 days of the event. The Black-Scholes model is an accepted pricing model for estimating fair market
value where no quoted market price for an instrument is available.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrants will be issued
in registered form under a warrant agreement between Continental Stock Transfer &amp; Trust Company, as warrant agent, and New Abpro.
The warrant agreement provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or
correct any defective provision, and that all other modifications or amendments will require the vote or written consent of the holders
of at least 50% of the then outstanding Public Warrants, and, solely with respect to any amendment to the terms of the Placement Warrants,
a majority of the then outstanding Placement Warrants. You should review a copy of the warrant agreement, which is filed as an exhibit
to the registration statement pertaining to our initial public offering, for a complete description of the terms and conditions applicable
to the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The warrant holders do not
have the rights or privileges of holders of Common Stock and any voting rights until they exercise their warrants and receive Common Stock.
After the issuance of Common Stock upon exercise of the warrants, each holder will be entitled to one vote for each share held of record
on all matters to be voted on by stockholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No fractional shares will
be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a fractional interest
in a share, New Abpro will, upon exercise, round down to the nearest whole number the number of shares of Common Stock to be issued to
the warrant holder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Private Placement Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are currently 461,667
Placement Warrants outstanding. The Placement Warrants (including the shares of Common Stock issuable upon exercise of the Placement Warrants)
will not be transferable, assignable or salable until thirty (30) days after the Closing (except in limited circumstances) and they will
not be redeemable by New Abpro so long as they are held by the Sponsor or its permitted transferees. The founders, or their permitted
transferees, have the option to exercise the Placement Warrants for cash or on a cashless basis. Otherwise, the Placement Warrants have
terms and provisions that are identical to the Public Warrants. If the Placement Warrants are held by holders other than the Sponsor or
its permitted transferees, the Placement Warrants will be redeemable by New Abpro in all redemption scenarios and exercisable by the holders
on the same basis as the Public Warrants.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->140<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If holders of the Placement
Warrants elect to exercise them on a cashless basis, they would pay the exercise price by surrendering his, her or its warrants for that
number of shares of Common Stock equal to the quotient obtained by dividing (x) the product of the number of shares of Common Stock underlying
the Placement Warrants, multiplied by the excess of the &#8220;fair market value&#8221; (defined below) less the exercise price of the
Placement Warrants by (y) the fair market value. For these purposes, the &#8220;fair market value&#8221; shall mean the average last reported
sale price of the shares of Common Stock for the ten (10) trading days ending on the third trading day prior to the date on which the
notice of warrant exercise is sent to the warrant agent. Even during such periods of time when insiders will be permitted to sell Post-Combination
Company securities, an insider cannot trade in Post-Combination Company securities if he or she is in possession of material non-public
information. Accordingly, unlike public stockholders who could exercise their Public Warrants and sell the shares of Common Stock received
upon such exercise freely in the open market in order to recoup the cost of such exercise, the insiders could be significantly restricted
from selling such securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Anti-Takeover Provisions of the Charter and the Bylaws</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Charter and the Bylaws
contain provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions, which
are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage
persons seeking to acquire control of us to first negotiate with the Board, which may result in an improvement of the terms of any such
acquisition in favor of the stockholders. However, they also give the Board the power to discourage acquisitions that some stockholders
may favor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Authorized but Unissued Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The authorized but unissued
shares of Common Stock and preferred stock are available for future issuance without stockholder approval, subject to any limitations
imposed by the listing standards of Nasdaq. These additional shares may be used for a variety of corporate finance transactions, acquisitions
and employee benefit plans. The existence of authorized but unissued and unreserved Common Stock and preferred stock could make more difficult
or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Classified Board of Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Charter provides that
the Board will be divided into three classes of directors, with the classes to be as nearly equal in number as possible, and with each
director serving a three-year term. As a result, approximately one-half of the Board will be elected each year. The classification of
directors will have the effect of making it more difficult for stockholders to change the composition of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Stockholder Action; Special Meetings of Stockholders</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Charter will provide that
stockholders may not take action by written consent, but may only take action at annual or special meetings of stockholders. As a result,
a holder controlling a majority of New Abpro capital stock would not be able to amend New Abpro&#8217;s bylaws or remove directors without
holding a meeting of stockholders called in accordance with New Abpro&#8217;s bylaws. Further, the Bylaws will provide that only the chairperson
of the Board, a majority of the Board or the Chief Executive Officer of New Abpro may call special meetings of stockholders, thus prohibiting
a stockholder from calling a special meeting. These provisions might delay the ability of stockholders to force consideration of a proposal
or for stockholders controlling a majority of New Abpro capital stock to take any action, including the removal of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->141<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Advance Notice Requirements for Stockholder Proposals and Director
Nominations</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Bylaws will
establish an advance notice procedure for stockholder proposals to be brought before an annual meeting or special meeting of stockholders.
Generally, in order for any matter to be &#8220;properly brought&#8221; before a meeting, the matter must be (a) specified in a notice
of meeting given by or at the direction of the Board, (b) if not specified in a notice of meeting, otherwise brought before the meeting
by the Board or the chairperson of the meeting, or (c) otherwise properly brought before the meeting by a stockholder present in person
who (1) was a stockholder at the time of giving the notice, (2) is entitled to vote at the meeting, and (3) has complied with the advance
notice procedures specified in New Abpro&#8217;s bylaws or properly made such proposal in accordance with Rule 14a-8 under the Exchange
Act and the rules and regulations thereunder, which proposal has been included in the proxy statement for the annual meeting. Further,
for business to be properly brought before an annual meeting by a stockholder, the stockholder must (a) provide Timely Notice (as defined
below) thereof in writing and in proper form to the secretary and (b) provide any updates or supplements to such notice at the times and
in the forms required by the Bylaws. To be timely, a stockholder&#8217;s notice must be delivered to, or mailed and received at, New Abpro&#8217;s
principal executive offices not less than ninety (90) days nor more than one hundred twenty (120) days prior to the one-year anniversary
of the preceding year&#8217;s annual meeting; <i>provided, however</i>, that if the date of the annual meeting is more than thirty (30)
days before or more than sixty (60) days after such anniversary date, notice by the stockholder to be timely must be so delivered, or
mailed and received, not later than the 90th day prior to such annual meeting or, if later, the 10th day following the day on which public
disclosure of the date of such annual meeting was first made (such notice within such time periods, &#8220;<b>Timely Notice</b>&#8221;).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stockholders at an annual
meeting or special meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting
by or at the direction of the Board or by a qualified stockholder of record on the record date for the meeting, who is entitled to vote
at the meeting and who has delivered timely written notice in proper form to New Abpro&#8217;s secretary of the stockholder&#8217;s intention
to bring such business before the meeting. These provisions could have the effect of delaying stockholder actions that are favored by
the holders of a majority of the outstanding voting securities until the next stockholder meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>No Cumulative Voting</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the DGCL, there is no
right to vote cumulatively (which allows stockholders to cast all of the votes such stockholder is entitled to for a single nominee for
a board of directors rather than only being able to vote the number of shares such stockholder holds for or against each nominee) unless
expressly authorized in the certificate of incorporation. The Charter does not authorize cumulative voting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Amendment of Charter or Bylaws</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Bylaws may be amended
or repealed by a majority vote of the Board or by the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares
entitled to vote generally in the election of directors, voting together as a single class. The affirmative vote of a majority of the
Board and at least 66 2/3% in voting power of the outstanding shares entitled to vote thereon would be required to amend certain provisions
of the Charter.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Limitations on Liability and Indemnification of Officers and Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Charter and Bylaws provide
indemnification and advancement of expenses for New Abpro&#8217;s directors and officers to the fullest extent permitted by the DGCL,
subject to certain limited exceptions. New Abpro has entered into indemnification agreements with each of its directors and officers.
In some cases, the provisions of those indemnification agreements may be broader than the specific indemnification provisions contained
under Delaware law. In addition, as permitted by Delaware law, the Charter and Bylaws include provisions that eliminate the personal liability
of directors for monetary damages resulting from breaches of certain fiduciary duties as a director. The effect of this provision is to
restrict New Abpro&#8217;s rights and the rights of New Abpro&#8217;s stockholders in derivative suits to recover monetary damages against
a director for breach of fiduciary duties as a director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These provisions may be held
not to be enforceable for violations of the federal securities laws of the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->142<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dissenters&#8217; Rights of Appraisal and Payment</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the DGCL, with certain
exceptions, New Abpro&#8217;s stockholders will have appraisal rights in connection with a merger or consolidation of New Abpro. Pursuant
to Section 262 of the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such merger or consolidation
will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stockholders&#8217; Derivative Actions</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the DGCL, any of New
Abpro&#8217;s stockholders may bring an action in the company&#8217;s name to procure a judgment in its favor, also known as a derivative
action, provided that the stockholder bringing the action is a holder of New Abpro&#8217;s shares at the time of the transaction to which
the action relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Forum Selection</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Charter and Bylaws provide
that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings
under Delaware statutory or common law: (i) any derivative action or proceeding brought on behalf of New Abpro; (ii) any action or proceeding
asserting a claim of breach of a fiduciary duty owed by any of New Abpro&#8217;s current or former directors, officers, or other employees
to New Abpro or its stockholders; (iii) any action or proceeding asserting a claim against New Abpro or any of its current or former directors,
officers, or other employees, arising out of or pursuant to any provision of the Delaware General Corporation Law, the Charter or the
Bylaws; (iv) any action or proceeding to interpret, apply, enforce, or determine the validity of the Charter or the Bylaws; (v) any action
or proceeding as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi) any action asserting
a claim against New Abpro or any of its directors, officers, or other employees governed by the internal affairs doctrine, in all cases
to the fullest extent permitted by law and subject to the court&#8217;s having personal jurisdiction over the indispensable parties named
as defendants. These provisions would not apply to suits brought to enforce a duty or liability created by the Exchange Act. Furthermore,
Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly,
both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions
and the threat of inconsistent or contrary rulings by different courts, among other considerations, the Charter and Bylaws will further
provide that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting
a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint.
For the avoidance of doubt, this provision is intended to benefit and may be enforced by New Abpro, its officers and directors, the underwriters
to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made
by that person or entity and who has prepared or certified any part of the documents underlying this offering. While the Delaware courts
have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue
other than those designated in the exclusive forum provisions. In such instance, New Abpro would expect to vigorously assert the validity
and enforceability of the exclusive forum provisions of the Charter and the Bylaws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These exclusive forum provisions
may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with New Abpro or its
directors, officers, or other employees and may discourage these types of lawsuits. Furthermore, the enforceability of similar choice
of forum provisions in other companies&#8217; certificates of incorporation or bylaws has been challenged in legal proceedings, and it
is possible that a court could find these types of provisions to be inapplicable or unenforceable. We note that investors cannot waive
compliance with the federal securities laws and the rules and regulations thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Transfer Agent and Registrar</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent and registrar
for our Common Stock is Continental Stock Transfer &amp; Trust Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Trading Symbol and Market</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Common Stock and our Public
Warrants are listed on the Nasdaq Global Market under the symbols &#8220;ABP&#8221; and &#8220;ABPWW,&#8221; respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>


</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->143<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SELLING SECURITYHOLDERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This prospectus relates to
the offer and sale by YA of up to 9,775,017 shares of our Common Stock which may be issued by us to Yorkville under the SEPA. We are registering
the shares of Common Stock included in this prospectus pursuant to the provisions of the SEPA we entered into with Yorkville on October
30, 2024 in order to permit the Selling Securityholders to offer the shares included in this prospectus for resale from time to time.
Except for the transactions contemplated by the SEPA, and as set forth in the section titled &#8220;<i>Plan of Distribution</i>&#8221;
in this prospectus, YA has not had any material relationship with us within the past three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">The table below presents
information regarding the Selling Securityholders and the shares of Common Stock that may be resold by the Selling Securityholders from
time to time under this prospectus. This table is prepared based on information supplied to us by the Selling Securityholders, and reflects
holdings as of November 28, 2025. The number of shares in the column &#8220;Maximum Number of Shares of Common Stock to be Offered Pursuant
to this Prospectus&#8221; represents all of the shares of Common Stock being offered for resale by the Selling Securityholders under
this prospectus. The Selling Securityholders may sell some, all or none of the shares being offered for resale in this offering. We do
not know how long the Selling Securityholders will hold the shares before selling them, and we are not aware of any existing arrangements
between the Selling Securityholders and any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution
of the shares of our Common Stock being offered for resale by this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Beneficial ownership is
determined in accordance with Rule 13d-3(d) promulgated by the SEC under the Exchange Act, and includes shares of Common Stock with respect
to which the Selling Securityholders have sole or shared voting and investment power. The percentage of shares of Common Stock beneficially
owned by the Selling Securityholders prior to the offering shown in the table below is based on an aggregate of 2,716,278 shares of our
Common Stock outstanding on November 28, 2025. Because the purchase price to be paid by YA for shares of Common Stock, if any, that we
may elect to sell to YA in one or more Advances from time to time under the SEPA will be determined on the applicable Advance Dates for
such Advances, the actual number of shares of Common Stock that we may sell to the Selling Securityholders under the SEPA may be fewer
than the number of shares being offered for resale under this prospectus. The fourth column assumes the resale by the Selling Securityholders
of all of the shares of Common Stock being offered for resale pursuant to this prospectus.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have determined beneficial
ownership in accordance with the rules of the SEC. Except as indicated by the footnotes below, we believe, based on the information furnished
to us, that the Selling Securityholders have sole voting and investment power with respect to all shares of Common Stock that they beneficially
own, subject to applicable community property laws. Except as otherwise described below, based on the information provided to us by the
Selling Securityholders, no Selling Securityholder is a broker-dealer or an affiliate of a broker-dealer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br/>
Shares <br/> of Common Stock<br/> Beneficially Owned</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Maximum<br/> Number of<br/> Shares of<br/> Common<br/> Stock Being</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares of Common Stock<br/> Beneficially Owned After <br/> the Offered Shares of<br/> Common Stock are Sold</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name of Selling Securityholder</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number<sup>(1)</sup></b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Offered</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percent</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%; text-align: left">YA II PN, LTD.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">9,775,017</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 7%; text-align: right">&#160;&#160;&#160;&#160;-</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior to the offering all of the shares that YA may be required to purchase under the SEPA, because the issuance of such shares is at our discretion and is subject to conditions contained in the SEPA, the satisfaction of which are entirely outside of YA&#8217;s control, including the registration statement that includes this prospectus becoming and remaining effective. Furthermore, the Advances of Common Stock under the SEPA are subject to certain agreed upon maximum amount limitations set forth in the SEPA. Also, the SEPA prohibits us from issuing and selling any shares of our Common Stock to YA to the extent such shares, when aggregated with all other shares of our Common Stock then beneficially owned by YA, would cause YA&#8217;s beneficial ownership of our Common Stock to exceed the 4.99% Beneficial Ownership Limitation. </span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->144<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PLAN OF DISTRIBUTION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each Selling Securityholder
of the securities and any of their pledgees, assignees and successors-in- interest may, from time to time, sell any or all of their securities
covered hereby on the principal trading market for such securities or any other stock exchange, market or trading facility on which the
securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Securityholder may use any
one or more of the following methods when selling securities:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in"/>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits Subscribers;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an
exchange distribution in accordance with the rules of the applicable exchange;</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">privately negotiated transactions;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement of short sales;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in transactions through broker-dealers that agree with the Selling Securityholders to sell a specified number of such securities at a stipulated price per security;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a combination of any such methods of sale; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other method permitted pursuant to applicable law.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders
may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Broker-dealers engaged by
the Selling Securityholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Securityholders (or, if any broker-dealer acts as agent for the Subscriber of securities, from the Subscriber) in amounts
to be negotiated, but except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a
customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in
compliance with FINRA IM-2440.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the sale
of the securities or interests therein, the Selling Securityholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling
Securityholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the
securities to broker-dealers that in turn may sell these securities. The Selling Securityholders may also enter into option or other transactions
with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->145<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Selling Securityholders
and any broker-dealers or agents that are involved in selling the securities may be deemed to be &#8220;underwriters&#8221; within the
meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents
and any profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. Each Selling Securityholder has informed the Company that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is required to
pay certain fees and expenses incurred incident to the registration of the securities. The Company has agreed to indemnify the Selling
Securityholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We agreed to keep this prospectus
effective until the earlier of (i) all of the securities have been sold pursuant to this prospectus or Rule 144 under the Securities Act
or any other rule of similar effect, (ii) they may be sold pursuant to Rule 144 without volume or manner-of-sale restrictions; or (iii)
it has been two years from the Closing Date. The resale securities will be sold only through registered or licensed brokers or dealers
if required under applicable state securities laws. In addition, in certain states, the resale securities covered hereby may not be sold
unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification
requirement is available and is complied with.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YA is an &#8220;underwriter&#8221;
within the meaning of Section 2(a)(11) of the Securities Act and any profits on the sales of shares of our Common Stock by YA and any
discounts, commissions, or concessions received by YA are deemed to be underwriting discounts and commissions under the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YA has informed us that it
intends to use one or more registered broker-dealers to effectuate all sales, if any, of our Common Stock that it has acquired and may
in the future acquire from us pursuant to the SEPA. Such sales will be made at prices and at terms then prevailing or at prices related
to the then current market price. Each such registered broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of
the Securities Act. YA has informed us that each such broker-dealer will receive commissions from YA that will not exceed customary brokerage
commissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">YA has represented to us that
at no time since initial discussions began between us and YA and prior to the date of the SEPA has YA or its agents, representatives or
affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200
of Regulation SHO of the Exchange Act) of our Common Stock, provided that nothing restricts YA from (1) selling &#8220;long&#8221; (as
defined under Rule 200 promulgated under Regulation SHO) any Common Stock; (2) selling a number of shares of Common Stock equal to the
number of Advance Shares that such Restricted Person is unconditionally obligated to purchase under a pending Advance Notice but has not
yet received from the Company or the transfer agent pursuant to this Agreement; or (3) selling a number of shares of Common Stock equal
to the number of shares of Common Stock that the Investor is entitled to receive, but has not yet received from the Company or the transfer
agent, upon the completion of a pending conversion of the Promissory Note for which a valid Conversion Notice (as defined in the Promissory
Note) has been submitted to the Company. YA has agreed that during the term of the SEPA, neither YA nor any of its agents, representatives
or affiliates will enter into or effect, directly or indirectly, any of the foregoing transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market
making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement
of the distribution. In addition, the Selling Securityholders will be subject to applicable provisions of the Exchange Act and the rules
and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling
Securityholders or any other person. We will make copies of this prospectus available to the Selling Securityholders and have informed
them of the need to deliver a copy of this prospectus to each Subscriber at or prior to the time of the sale (including by compliance
with Rule 172 under the Securities Act).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->146<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>UNITED STATES FEDERAL
INCOME TAX CONSIDERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following discussion is
a summary of certain material U.S. federal income tax considerations generally applicable to the ownership and disposition of our Common
Stock and Warrants, which we refer to collectively as our securities. This summary is based upon U.S. federal income tax law as of the
date of this prospectus, which is subject to change or differing interpretations, possibly with retroactive effect. This summary does
not discuss all aspects of U.S. federal income taxation that may be important to particular investors in light of their individual circumstances,
including investors subject to special tax rules (<i>e.g.</i>, financial institutions, insurance companies, broker-dealers, dealers or
traders in securities, tax-exempt organizations, taxpayers that have elected mark-to-market accounting, S corporations, regulated investment
companies, real estate investment trusts, passive foreign investment companies, controlled foreign corporations, U.S. Holders (as defined
below) that will hold Common Stock or Warrants as part of a straddle, hedge, conversion, or other integrated transaction for U.S. federal
income tax purposes, expatriates or former long-term residents of the United States, or investors that have a functional currency other
than the U.S. dollar), all of whom may be subject to tax rules that differ materially from those summarized below. This summary does not
discuss other U.S. federal tax consequences (<i>e.g.</i>, estate or gift tax), any state, local, or non-U.S. tax considerations, or the
Medicare tax or alternative minimum tax. In addition, this summary is limited to investors that will hold our securities as &#8220;capital
assets&#8221; (generally, property held for investment) under the Internal Revenue Code of 1986, as amended (the &#8220;<b>Code</b>&#8221;)
and that acquire our Common Stock and Warrants for cash pursuant to this prospectus. No ruling from the Internal Revenue Service, (the
&#8220;IRS&#8221;) has been or will be sought regarding any matter discussed herein. No assurance can be given that the IRS would not
assert, or that a court would not sustain a position contrary to, any of the tax aspects set forth below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of this summary,
a &#8220;U.S. Holder&#8221; is a beneficial holder of securities who or that, for U.S. federal income tax purposes is:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an individual who is a United States citizen or resident of the United States;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a corporation (or other entity taxable as a corporation) created in, or organized under the law of, the United States or any state or political subdivision thereof;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an estate the income of which is includible in gross income for United States federal income tax purposes regardless of its source; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a trust (A) the administration of which is subject to the primary supervision of a United States court and which has one or more United States persons (within the meaning of the Code) who have the authority to control all substantial decisions of the trust or (B) that has in effect a valid election under applicable Treasury regulations to be treated as a United States person.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A &#8220;Non-U.S. Holder&#8221;
is a beneficial holder of securities who or that is neither a U.S. Holder nor a partnership for U.S. federal income tax purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a partnership (including
an entity or arrangement treated as a partnership for U.S. federal income tax purposes) holds our securities, the tax treatment of a partner,
member, or other beneficial owner in such partnership will generally depend upon the status of the partner, member, or other beneficial
owner, the activities of the partnership, and certain determinations made at the partner, member, or other beneficial owner level. If
you are a partner, member, or other beneficial owner of a partnership holding our securities, you are urged to consult your tax advisor
regarding the tax consequences of the ownership and disposition of our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">THIS DISCUSSION OF U.S. FEDERAL
INCOME TAX CONSIDERATIONS IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE HOLDERS SHOULD CONSULT THEIR TAX
ADVISORS CONCERNING THE U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF OWNING AND DISPOSING OF OUR SECURITIES, AS WELL AS THE APPLICATION
OF ANY, STATE, LOCAL AND NON-U.S. INCOME, ESTATE, AND OTHER TAX CONSIDERATIONS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->147<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>U.S. Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Taxation of Distributions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we pay distributions or
make constructive distributions (other than certain distributions of our stock or rights to acquire our stock) to U.S. Holders of shares
of our Common Stock, such distributions generally will constitute dividends for U.S. federal income tax purposes to the extent paid from
our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Distributions in excess of our
current and accumulated earnings and profits will constitute a return of capital that will be applied against and reduce (but not below
zero) the U.S. Holder&#8217;s adjusted tax basis in our Common Stock. Any remaining excess will be treated as gain realized on the sale
or other disposition of the Common Stock and will be treated as described under &#8220;<i>U.S. Holders&#8201;-&#8201;Gain or Loss on
Sale, Taxable Exchange or Other Taxable Disposition of Common Stock</i>&#8221; below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends we pay to a U.S.
Holder that is a taxable corporation will generally qualify for the dividends received deduction if the requisite holding period is satisfied.
With certain exceptions (including dividends treated as investment income for purposes of investment interest deduction limitations),
and provided certain holding period requirements are met, dividends we pay to a non-corporate U.S. Holder will generally constitute &#8220;qualified
dividends&#8221; that will be subject to tax at the preferential tax rate accorded to long-term capital gains. If the holding period requirements
are not satisfied, a corporation may not be able to qualify for the dividends received deduction and would have taxable income equal to
the entire dividend amount, and non-corporate holders may be subject to tax on such dividend at ordinary income tax rates instead of the
preferential rates that apply to qualified dividend income.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Gain or Loss on Sale, Taxable Exchange
or Other Taxable Disposition of Common Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder generally will
recognize gain or loss on the sale, taxable exchange or other taxable disposition of our Common Stock. Any such gain or loss will be capital
gain or loss and will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period for the Common Stock so disposed of
exceeds one year. The amount of gain or loss recognized will generally be equal to the difference between (1) the sum of the amount of
cash and the fair market value of any property received in such disposition and (2) the U.S. Holder&#8217;s adjusted tax basis in its
Common Stock disposed. A U.S. Holder&#8217;s adjusted tax basis in its Common Stock will generally equal the U.S. Holder&#8217;s acquisition
cost for such Common Stock (or, in the case of Common Stock received upon exercise of a Warrant, the U.S. Holder&#8217;s initial basis
for such Common Stock, as discussed below), less any prior distributions treated as a return of capital. The deductibility of capital
losses is subject to limitations. Long-term capital gains recognized by non-corporate U.S. Holders are generally eligible for reduced
rates of tax. If the U.S. Holder&#8217;s holding period for the Common Stock so disposed of is one year or less, any gain on a sale or
other taxable disposition of the shares would be subject to short-term capital gain treatment and would be taxed at ordinary income tax
rates. The deductibility of capital losses is subject to limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Exercise of a Warrant</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as discussed below
with respect to the cashless exercise of a Warrant, a U.S. Holder generally will not recognize taxable gain or loss upon the exercise
of a Warrant for cash. The U.S. Holder&#8217;s initial tax basis in the share of our Common Stock received upon exercise of the Warrant
will generally be an amount equal to the sum of the U.S. Holder&#8217;s acquisition cost of the Warrant and the exercise price of such
Warrant. It is unclear whether a U.S. Holder&#8217;s holding period for the Common Stock received upon exercise of the Warrant would commence
on the date of exercise of the Warrant or the day following the date of exercise of the Warrant; however, in either case the holding period
will not include the period during which the U.S. Holder held the Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax consequences of a
cashless exercise of a Warrant are not clear under current tax law. A cashless exercise may be nontaxable, either because the exercise
is not a realization event or because the exercise is treated as a recapitalization for U.S. federal income tax purposes. In either situation,
a U.S. Holder&#8217;s initial tax basis in the Common Stock received generally should equal the holder&#8217;s adjusted tax basis in the
Warrant. If the cashless exercise were treated as not being a realization event, it is unclear whether a U.S. Holder&#8217;s holding period
for the Common Stock would commence on the date of exercise of the Warrant or the day following the date of exercise of the Warrant; in
either case, the holding period would not include the period during which the U.S. Holder held the Warrant. If, instead, the cashless
exercise were treated as a recapitalization, the holding period of the Common Stock generally would include the holding period of the
Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->148<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that a
cashless exercise of a Warrant could be treated in part as a taxable exchange in which gain or loss is recognized. In such event, a U.S.
Holder could be deemed to have surrendered a portion of the Warrants being exercised having a value equal to the exercise price of such
Warrants in satisfaction of such exercise price. Although not free from doubt, such U.S. Holder generally should recognize capital gain
or loss in an amount equal to the difference between the fair market value of the Warrants deemed surrendered to satisfy the exercise
price and the U.S. Holder&#8217;s adjusted tax basis in such Warrants. In this case, a U.S. Holder&#8217;s initial tax basis in the Common
Stock received would equal the sum of the exercise price and the U.S. holder&#8217;s adjusted tax basis in the Warrants exercised. It
is unclear whether a U.S. Holder&#8217;s holding period for the Common Stock would commence on the date of exercise of the Warrant or
the day following the date of exercise of the Warrant; in either case, the holding period would not include the period during which the
U.S. Holder held the Warrant. Due to the uncertainty and absence of authority on the U.S. federal income tax treatment of a cashless exercise,
including when a U.S. Holder&#8217;s holding period would commence with respect to the Common Stock received, U.S. Holders are urged to
consult their tax advisors regarding the tax consequences of a cashless exercise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Sale, Exchange, Redemption or Expiration
of a Warrant</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon a sale, exchange (other
than by exercise), redemption (other than a redemption for Common Stock), or expiration of a Warrant, a U.S. Holder will recognize taxable
gain or loss in an amount equal to the difference between (1) the amount realized upon such disposition or expiration and (2) the U.S.
Holder&#8217;s adjusted tax basis in the Warrant. A U.S. Holder&#8217;s adjusted tax basis in its Warrants will generally equal the U.S.
Holder&#8217;s acquisition cost, increased by the amount of any constructive distributions included in income by such U.S. Holder (as
described below under &#8220;<i>U.S. Holders&#8201;-&#8201;Possible Constructive Distributions</i>&#8221;). Such gain or loss generally
will be treated as long-term capital gain or loss if the Warrant is held by the U.S. Holder for more than one year at the time of such
disposition or expiration. If a Warrant is allowed to lapse unexercised, a U.S. Holder will generally recognize a capital loss equal to
such holder&#8217;s adjusted tax basis in the Warrant. The deductibility of capital losses is subject to certain limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A redemption of Warrants for
Common Stock described in this prospectus under &#8220;<i>Description of Securities&#8201;-&#8201;Warrants</i>&#8221; should be treated
as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes. Accordingly, you should not recognize any gain or loss on the
redemption of Warrants for shares of our Common Stock. Your aggregate initial tax basis in the Common Stock received in the redemption
should equal your aggregate adjusted tax basis in your Warrants redeemed and your holding period for the Common Stock received in redemption
of your Warrants should include your holding period for your surrendered Warrants. However, there is some uncertainty regarding this tax
treatment and, accordingly, U.S. Holders should consult their tax advisors regarding the tax consequences of a redemption of Warrants
for Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Possible Constructive Distributions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of each Warrant
provide for an adjustment to the number of shares of Common Stock for which the Warrant may be exercised or to the exercise price of the
Warrant in certain events, as discussed in the section of this prospectus captioned &#8220;<i>Description of Securities&#8201;-&#8201;Warrants</i>.&#8221;
An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a U.S. Holder of Warrants
would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s proportionate
interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would be obtained
upon exercise) as a result of a distribution of cash to the holders of shares of our Common Stock which is taxable to such holders as
a distribution. Such constructive distribution would be subject to tax as described above under &#8220;<i>U.S. Holders&#8201;-&#8201;Taxation
of Distributions</i>&#8221; in the same manner as if such U.S. Holder received a cash distribution from us on Common Stock equal to the
fair market value of such increased interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Information Reporting and Backup Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, information reporting
requirements may apply to dividends paid to a U.S. Holder and to the proceeds of the sale or other disposition of our Common Stock and
Warrants, unless the U.S. Holder is an exempt recipient. Backup withholding may apply to such payments if the U.S. Holder fails to provide
a taxpayer identification number, a certification of exempt status or has been notified by the IRS that it is subject to backup withholding
(and such notification has not been withdrawn).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. Any amounts withheld under the backup withholding rules will be allowed as a credit against a U.S. Holder&#8217;s U.S.
federal income tax liability and may entitle such holder to a refund, provided the required information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->149<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Non-U.S. Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Taxation of Distributions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, any distributions
(including constructive distributions) we make to a Non-U.S. Holder of shares of our Common Stock, to the extent paid out of our current
or accumulated earnings and profits (as determined under U.S. federal income tax principles), will constitute dividends for U.S. federal
income tax purposes and, provided such dividends are not effectively connected with the Non-U.S. Holder&#8217;s conduct of a trade or
business within the United States, we will be required to withhold tax from the gross amount of the dividend at a rate of 30%, unless
such Non-U.S. Holder is eligible for a reduced rate of withholding tax under an applicable income tax treaty and provides proper certification
of its eligibility for such reduced rate (usually on an IRS Form W-8BEN or W-8BEN-E, as applicable). In the case of any constructive dividend
(as described below under &#8220;<i>Non-U.S. Holders&#8201;-&#8201;Possible Constructive Distributions</i>&#8221;), it is possible that
this tax would be withheld from any amount owed to a Non-U.S. Holder by the applicable withholding agent, including cash distributions
on other property or sale proceeds from Warrants or other property subsequently paid or credited to such holder. Any distribution not
constituting a dividend will be treated first as reducing (but not below zero) the Non-U.S. Holder&#8217;s adjusted tax basis in its Common
Stock and, to the extent such distribution exceeds the Non-U.S. Holder&#8217;s adjusted tax basis, as gain realized from the sale or other
disposition of the Common Stock, which will be treated as described under &#8220;<i>Non-U.S. Holders - Gain on Sale, Taxable Exchange
or Other Taxable Disposition of Common Stock and Warrants</i>&#8221; below. In addition, if we determine that we are likely to be classified
as a &#8220;United States real property holding corporation&#8221; (see &#8220;<i>Non-U.S. Holders&#8201;-&#8201;Gain on Sale, Exchange
or Other Taxable Disposition of Common Stock and Warrants</i>&#8221; below), we will withhold 15% of any distribution that exceeds our
current and accumulated earnings and profits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends we pay to a Non-U.S.
Holder that are effectively connected with such Non-U.S. Holder&#8217;s conduct of a trade or business within the United States (or if
a tax treaty applies are attributable to a U.S. permanent establishment or fixed base maintained by the Non-U.S. Holder) will generally
not be subject to U.S. withholding tax, provided such Non-U.S. Holder complies with certain certification and disclosure requirements
(generally by providing an IRS Form W-8ECI). Instead, such dividends generally will be subject to U.S. federal income tax, net of certain
deductions, at the same graduated individual or corporate rates applicable to U.S. Holders. If the Non-U.S. Holder is a corporation, dividends
that are effectively connected income may also be subject to a &#8220;branch profits tax&#8221; at a rate of 30% (or such lower rate as
may be specified by an applicable income tax treaty).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Exercise of a Warrant</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. federal income tax
treatment of a Non-U.S. Holder&#8217;s exercise of a Warrant will generally correspond to the U.S. federal income tax treatment of the
exercise of a Warrant by a U.S. Holder, as described under &#8220;<i>U.S. Holders&#8201;-&#8201;Exercise of a Warrant</i>&#8221; above,
although to the extent a cashless exercise results in a taxable exchange, the tax consequences to the Non-U.S. Holder would be the same
as those described below in &#8220;<i>Non-U.S. Holders&#8201;-&#8201;Gain on Sale, Exchange or Other Taxable Disposition of Common Stock
and Warrants</i>.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Redemption of Warrants for Common Stock</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A redemption of Warrants for
Common Stock described in this prospectus under &#8220;<i>Description of Securities&#8201;-&#8201;Warrants</i>&#8221; should be treated
as a &#8220;recapitalization&#8221; for U.S. federal income tax purposes. Accordingly, you should not recognize any gain or loss on the
redemption of Warrants for shares of our Common Stock. Your aggregate initial tax basis in the Common Stock received in the redemption
should equal your aggregate adjusted tax basis in your Warrants redeemed and your holding period for the Common Stock received in redemption
of your Warrants should include your holding period for your surrendered Warrants. However, there is some uncertainty regarding this tax
treatment and, accordingly, Non-U.S. Holders should consult their tax advisors regarding the tax consequences of a redemption of Warrants
for Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->150<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Gain on Sale, Exchange or Other Taxable
Disposition of Common Stock and Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A Non-U.S. Holder generally
will not be subject to U.S. federal income or withholding tax in respect of gain recognized on a sale, taxable exchange or other taxable
disposition of our Common Stock or Warrants or an expiration or redemption of our Warrants, unless:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the gain is effectively connected with the conduct of a trade or business by the Non-U.S. Holder within the United States (and, if an applicable tax treaty so requires, is attributable to a U.S. permanent establishment or fixed base maintained by the Non-U.S. Holder);</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">the Non-U.S. Holder is an individual who is present in the United States for 183 days or more in the taxable year of disposition and certain other conditions are met; or</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.5in">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">we are or have been a &#8220;United States real property holding corporation&#8221; for U.S. federal income tax purposes at any time during the shorter of the five-year period ending on the date of disposition or the period that the Non-U.S. Holder held our Common Stock or Warrants and, in the case where shares of our Common Stock are regularly traded on an established securities market, the Non-U.S. Holder has owned, directly or constructively, more than 5% of our Common Stock at any time within the shorter of the five-year period preceding the disposition or such Non-U.S. Holder&#8217;s holding period for the shares of our Common Stock. There can be no assurance that our Common Stock will be treated as regularly traded on an established securities market for this purpose.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Gain described in the first
bullet point above will be subject to tax at generally applicable U.S. federal income tax rates as if the Non-U.S. Holder were a U.S.
resident. Any gains described in the first bullet point above of a Non-U.S. Holder that is a foreign corporation may also be subject to
an additional &#8220;branch profits tax&#8221; at a 30% rate (or lower applicable treaty rate). Gain described in the second bullet point
above will generally be subject to a flat 30% U.S. federal income tax. Non-U.S. Holders are urged to consult their tax advisors regarding
possible eligibility for benefits under income tax treaties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the third bullet point
above applies to a Non-U.S. Holder and applicable exceptions are not available, gain recognized by such holder on the sale, exchange or
other disposition of our Common Stock or Warrants will be subject to tax at generally applicable U.S. federal income tax rates. In addition,
a buyer of our Common Stock or Warrants from such holder may be required to withhold U.S. income tax at a rate of 15% of the amount realized
upon such disposition. Non-U.S. Holders are urged to consult their tax advisors regarding the application of these rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Possible Constructive Distributions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The terms of each Warrant
provide for an adjustment to the number of shares of Common Stock for which the Warrant may be exercised or to the exercise price of the
Warrant in certain events, as discussed in the section of this prospectus captioned &#8220;<i>Description of Securities&#8201;-&#8201;Warrants</i>.&#8221;
An adjustment which has the effect of preventing dilution generally should not be a taxable event. Nevertheless, a Non-U.S. Holder of
Warrants would be treated as receiving a constructive distribution from us if, for example, the adjustment increases the holder&#8217;s
proportionate interest in our assets or earnings and profits (e.g., through an increase in the number of shares of Common Stock that would
be obtained upon exercise) as a result of a distribution of cash to the holders of our Common Stock which is taxable to such holders as
a distribution. A Non-U.S. Holder would be subject to U.S. federal income tax withholding as described above under &#8220;<i>Non-U.S.
Holders&#8201;-&#8201;Taxation of Distributions</i>&#8221; under that section in the same manner as if such Non-U.S. Holder received
a cash distribution from us on Common Stock equal to the fair market value of such increased interest.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 158; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->151<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Foreign Account Tax Compliance Act</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of the Code and
Treasury Regulations and administrative guidance promulgated thereunder commonly referred as the &#8220;Foreign Account Tax Compliance
Act&#8221; (&#8220;FATCA&#8221;) generally impose withholding at a rate of 30% in certain circumstances on dividends (including constructive
dividends) in respect of our securities which are held by or through certain foreign financial institutions (including investment funds),
unless any such institution (1) enters into, and complies with, an agreement with the IRS to report, on an annual basis, information with
respect to interests in, and accounts maintained by, the institution that are owned by certain U.S. persons and by certain non-U.S. entities
that are wholly or partially owned by U.S. persons and to withhold on certain payments, or (2) if required under an intergovernmental
agreement between the United States and an applicable foreign country, reports such information to its local tax authority, which will
exchange such information with the U.S. authorities. An intergovernmental agreement between the United States and an applicable foreign
country may modify these requirements. Accordingly, the entity through which our securities are held will affect the determination of
whether such withholding is required. Similarly, dividends in respect of our securities held by an investor that is a non-financial non-U.S.
entity that does not qualify under certain exceptions will generally be subject to withholding at a rate of 30%, unless such entity either
(1) certifies to us or the applicable withholding agent that such entity does not have any &#8220;substantial United States owners&#8221;
or (2) provides certain information regarding the entity&#8217;s &#8220;substantial United States owners,&#8221; which will in turn be
provided to the U.S. Department of Treasury. Withholding under FATCA was scheduled to apply to payments of gross proceeds from the sale
or other disposition of property that produces U.S.-source interest or dividends, however, the IRS released proposed regulations that,
if finalized in their proposed form, would eliminate the obligation to withhold on such gross proceeds. Although these proposed Treasury
Regulations are not final, taxpayers generally may rely on them until final Treasury Regulations are issued. Prospective investors should
consult their tax advisors regarding the possible implications of FATCA on their investment in our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b><i>Information Reporting and Backup Withholding</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Information returns will be
filed with the IRS in connection with payments of dividends and the proceeds from a sale or other disposition of our shares of Common
Stock and Warrants. A Non-U.S. Holder may have to comply with certification procedures to establish that it is not a United States person
in order to avoid information reporting and backup withholding requirements. The certification procedures required to claim a reduced
rate of withholding under a treaty generally will satisfy the certification requirements necessary to avoid the backup withholding as
well. Backup withholding is not an additional tax. The amount of any backup withholding from a payment to a Non-U.S. Holder will be allowed
as a credit against such holder&#8217;s U.S. federal income tax liability and may entitle such holder to a refund, provided that the required
information is timely furnished to the IRS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>THE DISCUSSION ABOVE IS
A GENERAL SUMMARY. IT DOES NOT COVER ALL TAX MATTERS THAT MAY BE IMPORTANT TO YOU. EACH PROSPECTIVE PURCHASER SHOULD CONSULT ITS TAX ADVISOR
ABOUT THE TAX CONSEQUENCES OF AN INVESTMENT IN OUR COMMON STOCK AND WARRANTS BASED ON THE INVESTOR&#8217;S CIRCUMSTANCES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPERTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The consolidated financial
statements of Abpro Holdings, Inc. as of December 31, 2024 and 2023, and for each of the two years in the period ended December 31, 2024
have been audited by Wolf &amp; Company, P.C., independent registered public accounting firm, as set forth in their report appearing elsewhere
herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>LEGAL MATTERS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The validity of the securities
offered by this prospectus has been passed upon for us by Nelson Mullins Riley &amp; Scarborough LLP, Washington, DC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CHANGE IN REGISTRANT&#8217;S CERTIFYING ACCOUNTANT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective December 9, 2024,
the Company dismissed Marcum LLP (&#8220;<b>Marcum</b>&#8221;) as its independent registered public accounting firm. On December 9, 2024,
the Company engaged Wolf &amp; Company, P.C. (&#8220;<b>Wolf</b>&#8221;) as Marcum&#8217;s replacement. The decision to change independent
registered public accounting firms was made with the recommendation and approval of the Audit Committee of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 159; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->152<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Marcum&#8217;s audit reports
on the Company&#8217;s consolidated financial statements as of and for the fiscal years ended December 31, 2023 and December 31, 2022
did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to audit scope or accounting principles,
except that such reports expressed substantial doubt regarding the Company&#8217;s ability to continue as a going concern.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal years ended
December 31, 2023 and 2022, and the subsequent interim period through the date of this prospectus, there were no disagreements, as that
term is defined in Item 304(a)(1)(iv) of Regulation S-K, between the Company and Marcum on any matter of accounting principles or practices,
financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to Marcum&#8217;s satisfaction, would
have caused Marcum to make reference to such disagreements in its audit reports.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal years ended
December 31, 2023 and 2022, and the subsequent interim period through the date of this prospectus, there were no reportable events within
the meaning of Item 304(a)(1)(v) of Regulation S-K, except for the following material weaknesses which the Company identified in its internal
control over financial reporting: failure to timely file tax returns, utilizing cash withdrawn from the trust account for tax obligations
for operating purposes, and over-accrual of expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the fiscal years ended
December 31, 2023 and 2022, and the subsequent interim period through the date of this prospectus, neither the Company nor anyone acting
on our behalf of the Company consulted Wolf with respect to either (i) the application of accounting principles to a specified transaction,
either completed or proposed; or the type of audit opinion that might be rendered on the Company&#8217;s consolidated financial statements,
and no written report or oral advice was provided to the Company by Wolf that Wolf concluded was an important factor considered by the
Company in reaching a decision as to the accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject
of a disagreement, as that term is described in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation
S-K, or a reportable event, as that term is defined in Item 304(a) (1)(v) of Regulation S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company delivered a copy
of this disclosure to Marcum and requested that they furnish the Company a letter addressed to the SEC stating whether they agree with
the above statements. In their letter to the SEC dated December 9, 2024, attached as Exhibit 16.1 to the registration statement of which
this prospectus forms a part, Marcum states that they agree with the statements above concerning their firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WHERE YOU CAN FIND MORE INFORMATION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have filed with the SEC
a registration statement on Form S-1 under the Securities Act with respect to the shares of Common Stock offered by this prospectus. This
prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration
statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC.
For further information with respect to us and our Common Stock and Warrants, we refer you to the registration statement, including the
exhibits filed as a part of the registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Statements contained in this
prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been
filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement
is this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains
an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with
the SEC. The address of that website is <i>www.sec.gov</i>.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 160; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->153<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Unaudited Condensed Consolidated Financial
Statements of Abpro Holdings, Inc.<br/>
<span style="-keep: true">as of and for the nine months ended September 30, 2025 and 2024&#160;</span></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 91%; padding-left: 9.25pt; text-indent: -9pt"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="padding-left: 9.25pt; text-indent: -9pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Condensed
    Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024</span></a></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited
    Condensed Consolidated Statements of Operations for the Nine Months Ended September 30, 2025 and 2024</span></a></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited
    Condensed Consolidated Statements of Changes in Stockholders&#8217; Deficit for the Nine Months Ended September 30, 2025 and 2024</span></a></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unaudited
    Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024</span></a></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes
    to Unaudited Condensed Consolidated Financial Statements</span></a></td>
    <td style="vertical-align: top"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Consolidated Financial Statements of Abpro Holdings,
Inc.<br/>
as of and for the years ended December 31, 2024 and 2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="width: 91%; padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr>
  <tr>
    <td style="padding-left: 9.25pt; text-indent: -9pt">&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_011"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Report of Independent Registered Public Accounting Firm (PCAOB ID 392)</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-31</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Balance Sheets as of December 31, 2024 and 2023</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-32</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_007"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-33</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_008"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Changes in Stockholders&#8217; Equity for the Years Ended December 31, 2024 and 2023</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-34</span></td></tr>
  <tr style="background-color: #CCEEFF">
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_009"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023</span></a></td>
    <td style="vertical-align: top">&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-35</span></td></tr>
  <tr>
    <td style="vertical-align: top; padding-left: 9.25pt; text-indent: -9pt"><a href="#f_010"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Notes to Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="white-space: nowrap; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-36</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 161; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">ABPRO HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">CONDENSED CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(in thousands except for share and per share
data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December 31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">(unaudited)</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: right"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">Assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">Current assets:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -0.125in; padding-left: 0.25in"><span style="-keep: true">Cash</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-42263">328</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-42264">2,850</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="-keep: true">Accounts receivable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-42265">271</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-42266">271</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="-keep: true">Prepaid expenses and other current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-42267">611</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-42268">358</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.25in"><span style="-keep: true">Forward purchase agreement asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:ForwardPurchaseAgreementAsset" scale="3" unitRef="usd" id="ixv-42269">155</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.25in"><span style="-keep: true">Restricted cash</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-42270">15</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-42271">142</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.375in"><span style="-keep: true">Total current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-42272">1,225</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-42273">3,776</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-42274">37</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Right-of-use asset - operating lease</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-42275">418</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Security deposits</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="3" unitRef="usd" id="ixv-42276">66</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="3" unitRef="usd" id="ixv-42277">66</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Patents, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentsNet" scale="3" unitRef="usd" id="ixv-42278">169</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentsNet" scale="3" unitRef="usd" id="ixv-42279">176</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">SEPA put rights asset</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abp:SEPAPutRightsAsset" scale="3" unitRef="usd" id="ixv-42280">243</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:SEPAPutRightsAsset" scale="3" unitRef="usd" id="ixv-42281">188</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Total assets</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-42282">1,703</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-42283">4,661</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Liabilities and stockholders&#8217;
    deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Current liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Accounts payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-42284">4,724</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-42285">3,936</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Accrued expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42286">8,026</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42287">7,496</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Excise taxes payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" unitRef="usd" id="ixv-42288">4,401</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" unitRef="usd" id="ixv-42289">4,401</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Operating lease liability, current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-42290">456</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Income taxes payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" unitRef="usd" id="ixv-42291">366</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Notes payable &#8211; related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd" id="ixv-42292">147</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd" id="ixv-42293">147</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Convertible notes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:ConvertibleNotes" scale="3" unitRef="usd" id="ixv-42294">2,725</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Embedded derivative liability</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-7"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="3" unitRef="usd" id="ixv-42295">80</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Total current
    liabilities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42296">17,298</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42297">19,607</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Commitments and Contingencies (Note
    8)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Stockholders&#8217; deficit:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Preferred stock, $<ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-42298"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-42299">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-42300"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-42301">1,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-42302"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" unitRef="shares" id="ixv-42303"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42304"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42305">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Common stock, $<ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-42306"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-42307">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-42308"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-42309">110,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-42310">2,672,222</ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-42311">1,727,192</ix:nonFraction> shares issued, <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42312">2,672,222</ix:nonFraction> and <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42313">1,694,414</ix:nonFraction> shares outstanding at September 30, 2025 and December 31, 2024, respectively</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Treasury stock, zero and <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-42314"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-42315">32,778</ix:nonFraction></ix:nonFraction> shares at September 30, 2025 and December 31, 2024, respectively, at cost</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-14"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-42316">108,487</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-42317">100,608</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Accumulated deficit</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-42318">124,631</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-42319">116,103</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Total Abpro Holdings, Inc.&#8217;s
    stockholders&#8217; deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-42320">16,144</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-42321">15,495</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Non-controlling interest</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="3" unitRef="usd" id="ixv-42322">549</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="3" unitRef="usd" id="ixv-42323">549</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Total stockholders&#8217;
    deficit</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42324">15,595</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42325">14,946</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="-keep: true">Total liabilities
    and stockholders&#8217; deficit</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-42326">1,703</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-42327">4,661</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>





</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">Reflects a 1-for-30 reverse stock split effective
October 31, 2025</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 162; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b style="-keep: true">ABPRO
HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(in thousands except for share and per share
data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">For the Three Months Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">For the Nine Months Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Revenue:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-keep: true">Research and development services</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-42328">183</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-60"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-42329">183</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Operating expenses:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Research and development</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"/><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-42330">243</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"/><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-42331">642</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"/><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-42332">881</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"/><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-42333">2,469</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-42334">1,093</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-42335">1,472</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-42336">5,674</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-42337">4,864</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total operating expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-42338">1,336</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-42339">2,114</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-42340">6,555</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-42341">7,333</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Loss from operations</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-42342">1,336</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-42343">1,931</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-42344">6,555</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-42345">7,150</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Other (expense) income:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Other income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-62"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" unitRef="usd" id="ixv-42346">200</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" unitRef="usd" id="ixv-42347">3,556</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Change in fair value of forward purchase agreement asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-63"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-64"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfForwardPuchaseAgreementAsset" scale="3" sign="-" unitRef="usd" id="ixv-42348">23</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Change in fair value of SEPA put rights asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfSEPAPutRightsAsset" scale="3" unitRef="usd" id="ixv-42349">230</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfSEPAPutRightsAsset" scale="3" unitRef="usd" id="ixv-42350">55</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Change in fair value of embedded derivative liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfEmbeddedDerivativeLiability" scale="3" sign="-" unitRef="usd" id="ixv-42351">150</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-68"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfEmbeddedDerivativeLiability" scale="3" sign="-" unitRef="usd" id="ixv-42352">773</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-69"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Loss on settlement of convertible notes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="abp:LossOnSettlementOfConvertibleNotes" scale="3" unitRef="usd" id="ixv-42353">214</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-70"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:LossOnSettlementOfConvertibleNotes" scale="3" unitRef="usd" id="ixv-42354">358</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-71"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Interest income</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-42355">6</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-42356">2</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-42357">30</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-42358">3</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Interest expense</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd" id="ixv-42359">193</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd" id="ixv-42360">164</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd" id="ixv-42361">1,104</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd" id="ixv-42362">306</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Total other (expense) income, net</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-42363">321</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-42364">162</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd" id="ixv-42365">1,973</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-42366">3,253</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: right"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Net loss</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42367">1,657</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42368">2,093</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42369">8,528</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42370">3,897</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Net loss per share, basic and diluted</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c25" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-42371"><ix:nonFraction contextRef="c25" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-42372">0.63</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c26" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-42373"><ix:nonFraction contextRef="c26" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-42374">3.27</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-42375"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-42376">4.12</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-42377"><ix:nonFraction contextRef="c27" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-42378">6.09</ix:nonFraction></ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold"><span style="-keep: true">Weighted averages shares outstanding</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Weighted average shares outstanding - basic and diluted</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-42379"><ix:nonFraction contextRef="c25" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-42380">2,613,889</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-42381"><ix:nonFraction contextRef="c26" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-42382">640,606</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-42383"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-42384">2,069,965</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-42385"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-42386">639,996</ix:nonFraction></ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.&#160;&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">Reflects a 1-for-30 reverse stock split effective
October 31, 2025</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 163; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">ABPRO HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE
PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(in thousands except share and per share
data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>



</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series A<br/> Redeemable,</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series B</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series C</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series D</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series E</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series F</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Total<br/> Convertible</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Total</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Preferred
    <br/> Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Treasury
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Additional<br/>
    Paid-In</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Accumulated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Abpro&#8217;s<br/>
    Stockholders&#8217;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Non-controlling</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Total Stockholders&#8217;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Interest</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in; width: 5.4%"><span style="font-size: 8pt">Balances,
    as of December 31, 2024</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-81"><span style="font-size: 8pt">&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-82"><span style="font-size: 8pt">&#160;&#160;&#160;-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-83"><span style="font-size: 8pt">&#160;&#160;&#160;&#160;-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-84"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-85"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-86"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-87"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-88"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-89"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-90"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-91"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-92"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-93">&#160;&#160;&#160;&#160;&#160;&#160;<span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-42387">1,727,192</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-94"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c44" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-42388">32,778</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-95"><span style="font-size: 8pt">-</span></div></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-42389">100,608</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42390">116,103</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42391">15,495</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-42392">549</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42393">14,946</ix:nonFraction></span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Common stock issued for
    services</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-96"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-97"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-98"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-99"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-100"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-101"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-102"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c56" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares" id="ixv-42394">5,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-103"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-104"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-105"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-106"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-107"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-108"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-109"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Warrants issued to related
    party lender</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-110"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-111"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-112"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-113"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-114"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-115"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-116"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-117"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-118"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-42395">714</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-119"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-42396">714</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-120"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" unitRef="usd" id="ixv-42397">714</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-121"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-122"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-123"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-125"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-126"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-127"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-128"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-129"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-42398">308</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-130"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-42399">308</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-131"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-42400">308</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-132"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-133"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-134"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-135"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-136"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-137"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-138"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-139"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-140"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-141"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42401">3,887</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c60" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42402">3,887</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-142"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42403">3,887</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Balances,
    as of March 31, 2025</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c63" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-42404">1,732,192</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-143"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c64" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-42405">32,778</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-144"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-42406">101,630</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42407">119,990</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42408">18,360</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-42409">549</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42410">17,811</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-145"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-146"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-147"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-148"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-149"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-150"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-151"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-152"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-42411">154</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-42412">154</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-155"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-42413">154</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Common stock issued upon
    conversion of convertible notes</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-156"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-157"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-158"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-159"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-161"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-162"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c77" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-42414">513,981</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-163"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c79" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-42415">3,694</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-42416">3,694</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-42417">3,694</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-167"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-168"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-169"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-170"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-171"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-174"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-175"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-176"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c80" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42418">2,984</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c81" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42419">2,984</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-177"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c83" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42420">2,984</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Balances,
    as of June 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-180"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-181"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-182"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-183"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-184"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-185"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-186"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-187"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-188"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-189"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-190"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c91" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-42421">2,246,173</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-191"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c92" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-42422">32,778</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-192"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c93" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-42423">105,478</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42424">122,974</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c95" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42425">17,496</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c96" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-42426">549</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42427">16,947</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-193"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-194"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-195"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-196"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-197"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-198"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-42428">78</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-199"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-42429">78</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-200"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-42430">78</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Common stock issued upon
    conversion of convertible notes</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-201"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-202"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-203"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-204"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-205"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-206"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-207"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-42431">367,491</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-208"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-209"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-42432">2,243</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-210"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-42433">2,243</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-211"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" unitRef="usd" id="ixv-42434">2,243</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Issuance of Advance Shares,
    net of issuance costs</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-212"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-213"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-214"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-215"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-216"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-217"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42435">91,336</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-218"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-219"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c104" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-42436">688</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-220"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-42437">688</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-221"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-42438">688</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Cancellation of Treasury
    Stock</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-222"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-223"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-224"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-225"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-226"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-227"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-228"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares" id="ixv-42439">32,778</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">)</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-229"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c103" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="0" unitRef="shares" id="ixv-42440">32,778</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-230"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-231"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-232"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-233"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-234"><span style="font-size: 8pt">-</span></div></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-235"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-236"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-237"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-238"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-239"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-240"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-241"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-242"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-243"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42441">1,657</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c106" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42442">1,657</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-244"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42443">1,657</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Balances,
    as of September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-245"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-246"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-247"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-248"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-249"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-250"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-251"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-42444">2,672,222</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-252"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-253"><span style="font-size: 8pt">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-42445">108,487</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c121" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42446">124,631</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c122" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42447">16,144</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt"><ix:nonFraction contextRef="c123" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-42448">549</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-42449">15,595</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  </table><div>

</div><p style="margin: 0"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series A<br/> Redeemable,</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series B</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series C</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series D</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series E</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Series F</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Total<br/> Convertible</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">Total</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Convertible<br/>
    Preferred Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Preferred
    <br/> Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Treasury
    Stock</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Additional<br/>
    Paid-In</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Accumulated</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Abpro&#8217;s<br/>
    Stockholders&#8217;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Non-controlling</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 8pt">Total Stockholders&#8217;</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Amount</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Capital</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Interest</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 8pt">Deficit</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-indent: -0.125in; padding-left: 0.125in; width: 5.4%"><span style="font-size: 8pt">Balances,
    as of December 31, 2023</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">3,938,098</span></p></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">1,795</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">1,281,402</span></p></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">1,401</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">4,101,409</span></p></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">14,949</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">2,679,397</span></p></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">17,622</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">6,756,246</span></p></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">29,841</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">1,136,049</span></p></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">9,991</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">75,599</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">646,044</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">-</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(7,006</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(33</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">19,920</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(108,871</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(88,984</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">)</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">549</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="width: 0.1%"><span style="font-size: 8pt">&#160;</span></td>
    <td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">$</span></td><td style="width: 4%; text-align: right"><span style="font-size: 8pt">(88,435</span></td><td style="width: 0.1%; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Vesting of restricted
    stock units</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">639</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">563</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">563</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">563</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Net
    income</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">636</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">636</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">636</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Balances,
    as of March 31, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">3,938,098</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,795</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,281,402</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,401</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">4,101,409</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">14,949</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">2,679,397</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">17,622</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">6,756,246</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">29,841</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,136,049</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">9,991</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">75,599</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">646,683</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(7,006</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(33</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">20,483</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(108,235</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(87,785</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">549</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(87,236</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Vesting of restricted
    stock units</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">639</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">553</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">553</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">553</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(2,440</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(2,440</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(2,440</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Balances,
    as of June 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">3,938,098</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,795</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,281,402</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,401</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">4,101,409</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">14,949</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">2,679,397</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">17,622</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">6,756,246</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">29,841</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,136,049</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">9,991</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">75,599</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">647,322</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(7,006</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(33</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">21,036</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(110,675</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(89,672</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">549</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(89,123</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Vesting of restricted
    stock units</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">554</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Share-based compensation</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">415</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">415</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">-</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">415</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Net
    loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(2,093</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(2,093</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 8pt">(2,093</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid"><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td><span style="font-size: 8pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 2.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 8pt">Balances,
    as of September 30, 2024</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">3,938,098</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,795</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,281,402</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,401</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">4,101,409</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">14,949</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">2,679,397</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">17,622</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">6,756,246</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">29,841</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">1,136,049</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">9,991</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">75,599</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-left: Black 1.5pt solid; padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">647,876</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">-</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(7,006</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(33</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">21,451</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(112,768</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(91,350</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">549</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="padding-bottom: 4pt"><span style="font-size: 8pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-size: 8pt">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-size: 8pt">(90,801</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 8pt">)</span></td></tr>
  </table><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">Reflects a 1-for-30 reverse stock split effective
October 31, 2025</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 164; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">ABPRO HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">CONDENSED CONSOLIDATED STATEMENTS OF CASH
FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(in thousands except share and per share
data)</b>&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">For the Nine Months Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold"><span style="-keep: true">Cash Flows from Operating Activities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Net loss</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42450">8,528</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42451">3,897</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Depreciation and amortization expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-42452">18</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-42453">67</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Share-based compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-42454">1,158</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-42455">1,531</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Amortization of operating lease right-of-use assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-42456">418</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-42457">408</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Non-cash interest expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-42458">854</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-42459">53</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Loss on settlement of convertible notes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:LossOnSettlementsOfConvertibleNotes" scale="3" unitRef="usd" id="ixv-42460">358</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-363"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Other income (see Note 2)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="3" unitRef="usd" id="ixv-42461">200</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="3" unitRef="usd" id="ixv-42462">3,556</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Amortization of debt discount</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" unitRef="usd" id="ixv-42463">160</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-364"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Change in fair value of forward purchase agreement asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfForwardPurchaseAgreementAsset" scale="3" sign="-" unitRef="usd" id="ixv-42464">23</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-365"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Change in fair value of SEPA put rights asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfSEPAPutRightAsset" scale="3" unitRef="usd" id="ixv-42465">55</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-366"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Change in fair value of embedded derivative liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOnEmbeddedDerivativeLiability" scale="3" sign="-" unitRef="usd" id="ixv-42466">773</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-367"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Changes in operating assets and liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Accounts receivable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-368"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd" id="ixv-42467">183</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Prepaid expenses and other current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-42468">257</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-42469">93</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Accounts payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-42470">787</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" unitRef="usd" id="ixv-42471">325</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left"><span style="-keep: true">Accrued expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-42472">73</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)&#8239;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" unitRef="usd" id="ixv-42473">551</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.125in"><span style="-keep: true">Income taxes payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" sign="-" unitRef="usd" id="ixv-42474">366</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-369"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Operating lease liability</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-42475">456</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-42476">421</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Net cash used in operating activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-42477">5,386</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-42478">5,215</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Cash Flows from Investing Activities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Proceeds from sales of property and equipment</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-42479">26</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-370"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt"><b style="-keep: true">Net cash provided by investing activities</b></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd" id="ixv-42480">26</ix:nonFraction></span></p></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="-sec-ix-hidden: hidden-fact-371; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">-</span></p></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Cash Flows from Financing Activities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Proceeds from settlement of Forward Purchase Agreement</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-42481">132</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-372"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Proceeds from issuances of debt</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" unitRef="usd" id="ixv-42482">1,840</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" unitRef="usd" id="ixv-42483">4,877</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Proceeds from issuance of Note payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-42484">553</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-373"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Payments on Note payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd" id="ixv-42485">553</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-374"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Issuance of Advance Shares</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="3" unitRef="usd" id="ixv-42486">739</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-375"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Payment of offering costs</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-376"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd" id="ixv-42487">365</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Repayment of finance lease liabilities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-377"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-42488">17</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 0.25in; font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Net cash provided by financing activities</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-42489">2,711</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-42490">4,495</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Net change in cash and restricted cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-42491">2,649</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-42492">720</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Cash and restricted cash - beginning of period</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-42493">2,992</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-42494">861</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Cash and restricted cash - end of period</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-42495">343</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-42496">141</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">Supplemental disclosure of cash flow information and non-cash transactions:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Interest paid</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-42497">21</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-42498">1</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Issuance costs for Advance Shares included in accrued expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" scale="3" unitRef="usd" id="ixv-42499">51</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-378"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Fair value of common stock issued for services</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountIssued1" scale="3" unitRef="usd" id="ixv-42500">161</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-379"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Common stock issued in settlement of convertible notes and embedded derivative liability</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" scale="3" unitRef="usd" id="ixv-42501">5,937</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-380"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Deferred offering costs included in accounts payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-381"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="abp:DeferredOfferingCostsIncludedInAccountsPayable" scale="3" unitRef="usd" id="ixv-42502">575</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Reclassification of residual value guarantees under finance lease to accrued expense</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-382"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" scale="3" unitRef="usd" id="ixv-42503">113</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">As reported within the unaudited condensed consolidated balance sheets:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="-keep: true">Cash</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-42504">328</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-42505">1</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Restricted cash</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-42506">15</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-42507">140</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total&#160;cash and restricted cash&#160;as presented in the balance sheet</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-42508">343</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c177" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-42509">141</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">The accompanying notes are an integral part
of these unaudited condensed consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">&#160;</span></p><div>


</div><!-- Field: Page; Sequence: 165; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">ABPRO HOLDINGS, INC.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">NOTES TO CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(Amounts in thousands, except share and
per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">(unaudited)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-28366"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>1.</b></span></td>
    <td><span style="font-size: 10pt"><b>Organization and Description of the Business</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-keep: true"><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Abpro Holdings, Inc. and its subsidiaries,
(the &#8220;Company&#8221;) is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives
of patients with severe and life-threatening diseases. The Company is focused on the development of novel antibodies using its proprietary
discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology and infectious disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 13, 2024 (the &#8220;Closing Date&#8221;),
Atlantic Coastal Acquisition Corp. II (&#8220;ACAB&#8221;) consummated a merger (the &#8220;Merger&#8221;) pursuant to the terms of the
Merger Agreement, dated as of December 11, 2023 (the &#8220;Merger Agreement&#8221;) by and among Abpro Corporation (&#8220;Legacy Abpro&#8221;),
ACAB, and Abpro Merger Sub Corp., a Delaware corporation (&#8220;Merger Sub&#8221;) and wholly owned subsidiary of ACAB prior to the
Closing Date. Pursuant to the Merger Agreement, on the Closing Date, (i) ACAB changed its name to &#8220;Abpro Holdings, Inc.&#8221;
(&#8220;New Abpro&#8221;), and (ii)&#160;Merger Sub merged with and into Legacy Abpro, with Legacy Abpro as the surviving company in
the Merger (such transactions, the &#8220;Merger,&#8221; and, collectively with the other transactions described in the Merger Agreement,
the &#8220;Reverse Recapitalization&#8221;). Shares of the New Abpro common stock commenced trading on the Nasdaq Global Market on November
14, 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">After giving effect to the Merger, Legacy
Abpro became a wholly owned subsidiary of the Company. The Merger was accounted for as a reverse recapitalization in accordance with
U.S. GAAP, and under this method of accounting, ACAB was treated as the acquired company for financial reporting purposes and Legacy
Abpro was treated as the acquirer. Operations prior to the Merger are those of Legacy Abpro. Unless otherwise noted, the Company has
retroactively adjusted all common and preferred share and related price information to give effect to the Exchange Ratio as set forth
in the Merger Agreement (see Note 3). The &#8220;Company&#8221; refers to Abpro Holdings, Inc. and its subsidiaries, including Abpro
Corporation, prior to and subsequent to the Merger. Legacy Abpro is the accounting acquirer in the Merger and, as such, the condensed
consolidated financial statements for the three months and nine months ended September 30, 2024 present operations of Legacy Abpro prior
to the Merger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Refer to Note 3 &#8212; Merger for further
details of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 16 , 2025, the Company filed with
the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the &#8220;Certificate
of Amendment&#8221;), which became effective on October 31, 2025 (the &#8220;Effective Time&#8221;), to effect a one-for-thirty (1:30)
reverse stock split (the &#8220;Reverse Stock Split&#8221;), of the shares of the Company&#8217;s common stock, par value $<ix:nonFraction contextRef="c178" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-42510">0.0001</ix:nonFraction> per
share. The Reverse Stock Split was approved by the Company&#8217;s stockholders at the 2025 annual meeting of the stockholders on October
10, 2025. The Company&#8217;s common stock began trading on a reverse stock split-adjusted basis upon market opening on November 3, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As a result of the Reverse Stock Split, every
<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abp:ReverseStockSplitSharesOfIssued" scale="0" unitRef="shares" id="ixv-42511"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abp:ReverseStockSpllitSharesOfOutstanding" scale="0" unitRef="shares" id="ixv-42512">30</ix:nonFraction></ix:nonFraction> shares of issued and outstanding common stock will be automatically combined into <ix:nonFraction contextRef="c179" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-42513"><ix:nonFraction contextRef="c179" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42514">one</ix:nonFraction></ix:nonFraction> (1) issued and outstanding share of common stock,
without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split. Instead, stockholders
who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly divisible by the
Reverse Stock Split ratio will be entitled to receive an additional fraction of a share of common stock to round up to the next whole
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">All of the Company&#8217;s historical share
and per share information related to issued and outstanding common stock, restricted stock units, and options and warrants exercisable
for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1:30 reverse stock split.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 166; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Risks and Uncertainties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of more advanced
or effective therapies, dependence on key executives, protection of and dependence on proprietary technology, compliance with government
regulations and ability to secure additional capital to fund operations. Programs currently under development will require significant
additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization.
These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting
capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will
realize significant revenue from product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company is required to evaluate whether
there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern
within one year after the date that the condensed consolidated financial statements are issued. Through September 30, 2025, the Company
has funded its operations mainly through equity and debt financings, including the proceeds from the issuance of shares under SEPA (see
Notes 11 and 16), as well as from the Merger and the PIPE Financing (see Note 3), and to a lesser extent, payments received in connection
with collaboration and license agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of September&#160;30, 2025 and December&#160;31,
2024, the Company had an accumulated deficit of $<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-42515">124,631</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-42516">116,103</ix:nonFraction>, respectively. The Company&#8217;s net loss was $<ix:nonFraction contextRef="c180" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42517">1,657</ix:nonFraction> and $<ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-42518">8,528</ix:nonFraction>
for the three and nine months ended September&#160;30, 2025, respectively. Substantially all of the Company&#8217;s net losses resulted
from costs incurred in connection with the Company&#8217;s research and development programs and from general and administrative costs
associated with the Company&#8217;s operations. The Company expects to incur substantial operating losses and negative cash flows from
operations for the foreseeable future as the Company advances its product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 2, 2025, the Company received written
notice (the &#8220;Notice&#8221;) from the Listing Qualifications Department staff (the &#8220;Staff&#8221;) of the Nasdaq Stock Market
(&#8220;Nasdaq&#8221;) notifying the Company that, based on the closing bid price of the Company&#8217;s common stock for the last 30
consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq
Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $<ix:nonFraction contextRef="c182" decimals="2" format="ixt:num-dot-decimal" name="abp:SecurityBidPricePerShare" scale="0" unitRef="usdPershares" id="ixv-42519">1.00</ix:nonFraction> per share (the &#8220;Minimum
Bid Price Requirement&#8221;), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement
exists if the deficiency continues for a period of 30 consecutive business days. &#160;Pursuant to the Nasdaq Listing Rules, the Company
has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. The
letter stated that the Company had 180 calendar days, or until September 29, 2025, to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 10, 2025, the Company received two
letters from the Staff of Nasdaq. One letter (the &#8220;MVPHS Notice&#8221;) indicated that based upon Nasdaq&#8217;s review of the
Company&#8217;s Market Value of Publicly Held Shares (&#8220;MVPHS&#8221;) for the last 30 consecutive business days prior to the date
of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities
to maintain a minimum MVPHS of $<ix:nonFraction contextRef="c183" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd" id="ixv-42520">15,000,000</ix:nonFraction> (the &#8220;MVPHS Requirement&#8221;). The second letter notified the Company that from February
20, 2025, to April 9, 2025, the Company&#8217;s Market Value of Listed Securities (&#8220;MVLS&#8221;) was below the minimum of $<ix:nonFraction contextRef="c184" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="6" unitRef="usd" id="ixv-42521">50</ix:nonFraction> million
required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the &#8220;MVLS Requirement&#8221;).
Each letter stated that the Company had 180 calendar days, or until October 7, 2025, to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 30, 2025, the Company received
a letter from Nasdaq notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement during the compliance
period. Accordingly, the Company timely requested a hearing before the appeal panel (the &#8220;Panel&#8221;), which stayed the suspension
of the Company&#8217;s securities with Nasdaq pending the Panel&#8217;s decision or any extension of time provided by the Panel to regain
compliance.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 167; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 14, 2025, the Company received
a letter (the &#8220;Notice&#8221;) from Nasdaq notifying the Company that it had not regained compliance with either the MVPHS Requirement
or the MVLS Requirement during the compliance period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Hearing was held on October 30, 2025.
During the Hearing, the Company presented its plans to regain compliance with the Minimum Bid Price Requirement, the MVPHS Requirement
and the MVLS Requirement. On November 10, 2025, the Company received a decision letter from the Panel granting the Company&#8217;s request
for continued listing on The Nasdaq Stock Market, subject to the Company&#8217;s strict adherence to certain interim deadlines and conditions.
The Panel will maintain jurisdiction over the Company&#8217;s listing through March 30, 2026, and may reconsider the terms of the exception
or delist the Company if it fails to meet any of the imposed deadlines or becomes deficient with any listing rule during this period.
There can be no assurance that the Company will be able to meet the conditions imposed by the Panel or regain and maintain compliance
with Nasdaq&#8217;s listing requirements. Failure to do so may result in the delisting of the Company&#8217;s securities from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 23, 2025, the Company received net
proceeds of $<ix:nonFraction contextRef="c185" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-42522">1,840</ix:nonFraction> from the Second Convertible Note pursuant to the SEPA (see Note 11).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In July and August 2025, the Company issued
three Advance Notices to YA (see Note 11) in accordance with the terms of the SEPA, under which YA purchased from the Company <ix:nonFraction contextRef="c186" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42523"><ix:nonFraction contextRef="c187" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42524">91,336</ix:nonFraction></ix:nonFraction>
common stock shares, raising $<ix:nonFraction contextRef="c188" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-42525"><ix:nonFraction contextRef="c189" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-42526">688</ix:nonFraction></ix:nonFraction> in total net proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of September&#160;30, 2025, the Company
had cash of $<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-42527">328</ix:nonFraction>. Due to its current liabilities, the cash available to the Company will not be sufficient to allow the Company to operate
for at least 12 months from the date these financial statements are available for issuance. The future viability of the Company is largely
dependent on its ability to raise additional capital to finance its operations. The Company expects to seek additional funding through
equity and debt financings, collaboration agreements and research grants. Although the Company has been successful in raising capital
in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company,
if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development
programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Accordingly, based on the considerations discussed
above, management has concluded there is substantial doubt as to the Company&#8217;s ability to continue as a going concern within one
year after the date the condensed consolidated financial statements are issued. The Company plans to continue to fundraise, as well as
seek alternate revenues from collaboration and license agreements. If adequate funds are not available, the Company may be required to
initiate steps to slow cash burn, extending the cash runway until financing can be secured. The condensed consolidated financial statements
do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might result
from the outcome of this uncertainty.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-28511"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Summary of Significant Accounting Policies</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-28523"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Basis of Presentation</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accompanying condensed
consolidated financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation
(&#8220;AbMed&#8221;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts
have been reclassified to conform to the current period presentation with no material impact on the condensed consolidated financial
statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-28535"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Use of Estimates</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The preparation of condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported
in the condensed consolidated financial statements and accompanying notes. Significant estimates in these condensed consolidated financial
statements include stock-based compensation expense, the fair value of derivative instruments, the fair value of options and warrants,
pre-clinical&#160;and clinical accrued expenses, the valuation and realizability of deferred tax assets, and the ability to continue
as a going concern. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates
on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making
estimates, actual results could differ materially from those estimates.</span></p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 168; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:continuation id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In March 2022, the Company received an invoice
from Mabwell (Shanghai) Bioscience Co., Ltd. (&#8220;Mabwell&#8221;) for approximately $<ix:nonFraction contextRef="c190" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="usd" id="ixv-42528">3,500</ix:nonFraction> in connection with the manufacturing of
certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based on the information available
at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its validity. The Company continued to
dispute the amount and its contractual basis because the parties had neither finalized nor executed a clinical trial manufacturing agreement.
In July 2024, the Company received communication from Mabwell that they will not be pursuing the collection of the originally invoiced
amount. Accordingly, during the quarter ended March 31, 2024, the Company reversed the liability and recognized $<ix:nonFraction contextRef="c191" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="3" unitRef="usd" id="ixv-42529">3,500</ix:nonFraction> of other income.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_1" escape="true" name="abp:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" id="ixv-28568"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Unaudited Interim Condensed Consolidated
Financial Statements</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_2" id="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The accompanying interim condensed consolidated
financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared
on the same basis as the audited financial statements, and in management&#8217;s opinion, include all adjustments, consisting of only
normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of September&#160;30, 2025
and its results of operations for the three months and nine months ended September&#160;30, 2025 and 2024, and cash flows for the nine
months ended September&#160;30, 2025 and 2024. The results of operations for the three months and nine months ended September&#160;30,
2025 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2025 or any other period. The
December&#160;31, 2024 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not
include all disclosures from the annual financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Certain information and footnote disclosures
normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant
to the rules and regulations of the SEC. Accordingly, these condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements for the year ended December&#160;31, 2024 and the related notes included in the Company&#8217;s
Annual Report on Form 10-K, filed with the SEC on April 15, 2025 (the &#8220;Annual Report&#8221;), which provides a more complete discussion
of the Company&#8217;s accounting policies and certain other information. There have been no significant changes to the significant accounting
policies disclosed in Note 2 of the audited consolidated financial statements as of and for the year ended December&#160;31, 2024 included
in the Company&#8217;s Annual Report.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-28584"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Segment Reporting</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">ASC Topic No. 280, Segment Reporting (&#8220;ASC
280&#8221;), establishes standards for the way that public business enterprises report information about operating segments in their
annual consolidated financial statements and requires that those enterprises report selected information about operating segments in
interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and
major customers. The Company&#8217;s business segments are based on the organization structure used by the chief operating decision maker
(&#8220;CODM&#8221;) for making operating and investment decisions and for assessing performance.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In accordance with ASC 280, the Company has
determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in the
areas of immuno-oncology, ophthalmology and infectious disease. <ix:nonNumeric contextRef="c0" name="us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription" id="ixv-28598">The financial results of the Company&#8217;s operations are managed and
reported to the <span style="-sec-ix-hidden: hidden-fact-405">Chief Executive Officer</span>, who is considered the Company&#8217;s CODM, on a consolidated basis</ix:nonNumeric>. The CODM assesses performance
and allocates resources based on the Company&#8217;s consolidated statements of operations, and key components and processes of the Company&#8217;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development expenses, general and administrative
expenses, and interest expenses, which are each separately presented on the Company&#8217;s condensed consolidated statements of operations.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 169; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="abp_NoncontrollingInterestPolicyTextBlock-c0_cont_1" escape="true" name="abp:NoncontrollingInterestPolicyTextBlock" id="ixv-28618"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Non-controlling Interest</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abp_NoncontrollingInterestPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company holds an <ix:nonFraction contextRef="c192" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-42530">82</ix:nonFraction>% ownership interest
in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not owned by
the Company and is reported as a component in stockholders&#8217; equity on the condensed consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $<ix:nonFraction contextRef="c193" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares" id="ixv-42531">2.00</ix:nonFraction>
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling
interest holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the
nine month periods ending September 30, 2025 and 2024.</span></p></ix:continuation>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-28630"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Net Loss Per Share</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company follows the two-class method to
compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 12), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#8217;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#8217;s outstanding common
stock for all periods presented.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Basic net loss per share attributable to common
stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock outstanding
during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion of such
shares would be anti-dilutive. As the Company has incurred losses for the three and nine months ended September 30, 2025 and 2024, basic
and diluted net loss per share were the same all periods presented.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-28646"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_4" id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share, because their effect was anti-dilutive:</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Convertible Preferred Stock</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-404"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c195" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-42532">662,921</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-keep: true">Warrants</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c196" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-42533">990,000</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c197" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-42534">4,159</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Stock options</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c198" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-42535">222,635</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c199" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-42536">345,164</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Unvested restricted stock units</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c200" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-42537">16,667</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c201" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-42538">1,292</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-42539">1,229,302</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-42540">1,013,536</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" continuedAt="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock-c0_cont_1" escape="true" name="abp:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" id="ixv-28776"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Recently Adopted Accounting Pronouncements</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In December 2023, the&#160;Financial Accounting
Standards Board&#160;(&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted.
The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these unaudited
condensed consolidated financial statements.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 170; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-28803"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Recently Issued Accounting Pronouncements</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 4, 2024, the FASB issued&#160;ASU
2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the
same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting
periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.
The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Management does not believe that any additional
recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#8217;s
financial statements.&#160;</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="ixv-28821"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Merger</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 13, 2024, Merger Sub, a wholly-owned
subsidiary of ACAB, merged with Legacy Abpro, with Legacy Abpro surviving as a wholly-owned subsidiary of ACAB. At the effective time
of the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-keep: true">&#160;</span></td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">each outstanding share of Legacy Abpro common stock was converted into approximately&#160;<ix:nonFraction contextRef="c202" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-42541">0.068</ix:nonFraction>&#160;shares of the Company&#8217;s common stock;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-keep: true">&#160;</span></td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">each outstanding share of preferred stock of Legacy Abpro was converted into the aggregate number of shares of New Abpro&#8217;s common stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately&#160;<ix:nonFraction contextRef="c203" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-42542">0.068</ix:nonFraction>; and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-keep: true">&#160;</span></td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">each outstanding option or warrant to purchase Legacy Abpro common stock was converted into an option or warrant, as applicable, to purchase a number of shares of the Company&#8217;s common stock equal to the number of shares of Legacy Abpro common stock subject to such option or warrant multiplied by approximately&#160;<ix:nonFraction contextRef="c204" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-42543">0.068</ix:nonFraction>, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately&#160;<ix:nonFraction contextRef="c203" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-42544">0.068</ix:nonFraction>; in each case, rounded down to the nearest whole share.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition, at the Closing Date, <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-42545">6,744,550</ix:nonFraction>&#160;shares
of Series A common stock and <ix:nonFraction contextRef="c206" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-42546">1</ix:nonFraction> share of Series B common stock of ACAB, on a pre-split basis, automatically converted into shares of the
Company&#8217;s common stock, on a&#160;one-for-one&#160;basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Former holders of the Legacy Abpro common
stock and Legacy Abpro preferred stock are eligible to receive up to <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abp:AdditionSharesOfCommonStock" scale="0" unitRef="shares" id="ixv-42547">483,333</ix:nonFraction> additional shares of the Company&#8217;s common stock (&#8220;Contingent
Earnout Shares&#8221;) if, within five calendar years after the closing of the Merger, the volume weighted average price of shares of
the Company&#8217;s Common Stock on Nasdaq, or any other national securities exchange on which the shares of the Company&#8217;s Common
Stock are then traded (&#8220;VWAP&#8221;) meets or exceeds three-tier target prices defined in the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the Closing Date, the Company issued an
aggregate of&#160;<ix:nonFraction contextRef="c207" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42548">112,247</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;PIPE Shares&#8221;) in a private placement for the total
consideration of $<ix:nonFraction contextRef="c208" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="3" unitRef="usd" id="ixv-42549">11,225</ix:nonFraction> (the &#8220;PIPE Financing&#8221;). Out of the total PIPE Shares, <ix:nonFraction contextRef="c209" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42550">20,749</ix:nonFraction> shares were issued to Abpro Bio International,
Inc. (&#8220;ABI&#8221;), a significant investor in Legacy Abpro&#8217;s Series E and F convertible preferred stock, pursuant to the
terms of a subscription agreement dated August 22, 2024 with ABI (the &#8220;Abpro Bio Subscription Agreement&#8221;) for an aggregate
purchase price of $<ix:nonFraction contextRef="c207" decimals="-3" format="ixt:num-dot-decimal" name="abp:AggregatePurchasePrice" scale="3" unitRef="usd" id="ixv-42551">6,225</ix:nonFraction>, of which $<ix:nonFraction contextRef="c210" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd" id="ixv-42552">4,225</ix:nonFraction> was used to repay the balance due by Legacy Abpro to ABI under the promissory note agreement
(see Note 10) and the remainder of $<ix:nonFraction contextRef="c211" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-42553">2,000</ix:nonFraction> in cash. In addition, pursuant to the Abpro Bio Subscription Agreement, ABI received an aggregate
of <ix:nonFraction contextRef="c212" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42554">41,498</ix:nonFraction> shares of New Abpro common stock reserved for use in the PIPE Financing or to obtain capital for ACAB or the surviving company,
as defined in the Merger Agreement (the &#8220;Incentive Shares&#8221;). The Company also issued <ix:nonFraction contextRef="c213" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42555">16,667</ix:nonFraction> common stock shares of New Abpro
to Celltrion, Inc., a company organized and existing under the laws of South Korea (&#8220;Celltrion&#8221;), pursuant to the terms of
a subscription agreement dated August 22, 2024 with Celltrion (&#8220;Celltrion&#8221;) (the &#8220;Celltrion Subscription Agreement&#8221;,
together with the &#8220;Abpro Bio Subscription Agreement&#8221;, collectively the &#8220;PIPE Subscription Agreements&#8221;) for an
aggregate purchase price of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:AggregatePurchasePrice" scale="3" unitRef="usd" id="ixv-42556">5,000</ix:nonFraction>. In addition, Celltrion received an aggregate of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="abp:AggregateIncentiveShare" scale="0" unitRef="shares" id="ixv-42557">33,333</ix:nonFraction> Incentive Shares.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 171; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_2" id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Pursuant to the terms of the Merger Agreement,
at the Closing Date, ACAB&#8217;s sponsor, Atlantic Coastal Management II LLC (the &#8220;Sponsor&#8221;) received <ix:nonFraction contextRef="c214" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42558">20,020</ix:nonFraction> shares of New
Abpro common stock in lieu of repayment of $<ix:nonFraction contextRef="c215" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="3" unitRef="usd" id="ixv-42559">2,000</ix:nonFraction> of Unpaid SPAC Expenses (as defined in the Merger Agreement) owed to the Sponsor as
a result of advances made by the Sponsor to ACAB. This settlement was related to the ACAB liabilities incurred prior to the Merger and
had no financial impact on the Company&#8217;s December 31, 2024 consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the Closing, and in accordance with the
Sponsor Letter Agreement entered into on December&#160;11, 2023, as amended, the Sponsor transferred <ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42560">32,778</ix:nonFraction> common shares to Legacy Abpro
and <ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42561">32,778</ix:nonFraction> shares to ABI, and <ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" scale="0" unitRef="shares" id="ixv-42562">32,215</ix:nonFraction> shares were forfeited. The shares transferred to ABI for no consideration were accounted for as
a recapitalization with no impact on the December 31, 2024 consolidated financial statements. The Sponsor also transferred&#160;<ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42563">6,667</ix:nonFraction>
shares to one of ACAB&#8217;s financial advisors for the services provided prior to the Closing Date. The shares transferred to Legacy
Abpro were deemed to be repurchased by the Company for no consideration and included in treasury stock as of the Closing Date. These
treasury stock shares were retired on September 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition, at the Closing, the Company issued
<ix:nonFraction contextRef="c220" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42564">36,095</ix:nonFraction> common stock shares to various service providers, of which <ix:nonFraction contextRef="c221" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42565">1,095</ix:nonFraction> shares were issued to an investment advisor in the PIPE Financing
and the remaining <ix:nonFraction contextRef="c222" decimals="0" format="ixt:num-dot-decimal" name="abp:RemainingSharesIssued" scale="0" unitRef="shares" id="ixv-42566">35,000</ix:nonFraction> shares of common stock were issued in settlement of ACAB&#8217;s liabilities for the services provided by various
legal and investment advisors prior to the Closing Date. The issuance of these shares, related to the services provided to ACAB prior
to the Merger which were expensed on the books of ACAB, had no financial impact on the Company&#8217;s December 31, 2024 consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" id="ixv-28906"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The number of shares of the Company&#8217;s
common stock outstanding immediately following the consummation of the Merger was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-keep: true">Common stock of ACAB, net of redemptions</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c229" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42567">7,033</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">ACAB Founder Shares, less of forfeitures and transfers</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c230" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42568">126,076</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">New Abpro shares issued to PIPE investors</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42569">112,247</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">New Abpro shares issued to service providers</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c232" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42570">42,762</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">New Abpro shares issued in Merger to Legacy Abpro stockholders</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c233" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42571">1,304,107</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">New Abpro shares transferred to investors</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c234" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42572">72,285</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">New Abpro shares issued to settle the promissory note with executive</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c235" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42573">20,000</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total shares of common stock outstanding immediately after
    Merger</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c118" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42574">1,684,510</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Merger was accounted for as a reverse
recapitalization in accordance with U.S. GAAP. Under this method of accounting, ACAB is treated as the acquired company for financial
reporting purposes and Legacy Abpro is treated as the acquirer. This determination is primarily based on the fact that subsequent to
the Merger, the Legacy Abpro stockholders hold a majority of the voting rights of the combined company, Legacy Abpro comprises all of
the ongoing operations of the combined company, Legacy Abpro comprises a majority of the carryover governing body of the combined company,
and Legacy Abpro&#8217;s senior management comprises all of the senior management of the combined company. Accordingly, for accounting
purposes, the Merger was treated as the equivalent of Legacy Abpro issuing shares for the net assets of ACAB, accompanied by a recapitalization.
The net assets of ACAB were stated at historical costs. No goodwill or other intangible assets were recorded. Operations prior to the
Merger are those of Legacy Abpro.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 172; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company received $<ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-42575">5,700</ix:nonFraction> in proceeds from
the Merger and related PIPE Financing, net of ACAB transaction costs settled at the Closing. The Company incurred $<ix:nonFraction contextRef="c223" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="3" unitRef="usd" id="ixv-42576">2,100</ix:nonFraction> in transaction
costs and $<ix:nonFraction contextRef="c220" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-42577">900</ix:nonFraction> in issuance costs related to the PIPE Financing, consisting of banking, legal, investment advisory and other professional
fees, of which were recorded as a reduction of proceeds to additional paid-in capital. At the Closing Date, Legacy Abpro assumed $<ix:nonFraction contextRef="c224" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="3" unitRef="usd" id="ixv-42578">6,600</ix:nonFraction>
of net liabilities, including tax liabilities and legal fees, of ACAB. As of September 30, 2025, the ACAB liabilities were $<ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-42579">5,300</ix:nonFraction>, of
which $<ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42580">900</ix:nonFraction> was included in accrued expenses and $<ix:nonFraction contextRef="c225" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42581">4,400</ix:nonFraction> in excise tax payable. As of December 31, 2024, the ACAB liabilities were $<ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-42582">5,800</ix:nonFraction>,
of which $<ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42583">1,000</ix:nonFraction> was included in accrued expenses, $<ix:nonFraction contextRef="c226" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42584">4,400</ix:nonFraction> in excise tax payable and $<ix:nonFraction contextRef="c227" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaid" scale="3" unitRef="usd" id="ixv-42585">400</ix:nonFraction> in income tax payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In February 2025, the Company issued <ix:nonFraction contextRef="c228" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42586">5,000</ix:nonFraction>
shares of common stock to Roth Capital Partners (&#8220;Roth&#8221;) as an additional payment for the services provided under the engagement
letter dated July 17, 2024 between Roth and ACAB, which provided for an adjustment to their fees in shares based on the trading price
of the Company&#8217;s common stock. The issuance had zero impact on the September 30, 2025 condensed consolidated financial statements
as the fees to Roth were deemed to be related to the Merger and were recorded as a both an increase and reduction to additional paid-in
capital.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-29041"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt"><b>4.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Accrued Expenses</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-29052"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Accrued expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December 31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-keep: true">Accrued salaries and wages</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" unitRef="usd" id="ixv-42587">2,033</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" unitRef="usd" id="ixv-42588">1,549</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Accrued professional fees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-42589">1,121</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-42590">1,273</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Accrued license fees</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedLicenseFees" scale="3" unitRef="usd" id="ixv-42591">3,300</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedLicenseFees" scale="3" unitRef="usd" id="ixv-42592">3,300</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-keep: true">Accrued interest</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedInterest" scale="3" unitRef="usd" id="ixv-42593">273</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedInterest" scale="3" unitRef="usd" id="ixv-42594">267</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-keep: true">Board of Directors compensation</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedBODCompensation" scale="3" unitRef="usd" id="ixv-42595">285</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedBODCompensation" scale="3" unitRef="usd" id="ixv-42596">242</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Other accrued expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42597">1,014</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42598">865</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total accrued expenses</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42599">8,026</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42600">7,496</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-29225"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt"><b>5.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Fair Value Measurements</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="ixv-29236"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following table presents information about
the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025 and December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"><span style="-keep: true">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Level</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">Assets:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; text-align: justify"><span style="-keep: true">Forward purchase agreement asset (Note 9)</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="-keep: true">3</span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-406"><span style="-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-42601">155</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">SEPA put rights asset (Note 11)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">3</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c246" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-42602">243</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c247" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-42603">188</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Embedded derivative liability (Note 11)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">3</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-407"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c249" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-42604">80</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 173; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Forward Purchase Agreement was fully settled
on January 28, 2025 for $<ix:nonFraction contextRef="c236" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd" id="ixv-42605">132</ix:nonFraction> cash received by the Company. <ix:nonNumeric contextRef="c0" continuedAt="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="ixv-42606">The fair value of the Company&#8217;s position under the Forward Purchase
Agreement was calculated as of December 31, 2024 by multiplying the number of shares under the Forward Purchase Agreement by the market
price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation continuedAt="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_2" id="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_1"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="-keep: true">Stock price</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c250" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42607">53.70</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Risk-free interest rate</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c251" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42608">4.4</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Expected term (in years)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c252" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42609">0.1</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Expected volatility</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42610">98</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Expected dividend yield</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42611">0</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The fair value of the SEPA put rights asset
was estimated as the sum of the fair values of the put rights under each assumed advance notice over the term of the SEPA. The number
of shares under each advance notice was based on the historical trading volumes of the Company&#8217;s stock taking into account the
beneficial ownership and daily volume limitations. <ix:continuation continuedAt="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_3" id="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_2">The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:</ix:continuation></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:continuation id="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c0_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-keep: true">Stock price</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c255" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42613">6.72</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c256" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42614">53.70</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Risk-free interest rate</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c257" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42615">3.7</ix:nonFraction> &#8211; <ix:nonFraction contextRef="c258" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42616">4.1</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c259" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42617">4.2</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Exercise price</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c260" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42618">6.45</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c261" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42619">51.60</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Expected term (in years)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c262" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42620">0.1</ix:nonFraction> - <ix:nonFraction contextRef="c263" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42621">1.2</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42622">1</ix:nonFraction> - <ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42623">2</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Expected volatility</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c266" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42624">100</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="font-size: 10pt">&#160;<ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42625">93</ix:nonFraction>-<ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42626">99</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Expected dividend yield</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c269" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42627">0</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42628">0</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Number of shares under each advance notice</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c271" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42629">26,667</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42630">1,883</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The fair value of the embedded derivative
feature was $<ix:nonFraction contextRef="c237" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-42631">0</ix:nonFraction> as of September 30, 2025 and estimated to be $<ix:nonFraction contextRef="c238" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-42632">80</ix:nonFraction> as of December 31, 2024, based on the difference between the fair value
of the convertible note with these embedded features and the fair value without each one of these embedded features. As of December 31,
2024, the assumptions incorporated into the valuation model included the stock price of $<ix:nonFraction contextRef="c239" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-42633">53.70</ix:nonFraction>, the estimated future price per share
of $<ix:nonFraction contextRef="c240" decimals="2" format="ixt:num-dot-decimal" name="abp:EstimatedFuturePricePerShare" scale="0" unitRef="usdPershares" id="ixv-42634">61.80</ix:nonFraction> (derived using Monte Carlo Simulation), the expected volatility of <ix:nonFraction contextRef="c241" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-42635">99</ix:nonFraction>%, the risk-free rate of <ix:nonFraction contextRef="c241" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-42636">4.18</ix:nonFraction>% and the term of <ix:nonNumeric contextRef="c241" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-42637">0.9</ix:nonNumeric> years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The fair values of the Embedded Derivative
Liability associated with the conversion of the First and Second Convertible Notes (see Note 11) of $<ix:nonFraction contextRef="c242" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="3" unitRef="usd" id="ixv-42638">703</ix:nonFraction> and $<ix:nonFraction contextRef="c243" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="3" unitRef="usd" id="ixv-42639">243</ix:nonFraction>, respectively, were
based on the difference between the fair value of the common stock shares issued upon conversion and the outstanding note balance at
the conversion date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="ixv-29685"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The changes in the fair value of Level 3 financial
assets and liabilities for the nine months ended September 30, 2025 are as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Forward<br/> Purchase<br/> Agreement<br/>
    Asset</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">SEPA<br/> Put Rights<br/> Asset</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Embedded</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Derivative</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">Liabilities</b></p></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="-keep: true">Fair value as of January 1, 2025</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c273" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd" id="ixv-42640">155</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c274" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd" id="ixv-42641">188</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c275" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd" id="ixv-42642">80</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-keep: true">Initial measurement at the issuance date (see Note 11)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-408"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-409"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c278" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" unitRef="usd" id="ixv-42643">93</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">Settlement</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c276" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" scale="3" unitRef="usd" id="ixv-42644">132</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-410"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c278" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" scale="3" unitRef="usd" id="ixv-42645">946</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-keep: true">Change in fair value</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c276" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" unitRef="usd" id="ixv-42646">23</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c277" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" sign="-" unitRef="usd" id="ixv-42647">55</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c278" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" sign="-" unitRef="usd" id="ixv-42648">773</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-keep: true">Fair value as of September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-411"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c280" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd" id="ixv-42649">243</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-412"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="ixv-29893"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt"><b>6.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>License and Collaboration Agreements</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>NJCTTQ Collaboration Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In January 2019, the Company entered into
a collaboration agreement with Nanjing Chia Tai Tianquing Pharmaceutical Co., Ltd. (&#8220;NJCTTQ&#8221;) to research, develop and commercialize
two anti-Claudin 18.2 lead antibodies (the &#8220;NJCTTQ agreement&#8221;). Under the NJCTTQ agreement, the Company granted a non-exclusive,
non-sublicensable research license and an exclusive, sublicensable license to NJCTTQ within the People&#8217;s Republic of China and
Thailand (the &#8220;NJCTTQ Territory&#8221;). The initial term of this agreement was <ix:nonNumeric contextRef="c282" format="ixt-sec:duryear" name="abp:AgreementInitialTerm" id="ixv-42650">5</ix:nonNumeric> years, which could be automatically renewed for
another 5 years. If no collaboration project reached the clinical stage within the first 5 years of the NJCTTQ agreement, then this agreement
would not have been renewed. The agreement expired in January 2024.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 174; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c0_cont_2" id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company was eligible to receive up to
an aggregate of $<ix:nonFraction contextRef="c283" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42651">405,000</ix:nonFraction> of non-refundable milestone payments from NJCTTQ upon achieving certain development, regulatory approval, and
commercialization and sales milestones for each unique licensed antibody or product in NJCTTQ Territory. The Company agreed to pay NJCTTQ
up to an aggregate of $<ix:nonFraction contextRef="c283" decimals="-3" format="ixt:num-dot-decimal" name="abp:NonRefundablePayments" scale="3" unitRef="usd" id="ixv-42652">5,000</ix:nonFraction> in nonrefundable amounts upon achieving of a regulatory milestone in the Company&#8217;s territory, which
includes all other countries other than the NJCTTQ Territory. No milestones have been reached through the expiration of this agreement
in January 2024, no products were sold by NJCTTQ, and no related revenue amounts have been recorded in the condensed consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company and NJCTTQ agreed to pay reciprocal
royalties, with each of them paying the other party low single-digit royalties, tiered based on net sales per calendar year in its territory.
The agreement remains unrenewed as of September 30, 2025 after the expiration of its initial term. However, notwithstanding the agreement&#8217;s
expiration, the low single-digit royalties and the $<ix:nonFraction contextRef="c283" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-42653">5,000</ix:nonFraction> regulatory milestone payable to NJCTTQ based on commercial approval in the
Company&#8217;s territory, as described above, will continue to apply. Through September 30, 2025, no products were sold by NJCTTQ or
the Company under the NJCTTQ agreement and no regulatory milestones were achieved by the Company in the Company&#8217;s territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>ABP-201 Collaboration and License Agreement
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In January 2020, the Company&#8217;s consolidated
subsidiary, AbMed, entered into a collaboration and license agreement with ABI (the &#8220;ABP-201 Agreement&#8221;), pursuant to which
the Company granted to ABI an exclusive, royalty-bearing, license under specified patent rights to make, use and sell certain of its
proprietary ANG-2/VEGF-HIRK bispecific antibodies within the licensed territory comprising People&#8217;s Republic of China, Japan, South
Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States. Unless earlier terminated in accordance with its terms,
the agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under the ABP-201 agreement, ABI agreed to
use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within
specified territories and timeframes. ABI is committed to pay the Company up to $<ix:nonFraction contextRef="c284" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42654">56,500</ix:nonFraction> in milestone payments upon achieving certain
research and development events, up to $<ix:nonFraction contextRef="c212" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42655">485,000</ix:nonFraction> in milestone payments based on annual net sales per each licensed product, and a double-digit
percentage royalty in the low teens, tiered based on cumulative net sales by ABI, its affiliates or sublicensees beginning with the first
commercial sale of a licensed product in its territory. No milestones have been reached through September 30, 2025, no products were
sold by ABI, and no related revenue amounts have been recorded in the condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Celltrion Collaboration and License
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In September 2022, the Company entered into
an exclusive collaboration and license agreement with Celltrion, as amended in October 2024 in connection with the execution of the Celltrion
Subscription Agreement (the &#8220;Amended Celltrion Agreement&#8221;). Under the Amended Celltrion Agreement, the Company granted to
Celltrion a worldwide exclusive license under specified patent rights to develop, make, have made, import, export, use, have used, sell
and have sold certain of its proprietary ABP-102 bispecific antibodies. The License Agreement also provides that the Company is to perform
certain preclinical in vitro studies. The License Agreement will remain in effect for so long as ABP-102 is being developed or commercialized
anywhere in the world. Celltrion may terminate the license agreement at any time by providing&#160;six months prior written notice to
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Celltrion is committed to pay the Company
up to $<ix:nonFraction contextRef="c285" decimals="-3" format="ixt:num-dot-decimal" name="abp:OriginalCelltrionAgreement" scale="3" unitRef="usd" id="ixv-42656">10,000</ix:nonFraction> under the Original Celltrion Agreement and $<ix:nonFraction contextRef="c286" decimals="-3" format="ixt:num-dot-decimal" name="abp:OriginalCelltrionAgreement" scale="3" unitRef="usd" id="ixv-42657">6,000</ix:nonFraction> under the Amended Celltrion Agreement in milestone payments upon granting
the license and achieving certain research and development events, and up to $<ix:nonFraction contextRef="c285" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42658">1,750,000</ix:nonFraction> in milestone payments based on annual net sales
per each licensed product. The proceeds from commercialization are subject to a 50/50 profit split. Amounts that may be paid by third-party
collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization partners, are also subject
to a 50/50 split. Following commercial approval of ABP-102, the Company has agreed to reimburse Celltrion <ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="abp:PercentageOfOriginalCelltrionAgreement" scale="-2" unitRef="pure" id="ixv-42659">87.5</ix:nonFraction>% under the Original Celltrion
Agreement and <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAmendedCelltrionAgreement" scale="-2" unitRef="pure" id="ixv-42660">250</ix:nonFraction>% under the Amended Celltrion Agreement of its direct and certain indirect costs and expenses incurred through first
commercial sale. Under the Original Celltrion Agreement, Celltrion is entitled to offset amounts otherwise due to us under the agreement
until our share of these costs has been paid back; provided that the Company is entitled to a minimum <ix:nonFraction contextRef="c287" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAmendedCelltrionAgreement" scale="-2" unitRef="pure" id="ixv-42661">25</ix:nonFraction>% (or <ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAmendedCelltrionAgreement" scale="-2" unitRef="pure" id="ixv-42662">50</ix:nonFraction>% under the Amended Celltrion
Agreement) of profit from commercial sales and from third-party collaborators regardless of the amount of unreimbursed development costs
outstanding (and then <ix:nonFraction contextRef="c285" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfReimbursement" scale="-2" unitRef="pure" id="ixv-42663">50</ix:nonFraction>% once the reimbursement has been made in full).</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 175; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_CollaborativeArrangementDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The first milestone of $<ix:nonFraction contextRef="c288" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42664"><ix:nonFraction contextRef="c289" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42665">2,000</ix:nonFraction></ix:nonFraction> was achieved
upon granting the license at the collaboration effective date, as defined in the Celltrion Agreement, in December 2022, received in January
2023 and recognized in revenue prior to December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the three and nine months ended September
30, 2025 and 2024, the Company recognized <span style="-sec-ix-hidden: hidden-fact-413"><span style="-sec-ix-hidden: hidden-fact-414"><span style="-sec-ix-hidden: hidden-fact-415"><span style="-sec-ix-hidden: hidden-fact-416">no</span></span></span></span> revenue in connection with this arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><i>Milestone Payments.&#160;</i>The Company
is entitled to development milestones under the Celltrion Agreement and certain regulatory milestone payments which are paid upon receipt
of regulatory approvals.&#160;Except for the first milestone of $<ix:nonFraction contextRef="c290" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42666">2,000</ix:nonFraction> achieved in 2022, <span style="-sec-ix-hidden: hidden-fact-417">no</span>&#160;other milestone payments were earned
through September 30, 2025. The Company evaluated whether the remaining milestones are considered probable of being reached and determined
that their achievement is highly dependent on factors outside of the Company&#8217;s control. Therefore, these payments have been fully
constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achievement of each milestone and any related constraint, and if necessary, adjust its estimate of the overall transaction
price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect the reported amount of collaboration
revenues in the period of adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><i>Profit Splits. </i>As the license is deemed
to be the predominant item to which profit splits relate, the Company will recognize revenue when the related sales or third-party collaborator
income occur.&#160;No&#160;profit split revenue has been recognized from inception through September 30, 2025.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock" id="ixv-30006"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="font-size: 10pt"><b>7.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Commitments under Research and Collaboration Agreements</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>MedImmune License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In August 2016, the Company entered into a
collaboration and license agreement with MedImmune Limited (&#8220;MedImmune&#8221;), pursuant to which the Company received from MedImmune
an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license to certain intellectual property rights
relating to the Company&#8217;s ABP-200 product candidates (the &#8220;MedImmune License Agreement&#8221;). The Company agreed to use
commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within specified
timeframes. Unless earlier terminated in accordance with its terms, the MedImmune License Agreement, as amended, remains in effect on
a country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of products
based on the ABP-200 product candidates. The Company is no longer developing ABP-200.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under the MedImmune License Agreement, the
Company agreed to pay milestone and royalty payments, including up to $<ix:nonFraction contextRef="c292" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42667">244,000</ix:nonFraction> in milestone payments, which are comprised of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:ClinicalDevelopmentMilestones" scale="3" unitRef="usd" id="ixv-42668">14,000</ix:nonFraction>
upon meeting certain clinical development milestones, $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:RegulatoryEvents" scale="3" unitRef="usd" id="ixv-42669">80,000</ix:nonFraction> upon achieving certain regulatory events and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:CommercialSales" scale="3" unitRef="usd" id="ixv-42670">150,000</ix:nonFraction> upon meeting certain
worldwide commercial sales thresholds; and tiered high-single to low double-digit percentage royalties based on annualized net sales
of each product commercialized from our collaboration on a country-by-country basis. No milestones have been reached and no products
were sold by the Company through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>NCI License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In August 2017, the Company entered into a
patent license agreement with the National Cancer Institute (the &#8220;NCI&#8221;), a division of the National Institutes of Health
(the &#8220;NIH&#8221;), pursuant to which the Company received an exclusive, worldwide license to make, use, sell, offer to sell and
import products covered by the licensed patents in the field of using certain monoclonal antibodies as monospecific or bispecific antibodies
for the treatment of liver cancer (the &#8220;NCI License Agreement&#8221;). The license agreement was amended in May 2020 and October
2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the treatment of GPC-3 expressing
liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization was extended. Unless
earlier terminated, the Company&#8217;s agreement with NCI will expire upon expiration of all licensed patent rights. The Company may
also terminate the agreement as to any licenses in any country or territory upon 60 days written notice.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 176; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_CommitmentsDisclosureTextBlock-c0_cont_2" id="_CommitmentsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Pursuant to the NCI agreement and amendments,
the Company agreed to pay low single-digit royalties based on net sales of licensed products as well as milestone payments of up to $<ix:nonFraction contextRef="c293" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42671">3,995</ix:nonFraction>
due upon achievement of clinical and regulatory milestones, and up to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePaymentsCommercialMilestones" scale="3" unitRef="usd" id="ixv-42672">12,000</ix:nonFraction> milestone payments due upon achievement of commercial milestones.
No milestones have been reached and no products were sold by the Company through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company also has to pay the guaranteed
annual minimum royalties of $<ix:nonFraction contextRef="c293" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-42673">25</ix:nonFraction> starting on the effective date of the agreement (which annual minimum royalties may be credited against
the running royalties on net sales of any licensed products or services). During each of the three months ended September 30, 2025 and
2024, the Company incurred $<ix:nonFraction contextRef="c294" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-42674"><ix:nonFraction contextRef="c295" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-42675">6</ix:nonFraction></ix:nonFraction>, in minimum royalty payments, included in research and development expenses. During each of the nine months
ended September 30, 2025 and 2024, the Company incurred $<ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-42676"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-42677">19</ix:nonFraction></ix:nonFraction>, in minimum royalty payments, included in research and development expenses.
Under the amendment entered into in March 2020, the Company is also liable for the extension royalties of $<ix:nonFraction contextRef="c298" decimals="-3" format="ixt:num-dot-decimal" name="abp:PaymentForExtensionRoyalities" scale="3" unitRef="usd" id="ixv-42678">225</ix:nonFraction> payable under this agreement
which were rescheduled to become due in several installments starting in March 2022. As of both September 30, 2025 and December 31, 2024,
the accrued extension royalties were $<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42679"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42680">200</ix:nonFraction></ix:nonFraction>, included in accrued expenses on the condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company also agreed to reimburse patent
costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights. During
the three and nine months ended September 30, 2025 and 2024, the Company did not incur any expenses related to the patent costs reimbursements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Mabwell License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In October 2020, the Company entered into
an exclusive collaboration and license agreement with Mabwell (the &#8220;Mabwell License Agreement&#8221;). The agreement was amended
in November 2020. Under the Mabwell license agreement, the Company received a non-exclusive, royalty-free research purpose license as
well as an exclusive commercial license within certain territories, as defined in the agreement, to Mabwell&#8217;s series of anti-SARS-CoV-2
monoclonal antibodies. Under the agreement, the Company is responsible for conducting at its sole expense, research and preclinical,
clinical and other developments of any licensed products and bears all development costs and expenses related to obtaining or maintenance
of marketing authorizations of licensed products in its territories. Mabwell is obligated, at the Company&#8217;s request, to supply
the Licensed Antibodies to the Company for clinical trial purpose at costs plus margin as defined in the agreement. The parties agreed
to undertake certain joint clinical research and development activities with a portion of the costs contributed by Mabwell. Unless earlier
terminated, the Mabwell License Agreement will expire on the occurrence of the last to expire royalty term, which is the later of a)
the expiration of the last to expire valid claim of the patent rights and b) ten years from the first commercial sale of such Licensed
Product, and determined on jurisdiction-by-jurisdiction basis. Either party may terminate the agreement in the event of any uncured material
breach by the other party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The agreement provides for development milestones
of up to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:DevelopmentMilestones" scale="3" unitRef="usd" id="ixv-42681">32,500</ix:nonFraction> and annual sales milestone payments of up to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:AnnualSalesMilestonePayments" scale="3" unitRef="usd" id="ixv-42682">50,000</ix:nonFraction> payable by the Company to Mabwell. The agreement also provides
for a profit sharing, with Mabwell sharing <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abp:NetProfitsFromLicensedProductSales" scale="-2" unitRef="pure" id="ixv-42683">50</ix:nonFraction>% of the net profits from the licensed product sales in certain territories as defined in
the agreement. The Company will also make tiered royalty payments in the mid to high single digits on net sales of commercial products
in the licensed territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the three and nine months ended September
30, 2025 and 2024, development activities under the Mabwell collaboration agreement were immaterial to the condensed consolidated financial
statements. No milestones have been reached and no products were sold under the Mabwell License Agreement through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In March 2025, the Company received a draft
of a termination agreement from Mabwell which outlines Mabwell&#8217;s claim for the total payment of $<ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="abp:PaymentOfDevelopmentMilestones" scale="3" unitRef="usd" id="ixv-42684">3,300</ix:nonFraction> under certain development
milestones asserting that these development milestones were achieved by the Company during 2021. The Company does not believe that a
liability under the milestone related provisions invoked by Mabwell was triggered and is planning to engage in discussion with Mabwell
about the validity of their claim. This liability of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedToAmount" scale="3" unitRef="usd" id="ixv-42685"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedToAmount" scale="3" unitRef="usd" id="ixv-42686">3,300</ix:nonFraction></ix:nonFraction> is included in accrued expenses in the condensed consolidated financial statements
as of September 30, 2025 and December 31, 2024.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 177; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><ix:continuation id="_CommitmentsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>MSK License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In March 2017, the Company entered into an
exclusive license agreement with Memorial Sloan Kettering Cancer Center (the &#8220;MSK License Agreement&#8221;), pursuant to which
the Company received an exclusive, royalty-bearing, worldwide license under specified patent rights to make, use and sell certain of
MSK&#8217;s proprietary Her2-huOKT3 bispecific antibodies. The agreement was amended on March 31, 2017, March 31, 2018, and January 1,
2020. Unless earlier terminated in accordance with its terms, the agreement was to remain in effect on a country-by-country basis until
the expiration of the last royalty term in such country as to be determined by the launch of products based on MSK antibodies. On September
19, 2023, MSK License Agreement was terminated by MSK due to the Company&#8217;s failure to make the payments for the patent costs reimbursements
discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under the MSK License Agreement, as amended,
the Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific
antibodies within specified territories and timeframes. The Company was committed to pay MSK up to $<ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePaymentsUponAchievingRDAndCommercializationEvents" scale="3" unitRef="usd" id="ixv-42687">10,500</ix:nonFraction> in milestone payments upon
achieving certain research and development and commercialization events or within a certain number of months of the effective date, up
to $<ix:nonFraction contextRef="c299" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePaymentOnNetSales" scale="3" unitRef="usd" id="ixv-42688">30,000</ix:nonFraction> in milestone payments based on net sales, and tiered mid-single-digit percentage royalties based on annualized net sales of
each product commercialized from the collaboration with guaranteed annual minimum royalties between $<ix:nonFraction contextRef="c287" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-42689">20</ix:nonFraction> and $<ix:nonFraction contextRef="c181" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-42690">30</ix:nonFraction> depending on certain
development events. During the three and nine months ended September 30, 2025 and 2024, the Company did not incur any minimum royalties
or any milestone payments under this agreement. As of both September 30, 2025 and December 31, 2024, the accrued minimum royalty and
milestone payments were $<ix:nonFraction contextRef="c300" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" unitRef="usd" id="ixv-42691"><ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" unitRef="usd" id="ixv-42692">790</ix:nonFraction></ix:nonFraction>, included in accounts payable in the condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company also agreed to reimburse patent
costs for all documented out of pocket costs associated with the preparation, filing, prosecution and maintenance of patent rights in
the license territory. During the three and nine months ended September 30, 2025 and 2024, the Company did not incur any patent reimbursement
costs. As of both September 30, 2025 and December 31, 2024, the liabilities for the patent costs reimbursements were $<ix:nonFraction contextRef="c302" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentCostsReimbursements" scale="3" unitRef="usd" id="ixv-42693"><ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentCostsReimbursements" scale="3" unitRef="usd" id="ixv-42694">273</ix:nonFraction></ix:nonFraction>, included in
accrued expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of both September 30, 2025 and December
31, 2024, the accrued liabilities for the unpaid interest on the outstanding minimum royalty and milestone payments due to MSK were $<ix:nonFraction contextRef="c304" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentCostsReimbursements" scale="3" unitRef="usd" id="ixv-42695"><ix:nonFraction contextRef="c305" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentCostsReimbursements" scale="3" unitRef="usd" id="ixv-42696">169</ix:nonFraction></ix:nonFraction>,
included in accrued expenses. The company has ceased accruing further interest as a result of the termination of the MSK License Agreement.
See Note 8 for discussion of the June 2023 demand letter.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>VAZYME License agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In April 2021, the Company entered into a
License Agreement with VAZYME Biotech Co., Ltd (&#8220;VAZYME&#8221;) (the &#8220;VAZYME License Agreement&#8221;), pursuant to which
the Company was granted an exclusive, perpetual, royalty-bearing, worldwide license under specified patent rights to research, develop
and commercialize VAZYME proprietary anti-SARS-CoV-2 monoclonal antibodies. Unless earlier terminated in accordance with its terms, the
agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under the VAZYME License Agreement, the Company
agreed to use commercially reasonable efforts to reach certain research and development, and commercialization milestones for such antibodies.
The Company also agreed to pay $<ix:nonFraction contextRef="c306" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42697">200</ix:nonFraction> to VAZYME at the effective date of the agreement. The Company is committed to pay VAZYME up to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42698">11,100</ix:nonFraction>
in milestone payments upon achieving certain research and development events, up to $<ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-42699">70,000</ix:nonFraction> in milestone payments based on annual net
sales, and tiered low single-digit percentage royalties based on annualized net sales of each product commercialized from the collaboration.
No milestones in the VAZYME License Agreement have been reached through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In December 2021, the Company entered into
a Cooperation Agreement with Chengdu Bio-Innovate Pharmaceutical Technology Co., Ltd (&#8220;Bio-Innovate&#8221;) and a three-way sharing
agreement with VAZYME and Bio-Innovate (&#8220;the Company&#8221;, &#8220;VAZYME&#8221; and &#8220;Bio-Innovate&#8221;, collectively
&#8220;all parties&#8221;), pursuant to which the Company entrusted Bio-Innovate to perform certain preclinical testing and all parties
agreed that VAZYME will ship the agreed antibodies to Bio-Innovate rather than the Company to fulfill the requirements under the VAZYME
License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For the three and nine months Ended September
30, 2025 and 2024, the Company did not incur any expenses related to the VAZYME License Agreement. As of both September 30, 2025 and
December 31, 2024, the accrued liabilities under this agreement were $<ix:nonFraction contextRef="c307" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42700"><ix:nonFraction contextRef="c308" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42701">200</ix:nonFraction></ix:nonFraction>, included in accounts payable in the condensed consolidated
financial statements.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 178; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-30166"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>8.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Commitments and Contingencies</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Litigation and other matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company, from time to time, is subject
to legal proceedings and claims that arise in the ordinary course of business. Resolution of any such matter could have a material adverse
effect on the results of operations and financial condition. The Company considers all claims on a periodic basis and based on known
facts assesses whether potential losses are considered reasonably possible, probable and estimable. Based upon this assessment, the Company
then evaluates disclosure requirements and whether to accrue for such claims in its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company records a provision for contingent
liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On September 12, 2023, a contract research
organization (&#8220;CRO&#8221;) vendor filed a lawsuit against the Company based on the Company&#8217;s failure to make certain installments
pursuant to a settlement agreement entered into with this vendor on January 23, 2023. Under the settlement agreement, the Company agreed
to pay a total of $<ix:nonFraction contextRef="c309" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLegalSettlements" scale="3" unitRef="usd" id="ixv-42702">1,644</ix:nonFraction> to the vendor, with $<ix:nonFraction contextRef="c310" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLegalSettlements" scale="3" unitRef="usd" id="ixv-42703">600</ix:nonFraction> due <ix:nonNumeric contextRef="c311" format="ixt-sec:durday" name="abp:BusinessDays" id="ixv-42704">5</ix:nonNumeric> business days after the settlement effective date and ten monthly installments,
approximately $<ix:nonFraction contextRef="c311" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLegalSettlements" scale="3" unitRef="usd" id="ixv-42705">104</ix:nonFraction> each, starting in February 2023. The Company made the upfront payment and the first four monthly installments for
a total of $<ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="abp:MonthlyInstallmentPayments" scale="3" unitRef="usd" id="ixv-42706">1,016</ix:nonFraction> but failed to make the monthly installment payments due after May 2023. On January 24, 2024, the Company received endorsement
on motion for default judgment which requested the Company to pay approximately $<ix:nonFraction contextRef="c313" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="3" unitRef="usd" id="ixv-42707">700</ix:nonFraction> to the CRO vendor. During the three and nine months
ended September 30, 2025, the Company accrued an additional $<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="abp:AdditionalAccruedInterest" scale="3" unitRef="usd" id="ixv-42708">21</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:AdditionalAccruedInterest" scale="3" unitRef="usd" id="ixv-42709">63</ix:nonFraction> in interest, respectively, included in interest expense. As of
September 30, 2025 and December 31, 2024, the outstanding balance under this settlement agreement was $<ix:nonFraction contextRef="c314" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SettlementLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42710">848</ix:nonFraction> and $<ix:nonFraction contextRef="c315" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SettlementLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42711">785</ix:nonFraction>, respectively. These
amounts were included in accounts payable and accrued expenses in the condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition to the lawsuit from a CRO vendor
above, the Company accrued $<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42712"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42713">325</ix:nonFraction></ix:nonFraction> as of both September 30, 2025 and December 31, 2024 related to disputed invoices with vendors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In June 2023, the Company received a notice
of breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded payments totaling $<ix:nonFraction contextRef="c316" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnContractTermination" scale="3" unitRef="usd" id="ixv-42714">1,230</ix:nonFraction> for
the services performed under the MSK License Agreement (see Note 7). The corresponding liability is included in accrued expenses in the
condensed consolidated financial statements as of both September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The MedImmune License Agreement (see Note
7) provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement (December 2022). These
target dates were not met, which gives MedImmune (now AstraZeneca) a termination right. The Company does not expect a material impact
on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with the development
of ABP-200, which the Company is no longer developing. The Company believes that it does not need the intellectual property licensed
under that agreement for the development and eventual commercialization of ABP-201 or any of its other programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 17, 2025, the Company received a complaint
from a former director asserting that the Company owes the former director a total of $<ix:nonFraction contextRef="c317" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalFees" scale="3" unitRef="usd" id="ixv-42715">748</ix:nonFraction> for consulting fees, bonuses, and for unpaid
promissory note principal and interest. The principal and interest on the promissory note were $<ix:nonFraction contextRef="c318" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="3" unitRef="usd" id="ixv-42716">176</ix:nonFraction> and $<ix:nonFraction contextRef="c319" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="3" unitRef="usd" id="ixv-42717">9</ix:nonFraction>, respectively, as of September
30, 2025 and December 31, 2024 (see Note 10). The remaining liability of $<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-42718">560</ix:nonFraction> was included in accrued expenses in the condensed consolidated
financial statements as of September 30, 2025. On November 10, 2025, the Suffolk Superior Court in Massachusetts issued a preliminary
injunction prohibiting the transfer of the Company&#8217;s assets outside the ordinary course of business. At this stage, the Company
is unable to evaluate the likelihood of an unfavorable outcome or provide an estimate of the amount or range of potential loss, beyond
the amount already accrued above.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 22, 2025, the Company received
a demand for payment from Integral Molecular, Inc. in the amount of approximately $<ix:nonFraction contextRef="c320" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DemandDepositAccounts" scale="3" unitRef="usd" id="ixv-42719">182</ix:nonFraction>. The Company is currently in negotiations to settle
this claim.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 23, 2025, the Company received
a demand for payment from Brookline Capital Markets, a division of Arcadia Securities LLC, in the amount of $<ix:nonFraction contextRef="c321" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DemandDepositAccounts" scale="3" unitRef="usd" id="ixv-42720">140</ix:nonFraction>. The Company is currently
in negotiations to settle this claim.</span></p></ix:nonNumeric><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 179; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Non-Redemption&#160;Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 5, 2024, Legacy Abpro and ACAB
entered into a&#160;non-redemption&#160;agreement (the&#160;&#8220;Non-Redemption&#160;Agreement&#8221;), with Sandia Investment Management
LP on behalf of certain funds, investors, entities or accounts for which it or its affiliates acts as manager, sponsor or advisor (the
&#8220;NRA Investors&#8221;). Pursuant to such&#160;Non-Redemption&#160;Agreement, each NRA Investor agreed to rescind or reverse any
previously submitted redemption demand of the common stock of the Company held or to be acquired by such NRA Investor (the &#8220;NRA
Investor Shares&#8221;) up to <ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42721">4,145</ix:nonFraction> shares of common stock in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the Closing Date, the NRA Investors reversed
redemption demands with respect to <ix:nonFraction contextRef="c205" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42722">11,043</ix:nonFraction> Series A Common stock shares (pre-split) of ACAB. Pursuant to the Non-Redemption Agreement,
upon consummation of the Merger, the Company had to pay to the NRA Investors a payment equal to the number of NRA Investor Shares multiplied
by the redemption price, minus the number of NRA Investor Shares multiplied by $<ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-42723">9.00</ix:nonFraction> (pre-split). As of September 30, 2025 and December
31, 2024, the Company owed NRA Investors $<ix:nonFraction contextRef="c323" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnitsTotalCostToInvestors" scale="3" unitRef="usd" id="ixv-42724"><ix:nonFraction contextRef="c324" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnitsTotalCostToInvestors" scale="3" unitRef="usd" id="ixv-42725">26</ix:nonFraction></ix:nonFraction>, based on the redemption price of $<ix:nonFraction contextRef="c323" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" unitRef="usdPershares" id="ixv-42726"><ix:nonFraction contextRef="c324" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" unitRef="usdPershares" id="ixv-42727">340.80</ix:nonFraction></ix:nonFraction> at the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Excise Tax Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">At the Closing Date, the Company assumed the
excise tax liability of $<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="abp:ExciseTaxLiability" scale="3" unitRef="usd" id="ixv-42728">4,330</ix:nonFraction>, as adjusted, as discussed further below, from ACAB related to the redemptions of shares in 2023 and calculated
as <ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-42729">1</ix:nonFraction>% of the shares redeemed during fiscal year 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 16, 2022, the Inflation Reduction
Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal <ix:nonFraction contextRef="c325" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-42730">1</ix:nonFraction>%
excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly
traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself,
not its shareholders from which shares are repurchased. The amount of the excise tax is generally <ix:nonFraction contextRef="c326" decimals="2" format="ixt:num-dot-decimal" name="abp:ExciseTaxGenerallyOfTheFairMarketValuePercentage" scale="-2" unitRef="pure" id="ixv-42731">1</ix:nonFraction>% of the fair market value of the
shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are
permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same
taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;)
has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the second quarter of 2024, the Treasury
and Internal Revenue Service (&#8220;IRS&#8221;) issued final regulations with respect to the timing and payment of the excise tax. Pursuant
to those regulations, the Company would need to file a return and remit payment for any liability incurred during the period from January
1, 2023 to December 31, 2023 on or before October 31, 2024. The Company has filed the excise tax return and has engaged with the IRS
in determining a payment plan for the balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company is unable to pay its obligation
in full, and, as such, it is subject to additional interest and penalties which are currently estimated at <ix:nonFraction contextRef="c327" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate" scale="-2" unitRef="pure" id="ixv-42732">8</ix:nonFraction>% interest per annum and
a <ix:nonFraction contextRef="c327" decimals="3" format="ixt:num-dot-decimal" name="abp:PercentageOfUnderpaymentPenaltyPerMonth" scale="-2" unitRef="pure" id="ixv-42733">0.5</ix:nonFraction>% underpayment penalty per month or portion of a month up to <ix:nonFraction contextRef="c327" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfLiabilityTotal" scale="-2" unitRef="pure" id="ixv-42734">25</ix:nonFraction>% of the total liability for any amount that is unpaid from November
1, 2024 until paid in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In March 2025, the Company received the letter
from the IRS, requesting to set up a meeting with the Company to discuss the unsettled tax matters of ACAB and referencing $<ix:nonFraction contextRef="c328" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ExciseAndSalesTaxes" scale="3" unitRef="usd" id="ixv-42735">4,401</ix:nonFraction> amount
owed in relation to the 2023 excise taxes, of which $<ix:nonFraction contextRef="c328" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExaminationInterestExpense" scale="3" unitRef="usd" id="ixv-42736">210</ix:nonFraction> was in interest and penalties (the &#8220;IRS Letter&#8221;). The Company believes
that the excise tax liability in the IRS Letter is overstated as compared to the amounts in ACAB&#8217;s filed tax return for the year
ended December 31, 2023. Pending further discussions with the IRS, the Company recorded the excess of $<ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="abp:ExcessTaxes" scale="3" unitRef="usd" id="ixv-42737">1,268</ix:nonFraction> over the Company&#8217;s
estimate of $<ix:nonFraction contextRef="c62" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" scale="3" unitRef="usd" id="ixv-42738">3,133</ix:nonFraction> (inclusive of interest and penalties) as the additional excise tax liability assumed from ACAB at the Closing Date.
As of September 30, 2025, the Company recorded the excess of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentCompanyExcessExpenseReimbursable" scale="3" unitRef="usd" id="ixv-42739">946</ix:nonFraction> over the Company&#8217;s estimate of $<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="3" unitRef="usd" id="ixv-42740">3,455</ix:nonFraction> (inclusive of interest
and penalties) as the additional excise tax liability. As a result, management has not accrued any further interest or penalties on this
amount.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 180; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="ixv-30292"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>9.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Forward Purchase Agreement</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 7, 2024, ACAB and Legacy Abpro
entered into a Confirmation of an OTC Equity Prepaid Forward Transaction (the &#8220;Forward Purchase Agreement&#8221; or &#8220;Transaction&#8221;)
with YA (the &#8220;Seller&#8221;) to which a maximum of up to <ix:nonFraction contextRef="c329" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToIssuersEquityShares" scale="0" unitRef="shares" id="ixv-42741">16,667</ix:nonFraction> common stock shares were subject to the Transaction. At the Closing
Date, the Seller purchased <ix:nonFraction contextRef="c330" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" scale="0" unitRef="shares" id="ixv-42742">3,333</ix:nonFraction> shares from third parties (&#8220;Recycled Shares&#8221;), pursuant to the pricing date notice dated
November 12, 2024, and paid approximately $<ix:nonFraction contextRef="c330" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidRoyalties" scale="3" unitRef="usd" id="ixv-42743">1,100</ix:nonFraction> (the &#8220;Prepayment Amount&#8221;) to the redeeming shareholders. Pursuant to the
terms of the Forward Purchase Agreement, at the Closing Date, the Company remitted the Prepayment Amount into an escrow account for the
benefit of the Seller.<i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 28, 2025, YA elected to effect
an Optional Early Termination (as described in the Forward Purchase Agreement) with respect to all <ix:nonFraction contextRef="c331" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" scale="0" unitRef="shares" id="ixv-42744">3,333</ix:nonFraction> shares subject to the Forward
Purchase Agreement which terminated the agreement as a whole. YA paid the Company the Early Termination Obligation in the aggregate amount
of $<ix:nonFraction contextRef="c332" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnContractTermination" scale="3" unitRef="usd" id="ixv-42745">132</ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Forward Purchase Agreement was accounted
for at fair value as an asset in accordance with the guidance in ASC Topic 815 Derivatives and Hedging (&#8220;ASC 815&#8221;), with
subsequent changes in the fair value recorded in profits and losses. The fair value of the Forward Purchase Agreement asset was $<ix:nonFraction contextRef="c333" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-42746">494</ix:nonFraction>,
$<ix:nonFraction contextRef="c334" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-42747">155</ix:nonFraction> and $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-42748">132</ix:nonFraction> as of November 13, 2024, December 31, 2024 and the settlement date, respectively. The Company recorded losses on the change
in the fair value of $<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="abp:DerivativeChangeInFairValue" scale="3" unitRef="usd" id="ixv-42749">0</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:DerivativeChangeInFairValue" scale="3" unitRef="usd" id="ixv-42750">23</ix:nonFraction> in other (expense) income for the three and nine months ended September 30, 2025, respectively.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-30318"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>10.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Notes Payable</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true"><span style="text-decoration:underline">Note Payable</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In January 2025, the Company entered into
an insurance premium financing agreement and borrowed a total principal amount of $<ix:nonFraction contextRef="c335" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-42751">553</ix:nonFraction>. The note bore an annual interest rate of <ix:nonFraction contextRef="c336" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42752">7.74</ix:nonFraction>%
and matured in September 2025. The interest expense on the note amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-42753">21</ix:nonFraction> for the nine months ended September 30, 2025. The note
was paid in full prior to September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true"><span style="text-decoration:underline">Notes Payable &#8211; Related Parties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Promissory Note with ABI</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 18, 2023, the Company entered into
a promissory note agreement with ABI, a significant investor in the Company, to receive up to $<ix:nonFraction contextRef="c337" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-42754">6,000</ix:nonFraction>. The promissory note accrued interest
at a rate of <ix:nonFraction contextRef="c338" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42755">5</ix:nonFraction>% per annum on the principal amount of each installment from the installment funding date until the maturity date and at
a rate of <ix:nonFraction contextRef="c339" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42756">7</ix:nonFraction>% per annum after the maturity date if any amounts then remain outstanding. The &#8220;Maturity Date&#8221; was defined in
the agreement as the earlier of (i) eighteen months from the funding date and (ii) the successful closing of the Merger. On August 22,
2024, ACAB entered into the Abpro Bio Subscription Agreement (see Note 3) with ABI, pursuant to which ABI purchased <ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42757">20,749</ix:nonFraction> shares of
the Company&#8217;s common stock, concurrently with the closing of the Merger at a price of $<ix:nonFraction contextRef="c341" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-42758">300.00</ix:nonFraction> per share, for an aggregate purchase
price of $<ix:nonFraction contextRef="c340" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-42759">6,225</ix:nonFraction>, of which $<ix:nonFraction contextRef="c340" decimals="-3" format="ixt:num-dot-decimal" name="abp:ConversionOfConsiderationUnderPromissoryNoteAgreement" scale="3" unitRef="usd" id="ixv-42760">4,225</ix:nonFraction> was paid through the conversion of the balance due by the Company to ABI under the promissory note agreement
and the remainder of $<ix:nonFraction contextRef="c341" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-42761">2,000</ix:nonFraction> in cash. In addition, ABI received an aggregate of <ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="abp:IncentiveSharesReceivedBySubsidiary" scale="0" unitRef="shares" id="ixv-42762">41,498</ix:nonFraction> Incentive Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 7, 2024, the Company entered into
an additional promissory note with ABI (&#8220;the 2024 ABI Note&#8221;) to receive up to $<ix:nonFraction contextRef="c342" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-42763">1,000</ix:nonFraction> from ABI in weekly installments of $<ix:nonFraction contextRef="c343" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" unitRef="usd" id="ixv-42764">250</ix:nonFraction>.
The note accrued <ix:nonFraction contextRef="c343" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42765">10</ix:nonFraction>% interest and had a maturity date 5 business days after receipt of the proceeds under the PIPE Financing (see Note
3). The Company received $<ix:nonFraction contextRef="c343" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-42766">1,000</ix:nonFraction> under this note through the Closing Date, and the balance of $<ix:nonFraction contextRef="c343" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd" id="ixv-42767">1,000</ix:nonFraction> was repaid at the Closing from the
PIPE Financing proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of both September 30, 2025 and December
31, 2024, the outstanding principal balances under the promissory notes with ABI was $<ix:nonFraction contextRef="c344" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-42768"><ix:nonFraction contextRef="c345" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-42769">0</ix:nonFraction></ix:nonFraction>. During both the three and nine months ended
September 30, 2025, the Company recorded $<ix:nonFraction contextRef="c346" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-42770"><ix:nonFraction contextRef="c209" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-42771">0</ix:nonFraction></ix:nonFraction> of interest expense on these promissory notes with ABI. During the three and nine months
ended September 30, 2024, the Company recorded $<ix:nonFraction contextRef="c347" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-42772">53</ix:nonFraction> and $<ix:nonFraction contextRef="c348" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-42773">142</ix:nonFraction>, respectively, of interest expense on these promissory notes with ABI. As
of both September 30, 2025 and December 31, 2024, accrued interest totaling $<ix:nonFraction contextRef="c344" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42774"><ix:nonFraction contextRef="c345" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42775">191</ix:nonFraction></ix:nonFraction> was included in accrued expenses in the condensed consolidated
balance sheets.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 181; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Promissory Notes with Executive and Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On December 29, 2023, the Company issued promissory
notes to one of its executives and one of its directors, in the principal amount of $<ix:nonFraction contextRef="c349" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="3" unitRef="usd" id="ixv-42776">176</ix:nonFraction> and $<ix:nonFraction contextRef="c350" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="3" unitRef="usd" id="ixv-42777">124</ix:nonFraction>, respectively, for deferred bonuses.
Amounts under the promissory notes plus accrued interest are due and payable on the earlier of (i) the closing of the Merger and (ii)
June 29, 2025. These promissory notes accrued interest at <ix:nonFraction contextRef="c351" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42778">5</ix:nonFraction>% per annum until the maturity date and <ix:nonFraction contextRef="c352" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42779">7</ix:nonFraction>% thereafter. At the Closing Date,
the Company paid $<ix:nonFraction contextRef="c353" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd" id="ixv-42780">150</ix:nonFraction> towards these promissory notes. As of both September 30, 2025 and December 31, 2024, $<ix:nonFraction contextRef="c354" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-42781"><ix:nonFraction contextRef="c355" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-42782">150</ix:nonFraction></ix:nonFraction> of principal was outstanding.
Interest expense on these promissory notes totaled $<ix:nonFraction contextRef="c356" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-42783">2</ix:nonFraction> and $<ix:nonFraction contextRef="c357" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-42784">6</ix:nonFraction> for the three and nine months ended September 30, 2025, respectively, included
in interest expense in the condensed consolidated statement of operations. Interest expense on these promissory notes totaled $<ix:nonFraction contextRef="c358" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-42785">4</ix:nonFraction> and
$<ix:nonFraction contextRef="c359" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitRef="usd" id="ixv-42786">11</ix:nonFraction> for the three and nine months ended September 30, 2024, respectively, included in interest expense in the condensed consolidated
statement of operations. Accrued interest on these promissory notes totaled $<ix:nonFraction contextRef="c354" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42787">20</ix:nonFraction> and $<ix:nonFraction contextRef="c355" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42788">14</ix:nonFraction> as of September 30, 2025 and December 31, 2024,
respectively, included in accrued expenses in the condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 18, 2024, the Company entered into
a separate promissory note agreement with the same executive to receive, as amended, up to $<ix:nonFraction contextRef="c360" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-42789">2,158</ix:nonFraction> in funding. During the year ended December
31, 2024, the Company received $<ix:nonFraction contextRef="c361" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-42790">1,997</ix:nonFraction> from the executive under this agreement. These advances accrued interest at <ix:nonFraction contextRef="c362" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42791">7.5</ix:nonFraction>% per annum through
the maturity date and at <ix:nonFraction contextRef="c363" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42792">9.5</ix:nonFraction>% per annum after the maturity date if any amounts then remain outstanding. All advances, plus accrued interest,
were due and payable on the earlier of (i) the closing of the Merger and (ii) November 20, 2024. At the Closing, the outstanding promissory
notes of $<ix:nonFraction contextRef="c364" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-42793">1,997</ix:nonFraction> were converted into <ix:nonFraction contextRef="c365" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-42794">20,000</ix:nonFraction> newly issued common stock shares. Accrued interest on these promissory notes totaled $<ix:nonFraction contextRef="c366" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42795"><ix:nonFraction contextRef="c367" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-42796">62</ix:nonFraction></ix:nonFraction> as
of both September 30, 2025 and December 31, 2024, respectively, included in accrued expenses in the condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Pursuant to the terms of the promissory note
from April 18, 2024, the Company agreed to cause to be issued to the executive a number of New Abpro stock options or warrants in an
amount equal to the outstanding principal amount of such promissory note, subject to required approval by the New Abpro Board of Directors
(&#8220;BOD&#8221;) and Compensation Committee and registration of such securities on Form S-8. On February 7, 2025, the Company issued
<ix:nonFraction contextRef="c368" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42797">28,333</ix:nonFraction> common stock warrants to the executive (the &#8220;Executive Warrants&#8221;). The Executive Warrants are exercisable at $<ix:nonFraction contextRef="c369" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-42798">99.90</ix:nonFraction>
per share and bear an expiration date of <ix:nonNumeric contextRef="c370" format="ixt:date-monthname-day-year-en" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="ixv-42799">February 7, 2035</ix:nonNumeric>. <ix:nonFraction contextRef="c371" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42800">14,166</ix:nonFraction> of the Executive Warrants are exercisable on the issuance date, <ix:nonFraction contextRef="c372" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42801">6,667</ix:nonFraction>
warrants become exercisable on the one-year anniversary of the issuance date, and <ix:nonFraction contextRef="c373" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42802">7,500</ix:nonFraction> warrants become exercisable on the two-year anniversary
of the issuance date. The warrants were fair valued and immediately expensed at the issuance date as an additional interest expense related
to the promissory note. The fair value of the Executive Warrants at the issuance date was determined using the Black-Scholes option pricing
model based on the following assumptions: (a) fair value of common stock of $<span style="-sec-ix-hidden: hidden-fact-418"><ix:nonFraction contextRef="c374" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42803">32.10</ix:nonFraction></span>&#160;per share, (b) expected volatility of&#160;<ix:nonFraction contextRef="c376" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42804">90.00</ix:nonFraction>%,
(c) dividend yield of&#160;<ix:nonFraction contextRef="c377" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42805">0</ix:nonFraction>%, (d) risk-free interest rate of&#160;<ix:nonFraction contextRef="c378" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" unitRef="pure" id="ixv-42806">4.49</ix:nonFraction>%, and (e) expected life of&#160;10&#160;years. For the three
and nine months ended September 30, 2025, the Company recognized $<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="abp:AdditionalInterestExpense" scale="3" unitRef="usd" id="ixv-42807">0</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="abp:AdditionalInterestExpense" scale="3" unitRef="usd" id="ixv-42808">714</ix:nonFraction>, respectively, of additional interest expense related to
the Executive Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Promissory Note with ACAB Executive</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On August 16, 2024, an executive at ACAB agreed
to loan Legacy Abpro $<ix:nonFraction contextRef="c379" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-42809">103</ix:nonFraction> under a promissory note (the &#8220;ACAB Executive Note&#8221;). The ACAB Executive Note did not accrue interest
and the Company agreed to repay a total of $<ix:nonFraction contextRef="c380" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd" id="ixv-42810">206</ix:nonFraction> at the earlier of i) November 20, 2024, and ii) the closing of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 21, 2024, the ACAB Executive Note
was amended to clarify that it should have been between Legacy Abpro as borrower and ACAB as lender. Pursuant to the Severance Agreement
(see Note 15), the liability to the ACAB executive was cancelled. According to the terms of the amended note, Legacy Abpro was to repay
the principal amount of $<ix:nonFraction contextRef="c381" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepaidPrincipal" scale="3" unitRef="usd" id="ixv-42811">103</ix:nonFraction>. The amended note did not bear interest and was payable upon demand on or before December 31, 2024. The
note balance has not been repaid and was eliminated in consolidation at September 30, 2025 and December 31, 2024.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="abp_StandbyEquityPurchaseAgreementTextBlock-c0_cont_1" escape="true" name="abp:StandbyEquityPurchaseAgreementTextBlock" id="ixv-30406"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>11.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Standby Equity Purchase Agreement</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October&#160;30, 2024, Legacy Abpro and
ACAB entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd. (&#8220;YA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Subject to the satisfaction of the conditions
set forth in the SEPA, YA committed to advance to the Company the aggregate principal amount of up to $<ix:nonFraction contextRef="c382" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-42812">5,000</ix:nonFraction> (the&#160;&#8220;Pre-Paid&#160;Advance&#8221;),
which shall be evidenced by convertible promissory notes (each a &#8220;Convertible Note&#8221;). On November 14, 2024, the Company received
the first Pre-Paid Advance and entered into a Convertible Note (defined below). The second&#160;Pre-Paid&#160;Advance was to be in a
principal amount of $<ix:nonFraction contextRef="c383" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-42813">2,000</ix:nonFraction> and advanced on the later of (i)&#160;the second trading day after the initial registration statement filed
pursuant to the Registration Rights Agreement (as defined below) becomes effective and (ii)&#160;the second trading day after the required
shareholder approval to issue shares of the post-combination Company&#8217;s common stock in excess of <ix:nonFraction contextRef="c383" decimals="2" format="ixt:num-dot-decimal" name="abp:ExcessOfCommonStockPercentage" scale="-2" unitRef="pure" id="ixv-42814">20</ix:nonFraction>% of the Company&#8217;s outstanding
shares pursuant to Nasdaq Rules (the &#8220;Exchange Cap&#8221;) has been obtained. At the special meeting of stockholders held on April
8, 2025, the Company obtained stockholder approval for the issuance of shares over the Exchange Cap.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 182; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="abp_StandbyEquityPurchaseAgreementTextBlock-c0_cont_2" id="abp_StandbyEquityPurchaseAgreementTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 14, 2024 (the &#8220;First Convertible
Note Issuance Date&#8221;), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the &#8220;First Convertible
Note&#8221;) with YA for $<ix:nonFraction contextRef="c383" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="3" unitRef="usd" id="ixv-42815">3,000</ix:nonFraction> and received net proceeds of $<ix:nonFraction contextRef="c384" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-42816">2,755</ix:nonFraction>, net of the original issuance discount of <ix:nonFraction contextRef="c385" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-42817">8</ix:nonFraction>% (the &#8220;Convertible
Note Discount&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On June 23, 2025 (the &#8220;Second Convertible
Note Issuance Date&#8221;), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the &#8220;Second Convertible
Note&#8221; and together with the First Convertible Note, the &#8220;Convertible Notes&#8221;) with YA for $<ix:nonFraction contextRef="c386" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="3" unitRef="usd" id="ixv-42818">2,000</ix:nonFraction> and received net proceeds
of $<ix:nonFraction contextRef="c387" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfDebt" scale="3" unitRef="usd" id="ixv-42819">1,840</ix:nonFraction>, net of the Convertible Note Discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Convertible Notes have a maturity date
of <ix:nonNumeric contextRef="c388" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-42820">November 13, 2025</ix:nonNumeric> (subject to earlier repayments based on Amortization Event described below) and incur interest at a rate of <ix:nonFraction contextRef="c388" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42821">0</ix:nonFraction>% (or
<ix:nonFraction contextRef="c389" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-42822">18</ix:nonFraction>% upon the occurrence of an uncured Event of Default).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Convertible Notes are convertible at the
option of the holder at any time after the issuance dates based on the conversion price determined as the lower of (i) $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-42823">345.00</ix:nonFraction> per Common
Share (the &#8220;Fixed Price&#8221;), or (ii) <ix:nonFraction contextRef="c390" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfVolumeWeightedAveragePrice" scale="-2" unitRef="pure" id="ixv-42824">94</ix:nonFraction>% of the lowest daily VWAP during the <ix:nonNumeric contextRef="c391" format="ixt-sec:durday" name="abp:ConvertibleThresholdConsecutiveTradingDays" id="ixv-42825">5</ix:nonNumeric> consecutive trading days immediately preceding
the conversion date (the &#8220;Variable Price&#8221;), but which Variable Price shall not be lower than the Floor Price then in effect
(the &#8220;Conversion Feature&#8221;). The Floor Price at the First Issuance Date was $<ix:nonFraction contextRef="c392" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-42826">34.62</ix:nonFraction> per share calculated as <ix:nonFraction contextRef="c393" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfClosingPrice" scale="-2" unitRef="pure" id="ixv-42827">20</ix:nonFraction>% of the closing
price of the Company&#8217;s stock on November 12, 2024. The Floor Price was adjusted downward to $<ix:nonFraction contextRef="c394" decimals="2" format="ixt:num-dot-decimal" name="abp:FloorPrice" scale="0" unitRef="usdPershares" id="ixv-42828">5.70</ix:nonFraction> per share on February 12, 2025
when the initial registration statement was declared effective by the SEC. On April 29, 2025, in accordance with the terms of the Convertible
Promissory Note, the Company reduced the Floor Price down to $<ix:nonFraction contextRef="c395" decimals="2" format="ixt:num-dot-decimal" name="abp:FloorPrice" scale="0" unitRef="usdPershares" id="ixv-42829">4.50</ix:nonFraction> per share. The conversion is subject to the limitations including
beneficial ownership limitation, principal market limitation and monthly conversion limits. If the Company, at any time while the Convertible
Note is outstanding, shall issue any Common Shares (other than pursuant to the SEPA) for no consideration or for a price per share that
is lower than the Fixed Price then in effect, the Fixed Price shall be reduced to equal the lowest price per share of such issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 20, 2025, the Company entered into
an amendment to SEPA with YA, pursuant to which, the definition of the conversion price was amended to state that the Fixed Price should
be adjusted (downwards only) to equal the VWAP of the Common Shares over the three (3) Trading Days immediately preceding the 20th Trading
Day following the Issuance Date if such price is lower than the initial Fixed Price. As a result, at the amendment date, the Fixed Price
was reset down to $<ix:nonFraction contextRef="c396" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-42830">50.40</ix:nonFraction> per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Convertible Notes were redeemable at the
option of the Company if the volume-weighted-average price (&#8220;VWAP&#8221;) of the Company&#8217;s Common Stock was less than $<ix:nonFraction contextRef="c397" decimals="2" format="ixt:num-dot-decimal" name="abp:VolumeWeightedAveragePrice" scale="0" unitRef="usdPershares" id="ixv-42831">345.00</ix:nonFraction>
which may be adjusted downward upon payment of stock dividend, stock split or reclassification, or if the Company issued common stock
for no consideration or at a price lower than the then-effective Fixed Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under the terms of the Convertible Notes,
the Amortization Event was to be occur if i) the daily VWAP is less than the Floor Price for <ix:nonNumeric contextRef="c398" continuedAt="abp_ConvertibleThresholdConsecutiveTradingDays-c398_cont_1" format="ixt-sec:durwordsen" name="abp:ConvertibleThresholdConsecutiveTradingDays" id="ixv-42832">five</ix:nonNumeric> trading<ix:continuation id="abp_ConvertibleThresholdConsecutiveTradingDays-c398_cont_1"> days</ix:continuation> during a period of <ix:nonNumeric contextRef="c399" continuedAt="abp_ConvertibleThresholdConsecutiveTradingDays-c399_cont_1" format="ixt-sec:durwordsen" name="abp:ConvertibleThresholdConsecutiveTradingDays" id="ixv-42834">seven</ix:nonNumeric>
consecutive trading<ix:continuation id="abp_ConvertibleThresholdConsecutiveTradingDays-c399_cont_1"> days</ix:continuation> (a &#8220;Floor Price Event&#8221;), (ii) unless the Company has obtained the approval from its stockholders
for the issuance of shares pursuant to the transactions contemplated in the SEPA in excess of the Exchange Cap, the Company has issued
in excess of <ix:nonFraction contextRef="c400" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStock" scale="-2" unitRef="pure" id="ixv-42836">99</ix:nonFraction>% of the Common Shares available under the Exchange Cap (an &#8220;Exchange Cap Event&#8221;), or (iii) any time after
the Effectiveness Deadline (as defined in the Registration Rights Agreement entered into in relation to the SEPA), YA was unable to utilize
a Registration Statement to resell Underlying Shares for a period of <ix:nonNumeric contextRef="c401" format="ixt-sec:durday" name="abp:ConvertibleThresholdConsecutiveTradingDays" id="ixv-42837">10</ix:nonNumeric> consecutive trading days (a &#8220;Registration Event&#8221;).
If at any time after the Issuance Date, and from time to time thereafter, an Amortization Event was to occur, then the Company had to
make monthly payments beginning on the 7th trading day after the Amortization Event Date and continuing on the same day of each successive
month. Each monthly payment had to be in an amount equal to the sum of (i) $<ix:nonFraction contextRef="c1" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-42838">1,250</ix:nonFraction> of principal in the aggregate among the Convertible
Note (or the outstanding principal if less than such amount) (the &#8220;Amortization Principal Amount&#8221;), plus (ii) the payment
premium equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAmortizationPrincipalAmount" scale="-2" unitRef="pure" id="ixv-42839">5</ix:nonFraction>% of the Amortization Principal Amount, and (iii) accrued and unpaid interest hereunder as of each payment date. The
obligation of the Company to make monthly prepayments related to an Amortization Event was to be cease (with respect to any payment that
has not yet come due) if any time after the Amortization Date (A) in the event of a Floor Price Event, on the date that was the 7th consecutive
trading day that the daily VWAP was greater than the Floor Price then in effect, or the date that the Company reduces the Floor Price
in accordance with the terms of this Note, (B) in the event of a Registration Event, the condition or event causing the Registration
Event has been cured or the Holder was able to resell the Common Shares issuable upon conversion of this Note without limitations in
accordance with Rule 144 under the Securities Act, or (C) in the event of an Exchange Cap Event, the date the Company has obtained stockholder
approval to increase the number of Common Shares under the Exchange Cap and/or the Exchange Cap no longer applied, unless a subsequent
Amortization Event occurs. No Amortization Events occurred from the Note Issuance Dates through the date the Convertible Notes were converted
into common stock shares as discussed below.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 183; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="abp_StandbyEquityPurchaseAgreementTextBlock-c0_cont_3" id="abp_StandbyEquityPurchaseAgreementTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">It was determined, in accordance with ASC
815, that the Conversion Feature is required to be bifurcated due to the adjustments to the settlement amount of this embedded feature
that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares, and should be recorded as
a liability (the &#8220;Embedded Derivative Liability&#8221;) at fair value with a corresponding amount recorded as a discount on the
Convertible Notes. The Embedded Derivative Liability is marked to market at each reporting period end with any changes recorded in other
income or expense. The fair value of the Embedded Derivative Liability associated with the First Convertible Note was estimated at $<ix:nonFraction contextRef="c402" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-42840">69</ix:nonFraction>
at the issuance date based on the difference between the fair value of the convertible note with these embedded features and the fair
value without each one of these embedded features. The fair value of the Embedded Derivative Liability associated with the Second Convertible
Note was estimated at $<ix:nonFraction contextRef="c403" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-42841">93</ix:nonFraction> at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the second quarter of 2025, the First
Convertible note was fully converted at the option of YA into an aggregate of <ix:nonFraction contextRef="c404" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-42842">513,981</ix:nonFraction> Common stock shares. During the third quarter of
2025, the Second Convertible note was fully converted at the option of YA into an aggregate of <ix:nonFraction contextRef="c405" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" unitRef="shares" id="ixv-42843">367,491</ix:nonFraction> Common stock shares. At each of
the conversion dates, the Company calculated the fair value of the Embedded Derivative Liability associated with the converted portion
of the Convertible Note based on the difference between the fair value of the common stock shares issued upon conversion and the outstanding
note balance, resulting in the total loss on the change in the fair value of $<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueEmbeddedDerivativeLiability" scale="3" sign="-" unitRef="usd" id="ixv-42844">150</ix:nonFraction> and $<ix:nonFraction contextRef="c406" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueEmbeddedDerivativeLiability" scale="3" unitRef="usd" id="ixv-42845">773</ix:nonFraction> for the three and nine months ended September
30, 2025. The difference between (a) the carrying amount of the First Convertible Note and the fair value of the related Embedded Derivative
Liability at the conversion date, and (b) the fair value of the shares issued was $<ix:nonFraction contextRef="c407" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd" id="ixv-42846">144</ix:nonFraction> and was recorded to other (expense) income as
a loss on the settlement of the convertible notes during the second quarter of 2025. The difference between (a) the carrying amount of
the Second Convertible Note and the fair value of the related Embedded Derivative Liability at the conversion date, and (b) the fair
value of the shares issued was $<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd" id="ixv-42847">214</ix:nonFraction> and was recorded to other (expense) income as a loss on the settlement of the convertible notes during
the third quarter of 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The total discount resulting from the Convertible
Note Discount and the bifurcation of the Embedded Derivative Liability at the issuance dates was amortized over the terms of the Convertible
Notes through non-cash interest expense using the effective interest method. The non-cash interest expense related to the discount amortization
was $<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" scale="3" unitRef="usd" id="ixv-42848">27</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" scale="3" unitRef="usd" id="ixv-42849">160</ix:nonFraction> for the three and nine months ended September 30, 2025, respectively, and was included in interest expense in the condensed
consolidated statement of operations.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-keep: true">SEPA Put Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under the terms of the SEPA, starting at the
Closing Date, the Company has the right, but not the obligation (&#8220;SEPA Put Rights&#8221;), to issue shares of its common stock
to YA (&#8220;Advance Shares&#8221;, and such issuance and sale, an &#8220;Advance&#8221;) and YA shall subscribe for and purchase from
the Company such Advance Shares, through written notice by the Company to YA (&#8220;Advance Notice&#8221;), provided (i)&#160;no balance
is outstanding under a Convertible Note, or (ii)&#160;if there is a balance outstanding under a Convertible Note, an Amortization Event
(as defined above), has occurred in accordance with and subject to the terms of the SEPA. The SEPA contemplates purchase by YA of up
to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromPreviousAcquisition" scale="3" unitRef="usd" id="ixv-42850">50,000</ix:nonFraction> in aggregate gross purchase price for newly issued shares of the Company&#8217;s common stock. If any amount remains outstanding
under a Convertible Note, without the prior written consent of YA, the Company may only (other than with respect to a deemed Advance
Notice pursuant to an Investor Notice (described below)) submit an Advance Notice (A) if an Amortization Event has occurred and the obligation
of the Company to make monthly prepayments under the Convertible Note has not ceased, and (B)&#160;YA pays the aggregate purchase price
owed by the Company from such Advance by offsetting the amount of the Advance Proceeds against an equal amount outstanding under the
subject Convertible Note. Any such sales would be subject to certain limitations, including that YA could not purchase any shares that
would result in it owning more than <ix:nonFraction contextRef="c1" decimals="4" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStock" scale="-2" unitRef="pure" id="ixv-42851">4.99</ix:nonFraction>% of the Company&#8217;s common stock, or any shares that, aggregated with any related transaction,
would exceed <ix:nonFraction contextRef="c1" decimals="3" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStockOutstanding" scale="-2" unitRef="pure" id="ixv-42852">19.9</ix:nonFraction>% of all shares of common stock outstanding on the date of the SEPA unless shareholder approval was obtained allowing
for issuances in excess of such amount.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 184; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="abp_StandbyEquityPurchaseAgreementTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">For as long as there was an outstanding balance
under a Convertible Note, YA had the right, but not the obligation, by delivery to the Company of Investor Notices (as defined in the
SEPA), to cause an Advance Notice to be deemed delivered by YA, which triggers the issuance and sale of Advance Shares to YA, subject
to terms and conditions as specified in the SEPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The purchase price for the Advance Shares
shall be the price per Advance Share obtained by multiplying the Company&#8217;s stock price (i)&#160;by <ix:nonFraction contextRef="c287" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAdvanceNotice" scale="-2" unitRef="pure" id="ixv-42853">96</ix:nonFraction>% in respect of an Advance
Notice delivered by the Company with an Option 1 Pricing Period (defined by reference to VWAP on the trading day the Advance Notice is
submitted), (ii) <ix:nonFraction contextRef="c181" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAdvanceNotice" scale="-2" unitRef="pure" id="ixv-42854">97</ix:nonFraction>% in respect of an Advance Notice with an Option 2 Pricing Period (defined by reference to the lowest daily VWAP on
<ix:nonNumeric contextRef="c1" continuedAt="abp_ConvertibleThresholdConsecutiveTradingDays-c1_cont_1" format="ixt-sec:durwordsen" name="abp:ConvertibleThresholdConsecutiveTradingDays" id="ixv-42855">three</ix:nonNumeric> consecutive trading<ix:continuation id="abp_ConvertibleThresholdConsecutiveTradingDays-c1_cont_1"> days</ix:continuation> commencing on the Advance Notice Date), or (iii)&#160;in the case of any Advance Notice delivered pursuant
to an Investor Notice, equal to the Conversion Price (as defined in the Convertible Note).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company accounted for the SEPA Put Rights
as an asset at fair value in accordance with the guidance in ASC 815, due to the adjustments to the settlement amount of this derivative
instrument that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares. The fair value
of the SEPA Put Rights was $<ix:nonFraction contextRef="c408" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-42857">243</ix:nonFraction> and $<ix:nonFraction contextRef="c409" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-42858">188</ix:nonFraction> as of September 30, 2025 and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As consideration for YA&#8217;s commitment
to purchase shares of common stock, upon execution of the SEPA, the Company engaged to remit YA the commitment fee of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" scale="3" unitRef="usd" id="ixv-42859">500</ix:nonFraction>. In December
2024, the Company issued to YA <ix:nonFraction contextRef="c410" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42860">9,905</ix:nonFraction> shares of common stock in settlement of the commitment fee obligation. The fair value of the shares
issued to YA was $<ix:nonFraction contextRef="c411" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-42861">327</ix:nonFraction> at their issuance date and the difference of $<ix:nonFraction contextRef="c412" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" unitRef="usd" id="ixv-42862">173</ix:nonFraction> was recorded as a gain on extinguishment of accrued liabilities
in the fourth quarter of 2024. The excess of the fair value of the SEPA Put Rights above the commitment fee at the issuance date of $<ix:nonFraction contextRef="c412" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCommitmentFeeAmount" scale="3" unitRef="usd" id="ixv-42863">1,051</ix:nonFraction>
was included in the change in fair value of SEPA Put Rights in the consolidated statement of operations in the fourth quarter of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In July and August 2025, the Company issued
three Advance Notices to YA in accordance with the terms of the SEPA, under which YA purchased from the Company <ix:nonFraction contextRef="c102" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42864">91,336</ix:nonFraction> common stock shares,
raising $<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-42865">688</ix:nonFraction> in total net proceeds.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-30547"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>12.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Stockholders&#8217; Equity</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Convertible Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of December 31, 2023, and immediately prior
to the Closing Date, Legacy Abpro&#8217;s amended and restated articles of incorporation authorized the issuance of up to <ix:nonFraction contextRef="c413" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-42866">40,000,000</ix:nonFraction>
shares of common stock and up to <ix:nonFraction contextRef="c414" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-42867">11,620,248</ix:nonFraction> shares of preferred stock. Legacy Abpro&#8217;s Certificate of Incorporation, as amended,
authorizes the issuance of Series A Redeemable Convertible Preferred Stock (&#8220;Series A&#8221;), Series B Convertible Preferred Stock
(&#8220;Series B&#8221;), Series C Convertible Preferred Stock (&#8220;Series C&#8221;), Series D Convertible Preferred Stock (&#8220;Series
D&#8221;), Series E Convertible Preferred Stock (&#8220;Series E&#8221;) and Series F Convertible Preferred Stock (&#8220;Series F&#8221;),
collectively referred to as &#8220;Convertible Preferred Stock&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In connection with the Merger, all previously
issued and outstanding Convertible Preferred Stock was converted into the aggregate number of shares of New Abpro&#8217;s common stock
that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately
prior to the effective time, multiplied by the exchange ratio of approximately&#160;<ix:nonFraction contextRef="c415" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-42868">0.068</ix:nonFraction>, and the remaining amount was reclassified
to additional paid-in capital.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 185; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Common and Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In connection with the Closing, the Company&#8217;s
articles of incorporation were amended to designate two classes of stock; preferred and common stock. The articles of incorporation of
New Abpro authorize <ix:nonFraction contextRef="c193" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-42869">1,000,000</ix:nonFraction> shares of preferred stock and <ix:nonFraction contextRef="c1" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-42870">110,000,000</ix:nonFraction> shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company&#8217;s Amended and Restated Certificate
of Incorporation (and Certificate of Amendment, as referenced in Note 1) provides the Company&#8217;s board of directors with the authority
to issue up to <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-42871">1,000,000</ix:nonFraction> shares of $<ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-42872"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-42873">0.0001</ix:nonFraction></ix:nonFraction> par value preferred stock in one or more series and to establish from time to time the number
of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations,
powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions.
There were <ix:nonFraction contextRef="c1" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42874"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-42875">zero</ix:nonFraction></ix:nonFraction> preferred shares outstanding as of September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of both September 30, 2025 and December
31, 2024, there were <ix:nonFraction contextRef="c416" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42876"><ix:nonFraction contextRef="c417" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42877">500,000</ix:nonFraction></ix:nonFraction> outstanding Public Warrants. The Public Warrants became exercisable <ix:nonNumeric contextRef="c418" format="ixt-sec:durmonth" name="abp:WarrantsExercisableTerm" id="ixv-42878">12</ix:nonNumeric> months from the closing of ACAB&#8217;s
Initial Public Offering, which closed on January 19, 2022, and will expire <ix:nonNumeric contextRef="c418" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-42879">five years</ix:nonNumeric> from the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company will not be obligated to deliver
any common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless
a registration statement under the Securities Act covering the issuance of the common stock issuable upon exercise of the Public Warrants
is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration.
No warrant will be exercisable, and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless
common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the
state of residence of the registered holder of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company may redeem the Public Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">in whole and not in part;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-keep: true">&#160;</span></td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">at a price of $<ix:nonFraction contextRef="c416" decimals="2" format="ixt:num-dot-decimal" name="abp:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" scale="0" unitRef="usdPershares" id="ixv-42880">0.30</ix:nonFraction> per warrant;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">upon not less than 30 days&#8217; prior written notice of redemption
    given after the warrants become exercisable to each warrant holder; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-keep: true">&#160;</span></td> <td style="width: 24px"><span style="font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-size: 10pt">if, and only if, the reported last sale price of the Series A common stock equals or exceeds $<ix:nonFraction contextRef="c419" decimals="2" format="ixt:num-dot-decimal" name="abp:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" scale="0" unitRef="usdPershares" id="ixv-42881">540.00</ix:nonFraction> per share &#160;(as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any <ix:nonNumeric contextRef="c420" format="ixt-sec:durday" name="abp:NumberOfTradingDaysForDeterminingTheSharePrice" id="ixv-42882">20</ix:nonNumeric> trading days within a <ix:nonNumeric contextRef="c420" format="ixt-sec:durday" name="abp:PeriodAfterWhichTheWarrantsAreExercisable" id="ixv-42883">30</ix:nonNumeric>-trading day period commencing once the warrants become exercisable and ending three trading days before the Company sends the notice of redemption to the warrant holders (the &#8220;Redemption Trigger&#8221;). In November 2024, the Redemption Trigger was adjusted to $<ix:nonFraction contextRef="c421" decimals="2" format="ixt:num-dot-decimal" name="abp:PerShareRedemptionsTriggerPrice" scale="0" unitRef="usdPershares" id="ixv-42884">179.70</ix:nonFraction>, as further described below.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If and when the warrants become redeemable
by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for
sale under all applicable state securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">If the Company calls the Public Warrants for
redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless
basis,&#8221; as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of
the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization,
merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of both September 30, 2025 and December
31, 2024, there were <ix:nonFraction contextRef="c422" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42885"><ix:nonFraction contextRef="c423" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42886">461,667</ix:nonFraction></ix:nonFraction> Private Warrants, The Private Warrants are identical to the Public Warrants, except that the Private Warrants
are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees.
If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will
be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 186; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In addition, if (x) the Company were to issue
additional shares of common stock or equity-linked securities, for capital raising purposes in connection with the closing of a Merger
at an issue price or effective issue price of less than $<ix:nonFraction contextRef="c419" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-42887">276.00</ix:nonFraction> per share of common stock (with such issue price or effective issue price
to be determined in good faith by the Company&#8217;s board of directors, and, in the case of any such issuance to the Sponsor or its
affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such issuance)
(the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represented more than <ix:nonFraction contextRef="c424" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-42888">60</ix:nonFraction>% of the total equity
proceeds, and interest thereon, available for the funding of a Merger on the date of the completion of a Merger (net of redemptions),
and (z) the volume weighted average trading price of the Company&#8217;s Series A common stock during the <ix:nonNumeric contextRef="c420" format="ixt-sec:durday" name="abp:NumberOfTradingDaysForDeterminingTheSharePrice" id="ixv-42889">20</ix:nonNumeric> trading day period starting
on the trading day after the day on which the Company completes a Merger (such price, the &#8220;Market Value&#8221;) was below $<ix:nonFraction contextRef="c425" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-42890">276.00</ix:nonFraction>
per share, the exercise price of the warrants would be adjusted (to the nearest cent) to be equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfMarketValueAndNewlyIssuedPrice" scale="-2" unitRef="pure" id="ixv-42891">115</ix:nonFraction>% of the greater of the Market
Value and the Newly Issued Price, and the $<ix:nonFraction contextRef="c205" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" unitRef="usdPershares" id="ixv-42892">540.00</ix:nonFraction> per share redemption trigger price will be adjusted (to the nearest cent) to be equal
to <ix:nonFraction contextRef="c415" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfMarketValueAndNewlyIssuedPrice" scale="-2" unitRef="pure" id="ixv-42893">180</ix:nonFraction>% of the greater of the Market Value and the Newly Issued Price (the &#8220;Down Round Feature&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">In November 2024, the &#8220;Down Round Feature&#8221;
was triggered and the exercise price of the Public and Private Warrants was adjusted down to $<ix:nonFraction contextRef="c426" decimals="2" format="ixt:num-dot-decimal" name="abp:PerShareRedemptionsTriggerPrice" scale="0" unitRef="usdPershares" id="ixv-42894">114.90</ix:nonFraction> and the per share Redemption Trigger
was adjusted down to $<ix:nonFraction contextRef="c427" decimals="2" format="ixt:num-dot-decimal" name="abp:PerShareRedemptionsTriggerPrice" scale="0" unitRef="usdPershares" id="ixv-42895">179.70</ix:nonFraction> based on the Newly Issued Price of $<ix:nonFraction contextRef="c428" decimals="2" format="ixt:num-dot-decimal" name="abp:PerShareRedemptionsTriggerPrice" scale="0" unitRef="usdPershares" id="ixv-42896">99.90</ix:nonFraction>. The Company accounted for the change in fair value of the Public
and Private Warrants triggered by the down round as a deemed dividend under the guidance in ASC 260-10-25-1 related to financial instruments
that include a down round feature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company valued the deemed dividend as
the difference between the fair value of the warrants before and after the exercise price adjustment. The warrants were valued using
the Black-Scholes option pricing model immediately before and after the modification using the following assumptions: (a) fair value
of common stock of $<ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-42897">53.40</ix:nonFraction>&#160;per share, (b) expected volatility of&#160;<ix:nonFraction contextRef="c429" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-42898">90.00</ix:nonFraction>%, (c) dividend yield of&#160;<ix:nonFraction contextRef="c429" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-42899">0</ix:nonFraction>%, (d) risk-free interest
rate of&#160;<ix:nonFraction contextRef="c429" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-42900">4.09</ix:nonFraction>%, and (e) expected life of&#160;<ix:nonNumeric contextRef="c429" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-42901">4.9</ix:nonNumeric>&#160;years. The increase in the fair value of the warrants resulting from the exercise
price adjustment was $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" scale="3" unitRef="usd" id="ixv-42902">10,177</ix:nonFraction> and was reflected as a deemed dividend in the consolidated statements of operations for the fourth quarter
of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The <ix:nonFraction contextRef="c430" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42903">2,034</ix:nonFraction>&#160;outstanding common stock warrants
of Legacy Abpro (&#8220;Legacy Abpro Common Stock Warrants&#8221;) expired at the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On February 7, 2025, the Company issued <ix:nonFraction contextRef="c431" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42904">28,333</ix:nonFraction>
Executive Warrants (see Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c415" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-30706"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The following presents information about warrants
to purchase common stock outstanding as of September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Weighted-</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td style="font-weight: bold; text-align: center"><span style="-keep: true">Average</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Average</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td style="font-weight: bold; text-align: center"><span style="-keep: true">Remaining</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Contractual Life</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">Warrants</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c432" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-42905">990,000</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c432" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-42906">114.60</ix:nonFraction></span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="width: 11%; text-align: center; padding-bottom: 1.5pt"><span style="-keep: true"><ix:nonNumeric contextRef="c432" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-42907">4.3</ix:nonNumeric> years</span></td></tr> </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 10pt">No warrants
were exercised during the nine months ended September 30, 2025.</span>&#160;</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-30800"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>13.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Share-Based Compensation</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>2024 Equity Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company&#8217;s 2024 Equity Incentive
Plan (the &#8220;2024 Plan&#8221;) became effective at the Closing Date. As of September 30, 2025,&#160;<ix:nonFraction contextRef="c433" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-42908">183,279</ix:nonFraction>&#160;shares of common
stock were available for issuance under the 2024 Plan, which is equal to <ix:nonFraction contextRef="c433" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStock" scale="-2" unitRef="pure" id="ixv-42909">10</ix:nonFraction>% of the number of shares of common stock of the Company following
the Merger. The 2024 Plan provides that on January 1 of each year commencing January 1, 2026 and ending on December 31, 2034, the 2024
Plan reserve will automatically increase in an amount equal to the lesser of (a)&#160;<ix:nonFraction contextRef="c434" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStock" scale="-2" unitRef="pure" id="ixv-42910">5</ix:nonFraction>% of the number of shares of the Company&#8217;s
common stock outstanding on December&#160;31 of the preceding year and (b) a number of shares of common stock determined by the Company&#8217;s
board of directors.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 187; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">Under the 2024 Plan, the Company can grant
non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock
units, unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees. In July 2025, the Company
granted <ix:nonFraction contextRef="c435" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-42911">8,080</ix:nonFraction> options with the weighted average fair value of the option of $<ix:nonFraction contextRef="c435" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-42912">6.90</ix:nonFraction>, to the directors and <ix:nonFraction contextRef="c436" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-42913">16,667</ix:nonFraction> RSUs to the Company&#8217;s
Chief Executive Officer under the 2024 Plan. The stock options granted to directors vest in full in November 2025. The RSUs granted to
the CEO vest in three equal installments on each anniversary of March 3, 2025. The contractual term of the stock options and RSUs is
<ix:nonNumeric contextRef="c437" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="ixv-42914">ten years</ix:nonNumeric>. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The fair value of the options issued during
the three months ended September 30, 2025 was determined using the Black-Scholes option pricing model based on the following assumptions:
(a) fair value of common stock of $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" scale="0" unitRef="usdPershares" id="ixv-42915">9.45</ix:nonFraction>&#160;per share, (b) expected volatility of&#160;<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-42916">92.00</ix:nonFraction>%, (c) dividend yield of&#160;<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-42917">0</ix:nonFraction>%, (d) risk-free
interest rate of&#160;<ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-42918">3.95</ix:nonFraction>%, and (e) expected term of&#160;<ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-42919">5.2</ix:nonNumeric>&#160;years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>2014 Stock Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The 2014 Stock Incentive Plan (the &#8220;2014
Plan&#8221;) of Legacy Abpro was expired as of the Closing Date, in accordance with its original terms. As a result of the expiration,
no further awards may be granted under the 2014 Plan. All awards previously granted and outstanding as of the effective date of the Merger,
which totaled&#160;<ix:nonFraction contextRef="c438" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-42920">166,858</ix:nonFraction> options, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise
remain in effect pursuant to their original terms (see Note 3). Stock options granted to employees and directors typically vest over
<ix:nonNumeric contextRef="c438" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-42921">four years</ix:nonNumeric>. Stock options granted <span style="-sec-ix-hidden: hidden-fact-425">to</span> non-employees typically vest immediately at the grant date. The maximum contractual term of the
stock options is <ix:nonNumeric contextRef="c438" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-42922">ten years</ix:nonNumeric>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company granted restricted stock units
(&#8220;RSUs&#8221;) to various employees and directors under the 2014 Plan. These RSUs cliff vest on the first anniversary of the grant
date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160; </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-30865"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The summary of the Company&#8217;s stock option
activity is as follows:&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Number of<br/> Stock Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Weighted-<br/> Average<br/> Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="-keep: true">Outstanding at December 31, 2024</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-42923">329,395</ix:nonFraction></span></p></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-42924">51.30</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c449" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-30924"><span style="-keep: true">5.4</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-keep: true">Granted</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares" id="ixv-42925">8,080</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-42926">9.60</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" id="ixv-30952"><span style="-keep: true">10</span></ix:nonNumeric></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-keep: true">Exercised</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-419"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-420"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-421"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-keep: true">Forfeited/Expired/Cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-42927">114,840</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-42928">50.39</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-422"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-keep: true">Outstanding at September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-42929">222,635</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-42930">50.28</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-31038"><span style="-keep: true">4.4</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"><span style="-keep: true">Exercisable at&#160;&#160;September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-42931">180,146</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c1" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-42932">51.85</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-31066"><span style="-keep: true">4.4</span></ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> </table></ix:nonNumeric></ix:continuation><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 188; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Restricted Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-31097"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The summary of the Company&#8217;s restricted
stock unit activity is as follows:&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Weighted-<br/> Average</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Weighted-<br/> Average</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Number&#160;of</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Grant Date</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-keep: true">Remaining</span></td><td style="font-weight: bold"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Fair Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Vesting&#160;Period</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="-keep: true">Unvested at December&#160;31,&#160;2024</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c446" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-42933">739</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c446" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-42934">48.90</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c450" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-31192"><span style="-keep: true">0.2</span></ix:nonNumeric></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-keep: true">Granted</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c451" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" unitRef="shares" id="ixv-42935">16,667</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c451" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-42936">9.60</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c451" format="ixt-sec:duryear" name="abp:SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-31220"><span style="-keep: true">2.6</span></ix:nonNumeric></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-keep: true">Vested</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c451" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-42937">142</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c451" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-42938">48.90</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-423"><span style="-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-keep: true">Forfeited/Expired/Cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c451" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" unitRef="shares" id="ixv-42939">597</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c451" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-42940">48.90</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-424"><span style="-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-keep: true">Unvested at September 30, 2025</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c445" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-42941">16,667</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c445" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-42942">9.60</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><ix:nonNumeric contextRef="c451" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-31304"><span style="-keep: true">2.4</span></ix:nonNumeric></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr> </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">During the nine months ended September 30,
2025, <ix:nonFraction contextRef="c440" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-42943">142</ix:nonFraction> RSUs vested in accordance with their terms, but the shares of common stock were not issued to the holders as of September 30,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On October 22, 2024, the Company&#8217;s board
of directors authorized the issuance of <ix:nonFraction contextRef="c441" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-42944">10,000</ix:nonFraction> RSUs (or approximately <ix:nonFraction contextRef="c442" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-42945">20,449</ix:nonFraction> RSUs as adjusted for the Merger closing based on the Exchange
Ratio), that were not yet issued as of September 30, 2025. For the three and nine months ended September 30, 2025, the Company recorded
$<ix:nonFraction contextRef="c443" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42946">208</ix:nonFraction> and $<ix:nonFraction contextRef="c444" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42947">618</ix:nonFraction>, respectively, in stock compensation expense related to these authorized RSUs. The total accrued expenses related to these
authorized RSUs were $<ix:nonFraction contextRef="c445" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-42948">1,012</ix:nonFraction> and $<ix:nonFraction contextRef="c446" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-42949">394</ix:nonFraction> as of September 30, 2025 and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true"><i>Stock-Based Compensation Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-31324"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The summary of the recorded stock-based compensation
expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Three Months Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">Nine Months Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-keep: true">Research and development</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c294" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42950">4</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c295" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42951">11</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c296" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42952">22</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c297" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42953">62</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-keep: true">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c452" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42954">282</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c453" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42955">404</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c454" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42956">1,136</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c455" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42957">1,469</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="-keep: true">Total stock-based compensation</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42958">286</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42959">415</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42960">1,158</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-42961">1,531</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">As of September 30, 2025, there was approximately
$<ix:nonFraction contextRef="c447" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" unitRef="usd" id="ixv-42962">192</ix:nonFraction> of unrecognized compensation cost related to unvested stock option awards that are expected to be recognized over a weighted-average
period of <ix:nonNumeric contextRef="c439" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-42963">0.4</ix:nonNumeric> years. As of September 30, 2025, there was approximately $<ix:nonFraction contextRef="c448" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" unitRef="usd" id="ixv-42964">127</ix:nonFraction> of unrecognized compensation related to unvested restricted
stock awards that are expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c439" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="ixv-42965">1.3</ix:nonNumeric> years.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-31514"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>14.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Employee Benefit Plan</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has a 401(k) retirement plan available
to all eligible employees. During the three and nine months ended September 30, 2025, the Company made $<ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" unitRef="usd" id="ixv-42966">6</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" unitRef="usd" id="ixv-42967">35</ix:nonFraction> in matching contributions,
respectively, to the plan. During the three and nine months ended September 30, 2024, the Company made $<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" unitRef="usd" id="ixv-42968">29</ix:nonFraction> and $<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" unitRef="usd" id="ixv-42969">101</ix:nonFraction> in matching contributions,
respectively, to the plan.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 189; Value: 1 --><div>
    </div><div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>


</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-31547"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>15.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Related Parties</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">The Company has certain promissory notes outstanding
with executives and directors as of September 30, 2025. See Note 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On January 15, 2020, the Company entered into
an agreement for various consulting services, as defined in the agreement, with a member of the Company&#8217;s Board of Directors. On
January 1, 2023, the Company entered into a new consulting agreement with the same director, which superseded the agreement dated in
January 2020. The agreement was terminated during the year ended December 31, 2024. During the three and nine months ended September
30, 2025, the Company incurred $<ix:nonFraction contextRef="c456" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-42970"><ix:nonFraction contextRef="c457" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-42971">0</ix:nonFraction></ix:nonFraction> under this agreement. During the three and nine months ended September 30, 2024, the Company incurred
$<ix:nonFraction contextRef="c458" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-42972">0</ix:nonFraction> and $<ix:nonFraction contextRef="c459" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-42973">146</ix:nonFraction>, respectively, under this agreement. As of both September 30, 2025 and December 31, 2024, the unpaid amount was $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="abp:UnpaidAmount" scale="3" unitRef="usd" id="ixv-42974"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="abp:UnpaidAmount" scale="3" unitRef="usd" id="ixv-42975">189</ix:nonFraction></ix:nonFraction>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 18, 2024, the Company entered into
a promissory note agreement with an executive to receive, as amended, for up to $<ix:nonFraction contextRef="c460" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-42976">2,158</ix:nonFraction> in funding. During the year ended December 31,
2024, the Company received $<ix:nonFraction contextRef="c461" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-42977">1,997</ix:nonFraction> from the executive under this agreement. See Note 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On April 18, 2024, the Company entered into
an agreement with an executive to defer payment of compensation from April 18, 2024 until the earlier of (i) the closing of the Merger
and (ii) November 20, 2024. The executive&#8217;s deferred wages were repaid in the amount of $<ix:nonFraction contextRef="c462" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" unitRef="usd" id="ixv-42978">221</ix:nonFraction> in November 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On November 21, 2024, the Company entered
into a severance agreement with an executive (the &#8220;Severance Agreement&#8221;). Pursuant to the terms of the Severance Agreement,
the Company made a severance payment of $<ix:nonFraction contextRef="c463" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd" id="ixv-42979">221</ix:nonFraction> upon execution of the agreement. The Severance Agreement supersedes and extinguishes all
other agreements between the executive and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">On December 24, 2024, the Company made a payment
of $<ix:nonFraction contextRef="c464" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMergerRelatedCosts" scale="3" unitRef="usd" id="ixv-42980">574</ix:nonFraction> to the Sponsor in accordance with the terms of the Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true"><br/>
On July 25, 2025, in connection with a consulting agreement executed between the Company and the Chief Executive Officer (&#8220;CEO&#8221;)(the
&#8220;CEO Consulting Agreement&#8221;), the Company issued&#160;<ix:nonFraction contextRef="c465" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-42981">16,667</ix:nonFraction>&#160;RSUs, which vest in three equal installments on March 3,
2026, March 3, 2027, and March 3, 2028. The term of the CEO Consulting Agreement commenced on March 3, 2025, the date the Company&#8217;s
board of directors appointed the CEO, and shall remain in full force and effect until terminated by mutual written agreement between
the Company and the CEO, or by sixty days&#8217; prior written notice by either party. The Company will compensate the CEO with an annual
base fee of $<ix:nonFraction contextRef="c466" decimals="0" format="ixt:num-dot-decimal" name="abp:AnnualBaseFee" scale="0" unitRef="usd" id="ixv-42982">300,000</ix:nonFraction>, payable in bi-weekly installments. Under the terms of the CEO Consulting Agreement, the Company is obligated to
make the payment equal to three times the fair market value of the CEO&#8217;s equity interests in the Company, if within 12 months of
a change of control event (as defined in the CEO Consulting Agreement), the CEO is involuntarily terminated without cause or resigns
for good reason.&#160;</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-keep: true">&#160;</span></p><div>

</div><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-31587"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="font-size: 10pt"><b>16.</b></span></td>
    <td style="text-align: justify"><span style="font-size: 10pt"><b>Subsequent Events</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">On October 1, 2025, the Company issued <ix:nonFraction contextRef="c467" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-42983">32,778</ix:nonFraction> shares of common
stock with the aggregate net purchase price of $<ix:nonFraction contextRef="c468" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-42984">211</ix:nonFraction> under an Advance Notice to YA in accordance with the terms of the SEPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">On November 7, 2025, the Company issued <ix:nonFraction contextRef="c469" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-42985">11,217</ix:nonFraction> shares of common
stock with the aggregate net purchase price of $<ix:nonFraction contextRef="c470" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" unitRef="usd" id="ixv-42986">59</ix:nonFraction> under an Advance Notice to YA in accordance with the terms of the SEPA.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 190; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-keep: true">&#160;</span></p><div>


</div><div><a id="f_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Report of Independent
Registered Public Accounting Firm</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in; text-align: justify">To the Stockholders and the Board of Directors of Abpro Holdings, Inc.:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Opinion on the Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in; text-align: justify">We have audited the accompanying consolidated
balance sheets of Abpro Holdings, Inc. and Subsidiaries (the &#8220;Company&#8221;) as of December 31, 2024 and 2023, the related consolidated
statements of operations, convertible preferred stock and stockholders&#8217; deficit and cash flows for the years then ended, and the
related notes to the consolidated financial statements (collectively, the &#8220;financial statements&#8221;). In our opinion, the financial
statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results
of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United
States of America.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Restatement of 2023 Financial Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in; text-align: justify">As discussed in Note 2 to the financial statements,
the accompanying financial statements as of December 31, 2023 and 2022 and for the year then ended, have been restated to correct a misstatement
relating to the Company&#8217;s error in the amount of the accrued expenses recorded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Emphasis of a Matter Regarding Going Concern</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in; text-align: justify">The accompanying financial statements have
been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the
Company has incurred net losses since its inception, has negative cash flows from operations and will need additional funding to
complete planned development efforts. This raises substantial doubt about the Company&#8217;s ability to continue as a going
concern. Management&#8217;s plans in regard to these matters also are described in Note 1. The financial statements do not include
any adjustments that might result from the outcome of this uncertainty.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in; text-align: justify">These financial statements are the responsibility
of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;)
and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in; text-align: justify">We conducted our audits in accordance with the
standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged
to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding
of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s
internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0in; text-align: justify">Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating
the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Wolf &amp; Company, P.C.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have served as the Company&#8217;s auditor since 2023.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, MA</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">April 15, 2025, except for the reverse stock split effected October 31, 2025 in Note
1 as to which the date is November 6, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 191; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABPRO HOLDINGS, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Amounts in thousands, except share and per
share data) </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">Assets</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><span style="-keep: true">2023</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-keep: true">Current assets:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Cash</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-42987">2,850</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td><td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-42988">723</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Accounts receivable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-42989">323</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" unitRef="usd" id="ixv-42990">88</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Deferred offering costs</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-42991">878</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Prepaid expenses and other current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-42992">306</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd" id="ixv-42993">208</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Forward purchase agreement asset</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:ForwardPurchaseAgreementAsset" scale="3" unitRef="usd" id="ixv-42994">155</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Restricted cash</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-42995">142</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashCurrent" scale="3" unitRef="usd" id="ixv-42996">138</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt"><span style="-keep: true">Total current assets</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-42997">3,776</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd" id="ixv-42998">2,035</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 27pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Property and equipment, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-42999">37</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-43000">102</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Right-of-use asset - operating lease</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-43001">418</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd" id="ixv-43002">966</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Security deposits</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="3" unitRef="usd" id="ixv-43003">66</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SecurityDeposit" scale="3" unitRef="usd" id="ixv-43004">66</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Patents, net</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentsNet" scale="3" unitRef="usd" id="ixv-43005">176</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentsNet" scale="3" unitRef="usd" id="ixv-43006">186</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">SEPA put rights asset</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:SEPAPutRightsAsset" scale="3" unitRef="usd" id="ixv-43007">188</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-18"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Total assets</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-43008">4,661</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd" id="ixv-43009">3,355</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Liabilities, convertible preferred stock
    and stockholders&#8217; deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Current liabilities:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Accounts payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-43010">3,936</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">$</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd" id="ixv-43011">7,916</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Accrued expenses</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43012">7,496</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43013">5,381</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Excise taxes payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" unitRef="usd" id="ixv-43014">4,401</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Operating lease liability, current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-43015">456</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-43016">567</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Finance lease liability, current</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-43017">130</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Income taxes payable</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" unitRef="usd" id="ixv-43018">366</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Notes payable, current &#8211; related parties</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd" id="ixv-43019">147</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd" id="ixv-43020">1,742</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Convertible notes</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:ConvertibleNotes" scale="3" unitRef="usd" id="ixv-43021">2,725</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in"><span style="-keep: true">Embedded derivative liability</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" scale="3" unitRef="usd" id="ixv-43022">80</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-23"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 27pt"><span style="-keep: true">Total current liabilities</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43023">19,607</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43024">15,736</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Operating lease liability, noncurrent</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-24"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd" id="ixv-43025">455</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Total liabilities</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43026">19,607</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43027">16,191</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Commitments and Contingencies (Note 7)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26"><span style="-keep: true">&#160;</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Convertible preferred stock, $<ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-43028"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-43029"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-43030">0</ix:nonFraction></ix:nonFraction></ix:nonFraction>.001 par value, issuable in series:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Series F Convertible Preferred Stock; zero and <ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-43031">9,088,398</ix:nonFraction> shares authorized; zero and <ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-43032"><ix:nonFraction contextRef="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-43033">1,136,049</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation preference of $<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-43034">10,000</ix:nonFraction> at December 31, 2023</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" unitRef="usd" id="ixv-43035">9,991</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-29"><div style="-sec-ix-hidden: hidden-fact-31"><span style="-keep: true">Series E Convertible Preferred Stock; zero and <ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-43036">9,008,324</ix:nonFraction> shares authorized; zero and <ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-43037"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-43038">6,756,246</ix:nonFraction></ix:nonFraction> issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation preference of $<ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-43039">10,000</ix:nonFraction> at December 31, 2023</span></div></div></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" unitRef="usd" id="ixv-43040">29,841</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-33"><div style="-sec-ix-hidden: hidden-fact-35"><span style="-keep: true">Series D Convertible Preferred Stock; zero and <ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-43041"><ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-43042">2,679,397</ix:nonFraction></ix:nonFraction> shares authorized; zero and <ix:nonFraction contextRef="c14" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-43043">2,679,397</ix:nonFraction> issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation preference of $<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-43044">18,194</ix:nonFraction> at December 31, 2023</span></div></div></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" unitRef="usd" id="ixv-43045">17,622</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-37"><div style="-sec-ix-hidden: hidden-fact-39"><span style="-keep: true">Series C Convertible Preferred Stock; zero and <ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-43046"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-43047">4,101,409</ix:nonFraction></ix:nonFraction> shares authorized; zero and <ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-43048">4,101,409</ix:nonFraction> issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation preference of $<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-43049">15,725</ix:nonFraction> at December 31,</span></div></div></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" unitRef="usd" id="ixv-43050">14,949</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-41"><div style="-sec-ix-hidden: hidden-fact-43"><span style="-keep: true">Series B Convertible Preferred Stock; zero and <ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-43051"><ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-43052">1,281,402</ix:nonFraction></ix:nonFraction> shares authorized; zero and <ix:nonFraction contextRef="c18" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-43053">1,281,402</ix:nonFraction> issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation preference of $<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-43054">1,798</ix:nonFraction> at December 31, 2023</span></div></div></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" unitRef="usd" id="ixv-43055">1,401</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-45"><div style="-sec-ix-hidden: hidden-fact-47"><span style="-keep: true">Series A Redeemable, Convertible Preferred Stock; zero and <ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares" id="ixv-43056"><ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares" id="ixv-43057">3,938,098</ix:nonFraction></ix:nonFraction> shares authorized; zero and <ix:nonFraction contextRef="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" unitRef="shares" id="ixv-43058">3,938,098</ix:nonFraction> issued and outstanding as of December 31, 2024 and 2023, respectively; liquidation preference of $<ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" unitRef="usd" id="ixv-43059">1,795</ix:nonFraction> at December 31, 2023</span></div></div></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" unitRef="usd" id="ixv-43060">1,795</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Total convertible preferred stock</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48"><span style="-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" unitRef="usd" id="ixv-43061">75,599</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Stockholders&#8217; deficit:</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><div style="-sec-ix-hidden: hidden-fact-51"><div style="-sec-ix-hidden: hidden-fact-55"><span style="-keep: true">Preferred stock, $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-43062"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-43063">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-43064">1,000,000</ix:nonFraction> and zero shares authorized; zero shares issued and outstanding as of December 31, 2024 and 2023, respectively</span></div></div></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-49"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-50"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Common stock, $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-43065"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-43066">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-43067">110,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-43068">81,795,590</ix:nonFraction> shares authorized; <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-43069">1,727,192</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-43070">646,044</ix:nonFraction> shares issued, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43071">1,694,414</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43072">639,039</ix:nonFraction> shares outstanding at December 31, 2024 and 2023, respectively</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Treasury stock, <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-43073">32,778</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" unitRef="shares" id="ixv-43074">7,006</ix:nonFraction> shares at cost as of December 31, 2024 and 2023, respectively</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58"><span style="-keep: true">-</span></div></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonValue" scale="3" unitRef="usd" id="ixv-43075">33</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Additional paid-in capital</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-43076">100,608</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd" id="ixv-43077">19,920</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Accumulated deficit</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43078">116,103</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43079">108,871</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Total Abpro Corporation&#8217;s stockholders&#8217;
    deficit</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-43080">15,495</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td><td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-keep: true">&#160;</span></td><td style="text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd" id="ixv-43081">88,984</ix:nonFraction></span></td><td style="text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Non-controlling interest</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="3" unitRef="usd" id="ixv-43082">549</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MinorityInterest" scale="3" unitRef="usd" id="ixv-43083">549</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Total stockholders&#8217;
    deficit</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43084">14,946</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-keep: true">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43085">88,435</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt"><span style="-keep: true">Total liabilities,
    convertible preferred stock and stockholders&#8217; deficit</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-43086">4,661</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-keep: true">$</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-keep: true"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd" id="ixv-43087">3,355</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-keep: true">&#160;</span></td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Reflects a 1-for-30 reverse stock split effective
October 31, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 192; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABPRO HOLDINGS, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Amounts in thousands, except share and per
share data) </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/>
December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Revenue:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9.25pt">Research and development services</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-43088">183</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Collaboration revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-73">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-43089">99</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 9.25pt">Royalty</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-74">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-43090">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt">Total revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-43091">183</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd" id="ixv-43092">122</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-43093">2,983</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-43094">4,266</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-43095">7,121</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd" id="ixv-43096">7,602</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-43097">10,104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitRef="usd" id="ixv-43098">11,868</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-43099">9,921</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd" id="ixv-43100">11,746</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other (expense) income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Other income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" unitRef="usd" id="ixv-43101">3,556</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-75">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Change in fair value of Forward Purchase Agreement asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfForwardPuchaseAgreementAsset" scale="3" sign="-" unitRef="usd" id="ixv-43102">339</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-76">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Change in fair value of SEPA put rights asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfSEPAPutRightsAsset" scale="3" sign="-" unitRef="usd" id="ixv-43103">312</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-77">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Change in fair value of embedded derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfEmbeddedDerivativeLiability" scale="3" sign="-" unitRef="usd" id="ixv-43104">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-78">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Gain on extinguishment of accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" unitRef="usd" id="ixv-43105">173</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-79">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-43106">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitRef="usd" id="ixv-43107">63</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt">Interest expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd" id="ixv-43108">387</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" unitRef="usd" id="ixv-43109">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt">Total other income, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-43110">2,689</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd" id="ixv-43111">40</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43112">7,232</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43113">11,706</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Deemed dividend resulting from the warrant down round</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:DeemedDividendResultingFromTheWarrantDownRound" scale="3" unitRef="usd" id="ixv-43114">10,177</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-80">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><b>Net loss attributable to common stockholders</b></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" scale="3" sign="-" unitRef="usd" id="ixv-43115">17,409</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" scale="3" sign="-" unitRef="usd" id="ixv-43116">11,706</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Loss per share</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 0.25in">Basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-43117"><ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-43118">22.31</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitRef="usdPershares" id="ixv-43119"><ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitRef="usdPershares" id="ixv-43120">18.35</ix:nonFraction></ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Weighted average shares outstanding - basic and diluted</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-43121"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-43122">780,332</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitRef="shares" id="ixv-43123"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares" id="ixv-43124">637,777</ix:nonFraction></ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Reflects a 1-for-30 reverse stock split effective
October 31, 2025</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 193; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">ABPRO HOLDINGS, INC.
AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><b style="-keep: true">CONSOLIDATED STATEMENTS
OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-keep: true">For the Years Ended December 31, 2024 and
2023</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in"><b style="-keep: true">(Amounts in thousands,
except share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" style="font: 7pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="font-size: 7pt; vertical-align: bottom">
    <td style="font-size: 7pt; font-weight: bold; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="5" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series A Redeemable,<br/>
    Convertible</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series B<br/> Convertible</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series C<br/> Convertible</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series D <br/> Convertible</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series E <br/> Convertible</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series F<br/> Convertible</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Total<br/> Convertible<br/>
    Preferred</span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Additional</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Total<br/> Abpro&#8217;s</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Non-</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Total</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom">
    <td style="font-size: 7pt; font-weight: bold; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Stock</span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Common
    Stock</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Treasury
    Stock</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Paid-In</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Accumulated</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Stockholders&#8217;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">controlling</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Stockholders&#8217;</span></td><td style="font-size: 7pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom">
    <td style="font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="border-right: Black 1.5pt solid; text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Capital</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Deficit</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Deficit</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Interest</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: center; font-size: 7pt; font-weight: bold; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-size: 7pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Deficit</span></td><td style="text-align: center; font-size: 7pt; padding-bottom: 1.5pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 7pt; font-weight: bold; text-align: left; text-indent: -8pt; padding-left: 8pt; width: 9.9%"><span style="font-size: 7pt">Balances,
    as of December 31, 2023</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c124" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43125">3,938,098</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43126">1,795</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c125" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43127">1,281,402</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43128">1,401</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c126" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43129">4,101,409</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43130">14,949</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c127" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43131">2,679,397</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43132">17,622</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c128" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43133">6,756,246</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43134">29,841</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c129" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43135">1,136,049</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43136">9,991</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43137">75,599</ix:nonFraction></span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43138">646,044</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-254"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-43139">7,006</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43140">33</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43141">19,920</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43142">108,871</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43143">88,984</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43144">549</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; width: 0.1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; width: 3.8%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43145">88,435</ix:nonFraction></span></td><td style="font-size: 7pt; width: 0.1%; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; text-align: left; text-indent: -8pt; padding-left: 16pt"><span style="font-size: 7pt">Vesting of restricted
    stock units</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-255"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-256"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-257"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-258"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-259"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-260"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-261"><span style="font-size: 7pt">-</span></div></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-43146">2,017</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-262"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-263"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-264"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-265"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-266"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-267"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-268"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 7pt; text-align: left; text-indent: -8pt; padding-left: 16pt"><span style="font-size: 7pt">The Merger, net
    of transaction costs and acquired liabilities</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c137" decimals="INF" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="0" sign="-" unitRef="shares" id="ixv-43147">3,938,098</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c137" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-43148">1,795</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="0" sign="-" unitRef="shares" id="ixv-43149">1,281,402</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c138" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-43150">1,401</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c139" decimals="INF" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="0" sign="-" unitRef="shares" id="ixv-43151">4,101,409</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c139" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-43152">14,949</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c140" decimals="INF" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="0" sign="-" unitRef="shares" id="ixv-43153">2,679,397</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c140" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-43154">17,622</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c141" decimals="INF" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="0" sign="-" unitRef="shares" id="ixv-43155">6,756,246</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c141" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-43156">29,841</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c142" decimals="INF" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="0" sign="-" unitRef="shares" id="ixv-43157">1,136,049</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c142" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-43158">9,991</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c143" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" sign="-" unitRef="usd" id="ixv-43159">75,599</ix:nonFraction></span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="0" unitRef="shares" id="ixv-43160">955,884</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-269"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c145" decimals="INF" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="0" sign="-" unitRef="shares" id="ixv-43161">25,772</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c145" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" unitRef="usd" id="ixv-43162">33</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" unitRef="usd" id="ixv-43163">68,073</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-270"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" unitRef="usd" id="ixv-43164">68,106</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-271"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" scale="3" unitRef="usd" id="ixv-43165">68,106</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; text-align: left; text-indent: -8pt; padding-left: 16pt"><span style="font-size: 7pt">Issuance of common stock in the PIPE Financing, net of transaction costs of $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:IssuanceOfCommonStockInTransactionCost" scale="3" unitRef="usd" id="ixv-43166">863,474</ix:nonFraction></span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-272"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-273"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-274"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-275"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-276"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-277"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-278"><span style="font-size: 7pt">-</span></div></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="abp:IssuanceOfCommonStockInPIPEFinancing" scale="0" unitRef="shares" id="ixv-43167">113,342</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-279"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-280"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="abp:IssuanceOfCommonStockInThePIPEFinancing" scale="3" unitRef="usd" id="ixv-43168">10,361</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-281"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="abp:IssuanceOfCommonStockInThePIPEFinancing" scale="3" unitRef="usd" id="ixv-43169">10,361</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-282"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:IssuanceOfCommonStockInThePIPEFinancing" scale="3" unitRef="usd" id="ixv-43170">10,361</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 7pt; text-align: left; text-indent: -8pt; padding-left: 16pt"><span style="font-size: 7pt">SEPA commitment
    fee paid in shares</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-283"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-284"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-285"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-286"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-287"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-288"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-289"><span style="font-size: 7pt">-</span></div></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares" id="ixv-43171">9,905</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-290"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-291"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-43172">327</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-292"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-43173">327</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-293"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd" id="ixv-43174">327</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; text-align: left; text-indent: -8pt; padding-left: 16pt"><span style="font-size: 7pt">Share-based compensation</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-294"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-295"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-296"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-297"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-298"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-299"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-300"><span style="font-size: 7pt">-</span></div></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-301"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-302"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c146" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-43175">1,927</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-303"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-43176">1,927</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-304"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-43177">1,927</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 7pt; text-align: left; padding-bottom: 1.5pt; text-indent: -8pt; padding-left: 16pt"><span style="font-size: 7pt">Net
    loss</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-305"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-306"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-307"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-308"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-309"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-310"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-311"><span style="font-size: 7pt">-</span></div></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-312"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-313"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-314"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c147" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43178">7,232</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c148" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43179">7,232</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-315"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43180">7,232</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -8pt; padding-left: 8pt"><span style="font-size: 7pt">Balances,
    as of December 31, 2024</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-316"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-317"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-318"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-319"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-320"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-321"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-322"><span style="font-size: 7pt">-</span></div></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43181">1,727,192</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-323"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c44" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-43182">32,778</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-324"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c45" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43183">100,608</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43184">116,103</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43185">15,495</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43186">549</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43187">14,946</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; font-weight: bold; text-align: left; text-indent: -8pt; padding-left: 8pt"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="5" style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><p style="font-size: 7pt; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<p style="font-size: 7pt; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Series
A Redeemable,<br/> Convertible</b></span></p>

</td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Series
                                            B<br/> Convertible</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Series
                                            C<br/> Convertible</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Series
                                            D <br/> Convertible</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Series
                                            E <br/> Convertible</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Series
                                            F<br/> Convertible</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Total<br/>
                                            Convertible<br/> Preferred</b></span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Additional</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Total<br/>
                                            Abpro&#8217;s</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Non-&#160;</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Total</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Preferred
    Stock</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Preferred
                                            Stock</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Preferred
                                            Stock</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Preferred
                                            Stock</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Preferred
                                            Stock</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Preferred
                                            Stock</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="padding-bottom: 1.5pt; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Stock</b></span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Common
                                            Stock</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td colspan="5" style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Treasury
                                            Stock</b></span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Paid-In</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Accumulated</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Stockholders&#8217;</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>controlling</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Stockholders&#8217;</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Shares</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Amount</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Shares</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Amount</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Shares</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Amount</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Shares</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Amount</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Shares</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Amount</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Shares</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Amount</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Amount</b></span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Shares</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Amount</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Shares</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Amount</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Capital</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Deficit</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Deficit</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Interest</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; vertical-align: bottom; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 7pt"><b>Deficit</b></span></td><td style="font-size: 7pt; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 7pt; font-weight: bold; text-align: left; text-indent: -8pt; padding-left: 8pt"><span style="font-size: 7pt">Balances,
    as of December 31, 2022</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c150" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43188">3,938,098</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c150" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43189">1,795</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c151" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43190">1,281,402</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c151" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43191">1,401</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c152" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43192">4,101,409</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c152" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43193">14,949</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c153" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43194">2,679,397</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c153" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43195">17,622</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c154" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43196">6,756,246</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c154" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43197">29,841</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c155" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43198">1,136,049</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c155" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43199">9,991</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c156" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43200">75,599</ix:nonFraction></span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c157" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43201">643,488</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-325"><span style="-keep: true">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c158" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-43202">7,006</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c158" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43203">33</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c159" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43204">17,615</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c160" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43205">97,165</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c161" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43206">79,583</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c162" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43207">549</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43208">79,034</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; text-align: left; text-indent: -8pt; padding-left: 16pt"><span style="font-size: 7pt">Vesting of restricted
    stock units</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-326"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-327"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-328"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-329"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-330"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-331"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-332"><span style="font-size: 7pt">-</span></div></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c171" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares" id="ixv-43209">2,556</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-333"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-334"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-335"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-336"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-337"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-338"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-339"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 7pt; text-align: left; text-indent: -8pt; padding-left: 16pt"><span style="font-size: 7pt">Share-based compensation</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-340"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-341"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-342"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-343"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-344"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-345"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-346"><span style="font-size: 7pt">-</span></div></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-347"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-348"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c173" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-43210">2,305</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-349"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c175" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-43211">2,305</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-350"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" scale="3" unitRef="usd" id="ixv-43212">2,305</ix:nonFraction></span></td><td style="font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: White">
    <td style="font-size: 7pt; text-align: left; padding-bottom: 1.5pt; text-indent: -8pt; padding-left: 16pt"><span style="font-size: 7pt">Net
    loss</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-351"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-352"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-353"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-354"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-355"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-356"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-357"><span style="font-size: 7pt">-</span></div></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-358"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">-</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-359"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-360"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c174" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43213">11,706</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c175" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43214">11,706</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-361"><span style="font-size: 7pt">-</span></div></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43215">11,706</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr style="font-size: 7pt; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 7pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -8pt; padding-left: 8pt"><span style="font-size: 7pt">Balances,
    as of December 31, 2023</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c124" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43216">3,938,098</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c124" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43217">1,795</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c125" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43218">1,281,402</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43219">1,401</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c126" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43220">4,101,409</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c126" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43221">14,949</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c127" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43222">2,679,397</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c127" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43223">17,622</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c128" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43224">6,756,246</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c128" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43225">29,841</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c129" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43226">1,136,049</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c129" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43227">9,991</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c130" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43228">75,599</ix:nonFraction></span></td><td style="border-right: Black 1.5pt solid; font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c131" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares" id="ixv-43229">646,044</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-362"><span style="-keep: true">-</span></div></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockCommonShares" scale="0" sign="-" unitRef="shares" id="ixv-43230">7,006</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c132" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43231">33</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c133" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43232">19,920</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c134" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43233">108,871</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c135" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43234">88,984</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction contextRef="c136" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" unitRef="usd" id="ixv-43235">549</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 7pt; padding-bottom: 4pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 4pt double; font-size: 7pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43236">88,435</ix:nonFraction></span></td><td style="font-size: 7pt; padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">The accompanying notes are an integral part
of these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="-keep: true">Reflects a 1-for-30 reverse stock split effective
October 31, 2025</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 194; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="f_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABPRO HOLDINGS, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 13.5pt"><b>CONSOLIDATED STATEMENTS
OF CASH FLOWS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 13.5pt"><b>(Amounts in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 13.5pt">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Years Ended<br/> December 31,</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Cash Flows from Operating Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43237">7,232</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43238">11,706</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Depreciation and amortization expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-43239">74</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationAndAmortization" scale="3" unitRef="usd" id="ixv-43240">279</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-43241">1,927</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd" id="ixv-43242">2,305</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Amortization of operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-43243">548</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" unitRef="usd" id="ixv-43244">513</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Other income (see Note 2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="3" unitRef="usd" id="ixv-43245">3,556</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-383">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashExpense" scale="3" unitRef="usd" id="ixv-43246">39</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-384">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Change in fair value of Forward Purchase Agreement asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfForwardPurchaseAgreementAsset" scale="3" sign="-" unitRef="usd" id="ixv-43247">339</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-385">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Change in fair value of SEPA put rights asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOfSEPAPutRightAsset" scale="3" sign="-" unitRef="usd" id="ixv-43248">312</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-386">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Change in fair value of embedded derivative liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ChangeInFairValueOnEmbeddedDerivativeLiability" scale="3" sign="-" unitRef="usd" id="ixv-43249">11</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-387">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Gain on extinguishment of accrued liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" unitRef="usd" id="ixv-43250">173</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-388">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 18.25pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" unitRef="usd" id="ixv-43251">235</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" sign="-" unitRef="usd" id="ixv-43252">1,942</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 18.25pt">Prepaid expenses and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd" id="ixv-43253">98</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd" id="ixv-43254">84</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 18.25pt">Note receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-389">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInNotesReceivables" scale="3" sign="-" unitRef="usd" id="ixv-43255">4</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 18.25pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-43256">860</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" sign="-" unitRef="usd" id="ixv-43257">743</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 18.25pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" unitRef="usd" id="ixv-43258">383</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" unitRef="usd" id="ixv-43259">484</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 18.25pt">Excise taxes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" unitRef="usd" id="ixv-43260">57</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-390">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 18.25pt">Deferred revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-391">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" sign="-" unitRef="usd" id="ixv-43261">64</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 18.25pt">Operating lease liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-43262">566</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd" id="ixv-43263">500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-43264">9,030</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd" id="ixv-43265">7,402</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows from Investing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt">Purchase of property and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-392">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-43266">48</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Cash Flows from Financing Activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Net proceeds from the Merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:NetProceedsFromTheMerger" scale="3" unitRef="usd" id="ixv-43267">490</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-393">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Net proceeds from PIPE financing</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" scale="3" unitRef="usd" id="ixv-43268">10,361</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-394">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Cash transferred into escrow pursuant to Forward Purchase Agreement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:CashTransferredToEscrow" scale="3" unitRef="usd" id="ixv-43269">1,134</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-395">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Proceeds from issuance of notes payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-43270">5,883</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-43271">1,442</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Payment of notes payable - related party</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-43272">5,735</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-396">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 9.25pt">Proceeds from issuance of Convertible Notes, net of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromConvertibleDebt" scale="3" unitRef="usd" id="ixv-43273">2,755</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-397">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Payment of offering costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd" id="ixv-43274">1,442</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd" id="ixv-43275">371</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt">Repayment of finance lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-43276">17</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" unitRef="usd" id="ixv-43277">222</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-43278">11,161</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd" id="ixv-43279">849</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net change in cash and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd" id="ixv-43280">2,131</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd" id="ixv-43281">6,601</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Cash and restricted cash - beginning of year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-43282">861</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c163" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-43283">7,462</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt">Cash and restricted cash - end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-43284">2,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-43285">861</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Supplemental disclosure of cash flow information and non-cash transactions:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-43286">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd" id="ixv-43287">16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Offering costs included in accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:OfferingCostsIncludedInAccountsPayable" scale="3" unitRef="usd" id="ixv-43288">436</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="abp:OfferingCostsIncludedInAccountsPayable" scale="3" unitRef="usd" id="ixv-43289">507</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Reclassification of residual value guarantees under finance lease to accrued expense</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" scale="3" unitRef="usd" id="ixv-43290">113</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-398">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Settlement of bonus accrual through notes payable - related parties</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-399">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="abp:SettlementOfBonusAccrualThroughNotesPayableRelatedParties" scale="3" unitRef="usd" id="ixv-43291">300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">ACAB liabilities assumed in the Merger, net</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ACABLiabilitiesAssumedInTheMerger" scale="3" unitRef="usd" id="ixv-43292">6,585</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-400">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Conversion of notes payable-related parties into common stock of New Abpro</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" scale="3" unitRef="usd" id="ixv-43293">2,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-401">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Conversion of pre-merger preferred stock of Abpro into common stock of New Abpro</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" scale="3" unitRef="usd" id="ixv-43294">75,563</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-402">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">SEPA commitment fee paid in common stock shares</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:SEPACommitmentFeePaidInCommonStockShares" scale="3" unitRef="usd" id="ixv-43295">327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-403">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">As reported within consolidated balance sheets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Cash</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-43296">2,850</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-43297">723</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-43298">142</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitRef="usd" id="ixv-43299">138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Total cash and restricted cash as presented in the consolidated balance sheet</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-43300">2,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-43301">861</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 13.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part of
these consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 195; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><div><a id="f_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>ABPRO HOLDINGS, INC. AND SUBSIDIARIES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Amounts in thousands, except share and per
share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c34_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="ixv-37250"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization
and Description of the Business</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Abpro Holdings, Inc. and its subsidiaries,
(the &#8220;Company&#8221;) is a biotechnology company headquartered in Woburn, Massachusetts, dedicated to developing next-generation
antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. The Company is focused on the development
of novel antibodies using its proprietary discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology
and infectious disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 13, 2024 (the &#8220;Closing
Date&#8221;), Atlantic Costal Acquisition Corp. II (&#8220;ACAB&#8221;) consummated a merger (the &#8220;Merger&#8221;) pursuant to the
terms of the Merger Agreement, dated as of December 11, 2023 (the &#8220;Merger Agreement&#8221;) by and among Abpro Corporation (&#8220;Legacy
Abpro&#8221;), ACAB, and Abpro Merger Sub Corp., a Delaware corporation (&#8220;Merger Sub&#8221;) and wholly owned subsidiary of ACAB
prior to the Closing Date. Pursuant to the Merger Agreement, on the Closing Date, (i) ACAB changed its name to &#8220;Abpro Holdings,
Inc.&#8221; (&#8220;New Abpro&#8221;), and (ii) Merger Sub merged with and into Legacy Abpro, with Legacy Abpro as the surviving company
in the Merger (such transactions, the &#8220;Merger,&#8221; and, collectively with the other transactions described in the Merger Agreement,
the &#8220;Reverse Recapitalization&#8221;). Shares of the New Abpro common stock commenced trading on the Nasdaq Capital Market on November
14, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">After giving effect to the Merger,
Legacy Abpro became a wholly owned subsidiary of the Company. The Merger is accounted for as a reverse recapitalization in accordance
with U.S. GAAP, and under this method of accounting, ACAB is treated as the acquired company for financial reporting purposes and Legacy
Abpro is treated as the acquirer. Operations prior to the Merger are those of Legacy Abpro. Unless otherwise noted, the Company has retroactively
adjusted all common and preferred share and related price information to give effect to the Exchange Ratio as set forth in the Merger
Agreement. The &#8220;Company&#8221; refers to Abpro Holdings, Inc. and its subsidiaries, including Abpro Corporation, prior to and subsequent
to the Merger. As described in Note 3, Legacy Abpro is the accounting acquirer in the Merger and, as such, the consolidated financial
statements present operations of Legacy Abpro prior to the Merger Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Refer to Note 3 - Reverse Recapitalization
for further details of the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 16, 2025, the Company filed
with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the &#8220;Certificate
of Amendment&#8221;), which became effective on October 31, 2025 (the &#8220;Effective Time&#8221;), to effect a one-for-thirty (1:30)
reverse stock split (the &#8220;Reverse Stock Split&#8221;), of the shares of the Company&#8217;s common stock, par value $<ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-43302">0.0001</ix:nonFraction> per
share. The Reverse Stock Split was approved by the Company&#8217;s stockholders at the 2025 annual meeting of the stockholders on October
10, 2025. The Company&#8217;s common stock began trading on a reverse stock split-adjusted basis upon market opening on November 3, 2025.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 196; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c34_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As a result of the Reverse Stock
Split, every 30 shares of issued and outstanding Common Stock will be automatically combined into one (1) issued and outstanding share
of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split.
Instead, stockholders who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly
divisible by the Reverse Stock Split ratio will be entitled to receive an additional fraction of a share of Common Stock to round up to
the next whole share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">All of the Company&#8217;s historical
share and per share information related to issued and outstanding common stock, restricted stock units, and options and warrants exercisable
for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-30 reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Risks and Uncertainties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company is subject to risks and
uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors
of more advanced or effective therapies, dependence on key executives, protection of and dependence on proprietary technology, compliance
with government regulations and ability to secure additional capital to fund operations. Programs currently under development will require
significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization.
These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting
capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will
realize significant revenue from product sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company is required to evaluate
whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going
concern within one year after the date that the consolidated financial statements are issued. Through December 31, 2024, the Company has
funded its operations mainly through equity and debt financings, including the proceeds from the Merger and the PIPE Financing (as further
described in Note 3), and to a lesser extent, payments received in connection with collaboration and license agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Since inception, the Company has incurred
losses. The Company&#8217;s net losses totaled $<ix:nonFraction contextRef="c471" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43303">7,232</ix:nonFraction> and $<ix:nonFraction contextRef="c472" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd" id="ixv-43304">11,706</ix:nonFraction> for the years ended December 31, 2024 and 2023, respectively. The Company
had an accumulated deficit of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43305">116,103</ix:nonFraction> as of December 31, 2024. The Company expects to incur operating losses for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 18, 2023, the Company entered
into a promissory note agreement with Abpro Bio International, Inc. (&#8220;ABI&#8221;), a significant investor in Legacy Abpro&#8217;s
Series E and F convertible preferred stock (see Note 12), to receive up to $<ix:nonFraction contextRef="c473" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-43306">6,000</ix:nonFraction>. The Company received $<ix:nonFraction contextRef="c474" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="3" unitRef="usd" id="ixv-43307">4,225</ix:nonFraction> through the Closing Date,
including $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="3" unitRef="usd" id="ixv-43308">2,786</ix:nonFraction> during the year ended December 31, 2024, in which the aggregate principal amount was converted in common shares at the
Closing Date in connection with the PIPE Financing (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On April 18, 2024, the Company entered
into a promissory note agreement with one of its executives (see Note 12 for terms and conditions) to receive, as amended, up to $<ix:nonFraction contextRef="c475" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-43309">2,158</ix:nonFraction>
in funding. The Company received $<ix:nonFraction contextRef="c476" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="3" unitRef="usd" id="ixv-43310">1,997</ix:nonFraction> through the Closing Date. The principal amount of this note was converted into <ix:nonFraction contextRef="c476" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-43311">20,000</ix:nonFraction> common shares at the Closing Date as described in Note 12.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 197; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c34_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 7, 2024, the Company entered
into an additional promissory note with ABI (&#8220;the 2024 ABI Note&#8221;) to receive up to $<ix:nonFraction contextRef="c477" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-43312">1,000</ix:nonFraction> from ABI in weekly installments
of $<ix:nonFraction contextRef="c478" decimals="-3" format="ixt:num-dot-decimal" name="abp:InstallmentsAmount" scale="3" unitRef="usd" id="ixv-43313">250</ix:nonFraction>. The note accrued <ix:nonFraction contextRef="c478" decimals="2" format="ixt:num-dot-decimal" name="abp:AccrueInterestPercentage" scale="-2" unitRef="pure" id="ixv-43314">10</ix:nonFraction>% interest and had the maturity date which was 5 business days after receipt of the proceeds under the PIPE
Financing (see Note 3). The Company repaid the $<ix:nonFraction contextRef="c478" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="3" unitRef="usd" id="ixv-43315">1,000</ix:nonFraction> balance at the Closing out of the proceeds from the PIPE Financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company received $<ix:nonFraction contextRef="c474" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="6" unitRef="usd" id="ixv-43316">5.7</ix:nonFraction> million in
net proceeds from the Merger and related PIPE Financing, net of ACAB transaction costs and liabilities settled at the Closing. The Company
incurred $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" unitRef="usd" id="ixv-43317">2.1</ix:nonFraction> million in transaction costs and $<ix:nonFraction contextRef="c34" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd" id="ixv-43318">0.9</ix:nonFraction> million in issuance costs related to the PIPE Financing, consisting of banking, legal,
investment advisory and other professional fees, of which were recorded as a reduction of proceeds to additional paid-in capital. At the
Closing Date, Legacy Abpro assumed $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="6" unitRef="usd" id="ixv-43319">6.6</ix:nonFraction> million of net liabilities, including tax liabilities and legal fees of ACAB, of which $<ix:nonFraction contextRef="c34" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="6" unitRef="usd" id="ixv-43320">1.0</ix:nonFraction> million
was included in accrued expenses, $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="6" unitRef="usd" id="ixv-43321">4.4</ix:nonFraction> million in excise tax payable and $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" unitRef="usd" id="ixv-43322">0.4</ix:nonFraction> million in income tax payable as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 14, 2024, the Company entered
into a Convertible Promissory Note with YA II PN, Ltd. (&#8220;YA&#8221;) (see Note 13) for $<ix:nonFraction contextRef="c383" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-43323">3,000</ix:nonFraction> and received net proceeds of $<ix:nonFraction contextRef="c479" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-43324">2,755</ix:nonFraction>,
net of the original issuance discount of <ix:nonFraction contextRef="c480" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" unitRef="pure" id="ixv-43325">8</ix:nonFraction>% (the &#8220;Convertible Note Discount&#8221;). The convertible note has a maturity of <ix:nonNumeric contextRef="c481" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-43326">November
13, 2025</ix:nonNumeric> (subject to earlier repayments based on Amortization Event described below), incurs interest at a rate of <ix:nonFraction contextRef="c482" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure" id="ixv-43327">0</ix:nonFraction>% (or <ix:nonFraction contextRef="c483" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFixedInterestRate" scale="-2" unitRef="pure" id="ixv-43328">18</ix:nonFraction>% upon the
occurrence of an uncured Event of Default).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At the Merger Closing Date, the Company
paid approximately $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ForwardPurchaseAgreement" scale="3" unitRef="usd" id="ixv-43329">1,100</ix:nonFraction> pursuant to the terms of the Forward Purchase Agreement (see Note 11) with YA. On January 28, 2025, YA elected
to effect an Optional Early Termination with respect to all <ix:nonFraction contextRef="c484" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" scale="0" unitRef="shares" id="ixv-43330">3,333</ix:nonFraction> Shares subject to the Forward Purchase Agreement which terminated the
agreement as a whole. YA paid the Company the Early Termination Obligation in the aggregate amount of $<ix:nonFraction contextRef="c485" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnContractTermination" scale="3" unitRef="usd" id="ixv-43331">132</ix:nonFraction>, based on the Reset Price of
$<ix:nonFraction contextRef="c484" decimals="2" format="ixt:num-dot-decimal" name="abp:EarlyTerminationResetPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43332">39.60</ix:nonFraction> per share in effect on January 28, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On April 2, 2025, the Company received
written notice (the &#8220;Notice&#8221;) from the Listing Qualifications Department of Nasdaq notifying the Company that, based on the
closing bid price of the Company&#8217;s common stock for the last 30 consecutive business days, the Company no longer complies with the
minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities
to maintain a minimum bid price of $<ix:nonFraction contextRef="c486" decimals="2" format="ixt:num-dot-decimal" name="abp:SecurityBidPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43333">1.00</ix:nonFraction> per share (the &#8220;Minimum Bid Price Requirement&#8221;), and Nasdaq Listing Rule 5810(c)(3)(A)
provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business
days. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain
compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company&#8217;s common stock must
be at least $<ix:nonFraction contextRef="c487" decimals="2" format="ixt:num-dot-decimal" name="abp:SecurityBidPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43334">1.00</ix:nonFraction> per share for a minimum of 10 consecutive business days prior to September 29, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Due to its current liabilities, the
cash available to the Company may not be sufficient to allow the Company to operate for at least 12 months from the date these financial
statements are available for issuance. The future viability of the Company is largely dependent on its ability to raise additional capital
to finance its operations. The Company expects to seek additional funding through equity and debt financings, collaboration agreements
and research grants. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful
in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the
Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization
efforts, which could adversely affect its business prospects.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 198; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accordingly, based on the
considerations discussed above, management has concluded there is substantial doubt as to the Company&#8217;s ability to continue as
a going concern within one year after the date the consolidated financial statements are issued. The Company plans to continue to
fundraise, as well as seek alternate revenues from collaboration and license agreements. If adequate funds are not available, the
Company may be required to initiate steps to slow cash burn, extending the cash runway until financing can be secured. The
consolidated financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and
their classification that might result from the outcome of this uncertainty.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_SignificantAccountingPoliciesTextBlock-c34_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="ixv-37369"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Significant Accounting Policies</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_BasisOfAccountingPolicyPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="ixv-37382"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Basis of Presentation</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="_BasisOfAccountingPolicyPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accompanying consolidated
financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation (&#8220;AbMed&#8221;).
All intercompany balances and transactions have been eliminated in consolidation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="abp_EmergingGrowthCompanyPolicyTextBlock-c34_cont_1" escape="true" name="abp:EmergingGrowthCompanyPolicyTextBlock" id="ixv-37392"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Emerging Growth Company</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="abp_EmergingGrowthCompanyPolicyTextBlock-c34_cont_2" id="abp_EmergingGrowthCompanyPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company is an &#8220;emerging growth
company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but
not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section
404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden
parachute payments not previously approved.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="abp_EmergingGrowthCompanyPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" continuedAt="_UseOfEstimates-c34_cont_1" escape="true" name="us-gaap:UseOfEstimates" id="ixv-37403"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Use of Estimates</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_UseOfEstimates-c34_cont_2" id="_UseOfEstimates-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the
amounts reported in the consolidated financial statements and accompanying notes. Significant estimates in these consolidated financial
statements include stock-based compensation expense, fair value of common stock, pre-clinical and clinical accrued expenses, valuation
and realizability of deferred tax assets and the ability to continue as a going concern. On an ongoing basis, the Company evaluates its
estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed
to be reasonable. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from those estimates.</p></ix:continuation></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 199; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c34_cont_2" id="_SignificantAccountingPoliciesTextBlock-c34_cont_1"><ix:continuation id="_UseOfEstimates-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In March 2022, the Company
received an invoice from Mabwell (Shanghai) Bioscience Co., Ltd. (&#8220;Mabwell&#8221;) for approximately $<ix:nonFraction contextRef="c190" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivables" scale="3" unitRef="usd" id="ixv-43335">3,500</ix:nonFraction> in connection with
the manufacturing of certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based
on the information available at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its
validity. The Company continued to dispute the amount and its contractual basis because the parties had neither finalized nor
executed a clinical trial manufacturing agreement. In July 2024, the Company received communication from Mabwell that they will not
be pursuing the collection of the originally invoiced amount. Accordingly, during the year ended December 31, 2024, the Company
reversed the liability and recognized approximately $<ix:nonFraction contextRef="c488" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="3" unitRef="usd" id="ixv-43336">3,500</ix:nonFraction> of other income.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_SegmentReportingPolicyPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="ixv-37431"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Segment Reporting</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c34_cont_2" id="_SegmentReportingPolicyPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">ASC Topic No. 280, Segment Reporting
(&#8220;ASC 280&#8221;), establishes standards for the way that public business enterprises report information about operating segments
in their annual consolidated financial statements and requires that those enterprises report selected information about operating segments
in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas
and major customers. The Company&#8217;s business segments are based on the organization structure used by the chief operating decision
maker (&#8220;CODM&#8221;) for making operating and investment decisions and for assessing performance.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_SegmentReportingPolicyPolicyTextBlock-c34_cont_3" id="_SegmentReportingPolicyPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In accordance with ASC 280, the Company
has determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in
the areas of immuno-oncology, ophthalmology and infectious disease. The financial results of the Company&#8217;s operations are managed
and reported to the Chief Executive Officer, who is considered the Company&#8217;s CODM, on a consolidated basis. The CODM assesses performance
and allocates resources based on the Company&#8217;s consolidated statements of operations, and key components and processes of the Company&#8217;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development and general and administrative
expenses, which are each separately presented on the Company&#8217;s consolidated statements of operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On March 3, 2025, the Board removed
Ian Chan as Chief Executive Officer of the Company for cause, and Miles Suk was appointed as Chief Executive Officer of the Company. In
addition, pursuant to Mr. Chan&#8217;s employment agreement with the Company&#8217;s wholly-owned subsidiary, Abpro Corporation, Mr. Chan
was notified that he was terminated as Chief Executive Officer and director of Abpro Corporation, effective March 3, 2025.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="ixv-37447"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Cash</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in bank deposit accounts,
which, at times, may exceed federally insured limits. As of December 31, 2024 and 2023, the Company has not experienced a loss on its
accounts for which it exceeds federally insured deposit limits.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 200; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c34_cont_3" id="_SignificantAccountingPoliciesTextBlock-c34_cont_2"><ix:nonNumeric contextRef="c34" continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c34_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="ixv-37474"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Restricted Cash</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c34_cont_2" id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The restricted cash balance is related
to a balance provided as collateral associated with the letter of credit for one of the Company&#8217;s facility leases (see Note 9) and
is reported as a current asset in the consolidated balance sheets. <ix:nonNumeric contextRef="c34" continuedAt="_ScheduleOfCondensedCashFlowStatementTableTextBlock-c34_cont_1" escape="true" name="srt:ScheduleOfCondensedCashFlowStatementTableTextBlock" id="ixv-43337">The following tables reconcile cash and restricted cash to amounts
shown in the consolidated statements of cash flows:</ix:nonNumeric></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="_ScheduleOfCondensedCashFlowStatementTableTextBlock-c34_cont_1"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c34_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-43338">2,850</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd" id="ixv-43339">723</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-43340">142</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" unitRef="usd" id="ixv-43341">138</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total cash and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-43342">2,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitRef="usd" id="ixv-43343">861</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_TradeAndOtherAccountsReceivablePolicy-c34_cont_1" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="ixv-37531"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Accounts receivable</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="_TradeAndOtherAccountsReceivablePolicy-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accounts receivable are stated at the
amount management expects to collect from outstanding balances under its license and collaboration arrangements. The Company applies the
guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 326, <i>Financial Instruments-Credit Losses</i> (&#8220;ASC 326&#8221;),
which requires measurement and recognition of expected credit losses for financial assets. The Company records receivables net of any
allowances for doubtful accounts for current expected credit losses under its license and collaboration arrangements. An allowance for
doubtful accounts is determined based on the financial condition and creditworthiness of customers as well as the economic factors and
trends expected to affect future collections. Any allowance would reduce the accounts receivable to the amount that is expected to be
collected. As of December 31, 2024 and 2023, the Company determined that no allowance for doubtful accounts was required.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" continuedAt="_DeferredChargesPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:DeferredChargesPolicyTextBlock" id="ixv-37540"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Deferred Offering Costs</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="_DeferredChargesPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Deferred offering costs consist of
legal, accounting, underwriting fees and other costs of Legacy Abpro that are directly related to the Merger. These costs were accounted
for as a reduction of the proceeds received at the Closing Date of the Merger. As of December 31, 2024 and 2023, the Company had deferred
offering costs of <span style="-sec-ix-hidden: hidden-fact-429">$0</span> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredOfferingCosts" scale="3" unitRef="usd" id="ixv-43344">878</ix:nonFraction>, respectively.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="ixv-37551"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Property and Equipment</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c34_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Property and equipment are stated at
cost, less accumulated depreciation. Repairs and maintenance charges that do not increase the useful life of the assets are charged to
operations as incurred.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="abp:ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" id="ixv-37559"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c34_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Depreciation on property and equipment
is calculated using the straight-line method over the estimated useful lives as follows:&#160;</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c34_cont_3"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 77%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Useful Life<br/>
(in years)</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer hardware and software</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c492" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-43345">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c493" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-43346">5</ix:nonNumeric>&#160;</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c494" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-43347">3</ix:nonNumeric> - <ix:nonNumeric contextRef="c495" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-43348">5</ix:nonNumeric></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c496" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-43349">5</ix:nonNumeric> - <ix:nonNumeric contextRef="c497" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-43350">7</ix:nonNumeric></span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-426">Shorter of useful life or lease term</span></span></td></tr> </table></ix:continuation></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 201; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c34_cont_4" id="_SignificantAccountingPoliciesTextBlock-c34_cont_3"><ix:nonNumeric contextRef="c34" continuedAt="_LesseeLeasesPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock" id="ixv-37616"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Leases</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c34_cont_2" id="_LesseeLeasesPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company accounts for leases in
accordance with ASC Topic 842, <i>Leases </i>(&#8220;ASC 842&#8221;). Under ASC 842, the Company assesses its contracts at inception to
determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly
or implicitly identified asset for a period of time. As a lessee, the Company records a right-of-use asset and a lease liability in its
consolidated balance sheets for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with
classification affecting the pattern of expense recognition in the consolidated statement of operations.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_LesseeLeasesPolicyTextBlock-c34_cont_3" id="_LesseeLeasesPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company recognizes operating
lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets. ROU assets
represent the Company&#8217;s right to use an underlying asset during the lease term and lease liabilities represent the
Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at
commencement date based on the net present value of fixed lease payments over the lease term. The Company&#8217;s lease term
includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. ROU assets also
include any advance lease payments made and are net of any lease incentives. As most of the Company&#8217;s operating leases do not
provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in
determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would
expect to pay to borrow over a similar term, and on a collateralized basis, an amount equal to the lease payments in a similar
economic environment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="_LesseeLeasesPolicyTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company enters into lease agreements
for the use of laboratory and office space, and laboratory equipment, under both operating and finance leases. Operating leases are included
in Right-of-use asset - operating lease, and Operating lease liability - current and Operating lease liability - noncurrent in the consolidated
balance sheets. Finance leases are included in Property and Equipment, net, Finance lease liability - current and Finance lease liability
- noncurrent in the consolidated balance sheets.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="abp_PatentsPolicyTextBlock-c34_cont_1" escape="true" name="abp:PatentsPolicyTextBlock" id="ixv-37633"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Patents</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="abp_PatentsPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company incurs costs related to
patent license fees and patent applications. These payments are capitalized when the Company believes that there is a high likelihood
that the patent will be issued and there will be future economic benefit associated with the patent. These costs are amortized from the
date of the patent application on a straight-line basis over the estimated useful life of <ix:nonNumeric contextRef="c489" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="ixv-43351">20</ix:nonNumeric> years, which is the legal life of the patent.
All costs associated with abandoned patents applications are expensed.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="ixv-37643"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Impairment of Long-lived Assets</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company periodically evaluates
its long-lived assets for potential impairment. Potential impairment is assessed when there is evidence that events or changes in circumstances
indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is based on undiscounted expected future
cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market
trends, and product development cycles. An impairment of the carrying value of each asset is assessed when the undiscounted expected future
cash flows derived from the asset are less than its carrying value. The impairment loss would be measured as the excess of the carrying
value of the impaired asset over its fair value. No impairment charges were recorded for the years ended December 31, 2024 and 2023.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 202; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c34_cont_5" id="_SignificantAccountingPoliciesTextBlock-c34_cont_4"><ix:nonNumeric contextRef="c34" continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="ixv-37670"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Revenue Recognition</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_2" id="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company recognizes revenue in accordance
with the guidance of <i>Revenue From Contracts With Customers</i>, Accounting Standards Codification Topic 606 (&#8220;ASC 606&#8221;).
Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements
the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with
a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance
obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p></ix:continuation>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_3" id="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>License
and collaboration revenues - </i>The Company&#8217;s license and collaboration revenues have been generated primarily through collaborative
research, development, manufacturing and commercialization agreements. The terms of these agreements generally include the license of
intellectual property and associated know-how and the provision of other goods and services. Payments to the Company under these arrangements
typically include one or more of the following: non-refundable, up-front license fees; milestone payments; and royalties on future product
sales.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_4" id="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>License
of Intellectual Property</i> - If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to
the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation
is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue associated with the bundled performance obligation.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<ix:continuation continuedAt="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_5" id="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Milestone
Payments - </i>At the inception of each arrangement that includes milestone payments based upon the achievement of specified clinical
development, regulatory and/or sales milestones, the Company evaluates whether the milestones are considered probable of being achieved
and estimates the amount to be included in the transaction price. If it is probable that a significant revenue reversal would not occur,
the associated milestone amount is included in the transaction price. Milestone payments that are dependent on factors outside of the
Company&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.
These payments are fully constrained and therefore are not included in the transaction price. At the end of each reporting period, the
Company re-evaluates the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the reported amount
of license and collaboration revenues in the period of adjustment.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<ix:continuation id="_RevenueFromContractWithCustomerPolicyTextBlock-c34_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Royalties.
</i>For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is
deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales
occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially
satisfied).</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"></p><div>

</div><!-- Field: Page; Sequence: 203; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c34_cont_6" id="_SignificantAccountingPoliciesTextBlock-c34_cont_5"><ix:nonNumeric contextRef="c34" continuedAt="_ResearchAndDevelopmentExpensePolicy-c34_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="ixv-37710"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Research and Development Expenses</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s research and development
expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation charges for those individuals involved
in research and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies
and clinical materials. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods
or services to be used in research and development are capitalized until the goods or services are received.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_IncomeTaxPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock" id="ixv-37720"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Income Taxes</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c34_cont_2" id="_IncomeTaxPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Income taxes are accounted for under
the asset and liability method, as required by FASB ASC Topic 740, <i>Income Taxes </i>(&#8220;ASC 740&#8221;). The Company provides for
federal, and state income taxes currently payable. Deferred tax assets and liabilities are recognized for the future tax consequences
attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases as well as for tax loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted income
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c34_cont_3" id="_IncomeTaxPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The effect of a change in income tax
rates is recognized as income or expense in the period that includes the enactment date. The Company files income tax returns in the U.S.
federal jurisdiction and various state jurisdictions.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_IncomeTaxPolicyTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company recognizes the effect of
income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured
at the largest amount that is greater than <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" scale="-2" unitRef="pure" id="ixv-43352">50</ix:nonFraction>% likely of being realized. Changes in recognition or measurement are reflected in the period
in which the change in judgment occurs. The Company recognizes interest and/or penalties related to uncertain tax positions in income
tax expense. There were <span style="-sec-ix-hidden: hidden-fact-430"><span style="-sec-ix-hidden: hidden-fact-431">no</span></span> uncertain tax positions as of December 31, 2024 and 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c34_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="ixv-37739"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Share-Based Compensation</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c34_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company accounts for share-based
payments in accordance with Accounting Standard Codification Topic 718, <i>Compensation-Stock Compensation </i>(&#8220;ASC 718&#8221;).
Under ASC 718, the Company measures, and records compensation expense related to share-based payment awards (to employees and non-employees)
based on the grant date fair value using the Black-Scholes option-pricing model. The Company recognizes forfeitures related to employee
share-based payments when they occur. Forfeited share-based awards are recorded as a reduction to share-based compensation expense.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c34_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The determination of the fair value
of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including
expected volatility, expected term, risk-free interest rate and expected dividends.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c34_cont_4" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In determining the exercise prices
of options granted, the Company&#8217;s Board has considered the fair value of the common stock as of the measurement date. As Legacy
Abpro&#8217;s common stock was not traded prior to the Merger, the fair value of the common stock was determined by the Board at each
award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company&#8217;s
financial position and historical financial performance, the status of technological developments within the Company&#8217;s proposed
products, an evaluation or benchmark of the Company&#8217;s competition, the current business climate in the marketplace, the illiquid
nature of the common stock, arm&#8217;s length sales of the Company&#8217;s capital stock, including convertible preferred stock, the
effect of the rights and preferences of the preferred stockholders, and then prospects of a liquidity event, among others.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 204; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c34_cont_7" id="_SignificantAccountingPoliciesTextBlock-c34_cont_6"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c34_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company does not have sufficient
history of market prices of its common stock, and as such, volatility is estimated using historical volatilities of similar public entities.
The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a
sufficient amount of historical information regarding the volatility of its own stock price becomes available. The expected term of the
awards is estimated based on the simplified method for grants to employees and is based on the contractual term for non-employee awards.
The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield
assumption is based on history and expectation of paying no dividends.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" continuedAt="abp_ConvertiblePreferredStockPolicyTextBlock-c34_cont_1" escape="true" name="abp:ConvertiblePreferredStockPolicyTextBlock" id="ixv-37772"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="background-color: white"><b><i>Convertible
Preferred Stock </i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="abp_ConvertiblePreferredStockPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
Company accounts for its convertible preferred stock in accordance with the guidance in ASC Topic 480, <i>Distinguishing Liabilities from
Equity </i>(&#8220;ASC 480&#8221;). Preferred stock subject to mandatory redemption (if any) is classified as a liability instrument and
is measured at fair value. Conditionally redeemable common stock (including preferred stock that features redemption rights that are either
within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s
control) is classified as temporary equity (see Note 14).</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" continuedAt="_DerivativesPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:DerivativesPolicyTextBlock" id="ixv-37783"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="background-color: white"><b><i>Derivative
Financial Instruments</i></b></span></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DerivativesPolicyTextBlock-c34_cont_2" id="_DerivativesPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">In
connection with the Merger, the Company assumed the warrants for common stock shares issued by ACAB, which include warrants issued in
the ACAB&#8217;s initial public offering (&#8220;Public Warrants&#8221;) and warrants purchased by the Sponsor (the  &#8220;Private Warrants&#8221;)
(see Note 14). </span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_DerivativesPolicyTextBlock-c34_cont_3" id="_DerivativesPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
Company accounts for financial instruments as either equity-classified or liability-classified instruments based on an assessment of the
specific terms of the instruments and applicable authoritative guidance in ASC 480 and ASC Topic 815, <i>Derivatives and Hedging </i>(&#8220;ASC
815&#8221;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#8217;s own stock and whether the holders of the warrants could potentially require &#8220;net cash settlement&#8221;
in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification.</span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_DerivativesPolicyTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
Public and Private Warrants were accounted for as equity instruments as they meet all of the requirements for equity classification under
ASC 815 based on current expected terms, which are subject to change. </span></p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="abp_ContingentEarnoutPolicyTextBlock-c34_cont_1" escape="true" name="abp:ContingentEarnoutPolicyTextBlock" id="ixv-37804"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Contingent Earnout Shares</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="abp_ContingentEarnoutPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In connection with the Reverse Recapitalization
and pursuant to the Merger Agreement, Legacy Abpro equity holders are entitled to receive, as additional merger consideration, up to <ix:nonFraction contextRef="c490" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43353">483,333</ix:nonFraction>
shares of the Company&#8217;s common stock (the &#8220;Contingent Earnout Shares&#8221;), comprised of three separate equal tranches,
for no consideration upon the occurrence of certain triggering events, including a change of control event. It was determined that based
on its provisions, the contingent consideration is indexed to the Company&#8217;s stock and therefore qualify for the scope exception
from the derivative accounting in ASC 815-10-15-74(a). As a result, the Company elected to recognize the contingent consideration obligation
in accordance with ASC Topic 450, <i>Contingencies </i>(&#8220;ASC 450&#8221;) when the contingency is resolved, and the consideration
is paid or becomes payable. Based on the Company&#8217;s stock price, no amounts were due under the contingent earnout provisions as of
December 31, 2024.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 205; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c34_cont_8" id="_SignificantAccountingPoliciesTextBlock-c34_cont_7"><ix:nonNumeric contextRef="c34" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="ixv-37832"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Fair Value Measurements and Fair
Value of Financial Instruments </i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company categorizes its assets
and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1)
and lowest priority to unobservable inputs (Level 3). The carrying value of cash, accounts receivable, accounts payable, accrued expenses,
excise taxes payable, income taxes payable, and related party loans payable approximate fair value because of the short-term nature of
such instruments.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Level 1 - Inputs are unadjusted quoted
prices in active markets for identical assets or liabilities available at the measurement date.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Level 2 - Inputs are unadjusted quoted
prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market
data.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Level 3 - Unobservable inputs based
on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In some circumstances, the inputs used
to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement
is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c34_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Transfers to/from Levels 1, 2 and 3
are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="abp_NoncontrollingInterestPolicyTextBlock-c34_cont_1" escape="true" name="abp:NoncontrollingInterestPolicyTextBlock" id="ixv-37857"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Non-controlling Interest</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation id="abp_NoncontrollingInterestPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company holds an <ix:nonFraction contextRef="c491" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" unitRef="pure" id="ixv-43354">82</ix:nonFraction>% ownership
interest in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not
owned by the Company and is reported as a component in stockholders&#8217; equity on the consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockRedemptionPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43355">2.00</ix:nonFraction>
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling interest
holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the years ended
December 31, 2024 and 2023.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_EarningsPerSharePolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock" id="ixv-37867"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Net Loss Per Share</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c34_cont_2" id="_EarningsPerSharePolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company follows the two-class method
to compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 14), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#8217;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#8217;s outstanding common stock
for all periods presented.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 206; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c34_cont_9" id="_SignificantAccountingPoliciesTextBlock-c34_cont_8"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c34_cont_3" id="_EarningsPerSharePolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Basic net loss per share attributable
to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock
outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common
stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or
converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion
of such shares would be anti-dilutive. As the Company has incurred losses for the years ended December 31, 2024 and 2023, basic and diluted
net loss per share is the same all periods presented.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="ixv-37893"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c34_cont_4" id="_EarningsPerSharePolicyTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders,
because their effect was anti-dilutive:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<ix:continuation id="_EarningsPerSharePolicyTextBlock-c34_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Convertible Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-427">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c500" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43356">324,184</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c501" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43357">961,667</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c502" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43358">2,034</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c503" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43359">329,395</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c504" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43360">369,092</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c505" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43361">58,824</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-428">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unvested restricted stock units</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c507" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43362">739</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c508" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43363">1,528</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43364">1,350,625</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares" id="ixv-43365">696,838</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" continuedAt="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock-c34_cont_1" escape="true" name="abp:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" id="ixv-37975"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Recently Adopted Accounting Standards</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In November 2023, the FASB issued ASU
2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;), which enhances disclosure
requirements about significant segment expenses that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;).
ASU 2023-07, among other things, (i) requires a single segment public entity to provide all of the disclosures as required by ASC 280,
(ii) requires a public entity to disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s)
of segment profit or loss in assessing segment performance and deciding how to allocate resources and (iii) provides the ability for a
public entity to elect more than one performance measure. ASU 2023-07 is effective for the fiscal years beginning after December 15, 2023,
and interim periods beginning with the first quarter ending March 31, 2025. Early adoption is permitted, and retrospective adoption is
required for all prior periods presented. The Company has adopted ASU 2023-07 effective December 31, 2024, and concluded that the application
of this guidance did not have any material impact on its consolidated financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<ix:nonNumeric contextRef="c34" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c34_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="ixv-37985"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Recently Issued Accounting Pronouncements</i></b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c34_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In December 2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The
Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c34_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 4, 2024, the FASB issued
ASU 2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the same
tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods
beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company
is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 207; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c34_cont_9"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Management does not believe that any
additional recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#8217;s
financial statements.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" continuedAt="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_1" escape="true" name="abp:RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" id="ixv-38014"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b>Restatement of Previously Issued
Financial Statements</b></p></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_2" id="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company identified an error in
the amount of the accrued expenses within the audited balance sheets as of September 30, 2024, December 31, 2023 and 2022 included in
the Company&#8217;s Form 8-K, filed on November 26, 2024. In accordance with Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 99, <i>Materiality</i>,
and SAB No. 108, <i>Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</i>,
the Company evaluated these misstatements, and based on an analysis of quantitative and qualitative factors, determined that the impact
of these misstatements was material to its reporting periods ended December 31, 2023, December 31, 2022 and September 30, 2024.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_3" id="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accordingly, the Company has restated
its consolidated financial statements for the years ended December 31, 2023 and 2022, and its interim reporting period for the nine months
ended September 30, 2024, and has included that restated financial information within this annual report.</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="ixv-38026"><ix:continuation continuedAt="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_4" id="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of December 31, 2023 is reflected in the following table:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_5" id="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_4"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c509" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43366">2,081</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c510" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43367">3,300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c511" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43368">5,381</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c509" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43369">12,891</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c510" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43370">3,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c511" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43371">16,191</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c509" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43372">105,571</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c510" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43373">3,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c511" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43374">108,871</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c509" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43375">85,135</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c510" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43376">3,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c511" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43377">88,435</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_6" id="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of December 31, 2022 is reflected in the following table:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_7" id="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_6"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c512" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43378">1,897</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c513" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43379">3,300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c514" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43380">5,197</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c512" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43381">11,987</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c513" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43382">3,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c514" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43383">15,287</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c512" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43384">93,865</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c513" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43385">3,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c514" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43386">97,165</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c512" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43387">75,734</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c513" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43388">3,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c514" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43389">79,034</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation continuedAt="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_8" id="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of September 30, 2024 is reflected in the following table:</p></ix:continuation>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock-c34_cont_8"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c515" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43390">2,745</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c516" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43391">3,300</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c517" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43392">6,045</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c515" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43393">15,277</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c516" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43394">3,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c517" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitRef="usd" id="ixv-43395">18,577</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c515" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43396">109,468</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c516" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43397">3,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c517" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd" id="ixv-43398">112,768</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c515" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43399">87,501</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c516" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43400">3,300</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c517" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43401">90,801</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  </table></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 208; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c34_cont_1" escape="true" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="ixv-38263"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>3.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Merger</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 13, 2024, Merger Sub, a
wholly-owned subsidiary of ACAB, merged with Legacy Abpro, with Legacy Abpro surviving as a wholly-owned subsidiary of ACAB. At the effective
time of the Merger:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each outstanding share of Legacy Abpro common stock was converted into approximately <ix:nonFraction contextRef="c202" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-43402">0.068</ix:nonFraction> shares of the Company&#8217;s common stock;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each outstanding share of preferred stock of Legacy Abpro was converted into the aggregate number of shares of New Abpro&#8217;s common stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately <ix:nonFraction contextRef="c203" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitRef="shares" id="ixv-43403">0.068</ix:nonFraction>; and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each outstanding option or warrant to purchase Legacy Abpro common stock was converted into an option or warrant, as applicable, to purchase a number of shares of the Company&#8217;s common stock equal to the number of shares of Legacy Abpro common stock subject to such option or warrant multiplied by approximately <ix:nonFraction contextRef="c204" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares" id="ixv-43404">0.068</ix:nonFraction>, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately <ix:nonFraction contextRef="c204" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-43405">0.068</ix:nonFraction>; in each case, rounded down to the nearest whole share.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In addition, at the Closing Date, <ix:nonFraction contextRef="c518" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-43406">6,744,550</ix:nonFraction>
shares of Series A common stock and <ix:nonFraction contextRef="c519" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-43407">1</ix:nonFraction> share of Series B common stock of ACAB automatically converted into shares of the Company&#8217;s
common stock, on a one-for-one basis (pre-split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Former holders of the Legacy Abpro
common stock and Legacy Abpro preferred stock are eligible to receive up to <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="abp:AdditionSharesOfCommonStock" scale="0" unitRef="shares" id="ixv-43408">483,333</ix:nonFraction> additional shares of the Company&#8217;s common stock (&#8220;Contingent Earnout Shares&#8221;) if, within five calendar years after the closing of the Merger, the volume weighted
average price of shares of the Company&#8217;s Common Stock on Nasdaq, or any other national securities exchange on which the shares of
the Company&#8217;s Common Stock are then traded (&#8220;VWAP&#8221;) meets or exceeds three-tier target prices defined in the agreement,
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one-third of the total Earnout Shares, if, the VWAP is greater than or equal to $<ix:nonFraction contextRef="c520" decimals="2" format="ixt:num-dot-decimal" name="abp:EarnoutShare" scale="0" unitRef="usdPershares" id="ixv-43409">390.00</ix:nonFraction> over any <ix:nonNumeric contextRef="c520" format="ixt-sec:durday" name="abp:TradingDays" id="ixv-43410">20</ix:nonNumeric> trading days within any consecutive <ix:nonNumeric contextRef="c520" format="ixt-sec:durday" name="abp:NumberOfConsecutiveTradingDays" id="ixv-43411">30</ix:nonNumeric> trading day period (the &#8220;First Share Target&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="padding-left: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one-third of the total Earnout Shares, if, the VWAP is greater than or equal to $<ix:nonFraction contextRef="c521" decimals="2" format="ixt:num-dot-decimal" name="abp:EarnoutShare" scale="0" unitRef="usdPershares" id="ixv-43412">450.00</ix:nonFraction> over any <ix:nonNumeric contextRef="c521" format="ixt-sec:durday" name="abp:TradingDays" id="ixv-43413">20</ix:nonNumeric> trading days within any consecutive <ix:nonNumeric contextRef="c521" format="ixt-sec:durday" name="abp:NumberOfConsecutiveTradingDays" id="ixv-43414">30</ix:nonNumeric> trading day period (the &#8220;Second Share Target&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one-third of the total Earnout Shares, if, the VWAP is greater than or equal to $<ix:nonFraction contextRef="c522" decimals="2" format="ixt:num-dot-decimal" name="abp:EarnoutShare" scale="0" unitRef="usdPershares" id="ixv-43415">540.00</ix:nonFraction> over any <ix:nonNumeric contextRef="c522" format="ixt-sec:durday" name="abp:TradingDays" id="ixv-43416">20</ix:nonNumeric> trading days within any consecutive <ix:nonNumeric contextRef="c522" format="ixt-sec:durday" name="abp:NumberOfConsecutiveTradingDays" id="ixv-43417">30</ix:nonNumeric> trading day period (the &#8220;Third Share Target&#8221;).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">If following the Closing, a Change
of Control (as defined in the Merger Agreement) occurs on or before the five year anniversary of the Closing Date, then if (i) the per
share value of the consideration to be received by stockholders in connection with the Change of Control exceeds $<ix:nonFraction contextRef="c523" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43418">390.00</ix:nonFraction> per share and
the First Share Target has not been previously achieved, then the First Share Target will be deemed to have been achieved, (ii) the per
share value of the consideration to be received by stockholders exceeds $<ix:nonFraction contextRef="c524" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43419">450.00</ix:nonFraction> per share and the Second Share Target has not been previously
achieved, then the Second Share Target will be deemed to have been achieved, and (iii) the per share value of the consideration to be
received by stockholders exceeds $<ix:nonFraction contextRef="c525" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43420">540.00</ix:nonFraction> per share and the Third Share Target has not been previously achieved, then the Third Share Target
will be deemed to have been achieved. Any Contingency Consideration that is not deemed to be earned in connection with the Change of Control
shall be forfeited by the stockholders for no consideration.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 209; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c34_cont_2" id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At the Closing Date, the Company issued
an aggregate of <ix:nonFraction contextRef="c526" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43421">112,247</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;PIPE Shares&#8221;) in a private placement for the total
consideration of $<ix:nonFraction contextRef="c527" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="3" unitRef="usd" id="ixv-43422">11,225</ix:nonFraction> (the &#8220;PIPE Financing&#8221;). Out of the total PIPE Shares, <ix:nonFraction contextRef="c528" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43423">20,749</ix:nonFraction> shares were issued to Abpro Bio International,
Inc. (&#8220;ABI&#8221;), pursuant to the terms of a subscription agreement dated August 22, 2024 with ABI (the &#8220;Abpro Bio Subscription
Agreement&#8221;) for an aggregate purchase price of $<ix:nonFraction contextRef="c526" decimals="-3" format="ixt:num-dot-decimal" name="abp:AggregatePurchasePrice" scale="3" unitRef="usd" id="ixv-43424">6,225</ix:nonFraction>, of which $<ix:nonFraction contextRef="c526" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd" id="ixv-43425">4,225</ix:nonFraction> was used to repay the balance due by Legacy Abpro to ABI
under the promissory note agreement (see Note 8) and the remainder of $<ix:nonFraction contextRef="c529" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-43426">2,000</ix:nonFraction> in cash. In addition, pursuant to the Abpro Bio Subscription
Agreement, ABI received an aggregate of <ix:nonFraction contextRef="c530" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43427">41,498</ix:nonFraction> shares of New Abpro common stock reserved for use in the PIPE Financing or to obtain capital
for ACAB or the surviving company, as defined in the Merger Agreement (the &#8220;Incentive Shares&#8221;). The Company also issued <ix:nonFraction contextRef="c531" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43428">16,667</ix:nonFraction>
common stock shares of New Abpro to <span style="background-color: white">Celltrion, Inc., a company organized and existing under the
laws of South Korea (&#8220;Celltrion&#8221;)</span>, pursuant to the terms of a subscription agreement dated August 22, 2024 with <span style="background-color: white">Celltrion
(&#8220;Celltrion&#8221;) </span>(the &#8220;Celltrion Subscription Agreement&#8221;, together with the &#8220;Abpro Bio Subscription
Agreement&#8221;, collectively the &#8220;PIPE Subscription Agreements&#8221;) for an aggregate purchase price of $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:AggregatePurchasePrice" scale="3" unitRef="usd" id="ixv-43429">5,000</ix:nonFraction>. In addition,
Celltrion received an aggregate of <ix:nonFraction contextRef="c34" decimals="0" format="ixt:num-dot-decimal" name="abp:AggregateIncentiveShare" scale="0" unitRef="shares" id="ixv-43430">33,333</ix:nonFraction> Incentive Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Pursuant to the terms of the Merger
Agreement, at the Closing Date, ACAB&#8217;s sponsor, Atlantic Coastal Management II LLC (the &#8220;Sponsor&#8221;) received <ix:nonFraction contextRef="c532" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43431">20,020</ix:nonFraction> shares
of New Abpro common stock in lieu of repayment of $<ix:nonFraction contextRef="c533" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfDebt" scale="3" unitRef="usd" id="ixv-43432">2,000</ix:nonFraction> of Unpaid SPAC Expenses (as defined in the Merger Agreement) owed to the Sponsor
as a result of advances made by the Sponsor to ACAB. This settlement was related to the ACAB liabilities incurred prior to the Merger
and had no financial impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At the Closing, and in accordance with
the Sponsor Letter Agreement entered into on December 11, 2023, as amended, the Sponsor transferred <ix:nonFraction contextRef="c216" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43433">32,778</ix:nonFraction> common shares to Legacy Abpro
and <ix:nonFraction contextRef="c217" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43434">32,778</ix:nonFraction> shares to ABI, and <ix:nonFraction contextRef="c218" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" scale="0" unitRef="shares" id="ixv-43435">32,215</ix:nonFraction> shares were forfeited. The shares transferred to Legacy Abpro were deemed to be repurchased by the
post-merger Company for no consideration and included in treasury stock as of the Closing Date and December 31, 2024. The shares transferred
to ABI for no consideration were accounted for as a recapitalization with no impact on the consolidated financial statements. The Sponsor
also transferred <ix:nonFraction contextRef="c219" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43436">6,667</ix:nonFraction> shares to one of ACAB&#8217;s financial advisors for the services provided prior to the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, at the Closing, the Company
issued <ix:nonFraction contextRef="c534" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43437">36,095</ix:nonFraction> common stock shares to various service providers, of which <ix:nonFraction contextRef="c535" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43438">1,095</ix:nonFraction> shares were issued to an investment advisor in the PIPE
Financing and the remaining <ix:nonFraction contextRef="c536" decimals="0" format="ixt:num-dot-decimal" name="abp:RemainingSharesIssued" scale="0" unitRef="shares" id="ixv-43439">35,000</ix:nonFraction> common stock shares were issued in settlement of ACAB&#8217;s liabilities for the services provided
by various legal and investment advisors prior to the Closing Date. The issuance of these shares, related to the services provided to
ACAB prior to the Merger which were expensed on the books of ACAB, with no financial impact on the Company&#8217;s consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" id="ixv-38355"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The number of shares of the Company&#8217;s
common stock outstanding immediately following the consummation of the Merger was:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Common stock of ACAB, net of redemptions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c539" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43440">7,033</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ACAB Founder Shares, less of forfeitures and transfers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c540" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43441">126,076</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">New Abpro shares issued to PIPE investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c541" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43442">112,247</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">New Abpro shares issued to service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c542" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43443">42,762</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">New Abpro shares issued in Merger to Legacy Abpro stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c543" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43444">1,304,107</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">New Abpro shares transferred to investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c544" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43445">72,285</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">New Abpro shares issued to settle the promissory note with executive</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c545" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43446">20,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total shares of common stock outstanding immediately after Merger</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><ix:nonFraction contextRef="c43" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43447">1,684,510</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 210; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_MergersAcquisitionsAndDispositionsDisclosuresTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Merger was accounted for as a
reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, ACAB is treated as the acquired company for
financial reporting purposes and Legacy Abpro is treated as the acquirer. This determination is primarily based on the fact that
subsequent to the Merger, the Legacy Abpro stockholders hold a majority of the voting rights of the combined company, Legacy Abpro
comprises all of the ongoing operations of the combined company, Legacy Abpro comprises a majority of the carryover governing body
of the combined company, and Legacy Abpro&#8217;s senior management comprises all of the senior management of the combined company.
Accordingly, for accounting purposes, the Merger was treated as the equivalent of Legacy Abpro issuing shares for the net assets of
ACAB, accompanied by a recapitalization. The net assets of ACAB were stated at historical costs. No goodwill or other intangible
assets were recorded. Operations prior to the Merger are those of Legacy Abpro.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company received $<ix:nonFraction contextRef="c534" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="6" unitRef="usd" id="ixv-43448">5.7</ix:nonFraction> million in
proceeds from the Merger and related PIPE Financing, net of ACAB transaction costs settled at the Closing. The Company incurred $<ix:nonFraction contextRef="c537" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" scale="6" unitRef="usd" id="ixv-43449">2.1</ix:nonFraction> million
in transaction costs and $<ix:nonFraction contextRef="c534" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="6" unitRef="usd" id="ixv-43450">0.9</ix:nonFraction> million in issuance costs related to the PIPE Financing, consisting of banking, legal, investment advisory
and other professional fees, of which were recorded as a reduction of proceeds to additional paid-in capital. At the Closing Date, Legacy
Abpro assumed $<ix:nonFraction contextRef="c538" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilities" scale="6" unitRef="usd" id="ixv-43451">6.6</ix:nonFraction> million of net liabilities, including tax liabilities and legal fees, of ACAB, of which $<ix:nonFraction contextRef="c536" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LegalFees" scale="6" unitRef="usd" id="ixv-43452">1.0</ix:nonFraction> million was included in
accrued expenses, $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="6" unitRef="usd" id="ixv-43453">4.4</ix:nonFraction> million in excise tax payable and $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" unitRef="usd" id="ixv-43454">0.4</ix:nonFraction> million in income tax payable as of December 31, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="ixv-38434"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4</b>.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>&#160;</b></p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="ixv-38446"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s property and equipment
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c546" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43455">53</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c547" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43456">53</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c548" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43457">1,097</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c549" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43458">1,097</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer hardware and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c550" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43459">15</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c551" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43460">15</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c498" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43461">788</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c552" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43462">788</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equipment under finance leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c553" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43463">740</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c554" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43464">740</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43465">2,693</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd" id="ixv-43466">2,693</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-43467">2,656</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-43468">2,591</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-43469">37</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd" id="ixv-43470">102</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Depreciation expense was $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-43471">65</ix:nonFraction> and $<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd" id="ixv-43472">269</ix:nonFraction>
for the years ended December 31, 2024 and 2023, respectively.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="ixv-38549"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued
Expenses</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="ixv-38560"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accrued expenses consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/> (As&#160;Restated)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued salaries and wages</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" unitRef="usd" id="ixv-43473">1,549</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" unitRef="usd" id="ixv-43474">1,398</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-43475">1,273</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" unitRef="usd" id="ixv-43476">93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued license fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedLicenseFees" scale="3" unitRef="usd" id="ixv-43477">3,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedLicenseFees" scale="3" unitRef="usd" id="ixv-43478">3,300</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedInterest" scale="3" unitRef="usd" id="ixv-43479">267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-432">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BOD compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedBODCompensation" scale="3" unitRef="usd" id="ixv-43480">242</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-433">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43481">865</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43482">590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total accrued expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43483">7,496</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43484">5,381</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 211; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_FairValueDisclosuresTextBlock-c34_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock" id="ixv-38665"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value Measurements</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="ixv-38676"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table presents information
about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2024, and indicates
the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Forward purchase agreement asset (Note 11)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c245" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-43485">155</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SEPA put rights asset (Note 13)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c247" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-43486">188</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Embedded derivative liability (Note 13)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c249" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-43487">80</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">There were no assets or liabilities
measured at fair value on a recurring basis as of December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" continuedAt="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c34_cont_1" escape="true" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="ixv-38749"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The fair value of the Company&#8217;s
position under the Forward Purchase Agreement was calculated by multiplying the number of shares under the Forward Purchase Agreement
by the market price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">November&#160;13,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c562" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43488">173.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c250" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43489">53.70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c563" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43490">4.6</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c251" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43491">4.4</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c564" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43492">0.3</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c252" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43493">0.1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c565" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43494">90</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c253" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43495">98</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c566" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43496">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c254" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43497">0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table></ix:nonNumeric>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The fair value of the SEPA Put Rights
was estimated as the sum of the fair values of the put rights under each assumed advance notice over the term of the SEPA. The number
of shares under each advance notice was based on the historical trading volumes of the Company&#8217;s stock taking into account various
beneficial ownership and daily volume limitations. <ix:continuation continuedAt="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c34_cont_2" id="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c34_cont_1">The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:</ix:continuation></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:continuation id="_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock-c34_cont_2"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">November 13,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Stock price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c567" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43499">173.10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c256" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43500">53.70</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c568" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43501">4.3</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c259" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43502">4.2</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c569" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43503">166.20</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c261" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43504">51.60</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c570" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43505">1</ix:nonFraction> to <ix:nonFraction contextRef="c571" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43506">2</ix:nonFraction> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c264" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43507">1</ix:nonFraction> to <ix:nonFraction contextRef="c265" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43508">2</ix:nonFraction> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c572" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43509">82</ix:nonFraction>-<ix:nonFraction contextRef="c573" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43510">90</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"><ix:nonFraction contextRef="c267" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43511">93</ix:nonFraction>-<ix:nonFraction contextRef="c268" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43512">99</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c574" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43513">0</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c270" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43514">0</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Number of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c575" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43515">5,500</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c272" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="0" unitRef="pure" id="ixv-43516">1,883</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 212; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The fair value of the Embedded
Derivative Feature was estimated at $<ix:nonFraction contextRef="c555" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-43517">69</ix:nonFraction> at the issuance date based on the difference between the fair value of the convertible note
with these embedded features and the fair value without each one of these embedded features. The assumptions incorporated into the
valuation model as of November 13, 2024, the issuance date of the Convertible Note included the stock price of $<ix:nonFraction contextRef="c556" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-43518">173.10</ix:nonFraction>, the
estimated future price per share of $<ix:nonFraction contextRef="c556" decimals="2" format="ixt:num-dot-decimal" name="abp:EstimatedFuturePricePerShare" scale="0" unitRef="usdPershares" id="ixv-43519">130.80</ix:nonFraction> (derived using Monte Carlo Simulation), the expected volatility of <ix:nonFraction contextRef="c557" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-43520">90</ix:nonFraction>%, the risk-free
rate of <ix:nonFraction contextRef="c557" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-43521">4.31</ix:nonFraction>% and the term of <ix:nonNumeric contextRef="c557" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-43522">1</ix:nonNumeric> year. As of December 31, 2024 the assumptions incorporated into the valuation model included the
stock price of $<ix:nonFraction contextRef="c239" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-43523">53.70</ix:nonFraction>, the estimated future price per share of $<ix:nonFraction contextRef="c558" decimals="2" format="ixt:num-dot-decimal" name="abp:EstimatedFuturePricePerShare" scale="0" unitRef="usdPershares" id="ixv-43524">61.80</ix:nonFraction> (derived using Monte Carlo Simulation), the expected
volatility of <ix:nonFraction contextRef="c559" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-43525">99</ix:nonFraction>%, the risk-free rate of <ix:nonFraction contextRef="c560" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-43526">4.18</ix:nonFraction>% and the term of <ix:nonNumeric contextRef="c561" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-43527">0.9</ix:nonNumeric> years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="ixv-38932"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The changes in the fair value of Level
3 financial assets and liabilities for the year ended December 31, 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward<br/>
Purchase<br/>
Agreement<br/>
asset</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEPA<br/>
Put Rights<br/>
Asset</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Embedded <br/>
Derivative Liability</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 67%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value as of January 1, 2024</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-434; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-435; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial measurement at the issuance date</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c578" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" unitRef="usd" id="ixv-43528">494</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c579" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" unitRef="usd" id="ixv-43529">1,551</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c580" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="3" unitRef="usd" id="ixv-43530">69</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c578" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" sign="-" unitRef="usd" id="ixv-43531">339</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonFraction contextRef="c579" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" sign="-" unitRef="usd" id="ixv-43532">1,363</ix:nonFraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c580" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueOptionChangesInFairValueGainLoss1" scale="3" unitRef="usd" id="ixv-43533">11</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value as of December 31, 2024</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c273" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd" id="ixv-43534">155</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c274" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd" id="ixv-43535">188</ix:nonFraction></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c275" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd" id="ixv-43536">80</ix:nonFraction></span></td>
    <td>&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_CollaborativeArrangementDisclosureTextBlock-c34_cont_1" escape="true" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="ixv-39056"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
and Collaboration Agreements</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>NJCTTQ Collaboration Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In January 2019, the Company entered
into a collaboration agreement with Nanjing Chia Tai Tianquing Pharmaceutical Co., Ltd. (&#8220;NJCTTQ&#8221;) to research, develop and
commercialize two anti-Claudin 18.2 lead antibodies (the &#8220;NJCTTQ agreement&#8221;). Under the NJCTTQ agreement, the Company granted
a non-exclusive, non-sublicensable research license and an exclusive, sublicensable license to NJCTTQ within the People&#8217;s Republic
of China and Thailand (the &#8220;NJCTTQ Territory&#8221;). The initial term of this agreement was 5 years, which could be automatically
renewed for another 5 years. If no collaboration project reached the clinical stage within the first 5 years of the NJCTTQ agreement,
then this agreement would not have been renewed. The agreement expired in January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company was eligible to receive
up to an aggregate of $<ix:nonFraction contextRef="c581" decimals="-3" format="ixt:num-dot-decimal" name="abp:NonRefundablePayments" scale="3" unitRef="usd" id="ixv-43537">405,000</ix:nonFraction> of non-refundable milestone payments from NJCTTQ upon achieving certain development, regulatory approval,
and commercialization and sales milestones for each unique licensed antibody or product in NJCTTQ Territory. The Company agreed to pay
NJCTTQ up to an aggregate of $<ix:nonFraction contextRef="c582" decimals="-3" format="ixt:num-dot-decimal" name="abp:NonRefundablePayments" scale="3" unitRef="usd" id="ixv-43538">5,000</ix:nonFraction> in nonrefundable amounts upon achieving of a regulatory milestone in the Company&#8217;s territory,
which includes all other countries other than the NJCTTQ Territory. No <span style="background-color: white">milestones have been reached
through the expiration of this agreement in January 2024, no products were sold by NJCTTQ, and no related revenue amounts have been recorded
in the accompanying consolidated financial statements. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company and NJCTTQ agreed to pay
reciprocal royalties, with each of them paying the other party low single-digit royalties, tiered based on net sales per calendar year
in its territory. <span style="background-color: white">The agreement remains unrenewed as of December 31, 2024 after the expiration of
its initial term. However, notwithstanding the agreement&#8217;s expiration, the low single-digit royalties and the $<ix:nonFraction contextRef="c582" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-43539">5,000</ix:nonFraction>&#160;</span>regulatory
<span style="background-color: white">milestone payable to NJCTTQ based on commercial approval in </span>the Company&#8217;s <span style="background-color: white">territory,
as described above, will continue to apply.</span> Through <span style="background-color: white">December 31, 2024</span>, <span style="background-color: white">no
products were sold by NJCTTQ or the Company under the NJCTTQ agreement and no regulatory milestones were achieved by the Company in the
Company&#8217;s territory.</span></p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 213; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation continuedAt="_CollaborativeArrangementDisclosureTextBlock-c34_cont_2" id="_CollaborativeArrangementDisclosureTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>ABP-100 Collaboration and License
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In December 2019, the Company
entered into an exclusive collaboration and license agreement with a related party, ABI (the &#8220;ABP-100 agreement&#8221;). Under
the ABP-100 agreement, the Company granted ABI the license to develop and commercialize products and services based on the
Company&#8217;s Her2-hu-OKT3 bispecific antibody (&#8220;ABP-100&#8221;) within the territories of People&#8217;s Republic of China,
Japan, South Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States, as defined in the agreement. Unless
earlier terminated, the ABP-100 agreement, will expire upon the satisfaction of all obligations under the agreement following the
expiration of the last royalty payment obligation. Either party may terminate the agreement in the event of any uncured material
breach by the other party. The license granted under the ABP-100 agreement was a sub-license from Memorial Sloan Kettering Cancer
Center (&#8220;MSK&#8221;) pursuant to MSK License Agreement (see Note 6). This agreement was terminated due to the termination of
the MSK License Agreement in September 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the ABP-100 agreement, ABI agreed
to use commercially reasonable efforts to reach certain development and commercial milestones for at least one licensed product or licensed
service within specified timeframes. ABI is committed to pay the Company running royalties on net sales of any licensed products or services
from the mid-single digit percentages to the low double-digit percentage, and the guaranteed annual minimum royalties of $<ix:nonFraction contextRef="c583" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="3" unitRef="usd" id="ixv-43540">30</ix:nonFraction> starting
on the first anniversary of the effective date of the agreement (which annual minimum royalties may be credited against the running royalties
on net sales of any licensed products or services). Through the termination of this agreement in September 2023, <span style="background-color: white">no
products were sold by ABI under the ABP-100 agreement.</span> During the years ended December 31, 2024 and 2023, the Company earned <span style="-sec-ix-hidden: hidden-fact-436">$0</span>
and $<ix:nonFraction contextRef="c585" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" unitRef="usd" id="ixv-43541">23</ix:nonFraction> in minimum royalty payments, included in royalty revenue. As of both December 31, 2024 and 2023, the accounts receivable were
$<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNet" scale="3" unitRef="usd" id="ixv-43542">53</ix:nonFraction>, associated with the minimum royalties <span style="background-color: white">under this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In addition to the royalty payments,
the Company could receive up to $<ix:nonFraction contextRef="c586" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-43543">498,000</ix:nonFraction> in milestone payments per licensed product or licensed service upon the achievement of specified
research and development and sales milestone events. No milestones have been reached through the termination of this agreement in September
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company was also entitled to research
funding fees for costs incurred by the Company for certain sponsored research activities and the reimbursement of <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfReimbursement" scale="-2" unitRef="pure" id="ixv-43544">60</ix:nonFraction>% of the costs of
certain product development directed activities, as outlined in the agreement. During the years ended December 31, 2024 and 2023, the
Company did not earn any research funding fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Further, the Company was to be reimbursed
for patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights
in the license territory. The Company did not receive any reimbursements of patent costs during the years ended December 31, 2024 and
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>ABP-201 Collaboration and License
Agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In January 2020, the Company&#8217;s
consolidated subsidiary, AbMed, entered into a collaboration and license agreement with ABI (the &#8220;ABP-201 Agreement&#8221;), pursuant
to which the Company granted to ABI an exclusive, royalty-bearing, license under specified patent rights to make, use and sell certain
of its proprietary ANG-2/VEGF-HIRK bispecific antibodies within the licensed territory comprising People&#8217;s Republic of China, Japan,
South Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States. Unless earlier terminated in accordance with
its terms, the agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the ABP-201 agreement, ABI agreed
to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within
specified territories and timeframes. ABI is committed to pay the Company up to $<ix:nonFraction contextRef="c587" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43545">56,500</ix:nonFraction> in milestone payments upon achieving certain research
and development events, up to $<ix:nonFraction contextRef="c530" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43546">485,000</ix:nonFraction> in milestone payments based on annual net sales per each licensed product, and a double-digit percentage
royalty in the low teens, tiered based on cumulative net sales by ABI, its affiliates or sublicensees beginning with the first commercial
sale of a licensed product in its territory. No <span style="background-color: white">milestones have been reached through December 31,
2024, no products were sold by ABI, and no related revenue amounts have been recorded in the accompanying consolidated financial statements.
</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 214; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><ix:continuation id="_CollaborativeArrangementDisclosureTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Celltrion Collaboration and License
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">In
September 2022, the Company entered into an exclusive collaboration and license agreement with Celltrion (the &#8220;Original Celltrion
Agreement&#8221;). The Company and Celltrion entered into an amendment to the agreement in October 2024 in connection with the execution
of the Celltrion Subscription Agreement (the &#8220;Amended Celltrion Agreement&#8221;). The amendment is subject to termination by the
Company or Celltrion if (i) the share purchase under the Celltrion Subscription Agreement is not completed, or (ii) the Celltrion Subscription
Agreement is terminated pursuant to Section 7 of the Celltrion Subscription Agreement. Under the Amended Celltrion Agreement, the Company
granted to Celltrion a worldwide exclusive license under specified patent rights to develop, make, have made, import, export, use, have
used, sell and have sold certain of its proprietary ABP-102 bispecific antibodies. The License Agreement also provides that the Company
is to perform certain preclinical in vitro studies. The License Agreement will remain in effect for so long as ABP-102 is being developed
or commercialized anywhere in the world. Celltrion may terminate the license agreement at any time by providing six months prior written
notice to the Company. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">Celltrion
is committed to pay the Company up to $<ix:nonFraction contextRef="c588" decimals="-3" format="ixt:num-dot-decimal" name="abp:OriginalCelltrionAgreement" scale="3" unitRef="usd" id="ixv-43547">10,000</ix:nonFraction> under the Original Celltrion Agreement and $<ix:nonFraction contextRef="c589" decimals="-3" format="ixt:num-dot-decimal" name="abp:OriginalCelltrionAgreement" scale="3" unitRef="usd" id="ixv-43548">6,000</ix:nonFraction> under the Amended Celltrion Agreement
in milestone payments upon granting the license and achieving certain research and development events, up to $<ix:nonFraction contextRef="c588" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43549">1,750,000</ix:nonFraction> in milestone payments
based on annual net sales per each licensed product. The proceeds from commercialization are subject to a 50/50 profit split. Amounts
that may be paid by third-party collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization
partners, are also subject to a 50/50 split. Following commercial approval of ABP-102, the Company has agreed to reimburse Celltrion <ix:nonFraction contextRef="c34" decimals="3" format="ixt:num-dot-decimal" name="abp:PercentageOfOriginalCelltrionAgreement" scale="-2" unitRef="pure" id="ixv-43550">87.5</ix:nonFraction>%
under the Original Celltrion Agreement and <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAmendedCelltrionAgreement" scale="-2" unitRef="pure" id="ixv-43551">250</ix:nonFraction>% under the Amended Celltrion Agreement of its direct and certain indirect costs and expenses
incurred through first commercial sale. Under the Original Celltrion Agreement, Celltrion is entitled to offset amounts otherwise due
to us under the agreement until our share of these costs has been paid back; provided that the Company is entitled to a minimum <ix:nonFraction contextRef="c471" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAmendedCelltrionAgreement" scale="-2" unitRef="pure" id="ixv-43552">25</ix:nonFraction>% (or
<ix:nonFraction contextRef="c590" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAmendedCelltrionAgreement" scale="-2" unitRef="pure" id="ixv-43553">50</ix:nonFraction>% under the Amended Celltrion Agreement) of profit from commercial sales and from third-party collaborators regardless of the amount
of unreimbursed development costs outstanding (and then <ix:nonFraction contextRef="c588" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfReimbursement" scale="-2" unitRef="pure" id="ixv-43554">50</ix:nonFraction>% once the reimbursement has been made in full).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
first milestone of $<ix:nonFraction contextRef="c591" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43555">2,000</ix:nonFraction> was achieved upon granting the license at the collaboration effective date, as defined in the Celltrion Agreement,
in December 2022 and received in January 2023. During the year ended December 31, 2022, the Company allocated $<ix:nonFraction contextRef="c592" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-43556">64</ix:nonFraction> to the initial obligation
to perform in vitro testing for the research and development services and the remaining $<ix:nonFraction contextRef="c593" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitRef="usd" id="ixv-43557">1,936</ix:nonFraction> to the license of the Company&#8217;s intellectual
property, bundled with the associated know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s initial obligation
to <span style="background-color: white">perform in vitro testing for the research and development services</span> represents a distinct
performance obligation. The revenue for this performance obligation was be recognized on a straight-line based over the term of the studies.
During the years ended December 31, 2024 and 2023, the Company recognized $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" unitRef="usd" id="ixv-43558">0</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="3" unitRef="usd" id="ixv-43559">64</ix:nonFraction>, respectively, in connection with this performance
obligation, included in collaboration revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white"><i>Milestone
Payments. </i>The Company is entitled to development milestones under the Celltrion Agreement and certain regulatory milestone payments
which are paid upon receipt of regulatory approvals. Except for the first milestone of $<ix:nonFraction contextRef="c594" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43560">2,000</ix:nonFraction> achieved in 2022, no other milestone payments
were earned through December 31, 2024. The Company evaluated whether the remaining milestones are considered probable of being reached
and determined that their achievement is highly dependent on factors outside of the Company&#8217;s control. Therefore, these payments
have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company
will re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust its estimate of
the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect the reported amount
of collaboration revenues in the period of adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white"><i>Profit
Splits.</i> As the license is deemed to be the predominant item to which profit splits relate, the Company will recognize revenue when
the related sales or third-party collaborator income occur. No profit split revenue has been recognized from inception through December
31, 2024.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 215; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_CommitmentsDisclosureTextBlock-c34_cont_1" escape="true" name="us-gaap:CommitmentsDisclosureTextBlock" id="ixv-39189"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments
under Research and Collaboration Agreements</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>MedImmune License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In August 2016, the Company entered
into a collaboration and license agreement with MedImmune Limited (&#8220;MedImmune&#8221;), pursuant to which the Company received from
MedImmune an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license to certain intellectual property
rights relating to the Company&#8217;s ABP-200 product candidates (the &#8220;MedImmune License Agreement&#8221;). The Company agreed
to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within
specified timeframes. Unless earlier terminated in accordance with its terms, the MedImmune License Agreement, as amended, remains in
effect on a country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of
products based on the ABP-200 product candidates. The Company is no longer developing ABP-200.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the MedImmune License Agreement,
the Company agreed to pay milestone and royalty payments, including up to $<ix:nonFraction contextRef="c595" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43561">244,000</ix:nonFraction> in milestone payments, which are comprised of $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ClinicalDevelopmentMilestones" scale="3" unitRef="usd" id="ixv-43562">14,000</ix:nonFraction>
upon meeting certain clinical development milestones, $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:RegulatoryEvents" scale="3" unitRef="usd" id="ixv-43563">80,000</ix:nonFraction> upon achieving certain regulatory events and $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:CommercialSales" scale="3" unitRef="usd" id="ixv-43564">150,000</ix:nonFraction> upon meeting certain
worldwide commercial sales thresholds; and tiered high-single to low double-digit percentage royalties based on annualized net sales of
each product commercialized from our collaboration on a country-by-country basis. No milestones have been reached and no products were
sold by the Company through December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>NCI License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In August 2017, the Company entered
into a patent license agreement with the National Cancer Institute (the &#8220;NCI&#8221;), a division of the National Institutes of Health
(the &#8220;NIH&#8221;), pursuant to which the Company received an exclusive, worldwide license to make, use, sell, offer to sell and
import products covered by the licensed patents in the field of using certain monoclonal antibodies as monospecific or bispecific antibodies
for the treatment of liver cancer (the &#8220;NCI License Agreement&#8221;). The license agreement was amended in May 2020 and October
2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the treatment of GPC-3 expressing
liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization was extended. Unless
earlier terminated, the Company&#8217;s agreement with NCI will expire upon expiration of all licensed patent rights. The Company may
also terminate the agreement as to any licenses in any country or territory upon 60 days written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Pursuant to the NCI agreement and amendments,
the Company agreed to pay low single-digit royalties based on net sales of licensed products as well as milestone payments of up to <ix:nonNumeric contextRef="c34" name="us-gaap:LongTermPurchaseCommitmentMilestones" id="ixv-43565">$3,995</ix:nonNumeric>
due upon achievement of clinical and regulatory milestones, and up to $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePaymentsCommercialMilestones" scale="3" unitRef="usd" id="ixv-43566">12,000</ix:nonFraction> milestone payments due upon achievement of commercial milestones.
No milestones have been reached and no products were sold by the Company through December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company also has to pay the guaranteed
annual minimum royalties of $<ix:nonFraction contextRef="c596" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-43567">25</ix:nonFraction> starting on the effective date of the agreement (which annual minimum royalties may be credited against
the running royalties on net sales of any licensed products or services). During each of the years ended December 31, 2024 and 2023, the
Company incurred $<ix:nonFraction contextRef="c597" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-43568"><ix:nonFraction contextRef="c598" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-43569">25</ix:nonFraction></ix:nonFraction>, in minimum royalty payments, included in research and development expenses. Under the amendment entered into in
March 2020, the Company is also liable for the extension royalties of $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:PaymentForExtensionRoyalities" scale="3" unitRef="usd" id="ixv-43570">225</ix:nonFraction> payable under this agreement which were rescheduled to become
due in several installments starting in March 2022. As of both December 31, 2024 and 2023, the accrued extension royalties were $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-43571"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-43572">200</ix:nonFraction></ix:nonFraction>,
included in accrued expenses and accounts payable on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company also agreed to reimburse
patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights.
During both the years ended December 31, 2024 and 2023, the Company did not incur any expenses related to the patent costs reimbursements.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 216; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsDisclosureTextBlock-c34_cont_2" id="_CommitmentsDisclosureTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Mabwell License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In October 2020, the Company entered
into an exclusive collaboration and license agreement with Mabwell (the &#8220;Mabwell License Agreement&#8221;). The agreement was amended
in November 2020. Under the Mabwell license agreement, the Company received a non-exclusive, royalty-free research purpose license as
well as an exclusive commercial license within certain territories, as defined in the agreement, to Mabwell&#8217;s series of anti-SARS-CoV-2
monoclonal antibodies. Under the agreement, the Company is responsible for conducting at its sole expense, research and preclinical, clinical
and other developments of any licensed products and bears all development costs and expenses related to obtaining or maintenance of marketing
authorizations of licensed products in its territories. Mabwell is obligated, at the Company&#8217;s request, to supply the Licensed Antibodies
to the Company for clinical trial purpose at costs plus margin as defined in the agreement. The parties agreed to undertake certain joint
clinical research and development activities with a portion of the costs contributed by Mabwell. Unless earlier terminated, the Mabwell
License Agreement will expire on the occurrence of the last to expire royalty term, which is the later of a) the expiration of the last
to expire valid claim of the patent rights and b) ten years from the first commercial sale of such Licensed Product, and determined on
jurisdiction-by-jurisdiction basis. Either party may terminate the agreement in the event of any uncured material breach by the other
party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The agreement provides for development
milestones of up to $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:DevelopmentMilestones" scale="3" unitRef="usd" id="ixv-43573">32,500</ix:nonFraction> and annual sales milestone payments of up to $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:AnnualSalesMilestonePayments" scale="3" unitRef="usd" id="ixv-43574">50,000</ix:nonFraction> payable by the Company to Mabwell. The agreement also
provides for a profit sharing, with Mabwell sharing <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="abp:NetProfitsFromLicensedProductSales" scale="-2" unitRef="pure" id="ixv-43575">50</ix:nonFraction>% of the net profits from the licensed product sales in certain territories as defined
in the agreement. The Company will also make tiered royalty payments in the mid to high single digits on net sales of commercial products
in the licensed territory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">During the years ended December 31,
2024 and 2023, development activities under the Mabwell collaboration agreement were immaterial to the consolidated financial statements.
No <span style="background-color: white">milestones have been reached and </span>no products were sold under <span style="background-color: white">the
</span>Mabwell License Agreement <span style="background-color: white">through December 31, 2024. As discussed in Note 2 to these consolidated
financial statements, the Company recognized other income of $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherIncome" scale="3" unitRef="usd" id="ixv-43576">3,556</ix:nonFraction> during the year ended December 31, 2024 associated with the reversal
of the estimated liability associated with a disputed invoice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">In
March 2025, the Company received a draft of a termination agreement from Mabwell which outlines Mabwell&#8217;s claim for the total payment
of $<ix:nonFraction contextRef="c599" decimals="-3" format="ixt:num-dot-decimal" name="abp:PaymentOfDevelopmentMilestones" scale="3" unitRef="usd" id="ixv-43577">3,300</ix:nonFraction> under certain development milestones asserting that these development milestones were achieved by the Company during 2021. The
Company does not believe that a liability under the milestone related provisions invoked by Mabwell was triggered and is planning to engage
in discussion with Mabwell about the validity of their claim. The Company accrued $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:AccruedToAmount" scale="3" unitRef="usd" id="ixv-43578">3,300</ix:nonFraction> expense related to this claim in the consolidated
financial statements as of December 31, 2024 through debit to accumulated deficit. The Company also restated the accrued expenses in the
consolidated financial statements as of September 30, 2024, December 31, 2023 and 2022 included in the Company&#8217;s Form 8-K, filed
on November 26, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>MSK License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In March 2017, the Company
entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (the &#8220;MSK License Agreement&#8221;),
pursuant to which the Company received an exclusive, royalty-bearing, worldwide license under specified patent rights to make, use
and sell certain of MSK&#8217;s proprietary Her2-huOKT3 bispecific antibodies. The agreement was amended on March 31, 2017, on March
31, 2018, and January 1, 2020. Unless earlier terminated in accordance with its terms, the agreement was to remain in effect on a
country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of products
based on MSK antibodies. On September 19, 2023, MSK License Agreement was terminated by MSK due to the Company&#8217;s failure to
make the payments for the patent costs reimbursements discussed below.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 217; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CommitmentsDisclosureTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the MSK License Agreement, as
amended, the Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such
bispecific antibodies within specified territories and timeframes. The Company was committed to pay MSK up to $<ix:nonFraction contextRef="c600" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePaymentsUponAchievingRDAndCommercializationEvents" scale="3" unitRef="usd" id="ixv-43579">10,500</ix:nonFraction> in milestone payments
upon achieving certain research and development and commercialization events or within a certain number of months of the effective date,
up to $<ix:nonFraction contextRef="c600" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePaymentOnNetSales" scale="3" unitRef="usd" id="ixv-43580">30,000</ix:nonFraction> in milestone payments based on net sales, and tiered mid-single-digit percentage royalties based on annualized net sales
of each product commercialized from the collaboration with guaranteed annual minimum royalties between $<ix:nonFraction contextRef="c471" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-43581">20</ix:nonFraction> and $<ix:nonFraction contextRef="c590" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-43582">30</ix:nonFraction> depending on certain
development events. During the years ended December 31, 2024 and 2023, the Company incurred $<ix:nonFraction contextRef="c601" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-43583">0</ix:nonFraction> and $<ix:nonFraction contextRef="c602" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRoyalties" scale="3" unitRef="usd" id="ixv-43584">20</ix:nonFraction> in minimum royalties, included
in research and development expenses. During the years ended December 31, 2024 and 2023, the Company did not incur any milestone payments
under this agreement. As of both December 31, 2024 and 2023, the accrued minimum royalty and milestone payments were $<ix:nonFraction contextRef="c301" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" unitRef="usd" id="ixv-43585"><ix:nonFraction contextRef="c603" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43586">790</ix:nonFraction></ix:nonFraction>, included in
accounts payable in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company also agreed to reimburse
patent costs for all documented out of pocket costs associated with the preparation, filing, prosecution and maintenance of patent rights
in the license territory. During the years ended December 31, 2024 and 2023, the Company expensed $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentCostsReimbursements" scale="3" unitRef="usd" id="ixv-43587">0</ix:nonFraction> and $<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentCostsReimbursements" scale="3" unitRef="usd" id="ixv-43588">49</ix:nonFraction> respectively, related to
the patent costs reimbursements, included in general and administrative expenses. As of both December 31, 2024 and 2023, the liabilities
for the patent costs reimbursements were $<ix:nonFraction contextRef="c303" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentCostsReimbursements" scale="3" unitRef="usd" id="ixv-43589"><ix:nonFraction contextRef="c604" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentCostsReimbursements" scale="3" unitRef="usd" id="ixv-43590">273</ix:nonFraction></ix:nonFraction>, included in other accrued expenses and accounts payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of both December 31, 2024 and 2023,
the accrued liabilities for the unpaid interest on the outstanding minimum royalty and milestone payments due to MSK were $<ix:nonFraction contextRef="c605" decimals="-3" format="ixt:num-dot-decimal" name="abp:PatentCostsReimbursements" scale="3" unitRef="usd" id="ixv-43591">169</ix:nonFraction>, included
in other accrued expenses. See Note 10 for discussion of the June 2023 demand letter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>VAZYME License agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In April 2021, the Company entered
into a License Agreement with VAZYME Biotech Co., Ltd (&#8220;VAZYME&#8221;) (the &#8220;VAZYME License Agreement&#8221;), pursuant to
which the Company was granted an exclusive, perpetual, royalty-bearing, worldwide license under specified patent rights to research, develop
and commercialize VAZYME proprietary anti-SARS-CoV-2 monoclonal antibodies. Unless earlier terminated in accordance with its terms, the
agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the VAZYME License Agreement,
the Company agreed to use commercially reasonable efforts to reach certain research and development, and commercialization milestones
for such antibodies. The Company also agreed to pay $<ix:nonFraction contextRef="c606" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43592">200</ix:nonFraction> to VAZYME at the effective date of the agreement. The Company is committed to
pay VAZYME up to $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43593">11,100</ix:nonFraction> in milestone payments upon achieving certain research and development events, up to $<ix:nonFraction contextRef="c597" decimals="-3" format="ixt:num-dot-decimal" name="abp:MilestonePayments" scale="3" unitRef="usd" id="ixv-43594">70,000</ix:nonFraction> in milestone payments
based on annual net sales, and tiered low single-digit percentage royalties based on annualized net sales of each product commercialized
from the collaboration. No <span style="background-color: white">milestones in the </span>VAZYME License Agreement <span style="background-color: white">have
been reached through December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In December 2021, the Company
entered into a Cooperation Agreement with Chengdu Bio-Innovate Pharmaceutical Technology Co., Ltd (&#8220;Bio-Innovate&#8221;) and a
three-way sharing agreement with VAZYME and Bio-Innovate (&#8220;the Company&#8221;, &#8220;VAZYME&#8221; and
&#8220;Bio-Innovate&#8221;, collectively &#8220;all parties&#8221;), pursuant to which the Company entrusted Bio-Innovate to perform
certain preclinical testing and all parties agreed that VAZYME will ship the agreed antibodies to Bio-Innovate rather than the
Company to fulfill the requirements under the VAZYME License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">For the years ended December 31, 2024 and 2023, the Company
did not incur any expenses related to the VAZYME License Agreement. As of both December 31, 2024 and 2023, the accrued liabilities
under this agreement were $<ix:nonFraction contextRef="c308" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-43595"><ix:nonFraction contextRef="c607" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-43596">200</ix:nonFraction></ix:nonFraction>, included in accounts payable in the consolidated financial statements.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 218; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_LesseeOperatingLeasesTextBlock-c34_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock" id="ixv-39312"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s leases are for
office and laboratory spaces, classified as operating leases, and laboratory equipment, classified as finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 19, 2021, in connection
with its laboratory and office space in Woburn, MA, the Company provided to the landlord a standby letter of credit in the amount of $<ix:nonFraction contextRef="c608" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfLinesOfCredit" scale="3" unitRef="usd" id="ixv-43597">131</ix:nonFraction>
(the &#8220;LOC&#8221;), which serves as security for the Company&#8217;s performance of its obligations under the lease and bears interest
at a per annum rate of the U.S. prime rate plus <ix:nonFraction contextRef="c609" decimals="2" format="ixt:num-dot-decimal" name="srt:InterestBearingLiabilitiesAverageRatePaid" scale="-2" unitRef="pure" id="ixv-43598">1</ix:nonFraction>%, with the minimum interest rate no less than 4.25%. The letter of credit is automatically
extended without a written amendment for a period of <ix:nonNumeric contextRef="c608" format="ixt-sec:durwordsen" name="abp:LetterOfCreditExtendedPeriod" id="ixv-43599">one year</ix:nonNumeric>, for each and every future expiration date, unless the Company elects not
to extend this letter of credit through November 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:LeaseCostTableTextBlock" id="ixv-39327"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The components of lease expense were
as follows as of and for the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd" id="ixv-43600">594</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd" id="ixv-43601">594</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Amortization of ROU assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-43602">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" unitRef="usd" id="ixv-43603">240</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-43604">1</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" unitRef="usd" id="ixv-43605">16</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-43606">638</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd" id="ixv-43607">850</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The total cash paid for amounts included
in the measurement of lease liabilities for the years ended December 31, 2024 and 2023 included the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-43608">566</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" unitRef="usd" id="ixv-43609">500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="3" unitRef="usd" id="ixv-43610">130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseLiability" scale="3" unitRef="usd" id="ixv-43611">222</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Lease term and discount rate were as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term <i>(in years)</i></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-left: 9.25pt">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-43612">0.73</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-43613">1.73</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9.25pt">Finance leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-43614">0.00</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="ixv-43615">0.25</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted-average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9.25pt">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-43616">6.66</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-43617">6.66</ix:nonFraction></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9.25pt">Finance leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-43618">6.50</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure" id="ixv-43619">6.50</ix:nonFraction></td><td style="text-align: left">%</td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 219; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c34_cont_1"><ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="ixv-39526"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company had the following future minimum payments due
under its operating lease agreements as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">For the year ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating<br/>
 Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-bottom: 1.5pt">2025</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitRef="usd" id="ixv-43620">465</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd" id="ixv-43621">465</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd" id="ixv-43622">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd" id="ixv-43623">456</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd" id="ixv-43624">456</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Obligations under lease liability, noncurrent</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-437">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company had no future minimum payments
due under finance lease agreements as of December 31, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c34_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="ixv-39578"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10</b>.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments
and Contingencies</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company, from time to time, is
subject to legal proceedings and claims that arise in the ordinary course of business. Resolution of any such matter could have a material
adverse effect on the results of operations and financial condition. The Company considers all claims on a periodic basis and based on
known facts assesses whether potential losses are considered reasonably possible, probable and estimable. Based upon this assessment,
the Company then evaluates disclosure requirements and whether to accrue for such claims in its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company records a provision for
a contingent liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On August 12, 2024, the Company&#8217;s
landlord filed a court summons for eviction based on the Company&#8217;s failure to make payments pursuant to one of its lease agreements.
According to the summons, the landlord was claiming the full amount of rental payments over the term of the lease. As of September 30,
2024, the Company owed $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForRent" scale="3" unitRef="usd" id="ixv-43625">186</ix:nonFraction> to the landlord in late rent. On October 21, 2024, the Company paid the landlord $<ix:nonFraction contextRef="c610" decimals="-3" format="ixt:num-dot-decimal" name="abp:PaymentOfRentAndMaintenanceExpense" scale="3" unitRef="usd" id="ixv-43626">100</ix:nonFraction> for late rent and maintenance
expenses. A court date was scheduled for November 14, 2024, and was subsequently postponed to November 21, 2024. On November 20, 2024,
the Company paid the landlord $<ix:nonFraction contextRef="c611" decimals="-3" format="ixt:num-dot-decimal" name="abp:PaymentOfRentAndMaintenanceExpense" scale="3" unitRef="usd" id="ixv-43627">115</ix:nonFraction> and on November 25, 2024, the court summons for eviction was dismissed by the landlord. As of December
31, 2024, no amounts were due to the landlord for past due rent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On September 12, 2023, a contract research
organization (&#8220;CRO&#8221;) vendor filed a lawsuit against the Company based on the Company&#8217;s failure to make certain installments
pursuant to a settlement agreement entered into with this vendor on January 23, 2023. Under the settlement agreement, the Company agreed
to pay a total of $<ix:nonFraction contextRef="c612" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLegalSettlements" scale="3" unitRef="usd" id="ixv-43628">1,644</ix:nonFraction> to the vendor, with $<ix:nonFraction contextRef="c613" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLegalSettlements" scale="3" unitRef="usd" id="ixv-43629">600</ix:nonFraction> due 5 business days after the settlement effective date and ten monthly installments,
approximately $<ix:nonFraction contextRef="c311" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForLegalSettlements" scale="3" unitRef="usd" id="ixv-43630">104</ix:nonFraction> each, starting in February 2023. The Company made the upfront payment and the first four monthly installments for a
total of $<ix:nonFraction contextRef="c312" decimals="-3" format="ixt:num-dot-decimal" name="abp:MonthlyInstallmentPayments" scale="3" unitRef="usd" id="ixv-43631">1,016</ix:nonFraction> but failed to make the monthly installment payments due after May 2023. On January 24, 2024, the Company received the
endorsement on motion for default judgment which requested the Company to pay approximately $<ix:nonFraction contextRef="c313" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" scale="3" unitRef="usd" id="ixv-43632">700</ix:nonFraction> to the CRO vendor. During the year ended
December 31, 2024, the Company accrued an additional $<ix:nonFraction contextRef="c614" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" unitRef="usd" id="ixv-43633">83</ix:nonFraction> in interest, included in the interest expense. During the year ended December
31, 2024, the Company made an $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForFees" scale="3" unitRef="usd" id="ixv-43634">11</ix:nonFraction> payment to CRO. As of December 31, 2024 and 2023, the outstanding balance under this settlement agreement
was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SettlementLiabilitiesCurrent" scale="3" unitRef="usd" id="ixv-43635">785</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SettlementAssetsCurrent" scale="3" unitRef="usd" id="ixv-43636">751</ix:nonFraction>, respectively. These amounts were included in accounts payable and accrued expenses in the consolidated financial statements
as of December 31, 2024 and 2023.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 220; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c34_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In addition to the lawsuit from a CRO
vendor above, the Company accrued $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-43637">325</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="3" unitRef="usd" id="ixv-43638">379</ix:nonFraction> as of December 31, 2024 and 2023, respectively, related to disputed invoices with vendors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In June 2023, the Company received
a notice of breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded payments totaling $<ix:nonFraction contextRef="c600" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnContractTermination" scale="3" unitRef="usd" id="ixv-43639">1,230</ix:nonFraction>
for the services performed under the MSK License Agreement (see Note 8). The corresponding liability is included in accounts payable and
accrued expenses in the consolidated financial statements as of both December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The MedImmune License Agreement (see
Note 8) provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement (December 2022). These
target dates were not met, which gives MedImmune (now AstraZeneca) a termination right. The Company does not expect a material impact
on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with the development
of ABP-200, which the Company is no longer developing. The Company believes that it does not need the intellectual property licensed under
that agreement for the development and eventual commercialization of ABP-201 or any of its other programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Non-Redemption Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 5, 2024, Legacy Abpro and
ACAB entered into a non-redemption agreement (the &#8220;Non-Redemption Agreement&#8221;), with Sandia Investment Management LP on behalf
of certain funds, investors, entities or accounts for which it or its affiliates acts as manager, sponsor or advisor (the &#8220;NRA Investors&#8221;).
Pursuant to such Non-Redemption Agreement, each NRA Investor agreed to rescind or reverse any previously submitted redemption demand of
the common stock of the Company held or to be acquired by such NRA Investor (the &#8220;NRA Investor Shares&#8221;) up to <ix:nonFraction contextRef="c322" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43640">4,145</ix:nonFraction> shares
of common stock in the aggregate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">At the Closing Date, the NRA Investors
reversed redemption demands with respect to <ix:nonFraction contextRef="c615" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43641">11,043</ix:nonFraction> Series A Common stock shares of ACAB. Pursuant to the Non-Redemption Agreement, upon
consummation of the Merger, the Company had to pay to the NRA Investors a payment equal to the number of NRA Investor Shares multiplied
by the redemption price, minus the number of NRA Investor Shares multiplied by $<ix:nonFraction contextRef="c616" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43642">9.00</ix:nonFraction> (pre-split). At the Closing Date, the Company owed
to NRA Investors $<ix:nonFraction contextRef="c616" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalUnitsTotalCostToInvestors" scale="3" unitRef="usd" id="ixv-43643">26</ix:nonFraction>, based on the redemption price of $<ix:nonFraction contextRef="c616" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityRedemptionPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43644">340.80</ix:nonFraction> at the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Excise Tax Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">At the Closing Date, the Company assumed
the excise tax liability of $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:ExciseTaxLiability" scale="3" unitRef="usd" id="ixv-43645">4,330</ix:nonFraction>, as adjusted as discussed further below, from ACAB related to the redemptions of shares in 2023 and
calculated as <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" scale="-2" unitRef="pure" id="ixv-43646">1</ix:nonFraction>% of the shares redeemed during fiscal year 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On August 16, 2022, the Inflation Reduction
Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal <ix:nonFraction contextRef="c325" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-43647">1</ix:nonFraction>%
excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly
traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not
its shareholders from which shares are repurchased. The amount of the excise tax is generally <ix:nonFraction contextRef="c326" decimals="2" format="ixt:num-dot-decimal" name="abp:ExciseTaxGenerallyOfTheFairMarketValuePercentage" scale="-2" unitRef="pure" id="ixv-43648">1</ix:nonFraction>% of the fair market value of the shares
repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted
to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable
year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been
given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 221; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">During the second quarter of
2024, the IRS issued final regulations with respect to the timing and payment of the excise tax. Pursuant to those regulations, the
Company would need to file a return and remit payment for any liability incurred during the period from January 1, 2023 to December
31, 2023 on or before October 31, 2024. The Company has filed the excise tax return and has engaged with the IRS in determining a
payment plan for the balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company is unable to pay its obligation
in full, and, as such, it will be subject to additional interest and penalties which are currently estimated at <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate" scale="-2" unitRef="pure" id="ixv-43649">8</ix:nonFraction>% interest per annum
and a <ix:nonFraction contextRef="c34" decimals="3" format="ixt:num-dot-decimal" name="abp:PercentageOfUnderpaymentPenaltyPerMonth" scale="-2" unitRef="pure" id="ixv-43650">0.5</ix:nonFraction>% underpayment penalty per month or portion of a month up to <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfLiabilityTotal" scale="-2" unitRef="pure" id="ixv-43651">25</ix:nonFraction>% of the total liability for any amount that is unpaid from November
1, 2024 until paid in full. The Company accrued $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" scale="3" unitRef="usd" id="ixv-43652">71</ix:nonFraction> in penalties and interest through December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In March 2025, the Company received
the letter from the Internal Revenue Service of the United States Department of Treasury (the &#8220;IRS&#8221;), setting up the meeting
with the Company to discuss the unsettled tax matters of ACAB and referencing $<ix:nonFraction contextRef="c599" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ExciseAndSalesTaxes" scale="3" unitRef="usd" id="ixv-43653">4,401</ix:nonFraction> amount owed in relation to the 2023 excise taxes,
of which $<ix:nonFraction contextRef="c599" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExaminationInterestExpense" scale="3" unitRef="usd" id="ixv-43654">210</ix:nonFraction> in interest and penalties. The Company believes that the excise tax liability in the IRS Letter is overstated as compared
to the amounts in ACAB&#8217;s filed tax return for the year ended December 31, 2023, and is planning to request further information from
the IRS to reconcile the amounts reported to the Company&#8217;s records. Pending further discussions with the IRS, the Company recorded
the excess of $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ExciseAndSalesTaxes" scale="3" unitRef="usd" id="ixv-43655">1,268</ix:nonFraction> over the Company&#8217;s estimate as the additional excise tax liability assumed from ACAB in the consolidated financial
statements as of December 31, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c34_cont_1" escape="true" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="ixv-39665"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward
Purchase Agreement</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 7, 2024, ACAB and Legacy Abpro entered into a Confirmation
of an OTC Equity Prepaid Forward Transaction (the &#8220;Forward Purchase Agreement&#8221; or &#8220;Transaction&#8221;) with YA (the
&#8220;Seller&#8221;) to which a maximum of up to <ix:nonFraction contextRef="c617" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToIssuersEquityShares" scale="0" unitRef="shares" id="ixv-43656">16,667</ix:nonFraction> common stock shares will be subject. At the Closing Date, the Seller purchased
<ix:nonFraction contextRef="c618" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" scale="0" unitRef="shares" id="ixv-43657">3,333</ix:nonFraction> shares from third parties (&#8220;Recycled Shares&#8221;), pursuant to the pricing date notice dated November 12, 2024 and paid
approximately $<ix:nonFraction contextRef="c618" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PrepaidRoyalties" scale="6" unitRef="usd" id="ixv-43658">1.1</ix:nonFraction> million (the &#8220;Prepayment Amount&#8221;) equal to $<ix:nonFraction contextRef="c618" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToEquitySettlementShareFairValuePerShare" scale="0" unitRef="usdPershares" id="ixv-43659">340.80</ix:nonFraction> per Recycled Share (the &#8220;Initial Price&#8221;)
to the redeeming shareholders. Pursuant to the terms of the Forward Purchase Agreement, at the Closing Date, the Company remitted the
Prepayment Amount into an escrow account for the benefit of the Seller.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The number of Recycled Shares subject
to the Forward Purchase Agreement was also subject to reduction following a termination of the Forward Purchase Agreement with respect
to such shares as described under &#8220;Optional Early Termination&#8221; as discussed below. The contract was to settle based on the
settlement terms discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Optional Early Termination</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">From time to time and on any date following
the Closing Date (any such date, an &#8220;OET Date&#8221;) and subject to the terms and conditions in the Forward Purchase Agreement
(&#8220;Optional Early Termination&#8221;), the Seller may, in its absolute discretion, terminate the Transaction in whole or in part
by providing written notice to the Company (the &#8220;OET Notice&#8221;), by no later than the next payment date following the OET Date,
(which will specify the quantity by which the Number of Shares will be reduced (such quantity, the &#8220;Terminated Shares&#8221;)).
The effect of an OET Notice would be to reduce the Number of Shares by the number of Terminated Shares specified in such OET Notice with
effect as of the related OET Date. As of each OET Date, the Company would be entitled to an amount from the Seller, and the Seller would
pay to the Company an amount, equal to the product of (x) the number of Terminated Shares and (y) the reset price in respect of such OET
Date.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 222; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The reset price (the &#8220;Reset Price&#8221;)
was initially $<ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="abp:ForwardContractInitialResetPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43660">300.00</ix:nonFraction>. The Reset Price was subject to reset on a weekly basis commencing with the first full week following the Closing
Date, to be the lowest of (a) the then current Reset Price, (b) $<ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="abp:ForwardContractBaseResetPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43661">300.00</ix:nonFraction> and (c) the VWAP price of the shares of the last <ix:nonNumeric contextRef="c34" format="ixt-sec:durday" name="abp:NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" id="ixv-43662">3</ix:nonNumeric> trading days
in such week; provided, that in the event of a dilutive offering by the Company, the Reset Price will also be reduced to equal the effective
price per share in such dilutive offering immediately upon the occurrence of such dilutive offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Settlement </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On the Cash Settlement Payment Date,
which is the tenth local business day immediately following the Valuation Date (defined below), the Seller had to remit to the Company
a cash amount (the &#8220;Settlement Amount&#8221;) equal to (i) the Number of Shares as of the Valuation Date, multiplied by (ii) the
difference of (a) the volume weighted daily VWAP price over the Valuation Period, less (b) $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="abp:VolumeWeightedAveragePrice" scale="0" unitRef="usdPershares" id="ixv-43663">15.00</ix:nonFraction>, and the Seller will not otherwise be
required to return to the Counterparty any of the Prepayment Amount. In the event that the difference of (a) the volume weighted daily
VWAP Price over the Valuation Period, less (b) $15.00, is equal to or less than $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" scale="3" unitRef="usdPershares" id="ixv-43664">0</ix:nonFraction>, then the Settlement Amount shall be $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue" scale="3" unitRef="usd" id="ixv-43665">0</ix:nonFraction>. The &#8220;Valuation
Date&#8221; is the earliest to occur of (a) the date that is 3 months after the Closing Date and (b) the date specified by the Seller
in a written notice to be delivered to the Company at the Seller&#8217;s discretion (which Valuation Date will not be earlier than the
day such notice is effective) after the occurrence of any of (x) a VWAP Trigger Event, (y) a Delisting Event or (z) unless otherwise specified
therein, upon any Additional Termination Event (defined below). Each of the following was to constitute an Additional Termination Event;
(a) The Merger Agreement is terminated pursuant to its terms prior to the closing of the Merger; and (b) If it is, or, as a consequence
of a change in law, regulation or interpretation, it becomes or will become, unlawful for the Seller to perform any of its obligations
contemplated by the Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Forward Purchase Agreement was
accounted for at fair value as an asset in accordance with the guidance in ASC 815, with subsequent changes in the fair value recorded
in profits and losses. The fair value of the Forward Purchase Agreement asset was $<ix:nonFraction contextRef="c619" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-43666">494</ix:nonFraction> and $<ix:nonFraction contextRef="c620" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" unitRef="usd" id="ixv-43667">155</ix:nonFraction> as of November 13, 2024 and December 31,
2024, respectively. The loss on the change in the fair value of $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:DerivativeChangeInFairValue" scale="3" unitRef="usd" id="ixv-43668">339</ix:nonFraction> was recorded in other (expense) income during the year ended December
31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On January 28, 2025, YA elected to
effect an Optional Early Termination with respect to all <ix:nonFraction contextRef="c484" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" scale="0" unitRef="shares" id="ixv-43669">3,333</ix:nonFraction> Shares subject to the Forward Purchase Agreement which terminated the agreement
as a whole. YA paid the Company the Early Termination Obligation in the aggregate amount of $<ix:nonFraction contextRef="c485" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnContractTermination" scale="3" unitRef="usd" id="ixv-43670">132</ix:nonFraction>, based on the Reset Price of $<ix:nonFraction contextRef="c484" decimals="2" format="ixt:num-dot-decimal" name="abp:EarlyTerminationResetPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43671">39.60</ix:nonFraction> in
effect on January 28, 2025.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_DebtDisclosureTextBlock-c34_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock" id="ixv-39717"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
Payable - Related Parties</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Promissory Note with ABI</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 18, 2023, the Company entered
into a promissory note agreement with ABI, a significant investor in the Company, to receive up to $<ix:nonFraction contextRef="c337" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-43672">6,000</ix:nonFraction>. The promissory note accrues
interest at a rate of <ix:nonFraction contextRef="c338" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-43673">5</ix:nonFraction>% per annum on the principal amount of each installment from the installment funding date until the maturity date
and at a rate of <ix:nonFraction contextRef="c339" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-43674">7</ix:nonFraction>% per annum after the maturity date if any amounts then remain outstanding. The &#8220;Maturity Date&#8221; is defined
in the agreement as the earlier of (i) eighteen months from the funding date and (ii) the successful closing of the Merger. On August
22, 2024, ACAB entered into the Abpro Bio Subscription Agreement (see Note 3) with ABI, pursuant to which ABI purchased <ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares" id="ixv-43675">20,749</ix:nonFraction> shares of the Company&#8217;s common stock, concurrently with the closing of the Merger at a price of $<ix:nonFraction contextRef="c341" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-43676">300.00</ix:nonFraction> per share, for an aggregate
purchase price of $<ix:nonFraction contextRef="c340" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-43677">6,225</ix:nonFraction>, of which $<ix:nonFraction contextRef="c340" decimals="-3" format="ixt:num-dot-decimal" name="abp:ConversionOfConsiderationUnderPromissoryNoteAgreement" scale="3" unitRef="usd" id="ixv-43678">4,225</ix:nonFraction> was paid through the conversion of the balance due by the Company to ABI under the promissory
note agreement and the remainder of $<ix:nonFraction contextRef="c341" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitRef="usd" id="ixv-43679">2,000</ix:nonFraction> in cash. In addition, ABI received an aggregate of <ix:nonFraction contextRef="c340" decimals="0" format="ixt:num-dot-decimal" name="abp:IncentiveSharesReceivedBySubsidiary" scale="0" unitRef="shares" id="ixv-43680">41,498</ix:nonFraction> Incentive Shares.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 223; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DebtDisclosureTextBlock-c34_cont_2" id="_DebtDisclosureTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 7, 2024, the Company entered
into an additional promissory note with ABI (&#8220;the 2024 ABI Note&#8221;) to receive up to $<ix:nonFraction contextRef="c342" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-43681">1,000</ix:nonFraction> from ABI in weekly installments
of $<ix:nonFraction contextRef="c343" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="3" unitRef="usd" id="ixv-43682">250</ix:nonFraction>. The note accrued <ix:nonFraction contextRef="c343" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-43683">10</ix:nonFraction>% interest and had a maturity date 5 business days after receipt of the proceeds under the PIPE Financing
(see Note 3). The Company received $<ix:nonFraction contextRef="c343" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-43684">1,000</ix:nonFraction> under this note through the Closing Date, and the balance of $<ix:nonFraction contextRef="c343" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd" id="ixv-43685">1,000</ix:nonFraction> was repaid at the Closing
from the PIPE Financing proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024 and 2023,
the outstanding principal balances under the promissory notes with ABI was $<ix:nonFraction contextRef="c345" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-43686">0</ix:nonFraction> and $<ix:nonFraction contextRef="c621" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-43687">1,442</ix:nonFraction>, respectively. During the years ended
December 31, 2024 and 2023, the Company recorded $<ix:nonFraction contextRef="c528" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" unitRef="usd" id="ixv-43688">186</ix:nonFraction> and $<ix:nonFraction contextRef="c622" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseDebt" scale="3" unitRef="usd" id="ixv-43689">5</ix:nonFraction>, respectively, of interest expense on these promissory notes with ABI.
As of December 31, 2024 and 2023, accrued interest totaling $<ix:nonFraction contextRef="c345" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="3" unitRef="usd" id="ixv-43690">191</ix:nonFraction> and $<ix:nonFraction contextRef="c621" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="3" unitRef="usd" id="ixv-43691">5</ix:nonFraction>, respectively, is included in accrued expenses in the
consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Promissory Notes with Executive
and Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 29, 2023, the Company issued
promissory notes to one of its executives and one of its directors, in the principal amount of $<ix:nonFraction contextRef="c349" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="3" unitRef="usd" id="ixv-43692">176</ix:nonFraction> and $<ix:nonFraction contextRef="c350" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIssuedPrincipal" scale="3" unitRef="usd" id="ixv-43693">124</ix:nonFraction>, respectively, for deferred
bonuses. Amounts under the promissory notes plus accrued interest are due and payable on the earlier of (i) the closing of the Merger
and (ii) June 29, 2025. These promissory notes accrue interest at <ix:nonFraction contextRef="c351" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-43694">5</ix:nonFraction>% per annum until the maturity date and <ix:nonFraction contextRef="c352" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-43695">7</ix:nonFraction>% thereafter. At the Closing
Date, the Company paid $<ix:nonFraction contextRef="c353" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd" id="ixv-43696">150</ix:nonFraction> towards these promissory notes. As of December 31, 2024 and 2023, $<ix:nonFraction contextRef="c623" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-43697">147</ix:nonFraction> and $<ix:nonFraction contextRef="c624" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-43698">300</ix:nonFraction>, respectively, of principal
was outstanding. Accrued interest on these promissory notes totaled $<ix:nonFraction contextRef="c355" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="3" unitRef="usd" id="ixv-43699">14</ix:nonFraction> and <ix:nonFraction contextRef="c624" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestPayableCurrent" scale="3" unitRef="usd" id="ixv-43700">$0</ix:nonFraction> as of December 31, 2024 and 2023, respectively, included
in accrued expenses in the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On April 18, 2024, the Company entered
into a separate promissory note agreement with the same executive to receive, as amended, up to $<ix:nonFraction contextRef="c360" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-43701">2,158</ix:nonFraction> in funding. During the year ended
December 31, 2024, the Company received $<ix:nonFraction contextRef="c361" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromNotesPayable" scale="3" unitRef="usd" id="ixv-43702">1,997</ix:nonFraction> from the executive under this agreement. These advances accrued interest at <ix:nonFraction contextRef="c362" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-43703">7.5</ix:nonFraction>% per annum
through the maturity date and at <ix:nonFraction contextRef="c363" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-43704">9.5</ix:nonFraction>% per annum after the maturity date if any amounts then remain outstanding. All advances, plus accrued
interest, were due and payable on the earlier of (i) the closing of the Merger and (ii) November 20, 2024. At the Closing, the outstanding
promissory notes of $<ix:nonFraction contextRef="c367" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayable" scale="3" unitRef="usd" id="ixv-43705">1,997</ix:nonFraction> were converted into <ix:nonFraction contextRef="c625" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesIssued1" scale="0" unitRef="shares" id="ixv-43706">20,000</ix:nonFraction> newly issued common stock shares. Accrued interest on these promissory notes totaled
$<ix:nonFraction contextRef="c367" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPayableCurrent" scale="3" unitRef="usd" id="ixv-43707">62</ix:nonFraction> and <ix:nonFraction contextRef="c626" decimals="-3" format="ixt:fixed-zero" name="us-gaap:InterestPayableCurrent" scale="3" unitRef="usd" id="ixv-43708">$0</ix:nonFraction> as of December 31, 2024 and 2023, respectively, included in accrued expenses in the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Pursuant to the terms of the promissory
note, the Company agreed to cause to be issued to the executive a number of New Abpro stock options or warrants in an amount equal to
the outstanding principal amount of such promissory note, subject to required approval by the New Abpro Board of Directors and Compensation
Committee and registration of such securities on Form S-8. On February 7, 2025, the Company issued <ix:nonFraction contextRef="c627" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" unitRef="shares" id="ixv-43709">28,333</ix:nonFraction> common stock warrants to an
executive. The warrants are exercisable at $<ix:nonFraction contextRef="c628" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-43710">99.90</ix:nonFraction> per share and bear an expiration date of <ix:nonNumeric contextRef="c629" format="ixt:date-monthname-day-year-en" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" id="ixv-43711">February 7, 2035</ix:nonNumeric>. The warrants are exercisable
as follows: <ix:nonFraction contextRef="c630" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43712">14,166</ix:nonFraction> warrants are exercisable on the issuance date, <ix:nonFraction contextRef="c631" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43713">6,667</ix:nonFraction> warrants become exercisable on the one-year anniversary of the
issuance date, and <ix:nonFraction contextRef="c632" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43714">7,500</ix:nonFraction> warrants become exercisable on the two-year anniversary of the issuance date.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 224; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><i>Promissory Note with ACAB Executive</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On August 16, 2024, an executive at
ACAB agreed to loan Legacy Abpro $<ix:nonFraction contextRef="c379" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-43715">103</ix:nonFraction> under a promissory note (the &#8220;ACAB Executive Note&#8221;). The ACAB Executive Note did not
accrue interest and the Company agreed to repay a total of $<ix:nonFraction contextRef="c380" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" unitRef="usd" id="ixv-43716">206</ix:nonFraction> at the earlier of i) <ix:nonNumeric contextRef="c380" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentMaturityDate" id="ixv-43717">November 20, 2024</ix:nonNumeric>, and ii) the closing of the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 21, 2024, the ACAB Executive
Note was amended to clarify that it should have been for the benefit of ACAB. Pursuant to the Severance Agreement (see Note 17), the liability
to the ACAB executive was cancelled. According to the terms of the amended note, Legacy Abpro was to repay the principal amount of $<ix:nonFraction contextRef="c381" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRepaidPrincipal" scale="3" unitRef="usd" id="ixv-43718">103</ix:nonFraction>.
The note did not bear interest and was payable upon demand on or before December 31, 2024. The note balance was eliminated in consolidation
at the Closing Date and December 31, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="abp_StandbyEquityPurchaseAgreementTextBlock-c34_cont_1" escape="true" name="abp:StandbyEquityPurchaseAgreementTextBlock" id="ixv-39786"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Standby
Equity Purchase Agreement</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 30, 2024, Legacy Abpro and
ACAB entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd. (&#8220;YA&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Subject to the satisfaction of the
conditions set forth in the SEPA, YA committed to advance to the Company the aggregate principal amount of up to $<ix:nonFraction contextRef="c382" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-43719">5,000</ix:nonFraction> (the &#8220;Pre-Paid
Advance&#8221;), which shall be evidenced by convertible promissory notes (each a &#8220;Convertible Note&#8221;). On November 14, 2024,
the Company received the first Pre-Paid Advance and entered into a Convertible Note (defined below). The second Pre-Paid Advance shall
be in a principal amount of $<ix:nonFraction contextRef="c383" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-43720">2,000</ix:nonFraction> and advanced on the later of (i) the second trading day after the initial registration statement filed
pursuant to the Registration Rights Agreement (as defined below) becomes effective and (ii) the second trading day after the required
shareholder approval to issue shares of the post-combination Company&#8217;s common stock in excess of <ix:nonFraction contextRef="c383" decimals="2" format="ixt:num-dot-decimal" name="abp:ExcessOfCommonStockPercentage" scale="-2" unitRef="pure" id="ixv-43721">20</ix:nonFraction>% of the Company&#8217;s outstanding
shares pursuant to Nasdaq Rules (the &#8220;Exchange Cap&#8221;) has been obtained. At the special meeting of stockholders held on April
8, 2025, the Company obtained stockholder approval for the issuance of shares over the Exchange Cap.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 14, 2024 (the &#8220;Issuance
Date&#8221;), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the &#8220;Convertible Note&#8221;) with YA
for $<ix:nonFraction contextRef="c383" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleDebt" scale="3" unitRef="usd" id="ixv-43722">3,000</ix:nonFraction> and received net proceeds of $<ix:nonFraction contextRef="c384" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" unitRef="usd" id="ixv-43723">2,755</ix:nonFraction>, net of the original issuance discount of <ix:nonFraction contextRef="c385" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" unitRef="pure" id="ixv-43724">8</ix:nonFraction>% (the &#8220;Convertible Note Discount&#8221;).
The Convertible Note has a maturity of November 13, 2025 (subject to earlier repayments based on Amortization Event described below),
incurs interest at a rate of <ix:nonFraction contextRef="c633" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-43725">0</ix:nonFraction>% (or <ix:nonFraction contextRef="c634" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" unitRef="pure" id="ixv-43726">18</ix:nonFraction>% upon the occurrence of an uncured Event of Default).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Convertible Notes are convertible
at the option of the holder at any time after the Issuance Date based on the conversion price determined as the lower of (i) $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43727">345.00</ix:nonFraction> per
Common Share (the &#8220;Fixed Price&#8221;), or (ii) <ix:nonFraction contextRef="c633" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfVolumeWeightedAveragePrice" scale="-2" unitRef="pure" id="ixv-43728">94</ix:nonFraction>% of the lowest daily VWAP during the <ix:nonNumeric contextRef="c635" format="ixt-sec:duryear" name="abp:ConvertibleThresholdConsecutiveTradingDays" id="ixv-43729">5</ix:nonNumeric> consecutive trading days immediately preceding
the conversion date (the &#8220;Variable Price&#8221;), but which Variable Price shall not be lower than the Floor Price then in effect
(the &#8220;Conversion Feature&#8221;). The Floor Price at the Issuance Date was $<ix:nonFraction contextRef="c635" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares" id="ixv-43730">34.62</ix:nonFraction> per share calculated as <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfClosingPrice" scale="-2" unitRef="pure" id="ixv-43731">20</ix:nonFraction>% of the closing price
of the Company&#8217;s stock on November 12, 2024. The Floor Price was adjusted downward to $<ix:nonFraction contextRef="c636" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeAverageFloorPrice" scale="0" unitRef="usdPeritem" id="ixv-43732">5.70</ix:nonFraction> on February 12, 2025 when the initial
registration statement was declared effective by the SEC. The conversion is subject to the limitations including beneficial ownership
limitation, principal market limitation and monthly conversion limits. If the Company, at any time while the Convertible Note is outstanding,
shall issue any Common Shares (other than pursuant to the SEPA) for no consideration or for a price per share that is lower than the Fixed
Price then in effect, the Fixed Price shall be reduced to equal the lowest price per share of such issuances.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 225; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="abp_StandbyEquityPurchaseAgreementTextBlock-c34_cont_2" id="abp_StandbyEquityPurchaseAgreementTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Convertible Note is redeemable
at the option of the Company if the volume-weighted-average price (&#8220;VWAP&#8221;) of the Company&#8217;s Common Stock is less than
$<ix:nonFraction contextRef="c637" decimals="2" format="ixt:num-dot-decimal" name="abp:VolumeWeightedAveragePrice" scale="0" unitRef="usdPershares" id="ixv-43733">345.00</ix:nonFraction> which may be adjusted downward upon payment of stock dividend, stock split or reclassification, or if the Company issues common
stock for no consideration or at a price lower than the then-effective Fixed Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the terms of the Convertible
Notes, the Amortization Event occurs if i) the daily VWAP is less than the Floor Price for <span style="-sec-ix-hidden: hidden-fact-438">five</span> trading days during a period of <span style="-sec-ix-hidden: hidden-fact-439">seven</span>
consecutive trading days (a &#8220;Floor Price Event&#8221;), (ii) unless the Company has obtained the approval from its stockholders
for the issuance of shares pursuant to the transactions contemplated in the SEPA in excess of the Exchange Cap, the Company has issued
in excess of <ix:nonFraction contextRef="c640" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStock" scale="-2" unitRef="pure" id="ixv-43734">99</ix:nonFraction>% of the Common Shares available under the Exchange Cap (an &#8220;Exchange Cap Event&#8221;), or (iii) any time after
the Effectiveness Deadline (as defined in the Registration Rights Agreement entered into in relation to the SEPA), YA is unable to utilize
a Registration Statement to resell Underlying Shares for a period of <ix:nonFraction contextRef="c641" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" scale="0" unitRef="pure" id="ixv-43735">10</ix:nonFraction> consecutive trading days (a &#8220;Registration Event&#8221;).
If at any time after the Issuance Date, and from time to time thereafter, an Amortization Event occurs, then the Company shall make monthly
payments beginning on the 7th trading day after the Amortization Event Date and continuing on the same day of each successive month. Each
monthly payment shall be in an amount equal to the sum of (i) $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentFaceAmount" scale="3" unitRef="usd" id="ixv-43736">1,250</ix:nonFraction> of principal in the aggregate among the Convertible Note (or the
outstanding principal if less than such amount) (the &#8220;Amortization Principal Amount&#8221;), plus (ii) the payment premium equal
to <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAmortizationPrincipalAmount" scale="-2" unitRef="pure" id="ixv-43737">5</ix:nonFraction>% of the Amortization Principal Amount, and (iii) accrued and unpaid interest hereunder as of each payment date. The obligation of
the Company to make monthly prepayments related to an Amortization Event shall cease (with respect to any payment that has not yet come
due) if any time after the Amortization Date (A) in the event of a Floor Price Event, on the date that is the 7th consecutive trading
day that the daily VWAP is greater than the Floor Price then in effect, or the date that the Company reduces the Floor Price in accordance
with the terms of this Note, (B) in the event of a Registration Event, the condition or event causing the Registration Event has been
cured or the Holder is able to resell the Common Shares issuable upon conversion of this Note without limitations in accordance with Rule
144 under the Securities Act, or (C) in the event of an Exchange Cap Event, the date the Company has obtained stockholder approval to
increase the number of Common Shares under the Exchange Cap and/or the Exchange Cap no longer applies, unless a subsequent Amortization
Event occurs. No Amortization Event occurred through December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">It was determined, in accordance with
ASC 815, that the Conversion Feature is required to be bifurcated due to the adjustments to the settlement amount of this embedded feature
that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares, and should be recorded as a
liability (the &#8220;Embedded Derivative Liability&#8221;) at fair value with a corresponding amount recorded as a discount on the Convertible
Notes. The Embedded Derivative Liability is marked to market at each reporting period end with any changes recorded in other income or
expense. The fair value of the Embedded Derivative Liability was estimated at $<ix:nonFraction contextRef="c635" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-43738">69</ix:nonFraction> at the issuance date based on the difference between
the fair value of the convertible note with these embedded features and the fair value without each one of these embedded features.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The increase in the fair value of the
Embedded Derivative Liability was $<ix:nonFraction contextRef="c642" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-43739">11</ix:nonFraction>, between the issuance date and December 31, 2024, and was included in other (expense) income in
the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The total discount resulting from the
Convertible Note Discount and the bifurcation of the Embedded Derivative Liability at the Issuance Date was amortized over the term of
the Convertible Notes through non-cash interest expense using the effective interest method. The non-cash interest expense related to
the discount amortization was $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeAmortizationOfDiscount" scale="3" unitRef="usd" id="ixv-43740">39</ix:nonFraction> for the year ended December 31, 2024 and is included within interest expense in the consolidated statement
of operations.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 226; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="abp_StandbyEquityPurchaseAgreementTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>SEPA Put Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the terms of the SEPA, starting
at the Closing Date, the Company has the right, but not the obligation (&#8220;SEPA Put Rights&#8221;), to issue shares of its common
stock to YA (&#8220;Advance Shares&#8221;, and such issuance and sale, an &#8220;Advance&#8221;) and YA shall subscribe for and purchase
from the Company such Advance Shares, through written notice by the Company to YA (&#8220;Advance Notice&#8221;), provided (i) no balance
is outstanding under a Convertible Note, or (ii) if there is a balance outstanding under a Convertible Note, an Amortization Event (as
defined above), has occurred in accordance with and subject to the terms of the SEPA. The SEPA contemplates purchase by YA of up to $<ix:nonFraction contextRef="c34" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromPreviousAcquisition" scale="6" unitRef="usd" id="ixv-43741">50</ix:nonFraction>
million in aggregate gross purchase price for newly issued shares of the Company&#8217;s common stock. If any amount remains outstanding
under a Convertible Note, without the prior written consent of YA, the Company may only (other than with respect to a deemed Advance Notice
pursuant to an Investor Notice (described below)) submit an Advance Notice (A) if an Amortization Event has occurred and the obligation
of the Company to make monthly prepayments under the Convertible Note has not ceased, and (B) YA pays the aggregate purchase price owed
by the Company from such Advance by offsetting the amount of the Advance Proceeds against an equal amount outstanding under the subject
Convertible Note. Any such sales would be subject to certain limitations, including that YA could not purchase any shares that would result
in it owning more than <ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStock" scale="-2" unitRef="pure" id="ixv-43742">4.99</ix:nonFraction>% of the Company&#8217;s common stock, or any shares that, aggregated with any related transaction, would exceed
<ix:nonFraction contextRef="c2" decimals="3" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStockOutstanding" scale="-2" unitRef="pure" id="ixv-43743">19.9</ix:nonFraction>% of all shares of common stock outstanding on the date of the SEPA unless shareholder approval was obtained allowing for issuances
in excess of such amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">For as long as there is an outstanding
balance under a Convertible Note, YA has the right, but not the obligation, by delivery to the Company of Investor Notices (as defined
in the SEPA), to cause an Advance Notice to be deemed delivered by YA, which triggers the issuance and sale of Advance Shares to YA, subject
to terms and conditions as specified in the SEPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The purchase price for the Advance
Shares shall be the price per Advance Share obtained by multiplying the Company&#8217;s stock price (i) by <ix:nonFraction contextRef="c471" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAdvanceNotice" scale="-2" unitRef="pure" id="ixv-43744">96</ix:nonFraction>% in respect of an Advance
Notice delivered by the Company with an Option 1 Pricing Period (defined by reference to VWAP on the trading day the Advance Notice is
submitted), (ii) <ix:nonFraction contextRef="c590" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfAdvanceNotice" scale="-2" unitRef="pure" id="ixv-43745">97</ix:nonFraction>% in respect of an Advance Notice with an Option 2 Pricing Period (defined by reference to the lowest daily VWAP on
<span style="-sec-ix-hidden: hidden-fact-440">three</span> consecutive trading days commencing on the Advance Notice Date), or (iii) in the case of any Advance Notice delivered pursuant to
an Investor Notice, equal to the Conversion Price (as defined in the Convertible Note).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company accounted for the SEPA
Put Rights as an asset at fair value in accordance with the guidance in ASC 815, due to the adjustments to the settlement amount of this
derivative instrument that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares. The fair
value of the SEPA Put Rights was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-43746">1,551</ix:nonFraction> and $<ix:nonFraction contextRef="c409" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeNet" scale="3" unitRef="usd" id="ixv-43747">188</ix:nonFraction> as of the Closing Date and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As consideration for YA&#8217;s commitment
to purchase shares of common stock, upon execution of the SEPA, the Company engaged to remit YA the commitment fee of $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts" scale="3" unitRef="usd" id="ixv-43748">500,000</ix:nonFraction>. In December
2024, the Company issued to YA 9,905 shares of common stock in settlement of the commitment fee obligation. The fair value of the shares
issued to YA was $<ix:nonFraction contextRef="c411" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd" id="ixv-43749">327</ix:nonFraction> at their issuance date and the difference of $<ix:nonFraction contextRef="c412" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" scale="3" unitRef="usd" id="ixv-43750">173</ix:nonFraction> was recorded as a Gain on extinguishment of accrued liabilities.
The excess of the fair value of the SEPA Put Rights above the commitment fee at the issuance date was included in the change in fair value
of SEPA put rights in the consolidated statement of operations for the year ended December 31, 2024.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c34_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="ixv-39867"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
Equity</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Convertible Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2023, and immediately
prior to the Closing Date, Legacy Abpro&#8217;s amended and restated articles of incorporation authorized the issuance of up to <ix:nonFraction contextRef="c414" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-43751">40,000,000</ix:nonFraction>
shares of common stock and up to <ix:nonFraction contextRef="c414" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-43752">11,620,248</ix:nonFraction> shares of preferred stock. Legacy Abpro<span style="background-color: white">&#8217;s Certificate
of Incorporation, as amended, authorizes the issuance of Series A Redeemable Convertible Preferred Stock (&#8220;Series A&#8221;), Series
B Convertible Preferred Stock (&#8220;Series B&#8221;), Series C Convertible Preferred Stock (&#8220;Series C&#8221;), Series D Convertible
Preferred Stock (&#8220;Series D&#8221;), Series E Convertible Preferred Stock (&#8220;Series E&#8221;) and Series F Convertible Preferred
Stock (&#8220;Series F&#8221;), collectively referred to as &#8220;Convertible Preferred Stock&#8221;</span>.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 227; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c34_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In connection with the Merger, all
previously issued and outstanding Convertible Preferred Stock was converted into the aggregate number of shares of New Abpro&#8217;s common
stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately
prior to the effective time, multiplied by approximately <ix:nonFraction contextRef="c643" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockConvertibleConversionPriceIncrease" scale="0" unitRef="usdPershares" id="ixv-43753">0.068</ix:nonFraction>, and the remaining amount was reclassified to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Common and Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In connection with the Closing, the
Company&#8217;s articles of incorporation were amended to designate <ix:nonFraction contextRef="c35" decimals="0" format="ixt-sec:numwordsen" name="abp:DesignatedShares" scale="0" unitRef="shares" id="ixv-43754">two</ix:nonFraction> classes of stock; preferred and common stock. The articles of
incorporation of New Abpro authorize <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-43755">1,000,000</ix:nonFraction> shares of preferred stock and <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-43756">110,000,000</ix:nonFraction> shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s Amended and Restated
Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue up to <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitRef="shares" id="ixv-43757">1,000,000</ix:nonFraction> shares of $<ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-43758"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitRef="usdPershares" id="ixv-43759">0.0001</ix:nonFraction></ix:nonFraction>
par value preferred stock in one more series and to establish from time to time the number of shares to be included in each such series,
by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating,
optional, special and other rights shall be stated and expressed in such resolutions. There were <ix:nonFraction contextRef="c2" decimals="0" format="ixt:fixed-zero" name="us-gaap:PreferredStockSharesOutstanding" scale="0" unitRef="shares" id="ixv-43760">zero</ix:nonFraction> preferred shares outstanding as
of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2024, there were
<ix:nonFraction contextRef="c417" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43761">500,000</ix:nonFraction> outstanding Public Warrants. The Public Warrants became exercisable <ix:nonNumeric contextRef="c417" format="ixt-sec:durmonth" name="abp:WarrantsExercisableTerm" id="ixv-43762">12</ix:nonNumeric> months from the closing of ACAB&#8217;s Initial Public
Offering, which closed on January 19, 2022, and will expire <ix:nonNumeric contextRef="c417" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-43763">five years</ix:nonNumeric> from the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company will not be obligated to
deliver any common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise
unless a registration statement under the Securities Act covering the issuance of the common stock issuable upon exercise of the Public
Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect
to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of common stock upon exercise of
a warrant unless common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities
laws of the state of residence of the registered holder of the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The Company may redeem the Public Warrants:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in whole and not in part;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a price of $<ix:nonFraction contextRef="c417" decimals="2" format="ixt:num-dot-decimal" name="abp:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" scale="0" unitRef="usdPershares" id="ixv-43764">0.30</ix:nonFraction> per warrant;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon not less than 30 days&#8217; prior written notice of redemption given after the warrants become exercisable to each warrant holder; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt">if, and only if, the reported last sale price of the Series A common
stock equals or exceeds $<ix:nonFraction contextRef="c644" decimals="2" format="ixt:num-dot-decimal" name="abp:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" scale="0" unitRef="usdPershares" id="ixv-43765">540.00</ix:nonFraction> per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like)
for any <ix:nonNumeric contextRef="c645" format="ixt-sec:durday" name="abp:NumberOfTradingDaysForDeterminingTheSharePrice" id="ixv-43766">20</ix:nonNumeric> trading days within a <ix:nonNumeric contextRef="c645" format="ixt-sec:durday" name="abp:PeriodAfterWhichTheWarrantsAreExercisable" id="ixv-43767">30</ix:nonNumeric>-trading day period commencing once the warrants become exercisable and ending three trading days before
the Company sends the notice of redemption to the warrant holders (the &#8220;Redemption Trigger&#8221;). In November 2024, the Redemption
Trigger was adjusted to $<ix:nonFraction contextRef="c421" decimals="2" format="ixt:num-dot-decimal" name="abp:PerShareRedemptionsTriggerPrice" scale="0" unitRef="usdPershares" id="ixv-43768">179.70</ix:nonFraction>, as further described below.</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">If and when the warrants become redeemable
by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for
sale under all applicable state securities laws.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 228; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c34_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">If the Company calls the Public Warrants
for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless
basis,&#8221; as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of
the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization,
merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024, there were
<ix:nonFraction contextRef="c423" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43769">461,667</ix:nonFraction> Private Warrants, The Private Warrants are identical to the Public Warrants, except that the Private Warrants are exercisable
on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private
Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable
by the Company and exercisable by such holders on the same basis as the Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, if (x) the Company were
to issues additional shares of common stock or equity-linked securities, for capital raising purposes in connection with the closing of
a Merger at an issue price or effective issue price of less than $<ix:nonFraction contextRef="c644" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharesIssuedPricePerShare" scale="0" unitRef="usdPershares" id="ixv-43770">276.00</ix:nonFraction> per share of common stock (with such issue price or effective
issue price to be determined in good faith by the Company&#8217;s board of directors, and, in the case of any such issuance to the Sponsor
or its affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such
issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represented more than <ix:nonFraction contextRef="c646" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" scale="-2" unitRef="pure" id="ixv-43771">60</ix:nonFraction>% of the
total equity proceeds, and interest thereon, available for the funding of a Merger on the date of the completion of a Merger (net of redemptions),
and (z) the volume weighted average trading price of the Company&#8217;s Series A common stock during the <ix:nonNumeric contextRef="c645" format="ixt-sec:durday" name="abp:NumberOfTradingDaysForDeterminingTheSharePrice" id="ixv-43772">20</ix:nonNumeric> trading day period starting
on the trading day after the day on which the Company completes a Merger (such price, the &#8220;Market Value&#8221;) was below $<ix:nonFraction contextRef="c647" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-43773">276.00</ix:nonFraction>
per share, the exercise price of the warrants would be adjusted (to the nearest cent) to be equal to <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfMarketValueAndNewlyIssuedPrice" scale="-2" unitRef="pure" id="ixv-43774">115</ix:nonFraction>% of the greater of the Market
Value and the Newly Issued Price, and the $<ix:nonFraction contextRef="c518" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleStockPriceTrigger" scale="0" unitRef="usdPershares" id="ixv-43775">540.00</ix:nonFraction> per share redemption trigger price will be adjusted (to the nearest cent) to be equal
to <ix:nonFraction contextRef="c643" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfMarketValueAndNewlyIssuedPrice" scale="-2" unitRef="pure" id="ixv-43776">180</ix:nonFraction>% of the greater of the Market Value and the Newly Issued Price (the &#8220;Down Round Feature&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In November 2024, the &#8220;Down Round
Feature&#8221; was triggered and the exercise price of the Public and Private Warrants was adjusted down to $<ix:nonFraction contextRef="c426" decimals="2" format="ixt:num-dot-decimal" name="abp:PerShareRedemptionsTriggerPrice" scale="0" unitRef="usdPershares" id="ixv-43777">114.90</ix:nonFraction> and the per share
Redemption Trigger was adjusted down to $<ix:nonFraction contextRef="c427" decimals="2" format="ixt:num-dot-decimal" name="abp:PerShareRedemptionsTriggerPrice" scale="0" unitRef="usdPershares" id="ixv-43778">179.70</ix:nonFraction> based on the Newly Issued Price of $<ix:nonFraction contextRef="c428" decimals="2" format="ixt:num-dot-decimal" name="abp:PerShareRedemptionsTriggerPrice" scale="0" unitRef="usdPershares" id="ixv-43779">99.90</ix:nonFraction>. The Company accounted for the change in fair
value of the Public and Private Warrants triggered by the down round as a deemed dividend under the guidance in ASC 260-10-25-1 related
to financial instruments that include a down round feature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company valued the deemed dividend
as the difference between the fair value of the warrants before and after the exercise price adjustment. The warrants were valued using
the Black-Scholes option pricing model immediately before and after the modification using the following assumptions: (a) fair value of
common stock of $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares" id="ixv-43780">53.40</ix:nonFraction> per share, (b) expected volatility of <ix:nonFraction contextRef="c34" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-43781">90.00</ix:nonFraction>%, (c) dividend yield of <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-43782">0</ix:nonFraction>%, (d) risk-free interest rate of <ix:nonFraction contextRef="c34" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-43783">4.09</ix:nonFraction>%, and
(e) expected life of <ix:nonNumeric contextRef="c34" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-43784">4.9</ix:nonNumeric> years. The increase in the fair value of the warrants resulting from the exercise price adjustment was $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" scale="3" unitRef="usd" id="ixv-43785">10,177</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The <ix:nonFraction contextRef="c648" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43786">2,034</ix:nonFraction> outstanding common stock warrants of Legacy Abpro (&#8220;Legacy
Abpro Common Stock Warrants&#8221;) expired at the Merger Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-39982"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table sets forth the
common stock warrant activity for the year ended December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Legacy<br/> Abpro <br/> Common</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock <br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Private<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Public<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Outstanding as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c651" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43787">2,034</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-441">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-442">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expired at the Merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c654" decimals="0" format="ixt:num-dot-decimal" name="abp:ExpiredAtTheMerger" scale="0" sign="-" unitRef="shares" id="ixv-43788">2,034</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-443">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-444">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Common stock warrants of ACAB acquired in Merger</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-445">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c655" decimals="0" format="ixt:num-dot-decimal" name="abp:CommonStockWarrantsOfLegacyACABAcquiredInMerger" scale="0" unitRef="shares" id="ixv-43789">461,667</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c656" decimals="0" format="ixt:num-dot-decimal" name="abp:CommonStockWarrantsOfLegacyACABAcquiredInMerger" scale="0" unitRef="shares" id="ixv-43790">500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-446">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c658" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43791">461,667</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c417" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43792">500,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 229; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c34_cont_3"><ix:nonNumeric contextRef="c643" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="ixv-40091"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following presents information
about warrants to purchase common stock outstanding as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/>
Average <br/> Exercise <br/>
Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Remaining<br/> Contractual <br/>
Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Warrants</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares" id="ixv-43793">961,667</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares" id="ixv-43794">114.90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="text-align: right; width: 11%"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="ixv-43795">4.9</ix:nonNumeric> years</td></tr> </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="-sec-ix-hidden: hidden-fact-447"><span style="-sec-ix-hidden: hidden-fact-448">No</span></span> warrants were issued or exercised
during the years ended December 31, 2024 and 2023.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c34_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="ixv-40129"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Compensation</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>2024 Equity Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s 2024 Equity Incentive
Plan (the &#8220;2024 Plan&#8221;) became effective at the Closing Date. As of December 31, 2024, <ix:nonFraction contextRef="c659" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-43796">208,026</ix:nonFraction> shares of common stock
were available for issuance under the 2024 Plan, which is equal to <ix:nonFraction contextRef="c659" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStock" scale="-2" unitRef="pure" id="ixv-43797">10</ix:nonFraction>% of the number of shares of common stock of the Company following
the Merger. The 2024 Plan provides that on January 1 of each year commencing January 1, 2026 and ending on December 31, 2034, the 2024
Plan reserve will automatically increase in an amount equal to the lesser of (a) <ix:nonFraction contextRef="c660" decimals="2" format="ixt:num-dot-decimal" name="abp:PercentageOfCommonStock" scale="-2" unitRef="pure" id="ixv-43798">5</ix:nonFraction>% of the number of shares of the Company&#8217;s common
stock outstanding on December 31 of the preceding year and (b) a number of shares of common stock determined by the Company&#8217;s board
of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the 2024 Plan, the Company can
grant non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted
stock units, unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees. Through December
31, 2024, the Company has not granted any awards under the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>2014 Stock Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The 2014 Stock Incentive Plan (the
&#8220;2014 Plan&#8221;) of Legacy Abpro was expired as of the Closing Date, in accordance with its original terms. As a result of the
expiration, no further awards may be granted under the 2014 Plan. All awards previously granted and outstanding as of the effective date
of the Merger, which totaled <ix:nonFraction contextRef="c661" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-43799">166,858</ix:nonFraction> options, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement,
but otherwise remain in effect pursuant to their original terms (see Note 3). Stock options granted to employees and directors typically
vest over <ix:nonNumeric contextRef="c662" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="ixv-43800">four years</ix:nonNumeric>. Stock options granted to non-employees typically vest immediately at the grant date. The maximum contractual term
of the stock options is <ix:nonNumeric contextRef="c663" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-43801">ten years</ix:nonNumeric>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="ixv-40164"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The summary of the Company&#8217;s
stock option activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Stock<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average <br/> Remaining<br/> Contractual <br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at December 31, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-43802">369,092</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-43803">49.20</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c672" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-43804">6.1</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-449">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-450">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-451">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-452">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-453">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-454">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited/Expired/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c34" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="0" unitRef="shares" id="ixv-43805">39,698</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-43806">30.90</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-455">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares" id="ixv-43807">329,395</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-43808">51.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c34" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="ixv-43809">5.4</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" unitRef="shares" id="ixv-43810">276,060</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" unitRef="usdPershares" id="ixv-43811">51.30</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c34" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="ixv-43812">5.4</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric></ix:nonNumeric><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 230; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c34_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Stock Option Valuation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="ixv-40299"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The assumptions that the Company used
to determine the fair value of the stock options granted to employees, directors and nonemployees were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended<br/>
December 31,<br/>
2023</b></span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c673" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure" id="ixv-43813">3.53</ix:nonFraction></span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term (in years)</span></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><ix:nonNumeric contextRef="c673" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="ixv-40327"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</span></ix:nonNumeric></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c673" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure" id="ixv-43814">71</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c673" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure" id="ixv-43815">0</ix:nonFraction></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table></ix:nonNumeric>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The weighted average grant date fair
value of awards granted during the year ended December 31, 2023, was $<ix:nonFraction contextRef="c664" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-43816">127.80</ix:nonFraction> per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="-sec-ix-hidden: hidden-fact-461">No</span> stock options were granted during
the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Restricted Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company
granted restricted stock units (&#8220;RSUs&#8221;) to various employees and directors under the 2014 Plan. These RSUs cliff vest on the
first anniversary of the grant date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock
as of the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="ixv-40362"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The summary
of the Company&#8217;s restricted stock unit activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Grant Date <br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Remaining <br/> Vesting Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at December 31, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c674" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-43817">3,124</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c674" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-43818">48.90</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c675" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-43819">1.2</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-456">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-457">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c676" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-43820">2,386</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c676" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-43821">48.90</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-458">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-459">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c677" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares" id="ixv-43822">738</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c677" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares" id="ixv-43823">48.90</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonNumeric contextRef="c676" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="ixv-43824">0.2</ix:nonNumeric></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table></ix:nonNumeric>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In November
and December 2024, after the Closing Date, <ix:nonFraction contextRef="c666" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares" id="ixv-43825">369</ix:nonFraction> RSUs vested in accordance with their terms, but the shares of New Abpro common stock were
not issued to the holders as of December <span style="-sec-ix-hidden: hidden-fact-460">31, 2024</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October
22, 2024, the Company&#8217;s board of directors authorized the issuance of <ix:nonFraction contextRef="c668" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-43826">10,000</ix:nonFraction> RSUs (or approximately <ix:nonFraction contextRef="c442" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" unitRef="shares" id="ixv-43827">20,449</ix:nonFraction> RSUs as adjusted for
the Merger closing based on the Exchange Ratio), that were not yet issued as of December 31, 2024. The Company recorded the
fair value of these RSUs, totaling $<ix:nonFraction contextRef="c446" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesFairValueDisclosure" scale="3" unitRef="usd" id="ixv-43828">394</ix:nonFraction>, in accrued expenses as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Stock-Based Compensation Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="ixv-40468"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The summary of the recorded stock-based
compensation expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c597" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-43829">72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c598" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-43830">118</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c678" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-43831">1,855</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c679" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-43832">2,187</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 9.25pt">Total stock-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-43833">1,927</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd" id="ixv-43834">2,305</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 231; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024, there was
approximately $<ix:nonFraction contextRef="c669" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" scale="3" unitRef="usd" id="ixv-43835">1,302</ix:nonFraction> of unrecognized compensation cost related to unvested stock option awards that are expected to be recognized over
a weighted-average period of <ix:nonNumeric contextRef="c665" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-43836">1.1</ix:nonNumeric> years. As of December 31, 2024, there was approximately $<ix:nonFraction contextRef="c670" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="3" unitRef="usd" id="ixv-43837">31</ix:nonFraction> of unrecognized compensation cost related
to unvested restricted stock awards that are expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c671" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="ixv-43838">0.3</ix:nonNumeric> years.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="ixv-40535"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee
Benefit Plan</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company has a 401(k) retirement
plan available to all eligible employees. During the years ended December 31, 2024 and 2023, the Company made $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" unitRef="usd" id="ixv-43839">110</ix:nonFraction> and $<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="3" unitRef="usd" id="ixv-43840">136</ix:nonFraction> in matching
contributions, respectively, to the plan.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c34_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="ixv-40550"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Parties</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On January 15, 2020, the Company entered
into an agreement for various consulting services, as defined in the agreement, with a member of the Company&#8217;s Board of Directors.
On January 1, 2023, the Company entered into a new consulting agreement with the same director, which superseded the agreement dated in
January 2020. The agreement was terminated during the years ended December 31, 2024. During the years ended December 31, 2024 and 2023,
the Company incurred $<ix:nonFraction contextRef="c680" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-43841">83</ix:nonFraction> and $<ix:nonFraction contextRef="c681" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-43842">250</ix:nonFraction> under this agreement, respectively. As of both December 31, 2024 and 2023, the unpaid amount was $<ix:nonFraction contextRef="c682" decimals="-3" format="ixt:num-dot-decimal" name="abp:UnpaidAmount" scale="3" unitRef="usd" id="ixv-43843"><ix:nonFraction contextRef="c683" decimals="-3" format="ixt:num-dot-decimal" name="abp:UnpaidAmount" scale="3" unitRef="usd" id="ixv-43844">21</ix:nonFraction></ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 1, 2021, the Company entered
into a consulting agreement with a member of the Company&#8217;s Board of Directors. Under the agreement, the Company is obligated to
pay fees for various consulting services, as defined in the agreement. This agreement was terminated in May 2022. The Company did not
incur any expense under this agreement during the years ended December 31, 2024 and 2023. As of both December 31, 2024 and 2023, the unpaid
balance was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:UnpaidAmount" scale="3" unitRef="usd" id="ixv-43845"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="abp:UnpaidAmount" scale="3" unitRef="usd" id="ixv-43846">8</ix:nonFraction></ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In September 2022, the Company entered
into a collaboration and license agreement with Celltrion, a significant investor in the Company&#8217;s Series F, as discussed in Note
7. The Company entered into the ABP-100 Agreement and ABP-201 Agreement with ABI, a significant investor in the Company&#8217;s Series
E and F, described in Note 7.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On March 13, 2023, the Company&#8217;s
CEO, upon the approval of the Company&#8217;s Board of Directors, transferred $<ix:nonFraction contextRef="c684" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-43847">5,000</ix:nonFraction> from the Company&#8217;s bank account at First Republic
Bank to his personal bank account as an emergency response to the collapse of First Republic Bank. This amount was recorded as a receivable
from related party as of March 31, 2023. The full amount of $<ix:nonFraction contextRef="c685" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionAmountsOfTransaction" scale="3" unitRef="usd" id="ixv-43848">5,000</ix:nonFraction> plus accrued interest of $<ix:nonFraction contextRef="c686" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="3" unitRef="usd" id="ixv-43849">18</ix:nonFraction> was returned to the Company on May 3,
2023, and the remaining balance of accrued interest was $<ix:nonFraction contextRef="c687" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentIncreaseAccruedInterest" scale="3" unitRef="usd" id="ixv-43850">3</ix:nonFraction> as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 18, 2023, the Company issued
a promissory note to ABI in the principal amount of up to $<ix:nonFraction contextRef="c688" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="3" unitRef="usd" id="ixv-43851">6,000</ix:nonFraction> for expenses incurred in connection with the Merger and for its operating
expenses, as discussed in Note 12.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 29, 2023, the Company issued
promissory notes to one of its executives and one of its directors in the principal amount of $<ix:nonFraction contextRef="c689" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="3" unitRef="usd" id="ixv-43852">176</ix:nonFraction> and $<ix:nonFraction contextRef="c690" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="3" unitRef="usd" id="ixv-43853">124</ix:nonFraction>, respectively, as discussed
in Note 12.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On April 18, 2024, the Company entered
into a separate promissory note agreement with the same executive to receive, as amended, for up to $<ix:nonFraction contextRef="c460" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-43854">2,158</ix:nonFraction> in funding. During the year
ended December 31, 2024, the Company received $<ix:nonFraction contextRef="c461" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromRelatedPartyDebt" scale="3" unitRef="usd" id="ixv-43855">1,997</ix:nonFraction> from the executive under this agreement. See Note 12.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 232; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c34_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On April 18, 2024, the Company entered
into an agreement with an executive to defer payment of compensation from April 18, 2024 until the earlier of (i) the closing of the Merger
and (ii) November 20, 2024. The executive&#8217;s deferred wages were repaid in the amount of $<ix:nonFraction contextRef="c691" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SalariesWagesAndOfficersCompensation" scale="3" unitRef="usd" id="ixv-43856">221</ix:nonFraction> November 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 21, 2024, the Company entered
into a severance agreement with an executive (the &#8220;Severance Agreement&#8221;). Pursuant to the terms of the Severance Agreement,
the Company made a severance payment of $<ix:nonFraction contextRef="c463" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd" id="ixv-43857">221</ix:nonFraction> upon execution of the agreement. The Severance Agreement supersedes and extinguishes all
other agreements between the executive and the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 24, 2024, the Company made
a payment of $<ix:nonFraction contextRef="c464" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForMergerRelatedCosts" scale="3" unitRef="usd" id="ixv-43858">574</ix:nonFraction> to the Sponsor in accordance with the terms of the Merger Agreement.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" continuedAt="_IncomeTaxDisclosureTextBlock-c34_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock" id="ixv-40598"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="ixv-40609"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The components of income / (loss) before
provision for / (benefit from) income taxes are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" sign="-" unitRef="usd" id="ixv-43859">7,232</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" sign="-" unitRef="usd" id="ixv-43860">11,770</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-462">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" unitRef="usd" id="ixv-43861">64</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss before Income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43862">7,232</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43863">11,706</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">For the years ended December 31, 2024
and 2023, the Company did not record a current income tax provision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="ixv-40660"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">A reconciliation of the Company&#8217;s
effective income tax rate to the U.S. statutory federal income tax rate of <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-43864"><ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-43865">21</ix:nonFraction></ix:nonFraction>% for the years ended December 31, 2024 and 2023 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Net loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43866">7,232</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd" id="ixv-43867">11,706</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Statutory U.S. federal tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-43868">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitRef="pure" id="ixv-43869">21</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax computed at federal statutory rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-43870">1,519</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" sign="-" unitRef="usd" id="ixv-43871">2,458</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State income taxes, net of federal benefit and tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-43872">606</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" sign="-" unitRef="usd" id="ixv-43873">825</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Federal research and development credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" scale="3" sign="-" unitRef="usd" id="ixv-43874">290</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="abp:EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" scale="3" sign="-" unitRef="usd" id="ixv-43875">297</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" sign="-" unitRef="usd" id="ixv-43876">98</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" unitRef="usd" id="ixv-43877">40</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-43878">2,513</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-43879">3,540</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-463">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-464">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 233; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c34_cont_2" id="_IncomeTaxDisclosureTextBlock-c34_cont_1"><ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="ixv-40775"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Significant components of
the Company&#8217;s net deferred tax assets and liabilities as of December 31, 2024 and 2023 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/> (As Restated)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9.25pt">Operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-43880">23,229</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-43881">21,135</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9.25pt">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" unitRef="usd" id="ixv-43882">2,478</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" unitRef="usd" id="ixv-43883">2,054</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9.25pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-43884">2,691</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitRef="usd" id="ixv-43885">2,154</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9.25pt">Capitalized research expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-43886">2,547</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-43887">3,183</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9.25pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-43888">1,823</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" unitRef="usd" id="ixv-43889">539</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9.25pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:DeferredTaxAssetsLeaseLiability" scale="3" unitRef="usd" id="ixv-43890">124</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="abp:DeferredTaxAssetsLeaseLiability" scale="3" unitRef="usd" id="ixv-43891">279</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9.25pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" unitRef="usd" id="ixv-43892">314</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" unitRef="usd" id="ixv-43893">333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitRef="usd" id="ixv-43894">181</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-465">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-43895">33,387</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd" id="ixv-43896">29,677</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-43897">33,274</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd" id="ixv-43898">29,414</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-43899">113</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" unitRef="usd" id="ixv-43900">263</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt">Right-of-use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="abp:DeferredTaxLiabilitiesRightofuseAsset" scale="3" unitRef="usd" id="ixv-43901">113</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="abp:DeferredTaxLiabilitiesRightofuseAsset" scale="3" unitRef="usd" id="ixv-43902">263</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-466">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-467">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company regularly assesses the
need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative
evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence,
whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of
deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable
earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant
judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on
a jurisdiction-by-jurisdiction basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company continues to maintain a
full valuation allowance against its deferred tax assets. During the years ended December 31, 2024 and 2023, management assessed the positive
and negative evidence in its operations, and concluded that it is more likely than not that its deferred tax assets as of December 31,
2024 and 2023 will not be realized given the Company&#8217;s history of operating losses. The valuation allowance against deferred tax
assets increased by approximately $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-43903">3,860</ix:nonFraction> and $<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="3" unitRef="usd" id="ixv-43904">3,540</ix:nonFraction> during 2024 and 2023, respectively, related to a full valuation allowance recorded
against additional net operating losses and tax credits generated in the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 22, 2017, the Tax Cuts
and Jobs Act (the &#8220;Act&#8221;) was enacted. Under the Act, research and development expenditures incurred for tax years beginning
after December 31, 2021 must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on if the research
activities are conducted in the U.S. or outside the U.S., respectively. Effective January 1, 2022, the Company has complied with the mandatory
capitalization and amortization of research and experimentation expenditures. For the year ended December 31, 2024, the Company capitalized
$<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="3" unitRef="usd" id="ixv-43905">3,215</ix:nonFraction> and received $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationDeductions" scale="3" unitRef="usd" id="ixv-43906">2,370</ix:nonFraction> of amortization deductions related to such Section 174 expenditures, which on a tax effected basis represent
$<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-43907">2,547</ix:nonFraction> of the deferred tax assets shown in capitalized research and development costs in the components of deferred tax assets and liabilities
table above. For the year ended December 31, 2023, the Company capitalized $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="3" unitRef="usd" id="ixv-43908">4,416</ix:nonFraction> and received $<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationDeductions" scale="3" unitRef="usd" id="ixv-43909">1,850</ix:nonFraction> of amortization deductions related
to such Section 174 expenditures, which on a tax effected basis represent $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd" id="ixv-43910">3,183</ix:nonFraction> of the deferred tax assets shown in capitalized research
and development costs in the components of deferred tax assets and liabilities table above.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 234; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c34_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024, the Company
had federal net operating losses of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-43911">85,863</ix:nonFraction>, which may be available to offset future federal income tax liabilities. As a result of the
Act, for U.S. federal income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely,
but are limited to <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" unitRef="pure" id="ixv-43912">80</ix:nonFraction>% utilization against future taxable income each year. The Company&#8217;s federal net operating losses incurred
prior to 2018, $<ix:nonFraction contextRef="c692" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-43913">22,999</ix:nonFraction>, expire through 2037, while its federal net operating losses incurred in 2018 and onwards, $<ix:nonFraction contextRef="c693" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-43914">62,864</ix:nonFraction>, can be carried
forward indefinitely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2023, the Company
had federal net operating losses of $<ix:nonFraction contextRef="c694" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-43915">78,165</ix:nonFraction> (As Restated), which may be available to offset future federal income tax liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024 and 2023, the
Company had post-apportioned Massachusetts net operating losses of $<ix:nonFraction contextRef="c695" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-43916">82,240</ix:nonFraction> and $<ix:nonFraction contextRef="c696" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLossCarryforwards" scale="3" unitRef="usd" id="ixv-43917">74,656</ix:nonFraction> (As Restated), respectively, that can generally
be carried forward <ix:nonNumeric contextRef="c34" format="ixt-sec:duryear" name="abp:CarryforwardsTerm" id="ixv-43918">20</ix:nonNumeric> years and will expire at various dates through 2044.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024, the Company
had $<ix:nonFraction contextRef="c597" decimals="-3" format="ixt:num-dot-decimal" name="abp:FederalAndStateResearchAndDevelopmentCredits" scale="3" unitRef="usd" id="ixv-43919">1,772</ix:nonFraction> and $<ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="abp:FederalAndStateResearchAndDevelopmentCredits" scale="3" unitRef="usd" id="ixv-43920">877</ix:nonFraction> of federal and state research and development credits, respectively, which will expire at various dates through 2044.
As of December 31, 2023, the Company had $<ix:nonFraction contextRef="c598" decimals="-3" format="ixt:num-dot-decimal" name="abp:FederalAndStateResearchAndDevelopmentCredits" scale="3" unitRef="usd" id="ixv-43921">1,483</ix:nonFraction> and $<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="abp:FederalAndStateResearchAndDevelopmentCredits" scale="3" unitRef="usd" id="ixv-43922">708</ix:nonFraction> of federal and state research and development credits, respectively, which will
expire at various dates through 2043.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Pursuant to Internal Revenue Code Sections
382 and 383, annual use of the Company&#8217;s net operating losses and other carryforward tax attributes may be limited in the event
a cumulative change in ownership of more than <ix:nonFraction contextRef="c34" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" scale="-2" unitRef="pure" id="ixv-43923">50</ix:nonFraction>% that occurs within a three-year period. The Company has not completed an ownership change
analysis pursuant to IRS Section 382. If ownership changes have occurred or occur in the future, the amount of remaining tax attribute
carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated,
the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The calculation of the Company&#8217;s
tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The
Company recognizes liabilities for uncertain tax positions based on a two-step process. First, management determines whether it is more
likely than not that the tax positions will be sustained on audit, including resolution of related appeals or litigation processes, based
on their technical merits. Second, management measures the tax benefit of those positions as the largest amount that is more than 50%
likely to be realized upon ultimate settlement with the related tax authority. While the Company believes that it has appropriate support
for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in
determining the adequacy of its provision for income taxes. As of December 31, 2024 and 2023, the Company did not have any uncertain tax
positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s policy is to recognize
interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement
of operations and any accrued interest and penalties on the related tax liability line in the consolidated balance sheet. As of December
31, 2024 and 2023, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company files income tax returns
in the U.S. federal jurisdiction and various state jurisdictions. There are currently no pending income tax examinations. To the extent
the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination
by the Internal Revenue Service and state tax authorities to the extent the tax attributes are utilized in a future period. The Company&#8217;s
income tax returns since 2021 are subject to examination by the IRS and state tax authorities.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c34" escape="true" name="us-gaap:SubsequentEventsTextBlock" id="ixv-40994"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent
Events</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company evaluated subsequent events
and transactions that occurred after the balance sheet date up to the date that the consolidated financial statements were issued. Based
upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated
financial statements, other than those disclosed in Notes1, 2, 8, 10, 11, 12, and 13 and further below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">At the special meeting of stockholders
held on April 8, 2025, the Company obtained stockholder approval for the issuance of shares over <ix:nonFraction contextRef="c697" decimals="2" format="ixt:num-dot-decimal" name="abp:IssuanceOfSharesPercentage" scale="-2" unitRef="pure" id="ixv-43924">20</ix:nonFraction>% of the Company&#8217;s outstanding
shares to YA under the SEPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In April 2025, YA exercised its conversion
option for the total principal amount of $<ix:nonFraction contextRef="c698" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockAmountConverted1" scale="3" unitRef="usd" id="ixv-43925">250,000</ix:nonFraction> of the Convertible Notes. As a result of the exercise, the Company issued to YA <ix:nonFraction contextRef="c698" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ConversionOfStockSharesConverted1" scale="0" unitRef="shares" id="ixv-43926">25,998</ix:nonFraction>
shares of common stock based on the average conversion price of approximately $<ix:nonFraction contextRef="c699" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentConvertibleConversionPrice1" scale="0" unitRef="usdPershares" id="ixv-43927">9.60</ix:nonFraction>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In February 2025, the Company issued
<ix:nonFraction contextRef="c700" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares" id="ixv-43928">5,000</ix:nonFraction> shares of common stock to Roth Capital Partners (&#8220;Roth&#8221;) as an additional payment for the services provided
under the engagement letter dated July 17, 2024 between Roth and ACAB, which provided for an adjustment to their fees in shares based
on the trading price of the Company&#8217;s common stock.</p></ix:nonNumeric><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 235; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>PART II&#8201;-&#8201;INFORMATION NOT REQUIRED
IN PROSPECTUS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 13. Other Expenses of Issuance and Distribution</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The following table sets forth
the expenses in connection with this registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount<br/>
to be paid</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">SEC registration fee</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right">6<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">,844.14</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting fees and expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal fees and expenses</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printing and miscellaneous expenses</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td>&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
fees are calculated based on the securities offered and the number of issuances and accordingly cannot be determined at this time.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 14. Indemnification of Directors and Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Indemnification of Directors and Officers</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">Section 145 of the DGCL provides,
generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to
any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than
an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent
of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person
in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed
to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable
cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably
incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided
that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the
corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation,
provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances
of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with Section
102(b)(7) of the DGCL, the Charter provides that a director will not be personally liable to New Abpro or New Abpro&#8217;s stockholders
for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director&#8217;s duty
of loyalty to New Abpro or New Abpro&#8217;s stockholders, (ii) for acts of bad faith or which involve intentional misconduct or a knowing
violation of law, (iii) under Section 174 of the DGCL, or (iv) for any transaction from which the director derived an improper personal
benefit. No such provision shall eliminate or limit the liability of a director for any act or omission occurring prior to the date when
such provision became effective. Accordingly, these provisions will have no effect on the availability of equitable remedies such as an
injunction or rescission based on a director&#8217;s breach of his or her duty of care.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Charter provides that
New Abpro will indemnify its present and former directors and officers to the fullest extent permitted by the DGCL and that such indemnification
will not be exclusive of any other rights to which those seeking indemnification may have or hereafter acquire under law, the ACAB charter,
the Bylaws, an agreement, a vote of stockholders or disinterested directors, or otherwise.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New Abpro has entered into
indemnification agreements with each of its current directors and executive officers. These agreements require New Abpro to indemnify
these individuals to the fullest extent permitted under Delaware law against liabilities that may arise by reason of their service to
New Abpro, and to advance expenses incurred as a result of any proceeding against them as to which they could be indemnified. New Abpro
also intends to enter into indemnification agreements with future directors and executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 236; Options: NewSection --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 15. Recent Sales of Unregistered Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has not sold any
within the past three years which were not registered under the Securities Act of 1933 except as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Private Placements in Connection with ACAB&#8217;s
IPO</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2021, our Sponsor
purchased an aggregate of 7,187,500 Founder Shares (pre-split) for an aggregate purchase price of $25,000, or approximately $0.0035 per
share, in a private placement. On January 19, 2022, 3,750 shares (pre-split) were cancelled by the Company. Such securities were issued
pursuant to the exemption from registration contained in Section 4(a)(2) of the Securities Act of 1933.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">Simultaneous with the consummation
of the IPO and the issuance and sale of the IPO units, the Company consummated the private placement of 461,667 Placement Warrants at
a price of $30.00 per Placement Warrant, generating total proceeds of $13,850,000 (the &#8220;Private Placement&#8221;). The Placement
was conducted as a non-public transaction and, as a transaction by an issuer not involving a public offering and was exempt from registration
under the Securities Act of 1933 in reliance upon Section 4(a)(2) of the Securities Act of 1933.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>PIPE Financing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">Simultaneous with the Closing,
New Abpro also completed its previously announced private investment in public equity, issuing 37,416 shares of Common Stock and 74,831
Incentive Shares in the PIPE Financing, which raised $7.0 million in gross proceeds. The shares were issued to the investors in reliance
upon exemption from the registration requirements under Section 4(a)(2) under the Securities Act of 1933.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Underwriter and Vendor Shares</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the closing of the
Merger, New Abpro issued an aggregate of 36,095 shares of Common Stock to certain vendors, consisting of (i) 350,000 shares of
Common Stock issued to Pillsbury Winthrop Shaw Pittman LLC in consideration for legal services provided to ACAB issued at a value of
$300.00 per share, (ii) 20,000 shares of Common Stock issued to Cantor in satisfaction of Cantor&#8217;s deferred underwriting fee
from the ACAB IPO at the value of $ 300.00 per share (iii) 3,333 shares of Common Stock issued to Roth Capital Partners, LLC for
advisory services at a value of $10.00 per share, and (iv) 32,852 shares of Common Stock issued to Brookline Capital, in partial
satisfaction of financial advisory fees at a value of $300.00 per share. Also, the closing the Merger, New Abpro issued (i) 20,020
shares of Common Stock issued to the Sponsor in satisfaction of a working capital note issued to ACAB for aggregate consideration of
approximately $2.0 million, or approximately $99.90 per share, and (ii) 20,000 shares of Common Stock issued to Mr. Chan, Abpro
Corporation and New Abpro&#8217;s Chief Executive Officer, in satisfaction of an approximately $2.0 million promissory note of Abpro
Corporation, at a value of $99.90 per share. On February 6, 2025, the Company issued an additional 150,000 shares of Common Stock to
Roth Capital Partners, LLC, pursuant to a price reset provision in the engagement letter, bringing the aggregate value of all shares
issued for advisory services to $120.00 per share. All of such shares were issued in reliance upon exemption from the registration
requirements under Section 4(a)(2) under the Securities Act of 1933.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Standby Equity Purchase Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 30, 2024, the Company
and Abpro Corporation entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA. Subject to the satisfaction of
the conditions set forth in the SEPA, YA advanced to the Company the aggregate principal amount of $5,000,000 (the &#8220;Pre-Paid Advance&#8221;),
which was evidenced by convertible promissory notes (each a &#8220;Promissory Note&#8221;). The first tranche of the Pre-Paid Advance
was in a principal amount of $3,000,000 and advanced the first trading day following the Closing of the Merger, and the second and final
tranche of the Pre-Paid Advance shall be in a principal amount of $2,000,000 and advanced on the later of (i) the second trading day after
the initial registration statement filed pursuant to the registration rights agreement becomes effective and (ii) the second trading day
after the required shareholder approval to issue shares of the Company&#8217;s Common Stock in excess of the Exchange Cap, as defined
in the SEPA, has been obtained. At each closing of a tranche of the Pre-Paid Advance, YA shall advance to the Company the principal amount
of the Pre-Paid Advance, less a discount in an amount equal to 8% of the principal amount of the Pre-Paid Advance netted from the purchase
price due and structured as an original issue discount, in immediately available funds to an account designated by the Company in writing,
and the Company shall deliver a Promissory Note, as defined in the SEPA, having a principal amount equal to the full amount of such Pre-Paid
Advance, duly executed on behalf of the Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 237 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">On November 14, 2024, pursuant to the SEPA, New
Abpro entered into a Convertible Promissory Note (&#8220;Convertible Note&#8221;) for $3,000,000, issued with an 8% original issue discount,
and received net proceeds of $2,755,000. The Convertible Note has a maturity of November 13, 2025, incurs interest at a rate of 0% (or
18% upon the occurrence of an uncured Event of Default), and is redeemable at the option of New Abpro if the VWAP of the Common Stock
is less than $345. New Abpro has a right to convert any portion of the Convertible Note at any time at a conversion price equal to the
lower of $345.00, 94% of the daily VWAP during the previous 5 consecutive trading days, which may be adjusted downward upon payment of
stock dividend, stock split or reclassification, or if New Abpro issues Common Stock for no consideration or at a price lower than the
then-effective Fixed Price (as defined in the Convertible Note). The Floor Price was adjusted downward to $5.70 per share (post-split)
on February 12, 2025 when the initial registration statement was declared effective by the SEC. On April 29, 2025, in accordance with
the terms of the Convertible Promissory Note, the Company reduced the Floor Price down to $4.50 per share (post-split). The conversion
is subject to the limitations including beneficial ownership limitation, principal market limitation and monthly conversion limits. If
the Company, at any time while the Convertible Note is outstanding, shall issue any Common Shares (other than pursuant to the SEPA) for
no consideration or for a price per share that is lower than the Fixed Price then in effect, the Fixed Price shall be reduced to equal
the lowest price per share of such issuances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">&#160;On April 20, 2025, the Company entered into
an amendment to SEPA with YA, pursuant to which, the definition of the conversion price was amended to state that the Fixed Price should
be adjusted (downwards only) to equal the VWAP of the Common Shares over the three (3) Trading Days immediately preceding the 20th Trading
Day following the Issuance Date if such price is lower than the initial Fixed Price. As a result, at the amendment date, the Fixed Price
was reset down to $50.40 per share (post-split).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Closing of the Merger,
the Company has the right, but not the obligation, to issue shares of its Common Stock pursuant to the SEPA to YA (&#8220;Advance Shares&#8221;,
and such issuance and sale, an &#8220;Advance&#8221;) and YA shall subscribe for and purchase from the Company such Advance Shares, through
written notice by the Company to YA (&#8220;Advance Notice&#8221;), provided (i) no balance is outstanding under a Promissory Note, or
(ii) if there is a balance outstanding under a Promissory Note, an Amortization Event (as defined in the Promissory Note), has occurred
in accordance with and subject to the terms of the Promissory Note. The Company has the discretion to select the number of Advance Shares,
not to exceed the Maximum Advance Amount (as defined in the SEPA), that it desires to issue and sell to YA in each Advance Notice. If
any amount remains outstanding under any Promissory Note, without the prior written consent of YA, the Company may only (other than with
respect to a deemed Advance Notice pursuant to an Investor Notice (described in the SEPA)) submit an Advance Notice (A) if an Amortization
Event has occurred and the obligation of the Company to make monthly prepayments under the Promissory Note has not ceased, and (B) YA
pays the aggregate purchase price owed to the Company from such Advance by offsetting the amount of the Advance Proceeds against an equal
amount outstanding under the subject Promissory Note, subject to the terms and conditions of the SEPA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 238 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#8220;Maximum Advance Amount&#8221;
means (A) in respect of each Advance Notice delivered by the Company under the applicable provisions of the SEPA, an amount equal to one
hundred percent (100%) of the average of the daily traded amount of its shares of common stock during the five consecutive trading days
immediately preceding an Advance Notice, and (B) in respect of each Advance Notice deemed delivered by the Company pursuant to an Investor
Notice, the amount selected by YA in such Investor Notice, which amount shall not exceed the limitations set forth in Section 3.02 of
the SEPA, including, among other things, (i) that all shares of the Company&#8217;s Common Stock then beneficially owned by YA and its
affiliates shall not exceed 4.99% of the then outstanding voting power of the Company or number of shares of the Company&#8217;s Common
Stock, (ii) that the aggregate number of shares issued and sold to YA by the Company pursuant to Advance Notices under the SEPA shall
not exceed the amount registered in respect of the transaction contemplated by the SEPA under the Registration Statement (as defined below)
then in effect and (iii) that the aggregate number of shares of Common Stock issued pursuant to the SEPA and the Pre-Paid Advance cannot
exceed 19.9% of the Common Stock of the Company outstanding as of the effective date of the SEPA (the &#8220;Exchange Cap&#8221;). The
Exchange Cap shall not be applicable if: (a) the Company&#8217;s stockholders have approved the issuance of Common Stock in excess of
the Exchange Cap in accordance with the applicable rules of Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) or (b) the average price of
all sales of Common Stock under the SEPA equals or exceed the lower of (i) the Nasdaq official closing price immediately preceding the
effective date of the SEPA; or (ii) the average Nasdaq official closing price for the five trading days immediately preceding the effective
date. The SEPA contemplates purchase by YA of up to $50 million in aggregate gross purchase price for newly issued shares of the Company
Common Stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purchase price for the
Advance Shares shall be the price per Advance Share obtained by multiplying the Market Price (i) by 96% in respect of an Advance Notice
delivered by the Company with an Option 1 Pricing Period (defined by reference to VWAP on the trading day the Advance Notice is submitted,
starting at 9:00 a.m. New York City time or, if submitted after 9:00 a.m. New York City time, at the time the investor confirms receipt),
(ii) 97% in respect of an Advance Notice with an Option 2 Pricing Period (defined by reference to the lowest daily VWAP on three consecutive
trading days commencing on the Advance Notice Date), or (iii) in the case of any Advance Notice delivered pursuant to an Investor Notice,
equal to the Conversion Price (as defined in the Promissory Note).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the SEPA, YA represented
to the Company, among other things, that it is an &#8220;accredited investor&#8221; (as such term is defined in Rule 501(a) of Regulation
D under the Securities Act). The securities issuable in connection with the SEPA are being issued and sold by the Company to YA in reliance
upon the exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Convertible Note Conversions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On dates ranging from April
2, 2025 to May 15, 2025, we issued YA an aggregate of 326,828 shares of Common Stock in connection with the conversion of a portion of
outstanding and unpaid balance of the Convertible Note, in the aggregate amount of $1,895,000. In connection with the foregoing, the Company
relied upon the exemption from registration provided under Section 4(a)(2) under the Securities Act for transactions not involving a public
offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Ian Chan Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 7, 2025, the Company
issued warrants to purchase 28,333 shares of Common Stock (the &#8220;Ian Chan Warrants&#8221;) in full satisfaction of such agreement
to issue stock options or warrants. The Ian Chan Warrants are exercisable for $99.90 per share on or before the tenth anniversary of the
issuance. Of the Ian Chan Warrants, 14,167 were exercisable upon issuance, 6,666 are exercisable upon the first anniversary of issuance,
and the final 7,500 are exercisable on the second anniversary of issuance. The Ian Chan Warrants were issued by the Company to Ian Chan
in reliance upon the exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities
Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 239 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 16. Exhibits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a list of
exhibits filed as a part of this registration statement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524238946/d509388ds4a.htm#tx509388_36">Business Combination Agreement, dated as of December 11, 2023 (incorporated by reference to Annex A to ACAB&#8217;s registration statement on Form S-4/A filed with the SEC on October 17, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524213240/d866929dex101.htm">Amendment No. 1 to Business Combination Agreement, dated September 4, by and among ACAB, Merger Sub and Abpro (incorporated by reference to Exhibit 10.1 to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on September 4, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390024102382/ea022156701ex3-1_abpro.htm">New Abpro Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on November 25, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390025101285/ea026185501ex3-1_abpro.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certificate of Amendment to Certificate of Incorporation, as filed with the Secretary of State of the State of Delaware on October 16, 2025 (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on October 22, 2025).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390024102382/ea022156701ex3-2_abpro.htm">New Abpro Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on November 25, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312521362526/d482235dex42.htm">Specimen Series A Common Stock Certificate (incorporated by reference to ACAB&#8217;s Registration Statement on Form S-1/A filed with the SEC on December 20, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312521346558/d482235dex44.htm">Specimen Public Warrant Certificate (included in Exhibit 4.4) (incorporated by reference to ACAB&#8217;s Registration Statement on Form S-1 filed with the SEC on December 2, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex42.htm">Public Warrant Agreement, dated January 13, 2022, between ACAB and Continental Stock Transfer &amp; Trust Company, as warrant agent (incorporated by reference to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on January 19, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312521346558/d482235dex46.htm">Specimen Private Warrant Certificate (included in Exhibit 4.6) (incorporated by reference to ACAB&#8217;s Registration Statement on Form S-1 filed with the SEC on December 2, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex41.htm">Private Warrant Agreement, dated January 13, 2022, between ACAB and Continental Stock Transfer &amp; Trust Company (incorporated by reference to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on January 19, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390025011397/ea022700501ex4-6_abpro.htm">Warrant Agreement, dated February 7, 2025, between the Company and Ian Chan (incorporated by reference to the Company&#8217;s Registration Statement on Form S-1 filed with the SEC on February 7, 2025).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1**</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000121390025107374/ea026405701ex5-1_abpro.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Nelson Mullins Riley &amp; Scarborough LLP as to the validity of the securities being registered.</span></a></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex102.htm">Investment Management Trust Agreement, dated January 13, 2022, by and between ACAB and Continental Stock Transfer &amp; Trust Company, as trustee (incorporated by reference to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on January 19, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312521346558/d482235dex103.htm">Securities Subscription Agreement, dated October 25, 2021, between ACAB and the Sponsor (incorporated by reference to Exhibit 10.3 to ACAB&#8217;s registration statement on Form S-1 filed with the SEC on December 2, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex101.htm">Private Placement Warrant Purchase Agreement, dated January 13, 2022, by and between ACAB and the Sponsor (incorporated by reference to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on January 19, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex104.htm">Letter Agreement, dated January 13, 2022, among ACAB and its officers, directors, and the Sponsor (incorporated by reference to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on January 19, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312522012546/d292376dex103.htm">Registration Rights Agreement, dated January 13, 2022, among ACAB, the Sponsor and certain securityholders of ACAB (incorporated by reference to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on January 19, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524011224/d692726dex101.htm">Amended Sponsor Letter Agreement, dated as of January 18, 2024, by and among ACAB, Abpro, the Sponsor and directors and officers of ACAB (incorporated by reference to Exhibit 10.1 to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on January 19, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524238946/d509388ds4a.htm#ii509388_6">Form of Abpro Lock-Up Agreement (incorporated by reference to Exhibit 10.11 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on October 17, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524214784/d509388dex1012.htm">Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 10.12 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on October 17, 2024).</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 240 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390024102382/ea022156701ex10-9_abpro.htm">Abpro Holdings, Inc. 2024 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on November 25, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10+</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1014.htm">Employment Agreement, dated as of January 15, 2020, by and between Abpro and Ian Chan (incorporated by reference to Exhibit 10.14 to ACAB&#8217;s Registration Statement on Form S-4, filed with the SEC on January 19, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11+</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1015.htm">Offer Letter, dated June 11, 2018, by and between Abpro and Rob Markelewicz (incorporated by reference to Exhibit 10.15 to ACAB&#8217;s Registration Statement on Form S-4, filed with the SEC on January 19, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1018.htm">Consulting Agreement, dated January 1, 2023, by and between the Company and NEM LLC (incorporated by reference to Exhibit 10.18 to ACAB&#8217;s Registration Statement on Form S-4, filed with the SEC on January 19, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1019.htm">Commercial Lease Agreement, dated July 2, 2014, by and between Abpro and Cummings Properties, LLC (incorporated by reference to Exhibit 10.19 to ACAB&#8217;s Registration Statement on Form S-4, filed with the SEC on January 19, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1020.htm">Lease Extension #1 to Commercial Lease Agreement, dated May 22, 2017, by and between Abpro and Cummings Properties, LLC (incorporated by reference to Exhibit 10.20 to ACAB&#8217;s Registration Statement on Form S-4, filed with the SEC on January 19, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524011270/d509388dex1021.htm">Lease Extension #2 to Commercial Lease Agreement, dated March 9, 2021, by and between Abpro and Cummings Properties, LLC (incorporated by reference to Exhibit 10.21 to ACAB&#8217;s Registration Statement on Form S-4, filed with the SEC on January 19, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524084816/d509388dex1022.htm">Collaboration and License Agreement, dated August 26, 2016, as amended by the First Amendment to License Agreement dated November 11, 2016, as amended by the Second Amendment to License Agreement dated November 1, 2017, as amended by the Third Amendment to License Agreement dated March 5, 2018, and as amended by the Fourth Amendment to License Agreement dated December 9, 2019, by and between AbMed Corporation, MedImmune Limited and Abpro (incorporated by reference to Exhibit 10.22 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on April 2, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524084816/d509388dex1023.htm">Side Letter Agreement, dated August 8, 2017, by and among the Company, AbMed Corporation, and MedImmune Limited (incorporated by reference to Exhibit 10.23 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on April 2, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524084816/d509388dex1024.htm">Patent License Agreement, dated August 29, 2017, as amended by the First Amendment, dated May 20, 2020, and as amended by the Second Amendment, dated October 13, 2023, by and between Abpro and The U.S. Department of Health and Human Services, as represented by The National Cancer Institute (incorporated by reference to Exhibit 10.24 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on April 2, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524084816/d509388dex1025.htm">Collaboration Agreement, dated as of January 30, 2019, by and between Abpro and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (incorporated by reference to Exhibit 10.25 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on April 2, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524084816/d509388dex1026.htm">Collaboration and License Agreement, dated December 14, 2019, by and between Abpro and Abpro Bio International, Inc. (incorporated by reference to Exhibit 10.26 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on April 2, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21#</span></td>
    <td><span style="-keep: true">&#160;</span></td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000119312524084816/d509388dex1027.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Collaboration and License Agreement, dated January 15, 2020, by and between AbMed Corporation and Abpro Bio International, Inc. (incorporated by reference to Exhibit 10.27 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on April 2, 2024).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22#</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524084816/d509388dex1028.htm">Collaboration Agreement, dated September 21, 2022, by and between Abpro and Celltrion, Inc. (incorporated by reference to Exhibit 10.28 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on April 2, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524208786/d889794dex101.htm">Form of Investor Subscription Agreement (incorporated by reference to Exhibit 10.1 to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on August 28, 2024).</a></span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 241 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 90%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524208786/d889794dex102.htm">Investor Rights Agreement, dated August 22, 2024 by and between Atlantic Coastal Acquisition Corp. II and Celltrion, Inc. (incorporated by reference to Exhibit 10.2 to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on August 28, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524235243/d509388dex1034.htm">Amendment to Collaboration Agreement, dated October 9, 2024, by and between Abpro and Celltrion, Inc. (incorporated by reference to Exhibit 10.34 to ACAB&#8217;s Registration Statement on Form S-4/A, filed with the SEC on October 9, 2024).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="white-space: nowrap">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524253672/d899791dex101.htm">Confirmation of an OTC Equity Prepaid Forward Transaction, dated November 7, 2024, by and among the Company, Abpro and YA II PN, LTD. (incorporated by reference to Exhibit 10.1 to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on November 8, 2024).</a></span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524251745/d908993dex101.htm">Non-Redemption Agreement, dated November 5, 2024, by and among the Company and with Sandia Investment Management LP (incorporated by reference to Exhibit 10.1 to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on November 5, 2024).</a></span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524250197/d892646dex101.htm">Standby Equity Purchase Agreement dated October 30, 2024, by and among Atlantic Coastal Acquisition Corp. II, Abpro Corporation and YA II PN, Ltd. (incorporated by reference to Exhibit 10.1 to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on November 4, 2024).</a></span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000119312524250197/d892646dex102.htm">Registration Rights Agreement dated October 30, 2024, by and among Atlantic Coastal Acquisition Corp. II, Abpro Corporation and YA II PN, Ltd. (incorporated by reference to Exhibit 10.2 to ACAB&#8217;s Current Report on Form 8-K filed with the SEC on November 4, 2024).</a></span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390024102382/ea022156701ex10-30_abpro.htm">Convertible Promissory Note, dated November 13, 2024 (incorporated by reference to Exhibit 10.30 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on November 25, 2024).</a></span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390025035075/ea023916901ex10-1_abpro.htm">Amendment No. 1 to Convertible Promissory Note, dated April 20, 2025 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on April 24, 2025).</a></span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390025067345/ea025000501ex10-1_abpro.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consulting Agreement, dated July 20, 2025, by and between Abpro Holdings, Inc. and BioCelsus International Inc. (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on July 24, 2025).</span></a></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390024107083/ea022411101ex16-1_abprohold.htm">Letter from Marcum LLP to the Securities and Exchange Commission dated December 9, 2024 (incorporated by reference to Exhibit 16.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on December 10, 2024).</a></span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1893219/000121390024102382/ea022156701ex21-1_abpro.htm">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on November 25, 2024).</a></span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea026650201ex23-1_abpro.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Wolf &amp; Company, P.C.</span></a></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2**</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 91%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000121390025107374/ea026405701ex5-1_abpro.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Nelson Mullins Riley &amp; Scarborough LLP (included in Exhibit 5.1)</span></a></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24.1**</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 91%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000121390025107374/ea0264057-s1_abpro.htm#a_024"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Power of Attorney (included on the signature page to the initial filing of the registration statement)</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104*</span></td>
    <td>&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107**</span></td>
    <td style="width: 1%"><span style="-keep: true">&#160;</span></td>
    <td style="width: 91%; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1893219/000121390025107374/ea026405701ex-fee_abpro.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filing Fee Table</span></a></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
herewith.</span></td>
</tr>
     <tr style="vertical-align: top; text-align: justify">
<td>&#160;</td><td style="text-align: left">&#160;</td><td style="text-align: justify">&#160;</td></tr>
     <tr style="vertical-align: top; text-align: justify">
<td><span style="-keep: true">&#160;</span></td><td style="text-align: left"><span style="-keep: true">**</span></td><td style="text-align: justify"><span style="-keep: true">Previously filed.</span></td></tr>
     </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
a management or compensatory plan.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material
and would likely cause competitive harm to the Registrant if publicly disclosed. The Registrant agrees to furnish supplementally a copy
of any such omitted exhibits and schedules to the SEC upon its request.</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 242 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-keep: true">Item 17. Undertakings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0%"/><td style="width: 0.5in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
undersigned registrant hereby undertakes:</span></td>
</tr></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(1) To file, during any period in which
offers or sales are being made, a post-effective amendment to this registration statement:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i) To include any prospectus required
by Section 10(a)(3) of the Securities Act of 1933;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii) To reflect in the prospectus any
facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which,
individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding
the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed
that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the
form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no
more than 20 percent change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table
in the effective registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii) To include any material information
with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information
in the registration statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Provided, however, </i>that: provided, however,
that: Paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to Section
13 or Section 15(d) of the Securities and Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that are incorporated by
reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration
statement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(2) That, for the purpose of determining
any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement
relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(3) To remove from registration by means
of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(4) That, for the purpose of determining
liability under the Securities Act to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement
relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule
430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided,
however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document
incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement
will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such
date of first use.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">(5) That, for the purpose of determining
liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The undersigned registrant undertakes
that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to
such purchaser:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(i) Any preliminary prospectus or prospectus
of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(ii) Any free writing prospectus relating
to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iii) The portion of any other free writing
prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or
on behalf of the undersigned registrant; and</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">(iv) Any other communication that is an
offer in the offering made by the undersigned registrant to the purchaser.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Insofar as indemnification
for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant
to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission
such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a
claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director,
officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director,
officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 243 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Signatures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Pursuant
                                            to the requirements of the Securities Act, the registrant has duly caused this registration
                                            statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the
                                            City of Burlington, Massachusetts on November 28, 2025.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ABPRO HOLDINGS, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%; text-align: justify">&#160;</td>
    <td style="width: 5%; text-align: justify">&#160;</td>
    <td style="width: 35%; text-align: right">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>/s/ Miles Suk</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160; </span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miles Suk</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-keep: true">Pursuant to the requirements
of the&#160;Securities Act of 1933, as amended, this Registration Statement and Power of Attorney have been signed by the following persons
in the capacities indicated on the 28th day of November, 2025.</span></p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 45%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Signature</b></span></td>
    <td style="white-space: nowrap; width: 10%"><span style="-keep: true">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 45%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Miles Suk</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer
    and Chairman of the Board</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miles
    Suk</span></td>
    <td style="white-space: nowrap; vertical-align: bottom"><span style="-keep: true">&#160;</span></td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer, Principal Financial and Accounting Officer)</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">*</span></p></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Anthony D. Eisenberg</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">*</span></p></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soo Young Lee</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="-keep: true">&#160;</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><span style="-keep: true">*</span></p></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ian McDonald</span></td>
    <td style="white-space: nowrap"><span style="-keep: true">&#160;</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*By:</span>&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Miles Suk</span></td>
    <td style="width: 60%"><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Miles Suk</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td><span style="-keep: true">&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorney-in-fact</span></td>
    <td><span style="-keep: true">&#160;</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-9</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>






</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:DocumentType">S-1/A</ix:nonNumeric>
<ix:nonFraction contextRef="c1" id="hidden-fact-1" name="abp:ForwardPurchaseAgreementAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-2" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-3" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-4" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-5" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-6" name="abp:ConvertibleNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-7" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-8" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-9" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-10" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-11" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-12" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-13" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c1" id="hidden-fact-14" name="us-gaap:TreasuryStockCommonValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-15" name="us-gaap:TreasuryStockCommonValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-16" name="us-gaap:DeferredOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-17" name="abp:ForwardPurchaseAgreementAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-18" name="abp:SEPAPutRightsAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-19" name="us-gaap:SalesAndExciseTaxPayableCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-20" name="us-gaap:FinanceLeaseLiabilityCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-21" name="us-gaap:AccruedIncomeTaxesCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-22" name="abp:ConvertibleNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-23" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-24" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-25" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-26" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-27" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-28" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" decimals="INF" id="hidden-fact-29" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c11" decimals="INF" id="hidden-fact-30" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c11" decimals="INF" id="hidden-fact-31" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-32" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" decimals="INF" id="hidden-fact-33" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c13" decimals="INF" id="hidden-fact-34" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c13" decimals="INF" id="hidden-fact-35" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c15" id="hidden-fact-36" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c15" decimals="INF" id="hidden-fact-37" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c15" decimals="INF" id="hidden-fact-38" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c15" decimals="INF" id="hidden-fact-39" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c17" id="hidden-fact-40" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c17" decimals="INF" id="hidden-fact-41" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c17" decimals="INF" id="hidden-fact-42" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c17" decimals="INF" id="hidden-fact-43" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-44" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" decimals="INF" id="hidden-fact-45" name="us-gaap:TemporaryEquitySharesAuthorized" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c19" decimals="INF" id="hidden-fact-46" name="us-gaap:TemporaryEquitySharesIssued" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c19" decimals="INF" id="hidden-fact-47" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-48" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-49" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-50" name="us-gaap:PreferredStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="INF" id="hidden-fact-51" name="us-gaap:PreferredStockSharesAuthorized" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c2" decimals="INF" id="hidden-fact-52" name="us-gaap:PreferredStockSharesIssued" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="INF" id="hidden-fact-53" name="us-gaap:PreferredStockSharesIssued" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c2" decimals="INF" id="hidden-fact-54" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c5" decimals="INF" id="hidden-fact-55" name="us-gaap:PreferredStockSharesOutstanding" unitRef="shares">0</ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-56" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-57" name="us-gaap:CommonStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-58" name="us-gaap:TreasuryStockCommonValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-59" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-60" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-61" name="us-gaap:OtherNonoperatingIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-62" name="us-gaap:OtherNonoperatingIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-63" name="abp:ChangeInFairValueOfForwardPuchaseAgreementAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-64" name="abp:ChangeInFairValueOfForwardPuchaseAgreementAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-65" name="abp:ChangeInFairValueOfForwardPuchaseAgreementAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-66" name="abp:ChangeInFairValueOfSEPAPutRightsAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-67" name="abp:ChangeInFairValueOfSEPAPutRightsAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-68" name="abp:ChangeInFairValueOfEmbeddedDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-69" name="abp:ChangeInFairValueOfEmbeddedDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-70" name="abp:LossOnSettlementOfConvertibleNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-71" name="abp:LossOnSettlementOfConvertibleNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-72" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-73" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-74" name="us-gaap:Revenues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-75" name="us-gaap:OtherNonoperatingIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-76" name="abp:ChangeInFairValueOfForwardPuchaseAgreementAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-77" name="abp:ChangeInFairValueOfSEPAPutRightsAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-78" name="abp:ChangeInFairValueOfEmbeddedDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-79" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-80" name="abp:DeemedDividendResultingFromTheWarrantDownRound" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-81" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-82" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-83" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-84" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-85" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-86" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-87" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-88" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-89" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-90" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-91" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-92" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-93" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c43" id="hidden-fact-94" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-95" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-96" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-97" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-98" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-99" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-100" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-101" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-102" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-103" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-104" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-105" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-106" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-107" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-108" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c62" id="hidden-fact-109" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-110" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-111" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-112" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-113" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-114" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-115" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-116" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-117" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-118" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-119" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-120" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-121" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-122" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-123" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-124" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-125" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-126" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-127" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-128" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-129" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c59" id="hidden-fact-130" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-131" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c49" id="hidden-fact-132" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c50" id="hidden-fact-133" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c51" id="hidden-fact-134" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c52" id="hidden-fact-135" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c53" id="hidden-fact-136" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c54" id="hidden-fact-137" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c55" id="hidden-fact-138" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-139" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-140" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c58" id="hidden-fact-141" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-142" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c63" id="hidden-fact-143" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c64" id="hidden-fact-144" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-145" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-146" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-147" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-148" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-149" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-150" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-151" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-152" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-153" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-154" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-155" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-156" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-157" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-158" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-159" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-160" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-161" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-162" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-163" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-164" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c80" id="hidden-fact-165" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-166" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c70" id="hidden-fact-167" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c71" id="hidden-fact-168" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c72" id="hidden-fact-169" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c73" id="hidden-fact-170" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c74" id="hidden-fact-171" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c75" id="hidden-fact-172" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c76" id="hidden-fact-173" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c77" id="hidden-fact-174" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c78" id="hidden-fact-175" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c79" id="hidden-fact-176" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c82" id="hidden-fact-177" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-178" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c84" id="hidden-fact-179" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-180" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c85" id="hidden-fact-181" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-182" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c86" id="hidden-fact-183" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-184" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c87" id="hidden-fact-185" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-186" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c88" id="hidden-fact-187" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-188" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c89" id="hidden-fact-189" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c90" id="hidden-fact-190" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c91" id="hidden-fact-191" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c92" id="hidden-fact-192" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-193" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-194" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-195" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-196" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-197" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-198" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c105" id="hidden-fact-199" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-200" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-201" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c108" id="hidden-fact-202" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c109" id="hidden-fact-203" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c110" id="hidden-fact-204" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-205" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-206" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-207" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-208" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-209" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c105" id="hidden-fact-210" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-211" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-212" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c108" id="hidden-fact-213" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c109" id="hidden-fact-214" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-215" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-216" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-217" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-218" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-219" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c105" id="hidden-fact-220" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-221" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-222" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c108" id="hidden-fact-223" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c109" id="hidden-fact-224" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c110" id="hidden-fact-225" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-226" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-227" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-228" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-229" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-230" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-231" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c105" id="hidden-fact-232" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c106" id="hidden-fact-233" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-234" name="us-gaap:StockRepurchasedDuringPeriodValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c98" id="hidden-fact-235" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c108" id="hidden-fact-236" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c110" id="hidden-fact-237" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c99" id="hidden-fact-238" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c100" id="hidden-fact-239" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c101" id="hidden-fact-240" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c102" id="hidden-fact-241" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c103" id="hidden-fact-242" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c104" id="hidden-fact-243" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c107" id="hidden-fact-244" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c111" id="hidden-fact-245" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c112" id="hidden-fact-246" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c113" id="hidden-fact-247" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c114" id="hidden-fact-248" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c115" id="hidden-fact-249" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c116" id="hidden-fact-250" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c117" id="hidden-fact-251" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c118" id="hidden-fact-252" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c119" id="hidden-fact-253" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-254" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" id="hidden-fact-255" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c138" id="hidden-fact-256" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c139" id="hidden-fact-257" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-258" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c141" id="hidden-fact-259" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c142" id="hidden-fact-260" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c143" id="hidden-fact-261" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c144" id="hidden-fact-262" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-263" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c146" id="hidden-fact-264" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-265" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c148" id="hidden-fact-266" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-267" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-268" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c144" id="hidden-fact-269" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-270" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-271" name="abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" id="hidden-fact-272" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c138" id="hidden-fact-273" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c139" id="hidden-fact-274" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-275" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c141" id="hidden-fact-276" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c142" id="hidden-fact-277" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c143" id="hidden-fact-278" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c144" id="hidden-fact-279" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-280" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-281" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-282" name="abp:IssuanceOfCommonStockInThePIPEFinancing" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" id="hidden-fact-283" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c138" id="hidden-fact-284" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c139" id="hidden-fact-285" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-286" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c141" id="hidden-fact-287" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c142" id="hidden-fact-288" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c143" id="hidden-fact-289" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c144" id="hidden-fact-290" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-291" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-292" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-293" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" id="hidden-fact-294" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c138" id="hidden-fact-295" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c139" id="hidden-fact-296" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-297" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c141" id="hidden-fact-298" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c142" id="hidden-fact-299" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c143" id="hidden-fact-300" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c144" id="hidden-fact-301" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-302" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c147" id="hidden-fact-303" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-304" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c137" id="hidden-fact-305" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c138" id="hidden-fact-306" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c139" id="hidden-fact-307" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c140" id="hidden-fact-308" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c141" id="hidden-fact-309" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c142" id="hidden-fact-310" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c143" id="hidden-fact-311" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c144" id="hidden-fact-312" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c145" id="hidden-fact-313" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c146" id="hidden-fact-314" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c149" id="hidden-fact-315" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c36" id="hidden-fact-316" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c37" id="hidden-fact-317" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c38" id="hidden-fact-318" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c39" id="hidden-fact-319" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c40" id="hidden-fact-320" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c41" id="hidden-fact-321" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c42" id="hidden-fact-322" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c43" id="hidden-fact-323" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c44" id="hidden-fact-324" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c157" id="hidden-fact-325" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c164" id="hidden-fact-326" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-327" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c166" id="hidden-fact-328" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c167" id="hidden-fact-329" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c168" id="hidden-fact-330" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c169" id="hidden-fact-331" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-332" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-333" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c172" id="hidden-fact-334" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c173" id="hidden-fact-335" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-336" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c175" id="hidden-fact-337" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c176" id="hidden-fact-338" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-339" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c164" id="hidden-fact-340" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-341" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c166" id="hidden-fact-342" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c167" id="hidden-fact-343" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c168" id="hidden-fact-344" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c169" id="hidden-fact-345" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-346" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-347" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c172" id="hidden-fact-348" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c174" id="hidden-fact-349" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c176" id="hidden-fact-350" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c164" id="hidden-fact-351" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c165" id="hidden-fact-352" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c166" id="hidden-fact-353" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c167" id="hidden-fact-354" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c168" id="hidden-fact-355" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c169" id="hidden-fact-356" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c170" id="hidden-fact-357" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c171" id="hidden-fact-358" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c172" id="hidden-fact-359" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c173" id="hidden-fact-360" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c176" id="hidden-fact-361" name="us-gaap:ProfitLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c131" id="hidden-fact-362" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-363" name="abp:LossOnSettlementsOfConvertibleNotes" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-364" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-365" name="abp:ChangeInFairValueOfForwardPurchaseAgreementAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-366" name="abp:ChangeInFairValueOfSEPAPutRightAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-367" name="abp:ChangeInFairValueOnEmbeddedDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-368" name="us-gaap:IncreaseDecreaseInAccountsReceivable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-369" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-370" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-371" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-372" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-373" name="us-gaap:ProceedsFromNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-374" name="us-gaap:RepaymentsOfNotesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-375" name="us-gaap:ProceedsFromOtherEquity" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-376" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-377" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-378" name="abp:IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-379" name="us-gaap:ConversionOfStockAmountIssued1" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-380" name="abp:CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-381" name="abp:DeferredOfferingCostsIncludedInAccountsPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-382" name="abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-383" name="us-gaap:OtherIncome" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-384" name="us-gaap:OtherNoncashExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-385" name="abp:ChangeInFairValueOfForwardPurchaseAgreementAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-386" name="abp:ChangeInFairValueOfSEPAPutRightAsset" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-387" name="abp:ChangeInFairValueOnEmbeddedDerivativeLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-388" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-389" name="us-gaap:IncreaseDecreaseInNotesReceivables" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-390" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-391" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-392" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-393" name="abp:NetProceedsFromTheMerger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-394" name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-395" name="abp:CashTransferredToEscrow" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-396" name="us-gaap:RepaymentsOfRelatedPartyDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-397" name="us-gaap:ProceedsFromConvertibleDebt" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-398" name="abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-399" name="abp:SettlementOfBonusAccrualThroughNotesPayableRelatedParties" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-400" name="abp:ACABLiabilitiesAssumedInTheMerger" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-401" name="abp:ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-402" name="abp:ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-403" name="abp:SEPACommitmentFeePaidInCommonStockShares" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c194" id="hidden-fact-404" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-405" name="us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</ix:nonNumeric>
<ix:nonFraction contextRef="c244" id="hidden-fact-406" name="us-gaap:AssetsFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c248" id="hidden-fact-407" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c276" id="hidden-fact-408" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c277" id="hidden-fact-409" name="us-gaap:LiabilitiesFairValueAdjustment" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c277" id="hidden-fact-410" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c279" id="hidden-fact-411" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c281" id="hidden-fact-412" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c25" id="hidden-fact-413" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-414" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c26" id="hidden-fact-415" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c27" id="hidden-fact-416" name="us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c291" id="hidden-fact-417" name="abp:MilestonePayments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c375" decimals="0" id="hidden-fact-418" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" unitRef="pure">10</ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-419" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-420" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" id="hidden-fact-421" name="abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c0" id="hidden-fact-422" name="abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c451" id="hidden-fact-423" name="abp:SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c451" id="hidden-fact-424" name="abp:SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c439" id="hidden-fact-425" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c498" id="hidden-fact-426" name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">http://fasb.org/us-gaap/2025#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric>
<ix:nonFraction contextRef="c499" id="hidden-fact-427" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c506" id="hidden-fact-428" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-429" name="us-gaap:DeferredOfferingCosts" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-430" name="us-gaap:UnrecognizedTaxBenefits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-431" name="us-gaap:UnrecognizedTaxBenefits" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-432" name="abp:AccruedInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-433" name="abp:AccruedBODCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c576" id="hidden-fact-434" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c577" id="hidden-fact-435" name="us-gaap:FairValueNetAssetLiability" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c584" id="hidden-fact-436" name="us-gaap:RoyaltyIncomeNonoperating" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-437" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c638" id="hidden-fact-438" name="abp:ConvertibleThresholdConsecutiveTradingDays">P5Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c639" id="hidden-fact-439" name="abp:ConvertibleThresholdConsecutiveTradingDays">P7Y</ix:nonNumeric>
<ix:nonNumeric contextRef="c2" id="hidden-fact-440" name="abp:ConvertibleThresholdConsecutiveTradingDays">P3Y</ix:nonNumeric>
<ix:nonFraction contextRef="c652" id="hidden-fact-441" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c653" id="hidden-fact-442" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c655" id="hidden-fact-443" name="abp:ExpiredAtTheMerger" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c656" id="hidden-fact-444" name="abp:ExpiredAtTheMerger" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c654" id="hidden-fact-445" name="abp:CommonStockWarrantsOfLegacyACABAcquiredInMerger" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c657" id="hidden-fact-446" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c649" id="hidden-fact-447" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c650" id="hidden-fact-448" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-449" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-450" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c34" id="hidden-fact-451" name="abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c34" id="hidden-fact-452" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-453" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c34" id="hidden-fact-454" name="abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonNumeric contextRef="c34" id="hidden-fact-455" name="abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xsi:nil="true"></ix:nonNumeric>
<ix:nonFraction contextRef="c676" id="hidden-fact-456" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c676" id="hidden-fact-457" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c676" id="hidden-fact-458" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c676" id="hidden-fact-459" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="usdPershares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c667" decimals="0" id="hidden-fact-460" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="shares">312024</ix:nonFraction>
<ix:nonFraction contextRef="c665" id="hidden-fact-461" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-462" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-463" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-464" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-465" name="us-gaap:DeferredTaxAssetsOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-466" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-467" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey" id="ixv-44399">0001893219</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag" id="ixv-44400">true</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="abp-20250930.xsd" xlink:type="simple"/></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context xmlns="" id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:CollaborationRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:CollaborationRevenueMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c173">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c174">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c175">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c176">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c177">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c178">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-10-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c179">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ReverseStockSplitMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c180">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c181">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c182">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c183">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MarketValueOfPubliclyHeldSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-10</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c184">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MarketValueOfListedSecuritiesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c185">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:SecondConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-23</xbrli:startDate>
    <xbrli:endDate>2025-06-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c186">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-07-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c187">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-01</xbrli:startDate>
    <xbrli:endDate>2025-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c188">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-07-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c189">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-08-01</xbrli:startDate>
    <xbrli:endDate>2025-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c190">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MabwellShanghaiBioscienceCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c191">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MabwellShanghaiBioscienceCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c192">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abp:AbMedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c193">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c194">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c195">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c196">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c197">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c198">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c199">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c200">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c201">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c202">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-13</xbrli:startDate>
    <xbrli:endDate>2024-11-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c203">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-13</xbrli:startDate>
    <xbrli:endDate>2024-11-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c204">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c205">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c206">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesBCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c207">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPESharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c208">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c209">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c210">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:PromissoryNoteAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c211">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:PromissoryNoteAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c212">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ABIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c213">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:CelltrionIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c214">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c215">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c216">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-11</xbrli:startDate>
    <xbrli:endDate>2023-12-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c217">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ABIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-11</xbrli:startDate>
    <xbrli:endDate>2023-12-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c218">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-11</xbrli:startDate>
    <xbrli:endDate>2023-12-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c219">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-11</xbrli:startDate>
    <xbrli:endDate>2023-12-11</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c220">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c221">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:InvestmentAdvisorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c222">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c223">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c224">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c225">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c226">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c227">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c228">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-28</xbrli:startDate>
    <xbrli:endDate>2025-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c229">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:CommonStockOfACABNetOfRedemptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c230">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:ACABFounderSharesLessOfForfeituresAndTransfersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c231">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToPIPEInvestorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c232">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToServiceProvidersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c233">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c234">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesTransferredToInvestorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c235">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c236">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-28</xbrli:startDate>
    <xbrli:endDate>2025-01-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c237">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c238">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c239">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c240">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c241">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c242">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FirstConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c243">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:SecondConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c244">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c245">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c246">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c247">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c248">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c249">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c250">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c251">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c252">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c253">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c254">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c255">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c256">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c257">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c258">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c259">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c260">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c261">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c262">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c263">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c264">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c265">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c266">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c267">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c268">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c269">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c270">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c271">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abp:NumberOfSharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c272">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abp:NumberOfSharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c273">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c274">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c275">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c276">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c277">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c278">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c279">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c280">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c281">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c282">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c283">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NJCTTQCollaborationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c284">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ABP201CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c285">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c286">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c287">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c288">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-12-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c289">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c290">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c291">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c292">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MedImmuneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c293">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NCILicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c294">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c295">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c296">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c297">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c298">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-03-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c299">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c300">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c301">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c302">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesAndAccountsPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c303">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesAndAccountsPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c304">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c305">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c306">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c307">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c308">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c309">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">abp:VendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-28</xbrli:startDate>
    <xbrli:endDate>2023-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c310">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:SettlementAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-28</xbrli:startDate>
    <xbrli:endDate>2023-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c311">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-02-28</xbrli:startDate>
    <xbrli:endDate>2023-02-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c312">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-31</xbrli:startDate>
    <xbrli:endDate>2023-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c313">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">abp:CROVendorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-24</xbrli:startDate>
    <xbrli:endDate>2024-01-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c314">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:SettlementAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c315">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:SettlementAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c316">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-06-01</xbrli:startDate>
    <xbrli:endDate>2023-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c317">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-17</xbrli:startDate>
    <xbrli:endDate>2025-06-17</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c318">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c319">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c320">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-10-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c321">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-10-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c322">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NonRedemptionAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-05</xbrli:startDate>
    <xbrli:endDate>2024-11-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c323">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NonRedemptionAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c324">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NonRedemptionAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c325">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">abp:VendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-16</xbrli:startDate>
    <xbrli:endDate>2024-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c326">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-16</xbrli:startDate>
    <xbrli:endDate>2024-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c327">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-01</xbrli:startDate>
    <xbrli:endDate>2024-11-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c328">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c329">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-07</xbrli:startDate>
    <xbrli:endDate>2024-11-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c330">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c331">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c332">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-28</xbrli:startDate>
    <xbrli:endDate>2025-01-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c333">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c334">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c335">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:NotePayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c336">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:NotePayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c337">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c338">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:FundingDateToMaturityDateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-18</xbrli:startDate>
    <xbrli:endDate>2023-10-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c339">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:AfterMaturityDateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-18</xbrli:startDate>
    <xbrli:endDate>2023-10-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c340">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-22</xbrli:startDate>
    <xbrli:endDate>2024-08-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c341">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c342">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:YearTwoThousandTwentyFourABIPromissoryNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c343">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:YearTwoThousandTwentyFourABIPromissoryNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-07</xbrli:startDate>
    <xbrli:endDate>2024-10-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c344">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c345">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c346">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c347">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c348">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c349">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-29</xbrli:startDate>
    <xbrli:endDate>2023-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c350">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-29</xbrli:startDate>
    <xbrli:endDate>2023-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c351">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:FundingDateToMaturityDateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-29</xbrli:startDate>
    <xbrli:endDate>2023-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c352">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:AfterMaturityDateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-29</xbrli:startDate>
    <xbrli:endDate>2023-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c353">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-29</xbrli:startDate>
    <xbrli:endDate>2023-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c354">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c355">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c356">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c357">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c358">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c359">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c360">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c361">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c362">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:FundingDateToMaturityDateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c363">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:AfterMaturityDateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c364">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c365">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-20</xbrli:startDate>
    <xbrli:endDate>2024-11-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c366">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c367">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c368">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-07</xbrli:startDate>
    <xbrli:endDate>2025-02-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c369">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c370">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-07</xbrli:startDate>
    <xbrli:endDate>2025-02-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c371">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:IssuanceDateOfWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c372">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:OneYearAnniversaryOfIssuanceDateOfWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c373">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:TwoYearAnniversaryOfIssuanceDateOfWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c374">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c375">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c376">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c377">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c378">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c379">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithACABExecutiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExecutiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-08-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c380">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithACABExecutiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExecutiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-08-16</xbrli:startDate>
    <xbrli:endDate>2024-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c381">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithACABExecutiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExecutiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-21</xbrli:startDate>
    <xbrli:endDate>2024-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c382">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c383">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c384">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-14</xbrli:startDate>
    <xbrli:endDate>2024-11-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c385">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c386">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-06-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c387">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-23</xbrli:startDate>
    <xbrli:endDate>2025-06-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c388">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-23</xbrli:startDate>
    <xbrli:endDate>2025-06-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c389">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-06-23</xbrli:startDate>
    <xbrli:endDate>2025-06-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c390">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c391">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c392">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c393">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c394">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-12</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c395">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c396">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c397">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c398">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FloorPriceEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c399">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FloorPriceEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c400">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExchangeCapEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c401">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:RegistrationEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c402">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:FirstConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c403">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:SecondConvertibleNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c404">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c405">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c406">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c407">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-06-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c408">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c409">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c410">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c411">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:YAIIPNLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c412">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SEPAMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c413">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c414">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c415">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c416">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c417">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c418">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-01-19</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c419">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c420">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c421">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:RedemptionTriggerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c422">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c423">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c424">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c425">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c426">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c427">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c428">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c429">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c430">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c431">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:ExecutiveWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c432">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c433">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroTwoFourEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c434">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroTwoFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c435">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-31</xbrli:startDate>
    <xbrli:endDate>2025-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c436">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-07-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c437">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c438">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroOneFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c439">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c440">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c441">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c442">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c443">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c444">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c445">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c446">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c447">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c448">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c449">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-31</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c450">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c451">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c452">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c453">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c454">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c455">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c456">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c457">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-01</xbrli:startDate>
    <xbrli:endDate>2025-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c458">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-07-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c459">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c460">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:SeparatePromissoryNoteAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-18</xbrli:startDate>
    <xbrli:endDate>2024-04-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c461">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c462">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abp:ExecutiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-30</xbrli:startDate>
    <xbrli:endDate>2024-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c463">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-21</xbrli:startDate>
    <xbrli:endDate>2024-11-21</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c464">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-24</xbrli:startDate>
    <xbrli:endDate>2024-12-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c465">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-07-25</xbrli:startDate>
    <xbrli:endDate>2025-07-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c466">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-07-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c467">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:AdvanceNoticeToYAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-10-01</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c468">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:AdvanceNoticeToYAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-10-01</xbrli:startDate>
    <xbrli:endDate>2025-10-01</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c469">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:AdvanceNoticeToYAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-11-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c470">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:AdvanceNoticeToYAMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-11-07</xbrli:startDate>
    <xbrli:endDate>2025-11-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c471">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c472">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c473">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-10-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c474">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c475">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-04-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c476">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-04-18</xbrli:startDate>
    <xbrli:endDate>2024-04-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c477">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c478">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-10-07</xbrli:startDate>
    <xbrli:endDate>2024-10-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c479">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-14</xbrli:startDate>
    <xbrli:endDate>2024-11-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c480">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNoteDiscountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c481">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNoteDiscountMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c482">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c483">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c484">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-01-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c485">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-01-28</xbrli:startDate>
    <xbrli:endDate>2025-01-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c486">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-02</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c487">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-09-29</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c488">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MabwellShanghaiBioscienceCoLtdMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c489">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c490">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:ContingentEarnoutSharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c491">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abp:AbMedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c492">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c493">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c494">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abp:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c495">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abp:LabEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c496">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c497">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c498">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c499">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c500">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c501">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c502">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c503">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c504">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:StockOptionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c505">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c506">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c507">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c508">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c509">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c510">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c511">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c512">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c513">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c514">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c515">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c516">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c517">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c518">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c519">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesBCommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c520">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:FirstSharesTargetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c521">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:SecondShareTargetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c522">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:ThirdShareTargetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c523">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:FirstSharesTargetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c524">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:SecondShareTargetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c525">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:ThirdShareTargetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c526">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPESharesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c527">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c528">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c529">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:PromissoryNoteAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c530">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ABIMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c531">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:CelltrionIncMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c532">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c533">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c534">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c535">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:InvestmentAdvisorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c536">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ABCDMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c537">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c538">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c539">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:CommonStockOfACABNetOfRedemptionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c540">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:ACABFounderSharesLessOfForfeituresAndTransfersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c541">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToPIPEInvestorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c542">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToServiceProvidersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c543">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c544">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesTransferredToInvestorsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c545">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c546">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c547">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c548">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c549">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c550">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c551">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c552">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c553">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abp:EquipmentUnderFinanceLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c554">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abp:EquipmentUnderFinanceLeasesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c555">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c556">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-14</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c557">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-14</xbrli:startDate>
    <xbrli:endDate>2024-11-14</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c558">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c559">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-31</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c560">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-31</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c561">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-31</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c562">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c563">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c564">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c565">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c566">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c567">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c568">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c569">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c570">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c571">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c572">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c573">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c574">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c575">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abp:NumberOfSharesMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c576">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c577">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c578">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c579">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c580">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c581">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NJCTTQCollaborationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c582">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NJCTTQCollaborationAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c583">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c584">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c585">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c586">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c587">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ABP201CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c588">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c589">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c590">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c591">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-01-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c592">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c593">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c594">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c595">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MedImmuneLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c596">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NCILicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c597">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c598">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c599">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-03-31</xbrli:startDate>
    <xbrli:endDate>2025-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c600">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c601">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c602">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c603">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c604">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesAndAccountsPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c605">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c606">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c607">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c608">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-19</xbrli:startDate>
    <xbrli:endDate>2021-11-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c609">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-11-19</xbrli:startDate>
    <xbrli:endDate>2021-11-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c610">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-21</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c611">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-20</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c612">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">abp:VendorsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-23</xbrli:startDate>
    <xbrli:endDate>2023-01-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c613">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-30</xbrli:startDate>
    <xbrli:endDate>2023-01-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c614">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-24</xbrli:startDate>
    <xbrli:endDate>2024-01-24</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c615">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-05</xbrli:startDate>
    <xbrli:endDate>2024-11-05</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c616">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NonRedemptionAgreementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-05</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c617">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-07</xbrli:startDate>
    <xbrli:endDate>2024-11-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c618">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c619">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-11-13</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c620">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c621">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c622">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c623">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c624">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c625">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c626">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c627">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-07</xbrli:startDate>
    <xbrli:endDate>2025-02-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c628">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c629">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-02-07</xbrli:startDate>
    <xbrli:endDate>2025-02-07</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c630">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:IssuanceDateOfWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c631">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:OneYearAnniversaryOfIssuanceDateOfWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c632">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:TwoYearAnniversaryOfIssuanceDateOfWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-07</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c633">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c634">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c635">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c636">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-15</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c637">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c638">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FloorPriceEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c639">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FloorPriceEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c640">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExchangeCapEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c641">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:RegistrationEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c642">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c643">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c644">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c645">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c646">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c647">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c648">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c649">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c650">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c651">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c652">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c653">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c654">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c655">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c656">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c657">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c658">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivateWarrantsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c659">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroTwoFourEquityIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c660">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroTwoFourEquityIncentivePlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c661">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroOneFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c662">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroOneFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c663">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroOneFourStockIncentivePlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c664">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c665">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c666">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-01</xbrli:startDate>
    <xbrli:endDate>2024-11-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c667">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-12-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c668">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-10-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c669">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c670">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c671">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c672">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-31</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c673">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c674">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c675">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c676">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c677">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c678">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c679">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c680">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NewConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c681">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NewConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-01-01</xbrli:startDate>
    <xbrli:endDate>2023-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c682">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NewConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c683">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NewConsultingAgreementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c684">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-03-13</xbrli:startDate>
    <xbrli:endDate>2023-03-13</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c685">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-03</xbrli:startDate>
    <xbrli:endDate>2023-05-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c686">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-05-03</xbrli:startDate>
    <xbrli:endDate>2023-05-03</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c687">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-01-01</xbrli:startDate>
    <xbrli:endDate>2024-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c688">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-10-18</xbrli:startDate>
    <xbrli:endDate>2023-10-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c689">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-29</xbrli:startDate>
    <xbrli:endDate>2023-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c690">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2023-12-29</xbrli:startDate>
    <xbrli:endDate>2023-12-29</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c691">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abp:ExecutiveMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2024-11-20</xbrli:startDate>
    <xbrli:endDate>2024-11-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c692">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">abp:TaxYear2037Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c693">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c694">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c695">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">abp:PostApportionedMassachusettsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2024-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c696">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">abp:PostApportionedMassachusettsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2023-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c697">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-08</xbrli:startDate>
    <xbrli:endDate>2025-04-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c698">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2025-04-30</xbrli:startDate>
    <xbrli:endDate>2025-04-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c699">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-04-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context xmlns="" id="c700">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001893219</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abp:RothCapitalPartnersMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2025-02-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit xmlns="" id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit xmlns="" id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit xmlns="" id="usdPeritem">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
<!-- [WMV6][xOiDiJGxuGnoVqGUeKBMuynAuXKYB/o6PAdoiFvB2jIhbrlfJbYGv6vTdtlTb0OhM120KLZkSRcNqOoei9ijrtaJkVCXtDZ5hHPhb1vXQHCJ6cKIJhpSmOzjREUIaicfKZm/v5j4BCKIAHKsFgwP1u6hQDMxB/uvs6NC1tu+TVOnEDTtAFzjJiv56yr7imwXReufoSbBnLVT20i3Pn287mYVofcFfv51BPhB5+rFiaLN5n6RPVSc6gudA2GyiIq8r+SH2LeBFq9zuK5HYPCV4y4pCZa0fwR7gH14sWJNhZLmp+ULWqIfs3KS0cUP+YyzhgIwwDzaFiD7obXNMyNw+sQQFuRW8ddn2Vs=] CSR-->
    <xbrli:unitDenominator>
      <xbrli:measure>compsci:item</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit></ix:resources></ix:header>
</div></div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>ea026650201ex23-1_abpro.htm
<DESCRIPTION>CONSENT OF WOLF & COMPANY, P.C
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We consent to the use in this Amendment No. 1 to the Registration Statement
(No. 333-291347) on Form S-1 of Abpro Holdings, Inc., of our report dated April 15, 2025, except for the 1-for-30 reverse stock split
effected on October 31, 2025 described in Note 1 as to which the date is November 6, 2025, relating to the consolidated financial statements
of Abpro Holdings, Inc., appearing in the Prospectus, which is part of this Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also consent to the reference to our firm under the heading &ldquo;Experts&rdquo;
in such Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Wolf &amp; Company, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Boston, Massachusetts</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">November 28, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "  'L# 2(  A$! Q$!_\0
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M0JI'8X(!&00"..Q /L.E.R,XR,^G>NDYOSZ^H4444 %%%% !7S]^TA\8;3X
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M EKHRLRC[5<'Y>6+>8_\$^HO%G[8G_!0_P"/7_!2J'PCKW@SX%W7P\TGX'_
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M;/6?!-SI/P8\4O-IM[]LT"R\?:G;^++6_N(MA"QWVOZ9INDKJZIDQV^D:"A
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M[HOC_P#9<^(DFJ:]IOA6_P# \-K\2M$\2ZH1]@T?5_"4IOK224]52_,7]DN
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MEEO] L-]_H]_97I(9P5+#'T7:VJPVUO#&6\N*&*-#+/+=2%40*IDN;C=/.Y
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/ %& >H!HHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $- AD# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\!?A-\*?&/@;1=!^"[L/C-XJ_8PUWXX?%#P-X5 \7Q_&3QAH,?C2+P+XR5
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M'QYK.A:SH7PV'Q+UYD\/_'+QW'X0\,>*_%WB[P@G]O(LR^,<1A #L=-_;_\
MV?I=?&A:UXCUOPY+;MJMEK?BV]\#_$W3OA%IOB;0O@FW[2NM^#4^*7B+POX6
M\,-XD7X,1ZM\3\&1$?P7HDTS#>H23R_3?^"A/@W4OB9K/AJ_\*^)_"G@6"\\
M"&U\0_$+PW\2OAOXV_LO7/@%^TW\>]=UC1?!'B'X=>:P;PW^SNRA"W@^ )KO
MBE?^$T3QWX2'@AN_U3]@+X(:[X8_X0?7KSX@ZSX=N_B3XD\?:MI=WJVB:DM_
MJOB']B[7_P!A#7-(+'0!N\-/\&==UCQ"L:JLJ^.,DCRF'@]>0'_!/?P9J]Y=
M>(/'_P 9/CO\1O%%QJ&E!O$7B(_##3-3V:)^SW\?OV:]"T[9\/OAUX1\.B%O
MA]^T7XZ\1%G16/CA?#<H0P+_ ,(DP!Z!I7[?_P"SYJ-@)[%_BC=:MJGB7P3X
M8\.^!C\(OB99_$OQ<WC[P=K_ (_\#ZWX(\%/X:'BGQ!X;\3?#WP1X]\2)XD!
M5%C\!>)5POEHJ]1XC_:<^ 6O_!OX;?$.>W\3>-OA_P#M)WB^#O O@JS^%7C3
MQ'XD^)B^(=#\1Z[KNB#X6OX8;Q+\OP\\/>-O%7CB+Q-X4#Q^"M \1F0*A02^
M#_&#]C;5K/4?!_Q%^!>I^,U^+_AEOA!I_@[5;KQSX-\%:9H&D_";X8_%[X3*
MS-K?[.'Q@\-:\/&'AKXVZ]X9\9>&?%GA!%PR^-/ O_"%W/A)4/8>!/V,M4T;
M]G']EGX6>(_BEXE\-_%C]FZ\\+>)=*^+/PQM?!VH:G_PGB>"O'O@+QRW]A?$
M'X<^+?"VO>'_ !7X;^*WCOPNTGBKP@DQ36U\<!?"/CJ-&C ,#X*?MY_!CQ9\
M._A!<>)-+UWP1+XR\.?#'^V-)T?X<?$K4/!'PUTOXL>,-<\ ?"?1?&^NCPT?
M#?P__P"$K\1Z))X8_P"$9\5/$_@E@%\>#P>AS6O=_P#!2_\ 9BLK;4+Z:_\
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MK_BO$^%Y^)?B"3PM-I$:^ X?%WC#Q<_A"$MX-C!\"H\ ^C_"W[,/@'P?XO\
M"/C#2?$?CS^T_!OQ$_:@^(.C6=W>:(-(U#5OVJO&TOCSQPNL%O#P1M"\,^(]
M:8^"D67,<2*9F\5,8RX!]E4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445XA\=OC)X4_9
MW^#OQ1^.'C@:E_PA_P )/ ?B?XB^+[;1[)]2U)O#'@C1'UK6VT32 P\QQ$H#
M#.0"&).8R #V^BODCXZ_M-_#KX!:D=+\?)X@GG/P4^//QV \.:1_:?\ Q0?[
M.&E> ]>\?%@=?4KXD9?&^AOX,4C=YK21EE*^:WC^K?MVIX:^&,_Q5\9_LO?M
M,>$_"USXE^#?A;P=;:N_P!U+5?B9XD^.OQ+\._";P1I'@A?#O[17BM1*_BGQ
MMH:E/%9\'*%/F*ZG]RH!^B]%?G?'^WKX1DCO_"MM\'?C\/CAIOQ-TSX2WO[.
M0\)^"A\7$\3:[\-=;^+.A:N-<;XB'X&'X?3_  XT/7/%1^)X^+I\%[M"E\">
M>OCXQ>#6^D?@9\9?"OQ^^%^@?%OPM;:SIFGZW?\ BS1+S1_%6E-I_B;P_P"*
M? WC37_ /CCP=K>C-Y>SQ%X4^('@K7/#4J!&(;1#L9R \@![_1110 4444 %
M%%% !117@E[\9?"N@?&[P-\ [R+41XX\=_"WXJ_%G1[F"Q=_#K>%_A1XX^$/
M@7Q FKZV' _X2 Z]\;O!92)8GWK_ ,)!(,"+#@'O=%?G7JO[>_@&+Q'HW@[P
M?\)_C7\6O%_B3XD?M&_"G1?#7P[T+P6NI#5_V5M=T70/BGK^[XA?$?PIX<_L
M,:]K>C1^#F$Y\\L[,D2N$:KXY_;TT?P7KWB'PIJ7[.G[4$^L> _@EX8_:"^*
M=MX>\.?#/Q,WPD\">.M9^+FA: /&VA:%\:&\2:[XCW_ _P <$^&?A2GC7Y44
M;&9\Q@'Z/45^=UY^WO\ "*S\6Z/H6E>'/BUXC^']SXP^"WPSUK]H'P]X>TI_
M@_H'Q._:+TGP$WPB\&ZSJVN^)4^)FN-XO/Q2^%A;Q3X/\&>,/!7@U_'GA=/'
M_C;PFJ@5^B- !1110 4444 %%%% !1110 45^=U]^W'X!B\>:MH>G_#_ ...
MO?#/PI\6],^!WC#]H+P[X0T74OA+X?\ C1KVMZ!X"C\&:T#XC/Q-*>%OB'KN
MD^$_&GBOPG\)/%?@GP/XT#+X^\;^$U\+>-#;T(_V]O L/BC6K35/A=\<]$\
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M%3X5_ ?XFW'C+PY\.#^TKX1\-^)_A9X ^(?B_P '>&_'>O?VYI6]=#T/1_\
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MOC'\)M9M/B_^PCXQ\8>+?%W[7FM_$A?[*^!G[3GP>\>^/-8\#:^WQJ\7>)O
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M73L]];.S7I\ST,RRW'95B8_VOE=2ES13@YPE"Z<8M-<R4;6<7=2;6MT>JCD
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M_P (AK:^//%X^-OP_P#$T?PU\/?$.7XBZWX)/@?PSX2\7%!X+\.^)GD\<_\
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M[?M/B?PSJUA9<<C4V(;1>O\ >=8\XY&!FOY\_"MY_P )5X3^PZYI7V:XM?\
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MZ#%% .0#ZC-%!SA1110 4444 %%%% &?7YM?M6_\%%_AO^R_\2M/^&5]X/\
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M*],],**** *]>(?&_P"-?@;]G7X7^+OBK\1;W^S?"_@_2?M]Z00"^$"KI>D
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MK.NZUH?IS_GT_):'!6,PO$;>$_Y$S<FTM-VVU;39M]-^_3\MP_!6+PO$3O\
M\B:5[V?>]]%;:_:S/A?]@3PW\6_V9/V[_ ^N?%/X6>/O!&G_  PU?5++XIW9
MT<G2]!TO7M$.,C()&>W&?6O[C?!_C;PK\0= T[Q5X-US3O$GA_5+/[79:OI-
MWOTZ^4@#C&3UR2S X[@]*_ '4OC-X!^*G[2'Q/UOPM?@_P#">:/X7UJT\/:M
M_P A*Q_L+1?[!UXZV#G SSC)QCDFO0?AQ\1];_98\;'QOX<M[BZ^$VOWA'Q)
M\#VO(L<_\SGH@[C'!'<9'>OU++<NPF$PGU3"M[WL[^KW?X'Z3EV783*L+]4P
M=][VZ:]_OT1^_%%<GH6O:5XJTC3=<T&^M]1T;5;+3M9T>\M,D7VFOAE;G&1D
M$#'&6"\=NLKT=M.VGW:'HA01D$>HQ17">-O&>A?#CPGKWC?Q3>V^F^'_  SI
M+ZQK-W@#:$R"Q]L@*.I.[. ,X ,[X@_$SP1\*?#=SXO\?:]8>'- M1_I=Y>G
M@9XQQSP.N5(]^@K^$K]I[X3?'S]IK]O/XLW/PT^#OC[Q&/C'X[U76_AQ>7EI
M_9FEWWA8:(3_ &V2>/\ A'!W)X'.>*_?#Q%XO\4_M$^,O^%M?$V"YM='M3_Q
M;?X>W8_XEOA/3/\ H-G'7Q&3UYZ9K \$_M"> /A9^U!I^MZ[/_:=_P##KP%J
MEE9^$M)_XF?B77]3\=<:%HNA]0>/_P!5>=F67X7%X7ZJV]^9V?FGIT\OZU\[
M,LNPF:X3ZI)MZW?R=WY=/O\ F?AMXC_8G'[.'QWMO#OC[5K7Q+\3_!W@_2];
MU<V9_P"*8T+5-= _XDVA'N/"8Z8S[&O>?!_@/QA\8/'GA?X2?#FQNM2\8>,K
MPV/^B#_D Z7_ ,QW6M<Z_P#%.]OZU](?%_X5_'[]H/\ :DMO%,.B>"O!5A^T
M%XCTO1+,ZOK&L:EJGA0C1,9("A<GJ<*!G. !Q7[\?L?_ +$OP_\ V3/#\\UE
M<#Q9\3M=M-OC#XAZK;+_ &EJ$F#NBT7!SH&@@Y_=IN&%RS9(4?FU?@G%XKB)
M8O%V>31<6EH]8VLK/?5+9?D?E\>$L9B.(U]:3_L:+3C?9\K5M$E=Z*_S9[9^
MS=\%/#O[.OP<\(?";P[]E-MX8T?_ (FNK;&5M;\2LJG7M:?=\V6D!)P%P-JE
M<HS'Z+P/0?E2CH._%%?K$8QC%1BDHI))))*R22T22V2Z'[!&*C%1BDE%))))
M:))+9);)= HHHJAA1110 4444 %%%% 'RG^UE\ +']H?X-^(/ H M-?M@=<\
M(:F,9T_Q3HA+Z*_7)R[$$=,G/T_G+TV;58;K6/#GBK2KG0_&'A>\_L3QAX>N
M_P#D)V.J#\NN.N!_*OZUR,XSG@Y_S_\ 6K\V_P!L3]B*R^.-V/BG\,;W3O"7
MQLTNR^Q"[N[(_P#"-^.=+P7.BZ^&((!R%3Q*J[DXXVMA/QOQ7X _UJRJ6-P,
M$LZC:S25Y6V5TN;HD]=;GWW 7%TN'\7]3QK?]CRWW?*VM]]$F[]K]KZ?S)^%
MOV3/B9=_$OXOW'P7A'B.V^R#XFW?PRM2!J9TQB!K@T+)'_%1DD =\G YKWW_
M ()L?&;2_!'[;.@0>(I=<\&>'SX.\4^&/&-QX@T?5]-TW1/$V#_8>A:YKDA"
M>'RW0;F"\C<0N2/I+]EKXC^./@K^T5K/C[XI_"/Q)IWA#P;9ZK\,O$>JZ3?-
M?BQU4:U_Q/-9_L106UX9QR 2",CD8/J4U[X!\>?&C]H^^THZ)XE\/_$7Q?I?
MQ LR;/\ X_\ PMKNB_V#GV_K7/X?\ ?['E6;YPO[%SC)-'II42LEMOS>:>_R
M/I.+O$C&/"2X<P5LZR7.U=/3F@WS/K=1Y?=MM=)G]$EK>07UJ)[.<7%M<Y-O
M<VN",$>I_ND$YQR,UJ5^+O[,OQWU;X ^+='^%?C#5;G4?A!XRO1HW@3Q!JUT
M#_P@OB8'G0N<8\/'/RX(PV"21N4_M%7[9\[^??S^>_S/QWY6\NWE\MOD%%%%
M#V?H_P F U?NC\?YFOSE_P""EOQ5TOX>_LD?&;3(-;-KXV\4^#=5T;PAI.D[
M=3\3:W)K6%(T71<[G8G(R R_NSD@E=WT!^TK\=]+^ /P_G\4S6W]M>)]4NO[
M%\"^%>0=>\3\A4&,$8!Y)/'R@ ER4_(.&SU74M>UCXJ?%35?^$C^(&J_Z;K&
MK7?_ "#/"6EC_F"Z'P/^$?\ #O'X_G7+B8WP<UK[R<?D^9/SV9T87W<;!_RR
MC)=KQE&2\K72/QM^#7PN^)?[06A:[+\)O"^H6F@>$?#NJ77BWQKXCT@:9X:\
M*Z=H89M<5 3\WB0JCMM'.%)Z UZE^S'\*H/A7\.?W]\=<\0>*-8U3Q/K'B&[
M_P"0G?G_ )@1_+_/I^DWPV^.'AOP?^QMXW^"7A;0=1\7?%CXGZQ\4+ZQ\/\
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MV_Y4FW_X"DY?)*WGU/.P^9X3ZV\)ZZO:_778ZG_@H#^R-XQ_9]_9M^+'Q5^
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MC&<8[C]N_P#:$^#'[17[-VH?M"?L]_%O3+C4/A?NT7QW>60_XJ73_A;KC?\
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MPOX8\7^-_B%G33H7A?73C7SH8T #_A'P/EY!(.>< @GS7]LKPW\3OV2/VO=
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M[_8Z\2?\%,]7^"6D6'PC@_;I\6^"/!OB7Q3X+T?5?A[K&C#P/_Q(=:U_0?\
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MU_1]*UFRN[3HW]M_-QDG&"Q&3@D]L8-=U7P;_P $^M8FU/\ 9\T_29Y@=/\
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M^C6^NZ[_ ,AC7O\ 3;SW]?3C_)]:_>3_ ((E_LU7WQ)^-^K?M(ZY#<_\(?\
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M;T_97^$NO>'-8\4V-EJ6G?$?XM>(_#'P]TC2K36/[,\-:]XHUPD?\3T  ?\
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M."6+$'@?+'HGY _M:ZEI5GX<^%\^J_\ 'O\ \+@\+]_Y_P">>1P<5[1\6O\
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MB@O[)@^!.B_L_>"R_B/Q=XFC\.^*?$Y?Q/XV\3^*_"#>"8D\.>%W#>,"?+C
M/T\^"7[3?P?_ &A]1\16?PRUWQ)=:SX6TKPSXEU70/%7PY^)?PI\0OX8\<2:
MZ/ _C+1M"^+OAGP=XFU[X?\ BH>&M<'@SQ9X8B?P;XM?1/%$<$QPR5]9U^3W
M[)'A3XBZG^TU^T?\<]=\'?'7PQX0^(_PL^!>BV-Y^TQ;^$M,\:^$_'6A^,OB
M]K^O?!CX8:+X;* ?!KPK#XTT/;)("/%WC?Q!XE$?CKQH=O\ PB/ZPT %%%%
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M?\5>-O%C+XL!\':'X4A=O!4A/A!OV!H **** "BBB@ HHHH **** /C;XO\
M[8G[/?P)UZ?P?\3/%NN:3K^F>$3XV\2'PE\.?C#\2=-^&_@,IKP_X3;XL:W\
M/?AOXO\ #7PA^'H.A:W_ ,57\5'\(>$/^*?\1XDV^%)5&1XE_;C_ &9_#_Q
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M",!B"W05^N5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPU\(>&?#P_X1HN2Z^-%\;(RKM4ELJ ?Z"=%?QR?'O]L/XEK^W=_P5'\ >/\
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MGX&\*^$?&'F$R^9+%%(TH7]R?V)O%OQO^('[*/[/'CC]I'2KGPU\;_%/P6\
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MX<>+;7P@VC>.-#N+_P >>&_^$G\-Z!=W?_"-^)M<TG);^VM%\$Z_CQ-L [D
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M:ZG8:AINM$MI&J:/K _=C=%C:4) 5VD4% C, =E1110 4444 %%%% !1110
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MB[P_H&NR1^%L>"_!T:>!/$GC<^-?!'@M/&I'(>&/VL?B7XJDT?5(/!_@C3M
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M4^&7[,W@?7M6US^P/#GB@ZZ\FO\ P1UT>,_#+L$\7>$O$*[O&_A'#1O^C%%
M'Y:3?L8>*-7U3Q58>)#X:\2V-Q\1O'OC3P[K^J_$KQAF^TSXJ_'WP]\6M>\%
M:W\*_P#A7(\,#PZ/#>C+X7^;QAXN '@3PL6 # ^#OU+HHH **** "BBB@ HH
MHH **** "BBB@ KP+XR^)?AWH_AJVTKXC^'+GQKHWCOQ$?!=EX2M?#H\;_\
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MJ%^K: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ![ %@# 2(  A$! Q$!_\0
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M(6CS_P#"+_ >>QOO[-M[KQYX7LO$EI_S_P#A?QUC^W=%[#H>F./IB@#]5?\
M@E/9>&_#G['7@#P-HD%U:ZCX8U?Q5_PD7A[5"!JV@'7?&7B#7="_MG/\?_"-
M_P!B;<>^>*_3NOR>_8BU&?3OCE\2-"@.+?Q1\.-)\47AQ_S%-!UP:%^?_$[Z
M<#VZ5^L- !1110 4444 %%%% !1110!Q?BG0+;7?#'B?PY?3 :?X@T?4]%O
M.VG:WHSZ(P[\\D\=>3Z5_-9-X;U7XD7^L> +&^_LW6?V5?[4^(.L?:[S_BF=
M>U3P+K7]@Z%HNAZYG_BH!V_^MFOZ.OBEK']@_#?XA>([<XG\/^!/%>LVH]7T
M70]:DR,^Q/;N*_FT^(6CSCPO\#Y]*OO[-M]4\8^%]%\2>NO>%_'0_P")[HO?
M_P#70!^FW_!.V:W^(,GQ/^-5G!=6VGZG>Z7X+\-6FK*=/U33]+T/.N:]_;8
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M_I&_!OX?Z5\'OA?\/_AEH<'V;3_!WA#2/#%F.X&BZ.%'X9)^O3H*^'_V%O\
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M^+?$P(;(QXK+< $D%MJ\V8Y-];LT_-]-4[W]-#Q.(N"_[5SA8Y-VNF]?-/\
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M>)_COX<\2?$RU\ >$/BW\$_$_P 3OV9/&]UXD\&G_A$O^$%.O^ ]>UK0SQD
M_P#"J_BA_P 5:!_Q6GC[Q/X&Z^$:_6*;_4GZ#^5)]DM_^>2_K_C0!^-WC;X^
M_'[PIH.HZ5KI\2'XP>!/"'AB]UCQQX4LM8_X5!X\^%VO>-O 6A:Y^T#X'_M\
M#PN?$/A'X<:[XX\3^-O"V,^"_&>@ D^,_ G_  AI\9_6_A3XM>'I_$VL^#O!
M0\:_$8Z9X<\#7FKZLGB;P=XF\,[==9@FN?V]XA\1(P=DVLP ^1B57P4^T.WV
MU2?8K/\ Y]+;_OQ%_P#$4 ?"7[,?Q;\.?$#QS\9XO"W[1GAKXV>&+/6-*O\
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+:9^Z.I_E10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #+ AD# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#MOV]/^"FW
M[>GPJ_;,_:/^''P__:3\;^&_ W@SXO\ B?1/#6E6MIX.;3="TK0=9 &C,S>&
MRS$CJ6.?4FOE#_A\!_P4G_Z.V\?_ /@F\&__ #-UP'_!3?C_ (*$?M?#T^.W
MCS_T\BOA>OH\-AL(TG)+5)ZI-)VBWNO,YS])_P#A\!_P4G_Z.V\?_P#@F\&_
M_,W1_P /@/\ @I/_ -';>/\ _P $W@W_ .9NOS8HKI^K8+^6/_@,0/TG_P"'
MP'_!2?\ Z.V\?_\ @F\&_P#S-T?\/@/^"D__ $=MX_\ _!-X-_\ F;K\V**/
MJV"_EC_X#$#])_\ A\!_P4G_ .CMO'__ ()O!O\ \S='_#X#_@I/_P!';>/_
M /P3>#?_ )FZ_-BBCZM@OY8_^ Q_R _2?_A\!_P4G_Z.V\?_ /@F\&__ #-T
M?\/@/^"D_P#T=MX__P#!-X-_^9NOS8HH^K8+^6/_ (#'_(#])_\ A\!_P4G_
M .CMO'__ ()O!O\ \S='_#X#_@I/_P!';>/_ /P3>#?_ )FZ_-BBCZM@OY8_
M^ Q _2?_ (? ?\%)_P#H[;Q__P"";P;_ /,W1_P^ _X*3_\ 1VWC_P#\$W@W
M_P"9NOS8HH^K8+^6/_@,0/TG_P"'P'_!2?\ Z.V\?_\ @F\&_P#S-T?\/@/^
M"D__ $=MX_\ _!-X-_\ F;K\V**/JV"_EC_X#'_(#])_^'P'_!2?_H[;Q_\
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MX_\ _!-X-_\ F;K\V**/JV"_EC_X#$#])_\ A\!_P4G_ .CMO'__ ()O!O\
M\S='_#X#_@I/_P!';>/_ /P3>#?_ )FZ_-BBCZM@OY8_^ Q_R _2?_A\!_P4
MG_Z.V\?_ /@F\&__ #-T?\/@/^"D_P#T=MX__P#!-X-_^9NOS8HH^K8+^6/_
M (#$#])_^'P'_!2?_H[;Q_\ ^";P;_\ ,W1_P^ _X*3_ /1VWC__ ,$W@W_Y
MFZ_-BBCZM@OY8_\ @,0/TG_X? ?\%)_^CMO'_P#X)O!O_P S='_#X#_@I/\
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MC?P'K/B33/ >J?\ "SM?U[QUX*_Y%OQ=_P + \._\(X?^*'S_P R7_PC'@;
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M_P (YKGPK_YD\_\ ":>"] _X0;M7YOT5R?5_ZO\ _; ?IQ-\0OV4->\&^!_
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M(WPYN=.U#PO\>/ 8U>[_ .$D\&#4]0\+Z&= _MWQG\4SX?\ @G_PC/Q &?\
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M3_H-:9_X%_7W]S^9H_M[1/\ H-:9_P"!?U]_<_F:?]IO^9?>P_L_%_S2_P#
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M^@UIG_@7]??W/YFNG^TG_,OO8/+L6OM/_P !?^1_GW_\.3_^"F?_ $;/=?\
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M7HFDW?;H]]-M>IZ6'5LL3^TF_6W->_?=)7^78Z_6=-_X)\>%O".@^.?$=O\
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MV;_V<X?]?\"/@G; _P#5-_!OKQ_S+?Z^A/M7B?[4OP2^,_QF\1> =3^&6M^
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M%RK_ *$>&_\ !&'_ /E18\Z;_GM<?]]#_"CSIO\ GM<?]]#_  JO11]<Q_\
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M%<S<H1<6XVC/FC:+Y8I**V=BBBBOHS\J>[]7^;"BBB@ HHHH **** "BBB@
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MAQ_V>?\ HOGQI_\  ?P;_P#,O1_Q#C?L\_\ 1?/C3_X#^#O_ )EZ_HSHJ?\
M4OAW_GRB_P#B8WQF_P"BOXJ^7+;Y:;=O*Q_.9_Q#C?L\_P#1?/C3_P" _@[_
M .9>C_B'&_9Y_P"B^?&G_P !_!W_ ,R]?T9T4?ZE\._\^4'_ !,;XS?]%?Q5
M_P"2_P"1_.9_Q#C?L\_]%\^-/_@/X._^9>C_ (AQOV>?^B^?&G_P'\'?_,O7
M]&=%'^I?#O\ SY0?\3&^,W_17\5?^2_Y'\YG_$.-^SS_ -%\^-/_ (#^#O\
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MK^NNIT'M%%%?*)_X2#XX:MJ?D>)_%_@?X0:%XCU3PK9?\(C=:UX=\;?$C4]
MUD:+K>L/XW0GQ+X<^'8\1)KOA>*3PJ/!WC'QBV@'QLGCL>!9563+$8BRLOUN
MOPO^'_!Z,-A^K>GX6W>NJ[[/N?5F]?\ /^?\X^F3>OO^7^?\@^V?"/\ A0WP
MDA_?W%_X_'VKK=W?QX^,>+\_^''R<GN?R[T?\*!^%GF_9_M'C?[3C_CT_P"%
MV?&3/T_Y*/Z_XXKF^L8S^D=]LK_N?^ K_,]XW+ZC_/\ ^O\ GZ&C<OJ/\_\
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M24?\-A_M8_\ 1TW[0O\ X=/XE_\ S25M_P 1.P'\DUY6C]WP_(ZO^)$.-?\
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MT11GJ= XK^D.O,?A'\(O!'P,^'OACX:?#31-,\*^$?"&CKHOAW0+,86Q5<X
M!)PO).2>26SWKTUNAZ_AUZU^X9+@/J>4Y;@F[\D8\SUOS)7>Z5TGHF]W?9[?
MY)>)W%BXVXZXKXEC'E6>U)N"T3Y%-J#:6BDX*+:3:7-:[LQ:***]L^"6B2[)
M+[D@HHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 D/\ KA]3
M_.NIKGH?]</J?YUT-<^(^)?/\S2E\"_KHC N_P#6W/U'\A5:K-W_ *VY^H_D
M*K5TX?X7\OR1K'?Y/\F%%%%#W?J_S9S!1112 **** "BBB@%Y?A_P HHHH'[
MW][\0HHHH#WO[W_DP444477=?>O\PN^[^]_YA1111==U]Z_S#7S_ !"BBBBZ
M[K[U_F'O?WOQ"BBBBZ[K[U_F&OG^(444477=?>O\Q7?=_>_\PHHHI:>7X#][
M^]^(4444:>7X!=]W][_S"BBBC3R_ -79:OMN_NW_  "BBBG9=E]R_P A7\_Q
M_P""%%%%%EV7W+_(+^?X_P#!"BBBBWE^'_ "_GMOK^>H4444679?<O\ (+^8
M4444679?<O\ ( HHHHLNR^Y?Y %%%% ;Z/5=GJON84444?IMY>@!1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!8@[_C_2N@KGH?\
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MO%OAK1?@CXF/BE N1XA;QRW_ !0;&E]7_K^D/ZQZ+[M/Q^1]R?\ "0?M&?\
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M/UQ[<G%?R9?\'%_Q'\51?$+X%_"* W%OX/D\.>)?B!=6P(.F:CXC&KC0U)P
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M^#QCO%W?WWL^VS1XA_PTM^SE_P!'"_!+_P .GX,_^:6F?\--_LY_]'"_!/\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBA[/T?Y,"Q705ST/\
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MLV?_ $,H?^!+_P"0/<J*^??,_:A_Y\?@G_X.O&7_ ,SE6/M/[4'_ #Y?!/\
M\'?C7_YG*Z/;^OW?_;#>6RZ9G'\/\CWJBO#?M'[4'_/C\$O_  =>-/\ YG/8
M?E1]H_:@_P"?'X)?^#KQI_\ ,Y[#\JY_K/\ >?\ 7_;PO[-G_P!#*'_@2_\
MD#W*BO#?M'[4'_/C\$O_  =>-/\ YG/8?E4'F?M,_P#/E\#/_!SXU_\ F=H^
ML_WG_7_;P_[-GUS./WI_^VH]YHKPW[1^U!_SX_!+_P '7C3_ .9SV'Y5!YG[
M3/\ SY? S_P<^-?_ )G:/K/]Y_C_ /)!_9L^N9Q^]/\ ]M1[S17AOVC]J#_G
MQ^"7_@Z\:?\ S.>P_*J_VG]J#_GR^"?_ (._&O\ \SE'UGS?W/\ ^2#^S9]<
MSC]Z_P#D3WJBO!Q-^TU_SX_!/\=7\9_U\-YKRSXM?&3XP?!/P7X@^(?Q,O\
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M%O\ PZNI_P#S*_YS],5_^(DGXA?]&O>%O_#J:G_\RW^<GVPO]?.'?^?GX/\
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M.?!H)!_9>;_7'ZC^=05NMEZ+\D:'XQV_[=GQP\7>&=2U;0O"_@'X7:@WP?\
M@S\7+5?$-EJWC8:#IVN?\*$UWQW)XX(\0^$'T#0/"J?%3QLC?\)<W@] OAR/
MQPGC;Q?CQKX+\'^@_P##7WQOL]6L+CQ%HG@KPEI'C&UTP6WB'Q%9:T/AG\)]
M+/C/X]:$-;^*GW?$C'Q4/A5H'A59/^$O\(>#!XS\>>&4SG?_ ,)E^K=%%EV
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M]X%UW]GOQ[\=OA/K>O:[\7_AMXN\,> /#P\0J/"H)\'G_A-%^'X7IXM%>L?
M'XR_\% ?VE?B%\/K_P"'/C?XM:EXATSX$?\ !/WQ_P"+KS5;KX-_#CX&Z ?'
M?]OO\=M:^*GPL\0>&O\ A9VO#Q=X<T'7#X)/PI(4L #_ ,(<V!7[HS?M%?L^
M33>??>([6YN/^GOPAK1Q^'_",\<?A5C_ (:<^ 4,OGGQAIHN#Q_R!M9]^_\
MPCO;(['I^74\1AK;:VOM?7M_7W$_V/FOEVZ?_)?B?*O[4'QA_:$L_AEX"\>Z
M'9_$']E[4-!_:G_9P\ ^(_"7B(?!OQMJ/Q8\!>//V@OA+X"US;KWA[Q#\6QH
M/AT^'?&NO,P+^$/&R[LG:K(#^<_Q]_:R^.WPS^*?[9UEX8^.VL^+O&-M8_&"
M^\"^'_A[XY_X2/3/V6O G@+6_@'H>N:W\5/@;XB^"GA,^'=GA[QQKOBKP+\4
M6\8^,O!GC$]#GD_N%_PTY\ IHOW_ (PTVX'/71]9)Z^WAW./7C@_E1_PTM\
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M)M248\ST<6U_#[17T1XJ_9+_ &C/!^O:AH<_P=\?ZV;7_F+>$_#>M>)-,O\
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M?A_P1K3;3TT_*QBT5M?9X?\ GFOZ_P"-'V>'_GFOZ_XUGSQ[?@CIYI?S2_\
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MS7]?\:/L\/\ SS7]?\:/K#\_Q_S#ZNO+\/\ (Q:*Z+[/#_SS7]?\:K_9X?\
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#D__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #B -(# 2(  A$! Q$!_\0
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M83_A%R!Y7B#Q,'"LQ8;_ .TG^T7X"_9<^&6O?%3XARZB=/TM=-L/#7A;P[I
MU+Q1X]\=>(3_ &+X(^&G@;1AAO$'Q&\9>)0OAKP9X84[GD(9R2H8>!_L?_ W
MXFV>I^./VF?VF)Q/^T]^T%:::/$W@C2=7.H>!_@/\,-"8GP/^S]X&Y7PSK__
M  BG]N,?&_BP#'C7QJWB6125'(![II'[*?P(T&'P[;V7@ZYMSX$L]-M/#7D>
M)/&']HZ=IV@?#'7O@7H":,R^(P04^'&NZYX84@?=UQF8[MK-P'@[]F;2_AQ\
M3?\ A+]#\4>)+:P6]TH6O@?2O$?C72_#=]X8T/X7Z'\)]#T;6]!_X6*?A?XA
M7PIX=T'0O$RR?\*D/C%CH/AL+(S1A7^W888/LMO_ .VO3]#],]^F.1SH^3#_
M ,\?_'3_ (T ?,%[^SY\'->UVY\8:UX3M];U_4[A=6OM7OM8\5ZB]Y*=#^('
M@8"/;XA8KH;>&?BO\4/#GA'PS)YD C\<>(OL]JS22M'L^"_@9\/OAUK(U[PA
M8ZII-[8^&O#/A=19^,/%VH:7JFG>']'30=#UKQ#H>N:^?#WB#Q/!H$3>%6\4
M^*/^$K\9-X/T7P\DGBX*D2K]"0P0PQ>3#"((0.@^7&>O!R<^Y/Y<9M4 %%%%
M !1110 56,4$PSC\ <<=/?\ R?>K-% 'RU^T=\!_AW^TQ\+O%WP?^(D6I77A
M[7O[,O;75=)NQIOB;P'XJT#6AKG@?XE^!]<R?^$;^(?A'Q*NB^)_!7B<999/
M#XR<!U;Y?_9)_:.\:Z7K/C']EC]JO6]#T3]I;X)>'M-UN^\;7%IHOAOPQ^T/
M\'BYT#1OV@_ XR%'S_V/X8\>>%0-W@[QP6;GP/XN\&9_2R73;*87'GV]M<"Z
M_P"/S/7'X9/Y\\5^,/\ P57_ .";GCG_ (*%> /"T7PS_:(USX+?$?X9G53X
M,N[3PQH][X;UQ-<T3.NZ)K_C30@OQ2\.:!XI(T-)5;Q>?!RRZ!X9\=-X$\6^
M._"/@SQ?$!O\_P!=#]GH?MO.<8YSG'3C^M6"0.37Y]_M)?$GXE^!?V&OB5X_
MU3Q%J7PU^-&@? EM8.J?#ZUT3Q-_PC_QD&B *-"'CWP\_A;7$?XA"/PXJ>*_
M""DJRLZ)(Q _*OX6?\%:/VF_"USIX^,7@CX2_%G1[8:6-8M?@WH_C'P3XZT[
M2SQKNMZ$/$/B/Q?X6^(!&>-P^#PZ9!&17BYCG6$RII8QJ[:2\FVDMK=6>'F.
M>93E6+6#QCLW:W97M;JNY_2Q 0,^YX_'&*L_\LO\_P!VOFOX(_'[X<_'WP=8
M>-_AGKH\1Z/J=SJ5C=YSI^JZ#JB\MH^NZ,6+:%X@&0#N4-NR6)WC'T9#-F*W
MZ#^GUZ_X?D:]".)6+2<=8NS3B[K5)[JZZJ]F>GAL3A,6N;!NZMNG=??=IOKN
M:%?%'Q.^,IL?%GCCX1>';_1M-\7Z#\(=.^)FK7GB+Q&_AS5;'PMXX/CW0-!U
MOP9HC)NU]H_$?@778O&KF3PB/"*:[X7E\QV<;?K^66: <38[_P"E #/\OH,>
MM?)/[17QS_9O^!FF6'Q$_:-\1>%/".G&[7PQX!;7_#B^)?'GB[5M="*_@[X7
M^!M C\6?$GQ[XE\4<8\*>$/"3^,Y!O(C.W%=1TGS#X5_;/U30O@G/XJ\<>#[
M"Z\4> ='\"6FL:1:^/=&.I>/--?X,_"/XMZYXUT*0^&O")_X21?^%ILH5?"0
M\%?\)CH95_&W@U2N.Q\0?MA:[X:\27>E?\(AJ&MZ?IM]^T;K.LW6K>+]%\-?
M8_"_P+^)7PE\"ZZ- S\.@0V?C=H3?\56/"1">'W!\:G_ %GB[V+X:Q> ?C+\
M*;#Q;=_L]W?PVT_Q-8>)+/\ X5_\9/A3X2T#Q-8^%%;7? >DIKG@E)1)X?T/
MQ;X6QY?A?Q=AQX.<>"_'2^%MLD=>)>%?VG/V7M>^,^O?L^?$+P?_ ,*-^-]K
MXQ\56WAGP1\>? _A#P5J7QL\S6CCQK\*_$&]O"_Q@B\5_P!C:(P7PGXND\9*
MNT^.$&Q!0!^GEG%Y5O"GH,_F"/Y5:KGM(FF^P6_G@6]Q@_Z)W'3@\_7KGICO
MBMDGS8>2 3ZXYQ_4?B<CN:/(/(*SO-GSGSK;\_K[^YK/U'61IXS-#FW/<>P/
M;IU&>?Y<U^-?[2W_  5,_P"$*U_4O 'P"\.Z?XW\3Z;>-8^)?B#XL.LZ7\-/
M 6J$_P#(%0QE1\7O$74CPQX3\7^#_"&2#_PG8( KS<QS/!94D\9)*]G?K^:_
MK0\S,<TP64K_ &V45I?=7[]U?^D?LK/>3PQ7'VB?[-W%W]CX/'IT/7OT_EP/
MBWXD^#/AQH^L^)?&OB_1?"7A_0=%U7Q1K6J>*]:T?2],T[PSHA$NN:RVK-LV
M:%X7$A=BZJX+ .2#FOQZ_81_:G_: ^/O[2GQ 'QU\?Z)>0:%\"=*LOA7\,OA
MIX$UCPSX&US4F\<#_A._&GC<^(/$?B[Q-_PD,2GX6>&(Q_PEY\&$:YXE0G)W
M%?\ @H-_P3E^-/[>G[0O[/\ -<_&8?!C]GWX(^&_%&M^)]/M=+3QUXX^*_CG
MQSKVAZUK/@K6/!&N@?"_7_"I\->!-%/BX>+8_%G@YTU__A!Y? ?B[P49U7HP
MV8X3&818O!ZIZ+\.FOZE8;,<)FN$6,P=[-V72]K;7_X)[-^SGH/B#]LOXR>%
MOVZ/C=X<U+1OA-X$M-63]ASX/ZK:FP;3]-US2&T'7?VM/'.B'<3\0OBMX?9Q
M\$AG'@;X+Z^5VCQUXN;;^N5I%#+:V_' &1VY';\O\:Y3P_I!ATO1X[R:\U._
MTZR^R'5KZST9-1O, 8)70P/#J%AU4)@$$E5)9CV<,,,,7D0X ]._J>W'>NK?
M4]!;(M4444#"BBB@ HHHH **** "BBOE#]ISX^Z3^R]\"_BC\?\ Q%H'BWQK
MH7PI\'ZIXSU3PK\/=(DU+Q)?Z9X?+OK.R,R!3A<ERA7_ (1)5)<[-H4 ^EYL
M"7B;'_UOY9/KDG]:_G3_ ."B'_!4'XT?L3?M:2> ? %EX4^*/A#Q9\%O OBJ
M]\$^.+=O#Z^ O'G_  F?CU%_X1_6]! \2ZX/%OAG04;QS'XH4)X*DT'X:/X#
MWOXQ?PA)^GW[*/B#]HKQKH%[\6_CMXC^%5MIWQKM/"WB;X4_"?X.7>E^-O _
MP4\,'0BW]C/\<&Y^//B'Q4FLG_BJO"W@^+P5YF@A? >?!4@#?SN?\%X/AOKG
MAO\ :E^&_P 6_(NK;P_\4/@F?"_4:=_Q4_@36M?U[7=&UW&>OASQQX'YY/\
MQ3_/.17FYEB?JF$;UNG=V3]?S7]:'Q'&^99OE.4O&Y/NM=5M:[Z^:[?\'[\\
M(?\ !27X2_\ !0SX$_%?X"'2[KX%?M'^//AQX\T/P#X<U75WU+2]=\3OX,US
M7=#_ .%6_%!?#GA$>(V\*-_8GBD^&V'@[QG$O0*IE=OR<T?68-=T;1]<@L?L
MUOJEGI>M?9+NS/\ H'_4%]_;CZU^4_G3V<MAKEC/J6F:AI?]EZU9ZMI-Y_9O
MB:PU3_F!:UH?_8I^(]#_ .$I_P XK[ ^!OQRUSQMXR\7^#O'\^FGQ1JEYJGQ
M!T?Q#:?\2W3/%IUW6O\ BNO^YB_X2/\ XJCIG_B?^)_^A1K\EXMQ+S7"?6DM
M8IZ:WT\M]&NVI^!9EQ;B^*<)_MFF<Q;6FFWI;L?H!\"/C[XQ_9D^)=O\3? \
M%UK6CW6-&^*GPRLR1IGCSP'H)SKHT/!!_P"%A^$_#@'_  A()P1GP*<@D>#?
MZ?)OVBOA+!\ ;_\ :+N/B+HEA\'[7P)_PL__ (6"1JYTP>%O[(&O#6_[$)'B
M;Y <_P#"+\NVT^" '8$'^2OTS/\ Z./_ "?_ ,]\]>U?I_\ \$M?C7;Z#XX\
M0?LP>,9K6Z\,>._[5^(/PK.K_P#$R.G^)]#QKWCOP4#Z' ^*/@D<=/B;W'#\
M.>+;R_L;&:N[2;U>]EN[]MC](\,.++VR;&?%T>[OL]7>^J[ONNPS]DS_ (*:
M_M)_\%2['XA>'/V2O!_PP^ 7AWPQXQ\2MK'QL^,5\WC7Q-H/@5=;_L+P-K7P
MJ^"'A]A_PL#Q WAP+XG;XG^+/&'@WP1X,\9AO S>!O&8\*2 _J3^SW^P[\(_
M@;XH'Q;U6?Q;\<_VA[O1AHWB3]IKXX:R?&GQ-O\ 3&8+K6B:("/^$8^'_AQC
MD?\ "*?"GPAX-\&YPI4Y./N+3M.LH;$6]O;FWMCG-MQ\I'KWSBK_ -D@\K[/
MY2^3Z9[XZ^N>U?M9^V>FQ!#:0>5!F$<#GKQUY/7VZ8KQ#XT? SX3_M!^!]7^
M'/QQ^&_A'XG^"-<PM[X?\<:.-2TLX3.^,AV?0==#L0OB7PR5D!WGH(PWT!5?
M]Q-Z'CZ9!_S[=?>@#\6_'7A7]I__ ()\>%=7\??";XJ7G[2/[+O@VT6\\2_
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M.L>-O''C:P\,0>.+[_1_"UGJG]C^'K2\_P")9H.J:YK7]O:[Q_T,7_"1\?\
M"4\\?\(QX&_YE'P8#CP^%=<\;:IH_@;PK!_:7BCQYK&E^"O!]IU^W^*-=UHZ
M#H7Y^(]<T/\ #\*_6,CQ+RS"93@MWI?=]KW2O;YG1A/$;&<V4Y+E"^THSLM_
M>49-I+M?1[[]3_1D^!NMG5_A)\-[L^,=3\>WESX$\+7M[XUU72=+\/ZGXMD?
M1XFD\9ZOHVA1?\([H6M>*C./$9\/1*J6ZR;2D?E%8O=Q]P_7_"O./AUX-TGP
M!X!\'^!M*P-'\&>'-(\-V0/_ $#M TA=%7(ZC!0$XYQS7Y]_M'_M,?&_]CCX
MF:O\5_BOI&E_$G]B+Q-?>!?"_P#;_@C2I-(^+?[/'B?Q%)X<\"Z/)K_A]=R?
M&3P%XK^(>M@I)X67_A-_!S:^RIX+\61^&)&K])3V?H[']+8;F>"@Y:2Y$WON
MXQ;\][GZH45G:=*LUI!-YPN@5/\ I/ S]>^#QST[FM&D=84444 %%%% !111
M0 5R^HV8G%Q"(+2Z%U:?Z9:75H3]OP2.V!D=,=C]*ZBJ\\,$N/.&?Q_S_D4!
MZ;GX^? *6]_81^/UM^Q7XDFG/[.'QBUCQ1XH_8=\57N#IO@+Q.V[QUXY_9+U
MSJ0/"H&O_$[X(YVY\%'Q1X%R/^$0\&J>G_X*A?LC3_M4_LQ^(_"OAS3/M/Q'
M\!8^('PK3[4V;WQ5H._=HNX\8\6^&AK/A<* ,#7@^2/"ZU]3_M.?L]^#_P!I
MOX2^)_A%XJU'6M$DO&TW7?!_C?PK=C3/$_PU^)N@R#7O WQ,\#ZTN/[ \1>#
M_$.C+XD5R>#L9LEB&\8_8R_:%\2?%GPQXH^#GQLTW1/#?[3_ .SGJZ> /VA/
M#]K:+'I.O^;I+'P5\:?A4O+CX.?M ^&B?%G@O<BCP>S^)O N]F\(L4Y<2EBD
MU;2S5FEOU>S_  /,S/+?[5P4L'BNJDE]SM^-C^#OSI_-N/M'_$MN+6\U2RO/
M]#&FZG8:G_R ==T7V_[%;\.U9^I6>JQ&"^T*?^S?%&@C^VO#>K=?L&J?X_\
M(<\+^-_^P_FOZ#O^"Q7_  3NU/PCXD\4_M>? [2S<^$-=_T[]H7P1I%F2/"6
MJ;F1OC-H6BCY#X?\4LK#QTJL6C.WQTP&[QCXT\'?@#]L\Z+SX)R?^O2\[8Z]
M?UZY_*OSG,\L_P!K<6M'Y.UM;V5K'\><2<-YOP_Q&]'RN3U2=N5R>MTK?"^_
MY6/U \-Z]>ZOHWAB^URQMM-U#Q1X;TOQIH_^F?\ $L\6>%]=T7^WO[:\#_\
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M%OV<]<)'_"L]!UP$_P#"/_&7]H5=#/AGP1D[O!?@G_A)_'.P-_PAH/Z(>"/
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MV/IC6--TKQ5HVHZ'XCL=-UOP_JEGJG]L:3JW_$RTR_\ [=T7.N_Y_EFOJ/\
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M^,O!K>-/&GB#Q-XX<(WBUE4 R/V*/%UOX*T?]J?2M56?^P/!GB_3?C18V]J
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M%']D#]K3P=87.B?$C0?VA?AC^SEXBU:RL](TW5/'GP'_ &D-;'@/7_AEK_\
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MJ&T@ED$\L*^<!C).<=AR*MT4 588888O(AP!Z=_4]N.]6J** "BBB@ HHHH
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M'^NP<Y]>V: +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7YG?M6G/[<_P#P2Q _A^*O[4%X>A.3^R/\7#[^OK_];],:_-?]J_\
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M_B9XDU+^RSK9T#QSHFA,?#?A!?$7A[_A77'@A?%?A#(/!()%$WP.^+F@^$/
M'A3_ (6IXVN/%]G\:]3\,^$-5L_$GQCU/3=1^!&O_P#"?:#_ &/XYUH>(RP\
M0^$O@MK6N^)D\5;OF^-/A_X: ^-L*IH _3>T_P"/:']_]I&W_CXX^;WZ=SQZ
M]JMUB:1%;PZ9806^?(%H/LPN0"W8@-WQ@@],X/'I6W0 4444 %%%% !1110
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MZWI/B#P5HGASQ0= ^'GC'POXWU7/B(>*E;Q9X1U_PZI\&3Q^+Q(GZ@?8[/\
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#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "I )4# 2(  A$! Q$!_\0
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MP/[-9M=\9ZZOCDZ)CJ=NA:"OC;/.U?"PS@#' _$+XJ0>&_"^L:Y?<6^EZ/\
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M_#CQS\8OAQ\,_&NFKXH^!:_$#_A:VCZ"/$*MXET%@VN+A6 &-!)^;:%;U?\
MX)?ZE\./"L'[1/@#P1X(L/A;HWC'XV>)_CK\-O!-CX;T?PWIM]\'/'6C> =
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M1O!Q_P"%5#3O WCOX.:Z/ 2?%CQKK9_X1O/P_P#$F/\ A.?$Q\+?\)AGP6-
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MAB?^$T)SD8&/OF;X,_#+S;B<>"/"7VC5/]"O+O\ L?1LW_X>OX9'I7AGCO\
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K)1%X7\O:GVA10 F >H!_"C '0 ?A2T4 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #G +8# 2(  A$! Q$!_\0
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MO[97Q]^(<FH?#_PYKGA/PEX_^".D _%3Q"/")\1:9XL\>:UK@;X3C7-$0J=
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M/K>D@]?^$8U[QKX@U_P^<]P/#FLZ/GW /7K]=T %%%% !1110 4444 %%%%
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M/#?AR#]FGX.>&!\!_ 7A;Q?JWC<:#XJ^.>L^/M \<_%#Q!K6O?#CP8#\1/\
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MLUGPMH-IX#^V:MI7AEM0TNP;1M&_:;\?Z\?[;*KX88MXD^%WPL\+G_A*\_\
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MH'A#Q?J1\<_#'^Q/V]O 8^)>B[?#S#X@?#T?\+5^" /BI"ZD^//#./'>-O\
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M%C>)-5^Q6EW::UI@L=5T36G/CO.BZ\"Z_P#"*>) ?@1X*D(Y^#/P%^&&"S9
M /NWP'X9\/\ @;PQI'ASPSX>\,^$_#^E6@M-%\/>&=,T3PMX8T&Q7:4TK1]*
MT4>1!#&5#LHC"%@2"I)4E=?ID)@MQB*T%T3BZ-OPI<=,_P#Z_P ,T4 ;%<OJ
M7V>:7R)X+:X_T/\ Y>_7J3UQU_+C\>HJK+!#-_KH<X]?\0<?S- 'X_\ AO\
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MO@^9IRO=*3T;_KK_ ,'(\5:QJO@G5-&\8^')_P#BH/!OB32_&GAO[)_R$_\
MA*/ NM?V]H7;K_PD>A_\(O\ SS7]Q]G%!##;X@^F/PZ#CZ^GY5_)O^PA^S'X
MJ_:N^+7@?Q_?:'<VW[._PY\2:9XTUCQO=X.F>/-3T+6M U[0O!?@;/'B#PZ?
M$>AX\;>*?"?_ !1?_"%_\4-ZU_6?9_ZH_0?S%?CWB/F6#S7-_P#8K66C:MT\
MU_GU[W/UC@G+<9E63Q6-O>RTUOLM?O Z;92_9O/@'^BD_9/8?@.I],X-30PV
M<$4,$$0\BV)LP.RC &/4\]2,<G@8-6X._P"/]*L5\"?;'RO\4?V9/@A\8+RW
MUOQ?X \-W7BZVM_#0TCX@VFE)IOQ+\/ZEH'C)?'FAMH7C8 ^)_#WE>)P/$!1
M" &+2.">G??"WX<>'?A9X,TWX>>%[#[+X?T3^TGM5N+S5M5U._?7M7;Q!KVM
MZ]+KG^LU[Q3XBUO6_$?C%BB.6UH99]RD>Q3PP2X\X9_'_/\ D58H K6\<%N@
MBBP%';O_ "]Z*LT4 %%%% !1110 4444 8UW9P3R6YEAS]F&0>W;'3MU/J.:
M^4_'_P"Q_P#LI?$+Q%<>*OB#^R_\ ?&_BG4]MWK7B+Q7\'?AKXBU+43M!+:S
MK6O^'7DUP$]G9F&.O1C]>@YE!]1G_P >K/O+."8?Z@'&/RS_ )XY[_CRXE>[
M*R3?*[:7UY96Z/K8Z<+BI8312FD]+1E)+7R4EL?G'X4_:2\#^#_B'HOP8\'_
M  _M/!7PYT#QAJOPE_X2PV.B_#GPUX?\??VVV@Z!X+T#P3A,>&_%/B+1Y/"@
M\4[0Q\9-X8_X0/P3XQ\!^+CXT\'_ *&:;-!]E_<?Z/[_ *9Z_P NW-?E=^VO
M\(-*T#Q)_P +%AA^S^"/B/\ V9X,^*5I:W?]F?V?XH_Y /@7XFY'4_\ $\_X
M1?L3XS_X5C@':37TA^RO\7[WXG>"+_0_$=\!\4/ =[_PC/CW_0\#7\Y.A>-!
M@C!\6^'>3X7/_(F>-!XG\"_\RCD?G'#_ !IC%Q'+AO-O<;YO9MI*^KY=TKVT
M77]3TLPP_-A/KMW)O?5N5W;U;;NG?S^[[?M/]5^56JSK/_5'Z#^8K1K]1?7M
MK]VOZ'B%67_6C_@-9,V/M0_Y^,'\N<]/PZUL?\M?\_WJ\1^+?C32?AQX-\1>
M+_$EQ<VV@>&=&U76+NYMBK:@0I8G2=#0%"WB)O,5?!H P3M3[HWGRLSQ:P>#
MGC-%R1;;;LK)2?5V^SU_,<5=I;W:V5^J70^?_CI^U1IWP?\ $6@>%(?!^H_$
M?4;FV;6O$FD:5JVD:=J6A>%&<:)H0;_A(6;_ (J7Q5X@8Q^"/#'BF3P?%XT;
M0/%#?\)J!X0$'BZCX'_92_8?^).@Z#\3+']ECX!:G_PF%II/C+2=7\1_L]>#
MM+U34#KJ+K^A:YK6B^(?#0\2:%XA/]O+D^* OC -O7[ZLH^(O GA#Q'^T3\6
MKC2_&4%L+CQE_P 7!^-@M+PDZ#X#_P"0#H7PPP!G_A'O%O\ R*W_ &)F@>)_
M' &?%P%?MQIL$$%I;P0PBVM\?Z':\#H#WX&.O?W&._QW!G$G$>?2EB[N.3*4
MDK2<;VE)::J]DO,]#,<NPF&L[)R:3>B;U2?:XVUT.QMXK<PV-K;BTLOL-E:#
MG3[+3>H55P!R,]_7@ 5T0B@A&<?@3GCI[?Y'M26G^J_*K5?HU[ZMW]7?\[GG
M>73MT"BBB@ HHHH **** "BBB@ HHHH **** "BB@\ GTH \L^(/@[P[XW\+
M:_X6\26/]HZ#KWAS4]'UBR)_X_=,*X89'?!.">YSTK\8?#?B/QC^S5\7_P"U
M=<OM2_XMQ>GP7\5/M5GC_A//@WKN==T+XG:'[>$O^1HP<@'_ (7KX&\!<CC]
MUY;6"9P9AD], ?A[_P#Z\]><_GQ^VO\ #?S=+M_CAHEB!K'PYTC5!XOLK/C4
MM>^&!);7<=SXC\)C_BJ?!)ZMCQ1X'P/^$OQ7XYXF</8JT.*,E=LVR5QGIIS0
MNI2VLW[J;M9];GMY-F&^#Q:5I-K6S2[;Z=4O/3S/O?0;Y;RQAGAGMI[>Y&;1
MK7A<=>O3COP,=#P*Z$\CCVZ?7G]*_)3]F'X[WO@]_!7[/5_X;\2ZWIUUJ_\
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M-=\ ^$_''@WXJ:E\/?!^E6?B31QXH\>^&-"^#/@'XM?VWHFB:[V\*'XJ:WN
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MT/3=/\=ZYX=U32/B1I?Q&\>>'<GP_KGQ*LO''AC2_&WA7Q-)"C^ _$T-Q<^
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<HR![Y117HI);""BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #> ,8# 2(  A$! Q$!_\0
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MHHH *\N\?KXV/@KQ;!X N=)T_P >76EWP\%7NMVK7WA^Q\0?V=G2GU=$(?\
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MX.!['@^] "T4F1TR,\GJ.@."?P/!]#0>A^AH K<;_08_++?Y^II/W(ZD_0\
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MD:OI'PP^#S7"S:'I'V,:[IIU_P \W5T8_G?PU\0/ASI%UX!T*5M3\$3> /B
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M-0^&OC7P)J7[%_P&\?\ QP^ GC7Q3;2WFE_&G]G'1?)\':7JTQU>X\8?#_\
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ML:N=!TMO(M/[9N+O;N"1E2 H]+I&^ZV#C@\^G'6@#\UO^"A7[)=[^V!\$H?
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MD>K3:==:.EMK^D_$&+PO=1#7_P#A%[31?%0AG@BC;4=(26X.L0RVFE0SW?\
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MOXH;39/L_P!KTF#6[:32UTR/5[!HO'Q^283-,4L6TVU9;6[)6OMJMDM^MS]
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MJ<OA#6;>4/\ :K-=$^+4FFVWAN]NEN[[2[9?,9(XR"?O"Y_:R^!T>IV>A_\
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MVLN]W<$ZC(LDI:^NG\T,[Y^._P!@Q%BM/CEJT;R"#7?CKJ%U;A]TP+VGPS\
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M]_X+ Z_'X=^*W[*^I"8O;IX-_:#@DND;=LE.I?!I5A:0?*LK/:6ZA"P8M+$
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M>"_AGH.N0_"SPOJ%]\/F\->+/@W<:S>:NOQ!\;^*X?B/\/I9]!\5F_T_1O\
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MJ0M]KV,!TZU2QFO+J]VH%$\HC$NU5 Y9<9) &3ZDX% &W1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #B AD# 2(  A$! Q$!_\0
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MHKQOX-^('Q6/@G7]>?Q!)X9_X1[Q;\-OA7\5O$W@P;"P?P$T>_C?7S_\6?\
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M?^S+\8OBQK/BO]DWQ9X9TBP\)?&_XP^,/$_PSO\ X#^.-&_X0+XZZ/H>@_\
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MWP-X)O$_M/3/V>]*UT*WEH'4J_Q"96VR.,CP2NZ.,^;N:$ _J6HHHH ****
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M#3Q:GPK^)?P>\/\ @C1/ W@?P]^UJG_"/P_\([\5"S^)7^,/C/<_ASS I81
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M%'_"\M4_Z =M_P"!HKPBBN?ZSC._]?<='^K>4]GZ7W\CW?\ X7EJG_0#M?\
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M\(HH^LXSO^(?ZO92O^95^+_^2/=O^%XZIWT2V/UO5_PI?^%[:IG_ )%[3O\
MP.)_F#7@$LT$,5Q///\ 9K>U]?\ /XG/Y5^9_P >/VA-5\:W-QX5\*SW.F^#
M[7_0KR[M/^0GKWX]/^$=SVZCZ5RXG.WA;ZZ_KTT]?(^DX;\-\)Q3BK83*FH)
MKF?O62O9W=[*RONU]Q^EWC'_ (*#?#_P?+<6(@_X2/4+4$?8_#MX-27!.3_Q
M.C\N3W.,GH<@D5Y+-_P5!B\P^1\+KD\]?^$CP<8_[%O&/TQC\?R+HKQ?]9<V
MZ6WTT3]-V?M6'\">!L/;Z[S7LD[2FE>RNK)ZZWU>NFY^MO\ P]!N/^B6M_X4
MH_\ F<_SD^V#_AYY<_\ 1)O_ "XS[?\ 4M_YS],?DE11_K)F_=?<CI_X@CX=
M=I?^5/\ ,_6__AY[/_T24?\ A2'_ .9KV_GZFD_X>>S_ /1)?_+D/_S->W^<
MFOR1HH_UCS?^D8/P3\.D[-6?;W[_ '.5_P #];?^'H,W_1)I/_"F_P#P9_SD
M^V#_ (>@S?\ 1)I/_"F__!G_ #D^V/R2HI?ZVYMV7X?Y!_Q!+PZ[/_R?_,_6
MW_AZ#-_T2:3_ ,*;_P#!G_.3[8/^'H,W_1)I/_"F_P#P9_SD^V/R2HH_ULS;
MLOZ^0/P3\.EH[I]GSI_BT?K=_P //6_Z)8?_  I/_P &_;^?J:/^'GMQ_P!$
ME_\ +M'_ ,S=?DC16'^LN;;W7W(?_$$_#OL_NFC];?\ AZ%-_P!$F?\ \*;_
M /!G_.?IA?\ AZ#-_P!$L;_PIA_\S=?DC16_^MF;=E^'^0O^()>':Z/[IL_6
M[_AZ%-_T25__  I?_P &?;^?J:3_ (>A3?\ 1)7_ /"E_P#P9]O\Y-?DE13_
M -9,WW_0/^()>'7:7_E3_,_6W_AZ!+_T2Q__  IS_P#,Y[#\J/\ AZ!+_P!$
ML;_PI_I_U+GL/RK\DJ*/];<W[+\/_D37_B!_ ?\ +^,__DC];?\ AZ#-_P!$
MFD_\*;_\&?\ .3[83_AZ#-_T2:3_ ,*;_P#!G_.?IC\DZ*7^MF;=E^'^1E_Q
M!+P[[.__ &_O]_<_6[_AZ#-_T2QO_"F'_P S='_#SV?_ *)+_P"7*?\ YFJ_
M)&BG_K+F_=?<A?\ $$>!>S\M9_\ R1^LT'_!4*X  _X5,3T'/C <_P#EM9&!
MU_/BB?\ X*APPP^?-\+3:V_&/^*D!_0>&AG/^/3%?D3J6HV.CV&H:KJL_P!F
MT_2[+[;>78_3KZ?7OCI7YW_%3XPZY\0KFXL;">YTSPO_ ,N>D?\ /_V_XGG^
M>OTY\/,^-LWRN^J;=[:KMI^>I])D?T;>$,VQ2O&7)I?XMFU?6_:_4_HA\2?\
M%OOA]H$MS;CX?3ZW/;=1X>UY=2SGUQX>4'G/X^W3SS_A_/H1_P":#ZY_X5FD
M#^7A^OYN:*^4?B5Q'>]H]?LK_,_5L/\ 11\([>]EM9OJ_;UM7;7[?=/0_I(_
MX?S>'/\ HA&M_P#A6:1_\S_^<GVP?\/YO#G_ $0C6_\ PK-(_P#F?_SD^V/Y
MMZ*/^(E<1]H?^ 1_S%_Q*QX1?]"RM_X45O\ Y8?TD?\ #^;PY_T0C6__  K-
M(_\ F?\ \Y/MA/\ A_5H7_1"=<_\*[2?_E#_ )R?;'\W%%'_ !$KB/M#_P
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M^R%;?%KQA^QO_9?P7\2>(=6_:0\&^"=3\6^%]"_Y)1\3O^$'\0>&_P#A)_\
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MX2^&WPWU3QAJG@L_\%*=6^&_QDU+]F?_ (1?^Q?^2G:'\#_$'AO_ (6=X?\
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M\61\-S\6O!]W\/OB0?BU\,_'G@/^VCH.NC0]<\0>&O"'B?P_XB\)^(]<T/\
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MT!\=_#9^*/[;OQ/M-2T7]EG]E#P[>?VEI?P5\,:_G:.H&@,0'/QL^*.<D!_
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MC3^WSU_XK.NS#VTO;YV\SCQ.(^J]WKZ_HS[0_;,TW_AI;XE_#?\ 8)\^ZMO
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MPWIG]J:[_P @+11CL:["CI?IWZ??L=7U?-KM1:3U:25GUMI>_;H?']Y^V_\
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M[X/^*UW8C5/&_P -<8.A>#6UIBPT$$Y/@OQ.P*] !@[:]FT>SU7XI^#OB_\
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M^VK/2?$.L?\ $SL-+'_$A_MK6_\ H7O#N?\ F:?%G_%%G\*^F*_+?XD?!/\
M::^'OQJ_:H\5?!WX2?!SXZ^%_P!K[PWX$LKR[^)OQ(_X0K4OA+XHT+X9?\('
M_8WCG0_^$;\7#X@?!GG_ (2C_BE#_P )J?&FO^*,9_X2W-!QXE7TM?Y?X?(\
M_P#C!XD^*G[?GBCX7^*OV'['1/"7A_\ 9S\>:I\0?!_[:/Q-L]9_X0;Q[XH.
MBZ_H.N_##X5>!_#_ /Q4_P 0/AWXL_MP^%_&_P 4C_Q1?_0A'QEX\KWC3?\
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MOW_3-?$_[-/[$/PD^%?P'^$_@#XF_"OX.>/_ (H:#X/TL?$CXA7?@/1O$O\
MPEOQ1UW_ (GWCKQI_;GB#PW_ ,)/CQ9XCUS7/PQT-?=^HZ1JND#R=4L;C3K@
MX.;JSSP>_P"73MV%4*\NS[/[G_D?;+&8+%[3CK_>CUU5O>_4\._X9B_9L_Z-
M[^"7_AK/!W_S-UXA^T7^Q/\ #GXA?"ZXTKX+?#GX.?"[XKZ#XP^%_P 0?AM\
M0K7P'HOAO^P?%'@3XG:!X\_Y#GA[PW_PD_/]A_\ "+\X/\C]P446?9_<_P#(
MZ?8X+O'[X_\ R044446?9_<_\B^:/\T?_ H_YA11119]G]S_ ,@YH_S1_P#
MH_YA11119]G]S_R#FC_-'[X_YA7Y/P?L?_MB>"/ASXX_90^#OQB^">B_LO\
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M5)TG&5[^_"UG=;<V]K]3Z@_8@_Y-!_9G_P"R)?"__P!0KP_7T_7+^#_!^A>
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M=K:3AHH\S2TDM(=-;:/1!15B&&>\E\B""YNKBZ_X\[2TX_S]<Y]Z_43]D?\
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M;_9]OU/K74>8/0_Y_P G_)X/,'H?\_Y/^3P:=E]R_P @^M8K_GY+_P #E_\
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M_?)_QH\J+V_[Y-+ZK@_Y(?\ @$/_ )$?]M9S_P!#C$?*M7O\OWV_;SL>,_\
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M_C?^<^PQ[#Y4/]U/^^C[_P" _/VH\F'/W4_!CGO_ #X_/VH^J8/^2'_@%/\
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M]_;W_0>E+^Q,F_Z%5+_P"/\ D/\ UWXR_P"BNXI_\27%?_+3XL_X=]_L6?\
M1N_PP_\ ">B_^(H_X=]_L6?]&[_##_PGHO\ XBOM/!_N?J/?V]_T'I1@_P!S
M]1[^WO\ H/2C^Q,F_P"A52_\ C_D'^N_&/\ T5W%/_B2XK_Y:?%G_#OO]BS_
M *-W^&'_ (3T7_Q%'_#OO]BS_HW?X8?^$]%_\17VG@_W/U'O[>_Z#TINT?\
M//\ 0>_^S[_H/2C^Q,F_Z%5+_P  C_D'^N_&/_16\4_^)+BO_EI\8?\ #OG]
MC+_HWGX;?^$[%_\ &J/^'?/[&7_1O/PV_P#"=B_^-5]G>6/1O^^![_Y_#ZY/
M+'HW_? ]_P#/X?7)_8F3_P#0LI_^ +_(2X\XX6W%W%*7EQ)BE^55'Q?_ ,.^
M_P!BS_HW?X8?^$['_P#$>_\ /T-'_#OO]BP\#]G?X8\_]2['WQZI[]_?T-?:
M.QO3]1_C1M8<D<#D\CM3_L3)_P#H60_\!7_R(?Z]<8_]%;Q5Y_\ &1XFUGO?
M]]JM[]U<^?/ G[-OP*^%]P;[P/\ "?P%X4N<?\?/A_PCHVE7YQ]X>9'$&(/0
M_7IP:]^1%2 *MN !P ,#H,=@.,8YQ^&#0CJ6.)6.3T*D 9S@=<^WX#H*M=N#
MUQ@X]?;WKIP^$PF#TPL(QZV44OQY(OK;KIU/$Q.98[-&Y9AF=;.':W[ZI4G)
M*^JO.K.ROJTK)O6S99[=.W3^E)@>@_(4O6BNDY@HHHH ^1;S]J3X=:/8_M%:
MA?6'B&T_X9@NVL/'^E)I&D'5=<\SP7H'B+1?^$"TD>(1_P )$GB]M:'A7P87
M6,R^--!\1^#-Z31HLG1:]^T?\.]&^$VH?%(WEM=0:9X1U/Q.?"RW@'B2]U/1
M/A6WQU/A"-75@/$G_"NU_P"$D\O<^U2'8[20?)_$O[)&G:[\0]1\8S>/M4@M
M_%'C#Q)XD\9>$6L\:/XLQHN@/\+-)UADU\NY^%'Q#T1OB=X(4D#S=:\1($B$
MCR'S_7OV+_&&L:#>^"(OBQHMGX(N;W5+M[5?A C^(1XFUW]D?7?V3W<:X?B6
MGAQ_#2_VV?B.OAK_ (0Z-Q*?^$+;Q?Y)! !]'6G[2?P9N[O7_/\ &.B:98>#
M]<\=>&?$NK^(-:TCPUIFB:IX#UOPYH.N.[Z[KZ!-NO>,]&7_ (27:(GRJ-(#
M(&K/F^/_ ,.WU?P;H^EZO#XFT_QFVH_V?XBM-9T@Z9IVK^'_ (F_"+X3MH>N
MMK6OQ^7KQ\1?%#1<>&&8>+V.C/ 8_P#A-S% WBGQ,_9H\?:U-K_B'PAXPT_4
M=1N_'FK>)O!^D7O@R15T%O&WQ0^ OCKQ -;>3XAH/$7_  B9^%6N%.?!WG1:
M]_PAD:F/YVWKO]D^_P!>\16_B_Q+\1 GC/7O'>F>-?$0TKPF/#OAC4=1T#XF
M?LQ>/=$TK0M#/B7Q7+H2IX=_9:T'PJ^_Q=XN;S?$'B?QN<*4\(, >FZG^U)\
M%]'\/ZAXJ7QSX>UCP]H']K'5KO0-6T2^%KINC^"_'7Q"_P"$AT>)?$J/K^@>
M*_#_ ('UW_A#%\)_\)49)-"GW1 >$_&#>#O4M ^)WPY\2+I$VB>*-&U)]<\3
M+X9TBV%W'_:-]XF;P,?'W]D#YM_]NGX?*?$X7_6_\(B-Q7RL25\KR_LG^)M>
M\(>#_ 'BKXD:?<Z-\.](;PMX<O/#WPN;PWJ@\+CX+_'GX$1'6M9?Q'XK77_$
M+1_%=O%,N&7P>C^'MB^!/"8\7&1>H\ ?!7Q5I?[0VM>//%1NAI.@?#GPII%D
MMNNC67ACQY\8WT<Z%X[^,^A:$?$OBSQ/H)7X=)X+^&03Q3([H%\3%%*[/&'C
M0 [+XD_M,_";X>>'?B;JVI>.-$U#4_A1X3\5>,/$OA71M1TF^\3MIG@33/-U
M[1]'T3_A(\?V\$U?2 [R*B>%6\1>&#XU>$SQA]W6?CE\.?"&@>$M6^)7C#PC
MX+N?$WAO4_$MI::GXD4DZ5H*^'GUW5=)UQI(]V@>%4\0Z-_PF'B8DQQ"197'
MS(#XMXM_9.N_%^C>,/AW<?$:.T\#ZA>?M"^*_"6EVWA"1?$F@>.?VD-(^(.A
M:[K6N>(_^$GC3Q)X=\)?\+H\='PAX13PKX3<(?"YN?&31^& )/:/BQ\&8/BI
MJ&HWLNN2:*;GX#_';X1'=8MJ(Q\;7\ ?\3DB9@6D\,CP.ZCP\,QR#7%S)E4W
M &G_ ,-!_!?^PY_%'_"V? 7_  CMKXD_X1RZUG_A)=%*+JHT3^W!&P$A8M_P
MCH/BH$((_P#A"P/'6_\ X0D"0\!J/[7GP/TOQ5=>'I_&-J;G3/'FJ?#'5M7N
MPHTW3O$^A_"]/BP43"J?$"GPYJ\;9\+M(VXE-P14 Y#XC_LG#QCX\L?B'H7C
MK_A&O$>E:-_PC5G9ZII/C!_#8TB31Y- UE]O@#XD?"3Q0 ^S1",^+=@_X1]E
M!(\5L1TW@G]FS_A O'1\66.NZ7!X:TWQEIGB7PWX1TGPFVGC0HX_@#X$^ [:
M,NLCQ"2="2/P/HWBEHUB+M(GDO(0@D !ZK_PNWX3?VY_PBW_  LSP7_;?D?V
MU]C_ .$NTG_D&?V!_P )MYF/.QM_X1O_ (J[&[_D2?\ BM=O_"&\UP>G?M8?
M J]_X2Z=OB1X1T_P_P"%M:TO2'\0WGB32!IFH-KG@H>.U*+DA%'AS/BD*=^/
M!BKX[!'@?,R_/T/["VHGX96WP1O/BG;W/PR:T%EJ]FW@$_\ ";W_ (C/P#'P
M&.M'QM_PE("^'S#_ ,52/#)\(EQG_A"/^$Q;P(#;G=U_]F#XC>(O^$HUG5/C
M-X)MO%^O:PFHV7BWPW\'_&?AU?"0TKP:W@4GP1)X=_:+3XD:#XE60LSA?&DG
MA QA?!DO@@M*I< ]W^-'QPT3X6:1<WD^FZMXB2V^'7Q,^+&L6GAT:6VK#P#\
M*=&&K>(M6T$:V(O#^O>(#XAUSP1X;CT#S2T<GB+[0S>1$%;)@^/_ (/L=6\0
MVOQ'B\3_  ?\1Z$/"[GP[\0;_P 'I?ZAIWCF/78]"UG05\!>)_&?AK7D?_A!
MO')$*D^+5;P%XIF96\%_O7Y?XW_!CQ#\198/#D][/<^'O&'P(^._[/\ XQ\1
M-I.CK?Z!'\5M'\.'1_&[:.B^%AK[1CP6?#8\*^%Q'O;7>66(-,N!KO[*UWID
MFNK\'_%<7PNT'7O'6F?$V_\ "NC^#]7L-)76!\--;^'VM(Q^'?Q(^$?BL^')
M?,\$>+%\-+XH"Q^+O#OBF2Y_X2K_ (2U(_!X![7??M$?!BRNM1TL?%;P/<:I
MIEF=8NM*TSQ)I#:@FF'P8?BPK! 4.3\.3_PE6T$,W@MCXT$BJ0RLT/\ :(^#
M^NOX.&G_ !#\.F^\?>'=(\3>'-+U368]/U"\TG6]#D\1:*Y20JRF3P[H>N^(
M"$\PA=#\1%0%60Q_*WPD_9+^('A#[3X(UKQGHP^'/@_Q?\,]9\+V=KX0/_";
M^/6^'_[)OPE^ O\ ;;Z_%\1I8O#'AM_$>AZTZ^%V\(><RZ$R-XR'@CQ28AT^
MD_LG>(K/0F\ ZI\4-'N?"&MWWP?\9^.?LWP\UBQ\4^(?'?P1\&^ O!&B:[H.
MNCXFR+X<\+R?\*I^%7_"8>%9?"7BTJ%\3Q#QI"OBU!X/ /HKP1\:_ WQ \2V
MEIX6U73=9TGQ#X0TGQIX%\5Z7?\ V_PWX]\-+JSZ!KAT368P4FD\*>(/[#$@
M+%%7QSX6=3_Q5"X^B,#T'^?_ -0_*OECP3\,]5T'XA> -0G4W6@?!OX*#X3^
M&M40+YGBO4O'&K^ _P#A.-9?0UD8:&/"Q^%/@O9@;2-?\3*0&0N?J>@ P/0?
MY_\ U#\J,#T'^?\ ]0_*BB@!,#T'Y4M%% 'A/Q8^*5M\*V\ 0C1#K>I?$7QU
M_P (3HMH=9T;PY&=33P5XZ\>%M7U?7W*A%\/^!]:!Z.&R-V"&KS/PS^U)\(-
M?T>PU>ZU34]#U*[\(Z?XSO-(N-+UG5M1T#1M<\:Z]X \.[SX!'BCPS(WB_X@
MZ#K?AKP2OACQ9<-\89M%D3P!-XUB56;LOC=\)[CXLQ_#T6E[X5TW4?AUXZ;Q
M]:#QMX%'Q'\,W_\ Q1'CSP*VE:WH:^)O![E _CA?$2E/%?FB30P1&%;=7S['
M^QYX;N?"WB+1+OQ U\NMV7PQ6SL=5\'Z+J?@6QU?X4?&GXN?'C0C_P (05!;
MX<'Q#\4U\-6_PSCD"^#O!&B^'8O!?C&&>$>,P >_6_Q^^%]W<>&],TWQI"US
MKTNEFV#Z1JR?V9J6NZWX@\"Z+I'CLOH _P"$"\0^*?B'H6O^$8?"GBO_ (1/
MQ@?'>A:_X)POC5&\(IR7AK]JKX3ZG\/O#'CW7/$FC^&-&U+PCI'C7QA)XBUI
M%'@;3=:^#&N?'P:-K6L1@9U[PQ\.]%?Q/.&,3MX-4^-@&A='KS>]_8Z@FU;P
M5<VGBKPGH7ASPEXD\!>-&\(^&OA4VE>']-\=^!_C/K7QSU[6OA?HT?B=O#/@
M!_BGXEUMCXZGC\)>+O&?BZ(*/^$X;R_,.5I'["_ACPI\)-/^".A^-=>TWP!H
M>BZG9VFD_P!DQZB%\4>./@M\0?@5XY\8D-(4W>+!XW_X68_AE20?&K>)2&V>
M+2T0![EJ7[2GP4T73[GQ)>^,+O1K"SUCQ-9>);*Y\-^+SXDT4^'M#T3Q!KVM
M^-M!D\/KXC\->'/"_AO7-!\3-XH\41Q^#$\(^(O"[>9)'XL\&L.E\4_'#X?^
M"_&7A_POXHU;5--_MWX;^._BO_PE-UI6L?\ "":=X#\ 2:#_ &]K6N>.4SX9
MT$Y\;:'\CL, >61&9/"0;Y=_:"_9\^)NI7GQ,\;?">=M2^(/Q9T7XP^"UL-6
M.DR^'/#VD_%7X7_ CP*28=<\2^$T23=^SKX,\1#Q3"GC-_" USQ*K?!7QP2B
M1^O_ !#^ :_$C4O"-Q)XGO-$G\.>!O%/@!FM-$&H_86US6/ GCC0=?T-BP70
M]>\*?$+X2> _$J#Q0OC+P?M'B/P6ZLDOF  T)OVD_AW_ ,))8:=!JMS;:/<>
M'?%&OZM=ZG9ZOX8U+PIJW@C7_A+H8\&:[X&U[0$\5_\ "3>*O^%V^"'\'^%A
MX/C\73K+X<7$G_"7^#U7;M_VD_@Z8;5E\=W-U??85UJ[M;7PUXO;4;,'QIKG
M@,Z/K>B)X;'_  COB(_$30==^%R^%O%&SQ?_ ,)KH;>"#&_CO 'BOBO]CN#X
MC77B'Q'X]\>VOB+QEXHNQK.KBV\!H/ 9\2Q:W^S%K_@C'@C7O$GBUAX9C_X9
M;\#Q^-O"[>+]WC,Z_P")W7QEX0 \&#PCL67[+@TGPWXSL?#7BK1_!VL^*])^
M&6B7G_"NO ;^!O \C^ ?B7X]^++H/!.@^)(O$$GAWQ8?'NM^%O'/A@>,O^$N
M\8>$=\;>.$D\32,@!ZB?VD?@Q]O\/Z>/%\UUJ&O7N+2V31_%HU#2V'C77/
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M?#>@?M9^ (MW@GQPWPV)\0^'_P#A6_\ ;_B-FW^,G\9^"O#Z^-S_ ,(>KO\
M\)=ZKX%_:DUV:76=1^(.@:GH\%]\1_COX,\!>%-*T=9/$>MM\*OV@_ 7[-NB
M^7KT?Q#\4^&?+\7?$;QQ$A_X2QO!J>#QK2%E'@CPG+XXF]=A^/WA5(GL-4L/
M'&C^(-*OOA?9:OX?\1^'91JFB:K\6/C/XD^ ^AB<Q\21Q_$#P7XBV>)_#N_P
M3+X2\OQUX&E\7^"PDS 'RK8^/?CYI/BKQ!86[_$CPZ;+XIZHGPZ\$>'?@1I
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M_BF=S>#%#>,_ 0\#KXWSN\%>+OU<HH _(C4/B_\ M3?\+&\4Z5I\'Q&A\/\
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MVF_BQX%V?%-X/AM)X7\/Z!'\&-$^%\B>*5/PB!\(Z]XF\<+/XO3:_@S]-Z*
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MQX+G\:%8_"*+]ET4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!\L_";XR:W\1OB3\?_A[J?P.^*7PV
MT7X*>+_#7A;PW\0O&VC:5IG@GX\:9K^AGQ =;^%DB -KGA[PJ0WAEY6*D28^
M8R.*G^*4OC"]^)WP@\ >%OB%XB\ 6WBKPY\3]:UK4_#ND>#=4U&^;P0W@/\
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M-^S1X=^.VLO)HBQQ_P#"1>)/$S:UK8B4;?&!;_A)G/C1_!7@^'P='Z3^SO\
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MP\;OI_BHZ'^UL^N_V'XW\?*WBCQ Q\0_M5!AXG.TL= \2X3P>CKX.'U7\$_
M8^&/P:^%/PRNY[?4+GX>?#?P'X)O;JUP+*]U'P1X1T/0&E7)8@$Z*'0,,*H&
MY01L'L5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9>I6PO+
M"^LL_P#'S;-:CW+*P_\ 9_7M6I10!^7WQ!_94\5V?@SP1X;\%>)=1M/%MIX%
M_9@^!GAOQ7H.C_V<O@32?A4OQ>\"_%3XF*S:_%ME\4_!7XV>._#?@M-[M%XQ
M/A<L&5XWC@\1?LI>,OB+I_CSX;:U<Z-\.OA]!\4OBAXV^&]MX=TC5QXC9==^
M&/B#X2:)_;+Z!XEV'X?Q^'-=UAS'X7?P1XT>%O#G@J!O"C02^,/&/U-X4_:)
M^'?BJSMM6^W>(_"'A^X\.:EX_P##7BCQMHI\.>&O%G@'1%T$:UXQT76]:#+'
MH"MX@T 2'Q9_PBOBT1ZWYH2-6)3U,^,_#<WA_1_&&DZII>M>']<NO#-GHVJZ
M1?Z3J.EWS>(M;T70M%?2-54JKJS:R-C/DDF0J5(^8 ^/-)_94\06D7C#4[/Q
M5HWASQUXR^'GQ2\'-JSGXC_$J1?$GCY/A'HHU:37/BW\2/%/B+76@\/_  2T
M*$!#X8)A2*21W?PPTJ9?AO\ 97\>Z/XA\6^(8/''@W7]9^(/_"367B32O%NB
M^,?B-X:T/PQXX\%_ 7P\26\?_$;Q5XB\?D?\*-;>/%.Q?&@\0!=O@U/"JHWU
MJ/CE\&(YEL+;XI_#>YU"XU;3-%M+&S\<^#SJ-YXEUMO^))H2"/6PS^(/$PXM
MD54-PO'^U22?''X/V>IWVE7_ ,5/AS;ZAI=UI>CZOI-WXP\)+J%AJVM;ET?1
M=;)\1.$\0,VCZP$A:0;U5GC1A$Q< ^;[S]EGQ%<R:C OB_18=2TNZ_:>U7X<
MZJ=&U:^_L3Q3\</C_P"!?VF? ?C+5]%/B",3R?"GXC^"2"N\0^+POAPEH65U
MDI^#_P!D&/P?XU\/ZW%XAN/%^D6Q^&&L^(_[5UCXEZ9J5]X[^%6C#;XPDT+P
M]\2?"WPR\0/XK\0:+H?BACXJ\'/'X,\:)XH<GQ<OC!5\&?9EUXQ\+VL/G7_B
M+1].@+ZDGVF^U6*Q7.@:N=$U^1CK84*?#>O'86=O+1RJJN#M?FHOBU\+!I?A
MG6O^%E> 9]#\8:P-&\':S'XOT5M/\6:J/^),=$T/5SK^/$/B X" Q>:Y<\*K
M@NH!\[_$/]E,^-/%'QO\1'Q3:68^+?P[^,GP_L;6[T@7RZ$WQ;^&O[,G@/<I
M)7<?#$O[.P\2G;EI'\2#*E?"P)]#_P"&? /C=!\6AKFG&PM=+^PVGA[^R3D,
M?!G_  @_+9X7:0P7. I"8"Y6O5D^)GP\76O$/AMO''A'^W_!UDFL^+M('B/2
M&U7P]I87YM8U[2"V[0UR"0SHC')W99L#,;XQ_"J:'P_/#\2_ 5Y!XQN]+M?!
M_P!F\7:&?^$M;6)%T>,:(%\0,?$#%B"IC5F!7*YD"M0!\LZ;^R_XE\'ZM\(/
M$W@WQ5X0?Q%\)/ GP*\%6NE:IX;U9O#=[_PJGX9?M-> 6!(\2>9H&?#_ .T+
M_P )%M7<QD\/>65_XJH;,C0OV)+FV^#5S\+?$OQ"MO[1U.^^%Z^(_%?A#P]'
MX;U(Z7X'_9H\"? 76O[",I\4GP_(XT/6O%/@L$[?!;^(0L;28+-]KZ;\0O!>
MLW'BBRTOQUX4U"X\&SBT\86>E>(M%U-O"+!7!7Q#Y;G^P&/]C:R<>) C%XVQ
M)L94'+^%?CS\%O&VF> M;\%_%3P5K6G_ !7T9=;^':V_B'2QJ'B_2S'E-9\.
MZ.^WQ#KX&/WAC5P.CA'YH \8\%_L[:AH/PU^)WAC4I?#>N^(/B?X37X>W^JW
MEQ\9/&OAS4-&T;0]=T'1!K&B_$3XW>*/$R>&T.NZQ-+X8\)^+_"9(UJ2)?&C
M3;/&:>3O^S?X^'C;X00:GKEUK=O9?%+Q+XP^(VIDZMXD6P^#GA\> ?$&@?#+
M_A-_'GB/_A9OC[Q%)\9_A=\*?%!\4^+1XO \$CXF>" BJ/!F?JL?''P0?C9X
MB^!ZWMJ?%_A+P?X3\8>)W?5O"2Z?H>G>.M;UO0_ NCII#>(QXF.N^)]=T=QF
M/PE*CR2^'8W:-_%'A,/:\?\ QY^#'PRTS6M<\=?$WP7X2M]"TO4]:U>/5M?T
MK3=272]"U9-#UK6ET<_\5&RKX@7_ (1EV3=$)B8U8R* P!\\>%_V;?&WA>_L
M+VW\9^'1#X6\5?#+7/"/@ZST;Q=_PC5CIG@4^/= U_\ L)_$7B3Q?XB\ Z#X
MG\.^-C'X*^%?A&0^"/!!\"J?! *^,?%S5D_"/]C _#'4_A#>S^+!K!^#M[X3
ML='UB^U?XF>)?$GBWPOX(^&OQ=\!:)'K;>/OB7XJ\,>'Y6_X6F?$B'PEX3^2
M71/$C8?_ (2Y4\'_ %-X8^-WPK\8Z[K^BZ+XO\-MXB\*W.JKK&CW?B30_P"T
MK'2-%:,R>,%T4>(#(WALC5_F\3;567(5A]WR]G3/BW\,]8C\+C2_'W@*[_X3
MO^TSX1&E>+=(U'_A+?[&)&M#0'!V>(#&O$ACW$##L5)!(!YQ\(/@7<_#*\^'
M$ZZW:W4'@'X+W_PEN[*STM=._M*_DUKP]KAU\@'A1_8<NT'AFUHL,YX^IJ**
M "BBB@ HHHH **** "BBB@#QOXB> U\9^+/@MXB,]M;CX3?$K4_B"MM=8Q?-
MK'P;^+?PH"?WB2?B@<CI\C!NRGXMT_\ 8V\<:=X(L?A;I?Q#\)#P?:_\()>Z
MMJ]UX-UH>*/^$E\$?LS:#^S<5T1/^$D/AM-!(T/0?%#(?O?\5'X)(5V/B^/[
M8^(WQ-TKX<1>#S>:9KFMZAXR\3OX+\-Z1X6LCJ>IZAJP\'>(O'1"K\O T#P3
MK;;NX"C."&'G?A#]I'X2^+?%]OX0T_Q9#8>*+[2M/OM*T#Q6%\,:I?ZF_C/Q
M_P"!->T71M#UV6W\2-XC\)>(/A3XPM_%WAH(\\81=SNK2N #G-7_ &<UO9=7
MFTKQ+;:+_:Q_9.13:>&@OV'_ (9P^)Q\>8&2 ?\ A*HP/#0[^#D!D3(Z>1_"
M3]DOQGX0\?\ @?XA>-?B!!XEU'P<?AI:+:6]GXR5=1'PM^&W[3'@G^V?^*Z\
M2^+4T >*_P#AHK_A(XO#?A-/"7A#P6- /@I3*&E,WUV?B_\ "R?2?$6M'XF_
M#_\ X1_P?JS:-XOUAO&.B_V=X3U0  :+KFLKXB"Z%KPWX^=@P)X4C##8/Q&\
M 3ZIH.B6WC;PE<ZSXIL'UGPYI,'B72%U77M,(!&KZ'I 9FUQ<X):-9%&"5^8
M8H ^,;/]E3X@>%_"WA;P-H7C7PMK/A>TN_AK>>/=)\1>#]4TW2?%FF?"CX:^
M / GA_1C_P (]XF,A\/2>(/!#>*O&7A=/E\9)_PCG@:;9X('C!/&&9JO[(?Q
M'\0>)_%OBK5OB!I$YU/P;\=='TFS>T\7?V>FK?%CXQ^!/BSHD1T*/Q.WA3P_
MH?A >!AX6<^$O"*^+?&HD7QSXXED\=<5]PS_ ! \$P^(]7\*WOC#PC;^(=!\
M.+XIUGP_=^,='3Q)H?AOD-K>N:"K[]"\.@8_XJ1VVD%1OR,CB?$'Q\^#'AGP
M3?\ Q$OOB'X*_P"$/M/[5L[/Q%I?C'PC?Z;KNKZ+&^[0]!DCU\#6?$2)I05?
M#\3^8S;HR=RL2 ?/VJ_LI^*-0M/BMI.D>.?#=O;?'7PWX[\$?$=M4\-:L=2T
M+PSXW\9^/_'#ZOX'5?$N1XC0_$_7/"[+XJ"X;_A&/&H'_%(MX+\8>J^!_@8G
M@/QEX0\4MKUM<VWAFT_:<M$L(=)_LM=0?]HSX_\ @3XM(4;G#>%!X>_X1P;,
MMXO_ +;\[8K[B?<8_%&ARP'4EU338(+71M,UNZ^UW:Z>]CI6O#.BZKK#.56)
M7\K5B0S!"P8D*V'',7?QA^$<>GZ[K5Y\2OA_;:)X/U/^QO&&JWOCCPBFF>$/
M$I7"Z'K^KMX@4>'O$/SX,,K(X&X[<HV #V:BO#_%'QQ^$_@J+5[CQA\1O"7A
MHZ%X/U/Q_J]E>^(M(74K#P'HBAY/&3Z)&Y\1-H!//FJA126C7<68UM:C\4/A
MUIOAC3O&^J>-_">G>#M?_LO_ (1SQ7JOB/1M-\,ZW_;F#HHTC7C)M)?*JO&[
M+%@'7<P /5J*^=O"OQY^&?B;P]X6\4R^*M.\-:9XQ;PQ_P (C;>-M9T7PUJN
MNZIXV\':#XYT/1=&BF\0?-KDOAWQEHJ_\(XI,A+#RODS,MO7?CC\-='EU"V@
M\7^'-9UCP_XP\ >#-8\/:!KFCZEXFT+5?BG\2] ^%.A/K6C+F30P?$VN+&PF
MV%PK%@58"0 ]^HKR?2?B/X'U[4=1TK2?&_A36=1TK61X7U72=+\1Z/J>H6'B
M0C6T?1=8$)^3Q#_Q)-< \-R+OC_L.1@/+X$5[\6?AWHNO^!_"^J^+_#=MX@^
M*)U1?ASI(U= _BTZ)I"ZYK1T4E@&6),LV6+%0 JLWR$ ]=HK@?"'C3P=XVTP
MZWX/\5^&_%^DM=&R;5/">M:3XBTLZ@,=-7T(M&6/",2%/S#)&<5WU !1110
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M4F"GP\&\.Z'H9\8*GA#,_C'_ (2B2W'A"W\5GP>H!ZK>_M ?!_1]:USPY?\
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M-\2_B!XRO-(M-9U),^._@UXB^$9T1=<T!_"7B7Q!H$9UK1#+@^#V\:>"=!0
M^$6VA>T^%'[//_"(>.-/^)LFGZ9IWB(>'OB;8>);2V^)GQ,^*VHW^K^.6^ 0
M&K'QU\7B?$S_ /%/_!'0XW$9\)J"/#B;9G4^+7\2\(_M*_'?Q)IUMX\OE\ :
M9X>M_''@;P!>: /#?C3_ $Q_''[,WAWXMIXV763XA;Q!X>\/_P#"2>(-%?\
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M>:A#XIU2_N[AVFN;[4S\2]=)U&\GD+2W-^2H)NYG>X) )DX%?8U%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Y AH# 2(  A$! Q$!_\0
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M\*^&=9_9J^,/@11KG@A_$WA#Q+K_ (>\6>(]=T'PSCPIXOC\81'7S^\\L H
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MVI-$^*6H_$7X/ZO\-/$FO_%7]G#1?B1J?PWU36]9\>ZZ/&O[+&B2?$B+PI\
M&9?&T?A52WA/QEXS_P"$/\">&%/CG_A.8SXVH ^U/^'AGP2M_C+=_!]=*^*
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M&\,)\//$_P :?!6M^%LGXMGQ@$D3QJ RDJOC_P ,?^"F7Q:O/A_X&^)WQ,^
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M:+H?B#QYKFLIX=C<:)H/AC0M<T:20MM!\QF&Y@RM^3G_  5E_P""FWB_X/\
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MFFZQ\43=W?\ Q+==\;_V./'0_ML@G'ASX6>'4T/Q6,-SXPUU,JA\(X'XN?\
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MD+X@\2^$W(#^*0%:4#Q$6;]R@'[M?$OX<>&OBEX3U7P?XQBQI.J;OLEU9?\
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M_P!C+XL^-_#>E^'/#?A/P?J7B/4_B!XC\*^%3_9W@CQ=X"US;GXG>"-$.?\
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M"BCPYXFU#2]#UCX3:[KG_";:YKY7^W?^$K\.ZVK>"O#!7P>O@T>/?#(\=?\
M"8GPF2GZ/?\ !*?_ ()TZQ^R7H&J?$[XIV.BK\;?%VDMHUWI%O='4]*^%'@?
M^V#KJ^#=$UD*'/B'Q03HC>-6$BQO_8/A@!7/A-)/%GYZ_L2?M+?$[P-\ OCA
M^UUXB^'GA[XP_& ?'S]F3]G/PAXKN?"&IZ<--U;QTWAW0?&LFB:%X#\->,/%
M7F+_ ,+2;Q1XQ/A.-O%WC7^W7$@+"(#^@K]D+X\ZA^TU\"/!7QKU?PW;^"M>
M\3-XHT/Q#X3L[O7"NA>*O WC'7_ _B#1F/B+PSX2\20JFO>']:*^&O%?A:/Q
M9X1DF>&4++M9OF\QX7P6#X@E+%V>;0YDVG%I-)7VO'F2=M;-7Z.UOT[ >*G%
MN+X&7#.$S64<DSEQDX>]%V@TXP?PM0]R+<5I.VMXN2?VD.@^@I:0<@?04M=1
M\8%%%% >HF!Z#\J^8?BE\%M+^(]KJ\D&J7FC77B?1FT3QB;O14\1:9X@\+@N
M%8Z(&6,^)?"VPGP5XF0;AN#21^+%(%?3]%%WW8M+6TMVTM]VWX'Y(_$'XFV/
M[!OQM7POX5^$/QO^*7PU_:+\->)_B!I'P\^ GA#_ (374?AOX^^$[?#[P+XY
MUW^Q5\0HV@_#KQ7X<\;>" NPK%X0\8^!7W1NOC!=N_\  ;X.6WQX^'G@#]JB
MZO[K1/B]\:]7TW]I ZKJFC#Q'?>%/#/CWX:GP_X'^&>B:.?$(\+:!)X.^#.K
M^#?"\OB:.0OXQ\9Z"?'<L99XJ\L_;J\:^,-)^-&C7WA[51X=O_!WASP%X T:
M[M;K^S18:7\<_&W_  @OQ4.#G!\5>'!H1\#D\_\ ";> /###:W%?:_[%%X/^
M%!>'_":X6P^'6LZK\/\ PX".+'PKH+ ^"=&QTSX4\.-H?A<'^]H630/\_P ?
M\SZ#\&^$-*\%Z%;Z+H<-R+>W;[;>7EW>?\334-3UDAM:UG66"#?KC ,Y9BQS
M(55@"%7TC ].O6BB@6GE^!7QYT/09^@[?RZ^_/J:^)_$?[)GPW\97::%XP-Q
MXE\#P>&_%/ACPUX4:R;2=5\(Z;XZUK0SK::%XVT+;XGT'047P](?!\2L)8RG
MS^,U#?+]P44#VU6C[K1_>K/\3\,O^&JOB=\0[.Q_8;\2^ OCZ?B?XJ^*OB7]
ME;Q'^TP?!VDZ=\'M=\)^'QX@;QQXST+QL9/+'Q)\6?L\^"->\5GPXO@Q3X-^
M,NO)&ZGP)$D@^_-"_9B\$^'-7U"V\-3'1/!>J:QI>NWO@:RT93_;>J:!HOAW
M1?*\0:\6?Q#K^A,NC1^)=AE0R>,V9_'#^+T!\'Q_D?H_Q!\867BBV\5?\)%<
M@:!>:7^U39:0+O'V_P",GCK^W]!UW601_P R[XK^'']N>%O^$6_ZC_B?'M_2
M#D>HHO\ C^/^8?I^'^7X"8!Z@'\*7 '0 444 >6^-_!.E^-]$.F7LUSIMU:W
M0O=&U_2SC5-"U7&1K.BD;L8.>F0,G -?!?QY^&>G_LU> =0_:K\/:?=Z[\1O
M@YXFU/XM>.;/P5H;>'H_B7X%U?\ XDOQ8\''P4/$+#7?$@^'9UKQ1X'9Y,'Q
MQX<\,! O@96\%M^HU?$O[<=[-+\%X/!DY!TGXH>,-+\ >)<8S?\ A9M&\0Z[
MK>B\=1XL&A'PJ,GIKOX46[+TLOR_X 7\_P ?^"?-7PO\9V/[?GQ2\46?C#X7
M_%_X8_#C]GWPYIEC!X ^,7AT^"?$7BWXJ_%+^WXY/&6MZ"7?^V_#?A+X=^']
M%7P4H=O!?B]_BWXI+JQ\(^#VK[?^&/P;M_!,>GWM]JQUG7['2-*\-6ZV>D1^
M'=*T/POHBLNB>'?!NAA7'A[P^C?,\<+DDJ@9_+\*^#4\(? G[!OQ"\:>)/B;
MX@U7Q/JHUO6?'GA#Q-?>,=6-VS&_U'X3>-_#_@3P3K*A2I\QO#&ML/&9SA9-
MK,& *G]BZ+*]VE?S6OY7%IY?@%%%% PHHHH **** "D/((]0:6B@#^;3_@J/
M^R]KOC%?B!-//=VNL:[XE/Q9^%>K-=L-.\6^)] \&'P^/AAKH<EF\1<:X/!#
MY(\'>"]>\,2*2OA/QD3]3?\ !)/XC_$;3/@]?_LZ?'^VU/PW\3O@[XPU3PSX
M%TK7\_VGK_PRT/1?#NLI_8VM(#X9\1#PKXAU[7?"[-X5.V/P2GA=FX&Y?TU^
M+_@6Q^)WPY\8>$;O3M#U6YU72%.CVNOV0U+2SXCT9UUS07UK1R54A=?19)%1
MB2J@!69HPWY'>/?!WBKP3XWN?&'P?\.>([H7?]J>-+WP1I-G_P )+XX^"WQD
M^%.BZ!_Q)-$\#?\ ,P^'/%OAO^P_^*6\)_\ <AY\!^+O^*-^AQ.<+%\/+*'%
M<T6W&:2YKV:NI)7ORMQ:OMO<\7^S7_:KS6[M:UKNVUMKV^5C]U "8QD\Y]\<
MDC\!S7X;?\%:?BW\2]5^$NG?LV_!6*\U/QC\3/&&FZ=X^N] U=<6'PR&B:]K
M[:+KFN@>7H+>*3HFBHQ\3,8_&7@TR1'GQ45C_5^7XN>!Q\#F^/L6MZ'_ ,*^
M_P"%<'XN+XCN=6QX8_X1<^#!XA.MOK.XI_8?]@YD\SR\'(X4YK\E_A]X#\1^
M-O&7_"8_%OPYXDN?LO\ 9>M6?@CQ#9GPWXF^-/QD^*^BZ_\ \277/ _B'_D7
M_#OA/PYKG_(K>+.VO_\ %>_\(;X#\(UXN78E99C,L;2ERSOJKJ\;--W36^O7
M9;M'HXK#O%X:6&O9R3NTW>VKZ6?7R/*O^"7/[,%]X'NOA]YXN+K4/!U]J7Q/
M^*NK-=YTK0/$_CGP:N@Z%\,? Y ^^?#AT(>,P,L?!^@+_P )XI'BWP;C^BP_
MC^'^>*^:O ?@RP^"'PZT#PGI%O;VT.E>&TL3_9?AI[_PS8^)W!?7=971=!3_
M (28Z#XJ\0[G\L9*D*'V!\CO_A]\1O#?CJPN/[*O--;4-,_T36-+M+N/4#8/
M@)G.5SH;9^4JJK@!<I@%NC.\WQ.;9H\5RKE:Y7%)15DK)626N[\M-#GR_+_J
MN$^JMWUO>[;W\W^OF>O4445P'HA1110 4'@$^E%!Y!'K0!55MV>.E?-7[1'Q
M%^$GP\^'6LV/Q@GT34M \=VK>"K'P!J]WHG]J?$O4]=W:-%X*T/1-=:/_A(=
M;\3F1HECP6Z<C#2-ZQXZ\;:)\.? _C'QSXIN%M-!\">'-7\3^(KP*"5TK0M&
M;6]8D48Q@QJQP>#NQP#7\DO_  49_:*US1O"UMJOC'1--\7?'#]HOQ)I5E>>
M"=7O!J6F^$_@/H6MZ!KVO?#+0\8'A_P\?#G_ !2YP /&GC3_ (2?QSQQ7M9'
MD6,S_%*.#3:M;R_#[^WY'B9SG>%RE)O?2_0_5/6I/$.O:5^P7IOQH\(:+X]^
M$7QL^-7AG1O#5UXMU5A\3M"_X3C]GSX[^(-#\&_$_03X:'ACXC*ATB,-\4XS
MX0\8EV\,>,V\$?\ "?\ A%O&(]/TGQ9\-_\ @GG^T5K/@7QW\1=%\!?LL_M)
M6>K>/OASXL^+'Q(D&F?#3X[^!-&\/:'X\^&6M>-?'_B%Q)H/Q4^'(T3XG^!A
MXK\5NRR> ?BA""C'PB!\/_\ !*+XD?&G]M7XV_%#X[?M+^*=1^)+_L_V?A>R
M_9YTK^QM(\.?#3X:^/?BIHOC_0_&^L^"-%\/>'4)\0#X=G1/"R^)O%\OBSQA
MX-\&^(?$T>]/^$Q\8U];?\%/]#^$GB_7_P!DSPQ\5-+\5ZGX8\'_ !XU3XY?
M& ^$O%OB[PSXE\)?!GP]\&OB[X$UKQBNN_#_ ,1^%/%>@1Q>)?'/@S:OA9_^
M$T\8^#]#\6[1Y?A3Q>L?+F.7XK*\VEE&+M=73Y9)V=F[:-*]FNV]NYTY;F.%
MS7"+&)/;31W3UM;3:^YU7Q8^*GP[_;U^+/PX_9:^!GQB\)>/_A#X;_LG]H+]
MJ;X@_!SQUH_B+^SO"_@CQHI^!OP:TCQKX#\3Y\/^(_BK\1]$;Q42"A/@CX2>
M)HRC/XJ3.%X#\(^*K;XG_MF_#+]GWPAX;\ ^"OAA\2/ ?@"\\5V0+^.1JC_L
MS_"/XL:[X+\#>!D\,KX:?7O%!\=IXE/Q6\6^+0%\9>/?$TDG@CQ@-Q\8\G^P
MSX7^"?P6_;*_:L\+_!ZP\76/A#XC>&/A=HG@;5_%/CGQI\2/^$]U;]F_7/'6
M@_%@:%XR^(7BCQ=XF4>%_$7Q28?\(R\I'BPMXE\=>!RT0E8>9?\ !6F[^+'[
M)=UX9_:U_9>\;^+OA+XP^(GC#PS\,OCM>:!8^#?$/@?QWI>A^#M?UOX6ZSXV
M\#_$'PSXL\.'Q!X6DT ^'3XL\+#PAXSE\&N/!22.A\%[>;+Z&)Q>:K*<(TE)
MJ,7)I1<I7Y5=NUV]+7O>Z7GTO$?5,)+%XKLW:*^RKZV2[+L?I9^R-\7_ (+_
M !&^%^@:+\+9[;PYJ'@S1]+_ .$B^& U1]5\<>$_[=TM->.M:ZN\>(O$#>+1
MK:>)T\7287Q8VNO,3_PFWFHOW#7\7O["O[2GB+XJ^-?B?I%Q!X3^%_Q_\&>.
M_$WQU^#VK>%+,Z?X:O\ 3/BIK0U[QQHQT4Y8_#WQ7\1M:UH^-O#!.[_A#=>W
M9W>$?^$TK^M/X%_$RR^,GPG\'?$.PL+C3+G7K1TUK0KHKN\/^)]#UE]#\<>$
M#E5#2>%_$FBZWX98!<;M$8\C<3Z>=<.8WA]KZXMU?R3=M-ET>CZ]D>;DV=X/
M-;_5+63>C\F^_>WE;N>[T445XI[8F!Z#\J7 ZXY]:**//KWZ_?O^('QOX_\
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MF$>&^L_VE.VW/R/EVO:^_?963LF[M'J+CW-_JGUO^RU:R5_>TZ=K:>NY^?\
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MDJ#4+K2_%UD=*M/"'C:ZO=%U'P+\3-2US0]"UPZ'X)US0/$3;O$&-=S@;2"
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M:>%HY#R1KK*&1,@ 'X>?LUBWGB\)6.B6-SITY_;CU2\-I]B_XF1!_;,'CO\
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MCX9'0R"#\0A\9]:T/X8?\(TS%5\:'R2Q*MCX]^$OP#\;^%/B-J,&NZ7:W7Q
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M326_NQ6BOHDM%HDDE=="Q1117NK1)=DE]R1@%%%% !1110!^97Q/_P""O/\
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M$'_"0?$C_A(M:\,'Q!\#M&\4GPZWC$>8^NBW!:81>+F_9C('4@?C2T ?E/\
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M4M/.E>"/C,OQ5,A'_"0QJ?\ A*3_ ,4U(HP54Y Y2(_,_BW_ ()NZ)XIU'Q
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M0>&HMGE^#=$\4>.P&'A+RS^CAG4Y4$9..I]_][T].V*_-;]MVZ\ > ]&\/\
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M--%#%-/-,! !R3T7CD9'//H*]O1*_1*_R_X8^SLWILWIZ-Z?FS\Y?V[OV[_
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MM?>[_IGX7G.6XC*L8\).UHMM/1KE;=G]VC71K31HE'(!]:***^D6QYP4444
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ML_\ "; >.-VSY*_3+1?V:_AYX;U*VF\/6=QHOAC3#X<-O\,](M-&T_P&FIZ
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M_P#P2H_X*O\ BVXUOX;_ +/_ .T/XJTSQ+X-\8V?AGP9\&/BH;+1].U31=3
M_L#0/!WC<^'S_P (QKV@>*<+X8\$^*<?/XR5%W>,/^$L'_"&_P!5Z.'57'V?
M# $?C]*_,LOS?!9IS/!S<HW>[3:2;=GOJTD[K>[M;5+];XXX$XBX!S:.4<24
MY0<Z<*D)<KY*D)QA)2IS2LTG/EE&_-"6EN5QD]KK1UH'  ]*#T-=6VO;7[M3
MXZVEO*WX6,:0 0@3!0!G[6 >.HP?]WD=,\'GO7\;_P#P6*_;5\1_%SXV:_\
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MFO/ UGJMV=3/A'Q1X((37/!VA!5)/P\\5>'O[:\4>"B2@2/0&D8_\54!7SF
MR7A#,<VS3*7E48YI&\FY127)%7O%Z)62NW9_A<^J3XBED+SE9N^6]E%5'S/5
MW;73=66[6NFS_8G_ (8B^"'_ #[^(_\ PHV_^*H_X8B^"':W\1_^%&W_ ,57
MVESZC\C_ (UY[X\\7Z'\./!'C'Q[KI^S:/X#\->*/&FL_91D_P!EZ%HS:[K;
M \CL2..N.G(KZ1<(\-NT7E,'M%Z1\EO]Y\]'B'B*ZMFU2[:7Q2[KR_,^;T_8
MB^")APT/B(]LKXC8#'XY^O;COTH7]B?X(Y.Z#Q%C.1:+XC(/K@Y)_3^5?S4?
M##]I3]I+XV?M4^(/VF)_$>MZ;?Z#9ZGHWANTL_\ BH],T(^.2-"T+X8_"S0]
M>QX7\0@X^8<*WC,^&0?^*[\8$5_7'X(/BEO!7A<^+Y=-/C ^'-*'B6XTO;_9
MI\2-I&W76T4'G;_PD 9D!&2GRD;ABOF899P3C,\S/A[#Y3!SR6*<Y0@U3<FK
MRY).]TFVOBDW;S1]%G-'B+*<+3QF*SB3_ME*22J<TG;E^**]8[\NO0^<O^&(
M?@EU\CQ#C_L9&R/PW#/Z?XJ?V(O@>.L'B/\ \*,_X_YZU^ __!5_XO\ [4%E
M\7;_ ,.:IXEU#3] ^$GCS_A8'PNOO#=G_P (UXET+PUK>B[=%UO0]<T!G/B
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MQ!(\)>,2?B?X?_%/Q'\*_'?]J>*C_9OQH_9S\2?\(S\7M*M+,Z;IOCSX7@Z
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M#\42/^*S\9GPP 1_PEO@WP7X._;RTL(]+AM[&RA%K:VEF+2TMK; 50,')+8
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MW-$U_0=!^&/PM8D^&CXC_P")YKF2<DG0/#!S_P )[XOJ[:?%?]I?Q3J'A_\
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M(Y+>-^B:B[6>JU>[12+T'T'\J6OJB@HHHH **** "BBB@ K\7_VM/W7[3_Q
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M+G&"6&0>37K]?,G[8=U/9_LF_M,3V,PM;FV_9_\ C$UM>?\ /HP\#ZZN>O&
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MZ_M':7^TIXF'C[PAX6U'1;'PO9>%?A)?:5XK&CJFH-\5M9U[P%KVM:RC._\
M;J>%/#GC?_A*? Z!F \::!RQ)+'V[X4_M_?#OX">$K?X.>(_!7C76M6\":QJ
M5C>ZKX>T_17TS45UW6SK^BZNV_Q*5;Q!(NN+'XX&T%/&1D(;<RE/3Q'$>487
M!?VOBLU@LHM9/>*;T6UFU>W9]#EH9+G&)Q7U14VVOLI)2\U[UDGTU?>W2_[>
MX^OYGW_Q_P X%)@=?\]_\37Y/_\ #V?X/?\ 1.OB/^?@W_YI*/\ A[/\'O\
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MJ!D?0^M?@UJ(G_:G^+/_  F'C"XM].T_P'GXA>)/$5X3J?\ PI;POKVC:^?
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M,>*!X6P/^$+_ .*8]*_2/_@W^^!.J6,WQE_:+O[&;3?"^JVNF?!?P%OM=O\
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MR1XA\+>'CHL4F[#H5.U1D/7V-10 4444 %%%% !@=,<>E&!Z"BBE9=E]R_R
M3 ]!^0HP/0?D*6BCEC_+'_P&/^0"8'H/R%&!Z#\A2T4<L?Y8_P#@,?\ (!,#
MT'Y"C ]!^0I:*.5=E]R_R'=]W][_ ,Q,#T'Y"C ]!^0I:*.6/\L?_ 8_Y"$P
M/0?D*,#T'Y"EHHY8_P L?_ 8_P#R("8'H/R%&!Z#\A2T4<L?Y8_^ Q_R 3 ]
M!^0HP/0?D*6BERQ_EC_X#'_Y$!,#T'Y"C ]!^0I:*.6/\L?_  &/_P B 8'H
M/\__ *A^5)@>@_+_ #Z#\J6BG9=E]R_R , =!BBBBBR6B22[))+[D@"BBBF
M4444 %%%% 'YLS?L$^"+SQ/<^)+CQ9KRPW%Z_AC^Q3I$;6'_  JS6M>_MK6_
MAJ%C=RT<BC_A'$\4#,O_  A!"/$L_P#Q5P_2:BB@ HHHH **** "BBB@ KY
M^(W[37@KX9_%#1?AUXQ\+^/-+N]2\.>)O&0^(%U9>$-/^%^F^ ? Q\-MX^\8
M:YXUU_Q-$NA^'_"8\::'_P )A,R*\:L&"%3(LGU_7QM^T=^RGX&_:9: >-M6
M\1Z/:V_PW^)?PTL?^$>OM,L9 ?'NO_"3QR^NEOWH77/"GB'X(Z"8%P$^67YE
MC#-& 6(?VP?V6+C7[;PZWQY^$HO[K2/"_B>R#^/M%;2M?TSQOXA\?>"-#?1-
M55Q#K\C>)? GC7PW#X=4-(K:%ETCV%6X_4-?_8=^-7B"P^+=Y>_LJ_%KQ?\
M"ZRU"_T7XF7#?#+QQXJ\#:9X#;0=>U_5M#\9LOBOQ%X='A9?&OA_Q*6$B(/^
M$C\.,7B'BH2-YSX$_P""=7@+P'XC\!:Y9?$/X@W&H>#+[^V;N\^P^#M._M[Q
M/C]IESK>%\-DZ"0?VI_''$6XM_87A=205E_X2SB? ?\ P2_^&7@K[$+[XJ?$
M_P 9ZU:_%7P%\3-7\0^(K[1GU/Q5IO@;1/#NA#P3X@QX<4:]\/\ Q:W@KP+X
MG\:QB1B_C+0%*$>!#_PA:@'UY-^UA^SG;7>F0P?&?X<ZG;?VOXAT'6=7TCQA
MHFI>'/"FIZ!X-\0^.]:7QUK">(/+\.K%X=\%Z[+O\3&-@R@$A!5C5_VLOV:-
M(M;?4)OC]\)+B+4?#NJ>--)LK3XD>#?[0\0^%]#B\0-K6JZ%H[:\IU^-'\&>
M-\21*Q_XISQ/D;_"DJ#\K?$G[$7[%_ASQ3K/@'XF_MNW%S\0?&5[X!L=(TCQ
MO\5_AIIOQ*_M3P,?BUH7@<H=?4^*/$7B%1XY8+N"DMX>P0O@(_\ "&CZP\.?
M\$[?@]X:TZX\$+X^\1W>HZ\/#.M:L,^#]-U'46\#?$[XN>/=;UHZ./##;%/B
M+]HK6MS;6"Y\+@;L?, ?3;_M8_ "35_A1H=[\3/"6E7_ ,>/ FG^/_A%>:MJ
M^EZ3I_CWPMKVL:#H.B#P_-KC))K?B)G\;: W_"-J&)_MTX4DJRK%^UG^S@;:
M>^U;XW_"30_[-\/^%O$VLVFK?$CP?IVIZ!I7C8Z&VA'7%.NX!/\ PF>@Y9F
M!\1^&MLK'Q5#O^7OCC^SU\(?#>C_  3U3XT?M06WPDT'P;X&\,_ Q+WQ5K'P
M>\%:5\9=+T/6? 7Q5&BR:SXB\/1C0_$6?@@963PAM7_A#/\ A)S_ *P)-X3\
M,@_X)]_#]AX9/[/_ .U/=CQ3H _9C.C61O/AKJ6E:AX7^!?C7]FGQS_PF>N:
M+X>\-./B!XB/P[\"^"/^$)\3>*]TD8\?#S/&J^!?%_@Q/!QUOU[]?OW_ ! ^
MW/ 6N?L)_#KQ1K_B7X9ZA^RMX(\7_$/PDGQ:\0>(/ __  I_PWXE\?> U.OZ
MV_Q.U[6O#WEOXB\.L6U_Q+_PD\C30[5\0W !(8&#Q5^W=^S1X;U#P-8V_P 2
M/#7B3_A8UXUEX0OO"OC'P=J>F:]_8FE>.]?UY5UA/$H0CPJG@?7AXS=WW0_(
M2LN^1:^<#_P2A^"W]O7VN/X_^)ZS^*3XFUCQ-]K/@_-]\4]>\%:YX$UKXEZ'
M_P 4Q_Q3WB!_#NN:\!X8\+^5X-WA%"-X%D\9>"_&/I&M_P#!//0O&FJ>)_$/
MQ'^,7Q'\5>*/&'AS5M#U;Q -(^&WAQ<:UHOQ=T(#^Q=!\,J"=GQOULE<D!M
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MXB":\P0/!O!;<H(DC95\G\7?MY?LO>$-*\.ZM%\6?!?C+3O&'C'2O!OAJY\
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M0* 3Y:<JQ#'&YB_P1#_P2]TK6H_&'@#XA?&GXI>+?A!KGA'2O"[:5>W6D_\
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MZA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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HB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &- AD# 2(  A$! Q$!_\0
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M4>1T#, 0#C.*_EN^-?[)OPY_;5_X.+/C%\+?C;J'B+5?@MX9_8V^'?CSQ?\
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MWXB_:S^,_P )M+^)FH_M6:CXJ\6WOQ"\/_$OQKI(U]=:T8_V[L$'AK6=4PL
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M;7WC7XB?'#^PW F\)1:E(=NA^'_$+'=*HPRH=N"^%K^B_ ]!W[>O7\^_K2T
M?B[8_L/?&NU_X+1^-_V[8SX8'P.U[]CVR^"-B\NJEO$1\;KJ(U+YM*_Z W(R
MY_B.<G&*TO\ @CK^Q7\7?V%_@1\:OA]\:F\,2^(?B-^U5\7/C#HO_",ZD;_3
M5\+>--6TZ31F>3@)K!$?[V,]P@XQS^Q^!Z#\J,#T'KT'7UH 6BB@]#GTH K_
M .?RHZ<5A:EJ]AH=A?ZIJU];Z?I^FVCWMY=W;>7I]EI\8R[LP*@85<LQ('K@
M8S_-G^UY_P %3/BC\5_$FM?#;]E;4IO WPXTF];1-2^+4%HS>+_&<F2'B\$1
M\#2=%!##_A(6'J1CI7+BL5A,(D\5))VTOY=E=??\CVLCX<S;B'&+!X).SM>5
MK1BM'>]FF[:J*=[:Z(_HXUOQGX.\,1$^(?%7A[1<]M6UC3-//)_NR29'OA?P
M&*30_&7@_P 3P@^'/%6A^(<=M)U?2]0)[DD1R<]>A'&>E?Q*3_"[6/&=U<:Y
MXRUCQ)XUU>Z.;S4_$VNZQK=\,Y)Q'J3(F0<GA1C/'7@LOAIK_@:ZM]<\#ZSX
MD\%:M;9-GJGAK7=9T.^]0=FFNZ$YQR5/N.!7C?ZU8.]K.U^SVO;\C]8_X@EF
M_P!3YO[3CSVO\*WMMW\M_P 3^YVCI7\TO['O_!5#XB?#/Q#HWPO_ &KM2F\7
M^ =6O5T31/C#-:E==\.2D[4B\:J!G5=()V@>(5&.A.0,5_2+9:C8ZC:V]]83
MP7=K>6J7EI=VK K>1NNY63;D%&7!&#@@@YX->SA<5A,6KX5IZ:V_5-OUOV/R
M;/.',VX>Q;PF.3MK:=FXR6MW>VCMJXO6VNJU-&250G XZX)/ZGKT'0?6L^\U
M&STVW^TW\\%K:XS]HNKE(P?Q<@?^/*,#ZU^<W[>?[?OAK]D_1].\*^%M,A\>
M?&SQA:L/#/@]+@&RT:RQ@>*_&)4YBT)"<YZN1A2!G/\ .5\0_B-^T9^T?K-Q
MKGQE^*WBKQ"EUQ_PCFE:OJGAOP3IRD_=TCPMHQ$K@9QEF.X<FO/S+.L)A-'=
MR6_>^J_KY,]SA/@'.>*6\5A5RY5MS-;M;N*:2:O?7UT/[$(?BO\ #"[NOL4/
MQ"\&W%[R!9VWBO2?M_'8 :P6.20,=3G&.<5Z9!-#<1^=#*)UP"&5@P.0. 5X
MR01@\@]<U_"]_P *!TJVBW0:=);77/\ IEN;K<.>NXR;N<9]1V&<5[W\'?VG
M?VJOV5-8MK[P%X\UGQ?X-M67^V?AOX_U;4M?T.]TU3ECH-QJP_M[1F Z9X!P
M!\O%<V&XBP<K*S5[*ZO?6W?O?R]3[',_!W.<)@WB\)+VEDVU**2ZM[7:VTNK
M][]/[*CC8.>2,8_#(Y_SG^;J^.OV2_VLO '[7'PY7QOX-6XTK4].NETKQKX5
MU(N-3\*^)%4!])E5<!LY)36 NQE'?/R_8@&  .V.ISWYY^G%?1JS2:U32=UK
MOKT]?D?D&)PV*P6+GA,7#EE&ZE%JVJO^&EUW5GY%FBD'0?04M!@%%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !67>WMOIMG=7U].MK:6=F][>7C8"1QQJS.[8!&U55F.,
M9& .N1J5XI\>/%7A_P #?!WXE^+/%LME!H&D> _$UQJHU"Y"69SI#JD89LG]
MX<(" &RWRD'! !\">$_^"H'PV\1>,/#NEWGPL^+'A[X.^,O%TO@OP3^T1K-O
M81^ ?$.L7VJ#2=-OULO[5.LZ1H>OZTC1^&?$.O(L,HW%0%XK[G\"?M,? #XH
M^)-7\%?#GXR_#[QSXST$$:OX>\,>*=)U34[''##RXGRV,')3<!\W2OY2M?\
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MWK08(#:Y.?3/M^6/Z?KDUZ" 6N1GTS[?EC^GZ8\1[/1;/HNWH?K'W^FOY?\
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M*^H:SX_GTSQAK/BC1'9/&X^&-JVC_P!BW>A>%@&;1&UQE'B5/]2<\GZ&\/\
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M::;-H.L?"SXJ']H/3M:/A_5?V<=$L[+7_&MFAT\ZJ?$PNH=5&C'P6VC$R?\
M"2^8(<],DUN/_P %3/V8U\+>&M3@@^).I^/]1U74-$OO@OH7A.YU[XL^&]4T
M<L==B\5>'(<S:'I$(X_M^3;#K:@>03P"!Z;GS!_P6P^#>IWWA_X3?M&:)8W%
MS:_#F\U'P;X[-JHS9>'O%Q']B:S(0,^7X>UI2KD_+C55)':OS!^%7B^#R;;%
MR&X'S$X/(!![#GU&1U[5_43X&^(?P4_; ^#%WJOAV>+QG\,?&]AJWA;7-(U?
M36M;ZW5E.EZOX<\3Z+JFV;1->MIF 5)%259$#QX*HS?S(?MG?LA^-_V$_$3>
M);"]N/%?[/7B;5A;>%/$&W[9X@\%W[EL:+XBB!!U28 $+K8Q&%!7J"*^2XCR
MU_[YA%?O?5>>S?\ P-K]_P!U\)>-<'E=\FS?1-KD72[=^NETWM;9Z;,^N- \
M<Q?9>)UZ\9/;\/7_ #BC7O','E9^T#D^I[\^G3VK\UO#GQTTVZM;<V6LZ?=8
M&>+P'!]QDX]?;\ZK>*/V@=%TJQGO=2\0Z;IT%J,WEU=WJ@ #G P?;M^O%?*V
M;T2=^UGOITM??R/Z/>:X%)XQRBEOK**7+:^S:Z>7F>P_%7QK;B*X8W QC+8Y
M.!G)&<YX'/\ G/Z ?\$OOV66^)G[//[2?CCQE8BVL?VBM%U+X:>##=VVTMX3
MTC3-5,>L '^&37=2501CY]*XSP!\"?L<_L]G]M]M2^*OB?X@>%_"O[*W@N]%
MUXY\8W6NZ38:YK90ACH5HGF(/"FDC&&\0>(6C1EW;2217]1/P\^*/[-^E?"2
M'7_AM\1?AC;_  =\"67]B/KFA>+=%?P9X9320%;3)M:CF$&FMDEI&F(9VW,
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M0(UI57P\-K,T^3BO2VT/B#]-\#T'4'IW&,'ZC QZ8'I1@9S@9]<<U^4&K?\
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M(]K%O(88I_$&I/\ V!,8 'U^XU")(#A%V]%\.8V^$VA_&;7+B;Q1>6/[&_\
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M_P#@EOX;N+C3]?U$:W97GC/XVR^+/%NL:I8_,1H-NVJ'RIO#YVR^(/[2ACB
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MA?J^H^+=,+K:_%C]GS5=7\*:IHFE^7L76IH)4O\ 7 \69(EB5T.Y$%8'P?\
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M8O!GB!Y;YX[*/;=%M&9A)A>/B7]L7Q]\.O#6M>-/"WB;Q5H?V_2/^":7P_\
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MTVUL?V1O#7PX_:6\=:+X0\7:[\%O#W@SQ_X@U+6],TJ]/B>3PLNE:K?*))D
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M:@VL:1JGAMIP9&TGQ&=4F\TB8[77-?LF%48PJC;G;@#Y<]<<<9[XZ]Z7:O'
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MPD:W&@C4-*EV >9<H&E+. 1K_$Y;?RKG@'KZ$$Y&.GX<]QTKY&^#DDX_:_\
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M.+Q%'%J+/IK2MY.')\N-L '] -%?A?XN_P""@/QG\"?##_@FO\1]1DT;4_\
MAH?X=>-_'/QFTRST>$MKJ>#/@=JGQ*,?A:7>1IH;55C61F^7R%3/(K%^#VO?
M\%&?B5\)/!O[2?B?]J+X0GX<?M(_"7QEKE_\(+GX=6>D7WP=A\1^!-:U?P%=
M_"GQ.MS_ &IXYUO156,ZM#K<-Z-<Y>T!CC#@ _=.TN;.^ACGL[J.]MI\B":&
MX6[M&*CH9(CC(],\'N.E:]?S._\ !)'XV_M!>$_#/_!.#]G[QS\1M.\?^$_C
M1\!/VB/B'JE]?^&BGB:WN_!'BZR70=,N-8:5]TNB_P!HZFEUO+L4OH(G^5$
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MW[1_;6KZ'_;FHZ5!]KMH,(DR#.3\VG\;O^"OWA/X,ZC\5]=T7]FKX_\ Q8^
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MK1/&.K>#/B!!=>#_ !IX\TC1(]3M+SP[>3VMO>R)*R/H.MK;W0#!0 !S[/\
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MCXN7&O#X=_"3PIJGAW1=0UJ#PQ&6USQ%JFO>*+JTT/PWH$(*YNIIU7.\*>:
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MI.%NK..=1T($D0D7OC.) "<]O05<H **** "BBB@ HHHH **** /A/\ ;/\
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MQ_P3G@'VGXJ1?M _'W55;=_:7Q=^./CC63P223:VVIPQ'UX4X'\/I_040#U
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M4 FN4_X*3_L+>)OVD_B/^SW\?/A[\.?AK\=_$GP9A\=^#-?^!OQ;\3:WX/\
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M#7/ 7C+P5X6\2#1;R"*PT>71=/U+2YKK1+B1KAGD>0MM Q]":1^P/\9--_9
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M>G.48J*E'WHP4XP;C'XDXMM*ZO))/^ '_A&O VI?%/X*^(?'EG=76B:)\0]
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M9C(81O!<U[-OE;3_ /)7?;4^BRB,6W=1>LM9)/OW3_/8_"3X>Z;'_P $IO\
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M[8@RR2+C'PS_ ,%!_P#@HA^TC_P4(UGX'?L*^*/V2O'/[*MM^U7\;? OP_\
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MFMG5-)\$Z\@:\T_6]/T[1[B8)<>2?V[_ &5?^"@G@/\ :*UO4_A;XN\-:_\
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M\+M97VJ/K6BQV>C/=6FJ:@^I:<;/2)].+?VCI^I7AG^R:;<6YW &\*M&6?&
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M3XMVBQ?'+XW3:M\?/C:QB(5/B+\4;Y/$>M6!# $&ST:^T[1(8FSY TZ2)-J
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MB&S$+?!GXD> -&^%WQ1&K.$#V.J7WALZCJ&GZ<K"..YTG3KA$6:57.M\3?\
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MY!-]->T"6'4IEUW3[JUT.ZNH-8NX[_3_ +%H5_IA-W+#?W/G[=( B9XW2Z9
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M.*I6I\*:[#K>F1P>&]6B^T"S\2Z:4TV_C=VV?N?$5ND3QOJ# ?\ 'G>(^0
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MQ_8T\/VVO:SXK2ZU7XT? .&:&PG\27C -?\ CCX;S$)86WB%E)_MS2M@_M,
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MQ\\1W+>&]5LO'OAK]I3Q1X@>32_L9N_F6\\2ON:>,2Z$8P(Y:_M+V+Z?J?\
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M3(SSM7/W1A0 ,X &22< #)/4GW/<]:6B@"-HXR58QHS1Y\LE%+)D8.PD97(
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M7LLXW9R?ECDXQCMP.@'-/^%_B[Q//XH_L6+5+SQ'X<;)GU&[@=7A;!QB5R6
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MM4CAT?3[#3I+WP^L:C4-3;+ -DD ']#XCC"J@C0(FT(@10JA#E JXPNP@%<
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M8S]IT_Q3&D4EO'=74"VR:IHVLW"L)]0@=\/]F.[FN_C-^S;JTTEB+>^\?_\
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M\'+O7_&MG=R+X(\.7VF:O<>%O'6I368?R/#?BI;Z#5[FP:2.XTZUAA8@1**
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M<MEJMFD(TB5W6W2'48EB4R29\4T76]#^%/[;/A3X<7WB/2M#N= _:_\ C?\
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M?$+M))X4$%S%)I4?E36P\K3X]57#7S2/I?$%Y-/_ &FOB1!/(UI'IW_!2O\
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M?3OP_P#'&@^,K"9=)C&G7]B?^)EI@40OI[$==D2HMV" N&96 R>G&?K?7?\
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M)R@+8R=A)*Y/RYXQ08HCO!BC(D)9P44[V*",L^1\Q,8"$G)V +TXH _$=?\
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M= $09*@%17]%&GWIO]/L[UHIK07]G%,MO,I$UKYL8?9/S\LB!@KY^ZX(SWH
MU:*** "B@]#BO@W]J?\ ;L^''[)7Q7_9-^$7CS1O$VLZ]^U[\5;WX3> M2T%
M8I;'1=<T[3]/FEO/$ID.V&T9M109MUP67/)!R ?>5%?#'A7]N'X>>,/VX_B?
M^P=8:'XMM/B9\*_A7X9^,>O>()XK;_A&+SP[XJO_ .S;2SM)B1<+.LV"H'.?
M3O\ <] !1110 5XE\7OC1\-_@#X!\0?%/XP^-M+\"^ = :.YU/7=;EN+2& 3
M!;.&QM8%:XN]3U34K@G^S-,L(9)96V>6CN1N]M/0]_;UK\2_^"M9L= UK]@7
MQO\ $0PG]FWP7^V+X,U#XTPZDXN/#MO)J6GZM;^ =2\1PP0310^%?#7B^XM;
MO5[J]B:SAMHH/- "*: /J;X%_P#!17]F_P#: \=2_#7P?XP\5>'OB"_AW4_%
M6B^#?B;X$\5?#C6_&/AJT<73^)_"FD^,=*T>?Q)I&E:2GVF_O-'NTC56WO:X
M; \RT#_@L7^P%XBDTE%^-^K:=H^MZS>^'K'QSK7@#QUH/@%]=TN_.G7%BOCN
MYT!_!T$YU7_1&EOM8CL6(\D.<C/<?'3XS?LA7GQW_9[\&>)++PY\0OV@/%OA
M_P")M_\  B^\)VUIXIU+PWI$G@F8Z]XEU;6]!>Z/@[P9K.D*+*SUR]FM+*>]
M8!+4N0X_+K]ESXJ_LZ:#_P $*M2T7XO^(_AYJVGZI\,_CQIMSX)U/4=(U+6M
M1\2:GXR\96OA71+7PY')/KD^O+JLNFW%DT=HUY;W5O;7$3*R))& ?L[\>_V]
MOV4/V8-4\'Z1\;_C/X:\%:MX^M!JGAC3Y_MVLS7WA_( \43)H=O?G2O#6YOF
MU?4!#:C_ )Z8%>\S?$_P3%X!G^++>*],N?AY;^&3XM?Q58ZC!?>')-#6P&IC
M5["[M%:6]LC <AE8JR<*I/%?SZZ+IWP_N/V2?!/P(\6?&7X;_LV?M\-^P5\/
M%^)?Q1^,?@.QU?5;_P"#UWI6KV4_A>RO_%VHZ7:S7%O)"[:]9Z;.=2,DEE<W
M4;M'&T?WY_P3V\:Z+J7_  2R^#7B2W^'']FZ1X:^ 7B+0K7P+?\ V[5K+7M#
M\'/K6CK-86>LB6;4/#_BNWT5M5LOMT,L\FE:A BJ\++E/9^C_(#[[^'OQ:\$
M?$_P_H7B'P9XIM]23Q-IYU?0[6Z$NB7FL:;QMU1-!U!9-:M;!LX63R$B8!6&
M ]<'\>XGDO/" !(!;4&*J3MW8]!@9SGYB,\]<U\F_L9_!_\ 8NFM/AS^T+\.
M;3X;:M\=/%'PVTTW/B72?&8UCQ-IUCJMH-8US1M)\/7=_/!X?@TFZGNK%-%L
MM-MH+."V$1A18=H^N_CG_P ?OA7V^W8SU''MP/?&*YL1IA&UHVI:]?M==^W7
MH<>96^JR]/Q_R[>=SQ3[.?0?D/\ &M'PU$8O$>6Y/_".>(ADX/\ S"SW[<?_
M *ZAJQH+,?$7+$_\4]XBZDG_ )A;5\Y@/]Z;>MD]_F?*Y<E]:>B^UT7>1SFD
M0YL;$D YM6)Z8/S'[W&3_G/'6>^@'V2Y.!G[(7R>N[^]D#EO4]??O4FD?\@V
MP/?[._/?KZU8OO\ CS;WL^??Y1U]?QHN_KENG;I\2Z;?@)?&GUYEKU^)=3[!
M^''_ ")'A+_L 6'_ *$M?G!_P4)\ >-_&?QP_P"":6K>$O"^K^(]+\#_ +9!
M\2>.M0TJPGGB\+^&C\./&-D=:U&1I"(;$ZE-8632-B/;.T8^0[:_1_X<?\B1
MX2_[ %A_Z$M=R;>W(8&"$AUVN#$A#KP=K KAER <'(X''%?6+9>B_)'VRV7H
MOR1^8G[3?[/7[9OQ-U/XP7?P_P#VJK30/A?XN^&7BK1=!^![?"[14O%UG4?"
MVK:7;*WQ.&J+<1S-JMS:W4151)%:Q1D82-"/RF@_X2#]H+]D[0_V,?A%^PO\
M2/AM^T)X#_94^)GPZ\3?%+Q?X D^'.D_"/Q9)X*70[O2/!GCS4](FM_&4_Q7
MUV.2)[W0I8C'=2#7YY'G;S$_J6\F'.?*CSNWY\M<[_+\G?G&=WE?NMW7R_DS
MMXJL8;41J?+CCCA(&QHT ^6/RE!7':/]VO!(7*@8XIC/Y(OV5O@QJ_CSQ[\%
M8[5/V\O$'C7X _L^_%G0-4TOXH?!_P  _"GX:?#2^U'X=2>%-2^'<OB'3_#7
MAG4/B):ZEK -EI(\,R:Q$9BNMJOG%IJ^]_\ @F_\(/BCX*^-7P"UCQGX#\5>
M$['2/^":7P[\"ZS=:WI<UK!8>-[/XF:K=WOANY9)5'VRWTE8KE(I"'4;6&"
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M;NM8-VG -;EH8F$9,:5[=0 4444 %%%% !1110 4444 %%%% !1110 4444
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M%%*8QM*@KCTQC&/;%.HH C6&)"Q6.-2[;W(107?^\Q Y8=B>10(HE0QB- C
MAD"@*0PP01C!R, YZ@ 5)10 WRTSG8F=NW.T9V_W<X^[[=*/+3CY$^7[ORCC
MZ<<?A3J* (_)BPB^5'MC.8QL7"$=U&,*?<8J2BB@ HHHH **** "BBB@ HHH
HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #B AH# 2(  A$! Q$!_\0
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MOP79W\'BGXG>)?B?<:F1]DNO$-CHVF_8 !DJ/[! X/\ >P.,XVM]WVJJ\'$
M'^R?Y58KT%>ROO97];*_XW/F'9-I;)M+T3:7X)!1110(**** "BBB@ HHHH
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M_&NR_P""COQ_LOV7?AIX?^*7C+XP?!/X$ZO;Z[XD\6CPWX(\*^%_#DGB)/\
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M** /S.^._P"T-\5/ '[1?@W0O#'@_P 2ZS\&O!FDZ9H_Q?\ $-IX=_M/2_\
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M]<T30S_; T8>)?%CA7;#!E\5S\[\<,I3H.%2DG?FDGU:E)/[U)/\3WGR8/\
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M#Q?K[2[Q)/*A_P _>&SOII;?R(+FY^U7GV*S-I9_\?\ J@_K_3\*ZC7OAO\
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MAU6QN=-U#_C]^R7=G_9NI_C^OO\ SH_LS"=Y?U\@^L+R_KYG^A'X9_X+N_\
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MW_SQ:[RB@#RS3/'VH:SIECJ=A\/_ !I<V&IVHO;.Z^W?#8 JPR#G_A8HY/\
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MU[=?NW_ X3_A*O$?_1-?&W_@9\-O_GBT?\)5XC_Z)KXV_P# SX;?_/%KO**
M/*;_ ,?:II@_TSX?>+;4_;--LR#>?#?KKNLC1-%/_)0P<M(V",<D'"AE9!M?
M\)5XC_Z)KXV_\#/AM_\ /%I/'G_(&L_^QQ^%_P#ZLKPY7A7[3/CGQQ\,_A/<
M^)/ $WA-?&R>,OACH^BVOBR]T4:9J3Z]XTTC0-?T30T\0_$3X2>%M=^(!\.2
MZU)X&\.>)O&G@[PC-XT;PRD[#RV60 ]V_P"$J\1_]$U\;?\ @9\-O_GBT?\
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M_P"!GPV_^>+7PW^S]^VU8_M'^+?#/A[PQX)DT6Q\??"_QQ\3?!UYJ?C#2_\
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M\-O_ )XM>(?!/XR7WQLL/%\\WA^'P[K7@/Q+HOA755T?Q=H7CKPU?#Q!\./
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M\W_%0>'3_P *O\<_\(:WA&3Q7X08IX7R2/%O@P^+LZTMO^"<6LV]CK^K>+_
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M-Q*\KX<_X)_?!+PAXD\+:]I7Q9^*%Q?^#])\+Z+X=U75O$GPTU/5-!TGP/\
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M_P!"WHW_ (*])H /^$CT+_H.:-_X-]+_ /BJ/^$CT+_H.:-_X-]+_P#BJ/[
M\._]"WHW_@KTFD_X1KPY_P!"WHO_ (*=)_\ B* %_P"$CT+_ *#FC?\ @WTO
M_P"*H_X2/0O^@YHW_@WTO_XJD_X1KPY_T+>B_P#@ITG_ .(H_P"$:\.?]"WH
MO_@ITG_XB@!?^$CT+_H.:-_X-]+_ /BJ_,?X@:G8_P#">>-O].MO^1N\2?\
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M^9C0?'O_  62\>^%- _X*#Z5_P %)OV;_#O[+4WP)\3_ !W\2ZJVCZ.WP/\
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M,O#I8'P@OBMG'$^&OC-^W_J6E?V[_P (3X;U&WT#6? O_"-:9_PKCXE^'O\
MA:^G>-_C+H?@'7SKA^(/AOX2^)OA[_PB/AO6M>\3-_Q1X&[0/#7C<Y\"L?\
MA,^F\ ?'[]I+6/'OP8\ ZI =4'QD.HC7]7\5?!?7?@KXF^&__"J=&\ >//BF
M7\%:[XC?Q3XA\-^+6\;ZW\+_  9XK(\)+X,\7_\ ",O(?&:-)XQ\8@''0_#K
M]O#7+&_UK6=:\2^&I]+\#>/+/2?"=E\3=*']H^.Y/AM^R5X!T/7=:/AY0/$
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M#A?^$ZT/_GS\;?\ AM_B5_\ ,U1_PG6A_P#/GXV_\-O\2O\ YFJ[JB@#A?\
MA.M#_P"?/QM_X;?XE?\ S-4?\)UH?_/GXV_\-O\ $K_YFJ[JB@#A?^$ZT/\
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M44 <+_PG6A_\^7C;_P -O\2O_F:H_P"$WT(];'QH?^Z<?$C_ .9NNZJK-/#
M/WTP7TSP,^^!C^1_.E=):M6\VK?Y#2;:44W+HDFW\DDW]R.-'CO0B,?8O&O/
M;_A7'Q)/\O#5-;QSH>>;+QL?0GX;_$C/X9\,YK:TW5-)U>'[1I=_IVH0'I<V
MMXFH D8X!!//3^(_2NB4YX/7N.G^>*<9+[-FO)I_^DMDXG#RBU&:E"2M[LXR
M@^C^&2C9OI=7.'_X3K0_^?/QM_X;?XE?_,U1_P )UH?_ #Y^-O\ PV_Q*_\
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M5]H^WZ?]G_Y^?MBX]/SSWWX[>U '/_\ "=:'_P ^?C;_ ,-O\2O_ )FJSO\
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M/_GS\;?^&W^)7_S-4?\ "=:'_P ^?C;_ ,-O\2O_ )FJYX?%KX<GQQ/\.?\
MA+]%_P"$WM?#K>)[OP\;O;J8\,C^PU;6\$*2I_MO1<'YBV_(^7!'K= '"_\
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M#=+>_P#(_P#A?_L3_'G_ *>O %=Q0!PW]I^-_P#H3]$_\*[_ /!NC^T_&_\
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M_H3]$_\ "N__  ;H_M/QO_T)^B?^%=_^#==S10!PW]I^-_\ H3]$_P#"N_\
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M)JZ]V<822:U5MUKKN<?_ &GXW_Z$_1/_  KO\?#=']I^-_\ H3]$_P#"N_\
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M;'6;/_A!/B8-3,<>B?$'Q"FN:'HZ_#Q9-?\ AX^@_"SXG>))/BGX4-QX*9?
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MJ/\ X6L8?^%.*@;'C<DY8 ^G?[3\;_\ 0GZ)_P"%=_\ @W1_:?C?_H3]$_\
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M^$CF_:,UC_A#H/M/C#_A=NJ?\(W:?]31_P )K_Q(L_\ <Q_KTXK[XU[]K/\
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M?P?_ +.&O> _[:^$6O:Z-#_XIO\ XJ#P[_Q8_P #_P#"<?\ ")_\47_R,_\
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M_92L_'X\57OBSXHZKX0@OA?+\-[_ %G2)-**;LG1/[83PZ/$W_"/E"55S/\
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M.F>&_AOX&.L'7="^,>L:WX?;CQ#XG8_\4;+AD=@$B9QYA']EO[.'B/Q'XR^
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M4:4%:U&BFU&,G-*_Q3DZDGT8Y /J!2TW^#_@/]*=7U)^3_AY=O+Y;'!>//\
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M7-A!L;QW4?\ @F%X1\2WGB&;Q?\ $[Q)_P 5[I'Q4L?'%KX5TK6/#>E?VO\
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M_@]-!8X \$J7\7^#!D'Q[X*\9;@!#XJ_X)\^"?%>HZUJ5OXVUFW?4O&.L>-
M%\/:.[/J>L>./VTO'.W55981XB\/'7_VP]:6?PV7$/BGPGX&2-GF_P"$KDV
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M  L@>"[RT\/?\)EX)\3:]I?]M>/O ?\ PFG@?_A8'PW_ .1=/Q&^%>N>%O\
MA*?^$._X0O\ XD';QX/&?@OP;H:/_P $E_[!\)>,/&/QB^._AOPWH^@_#?Q1
MK5Y>>'O#7Q+_ .*2\>Z%X+^ ?CS^Q==_XMO_ ,5_X=_X1SXX:'_R2?'_ !6E
M9_6'_2_^U _+C^T_A)_T(WC_ /\ #J:/_P#.2H_M/X2?]"-X_P#_  ZFC_\
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M^*="\=_ SPO::MX@OSX;\+^+=(^+'Q.^ 7@/QQK7@G6BJ+XA;PJ/VA]!<_\
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M\#']K/7]%&C%O$+AO$$WAO\ 98UM'^9=OB_7$2%5V!TN:S_P4,L?!-_\3O\
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M<?\ "4'PYX3^'7QO^*GA?P0"<>#/!>OD> _^$-'A'P8*S_?^7X ?0\G[,O\
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MB'E/#&#S;*LV7$CI3_>)X:=.*Q/N->SKRG"\J;<:5IT:T:C@I4Y-4YSOP?\
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M-XPT=]%\3>%/$ED-0TK7-(UG[^D:YHI&"A^49)SCG VM@ _DQ_X*JS?LL?\
M#%_[6!_9T_X8@/[:'_"1_LP_\-]?\(23_:?]IE] )_X9T&O?N_\ A(?^%C!!
M&?"@,FW_ (2G_A/O^*]+U_5+^SC_ ,+ _P"&>?@/_P +;Q_PMG_A2OPO_P"%
ME;MOV_\ X3[_ (0K0?\ A-\Y^;/_  DO]L9V]\8YS7YS?!7_ ((6_P#!-3X
M_%_3_C1X ^!#7'C#0=8&N^$+3Q7X[\9>-?#?@/4^#_:NA:)XA\12)(S$,K?\
M)2WBY@N-AW#=7['$D$<9S^E+$5[627].R_RM?_-@+1113 **** .&^'G_(B>
M O\ L4/"_P#Z8HZ[FN&^'G_(B> O^Q0\+_\ IBCKN: "BBD/0X]#2>S]'^3
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M_>PK+_X5;\,O^B=>!/\ PD?#_P#\KZ**]@YP_P"%6_#+_HG7@3_PD?#_ /\
M*^C_ (5;\,O^B=>!/_"1\/\ _P KZ** #_A5OPR_Z)UX$_\ "1\/_P#ROH_X
M5;\,O^B=>!/_  D?#_\ \KZ**=WW?WO_ # /^%6_#+_HG7@3_P )'P__ /*^
MC_A5OPR_Z)UX$_\ "1\/_P#ROHHI '_"K?AE_P!$Z\"?^$CX?_\ E?1_PJWX
M9?\ 1.O G_A(^'__ )7T44[ON_O?^8'[<?\ !&V&'X?V/[4/_"!Q1^"?.O?
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M0QX7_P"9CUC_ *#6@?\ 3Y75?\)]X[_Z'7Q;_P"%'K'_ ,F444 '_"?>._\
MH=?%O_A1ZQ_\F4?\)]X[_P"AU\6_^%'K'_R9110 ?\)]X[_Z'7Q;_P"%'K'_
M ,F4?\)]X[_Z'7Q;_P"%'K'_ ,F444 '_"?>._\ H=?%O_A1ZQ_\F4?\)]X[
M_P"AU\6_^%'K'_R9110 ?\)]X[_Z'7Q;_P"%'K'_ ,F4?\)]X[_Z'7Q;_P"%
M'K'_ ,F444 '_"?>._\ H=?%O_A1ZQ_\F4?\)]X[_P"AU\6_^%'K'_R9110
M?\)]X[_Z'7Q;_P"%'K'_ ,F4?\)]X[_Z'7Q;_P"%'K'_ ,F444 '_"?>._\
MH=?%O_A1ZQ_\F4?\)]X[_P"AU\6_^%'K'_R9110 ?\)]X[_Z'7Q;_P"%'K'_
M ,F4?\)]X[_Z'7Q;_P"%'K'_ ,F444 '_"?>._\ H=?%O_A1ZQ_\F4?\)]X[
M_P"AU\6_^%'K'_R9110 ?\)]X[_Z'7Q;_P"%'K'_ ,F4?\)]X[_Z'7Q;_P"%
M'K'_ ,F444 '_"?>._\ H=?%O_A1ZQ_\F4?\)]X[_P"AU\6_^%'K'_R9110
M?\)]X[_Z'7Q;_P"%'K'_ ,F5\F^)_%?BC_A)/$/_ !4FO_\ (<U;_F,:C_S_
* -Q_T\T44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'K AD# 2(  A$! Q$!_\0
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MQA=)U/2];TO0#/KC:Q_:!55$C2+M!P5;'XX_L!?\K*W_  6&]!\'?@G] /\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>A[T44
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MUQG_ #VR*BW-_='7'WA7\VL7_!;OXYF03WG[+O@;[!D_Z':_%/6QJ./7<WA
MKNP<\C&<Y ZU]E_ ;_@L)^SM\3=2T_PG\4-*\1?L]^+-1NUL;.?Q\]C=^!]0
MU%AA5TSQAH^_2X [$?/XD70SQCDFHPV88/$WM-+73FMZ+JEK=6ZZGK9CP?Q)
ME6%^MXK*:CCWBN:V^Z2;5EY:^A^Q/;GCCFBLRWN;6ZMX[NUECO;2^1)8I(I(
MY(I8Y!F.6*1&9)8W'W)(V96R-C'C.ED>HXXZCCVKL/FMM]&MT]&GU3O9JVN]
MA:*** "BBB@ HHHH **** "BBB@ HHHH **** "C(]1ST_+/\N?I17RK\._V
MDO!GQ'_:$_: _9YTVPUK3/&W[/%G\.=1U]M3AC.GZ[I/Q,TS4=4TC5M&4@%8
MT?2]3T=V9@V<8RI"!77=?>O\P/JJB@=!V]O2BF 4444 %%%% !1110 4444
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M^N!GJ>U?PZ?&CPX)-.U![&;[/<H!?V=S:Y4V6I1D2:+JPX!#*R<]".IZ9/\
M7-^QU\6Y?C=^R_\  GXHW[[M8\4_#SP]+XA)ZMXBM NB:S*2."&U?3+YOH<G
MI7V?#F8RQ6%Y<4_>6JNKW2>FF_3MW[G\F^+/">%X>SB..P2ME.=-RC:ZY9N[
M=E96U;OL?60Z#'I12#H/H*6OI#\M"BBB@ HHHH **** "BBB@ HHHH *#T./
M2BB@#- /F8Y!QZYP=V,^GOCI7\_NF^)=4^%/_!Q3XVTB]G^S>$/VF_V+OA_H
M>S('V[QO\.=1\5ZUHA(Z _V+I/B8#N1G' ./Z"\Y&1[XK^8S_@J!JEU\'?\
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MQ=>*?B7JXL#>6QV_V!X020/X@\7NV?W6D:%HN8HT<KN9MHR2 /[0/ G@O0_
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MXP>/M ^,FH>'TL_".K>!M:T4_'#P?\,]0U&(&7QI+XE\9W]E<W/A^=3'X?\
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M*EUH4&I/)>Z.=".E1))X@\*E)T<+M_L.?!_P[\/OB1\"9==F\;:U??&CPO\
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M3>%M$TKQ1)I_P:\1Z%I>BE;74_'6K:#J>F?\)I<W.LHNAHC.A=0P'+>#+/\
M9#_:4U;X97&F:SX^TGXB_M#_ +1.N_M!77AW6(7^(-YXUD_9SU;5/"44OB6\
MLQ_86D_"?35TX+X-9A_PCR^;I$<4<FN#S:\BUGQ/H?@?X??\%)?VAO"_A_PD
MUKI$?A7]B;X):!<:W->.=.^'OAC2/ <%CX>UN$OMT3Q'J_BNYUNV\*>&RVJ>
M)+C2E6Y?SU4+T7PUN-&^#GC7]H?XDW_B?5#X,_X)[_L8>#OV>/!WC'PYX132
MM-A\=:UH7_"6_$Q;G1DXUOQ!H%W:_#_S-*GS;>'UO 5.[5;C !ZAXY_9J\5?
M&.;XO^*O"_Q.\#^*_"/[5?[4/PBA\<Z7X-U?3D1O@5\#I/['UO0]#U+Q!NGN
MO'MOK>DL?&@T+;+I2Z5CPX(R&(\G_:S^%OQ*\7>,?VM=7NOAQXB-E\<_B1^S
M#^R3\(/%'B%=42+PW\.)=6T?5_B/XFBT>%I#J?@-O&=Y).JW&!XAN-VEW3+X
M=5DK/_9:\#ZCX(^,_P !+'QCI-G8ZK^R=^Q1XC^.7Q>7Q?XA,AN_CA^TCX@G
M\0:IKFEV@=M M=4\KPKXO?Q7XDE2-](_MO;;LV[<W2_LA_&/XL^,?%/[&_A+
M4/B9XBN/#7Q!^&7Q[_;#^-?AO3[:;4I=$TGQOXLFU;X1^!M:\5ZR#=:7X(\-
M2Z]K6DZ79P_/XB_X1J*<@:&?+ !YY^U+XGFF^(_[<O\ PC>L1V>MZ%\,?V;O
MV#/A7I_@SP\9+;Q5XB^+&LPZOXB\)S7L_P#Q(-*UQ#J.I:5<:/;9M?"?A>1=
M8UC?*8UJS^U/)IO@#QA^U/+HGAJ:X\-?LG?\$]_ WP#\-:=XL\1-%)I7C;]H
M'5]0TI]5\+0(6_MC9X2L+&+Q'JBH;G5+C28_#OAU$1F-?0/PK_:0UKXTW7[+
M?AGQG\)?AWXBT[]I?XX_&_XG>&/$NI:?#H\%M\*?@5XG;4_AM\0/[#A5O[2^
M*FKZ8_AM;C4)0GDF+#R+LVFH?$O[(?QX\2OIE[X*\>VOC_XX?MG76G6VK>'[
M]O$E_P",O$/[(6J+J=OXNEU)EUCP[IWPOT'2](CMX;6WX,E_JUK$O]NR^8 #
MQ[X_:I;_  E\=0:?;>)];ELOV(_^":7B4VNM_#_1$TB_T'XF_%B'2/"&CR:]
M,NTZ3)XFA\/:9K&@Z.I*V@M]8=]I85SWQ4^&_A/P+#^RU\*_B!X6^&>F:!^S
M#_P3X^,?QL\8Z#\0[6+QMX U;QYJFD>%O"$.F-8ZR+C<-+\7F]URSUPJLUQ<
M:HD=J6;4Y2OTI\8?@S\*/C1JW[16I67[1-IIFO\ QY^.7P9^!?BKPQXGT\>&
M_#K1_!34X-?U_P"!-O8V_P#Q.-;N?B+H6H^(9;C7V9G:/6=/<#9$:H_M,_LR
M_%SXAZS^V?XC^'%GX#O-'^+G@S]G/]G+PUI&CZEI.I^*X_!'A?Q+J*_&"=;G
M62R^"O%&F:!XEFM/"6@1E0NL^'+;Q*J"Y>,T ?(FI_ +P'K?PX_X)N_ O7/"
MWBV+1/A%^RM\8?VG_&^@Z?J#?"?Q%X;U/4O FFOINLIK6@FVUG2+NW\:^)I-
M)71+:=H[&T<7'B19%TF('S+PQ^S=H&E?#;_@F=I_@KXA:M\*_B9XW^'7Q^_:
M*^*/QM^'>GMXU^*M[X<U/P-8^*8V\?S^,S/)XU\-BX;PWX7\3ZQXE$DE_P"(
MM+T,^'_[&.HR8^R_VTOAU\0#K/[7^N6_P^^('BGPIX>_8L^%7[-'PI\1ZD^H
MZ?#I>L_$WQ3J6E_$_5O#,%J6DUR*VT&3P?K/BW7-AEGN]$/A]LP*37,?M5:T
MWPS^(_QH2SUC5],E_9R_X)C:?X!\+ZYX(T 6*6/CSXS^(8O!]AI&N7*QK'I]
MP]YX=\*^(/#NC1.4LH+S6;B4J#D@'R/X4^ GQ+T/3?V%_P!HCP'XLTF?]L']
MJF^^,&K>/_BC\<M5D;P3XP^$]OX$D\6:=X/U30?!NF)_PBULVA^&]%U?0CX<
M6-?!5R-2CUMM<EGC5N>\*_#WXT#QW^RG^W[8>'[#XS_M&?M0ZU\6/A:GP=T8
MCP9X(A^#OA#3-9?19_AOXI\5"1Y-7\GPG>>)K/Q!XF.CS^)O#_BBXBG72 IS
M]K_%#R?@;XV^%^DVMIX)^'U[^R=_P2N^+/BJV/B&Z/B7PQ+XF\4Q>%/"(TG2
MK3=(8AH>M^'5EU#7'2.3Q<VK&/$JQ.U69=/_ .$!O/V!?!L>C>(M:@_9J_8)
M^./QTU_PSX_U8>&Y++5M1\">%_"_AF_U&1&V2^.()-5\0Z--I:LT?AVUUC,9
M0.I(!^=MYIOC'5_C9\&_^"B/Q.^&-YXE\&?%SXA>*?@!X;_9<\#VZ?$OQYHO
MB'X2Z=XLTW2OBY<:%:;++Q5XA\.G2/&VF_:/#KZTNA^%KK1Q:R,@!KFO%=]X
M?\5_%S1OVI?B1X-UOX<_\$\/BI\4;3X5>)_!FOZ=J>CP^.OCO\--.\6Z+H_C
MKXI?#S3?,DL=)MM<36] DBU6"=[76_#FBW'B,.D88?I=\,DAT#PA_P $EO!4
ME_>>(=-^'?[.GQF_:1UC2O!>EBP\3V#Z5\(I])T/6Q,P1TTJUF\=:MX:A0[9
M->U^32[BX4"+<,'X0V+VOPO_ ."0>AZU<:391^)O%?QC_:1O]?T]SXB\37Z6
MWPS^(7BF!M57:\FM:CJ^D>*HKKQ=XAN&_>^*O(C!\V51( ? =GXQ\.S?&2'2
M?@WXW\5_!K_@F-\7?'FF^$/'GBWP5K.L_#/X=^*OVA=!\.>*-0@\&>#]=C,-
MUX$\,:S,=,M?%!\/K;)XG\6Z3'H4["*/5"_J4'QX^)?@7]H<?LB_L[_M!^.]
M%_99^*5_X>B\3_&-?%,OCRY^$7Q%T/PWXFU34O@A\)OB#XP?7[>QO/B/I.F:
M5J>I76I7&O)X:O(]4@A9)I1&?I?P1X'T[Q_^S5_P3=\$>,M"TN\T3XX?M<?%
M+XW^*-3\?6FD7WAKQ;H-NOQ:^(B#Q%X+96MYI?B'HAT[6+3170P^$I4F#[&T
MJ(5Q7@_X5?#[Q]^R#^R!\*)?!>DZAX0_:&_X**>./%6I>"]+TI/"7PMUC0-(
M\<_$'6KZ7P]=:*(O[$\'7N@>&(]:\'P:*(6UN1D+*<L: ,YOVL?VG?@C^T1:
M_L.?#/X[WWQ(/Q:A\-ZSX8^,7Q;ATOQKKOP&B_LCQ;K7BWPJU]IPTBU\5>(]
M0T7P_IC^%(_$$C3JT.IL$*,JGTW7/V^_VN?@%\8=,_8VNO$W@G]H'XM?&>T\
M.ZQ\#/BCXM\.V_@U/ ]BY\6S>,H?C'HFAZJ(]1DT_0O##:WX(72AH,OB!U8.
M<JQKR&P^ 7PHO_V1_!W@/PWH"Z'#\<O^"K^IZ##HO@J_U2V\9V6C>%/B!XJ\
M.KI/@KXO[AXBANM"\$^%;SQ!9^*//(ETP:KX6A=H9PK\_-^S=X'7]G3XC7&E
MZEXJT[XD^*/^"J6@_"7PA\1;[Q#JGBW]I+PQH7@[Q[!X%T?1M#\;ZX\E@OB"
MW\.W'B'Q']A7;X93P[XC\00R1%W.-M/Z_K_AP/K34?\ @I-^T-\ _B _[-OQ
M;\#?#WXP_M"_%JQTW6OV7-3\!W&K_#CP=XZBM]2+>-U^(UM<R:X_@ZT^&T(D
M\2:AK=G_ &R_BG0E:$!W0BNX_P"'IWQ(^#&M77PF_:>^"FBWGQW\7VME?_LZ
M:-\"?$]QK7A3XZ2ZIJ;6%UHC:GXCTG2)? 6J^#EW77B275E>-O"B'78_G C'
MP/XL_9\MH_@]^TG\:+[Q]X\\2?'?P'^WE\,_@?\ !W]H/QV^GWOQ8\">#=&\
M=^$O -\EOX.L!H?AYK%M3\9>.K^P\-1(R?$#PQ<Z2;U?*7=5?XD? ;Q)?^!_
MVJ_VDO%?Q5USX@?'7]F7]I7P%\'_ -G;XWZEH&D^$=!\$:8-8^'.D^/M6U+X
M86PUBU&FS:WXW\4:=K=J-5,GC7PU911Z$L89=V('Z.V?_!4\?"Z\U?PC^TY\
M"M6^%OQ4O=.T_5_@]X#^'GBBQ^)-C\=+C5]2726\,^"-7MH]%.F>.+/4M4TV
M?Q-INO'R&L[P^(5DVQR$?47P _;;@^,_Q,N_@CXV^#7C7]G[XJIX';XE:9X8
M\;:CX8U>Q\9>#(=332]>OO"'B'PAJ>K:/J%UX7U75-)?Q'!*!*RZF7$;1@X_
M$#XO_ SXH>+= _:H_:8^)?Q&T+QM\</V#_B'\-_!W[._BGP1X2G\'?"'P_K_
M /Q1^L_$F?Q%H^IZH^M:ZDLGBUM,\822L1I_AFPBC\* ;@M?H%^P[X,^+WQ$
M_:Y^,'C_ /:'UWX>W/BO]EK0-(^$'@?1_@LVMZI\.X-0^+^A^%O&_CC5+WQ)
MXCTW1KW6O$KZ38^%]&N=&?1C%X>@U%C"Y!#T!MJ]CW[]OO\ 8$\.?M;:5#X[
M\'ZB/!/QY\)63V_AWQ;!9;]&\06 !,GA'QC"HW7-G*5&[6PK2Z$3^X%?RT0_
M&"_\ >)-=\#_ !#L[OPIXH\.:QJ6B:S;WJ/)I4E_HC?V3JDNE:B )H4E&&C9
MU"NA!&>M?WG375K96KWEXT5G:Q*7>1[HQ1( "=SNY6-$4 ;F9@ .YP*_#/\
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M@3^ 9M4\=-HUAXXD\"ZC\9;;X>:__P *-TSQHNK-H;>'-4^( M/[,6Y37O\
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M\=6/_!4KQ=XRT/0K32=4\?>+KKQ[JWQXUWQ*VG>-/AOX[^'%QK*>'=)\!Z)
MVJ7$.AG0EMM$\-Z="UJS*ZD\_K]M\*/$GPD^&'[-'PW\/:I\,_\ @I5J'Q(T
M/X8ZGXQF\.ZIIOQ \%_'[5M5+?$CQCXZ^*"K]BU_2[W1SXCUFUM7\2F;Q-H5
MQ'::)%#(RQG[^^,_A'PUX+_:%^//BN'2/#/_  E?P\_X*6?L@_$J.SUC1]+'
MQ3\6:#\8['PMX.E@L?';I]HM_ LVN:E._ANT>4):77A+4O#KE(Y4!U_C^(O!
M/Q6_:.M0U]H3?#G_ (*/_L9?M#:1X7N VK?#^^TSXM:9X7\':WXO\2ZA@G2-
M.U^_7Q/K&H0CYO#OB/P_X=NHPJ:H[4 ?#?B[1=1^,WP.^#W[ 5_\&_$_PG\6
M:7\>?"'[+?CG]H2#2K=OA)\//B-X*R_B75O!'C>)S;ZAXZ\6Z0M_'X:TEH@F
MHZ]JTDGBAI!\PZ[4_"'Q<^/'AKX5?L*_&SP+X1TKX%^'/VK-!_9-^)'QG\(>
M)[.Y\2^-KOX<:0VM6-GX)^&#1#4_"MKXBCTN&XO/$6LAO["&IR2V1UB+D?7?
M[044G@#XP_M7ZO9V:VZ?"K]N_P#8O_:/_P"$HT/%WX,\(>'OB#X;T?PAXOOO
M$OALD"YUZ/P^/$.J>)98XV%RNNZ3KJL;B,J$_:=67PA\7?VRO$5B]HTOPK_:
MR_8*_:>.O6-P^D^/+'0O&%MI'P\\3Z1X7L<!=8AETG3H(K5LD>(+KQ'XB\-S
M_N]+C6@#YTT[X5_$SQ9X\^$_[,/[1/CCPEX__9U^'_[<@_9:U;X>3^&;W0OB
M[XXT'P[X$U?Q9\)M9^*6L[UT*+1];T73]+UJT30-C>)-'C6VD'FG8.E^'OP;
M7X??'3X5Z5\1_B+X^\;?#;X)_P#!0[Q+^SI9_"KXAR:#KGP4\%^ M6^&GB?5
MO@?<SZQ8:*NM^)]<33M<\+>&/#)\3O)]B\3:G_84NR#!/J?[6PN/!?Q)_;1>
MX9K=/"?Q]_84_;#\.>'->427_BQEUK1O"6O7NA>+<FY\-:(ATW2]#O8PR)X9
MURVU.]!&A:RZ5T'[7%OJ?@SXE?ML7V@6VKQZII'B?]BS]L;P)I'A])/$?A1V
MT3Q1I7A;QAXH\8Z BR)9WT45C<W'B06RN]SX5\.:'KJJTL>  >-_"OX(^ ?V
M>/VFO"_Q%\.>'ITO/@M_P4E\?_ O4O$%OXA\1:KI%G\-_C=X%U;6O GA3PQ\
M.M:UJ30/"-MX:UWQ3H'A%'\,VT2+9Z.TX)B#%?/_ (K?#3PMX#^*WAZUTK2O
M#VAZ[\(_^"I/Q*L[V.3POI&G^/M2\$_M _"#Q7XLTN;Q5XA1/-U_1+K7]3UF
M7PNDC.(M LM,MU&[14!^V_VG_@C\5?%?Q._;"U;X6>!-;\8:YXPTK]B[]I#X
M9>+_  ;#_9E_H?BOP/XIBT#QCX>\+7CE-'\3^,&\$:9?^(8)YEW:YHVK-X9N
M-L0K@_\ @HY\(O&GASQQXS^.4=I/9?"_QA\5?V$_&UPVJ7>E?VV?B;HOBF^^
M'FL6^G68_P")Y;^'SX1U7PQ8E2XC/B:\UID.'Q7YKXRTGB/"SQ#PL;Z<*5Y*
MT>;F:H57))<LKRM=:*4ETLTI+W.&\1]6XBRA/9S@F^W-)+7I?5:-KMZ_)&K^
M(C\#/^"F'[//Q-FNKW1](^(&J> 4O]1>V_M#PA80:%K>H_"OQA?ZO;'F35[S
M1OBAX+T+PSXA ,UM"C$D*N1]:^*8IOA5\:_'M_;Q:9=+^SQ_P4[^'GC^[U?2
MKC^Q_'DOP\_:Z\-Z;X?U?PU:6.%CUKPY#XR\4:&?$ <M'XH.BW$$I_MW0Q(/
MDO\ ;G\*^$9;C]G3XE>/?&FI?#'P=\.?CEX;/B?XC:?;_;CX3\,^+&:/2]7O
M=(/RZQ8)XRLO!ABT"3Y-;.D*UQMP*_67XUR?LGW&N>*/&/CKP7\0?B;JG[2W
M[)>D_$/P[;O9:AIND>-_#G[-T*_$31-+\-W.CG^WO#_Q,,OB<:Z"CKJ\)D5%
MF7"1G\6^AAQ6N*?!3AV$_BR"=6C*[]YJ%6K%J5VGIU3VO9I-GT7B?ERPO%47
M_-%2T5K\T(OHK/==]CY)^+,,OP*^,?Q@%K+J&C6O[/W[?7P1_:;\'^%M9LVO
MO"\?PV_:@L%^&_Q,\6R>(H$DN-'TJ3Q5X@\>>(+N-54^'7T]#$,,6KNOB)\(
MOB9I7QT_:3N/AKX$U_Q#JG@3]KS]F#]L'X<Z]X!MSIVHS^&?&^F:1\/_ (Z^
M"/#D$H3P_JNKIX<\+ZYK?B)V4GQ*OBIX;C_B>GS:^A/%7Q^UC5-5^%VL_!WX
M2?#;6_%'[7/[%WB[QOX1U?4=7_MW55^(7PP\*Z/K/A/P5XLN;D'2O$'@73X?
M%T]O+>2?Z3'X@2>::+"ET\O\0_M!?$;XS:-^R)/H/Q6\4^!_"G[67[,WQI^'
MOBG4H]&-AI.@?'W1O"5AJNA:IHMO#C4]'\;R:[;>+'MM/CUTV\WA_356'<Q6
MOZS_ *^_4^!.[^*/[)_CH^.OVE?%-MXQ\)?#OP$OQS_9[_;"\&?\)_?:9>65
MEXT\"6.DK\7M7\12:2W]OZ)X%GTGPYI5K'&&\O\ X2:+5KC>=#<QFK\;M!_9
M.\%^-_V@?B!XO\1^*=4UGQ9X3\&?MP^'/"?@%9_#LMV?@#IL>G7_ (X^%GB"
M,'2_$OBC6FDAT[Q:+B,SR^%M;TJ-U*@N/G;1[Y/C9X4_X)T_%?XBZ)::IX>^
M/GP7^+_[%/Q<TS1/%VJR^)?%&L>+?#-S:Z+_ &\\TBC5])6;X?:[JMSIUV%\
M0>'/$VL;X79U8F/P3XG\1'X4?\$_/BQ\1]5U&/Q1\'?B=XZ_8*_:*D\5:,EW
MX>\+:9XQLKGP)J!\2Q?,MS?Q^,/!_P .M&L_%JN^BZ^MZ@NHU_M24@ _?OP1
MXTTOQKX*\'^.=,:*32_%WAK2/%%D\4L<P^P:YI,>K*-\19'="X24J2%DRA(S
MBN[ZU^:?_!,65=!_9QN/@IJ-UIM_K/[,/Q1^)7P DO;"4PW6M6/@/Q3J=OX=
MUN[T9@O]C/XB\,W&DZRNE1#[.P9)4+*5-?I90 4444 %%%% !1110 4444 ?
MB]\<_P!GO]K3P%^T1\7OC3^SQX)\!?&GPC\;?^$2NO%/@CQ;XT/PV\3>#/&W
M@[PWI?A>WU*Q\2W&E3Z=KW@WQ#H6GZ9%J%K(#/HIAD:W4$G'Y5O^SEX8_9=^
M-OQ @_X*/Z;IWC71_B5:I\4OA1K]UX7UOQ/\ ?"'B?Q3J.J:M\2_ /A+3[2&
MXTG2?%.AZRVFSZ?XBURV_P"$B\2:"OE-/G"C^O6LN]M;*^A,-]:0WL'.ZVGM
MEO$^N'#+[CJ.WM0!_'M^S]H'Q7^+^I:Q^R;X;US7/V:/V<_A1\2K']KC]G+3
MI?"$$?QA\1V&N>-]57P%X@T:P\6[Y+#P-X0U7PWK_B&WOM3T;7+G6?[?TDW*
MQA5:MVS^+WQ1\6>"OVHOV%/"UE??M#?M&^)/VIX/B#\>_B9?:_9?#SX<>(_@
M[;V?@"2[MO$][9<:#>?$+PQH9^&][H'A=-6B&JV^M>(G\N5Y%/\ 1O\ M"_L
M8_L__M-WWAS5OB;X1U2_\1>$M/?3_#7C+PMXF\3?#WQ=I.D:KYAGL(?$7@[6
M/#]SJ.D,PQ)H,[& _(0NX\_*/CW_ ()FZ5X,UCP5XN_8L\4:#^SWXQ\->$[_
M ,&^)-)\1^'KCQ]X.^*VA2ZG_:K3^.UN]33Q5>>*X]8O]0E7Q*WB)[EAJ4H8
MD\D _+SQ#^TAI&F_L_\ _!1#5?BGX5T+X5_M%?M$?%7PS\'(/@G)J4WQ"\>>
M'_ $'@/P=X0GO/"4^F(9O&O@W1_"5[XB^)_A30-,BBL[:[U*6*4I))M;WKP7
M\>O ^H>!/^"A'[4_P[\>:]JGA3X._ 'X;?LK?!?Q;I7AO_A#GCO--\ PW#P7
MNA7&FP2VGC&3XI^)SID^K3QIH6@6S"6WC\L,PM>)_P!@']H/]FOXWZ5^UYX:
MTB]_;-^(WC?0-?\ "_QUTS1HM&^'^N>'X)'TP^#]6^"WAO4]0^P6&E6&GZ;_
M &!XCL!K0UR\@\MQ,VXA?CSXI_!KQ_I_QRL?V@/VROACXA^#W[(_QOU)],\2
M?""?4)M;\-6GCSX>Z;IFE?"WQQ^TM#X&OO[$2YU@:CXKWZ3JFH75O9_V%H)\
M0-,46@#[S^ NF:3\)OB5X[\7V>G>#])L?V)?^"='P\\)B'6O%<?B/3+CXB_$
M6SUSXD>+]=L/$L,DNBZ+HL5S9#0O$.HVW^F^)GF<SIY>E0YYW]CS0E;XE?L=
M:3J;Z]KFA?LU_L6^-OVB_$=GI^D0^&;/P/\ %']I'Q+)K^G6$\("-K4K>$(_
M%5KX:T-XQ'IL&G)KWB#?=,BG\Z;:[T:_^,'C[]E_]E[4[?X8?L6?MJ7FE^&/
MB/\ %C3-%FGL-1^)'@OPYJDOB+X?_!+5O%,,6F3:EXNTD^&8Y]12+5] T5[7
M5DLHI&DVGU?Q5\2OB'\ /CQ\;?V7=&\=^-/VB_C7^V)^S_X+^%_PB^)GC3Q#
MHF@^)O@?HVBQ^.]+>U\8:KX/TG0M,;P_X?TZ+4_'.GSG1E\4^(KQCH<C_9R'
M !]0_LG:<WC#XA_\$])];&C:7J7B:\_:_P#VX=<\375])XS\3ZYINOZ_+X7\
M)0>*KJ;=I&B:C)X/\;Z1#-XB>-9=+N?"2^'?"QCA1]MCX.W>I?$OXB?LR7=G
M<^(]2F_:._X*!_M,_M%^*)K21O"/P_\ &7PI^!VEZKX1\#:KH]I"0VJZ2EK+
M\-M9LX9AN\2>(++5[R4%&W'QKP#\<_%O['GQ3\9V/[0&G_"_PIXWB_8J\+?!
M3]E"S^"GAS7O$>C?&'6O!6OZK$=$@\*ZW*?%EKX@BUGQ;X<N%TN29M-URSU&
M_P!?O=8#Z2F-_P#8O^,.D>"/B_\ "+3_ (V^ /'7P1;]D[]@_P ?:C#I_P ?
M_$?ARPM]7\<:SXGT^[\9>+/AAJ&A:@VB75M<V,S:)-:2(MUX?T"[T6PMHVE1
M=P!])Z=^T%\:=5^(\MGX5^(.L:)_PN/_ (*<ZQ\)K'P)I4I\3>)_#GP?^"7A
MH0?$%M%U/63+H6CZ#X@UKPU;Z[XWBMEVZ+HWB6;2X<^( S#N/B/^U?XW.O\
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M)]G^''_$CU-E'P8\"H-<T^3,87PH':/PU)9YW/KFL:9=;"L;&D^$I%W\,_\
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M1N,,AXR5"\&N9N/VH?\ @IQ^S_X7DN/$O[._PTT#P3X:@_TE],\+1Z-IUK8
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MQ9X_U/P?X=U-A+J>@^$9?&.M79\/61=1OM[<C52JE#+L.ROO,< #T Z]?QH
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MW)O)_AQXA\4^'7OYM.SDP6V@WM_/9>(!QM^SZ88-=.1B9JN?\%0?A'\5K/\
M:+/Q6^(6@^.OB#^SQ=#3;.U/A>ZNY+?0-.CTSR=7T20!9-.TG4Y=95I$ND@P
MX&\N1FNN_9;_ &9_^"6'QXBT^#1/$OCVW\:R,([KP%XX\6Q:/K,\W3R1:G38
M[6\=>@319(G(P2N<U\_B&L3C)*T4]HS<Y0::NDT]I7MJGOIW:/VKA_"_ZO\
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MX/-)[/T?Y,#^6BW^!'B3XS_'C1?CQ^PC\'Y_%7P ^!S:!XT^(/PH&BW'PN\
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MA4=@BDA64$@ _>C<O&67D[>H^]_='OUXZTNY?[PZ[>H^]_=^OMUK\SOVF?\
M@J5^R+^R_;?#3_A*->\:?$C6/B]X4A\>?#WPU\"? /B3XL^*M:\ S!FC\?-I
M/A6ROSIOA=@&QK5Z(6D965"S(ZCZI_9V_:*^#_[4_P )_"'QO^"'BVT\7_#G
MQK$XTC6 DME(MS#(([K3+[3KA4NK/Q!:S"2.ZCN8XYX7C=)55P5 !]$T444
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M<(H])00@-*5)49SBOF[]H/\ X)K?L-_M5:UX4\0_M$_LU?#WXM:QX'\(Z?X
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M  /:W>OW<7AS25O5TJV;Q9J.JZGKQ2*_>3 O-8U/4KAT7.4GZ#<0?G#XG_\
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ME?\ !16/]IO_ (*,1?#WXL_#?X-^%/@=X,_9]T_X@^(O!'A3XQ^(=2O/BO\
M$VP\7:18&Z&K^'O#EO=:%\/SJ \-I)X?CU/45U#3C*HFM$9@I^I[GQAXC_;M
M^*5C^U)\5=+N=/\ @UX-O+AOV//@IJZNVEZ5X;N<))\<_'VB3*;?6_B?\08T
M2X\-65ZFWP+X3%E!;F'7K^YF&I^U/\1F^%OP!^)GC"(1/KB^&;KP[X8TSS%M
M9K_QOXK8>'_"%O<W,K*JV^H:AK%I<WY+9BCMG>7"QMCFQ.'P>+PLL'C$VI:6
MMMOY=GO>_3R?K\/<0YOPMGV6<0Y)-4\XR2;G">R3;NFI7U:T>_3H?GW\ /\
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M<F658P#K_P#@YVLOB_IW_!*W_@D!IG[0 U0_'NRL-%L?BRNL.K7X\>VWP?\
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M@TZQMXHK.*V%I:6]G&8["RTQ2(U@A@(^9@1LVA2V\8(S7Y ?&W1Y_P#@H_\
MM*V/[/NC:SJ=I^R=^RAXHM_$OQZ\3Z1J#V!^)GQ>!\G0/A+HNLV[;IQX?C/]
MH^/+B%Y8K&])M[<B;*5Z#^UG^T[\0_'7P3^+UM^QV)K[1M!MH/!/B[]IJ))6
M\!:;XS\5:TOAKP9\.?@W<RJO_"P_B)KNNZO9Z1IU_IDAT[PMH\$FJ:I-/>HP
M'UI^R7^SSX=_98_9^^'?P;T#_3;O1M%75?%NN3 7=WXO\<WT?]J>-?&?B'4I
MO])N;Z;7F,CN=QW*6+8I73UT?GH_\QV:=K-/M9I_=O\ @>]:!H.@>&=$T;PU
MX9TJPT#POX:TG^S-+T33;2+3])TS1XHP[+%##@#9&1(V%  97/# GUS_ ()(
M^&IO&$?[4?[7+C&D_'OXMVWA#X;2GY3=?#+X&6*>!M&U9'QMGB\2>*;?Q%>B
M:,O#-'/',CLCAF^)OC1>^,_B;XE\"_LA_!.\=?C+^T&+Z"ZUVQ)"_"/X,K<F
M+XI_%G4)8MWDQ:-I[R:%X:AN#&=2\87NG65AY]G:L5_H>^#/PM\(?!/X:> O
MA'\/])31?!OP[\*:7X-\.:?%'B&+1]"B$5M,P55 U36X]^JWLP'%T[;\/@%B
M/:*, ]1FBB@ HHHH **** "BBB@ HHHH *0\@CU!I:* *IP <GKD_GV%?@U\
M5=>/Q7_X*(?&SQ'$1<>'OV;_ (0>!?@SX=RVZ)?&?C>Z;XE>-WC<91V_LP>"
M(945RZ&V42*K8%?NS=7'V6TOKJ5#)]CMYIU502S"*(R;5"@DE@-H &>G&17\
MY7[(=Y-XN^'?CGXO:G)NUGX]_&WXN_%W4V=L2V-MK?C:XTW1] 93ATD\+>']
M/T#PRD#*)8Q:2PLJ-"ZI_"7T^N,L;POX(9I@L$W%Y\U3DDG>S:3U6EK2=T^^
MV]OK>$<*L5F\;KX5\NFNOEMY'U6"2<]^I'7DUYE\/='?XC_\%#?V:?#9A6?3
M?@G\/OC#\?-:# D6.M:K;Z3\*/!C'C]TWV?Q3XT,)?;YJ:>?+WJCX]-_Y:\<
M_P#[59/["8M)OV\OVOY?$$RQ^+X/@U^SXO@>Q#86Y^%]QJ?CRYUR[ 8XD:+Q
MZVJ6%QM!\F&&R+[5N(M_^;/T!<@PF>^/668W&J/M,EC*5-3:3E/EYO=3:YFI
M-+12>NJUL??<:UWALH<5=IKEOOI:W;M>Q^VPZ#^G3\**!P /2BO^A/3_ "/Q
M0*K3NBPDLZ*,=695' )/+$#Y0"3Z $G !JS7E/Q=N9X/A=\3KBU;[-<V_P .
MO%]Q:W43 2V=\GA[5F$L3 AD9&8,)%P5RK@C(-#V [*[BEVNP1BJ_>8 D#;D
MMDCCY<$M_=P2<8..?N(90F\QN$ 1F8J=H5]P1FXX5NBL<!N@)K^)+PQ\!/B>
MO_!#WP[_ ,%*]4_:T_:??]KOX7>'I_'7P>UI/BQX@_X0KP=I?@WXS/X4TKP/
MJ/@L7']C^-+*ZT)8X?$NL^*8[VZU ZA.F[$;*?N+X_\ P+\9_L=>*_\ @F'^
MV#X8_:0_:'\8?'O]HC]J#X&_"_\ :+N/&'Q5UF]^&_Q,\)_&30-3UKQC90_#
MMU;PQX9%B^GA?#"Z38+_ &> J[4(W'Y/,L*GIM?;YM[:=WU[WNSH3_#U/Z>Y
M(I90&CC>1<JNY%++N;(501D%F)&U026_A!JK,CM((0C-,,XA )E& 2WR8+#
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M)FG\3>)=!U+5_"<_CC45P;NZ\4C2KBWL-8NI&&W^VFMK74)58A9?E5A]9/\
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M+PS:6TTA\K[/KUVZMM!Q[VP()!Y)8KTZOD@J/4Y!&!S[5Y%\=/AA8?&WX/\
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M$8&?[)U<G!/9@6QM;&#D'!KOTG 8$X"*6+XQ\JQ\R'_@ R6YX[^E<5Y1\/\
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ME'$DLIQ49.G+F2ERR4/><N5J7+RVO*+^+I8_K'\/ZYX,^,WPZT;Q#I<T6M^
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !110>A_\
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M)94 DTW7OBAX6.OP1AFS(QT"RU)I(U!98=TC@1*S#]1YP>" 3TZ#/KZ5^/\
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MIZ,,@$E%-\Q,9WICYN=PQ\C;7YS_  M\K?W6X.#Q3?-BW!/,CWL6"IO7<Q0
MN N<DH""P RH()Q0!)130Z$@!E))*@!ADLN=P'/)7!R.HP<]#35EB=F1)(W9
M,;U5U9EW*KKN4$E=R.CC(&596'# D DHJ/S8N?WD?R[]WSK\OE@%\\\; 07S
M]T$$XR*=N4EE#*60 L,C*@@D%AG*@@$C.,@''2@!U%0R7-O%$T\L\,4"0M</
M-)*B1) BAWG:1F"+"BD,TA(15()8 YJJ=7TD::=9.IZ<-'%M]L.K&]MAIHM
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M^MX5JVOX^6FGY:&^2Y[AL-FWU5*\+>].*O#?^9>ZNO6^C['R]\8/#.K^*(O
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M<YJ5G[\U+9_:DGV_O']7/#NSWV??LSJ/V"C<S?MZ_M,7=R'$&G_LZ? :SM1
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MAMM#\/6%[<-.S(-V[59;$JK&3;C&?V',J"Q^5I\0IY/*-/\ =1A5@W/W-/\
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M>,(/M'PU\(?;IM'B6*&/2 C6!U+P1+IRK]O^(;:MIDYD6&YA2+XQ">Y^&?\
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M%\KZGX?O-'\)>(/%DEAK']HB#0(/%FF0R6^I:0TEN[MX9EC>'_B?P"78^/\
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MS>>'X?#MJWFOI3?$J]\4:1H[:A#]E%U=-XFU5UN;K2[63XY;XA_%3]B[Q/\
ML\_M._M$ZWX=\=> _'?QM^+GQ"TSX6_"O0TTKQIX=^/O[1_A77!X:\.6WQ >
M2[O/&?AO4+VXL/#UN^HQ0V^D1MIC931;1&K[ _X)<>%?BO9_M7Z[I/[0GA;P
MSH7Q*^'7[/>H^)89](UR]\5WGC6]^./QDUSQ)XE\9:[J=W%'%I'C714T"UT'
M5O[)MX[;5+:2,%V'EU]@>4?T?#&..G;'3%%'^?\ .:* "BBB@ HHHH ****
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MVVWZMMO[VVPHHHKJ$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME1-@)'W-7YM_!O3?&?C+]H/3_B9X8^ 7B?\ 9[\':?X6\16/Q.'BB/3-&O\
MXF^)M3U")M#BA\/Z3<7UKJT&DB&]F/BF_GMKY1=*# L;BOTD'0=O;TH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M07'*@\L.F: '&:(*[F6,)%N$C[UVQE?O!VSA2O\ $&(QWJ2ODSX[_M=? _\
M9N\8? CX??%7Q.-+\9_M'_$&V^%OP>T&SL'O-5\2>*KB*&;4+E&&8K+3K*"[
MMI+ZYNBL=NLUN92JSI7U<9X%1G::((F_>[2(%7RMWF;F) &S8^_.-NULXP<
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M::@KPS7NGS7,#_9-4TIR3IVHJ!)'( 4<$ 5_+?\ LY_&#P3_ ,$5_P#@KO\
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M']J!M06YN+#Q'=?!WQ/'X=_9^L+XSJ$NX9F&G1HER?WNEW%R\(:+<: /2?\
M@K/X _X*D:C^UM_P17O/%WQ]^"__  L_QOXGTQ/@_<W_ ,/8=-A^'G[1+>%?
M"6J^/]4\76VG:7,=5\''5[VPTZQTNW7[5)# 54;U8#]7_P!MG]L[_@H/X&^)
MW[%G_!+[]G#7OA5KW_!0WX^?#&;Q_P#&W]HO5- NQ\-/AQ\/_"UU+::WXW\.
M^%MK/')K%UI^LV]K;7\:)<3Z?:VX#2WZ*>'_ ."_GCCPE\*?VT?^"(GQ?^(N
MNZ=X,^&OP_\ VM/%M[XS\;:PA31O#%E/#X&%M<:MJ#%+'2[686=R8KB\FAC=
M8)]K-Y+[?+/VX?CU\//V/?\ @LQ^Q=_P59\0:O;>)_V&_P!H;]F35_V9]3^.
MW@N/_A+/"7A3Q%J'B+4=6T?6[O6-)^VRIH6HG4=-:SO+-5MYA!J)B9OL\V #
M3^/WQE_X*Z?\$<4^'_[2G[4_[5G@?_@H)^Q[JWQ%\/> _CW86_PGT_X4>.?A
M-/XKU%-,L/%/@Z\T&6XBO+"UOIA:F"Z+(MPR6[HLDH4?.'_!;'1?VX/&_P#P
M50_X)3^)/@E\;_A!H?A7XC>-=:U;]BA];\'WFH3?#;Q5JW@WPA/XXU_XA-"L
MG_"3:7XGAGA;2+>%Y8[!'41E3G'N'_!<[_@HG^R[^V?^RSH'_!/K]C+XF>%/
MVH_VA/VOO'OPPT3PUI'PFU"3QG:>#?"EAXUTK7=1\:Z_K5FMU8:3%8KI5C)<
M:7=O#?PK/>--LVNU;/\ P5YO_"/[+'[8G_!O;K?Q:\5:;X4^'?P-\=>*/"WC
MGXA^(-L7A+29K+P#X#\,V-UK5[*\<6GQ7=]97-U;37<\*2K;3%,^1)@ ]>_:
M4_;%_P""C7Q+_:R^$?\ P2C_ &0O'GPO\)_M,^&/@+X7^*O[:?[6^K>$'USP
M=\/I+C28HI+?P)X U%H=/%SJU_<VM_9QWD@EGBU/37A&S3KTKP/C7]I;_@J%
M_P $BOCE^S99_MQ?M%^"OVWOV,_VD_BCHWP2U?XK6'PTTOX6_$/X/_$GQ0UP
MFFS30^'I[J"ZT)&M;L^;*ZQ^7!,#L:&0+YOXL_:9^$?_  3Y_P""[7C']KGX
MV^)K*W_8Q_X*3_LS> =-^%7[26G)'XA^'6E^+/",>GV\=IJGC.Q,\.BZ-J5A
MIEQ=VLLDR02VFL)/"6BM RY?_!9?]L+X&?\ !3#Q%^QG_P $W?V'_'>@_M$?
M$CQ[^U%\+_BM\2O%7PRGF\4^#_A;\-/!L]W)J&L:QXOMEN-+CN[D73.LJ7<1
M466)"AO=E 'Z$?MG_MT_M'_\$Z_V[/@5XH^-^L^&_%'_  3"_:*NHOA1-XOM
M_#5IHFN_LV_%>Z9OLM_XC\5V+27,_@&Z%I 4;4!%(SKJ2+(?[,M1/5_8Y_;^
M_:2_X*+_ /!0KXN77[.FN>'O#W_!,?\ 9;D?X<:OXUU#PY::KKO[1_QJC>ZB
MG?P3XAU![>[L?#5L+M/,N(T:$?8M-RQ?58!-XG_P7#^*6K?M1^(OA5_P1'_9
MRL=!\6?&;]J&;P[XA^./BS5;6'6-$_9U^!7AJ_M_MOC&_$37$UGXOU!;&>2R
MR+:Y,,:;& U0*U/_ ((F?$C7?V&/BE\2O^"(_P"T9INC:#\2_@Q=Z[\1?V8?
MB/9:;#X7T?\ :0^"6L:F\AUM9H0LM]XYTI;R.6]@+W-]#$[>8O\ Q+,( >K_
M +%7_!4;XG:]/_P6;\>_M0:MIMY\+O\ @G_\:/%NC?#RPT/2+#1=13P)X0TC
MQ3<_V'/+I\TS:EJ&H7]A8V%K>9=Y;B>*&/+,J'Y6^!%K_P %[/\ @HA\$8?V
MY?A_^V7\(OV//#7Q&TZ[\:_L^_LSV/P;M/&=KXB\)V@=_"H^(GCG6)4U.SN=
M?CM[9)FEBUE98[B(C:CH*^<_V/\ X'^*OVEOAI_P= _ /P&8I/&_Q'_:,\>>
M'/"6G&4JP\43VWB_4K;35E0F1GNKK3X(K>'#-)(X"J6( ^Z/^"5__!9K]@KX
M??\ !.[X2_#S]H7XY^$/V?OC)^RG\--*^%'Q<^$7Q&-UX8^(&GZ]X%L)M&$F
MB:&PBOO%[:MIFGV]Q:'1K.X::^E0+^\V%@#]4_\ @E_\>OVJOV@OV7- \1_M
MF_ ;4_@'\=O#WB75/!?BW1+O31H&B>+[G0WVGQ_X0L&07MOHVL??M-ZK;3CB
M#?D[?TM4.0<;XS_M>6^>V>"3G'J>U?EG_P $JOV\/B1_P4/^!'BS]H7Q?\#;
MWX)_#[4_B/XBT'X&3ZAJVHW^H?$CX:Z=(4T_X@WECK%M:SZ:E]M5H(PA@D4D
M1MQ7ZH]NOX_UH _E*^#TLO\ Q%F_M3IF;!_84\%#;F/RRJZ5X!(R>O!"D G(
M('0YQ_5<V['_ "V8X/*A%/X<*?Y_TK^5#X.2(?\ @[,_:G8.I6/]@[P7<.VX
M82#^S? $?G,<X6(2,J%SA0Y"DY(%?U;4 ?F+_P %5?V[+?\ X)U?L<>/?VA+
M3PZGC/Q]_:.@^!/A#X.N[C9'XN^*WC1VT;P;97 )5Q86\Z2:EJL<:EHK6&2:
M0*BEJ_&[Q9\,_P#@X\^'OP(A_;)@_;)^&7Q,^*=EH^F_$35_V%=%^!FB3>%;
M[1_+3Q')\/=!\5VLSZ]>:ZFGN+,&WMGU/S, :T1FOK3_ (.0O@M\2OBW_P $
M](O&?PL\-:EXWUS]FSX\_"O]HC5/"NC1237WB#PQX UN^M_$EK96,4<T]Y]E
ML-72YNA$C^3!:2ROB..1A>\;?\'"W_!.GP[^Q=/^TSX,^.W@GQKX_;P+;S>$
M_P!GA=1,7Q@UGXH'2XX]$\&:AX4B9M9L+M=87['K&I/8+:0V)WRE5"@@'G_[
M87_!43]KK3_"/[!?[-?[.OP=T;X5?\%!OV\_"@\07.@?&1Q<:!^S=HGAV(R?
M$;Q9XMM,1-?FU6.=M.LW2-/+C(;<58CYU^.WQ)_X+%?\$C_"_A_]K3]HC]L/
MX9_M^_LSZ;XL\(V7[1_PZ7X8Z+\.?&/@/PUXR\00Z,/%OPXU;3;F1)[?2_M*
M*]O<,$5!N*E'#G\\O^"KWA.U^._Q0_X)._\ !2C_ (*.? CXB_#+]F'XA?"7
M4_A_^TAX.^'?B_Q;)XI^ 5WXLU74O$GPU\1:OXCTF&R\3:?:ZM!K=O+KEJT5
ML-UI)HTV^166N1_:Z^ 7_!MY\%_ O@:U^!4OQ2_;9^+_ ,8?%OA_P_X"^ ?P
M8_:B^)/B+Q'XG/B&_P!,CU34-<,']N:1H3>'-/4WL.GZW:QF*]BDC,22Y* '
MZT_\%./$^E^._P#@K_\ \$!O&OAZY6_T/Q+KGQ%\6>&;HA=EQI?B#0=&O8F\
MY?DE22RFAE#*2AC97!92K'NOV./^5E'_ (*D_P#9M7P&_P#39X4KPS]O[PSI
M7@#_ (*H_P#!NMX'T/1;[PW8>%+7QUX=T/0-5U!=5UO1+'2/#7AC2HO#=]JD
M;O#=W$,$$D4MZQW%K:7"H%*K[C^QPZ?\1*/_  5+^9?D_9I^ K/\P^56T[PH
MBEN> 7^0$]6XZT ?TVT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4'D$?SY'XT44 ?.OQX_9>^ O[3G@P^ /VAO@WX$^,W@^*Y^V6V
M@^.- T[6;*TF(VEM+CN#'/I[;0JAX[M&&,DYQCXR^!__  1?_P""9/[/WQ M
M?B;\+OV.?A7H/C;2+K[9X>UO5;36/%W_  C3G);_ (1VP\3W=[8Z$^[!46,4
MA4CJ17ZKT4 ?$'[;G[2/Q#_9+^#4OQ7^'7[,OQ7_ &L-:M_$&G:0WPN^#EM:
MS>,(K+5O,9=>%K/&TE[9Z7?6EM!=P643+;Z?())0L81C^=?_  1D_9"^-?@;
MQ)^UO^WS^UM\,;/X4_M/?MZ?$ZW\6WGPY5(+W5?A1\)_#UNUEX+\#ZU=VT8C
M;6-2#SZKXC"+$\=[%:-<@/C'[WJJM&H8 \=_?KSUYJ.@#PKXW?L^_!;]I+P3
M<?#WX]?"+P9\6O",TWVY?"OC[PW9^)=)6;H+EK>[V6L5[P<_8[A9,-G:>T<O
M[./P.D^#VC_ 1_@O\.[OX*Z9HEMX=L?A#=>%=$O/AS8Z)9JWV#3H_#6HZ;)I
MMO:VP9@KVFG?;(W*G>2I)^@:* /D+X$_L-_L>?LQZMJ7B3]GS]EWX+_![Q+K
M0/\ :.O> _AUX:\/:M>G;N^:]TW3K6=%)^4AWL]V?GR,UW'QP_9P^"/[2GA2
M/P!^T!\'_ /QF\(FZ&JQ>'_B-X9TSQ)IMAJ8&!/I]MJNG:G!92%5 WQW0(Z<
M]_H6B@#YIUO]E?\ 9W\5?"#0_@1XH^!/PP\1?![PMI-MI'A;X::UX,T74?!^
M@Z;IMD-.M[72](N]*EL].VP,0GV>P16&XKNR,4/@3^QU^R[^S NH#]G?]G7X
M2? ^35PK:M<_#'P#X9\,7^JE?F^R7FJ:7IUIJ%W:JXW!+F2! 0#CD@?4M% '
MSEX7_9D^!?@CXK>.?CMX2^#G@'P]\8_B1;QV7Q ^)UAX:TM/&_BZQC.?)UCQ
M&+:XU"]LQA=NGJEJA.<H0,T_QA^S5\#_ (@?%#X??&7QM\(? OB?XM_"07L?
MPT^(^J>&=-N_&?@.VU0?OH?"_BI[6WO;*S !\S3MMTF[&$^8FOHJB@#P+X8_
MLZ_!_P"#FO\ Q#\3?"SX7>#O &O?%CQ5_P )?\3]5\+Z5%HESXZ\3!+\'Q!X
MDDMVD.O7_P#Q,9QYUX8F.YB.,(/(OB;_ ,$[_P!AWXS^/8/BC\7?V1OV?_B1
M\0H;R._C\8^+?A3X/UOQ'+?(>+C4M2O["Y-[V(,T#[,#& *^VJ* .7T;0-+\
M-V&GZ/H.CV>BZ+IME]ATO2=&L+/2]$T2P4?+;:?I5BD4$*KQB**(*.BA5&VN
MH[?A]/Z?T_"BB@#YYL_V:O@?IWQMU?\ :/T_X2^![3]H'Q!X>M/">M?%R+0[
M<>-M0\-Z<;3R=$N?$7V'S&T__1;'9 8RA%N0 =G'T-SCU./U_2BB@#!GL8M0
M26.^LXI[::WGMI+5[=)E>*[!&I65W'<!K.[M+H$!E=#'("P(;J/C.V_X)L_L
M$:;\2)?C'8?L<?L]VOQ.>\^WIXRLOA1X07Q!!J+88WD%S+8_9%8'^*.T!!^;
M.X5]U44 ><>+? GA3Q]X<U;PEXU\'Z%XK\,:U;K9ZKX:\3:'INL:%JT$6W"7
MMA=6\T-VEB%"Z>)8K4+@&(YVD?-_PB_X)]?L2_L^^*9O'OP6_9*^!'PS\<S!
MIF\7^"_AOX;TC78I2IW7*:C9:;!>073\Y%A%'(#@,Q!K[7HH \!\;_L_?![X
MC_$7X;?%'QU\*/!_B_XC_"F;5;SX;>.M<T:/4?$?@*_OE"WUQX7UZ[>.\T!K
MP[5W64,@D&2IP#EV@_L_?!_PM\8?&/QVT3X7>%M+^,OC[1].T+QG\3=*TB&#
MQ+XDT'0_L8T;3=?U<L+J_6T6PA6-(8& "KE=WS'WRB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #V ET# 2(  A$! Q$!_\0
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M\ ZU]F\7:G87EWH_C_2%&N^%@?$!T'6M!&O>)@%R?[#W'Q3@O@!CX.'BQ?\
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M5?\ A//^$';6S_PL?PB7#>(=%\#Q2 ^$61HM?/C0_P#"&JS^"_"&C\8/'?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !117E?Q.\'S?$/X?>+O NE>*M:\!W_BCPYJFC67BWPI=?8/$OA\ZS@?
MVSHC9(#J_*EN<AAPP! !:N_%0@^)?A?P=]G'DZ[X.\>^*/M6<G/@?6_ .A$>
MP+>.!VP<"O2J^"?AI\)_$?PJ^+WP_P!#U_XQ?%#XLVS_  B^.L<=Q\0+K2-4
MU;?_ ,+1^$>O#6VUU?#H\4-KY36T\-LG_"7KX*2+P]X<;P/X)\'QE@GWM0 4
M449 ZG%+R B"XR6X 'K_ (4NWD%>1D'K[^_/]<YJE=S^5$>>_I^/''/?I_\
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M44GBCPUX692%69%4[D;Q#P1^W1XY^(/Q /@[P1\#QXELCJWB>\;Q%9^+R/\
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M]LGQ#\;?&E_\.M+^$>H^$O$^@_#<>--7U7Q#=ZS_ ,(QI_B;6RC:!X,;6O\
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M/D?HWY_I]MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?..I_M$_"S1]&^+.NZIXJM]/T?X)G4O^%IW=W9:PO\
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M=?7XF_;+^-7P[^"GPO/BOXB_"[5/C#X?M=9TPWOAZTT70]26SRIQK3#Q /\
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M+*\+ZE9^.+O6_A ?%5A\'#^S,=&_X0O7-#_X27_A:/\ PT/_ ,+(./!'B/\
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MBW\5/VI?&W[(/P6O/''PR\.:CH7BCXD?LOW_ (\^(7BOQ9K7PX^)=F/^&S_
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MC[Q!X-\9?%"^O?$0NRVF^//C#KFB_P!O:Z-"09(\/_"CQ$-$\3>-MN1X,\&
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MAX9.#H6Y2?&#>#@Q)\>>./!P( ^E=+_:;^#WB;X#^$?VAO!U_<>/OAAXILO
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MT46/B#2-%TQ?"1'PST3XKY4<9\/MX;U[1./#!,>=<1@J$$UQ&F_M6?L_:SX
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M  5DUWX8Q_M!_"^?P=XY^!OASXW^&O#.JZ+]LU?6_P!@8>//"7Q1;6O 6O?
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M\;+[X[?%'5=/^(WC_2[_ %;2/A?JM[X.T?PZW@+P%K6L-K7A_1%_>C^VM?\
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MMMO$;)_PCOA;PWK>M^)S\N[QDFAMX(3P3X*8[Z /TKJO-%YT8'?^?K_6K%%
M'.:-X;T/0K4V^B:3IVEP$?=TNR33Q]1M)ST[G_Z_1U^77Q>^$_\ P4&\2_&/
M7O$7PD_:4\#^%/A$MZ%\.?#VZT?15U73Y/\ A!]!T0C7-;;X*>+VUS0/"OQ!
MT;6_%7_"*$[_ !FGB'Q-X(/CCP:#X./@['\<?";_ (*=ZAX8\)6?A?\ :?\
M@YX>\3VEUXG/BS5K/P(-VO'6_&>A:]HB:&/$7AKQ9'&OA/PZFL?#)&?PH-W@
M]CXX8^+O'/BI?^$/ /HSXE?"WX^^(O'4'BGX:_M 'P)I/_"/:7HH\/77@T^*
M-+&IC7CK&M:R&U[Q"/#1'BCP^-#\,R[_  C(UNVAD^!Y?!R>+?&+GS^7X$?M
MRF73H/\ AM_$%L-5-W=_\*'^&@-_G^P/[$'J.?[;W>^,]JY2/X6_\%$!I_PF
MBU;]H7X875SH&D[OB1_9&D?V7J7BS4CXTT#7"SZZ?AQXK3Q J>&M&USPT5\+
M>$/@^2-=W*K.%%8WBOX+_P#!0[4XO!VN>"OVK?"/AJ_TWPUX$T/Q+H%]X0T+
M^R]=U;1FUM?&_BUM</PZSF4OH83PJO@[P@K;?$ZEO!I,>X Z*;]G']N2:+PC
M!I_[;]S;'0;4B^-S\'O!G_$^U95U_.LMCIX>"ZUH0/A=RHQH"+G.!742_!O]
MLN?1[#23^UH9]?M;O4S<^+3\*_!>F?8ACP__ &&5T(>'#X;\0!?[$UM6WJN&
MU_.,'-<)\*/@Y_P4*\.OKUS\5OVB_ 'Q'OU\-ZK8>#S9Z+HWAKP]8^*/^$-A
MT;0=:\:Z0GP6'B?7HF\21?\ "321^%O%W@X>$?\ BI Y\8KXLV^$GZUX)_X*
M+ZQ8>(+BR^*7PH\.7-Q_Q)]'M)[1K_\ L1M$7Q G]LG'PY\6#Q$?%BG1  [!
M5;:Y\$ KXP\'>, #VS]E[X0_'WX6MXEM/C?\?M1^/D.HVOA9?#?B+6-&7PYJ
M=CJ6C-KW]O(-&0,H$BKH,BJK@EO^$@WC!"G[7K\V;7P+_P %%4U.W-_\4O@&
M=.!TO[6;:RUG!=M;UQM:4>9\.007\.G00F/E#CQ-'E7\6+XQ\'>L?LX:%^U'
MH?\ PEMG^T7XP\/>,[BVUK2K/PCJGA^SBT_[?I>=?UO7=7?'AWPEP/[=T3PT
M#'X3!!\/*,MD^+V /LZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^8S
M]DSQI^SE\=_V^3\3?%/[3_P=N?VA]+O3J%EX&U3X;_L;+\3=?U;^W/CY\*/^
M%8:%XX\/_#CP?\=?^$B^%/PZ^%FAELL/&3>"_$'AD-E2U?TYU^6?_#4?C<_M
MP:C^S[-H?PY\-^#M!\1>&-&T?^UOA5\?_$?CGQWI>N_##0/'G]LZ'\4?#_AH
M? WP\W_"1Z[KOA?;XM\6E@WA_##/BU< 'RO_ ,%:M2L?!'C#X(?$2#QEX*\.
M>,M)\(?%'1=*T"\^+_A'X;_$KXFZ<VM> /$1\&>!/ _B7]DS]HP_$'7O^$CT
M;0]BJ_A&./\ U*M_Q56!^\6G_P#'K;_]>H_]"-?C+^W/\*OVF_&WQQ^#^H6>
MGZ+K?P9N_$?_  K#PCX4TK]H3]J[X3:J?%'C?1= US_A9_Q4/[/H\( ^'/"O
M_"#Z[X:4>*O%WBX'_A(=VQ68K7[06@\JVMX>ZVRG]!_B?>@"Y17X1_M0>-OV
M[-*_:5^*,'PEF^/NI_"\>$? ]A9Z3X5^#97PWX"\+_VY\(U\=_$[P/XW?PUX
MM;XP?$-O#FM_%3_A"/A>/^*R\'^,M $B>!_&:,IKQ(_%/_@J>3;&>#X_97P)
MIE[JY'P@T;_DC>/ (/C/0\?#<9_;+/\ Q7'_ !:PY&0K?\(-E00 ?K?^WK_R
M;AJ/_9:OV2__ %K?X/U_'E_P=T?\G9_LJ_\ 9O6I_P#JS]>K^A/XM^(/VP]8
M_8_^!TWQ%\'>"[K2-3\>_LP7?Q5\6^-?%^M>"OCAI^JG]L[P V@I)\*_#WPV
M/A=?$9\-:'X';QJ3XP\&[?&>O^)A_P (2O\ PBJ+)_/9_P '='_)V?[*O_9O
M6I_^K/UZ@#._X-)/^3R?VF?^S8Q_ZLWP!7XK?\%@?^4H'[=7_9R/CS_T]FOV
MI_X-)/\ D\G]IG_LV,?^K-\ 5^*W_!8'_E*!^W5_V<CX\_\ 3V: /ZH/^".G
M_*N#^V__ -BA^WC_ .J3K^$"O[O_ /@CI_RK@_MO_P#8H?MX_P#JDZ_A H _
MT#?^"^'Q9^+/P1_X)/?L@^*?@I\3?B/\)/%&J?$CX#^&=8U[X8^.]8\$:C?>
M&'^ 'Q!;7](US7/#XS_PCSMHFB[SD@D9 !+$_P \7_!$3]KK]J_Q7_P4Z_9(
M^''B/]IKX_>)/A_XR\=^/!XP\$^(/C!\2]2\->+,_#'Q]KV=;T,^)#X7\0$>
M(S_PE&"",]1US^]/_!R-_P H>?V+_P#LL/P(_P#68_B_7\RW_!"3_E+=^Q/_
M -CYXG_]5CX]H _N;_;[_P""W/[*'_!/;XHK\#_B=I?C[Q)\1QX/\,^-6TCP
M[HS?V8?#6O'7SHA776<@:\?[#;,>TC)5E8%1GV#_ ()R_P#!57]FW_@I1_PL
M&S^!,/C?3]?^$UIX6OO'ND^+-%;3=-LO^$YU77UT,Z+KN=NOY_L#6C\J(F>,
M9;)_C,_X.E?^4H!_[-O^#7_IZ\?U]\?\&?\ _P CY^W?_P!B?^SG_P"GGXNT
M ?W(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6)K$5]/IE]!I<
M_P!FU VF+.Z.#ANH^G3KZD=^:VZ* /@'X?:A^T_\*-9^#/A/XT_$3P9\4I?B
MY\4O$WAB]N]*\'C3]1T32]%_9^\1>/=%CT36-"/A/PSSXA^%FN"4/X*4;/$:
MA260^7]_5\S?&?\ Y*Y^R#_V77QW_P"LQ_'ZOIF@ HHHH *#P"?2BJ__ "R_
MS_=HWV <& Y"\\C.3_7_ ":J^?[?I_\ 7K\\=2_;)\)Z%^UUXO\ V;]1U&YU
M+5M ^%?AWXA:/X1\.^ =8U#Q+KNJ^(-:"C2-$UYO$C>'==DBC&B^(P4\*1C'
MB)PWC4?\(EXO6/RFS^,WQ?3_ (*#>!OA9K1^$VA^#=3^!'BCQ1=^$[J^/B7X
MO6&J-K>-"_XGN1_Q/U\.Z+PN=J*/$P \8JH\9T?5\4WHK+U3].B9U4,NQ6)3
M:A91BY/1ZI=;6V\[6Z7[?KI14$/^I'T/\J.88?<?AU_K^1R>QH.5Z-KMI]QX
M/\0O%'B/P[K'P>M].M]+N8/&'Q&T[P=XE^TZ2=2*::_@OQ!K@\N0>((_^$?/
M_"0Z)HZ^:I\6.JD;@Q<L/?Z_-:T_:"M_COXD^"./A)\6OA_<Z%\=],4GX@^!
M-9TT'/PQ\><G6^F@D?VT K,I(' X)!_2F@ HHH) ZD#ZT %%8_\ :5A]K^Q>
M?_I./^/7/'TZ?TZ]L\UL4 %%%&0.IQ0 5@:AJ5AHMA<:G?7MKIVFZ9:_;+N[
MNR;'3[+3E!+%V/RI@)QD\8V\$*AWZX'QMX(\-_$3PEXF\ ^*K!-2\,>,='U/
M0]8TLW07[?I>M_+K*=R.9"!C(!+  ;L4 < ?%\VJ?&CPCH6EZY;ZCX8U7X7>
M/=9OK:QNM*OM-U#5-"\9> M$4AEY<JNMZRC,K;6PR  CRQ[[7QAX#^$/@'X/
M?'#P3X>\!^';?0K'_A2_Q/&#=:OJFI;C\2O .M #6=<+N4+ZYK;;6?S 6(+A
M0!7V?0 4'_Z_Y45YGK-WJJZII&BZ7?6]MJ.IC5KP7-S:#419Z9HI4DA68#<7
MUS1 I9L_,?F.XFN3$XE8>*TO=:>7;] -^#7M#N-4N=#@U2UN=8M1]LNM+^V*
MU_9J0,$KG.T$D8) P3S@YKJ 5XSG]?4^_OZ>OK7SS9_#/6]-\>>(/'T'BG3C
MXAU[1M*T:[%UHVL_V6=+T+<0!HO_  DNP-_Q.<_>X)4D@LIKG_%'BO6_"_BB
MP/B/XT?!SPGX?_X1O5;V\M?$&DCP[J/#Z&O]L_\ %0?$@8T!<$2#'RD[0[;2
M:X,/B,9K>,FGY/Y;KS_X)T/#T';E:O;LWK;RUW_X/0^HZ*_-GXD_MP^%/A?\
M7?V?/A:=2M_B%_PT%X[U+P3H^O\ A/1]6T_3=#U%4!&K#72?%?AGQ$I;7='P
M/#+GYG<D[& 'Z1Q2+*,\#\L?7MQUQQ^/IW\N*M]9TM:W+\[?UU,+>3MWL_\
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M6FI6&IP^?97MM<VQ_P"7BVN@P!'/;('XL1_33H **** "BBB@ HHHH ****
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M"K$ <L=NZ@#U:BBJ\TWE?Y_G[=.U&^BUOI]_I<._DF_N3_R*MPRK%YYR#_\
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M=%US7ET'6!KK^'3_ &_\.R^O:XJHI\'#QH2%5?&/@,@5][VGP*^%>C>,=/\
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M<5\U^#_^"AO[0GQ3^-'Q?^#?A7X+V_A&?X7CPM>W=V?"/QF\2ZKJ&EZYP/\
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M)?%RYE7PX2F]B2OC3]HO0_!?QG^%_P &;W2;FYUGXI67BB^T:[7^U_[-L/\
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M8.D>-='U?PWXFLCHGQ,\ Z$=^AN,J2VCEB Q8CD%BVVOLT\ GTKPW4_^3C_
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MO_#[[9^UQ\/K[5K'1=.\;CX7>.QH_A3_ (2/XE^)?[0\,G6@-=UH?%0>&O\
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MQ7JFM_"7]F;0OB_\4+WQ)=_$+]LO]FG]I'P,0-:UX?VT=</[2'A+XF_!\_\
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M1Z_X)#_MH?L":UJ/[2_PZ^)O[,WQ(/[07P3\+69\.>+/^%F>&_["TG7CX?\
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M7@7Q%JD?P[UOX9>._ GC%/A_\4_!5[?:1J&EZ'\3&\(^'_'GB--#\0^'_/\
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M0 *^!&_X3HO)X+^5?V;_ -K_ ,#^*O /Q1TGQ9J-Y^SEX?T3XV_&6T\7:_\
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MI.A:)X#\">-_&8'A_P")*>&]<8/X(ULDN&\9^,UT!_ G@1/&+,/!R?1OQ^\
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M+0%T/P?_ ,+*\2I-X[\9^$? WA-?B#XS\8?\(INC^XJ "BBB@ HHHH ****
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M(/A)I7PSNO&VH6GQK/\ ;(U:S&F^&/A+X7T/P7X U[0M;T/1/#X\6_\ "/\
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M >)-)\/?V?I.C>,V\0$:)KQ\-R>)=!'BMLCQN@8)XOCT/PJ@VKX3B5_.[O\
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MO"VW3M:T:]U3XU#XN?;M7UGYM<T?0V=3XA30%8;D,I5=XY! P/N:B@ HHHH
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M?4/$VNZ/HGA_P/E?#WBH^&O^$@\6>&]:T'PT" K>,A+X3R'9?"2+XS-\ O\
M@F-#J%QI4\_P*7Q%I8\2>&;W1KKXV$ZAI_\ 83?\5!HJZ,?B+G03X3&000I\
M& +@1%BQ]\T;]CWX,Z/<)-9Z#J-K;MXQ\#>-;+2;.^UC3/#6@^)/ NLZ'K^A
M:[HWA_0]GAM?$"^(M$AC;Q2 _C8>$9#X&;QFOP_5?"%>1>-O^"7_ .R5XV\1
MMKNK>%=:MI[N[\=7GB"TTK6&TO\ X2W5?'>LZ[KFN:OK^5)UQBVO:V N"Q5@
M=N584"&>'/V.O^"??B37;_\ X0OPY\/]<\46NFZ<NM6V@_%36[_5M-T@;]"
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M&_&8UB[\1:+IFEKX6\0ZY_8F@ZQ_;&6C;0/$VO;(A+N8$^82H!93S-O^U_\
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MM\=_B)^R1??"SQSIGBX6OQV\=(21J^F:F5'[)7Q?UTDZ'X@"^),;==T,E0@
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M ,]RQ1117I& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MXD\?Z3X1T?PWI^HJ-8;^PT70=!VA6'A]H_F)'7#D86OHVND6VCT?9Z,****
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M;^._QN\+>%?AFVB>%_%'CO2KWQA\0M6#>-CH7]B:-X?UT>#-%UK7_$8\3_\
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M!^Y06"^"0/"K*VC^PK/^U/:?LV0?$7QOH?@ >&-+^#XT;X<?![P0I\-^&/\
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MDE\EY&B.@SZ4445U& 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117*>)?^$B_
ML'4?^$6_LW_A(/L8_LC^U/\ D&_VESMW8^;&<_K[T ?+_P"TYXOT/P)XH_9A
M\9^*K]M,\,>&?B_X[UC6=6%CK&H_8-,7]F/X^@L!H"DD'..2P*A<8SD^ ? +
MPM\6_B!\5=8^,>JS'P%\ ="OM3'P4\#^'=9U;Q(?'@UYO^)[\3]<UT^)0"/$
MZL6P,^#2NO' 9_"7_"9^,_7? ?P:_:"UW4/AAKG[0OQ'\!>*]1\!_$;Q+XTM
M;/PGX<8IKFE:W\%_$7PG71CK>?",:C_BM]?\3NP\( L JL3M3'VQ!#;Z=:+9
MV=N+>VM@+6UM;8#Y1@$8!Z#G(SD@9R3FDTFFNZ:OUU37ZCNUU=O5_P"9^27[
M+/P.^)M[X[U#QO<3>)? /P/TWQAXH\9^#_ACK_A'6?#/CN_\=Z]K>O#7M<\;
MG_A)E(V[AX8)!\8^#?&?@OE,L1XS/MME\%/C!K7[0.LZCJOBOQ)X;^$&A>.A
M\0=)%IK6C,OQ*U/7?!>@Z&NC8\.^'?"7B/PZ/A3XBT,G=XK/C#_A-UU]5+''
MC''>?$G]G_XB^)_&NN^*O _[17Q ^'4/BK^RT73-*LQJ4>AG1/#YT;^R=&T?
M7?$(\+I$[+_PDID'@O\ X3,R-XE"^-"#X*'@WEI_V6OC=-F&?]LSXLG3QI!L
M"+/PUX.T_5 V 3K)UM0>>> >ORXSN\9?\)ESX?+L+AL*\+?1\S>_,[MW=_*_
MI;Y!]:DK/"\VEMW*VG>[[WNOP/#/AA^Q?XY\%?M%_&CQ[!XWNK;X=?%GQV/$
MWB;P_JH.GWZ-H2MKVA:WX'UWP_XCB\3:'XA'B76M<4_\)2 1X,(#+XNR2OZ#
M:[\-/!/B!_$%Q?66I6FH^)K/3;+6;K2/$>M^'M39M +ZUHJG6M!U]'T*-&"E
M6389/E8?(P#_ "#8_LD?'FUUBVU8_MG?&(#3=*-CH^D7=IG30%4_V\^O#_A(
ML:\?%CJ5P^T^"DVGP)ME_P"*N'0>,/V7/C-KVBZ7H4'[6OQ:T.WMF\3KK'B+
MP]9Z)I?B2\.O?V"HYT/:2?,&M>(PJ@NKO&I0 DAX;#X7"86V$TU=[73OU_K4
M[L1F.+S.WUMM<L5%:VNHI=K7>BU_S/IOXL_"L?%3P+<>!CXKUKPW878^QWES
MI3 F_P!,7 .C:UGJOS88\<]LN:\K^,WPN^(GC#X7V_P=^'7Q%O/",%Y9:5X8
M\1>.?$ UKQ)XW/ADI_8;ZSHVMH2R>)%2)"7G15\9>;XCC23P>\A\8+J?LY_!
M?QK\%_#VO:)XY^+/C;XTZCJ6M:CK%IXM\<:RNI^)1_;,\<NL*R%7BT NT8,/
MACPJ/^$2@&B@PB&25L?65=!P' >"_"L'@OPAX>\'6U_J.IVOAC1]+T:VU?5K
MLZCJ=^NBIM#:M*HP6RHR=Q(5OO*0H/>_P?\  ?Z4ZLV6""\BGAN +F"Y7!M+
MD#''89!(7.,#]<]0#Y%^,OC;X:?$CPG<>%M)\5>!_%RZ7\7O@5HOB_2-*U72
M/$;V.[]H'P[H8T76]%+LRKG0]>!0QYSH/B10%$0,GQE_P3A_9\^(WPX\<?M;
MS_$S1/$NF>%] _:#\46?[/EIXK&L_P!EV'@3:<ZWX('B##%1X=&A^%_^$G7!
M)T #[O%?HWX7_9]^#W@G6=0UWPW\._">FZQJ>KG6KW4UTB,:C)JQUG7M<75=
MQ&0PDU[6BI!4DL!\P! ]^H \)O/&?P>^'&O:AH>H>(_!/@K6-3'_  FFLV=Y
MJVC>'OM[ZVPT6/6]9+!5_P"*G.B$*^W<YT %V5DP8#\>_@5:LTO_  N;X76P
MNO\ 3/F\=^$0",Z$.IU_;_S&M'SABN->B.0)A5CQ[\"/@]\3]5N=4^(OP\\%
M^-;_ .Q+HOVC7]&34G32SY@_LD[RPP?[<UL@;0<ZT00X++7,S?LB_LSS70OY
M_@1\+3?D:IF[/A'1<_\ $]8G6SC9_$,[CGY2,*#UI-)]%?O9?G8#Q[X9>)/V
M>OA[\1/BAXO@^/OPEU2X^-WB1/&5K:6WCSP?_H0T315#'(\1'=\K%N.,@ABH
MR5\.\(:]\7-!^+_[1/C/XS?\% O@Z/@!X[\1Z3K'[./ASP39?![3O$O@3P(A
MU[1->T/6?&_B/PYXJ3Q 6\0Z,RB3/B\!M!\2[_\ A#PFP?8%K^QS^S"%N-_P
M+^%UV;JUT^TO#_PAVB WR:+I+:)&I&Q0-D1"$G!RN&+,=YFN_P!F+]G74[2U
MTN^^$?@BYTBV\.Z;X8LM'N?#JMIEEH^B:\VNQ:6NCG:FUM=UDRE I(.$#?+E
M\,/A[7O>UV_7?SM_6GES4</;_=M%=MW]=='^!X!^Q[^S7\#OAQXX^/\ ^T5\
M#_%'AWX@0_M4^)/"WC75O&_AS4/&7B'5-0;P_HW]BH-<U[7_ (E^+?#.OJS:
MQKGB9E\*>#_!XD&OLK*T7_"(D?;_ (<\%>%?"VJ>)]4TFP>UO_&5^NL^([I=
M5U;4/M^IA5T=3B4D\!1'\H!#%CL&T.C_ (?_  Y\&_#'05\+>!_#NF>&_#UM
M=->6>D:19_V?IUD3CA0.IXR?O<=L9->B5T'2%<OKUW=VFEW$^G6>IZE>V]JS
MVNEV+Z2NHWV!C@ZWA0<CYMS DYSN)XZBB@#X?TY?B_\ &FY\)P?%CX('X;Z?
MI?C#Q&VKV$_C+0_&>G:CX;U?X,Z[H( ?=&3))XB\;:O"1)X5\LIX?CC8!"P?
M</P#\(?#'X6:_I/A70]:\::_H7A[Q/>>&[?5_$NK'Q'KVI9US7M#T7^V]ZMN
M9BT:8!PW)0C ;Z\_S^=/+D].*/3S_(VHXK$06NB[6T:7E9GYX_ ?P5XL\5?L
MX:/JOQ&^'-MX;^-W_"-^*+&]\.>*_$?S6'B@ZWKO]A-K;:"ZJ!XI']B^*6&&
M9AKW'( ?V#X,_!G3/#?@3P!;_$70O"=U\0/"^C:9::M>Z5>ZOJ.D_P!JZ%_S
M%]#.OY<<X8DH1@Y#' 4<KKO[&_PSU_Q1J/BJ?5?B+IU]JGB;Q)XENK;PEXRU
MGP[IAU/Q!K*Z]KFX: L8UYCXB*D+XJ9N&# 9\)^"QX.Y>+]@+X*PZIIVK7OB
MKXQZU/H5UI=[9#6/BEK>H:78MHACV8T<_( ?[&QC#%F.%(,;@^=_9[O>^[[R
M[W'B,3]9Q2Z+=Z:;;67W+37\#[S^W67_ #^V_P#WT/\ XNC^T;#_ )_;7_P,
M_P#KU\!^%/\ @GY\%?"-YH$VE>(OCKY^A:MI6NJ]S\2=9<:AJ&BG055M=P-V
MNY.AY&X;2N2KML\(>5%_P[L^ 3>./"'Q&FU7XCW7B_P'XBTOQ/H]U>>,&U'2
M['5-#QM_XDH''0[L D<''//H679?<O\ (P/N7Q+X6T#Q?HVH^'?%.AZ;KN@:
ME:K'>Z7JUF-2TR]48)#Z.^2P&<D9W9(XW9-;-I!;:=:+965NMO:VH%I:VMN
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M[>^*/&6K^-OB#XPT?3?&VM:GXY!9O&NCZ'\09%#^'#_8*^)$*1MX/\8/H?\
MPG(#QERO.\OEK[STO?67KW+H9EC/K7UM7?E>_?=;=>W_  /F?PO^QKXM\9_"
MG3_@CJGC#]EW1KBZ^!7A;_A/;GP5\']:'Q+\/ZCK@&AZ*R[/B)X3\-R>'P-$
MUW'B4>#?"!>30%0>"4#%D]H^'?[,WB3P%H6C?LZ:7\1/V>_%FCZ'\+-2L]8;
MQ%\"-8U'XE?\(QKVL-H.@C6QH7QM5QX=\5$>-5;Q/Y8^;1%P#B0KWWPA\4_L
MQ_"&>]>^_:"^"GB/XL>.]9 \7Z_:^,_!>FG7/$S*/[<DT70E\1_\2%_$S>"2
MC1I*J-XNT)W#2/LC'0_#KXJ?LH^&[[Q!XATG]I'P5XC'B;Q%JVN66J^*?C'H
MWB/3=./C76_#XUK1/ NN>(/$7EGP\WB$:(=OA=E7_B?>&4*O&?"!5X?+L*W]
M;;;>UFWTTZM_DKG1B,\S;%+^RE)J&LK;)7NWV>J^Y:)+I!X=^'OQ<\ C0O@5
MX(^,'[/&B:/H/PWU2_L/#@^%GC/4_'&B:6NL:%HFA:S_ &%KO[1I?7M +?VZ
MK>)_%/F@^+PI7)8H*/A_PY\:O!]UX0^ ;?'W]GG66M/"&IB^\/>(?A!K>F^-
MK_PQ@:)HFS1=!^-:AE4N26"J3C!&5VCU7Q5^U)^RSX6\0I!XK^+?PNM?%&E:
MMJ'ADV5[K>C_ /"2Z#J@UG0] DT5]$#'Q)H>[7Y-$P#'@L Q)/EF/T^+X6?#
M.?QV/C!;>&M$NO&^J6NE_8_%IM&OM133%T3^Q0=$;*MHBOH)"ED!5PQ#[L/N
M[[);)+Y+_(\ZVMWJUI=K7[WK^)X#\,-!\5? [Q'\,?A!!XV^ 5MX1NF\3_\
M%O=)\'>,_!'CDZ8N[7#K'@8^(OC9\6#XB \2ZYHW_":;P4;=YBG!X^[:^8-'
M_9Y^'&D?%W7OC??0:EXD^(VI+]BT;5_$ &HCPGI0!QH^A9P%&X;@Q#>+BN,,
M0>/I^F 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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=5 FWGJW&6&.2< T44 :M%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "  ED# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BD/0XZ\
MX^O_ .NEKAKSQ!X:T&40ZCJ^DV%Q=O\ :1:ZIJFGV3$?V@ .9'&,ZI?K&">-
MV$R3D, ?G3JO_!3+X!:7XFUKP-XB\(_%#PGXSL_BE8?"W2M!U32O#]E?>,_$
M6I:M_96DZOHVFQ^+A+I.A>(M96__ .$=UWQ$=#C94.N[3'P?.O$O_!8[]GWP
MS+XDBO?AW\:IKGPUX[A^']Y:-8>"_P#B:ZK(?'</]K:8R^,65M C;X;^)R\P
M/]O8CTMO^$=;^V 3]Z']DS]FS[7XLOX_@=\/4O\ QP;R3Q3J4WAZREEU>74S
MJ;ZA+J$CDR1O%_:6I-%)$R>4=04Q;2,C'L/V.?V7]*O-:ET_X&_#@-XB-_)X
MHO6\/6$CZI+J6FZII.JM>[BP5M6TOQ)XB\J140I_:FJN) ^IB@#SK7?VX?A/
MX4\"_M ?$#QGX>\?^$;3]G"]AT_Q+8:OIFG7FN>+7NM-35M$U?PGHVE:U-_;
M.B:Z)0OAR36_["9F+,8]& ^5UQ^V[\.++0?B#XS\5^$_B1H&C_#7XA>#/AKJ
MUT^@:=KBZI?_ !*U#3-*T+6-(TKPIK.OZKJFC :K8ZS+H)!\0KH.HZ9KS: Z
M:GI!KV@?LQ?L^IX=\9^#1\(? Q\(_$F\FU;X@:)=>'[66S\8:E>A1%J&K22"
M1[_4HDB58D#?NU)$81E0TW0?V9?@)X:T[7O#VB?#'POI6B>*?%FF>-_$&D16
M5LVG:OXQT74!J>CZNP>7*ZO'J,4.I1X/RI''$ (PJJ ?-_Q _P""AOP)\#?"
MRQ^,/AZ;QI\6/!MW\2U^%-I<^#_#\FCR7WBIM.U34=4TK3#\0!X&TK6DA3PY
MJ32IH6KS./$&WP\JF53'7C3_ /!7G]F_0M?U:+Q)X:^*?A:RTWQQ8?#ZYU'7
M=(\.6%E)JDE_XZL-1\2II1\7MK6DZ)X?/@;6$\4MKFB1ZY&=3T50CQX8?HMH
M'P6^%/A+2/#7AGPS\/\ PKHGAWP/XAE\5^$=)T[2K"#2=#\5:T=6L-4UO3(Y
M5D0ZSNU75G=R P?4%SER"/.KK]C+]E36]0\47NK_  '^'FIZGXMUG4];\17F
MJ^'+"]_MG4]9.K_VOJF69RKZX/$WB!F8;<R:GJ3'&T* #S;X,_MW?#3X]V]Y
MKO@[PEX_T/PKI/A;^V=>\>>+;+PWH'AGPUJ*^#?#7C[5O"NJD^*V\0_VYH_@
MWQ'INM_+X<;075@J:^)3M-KQ-^WY^S#X:TK2[Z?Q3XHN;K6K;PIJFF^'X_ ?
MC6S\777AKQ;XD/A/2/& TC5]%T;5F\$+K-^H;Q  8@K.ZLRMA_9=#_9Q^ OA
M;Q)=>*/#?PJ\!Z-KUUX>_P"$/U'5K+0+6SNK[PSY":0VD276_P AF>'2]+@<
MM&9&@TX1%C&P5>2L?V/OV=K'Q#/J4'PT\/31-X%T[P!:Z%-8VDFA:?X8TKQ0
MWBT:5I=@S-,%;7!IVLD$A573-,"[0QH \QM_^"AW[,+:I9:5%XP\03'5]-/B
M""]C\!^-+N-_*ET?4--TK3+#^QSK>LG7-)\1:;K?AL:+H3@Z!NU^218R2";_
M (*!_LP_VE'X<T[QQK-]>WNLZYI4MQ8^"?&VH";Q%HVJ^%()]$T_2;#23K>J
M:SXA;QKX=U7PY'H4>M-_8&IZ;XA(71"Q/KH_8Y_9C5+/3%^!GPW73;(WLL4/
M_",VXMU.IC25&'SE%1?#>E1KL<;(].TV.+8GRTV+]CS]FG[1>W$GP6^'T=SJ
M]]J&HWK1Z':(TVJ:EJ&D:EJ.K0N"LD++J.C:.JLA+(FDZ7$K"-$4@'FOAW]O
M;]G?7_']_P##Z77=:T#Q#:>*-,\*6XU_PEXGT[3M8U[5_&WB;P!I'A72-5;2
M"K:^=<\-ZD&T/"N%/S<#6!I7W[7R3<?LH_ FX\3^"O%MKX%T/1M2\&>.CX\T
MO^Q(+*TLK_Q+'_PE3Z3JFMDX.J,NM>./$>O1.AWCQ!J(.XL!7UM0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 (>A^A]?Z$'\B#[BOSQ_:$_
M8B^'OQ^^(DWQ)\6>/_B/X:UN;X?Z9\-KG3O#5_I4NBWFAZ+XK'BX7BZ5JFEZ
MP4UJ1;[4]%,FQ7 U!)@?[>MM'U$?H?3=JYSM7.<YP,YRISG'7*J?JJGJ!0!\
M=_"_2;GPU^T)\8/!]GK_ (YOO#TOPQ^#WB^/3?&7C#7_ !>=+U_Q5XE^,$6K
M1Z./$^H:H-$A>'1M+4:!I#'1D&FX^3[B?8H4 8P.V>!S@ #. !T ^G:OFGPK
MS^U3\:<\X^#'P"(SS@_\)/\ &WD9Z=3^9]:^EZ $P..!QR..A'0CTQ1M7T'!
MR.!UZ9^N.,]:6B@!-J],#&<]!USG/USSGUYZT8'H.PZ=AG _#)Q]32T4 (54
M\%01G." ><DY^N23]2:0JO)P 1GD#D< 9R.>@ ]P .E.KAO%'BBU\-Z<UU+%
M/?74UPMIIFFV@+7^H:B256*-/=@ >"-O/H*Y<1B%ATM+W5EOH]E^@UJ;XOX,
M&$S 3$$ '!)Y';)']./45Y%\7M1L=+\*C4KSQ$?"T,'B'0!_:@U--& \W5=+
MTMT)E/*.S;0N,'CC)%?-'PP^,V@>)_VA_C)X"\+>$]#3XF>%=(\-MXTTB3Q
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M2OC+\/;#2/B3X9NM:UGQO\6O%WCS1;IDL=4TO2-)CM+RWLIQJ$DNHHXU??Y
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MVJ?"K7OA7INE:[$L>FZ!IFIOH\G]HV<,$ZW-Q>(/#EKMNVD:Y4W$NR5?-DR
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M$$;*:WP]#5JSND[WV6F^^VOZ;&^&P.)QF)^K06C3>GDF]]^G=7_ _H<!C &
M!CI@=,]<8'?OCK3MZ^OZ'_"N3M-:MM0T*WUG19K?6(KW2?M^FM:72O#?H4#J
MT6HKOA(?(7(!*L2#C%<M\/O%M[XW\,VGB*\TB;07U&W?&E_VE::A=KL;:2+^
MSM+&$' S@#..]8=;$NC)-K^5M/1]&UV[Q?W/70]7H/0__J_7M2 \ GC@=?\
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M;TRWNM8T.UAD_2K3(XQING (I'V.SQD DB.!6C))4$E&^921D-\PYYK\M?\
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M(=D#\$ C/\._#RXT3XE>+/&[^+-4U>V\3:?I%HWAVYBMX=*T9M ,ITI;&X1
MTV?[5O6RY;E4VX,8%>RE5/)52001D X(X!Y'4=CU':M\3B/K6*4;W223NVT[
M))[Z_?=W;;=SHQ.);U;;T26LG:WKKOKJGOYW*EI:)96EO9HTTT5NH7?<S_O"
M%Z!VY+$9R<_B3Q6I2%5/4 _4"E/0_3_/I3.<^(_VQ_V=]>_:<^%-S\//#_Q
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M?O/71)+Y^M/V%_"]IKJ:AXZ^,WB_7M)M[[3U&F#7;JQU7518^!?^$!T>QO\
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M:6B@!-JXQM&,;<8&-O\ =QZ>W2DV)R=JY8Y/RCDA0@)XY(4!<GG: .@Q3J*
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M(+C$L2JYS0!^A-!Z'Z?2JL \F".%F+-'&J!F)+,%4*&)))RV-QR>I/)JUTH
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M:SBU2[U"-4A3;'Y97 +$5]'^+5V_M"?!88Q_Q1?QC)X R?MOP^^8X[[3]X=
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MDY+FNGR\SYK2MO:2DDV];K>R;U/0N2/?'ZX_'O\ 6OS[N[+PO-^WSHT#^#_
M>H:UI_P1F\03>,7T759OB'IFISZK<:*;.TUMK]M'L=(?3IKV:;3(+&*ZEEU-
M9V#&0NWZ"=N!VX!_0&OS1EO3IO\ P4DLI=1NKG3X]?\ V>)8="M=6OFET[6M
M87Q*L<S^%[&RL5CM+B,:7)'JLUY=7$EWL9=/9<$5Z*V///O*/X:?#I)H+E/
MO@Y9[=X)+>=?#6CI-;O;>6;5X)EL!) ]L883;-$R-;F&'R2GE1[?B_\ X)SW
M%K=?!SXER6C0- G[4O[2B(;>*2((O_"T/$V5 FY4#C;C@=QS7Z$._P G?<01
MC!ZX/3OU_ES@U^=__!-:VGM_@?\ $NSN00]O^U-^TQDG[S _%_Q..3SN^4!>
M>W&,<4 ?HK1110 T9V\]><G//YU\\_&N[O-3T72?AUHUQ*FK_$W6XO#)DMYI
M8Y=,T&?S-6\4:]]H1U>!+/PQ::CY,JLOEZ]J&AVJLIG0'IOB]XG\0^"_A?\
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M+=UU@Q2*T#8^3?!GP\\9?%C]N?XS_&:?Q/XR\/\ AOQOX!\(:9\.?"^H:O\
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M9)I-N23M+F2=VGUL[:;'J5\/B,LQ3PLH*3V]Z";=EHUS1;W>CVTNKM7-O0?
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MXTG0+N_\+Z_\(O$VJP3Z6EMH[>#=<L2T5UJT5IJ.9H_$"G;::9/=W*@G:C0
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ML_B-K=KJ^DP:AX:N=5FL9[_PQ?EX]3;0YPZO)J$*QVC17%PY=&F<V)U"\/\
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M]H'X&^ /B!^TM8W7Q@\96FKM\/K!;CQ%J%AJGGY%VT_B+0/[-\-^'OM '/\
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M/XX\1/K&@:?9>'1?I8B\BO=42UU6^@FFD"M<V^FRW=T+,DJK6RN0%4L/8/\
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M]-.BRW4NF>.+NS:4ZEN>^MKU5;S?#]\901E?LX_MO?M9?%F#XP2_%7_@G?\
M&+X*6WPT\;ZEX?\ #LNK?$'P1IQ\9>%K .;#68AXVO\ PX]S]M0EGFT!M6L&
MP#'JI.%/Z4>$O$(\3>&-$\21PZA91ZWH^E:J+2ZDMWFTUM14,^FW)B;:;K1V
M;;?G+?-\LC$#CE?BG\*M#^,'A&7P?XGOO$6GV37=G?Q7_AC4YO#^J13QL0L$
M-X\CRQQGG?$CHIW8P-N#C?!KX.:#\&O#4_A'P[KGB_7=/N]7EU=KSQCK<7B"
M]@DN/+-Q9Q7"JD@@G:RD$L0/E.SOY@)9J /=9I%2)G9AL"D@AMNY@.!N)XR1
MU) '4G S7YN:Q\7/C;/\5/@KXAUG]FWQ+>7UOX.^+RZC:Z#\2/AFEI!'<:QH
M5EIQ\_6?$.E>7Y^EZ>EW"KLBZO\ ;9FT)M3&GYC_ $&US3H-;TK4M*NY;JTM
M-0L[^PGEM9I+>[BA*LOVFSEA97AF0,0LD>&7CG@5\-7G_!/;X1ZGJ-I?WGC;
MXT3"QT[0]/@N(O']E!#)::/@Z6?L<>A^65TP6EJFG,5S:+<:F+79]JN-X!XK
MX4^,_P"V?I7B;X[WEI^QM:7FG>(OB))XA\.SZU\8? _AVX.G1>$=%\-.DPO+
MJ:TU'4M+TWPU!)??V)_:NANUVPDU;,CJ?BW]HG]GC]IK]NB'X.^/I/V:_"GP
MRB\/^*=+^*%_<V/B;X6/XD\06-\L$SZ/KEM8>)$FO=4TNRLX;*RE\5?8GM-1
MAOC"8Y'F#?JW\9O@Y\(O#GPRT_Q3XL\2?$71O"'PC\->/3:3>%=3GOM5?2/&
M5G+IFOV,UE#INJMK.I26=W+9Z5(T<D]O?RVCV^V5$*>)_!KXF?L4?L[:AX@_
MX1+XWZ_KNI>)+71+363K>MZSXOM]'M=+:YFTBXU"Y;2%&@W1;Q)&VMSEYFFG
M9&N][K1SXO6T?5ZZK_AO\QX7&8K#8O57TTN[Z->=]=;?CY'9^"/%'C7P7XC.
MFG]EKXG^(OB#J&AW&JZEX\\0?$_X$37MY#H\VGZ//I/]JCQR=-T626_OXXFT
M71[:""/3,RS12:@O/!? G]L3]KKQ5\./B/XR^,__  3T^)7PCO?!7C;QOHFC
M>&K'XN?"V\O-;\,>&I2-/\06</BG4O"E_<M>H<:'#H6EZOIFI_*-.U'520#!
MX7B_8V\0_%"_&C?';Q1K7B*WU!?B FCR^,+F/2;:]M_%3_$;-@HT)(;I;(>#
MY]5U_24!CLO"TQN-<BOY;^SU2W^A_B=\9/V9OB"G@W0=:^,EIH-[I'BO2?%G
MA2'1-;&EZC>ZWX=#M910I=VTUI>:;,+Y<V]ZC02$1X4; 0+166BWLM%]RT_
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MD<=Q<Z3I6K2;H+Z[T(UD_91^("7/B"ZM_P!J;XPF37+5+>))RY'AN2-BJ/H
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5M0$*N0 =JAF"CH 3@#)I]%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !W ED# 2(  A$! Q$!_\0
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M1^(O#(;>?%2@U=._;T^',?@OX<^./&O@CXE?#[2?B9XN\=^%[*2\L]%\3QZ
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M4/['T5X5UO1I- \/PMKZ^)E<7$OB?Q+-XKN&"*()#\T<GUU2 **** "BBB@
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M"U;0]'71-;1-&)7Q)X_U_P#X2"-PZ^$T;P<P*L?':&,EOJ'X[3"#X6>)]-B
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MW2+NU_X2P,_CCQ!J+&37!K'C361(!K91G5_!WAHH1X.C&U@VU6C]\UFSL_\
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ME.!L;4_[(_X0;P1H^M#=QYIU[7/$H))(/@-3A\*&Z3]GO_DA?P8_[)5X"_\
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M]NS]N_Q[;_MB>'?VAK_XC^/-3M-(^!.J_P#"R-2TP>*-:UU#H2:&&SX:\/\
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M5?#[6"UYHVF:7>:9XWT5M 9M&T)O#:CP_KZ^'0@!1V+%L^._^$Q0>97Z&44
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MSUU_X'R,7AJC3?)/7^[+?7KRV\_^'1[1J^I6^AZ7<ZO>G[/;:;9:E>W1&",
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M^R?B7_:8/]LDG<=QSC/J1D@@]ZYV71/V^8=3M;C_ (3?]G"YL(/#>JV0LO\
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MVP;OP]X7FFG^">F^*;C1?^*CM=6L];Q_PDQUO7F.UM X'_%/#0]P7[JCQ("
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MCD'&X@>]T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%)@>@_*BB@!<#T'^?_U#\J,#T'^?_P!0_*BB@ P#U&:*** "BBB@ HHHH **
M** "BBB@ I,#T'Y444 +1@'J,T44 %%%% !1110 4444 %%%% !1110 4444
M &!Z?Y_R!^5&!Z#_ #_^H?E110 4444 %%%% !1110 8 Z#%& >HS1118!,
B= !^%+110 8'I_G_ "!^5&!Z#_/_ .H?E110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "G ET# 2(  A$! Q$!_\0
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M(!^L>C?MV?LZ:CI/Q'U.^\2>/O!?_"K_  %J7Q,\8^'OB?\ !+X_?"?QQ9>
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M@?BYX[\>KKFAKX<C\4:%\0_BSXA^*K^*$:3P<1XR;0?$K^ T;8J@ _3SQ/\
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M/%.N>&CXH\.Z1\3O@3\>_@KJ/BSPR%0C6_!'_"XOAOX0_P"$]5?[95\>$/\
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MX^Z;]O\ 'G_"9Z#_ ,CQ_P +?^)'BT'XRC_B>#QH?"7@\_\ ,S=>"0#^G?\
MM=3_ ,L'_2K\$T-W&)H>0<X.,'O_ #K\$/!4/B3PK^W)]HTK2?%OCZYU[XO:
MG_:]IXAT?XR>"OB9\-/#&N:*!_;?]MK_ ,)=\"OB!\&?^A*!_P"$-^HR:_>C
M3O\ CQM?HO\ 6@#1HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***K33"*(S8Z8S[@_\ ZOPH LT5G_:QYN,=L>V/_P!?;],T?:QY
M6<=L>^/_ -7;],4 :%%8_P!L\[B VQ_S_CZ?3O5B&\\[V_+^O^>M &A1110
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M"3_A]>]6J* "BBB@ HHHH **,@]"#10 4444 %%%% %?S_;]/_KT>?[?I_\
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MA+H&BZUK9V[7.O:[H@)7[K-@F15 ;P#Q)^P[\0/&&F?''7/$?B_X7^%/B/\
M%GPW\+=%L]*^&/@_5M-^&5A_PJGQMH/CK1-:US+CQ1X@\1>*/$66?(&5.(][
MY0<C\0O^"?\ \3/B3XN\0>(O$?Q&\%ZE<ZK\5OA?\6;+Q%=V'C34O$WA(^!/
M&>@^(/\ A66B:(?$8\+_ /"-XT+ ;CQCNPJL6(% 'L_P9_;DTGQ)K7B?P?\
M$WPYXLT34;7]I#XH?!?PYXWM/!^L_P#"M-0U/0?&FO\ _""Z+_;A&?\ A(?%
M?AS1,_4XS@G-#X6?\%"/#L_PK^&^J^/]#\2>(_BAXR\!ZK\0?$GA/X9>&_\
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MCX:O]+T31_#^W6=$'AWQ%QXA4Z)MSR @#.V=S4 ?I!\,OB#X5^*G@SP_X_\
M!U[_ &GX7\4V8UC2+O!Z'J/R)/?'3WKTJO!?@)\,8/@Q\*?!_P ,X;C3+C_A
M%M'^Q_\ $ITC^R]+^7<W_$FT4<A,CD].H((.*]ZH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** *_G^WZ?_7I#+G@Y_(5GWEYY'T_
M#G_ZWKVK(L_$EC>#_1Y[6Y_Z]+S/?GC(^O7^E<F(QF#PC49RIJ3MISQ37R<T
M_P $;J":NHW\TFU]Z3.H\_V_3_Z]'G9[?I_]>LZ&\@P?/QSZ\^_2E\_V_3_Z
M]=*G%I-2BT[:J46M?-2:_$Q::W37JFOS2+WF >OZ?X^PJ'S_ &_3_P"O6-J6
ML6.FQ>?//;?9_P#(SG_$XQVKP_Q'^T)\.M&E^SPWYU/4/^?721_:)_$CCCT
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M=4^"'Q,O1>:O\,[;1ETWQ/\ "?P)KFL[=$US0]=  \?MX5']B?\ ";X 'S$
M 8%?L!9ZO#/:VT\#6US;W5IFSN[6[SIM\",?+Z9SU(;&6&?3F>(BNJ_#_,Z'
MAY:6OKY-_HCP+XW_ +4?PC_9[BM6^)>L7FFSZF-1O-$LM*L-6\2:I>Z7H9+^
M(-;_ +#T*,S?V!X9!"S[V+<9 CD+.WT%H^NV'B31].UW2+@7.G:G9Z?K-G=6
MO/V[3Y"'XY'3YN,CAL#'-?AI\0?&WB3XD>$OVA_VA=,@'_"8?M$W?_#*_P"R
MQ:77/V#P+KNM:_\ ";P/K0]1XK\1ZYKGQV\; G/_  A8\,9_Y%+-?MSX%\':
M5X)\$^%? VEY_L?P;X=TKPSI0N,9.GZ%H\>B+D]E"J0V>JG'3!I8?$7\]7^O
MEVOT\][7*Z2:_KOO^!W]%%%=1SA1THK/^V9[_P#CM 'YS_M?^//'&@ZG\/\
MPMX6\2:EX2M_$]YXG%[XATG^Q1J?_$B!_P")+HG]O\9XYQQZ<"O#_A[^TK\6
M_AA<VX\4ZKJ/Q1\#"['VNZU7_D>+#2ATUK'3Q .W YK]'_BS\(/"OQ:\.:AX
M<\117!^TG[9I-W:'.IZ#JG3^V-$(/!!P><GU'0C\L/B=\*_B;\&3<3^(X/\
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M_JWC#PYXMUS^P/ 7@3Q1\;/%?@GPXVH^!OAJ=>T7^WA_;I&< >'<^*,>$U;
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M_P )9\./&WCA<J0C/_PC;;<X"_/_ ,9?V (?&OQ+\4^-_AU;?#+1K?QU\.?
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MGP]C6]"\3Y]-> S@#'[7P5Q[G'$.$_X6<I>1RTO>^K?KKJ_SU/D\RX<^J/\
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M17SW\'_CMX'^.?@VW\7>![W:!=KHGB/P[JX&G^)_"?BA=K:UX.\;:)N)\/\
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MV@@G_P!'NO$7POUJ\M/35/\ A#?[ _\ <'H?;_ZWTAY_M^G_ ->OD_X-3?\
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M1X^US_23H-G_ *'I6/\ B::]J@YT+1?P\15Q_P 1_CE\)/A!I?\ ;GQ&\?\
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MXL]>A/IS7[3^"?V+?V;)O ?@>>?X2:)HFH77@_PO]LN_"=YK/@G[?_Q)N/\
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M'[/7Q/\ ''Q'NO% \1_V)K>CZ7_9?]C^+/#VCZSINF?VI_S'=%_ZF#_A$_\
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MI\(/#&L_:^?^07H/C4Z!KP_$ZYH?/']!_5Q/V]\?UK\'O^"X/PXGA^#G@?\
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M]GO7-2^(NG^(_!U]HFF^&->\7^!/&?B2TN_^);J=AXH\#>-- UW^VM#'./\
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MZ[@ZYK__ " !ST\)\9P>N*]/N_\ @G[^R'@Y^%8MSSR/'?Q+ ]^/^$F;^?\
M/G)F_8"_9)/_ ![_  YU*VN/2T^)/Q+Z<_\ 4R'^AKF?#B6K:775I?FT'^L;
MM:S^Y]/EW1U'D^3%^?IWZ?CTZ\]>*/L?[VX_\G/],XX_'W]JTM)_9*^$OA_P
M'X@\ Z);>)?#>BZ]JEAJ%[<Z3XOUI]7)0H %UO7"[,,;LJB2,3M7 ;Y3J>*O
MV7O!/BJ+X?03>*?BAHMOX#M/L5I:>'_&)TL:\I Y\;85O^$B(Z8)7G/S8QE?
MV*UZ?/\ S'_K(V?$7PKL_._:J_:HGL<_8/\ A&_V<]%O;O\ ZFC^Q?'WIZ_\
M2/W_  &*^K_L?M_X]7HNL?LT_"#6=&UG0O\ A';C1(-?\2_\)KJ]YX?U;6=.
MU*]\3Y'_ !.#K?F;BVT_>R%/7 Z&OK'[._@Z\\3ZCXD.N>/;6;4_#;>&;/2;
M7Q>R^&=/ #'^VM$T-N%\0C ^?E3AL <$=7]C>5_Q_0G^VK]7_7S."FL\P^1_
MGW_'IWZ<57^QP0VMQ///;6T'_/W_ (=/YY]<\UBW?[$4,4HN-*_:2_:BTT8X
MM+OXCZ1J&F9[Y5O#60?KS[>N?<_L(>%M8A-OXV^-/Q^^(&@W0_TOPGXA\>#3
MO#.NGH#KHT#PZF1GMN4GIG)R#^QO(?\ ;.F[/"?V78;?Q)+\</B;I4YN?#WQ
M&^,'BC6O!]W_ ,_^E>!=%T#P'_;6,Y_X1WQ9_873IS[5] :EXP\#Z/=?8=5\
M5>&]-U#_ )?+35M8T8_3'?MS_G'+:Q^P?X'\(6OD? 'XC?$GX%:?C/\ PCWA
M[Q)_:7@6P'./^*(\0 C]<\$XQQ7Q!K'[/?C[P'K/B&Q\9> =;^+5S=:QJM[_
M ,+,M/!^C:D?%HUWK_;G_0O^(O\ ZW-?G''N89QPKA/K>390\][I1DVO1)-Z
M?A8]K)<5@\5_ODDOFE:_S6I]T>*OA[\,OBI:Z?\ \)'I6B>+;>U_X\\7GKQ_
MS+__ #+O/_(K?CQFNPU+7O#FC_\ (5\1Z)IO_86UC1M._P XYS_^JOS7/P9\
M1WDH@@^!'QCMNY^QV>LZ;IF?_"D_7'TX-=19_LX?$:;]Q8_ '6]2^U?]#9>Z
M-Z<?\C!_CQQWK\FPWB)QCBO^:2J*[VY)KY7Y/D>Y]6R7_H:KTYE]V_R/J#7O
MVD/@[H,MQ8P>(_\ A)-8M?\ F7O"5G_PDFIW_/\ +CCMU],5\+ZE-XJ\2_$;
MXH:[X-^T^ /AO\4+/PO>>,-)N_\ D9M?\3Z%_;^@Z[K.A]?^$?\ ^$K\.?V)
MX7\;\_\ ,!->[V?[._[0?V2'1+?X.Z;HNG 9M/L7COP=I_V 8XQMR3]!W/->
MD>%OV)_B=%F#Q%XQ\->$](NA]MN_^$4L]9\1^)23T!/B $@9X) )'/!->'G<
M?%WC67U+"93/(LF>C=I)M/1](O5-]3H^N<.97JI*3M?1J3>_F[W:TMZ'PAXQ
ML_%7B_QY\+_@1\#[&V_X6!JEW_Q]V@_XEGPT\!_V)_8.N^--< !.?^97QC/I
MFOZ!OACX(TGX<?#3P/X T/[1_8W@+PWI?AG2/M?4Z;H.C+H2G@^H.1].<#GS
M_P"!W[-_PK^!MCJ%QX(TJX_M_7KO[;XC\6:O>'4O$^O-U_XGFM_Q< XZ$8[_
M ,/T5##Y7^?\\=>]?T1X3\&3X,X>^JXYRE-V;;<I/F>KU;;W;ZGYSQ'G7]JX
MSW5HKV^6WEM;\31A_P!2/H?Y5/4$/^I'T/\ *IZ_6#PPHHHH **** .6O(?,
MDG@G@^T6UR.;3/%\ /7I@>YXXSQ7\D'Q@TCXP_\ !-3XY^(/ -[X'MO$G[$_
MCWQAJOB?X*^++0'3/^$#U7QSK?\ ;FN_#'^V\#PQX?!\1ZWK>",@]<X()_KX
M\D>;YV1Z]^G^.*X7QMX#\'?$/PY?^#O&_AW1O%GA?5+06=[X?U^S&I:9J ]"
M&!ZXQP-W)P17-BL-];7R_K^NIZ66YE+*L6L7J^F[M9JW1VOZK[M#^;'1OVM/
M@#K%U;P:KXJ_X1+4-4O/L7V/Q#9_V;_Q-/\ L._\BQV__6<UX_\ M@_'F>SM
M?#_P(^#NE:E\4?BO\6O]"_X1[P1_Q,M3T_POVUK_ *E_/ISGH*_:;7_^"-__
M  3O\26]S93? &TT[3]34F[TG2?$WC/3-*8#H3HW_"1$ <'. W]*W?#?_!*3
M]B_P3>W&K> ? _B+P#K5U8?V/=^(?"7B_6M+U5M- .0-8)9AQU^8GG&.]>)_
M8WD?1OBZ3OK+6_5];^?F?+?[!_[*/B3X'>'/$'Q&^+G]B?\ "Z/B?_98U>ST
MG_D&> _"^A'_ (H;X9:'UY\*'\>2>^!]4_%KX,:5\6O#EOH>JWW]F?9=8_MJ
MSN_^0EIG]J?]1S0_^9@[?2N]_P"&!/AUYGVC_A:O[0T!'7;\4\?H?#Q_G3O^
M&"O!'E?N/C?^TU;#.?\ 1/BH.V>G_%.$\_3TZ]:/[&\CSO[:UO=WOY_HSP#0
M?V4?"O\ H_\ PG'B/6_&Q_Y<])^V?\(3X9L/?0]#\/\ \AU_#-?0&C^%-)\-
MZ7;Z'H>DZ;INCZ7S9Z3:6?\ 9NF6 _SQ50?L(:+#$8++]I']K+31ZCXK:0Q_
M ?\ "+\\Y/Y<\Y$1_8;GA_X\OVH?VF.__'WXPT;4AU_[%O/IS]?:N?\ U;W^
M\Z%Q*=!]C_>]>?T^GY]_7OFOE_PK#_QFO\;H(/\ 2;?_ (9[_9U-YU_T#5/^
M$S^//_$EZXS_ ,@//IT[UX[^T3\'/%_P4^(/@"]\<?M-_'34O@AXQ_M3P9K!
M'C'1/#FI^$_'FA:/K_CG1=9UO6QX=S_PCWBCP_H>M!^, Z$%ZYQ\D_";P'KG
MQK\>^./#G[-GBKXQ^"OBQ=?V7>^._BQ=?%3^T_#/A+P'_8W_ !0NM:Y_Q38_
MM_Q#G^V\^%CQ_P 2#G&*Y?[.U^I^5[_\'?\ 4ZO[2]WZY?2]GKU_+=^A^W'V
M/V_\>I/L9_Z=OS/^->;Z;^R9\:M,TO3X#^V'XWN=0M;/['>7FK?#?P9J7V\_
M]!CG'..AQCZ< Z,/[,7[34/V?R/VQ./^GO\ 9[\&].N/^1D_Q^O/'1_8N,^7
MSV_X8Y_[:5_GV7<[CR/?]?\ ZU?)_P "(3XD^-_[5_C"QGSH]KXN\!_#ZSN[
M0_\ '_JG@;P9_;VNY]/^*B\<#POC\QFO=Y?V0?C5K,4\'C']KWQM<Z=='_2[
M7P/\-_!GPWU,Z5@'^Q_[<!\7'!)(QC)QG&"">.T+]AWQC\';"YLOV>_C[XE\
M.>'_ +;J5Z?!'Q-TC1/B1I@U/7M;&NZ\YUU]OB7'BGQ"-S88G:N%#'"LGDK2
M;LVTF[:ZV3=OG:WS-_[:P7ITO9*S[ZH]JG-O92^1<3VWM_T_]>F.G^3VKR_X
MD?!/P/\ %2'3_P#A*K&Y^T6MG]BL]6TF\UK3=3&E]/[%_P"Q=..![5\'>//
M?C+PKXM\0?\ #0O]I:UXHU35\Z-XL\)_\)E_PC%_I?\ U _^$?'_ !3_ *YQ
M[5D:;J4%GF#PYXJ^+6B6QY^R:39^,O\ W8?#??UYYK^?,[\1<=E7$3R=<*3E
M&+E>2C-K1M7NHM*]KVOU/I,-E^#Q6$6-_M9):.UXW]-S]4--TV#1[#3]*@_X
M]]+L_L5G:?S_ !Z9SG^AX_Q5\2?ASX/BN)_$?C'PWIGV7_ET_MCO_P!@/_/\
MZ_/\>"?%7B2+_D7/CKX__'6<\<]_^$1]<#I[UT&F_!/QN?\ D%? CQMINH=+
M.[N_#?\ Q,\_]AS7_P ^_4=J\3%^(?&.+NLHX2J*]XZPFM[KK'_AST5A\G_Y
MC,V3TV3CKIZG+ZGXP\1Q?%_XCZY\#X+G3? 'Q9\->&+SQ)XAU:S.FBQ\=Y_L
M'6_&G@?G_BH/^$K\._V&.G7'N*\G^(6O7OP]NOA!X=^&?AS_ (23XOZ]X\%E
M\+-)M3_Q,[_Q0-&U[^W=:UOI_P 4[G6_^*W\4'@X'L*^P/!_[,?[1FL2W$$_
MAS3?"5O=?\Q;Q9XD_P"$DYS_ - /P_CV_$?6OL;X$?L?^!_@UK^K_$:_N-2\
M??%#7K/[%=^*_$(P-"TOC_B2^"-#/_(O^'L]LY.!U&17/PEPIXC\5\7Y5G'$
MBGD>2Y))2<&YVEJG;ET3OHM4]SSLSSOA["Y2\%@US3U5]V]];W=MV][^1[+^
MSA\*U^!WP<^'_P *S?+J=UX7\.Z99:OJA89O]8*,VNZN 3C)U\MU/"_-TY'T
M;56*&(L)L#SB.3G'//&/QY/?K5JO[4BDHI)W225^]DE?YVO\S\G;NV^[;^]M
M_J%%%%,057\J'T_0_P"%6** "BBB@"M+$"/TY_S^1_ TODP_\\?_ !T_XU8H
MH\NG;I]P%;[)#Z'\Q_A1]DA]#^8_PJS12Y8_RQ_\!C_D!G?V?;_\\1^?_P!>
MK'V2'T/YC_"K-%-:;:>FGY6 K^5#Z?H?\*;-:03_ .N&[GKG'/\ *K5% %;[
M)#Z'\Q_A5?\ L^W_ .>(_/\ ^O6AN'O^1_P]Q^=&X?Y!]O;W'YUDZ--ZN,6^
M[C%O\8L+O:[MVN[?=M^!7^R0^A_,?X4?9(?0_F/\*LT5:C%;1BO2,5^44!0^
MQV_J?R_^M6+J^J6&A6%UJM]/]FT^UM#>7EV>!8Z8/3KQ^O'?&:ZFO+OBI$)O
MA_XYMQ!]I-UX/\469 ]#HQ _4'N#5679 ?/WA+]M#]G'XE:OH/ASP3\5/#NI
M7_C)3_PCGVBTUS2]/\6#'/\ 8&O:YX<'AS7V(Z;#N.,+7UE#>3^5_P NWVC_
M  /K]/Y?A7\\NG?$;X9_$[_@G[^R+\ _AS<VWBS]H@:/^QS8Z3I'A[1];/B7
MP)XG\#^-/ .O>._&>MZV/#H'A]O"?A[0?&Q\;,RL5&]5V[R:T/!'Q!^/VH?'
ML7OB3XCGP[\6%_;C\3_#W6/A_?>)/B7J>JZA\!U^-&OZ#_PANB_"S \+_P#"
MO3\%P/%/@CQ3@#=_Q70 X% '[X:QKUOH]C?:KJUQ::9IVF69O+O5;N[QIMCI
MO?\ MK)ZA=W !)R3D '*Z;KUOK.EZ?JVE3VVI:?JEG]MLKNTYTV^TO!&1GH<
M'@GL<=":_G/T+QAXR\2:?\9_AEJGC#QK\6]0^*'P4_:?_P"*L\/^,?&8U.PU
M/0B->T,_%3X'^( ?^%?^(P,^& /">,D 'P0 =PY?XD?%.>#X(Z/I?PL\<>/K
M:Y^%_P"Q_P#!O6? >K77Q3\9>&O^*GUS1M?_ +<'PK\#^'\^)_B#XB'B/1#X
M7\;_ /"6?\B6= /@<8S@ ']'ND?$+PSKVK>)]!T35;34M9\':QI>C^,+*V )
MT+4M9T9=?']L\@*5\/F-LD'!('&5*\+=_'+X;6>M_P!BS^,-$MM;6[\56(TR
M\35?[4&I>"M'3Q#XCC'R?=\,^']85YL@EF.0P(39^&FL>*OL>O?M0>/K'XF?
M$CPU^TQJEW^SIXH^#_A3P]K.L:;I?COQ1KOP8\ 8']A9_P"$9\0?\);XB)\+
M^-@ 0 #DC(ST/C;7OBI>>-_%&N3SZU_PD'A?XD?MN66CW?\ T ?^,?? )T/^
MPP/^IC[_ .0 ?T'Z-JXU?3[;5+><7&G:I9"]LKI>P[8'&,8SV[>XJS#>?]-_
MU_(?U.?Q[&OP6'Q#\#_$GXT?!_P<?C?X_P#AM<^ _"'P=\3_ !@U6[^)/C+P
MYIGCSQV/!F@#0?AEH>B#L1AO&_BGJ.AYS7/_  #\=_&GQ!\:/A?>^,OB*+?X
MD:I\;?'FC?$CX>WGB3QCJ>ICP(#KS+HVN>!S_P 4OX?\/+X>&A,/%79@#SC-
M ']#%G-]LB\_OCT[\\8X_P ]*L^1[_K_ /6K/T>;SK7_ #WZ>_Y_K6Q0!7G[
M?A_6BK%9TTWE2'T.?_U=JYKZ7NEYW5EY[VW\PLWM>_DKF-JQF,%R;<8_T0@]
M,Y!YQ_3\*_$"]\8?$UO'?Q!U.X^(OC7PYXWT+XD>/;$V9U@'2['2M"UGQ /
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M^)EX%\6Z7U&C:%KG_,P>'>-"/_"+?\CH/7.*^QM!_;=URSA^P>/OAEKGVFU
MQK'P^O='U/3+_: !G1/$!#:$!U.XY;).<FO#X3\5\+@<%')^,^:.<Q2BY23C
M'W4DY<TN5=+[AF62*4KY0KQ;;ONTFVWIZ,_3*&;_ #_G]1GW!JP9@>"/T_\
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MX?;XYEN?^*=/Q7^'&B>-FPPS_P )EX@#8((-?T7V<HFMH93W7K^)7KZ=/RH
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M#^B>?1]*FE\_[#IMS<$?\?=W9_\ Z^W/4?C5B&&QAEN)[>"VMKBZ'^F?R_\
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M** "JWV2'T/YC_"BB@ ^R0^A_,?X4?9(?0_F/\***/+IV LT444679 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $# E@# 2(  A$! Q$!_\0
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MK_P5V^#/P3\1^#]*^(WP&_:^\-^$-=MO@X_B_P"+6K?"G03\-/A/JGQVW?\
M""Z!X[UK_A8:^)]?UP?VY&?&A^$OA/XP^$?!GE@/+\I,GS/XX_X(2> /%7P<
M_8*^#MA\8M1MK']DSQ[JFL?&KQ!=^#_^)K^TQ\-?''Q.T+XM?%CX7:ZNA>(X
MT\.^'O%OQ"T1'0&7Q@?!Z$L@"KO?B/VXO^")WQ-_:N^.WQN^+FC_ !\^#6DZ
M3\;]7^ _B?1[GXK_  (/Q(^)7P6/P.;P\$\%? [QU)\1H_\ A7_P]\7OHP\2
M^-5\+)&Y<L IP30!]^^&?^"IOP9\7?M+^+_V;O"GPD_:<\2P> OC1JW[/OB_
MXZ^'?AQHNI_!#PI\8M$T<Z_K/@S7Y-&\2R?%#0=#2,[1\47^$A\#-(S;O&X7
M:4\RT;_@M9^SIK']O:K!\'OVJ[3X46?A']HWQC\-_CS=?"S1/^%0?'@?LHZ)
MXAUSXJZ)\+-=/Q%'BI?$17P3K3>"A\5/"'@L>,'4*C;-Q;S_ ,0?\$G/BEXN
M_;FTC]J?5?C[X!TOP_X?^/7_  N4^(?!7P47X;_M,Z[X$_L37=#'[,GCGXI?
M#[Q-X2\->/?@TZ:^CCQ-XP\'>+_'&W0P6\:+D@:'PF_X);_M'?#OX9WW[).L
M?MD6EU^PSIGPY_:<^&O@_P"$>@_![0['XG:WX:_:-T?QSHNA:-\5?BIKWB5T
MU\_"%_&^L/X(?PCX1\'CQBZH_CIBP4D Z']J;_@J7X9M/V>O'O\ PI>P^(WA
M'XR^//\ @EU\=O\ @H'\"/%>OZ5X-;PUX2\->!O!A_L5/' ;7_%8_P"$_C\1
MZYH)3PV/"/C'P:^6#>,U(!,_B3_@KK\//V?_  A\'S\=_A#^U'K%O=?#G]G;
M5_C#^T5X6^%FA_\ "C/ OB3XY:7X?70Y=<UW7/$GA4^("VNZR9/&"_"CPEXO
M/@Q9 LZ1ME8_F'PY_P $9/VJ-0T'5_#OQ?\ VO/A=XVM],_X)Q_'C_@G?\.!
MX7^!&N^&%T'PM\5G\/QZ-XUUMC\16&O>(PNAEO&:X5)6QM*J[2#A?VG?^"#/
MQ,^-^O>,IK/]HGX37&C^,/A5^S'\/K+5OBM\"-7^)7Q*^%&I?LVZ+H>B?V1\
M#]>/Q)4?#OPY\5UT(>)_'#>&/+\8JY"AV!5F /HW]IO_ (*Z>$M \*_MO^'?
MA)X)_:A\%WW['%\G@WQ_^T<_P(^''Q,^#VA>.5\8^!-%&B^'D\1_&[P@OC?Q
M)XIT3QR)%\,^+#X5)C7_ (3/(58#XJ^@O&?_  5.\)> _P!J/X0_LH^)OV4_
MVSK7QQ\</'L?P_\ A9\0F^'_ ,'Y/AIXN&A,O_"1_$S0MOQR3Q2/A]X6AUK_
M (27QCXI3P>!#X0_?&.<8B/G?CW_ ()1^+/&W[-?_!2?X(3_ !J\.6NK_MW?
MM"'XYZ/XK_X0_5QIOPXQ'\(P-$UO0V\1G_A( ?\ A5I.0R$/K@R2NX5'X7_8
M&_;(T3]O3Q=^V0?VF?@)XUL=<M_"_P +_!_ASQK\%?&6H>*/A+^SMX=UP/KG
MPR^%FNQ?$P>&- \0>+T42>-_$G_"(9E\6,5DC*ETH [K2?\ @KA\+M1^*E_\
M%G_9T_;#TOQGJGAWXR7WP6/BGX5>#O#FE?M$ZO\  S1_[=\<^#OA3HGB/XD>
M$O%">(70;?!2?%CP?\(#XP!\N.4J@D;YC_9"_P""JOCC]I;1?^">?C+XG:/K
MO[.Q_:8TW]J[Q-XL\++\.?"/C;X:^.=+^!?PT'CU?&FA_%,_'%O$O@#X?^%9
M7<9'@SQ=XO\ &WB[0O$=O+%X2@C/C%N+_9F_X(D?$OX ?M/_  1^.^J?'WX3
M>-K#X(^,/COXHNM6/[/1TW]H7XUZ9\<M"\1:)M^-OQP7XCLWB#Q)X2_MG1AX
M)C1&\(*5\3DQE<%O0?V??^"-_C_X;Z'^QQ\/OBC\>/"?C_X<_LAZ7^V+\-M'
ML_#_ ,.M9\-^)O%OP:_:K^&FN> M&T36]=_X2-R/$7A)-=UK_BIMJABR@,N]
MF4 ]G\&_\%JOV;?$-I/J^J_"K]I[X?>&M5^#/QW_ &@/@7XV\>?"K2O#?AG]
MJ/X8_L[^$-<\>>/D^!TG_"Q99!X@_P"$;T/6?%7@WPS\5(O XF\(Q_:9&MUD
M<IZQ^R=_P56^#W[77Q4T?X/Z%\%?VF?@]XI\8? =OVD/A5=_'GX<>#_!6F?%
MKX/C6=!T+_A,O S^'OB/XP8+_P )#KNBKM\5Q>$"0P**I !^)-%_X(T?';4/
M#7A3X9?&7]K7PK\0/AO^S7^S3^T]^SI^R'9V_P )'\/^)?#Y_:/^%VN_"(^,
MOC7K0\32CQV/"GPVUF/PV(/"*>"4?^Q3-CS9)F/VU\#_ /@GKJWPF^/7[(?Q
MFD^)FFZQ#^S%^P-_PQ?>Z#8^$/[*?Q;JC:O\/];;QP&_X2!O^$?T%$\$'R_"
MQ#J3K:*S+R$ /-_VC/\ @LO\#/V:/BI\=_AEXS^"'[6OBR']E>[^#7_#0?Q6
M^'WPW\%>)OA#\--*^.1/_"#:YKVNI\1D\2C0I!S(J^$&\7*1^[##>7K:=_P6
M;_9GL_#GQMO?''PE_:B^%'C?X(WGP;LQ\'OB)\*=%T[XN_$A?VC]<_L7X&M\
M+=!\._$KQ4OB+_A:_B)$2(^*O%G@]XG(?Q]_PB*LYJ']H/\ X)6^(_CE-_P5
M$^P_&#1?#O\ P\-T;]DW1-':X\':SJ:?#-?V;U8ZVVM@^)0?$8\6C@+$/"95
MCAL ;CS'[2/_  2.UWX[?&3XK?&[1/CO:>"O&^I>&OV)[[X+ZQ;^!?\ A(?^
M%9?%_P#8U\9^(?'N@^-M9T0>(-GB+P]XJ;6T5O"99-B-O:0LJB4 ],G_ ."P
M7[/NG_##XH^.?''PL_:.^'WQ*^$7Q=\!_ GQ%^RIXN^&VBG]IK4_B=\5M$37
MOA-I'@WP/X<^(WBCPQKX^*V@>8?!7B*+QD%D_L#Q(V] S(GRI\$_^"PM_HWB
M/]N?QM^T'X.^.FE:+X6_:R^#7[/_ .S+^S->_#7P=IO[0I\4^.O@UX?U\_!C
M^PO#_B3_ (1G_A)'\1'7?%'_  E7BSQB?!8\'88^-VPPKK?%7_!(_P",GQ.T
MWXG_ !9^)'[3'A)/VWO'O[2'[.G[3/@_XL^%OA8!\(? GB?]E'1QH'PF\'+\
M+==\2/XD\0>'GT#7?&J^-$D\91N_]ON54>60_F/C[_@B#\5?C+X=^-_B/X[_
M +0?PF\;_';XH?M9_"W]K+P[XB'P&<_"'3_$_@;X8'X3:Y\,_&GPJU[XC.?$
MGP[\5^'C&K'_ (3!/&"(S-YFZ,H0#V;PQ_P4[D_:6_;0_P""?_@CX$WWC3X?
M_#CXB^,_VZ_A[^TW\'?B?X/T;3?B7H/Q0_9O^&6@ZYH7@KQL,^+%\.MX6\0Z
M\?$>?"7C$;@0C!U&VO:/VL_^"B'AC]C3]H3XL0?$S5_B/K7PT^$G[%/AK]H[
MQ!X \%_"GP;JNI7YUWX_K\)1KFB_%'7_ (F>$2_B $;!\+3X13PB4#>-CX[#
M$^#W\O\ V</^"4.M?!7XR?LD?&B]\8? O1=0_9_\9?M/>,O%_@CX'_ C_A4W
M@?7_ /AH_P"&^@_#[1M&T+0XO$LCC_A$#H@+>*_%H\7^,O&&Y=YC._9V/[?/
M_!+3Q%^VEXZ^/'CC3/C#HW@B#XQ_L/\ AC]D>VTG6/!DGB,:#J^A?M+K\=V\
M:!VU^/?& O\ PBX\.8"$@J&& J@'T9^RA_P4 \$?M9_$SXS_  ?T_P"%7[07
MP5^*'P2T;P'XI\1_#W]H+P+HW@?Q1KW@3XJ#7V\#>,O#_P#8'B7Q6O\ PCLH
MT'6U99I4\5AUC9D8E]WC.C?\%9_A5J_C+]J_POHG[-O[9^N6/[(7B_QYX,^*
MOQ!\)_"'1O&_@37_ ![X&\:>'_ R_#7X7#0/B1XM\4>(?$?BK^W!XG16\(>$
MA%X,T#Q+XW\;CP6%Y^B/AA^R#JGP[_;?^/?[6LWCG3M5TCXQ? OX%_"2S\%6
M^EB/5-!U+X4MX@$NN?VWW7Q-_;K+L(. J@G(#U\9>/?^"7/B?Q?^S1^W[\"M
M)_:$/A+6?VT_VLO'G[3&B^+=(\-ZN--\)Z7KWC'P[X@/PP\::(WB4/XC\.LF
M@GPYXW,0\( C6GW9= H /'OCQ_P7&@\.?!GQ5XQ^"W[*WQ\U+XK_  Q_:9^!
M7P.^,'P<^*_@_P ':7JWPF/Q6UKPTN@:WKH\/_&L^&''Q7\-ZT?^%*'PIXR\
M7[?&(CC\?1^$0=R_6Q_X*N_".?\ :(N?V<=)^!'[6NL>(?#/B+X8>#/B]XM\
M-_"WP9XG\#_ 3QW\6-'77O#_ (/^*"Z)\1G^).8RJ2>,O$WA3P9XS\#HPVKX
MV*YS\#Z!_P $0_B5HWPG_:[\*6_QU^!O@GQQ^T5\4?V3?C)X#M?@Y^S;_P *
MV^#_ ,)_'W[*.K:#XAT711\+M \2 >(/#GB<:&JO(<>+1(P\9^9YWF(OK_Q8
M_P""47QZ^,'[5WP]_:"\;?M$?"/2M1T+XC?![XFZQXW\#_ !/!G[07AX>!=+
M\/IXR^&'@KXJ^ O$O@V37_@_XT\0Z*&V?%2/QKXN\$^$-<EB$K[8I)@#^A"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBOG?]H_P_HGB#X!?'30_$/CB
MY^$OA_7/A!X]T?6/BO87J:9J?PWTS6O#^MIK7C.+67D"1GPHF?$8W,B_NCN*
MJX( /HBBO-_A_965IX$\$6-AKG_"6:?;>#_"]E:>(;H1LVO:>='C":\0W0^)
M557((VG<I&X@ ^D4 %%%% !1152&:&<8AF@GQZ%2?QVD_P OSH MT444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 445\?6_[3?ABT^/^N?L_
M^(_"OB7P5J6F_#;5OBY9?$#Q!>>"=,\#ZYX3T36-#T/6]4^7Q,_B30&3Q%KL
M89O$_A2-9&C\1L9=@Y /L&BO._"'Q#\ ^.HKZ;P3XY\)>-AIG%X?"?B/1O$B
MV))P%8Z 6/S$@ $Y)(4')P?1* "BBB@ HHHH **\#U_XX>%_"WB[Q!X6O;'6
MO^*7'@3_ (2/7_L17PWH7_"=ZR-"T,-(&8J-^"Y52>,8/)-Y/CA\(+N:^AT[
MXD>$;B;2KJ1;T6VKZ5(;)M&T9=?UDY#@A5\.Y+$@[5RJ[!E@ >W45X_KOQ.T
MKPYJW@?1)M*UF[N/B#K)T7PY>:4-(ETYC'HK:VVM$#Q"K_V"4 &5WMEF4*Z[
M2_L% !1110 4444 >01?$?P1-\4=6^%<6H3GQSHW@[PWX^U72&T75P!X6U[6
MO$&BZ%K UK"^'"3K^A:WO4N3\@.WAF7U^OFG2?B9XBO?VD?%WP@NO#IM?"&A
M_"#P1X_T;QKC5F.H^)-=\9>/= U[0 0A\.;?"XT#0IF56\TOKB@MM0I7TM0
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MGAOXC#^P?#?BOXV+KOBCP<F\^"8XF)\$JL,F6_H-KG?$'_('U?\ [!.K?R-
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M+U3XC^*V\8:#K9\:*O@#XCGPUKS^%8](UU?^$H\5^+_!OC8IXC*XP^#^YM%
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MZ;X9N_!_AB[\.Z3. #8^&GT2--"TKDD[D3 #$G:O&6. ?3J\Q^&6HV&O^ /
M^MZ5I(\.:;J?A#PQKFD^'FM%!T+3M:T:*2/1P!C(3H2<'(4$$8->G4 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
ME;^R_P#\I/?^"GW_ &!_V./_ %3!K]4J_*W]E_\ Y2>_\%/O^P/^QQ_ZI@U^
MJ5 !1110 4444 %%%% !1110 4444 %%%% 'SCIFC_%$?M(>-O%%[XC%S\%K
MKX0^!M&\.>'O[5)%A\4-&\9^/G\<ZT-&'R@'PXW@@;P65CN3)<D#Z.KYJT_P
M%KEK^TUXM^)LWC>"Y\+ZU\%_ ?@RR^'8U?5?[2T/4]"\9^/=<UOQJ=$;*^7X
MH_MW0O#@,960?\(Z "S!HF^E: "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#\C_VU/AU\'/A'+<?MKZ%\)=-\;_M#:9\4_A OA[6+N^\::CJJ:OK3CX1
M:'$NB_#SPUXP^)7B'P_'X=UU_$DOPO\ "'A8-XQEBP Q+F/[H_9^\=^+?B-\
M*_"OC'QMHMOX;\5:I9:JVL:4WA'XF>"?L;?VK(JK_P (_P#&#PSX/^)>@C*^
M8R>*/"</*[R5'WOEC_@IUJ-GHW[(_BB;5O#WA3Q;87'CSX-Z->:5XYT;1?$G
MAIO[=^)V@>'MHT7Q!\1_A+X9.NG^VED!\6>-/"7A'.T2N,%&]A_8DT^QC_9A
M^&L%C8Z=IMO]@UA#::/I.C:3IVU];US=MT;P[\1_BYX=4\ @Q^-/%O(!8DA"
MH!]G5^&?P9_X*!_%/78OVSK[Q1KOPN\2:A\&O WBOQ3\.?A_I>D2>'M6\)?$
M_1=<^/NBZ)^SWXUD;Q.#KOB Z!\*M \4[/\ BD/& CUWR1&$V[/W,KDH?#/A
MR'[1,-#T8SW5U_:UY=_V7I8:]U(JN=99LL3)QD2,PD ) ;)8L ?AC\%/V[?V
MH?&_AWX >)#XL^"OQ(\"^,OVFO$WPB\7?$GPEX;UC2Q\2/# ^"_B+XM:&_@3
M15\1>+?#GAU_"OB#1M;\*>./%0D\8@#P\NP(2Y>]^S!_P4&_:*^(7P&^(WBK
M7O@QXE_:R\;:#\5K_1+S_AF;4/@\O@?0O#&M^#AX\\/+H>N^(/%'@_\ X2 ^
M%I"OA7QSG=XT\(^,SY3APV*_<.S\.:)8VEK;V>BZ;;6^E?\ ((M;6S"_8>#Q
M@8 )/.!@ =#WK.FT?3='T'78-(TRUTZVN;34[U[;2[,:<6U':?F 7:H8MCD*
M%'.!@ 4 ?ES_ ,$/KP_\.M?V;]5OH/[,'V/XGWUY:W6/] _XN?X^SUQQZ\DD
M$@>M?EK^W3_P5L_X)F_M1? +QL8?A/\ &3XH^*=*T;4]%^'7Q-U7]DOQEXD\
M+Z&1XRT%=>_L/QN_AM_#:J3HBL K[@5'S$%]_P"F/_!'/_E$O\)?^Q=^/'_J
MSO'U?&W_  3#^!'Q:_:)_P""-?[,WPR\$?'#PW\)O"'BCPWX\M/%UEJOPL/Q
M(U74!_PL_7];T,Z'K(^)/A'^P4C_ +&4\[N6R%#!20#Z'_9._P""K/\ P3GN
M/&_PN_9@^!'PK^,?P5U+XP^,?['\&:1J_P"S#XQ^$W@:^\4_V(^N,4UP^'4\
M,"1H]%:,,7 &<\ D']W*_";]L;0?BIX6^,O_  2@TKXQ>/O#?Q0\8']N_4S9
M^(?"?@/_ (5OI@TP_!?Q^#HIT+_A)/%PZ@<@DG!'&*_=F@ HHHH **ISM!!'
MYLLOD06V23G  Z D\GV P<\_AG1:E832&&&]M9[@6OVP6MM=9/\ 9YPJO@>_
M )Q[%0: -VBBB@ HHHH *^=OVE/B!??"O]G3XX_%/1/#-IX_U+X=_"'Q]XWL
M?!%P$33_ !?J/A[PAKFOKH;;<DKXES]G? (*, VUG-?1-?-W[2'B_P ;?#3]
MGSXV^./A5X7/C+XG^#_AQXY\3_#CPI_8^K^)/^$K\>:%HVLZYX?T)=%T$GQ%
MK:2^(U2(PQ*"[R;X@C[I  >D_#CQ!)XI\#>!]=GTJVT2Z\0>$?#&MW>D6FW_
M (DAUS1HM8.D\98"+<(F''<D'Y6KTBO,?A_?:YXA\$>"M;\4V":+XAU3PUX9
MUKQ#I)M019:MK&BJ=<T?;S@1S$J_&X,H)!R /3J "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#@/%?BKPYX+T36/%?B_Q%IOA/PM
MX?LWUG6?$7B+6M)TGPWH6FIC&L:WK/B!4CT6/YF7+2;4/3)+%8/!'CKP/\2_
M#UMXK^'?C+PUX^T"\&+3Q%X3UO2/$6E7V!QLUC0&>,>Y4@C&>>:\!_;4.B0?
MLP_%V?Q%HNA>*_#]MX2-YK7A[Q%XZ/PGTW4E&K:*0J>.0R?\(YXD!P_@EF#C
M_A,D\-IMRRNOS3^Q5\1OV?/A9^R#XF^)VG:3<?";X9?#J[\3ZU\2M8\;?%'5
MOBSXHT%-"TCP^-9UOQQKSQGQ/H?B%/#FBZ2'\*#PK$R1Z-X=*J9'C( /U:HK
MY(^ _P"UQ\ _VG)KZ+X+^.+WQN=*TC3=<O;G_A _B1X;TC^S];! D_MOQ%X;
M\+>'==#8&Q868KNRR;BYKXIN?CC\5H_VY_C'X5^&7C?QO\6=/^''P[U._P!7
M_9\\0/\ #7P1I6N^._[!T(>!_!GP5UC7_#L?B<@DZ]XE\:_$_P 6^,)?!2R>
M((O!I3*90 [O]E__ )2>_P#!3[_L#_L<?^J8-?H+X[\4:MX*\,7_ (EL/!/B
M[Q]/I=G\WA'P/9:+J'B;42!\O]C#Q%XB\)^'2P&W.70\?,,?+7X__P#!.GXA
M?$SXD?MU?\%'/%GQ>^"FL?L]>.)[/]EZTO/AIK'CWP7\1M1&F+\,P-$UW^W?
M );PPI\4#>V,YR -W)(XGXS?&;]MGQ?^U5^V;X<\#?MG^%/V7?@/^RP?@3:6
MMI=_L@+^TCJ>MZI\5O!1U[<_]@>)O"'B@Y\1@1@1[R"R *$!90#]-/V=_P!J
MZV_:(U#4+;1?@A\<O FDZ7>^*-%O?%7Q%T;P7IOAQ?$G@K73H6N:(/\ A'/B
M-XN(UY?$"R!04)D6/YY/E=Z^SZ_DN_9W\5?MZ0_!WXW7WPR_X*6>'M.\0^!+
MW]HOXRGX?>*O^":FM>&QXKTK1-9U[7_[<?QOX_\ $OA#PSH'_"5E5\2CPP%+
M+_PD&1M4R,/Z&OV,/B9XO^,O[)?[./Q5^(%U:ZAXO^)'P?\  GC'Q)>VEF=-
MT^^U?7]%76=9\O1LD1XW$ ;3N:0,"OS!@#ZWHHHH **** "BBB@ HHHH ***
M* /EC1OAS86O[5WC_P",7_"6:7>WWB3X%?#3X>KX+4H/$6A:=H'CKX@:U_PE
MG$A/]@^)FUH1.2 /,\/@'#AD'U/7RUHGA7X<Q?M7^/\ QE:>,Q>_%C4O@7\-
M/#.K> ?D T'P+HGCCX@ZWH7B\!3][Q-XAUS7(22,M_8')+[P/J6@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH ^%?VQ_"WAS5OA%=:UXN^.>C? KP;X9
MO%USQ%XC\6>'/!OC;P#KBEL#0O&O@?X@>'Y/#.N@:[&K*J1IXL9U(#K(Y5?!
M-0\$V7AO]@GXX0:'\5?BA^U!X>\3>#=63PY9?LS+\-O@GJS'Y-"3P=\#7^'[
M^$/"_@#7U\1;E(/BUB'8XD7:P?MO^"G0LQ^R1XQM[[PZ?%HU[QC\,/#5GI5B
MOQ*2_L=5U[XF>'="T36M#7X/^)/"/Q.'B+PN[-(O_")^,O"3;M^9N=@\?A^'
M7A[1O^"6WB#PCXCU^[^#VC0^$-3UJ[U^\^&_QBU#4M+U-/B6VN_VQK/@?QY\
M0O%OQ1\2>(/%WB4EF%QXU;QGXRD\0YC(.U* ."_X(X^#_CEX)\)?&#2_C=X;
M^+7AS4+G5_#%[X:\._&.^^)WB+QS8^&LZZ(QKWCCQ[XA?PUX@U\DL'?PGX.\
M'A%PS1L,E?W,K\1/^"7.9O%GQXN)OBKJ/Q(\0>'_  YX6\-6=Y>?!W6OA1IM
M_P"%A\3_ (^:\WC/0AK_ ,2/%Q\0>'W^(FN>.O"HQ_PAY!\!#"M]T_MW0 5S
MOB#_ ) ^K_\ 8)U;^1KHJYWQ!_R!]7_[!.K?R- 'Y#_\$<_^42_PE_[%WX\?
M^K.\?57_ ." 7_*)[]EC_KS\=?\ JS_$56/^".?_ "B7^$O_ &+OQX_]6=X^
MJO\ \$ O^43W[+'_ %Y^.O\ U9_B*@#I_P#@I2<_M)_\$G3CC_AM;4__ %2_
MCS_/XU^NX91T!STSZ_K_ $K\B?\ @I)Q^TA_P26_[/F?]?@QX_-?>?QW^/WP
MK_9O\'6_CGXP>+K7P7X:NM6TS0[/6+RUUC4Q>ZIK+$+&VCZ"OG-EB3DHPR'8
MD$J'S4<7BL3#"86/-*WNI1<FV[MV23;V\]%V'IU_.QXAXBB_;R.N^/SX/G^
M8\,GXJ> #\.%U:UUG^U!\'58_P#">#71$S1_\)('R/!P0E./WA*8K[MVCW_,
M^_O[G\S7\VOQ'_X*&_!:7]HKX?6'@?\ X*@?&WPW\+_&&C_$_P 3>+])TOX$
M_#35#H.J:#K/@ >!=&T1_$7[)C>*3X>(UW702S>,68]6^8FOV<_9\_:U^ 7[
M35KXB;X)?$O_ (63-X._LVV\2XT76O#K:>VLA2HV:]X<\*.[$*2H1"05  +$
M9ZZ^39MAL,L5BH3>C?\ #FHI<UK2;BE%MZ6=GJG:UF<WM\'KM][O^>I[7\0/
M!'ASXF>"_$_P^\7V"ZEX6\8Z-J>A^(K/[5MSI>M@KC';('&!@ $C*UX)\*/V
M/O@5\&_&&C^//AWH5WIWBC3/A9H_PBM+N?Q'J^H ^ ]"8-HK$/(?^)XV-K^)
M>7*;P-Y8$?-?[8G_  4(_9@^#7B+Q!^SG\;_  #\1_'YU[PAIM]XDTGP]X/_
M .$D\,:CX7UPD -_Q4*XZ L ,@C 9L9/Y,?LC?MW?\$]?@=XG^,/C>S_ &>O
MBAHGB>V^-?Q/'@_Q!:> LZEX2\!Z[G^Q-$.?$A&@*PT/7!C [^HV^SAN%>(L
M9@EC<'E,W%QYHRM>,HN]W%\VNEVU;9)]T'UC!WW5[^>GK=Z']7Y <9'&,]?\
M_2DX( 8X(Q_GTZ?E^=>,?!KXL>&_C9\,_!'Q:\'Q:E:Z!X]\-Z9XGT:WU:T_
MLW5%TU@5_P")SOW8//RC/&>F"17L?^M_SC&/S]??K^7S<H.,GAL395%=27FG
MJFD[IIIKY'1=:-/TU+%5O-\F+,W8?7(Z#/\ G^@JSD>O7I7E'Q)^&_ASXI_#
M[QE\.O%)U(>&/&>CZMHVKG2M4;3M5.EZT K_ -C:RCJVB,0,*47CY0 >,Z+R
MZ=M?\P/1?[1L/^?VU_\  S_Z]>"?M':M\3--_9]^.UY\#X'U'XO:3\'_ !]?
M?"JSM;72]3<_%!?!VO'P'HS:.6!P?$8T/*ONWHQ&XH'#?.=Y_P $ZOV?=2M=
M7L;W4/BQ;V^J^&_A5X7NC9_%'QF0VE_ J1!X(D7;*Q.NN-(0>-64$>+#EY6D
M'R#I/%?[.FI?"3X&_M76/[+-_KNE?&#XR>&O'WBGP?JWB+Q@VHII_P 9-<\%
M/H7@8:*^OYB\/^'E\1+HNY2Q (W<X5J /H[0?&!T'X5:5XO^+^JZ;X;N=*\"
M:7K?Q&U;Q'=Z3X<TS0=3;14?76ULLZC0U0L>$8!5Q&H!78W%>"OVN?V8/B;X
MBMO!OPX_:,^"?C[QC=6F;3PIX3^)?@WQ+XEO!SG&BZ%XB8G/8!5SDC*C%?'W
MQC_X*2_!#]E'7_AS^SK\<-#^.OQ1_:!U7X*^&_B!XD\(_!+X(^-OCWJG]E*W
M_"/:YK6MCP#X>?"_\)#'K(RJA'YF4#S-M?GU^SM_P55_98^'WQ _:P\4S_LV
M?MC6O]J?'<^);6[\._L._&8ZIH6E'X7^ M!_XG3#PXI\/-G0];(\-$%L!@ K
M-D '],5%?-_[-W[0WPQ_:M^"?P^_:#^$&H:AK7PX^*>CMK/AN]U;2CI6J7^F
M_P!JR:(3K.BG(1AL=L%B$C!).,"N8_::^+'QC^#7PRU_XF?#;X5^"?BG8^#?
M#GBCQEXRT?Q!\1]8^&NH6&EZ#H;:V?[#1/ASXR&OZY(%=U65_".TN%)$@55
M/K>BOFCX!^./C!X[\$Z=XJ^+GP[\%?#C4-=L=.UOPWI7@CXD:S\2MVFZWHR:
MV1KNLZ[\.?![:&S%BH58W&_"_(X1'^EZ "BBB@ HHHH **3(/0@_C2T %%%&
M0.IHNNZ^] %%%% !1110 4444 %%%% 'QQ^V/;RW_P"SSX_T-?"-WX[N-4TO
M1["W\*IK?_".:GK6HPZYH<RC0-7T/7/#/B >)/#RLWB+PC_PBDD,R^*=%C*2
M1W'DX^-/!'BF]\'?L&?M3?$;P-;>(_A_?W'B+XGZSX#^)OQ! ^+7CCQV/[%\
M/Z!H7Q+\;Z)\0/$N=>\0\?\ "+_\(MXK\7\CP^.1@ _4?[:7[/[_ +0/PZ\.
M:1!\28/@Z?"/B_5/%3>-KS1M,U0:;I.M^"_'?@'71NUWQ!X7C\/>)!H'CK5O
M$W@CQ,7C'@[QEH'A^X7*Q2 ^':?^R[H?P\_8K_:5^$'P(F\&?%J#XGK\3]9\
M"^%;/PAX+;X: :_X.T#P[X?\$:+X? ?X:!)?#^BZ)*TOB@)_PF?C36/$GCF5
MPGBLJ #YC_X)6_#*X^#OQ4\?65[XY\.>-O$'Q/\ #GC[Q/K.J>$O 6L_#C3&
MU3X4_&5O 6N:P? X^-/C+X9^'U\6,0Q;PCX.\'$;<DE=RG]_*_#+_@FQ^RQX
MK^ WQ9\>^/I_@?X2^#F@?$CP*%O= M?#/P!\.ZAX?U/0OB=KHT3P7HA^$#)X
MH#>%_#IT+Q'\:1XJ+>#?^$X\1(? :2(CU^YM 'Y6_LO_ /*3W_@I]_V!_P!C
MC_U3!J']D#_E(Y_P58_["G[''_JF/$%3?LO_ /*3W_@I]_V!_P!CC_U3!J']
MD#_E(Y_P58_["G[''_JF/$% 'VA^UG_R;#^T?_V0GXH?^H7K]>.?\$TO^3 /
MV-_^S;OA=_ZAVA5['^UG_P FP_M'_P#9"?BA_P"H7K]>.?\ !-+_ ), _8W_
M .S;OA=_ZAVA4 ?==%?)WB;]IWX5>#O%GB#P3KMQXU.O:)J_@3PS>?8OASXV
MU+2_[2\=R,_A\#6?#^@2("5/[]U/_%*N?,<!<+2^$?VE?A+X\\2:#X%\-W?B
MV?6/%>K^.M"M3=?#CQKI>EKJ'@9@?$2ZOKFM^'X_#T992XB?SF/BIF5D^52C
M 'UA117Q9<:1^W']J)@\;? 06!U;Q]G[5X.\:Y&E<#X5 E/$A!8GCQF!EB,F
M/C=0!]IT5YEX%3QQ#X-T"W^)E_HFI^.5TA!XDN_"5D]AX:OM5;!_XDJ:Y\P!
M7D%B <Y.% )Y;XF_&;PC\+;[PAIGBY?$7G^--7U'1M';P[X=UGQ& VB:-_;D
MC:R= C)T+:F6C9E"R?(N0CEE V/=J*^*9OVV/@1!I%OKLU_X_P#LMWX#_P"%
M@VB?\*@^)AO_ /A&/[:'AXC9_P (YG_A(#KPVCPKO'B[<0_E%N1]AV=[!J-K
M;7MOAH+JU%W:D@ \@'...1N7(/J??!MOIZ@:=%%% 'RWI'_"IO\ AJWQQ]A_
MM[_A>/\ PHGX9?\ "79_M;_A'?\ A5__  G'C_\ X0;&/D_M_P#X2'_A-]F?
MGV9W?O*Z_P"(7[0?P1^%6J6_AWXE_%OX7^ -9O;,WMEI?CCQUHGAN_O=-P3O
M*:^R,RL3R-S$]B!\U?._Q?\ C)\&O@=\0?VE?B_KGACQ?J7Q'^#G[)7ASXF>
M/)-*VBQUSX.Z%KGQ;US0-'T%3K_EMXA_X2+0_'/)3& I&\$L?RI_::_;D^+?
MQF^%7PG\87'_  2D_:9/A_7_ (I?L\>*/#7BKQ#K'[-6I#7]*/C;P_KVAZ1A
MOB0SX\4!@HPP4!P-O^K"@']"W@_Q?X.\>:%;^*O!/BK1/%^@:HN;3Q#X=UC2
M-2TN_P 8QLUC0=RY'^]D'''(SWM?D9\)O^"AOB.;XY?!C]FWXB_L&?'_ /9=
MN/C;>>/+#X=>(?&][\&?^$9.I^!M%.OZX&T3X?\ Q'\6L, DJ5(QG+ @\_KG
M0 4444 %%%% !1110 4444 %%%% !1110!^>7_!0O5_A9#^SIKOAWXG:OHMO
MI_BC5?#%EH^DZM9_ 74-2U[5-"UJ/7A_8F@_M!>)/"GPR\0$CGYW+C+<$%MO
M(?LC>#-+\>_L&Z/\/_%_ACX?^-?#_B;1?'MDW@?2A\,].\+Z]X7;QIKX\/Z-
MKJ_!]O%?PS\/^(CX>_L3_A-#X2)3P;XT61<A]I2E_P %+/%&B>$OV?X+;6[^
M\T6;5?%_A:VL_$5]::[IFEV.E:)K7A[6O&^AZU\;M!\->+XOV?1XL\,PZYX:
M;XG>)6B5"^YO%Z-(&/I?[*=A?Z-^QWX6M?%/B&P\2VUUX:\=7]K?>$O%NC_%
MD6'AC7]>U_6] T-/'.@J$^(?B+PGX;71_#4OBE&9_&'C!0Q7]]&Q .!_82\)
MZ5H5UX__ +,^%?PU^$U^(/"FC7>C_#[QT/B0+#3/ FM>/="T#13KS^&?"@T!
MD\/_ +R/PPH0^9KOB/QOD'Q:6:M\-O\ @H)X<\;6/[3&N:W\.O%WA+PM\!_A
MUJOQ>\.:J-9T7Q%_PLGX7Z'KGQ<\"G6ET)-HT#Q$?$OPJUTMX6?<S>9X;RY4
ME&^7O^",_B[0]5T#XN^#O#?A[5-"L? 6E?"^^L&U7PA^S=X;\27WAK74\1#P
M^?$*?L]:!"9-=_X1[1!NC\7EO&+\ A6Q(OZ)Z%^Q7^SQX5U+XC2:%X!:V/Q:
MNC??$:S@\6^-%TKQ'I0&O_\ %&MI(UYHU\ /)XW\;>)AX/ 7P<OB[Q!+)Y;-
MM6( ^7?"?_!2Z'4;'X83^,/V?/'WA'4/&7Q8\4?"?QU=VOB+1?$?ACX9:EHO
MPQ7XMZ,O]M(4'B,^+?#@T4KX:\*Y8%\MNP0V9X-_X*G_ +/-S\,O%'CKX^?\
M8R6SWOA;1M*TCQMK#^(X]?TOXK?#+1?B]X'UN/5_#V@!(YI?A_XCT:27PX$=
M_"2_NYR^V%D^N_!'[&O[.W@GP9X-\ :#\.5@\/\ @7QAJ?Q#\.6FK>)/&?B/
M4O\ A.==T37] ;6]9UW7_$C>)O$'_%.ZYK?AI1XN8DJ2H/ :M7X.?LU?"C]G
M#PCXO\+_  D\*P>&]$\0WAUO5P=4U?4-134ET4Z!H<?]O>()3(=#\*^']$T+
MPSX)\-#?;^#HH@(U4GS' /@[_@C/=V^I?\$D_@]?6,_VFPN?#7QDO;.Z'OXU
M\??CVR/J>:G_ ." 7_*)[]EC_KS\=?\ JS_$56/^".?_ "B7^$O_ &+OQX_]
M6=X^JO\ \$ O^43W[+'_ %Y^.O\ U9_B*@3V?H_R9U'_  4C_P"3D/\ @DM_
MV?,__JF/']<K_P %FOLX^"WP.^V3ZU;6O_#3/@'[7=^'++^TO$E@/[&\08.@
MZ&"PU_Q 0?E )P. ,"NJ_P""D?\ R<A_P26_[/F?_P!4QX_KG_\ @LC/Y/P=
M^ ,_G^)+;'[37@'_ $OP1:'4_'5A_P 2?Q%_R) X_P"*A../7YN@'/T_"%O]
M8LIV?OMO1.]H5'K=/MU,,3_N;]'_ .E'YSZQ\'_A!K'C+1_'$_[17_!3FV\0
M^%[+Q19:/]D_99^&O]F6&EZ[_8']NZ+S^S9_U ]#Z#CW)X^M/^"5$6F0?M3_
M +:\.AZY\2/$FGC1_@W]EU;XK>$&\%>.[U?[!<DZQH \+^%/[%8'&R,Q_,>=
MI*A3D_V[XI\C'_":_P#!:/K_ -$@\&;>N.O_  C/Z8Z<9[UT_P#P2]O+B\_:
MW_;5GN+[XLZA.='^#8-U\=]'/ASXOX.@MQXST4%-I!QM?:N0, *6X^SQ&*>*
MR#BF,I2>D)14KZ?[1"-XWI0]$T[_ -WJ<-EI9+?2R7;IJ_P/AO\ X*GZ//J_
M[>OCG2H-5U+PW]J^!'@3_BH=)O/[-U/3^?$'_(#]3[U^='AOX)P?#>+Q3JMC
M\3?BCK=OJEGXHUK6-)\6ZQHVI:9?ZIKO_,:_Y%OPC_T ^A_X0[C0,<_\R;^E
M_P#P4Q_Y2)^*)_\ JBG@7T]3_P#JY YQ[U\@:Q^YT;6,_P"C?\2?].G_ +@^
MO_%'?\@#_P ,W^J\,_\ )+<*76]-W7?W9Z/OMUN<+_YFWRMY;;']0O\ P38;
M_C!W]F\8X'PWTD _@#C]<U6O?V9OC;+XG_X2.W_;#^*5MIQ^-?\ PM'_ (1T
M>&/!YTT> SHO]AGX+[=N3H/._P#X27'FGJ%)J?\ X)S36^F_L+_LWS3R_9X+
M;X6:3>7C8R%PK,<GZ9'7DGJ1S7Y@?MO?\%-OV0_&WPL^(%[\.OVM/CW\./B+
MX#\'^.CX//PHM/&?AO3==\5+HQ;0?[;0^&2/$ 5@FT;N/F(P5 ;^<:^39OFO
M$><_V1EDJML16B^6+ERWK5$HRMI&,$N5R=K*S>C/3H8G"X3"Y8\6[746KW];
MO^;TU/T_^$W[.7QI\$^+/AOXC\9?M:?%#XH:/X-M/'EEXC\*>(?#?@[34\=C
MQQK"OH;:\V@(H \)'*J0#NV@Y&&"?0OQ?^+_ ((^!WA.Y\;^/KW^S?#]M>Z=
M8F[^S-?$:CK#E8U55YP<Y)& 1D\C K\N?V3?^"AG['$,7A#X2>&_VE/C3\6O
M''CWQ'I=A9:Q\8;+QEXBU=/$^N'1-!_L9==?PSX530O#X\1,@1&14#>822'V
M#Z#_ ."H4WF_LP:@<=?%WA4]^ -:Z<XYZ=OK[?)\6X;->%\KS/%8ZG+)9PBZ
MD%.#[J+:NMVW:\>_9W.3B+.OJ>39IG&#M+DB]K632[)V5MUL?G/\8/VKOAKK
MW[2/@/\ X1S]NW]KKP/\./B,?BAK/BSPKX(L_!UAIFA?V%H?A\Z"W@M?$'P2
M\5>*!X=$A?Y%=LJ%;>"Y5?T>/Q@T7]KK]GCX[?"7]G7XE:W!\6+GX0>*/"WA
MSX@Z[:ZUX<U/0/%&O>#]<T'0/&QUK00JML\1 2,_A3YH]K",,6.?Y+?$GP'T
MKQ)XHM_&,_Q&^,>FZQ:WFJ?V/::3XP.FZ;H/]NX_M[^P_P#BF\\=>_%?L)^P
MO\-[CXD?!']L[X66WCFV\$W'COX$ZG\/K7QMJUV"="77M$\0^'_^$TUPD@#:
M2'8\G"LH!+"OQ[AKCW-LVS?ZEHXW6ZW7>^NZ5_GT/Q;@GQ7QG$'$;R7&)6O:
MZ6UKJUUWM]^NBV]@T'1O'V@_\%IKGPWI5YX<U#XCZ7_P2+\#:+::KXJ;6=1\
M-W_BC0_C2V=<ULQG_A*!X>;Q(=P*D/D@\/T^L/!'P@_;!^'$7[4'B'XJ>)OV
M;];\$?&/_A.OB'XEL_A[H_Q+7Q3H&I_\*8T'P&NBZ(/$7B/_ (1K:XT#1@"1
M\P5@#P37SC\*]!/A;_@NAX?\*_VK;ZS_ &#_ ,$C/ >BG5;4C.O?V#\:O[!.
MM=2,-SSG.,=#Q7[3?%[_ ))-\5O^R=>.O_3%KE?MBV3V>COVV9_0I^8/_!!O
MC_@D[^R>?^H-\4/_ %=/C^OS/^./_!3;]J#QU\$?VB+"]^(O[#WA'3KKPU\8
M_!0\#^*[SXE:;\2QI0T37]  _L/.!XA'8#\J_2[_ ((-G'_!);]E#_L#?%']
M?C1\0 /Y5^.'A;^Q/B1\%O%/PKUO_@I)=?LO>'KOXC?&2R\2?#/PG^S>/&VI
MW^F:[K6O_P!N#7?'!Y\0<Y/H,?2OLN#*&"B\TQ>-RK^W$N3W5%R<>:4TG9*5
MDU'EO9*-KMJZOYV8XAVT\_)/1=O(^J?A7_P4R_:9T<_L\:)/X_\ V'_'_A_Q
M1K'PO^'MWX>^&=[\2_\ A.+#2]=_L#03K6/$!_F/<#BOZ<.H!Z=#_6OY#KO4
M[+PKIGP'^'.E?\%%KK]K/3A^T?\  >]LO!/BSX$?\(3XET+2]#UH:#_Q)/&^
M<_\ "/# _P"*6(XY )!K^N^+E2 .H&/?H<?@!4<:4L&WED\%E3R1-5&X6M*;
M4XVT:C>RO%:-23YE*5[HR_$-JSO9^MEI>U]?7IYV,V;6-)@^T&74M.4Z;@WI
MN;I UF2.K9Y!]VPWN"<5NU\*?%/]B[]E+XF^(OBQXB\?Z%;7/B'XQV7A>Q\>
M'_A(VTW[</ H(T'DEFT,CY=QR-V3@[@5K[1TVRL=-L+"QL<?8+:T%G:8.>.G
M7CJ%/..IQ7R'K]YZ)M5\\?#CXU>%?BSXS^,'@G1M%\:Z;J/P<\8:;X5\17NO
M^'GTK2M<U-])_MR+^P-7+/'X@T(1OL,HPS-\H"HY5/5?$FKP^']#UC6I;'5=
M3&FVLE\++P]I$FIZI?-AF5=&T@;_ .V=:.U0B*O)*@*!N1_CKX5_MQ?#3XO_
M ! O_AGX7^''[1^F>(-+U7^Q/$UUXU_9U^)W@OPYX1U8Z(->V^-/$/B'PU%X
M;T#?X>.B .SK_P AQ"$!=MC2;5TFUW2;7WI-?B'E=)^I]UJ>?N%>V23T_+].
M.:7G_GF!^(JI)=I!";AR>">!GWQDC/;!^GM7X0?MB_MS_LZ>-/#'Q/\ !'B+
MPO\ '8:OX$M/'Q\/:IX*\>ZW\.L^*M$T;7M"_MI6\!?$KPD==56W;4\5_( 2
M HP"OF9GG6#RG_?&HKI;7I>VO7Y/[CPLXSO*,@2EG&8^R3VC+?;HEWZ:_<?O
M)CTB)_$8_1?ZU*V[/W0><#Z>IYK\!OV+_P!NS]GOP!\-?A=X>TOPQ\=KCQ!\
M0_#OPNU#Q;X@\:^/M=^(HOO%.N:%H*Z[K+CQY\3/%?\ 8JY8LT?A?,9(4A Z
M*]?O=%=^?;+<1D]B1C&!GJ#QCTZ\=\5AEF=Y3FS_ -C:=M[\R2?F^G;U#)\[
MRC/HN63YE[5*W,ETV[]MGJ:_2BD'09]!2U[)[H4444 %%%% !1110!\5_MWZ
M/!J?[)/QOLKCPI<^+8+CP@<^'K.\U?3A\VL:#_Q.F.@>&_%\@_X1(D^)UV^#
M_%V5T3&TKG'Q+_P2JU2^T[PK\4/@I;>#=3G\)>#[E=7TGXW_ /"1>+_$FF_%
ML:TQ\#)K.CZ_KWP3^$7AL^7X=\$Z.JKX2\*;/^)+)E7!-?8G[<WB3P1X:_9F
M^)8^(WQ&U?X8>'=>T;2["\\6Z "/$UAIXU;_ (2#7-'T;0XO$/A+Q'XD$GAG
M2->$OAKPO+_PEW_")1^(Q$AD)(\;_P""7%CX'N/V9M1U/X9_$;4/BC\/_$_Q
M&\3:UX,\<7FBMI;7OAA_[$71=NCZ_P#$GXM>)PS)GQ,/^$H/@YT_M\L? W@]
M60$ Y'_@G)XV^'7B^]^).H?##2?AKHMEJ=[XI\476D:7^UOK?[1OQ+L6UWQF
M4 \<^!]?5S\/_P#D"\ ^+),L1A=VTC]?*_!+_@F"/ %]\>/CO>^!_CQXX^+,
MH\(&TUO2?&EIKO\ :YU-/&9;6]74ZW\2O%GAOP_X<+ 'P5X5'A#P>7&N^)XB
MCCPJV/WMH _*W]E__E)[_P %/O\ L#_L<?\ JF#4/[('_*1S_@JQ_P!A3]CC
M_P!4QX@J;]E__E)[_P %/O\ L#_L<?\ JF#4/[('_*1S_@JQ_P!A3]CC_P!4
MQX@H ^T/VL_^38?VC_\ LA/Q0_\ 4+U^O'/^":7_ "8!^QO_ -FW?"[_ -0[
M0J]C_:S_ .38?VC_ /LA/Q0_]0O7Z^:OV(=4O-&_X)@?LWZY9YM=1T#]D'PM
MK%C<\'[#JFC?#0!&VD=0RD ]0 Y],-*[2[M+[VE^H'O/[0?Q]TO]G7PGJ'C?
MQ'\)OBCX^\,Z9H^I:SXEU7X::-X/U(:'I:_>_ME?$7B?PB1E3D%=P'5MQ!KT
MCX<>-[WQYH8UR?X<^-_AO 1_H>D_$&S\(:;J0Z8)'AWQ+XN"9P<$D'T)-?RM
M?%O]ISXU>-OV2-1'BKXM?\%!/$GC;XL^!-4^QZ5X(_9,T?QM\(M>U0ZT<?V'
MXV\/^&L?\([T'+=.U?5OPQ_:O^+MY\2OV:8/"WQ@_;5UGP[XP^-7A7X?^+M*
M_:-_9ET?X3^!]0TL:*QUW1=%UL^&4\3+XA'!'S,2Q8<8!/TCX9QG+>]K<S;Y
M6E:--U&[MV5TFHR?NMII:IVY_;J^ZZ=N_J?TDG*CCU^N!_3]>_/>OSC^-'BK
M]L+0OCM\'_ ?P^^,OP#\/^"OC+J_CNTTJP\2?LX>,?$?B;PCIW@OP8=?;S-=
MB_:2\*P>(I RG)3PCX2V_P +;7&ZC_P5-\4>(_ W[&OC_P 0>%=<UKPCJ]KX
MB^&977O#NM:SX=U+3UUKXG>'DULKK6@\K\I&[:,;B<L20:_DL^*GQR^(UG\6
MOAO/_P )_P#MGZW;^ [SQ/\ VQXAM+SXE^)/L!UW1>/[#USU]P?\*]#AG@+&
M<0X26+CF:@H5)0LUK>+5G9.UKM-=;)I]SEQ.)Y<2DNBOH_+_ (!_>QH$6IPZ
M580:W>V^I:Q;6175;^TM3IUC?:BPPQ32"SNJG[R@-E< @@D!:^M:E#I.FW&K
M26VIW-OI=H]Z;/1[75M2U%@$!5-+T30XR^N9+<)&K,,[B2I8#\"_^"07Q#^(
M'BKXW?&;0_%/Q%^*'B[P_:?"SP'K5II'Q-\2ZUXDU30M3_MO7RV!KX)T(@9(
M4#YCQD<U]T?MT_\ !1[P?^P]XB\ >%O$GPR\6^/Y_'NDZMK%G<^']6T?318K
MH> 5</R0<9R H(( W+DGCS#A+-L%Q"^&<#'^V<VLG%0M%.\>:R3MJK;7]7:R
M3_M'"K"?6\6VDG9V3[VU];;M_P"1[+X%_;0^#'Q-\=WGPS\,:-\=+7Q=9WNF
M:-JMKKW[,GQ]\,Z=H6HZ[H(UW11X@U[Q!\-U\,>'O^)"6?=XG:,8"*2 K;OM
M;J>1TZ<]?P']:_E6^&7_  79^&6A?&/]H;Q%_P *#\?^1XZ\1_"^\M+3_A(]
M%_T$:'\,M!T'G@_] 3)QU(';(K^@7]E#]H_2?VI_@9X7^,^A^'-3\):?XEN]
M5M+32-6NAJ&HV9T;6CH;,Q V[F8%VXX))((.:Y\\X4XBX?PBQ6<Y7*DFTDVX
MV;:;45J]59I]/=>KW-\-F.#Q:M@WTN^NGW:*VW4@^)?Q!_:$\(>(M1L?AE^S
MW;?%+0+?P)JFM6GB&[^*NC>"_MOCO^V J^#!H3>'' ##YAXGX')+ LSEN7TO
MXL_M/2:Q;:?>_LP:;;:.?&/A?1;O7S\;=%R/#.O:&&U_QB-%_P"$:+%O"OB(
M'PXWAABSMEFW8QCV#XO:=X^U[PO+9?#/XK6_PGU_3;I;R[\0GP=HGC?.F*&;
M^R3HFNG8-XP055<<8 S@>!_L5^)_C?XO^#O@_P"*7QO^,/A[Q_=?$/PGI>L6
M>E:1\-M'^'6F^$]1?+-EH_$,\FN(Q7!++%R@"E5"$_*?6H;<T%Y<\-.G6II9
MZ= ^M8&]G.FG>VLXK6]FM9JSOI;>_0\#_P""@OC#P->_#;_@H5X"A\&^5\0-
M,_X)]ZKKFK?$(JN-:\+:\/B_H.@^#@2-P/A7Q!HNM^(VVD\>(,  %R=7PA^Q
MI\+/VE/V:_V8M;\>>.?C[ID.E_!+X%7MGX?^'OQV^)GPZ\,_VOH6AZ#KVA:T
M?#_ASQ*OAR3Q&/$"Y_X25<,Z@*K+G*Y?_!07XFSWGPJ_X*"?![_A'=$M+?PO
M_P $^]7^(7_"5J5_X234?^$Z/Q?T#^QCA1GP]X6'@KS& X#:\,=&W?</[(7_
M ":Q^S;_ -D'^&'_ *A>@5U'4M5=:KN?FW\>? EG\,OVW?\ @DIX(TKQ)\0/
M%5AI?C/]IS&K_$'Q;K'Q&\47N?@IKF?[<U[Q&S^(W8$G#X" X0J2K,W[;5^2
MW[9O_*1?_@D__P!CC^T__P"J7>OUIH \7O=:^)@^+>C:);>!M-NOA7<^&]1N
MM8^()\7JFIZ;XD\P'1M$3P2$9BKA23XDWL,*B@)D&O:*_,O6?%O[;MO^TIHW
MP7LO''[,%QX=USP-XH^)UGJMW\(OB;_:=AI>@>,-!\/C12D?QMV-X@9=;R/$
M@79NPVS?BOTTIM-;IKU37YI!<*\K\%_%3X=?$BZ\7Z=X&\;^&_%FH>!/$0\+
M^,;3P_?#4/\ A'_$V.=%UHKG#C((Z#&2#QQ=\=>//"'PQ\*:QXX\>>(]$\(^
M%=!LOM^L^*?%&K+I?A[1=.)PS/K4BKM& O3ELY+ 8#>#_![]JO\ 8\^)OBJ3
MP+\$?CO\ ?&WB_4AJ.L_V-\/_'W@_5O$^H;2/[:UAM&T%I'9E;!>0ABY4L_&
M12 ^OZ\Q\6?$+P#X/N+:R\7^,?#?A6YU2UU&[L[7Q#XBT?33J":,R;RIUXJ,
M -NW+PNWY@2IKTZOF_XSQ_LWPRZ%>?'V]^$^G8M?$FB^&KSXF:KX0TP :[HQ
M77=(T9O$)B1R-!5F=8R3Y94[<2*:-]M?34#VK0M=TKQ+IFGZYH6IVFIZ+J=K
M]MTG5=+N_P"T-.O]/(4B17QM)PP'RC.<C=N4J.FKQGX5>)/A+K'AFWTOX.^(
M?A]K/A#PUMT2TM/AGXCT3Q%X>T$*'QI&[PZ771"/O*F%V@LQ.0 ?9J-M]/73
M\[ %%?(/Q6^&GQU\7>*M8U/X=?M+:G\+] NO#FCZ-I'A:R^%7@SQO_8?BC1-
M=.MZWK8UG7RTA_X23P_Y?AJ3PRRK&BMO5B4=5^J;:&:*VMX+B?[5.MJ!<W.T
M#[60,$C&>3G(]F '!(HL^S^Y_P"06-6BBB@#X0_;0T/X<ZI\*K#5/B_\8OBU
M\+/AEI'B+2['QAI?P4NM:T_Q-\5_[=;_ (1[0_!./ 7AOQ5\5'1O$NKLR^&O
MA3CQC+@.CL!A<_PAXO\ V=?V:OV,)_%_PE\.>(_@Y\ OA;X%U34=%TRW^#?Q
M,L?$G@_2?,8'64^%NO\ AF+XF:_*VN-)XDX\)%_%^06692QDS_\ @H?X=N?$
M?[,'B_18/#FL^(C=>(? =W?CPZ/B7J7B7PEI2^-M".M?$K0-$^#_ (C\'?$[
M7]>\&[G\3#POX3\5J9%T%&W##!N5_9\^'GQ-^(/["MOX#TOX@_$CX$>-O$^D
M^._#.C_%<_\ ":>(OB9HFG/XQUR'0?B6-$^/_B7XK_$G0?$/BSPZ4\4KX6\8
M^,;AO!TGB%D3885  /FK_@CS\3_B=\6?"/Q>\8>+_B;J?Q:T&]UOPLGAO6+O
MP?\ $K31KBC^WWD\:'7?B!\,OA0%/E+HWAE?"OA5?&">#G\/+&9(V=&K]SJ_
M-?\ 87_8-7]BB+XC^?\ $T_&/Q%\3M6TK7?%_C?5/ >D>&O&WB'5M&&Q=6\9
M^(F\2>*O$'B1V+%4#29!*L57(8?I10 5SOB#_D#ZO_V"=6_D:Z*N=\0?\@?5
M_P#L$ZM_(T ?D/\ \$<_^42_PE_[%WX\?^K.\?56_P"" ?\ RB=_99_Z\O'?
M_JS_ !%5G_@CG_RB7^$O_8N_'C_U9WCZJW_! /\ Y1._LL_]>7CO_P!6?XBI
M/9^C_)@='_P4G_Y.6_X),?\ 9[&J?^J8\?UB?\%ES_Q9WX C[1XLMO\ C)KP
M#_I7P]X\>#_B3^(^?!'/&OG'R\#'S5T/_!2/_DY#_@DM_P!GS/\ ^J8\?UC?
M\%D(3-\'?@"(8/%ESC]J?X7<>".?'8!TCQ'_ ,B/_P!3 0!LS_M?2OH>#].(
M<I]9?^D5#FQ/^Y2])?FSYP\C]U_R-_\ P6NQZ?9-9V]?]W\.G3GVKM?^"7O_
M "=M^VM_IWQCU'_B3_!O_2OV@3GXP?\ (";CQITY_N\=<=!TH_V1KGD?\BA_
MP6;]?^1[\&XZ9SC_ (2;&/UQ5_\ X)A13C]L']MV":Q^+&G?\2?X-8M/CO>_
MVC\7S_Q(C_R.O.,D'Y1G.".:^GJ.#RG.>6R]Q<UO9;>WAO[-MVOW]V^VIY^M
M\JWWG??L][_J?&7_  4X_P"4B'B?_LBG@3^;5\<:_#_Q(=8'D?\ ,'U0?YY_
MH,?]RC_Q1OV?_P %,?\ E(KXH_[(IX%_]#KXXU[_ ) VL9Z'1_\ G\_(_EQ_
MW /_  C?VCAC_DE>$_\ KT__ $B9R/?-_E^A_35^P5_RCU^ _P#V0?2__3+7
M\"OQ(\'_ /";2ZCI4_B/Q)HNGW7]J65Y::3>:-_I_;Z>W)Y^E?WV_L(\?\$]
M?@=_V132?_3(17\)6H?\?^H?]?FJ?TKS/"/#+%9WQDWO&O4Z;?O*KW^?X'G\
M2O\ V3*+?W?R1[!^P=H,^@_M2_LT6,^N:WXD_P"+\?"__2_$/]C?VGQXUT#\
M,U_9I_P5'_Y-@U'V\7>% /8?VR.*_CL_8Q_Y.T_9F_[+S\+_ /U,M K^PW_@
MJ%_R:]J__8W>%?\ T\K7YG]*I)86R2M_JP^BU=XZ[:O3??S/!S/7@;BEWVOU
MOO%>>A_-37Z-_L5^$?"GQ ^"W[;G@'QSXX/PX\(>,_@5JWACQ#X^!_XEWA;P
MSKOA_P 2:%KGC!?^$A95W>%%#$>80G')4X(_.2OT<_8KT'P!XJ^"_P"V[H?Q
M:\1_\(5\,=4^!.JZ+\1?%>XC4M"\"Z[H'B,ZYK+$ D+X4\-[LG#8]"<"OX&X
M!_Y*->OZ/^O0_G+PFM_KWM^5^O\ 3\KGN?PKTW2_#?\ P70T#0]+OAJ.D:#_
M ,$C/ ?A?1M6SQKVE:%\:?EUK/7IC/U(&>*_:;XO?\DF^*W_ &3KQU_Z8M<K
M\4/A79:):?\ !<;P_8^%;[^T?"^E_P#!(SP'9>&]6NL-_:&E#XTYT+6>0!\P
M!!Q]TDX)*YK]K_B]_P DF^*W_9.O'7_IBUROZH6R]%^2/[>6R]%^2/R^_P""
M#W_*)K]E#_L"_$__ -73X^K\Z?V6?C+?>"O &OZ'!^VP?@G]D^*GQ0'_  KZ
MZ_98/Q9^P?\ %:\#_A-QX;]^M?HM_P $'O\ E$U^RA_V!?B?_P"KI\?5^</[
M+'QFN/!/@#7]#_X;1^*'P3%K\1_BC>GX?>$_V0#\6=.L#_PFNO?\3G_A-O\
MA6WB\$'']X=,=S7V'"R;R[-TDW_N^B3=OWM75VC*R6EW[ME?WH[GFXK;Y/\
M0W_CO\7Y_'>I? G0Y_VT;?XZC_AH_P"#5Z/!-K^RR?A,#_Q.C_Q.1XV_X1S
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M_P"D3.)[YO\ +]#^FW]@/_E'O\!_^R*:3_Z9Q7\)6H?\?^H?]?FJ?TK^Z_\
M8*_Y1^_ W_LAVG_^F?5Z_A.U/_C_ -0_Z_!_Z"*Y/!O3.N-?^OLG]\J_^1XG
M$O\ N>4>K_-'T'^QC_R=I^S-_P!EY^%__J9:!7]AW_!4/_DUV^_[&_PM_P"G
MDU_'C^QC_P G:?LS?]EY^%__ *F6@5_8=_P5#_Y-=OO^QO\ "W_IY-?FGTJO
M]W_[M:?YH\/%?\D-Q9\_R9_-17Z+?L4_\*R_X4W^V]_PO#^T_P#A3'_"B=5_
MX6E_9./[2_X03^PO$/\ PG7]BX_A_P"$;SC'?&.U?G37Z*_L5Z_X \*?!?\
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M%Z0_)']N_P#P2 _Y1^?"?_K[\<_^IIXBK\$/B]_R53XH?]CYXH_]/35^]_\
MP2 _Y1^?"?\ Z^_'/_J:>(J_!#XM_P#)5/B/_P!CYXH_]/5?YM?2/_Y*&?\
MV5-7_P!*F?FWC9_R3W"OFM?/8H> _P#D?/ __8W^%_\ T]&O[.M/_P"0=#_U
M['^1K^,7P'_R/G@?_L;_  O_ .GHU_9UI_\ R#H?^O8_R-?*^$&V;?XU_P"E
MR.KP"_W/./6/Y2-VBBBOVL_H\**** "BBB@ HHHH **** "BBB@#\K?V7_\
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M]/ KV_\ X) @_P##4/Q^/G_\TL\!GKT_XG>O=L>GZ5XA_P '!O\ R5[X!?\
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MX>K\Q*_3K_@E%_R<IJ__ &3GQ+_Z?- K_.W@F_\ K+E.K^+O_>]3^8O#!O\
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MV^Q4>W7;^K'+F-OJCV_#NCQ _ \B'_E'E^UR..I_;CXZ8S_R7 =N/_K\5O\
M_!,/0)_#G[6_[:^E'X=^)/A?<6NC?!L'X?>-/'A^(WB;0@=#;_D,^.1XG\6M
MKI.<JV\XXPQ/-<>?V?-=\DG_ (=\?'+_ ,6#:UUQ_P!C/_3]*ZC_ ()>>&[C
MPK^UO^VMHEQX!UKX87-KHOP;SX)\0>/#\5]2T/.A')'CC+'75/./F8KD9)(%
M?7UW_P (6<J\OLNTIM_\Q$%>WMIZ]+\J;6G.U[KX,-L]MG^ODOZZ'QS_ ,%/
M?^4AOBG_ +(KX%_GXBKXYU[_ ) .L?\ 8'U3\/KQW_MS]>G_ !5W_%9_8_\
MP4Q/_&PWQ1 /^B*>!#]D^KD_T]*^0->/GZ#K'_+S]IT?53_G_P 'GKXQ_P"0
M_P"V?C+^P<,_\DKPG_UZ:^Z$U^G2YR/?-O.UO/;;O\C^FW]@K_E'Q\"/^R$:
M1_Z96K^$K4/^/_4/^OS5/Z5_=?\ L%?\H_?@:>W_  H[3_\ TSZO7\*&H?\
M'_J'_7YJG]*Y/!I?\+?&O_7V3>FWOXC?_@V/$XE_W/*?*]_P/H']C'_D[3]F
M;_LO/PO_ /4RT"O[#O\ @J'_ ,FNWW_8W^%O_3R:_CQ_8Q_Y.T_9F_[+S\+_
M /U,M K^P[_@J'_R:[??]C?X6_\ 3R:_-?I5?[N_^R6FOG=:>OEOY'A8K_DA
MN+/G^3/YJ*_1S]B7Q?X4\"?!;]MWQ]XX\'_\+&\(>#?@3JWB;Q#X*&TZ=K?A
MG0] \1Z]KO@U0P*[O%:EL!E9>N01FOSCK]'/V'O'EQ\+/A#^VY\2[#P?;>/K
MCX=_ K5?&5GX)U; T[Q9_8.@^(O$']C:UN!!;Q;M ((P5WY!R*_S[X!_Y*-+
MK?T>S_K\#^?/!W7CM][RZZ[OY_+JM.I[7\+-8TK7O^"Y>@:MI=@-&TC7O^"2
M_@36]&TC_H Z9KGQI!711G.""!@GN 0.*_:[XO?\DF^*W_9.O'7_ *8M<K\6
M?A7K'_"4_P#!='P_XC_LJVT7^W?^"1G@/Q0-)P =!&O?&HG^Q>@X4'TS@9Y/
M)_:;XO?\DF^*W_9.O'7_ *8M<K^J5LO1?DC^WS\O?^"#G_*)7]E+_L"?%#_U
M=7C^OSR_97\1ZK9^ -?LK'XP?M]^$[?_ (6I\4/^)7\!O@G_ ,)M\-<?\)H2
M/[#US_A6WB_U'4CJ3QDY_0W_ ((.?\HE?V4_^P)\4/\ U=7C^OSP_99UC5;/
MP#K\%AJ?_!3?3H/^%C?%(?9?V7/"&C>)/A&!_P )KKV!H6M^(/#))\0'JQW#
M!P,'-?7\+M++,WND]</HTFK\]6VCC+6^UDGVDMSSL3LO3_(VOCOKNJ:OJ/P(
MLK[XL?MT>+;<_M-_!K_B5_M'_!/_ (0GX:G&M'@ZV/AMX0)\0 G@;CSGCJ:_
M2C_@LO\ \F(_$'_L</AG_P"IKX?K\UOCMJ6JWNH? B&?4_\ @I-J)/[1_P &
MLVG[4?A#1O#OPTS_ &UT/_"/^&0?^$A]#^&!7Z4_\%DO^3%/'/\ V/'PN_\
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MM,-_O5+_ !T__3D _P"#^3/R/_9D^$/B/7O@3\,=4L?V$OBS\2+;4_#@O/\
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MQ5^V=_RD6_X)1?\ 8X_M/_\ JEFKE_\ @J/!;WGB7]CN&:S^&&I!OC;XE/\
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M  65TUM7^#OP)T@^'3XN.I_M-> ;,^%/[7;PY_;V[2/$A_L;^WVX\/[L _\
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M OBW_P %8_VJO%WA#5+S3+R[\/W?PK_9FTO3KS4-$UI=?T5C_87PX1@@8*9
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MD'A2%P%X'F_[-W[>OA[X>?L*_"CX ^*_V7_VZ;?XC^&/V<M+^&>KVEI^RO\
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M'/V;/VF=;\4^ [S2[+QAX>TGX)^,M2U/PEJ>NZ+_ &]H7]N?]"__ ,4Z/?\
M6OZC/^">7[<.B?LZ_LK^ /A7\3/V7OVZ;7QAH-WXH_M<Z5^R;\3-2TU6UW66
MUS/]LXVD88YR3G@$5^MG[-?A']GO6?%7QP_:7^!7C.U\?O\ M)^,/#=]XZ\0
M:1XD/B/PRWB7X4Z,/ 0TC0D$G_$C6)=(VRJPYD <*F8@?M"NOBWQ%S?BS"+!
MYPG9.Z:Z.TEI96M:3_I'+@,DPF#BUA'HTXM^35GV[L_B?_:*^+7BKQA\6OBQ
M\1M*_9?_ &Q_^$/U3Q'XGUFSN]7_ &8_B7II.F  '^7&,=<<5X?X)^)'B/QY
MH/A_QQX._9L_:T\7>#]=L]+UKPWXA\/?L^>,M2TS7M,XSK6B:YG@^W/M[?VK
M_&SXD_!_P)X*O_\ A=WC_P )_#CPCXP)\'+JOB[Q'HWAK[?J6NZ3(@T?1FUQ
MQ&^NM&3Y4;JS*=LA5G3"R? ?X-^!O@%\'/AO\&?AR+BX\!?#'PCI?@[PB-5O
M3J6HOI>B!4T4/K:D"0A %1F!P F!@$'\*Q'AUE&*QJQWVE)2V^US<WYK_/H?
M!XGP@X>Q6/\ K[OS*:J;:\ZGSWOYM.[T/P+_ &E/VO\ X._$;X3_ +3VD_#[
M]G/]OO4?C[\6?V*6_9_M?#UY^R7\3=/\--_8NC>/V\#@'_A',J?^$E\<:T0Q
M+#;E0H^5E^C?AA_P5E^!'[//P&^!/@[XM? []M;PCK&F^#_A=\,F.J_LK?$L
M:;J'CQ=%T#P^=&T4D,#_ ,5#M4$@' QD9!7]Y*^)_P!H2R_9G^+WC?X4_ OX
MP?$[P[HGQ%TSXB> _CC\./A];>/-(\/^-]=\3> -:;7M"*: &W^(-"9]'(?Y
M6>41A696V$_?12BE%;122^22_1'ZM&*A&,5M",8KTC&,5IZ16Q^0?[1/[;VF
M_$C]KK]AGXP^&_V7/VX+GP3^S[XF^,U[\1KF[_9/^)NGZE9+XY^&;:#X?.B:
M.4#:Z6\0;2P57,9)"F3 9LG]N+]LJ#X[ZM^SU>?"7]E_]JVYN/AC\2=6\4>)
M#\6/V*?B7XD\#6&EMX.;0S_;FB#!U_[Q4 9VC !.,G^F8_,<8( SSV[\]/4>
MOJ*CQU]ZWPV)Q&%Q7UI-:+9;)6:^YIM?,QQ"^LV2[[6M9K^NQ_(]>_MQ:W9^
M-M'^'-]\"/!5MX_U_1]4\3:/X3N_^"7WQF'B:_\ "^A_\AW6O[$_X28$^'CZ
MCGZU[Y^P_P#MDW'P/\<?M+:Y\4_V7OVJ;8?$[Q;X$UGPT?A3^QE\2_#GAN^T
MW0=&UW0]9?\ X0DY_L JR X*G<?F+97#?LSX9\%_L_\ QO\ CQH'[4'@WQ0O
MBOX@?"?PCXY^!UM>>'O$?_%.6>GZYJ_A_6M>TB711]]O[>T"- Q+,!& 254"
MOLRO2Q/$&(Q.%EA>2*;W:ZJ+YH[MIV:OZ]1?5UY?AZ?RG\=_[:/QX\2?&S]I
MZ_\ B;X!_96_;8N/"-U\-_#'A@W5U^S)\3-.U+^U=$UO)QHA"DC)..!QU Z#
MXOT'XP:Y\0;7QA;^!_V>OVM/$EQX6U?5/!?B3^R/V>_&6I?V#XHT,?\ $\T7
M7.N/$7O^M?W5^-?&W@[X<>%[_P ;^-_$.B^%/"&@69O-8\0:O>?V=INGZ:,'
M<S D$9(( !/=5P,+X!^S)\,_@MX+T/XA?$#X(^(?^$O\+_M%_%+Q-\==8U]?
M$1\2Z9?^*/&W]@Z%K7]A,P5#H'_$B3"XRC Y9N"/<R_C[-\%@LMP6%2C"":W
M>UI7NK>ZEK;>]_D<_P#9V&OYWOOUOIU?D?F?^R7_ ,%#/!/PE_9I^#'PR\8_
MLR_MTVWBCP)\.=+\,^)+.T_9,^)FH:98:EH8VXS@\]Q^1(Q7\JOQGT?XQ:3J
MWQ0^)NM_LN_M1>'/ ]KK/BCQI>>(?$/P&\9:;IF@^%_[9_M[^VM<[X_7OP1B
MO](S<-P7\_;_ #^E?(G[5U]^SIXC^&VL?L_?M!?$71? .@_M%:-JGPEL[2\\
M2Z1X:\1:^/$&-!.BZ$2-K-_Q.0%QD*2>FXDKAOC?-N%<=F^,P7*YYT[5+MNS
M<G-K;7WI2?3?<,PRW"8M+ZWLE:-NEK+]%V/X>OV7]-^,7A'XS? 'XM7W[*_[
M6ESX'T+XC_##X@7FKZ3^SW\2]2^W^%]#UK0-=_MK0_\ N7/S_6OZ7?VJ?^"A
M?@[XK? /QM\/_!_[,W[<-UXG\3V/V#1[:\_9,^)>GV#'^UXUW$[1T*')R<\$
MC(P/VL\(>$-,\#^$_"G@;0<II'@[PYI'AC2#=W1:_.E:'I"Z)HX+8 SY:E58
M[1W&6X':G:L1P.,J,8XSCCKTP,]..1@'I7G<:<18OC9MYPD[TW3NG=<C=VO2
M_2SZJUF<3X=P7]D9MD[ORYTFI2_E4HM.WR?=6TWV/X(]?^*FN>%-8\'^'?$G
M[.?[5>B:_P".]8U/1?"&E:M^SWXRTW4_%NJ'1AKHT70SQ_PD!/AW0\#^>.:^
M_OV$?VB;_P" /Q>U#QS\1/V5_P!M>UT"Y\-G11_97[*_Q+U'.J8/< ]R#T([
MX[5_05XWL_V;OC9^TM\*?"FK^.]%U#X[_LR>(M2^,O@_P!I/BQ6U2P.M^#==
M\":SJ^NZ$C&1HU\/>/'.6 5/[<\/N[*C*P^TQ$BABH &0, 8SGUPO/?'4= *
M_(,MX"RG*L:\=@[N7,FM$^O^?9?<?%Y-X3\.Y%FV59MA&^?)^:R>\F[WN]=;
MR??\#XM_9_\ VS_!'[2'BS6?!OASX1_M,^ K[0]'&KW>K?&/X">,?A1X9OM[
M%2NC:UX@"AM<4/DKG(16PV2,%?;_ $HK[T_4M]>^OWZA1110 4444 %%%% !
M7XQ?M ?\%&[#PQJ]SX]^#WCCX7W/P ^"7C+PKHW[3NJ^+-)\:-XDOO\ A-_B
M9X=\ +_P@B-_PB20^&_"BZQK7BG_ (6;$OB_P1XR?07\$ %V:1O=/VT/VN]-
M^!'A>]^'?@KQ7::5\>O$^DC_ (1*YNM$UCQ-X;\#KK6L-H/A_5O'4I/_  C.
M@:_XJG9O#W@1OBMXM\$^"_&?C,JA\9QCS W$_ _]AN:[\5_!#XV?M"Z=X#U'
MXH> _AL?#-[X6\*?#;X91Z3_ &MK6QAJ_C?QT_AT>*/B)XD\+QG1G7RU\(^"
M!XRBD\<>"/!<+;0P!^B_@SQ7IWC?PEX?\7Z3#J7]G^)]%T[6=*M]>TG5_#FL
MKIVNH&B.L:%XAB/B'0FYR4E"C[KA64<\K\6OBOX ^#O@/6/'GQ&U6Y\*>&M+
M6P!NFLM<U&_DU/6'$6C:'HNB: )/$FN^('D "^%_"^^5HS*8P<.R^U?ZK_.<
MY_+T]NGY_BQX^_:2\=?M(_M#^ O@C^S!K/A;Q5X2\,:O_;7Q3N_B'I./#/BW
M2=!UR31-:\8Z!'X@\.+#X_\ AYX1\1Z.?":R?"@++)\8UA6YF\)^!HA+XS /
M?O@5^U?X]^)'Q=U#PYXP\!0_\*/^+-_?ZY^R5\>/AY=ZIXF\,^.?"V@:.%DT
M7XI><K+\//B!)"6\2>#E\4D-XS@+_9Q'-X3W'],:^-OV7/V7_#O[+OA[QOH7
MAS5UUN?XC^/=1\?:RMGX/\&^!_#FF:LVC:#H/]DZ'X,\ Z%!X9T&(^']#C39
M&A=VRN&W$)ZA\7OBUX&^!_@7Q#X]\<7\UMH6DG3K1;/2;)M2\2:_JFNZU_87
MA_P=X?T-B#XA\1^*_$$R^%_!WAN/.Z239YHQL!9=D!X!^U+^TUX?^$"P?#+P
MYXG\(:5^T/\ $ZS<_!_0?&MEK#>&'U228Z&-9\:Z^2OAKPZ2D>M-X17Q;XI\
M'+XVDT9? T4S-$YK!_8=_:NN/VCO"/C#3/$NH6NI?%3X.^,/$GPN^*FJ>$_!
MVM^&_AG?>*M \:>)-!)T5O$)9?\ A(7\.Z)%XG\9^%%\6^*W\%R:YAII=\<2
M_%?@/P#\5/\ @H\/VB-5^(VJ^ +?]GCQF=+^'W@6]O/A5X,\2>._"C:#K'_$
M]\&Z)H7CWPU_PD_@'Q+X4&M:W_PF_BCXKC_A-/\ A,]?QX \#>#!X/'C/QE^
MSGPZ\ ^%OASX8TGP=X/L(-,T?0;4V-FEL%YQY2[M6*[2^MY8L7?YMQ(^4;4!
M9=E]R_R ].K\8_VFO^"A4O@U_%^M? 'QO\);KP=^S,#K7[37_"<Z/XS;5+_2
M_P#A9N@^ 3HW@AG/A-FT!@WCG=\5?"K>,O!O@[QKX"/@=LEC7O?[:/[7GAW]
MGSPE?>%=+UR#2OB[XF\.ZCJ'AE;K1]8\0>&O .E)K@T)?B3\47\-%&\/>%_^
M$DU=/#+>)?%_B[P;X+D\8GRI?''@]&;Q<OC_ ,!_V,==\93? OXW?M/6_A;4
M?BAX%\->+/M?A7P]X!^' T_79/&I\00N/BEXVT;PK_PD/CSQ%_PCNMZLWC#P
MKX5<>![GQF[SHC1*9)2R[(#]*_AA\2-!^*?P^\+_ !#\+G6XO#_B?2!K&DGQ
M#X;UCP[JK:<45LS:#KJQ^(D8@@C*C<"FW&Y5-/XH_$?P/\'? GB'XA^/]<B\
M->$O#-F+[6-8%EJ^J^5L9='&[1="23Q!KK!RJ;565R-DBY6+?'[%7XN_'/\
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M+L:_QX_::^'?[/$W@B?XC0^(H/#WC#Q>WA>[\4:/I#:CI/@1AH[ZV-:\=2#
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M>&?C7X8 3QIX,C=/&Q3_ (09-WC']0_V9_@3XE^#/@+PNOQ \=^+_'_Q'M?
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M"'CC7_$6&\1:[\*2G_")^"O$R1^%F_X1#1(#Y: 2,?NOXM?$;P]\&/AUXO\
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M>B_M%_LLZ]X:\7_"[]H+8^@ZX/@IXG\)>$/!YBRIF";@3_4Y0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?%'[=_[0'Q%_99_9
M1^,W[1?PR^&,'QB\3_!SPAJ7Q"O/A]<ZUK'AH:WX7T!E;QJKZUH7ASQ6ZMX9
M\-'6O$S((B0-"VEL*&/VO7%>(-!T/Q=HVL>%M=TNWUG0=?T?4]#UG3+L!M,O
M]*UD/HNN:,_ (4@."% /SX1E)#  _-;QE_P4N\-G]H3]C[X3?#;0-&\6_#[]
MH3]G/XF_M??%/XK:IXA;0--^!'[.G@?PAX?UKP_XWUU45R$\5^)-=3PTS%0L
M(W22LJ(S+VW@'_@JK^P+\5- ^)GB/P-^TIX>N?#_ ,'? _\ PLWXBZKX@\-^
M-_!0T#X9;'8^-M(;QYX;\)KXA\- )\GB;PL?%D+.0A=I'B _-O\ 8,_X)9?M
M/_LQ>!OVU8/&/Q6\%ZU\7M<^$.K?L??L(^-M4QXETKX:?LY^!D^(!^% \0Z'
M_P (RQ1#XC\;Z(_C7PSGQ<"_AX+OPVQ_E;X-?\$H_P!NRW\0_%S6OC1\,?@_
MXO;Q]_P3K;]DS5]+^,'[3'QF^/VD?$OXG:%\4/#?CC^V]=EV^$/$'P>^'OBP
MZ5K+>!O"7PID\&^$/@\@\.F%)#%)L /W-\.?\%0OV"_$7P:^*'QET[]HK1].
M^'/P;N/#7AKXC7GBOPC\3/!/BCPIJOC9%3P'N^&'B3PUX3^);OXN!7_A!_\
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M\"?%7X+GX4-K/Q6^.)\-$>/?C'X3!.SQ0?!ZJ5VJG&T4 ?3WB#_@I=X)U/\
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M&+#X$:&S(/ACH'[+.@>&?^%8Z'\1?"K*?^$V^*'BG=XU\9@H1XWQ)XO+ '[
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?.0.O8"M:BB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $\ E@# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *_-+_@I[^U#X_P#V5_V>M&O_
M (&PZ-J7[1_QB^*OPR^!?[/OA[5[,ZGINH^/O'>M<*=$(^:-?#FC:^< X#*H
M!^5@?TMK\M?VRO\ @GAX*_;=^-7[/WBWXU>+]<N_A%\$K7QY>M\!] M-7\,I
MXK\=>.-(CB/C;6?BKX;\2^%_%'AW_A%VT31GAC\,MO<K(K.@\684 _,WXU_\
M%7_CJ?V!_P!ACXX>#_%_@+X2?$GXV_M&Z5^SA^TWXE\5_#@^---^&OB?1/\
MA(= \=ZNO@E<-A#H9\588D+X,=2N,#;Y->_\%<?VO8?V+/VKOBYH?C?X-^+M
M6^"/[37PQ^#'PV_:.\/_  WUCPUX8^)'AOQT?^)]KFM?"GQ_X@/B?0&\+J^C
M"1FERG]NA40CPM*Q^L-:_P""&W_"/Q#0_@'^U-KGP:\#^&?VM? 7[8/P2\/7
MGPL7XLCX3>/? VC:[H"G^V_B!\22_P 05+OH'B4'Q6A*MH/S+XP%=1XS_P""
M*1^('P>_:*\/?$3]J?Q'\0OCC^T_\7?@Y\3_ (O?&O5OA5X1TW3-2?X&'71X
M?T70_A9X;\1>%?#?AU ==UP2,/%4A4,'Z*0W=_LEMW]VM^WHMKWOY 7_ -BG
M_@H/\0/%G[2O[0_P4^-'[1/[+_[0WPC^#7P0\+_&C_AL'X)V@\%_#/PDIUL:
M'X@\$>.-8'BKQ9X1\YE!\2I*?&1"'0?$^6:,LO@_ZU_:'^,GQ<^*7PI\#>*_
MV$/CA^SM_P (#>^,-1'QM_:CU7Q-X.^)O@;X,?#3P,B:YXAUK0M$_P"$A3PO
MK_B#"'*^*/%<4?@Q5>>1 78)]F:;\%/@_H?A;4? NA_"/X<:'X&UX+_PDO@K
M2O 7@S3/#'B#*Y*ZUH2^'QX<UT@]2X&.<9 P/A3]MS_@GJ/VJ?@'HW[.GP7^
M*EO^R%\-CXMU/Q/X\\)_#3X0:1J'AGXEZ9N?9HNMZ'H7B#P:O]@OXC5O%$R!
ME;Q>ZHK)@EASZ7_X:W]?@!^:GPK_ ."C'[;_ ,;/A?\ L0_#/1/$?@'P%\:/
MVP/VA?VC?A_X;_:.O/AN-2\,:[\&OV;M#773\2]!^%?B#Q)QX@\7?VU_PC!!
M/+:#GI@#MK?_ (*5_MP:M_P3,\5?M7>!_!'P!UOXG_!+Q)\8O!OQVU_Q;<^,
M=*\,*?A5K6A:#HFL^!?!7AX*OB3Q%XN.M,[(?&'A#P<K:$S,VQX_!*?4WB/_
M ()K?&_Q3X$^ T^K?MGBT_:-_98^(^K>*?V>_CCX3_9P^&W@OPSX$\":YX+T
M'P'KOP8?X(>'O$+>%=>\-&+0059Y5Q\L:KD #T'P_P#\$Q_"_A;_ ()Z?$G]
M@S3/B=K=S<_%"R\5KXX^->J^&=+U'4]=\>>.M;&O>(?&K^!V\2[7RZ#R_#1\
M5IM4X0L)"6']5\M]?O=_PM\_+</0/CY^TE\1? '_  3*\8?M4^&KC0[?XJZ5
M^S+X:^+5I=W>C'4?#B^*M:\'Z'KK-_8I?)0R:SMV!<'Y>J@@?E?^R[_P52\:
MP?"7Q/\ M,_%O]J'P9^UGX'^'7PL\#^*?C5^SY\!_P!G63P3\3/@/JWCS7O#
M^CGQEKOC?Q#XI'AKQ%X<^%#+KGA?QJGA+*+"K^,P%A.P_LO\4_V4;;XJ?L3^
M(/V.I_'%QH4.N?!/3/@P?'X\/'4Q9)HFCZ)H(UU?#Y\2!0SMHP:3PT/%OWF9
M#*ZJ:_/^;_@E[^UYJ'P#N?V6O&'_  4RUO7?V?K[X5^&?@NWA/2?V7/AKX+U
M73OAIX?_ .$>0:!H'C;0/$I\1(&\.Z WA5_^$KD\6J/".N^)00[R,ZX+ZK?9
M;^>WW >)?&#_ (*V^,?'_P 4/V*?&G[+7A7XU:[\#?&?[3/QW^$FM:/I?@#X
M:ZGJ/[6NE?"OP9H8T76/A8_B(?\ "2:'X;/B+6\?\)-M\&LJCQ.7&/"JBO7M
M/_X*5Z1\;_&/[ 7B+X,>,?BS\,- ^/?B3]LCP5XT^%/B'X._#/Q#JFJ>*/@5
MX(&M#2/'OC;7?$@\1^ 9?"GB!%\3>"I/"*>+AXU77@GCM4C5%7I?A9_P2,@^
M#'C#]F[_ (1S]H;6=0^#W[)G[1_Q@^.OP5^&OB3P*;[5/"7ACXNZ2L6L?!B/
MQP?B+(C>'O#'B/?XI3Q,?"6\/X@\0QL@,N4H_"3_ ((^0?"OQ+^S5KR_'N?7
M#^SI\7_VLOBQ96H^'!TYO&#?M6>$=$\.G1&\OXBO_P (]'X/.B!MVYSXQWOY
MJ0D,3WKZIIO^-[:[I[NUK^=P/"O^";?_  5E\6?%7X(_LV_#/]ICPY\8S\:/
MCQX1^.^M^!/VC=7\#?#;2_AC\6_$_P *-=\=:]KVCZ&?#WB/PF?^$C\(^&DT
M3PP$_P"$.\'*_C306C<J)&<9W[/'_!5[X[2:C_P3*\'S^#O%O[0_A?\ :_\
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MK1OBIKP\=^/3X%UI_$OB@A_%WQ"9/$Q)\(;(9=%0/O4#>?['_7?^M0.8UO\
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M?"K]DWXA>&3\-? 7@Y]+^"OAOXL>"]!U_7/&OC?6_$#>#_%)7Q5_;FB'_A%
MWB["\ I@8[UO^"H$'P:_:?\ ^"EVN?%KQSXF\>?LU?!+PW^Q#J/[/W@SPEX9
MT'_A*M0U?]H_X8IK9T;P5^[\*>(_$+^+M?3_ (2)V\5^+@1&S")DPI"?$K_@
MBQXO\::Y\5DT3]LC6_ /A#XZ_!_]F'X&_&GPMI?P*\%ZH?%?@;]G'P;X?\.C
M^P]<\0^)7E\.>(?%Y\&OXD5E0IX)379$;_A+T$8D[SXM?\$6?A?\6;O]K0:M
M\3-:T[P]^TKX<_9*L/ ^EV_@'2=0/P5U7]E+P6W@CP5K)_MWQ T7CM/%$15O
M&7AIO"GA))6 MRX=A,3_ &3K?;^K_P# Z7OJ!]I?L@?MM>$/VP;CXL:+8^ ?
M&WPF^)'P(\1:7X6^)'PQ^(%WH>H:KH>IZ_I!U[0M9_MWX?\ B/Q7X=U[P]XE
MB+B)UN/O:1,S19$8'\_GPT_X+#?M=1Z9X!^*VO?'C]E[XI:CXH_:R7]GR[_8
MCTOP*UA^T%>^!-9UW^Q8_'&@ZMH7B5O$(E23#K(?!9\'95<L0B@?O7^P;^Q/
M<?L>>'/']EK'B+X4>-/&7CO6]+NM9\1?"G]F;X-_LPZ7I^E:)HZ:-I.B'0?@
M]H03Q$R[#XB5_%32-"^ONJ QAE;+_82_X)V_#7]B?P??:(?^$1^)'C^[^(_C
MWQI;?%^Y^&^B^&_'EAIGCIHO^*/'B R>*O$WDQ#=YB_\)8SN&0C;M*2</^R7
M>G]:^0'Y#ZM_P5<_:E\3?M3?&[]A'X-:Y\-]+^/OB?\ ;A\4_!?X*>*O%OAO
M2=/\,_";X%>!VUZ37==UT&0K\0?$I?1'\,^#/#3(\LCMXF9I!M\&[OT\_P""
M@W[4'QO_ &=- _93^"OP)U+PW>?'S]JGXU>%O@9I/Q,^('AO^U/#7A/3O+SX
MY^)>J^#=#$?_  D.O*'T?R_# *H&ED'[L[Q7@?CK_@BCX \877[2OC&'XWW7
MA#XS?&[]K/2_VIOA5\;/#_PWTJP\=?L]>.]"UK7]>CT;1FD\0J_C[0-NMZT3
MO/@[YW?QHQ=@&/VI^UM^Q5/^UG\-_@Q8ZM\5-1^'_P ??@-X]\,?$WX<_'CP
M;X0TN^/AWXEZ##OUG7!X(F\0*7\/^+ %,OA5O%XV.WAY6E+P%6/]DTT]?7[M
M@/G&#]J[]I?]A[X?_%_Q'_P4'LM#^,N@:!XY^&'@K]G+XF_ CPEHWAOQW^TC
MXE\>98^"U^"*^(RWA_Q'X8\2! I\P(0OB61"VS#TKS_@M!\#-(M-&T;7/@1^
MTAIOQA'[06E?LR^(OV?CX0\&?\+?T'XGZ]HVOZ]X&9-#_P"%D?\ "+:[X>\7
MC16'@QH_%ZLP;[V0,9OB;_@DWXK^)WPQ^)UC\=OVT?BS\4?VAO&?Q5^%OQF\
M)_&-_#FD>&?"_P )?$WP0/B > F\"?!%=??PMHF@>9K6M+XVC$B#QFDA:0@A
M%?'T'_@CQ<?\+(\$_&[XB_M/ZW\2?C[:?M??"[]K3XI_$.X^%>B^&M,^)'_"
MI])D\/\ @GX9:+X)T#Q*L7P_\-K_ &UK)_X297\93#G=&,+G=?5.O^6O3J_G
MY^0&S\)_^"U'P7^+GC'X0>##\!?VD?A_%\8_C3J?[.%IXX\:>&_!8\#>$/CQ
MH@=#\-=;UK0?B1(#XB.=$*IX8\R,MK@P"5)K9^!?_!9[X,?'WQ?\&/#MM\!_
MVC_ASH'[0'B7QW\/_A;\3/&_AGP8? _B+QYX$_Y#O@E#H'B?Q3XE5VP COX1
MVH<$\#(S_"'_  2!L_"L7PQ@_P"%ZW.HCX9?\%$?$O[>B&[^'!+:\^N_V$#\
M,'"_$5U15&A)CQ869268'P*H53)\2_\ !-C_ ()=?';4/A[^SYXS_:?^)GQ(
M^'6@?L^_$KXZ^,O ?[,@\">#_#GB30?'_CW6]>T!/B8_Q4C27Q5&A\Q?%7@W
MPUY16/Q<QF<[%)&_^R?Y:OSUMWVOTW ^]] _X+ ?#.;XA>*/!'Q _9]_:/\
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M#XDK\5FUE&UG</$LR^'CX636V:-$7Q<KL&#>5(QDKH_^"F/_  3.\,_\%&=
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M 2/[</\ PF7_  EO_"(>2^9,OG:;N@_\%;OAIXK^(GQ8\"^'/@'^T?XC\/\
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M5SJIC;4M0_L0!)-7UEB$9]<\2N_F.S#)+G8>5CKZ)KA **** "BBB@ HHHH
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M-+T+_D.ZUKOY_7ITHF^(7Q^L]&T_Q'?>./C';>'M>O-5LM'U:[\2>,O[,O\
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M_K(45_D[Z;\3?CAJ7VC^ROB-\4;G^R[/5-:O/L?C#QE_H&E_^%)^'_UJS_\
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M_G5_\$6OB;\1M>_X*<?LGZ5JOQ!\;:SI]UK7Q-%YI>K>,-8U+3+W/P:^+GS
M,"N1Z$$>WH4 >8?\%J/^4IW[8W_8]^ __5+?"*OS"K^J;]O7_@BY^V+^V7^W
M!^U/\??@_JWP)M_ 'B?XC:5HVD6OC;QWXR\,^)?[4T'X8> = U\_\4_\./%X
M4$Z'\J[CD9P3@FOEG_B&N_X*,_\ 0>_9=_\ #I^,O_G)US@?S_T5_0!_Q#7?
M\%&?^@]^R[_X=/QE_P#.3H_XAKO^"C/_ $'OV7?_  Z?C+_YR= '\_\ 17]
M'_$-=_P49_Z#W[+O_AT_&7_SDZ/^(:[_ (*,_P#0>_9=_P##I^,O_G)T ?S_
M -%?NQKO_!N[_P %"?#<6D3WVJ_LS?\ $]\2:7HMG]D^*?C,?\33721W^&WJ
M.O.>O0C/4?\ $-=_P49_Z#W[+O\ X=/QE_\ .3H _G_HK^@#_B&N_P""C/\
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M$MM0'QX\>?'7P>=6T?XE_P#%I?"^NZ+\(M!\"_#'CX;C_BHO"?\ 88_Y%/\
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M2YN/"_P'\!^"]8TG2?!__"-ZGH.J>!O^)!KO]M_\4WX1_P"$@Z_\)1_PE/\
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M_LO7/V@/ 7CKP+G_ (2#_BF/^*3^'6B:YX7\$?\ 0E_V_P#\(/G_ (03%?N
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M5 '\YWP:_:*T/X<?\,\WWB.'Q)K>H?";]IS4_C1K'^A:-J7_ !3']B?"3/\
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M>LOB1J>HV7@'X3_M Z'\"/ OC#Q!KA\,GPUH&O\ BWS=<^*13PH?&*_\(5H
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MX0:UJ:_"7X/>"?V@?V"/@-XA/C?0/#_AO_A9?_"2./''[1WQ1\%>*5\7@_\
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M2_#S51JPU+P_JVBZYKNAR:+MUT!MQ_L8RL6&6+[F<!@1Z9]O^-__ $+GPO\
M_"S\7_\ SN:/M_QO_P"A<^%__A9^+_\ YW- 'K5>*_!S_D#>,?\ LL'QA_\
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M]!]!_*EKP8?M(? ( ?\ %X_ _0?\S'H__P 52_\ #2'P"_Z+'X'_ /"CT?\
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M&C#]1R,>O!S[T ?1%%>#_P##2'P"_P"BQ^!__"CT?_XJC_AI#X!?]%C\#_\
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M_"N/^&IO%7_"Z_\ A6=GXOU/QS_P@G_"E]=.A?V'_P *_P#^+H;O^%T?\*L
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MC_X;?\E3\!_\T@\8\#^VASD?&S@<C)[^W6O3_P"R/C?_ -%"^%__ (9[Q?\
M_/MH"Z[K[U_F>M45Y+_9'QJ_Z*)\,?\ PT'B_P#^?=1_9'QJ_P"BB?#'_P -
M!XO_ /GW4!==U]Z_S.0^,OQ U;X</\-[FSM-5OH/$OCO4/#.MVN@>&]7\9:K
M_90^&'Q8\0Z-_9.A^'0VOR,?$?A_0T=XTVHK/'$\9RP^//A]\?/CI\0-7O\
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MCXGQ-GQ3XDUX;_%7Q6\('QEGP'XG//@,^"S7UE_9'QO_ .BA?"__ ,,]XO\
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M-']K?" 3?$#X:_\ )8-,-J1\(/&)(8>"_'F-V/C9G.,\D]!T.<U[#_9'QO\
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MO%__ ,^VC^R/C?\ ]%"^%_\ X9[Q?_\ /MH%==U]Z_S/6J\5^#G_ "!O&/\
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M.6_@W61K5GI.DWO[*/\ 9E_J?]A^ -#)UW1!XB8:]A?A;HC $@'/B,%E\P$
M'ZV0302Y\DY_#_/^15BOB[X,Z;?_  2^'/@_X;^&/A!\8Y_#_@NW_P"$:T?_
M (2'6?@2=1_LM==\K16UW6?^%E(-?UUH\,?%#*?%WBYR9_'IE\=?O#[M_P )
M]XO_ .B(_%'_ ,&_P8_^?52NNZ^]?Y@>MT5XY_PL+Q?_ -$)^+?_ (.?@U[_
M /5:_8_D:/\ A87B_P#Z(3\6_P#P<_!KW_ZK7['\C1==U]Z_S ]CKR7XX?\
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M[VQ#7737V;O?T5M5K<_N%^;^]'_WR?\ #Z_Y/!\W]Z/_ +Y/^'U_R>/X</\
MA\!_P4'_ .B_0_\ AO/@_P#_ #NJL?\ #WK_ (*&_P#1?H?_  V/PA_^=W3_
M .(C<-_S2_\ !:_S.C_B4OQ5[<-_^%,O_E)_</\ -_>C_P"^3_A]?\G@^;^]
M'_WR?\/K_D\?PX?\/?\ _@H-_P!%_A_\-C\(?_G=T?\ #WK_ (*&C_FOT/\
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M?IU_#([U['QZK_X]_A_G)]L?PE>$/^"M7[?>D6VOP6/QXAM?[3\7^)]9O/\
MBV'P?'_$TUS6CUQ\.1DGG+-DGN3BNG_X? _\%"/^C@(?_#8?"'_YW='_ !$;
MAS^:?RBS#_B4WQ5;=J?#3_PXAKMT]F^M_P ^ME_<=QZK_P"/?X?YR?;'@.J>
M"M<N?C?X1\7PSZP= L_AOX[TC6;8>(M;'AK^V9/%_P )]8\$.?!+>)#X:'B$
M1Z+XV*^*8O"PG1?W9E$;*C?QW_\ #X+_ (*$_P#1?H?_  W?P>_^=S5G_A[[
M_P %#_\ HNQ^[]K_ .27_#;I_=_Y)Q^G2C_B(W#CV<W_ -NM_E</^)3O%1?9
MX87^+$7^Z\%;^NVO]PGS?WH_^^3_ (?7_)X/F_O1_P#?)_P^O^3Q_#A_P]__
M ."@W_1?X?\ PV/PB_\ G>4?\/>O^"AH_P":_0_^&Q^$/_SNJ/\ B(W#?\S_
M /!9O_Q*7XJ]N&O_  IE_P#*3^S#XI8_M7X/\J?^+NZ;GY3_ -"5XZ_,=<CK
M_3U_ ]1_X]_A_G/TQ_"9XC_X*U_M]ZC=>$+B?X[P7/\ 9GB,:S9D_"_X/'_B
M9C1=?Q@GX<G!Y^\"&.220:Z7_A\/_P %#O\ HX"+_P -A\(O_G=T?\1&X<UU
MFO2+_K_AS#_B4WQ5T]SAGK>V(:ZZ:^S=[K796U6M[G]Q>5_O+_WRWO[>_P#/
MUX^8?CYX8\4>(-$\.Z?X7\+>+/$.H7/B$V=YJ?A/Q=HOAK5/"&D#1M>'_"8*
M-=\1^$D\0>(XR5B\$JC2?\(7XTU^/QP"Q\**6_D2_P"'OG_!0?\ Z+RG_AL/
MA!_\[JK _P""O?\ P4/E_P":_P ?_AL?A#^G_%NC^G/7WKF_XB/P\WM)_)O\
MGH'_ !*;XJ+>'#-O[V(_SIH_K2^!^@_&W1?&7QHU/XM6FC7*^+_%_AK6O!UY
MH'CC6_$6DQZ<-"&AZSHFBZ'K_ACPFWAU/#":)HZB1$9?&;*_C%R+@^2?K48]
M5_)CZ>W^<GVQ_#U+_P %?/\ @H? +GSOCNV;7DG_ (5=\-^<GCG_ (5SU^E5
MO^'P7_!0G_HOT/\ X;OX/?\ SN:Z/^(C<.+=S7R?ZV#_ (E.\5'JH<,WU^#$
M6UZ?8=WVVU9_<2")<^2,#/))'J>ISP3VY_+OY#\(,'1O&/O\8/C'S_W.FO8_
M_77\9L__  5\_P""@Y//Q]R?^R<?#4?3_FG';Z\CO7]+/_!*SXJ>-OC;^QGX
M*^)7Q-U4^(_&'B7QO\9+SQ%JO]E:-I'V[4S\9_'NAG.D>'1_PCJ@;%RT>1W(
M9EX]C)>+,IS_ !3PF"YKQBY.ZZ+S[W^1^?\ 'O@OQQX:95'-^)524:DE&GR3
MNI2=VE%6LU:-URN3=C]/%"!!R< GOR3GW_#OC\Z\R\=_\C5\%B,G_BZ.J<?]
MT8^+1&3Z\UZ4J@(BMT +'UXR>GT .#^O%?EM_P %1OVH/&_[)OP?^%WQ9^'^
MF^'-:U^V^-&G:*VF>*K35WTQM/UGX:?%B-G8:)XB\+L&0J5CS(_!;>'8*R>W
MBL3A<'AI8O%NT(MWD_5[?)7\['YQDN6XS/LVRO)<!&^:YQ.-.E':\G\*N_=C
MS.R3>BU;MJ,^%W[7[_#_ ,4_'_P-^T3\0-;\0Z]H7[0GQ/M/ VE^!_@I\2M1
MU7PE\,5;PX? FA:XG@*'QDK+,NM-'X-<[)?&"?ZK$A#Q_2</[8_[/>H^.;3P
M#H_C>XU+QI=>(_"W@VST2UT'QI$S>(_'&DZWK_@S1]J>'&5V\3^'-"\9^*%)
M5T;P=X#\3>,7>&+PP\H_FCUC_@MC\>==OSKFM_ C]FS6M0MK3['9W6J^#O%N
MIZG_ &6%&NX&[XAMA>,\8&[)[D'A-._X*S>--(UFXUS2_P!EO]DO3M?N[QM9
M_M6S^&WBI-3.IZ)K<NOZ%K >/X@I(N/$7B#6O$RLDBN!K'B)MV_Q=*\OR;X\
MX;6^:KKHXR\]-EZ?TS]I7T;/%U[9)S>E2B[I^:;>SOMULE<_M5\X?W/_ $.C
MSA_<_P#0Z_D6_P"'^_[6'_1.?V?O_"=^)/\ \\2C_A_O^UA_T3G]G[_PG?B3
M_P#/$I?Z^<*_\_G_ . /_P"2+_XEL\7_ /HD:G_@^G_D?UT^</[G_H='G#^Y
M_P"AU_(M_P /]_VL/^B<_L_?^$[\2?\ YXE'_#_?]K#_ *)S^S]_X3OQ)_\
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MVM?^B7_ 7_PG?B1_\\2I_P"(B\*;>WE_X+?_ ,D'_$MGB_\ ]$C4_P#!]/\
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M_P#!./\ Z(3KO_A]_CW_ //)H_XA-FO_ $-8_=_P!_\ $Z_"'_1*<2OT=/\
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M(T?4A_9>AZ+X]T'IK_&@>(O^*WT/!(W#)QP2#Y!HO_,8_P"PQJO]*_MDU/\
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M(O?\$X\?\D+\3CW_ .%\?M'>O_93.]=6(\+<7B]LV2=NS6VVB3Z]SHR_Z8W
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M<3;+_E[2[?XS^*6BO[6_^')O_!.3_HB/BS_Q(C]I3_Y\_P#G)]L)_P .3?\
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M/_4TUZMBO["OA7_P1O\ ^">VL>&M7N[_ ."7B075M\1_C)HZJ/VA?VE<G2=
M^,OCK0=%(S\9\9_X1_1XP1D?>!&!\H]1_P"')W_!./\ Z(7XM_\ $A?VD_\
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M /!'_0D>$O\ PF]%_P *\N^-?@3P1_PISXKSP^#O"0/_  J[QWC'AS1R<?\
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M'_\ "&?VXI0^+SN#X^C_ !HLM>U7X;Z7!\$OAN;WXP:3X9\1?".RN]58Z?\
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MT\*L$^,G@]=?"S>!%W,P^O\ _A6'PZ_Z$+P'_P"$?HO_ ,30!TO_  D&A?\
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M3M&]@P+'R6P_:F^*'CZ+PO=> ?"WP_TR\^(:ZGX7\(>'?$'B'5M2\1V/CL?
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M4*K$+(H8G&6]XH ^0O%7Q9TKQ5XR^#>B:9X=^*&F7%U\4E!N?%/P@^)7AO3
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MA+_X<;P;_P#-%7L5% 'R;\2?C9\'[V'P3]@^+GPNN6M?B/X$O+K[+X]\'?\
M(,_MD@9!\19 Z9.&!SG%>H?\+_\ @;_T6KX2_P#AQO!O_P T5>Q44 >._P#"
M_P#X&_\ 1:OA+_X<;P;_ /-%1_PO_P"!O_1:OA+_ .'&\&__ #15[%10!X[_
M ,+_ /@;_P!%J^$O_AQO!O\ \T54[WXU_ /4K6XL;WXQ?"6YL;JU-I=VA^(_
M@[!4XX9O[?\ EX)X&6X!W'FO;J* /SSAM/V?-,\/6.B#]H7X<76HE=*L?$.I
MGQYX.":[X9 ^$NAZ[HS:,OB#Y3XN\._"K0_"KY=U4:YXC*J'DP_K/P]^.7P?
MLX_&QOOC#\+;7[5\1O%5[:&Z\?>#B;[324P%!\18(P&.XE0, ;6R2OUG10!X
M[_PO_P"!O_1:OA+_ .'&\&__ #14?\+_ /@;_P!%J^$O_AQO!O\ \T5>Q44
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M>#OA-X$CC4:Y^SB?GC\,_!/P,A<?>700P/SY'WQ10!XI_;?[1/\ T3'X.?\
MA^?&?_T-U4O[8_:+_P"B5?!/_P /OXQ_^AOKWBB@#P?^V/VB_P#HE7P3_P##
M[^,?_H;Z\U^,VN_M"_\ "H?B<9_AC\'+>'_A7'CO[5_Q??QE]W_A#=<SS_PS
M@.X!SGL#@]#]A5Y+\</^2-_%_P#[);X[_P#4/UZ@# &L?M%X&/A7\$\8&/\
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M2ZA?7/SZ7IZ^)_$&K:#KVN>,=<.@^&/%/A[7!X4\/:T?"W@IO%_BSP7(/^$
M\4@+XND'@S8 >C?!_7?VA?\ A$]9$/PR^#ESCXJ?'7_CY^/'C,<CXS>//[O[
M.&0/;H!GJ#7KW]M_M$_]$Q^#G_A^?&?_ -#=5GX+_P#(JZU_V5[X[?\ JYO'
MU>Q4 >*?VW^T3_T3'X.?^'Y\9_\ T-U<!XJ\-?$OQJMA_P )Q^SU^SAXM6UW
M?9/^$J^*>M>)/L /4C^WOV;R<]3Q\V22.>:^JJ^:/B#X>OY_BI\$?&5D_B,+
MI?CSQ#9>(5MM6UJ+PY_PC#_!KXN#?KVAEQX;VOXC.A*OB.2.-Q(GAQ"SAP%
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MM&QL[*SMOL=C;V]M;P  6MI:FP0'&1A05 ![L!UZM0!JT444 %%%% !1110
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M$C_P3?!W_P"=O1_P@?C#_HM/Q(_\$WP=_P#G;U\J_#GQY\:-6^)OPQBU>_\
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MMZ]:HH \!M_A9KD/B76O%=O\9_B/_:^K:1X8\-7S#2/@[SIV@ZSK^LZ* /\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^)/C;]B\8^(_B]XN?7O!O@*;X4^-A\#O^%D?\)-X ^'OA3Q-_P )UX;/PO\
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M_P#MOQ'!:?VH=+%DQMI)'O6UMBNBA3H\9^0E<*0N'0[E."IH ]0HKSQO&OA
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M670-"UER^'4E-HY*L #T2BOGB7]HWX,9U^;_ (3_ $U;?PI;?;?$7^B:LRZ
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M^$>M>&?#FG^/O&VC^'?$&@>"=;U[7/#4/]@Z_)X>UG1'DC8[?WCP#/C,K&H
MZ#]DW]G@#48;GQ?=75MJ?AKQUX7O+.Y\0^#1IW]F>.?[!_X2"0+_ & 2=?/]
MB:%M\28\U0K#]X755O7O[-7P'U$:J=4\1#6XKK5?%&LW']KZMX0?YO'33#6@
M=6_X1]?$0V_V[K!\%.LZGP>/$!_X0;[.BH1]?_\ "$^#_P#H3_"G_A.:-_\
M$T?\(3X/_P"A/\*?^$YHW_Q- 'RQ\4/@7\&OB9H+:%KGC#4_LY\(:3\/;FXM
M/%FF/J5_INB:3XCT#02\NN"0#Q Z^-]:)8)_Q58(:7<K(HM?%[X-?"[XUW&C
MS^,_B!=:9_95B]H/^$=\0>$-/(TK7-'U[0M:T,_V]X?ESH'BE-="N Q,S^'_
M  R\85?E'T[_ ,(3X/\ ^A/\*?\ A.:-_P#$T?\ "$^#_P#H3_"G_A.:-_\
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M (![/XU^$_P@\>:EXI\1ZKXIMK74?&.D>!-#UDZ7XCTG30VG>!O&G_"=Z#M
MRRZ\'/\ K&Z(K87:5DKR?2/V4O@;I=I!97'BF=K&U\.ZIHMW97'B'P=J8O\
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M#;@8RKB1/K7_ (0GP?\ ]"?X4_\ "<T;_P")H_X0GP?_ -"?X4_\)S1O_B:
M/EGPW\ O@EX<^'6K?#32_&%PWA?4AX6%X;SQ?I%__:#^!'T%-(<(T3^&TVIH
M6B_\)@1X3*RB1E8A2DAYL?LE_ 07POH?B+K9@_X2X^-&TL>)/!HTO^UQXUU[
MQWD(?#C$*WB/76;!D+  +EF/'V5_PA/@_P#Z$_PI_P"$YHW_ ,31_P (3X/_
M .A/\*?^$YHW_P 30!\2P?L?_LWP^%]0\'-\0-9_L?5+33K*]5?%W@X%AH6C
MZ_H,7)\.X!$>N:X'!!!<Y!4 J>\\??"'X=?%7P]I7AWQ7\3+NVTW1#JYL5\/
MZI\-]*VZ9J[>5HI9F\/NNWPQX= \-P[(XU9-TF'+;J^GO^$)\'_]"?X4_P#"
M<T;_ .)H_P"$)\'_ /0G^%/_  G-&_\ B: /E3P+^SW\'OAOXO\ ^$W\-_$?
M4O[2M_$GB;Q*;;5?%O@\Z9_:NO\ ]OC7CM7PZ' SKI.=X* 9+#%<AIG[)OP"
MTZ\U@?\ ";:Y<Z=KMGX[LM8TK5O$G@[4M,SXZ?01KVM?-X;7_A'_ !"/^$&T
M,J1N)7P^6P WB_?]#?$Z]\$?#'P!XO\ &T_PUT7Q)_PB^CZOK=EX=\/:/H@U
M7Q!J@)&BZ+HBF-<Z]XHW(%=>6+*9,CEOF;3/VS_V.-7_ +&_L-]$U6#7?^$:
M:SO-*\"?;]-;^WF^ ;1H0B%=H'[1GPI!DV[P-< VM_PBKT =$/V8?@>=<N?$
M,'Q+UW3-8N=9_MD7MKXA^&P%CJO]B>.]")!/A@+C'CS6A][EAX<4?ZIL>GZ!
M\)_@_H"?#A=,\<W+ZU\)=(.C>#O$-UXWTG4=0T]/^$-/@10-%;=X6,H\-E58
MGPFH.-ZQH,J?$-!_;0_8V\5^%=/\8>';0ZGX?U1FM+*\_P"%0:V#?:J/AK_P
MMW6M$^7PXI.OK\.,>)F0\.F49B-VZIH?[8?[&WB3Q'H?A;2[JPM;[Q1JNG:+
MH]S<_#B2PTW^U=?\9^/_  )HG]N:X/#7_".Z ?%/B7X5Z]X7C/B5XF(?PO&$
MSXJC- '>0_LQ_ ;^U-?\1CX@W]P/$]J;+60?%O@TZ:5_X66?BP ,:  &_P"$
MH*R;CD>7F,H'(D7!U?\ 9%_9TUCP[I'@T^,-2TW1]+M-+LK,Z3X\&F:D1H>C
M> M!'=B2!\*M"SZY\3?=!('">//VR_@?\.?B1XH\ >,/A;;Z?H_@_P"(WBGX
M?:OXMLM)T?4!8Z1X'_9A/[2NMZR-'7PXSC_BFR/#'_"-J=^[YUP#MKH;S]MC
M]CW3+_4;&?2_W^@7GBFRU:[M/AO_ ,2VQ_X0;6_B]H.NY^7"X/P/^*84@,,:
M =P)/ !Z^/@U\()O#$'A75_'%QJ=M;:SXZUJZNKGQAH^FZI>ZGXZUC^W]?+'
M0=N<L2 %7.T GJ0M;_A2GP@&A?#'1(/%%K=6OP=\(:IX,\'6>J:MX.O]/O\
M2]<C\/D?VZ3X<*L6.A:(H/A;R0N%0@G!/(:1^U!^RCXKUKPOX=\*Z+;>([_Q
MYK'AG0_#EII'PL?4/[03Q!H?C[7M"UGY?#X4: - ^%7C<K+ABB: T:!2S25]
ME_\ "$^#_P#H3_"G_A.:-_\ $T ?(NF_LU? F#2C97WC W5P/#G@3PP+L>+M
M'&I:?JG@1<Z%K6B:X2?%.@^(BP.#'XN/! VD@D]-XA^"7P.\3^)M8\3ZUXBM
M)]0U[QCX9\57V/$'@]5.L>"_!I\#Z+I&WU;0'=W7<6!;YG!))^E/^$)\'_\
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M]O:!K"."X+;<!0685W,WQ-\!06-M?6WC'PU<V^JW6JV.DFT\0Z.1KFK:&O\
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MT0$,"$Q]!?\ "S/ UE803ZKXHT0S_;O[(N[FU&J_V8-5_MO_ (00J!C&1XF
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MD^)/V4_@]XD^TWFGWMU:^(/C%I.I"^U+12K:'K3!O@LR,P8?(S#]VI*1A4+
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MQA^S;\3O"OPY^&47Q9\9>)=);0/#7A/5;[2M/TEM4;5X](;6M<77O$?A*+Q
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MX;>!_A#XL\=+\3M"USX4^"];T-OB0#X?#?#S0B?&TGA,-X*?QCX@\3%"596
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M/X?TCQ5K6E7-_P"'[CQAX3T36+NW0D:#I6NZVFB2^-"%E"MX>\*QG_A)/&;
M8B\()(Q\Q<HWO]>/>-_$_A#2H?#=EXCL;?6-0\3>-?\ A%_!^E-9+J6H:CXF
M&AZYKY6-1+)@)X:T37?$,A#1X\*PR,(]AVL ?!^A?M(?"379/&,^E?!C4[74
M/#'@_P 4?M :M:W7B,:<;T^!C_;FN$<$?\)%GQSK9RP(R3GY>*^KO&'QMT+X
M<^%_AQXI\7^'KG3M.\8WK61^Q[=33PII>A>"_$?CHZNQVMC;X?T([@N&##!S
MR#W&F?#'X9Q6"Y^'_@K1;C5-(%CJ^EC2-&&1K@W:YH[8  R1@@<-Z88@9OQ$
M'P>\%>#K6;Q[IGARU\(VM[J7V3[;I/\ :.FV.HZSHWB ZZ54 K\_A_\ MI)2
M%!,;$$@A!0!Z/X4U'4M7TL7VJZ)<>'KC[9J5JVF7EXFH-C^UF42$H%#9"D9
M &3C:H ';5\YZE^T=\)M.-R3XJ^TC2]7&C:LMK9ZN?[/;_BHMV2%./\ D2=;
M'#$Y4<\MNQ/"_P"TC\.?%_B*+0_#$^J>)YV\.>*-:OKN#1M5TUK(^ T\ ZNV
MCOH6N8\1-K\J?%+06";  <DJ#M6, ^IZ*Y'PKK<'B70='\10V]S:6VJ:5I]Z
MMIJMHUAJ%F'4M^]1AQR6^7.!@$, VP==0 4444 %%%% !1110 4444 %?-'C
MSXY:)X*G^((U3P]J>H6OPRO? EWK%S;A=1QIWC=R3K"H8\Z$OAD"1G9I"VQ0
MT0&\NOTO7G4W@_PK=W6HW=YI>G7%QJO]E?VM>"S!_MP:&&&AKK8"G^W@G]LE
ME+@H6(0<84 'S)XF_:8\+^&_"WQ)\9>(_!6NVP\"?$<^"[KP[_8VL#Q/=YT8
M:]H^L#1QX>63Q )/#6/%"#PD/&'E>#@S,[8\5I'[7J/Q'L(=4^'$-MX/\6^(
MCX^M5N[3Q!H&D:3J6E: %T?^V@-9UDLOE[E!"E %8X<!^,V_&=QX/T70V\4^
M(O#_ /;5N-:TNT-I'I U0#4=>UO2/#::P=\3 %3K"L_B4!6C\)*X+-&"K_*N
MC?MH?LZ>+[.WU.WT37+FWT+1]-UMKR]\.NQT'3&?7V;;N=G4?\21@@#[?%ZA
M BE54  ]O^)'QK\+?#GQQHW@_6_#]P?$/B_2]+_LG519L=,US/B[0-!&A-KB
MZ !NSKR2?,&781M0,5E$&A_'SPIXD\3_  NL;+PYXC@M_BAX=TG6?#6K7VDX
M _MWP?KOCT8P""R>'-#'_"9<;MVN^%UWKDN-_1OB)\-?&WQ*\7?#LV)U'Q1H
M=KJ?VQ=5L!?Z=>KH@\/C7!H^]SEE.NZ'NV8)) 4<$-[1%X<T.SNTO++3+2UN
MK:T-E:7-O:KNLT(8$*!UQE3P!P,'J30!TM%%% !1110 4444 %%%% !7E'Q'
M\;:/X \.IKFJ6=QJ1U/Q)X9\+V5K96P+7VJ>-M=C\/Z,@R,E0^LA)&))!PIY
M85ZO6)J>F:7J]I]BU6RM=2L+@#-K>6AOT(]?X\#CD\^F>M 'S)\-OCYX8^*<
MM_8Z'HMS<VVF>$&\;:3JNJ67]FZ9KOA@ZUKV@Z!K08L/[ 3Q8-";Q/X,#1N\
MG@^02 Q[<#L[OXGW/_"'^ ?&%_\ #+Q]<W'C/^R_M7A2TTC2-3U3PG_;H&3K
MJ$*  2H.UB&R=Q5N*[?5/!/@Z]T;5K'5?!^C:C87=HRZMI5UHVD:B+[3=K9T
M<IG#CC(WY7."I)((^/YOVK/V=;/P1X6GN/#%U;^&+31]*O/#>E?\(WHW]F:$
MH\%^ -?.C,N!'H#>%O#OQ2\$9*J@4/A?N@L >_?%?XY^'?A;=Z?!K>F:EJ,&
MH^'/%/B7[3:@$E= ?P^ATAAG@L?&NC>6P(7!R02,4_3?B_!K.D^$-6TOPMJ6
MI6_B?QWJ?@J\M+.S_P"0'JFA:SK^@ZYK3G:O_%/+XDT23;XFR5&[>0&*[<&'
MXE_"C6?'6@>#[OPZD^O^(/#O]G^'=5N]*T>_0Z=K_A ^.VT9<;@N@RZ#H\C,
M<'PC--H:JTN0I7UV]^&_@&\U70-<G\#^&[C6?"X;_A&M5_LC1QJ.A?*,'17V
M'R_P/?\ C)( !Z91110 4444 %%%% !1110 4444 ?&>D_M3^ =9\9:_X-.E
M:IINKZ#XN\,^#=VJV>S[?JNN>-==\"+K&B L/^$A\/?\)'H?_(S^%496P5<C
M_A$?&:^$._\  GQB\(>,?$GC;PYHNBZG!?\ A\ZM>WH.D%?[=.A>-O'GPJUD
M@( K%/$G@765 ;!V$[F)+*WI_P#PB'@[R<_\(QHGV;[?_:__ "!M(V_VIN_M
MC^U]^/O>9W^]N[[?FKG_ !5J>B?#[PIXG\4P>$!J1M;(WNKZ3X>T_2?[3UZ4
M#']D8W8US7AM8 ,WS[@ ^3\X!S-E\3H)_A7XP^(G_"$>*_#O_",:3X[O[GPI
MXATD>'=6O_\ A!WU\D[=O"^*!HJ%6!)VL P& S\!XB_:B\"Z'%J)U/POK=VM
MK::9K'^B6FD:G]OTW6OAGK_Q7;/S8_Y%[0=<4C R0>?FYVY?B'\,-)\,^/HV
M\'"+0?#WCQ/A-XATQ]'T9],O-6UM-#CWZP@_=1Z#)'XATI9)?$RQ,R/L8,@P
M/2_!VF^ ?&'A[0/&6A>'=..C^,/#GAG6;);K2LYTI]&']A%U88#+H&LM'&,D
M!<\Y)  .8TWXP:7J/Q+N/AI'X>\1:;?V^CZCK-GJMW9XTN^T[0SX"!(8G.';
MQRJJ-HP= \3XR?"IQ]"5S<&@Z)IUW<7MGI=M:W-U:FTNKFTM0"5'.&"CE1DY
MQDXP&)YKI* /B?\ ;=^+WB/X*_L_ZCX]\.>*?#O@>^_X6-\#/!U[XT\56^C7
MWAKP?X9\>?&GP)X"\<:YKJZYM\-G_A&_#FO>()"7;"N@X$H)'YB?\/%_VBS_
M &ACQ'\+C?\ @W^S/^%6:6/ K _MWC6_VM?'OP*&L_"LCQ-GP_GX>>"-#\3E
M?"A\8@K\7/#'C@_\4'\I_:[XM^/_  K\.?"=MXB\8V=OJ7A_4O%W@3P:UK=G
M2%T\ZKXZ\::#X#T$,-;9%9?^$BUS1P1@KOVLHW#=7S-IW[=_[&VHV]A>:5\8
MO!=SI^GG3;^SO;K1M:L$T[2]:U?X?^']"U;10WAXXW_\+1^%Q&Q$0^"_'OAO
MQP=G@EP\@!\E-^WIX^C^!?[.GQ$\5^,?@9X(\0>-/VC/@3\//'NE:IK&D(==
M\+?%7XFGP%KNW2-=\2*WP];_ (1R3_A)U(?Q>P(+)@JY,O[,_P"W-XV^(_AO
MX[7/Q3^(_P ,/!.H:!X'TSQIX0^U6>D^'7^&WCMW^+@\;_!;7M%UWQ,'\0:_
M\)] \%^"/%7C8,/"/BU(_'C;D555X_M;QO\ M,?"?2?@UX ^-'AGPO<?%+X=
M?$/XC_"#X?\ A[4_#^CZ/I:V/_"U_B7H/PFT#Q<^D^/&\+>3H*^(_$$3%P'9
ME#-&C G;#\$/VH_A-^T;J'QBLOAU:6^J+\,/%_B?P4MH-6\&ZCJGBK5]#UOQ
M%H6O._@D>)3XGT"+_A(O!>L1C_A+(O"'_"7A#)(SJ69 #\ZM>_X*4_$/0_A9
M\'_B!HGC#X.^/O%/Q&_X)F^)_P!IN\^'^DG1AJA^,?A[_A4FW605\2Y'AP?V
MYXX_XI0$ CP)XI5_&H'A1@?1_#'[:WC;Q!??"_Q?#X^NM2^&'AKX*?M%?&3]
MH_2-?\#>#4)\!_ W6M>\"Z'K>@Z[\/O$WBSPSGXJ?$1=_@AO"/C'QAX/\8>"
M_ /B@I\^0?1M!_X*._ R[UGX$Z$WPO\ %FB>(/C=;26/ATW%A\-M,.@ZGKOQ
M2\=_"CP[HBEO%,G]O#Q5\0/!&N1RGPD/&#>$&U_PS)XX^SCQ<J5D_P##P;]G
MSX@)8_#KQ_\ !?QJ?#^J>,-5^&/Q'M/$-G\-M2\#_#7^P_C3K_P)T7^W=;'B
M51XA\.>*_B'X(UE$/A,>,2@!R6#$$ ^]OV<Q\3?^%)?#F]^,U]=:A\5M5\):
M7K?CO[99Z3IAT[Q-K:_VWK>B*FA#:J^%/[9_X1<! %(T$R  R;C]#5\K?LQ?
MM#>%OVGOAHWQ3\'^'_%_A_P_:>,_%W@VVMO%EII.F:G?IX+UU]$&L*D8R^@>
M)XUC\0PL&#*O*X^5)/JF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "O$/B[K'@[PWX9TWQ%XWT:[UNPTGQ)IATI=*LEU'5++Q-KID\/Z$VC*,
M;3*^N'PVKJN&_MS  Y#>WUY3\28/  \.6U[\1)M.M?#&E^,/ NM6EWJEVNGZ
M;8>*=%\9Z$_@9MQ 5#_PDRZ*%+#RRP7(Q@* >(R_LF_"77M;N?&$^E^+-$O]
M?O-3UOQ%I/\ PD3)IE_J>N8#_P!NZ.2R.><J%"D8P3U(;\3O!_P#\"?#GX?>
M ?B;#J'_  KH^+M.LK'^UKLZCIO]HZ%X,\0:\H\;:PYS_P (^OAS1=8\US\K
ML%^4!E">13_#;P1>W'V*#]J7XZVQ\8^+_%&BV-O:^,-8_M._\4>!SX@T'7]"
MT(C<XP4UDL,!2-!4@D@@?5^K_"OP?XW\+6/ASQC%JGBW1L:E>65SXBUC5/[1
M!UWP9K_@377XS+F7PWKVNI\QV_\ $Z;"J2&< \E^%GPB^".K:CX_UOP]X<UO
M4QJNK^)_#/B,^*KO6!I9/]MKK;?V+H1+>&QN:0,OBA4_X3--F9)L, /6[/X$
M_"/3=0&IZ5X(T/3=2(YU2SSIVIC'_"/9Y !''@K0>N/^0$&Q@&I="G\#_#[Q
M'!X#AUK[+X@\>WGBGQ_I.EZK>%#>A=9T0:__ &*[!&"*^N:)Y?AI!G#;E4)N
M<^AP^+_#<^LW'AZ#5;4Z]:@&ZTG/_$Q QP<9P>O!R?8K0!+H6B6'AS1]-T73
M(1;6&D:5IFCV-MTV:?HJ>4O'/6-RON2"<$UTU<3_ ,)1X4P8?[<T4RW%W]E^
MQC5]++;MXT8X4,6(^7[F"2?E V_(>=/Q5^',-K<ZH/&'AL6UK8RWUWC6%_M$
M6&DEF9QH^/-!!+ D*N0^<,>% /6**X+0?&WA'Q)<VNE:/KEIJ.HW?AG2/&=K
M:+DZ@?#.NY_L76,.N=C_ '58_-SRH/![V@ HHHH **** "BBB@ HHHH QM1T
MVRUBPN=+OX1<Z?=6AL[NU_V3C@X[XX'L,G(XKQ*\\-_"?P?KO@;PK+X1T33K
M_P =ZYJ]GI5OI>CJ-.O]0T'_ (2+Q^%UH"-47#_VUXD4L#N\6C?YK2-N.]>?
M%SX>:=I0U2^\30VUC_;/CG1FOC:ZL-/_ +2\ G73XY0D1$,OA@Z!KOF\97^Q
M9?*<?)LP=6\8?"?7=:^$VI:YJ<#>(-4!\3_#FVNVUC3-1_XGFBIH UHZ(0A#
M2)KP\-;?$\?EJVN2(7!"AP#U/3O!7A71M3NM=TK1-,T[6-3'^G:K;6@74+WC
M/S-@D9'L<#' ZGLZ\2TGXR_#GQ%<Z+!H7C'1-1FU_2QK6D6=I\QOM,?2&UU7
M4'=@_P!@Z-K39; 5 >!M 'H7AO7M)\8Z-:^(_#U]::EI&J -9:I:_,M]IV3R
M&*@YSD X' R%4GD ZNBBB@ HHHH **** "BBB@ HHHH K2Q">+R9C][KCOP0
M/\FOE/QI#^SO\(+6P_MWP[X3T33M+TK_ (D]I:Z/&!8:3H6AKPH0/G;X<T1M
MQ8JS>$?#K!<0^$U"^U:S\0?"WAJ]U'2=:UM;74=*\':IXTNK-K0C41X:T$;=
M:UG _AW8 QCD?*,G(\>^)NI_LW:QK&@7'Q<O?#O]L:7I1UKPU<^(FU;3M2T_
M2=<&O %2,?>&@ZX0"<AM$.[@# !Z)X!'PY\2>'_#'C?P+I.GW.CW>C;O!]]8
MVRH;#PWK:G T+C&AZ"08P8_#3"(HJD!@C"O:*^<O!?Q-^"^G:,?#?@#5=/\
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M^'#HK:3=>(LZI?Z4-&'A[&MJ6!Y\.ZZ?#88!QY>N$!2SJ:]9^#_A'P'X/\)
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MJ;F3T[PMX(TCPQK_ (Z\0:?-/<:EX[\1:3KOB/=<Y_XFNB^#= \#QR8R,?\
M$AT'1F*_*Y= Q(PI:[I.@V=CJ6KZH+C7&EUI-,^T?;?$FO:C8<( BZ3HTT[>
M'-$?!^9O# 4LV'8JP4GN: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^);]<6-GJUY:1_VA9>&-ZG0_!P($C#0(-IV A 7R#G =,C_ADK]GC_HG%O\
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M'Q2_X2<^%^5/C31(R&(9BOM/_#)7[/'_ $3BW_\ "E\9_P#S1T?\,E?L\?\
M1.+?_P *7QG_ /-'0![OH>F#1]&TG2C<?:CIFD:78_:QC==C1E"<#)/)&?7Y
MCVS72U\R_P##)G[/7_1.;?\ \*3QG_\ -'3?^&2OV>/^B<6__A2^,_\ YHZ
M/IRBOF/_ (9*_9X_Z)Q;_P#A2^,__FCH_P"&2OV>/^B<6_\ X4OC/_YHZ /I
MRBOF7_ADS]GK_HG-O_X4GC/_ .:.F_\ #)7[/'_1.+?_ ,*7QG_\T= 'TY17
MS+_PR9^SU_T3FW_\*3QG_P#-'3?^&2OV>/\ HG%O_P"%+XS_ /FCH ^G**^8
M_P#ADK]GC_HG%O\ ^%+XS_\ FCIW_#)G[/7_ $3FW_\ "D\9_P#S1T ?35<1
MJ^G:CK"6\,.NZUX:^S76G7@N-)71]]\49B-)/]O: ZE6P. @?YE#%6RB^.?\
M,F?L]?\ 1.;?_P *3QG_ /-'3?\ ADK]GC_HG%O_ .%+XS_^:.@#Z<HKYC_X
M9*_9X_Z)Q;_^%+XS_P#FCIW_  R9^SU_T3FW_P#"D\9__-'0!]-45\Q_\,E?
ML\?]$XM__"E\9_\ S1T[_ADS]GK_ *)S;_\ A2>,_P#YHZ /IJBOF/\ X9*_
M9X_Z)Q;_ /A2^,__ )HZ/^&2OV>/^B<6_P#X4OC/_P":.@#Z<HKYC_X9*_9X
M_P"B<6__ (4OC/\ ^:.C_ADK]GC_ *)Q;_\ A2^,_P#YHZ /IRBOF/\ X9*_
M9X_Z)Q;_ /A2^,__ )HZ=_PR9^SU_P!$YM__  I/&?\ \T= 'TU17S'_ ,,E
M?L\?]$XM_P#PI?&?_P T='_#)7[/'_1.+?\ \*7QG_\ -'0!].45\Q_\,E?L
M\?\ 1.+?_P *7QG_ /-'1_PR5^SQ_P!$XM__  I?&?\ \T= 'LMIH%S!?:A?
MR^(]9OX-2.FM::5>C1VTS0RJ;0VBXT%22?O?.SG ^8J^TCMZ^8_^&2OV>/\
MHG%O_P"%+XS_ /FCIW_#)G[/7_1.;?\ \*3QG_\ -'0!]-45\Q_\,E?L\?\
M1.+?_P *7QG_ /-'7KO@KX<^$?AKHD?A[P=I8TK2&ODN#:":6=?,<\X,[.=H
MQD#KGJ3@8 ._HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
.HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #H EL# 2(  A$! Q$!_\0
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M\<ZZTO@G_A)/%_AD^(?"GB :$C?\(L3X+9M=B7(&0_7?"?\ :]_;P^#'QO\
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MAW1Q\*IO#C_\+"D\4KXY'A9I4\9>#?\ A#WW/)EE18_D/QA\!OV[O@#\)_\
M@I1^P)\)/V/?%_QL\+?MS?&S]HOQG\!OVC?#_CSX::7\,? 7@3]JW1M"T#QW
MH_Q4'B#Q&/%6@^(OA26UP?-X1*>--JL@!RS>^_\ !4#]GS]I:/\ X)>>"?\
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M_%GQ/X/U;Q_X"\*?M2_!+5?A-J/Q)\,Z'(S:]-X)(\0^*/\ A('\,JXDN%#
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M*]^*VD?%G_A4WCSQO\9M \;Z)\,F\<-X@;Q/X]\1#0%93XH"R*1AQD-@ ']
MU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !7B_P 6_A-\._CCX0U3X9?%CP?X=^)'@'7KO1KW6?!_BRS3
M5=*OM0T'7-#\0Z(XBW(RMX:\1Z'H_B$-S\\:,%*H:]HHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#Q'2?@Y\*O#7Q+\:_&O1? 7AO2_BO\1M
M'\,:'X[^(%M:K_PDNOZ7X(;'A_1M;UO&YM!\+XVH@(')!!=5%>W444 %%%%
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MQ ==#)HC:)XV?Q"?#6MJS*PCVRN'"[P6 8G\8-$_X))_$K1?V>/BEX @\8>
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M,'Q*_:T\2?&C0O%GPNT_X;ZW\9/V3OC/>6VK-J[^.++4_P!F[P;\0/ 6NZ*
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MC#0?%$BM'_PEOFOP?@/_ ()"?%GPKXE^"_AJ?XM::/ACX8_9$T[PO\2/LO\
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MI>)_B1I?CCXR>(/BR^N^.? Y^&OA$>'M>4:V5,GBWQE\7_&/_"9-XE5/'/\
MP@[(C@'[C4444 %%%% !1110 4444 %%?&'[0'Q=\7_"S7O@+8>'-=^#UOI_
MC[XBZEHGB;PK\1O$*^&?$_B+2QX*U[72?A?K'_"0Q(/$;>(1H:,/*\6G;KX4
M! JX^;=$_;8^(W@SX#>%_BY\:/V??C%XIN;.3QP_Q5\0_"7PW\&M.\$?#9=
M\:2:$-W_  D/[1VWQ!X<?P^Q\3#Q1\*_%WC9?&*)NA$<Q7P=$ ?K#1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%? '[7OQV\<?!6\^$+>
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M;K[-:"T^TW>#J-X5&,Y(4DGUQG/('&X@&Y1110 4444 %%%% !1110 4444
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M_P#A'>,/_F>KJZ* .4_X2_2_^??Q'_X1WC#_ .9ZC_A+]+_Y]_$?_A'>,/\
MYGJZNB@#E/\ A+]+_P"??Q'_ .$=XP_^9ZC_ (2_2_\ GW\1_P#A'>,/_F>K
MJZ* .4_X2_2_^??Q'_X1WC#_ .9ZC_A+]+_Y]_$?_A'>,/\ YGJZNB@#E/\
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M@DW^!^H7_".?]1WQ)_X.?_KT?\(Y_P!1WQ)_X.?_ *]=>.@^@S^5+6(CA_\
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M$_4>G?"'X6Z+>&YTOX=^ M.G^UB^6YLO#>C6&=2'_"0%G"K 7R#K^NC:&?\
MY#7B#!#3.#N^&?!/@7P>/^*7\(^&O# ^P6&CG^P-'TK22NEQMMTK2C_8RK^Y
MC9U*9'E[2""4VD 'H5%%% !1110 4444 %%%% !1110 4444 ?C3\:OCI\5/
MAA_P4<^#_P .]#U#]F77O#/Q.\-?#.Q?2OB5XC^)I^+OA33TUOX@#Q]K7PH3
MP]\.9_AIX?\ $7BSP_K3*(_%?C'PDWC$>'Q& S+BJ'[8,/@^U_:\^$^H0_$/
MP19_&BW\-^ 6\"^"/&_[/LGQ;\36.G-XQ\>'7_&GPM\;> O$$7QU^$&S^PU7
MQKXJQ_PI@*/#*>/5\6_\):4KNOCEI7AF?]NSX'ZMJG[,_P"T?XY\3?8/"S^&
MOB=X%\2>,]/_ &>]#4ZSKYUS7/C=H2>)#\,V\0_"G;HGBCP+_P )5X./C1_[
M>.W/2OI3]H+Q%XLT+5O"$4G[/4/Q8^'&N7QLO%OB"R\3Z/IOB+P$%UO1=:T#
M6M;T'7UC/B+P\VOZ+H3NOACQ<_C .4\OP3)Y2.H!]KU\6_MY_P#)JWQ _P"Q
MN^#?_J_OA_7>_'']HCP=\ ?^%?W'C:QUL:?X[UCQSIRZGI5H;]?#X\!_!GQ_
M\=->?60H.W/AKX6ZZ%Z!@JC*C##X'_:E_;0^ ?Q'_93:&Y^)'A/P#XW^(OCO
MP)HOAKX4>-_&'@O2OB5KVJ^!OVG/ O@37=%T/01XDW>(67Q!HFL*6\+NP.U2
MH5PY8 _8VBN>_P"$C\._]!:P_P# O_Z]+_PDFB_]!;3?_ S_ .M0!T%%<_\
M\))HO_06TW_P,_\ K4G_  D?AW_H+V'_ (%__7H Z&BN>_X2/P[_ -!>P_\
M O\ ^O2_\))HO_06TW_P,_\ K4 =!17/_P#"2:+_ -!;3?\ P,_^M1_PDFB_
M]!;3?_ S_P"M0!T%%<__ ,))HO\ T%M-_P# S_ZU'_"2:+_T%M-_\#/_ *U
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M^Y\'?$"ZTT:_XO\ "VL#5M6^-?C34O$_]F:)K?[-"XUT#X;>$?#.OGPGX?\
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M%74\_C\&/B[G_'\::=KV=G^/W[_B;X#'XK+<6L7ADFM5:2NK234EJGT;Z?\
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MUUX ;/\ A)/!.N^&FP4Y&,@5[]=?M1:/K\QTSX/^&_$?Q@U'I_:OA0I8>!+
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MJ$GB3QCJ.H:@PT31/!(_MB37?$+OXBE_X1K1-"\-,/%#2A?)C*K'EG;Z2HH
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MG_GL=#_;5S_T!_$G_@+I7_QVO$O$NKS_ /"]_A!_Q)/$F3X"^,@!^QZ. /\
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M::66;3AJ6PY_L@R$M@XQER6)(SR":ZRB@ HHHH **** "BBB@ HHHH ****
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M?!;XLZYH@W'XDDZ&!\2]%^%8#HB@[XTVY.]P#]=:*_/[_AWG\*_^BQ_MK_\
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MZE?K^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO"'[9'@C3-09V_MM=9T3P3X ^)/_  C&@;V*JH"@EB%!8D >L_\ "3? /M\
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MN_V;?/W.;7JN:WDNB]@K;:=-.G]?J?EO_P ))\ _^B ?\%>?_ 3]N+_YY/\
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M\;>)-%\2>)]0\--K+:_H0UC6] \-^% TD<>L?\(WL,+ C0D(RK/0!]'U\O\
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M;Q!X=\5#P]HGB)(R)?*S;_+%XSA8+]AT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%95Q/;V<5Q<3SV]O;V^;N
MZN+E@1:9 .<G ' /)(P,CYB0* *VHW@TVQGO1!=70M;4W1M+.U-_J-X%!P%4
M?>8' Z]B=P "G\0_&/QR^(O[?/B;2?@O\' ?"?PANK/3?%'Q'U6T;.JGPN?&
MIU_1/&0/B/PZ1UT5O"R^%3X0\8*GQF\!?'/X&?'CP.%_X0SQF/H3]H[]J1O'
M]]H7P)_9F\6>$/&WBSXR>#]3_L_Q1I/B$CPW>>'&TCQ&9G^%OCOP]X?\7^%O
M$?Q!\,93Q0GA3Q;$/!_B_P &^'_%F9'7POXQCA^L/V=O@5H7P'\"-X=L8-$/
MB+6[K3-0\=^*O#GAQ_#>G>+?$Z:+H/AXZVWA]?$?B]]!4^'M$T4*%\5R E0R
MY?8% />/#^F'0M!T?2FOM1UAM-TK3K+^U=6<-JE]M#)OU<[5^8C:S#;\A9Q@
MGD]=17YL_MW>%/CUXK\,^$;+X3:IX]M?#>IWFI:-XOTKX47>M>'OB]X0\2:_
MK'AS_A5OQD\/^(!K\/AG7_#OPJ\31L?&_P +?%A;P;XS\&:]XCD<*OA1(D .
MB\2>-O@[^UQJ?CO]G7Q+H>N>(O ]QX=U*\TCXEZ7:,?#?_">>"=8\O6]7^%O
MQ4\.R%= ^(WPG\2.H+,?"7C'P9XT\/Y W%67[ \&:-+HGA?P]I&K>(M5\6:G
MI>CZ;HU]XA\0#2#JVM:CHRHK:KK/]AQ)X?779&B20^4D>Z9-S$L'-?.?[-W[
M+GP[^ ?AZ 66EVESXXU[Q#J_Q$\7^(E5VT[_ (3O6]'T'P]K?]A9 _L'0$\.
M:#HOACP?&$)C\'Z(B'/WG^T* "O@_P 5?$SX6?'CQ3XR_9TNO"I^(6@:EX<\
M?>&F\3:_X03QO\$-0\<Z&G]@>-?!.L:WH/B-$B\1^$1J^M1^,_"OBUO!?BTK
MO;P0S2,91@_MP>$?C?KGA'PTWPYU#X@/X*/B(:+\4]*^#^KZUX;^.6GIK\NC
M:+X&^)GPIUOP]MAU[_A5'B-AXE\;_"[Q5&/"/C;P3K7B,W$LQ\(Q^#?%_;?L
MS?LM^"_@MX>L+W4-)T2?XH:[?:=XQ\>ZK9"2QTP^/#X-_P"$&U9]$TAUB">'
MQ;_VWX<\'QM"RIX1E$4<LAC_ 'P!](>!/"%CX&\ >#O!&E2W<UKX,\.:3X:L
M[C)9L:#I*Z(K#^V7?*D*VT9(8\-\I8-Z117Y@?MS?&#X^?#K4O!'ASX='3?#
M9\8_VG:> O&VJZ,^O^&O''Q-R&3]GK71N8_#[Q'\5?#::PGP8^)P?:WC0?\
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MJ0N0/"'PP;Q5XS3P,)/$;'QSXS"^$!X+_6>JPB\F+R8!@\D>P/4_C]1^M6:
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M:/IXUO6[N\PDMYJ-Y?Z]KK:UK3'5V5FF971(]X8QE-$\.>$@T<7A:&(>Z44
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MZ]^G^.*L444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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; ,M)+EGRQ9I6R2Q88[^BB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $; EL# 2(  A$! Q$!_\0
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M&?\ X*R?LW?"+]J?X3_L\Z]XPTJUL-=M?CS:?%SQ#=^&_B3_ &GX!\4?"@>
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MJ<!@ 9G[!7[=X_;F\,>+O&&D^$/AWHFBZ"O@6[LKOX:?M#>"_C<$_P"$Y7Q
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M!X_T(:YH@UG1=:\0>'/%OAF1V\.Z[XC\-MX;\4>#O%<;)KSAX@P5U^(/$?\
MP1)_91\8?#_X?>!K'X@_M&^%1X/\._%/X8?$CQ9X2^*L>E^./VAOA?\ ''QS
M_P +7^+?@GXWZ[_8#GQ!H'Q/^(8?Q1./"8\'%GUQ]I7_ %:_MU10!^:/B^SO
M_#?[?/['?@_2O"MOH?PX\+_LK_M067AJ[L]89G74/[;_ &9-"'@X>'SX;D_X
MD'A/P]HFC$>*/^$K0DZZL3*5C!K]+J_/'XG:9XA_X>+?LE:NGB(7&@']FW]K
M.QM/"PT8*;34E\:?LRMK>L_V_P L5(;10/#)/!T(NI!)Q^AU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5\ _MT_MG^ OV$/@=XA^-WQ#TKQKX
MT333JMCX1^'_ ,//#NM>)?$_CKQ5HG@SQ#X[.CHF@QNOA_0$\/Z#K'BCQMXH
M\5NO@KP;X-T261T#*HD^_J^2?VQ/A!XE_: _9-_:/^ _@^_TW3/%WQA^!7QA
M^&/AK5?$)UJQ\-V?B/QWX)\0>'EUC77T)@YT$2:V)68AF8?*ID=V( /@W]HG
M_@K!I7P0T+X9:IX4_9S^(OQLU;QA^R+JG[=7Q4\.^%?&/@_0'^#'[,6A'P[-
MKOC8GQ"^?'?B*-M><)X3\*!O^$P/A_Q%)&555C,&O_\ !8+X8Z;\?=&\ ^$_
MA+X\\;_ C_A9'[,?P:\8_M1:5XB\&6'@CP+\3/VL?!N@>//@CH/_  A+N/%&
MO^''\/Z[H+>./%("IX).O("&0#'@O[2__!,3]JSQ;8^ 9/V>?%?[/W_"3Z]_
MP3!\4?\ !,#X[#XJ:Q\2=-TK0/ 7B4>'B/B?\+%\.^%_%C:_XA\-3GQ%)_PC
M7BS_ (1578>'6:;/R1\CJ7_!'[XZ>'/BH?AG\//'?PDN_P!BC7_CM^PG\??'
M>J^(KWQGIO[0&A:Q^QI\-? ?@%O!&B:1X=\,/X7U_0/BK)X#\%^)&\3CQCX/
M/@D_\)0&4DJ* /Z1(=1L;P^5!>VMPV#G[-=*6 ^JL<G\3]*TZ_&#X0>$?@[\
M.O\ @K+X^\+?"7PM^SCX4N8/V3?%6M>+O#_P6\'Z+X9^)=AJNO\ Q,^ WB!-
M8^.1\/*/[<U[Q5_;FM^(_ Y9 Y\&A=X>1B6_9^@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#
M\P?B3#X2'_!37]EDV/BT#Q^?V6?VFQJWA,>-];;4]/\  9\;_ (:-K7_  @P
M\3#PSX>1_$9UT#Q4?![?\)?_ & W@MI&3PCLC_3ZOSO^*GB C_@HK^RCX>7P
MWK[V]O\ LY_M8ZO_ ,)99V3'PTKZ[KOP!A.D?VR9$VZXC:"))44I\NN^'&PS
M-@_:?BOQOX6\(:8-5\3ZYIVB:<=7TG1OM=X!M&IZWK::%HJ\X^:3Q VU<_*"
M"20>2;*[T7=Z+[]OQ$VEJVDN[:2^]M+\3O:*^:_VA?B7XZ^$WP6^(WQ2^&OP
MHU'XY^+_  %X;UGQ1H_PHTG5W\.>)/':Z([#6-&T36F\,^)A_P )*?#J$^$(
M0IE\5RGR=OEN)J_-NV_X+'?"/XHS^$9?V=?A_K?QQ\/W'[&WCO\ ;=^+GB*T
M\3Z1X:TOX$^!/ >CZX_AWP9XW\KP_P"*6_X7%XM^(^B:YX3E\'G8/"(T!_&3
M[X&S*#WU6J[K;[]OQ/VXHK\%_@[_ ,%?/B1\0]=_99T+XH_L,>/O@WX?_;H\
M"^)/&G[)GC>U^-GPT\::;\2=5T'X9_\ "VM$\(:WHNAQ^%_$G@%_%'AHK+ O
MBR( S:PD<DH0GR_</V;/^"B/Q2^-G[56O?LH^/OV&OC%^SMXRT+X7)\6_%WB
M+QM\4_@YXWTWPKX6UW6QH7@===_X5]XF\7MH?B/Q?KJ:XO@OPN[,H7P[XFEV
M@1\ 'Z\45\J^+OVJ?V9_AAJWC_PY\1?CY\)? ^M_##1_#'B?XE6GC7XE^#?#
M>H>!/#/CW7)-!\#Z]XY&N^(8QX<T'Q=XC<^'?!S>*%A9Y,()",&N-_;0_;$\
M _L8_ <?&'Q3X;\2>/K_ %_QAX#^&/PM^'O@FT)\;_$GXH_%?6DT'P)X)\/C
MY<:_XK\0Y1=H49&YE9BQ(!]N45^)H_X*6_'SX??#7]J7QK^U9_P3Q^,G[._B
MG]G3]GS6/V@M*MU^)/A+XM?"#XM>&-$!W^#-#_:(\!: ?"WA[XDI*BJOA>5)
M6AC5O%X18F8#=^!__!3WQEXE^,7[/_PD_:0_8\\?_LMW'[6?AG5O$W[,OC6\
M^*7PU^+7@;XF:MHG@I/'NM>#M</P_*^*? 'B%?#FLGQ,5\5>$55]S MNC  !
M^RM%?DM^S[_P47U[XP_M/Z;^S#\3/V4/C#^SCXK\8_#;QW\9_A7>_$'6/!VH
MZIK_ (#\#>-D\#>(-8\;>"- $_B?X.ZY,^L1KX,7Q8I/C&(LZR909_6F@ HH
MHH **** "BBB@ HHHH **** "BBB@ HI,CU'YT9'7(QZYH"ZWNK=[JWWWM^(
MM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?E!HUUKX_P""
MJNK6%]XF^)&HZ3:?L:^*FTC2?%O@71M!\"Z%(WQ-^ _]O#X6^.="\-)XH^("
M%W)\:)XI\8>+!X+\7[%01(?+7[W^)GQ3\(?!_P &ZCXQ\7W]OIFCZ79F[)-S
M'N=@B@:9I& FXG8%4(%!4@D!<!/A'1])N(_^"K>O:M)I>M06'B#]D/Q1]@U>
M\^+VM^--,UO^POB9\!=PT;X5:_\ \4S\'S&P<?\ %+",^-6 \9R%9/G/W!\9
M?@OX-^.'@VX\#^-QJ-SX?NKS3KV\M+2[.G->MHS^9R1DA"Q^8=.%YPN:Y<3]
M:^J_[);FMI>WSM?]-;7Z'GYC];^JOZIO?KWZ[K^O0H?"7XL>&/CM\.[3Q?X*
MU@P6VL:(A(L[Q+[4O#VK:MI"O)I6LJH9CK_AMW19$9^"JCD.S5^"/A;]OS_@
MH3XB^,ND?\$P)[+3]-_;N\,_M!ZI>_%']HVU^&^D#X0#]A#12/'>A?M Z)H+
M'_A&!XC\5>'-;T+X7CPJ0I7QH3W8@_OG\%?@;X(^!'AB?PA\/[?4+709[[4=
M7-M?:H=2^Q:C*8RZHQY4.VW(RWS1C=VQX1I/[(L&D_M_>+?VYH?&PN9O%'[,
MOAC]F.Z^&1\/9T^R.@_$O7O'R^,QXW;Q%RY;6V\,#PP/"0P$$JOSP9>\4\+;
M&6YK:V]7KZ:_YAE_UOZK_MB][K;>_1_<U^I_-)\?_P#@L)^UW\./B#^W=+IG
M[<O[/&B^+OV:/VO_ !S\&/@G^P?XY_9O'B;XE_M"^!= \:>'M$T!M$\<> ?$
MQ\4%O%;ZUK?AE3_PA[%7T -D$9K](_VM?C5_P5@\#_'[X!>"O@?\7_V<="MO
MVO/'FFVGPX_9Z\4_!+7/$?Q/^&W@70_!>AZ_\=O&GQ0\;1^)/^$;/A_X4LS.
M-BEW?Q!X8\%+E]K']'OV4_V)?!W[-7BW]J#Q@=>MO'WB/]I3]J;XD?M.6>JZ
MMX'T32]6^&C>/M(T%(_!FC:R6\3G7T\+/H9"^)SL:8ZY)&(\@(_9W7[*5IJ7
M[=6C?MGZKXZGU.Z\*_LS/^SEX2^&EYI6=-\/G7_B9_PG^N_$W^V?^$D(_P"$
MA\5-HVA>%0A\)C;%H*D2LU=1Z!4_:[_;3^'7[%G@#P7\3OC%X=\?W_PQUWXB
M>$O 7CSQ_P"!]%TK4?#?PBTWQWJYT'1?B;\4Q)XBB\4:!\.O^$@=5_X27PQ!
MXL>/[[Q!G4*?LT_M@>"/VH?V?#^T]X;\$_%'P7\)[NV\5:UX<N_B'HFC^'?$
M?CWP)X),I7XEZ!HF@^*/%KC0?%@T96\&?\)6WA+QB(H7(B@$B$XW[</[(%Q^
MVS\.-"^!^L?%#7?AO\%M3\=^&-:^//@KPYHRC4?CKX#T#7$UQOA</&B:^)O
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MASX&_!WPQ\6?V3?%'P8^ W[.'P[\>'XCZG??&3Q!H[+K?Q-\=?&[7/#7@_\
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MAPA)]_!^1SWID'P[LYH[8>(]<\1>)[@C-VWB#5G"W^.QT7P\OA3PMP,9)\)
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M#?5?K3^MWV=K7M?RMYI?B>3:7\3?B;\1?V9KOXI_!WPKX2N/BIXE^&VI^)O
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M:(%4E5)3 DR1BOU4?QU^T3JUN+?0O@ZWARYVY^U^*]7\'ZGI '' ?P]\1O\
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MOA_1/BMX+^.*N-_AKP_X4\,ZW%XI\'>)O"A\7KXT91X*$4;$F@#]R**_'O\
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M_P"";/[#7[5DOP_O/CO^S;X<\;7WPP\-?\(3X"?2+[Q=X).F^!-C'_A6S?\
M" >(O!XU[X>$@*/"WBD/X++,I,87>0 >]_LW^-['XF_L_? _XCZ)XGU+QA8>
M/?A9X!\8:3XUU313X>U;Q?I6O>$M UI-<U[1F*?V#KGB=7:25,,(@6*,Q #?
M25<9X?\ #.D>%=&T?PYX;TG3]%T'2-)T_1]'TO2[06&FZ%I>CAO[%B@T@D%5
MC("$+Y97R@&YW-79T %(>A^AI:0_7!/3_/>C\//L!\ ?MX_&#XR_ 3X'7_Q8
M^#MCX*U.Z\,:MIH\7Z7XNTG6M48>%]:)T5=4T=]"\3^%7,JZ_+HCA2QW*'90
MJC Y'X+>*?VBOB5\,O"5]\:=4T7P[XO\3VHUS_A /@];:UX>\27_ (;UM=FW
MQMXV\0R/_P *\\/*%#./"BKXQ+:&'\ ^-V<OX-$_[;7A+Q%\7]%L/@SX(O1<
M7.-,\9>(M((T<:;XK)UMM$\%^#M:W$ HYT7QGXHW(,AOA*ZL>65?HG]GOX>:
MQ\-/AWX?\/>(];?Q'XGMT>Y\0^(+O!U&]U),[D:2,%]9/AW=%X<1ADE8D!P_
M[NO-?$6)^LOAW^R'9+G_ -9VNK_Y=V=]5M?>Z>ZLW]/_ &?E<>'XYH\Q7]L.
MJX1I+=4HI/GE=6W5K*+;4HJ_,I6TOA[\+-&\)7D%ZNE:<M^+O4KVU^QV,9TS
M0]2ULYULZ02ZR-X@E5V'BWQ5XE4^,/%[QRF9R28$]]=PHP.@X'J?R[>O^14Y
M&01ZU\]ZA->?%/5+G0H+BXM?ASI=V+3Q+JUJ<'QUJ>3M\&:+\SG^P H \</G
MD@^"/^AQQUIKK[UETZOO\]_GV/E\=7Q6(\W;TOI_PW3?5W>K^$/B_P",/VEO
M&'[1'P_\0_"?PMXTN?@WX8+Z/K&K>'5T91XKTG7&8^-=9T5?$,CY9$VKX-<.
M%=] 9U$88(/TA\,>!O#'AL+<6.E!=7NK79>:_>*NI^(]055VG^VM=UIW\2:R
M-W3S&<<;"%.,=K!I]O;1PQ00P6]O;C_1;6WM< *!@8  50,]L>N<ULL%  .<
M#IC_ #CT_I7FX?+[8IXO%ZWV6J7W7VV5[:VN>/E^7/#8F6*Q4FW+X=[+?9-O
M2[LKKI?K8MCH/<9_.LR\M+>_M9K.\A@NK6Z7[+=6UQRC*P^[WSD88#&3P00<
MUICH,=,#%+7LZ=+?(]DXK3O"'@_1KEKC2?"_AS1=0N1_Q\Z5HVC:;J'U!2/>
M3CCC=CTKM,#T'Y4M% !1110!^"7_  6)\6?!'QYX:^$'[*_B7P9^Q5\4/BS\
M3/'>ICPY:_M=_&S5OA3X9^!9T'P1KGCU_B@FN?#S_BY^@>(1X>T-H_!(\*>*
M_!+LZ-M\9JNQF\4_X)B_";]JGX??%K0/#G@'_@I9X:_;F^!'@/QWXH\+_M<_
M"B\M]:\2>"?@3)K?PS?X@? S1/V=/BCX]\3_ !9^)OB*/PGXAU;P_P"'-O\
MPFP\&2>!C(DJ0^._![!NA_X*=_LS^+/B7\:OA_\ $WQC\&_^"2'BWQ3K?QA^
M&'P5_98U7]L_2?CQJOC;Q]IGCKX7Z]H>O_#3QOHG@ _\(W\0?$"?$K6_$'B#
MP/X69?%G@WP7X.$GCIHAXY"2#ZP_X)#Z=<:=\(?C/X?/A3_@G9X-N/!WQ_\
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MO!&F^*?@:WB)? 6C1Z+XDU]H)/#H'C5VE\)E_P#A#_%9\/\ A(S0LOAI-O[
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M&\,? WP!XAUM];\1>"O@EHGB37V7X?\ A[Q-KP,Y6&0R2-$JEHXV^?[5\?\
MQE^$WPG72#\7/BG\-_A>NO78L]#N?B'X[\'>"1KS=5TO1_\ A(M=B.LS_,0\
M:,6PV_;DDU+XO^+_ ,*O ?V.'X@?$OP#X)GU.U^U:3_PEOC?P=X;;4D&1_:N
MAKX@\0+YD2[SL8%QW+$!\@'K]%<!J7CKP1HOA8>,-3\9>%M.\*BR^U?\)7JW
MB/2-.\,#3B3^].O.P\/%>, B0J5S@X^:NALM1L-4M(;^QO+>^TZ[M#>6MU:W
M(O\ 3[[3V ^=7!*-E6 W+NR<@L<%  ;U%%% !1110!7KY,\#V:>-?VAOB?\
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MCCD"HK% #^;?3O@W^W?>:?\ !3]DR^_98_:'L?CM\)_V_!^T[J?_  4&U/\
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M^T)XU/PVT7Q+J?[ (UGQL="\/-H7C@>&SX8\/C]JW/\ PC*#XL'QC_PA>?\
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M[6\T73OV>=/\#+H[#Q]_PU2WB \_#W_A'\CP4/"@'C8>-QX:_P"$$.2:J_\
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MLQ"S\9"7Q^?V6OVG?[7\)VGC77-2:P\"KXY^ 8TC6SX'_P"$E'AK0%F\1C7
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ML;^ O!?C[P(GC/0V^(?PY+'Q'\5_B/X&UWQ4/%7BX^,?^$+8^&6R? A;P97
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M[=/NV_ :;333::V:;37HTTU\FBL(( ,"  >@7 _(&OF#Q+^RI^ROXI\%:?\
M#_QA^S=\"_%7@#PQJS^)_#7@76?A!\-]4\%:'XEU1MC:[H/A[Q#X<;PUHGB%
MBZ[I% D(:+<S%D ^J**222LDDNR22^Y)+\ ;;O=MWWNV[^MV[_.Y\\>.?V;_
M -GWXJ>'=!\'?$WX%_!KXC^%?![:;=^#_"?Q ^&G@SQIX<\)E1M5M#T7Q!X>
M=-"8*N<[%X4 JNUHZ3QM\#_A3XZU#PEK.N_#SX;ZGXN^%H^U?!3Q7XA^&_A#
MQ)XD^$/B98T8ZS\,9/$/AV3_ (1Z54T71'#>%C%O71%!#8\ROHBBF(_*?X#?
M\$Y-#^%?P=_;!\$>-_C/XK^,7Q>_;ANO'E[^T%^T+J_@_P '>&?$6NZCXY\%
MGP%HB:+X+\/1-X4\.^'?!_A_5Y!X,\*HYV?VYX@W,!*%'O/[(_[$OP1_8_\
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M4?&.D:7\,M#G_96_93T;3]"_;O\ #/Q:_P"'YMK^TA\&O^$E\=Z6?VM1KO\
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M%D9FC/B8'P@@13X+\&0SHWC";/\ &O[07A[^QO$%AX<^'?CCXHW%KH^I?;-
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M#5MXK\6Z-X>.O^)\!AHV@C763^W]?)4#RT$C, O7->KU_)W_ ,%RM'\#P_M
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MO+6S;4+ZQ\-^"-%?7]>D$:OAR?#^CLQ0L&8X/F A7!K:XKI=5=:VTOIKMO\
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M@M\3M!*MKWPS^*7@D@?\(_XC\,L54JTI5D56# [J^QZ]@^6]=PHHHH ****
M/S&^)NF>&8_^"FG[+5Q8^*[E?&#?LL_M/65YX33QMKM]I]EX77QO\ 1HVM?\
M(*_B9?#/ATR>(5UR-?%?_"(D^,!X?'@P2%?"2*GZ<'H<],'-?G%\5M1TE/\
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M^'GB;Q3_ ,+@^'I@SX2\8^+?"C>,_!?@?P9LD=9QXK9'_3[]A;PWI7_!0O\
M94^&?B/]K;2]/^-FO_LY_M->*)?@M^TAX>T;7/A,WQI'PH\9E? G[3/@/^P(
M_"?B;0E^*^&\->.(XV'@[Q@^@>)<J5G H _<^DP/0?E2T4K)[I/Y+_( K\R/
M^"B?[;GBO]B3PW\!_%?A/X(>)OCT_P 3OC8?!/C#P1\/;,ZI\2;+X8Z%\,?B
MS\6_'?C;P1H3;6\2^(?"7AWP'_PDG_",'863?M*[E8?4WC?Q;I/Q#\.?&GX9
M_"_XP^$]"^)NF>$/$OAB\UKP_P"(M#\1>*/A-XKUW1-93P_K&OZ&DF=#D\,R
M,OB2-?%$8W,OEA2"AD_EL_8O^(7Q-_9._:D_97^!]C!\?_"7[1WB'XB^&?@5
M^W%^Q1\2_$OQ)^+7@;XD*=$UW'_!1[]G+XJ^(3XO)\/-_8G_  E?QL(\6LN-
M<_X09^<?\)H]MM/33\K ?U<_ [XX_##]H;X7^$/C%\&/&&B>/OAMX[T@:WX:
M\6^'[T:CIE_IIZ%2#D<DKU!SVP03Z'K5S-%83S65G=ZG<06ANK32K)M+74;X
M '*C^VRJH<C:"2K$\!BV%/@OP,_9F^#/[.%U\5YO@[X+MO 6G_%KXCZC\7/'
M&E>'[O6H_#5_X[U_2=!T/7M:T3P.\C^'?#S^)8M"B:7_ (1B)!))@CYG,<?U
M%0]4UW_X/^8)V:EU333ZJUGONMNC1\P_"8^(K?7O'$6N> ?$7A"W\3>(CXGL
M]6O;OP9J&G +H_A_0/[(8Z!XF\5#^W4_L-BXQAARA!P&^D^/)Z=6_D1U_.GP
M <\>H_#CBOYLS_P5'_:N^'OQ._:8^)GC_P *?"/QO^S?^RK^T+XK^$O[3OP%
M\%>&O&6F?M4_LM_!O1=;.A?"O]K0C7_$H\+_ !A^'/B_PXQ^*'C?_A%?!_A#
M/@S#>! [>#_&>>;#X?ZK?6ZW:^;?IU['1B<0\7B?K4FV]GN]DENVVMN[]6?7
MG[('_!4'PO\ 'OX^?%K]FWXI^"-5^#/Q.TWXK?'C1/V<-2U:ZU$>!_VI/A=\
M#OC=X]^$NN>-?A6?$ B4^/\ P;KW@G74\=>%&625H(4\<IO\%[CX4_9? ]!^
M7^?0?E7P!XO^$WPQ_;#U&;1?C-^SEK*>"/@E\4_A9\6/V;OC'_PEFB:9JGCK
MQ&FD:%\0/^%D_"W7/AWXFC^)?@%8_$!/A/Q>/%@\'GQ>2[D2AI<_H!739'.W
MU]7^IX)XY^#WA;QU=0:MXA_X2R[:V%A=6EIIGCKQGX<T\2:.PDCU4Z/X>U_P
ML$UKYR&8HRKB,'<<J?0?#VEV^C:9!I-L=0_T.U6Q^T:G<ZMJ6H$[3S_;6O!G
MULY^;<S-TSR"%':*Q'T]*>2 !E?H/3^G3MZX^HYGAL)%WY(7>KDK<SM=ZM1O
M][]+:G3/,<;B,+'"2G-PIM\D93FXQO:_+%R<5>VO*HWLN9RM%Q_+O_@H_P#M
M>:W^QUX*^"'B;PU\!=>_:._X6?\ ' _#_P 8?#/P+:?VGXX_X5?H7PT^+/Q;
M\?>,O!.A/YB>(_$7A3PYX"_X2+_A&"@?Q=&7CA:,_-7K_P $3^S%^T?\)O!O
MQH_9\U6PU+X;>,-(TW7/#WB+X3>)=9^'0OW8,[1ZY_P@6O\ @UWUZ(,J^,/#
M/B8;B1LD52C!_M;R8)?L_G #[.P-K^"@<CU  &/08YZU\R_!W]F+X._ 36OC
M#KGP?\(Q> (OCK\0_P#A:7Q'T?2;S6(_#5_X^.C:%H6N:[H_@EG7PUX>?Q4N
MA:&/& \+I&OB^5&EE9Y1"T;MA7IK=Z7U]%T(6(Q<59.UN[=OGJ]--?)->OG'
M[2'@;XE:5\"?BW=>!OB7\1M=U.V^''CFS\-^%K2VT;4=1_M9]$UMH7T/6="\
M-I\2Y/$3-L$;CQ?(V\ +AE('XY?\$[M&_;-;]H=G\:W?QLTG0U\">) NI?%?
MP[\3=0\--NE\/ Y.O>(?"WAH>(0-S';&QVJ0,'D?TP%)RY$$\7D]"/LP!XQD
M<J#VQT[ 9[T^&&2,3^2%!.,E1C)_#&>V<DY]^E?/9APJ\7F^3YQ_:DXK)G?V
M=YVFKWM))Q3OS<MK7Z]#]+X8\4,5D'"6=\-?V1PSF[S^,O\ :*E&#K4&X\B=
M.4J*YI4[<ZYI64KWNG8\?M_A;XLGN1=7_P :?B/<6Y W:/9Z1\-?#^EY('",
MOPX_X2? /&1XLPV,X '/X+? +_@HU#XPUGX:_$;]HWX*:[X(_9B_: ^*OBGX
M&_#GXV6/[37QA^(^F?!KXQ:!XPU_P#HGP6_;"^%/B)/"OAOX0?$#Q4^CI(/%
M,9_X0X3:_P"%8S*4+>,&^_?V_?V2_P!J;X]^.OV;?B7^RO\ M Z=^S[XX_9J
M7XQ>--'NM5_MK5O#?CSQ]K__  @.A^!_!7CSP4 ?#7B'X/>*_#^C>.O#7CIV
M9O&O@X>(/#4_@-_]:5^6_@__ ,$_OAE^V#;7_P ?_C3\,OVF_P!BWXC^._'V
ME67[97[*/A[QBGAWX'_';XG? [QO_;FA>-M=T0^&T7X@>&O$WB+1M$\4>"OB
MI\*#X0?QI$A9VDD+;OJ/8)WVL[_=]S?7S/S?^T,3=MJVK>VB=VW:R25O+331
M(_:'1_A!\,O"=R+WPQX \!Z)J3#/VNR\,Z18:D.>FY(QC\0/6OC']KC]FG]G
MWXL^*= \1^./AIXN\9>.($\,:)<:GH&C_&'4M-LO Y\9DZYSX )\->8BZOKI
M*X/C#:Q"EE3*_I>KJQ(&<^X/Z=NU13CIGV]N>:X,3E^%Q6%>$<4W=?$KZIWV
M::W7K8[LGX@S?*<T_M;!9I4IS2DO<G.#7-&46G*,HNSYKV=TVHZ65CR7X2>"
M_"GP\\!>&/"_@33-3T3PEH6D16/A[2M5_M@:A9:6OF>6&'B3=XDW!N_B;$H/
MEECLVY^*?V\/VQ/BK^SGXH_9H^$?P0^'GPY\>_%_]I7QAX[\,^#KKXQ?$C6/
MA-\-1J_@3P8_CH>"_P#A--%\*^+R/B%\5'C7PYX"\-Y_?2 N1Y2@-<_:Q_;.
M^#WP4^*WPM_9&\7?$G5O@I\3OVN?AS\4+/X$?%6\M]+'@CPCX]T./P_H&AKK
M^L"3_B2>(Y?$'C?0F\$1W*MX/\82Z,W@W>),*?YC_!/PJT4>/?@5^Q1\8_!W
MQS;XQ>._BIX%^"_[;_[%_P 3/$/QD\:^&OB5J)&N?V'_ ,%:/V/?CCXAD\7?
M\(#XB\*R:!_PM+QQXJ\(^,8U('B3P*RY3?XSZ,-AOJBMNK+39))6LEM9+[M%
M:VAP8C$8K%8N6+Q3YG-RE*4FY2FY2<G*3>LFVVVW>[=WW?\ 57^Q1^V#X6_;
M#^'?BC6K;PIXL^$WQB^%_C!_AA\>?@E\0%"^.OA+\3-#;<^BZV!)"==T&50/
M$O@GQ8C!?&?A)DG,87<M??-?!_[)O[$_A+]DM_B?KMA\5/C7\<OB5\8=6\,W
MGQ(^,?QZ\6:-XH^(_BS3O ^A#P-X&TK6M9\/>&_!WAUQX1\/;D4)X2C9R\@8
M$["/O"N@YPHHHH **** "BBB@ HHHH *0]#]#2T4 ?D-X<:Q?_@K7XRN=&@^
M'+:Q_P ,:^)3JMUX>^).O>(_'=\4\9_ 8Z&OQ7\$/X<3PW\'V!#)X+'AIO%O
M_";>#\^-)@I+)7V9^V!9SW'[,'Q\A@0\_"/XFD 9P<^"]=P.#P,=?0GM7R;X
M=U/S/^"LFO6*:I//!IO[''BH+HY^#_C'P4-$+?%#X$,<?%/7,^&/C#Y@)?=X
M5!_X0E6_X0R4$HRU]*_ML?$/XI_"C]D[X_\ Q)^"'@&/XG_$[P9\+/%VM^!O
M!-W;S:G_ &_J>D:.[!5T;"C7B""Z^&4=7\4E(XH6"2?-S8K#O%X.6$NUS1E'
M1ZZJ7SN[KR.K+<Q^IYQE6/Y5)9)4I3Y'M-TZD*BB]+._(E=WWU36C_D/^!7Q
M,T+X*>-;?Q_XQ\8V'PO\,6FD"UU?X@^*/ NM>-/!&A'6CN"^.-$\/?#GQ7_8
M'AUF4 ^*&;9X.!VOXX*LP.QH'QH\5>$=9N-7\?\ QOT3Q9\5=-_:.^%O@[XI
M?LH?$Y=(75?$/@+XL?$[0="^%/[9O[$.LZ%XA\(-\7?#P'CC0O$_@GPK^S[X
MP\'>#SX,)5E4CGW6S\1?M3_%+]H7]FOXG?#CXJ_L^_'3Q!^T%\(O'FC?LX_'
MFU^'$GP[_9J_;<^#W]AIXX^.?["_[8'PJT)O& ^#_P 8O"::#K?BKP3XFC&&
M;0/%/@CQZC2N_P#PA_[>_P#!/#]B*Z_9Z^!FA:)\;OAO\'?^%@>#OBE\9?B#
M\$?"6E7H^+2?LN?#'QOXR_M_0?@Q\*?BGX_\->%O%.OZ!X4W/M\3^3X2+?VU
M]T *7^4X?X-PV5X62QDI.\I-6E+:3EK:_G?N?J7B'XR9IQ]GT<UCE,,BY:<*
M5HP@[^S@H*5U%7NDVDHK>][F'\./^"8UY\,-0UG_ (1;XXZY:>&-=O/MY^'N
M@67Q+\,^!= U+ _M]M"T70?C8JZ"/%(.Z386VC@_,0#\L?M^_L/_ !?U;1?A
MO%\+O#"^/KZVUCQ,=6.E-XP&I6(QH9T(ZWKOQ ^)'Q;'0 \DC !&,'/]#RXB
MR"820.I! &<<9(7D8SV''?%?E)XV_P""L7[,?PT^./B;X4>-_#GQD\.^"/!?
MQ2TOX >+_P!JR\\!HW[*_A3X[:UHGA[6O^%9>-?&S>(QXC\-^(-FN:&O_"3>
M)_!L?@A3)_R/$>YBWI9AP]EF*RV6#YI15])1E-2=WKUNEVUMWMJ?.\+>(?$'
M"W$&5\1X6%+.99-S/EJPC*&JE\:4?>MS::2>B\V?SF0?'NRT;]F36OA!\+/'
M.J>&_C1H7Q<U+QA\1O#GPG\#:UX:_:"\=_ GP+K;:'\=?^&5_C;X@ \+?%_Q
M+\*1HJCQM\,/A1XQ;QJ?!7A_Q,H\<+MR_P![?LE-X&_;CF^//[%'C_Q_\%_V
MY_A_KO[/_P '?'WAS]L1_#?_ !=_QY\,#XU\=:%X%\%_&[7/ '_")>)?A#^T
M+\ /$0\;?\(,?%!/C3<S>-OEG'C4)0^.?_!/_P",7B3QQ\;_ -CW]DGXB_L]
M?$CX<:%\8/ O[3?@31?B#\5-8\-_M"?\$K?C'\5/&1\>#XG?"LZ%X:\7?V_\
M._%@'C?Q1X'^%_\ Q1@W:[@.48[_ .EGP)\,?AY\.?\ A(9O!'@?PCX+N?%%
MX-;\6W7A+PAHGAQO$/B7:5?6->&@1)_;>O$CYG)D;#,$()05TY+DV%RO"?4V
MW*R2NVV[>K;OOWNCGXCXYQ'$_$.:YSBJ4(_VU.53EC"*49-J3M9+EVM9<L;*
MUD>(_"#P)\:_@]\)_!_P]O\ 6[?XUWW@;PEINB+\1/B9X\UEO'7BO^QQM.M^
M-'C^'+#6O$#D [@R+OPQ.]LM_.]^UA\9OVK]-_:7^)=C8ZYXWT2P/B!3::3X
M5N]:\1^&K#_B2>'_ /D"ZU_PCGA':V/O#)P3U-?UNQR$KMAB&#U!N01^*DD8
M/;/7/.<U_/C_ ,%A?@#J?B3Q_P#!'X^_$+P!\8OCG^REX%\/^//A]\;/!'P;
MU/QII7Q;_9Z\3>--9\.ZWX)_;,^%.A^ $C?Q]X@^%,FBR>'/%_F-)_PB'@J1
MKB)I86\9"O-XBX>6:82.%P=U)34K7O91DG9WVV;T;_4]_P -?$#*.#,US7$X
M_A2CGT,[HSHKGC&]-R4ESP4H2@ES6=DH6LW=WL>!_P#!0GXM?M7?#7]I;1-<
M\7_M*?&/]E?1/&'@/P)9_L5>(O#GB+P9J/[(@^.VA_V]K_Q2^&'[8*>/4\(^
M&-?3XJ*-$A\#>)?%GB[P>W@P(!X%=Y$??]0?LN^%?A!^U-X*_8D_;?\ !_P4
M\>_L]?$?X->'#X-L=5_9<;P=IOPS\<>!="UK7O OCO\ 9_\ [$(=OB#^SO)X
MFT=O$_@S_BDC'&BQ>-?A]XS&'\:MT'_!/%?C'^UW^SQX:MOCE\6=1^,'P0^#
M?QL^,'PTL_$/Q ^ S _M^_ ?1O!V@GX4?$SQSHGQ=\-?\)/X>U[PIXGUMC)X
MI\)97QGXS\!R/(#N=C^TVD:/IWAW3+#0]+T_3=$TG3[-;/2=-TBRTK3-+L0@
MXTC1])1-D:A0<*<+D\8W''T&&P^)A%1;T45&TK=(J.U[7T[?YKXC%YCE<Y2;
MRJ,7*<Y-1<E&*E*H[*Z;LE*UGHK7O?0^:OBS^TKX?^'?PY\9>+K3P]\0;J^\
M*^$_$NMVVE:M\/?BAX?L+_4M"T:37CI$GB"3X?'PYHJ.-JKXC<R*G)!DV*!^
M+GBC_@N;X^MK33K#PI^SKX*M?%_B_P 8>%?A]X:\0^*?BCJX^&GA/4O&_C/P
M_H'_  F7Q4UOP_\ #@^(_#_P]\*)K:^(_&SB,.L7R*P8AQ_0UXV\%Z%\0/"/
MBCP-XH@M]0T+QAH^I:#JMI;YL,Z9K49T77 3EB?E)!8_,>>IQ7Q3X2_X)D_L
M?^%K?QAI\/PLM=<T?QYX:U+P'XO\/>*/$/C#Q)X;U[PKKK'^V]%?1O$'B2:/
MRY@"N0JN0"8V!&1\_FE#B!YIECRN4%2AS.HY*Z<;WDY:.-DKK6RMZ7/N>%,X
M\,\+POG.&XDR?$5,\JZ<,SA+W*;46O>]^+2<M;RC-W2M92L?._PD_P""@/@O
MXQZ#\7_"O[4_[-FI:9^T_P#L?1^%_C1XB^#WPRT?2?VC&\>Z0RG1/ GQ_P#V
M/M<T$++X\\/^*MS$*0OC?P1_PD#>!_'@4G!^N_V;/V2?A1^RWXC^+WB+X):I
MXU\,> ?CQXFTOX@7OP'76$'PC^'/CK]XGC36/A;X+/AE?%/P]?Q89M%;QGX8
MCD3P:LNA$#P9X/5G#^+_ +-/_!*C]G[]FKQ9J?B*T\1?%OXU6]CX<'PQ^''A
M?]H#Q;H_Q)\,_!KX7G6!KS>$/ -NGASPRX 8Z+$OB?QDWC#QL/!_AWP]X*_X
M31HXU:7[F7X(> +4VT-C;>,-#0IG[-X5^(WQ+\,Z9UY']A:#XE7PXI]0\8'3
M! Z_4KZW;6U[:ZZ/O^O^2/S7$O*W*ZYK-[6MOTW]-K[VUM<[S6/&7AGPY#;C
MQ#X@T[13/D*=3NTT\79QQMW'@X(^49XZ#K5O1=>TCQ):"\TK4-.UJ$C&=*O!
M?Z>?3HJC(_V1UZ "OQ=_X*2?L>_';XR:7\*H/A/#XB^(YT'5_$U]K-KX@\1>
M#Q_89UL:*-&QK>OGPGXE)7:?D5G=5 #]%)]<_P"">'[,_P :?@S\&KGP_P#$
M+7_$OPIU?_A+/$NLGP]H[?#3Q%IXTJ1N/^)S+X<\5)MQ\Q.X.-I4J3@5\K1S
MC-Y<12RS^R6LH46U5>MI;KWFK/WM6D[]$S])Q/ _"4?#Z/%N&XOIRSV511?"
M=ES\O-*//;F<](I-MJVO,_=:/K/X\?LA_L\_M*>#_B/X'^,?PW\.>(X?BYI'
MA71O%WB"RL1I?C>^3P,^NCP%JVC^-]%#>)H_$GPM\1Z]K'B+P3XE+*_A%M>+
MQ)&PDV>I_![X<7GPD^&O@KX?WGQ"\;_%"]\(^&])\-W?Q"^)=[HVJ^//%G]B
MZ2D:ZWXUUC0/#GA=#KLG)9UC10K!CND9V%O_ (5QXR/_ #7;XHY'KI/P;Q^!
M/PU_455G^&6N3Q'/Q?\ BD.">1X*T_..V!\.L_AC//8"OH98C$VE9?S65EH[
M2M^A^:8?#X6ZO)+5:6;>KUZ]+_.VMCBO&/[77[-_@G7M0\(>*_C)X#\.^(-*
M'_$UTC5?$^CZ;J-D& P7CDD4#GKD$KZ@X%?F!^V_XD_;@3]I7X:_$;]E+7-%
M^*'PQ^&_PBU/1?C3^R]>7NL^(O#?QY7QOXR\/'7/!NNZ%X=B\3GX?_$'PU\/
M4_X2GP5\4/%*E&!'@? 7Q<T?B[QO]I#_ ()4?M)?%7XV^/O'_A7Q1\.M1T?Q
M/JH.D7?BWQ'K&F^)1G1RI&N-X>^'!4D=?E)(7![BOZ!?"WA>P\+>&['P[H]C
MI^CZ?9V"6:6>E6BZ?I]BR %BD:A5!+#'')+'H"*\#)\3GV(Q53"XY*G%-OG:
M;7+S2LNVJMUN[62>A^E\9\/>'V09-PIC>&,[EQ#G.=T92XGHRC&*X=G:'+%2
MM%W;;=TI]GM=_P [7[(G_!/_ $GXXZ!\&_B;\'OCM\3OAM^Q1\._V@6_:-_9
MH_9N\7^!=%U#XW_ CQ[H&M>/-"\<_#+1/'/Q \-_\)/\/OAR?$AUH'X8A/&>
M/[#!'C49-?NEJ_[/GPX\3Z??V7B_3M1\=SZ_::GH^JZOXIU;6-4U#9K>D-H>
MM?V&Q.WP$TL+;7_X1%?"2JW*D,H9OI"W4 8QT'ISQCD^])*I[QD\]L '\1D\
M?_6[\>^\!A7=8E*>_P 3TUOLG=>>WEL?GG]KXO#23P3<'!KEE!N+CJK/FBE)
M6:4K*45=7M=(_*Z[T']@W]C#XT_!GPM<1>#/@Q\7/VA[[QW\/O@M=ZK9>,4T
MWQ=K&@Z3X>.L^"QKS)_PBVA\ZWHW_"&^&/%,R?\ "7E1'X&C+NVW^9_XE>(/
MBAXBM=#^&'[6'[3WQTUWX]^$/VFOAIX0_:8_9>^*WCK0]+^-?PT^+OC?XF1:
M!\"OVXO^"6VNMH'A*1]$\+G7='DC^&/@^+Q?X('@G6O%"2E'">-9OZS/VG?V
M&/V;OVS(M''[0G@D^.AH'@+XF^$/#GVN\U73!X5_X6L? PUOQKH8^7_A'_B+
MX9'@?0_^$*\5A1XL\'X9H2N3MH?LS?LN:[\,_!/@G3_VBO&7A#]J'XJ_"75_
M$WAOX-_M >+?AUHQ^,&G_# ;E\$KKWC4 ;OB$/#3@>-/%7A8^$T\8OM8QAHE
M#WA\+A,)=8.,8[MJ*48Z[Z*,5KZ?D/,,QS;-<7]<SC-)YU*T5>K.<YI)6BG.
MI*<FH*R2NK+HW=OSS]BC]BGXG?LW^-OCU\;/C-\?=-_:1^-W[0%E\'=$\0^*
M]-^#FD?!3P[>Z;\#]$U_0=!US6_!OAWQ-XN#?$3Q4FNNGC7Q4CA9/[#\+A?!
MZKX3._\ 4*BBN@\\**** "BBB@#\W_BO+XEG_P""B?[)=B-)\+W?A%OV<_VL
MKRSU6^\::Y_PDE[XG&O?LQKKVD#P/'X8_P"$:_L)/#@T62/Q,/&(8RZ[XDB_
MX0Z(;9/%OZ05^;OQ-T_5(/\ @HE^R7KSZ_KUQH%Q^SU^UAH]OX76RT%]+L-2
M77_V:0?&":\/#8\4/K_B4:UHOAK:?%B^#Q%HBE5-RSJ/H/\ :H\$_%3XA?LZ
M?';P#\ /&)^&_P 9_%WPM\>:+\+?&MFS@^'_ !YKV@^(!H.M$+QHA/B%D)\1
MOD*Q,BEF6,4 >/?\%&?$O[1?@S]C7XV^+_V68?$D_P 8/#6C^&]8L%\#Z3HG
MB3QL_A=/&GAP_%0?"O0O$07PWK_Q('PU7QTW@>/Q,/*'C(>'G=2<&OYROA._
MQG_:#_:\^&WB7X"?ME>"_C3XX^)_[/\ XZUC]GK]H_QSX&T/Q%X:_:(_9T\"
M^(/#Z?%3]C'_ (*:?LZ_#V3P@/\ A8?PK\2>. ? WQ/\*>$O!WC9U;Q-&T?F
M,T/@WVK_ ()Y?M+>-/AI^U)\%OV;?AWXL^-.G7/QC;QW\/OVLOV#?VB]7^)?
MQ$^+O[#_ ,=/ GPQU_QTG[0/PM\;>/\ =XF\1?LK_%?7]#P['Q@?!4LOCWPQ
M-X"V.P\%I^^?[-?[*7@3X$60\?WO@?X(W/[3WCGPUIUE\>/CM\,O@KX0^$NJ
M_%OQ8K#^VM:U[2/#LA)#:\2WE'Q1(22K%P57>;;:>F@;Z=.W0SOV#?V8;K]C
MW]EWX6_LZ7WC+3_%VI^!;3Q3=W6J^'=)UKP[X7TYO&GC;Q!X]_X1#P1X?\0^
M)O&'B+P_\/?![ZTOA?P-X:;Q6[)X0T&'(#*JC[IHHH \V\=^+K/P3X/\8>.-
M6L=0U#3O!GAOQ#XGO++1[5]1U6^T[0='DUUQHVCG!DUUAM6)&C7<ZD%L.OE_
MB?\ "O\ X*&>"_VV]!\ _L[?MA_LLI\*?A7_ ,%!/A7J5]^SAXIN_BII'QH^
M#G[0_A77=";7==^&.M>-] \/>%?^%<_M$>%="9Y'^&6V60^,- ,7@/QM*4C(
M_?FOQ?MO^"0?PD\*?%WPOXH\!_%SXM> OV>O#W[07A?]K:W_ &.=&;P9JOP0
MT_X[^!=9;7M \;^!M9USPV/%7P@\.-XDUB3Q+XV^%WA'Q:O@[QM(C;85&X1@
M'S_^Q!^Q7\5-1^,7[.'[3.K_ +2.I_%CX'?LT>&?CO\ #_\ 9^\2?$'X$?$G
MX3_MG>*O GCEM<\!+\%_VCM=\0^(O"C^/_AQ\*6T5O%/@F0^"3XQ\8^,8O#O
MCV1HP%W?T0444 %%%% '\;/CO]CS]J3]D+XMVNA_ ?\ 95^(_B+]I?P;\>=8
M^(/[(?[>'P(\/:(/#OQW^%?Q8^-,GCKXI?LT_P#!3'RF\*J?#7ACP[K.N,GQ
M0\7-&WEZ'X9?P(T4L3P>-/ZOOAQ\.#\.AX_)\;_$KQF?&/Q(\3_$#_BX'B^7
MQ-_PB:>()5V^"/!"M$HT#X=^&(TQX.\+%=UKN8;@!YE>T44 %%%% !7Y\_M%
M_P#!.#]C[]JWQS8?$OXW?"L>)/'%MH[^"];\6>%/&?C+X<:MXY\!-YAUKX:?
M%%?A_P"(_"9^(7P[=AM/A3QA)XM154[>%(;]!J* ,"STVPT>PM]*TNQMK#3K
M2T^QVEI:VHL-/L+!1]Q5 V+M49PNW+98J"68[]%% !@>G^?\D_G1110 4444
MK+LON7^0"8'H/RI< =!BBBF*R[+[E_D%%%% PP/3_/\ DG\Z*** /CC]H3]D
M/]G?]J'3_%&G_&KX/>$?'K>*/A;J_P &-4UC5]&,FK'P)K6MZ!XY?1]#U4NC
M:,L7B;0M#\3^$?$:LK>$?%^B>;;3BYVH=[]EWX.:W\ _@EX%^#_B3XM_$#XY
MR^#[+5]%T;XF?$^ST<>.K[PJNMG_ (0C1?$&LZ"NW7=?\)^&1H7A=O%3['\8
M'0?^$T;#/LKZIHH **** "BBB@ HHHH **** "O.O%FOZ1X3\.Z_XHU:6YM-
M/\+:1J.M:M=6EEK.IZBFF:+I:ZMJDD.D:*1KVN,B?.T"!I"678C,P67T6B@#
M^:_]O[X]:E^T7X \$?%']DS]L']JOP?XY\9>'/BC\*?V3_V6_@+X!\9_!7XD
M?'?]K!AH>M^'?B3\49?C!X<\'>)?^&?OA5X=7SO':^*/!WA7P3%X,W>-7\=;
M7A\)2_-?Q!_:-_;1\*?M$^.?BAXP_:4^(5MXN_9@_;@_X)V_L@:U^SYX4O\
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M8_M6.?7..F=WS8].*TJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH ^5/VB?VGO@1^RAX.T?QK^T%X_M? 'AG
M7/$&D^#/#3_V+KWB;Q-K_BS7%QHNC>#/!/@#P_XM\4^(O$+#^U<1^%_"[LP4
M;AMC#CYQ\8?\%5?V!_"/P]^#'Q)\1_M+>#++X??M!6FL7OPT\8M;^+GT_6M*
MT#7%\/:YKVNMH7AV8^ -!\+^(F?PYXP\4>+4\))X,\7J([@1.WEU\M?MD^(/
M^"BOP;\ >,_%?A+P#X>_;9^)WC+XJZ1:?LR/\,_V<='T[Q%^QAX$:/QW_P )
MQ\3=7_X6#\26'Q ^((\-?\(_X9\$^4/!L;>-W)\=LW@?S@/RJ^(7[)?QP\$_
M"OP_-\$/V&OVJ_$GA?X\_P#!+S]K3_@G]9>!_&Q^&E_\8/ ?[17Q5_:#U[Q[
M_P +H_:+ \2_\(UH'ASXK^(]<UKXH/XI\*$CP86((\&JP0 ']"WQ*FUJ3_@H
M=^R1?MJ'ANY^']U^SA^UB='-O::T_B4^*#K_ .S*=:UA=9!'A@: ?#IT-4(7
M>3_PD@_>,H4?H[7P!\"_V03\-=?^$'Q)\8_$7XC^+?B!\+O@3IOP9TKPKJ?B
M'1K_ .&6@"7P;\)=#\<ZSX'T1O#P\3%_%?B'X6:$\C^*?&3LV&<I&9(Q7W_0
M 4444 %%%% !1110 5_,9^SW+^W1^WM\'_&/_!0'0_\ @HOXD_9=OC^T?X[\
M+_!_X#W/A[X:ZC^S3X$^#GPJ^-#> V\%_'#0_$'AM?$_C[XB>*AH>M8\5IXR
M\'-GQ!X8"JNQ=W].=?BM\0O^",7[(7C/QUXR\6:UK?[1.A_"[XG?%,_&KXP?
MLH>$OC3K?A_]E/XF_%#^VH_$&O>,O&OPJC1I&;Q9XCTA?$7C&%O%D7A2>2-M
MD+;@U &!\</^"J_BKX5^*/VKO$G@_P#9BU7XM_LW_L,>,/ W@S]J;XPVOQ4T
M3PUXET_Q-KNE:!XA\;?\*J^%*>&/%+>/O^%0^&->T/Q%XV'BOQAX-+1-L\%F
M=@'/ _%G_@L-XA\!^*/VF?$>A?LGW'C7X$?LJ_'CX#_!?XN?&4?';1O#FJW>
ME_'-/ 2Z#XT\#?"Z3X;N/$&P^.]''C/PIXK\7>"T5)/#2CQGC<?!_P!+?%[_
M ()-_ 3XV^//BIXFUOQ[\=_"'@#]H+6? _B;]IC]F[P!XYT?PU\#_P!H;5/
M7]A)X?;QUH+>'_%GB?0A)X>T'0_#?C4_"GQGX'_X36+0TWE&#,>P\=?\$Q?V
M??'OA7]K;P+JNM_%"VT#]LGXO_"WXT?%,:9XDT?2SH?B7X3#X??\(5I7@5E\
M,M_8/AU6^%_A]%BDC\5/N61LE=N #F]'_;R^,'Q._:'^+'@'X _LA:E\8O@C
M\!_VA?#7[,?QK^,EE\;/!O@CQQX?\>MHVAZ_XZUWP-\*/$/ALI\0/A_\*!K^
MB?\ "<N?B]X/\:L2?^$#\#^,QQ7RW\&_^"Y7PW^,/[27@+X26'@OP19_#'XS
M_'/XJ?L^?"OQOI?[0G@WQ-\;[WQ_\*AKVW7/'/[+,?ANW\5^ ?AS\4O["UT>
M!O%2^,_%DDBGPQN\%H_BU77Z[\1_\$UOAWJ/QT\8_&CP[\8?VF?AQX=^*'Q2
M\"?'?XO_  '^&/Q&TGPW\(OB5\8_ ;>'UT/QEKBGPU_PLW0/^$J_L30_^$U\
M,>$O&?@[P;XW_L'/CN,@9:I\(/\ @FI\-_@3\7U\=_#;XQ?M):#X!M?'GQ-^
M*'AW]G2W\>:+IWP,T#QW\6 ^O^.M:_L,>&#\2O$OA\^)M97Q+X.\)>*?&?BS
MP7X*\7R-)'X,5@F0#X^^ 7_!8WXI?'H_LD7T7[$[>$_#7[<W@3]HR_\ V;]7
MN/VC=)O]2O\ XG_LX^"_$OC?6O!GC711\.&_X1OP%XKC\%Z\O@SQ? _BZ;A&
M;P.D11*\8_9B_P""NW[7NN?LN?\ !/2X\6?LH6O[2'[3'[>6M?M.6?PTMO"7
MQL\'_"7PSKNE_ K0QXY&LZ\7^'C^&/ 6AGPZ=>\+'PVJ^+',?@2+QIGQH?%(
M:OU ^$7_  3$_9Y^#.@?L1^'_"NJ_$^?3OV!K[XS7WP5_P"$@\2:-J8UT_'/
M1=?\/^-CX\?_ (1=&UUA%XTUIO!R^&%\'F%BL8=D1<\?\ _^"5?P0_9VE_9.
MN/#_ ,2_V@O%EK^Q;XT_:*UO]GW2O&OB3P?J&F>'M+_:/\()X$\;>"]>_P"$
M:^'/A.7Q#X=\+[M9\4^# ^/%X\6Z[(;CQQXM3=&X!X#XH_X+'7W@C]L#P/\
MLD^+?@5X >[\>?M!:9^SA:7OA']K/PA\2/B9H/CWQ!HRMHOC3QK\*? 7PYE\
M-?#_ .'!\3@^&$B\6_&+PC\9U3;XT'P/9% KYQ_9L_X*+_M0?%WPW^R3XJ_:
M-L]=\$ZA\7/^"E7QV_9\T8?!SXC^"=.\,W?AGP$WQ>9?"'Q1T/Q'\$&_X2'X
M?^$7\#IX9!\+>,/"'C+QF8T\=#QLI#>"V^YK+_@CO\ K3XO6WQ4L_BW^T/IF
MD:7^V8_[?'ASX-6OB[P?_P *CT/]HK6=:_MSQ#K:QM\-QXJ\0>'/%<A"CPOX
MI\83+X-0HW@%O!PE5AT_@'_@E/\  _X>:[X&U2R^(_QTUS0/A;^UOXZ_:^^$
M7@#Q%K7@AO#'@3Q]\6/^$]_X3KP9HFWX<IXGU_X>._CC7?$87Q7XL\7^-O./
M'C0(!D \?^$/_!6O5/BCJW[-?B[Q7^S=JGP__9'_ &U/C3XG_9]_9F^/-S\4
M])\0>-]>\=/_ ,+"7P(?BC\%(_APA^'^B?%@>!-:'@EU\:^,WB"(WCM83*I;
MC_V<O^"QWC/XVZ_^R!J_B3]D.Y\!_!#]M/XO_%_X$_#CX@6GQXTGQIXCT_XH
M_"63Q\[R:UX&_P"%;^%1_P *^\5#P/KK1^*5\7+(6 5O!GW&\6?1_P )O^"3
M7P"^$OC[X4>)-)\<_'7Q?\)_@!\1?%7Q<_9[_9I\:^+]$U3X&? CXG>-#K@'
MBWP7H;^'(O%.NR^%7\0^(AX#7Q;XP\9Q^"?[<E?P.T;-L/5_#?\ X)9?L]?"
MSP=^R1\/]"\1?%"ZTG]B[XV?%'XZ_!V\U3Q)HYU2_P#'/Q4UKQWKVOKX[+>&
M577-!#>/->"1^%F\'D\OT$BH 7/CC\;?B'?_ /!0W]C+]EKP/XB_X1KPC<?#
MOX\_M3?'F>U\H:IXK\#^ FT#X1^ _AJ "P_L&3XA_%6/Q7XQ\QL^7X#B!$1=
M\_&G[.O_  61\9?'_4/V.+[Q'^R7=?";X7?MS']HWPO\+OB7:_'C1?&WB70O
M'?[-X\??VZNN^"/^%:^$A_PCGBI?!&NMX(\4#Q<'8A W@H+D-]^?&7]GCQEJ
MO[:7[('[5_@(Z9<#X8>'?C)\"_C7I=U<OIVH:Y\&_BQH>A>(]%UG1"JJ!KWA
M+XS>!/ Y_P"$=D?:_A'Q%XI7Y&V1'S?X8_\ !+']G7X1^#OV,?!/AO6_BU=:
M/^PCXR^._C3X/#5?$>COJ>I:K\=F\>1>-CXY9?# DUX*OCC6SX/'A5/"7E*P
M.\I&00#^4WX;_P#!7']OJ;_@FC\4/"-]\??$FM?MI>//%_AGXZ?"#XLW6C^#
M?^$FLOV7]$^"WQ:^+7CLZ)H0\-_\(LWA_P )^(OV4_BCX6#,"0/'@52 2#_1
M7^Q=^U%\;[C]H']D'X=_%KQAJOC_ ,+_ +7G_!++X.?M.6?]KOI.I:EX2^/'
MPMT?X?:'\66T8Z%E?^$9^*WASXJZ%XHW .(?%_AYDBV#Q:8UL:'_ ,$,/V)=
M'M_ UO%??%N?4/AS^Q_\8OV(O#>J7GB_P=_:P^%WQT;XM?\ "0:YK97X<G?\
M0$_X6SXS7P;XK4&&,>(6W^"V *CZ ^"?[%^I_#G]K/P#\2KFXMQ\(?V7_P!A
MKP!^Q]^SD-6UAM2\<:X7UO0M;^*GC3QI(ZHI(T'P'\+/#"'&XD>)GVJKQY /
MU/HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUG4="\#O\2]8TG2?BIX.U/5+'P$N=8_X30Z'HNOL3X=V#>/$X4H[@?-(CEW
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M/$7BWPZNO^)O!F5+,O@7Q&IPRAW_ &(H **** "BBB@ HHHH **** "BBB@
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MOB3QM#^R_IUO^T!>?\'! _:GL/'.WX<?\+'/[)H^-2:T?&1\=_\ "1?\)$/
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6 K*&D#^M4 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $R 6T# 2(  A$! Q$!_\0
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MXA>%/!^C>&O$WBS5-=\%?"'QYKNL^-]<\/J/$_B'Q!_PD8'BK/BQG.]F&1M
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M;@CY3] >"/VCOV>OB/\ %7Q]\%O _P 8OASXM^,/PF)'Q&^&7A[Q?HVI^-_
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M[/7P?\!?!36?&7QC\":+XOU7X:^&=&\-ZEXZTL^,?V8BH\:_\(ZB?\)'K_\
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M_P (7\ ]!&M#TQXCUS1,C!SD<CN ?V>?\%!_V_OC'^R7_P $GH/V]?AYX>\
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M-%&LZU_PC_A</+XHT'1-'\5$/#$,:\L>U_*WD ^NZ*** "BBB@ HHHH ^/\
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MB#Q3XDUD>*)-?UV5A)([LNM'8-Q,4?&? ?\ X)__ +'G[,7P8\;_ +//P/\
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M[7__  3F^#O[-7_!8'_@GA\"/@O\3?VD/"7@_P#;F\":GHO[5&K6GQW\9_\
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M;G3?&'QD_8/\,?$+Q?9VEH3IO_"4>.OAG\7=?UT<]!G7#M&0 N ,!17Z ?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O+/&/Q9^&?P]EL;'QS\1O
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^P%XQ_8=\-_M&ZM\1IO -I\0?VE/CEJ/Q<U?PI\*/$/Q*\=>"/".E#P=X?\
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M"(R*:^8/%7_!&W]@WQG<?"^^\0_#_P"+.FZE\$?@AX6_9^^'&K>$OVG/VE/
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MC5\0'Q ^O?$]=?/B3QWX?\*'QOX@'@/PO_PB'A+_ (1/^W4(:0[4'G7[0O\
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M ,$POVX/V6/!7_!/#XL^%O _PF^*/QO_ &-_%_[=]EXO^ _B#XOMX*\,^+O
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M9F\'X\9^$"\(?/EI7]#M% '\S'P0_P""67[3'P]^)G[&7Q2\67'@)?%.G?\
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M_,FN>_\ M6O;\[_+R._V[_LQ85)OW^:UWK:/*H]G=_CKYGJ<9N#*=P"Q\@9
M&?0^A&.O7\^*AO)X[>&<SE0 ,CDC"]<_AZGL.I-,C&266;=@Y(P1SD]N.._4
MU\1_MF:%-XZ^$^O_  PT+5/$EE\1?&.CZC%X#M?"NK?V1XF/B710OEZNNM'<
M_A_P]OD2+QGXD*QL/"&NRJ!F0"C%UUA</S)KFY9)*UFFKM+5WUV5T^@LDPW]
MJ9I1PF,E_9,'.G&562YER\T5*<K.SLO>>JZ[6U[GX0^.O#?A;]G7X2ZCKE[
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MGK&[0?#&A>"_[!T/1?\ A1[-_P (M_PC^,A?BGN_X3!2%\#@;!B@#];:***
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M+WQ;JE_IT,P^UB\71-8OTX4#=JZ^'_#\AB7'RX)+#;C. "?7J\2^/,@'PO\
M&TG&3X;U7C/7Y2?KP!TQ[]\UA77^R-[:7;OVD_-?F=&7T/K.+6$:>KLK*[;=
M[+:[U[;W.S\(>*=*\5:5;:KI?VFYL+K_ $,?:](UKPW@@=%T37P#C'&>IZ'(
M.*[JN+USQ5X=\+:+<:YK>KZ;HFCZ7: WEY=W@T[3;)3W.W &<D<9P ,>WCK:
MG\2?B*/^*4@U3X>>!Q9+_P 57XAT=%\<Z^QR"?!?@GQ /^*?5B5)\4?%*,R
MCY? CAAXP"6(32M9[:JS73LV-X=Q=I*4-;:W32N];.*;LM=O31IGR)_P4O\
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MMNWIN];Z?K^IROB7_D#W_P#UYZE_-JXOX.?\DD^&7_8A^!?_ $R:'7:>)?\
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M"97B_P#:'\<? 3Q%JO[3?[6O[,'[8GCVT^*GB&QL?B9^R)J^@ZI\-=#\,?\
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M;5_@X/#?C?PI>#3]5T]/$'QI\ :!KX!Z[7\.:SK9*YP2HW#(&/B&S_X.M_\
M@F)#86$%[H?[5=Q<?8_]+(^#^BYX Y_Y*/U./R&,^GZY_P#!1_\ 8MM/^"@_
M[)'Q&_91OOB!J7PPTWXCZQX"O;[QOI>C_P#"0ZGIJ>!OB7H'COY-$'B+PKYK
MM+H*@J9U 5RVYBJAOO33K(6=A;60/%K:BUSVX '!], >] 'PE^P3^WK\#_\
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M-_&VM?L7?$OXFW/AK6+BU\!_!GQ9I.D_#KXF'X9_#8_'71?[$^%7@GQW\5=
M\+M\,?@[K_B_P]E/!/\ PE?C#PD FUX]K*NWG#\OT_X8Q?BS^V-_P2?^._AB
MR\)_%K]JS]D'Q[X6M-777+'3+GX\^"WTZ75!I,@.K?\ $B\3@A_*UG5_WDC8
M)EX(*L13^#?[6G_!(WX!:+J&B?![]J;]CKP#H.NWW]M:M:>'?CQX*&G7NID%
M"X+>)BI(4GGJ0=NPY(/8_"+]M']B/6OB+;_L.?##QZ=3\7>!+/Q1\)-'\&ZC
MX!^)+>!];E^!^C:%H7COX:>'OBGXA\*CX9?$+Q/\*] DT0>.O#7AGQKXK\6Q
MH?.E4*LK-]XZ%X3\.^&M!T_PKX<TRPT7P]X?TC3O#6B^'[>T%EIMAX9T72FT
M71M#5%5B=!MT4B !6"@[ &"M71[>2CRWER_RW=ONYK?AY[D_5L)]9^M6>WE:
M^WI^J[H^48?^"GW_  3GGA\^']N?]DLV_J/CQ\-,9^@\2>O^2:YW6O\ @HG_
M ,$S?&&E&Q\1?MF?LA^(]'N\9MM5^,/PRU/3L],!6\1%>?<]NU?9'A+P=X:\
M'^%_#W@CPMHFFZ+X.\+Z3IVA>&?"WA_3])T_PWH/AC1M)30M&T+1M% \M-!7
M1,Q1PHS*BH(X?+7,*,\.>%/#O@#P[H'@_P ):)IWAOP?X7T?2/#7ACP[I%F-
M/TO0/#6BZ6NB:'H&A:3I#!-#T#PUH6V.)0D?E@(J>3E#6%WO=W[W?YWO^)5E
MV7W+_(^*_"W[?G_!+;PK$9_!O[6W[$_AJ#5<_:SX4^,'P;T[[<>Q \/^).W%
M=C#_ ,%/?^"<\\0N(?VY_P!E/R .O_"^/AI_\TF?3W^IKZJ\*>%?#?@G0=(\
M'^#=#T?PGX7\+:5IFCZ/X>\.Z1I6F>&=!TS1L@Z/H>BZ&RKH<:J^0@#(F J*
M2BXG\'^%/#G@GP_I/A'P?X<T/PCX9T&RCL='\.^'-&T?PUX;T/355R8]#T;0
MBJZ)'\[;5PH5B['#$D)MO5MOU;?YMAMMIZ'R;!_P4X_X)TS0_:(?VY_V4S#C
M&?\ A?'PT[_7Q%D9^G\\UX9\=OV[_P#@FY\6OA!XY^'.H_MI_L_ZIH/C+29=
M%U:U^'?[1_P;TWQ)?(SG^V1H>M^(?$O_  C198]H<@C<P8_*I4#])O#/A?PM
MX+T2#P[X0T#1/">A:6I-IX=T72-(T[2K$'_GGI&A+$ISP>-OKR1D4?"'A3PK
MX(T;_A'/"&A:-X3T*WO=6O['P[I&E:5I^G64NNZNVM:P8-'T(1PQ,VMZO(94
M0(JN^XDE_,DY7+%<RQ>%W3NDV]T]U?JGMU^=A8A)II:732?JI+R[_P!(_#_]
MA+X[?\$L?V6;7Q]!X&_:J^%O@C_A,;P_VO\ \)O^U/\  3Q+X:OSH6MZZ= .
MAGP[\3/%9'B >'=:!=3GS%^3(R<_HU!_P4V_X)VS+B+]N;]E,\Y/_%^/AHV?
MKGQ)UR/TKZG\%>$_#?A+13HWA'0]&\/:6;_6M8&F:3I$>EZ>NI>(=>UWQ!K^
MJKHT,A"#Q+XBUK6O$$@5E9Y-79R&?+M\5?';]LS]CG_@GU/I/ACXM>(O^%:I
MXS_X6E\6K'P_\/\ X0_$OQP;/3!K9\>?&_XH>-="^#OPZ\6KX=\-CQ'K+>*/
M''Q.\6+^\\7^(O$3F9762.NCZQBL4_K>+>ME==6[6O\ AU['/AL/]5POU5.[
MWN_-W?=WUZ?D?6_PN^*?PZ^.7@[2OB-\)/'OA#XC> =4;5++1_''@;Q)H_B+
MPUJ(T/6WT+7%T36]"P'6/Q#H^M>&G,<C*9M!E*J'&']IK\J)OVXO^">W[)'B
MCPM\(;[XQOH<WQAU:3X_65U:>'?B=\1_ NBC]K#XT:UK^B^-?''Q/\.^'O%W
MA3X0>'/BK\1_&>MKX'D\8^+/"'A ;I1$T4;LTWZKU1TA1110 4444 %%%% !
M1110 4444 %%%% !7\I?[?/[,O[37BO]H#_@HQ\+/ /P&^*'Q%T__@I6W_!-
M6S^%?QC\)V>DZC\,OA*O[-_C0M\56^*NN-XAC_X0 ^%/#.BCQ5X,&"OC&3Q
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M*Y^R]^S7^TSX;_:8_9'^"/BG]GKXD^"M._8C_;+_ ."@G[3WCS]H[5K+2/\
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MB3P?\%/^"@'[*6M_M<ZYXE_9'_;)\2^/OB=X/^$]K\(=#TOQQ\)?C'XY\:^
MO'6A>-6^*A\39\?#PF/ VA^&CX5 \'^#O&2\&/P8X*  Z']H_P#X* _M,_##
MXG_\$(?"OA/Q%X<_L?\ ;ZUC3;+]H[[5X:T74FUW=X+^ FOL-!WG_BG]S^-]
M=8'PKA>1CY5X^+_'G[3W_!2K]O75O^"L^N_ 'XP_!3X.?LK_ +%NL?'G]G"R
M^ OBOX0-XU\1?M#ZMX'\':_HOCQM>^**^)%\1_#]_%OA\;O!$GA5=V[Q!X:
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M/I T!=9?;(WS^)RO_"1L%8AI') '0?0U !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %@ >H# 2(  A$! Q$!_\0
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M^YO_  5A^.VO_LT?L)_%_P"-?AOXY:W^SU?^#;SX8+;_ !M\/?!_1?CYJ/A
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M?M!67B'P]9#4]2UOX8+X,7QVNMZ+HJL"3)X;82!,J2-P8J:_FJ_X*8?LL_\
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M0OB__A$MP''*%P ?H/#_ ,%"/A]X/_;E_:FN/&_[76IS?LT_#/\ 8J^&/[3
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M[;'[1/Q;\-Z7>:WX0\1?;_ GCH>!/[ UG^V/#WB3Q8K9;1-:RI8;@V3@I'D
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M\3CQ'XI&NKX=\$)X<2;>T@!"J$V?@7^QM^P=_P %#_@E_P %$_#'_!3+Q_\
MLY^%;B__ &P_C'\<_!G[37[/OAS6_AQ'XF_9.^&'C77/#S_"CXF:'KZ>)D\-
M>(O$(.@#Q/X[7PJQ\82>"2T,HD\=>+I8Z_4__@I5^R[\>?CU^V5_P23^)OPK
M^'__  F_P^_9L_:0\3?$+XT>(;?6?!VF-X%\+:ZG@'^P]:>/Q#KZ>)M<(;1-
M=R/"8=B,;L<*H!YK/_P<*_L36GA/QEXIE^'/[8UK_P *F\8MX/\ VA?"MU^S
M#XP7Q3^SU*=:'AZ/7?C>5_XI3P%X>\1Z\-;"K/XJD\:,?#VOM_PA6Z+-?5?[
M1_\ P5A_9;_9VU3X3^%K>R^,7Q\^('QD^%J_'3PA\/?V7?A5K/Q<\<GX#X7=
M\9=8T)-A\/\ PZ'($CDLK Y1E(!_+'QY^P+^UMJ_P\_X.&?#=E\'M0NM8_;0
M\<^&=:_9FM1XN\&@?%G3%37P64'Q/_Q38#$ #Q7_ ,(D<-M(V[G&+X)_9D_;
MN_82_:!_9?\ VR/A)^R7<?M4OJ'_  2S^!7['OQK^#?AWXK?#7P3XY^$_P 8
M?A3HO@$D_P!MZ[(OAG7_  ]_PD'@P>%O^*5X60^)9-I&S< ?J7XT_P""OG[&
MG@_]E[X/_M?^'O%WB[XQ>!OV@?'NE?#/X+?#[X2> ]6\1?%SXD_%#6EUY3\+
MM#\"R?\ "+R#Q'X;.BEF'BAT6-44*V_Q9X1DG^!/V,/^"L,_B_\ :5_X+"?%
M']HGXA_$GX7_ +('[*VD_LN^*/!_P\^-OPY;P-XY^ YUWP?KVA^/?"&O^"E\
M-'Q1_P )%XI^(>AMX9/A9F\8+-XT'E>!3F2ODC0_^"5/[=W[./[,'[!GQPT7
MX6:+\:OVA?V;?V[?B;^V=\7_ -E#P/X^T;2R/#'QR.AC7_!7@CQQKZKX:U_Q
M%X5_X0G0=C!R,Z]XGP/%V 9*'B[_ ()I?MU_MLZ/_P %N-?^(WP)/[+OB;]M
MFS_8F\7_ +/WA3Q;\1O!WC73=;U;X&'7==UWP9KVM_#_ ,1_\4]K^-$T/PV'
MV[/!GB_Q )0WC*/PF&H _5P?\%B?A+\??@Y^U'X.^&/A3]H_]F?]HCP?^QI\
M8OVC?A#H'[1_P?/PI\2^+? /A_P9K[:%\9?A<\C>+O#GB3PZOB/^QE5LC#2!
MFB8;@/J?_@D+\6?B-\??^"<'[*7QD^,?BG4O&OQ/^(WPZ;6_%_B_5K;2-.U+
M7-3_ .$OU]2[+H.U$4!0H R.6<[3(^?P\^ 7[!_QF^),?Q4\7^._^">W[3_P
MO^+_ (-_84_:+^#'@[XF?M(?M^?\+_77_BI\4OAEX@\#+\,?A3X&\0^)?%VW
MX?\ BEM9UMQXI\5^+_!_@U=GAH@ KN7]R?\ @DO\$?BM^S?_ ,$[OV5?@C\:
M/"DW@?XG_#KX;'1?%_A:ZN]'U5]#U@ZUKNN./[9\-^(?%?AH[4UA K).69MR
M,@$24 ?IE1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>;^.
MO _A7X@>#/%_@#QCH>F^(?!'C/P[JGACQCX>U7G2M>\-:]I#:'X@T?6E))VR
M:!(5))4[3P5P&KTBB@#S'X9?#'X??!GX?^$/AI\+?">B>"? '@/1TT3PCX4\
M/6FW3-!TF/>ZZ3HH+C:@;?@?,3G# C./3J** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /"?C7\?_@O^S5X)_P"%C?'?XF>$_A/\
M/K?5],T/_A*_%VJC2]*&JZR[)HVCEL'F0,-JDX8)Q@,Q&/\ !7]HSX#_ +2_
MA74/B+\ OBIX"^,GA"QUI_#%SXC\ ^)]*\1:99^)]( 8Z&Q5]FCZ\BZUI&Z*
M7#+_ &S%N4*$G?X6_P""M_P0^-_QP_9S^%^E_ 'PEX]\6?$'P'^UI^SM\7+J
MV^%_B+X8>&OB7H7A?X6^.7\1>(-<\#:Y\7E3X9KXG\,_)+X07Q8JHTI!7<0S
M'\PO 7['?[<@\+^.=9^)7P6^/OQ&^$'C']OOPQ\<_B[\#_''QJ^ ?AK]L_\
M:6^%Z_LPK\)<_%+QO\'OB1X/^!+>&O"/QIT3P+XG\%?"Y/&/@X>,_!F@[/'K
M*P(H _IF\<>/?!_PK\$^+_B/\1O$.F^%/ O@+PYJGBCQCXKU:[&FZ;H/AK0]
M'_MO7=<UEF=541H)&D4*SE<;!O)5^RT[4K#5+2#5+&>UNK'4;07MG=VHW"\T
M_:&4@D GB1>1CKQCD#^1?X]?\$]_^"A'B_\ 9_3P+\1?A/\ &S]HRYU/]BC]
MH[X4?!/P+X>_:<T/3/\ AE[XQ>.?B;X_UWP/_P +6USQ%\:O"1^,"#]G;Q!X
M$^!3>*XS\8'W^ ?$G@5G/@'Q@WC&3[(_9AT7XFZW_P %*?%_P#T+XEZGXB_9
M_P#V=+[3/VS_ (C?\(]\1]8\4?\ ""_';XK_  :T#X#)^R9XW,+2#P\GACQ!
MH?Q4^/B?# D%4\0^%C*J,'10#^CRBOYNOV^OV:_^"DEU^U=X@^)?['NH^)==
M^%.F6GP>_;&L_#U]\4U\,Z=XJ_:?_9O;7_A2?V8CH6O>(DV_#G]H#X;Z_H'B
M7+J/!O\ PF?@%/,9I'+-XMIG[ 7_  40\$_M ?LTG4/%/Q;\9Z/X+\"?L<BT
M^-ND_$72]3_X5KX[\":_XC\<?MD_\)M_PD?[1G@XOX?^+?B/6=;(1/@]\93X
MU\%^(4\#1GPBGA2)Y #^E;X<_$?P/\6O#^G>./AYXGT7QOX1U2[UJQL?$OAZ
M\35-,O-1T+7-:T#7%5_+C<?\(WXBT+6?#K*-P$BNI<^6E6?"OQ!\#>-=4\?:
M)X2\4Z%XEU;X7^,O^$*\>:3I-WN;PEXJDT7P]XX71-;54 7Q /#FOZ)XDY)P
MFN(78Y<U_%]^V-#\=_V;_@W;^'?VK]<\?W/Q0UW]C3]LC1?V;_"=I^UIHW@G
MXF?#3]HS7?VMOB[KW@7XFG0_^%U^$?$_Q@_X2SX+:W\*_"_@GPM\)O\ A<7C
M7_BG_P#A!O\ A"/!O_"7$5^F>D?L'?M!#]H#5_C;#X(^(&F^,?%/_!1/X.>*
M-8\16?Q>UOPXE]^R8O["_P //A)\<]7;2/#_ ,1_+27Q?\1])UCPOXRB?PDO
MCB4:#X9>)77P=X09 #^@SP+XW\,?$GP[!XS\$^(M#\6^%M4N]3M-/\1>%=6T
MOQ!X:O6T36I=#UU=&UG0O,&N!->T76(VE1AOD\T%$XBKU&OXSIO^"<W[=W@G
MX!_LG^#?A9\ ?C';?$#X)#XRZ-J_A/5OCOX/U+X/Z[X\USXS^'?'FA_$TGP]
M^UI\(_B9\'_#WBWPZV1\4?A1XP\8>-?!BZ!XH\##X&D>+&/C+^QZT\W[./M/
MV;[3]F'VK[-_>VGIW_O8]_;% &G1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% %.6X@M(?/N)Q;PC[QN" !GMDG(^G/O1%<07</GV\XN(3]T
MVY!!QVR#D_3CVKXM_;M^!O@[]H7]DOX^_#GQ3\+O#GQ:U)OA7\3]:\"^$O$7
MA+1/&Q_X6;%X/U\>"-8T30?$'F(?$B^(VV>#F0C<^T;P-@7\0=7^%7[=W[-V
MG_L$_#/]D3X9>(_@'\,KO]G'X%:UX]TKX(?!W1AX:O\ ]K'7-<\!Z%\<!^U1
MH6@>'6)V_#?10#XJ\5GP<K.?%+#QM'X\\*^#5 !_4Y17\IGC?1?^"L%YH7Q'
M\<Z+\4OVP],\7GX1?MM?$[PAX4TKP%X+&F'XI? W]K9-#_91^&6AZ(?AO_R
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M/^6;;P"C?,,;MI'/4!L?EM^RA8?'_P"(O[5_QE_:6\4_ KXN?LO?![QC\(O
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MM)_%OP%X&_MI?A_X;\'^%QK0\-:%HHQX6\'P*TB[O+$TBNP!]D4444 %%%%
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MY_L3Q)IWA+5O^$/\2+H_BK5A'_9GA+4ET9GT;7=9R'8IX:8KXAD1]IQ&Q4C
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MZ.HHHKK *Q_(LO6W_,_X5L5R@T?@<MT'3I^% '5T444 %%%% !1110 4444
M%%%% 'DWQ&7Q]J/@7Q?8_"[6_#/A/X@7?AS55\&>)O%?AW5O&GA?0_%+:.!H
MNK:YH&A>)?!\FNZ#O!+1CQ?X1X1<R-)E1^!'_!.[]K3]J#XU?&7X(^!?BK^V
MQX4^->A>&-'^)Q\1I\'OV$_VE?!/@CXTZQHG]M^'TU36OVJ?B#H*_"W7O#WA
M:18_$O@CQ)X1\*>"X?',F@_,QWLQ_=SXP?#BY^+?P\\0> ++XB_$CX377B:T
M%K'\0?A!JNC^'/B7X6SJBZR'\/\ B'Q'X:\5KH,C#2DA+MX4E!&8\@EMO\GW
M[./[4/Q!_8D;X'_&C5?"/[>'BW]D7Q1I/QC\4_#JR^(7[=O[-?Q(\$Z_\*O
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M#Q'HA*^.6T'0]!\+>%_"^AR#Q$5(\2L%'@]^&D"Y#<Z6&5[[KR=KJ[\]VO\
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MF!CL<CCMGO5>P7UJ^MK7M^/I:_G^!/ML2MDM_)/R^7Z]"_/9P7D/V>]@M[B
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M%X/A=AXX\92HK@ _4W]K#XD_MF>#_%G[8UCX!\8>/KK0=*\"?\$_==^#]SX
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MIWNI?%3P5I>G_#3Q9.7&D^#?'+_\)"I\-^(FW^9_PC/B9XY9&9R%P,'^?_\
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M\:?&'Q_^$'Q,\8_%CP9=^'_!VE_!_1_%[:'I&M67CJ^T[]G;Q!\7O$'@/5_
M^,^&?#^O_%1OBQK2?&E>!'#H"+X". 2/J']A?0;?PS\#=?T6TO\ 6]0@TO\
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M7CL6A^*;?XGZQXDN)_#?_"/ZIX=TC0A:VIU<>)B=$DU_6A@E@F2VN#Y00W.
MNXA:]I"@<XYR?7U./TIC,<D9XX]/8_SKG]@K[_C_ , 5&7*KJ[_#_,D'(!]0
M*6D'0?04M= PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ."\8>%
M?"WCK1=0\*^,O"WAWQ;X6U.U/]K:1XLT;1O$7AN]!&W&LZ#KJE9 !\R!E;ON
M;*\>?^%?V</V?/AYK2^*/A_\"?@YX \1?8_LEKXB\$_"KP7X<\268/#*-:T#
MP^709/'\*G^\,@^^T4 %?+VK_P#)YW@#_LV3XS?^K1^ =?GG^U9^V]^TS\#O
M&7[6_AW1_#?PXGT[X7>$?^"?^L?"&Z:/7+\Z'I?[5?[3OQ?^ GCSQI\4M:\0
M^(_!OAC_ (I/P]X$'BI)/^$N\(>"?!\0W>.?'+)(KUUWP3^/'QI^*^H_LU_M
M,0_LW?%WXEZ!XT_90:SUCQ=X)N_@)X'TO7/$_CW6/A1X^76-#\#^._VC!XBT
M#PVG]A:Y&HD\8^+QC8? S^-?!3)XUE /U_HKXATW]I3XF:A-H6W]AK]K*T.O
M:*GB>T_MC6/V4M/.GJHT!1H^O[OVD\Z!XD*ZTP/AHX9@OB0-N\K!++]J'XG7
MB>'P?V&_VJ;:?7KS4[*R6ZU?]E)7L"HUPG^WC_PTIG00?[%S@C'SJ#G^( ^W
MJ*^"-"_:S\>^(X[/5-,_8A_:JNH+GQCX[\ EC?\ [*@&GZMX)UOQ#X>US^VP
M?VDF5?#C^)/!6NI%XE+D9/AC8"?% %;,O[37Q-B:>Y'[#?[51G_X233O"Y']
ML_LI,2^Y/^)TK']I/*^&U_MAE;Q(/E;/.-N& /MZBOB#_AIKXEYUD)^Q!^U7
M.VFZSI6D70M=8_94/V\ZROA]5UK0A_PTFO\ ;OAE3KB[_$JE4)T+Q2&&_P +
ML6?J7[2GQ.TR+7IKC]AG]JNY_P"$8T8:R?L6K_LI:B-08+Q_8)_X:2/]MZ_A
M3\N>I'S;BVX ^W**^*=2_:2^*EI+K$+?L,_M4W0T+1CK5W]AU?\ 94U#[=IK
M_P#"0[](T(C]I1AK_B(KHJX\,* R_P!O^'6W_O#MH']J?XF+XOT_PB?V*/VH
M;;6-1\':KXRM;4ZU^RC_ &6-*T76] T1P=9'[2*QIXB']MQD>&6#/LW X'SL
M ?<M%?$>E_M-?%74)O#X7]AO]JJV7Q-X;3Q+9_VQK/[*>G_V>BCP_G1-?9OV
ME#_8/B4C7'SX:8;B="\2%P_E_,EE^TI\39(M F7]AK]K&U?Q 6M+*UO-6_91
MT\V*_P!E%V_MP?\ #2@;0 HT? YPC-D+M94H ^W:*^((/VH/B6+C1+<_L-_M
M5?:M3\1ZOX:.=8_94)L#HSZ[G6M;<_M*'9X9<Z&PC\1L67.O>%C'_P C/@./
M[37Q1ABGD;]AK]JO%OXG_P"$: _MO]E(,TH?^R/[9#?\-)[O^$<&TG_A)/N[
M,KCRP4H ^W:*_/\ UG]K'Q]HUCK6J:O^Q!^U6=.T'Q-X3\-[K/6/V5-0.H:M
MXU?P]HD?]AL/VD4_M[PZDGC31!)XC#,K_P#%3[P%\*R*W5WG[3GQ3LH-?E?]
MAK]K*<>&[3[5="SUC]E&^;4,J2%T#/[28;7W"@D;2& !("D9H ^U:*^*;[]I
M3XM6DFL1/^PW^U9=#0O#;>);PV.L?LJZ@;]9#XAQHV@E/VE/^)[XD T-/^*<
M W(->\.,IC5VV6(OVD/BD=1^QG]A_P#:BM[FXT@:S]J_X2+]E,Z7@O@:/_:_
M_#2) \1[@,>'-N N6#>7DT ?9U%?%6F_M*?%74)=!,'[#7[55J->\-CQ-9'5
M]8_93TXZ>BCP]G1=>9OVE#_8/B8_VX^?#> Q&A>(]^[RLLZR_:;^*EY%H$Q_
M89_:RMO[>YM!=:O^RB#I^1C_ (GV?VDC_8!*\#(QQZ] #[3HKPSX6?$#_A:G
M@ZP\81^$/%_@2=O%'BOPU=>%/&J:,/$?A_5O _C#Q#X#UM&_X1OQ)XP\,,J:
M]H6N-GP[XND5_"+QLA#>3%'[G0 4444 %><_$H$_#WX@*/"C>-2?"/B@#PF/
M*)\<$Z-_R)X#*RD^*>/#@W!CE^5;A:]&K\Z?^"D=I\7]3_9FU"R^!^D?&KQ)
MX@N?BG\"K3QWI?[.'B7_ (1WXY:A\&S\9O "_''2?A;KI\2>#SH'B1_AN-=
M<>+_  B-JL/-Y((!^6W_  19M?#<GQ/^)UMHVG^ _'5SJ/P3\"ZQJWC#P0?V
MK%D_99+>+70_L-ZQ)^TY\2OBN8I/"HD?Q'_PC/@X>"G4Z$X\=>!DC/@UA_2_
M7\\/_!)SPK^UYH7Q>\7W_P </ _[:_A.QU[X+:F/'7B/]J_XD'QMIGCGXQZ'
M\9]=;P-K?@C1/^%D>,4\/M_PI76]#\->,_\ A%_!W@V/S= B! ;:U9'[1/\
MP4__ &C?AEXJ_:8\+> ?%W[)WBU?AA\1? !\(>,_LND?V7X?\#1O^UNWQ6\&
MZUH^O_M:>#_#GQ ^,OA8?LY_\(M)X4;QC\'O&#^,E^)F? H\">$_"7C24 _H
MUKY&_8X_Y)7XX_[.S_;;_P#6S_CQ7PM\5/V\OB)H/[1W[)?@+P%??"[4/A-\
M3=(\-?\ "T_(TC1_$7QMU'QUXYUF30=#\&^"? O_  TIX2\4^!(E\1:2Z>-O
M$LOA+XPQ>"SK6_QO'&OA'Q?)7L?P/^*/Q;^$W@K4/#7B_P#8Q_:6NM1\5?M!
M?M&^--(&@:W^S1XBL!I?Q2_:#^+'Q7\%/K0'[1Q&@;/#FO:(&. J2%%;;O\
ME /T_I&Z'Z'^5?#Y_:E\??:+^/\ X8P_:U86>OZ7X94/:?LUG[?J>MMH !Y_
M:/Q+X>3^W%)\6*X\)1%/$99_^*99CD>(OVM_$/AFR\2ZYK7['?[5%KI_A?6-
M-T'6"/\ AFQVDU+7/[ ;1/[&S^TD/[?=9==T7+^&#*1E@6$GAEL 'W7M;R2/
MIQ_P$\?GSZ=Z\E^+D7B*7X>^);?PAX=?Q+XBO-&U+1+/2/[6TC2Q>G7%.BA7
MUG7<QPD \[B-_P J$L0@/@NL_M0>/M,_X2"*?]BK]K6X/AO1GUJ[.E/^S5JK
MWNF'^W\G0ET/]I"1?$7B '1^/"WA?/B^-C"@B.X"G7/[3GQ$L;K4-.E_8N_:
MINI](T8>([PV=W^S1J.GWNEJ-;4)H>L#]HX+K_B$C1 __"+*L?C%04(C9&W4
M[_G<E*V(6)Z);/TOL?0?PO7Q$W@?0%\8Z)<>&O$%MHNFZ?J^DMK&CZFM@=%&
M #K.@$+)WR.XW+P&:O5*^)M._:0^(MWJ&GV-M^Q?^UCYVL:4VN$7A_9NTO3
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MB:$LG]D*O[1Q77_#BC7=) \2^&2T:RIX@Z2^$_%_E@'W117P_K'[4/CW2_\
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MM?#^C+K.FW&JW=AJO]E1_P!HV;:ZQ_M]AJ['=O\ $8XDP5W!]KJY5 GH%%%
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M_6_G>1;_ &C'VC:-^,_>Q\W3MZ]L5;HH **** "OPX_;"^,G[=7@/]L[X?\
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M>?BP-#UK7_$WA!?$&@_"KX>/HW_";.H5F\:^(8_ O@7_ (39DR?=O O_  3
M_9R\(?M0ZC^T^)_$WB+Q#;MJMSX-^'VJ6/@[3_AK\-=6U[6/A+KPUS0_^$<\
M->%?$^N>( WPH\$_O/&/B[Q@NZ-@5.5)\F^/O_!/G]A;XI?\(]^S%I?B[3_@
M%XPU2T\*_8_"_@'6OAC_ ,+*\7^%M"^&GQ>\ :'HVAZ)\6_#/BYE<?#1/'/A
MX^*/"T*^+_&O@[P,D7CR;Q?X#\(GRP#]8/!7B[2O'G@[P=XQTE9SI7C'PWX8
M\4:/!=KMU)=,U[1DUS2#JX)=D9E9NA*E\EB27KT"N(\(^%-+\%>%O"_A#P]
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M!"/(Q;^@ZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_9G\$>,-<NO /Q%^"?QC\*:/X"^)%AX.\<^&1\>?BQX@\=^.'_:9\;^-]?\
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M'>&]?^(?BB-8O"G@OQ+)'XO'@9M?\2^-/^$.E8FOU*HH _F&F_8&_P""A/\
MPAQTF#_A)#K ^*?VXJ?V@_F_X7&/AGX@T'_AM#^V_P#A(\CPZ?B-K6B>)_\
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M?"AL_!W]F#4="UKP#HFBXU@>&AXG5RNNZXQ"^+@7.P,,(H ![;1110 4444
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M,O%_63_A-_%N7\6T ?8=?)?P#GU27XL?MCF_L;;3 ?CMX4^P_9KT7XU#3O\
MAF;X!^7JY!P078JH7;DGY2,D V?^&S/V4?L']I_\-%?!S^S_ /A:'_"F/MG_
M  G>B[/^%I9_Y$G[^?\ A(_]G[N.=^:J_ 2WOH/BU^V;]NOSJ8N?CMX4N[-?
ML/V'[!IQ_9G^ 2II!9OF)C()W'KDL3D<#V?H_P F!]:UY7J?_)7O!G_9.?BA
M_P"IE\)*]4KRO4_^2O>#/^R<_%#_ -3+X25-';[_ ,@/5****H HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM@GG^W5&[*C)QD;<DCC) .\HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^[7@<^I:GI]]\1YM+GT\3?\ "T_"FC77VJT:_P G7/!GPBT-1@%6R/[9!=2
M"IVD%2P/OF0.IQ7A\O\ Q_?$'_LL'PQ_],WPBKGKNW77UUZ_,YZ[TWU5NOJ>
MW0>;Y,'GX\_'.,XS@YZ=L8SVQ5JD'0?04M;K9>B_)'0%%%%, HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^!OVQ_VT_AG^Q?I?PH
MU?XF>'/&WBK4?B[\21\,_ WA[PCK7P<\-ZC?ZRG@G7=>#:WKOQ[^)/P<^&NA
M^'0=!CB<R^,LMXNUGPQ#L597-=[\!IH9?C-^UMY'B$Z["OQ'\ 94'1B=!/\
MPICP!_Q)LZ&5)*XW98[N.<MUS/VIOV6-"_:K\"M\.?%7Q'^*/@'P[J=KX^T?
MQ?:?#[5_!H/CSP%X^\':_P"!/'/@C7!X\\+>+ N@>*O#VOF-/$OA-?"/CGP<
M%0^!?'?@^1G)B_9\T?2]'^,O[6^EZ9X./AK3_P#A8_@1K0BST14UT#X-?#\C
M6&/A]B^=N1_Q51_X3%L.7 RBT ?:E1RC,;CU4C\ZDH/0Y]*%N%VM5NM5ZK5?
MBD?S*>"8/"T__!<._P!*3P=X\.I6J^)MVKW7B/1SI1U;_A6&O?\ $[&AGPYN
M_P"$;_X1[_BEP3XPX\9\D_\ ,F5_2/(DJV96P%L)_LFZT^TVA SQZ%3C&.,$
M>H(XKQ/3O$.BO\:]?TDOK0U"Z\#^&-$M+P>'-;&F-J6BZWX_UG65_MU]!'AH
M.H:,LV_+NA\M%9E5??\ S9O+Z#ZX_'T]>?\ ZW-;U_JUT\+%1DXKFMJ^:VNM
MDWKW?;S.C$9QFN9\JS5MQA'D@M5:*LEHM+M15]->W;S#X<>"[_P'H>HZ9/+X
M;NK>Y\1^*/$]H-(\.GPS8VFI>-_&7B#Q!K0V-XB\5<F377& _EX&&SN=(^ZO
M+:XN["XA@GN=.GN;5K6TU6U51J=EG^)1KB\MDY&Y6+'DC=M=>FHK YSQ+0OA
M7IFD^';[POKFJZGX]\/ZIJ^L:Q>6GBNU\&G_ (F>O:[KNOZVP'A[PYX3C8'Q
M#K)92ZEEW;5*[GSZ!IGA7P[H^A_\(YI6B:;8:!;V?V1-)M;$#3 IV[E&CJ"N
M,@''+,!RQP&'6T4!;2W3MT^[;\#DM(\*^'/#EN+/P[H6BZ);_P#+Q:Z-I6EZ
M>K \YD5%"^F,EACH157Q7-##X<UB:>>\L8%TB_\ ],']KYLN@WG^P@OB( ??
M?R2& 4;1G:A[>B@#XC^ ?@/0_$?[/]OX*\5W^J:WIURNJV.L6>D^(_B3X;U
M?,,Z06;Q&/% (4\_. 5!(4MS7TL-.\,^%/"=Q8>)+PGPQIEB!?7OBS6=6\1
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MG\I2%5)V*2C?X<\7JK(S^#]<\10L8_,EV4_A[X;\._$O]F7PCX)\'>(;#1=
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M?J>NZY_8408^'_#7BWE=>*AL@Y/.<#)^3_\ @H+9?'[XI_!+0?!_[,_CG_A
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MZL?[$9CN((1M[*0PPJ)]U #Z^HHHH ,#T_S_ ) HHHH **** "BBB@ HHHH
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M +1WA>RN[3Q8=&\1G3],T,'QUKQ!_P"$DROB+_A(?^$W"GQ6<_\ $A\,]/\
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M.ZZ!_P 4#X;\6MN;^Q3X80H-O@U4\.;CE%Q\Q?MN_$WX=Z;\#/ASI>E_ _\
MX7E;6OQ*^&%E9>"-4L]8TXV2Z%K&!_8V?#/_ !/B#HFN>&/E)_Y#?B3+8)CK
MYT_X*9Z7X:^(/P*\%^,?@UX7NX->/B7P&?$7_"*>#O%^FZE>^%M=T;7]!T%5
MV^&M_B CQ#_8@\%^9D$@,FT$K7@YE6S)Y;.64QBI<VK:2;2FW^"N[::Z[V/?
MR?(,JS3-8Y0KY-%\UYMQ:LHSDG)N2MS-<JM=)M75K7_9GPA>S:#XMO\ P]>0
MBV@\96W_  F7ARU1M746&J2!?^$YT0@AP6_X2'7$\4)G!9M?\2+E4\*&O="
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M!S4@/]-(M+SXR:=D#1CKQ'S?#<\?\(YGQ.>.A.,$#!;#=&ON?R.;V#_I_P#
M/T1II&<<GJ,C)YY'OQCVK\-_VQ?VUOVKO 7P2UC7OA5X/\.>$?$!U?PO9VFO
MVEIK'B34K'3-=& VB:)\0/#7A'PTS;0!DL1@+QD C]&_V6?BMK_Q(^ /P/\
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M?MI^-/$'PV_9J^('B?PJGQU3Q1I8\+W>C6?[.7@./XD?%W4;]?&/A[&B>'M
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M;H?B;P:LBS>%!N76/VI=<TE+/^WOV._VEX+"?Q%INBV;W@_9H:P&J_\ "S]
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MUS^RTNMG2/$7P4T73? _BSXR'P?^UM_PL\_&_6/^%;-_PK_Q!X5\2:#^Q^/
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JX%O W@U<'QE_0H,X&>N.?K^E !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>26
<FILENAME>abp-20250930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 28 18:01:32 UTC 2025 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2025" targetNamespace="http://www.abpro.com/20250930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:abp="http://www.abpro.com/20250930" xmlns:dtr="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="abp-20250930_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abp-20250930_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abp-20250930_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="abp-20250930_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.abpro.com/role/ConsolidatedBalanceSheet" id="abp_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals" id="abp_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ConsolidatedIncomeStatement" id="abp_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ShareholdersEquityType2or3" id="abp_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ShareholdersEquityType2or3_Parentheticals" id="abp_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ConsolidatedCashFlow" id="abp_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/OrganizationandDescriptionoftheBusiness" id="abp_r_OrganizationandDescriptionoftheBusiness">
        <link:definition>007 - Disclosure - Organization and Description of the Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPolicies" id="abp_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/Merger" id="abp_r_Merger">
        <link:definition>009 - Disclosure - Merger</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/AccruedExpenses" id="abp_r_AccruedExpenses">
        <link:definition>010 - Disclosure - Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/FairValueMeasurements" id="abp_r_FairValueMeasurements">
        <link:definition>011 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/LicenseandCollaborationAgreements" id="abp_r_LicenseandCollaborationAgreements">
        <link:definition>012 - Disclosure - License and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreements" id="abp_r_CommitmentsunderResearchandCollaborationAgreements">
        <link:definition>013 - Disclosure - Commitments under Research and Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/CommitmentsandContingencies" id="abp_r_CommitmentsandContingencies">
        <link:definition>014 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ForwardPurchaseAgreement" id="abp_r_ForwardPurchaseAgreement">
        <link:definition>015 - Disclosure - Forward Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/NotesPayable" id="abp_r_NotesPayable">
        <link:definition>016 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/StandbyEquityPurchaseAgreement" id="abp_r_StandbyEquityPurchaseAgreement">
        <link:definition>017 - Disclosure - Standby Equity Purchase Agreement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/StockholdersEquity" id="abp_r_StockholdersEquity">
        <link:definition>018 - Disclosure - Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ShareBasedCompensation" id="abp_r_ShareBasedCompensation">
        <link:definition>019 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/EmployeeBenefitPlan" id="abp_r_EmployeeBenefitPlan">
        <link:definition>020 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/RelatedParties" id="abp_r_RelatedParties">
        <link:definition>021 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/SubsequentEvents" id="abp_r_SubsequentEvents">
        <link:definition>022 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/PropertyandEquipment" id="abp_r_PropertyandEquipment">
        <link:definition>023 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/Leases" id="abp_r_Leases">
        <link:definition>024 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/IncomeTaxes" id="abp_r_IncomeTaxes">
        <link:definition>025 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/AccountingPoliciesByPolicy" id="abp_r_AccountingPoliciesByPolicy">
        <link:definition>996000 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables" id="abp_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/MergerTables" id="abp_r_MergerTables">
        <link:definition>996002 - Disclosure - Merger (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/AccruedExpensesTables" id="abp_r_AccruedExpensesTables">
        <link:definition>996003 - Disclosure - Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/FairValueMeasurementsTables" id="abp_r_FairValueMeasurementsTables">
        <link:definition>996004 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/StockholdersEquityTables" id="abp_r_StockholdersEquityTables">
        <link:definition>996005 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ShareBasedCompensationTables" id="abp_r_ShareBasedCompensationTables">
        <link:definition>996006 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/PropertyandEquipmentTables" id="abp_r_PropertyandEquipmentTables">
        <link:definition>996007 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/LeasesTables" id="abp_r_LeasesTables">
        <link:definition>996008 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/IncomeTaxesTables" id="abp_r_IncomeTaxesTables">
        <link:definition>996009 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails" id="abp_r_OrganizationandDescriptionoftheBusinessDetails">
        <link:definition>996010 - Disclosure - Organization and Description of the Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails" id="abp_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>996011 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable" id="abp_r_ScheduleofDilutedNetLossPerShareTable">
        <link:definition>996012 - Disclosure - Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/MergerDetails" id="abp_r_MergerDetails">
        <link:definition>996013 - Disclosure - Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable" id="abp_r_ScheduleofCommonStockOutstandingTable">
        <link:definition>996014 - Disclosure - Merger - Schedule of Common Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofAccruedExpensesTable" id="abp_r_ScheduleofAccruedExpensesTable">
        <link:definition>996015 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/FairValueMeasurementsDetails" id="abp_r_FairValueMeasurementsDetails">
        <link:definition>996016 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable" id="abp_r_ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable">
        <link:definition>996017 - Disclosure - Fair Value Measurements - Schedule of Company&#8217;s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable" id="abp_r_ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable">
        <link:definition>996018 - Disclosure - Fair Value Measurements - Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable" id="abp_r_ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable">
        <link:definition>996019 - Disclosure - Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails" id="abp_r_LicenseandCollaborationAgreementsDetails">
        <link:definition>996020 - Disclosure - License and Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails" id="abp_r_CommitmentsunderResearchandCollaborationAgreementsDetails">
        <link:definition>996021 - Disclosure - Commitments under Research and Collaboration Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/CommitmentsandContingenciesDetails" id="abp_r_CommitmentsandContingenciesDetails">
        <link:definition>996022 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ForwardPurchaseAgreementDetails" id="abp_r_ForwardPurchaseAgreementDetails">
        <link:definition>996023 - Disclosure - Forward Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/NotesPayableDetails" id="abp_r_NotesPayableDetails">
        <link:definition>996024 - Disclosure - Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails" id="abp_r_StandbyEquityPurchaseAgreementDetails">
        <link:definition>996025 - Disclosure - Standby Equity Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/StockholdersEquityDetails" id="abp_r_StockholdersEquityDetails">
        <link:definition>996026 - Disclosure - Stockholders&#8217; Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable" id="abp_r_ScheduleofWarrantstoPurchaseCommonStockOutstandingTable">
        <link:definition>996027 - Disclosure - Stockholders&#8217; Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ShareBasedCompensationDetails" id="abp_r_ShareBasedCompensationDetails">
        <link:definition>996028 - Disclosure - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable" id="abp_r_ScheduleofCompanysStockOptionActivityTable">
        <link:definition>996029 - Disclosure - Share-Based Compensation - Schedule of Company&#8217;s Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable" id="abp_r_ScheduleofCompanysRestrictedStockUnitActivityTable">
        <link:definition>996030 - Disclosure - Share-Based Compensation - Schedule of Company&#8217;s Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable" id="abp_r_ScheduleofRecordedStockBasedCompensationExpenseTable">
        <link:definition>996031 - Disclosure - Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/EmployeeBenefitPlanDetails" id="abp_r_EmployeeBenefitPlanDetails">
        <link:definition>996032 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/RelatedPartiesDetails" id="abp_r_RelatedPartiesDetails">
        <link:definition>996033 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/SubsequentEventsDetails" id="abp_r_SubsequentEventsDetails">
        <link:definition>996034 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable" id="abp_r_ScheduleofConsolidatedStatementsofCashFlowsTable">
        <link:definition>996035 - Disclosure - Summary of Significant Accounting Policies - Schedule of Consolidated Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives" id="abp_r_SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives">
        <link:definition>996036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation on Property and Equipment Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable" id="abp_r_ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable">
        <link:definition>996037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofBalanceSheetTable" id="abp_r_ScheduleofBalanceSheetTable">
        <link:definition>996038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0" id="abp_r_ScheduleofCommonStockOutstandingTable0">
        <link:definition>996039 - Disclosure - Merger - Schedule of Common Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/PropertyandEquipmentDetails" id="abp_r_PropertyandEquipmentDetails">
        <link:definition>996040 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable" id="abp_r_ScheduleofPropertyandEquipmentTable">
        <link:definition>996041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofAccruedExpensesTable0" id="abp_r_ScheduleofAccruedExpensesTable0">
        <link:definition>996042 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0" id="abp_r_ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0">
        <link:definition>996043 - Disclosure - Fair Value Measurements - Schedule of Company&#8217;s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0" id="abp_r_ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0">
        <link:definition>996044 - Disclosure - Fair Value Measurements - Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0" id="abp_r_ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0">
        <link:definition>996045 - Disclosure - Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/LeasesDetails" id="abp_r_LeasesDetails">
        <link:definition>996046 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofLeaseExpenseTable" id="abp_r_ScheduleofLeaseExpenseTable">
        <link:definition>996047 - Disclosure - Leases - Schedule of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable" id="abp_r_ScheduleofFutureMinimumPaymentsTable">
        <link:definition>996048 - Disclosure - Leases - Schedule of Future Minimum Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable" id="abp_r_ScheduleofCommonStockWarrantActivityTable">
        <link:definition>996049 - Disclosure - Stockholders&#8217; Equity - Schedule of Common Stock Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0" id="abp_r_ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0">
        <link:definition>996050 - Disclosure - Stockholders&#8217; Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0" id="abp_r_ScheduleofCompanysStockOptionActivityTable0">
        <link:definition>996051 - Disclosure - Share-Based Compensation - Schedule of Company&#8217;s Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable" id="abp_r_ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable">
        <link:definition>996052 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0" id="abp_r_ScheduleofCompanysRestrictedStockUnitActivityTable0">
        <link:definition>996053 - Disclosure - Share-Based Compensation - Schedule of Company&#8217;s Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0" id="abp_r_ScheduleofRecordedStockBasedCompensationExpenseTable0">
        <link:definition>996054 - Disclosure - Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/IncomeTaxesDetails" id="abp_r_IncomeTaxesDetails">
        <link:definition>996055 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable" id="abp_r_ScheduleofIncomeLossBeforeProvisionTable">
        <link:definition>996056 - Disclosure - Income Taxes - Schedule of Income / (Loss) Before Provision (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable" id="abp_r_ScheduleofEffectiveIncomeTaxRateTable">
        <link:definition>996057 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable" id="abp_r_ScheduleofNetDeferredTaxAssetsandLiabilitiesTable">
        <link:definition>996058 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.abpro.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2025" schemaLocation="https://xbrl.sec.gov/sic/2025/sic-2025.xsd"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfDilutedNetLossPerShareAbstract"/>
  <xs:element name="ScheduleOfCommonStockOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfCommonStockOutstandingAbstract"/>
  <xs:element name="ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract"/>
  <xs:element name="ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract"/>
  <xs:element name="ScheduleOfCompanySRestrictedStockUnitActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfCompanySRestrictedStockUnitActivityAbstract"/>
  <xs:element name="ScheduleOfRecordedStockBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfRecordedStockBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract"/>
  <xs:element name="ScheduleOfBalanceSheetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfBalanceSheetAbstract"/>
  <xs:element name="ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfPropertyAndEquipmentAbstract"/>
  <xs:element name="StandbyEquityPurchaseAgreementAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_StandbyEquityPurchaseAgreementAbstract"/>
  <xs:element name="ScheduleOfCommonStockWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfCommonStockWarrantActivityAbstract"/>
  <xs:element name="ScheduleOfCompanySStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfCompanySStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract"/>
  <xs:element name="ScheduleOfEffectiveIncomeTaxRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfEffectiveIncomeTaxRateAbstract"/>
  <xs:element name="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract"/>
  <xs:element name="RevenueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_RevenueAbstract"/>
  <xs:element name="WeightedAverageRemainingLeaseTermInYearsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_WeightedAverageRemainingLeaseTermInYearsAbstract"/>
  <xs:element name="WeightedAverageDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_WeightedAverageDiscountRateAbstract"/>
  <xs:element name="ForwardPurchaseAgreementAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_ForwardPurchaseAgreementAsset"/>
  <xs:element name="PatentsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_PatentsNet"/>
  <xs:element name="SEPAPutRightsAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_SEPAPutRightsAsset"/>
  <xs:element name="ConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ConvertibleNotes"/>
  <xs:element name="ChangeInFairValueOfForwardPuchaseAgreementAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset"/>
  <xs:element name="ChangeInFairValueOfSEPAPutRightsAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ChangeInFairValueOfSEPAPutRightsAsset"/>
  <xs:element name="ChangeInFairValueOfEmbeddedDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ChangeInFairValueOfEmbeddedDerivativeLiability"/>
  <xs:element name="LossOnSettlementOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_LossOnSettlementOfConvertibleNotes"/>
  <xs:element name="DeemedDividendResultingFromTheWarrantDownRound" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_DeemedDividendResultingFromTheWarrantDownRound"/>
  <xs:element name="StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities"/>
  <xs:element name="StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities"/>
  <xs:element name="IssuanceOfCommonStockInThePIPEFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_IssuanceOfCommonStockInThePIPEFinancing"/>
  <xs:element name="IssuanceOfCommonStockInPIPEFinancing" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_IssuanceOfCommonStockInPIPEFinancing"/>
  <xs:element name="IssuanceOfCommonStockInTransactionCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_IssuanceOfCommonStockInTransactionCost"/>
  <xs:element name="LossOnSettlementsOfConvertibleNotes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_LossOnSettlementsOfConvertibleNotes"/>
  <xs:element name="ChangeInFairValueOfForwardPurchaseAgreementAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset"/>
  <xs:element name="ChangeInFairValueOfSEPAPutRightAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ChangeInFairValueOfSEPAPutRightAsset"/>
  <xs:element name="ChangeInFairValueOnEmbeddedDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ChangeInFairValueOnEmbeddedDerivativeLiability"/>
  <xs:element name="NetProceedsFromTheMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_NetProceedsFromTheMerger"/>
  <xs:element name="CashTransferredToEscrow" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_CashTransferredToEscrow"/>
  <xs:element name="IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses"/>
  <xs:element name="CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability"/>
  <xs:element name="DeferredOfferingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_DeferredOfferingCostsIncludedInAccountsPayable"/>
  <xs:element name="ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense"/>
  <xs:element name="OfferingCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_OfferingCostsIncludedInAccountsPayable"/>
  <xs:element name="SettlementOfBonusAccrualThroughNotesPayableRelatedParties" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties"/>
  <xs:element name="ACABLiabilitiesAssumedInTheMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ACABLiabilitiesAssumedInTheMerger"/>
  <xs:element name="ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro"/>
  <xs:element name="ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro"/>
  <xs:element name="SEPACommitmentFeePaidInCommonStockShares" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_SEPACommitmentFeePaidInCommonStockShares"/>
  <xs:element name="StandbyEquityPurchaseAgreementTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_StandbyEquityPurchaseAgreementTextBlock"/>
  <xs:element name="UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock"/>
  <xs:element name="NoncontrollingInterestPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NoncontrollingInterestPolicyTextBlock"/>
  <xs:element name="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
  <xs:element name="EmergingGrowthCompanyPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_EmergingGrowthCompanyPolicyTextBlock"/>
  <xs:element name="PatentsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PatentsPolicyTextBlock"/>
  <xs:element name="ConvertiblePreferredStockPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ConvertiblePreferredStockPolicyTextBlock"/>
  <xs:element name="ContingentEarnoutPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ContingentEarnoutPolicyTextBlock"/>
  <xs:element name="RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock"/>
  <xs:element name="ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
  <xs:element name="StockholdersEquityTablesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_StockholdersEquityTablesTable"/>
  <xs:element name="StockholdersEquityTablesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_StockholdersEquityTablesLineItems"/>
  <xs:element name="MergerScheduleofCommonStockOutstandingDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_MergerScheduleofCommonStockOutstandingDetailsTable"/>
  <xs:element name="AccruedLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_AccruedLicenseFees"/>
  <xs:element name="AccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_AccruedInterest"/>
  <xs:element name="AccruedBODCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_AccruedBODCompensation"/>
  <xs:element name="FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2"/>
  <xs:element name="ExpiredAtTheMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ExpiredAtTheMerger"/>
  <xs:element name="CommonStockWarrantsOfLegacyACABAcquiredInMerger" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger"/>
  <xs:element name="ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable"/>
  <xs:element name="ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit"/>
  <xs:element name="IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable"/>
  <xs:element name="DeferredTaxAssetsLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_DeferredTaxAssetsLeaseLiability"/>
  <xs:element name="DeferredTaxLiabilitiesRightofuseAsset" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_DeferredTaxLiabilitiesRightofuseAsset"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable"/>
  <xs:element name="OrganizationandDescriptionoftheBusinessDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_OrganizationandDescriptionoftheBusinessDetailsTable"/>
  <xs:element name="ReverseStockSplitSharesOfIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ReverseStockSplitSharesOfIssued"/>
  <xs:element name="ReverseStockSpllitSharesOfOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ReverseStockSpllitSharesOfOutstanding"/>
  <xs:element name="SecurityBidPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_SecurityBidPricePerShare"/>
  <xs:element name="InstallmentsAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_InstallmentsAmount"/>
  <xs:element name="AccrueInterestPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_AccrueInterestPercentage"/>
  <xs:element name="ForwardPurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_ForwardPurchaseAgreement"/>
  <xs:element name="EarlyTerminationResetPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_EarlyTerminationResetPricePerShare"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="MergerDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_MergerDetailsTable"/>
  <xs:element name="AdditionSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_AdditionSharesOfCommonStock"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_AggregatePurchasePrice"/>
  <xs:element name="AggregateIncentiveShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_AggregateIncentiveShare"/>
  <xs:element name="RemainingSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_RemainingSharesIssued"/>
  <xs:element name="EarnoutShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_EarnoutShare"/>
  <xs:element name="TradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_TradingDays"/>
  <xs:element name="NumberOfConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NumberOfConsecutiveTradingDays"/>
  <xs:element name="FairValueMeasurementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_FairValueMeasurementsDetailsTable"/>
  <xs:element name="EstimatedFuturePricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_EstimatedFuturePricePerShare"/>
  <xs:element name="LicenseandCollaborationAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_LicenseandCollaborationAgreementsDetailsTable"/>
  <xs:element name="AgreementInitialTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_AgreementInitialTerm"/>
  <xs:element name="MilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_MilestonePayments"/>
  <xs:element name="NonRefundablePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_NonRefundablePayments"/>
  <xs:element name="OriginalCelltrionAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_OriginalCelltrionAgreement"/>
  <xs:element name="PercentageOfOriginalCelltrionAgreement" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfOriginalCelltrionAgreement"/>
  <xs:element name="PercentageOfAmendedCelltrionAgreement" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfAmendedCelltrionAgreement"/>
  <xs:element name="PercentageOfReimbursement" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfReimbursement"/>
  <xs:element name="CommitmentsunderResearchandCollaborationAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable"/>
  <xs:element name="ClinicalDevelopmentMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_ClinicalDevelopmentMilestones"/>
  <xs:element name="RegulatoryEvents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_RegulatoryEvents"/>
  <xs:element name="CommercialSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_CommercialSales"/>
  <xs:element name="MilestonePaymentsCommercialMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_MilestonePaymentsCommercialMilestones"/>
  <xs:element name="PaymentForExtensionRoyalities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_PaymentForExtensionRoyalities"/>
  <xs:element name="DevelopmentMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_DevelopmentMilestones"/>
  <xs:element name="AnnualSalesMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_AnnualSalesMilestonePayments"/>
  <xs:element name="NetProfitsFromLicensedProductSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NetProfitsFromLicensedProductSales"/>
  <xs:element name="PaymentOfDevelopmentMilestones" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_PaymentOfDevelopmentMilestones"/>
  <xs:element name="AccruedToAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_AccruedToAmount"/>
  <xs:element name="MilestonePaymentsUponAchievingRDAndCommercializationEvents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents"/>
  <xs:element name="MilestonePaymentOnNetSales" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_MilestonePaymentOnNetSales"/>
  <xs:element name="PatentCostsReimbursements" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_PatentCostsReimbursements"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="BusinessDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_BusinessDays"/>
  <xs:element name="MonthlyInstallmentPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_MonthlyInstallmentPayments"/>
  <xs:element name="AdditionalAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_AdditionalAccruedInterest"/>
  <xs:element name="ExciseTaxLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ExciseTaxLiability"/>
  <xs:element name="ExciseTaxGenerallyOfTheFairMarketValuePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage"/>
  <xs:element name="PercentageOfUnderpaymentPenaltyPerMonth" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfUnderpaymentPenaltyPerMonth"/>
  <xs:element name="PercentageOfLiabilityTotal" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfLiabilityTotal"/>
  <xs:element name="ExcessTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ExcessTaxes"/>
  <xs:element name="PaymentOfRentAndMaintenanceExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_PaymentOfRentAndMaintenanceExpense"/>
  <xs:element name="ForwardPurchaseAgreementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_ForwardPurchaseAgreementDetailsTable"/>
  <xs:element name="DerivativeChangeInFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_DerivativeChangeInFairValue"/>
  <xs:element name="ForwardContractInitialResetPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ForwardContractInitialResetPricePerShare"/>
  <xs:element name="ForwardContractBaseResetPricePerShare" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ForwardContractBaseResetPricePerShare"/>
  <xs:element name="NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare"/>
  <xs:element name="VolumeWeightedAveragePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_VolumeWeightedAveragePrice"/>
  <xs:element name="SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount"/>
  <xs:element name="WarrantsExercisableDateDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_WarrantsExercisableDateDomainDomain"/>
  <xs:element name="DebtInstrumentInterestRateTermDomainDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_DebtInstrumentInterestRateTermDomainDomain"/>
  <xs:element name="NotesPayableDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_NotesPayableDetailsTable"/>
  <xs:element name="ConversionOfConsiderationUnderPromissoryNoteAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement"/>
  <xs:element name="IncentiveSharesReceivedBySubsidiary" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_IncentiveSharesReceivedBySubsidiary"/>
  <xs:element name="AdditionalInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_AdditionalInterestExpense"/>
  <xs:element name="StandbyEquityPurchaseAgreementDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_StandbyEquityPurchaseAgreementDetailsTable"/>
  <xs:element name="ExcessOfCommonStockPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_ExcessOfCommonStockPercentage"/>
  <xs:element name="PercentageOfVolumeWeightedAveragePrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfVolumeWeightedAveragePrice"/>
  <xs:element name="ConvertibleThresholdConsecutiveTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_ConvertibleThresholdConsecutiveTradingDays"/>
  <xs:element name="PercentageOfClosingPrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfClosingPrice"/>
  <xs:element name="FloorPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_FloorPrice"/>
  <xs:element name="PercentageOfCommonStock" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfCommonStock"/>
  <xs:element name="PercentageOfAmortizationPrincipalAmount" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfAmortizationPrincipalAmount"/>
  <xs:element name="ChangeInFairValueEmbeddedDerivativeLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_ChangeInFairValueEmbeddedDerivativeLiability"/>
  <xs:element name="PercentageOfCommonStockOutstanding" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfCommonStockOutstanding"/>
  <xs:element name="PercentageOfAdvanceNotice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfAdvanceNotice"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_StockholdersEquityDetailsTable"/>
  <xs:element name="WarrantsExercisableTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_WarrantsExercisableTerm"/>
  <xs:element name="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights"/>
  <xs:element name="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger"/>
  <xs:element name="NumberOfTradingDaysForDeterminingTheSharePrice" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NumberOfTradingDaysForDeterminingTheSharePrice"/>
  <xs:element name="PeriodAfterWhichTheWarrantsAreExercisable" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PeriodAfterWhichTheWarrantsAreExercisable"/>
  <xs:element name="PerShareRedemptionsTriggerPrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="abp_PerShareRedemptionsTriggerPrice"/>
  <xs:element name="PercentageOfMarketValueAndNewlyIssuedPrice" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PercentageOfMarketValueAndNewlyIssuedPrice"/>
  <xs:element name="DesignatedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_DesignatedShares"/>
  <xs:element name="ShareBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_ShareBasedCompensationDetailsTable"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
  <xs:element name="RelatedPartiesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_RelatedPartiesDetailsTable"/>
  <xs:element name="UnpaidAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_UnpaidAmount"/>
  <xs:element name="AnnualBaseFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="abp_AnnualBaseFee"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_SubsequentEventsDetailsTable"/>
  <xs:element name="IssuanceOfSharesPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_IssuanceOfSharesPercentage"/>
  <xs:element name="LeasesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_LeasesDetailsTable"/>
  <xs:element name="LetterOfCreditExtendedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_LetterOfCreditExtendedPeriod"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="abp_IncomeTaxesDetailsTable"/>
  <xs:element name="CarryforwardsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_CarryforwardsTerm"/>
  <xs:element name="FederalAndStateResearchAndDevelopmentCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="abp_FederalAndStateResearchAndDevelopmentCredits"/>
  <xs:element name="DebtInstrumentInterestRateTermAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="abp_DebtInstrumentInterestRateTermAxis"/>
  <xs:element name="WarrantsExercisableDateAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="abp_WarrantsExercisableDateAxis"/>
  <xs:element name="ABCDMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ABCDMember"/>
  <xs:element name="ABIMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ABIMember"/>
  <xs:element name="ABP201CollaborationAndLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ABP201CollaborationAndLicenseAgreementMember"/>
  <xs:element name="ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember"/>
  <xs:element name="ACABFounderSharesLessOfForfeituresAndTransfersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember"/>
  <xs:element name="ACABMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ACABMember"/>
  <xs:element name="AbMedMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_AbMedMember"/>
  <xs:element name="AbproBioInternationalIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_AbproBioInternationalIncMember"/>
  <xs:element name="AbproHoldingsIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_AbproHoldingsIncMember"/>
  <xs:element name="AdvanceNoticeToYAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_AdvanceNoticeToYAMember"/>
  <xs:element name="AfterMaturityDateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_AfterMaturityDateMember"/>
  <xs:element name="BlackAndScholesModelMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_BlackAndScholesModelMember"/>
  <xs:element name="CROVendorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_CROVendorMember"/>
  <xs:element name="CelltrionCollaborationAndLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_CelltrionCollaborationAndLicenseAgreementMember"/>
  <xs:element name="CelltrionIncMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_CelltrionIncMember"/>
  <xs:element name="CollaborationRevenueMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_CollaborationRevenueMember"/>
  <xs:element name="CommonStockOfACABNetOfRedemptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_CommonStockOfACABNetOfRedemptionsMember"/>
  <xs:element name="ContingentEarnoutSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ContingentEarnoutSharesMember"/>
  <xs:element name="ConvertibleNoteDiscountMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ConvertibleNoteDiscountMember"/>
  <xs:element name="ConvertibleNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ConvertibleNotesMember"/>
  <xs:element name="ConvertiblePreferredStocksMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ConvertiblePreferredStocksMember"/>
  <xs:element name="ConvertiblePromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ConvertiblePromissoryNoteMember"/>
  <xs:element name="EmbeddedDerivativeLiabilityMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_EmbeddedDerivativeLiabilityMember"/>
  <xs:element name="EquipmentUnderFinanceLeasesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_EquipmentUnderFinanceLeasesMember"/>
  <xs:element name="ExchangeCapEventMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ExchangeCapEventMember"/>
  <xs:element name="ExecutiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ExecutiveMember"/>
  <xs:element name="ExecutiveWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ExecutiveWarrantsMember"/>
  <xs:element name="FirstConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_FirstConvertibleNoteMember"/>
  <xs:element name="FirstConvertibleNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_FirstConvertibleNotesMember"/>
  <xs:element name="FirstMilestoneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_FirstMilestoneMember"/>
  <xs:element name="FirstSharesTargetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_FirstSharesTargetMember"/>
  <xs:element name="FloorPriceEventMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_FloorPriceEventMember"/>
  <xs:element name="ForwardPurchaseAgreementAssetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ForwardPurchaseAgreementAssetMember"/>
  <xs:element name="ForwardPurchaseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ForwardPurchaseAgreementMember"/>
  <xs:element name="FundingDateToMaturityDateMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_FundingDateToMaturityDateMember"/>
  <xs:element name="InvestmentAdvisorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_InvestmentAdvisorMember"/>
  <xs:element name="IssuanceDateOfWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_IssuanceDateOfWarrantsMember"/>
  <xs:element name="LabEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_LabEquipmentMember"/>
  <xs:element name="LegacyAbproCommonStockWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_LegacyAbproCommonStockWarrantsMember"/>
  <xs:element name="LegacyAbproMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_LegacyAbproMember"/>
  <xs:element name="MSKLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_MSKLicenseAgreementMember"/>
  <xs:element name="MabwellShanghaiBioscienceCoLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_MabwellShanghaiBioscienceCoLtdMember"/>
  <xs:element name="MarketValueOfListedSecuritiesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_MarketValueOfListedSecuritiesMember"/>
  <xs:element name="MarketValueOfPubliclyHeldSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_MarketValueOfPubliclyHeldSharesMember"/>
  <xs:element name="MedImmuneLicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_MedImmuneLicenseAgreementMember"/>
  <xs:element name="MonteCarloSimulationMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_MonteCarloSimulationMember"/>
  <xs:element name="NCILicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NCILicenseAgreementMember"/>
  <xs:element name="NJCTTQCollaborationAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NJCTTQCollaborationAgreementMember"/>
  <xs:element name="NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember"/>
  <xs:element name="NewAbproSharesIssuedToPIPEInvestorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NewAbproSharesIssuedToPIPEInvestorsMember"/>
  <xs:element name="NewAbproSharesIssuedToServiceProvidersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NewAbproSharesIssuedToServiceProvidersMember"/>
  <xs:element name="NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember"/>
  <xs:element name="NewAbproSharesTransferredToInvestorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NewAbproSharesTransferredToInvestorsMember"/>
  <xs:element name="NewConsultingAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NewConsultingAgreementMember"/>
  <xs:element name="NonRedemptionAgreementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NonRedemptionAgreementsMember"/>
  <xs:element name="NotePayableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NotePayableMember"/>
  <xs:element name="NumberOfSharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_NumberOfSharesMember"/>
  <xs:element name="OneYearAnniversaryOfIssuanceDateOfWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember"/>
  <xs:element name="OtherAccruedExpensesAndAccountsPayableMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_OtherAccruedExpensesAndAccountsPayableMember"/>
  <xs:element name="OtherAccruedExpensesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_OtherAccruedExpensesMember"/>
  <xs:element name="PIPEFinancingMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PIPEFinancingMember"/>
  <xs:element name="PIPESharesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PIPESharesMember"/>
  <xs:element name="PostApportionedMassachusettsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PostApportionedMassachusettsMember"/>
  <xs:element name="PrivatePlacementWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PrivatePlacementWarrantsMember"/>
  <xs:element name="PrivateWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PrivateWarrantsMember"/>
  <xs:element name="PromissoryNoteAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PromissoryNoteAgreementMember"/>
  <xs:element name="PromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PromissoryNoteMember"/>
  <xs:element name="PromissoryNoteWithABIMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PromissoryNoteWithABIMember"/>
  <xs:element name="PromissoryNoteWithACABExecutiveMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PromissoryNoteWithACABExecutiveMember"/>
  <xs:element name="PromissoryNotesWithExecutiveAndDirectorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PromissoryNotesWithExecutiveAndDirectorMember"/>
  <xs:element name="PublicWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_PublicWarrantsMember"/>
  <xs:element name="RedemptionTriggerMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_RedemptionTriggerMember"/>
  <xs:element name="RegistrationEventMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_RegistrationEventMember"/>
  <xs:element name="ResearchAndDevelopmentServicesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ResearchAndDevelopmentServicesMember"/>
  <xs:element name="ReverseStockSplitMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ReverseStockSplitMember"/>
  <xs:element name="RothCapitalPartnersMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_RothCapitalPartnersMember"/>
  <xs:element name="SEPAMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SEPAMember"/>
  <xs:element name="SEPAPutRightsAssetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SEPAPutRightsAssetMember"/>
  <xs:element name="SecondConvertibleNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SecondConvertibleNoteMember"/>
  <xs:element name="SecondConvertibleNotesMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SecondConvertibleNotesMember"/>
  <xs:element name="SecondShareTargetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SecondShareTargetMember"/>
  <xs:element name="SeparatePromissoryNoteAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SeparatePromissoryNoteAgreementMember"/>
  <xs:element name="SeriesACommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SeriesACommonStockMember"/>
  <xs:element name="SeriesARedeemableConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SeriesARedeemableConvertiblePreferredStockMember"/>
  <xs:element name="SeriesBCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SeriesBCommonStockMember"/>
  <xs:element name="SeriesBConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SeriesBConvertiblePreferredStockMember"/>
  <xs:element name="SeriesCConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SeriesCConvertiblePreferredStockMember"/>
  <xs:element name="SeriesDConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SeriesDConvertiblePreferredStockMember"/>
  <xs:element name="SeriesEConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SeriesEConvertiblePreferredStockMember"/>
  <xs:element name="SeriesFConvertiblePreferredStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SeriesFConvertiblePreferredStockMember"/>
  <xs:element name="SettlementAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SettlementAgreementMember"/>
  <xs:element name="SponsorMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_SponsorMember"/>
  <xs:element name="StockOptionsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_StockOptionsMember"/>
  <xs:element name="TaxYear2037Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_TaxYear2037Member"/>
  <xs:element name="ThirdShareTargetMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_ThirdShareTargetMember"/>
  <xs:element name="TwoYearAnniversaryOfIssuanceDateOfWarrantsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember"/>
  <xs:element name="TwoZeroOneFourStockIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_TwoZeroOneFourStockIncentivePlanMember"/>
  <xs:element name="TwoZeroTwoFourEquityIncentivePlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_TwoZeroTwoFourEquityIncentivePlanMember"/>
  <xs:element name="UnvestedRestrictedStockUnitsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_UnvestedRestrictedStockUnitsMember"/>
  <xs:element name="VAZYMELicenseAgreementMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_VAZYMELicenseAgreementMember"/>
  <xs:element name="VendorsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_VendorsMember"/>
  <xs:element name="WarrantsToPurchaseCommonStockMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_WarrantsToPurchaseCommonStockMember"/>
  <xs:element name="YAIIPNLtdMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_YAIIPNLtdMember"/>
  <xs:element name="YearTwoThousandTwentyFourABIPromissoryNoteMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember"/>
  <xs:element name="MergerLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_MergerLineItems"/>
  <xs:element name="StandbyEquityPurchaseAgreementLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_StandbyEquityPurchaseAgreementLineItems"/>
<!-- [WMV6][6sj9sT6YVGD56eS56d+timI+OFX77z/IUha2WLY8amC/g2rES2TLpBISrGMdMcRKG0qVIVgVZG34BLpZMZzt0Y8eIxO7DeLXYyWSTGJfsxJooRsg/lVd/OZ1Qkd9MBe2h+E1qL6i6j1cPvc8Imq36NyA6/qYDvxxclhDdjWp6il1QSugzVx2hszTNjUx89kYxLZtlx597mrCwueCrGBprGRnKvoiUWASZ2A03kkf5EHC/+ehPs5J+Xi/rpU8LyVkyJPEeoklxZR17yUdqiWdC8raj5DpB0Ju6VP2m7XZu2SyXOjvmx6Mz0HY2o8TCMlqhb44nPhKSoN+MHYBpjQFvQgQvcpVAnOFOw==] CSR-->
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="abp_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>27
<FILENAME>abp-20250930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 28 18:01:32 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedBalanceSheet" roleURI="http://www.abpro.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedIncomeStatement" roleURI="http://www.abpro.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedCashFlow" roleURI="http://www.abpro.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofAccruedExpensesTable" roleURI="http://www.abpro.com/role/ScheduleofAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofConsolidatedStatementsofCashFlowsTable" roleURI="http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofAccruedExpensesTable0" roleURI="http://www.abpro.com/role/ScheduleofAccruedExpensesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofLeaseExpenseTable" roleURI="http://www.abpro.com/role/ScheduleofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofFutureMinimumPaymentsTable" roleURI="http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofIncomeLossBeforeProvisionTable" roleURI="http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofEffectiveIncomeTaxRateTable" roleURI="http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofNetDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"/>
  <calculationLink xlink:role="http://www.abpro.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="abp_ForwardPurchaseAgreementAsset" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DeferredOfferingCosts" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_PatentsNet" xlink:href="abp-20250930.xsd#abp_PatentsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="abp_PatentsNet" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAPutRightsAsset" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="abp_SEPAPutRightsAsset" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleNotes" xlink:href="abp-20250930.xsd#abp_ConvertibleNotes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="abp_ConvertibleNotes" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockCommonValue" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncome" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfForwardPuchaseAgreementAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfSEPAPutRightsAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfSEPAPutRightsAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="abp_ChangeInFairValueOfSEPAPutRightsAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfEmbeddedDerivativeLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="abp_ChangeInFairValueOfEmbeddedDerivativeLiability" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeInterest" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_LossOnSettlementOfConvertibleNotes" xlink:href="abp-20250930.xsd#abp_LossOnSettlementOfConvertibleNotes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="abp_LossOnSettlementOfConvertibleNotes" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpenseNonoperating" order="8" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_DeemedDividendResultingFromTheWarrantDownRound" xlink:href="abp-20250930.xsd#abp_DeemedDividendResultingFromTheWarrantDownRound"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="abp_DeemedDividendResultingFromTheWarrantDownRound" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_LossOnSettlementsOfConvertibleNotes" xlink:href="abp-20250930.xsd#abp_LossOnSettlementsOfConvertibleNotes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="abp_LossOnSettlementsOfConvertibleNotes" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="11" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="12" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherIncome" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfForwardPurchaseAgreementAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset" order="14" weight="-1"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfSEPAPutRightAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfSEPAPutRightAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="abp_ChangeInFairValueOfSEPAPutRightAsset" order="15" weight="-1"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOnEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOnEmbeddedDerivativeLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="abp_ChangeInFairValueOnEmbeddedDerivativeLiability" order="16" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="17" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="18" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="19" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="20" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromOtherEquity" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_NetProceedsFromTheMerger" xlink:href="abp-20250930.xsd#abp_NetProceedsFromTheMerger"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="abp_NetProceedsFromTheMerger" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="abp_CashTransferredToEscrow" xlink:href="abp-20250930.xsd#abp_CashTransferredToEscrow"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="abp_CashTransferredToEscrow" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_Cash" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCash" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ScheduleofAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedLicenseFees" xlink:href="abp-20250930.xsd#abp_AccruedLicenseFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="abp_AccruedLicenseFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedInterest" xlink:href="abp-20250930.xsd#abp_AccruedInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="abp_AccruedInterest" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedBODCompensation" xlink:href="abp-20250930.xsd#abp_AccruedBODCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="abp_AccruedBODCompensation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ScheduleofAccruedExpensesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedLicenseFees" xlink:href="abp-20250930.xsd#abp_AccruedLicenseFees"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="abp_AccruedLicenseFees" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedInterest" xlink:href="abp-20250930.xsd#abp_AccruedInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="abp_AccruedInterest" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedBODCompensation" xlink:href="abp-20250930.xsd#abp_AccruedBODCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="abp_AccruedBODCompensation" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ScheduleofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" xlink:href="abp-20250930.xsd#abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" weight="1"/>
  </calculationLink>
  <calculationLink xlink:role="http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_DeferredTaxAssetsLeaseLiability" xlink:href="abp-20250930.xsd#abp_DeferredTaxAssetsLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="abp_DeferredTaxAssetsLeaseLiability" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="abp_DeferredTaxLiabilitiesRightofuseAsset" xlink:href="abp-20250930.xsd#abp_DeferredTaxLiabilitiesRightofuseAsset"/>
<!-- [WMV6][Yi20nFs/1jIEZmF3hGuSPD5oJyctgRzQCfmhrtBGnCtCHwCEm8y2/E1CQSVP9S/1cV98S6tuQ+N8664KxxRoWXgpsHT/JXLSJ+tRhs+gZQKFGZplZ4ySYGUOB0+pCeJOILrpSUubg5PmJlBwEOBGCm53CEGNBWHkkffUxbyRRg0sPHXP8Vn4HSq8xXXL2nimCrtckag3bpnCBjPTMeF+JWsZT2xXExLnbkWAbF/76TW4vHkt+Pz+dHnf4rpnaNjM7hDAKecfaSNunUvU+CBsjJMp/rI8UTwF8zbPUp7YJqvpWr/BB61Cb+zCzi7eaFYjv1OOmgvK5YXyoqmHM77oVS4i5z7tfafz4w==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="abp_DeferredTaxLiabilitiesRightofuseAsset" order="2" weight="-1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>28
<FILENAME>abp-20250930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 28 18:01:32 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedBalanceSheet" roleURI="http://www.abpro.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedIncomeStatement" roleURI="http://www.abpro.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareholdersEquityType2or3" roleURI="http://www.abpro.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.abpro.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedCashFlow" roleURI="http://www.abpro.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_OrganizationandDescriptionoftheBusiness" roleURI="http://www.abpro.com/role/OrganizationandDescriptionoftheBusiness"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_Merger" roleURI="http://www.abpro.com/role/Merger"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_AccruedExpenses" roleURI="http://www.abpro.com/role/AccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_FairValueMeasurements" roleURI="http://www.abpro.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_LicenseandCollaborationAgreements" roleURI="http://www.abpro.com/role/LicenseandCollaborationAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_CommitmentsunderResearchandCollaborationAgreements" roleURI="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_CommitmentsandContingencies" roleURI="http://www.abpro.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ForwardPurchaseAgreement" roleURI="http://www.abpro.com/role/ForwardPurchaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_NotesPayable" roleURI="http://www.abpro.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StandbyEquityPurchaseAgreement" roleURI="http://www.abpro.com/role/StandbyEquityPurchaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StockholdersEquity" roleURI="http://www.abpro.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareBasedCompensation" roleURI="http://www.abpro.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_EmployeeBenefitPlan" roleURI="http://www.abpro.com/role/EmployeeBenefitPlan"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_RelatedParties" roleURI="http://www.abpro.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SubsequentEvents" roleURI="http://www.abpro.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_PropertyandEquipment" roleURI="http://www.abpro.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_Leases" roleURI="http://www.abpro.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_IncomeTaxes" roleURI="http://www.abpro.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_AccountingPoliciesByPolicy" roleURI="http://www.abpro.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_MergerTables" roleURI="http://www.abpro.com/role/MergerTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_AccruedExpensesTables" roleURI="http://www.abpro.com/role/AccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_FairValueMeasurementsTables" roleURI="http://www.abpro.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StockholdersEquityTables" roleURI="http://www.abpro.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareBasedCompensationTables" roleURI="http://www.abpro.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_PropertyandEquipmentTables" roleURI="http://www.abpro.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_LeasesTables" roleURI="http://www.abpro.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_IncomeTaxesTables" roleURI="http://www.abpro.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCommonStockOutstandingTable" roleURI="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofAccruedExpensesTable" roleURI="http://www.abpro.com/role/ScheduleofAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable" roleURI="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable" roleURI="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable" roleURI="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofWarrantstoPurchaseCommonStockOutstandingTable" roleURI="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysStockOptionActivityTable" roleURI="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysRestrictedStockUnitActivityTable" roleURI="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofRecordedStockBasedCompensationExpenseTable" roleURI="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofConsolidatedStatementsofCashFlowsTable" roleURI="http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable" roleURI="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofBalanceSheetTable" roleURI="http://www.abpro.com/role/ScheduleofBalanceSheetTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCommonStockOutstandingTable0" roleURI="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofAccruedExpensesTable0" roleURI="http://www.abpro.com/role/ScheduleofAccruedExpensesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0" roleURI="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0" roleURI="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0" roleURI="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofLeaseExpenseTable" roleURI="http://www.abpro.com/role/ScheduleofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofFutureMinimumPaymentsTable" roleURI="http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCommonStockWarrantActivityTable" roleURI="http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0" roleURI="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysStockOptionActivityTable0" roleURI="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable" roleURI="http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysRestrictedStockUnitActivityTable0" roleURI="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofRecordedStockBasedCompensationExpenseTable0" roleURI="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofIncomeLossBeforeProvisionTable" roleURI="http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofEffectiveIncomeTaxRateTable" roleURI="http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofNetDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives" roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_OrganizationandDescriptionoftheBusinessDetails" roleURI="http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_MergerDetails" roleURI="http://www.abpro.com/role/MergerDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_FairValueMeasurementsDetails" roleURI="http://www.abpro.com/role/FairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_LicenseandCollaborationAgreementsDetails" roleURI="http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_CommitmentsunderResearchandCollaborationAgreementsDetails" roleURI="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_CommitmentsandContingenciesDetails" roleURI="http://www.abpro.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ForwardPurchaseAgreementDetails" roleURI="http://www.abpro.com/role/ForwardPurchaseAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_NotesPayableDetails" roleURI="http://www.abpro.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StandbyEquityPurchaseAgreementDetails" roleURI="http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StockholdersEquityDetails" roleURI="http://www.abpro.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareBasedCompensationDetails" roleURI="http://www.abpro.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_EmployeeBenefitPlanDetails" roleURI="http://www.abpro.com/role/EmployeeBenefitPlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_RelatedPartiesDetails" roleURI="http://www.abpro.com/role/RelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SubsequentEventsDetails" roleURI="http://www.abpro.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_PropertyandEquipmentDetails" roleURI="http://www.abpro.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_LeasesDetails" roleURI="http://www.abpro.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_IncomeTaxesDetails" roleURI="http://www.abpro.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:role="http://www.abpro.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesFConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesFConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesFConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesEConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesEConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesEConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesDConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesDConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesDConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesCConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesCConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesCConvertiblePreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesBConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesBConvertiblePreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesARedeemableConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesARedeemableConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesARedeemableConvertiblePreferredStockMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_ForwardPurchaseAgreementAsset" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PatentsNet" xlink:href="abp-20250930.xsd#abp_PatentsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_PatentsNet" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAPutRightsAsset" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_SEPAPutRightsAsset" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NotesPayableCurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleNotes" xlink:href="abp-20250930.xsd#abp_ConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_ConvertibleNotes" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonValue" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapital" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MinorityInterest" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="35" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesFConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesFConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesFConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesEConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesEConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesEConvertiblePreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesDConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesDConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesDConvertiblePreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesCConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesCConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesCConvertiblePreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesBConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesBConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesBConvertiblePreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesARedeemableConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesARedeemableConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesARedeemableConvertiblePreferredStockMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ResearchAndDevelopmentServicesMember" xlink:href="abp-20250930.xsd#abp_ResearchAndDevelopmentServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="abp_ResearchAndDevelopmentServicesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CollaborationRevenueMember" xlink:href="abp-20250930.xsd#abp_CollaborationRevenueMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="abp_CollaborationRevenueMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfForwardPuchaseAgreementAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfSEPAPutRightsAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfSEPAPutRightsAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_ChangeInFairValueOfSEPAPutRightsAsset" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfEmbeddedDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_ChangeInFairValueOfEmbeddedDerivativeLiability" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_LossOnSettlementOfConvertibleNotes" xlink:href="abp-20250930.xsd#abp_LossOnSettlementOfConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_LossOnSettlementOfConvertibleNotes" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DeemedDividendResultingFromTheWarrantDownRound" xlink:href="abp-20250930.xsd#abp_DeemedDividendResultingFromTheWarrantDownRound"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_DeemedDividendResultingFromTheWarrantDownRound" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesEPreferredStockMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesFPreferredStockMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertiblePreferredStocksMember" xlink:href="abp-20250930.xsd#abp_ConvertiblePreferredStocksMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abp_ConvertiblePreferredStocksMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockCommonMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:href="abp-20250930.xsd#abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:href="abp-20250930.xsd#abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceOfCommonStockInThePIPEFinancing" xlink:href="abp-20250930.xsd#abp_IssuanceOfCommonStockInThePIPEFinancing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_IssuanceOfCommonStockInThePIPEFinancing" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceOfCommonStockInPIPEFinancing" xlink:href="abp-20250930.xsd#abp_IssuanceOfCommonStockInPIPEFinancing"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="abp_IssuanceOfCommonStockInPIPEFinancing" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="21" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceOfCommonStockInTransactionCost" xlink:href="abp-20250930.xsd#abp_IssuanceOfCommonStockInTransactionCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="abp_IssuanceOfCommonStockInTransactionCost" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_LossOnSettlementsOfConvertibleNotes" xlink:href="abp-20250930.xsd#abp_LossOnSettlementsOfConvertibleNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_LossOnSettlementsOfConvertibleNotes" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_OtherIncome" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfForwardPurchaseAgreementAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfSEPAPutRightAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfSEPAPutRightAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_ChangeInFairValueOfSEPAPutRightAsset" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOnEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOnEmbeddedDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_ChangeInFairValueOnEmbeddedDerivativeLiability" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_InterestPaidNet" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" xlink:href="abp-20250930.xsd#abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DeferredOfferingCostsIncludedInAccountsPayable" xlink:href="abp-20250930.xsd#abp_DeferredOfferingCostsIncludedInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_DeferredOfferingCostsIncludedInAccountsPayable" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" xlink:href="abp-20250930.xsd#abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_Cash" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCash" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="41" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NetProceedsFromTheMerger" xlink:href="abp-20250930.xsd#abp_NetProceedsFromTheMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_NetProceedsFromTheMerger" order="42" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="43" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CashTransferredToEscrow" xlink:href="abp-20250930.xsd#abp_CashTransferredToEscrow"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_CashTransferredToEscrow" order="44" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="45" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="46" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="47" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_OfferingCostsIncludedInAccountsPayable" xlink:href="abp-20250930.xsd#abp_OfferingCostsIncludedInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_OfferingCostsIncludedInAccountsPayable" order="48" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties" xlink:href="abp-20250930.xsd#abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties" order="49" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ACABLiabilitiesAssumedInTheMerger" xlink:href="abp-20250930.xsd#abp_ACABLiabilitiesAssumedInTheMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_ACABLiabilitiesAssumedInTheMerger" order="50" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" xlink:href="abp-20250930.xsd#abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" order="51" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" xlink:href="abp-20250930.xsd#abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" order="52" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SEPACommitmentFeePaidInCommonStockShares" xlink:href="abp-20250930.xsd#abp_SEPACommitmentFeePaidInCommonStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="abp_SEPACommitmentFeePaidInCommonStockShares" order="53" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/OrganizationandDescriptionoftheBusiness" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/Merger" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/AccruedExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralizedAgreementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralizedAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollateralizedAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ForwardPurchaseAgreement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/NotesPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/StandbyEquityPurchaseAgreement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abp_StandbyEquityPurchaseAgreementAbstract" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="abp_StandbyEquityPurchaseAgreementTextBlock" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementAbstract" xlink:to="abp_StandbyEquityPurchaseAgreementTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ShareBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/RelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NoncontrollingInterestPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_NoncontrollingInterestPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abp_NoncontrollingInterestPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EmergingGrowthCompanyPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_EmergingGrowthCompanyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abp_EmergingGrowthCompanyPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PatentsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_PatentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abp_PatentsPolicyTextBlock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertiblePreferredStockPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_ConvertiblePreferredStockPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abp_ConvertiblePreferredStockPolicyTextBlock" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ContingentEarnoutPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_ContingentEarnoutPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abp_ContingentEarnoutPolicyTextBlock" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:href="abp-20250930.xsd#abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/MergerTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/AccruedExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abp_StockholdersEquityTablesLineItems" xlink:href="abp-20250930.xsd#abp_StockholdersEquityTablesLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_StockholdersEquityTablesTable" xlink:href="abp-20250930.xsd#abp_StockholdersEquityTablesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abp_StockholdersEquityTablesLineItems" xlink:to="abp_StockholdersEquityTablesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StockholdersEquityTablesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StockholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_StockOptionsMember" xlink:href="abp-20250930.xsd#abp_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="abp_StockOptionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_UnvestedRestrictedStockUnitsMember" xlink:href="abp-20250930.xsd#abp_UnvestedRestrictedStockUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="abp_UnvestedRestrictedStockUnitsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_MergerScheduleofCommonStockOutstandingDetailsTable" xlink:href="abp-20250930.xsd#abp_MergerScheduleofCommonStockOutstandingDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="abp_MergerScheduleofCommonStockOutstandingDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CommonStockOfACABNetOfRedemptionsMember" xlink:href="abp-20250930.xsd#abp_CommonStockOfACABNetOfRedemptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_CommonStockOfACABNetOfRedemptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember" xlink:href="abp-20250930.xsd#abp_ACABFounderSharesLessOfForfeituresAndTransfersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedToPIPEInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToPIPEInvestorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesIssuedToPIPEInvestorsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedToServiceProvidersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToServiceProvidersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesIssuedToServiceProvidersMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesTransferredToInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesTransferredToInvestorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesTransferredToInvestorsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedLicenseFees" xlink:href="abp-20250930.xsd#abp_AccruedLicenseFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="abp_AccruedLicenseFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedInterest" xlink:href="abp-20250930.xsd#abp_AccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="abp_AccruedInterest" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedBODCompensation" xlink:href="abp-20250930.xsd#abp_AccruedBODCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="abp_AccruedBODCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementAssetMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_ForwardPurchaseAgreementAssetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAPutRightsAssetMember" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_SEPAPutRightsAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EmbeddedDerivativeLiabilityMember" xlink:href="abp-20250930.xsd#abp_EmbeddedDerivativeLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_EmbeddedDerivativeLiabilityMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_ForwardPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_BlackAndScholesModelMember" xlink:href="abp-20250930.xsd#abp_BlackAndScholesModelMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_BlackAndScholesModelMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NumberOfSharesMember" xlink:href="abp-20250930.xsd#abp_NumberOfSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="abp_NumberOfSharesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:href="abp-20250930.xsd#abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementAssetMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_ForwardPurchaseAgreementAssetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAPutRightsAssetMember" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_SEPAPutRightsAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EmbeddedDerivativeLiabilityMember" xlink:href="abp-20250930.xsd#abp_EmbeddedDerivativeLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_EmbeddedDerivativeLiabilityMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_WarrantsToPurchaseCommonStockMember" xlink:href="abp-20250930.xsd#abp_WarrantsToPurchaseCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abp_WarrantsToPurchaseCommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="abp-20250930.xsd#abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="abp-20250930.xsd#abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="abp-20250930.xsd#abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_StockOptionsMember" xlink:href="abp-20250930.xsd#abp_StockOptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="abp_StockOptionsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_ConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="abp_ConvertibleNotesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_UnvestedRestrictedStockUnitsMember" xlink:href="abp-20250930.xsd#abp_UnvestedRestrictedStockUnitsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="abp_UnvestedRestrictedStockUnitsMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofBalanceSheetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_RestatementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AbproHoldingsIncMember" xlink:href="abp-20250930.xsd#abp_AbproHoldingsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="abp_AbproHoldingsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_MergerScheduleofCommonStockOutstandingDetailsTable" xlink:href="abp-20250930.xsd#abp_MergerScheduleofCommonStockOutstandingDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="abp_MergerScheduleofCommonStockOutstandingDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CommonStockOfACABNetOfRedemptionsMember" xlink:href="abp-20250930.xsd#abp_CommonStockOfACABNetOfRedemptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_CommonStockOfACABNetOfRedemptionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember" xlink:href="abp-20250930.xsd#abp_ACABFounderSharesLessOfForfeituresAndTransfersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedToPIPEInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToPIPEInvestorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesIssuedToPIPEInvestorsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedToServiceProvidersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToServiceProvidersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesIssuedToServiceProvidersMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesTransferredToInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesTransferredToInvestorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesTransferredToInvestorsMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EquipmentUnderFinanceLeasesMember" xlink:href="abp-20250930.xsd#abp_EquipmentUnderFinanceLeasesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="abp_EquipmentUnderFinanceLeasesMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofAccruedExpensesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedLicenseFees" xlink:href="abp-20250930.xsd#abp_AccruedLicenseFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="abp_AccruedLicenseFees" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedInterest" xlink:href="abp-20250930.xsd#abp_AccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="abp_AccruedInterest" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedBODCompensation" xlink:href="abp-20250930.xsd#abp_AccruedBODCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="abp_AccruedBODCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementAssetMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_ForwardPurchaseAgreementAssetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAPutRightsAssetMember" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_SEPAPutRightsAssetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EmbeddedDerivativeLiabilityMember" xlink:href="abp-20250930.xsd#abp_EmbeddedDerivativeLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_EmbeddedDerivativeLiabilityMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_ForwardPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_BlackAndScholesModelMember" xlink:href="abp-20250930.xsd#abp_BlackAndScholesModelMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_BlackAndScholesModelMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NumberOfSharesMember" xlink:href="abp-20250930.xsd#abp_NumberOfSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="abp_NumberOfSharesMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:href="abp-20250930.xsd#abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementAssetMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_ForwardPurchaseAgreementAssetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EmbeddedDerivativeLiabilityMember" xlink:href="abp-20250930.xsd#abp_EmbeddedDerivativeLiabilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_EmbeddedDerivativeLiabilityMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAPutRightsAssetMember" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAssetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="abp_SEPAPutRightsAssetMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_LegacyAbproCommonStockWarrantsMember" xlink:href="abp-20250930.xsd#abp_LegacyAbproCommonStockWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abp_LegacyAbproCommonStockWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PrivateWarrantsMember" xlink:href="abp-20250930.xsd#abp_PrivateWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abp_PrivateWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PublicWarrantsMember" xlink:href="abp-20250930.xsd#abp_PublicWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abp_PublicWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ExpiredAtTheMerger" xlink:href="abp-20250930.xsd#abp_ExpiredAtTheMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abp_ExpiredAtTheMerger" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger" xlink:href="abp-20250930.xsd#abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:to="srt_RestatementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" xlink:href="abp-20250930.xsd#abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" xlink:href="abp-20250930.xsd#abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DeferredTaxAssetsLeaseLiability" xlink:href="abp-20250930.xsd#abp_DeferredTaxAssetsLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="abp_DeferredTaxAssetsLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DeferredTaxLiabilitiesRightofuseAsset" xlink:href="abp-20250930.xsd#abp_DeferredTaxLiabilitiesRightofuseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="abp_DeferredTaxLiabilitiesRightofuseAsset" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" xlink:href="abp-20250930.xsd#abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_LabEquipmentMember" xlink:href="abp-20250930.xsd#abp_LabEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="abp_LabEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:href="abp-20250930.xsd#abp_OrganizationandDescriptionoftheBusinessDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_OrganizationandDescriptionoftheBusinessDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="srt_StatementScenarioAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ReverseStockSplitMember" xlink:href="abp-20250930.xsd#abp_ReverseStockSplitMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="abp_ReverseStockSplitMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MarketValueOfPubliclyHeldSharesMember" xlink:href="abp-20250930.xsd#abp_MarketValueOfPubliclyHeldSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_MarketValueOfPubliclyHeldSharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MarketValueOfListedSecuritiesMember" xlink:href="abp-20250930.xsd#abp_MarketValueOfListedSecuritiesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_MarketValueOfListedSecuritiesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SecondConvertibleNoteMember" xlink:href="abp-20250930.xsd#abp_SecondConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_SecondConvertibleNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PIPEFinancingMember" xlink:href="abp-20250930.xsd#abp_PIPEFinancingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_PIPEFinancingMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_PromissoryNoteMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleNoteDiscountMember" xlink:href="abp-20250930.xsd#abp_ConvertibleNoteDiscountMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_ConvertibleNoteDiscountMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ReverseStockSplitSharesOfIssued" xlink:href="abp-20250930.xsd#abp_ReverseStockSplitSharesOfIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_ReverseStockSplitSharesOfIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ReverseStockSpllitSharesOfOutstanding" xlink:href="abp-20250930.xsd#abp_ReverseStockSpllitSharesOfOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_ReverseStockSpllitSharesOfOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProfitLoss" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SecurityBidPricePerShare" xlink:href="abp-20250930.xsd#abp_SecurityBidPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_SecurityBidPricePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NotesPayable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_InstallmentsAmount" xlink:href="abp-20250930.xsd#abp_InstallmentsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_InstallmentsAmount" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AccrueInterestPercentage" xlink:href="abp-20250930.xsd#abp_AccrueInterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_AccrueInterestPercentage" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherLiabilities" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LegalFees" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreement" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_ForwardPurchaseAgreement" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GainLossOnContractTermination" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EarlyTerminationResetPricePerShare" xlink:href="abp-20250930.xsd#abp_EarlyTerminationResetPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_EarlyTerminationResetPricePerShare" order="32" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="abp-20250930.xsd#abp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="abp_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ContingentEarnoutSharesMember" xlink:href="abp-20250930.xsd#abp_ContingentEarnoutSharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_ContingentEarnoutSharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MabwellShanghaiBioscienceCoLtdMember" xlink:href="abp-20250930.xsd#abp_MabwellShanghaiBioscienceCoLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_MabwellShanghaiBioscienceCoLtdMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AbMedMember" xlink:href="abp-20250930.xsd#abp_AbMedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="abp_AbMedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OtherReceivables" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OtherIncome" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/MergerDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abp_MergerLineItems" xlink:href="abp-20250930.xsd#abp_MergerLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_MergerDetailsTable" xlink:href="abp-20250930.xsd#abp_MergerDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abp_MergerLineItems" xlink:to="abp_MergerDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_MergerDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesACommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesACommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesACommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesBCommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesBCommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesBCommonStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteAgreementMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_PromissoryNoteAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_FirstSharesTargetMember" xlink:href="abp-20250930.xsd#abp_FirstSharesTargetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="abp_FirstSharesTargetMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SecondShareTargetMember" xlink:href="abp-20250930.xsd#abp_SecondShareTargetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="abp_SecondShareTargetMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ThirdShareTargetMember" xlink:href="abp-20250930.xsd#abp_ThirdShareTargetMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="abp_ThirdShareTargetMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PIPESharesMember" xlink:href="abp-20250930.xsd#abp_PIPESharesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_PIPESharesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AbproBioInternationalIncMember" xlink:href="abp-20250930.xsd#abp_AbproBioInternationalIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_AbproBioInternationalIncMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ABIMember" xlink:href="abp-20250930.xsd#abp_ABIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_ABIMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CelltrionIncMember" xlink:href="abp-20250930.xsd#abp_CelltrionIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_CelltrionIncMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SponsorMember" xlink:href="abp-20250930.xsd#abp_SponsorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_SponsorMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ACABMember" xlink:href="abp-20250930.xsd#abp_ACABMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_ACABMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PIPEFinancingMember" xlink:href="abp-20250930.xsd#abp_PIPEFinancingMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_PIPEFinancingMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_InvestmentAdvisorMember" xlink:href="abp-20250930.xsd#abp_InvestmentAdvisorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_InvestmentAdvisorMember" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_LegacyAbproMember" xlink:href="abp-20250930.xsd#abp_LegacyAbproMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_LegacyAbproMember" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ABCDMember" xlink:href="abp-20250930.xsd#abp_ABCDMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_ABCDMember" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AdditionSharesOfCommonStock" xlink:href="abp-20250930.xsd#abp_AdditionSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="abp_AdditionSharesOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AggregatePurchasePrice" xlink:href="abp-20250930.xsd#abp_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="abp_AggregatePurchasePrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_Cash" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AggregateIncentiveShare" xlink:href="abp-20250930.xsd#abp_AggregateIncentiveShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="abp_AggregateIncentiveShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_RemainingSharesIssued" xlink:href="abp-20250930.xsd#abp_RemainingSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="abp_RemainingSharesIssued" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_OtherLiabilities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_Liabilities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_IncomeTaxesPaid" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EarnoutShare" xlink:href="abp-20250930.xsd#abp_EarnoutShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="abp_EarnoutShare" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_TradingDays" xlink:href="abp-20250930.xsd#abp_TradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="abp_TradingDays" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NumberOfConsecutiveTradingDays" xlink:href="abp-20250930.xsd#abp_NumberOfConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="abp_NumberOfConsecutiveTradingDays" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_LegalFees" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_MergerLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="28" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_FairValueMeasurementsDetailsTable" xlink:href="abp-20250930.xsd#abp_FairValueMeasurementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="abp_FairValueMeasurementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_FairValueMeasurementsDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_FairValueMeasurementsDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_FairValueMeasurementsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_FairValueMeasurementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_FairValueMeasurementsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_FirstConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_FirstConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_FirstConvertibleNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SecondConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_SecondConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_SecondConvertibleNotesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MonteCarloSimulationMember" xlink:href="abp-20250930.xsd#abp_MonteCarloSimulationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_MonteCarloSimulationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EstimatedFuturePricePerShare" xlink:href="abp-20250930.xsd#abp_EstimatedFuturePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="abp_EstimatedFuturePricePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_LicenseandCollaborationAgreementsDetailsTable" xlink:href="abp-20250930.xsd#abp_LicenseandCollaborationAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_LicenseandCollaborationAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_LicenseandCollaborationAgreementsDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_LicenseandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_LicenseandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_LicenseandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_LicenseandCollaborationAgreementsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_LicenseandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NJCTTQCollaborationAgreementMember" xlink:href="abp-20250930.xsd#abp_NJCTTQCollaborationAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_NJCTTQCollaborationAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ABP201CollaborationAndLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_ABP201CollaborationAndLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_ABP201CollaborationAndLicenseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CelltrionCollaborationAndLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_CelltrionCollaborationAndLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_CelltrionCollaborationAndLicenseAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntellectualPropertyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ABIMember" xlink:href="abp-20250930.xsd#abp_ABIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_ABIMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_FirstMilestoneMember" xlink:href="abp-20250930.xsd#abp_FirstMilestoneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="abp_FirstMilestoneMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AgreementInitialTerm" xlink:href="abp-20250930.xsd#abp_AgreementInitialTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_AgreementInitialTerm" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MilestonePayments" xlink:href="abp-20250930.xsd#abp_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_MilestonePayments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NonRefundablePayments" xlink:href="abp-20250930.xsd#abp_NonRefundablePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_NonRefundablePayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_OriginalCelltrionAgreement" xlink:href="abp-20250930.xsd#abp_OriginalCelltrionAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_OriginalCelltrionAgreement" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfOriginalCelltrionAgreement" xlink:href="abp-20250930.xsd#abp_PercentageOfOriginalCelltrionAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_PercentageOfOriginalCelltrionAgreement" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfAmendedCelltrionAgreement" xlink:href="abp-20250930.xsd#abp_PercentageOfAmendedCelltrionAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_PercentageOfAmendedCelltrionAgreement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfReimbursement" xlink:href="abp-20250930.xsd#abp_PercentageOfReimbursement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_PercentageOfReimbursement" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:href="abp-20250930.xsd#abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MedImmuneLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_MedImmuneLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_MedImmuneLicenseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NCILicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_NCILicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_NCILicenseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MSKLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_MSKLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_MSKLicenseAgreementMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_VAZYMELicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_VAZYMELicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_VAZYMELicenseAgreementMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_OtherAccruedExpensesAndAccountsPayableMember" xlink:href="abp-20250930.xsd#abp_OtherAccruedExpensesAndAccountsPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="abp_OtherAccruedExpensesAndAccountsPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_OtherAccruedExpensesMember" xlink:href="abp-20250930.xsd#abp_OtherAccruedExpensesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="abp_OtherAccruedExpensesMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_AccountsPayableMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MilestonePayments" xlink:href="abp-20250930.xsd#abp_MilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_MilestonePayments" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ClinicalDevelopmentMilestones" xlink:href="abp-20250930.xsd#abp_ClinicalDevelopmentMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_ClinicalDevelopmentMilestones" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_RegulatoryEvents" xlink:href="abp-20250930.xsd#abp_RegulatoryEvents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_RegulatoryEvents" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CommercialSales" xlink:href="abp-20250930.xsd#abp_CommercialSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_CommercialSales" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MilestonePaymentsCommercialMilestones" xlink:href="abp-20250930.xsd#abp_MilestonePaymentsCommercialMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_MilestonePaymentsCommercialMilestones" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PaymentForExtensionRoyalities" xlink:href="abp-20250930.xsd#abp_PaymentForExtensionRoyalities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_PaymentForExtensionRoyalities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DevelopmentMilestones" xlink:href="abp-20250930.xsd#abp_DevelopmentMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_DevelopmentMilestones" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AnnualSalesMilestonePayments" xlink:href="abp-20250930.xsd#abp_AnnualSalesMilestonePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_AnnualSalesMilestonePayments" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NetProfitsFromLicensedProductSales" xlink:href="abp-20250930.xsd#abp_NetProfitsFromLicensedProductSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_NetProfitsFromLicensedProductSales" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PaymentOfDevelopmentMilestones" xlink:href="abp-20250930.xsd#abp_PaymentOfDevelopmentMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_PaymentOfDevelopmentMilestones" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedToAmount" xlink:href="abp-20250930.xsd#abp_AccruedToAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_AccruedToAmount" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents" xlink:href="abp-20250930.xsd#abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MilestonePaymentOnNetSales" xlink:href="abp-20250930.xsd#abp_MilestonePaymentOnNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_MilestonePaymentOnNetSales" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PatentCostsReimbursements" xlink:href="abp-20250930.xsd#abp_PatentCostsReimbursements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="abp_PatentCostsReimbursements" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentMilestones"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentMilestones" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherIncome" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_CommitmentsandContingenciesDetailsTable" xlink:href="abp-20250930.xsd#abp_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesACommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesACommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesACommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_PromissoryNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SettlementAgreementMember" xlink:href="abp-20250930.xsd#abp_SettlementAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_SettlementAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MSKLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_MSKLicenseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_MSKLicenseAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NonRedemptionAgreementsMember" xlink:href="abp-20250930.xsd#abp_NonRedemptionAgreementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_NonRedemptionAgreementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_VendorsMember" xlink:href="abp-20250930.xsd#abp_VendorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="abp_VendorsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CROVendorMember" xlink:href="abp-20250930.xsd#abp_CROVendorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="abp_CROVendorMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_BusinessDays" xlink:href="abp-20250930.xsd#abp_BusinessDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_BusinessDays" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_MonthlyInstallmentPayments" xlink:href="abp-20250930.xsd#abp_MonthlyInstallmentPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_MonthlyInstallmentPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AdditionalAccruedInterest" xlink:href="abp-20250930.xsd#abp_AdditionalAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_AdditionalAccruedInterest" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SettlementLiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_GainLossOnContractTermination" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProfessionalFees" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DemandDepositAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DemandDepositAccounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DemandDepositAccounts" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsTotalCostToInvestors"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ExciseTaxLiability" xlink:href="abp-20250930.xsd#abp_ExciseTaxLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_ExciseTaxLiability" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage" xlink:href="abp-20250930.xsd#abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfUnderpaymentPenaltyPerMonth" xlink:href="abp-20250930.xsd#abp_PercentageOfUnderpaymentPenaltyPerMonth"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_PercentageOfUnderpaymentPenaltyPerMonth" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfLiabilityTotal" xlink:href="abp-20250930.xsd#abp_PercentageOfLiabilityTotal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_PercentageOfLiabilityTotal" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExciseAndSalesTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExciseAndSalesTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ExciseAndSalesTaxes" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncomeTaxExaminationInterestExpense" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ExcessTaxes" xlink:href="abp-20250930.xsd#abp_ExcessTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_ExcessTaxes" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyExcessExpenseReimbursable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PaymentOfRentAndMaintenanceExpense" xlink:href="abp-20250930.xsd#abp_PaymentOfRentAndMaintenanceExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="abp_PaymentOfRentAndMaintenanceExpense" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForFees" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettlementAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SettlementAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SettlementAssetsCurrent" order="33" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ForwardPurchaseAgreementDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquityLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementDetailsTable" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="abp_ForwardPurchaseAgreementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ForwardPurchaseAgreementDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ForwardPurchaseAgreementDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ForwardPurchaseAgreementDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ForwardPurchaseAgreementDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="abp_ForwardPurchaseAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_ContractTerminationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquityShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquityShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquityShares" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_PrepaidRoyalties" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_GainLossOnContractTermination" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DerivativeChangeInFairValue" xlink:href="abp-20250930.xsd#abp_DerivativeChangeInFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="abp_DerivativeChangeInFairValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardContractInitialResetPricePerShare" xlink:href="abp-20250930.xsd#abp_ForwardContractInitialResetPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="abp_ForwardContractInitialResetPricePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardContractBaseResetPricePerShare" xlink:href="abp-20250930.xsd#abp_ForwardContractBaseResetPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="abp_ForwardContractBaseResetPricePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" xlink:href="abp-20250930.xsd#abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_VolumeWeightedAveragePrice" xlink:href="abp-20250930.xsd#abp_VolumeWeightedAveragePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="abp_VolumeWeightedAveragePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" xlink:href="abp-20250930.xsd#abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_EarlyTerminationResetPricePerShare" xlink:href="abp-20250930.xsd#abp_EarlyTerminationResetPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="abp_EarlyTerminationResetPricePerShare" order="13" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/NotesPayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_NotesPayableDetailsTable" xlink:href="abp-20250930.xsd#abp_NotesPayableDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abp_NotesPayableDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_NotesPayableDetailsTable" xlink:to="srt_RestatementAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_WarrantsExercisableDateAxis" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_NotesPayableDetailsTable" xlink:to="abp_WarrantsExercisableDateAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_WarrantsExercisableDateDomainDomain" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableDateDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="abp_WarrantsExercisableDateAxis" xlink:to="abp_WarrantsExercisableDateDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_WarrantsExercisableDateDomainDomain_0" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableDateDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="abp_WarrantsExercisableDateAxis" xlink:to="abp_WarrantsExercisableDateDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_NotesPayableDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_NotesPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DebtInstrumentInterestRateTermAxis" xlink:href="abp-20250930.xsd#abp_DebtInstrumentInterestRateTermAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_NotesPayableDetailsTable" xlink:to="abp_DebtInstrumentInterestRateTermAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DebtInstrumentInterestRateTermDomainDomain" xlink:href="abp-20250930.xsd#abp_DebtInstrumentInterestRateTermDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="abp_DebtInstrumentInterestRateTermAxis" xlink:to="abp_DebtInstrumentInterestRateTermDomainDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DebtInstrumentInterestRateTermDomainDomain_0" xlink:href="abp-20250930.xsd#abp_DebtInstrumentInterestRateTermDomainDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="abp_DebtInstrumentInterestRateTermAxis" xlink:to="abp_DebtInstrumentInterestRateTermDomainDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_NotesPayableDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_NotesPayableDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_NotesPayableDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceDateOfWarrantsMember" xlink:href="abp-20250930.xsd#abp_IssuanceDateOfWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_WarrantsExercisableDateDomainDomain" xlink:to="abp_IssuanceDateOfWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:href="abp-20250930.xsd#abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_WarrantsExercisableDateDomainDomain" xlink:to="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:href="abp-20250930.xsd#abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_WarrantsExercisableDateDomainDomain" xlink:to="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_FundingDateToMaturityDateMember" xlink:href="abp-20250930.xsd#abp_FundingDateToMaturityDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_DebtInstrumentInterestRateTermDomainDomain" xlink:to="abp_FundingDateToMaturityDateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AfterMaturityDateMember" xlink:href="abp-20250930.xsd#abp_AfterMaturityDateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_DebtInstrumentInterestRateTermDomainDomain" xlink:to="abp_AfterMaturityDateMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AbproBioInternationalIncMember" xlink:href="abp-20250930.xsd#abp_AbproBioInternationalIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_AbproBioInternationalIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ExecutiveOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_DirectorMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ExecutiveMember" xlink:href="abp-20250930.xsd#abp_ExecutiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_ExecutiveMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NotePayableMember" xlink:href="abp-20250930.xsd#abp_NotePayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_NotePayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteWithABIMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteWithABIMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_PromissoryNoteWithABIMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_YearTwoThousandTwentyFourABIPromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNotesWithExecutiveAndDirectorMember" xlink:href="abp-20250930.xsd#abp_PromissoryNotesWithExecutiveAndDirectorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_PromissoryNotesWithExecutiveAndDirectorMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteWithACABExecutiveMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteWithACABExecutiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_PromissoryNoteWithACABExecutiveMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaidNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement" xlink:href="abp-20250930.xsd#abp_ConversionOfConsiderationUnderPromissoryNoteAgreement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Cash" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_IncentiveSharesReceivedBySubsidiary" xlink:href="abp-20250930.xsd#abp_IncentiveSharesReceivedBySubsidiary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abp_IncentiveSharesReceivedBySubsidiary" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AdditionalInterestExpense" xlink:href="abp-20250930.xsd#abp_AdditionalInterestExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="abp_AdditionalInterestExpense" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRepaidPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepaidPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepaidPrincipal" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="26" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="abp_StandbyEquityPurchaseAgreementLineItems" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_StandbyEquityPurchaseAgreementDetailsTable" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_StandbyEquityPurchaseAgreementDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StandbyEquityPurchaseAgreementDetailsTable" xlink:to="srt_RangeAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ExchangeCapEventMember" xlink:href="abp-20250930.xsd#abp_ExchangeCapEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_ExchangeCapEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAMember" xlink:href="abp-20250930.xsd#abp_SEPAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_SEPAMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_YAIIPNLtdMember" xlink:href="abp-20250930.xsd#abp_YAIIPNLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_YAIIPNLtdMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_FirstConvertibleNoteMember" xlink:href="abp-20250930.xsd#abp_FirstConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="abp_FirstConvertibleNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SecondConvertibleNoteMember" xlink:href="abp-20250930.xsd#abp_SecondConvertibleNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="abp_SecondConvertibleNoteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_ConvertibleNotesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_ConvertibleNotesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertiblePromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_ConvertiblePromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_ConvertiblePromissoryNoteMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_FloorPriceEventMember" xlink:href="abp-20250930.xsd#abp_FloorPriceEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_FloorPriceEventMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_RegistrationEventMember" xlink:href="abp-20250930.xsd#abp_RegistrationEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_RegistrationEventMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ExcessOfCommonStockPercentage" xlink:href="abp-20250930.xsd#abp_ExcessOfCommonStockPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_ExcessOfCommonStockPercentage" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_ConvertibleDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfVolumeWeightedAveragePrice" xlink:href="abp-20250930.xsd#abp_PercentageOfVolumeWeightedAveragePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_PercentageOfVolumeWeightedAveragePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleThresholdConsecutiveTradingDays" xlink:href="abp-20250930.xsd#abp_ConvertibleThresholdConsecutiveTradingDays"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_ConvertibleThresholdConsecutiveTradingDays" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_SharePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfClosingPrice" xlink:href="abp-20250930.xsd#abp_PercentageOfClosingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_PercentageOfClosingPrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_FloorPrice" xlink:href="abp-20250930.xsd#abp_FloorPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_FloorPrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_VolumeWeightedAveragePrice" xlink:href="abp-20250930.xsd#abp_VolumeWeightedAveragePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_VolumeWeightedAveragePrice" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfCommonStock" xlink:href="abp-20250930.xsd#abp_PercentageOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_PercentageOfCommonStock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfAmortizationPrincipalAmount" xlink:href="abp-20250930.xsd#abp_PercentageOfAmortizationPrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_PercentageOfAmortizationPrincipalAmount" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueEmbeddedDerivativeLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_ChangeInFairValueEmbeddedDerivativeLiability" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_OtherExpenses" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromPreviousAcquisition"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfCommonStockOutstanding" xlink:href="abp-20250930.xsd#abp_PercentageOfCommonStockOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_PercentageOfCommonStockOutstanding" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfAdvanceNotice" xlink:href="abp-20250930.xsd#abp_PercentageOfAdvanceNotice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_PercentageOfAdvanceNotice" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeAverageFloorPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAverageFloorPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DerivativeAverageFloorPrice" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" order="32" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_StockholdersEquityDetailsTable" xlink:href="abp-20250930.xsd#abp_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abp_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StockholdersEquityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesACommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesACommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="abp_SeriesACommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_LegacyAbproCommonStockWarrantsMember" xlink:href="abp-20250930.xsd#abp_LegacyAbproCommonStockWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_LegacyAbproCommonStockWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_RedemptionTriggerMember" xlink:href="abp-20250930.xsd#abp_RedemptionTriggerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="abp_RedemptionTriggerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PublicWarrantsMember" xlink:href="abp-20250930.xsd#abp_PublicWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abp_PublicWarrantsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PrivatePlacementWarrantsMember" xlink:href="abp-20250930.xsd#abp_PrivatePlacementWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abp_PrivatePlacementWarrantsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ExecutiveWarrantsMember" xlink:href="abp-20250930.xsd#abp_ExecutiveWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="abp_ExecutiveWarrantsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_WarrantsExercisableTerm" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abp_WarrantsExercisableTerm" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:href="abp-20250930.xsd#abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" xlink:href="abp-20250930.xsd#abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:href="abp-20250930.xsd#abp_NumberOfTradingDaysForDeterminingTheSharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abp_NumberOfTradingDaysForDeterminingTheSharePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PeriodAfterWhichTheWarrantsAreExercisable" xlink:href="abp-20250930.xsd#abp_PeriodAfterWhichTheWarrantsAreExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abp_PeriodAfterWhichTheWarrantsAreExercisable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PerShareRedemptionsTriggerPrice" xlink:href="abp-20250930.xsd#abp_PerShareRedemptionsTriggerPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abp_PerShareRedemptionsTriggerPrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfMarketValueAndNewlyIssuedPrice" xlink:href="abp-20250930.xsd#abp_PercentageOfMarketValueAndNewlyIssuedPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abp_PercentageOfMarketValueAndNewlyIssuedPrice" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_DesignatedShares" xlink:href="abp-20250930.xsd#abp_DesignatedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="abp_DesignatedShares" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="25" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_ShareBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_TwoZeroTwoFourEquityIncentivePlanMember" xlink:href="abp-20250930.xsd#abp_TwoZeroTwoFourEquityIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abp_TwoZeroTwoFourEquityIncentivePlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_TwoZeroOneFourStockIncentivePlanMember" xlink:href="abp-20250930.xsd#abp_TwoZeroOneFourStockIncentivePlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="abp_TwoZeroOneFourStockIncentivePlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfCommonStock" xlink:href="abp-20250930.xsd#abp_PercentageOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_PercentageOfCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/RelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_RelatedPartiesDetailsTable" xlink:href="abp-20250930.xsd#abp_RelatedPartiesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abp_RelatedPartiesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_RelatedPartiesDetailsTable" xlink:to="srt_RangeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_RelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_RelatedPartiesDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_RelatedPartiesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_RelatedPartiesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_RelatedPartiesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_ExecutiveMember" xlink:href="abp-20250930.xsd#abp_ExecutiveMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="abp_ExecutiveMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_SeparatePromissoryNoteAgreementMember" xlink:href="abp-20250930.xsd#abp_SeparatePromissoryNoteAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_SeparatePromissoryNoteAgreementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_NewConsultingAgreementMember" xlink:href="abp-20250930.xsd#abp_NewConsultingAgreementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="abp_NewConsultingAgreementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_PromissoryNoteMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_UnpaidAmount" xlink:href="abp-20250930.xsd#abp_UnpaidAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abp_UnpaidAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SeveranceCosts1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForMergerRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsForMergerRelatedCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AnnualBaseFee" xlink:href="abp-20250930.xsd#abp_AnnualBaseFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="abp_AnnualBaseFee" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_SubsequentEventsDetailsTable" xlink:href="abp-20250930.xsd#abp_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="abp_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain_0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_RothCapitalPartnersMember" xlink:href="abp-20250930.xsd#abp_RothCapitalPartnersMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="abp_RothCapitalPartnersMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_AdvanceNoticeToYAMember" xlink:href="abp-20250930.xsd#abp_AdvanceNoticeToYAMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="abp_AdvanceNoticeToYAMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceOfSharesPercentage" xlink:href="abp-20250930.xsd#abp_IssuanceOfSharesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="abp_IssuanceOfSharesPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_LeasesDetailsTable" xlink:href="abp-20250930.xsd#abp_LeasesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="abp_LeasesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_LeasesDetailsTable" xlink:to="us-gaap_PledgingPurposeAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_LetterOfCreditMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_InterestBearingLiabilitiesAverageRatePaid" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_InterestBearingLiabilitiesAverageRatePaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="srt_InterestBearingLiabilitiesAverageRatePaid" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_LetterOfCreditExtendedPeriod" xlink:href="abp-20250930.xsd#abp_LetterOfCreditExtendedPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="abp_LetterOfCreditExtendedPeriod" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://www.abpro.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <loc xlink:type="locator" xlink:label="abp_IncomeTaxesDetailsTable" xlink:href="abp-20250930.xsd#abp_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="abp_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="abp_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_TaxYear2037Member" xlink:href="abp-20250930.xsd#abp_TaxYear2037Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="abp_TaxYear2037Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_PostApportionedMassachusettsMember" xlink:href="abp-20250930.xsd#abp_PostApportionedMassachusettsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="abp_PostApportionedMassachusettsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationDeductions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationDeductions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_CarryforwardsTerm" xlink:href="abp-20250930.xsd#abp_CarryforwardsTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="abp_CarryforwardsTerm" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="abp_FederalAndStateResearchAndDevelopmentCredits" xlink:href="abp-20250930.xsd#abp_FederalAndStateResearchAndDevelopmentCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="abp_FederalAndStateResearchAndDevelopmentCredits" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeDescriptionOfTermDomain"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UsefulLifeDescriptionOfTermDomain" xlink:to="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
<!-- [WMV6][yMi2alsa1tuNXTi/dOcLgQd9T0E2FNmb8SfbzvSJKkyIreFxBGBKfJ3Up3IZmpvRfrjXLnpFxqYBrqhc7SG1L0g5vFzWqxFgL/mYxV7faKw9liNHBowdQHfEAb0ojSeMpzqwx7M227OHjTvppLIVuyfnvEvrJjp7vzbcMgtXQ6OPlQTVgPUCcS3Rq7B66uw8GftJT0lewIBAHXI9EQUjr7vZAoXCV4e+TGote9f6yaoe03LZ4gYViKpoYmHHneElzz13vhk8SZTXZwUl85vEk0V4XkoquzHc5IAZg5FR6pkOmYdK2hihErccqDVsHBRehcTzZsyYsL+fgNGefIrah80TCXOWmn4ehA==] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ChiefExecutiveOfficerMember" order="1" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>29
<FILENAME>abp-20250930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 28 18:01:32 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related and Nonrelated Parties [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Abpro Holdings, Inc.&#8217;s stockholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total stockholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2" xml:lang="en-US">Total stockholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAxis_lbl" xml:lang="en-US">Revision of Prior Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (expense) income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProfitLoss_lbl2" xml:lang="en-US">Net losses amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonShares_lbl1" xml:lang="en-US">Treasury stock, shares cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash and restricted cash - beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0" xml:lang="en-US">Cash and restricted cash - end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1" xml:lang="en-US">Total cash and restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US">Total cash and restricted cash as presented in the balance sheet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization and Description of the Business [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Merger [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl" xml:lang="en-US">Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Schedule of Accrued Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Total accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Measurements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Fair value, Begining balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl0" xml:lang="en-US">Fair value, Ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralizedAgreementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralizedAgreementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollateralizedAgreementsAbstract_lbl" xml:lang="en-US">License and Collaboration Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollateralizedAgreementsAbstract" xlink:to="us-gaap_CollateralizedAgreementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsAbstract_lbl" xml:lang="en-US">Commitments Under Research and Collaboration Agreements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAbstract" xlink:to="us-gaap_OtherCommitmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Forward Purchase Agreement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Notes Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_StandbyEquityPurchaseAgreementAbstract" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StandbyEquityPurchaseAgreementAbstract_lbl" xml:lang="en-US">Standby Equity Purchase Agreement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StandbyEquityPurchaseAgreementAbstract" xlink:to="abp_StandbyEquityPurchaseAgreementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Compensation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_lbl" xml:lang="en-US">Schedule of Company&#8217;s Stock Option Activity [Absstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of stock options, outstanding balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Granted and outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Number of shares, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee Benefit Plan [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Parties [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Schedule of Consolidated Statements of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesAxis_lbl" xml:lang="en-US">Consolidated Entities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="srt_ConsolidatedEntitiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Schedule of Lease Expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Schedule of Future Minimum Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Outstanding as of December 31, 2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Outstanding as of December 31, 2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US">Warrants, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl2" xml:lang="en-US">Warrants exercisable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl3" xml:lang="en-US">Number of warrant shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl3"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl" xml:lang="en-US">Schedule of Warrants to Purchase Common Stock Outstanding [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsNoteDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl" xml:lang="en-US">Schedule of Income / (Loss) Before Provision [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before Income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Net loss before tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ForwardPurchaseAgreementAsset_lbl" xml:lang="en-US">Forward purchase agreement asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreementAsset" xlink:to="abp_ForwardPurchaseAgreementAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use asset - operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PatentsNet" xlink:href="abp-20250930.xsd#abp_PatentsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PatentsNet_lbl" xml:lang="en-US">Patents, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PatentsNet" xlink:to="abp_PatentsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAPutRightsAsset" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SEPAPutRightsAsset_lbl" xml:lang="en-US">SEPA put rights asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPAPutRightsAsset" xlink:to="abp_SEPAPutRightsAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and stockholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xml:lang="en-US">Excise taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl0" xml:lang="en-US">Excise tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl1" xml:lang="en-US">Excise tax payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Less: current maturities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl0" xml:lang="en-US">Income tax payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl1" xml:lang="en-US">Income tax payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable &#8211; related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleNotes" xlink:href="abp-20250930.xsd#abp_ConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConvertibleNotes_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleNotes" xlink:to="abp_ConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xml:lang="en-US">Embedded derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies (Note 8)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; deficit:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred stock, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred Stock, Shares Outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common stock par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common stock, shares authorized (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Issued shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Total shares of common stock outstanding immediately after Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common stock shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MinorityInterest_lbl" xml:lang="en-US">Non-controlling interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred offering cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:href="abp-20250930.xsd#abp_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract_lbl" xml:lang="en-US">Liabilities, convertible preferred stock and stockholders&#8217; deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="abp_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease liability, current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Obligations under lease liability, noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Liabilities_lbl1" xml:lang="en-US">Liabilities (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl" xml:lang="en-US">Convertible preferred stock, $0.001 par value, issuable in series:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xml:lang="en-US">Convertible preferred stock, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Convertible Preferred Stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Convertible Preferred Stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xml:lang="en-US">Convertible Preferred Stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US">Liquidation preference (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_RevenueAbstract" xlink:href="abp-20250930.xsd#abp_RevenueAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_RevenueAbstract_lbl" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RevenueAbstract" xlink:to="abp_RevenueAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other (expense) income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfForwardPuchaseAgreementAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset_lbl" xml:lang="en-US">Change in fair value of forward purchase agreement asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset" xlink:to="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfSEPAPutRightsAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfSEPAPutRightsAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ChangeInFairValueOfSEPAPutRightsAsset_lbl" xml:lang="en-US">Change in fair value of SEPA put rights asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfSEPAPutRightsAsset" xlink:to="abp_ChangeInFairValueOfSEPAPutRightsAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfEmbeddedDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ChangeInFairValueOfEmbeddedDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of embedded derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfEmbeddedDerivativeLiability" xlink:to="abp_ChangeInFairValueOfEmbeddedDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share, basic (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Net loss per share, diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted averages shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares outstanding - basic (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares outstanding - diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">Revenue:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl" xml:lang="en-US">Gain on extinguishment of accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0" xml:lang="en-US">Gain on extinguishment of accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl" xml:lang="en-US">Net loss attributable to common stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Common stock issued for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued to related party lender</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon conversion of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Common stock issued upon conversion of convertible notes (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Advance Shares, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Aggregate net purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Aggregate purchase price of newly issued shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2" xml:lang="en-US">Fair value of shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl3" xml:lang="en-US">Aggregate purchase price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl3"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Advance Shares, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Purchase of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Additional shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2" xml:lang="en-US">Shares of common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl3" xml:lang="en-US">Aggregate of shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl3"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl" xml:lang="en-US">Cancellation of Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl" xml:lang="en-US">Cancellation of Treasury Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl0" xml:lang="en-US">Cancellation of Treasury Stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of restricted stock units (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:href="abp-20250930.xsd#abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl" xml:lang="en-US">The Merger, net of transaction costs and acquired liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:to="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:href="abp-20250930.xsd#abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl" xml:lang="en-US">The Merger, net of transaction costs and acquired liabilities (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:to="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceOfCommonStockInThePIPEFinancing" xlink:href="abp-20250930.xsd#abp_IssuanceOfCommonStockInThePIPEFinancing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_IssuanceOfCommonStockInThePIPEFinancing_lbl" xml:lang="en-US">Issuance of common stock in the PIPE Financing, net of transaction costs of $863,474</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfCommonStockInThePIPEFinancing" xlink:to="abp_IssuanceOfCommonStockInThePIPEFinancing_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceOfCommonStockInPIPEFinancing" xlink:href="abp-20250930.xsd#abp_IssuanceOfCommonStockInPIPEFinancing"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_IssuanceOfCommonStockInPIPEFinancing_lbl" xml:lang="en-US">Issuance of common stock in the PIPE Financing, net of transaction costs of $863,474 (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfCommonStockInPIPEFinancing" xlink:to="abp_IssuanceOfCommonStockInPIPEFinancing_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceOfCommonStockInTransactionCost" xlink:href="abp-20250930.xsd#abp_IssuanceOfCommonStockInTransactionCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_IssuanceOfCommonStockInTransactionCost_lbl" xml:lang="en-US">Issuance of common stock in transaction costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfCommonStockInTransactionCost" xlink:to="abp_IssuanceOfCommonStockInTransactionCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">SEPA commitment fee paid in shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">SEPA commitment fee paid in shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Non-cash interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_LossOnSettlementsOfConvertibleNotes" xlink:href="abp-20250930.xsd#abp_LossOnSettlementsOfConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_LossOnSettlementsOfConvertibleNotes_lbl" xml:lang="en-US">Loss on settlement of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LossOnSettlementsOfConvertibleNotes" xlink:to="abp_LossOnSettlementsOfConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of debt discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl" xml:lang="en-US">Income taxes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sales of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows from Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from settlement of Forward Purchase Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Cash received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from issuances of debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl0" xml:lang="en-US">Net convertible note discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of Note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl1" xml:lang="en-US">Proceeds from financing (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl2" xml:lang="en-US">Received from promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Issuance of Advance Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information and non-cash transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" xlink:href="abp-20250930.xsd#abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses_lbl" xml:lang="en-US">Issuance costs for Advance Shares included in accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" xlink:to="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl" xml:lang="en-US">Fair value of common stock issued for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability_lbl" xml:lang="en-US">Common stock issued in settlement of convertible notes and embedded derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" xlink:to="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_DeferredOfferingCostsIncludedInAccountsPayable" xlink:href="abp-20250930.xsd#abp_DeferredOfferingCostsIncludedInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_DeferredOfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Deferred offering costs included in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeferredOfferingCostsIncludedInAccountsPayable" xlink:to="abp_DeferredOfferingCostsIncludedInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" xlink:href="abp-20250930.xsd#abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense_lbl" xml:lang="en-US">Reclassification of residual value guarantees under finance lease to accrued expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" xlink:to="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl" xml:lang="en-US">As reported within the unaudited condensed consolidated balance sheets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl0" xml:lang="en-US">As reported within consolidated balance sheets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NetProceedsFromTheMerger" xlink:href="abp-20250930.xsd#abp_NetProceedsFromTheMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NetProceedsFromTheMerger_lbl" xml:lang="en-US">Net proceeds from the Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NetProceedsFromTheMerger" xlink:to="abp_NetProceedsFromTheMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Net proceeds from PIPE financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl" xml:lang="en-US">Proceeds from issuance of notes payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl0" xml:lang="en-US">Received from promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl1" xml:lang="en-US">Executive to receive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from issuance of Convertible Notes, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_OfferingCostsIncludedInAccountsPayable" xlink:href="abp-20250930.xsd#abp_OfferingCostsIncludedInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_OfferingCostsIncludedInAccountsPayable_lbl" xml:lang="en-US">Offering costs included in accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OfferingCostsIncludedInAccountsPayable" xlink:to="abp_OfferingCostsIncludedInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties" xlink:href="abp-20250930.xsd#abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties_lbl" xml:lang="en-US">Settlement of bonus accrual through notes payable - related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties" xlink:to="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ACABLiabilitiesAssumedInTheMerger" xlink:href="abp-20250930.xsd#abp_ACABLiabilitiesAssumedInTheMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ACABLiabilitiesAssumedInTheMerger_lbl" xml:lang="en-US">ACAB liabilities assumed in the Merger, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ACABLiabilitiesAssumedInTheMerger" xlink:to="abp_ACABLiabilitiesAssumedInTheMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" xlink:href="abp-20250930.xsd#abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro_lbl" xml:lang="en-US">Conversion of notes payable-related parties into common stock of New Abpro</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" xlink:to="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" xlink:href="abp-20250930.xsd#abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro_lbl" xml:lang="en-US">Conversion of pre-merger preferred stock of Abpro into common stock of New Abpro</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" xlink:to="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SEPACommitmentFeePaidInCommonStockShares" xlink:href="abp-20250930.xsd#abp_SEPACommitmentFeePaidInCommonStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SEPACommitmentFeePaidInCommonStockShares_lbl" xml:lang="en-US">SEPA commitment fee paid in common stock shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPACommitmentFeePaidInCommonStockShares" xlink:to="abp_SEPACommitmentFeePaidInCommonStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockCommonValue_lbl" xml:lang="en-US">Treasury stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_LossOnSettlementOfConvertibleNotes" xlink:href="abp-20250930.xsd#abp_LossOnSettlementOfConvertibleNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abp_LossOnSettlementOfConvertibleNotes_lbl" xml:lang="en-US">Loss on settlement of convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LossOnSettlementOfConvertibleNotes" xlink:to="abp_LossOnSettlementOfConvertibleNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_DeemedDividendResultingFromTheWarrantDownRound" xlink:href="abp-20250930.xsd#abp_DeemedDividendResultingFromTheWarrantDownRound"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abp_DeemedDividendResultingFromTheWarrantDownRound_lbl" xml:lang="en-US">Deemed dividend resulting from the warrant down round</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeemedDividendResultingFromTheWarrantDownRound" xlink:to="abp_DeemedDividendResultingFromTheWarrantDownRound_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherIncome_lbl" xml:lang="en-US">Other income (see Note 2)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncome_lbl0" xml:lang="en-US">Other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfForwardPurchaseAgreementAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset_lbl" xml:lang="en-US">Change in fair value of forward purchase agreement asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset" xlink:to="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOfSEPAPutRightAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfSEPAPutRightAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abp_ChangeInFairValueOfSEPAPutRightAsset_lbl" xml:lang="en-US">Change in fair value of SEPA put rights asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfSEPAPutRightAsset" xlink:to="abp_ChangeInFairValueOfSEPAPutRightAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueOnEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOnEmbeddedDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abp_ChangeInFairValueOnEmbeddedDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of embedded derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOnEmbeddedDerivativeLiability" xlink:to="abp_ChangeInFairValueOnEmbeddedDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payments on Note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl0" xml:lang="en-US">Repay promissory note (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl1" xml:lang="en-US">Repayment of note payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payment of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Repayment of finance lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables_lbl" xml:lang="en-US">Note receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CashTransferredToEscrow" xlink:href="abp-20250930.xsd#abp_CashTransferredToEscrow"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abp_CashTransferredToEscrow_lbl" xml:lang="en-US">Cash transferred into escrow pursuant to Forward Purchase Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CashTransferredToEscrow" xlink:to="abp_CashTransferredToEscrow_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl" xml:lang="en-US">Payment of notes payable - related party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl" xml:lang="en-US">Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyMember_lbl0" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xml:lang="en-US">Previously Reported</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl0" xml:lang="en-US">As previously reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl1" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesFConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesFConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SeriesFConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series F Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesFConvertiblePreferredStockMember" xlink:to="abp_SeriesFConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesEConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesEConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SeriesEConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series E Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesEConvertiblePreferredStockMember" xlink:to="abp_SeriesEConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesDConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesDConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series D Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesDConvertiblePreferredStockMember" xlink:to="abp_SeriesDConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesCConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesCConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesCConvertiblePreferredStockMember" xlink:to="abp_SeriesCConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesBConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesBConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesBConvertiblePreferredStockMember" xlink:to="abp_SeriesBConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesARedeemableConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesARedeemableConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SeriesARedeemableConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Redeemable, Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="abp_SeriesARedeemableConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ResearchAndDevelopmentServicesMember" xlink:href="abp-20250930.xsd#abp_ResearchAndDevelopmentServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ResearchAndDevelopmentServicesMember_lbl" xml:lang="en-US">Research and development services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ResearchAndDevelopmentServicesMember" xlink:to="abp_ResearchAndDevelopmentServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CollaborationRevenueMember" xlink:href="abp-20250930.xsd#abp_CollaborationRevenueMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_CollaborationRevenueMember_lbl" xml:lang="en-US">Collaboration revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CollaborationRevenueMember" xlink:to="abp_CollaborationRevenueMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyMember_lbl" xml:lang="en-US">Royalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Redeemable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertiblePreferredStocksMember" xlink:href="abp-20250930.xsd#abp_ConvertiblePreferredStocksMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConvertiblePreferredStocksMember_lbl" xml:lang="en-US">Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertiblePreferredStocksMember" xlink:to="abp_ConvertiblePreferredStocksMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xml:lang="en-US">Series B</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl" xml:lang="en-US">Series C</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl" xml:lang="en-US">Series D</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl" xml:lang="en-US">Series E</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl" xml:lang="en-US">Series F</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockCommonMember_lbl" xml:lang="en-US">Treasury Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-In Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ParentMember_lbl" xml:lang="en-US">Total Abpro&#8217;s Stockholders&#8217; Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncontrollingInterestMember_lbl" xml:lang="en-US">Non-controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization and Description of the Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0" xml:lang="en-US">Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Dilutive shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Common stockholders, anti-dilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl" xml:lang="en-US">Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of Common Stock Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued salaries and wages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedLicenseFees" xlink:href="abp-20250930.xsd#abp_AccruedLicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AccruedLicenseFees_lbl" xml:lang="en-US">Accrued license fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedLicenseFees" xlink:to="abp_AccruedLicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedInterest" xlink:href="abp-20250930.xsd#abp_AccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedInterest" xlink:to="abp_AccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedBODCompensation" xlink:href="abp-20250930.xsd#abp_AccruedBODCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AccruedBODCompensation_lbl" xml:lang="en-US">Board of Directors compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedBODCompensation" xlink:to="abp_AccruedBODCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_AccruedBODCompensation_lbl0" xml:lang="en-US">BOD compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedBODCompensation" xlink:to="abp_AccruedBODCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl" xml:lang="en-US">Assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Fair value measured assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl0" xml:lang="en-US">Fair value measured Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl1" xml:lang="en-US">Asset fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl" xml:lang="en-US">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value measured liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Fair value measured Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Fair value input assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl0" xml:lang="en-US">Fair value of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xml:lang="en-US">Initial measurement at the issuance date (see Note 11)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl0" xml:lang="en-US">Initial measurement at the issuance date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xml:lang="en-US">License and Collaboration Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl" xml:lang="en-US">Commitments under Research and Collaboration Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl" xml:lang="en-US">Forward Purchase Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_StandbyEquityPurchaseAgreementTextBlock" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_StandbyEquityPurchaseAgreementTextBlock_lbl" xml:lang="en-US">Standby Equity Purchase Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StandbyEquityPurchaseAgreementTextBlock" xlink:to="abp_StandbyEquityPurchaseAgreementTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Warrants to Purchase Common Stock Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants, Weighted-Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Exercise price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Warrants exercisable, price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2" xml:lang="en-US">Number of exercise price of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants, Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0" xml:lang="en-US">Warrants, Weighted- Average Remaining Contractual Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average remaining contractual life, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Contractual term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of stock options, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of stock options, exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life, exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, forfeited/expired/cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life, forfeited/expired/cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of stock options, exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price, exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-average remaining contractual life, exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Company&#8217;s Restricted Stock Unit Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted-average remaining vesting period, outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of shares, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="abp-20250930.xsd#abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Vesting Period, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="abp-20250930.xsd#abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Vesting Period, vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted-average grant date fair value, Forfeited/Expired/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Weighted-average grant date fair value, forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="abp-20250930.xsd#abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Vesting Period, Forfeited/Expired/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Recorded Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Stock compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl" xml:lang="en-US">Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl" xml:lang="en-US">Schedule of Consolidated Statements of Cash Flows</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:href="abp-20250930.xsd#abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US">Schedule of Depreciation on Property and Equipment Estimated Useful Lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl" xml:lang="en-US">Schedule of Balance Sheet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl" xml:lang="en-US">Fair value input assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl" xml:lang="en-US">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0" xml:lang="en-US">Change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Lease Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl" xml:lang="en-US">Finance lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of ROU assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Financing cash flows from finance leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_WeightedAverageRemainingLeaseTermInYearsAbstract" xlink:href="abp-20250930.xsd#abp_WeightedAverageRemainingLeaseTermInYearsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_WeightedAverageRemainingLeaseTermInYearsAbstract_lbl" xml:lang="en-US">Weighted-average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WeightedAverageRemainingLeaseTermInYearsAbstract" xlink:to="abp_WeightedAverageRemainingLeaseTermInYearsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating leases, Weighted-average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance leases, Weighted-average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_WeightedAverageDiscountRateAbstract" xlink:href="abp-20250930.xsd#abp_WeightedAverageDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_WeightedAverageDiscountRateAbstract_lbl" xml:lang="en-US">Weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WeightedAverageDiscountRateAbstract" xlink:to="abp_WeightedAverageDiscountRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating leases, Weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance leases, Weighted-average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ExpiredAtTheMerger" xlink:href="abp-20250930.xsd#abp_ExpiredAtTheMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ExpiredAtTheMerger_lbl" xml:lang="en-US">Expired at the Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExpiredAtTheMerger" xlink:to="abp_ExpiredAtTheMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger" xlink:href="abp-20250930.xsd#abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger_lbl" xml:lang="en-US">Common stock warrants of ACAB acquired in Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger" xlink:to="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Risk-free rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1" xml:lang="en-US">Expected life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl2" xml:lang="en-US">Expected term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl2"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Volatility rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xml:lang="en-US">Number of shares, forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0" xml:lang="en-US">Number of shares, Forfeited/Expired/Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl" xml:lang="en-US">Schedule of Income / (Loss) Before Provision</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl" xml:lang="en-US">Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory U.S. federal tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">New U.S. federal excise tax percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1" xml:lang="en-US">U.S. statutory federal income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Tax computed at federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State income taxes, net of federal benefit and tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" xlink:href="abp-20250930.xsd#abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit_lbl" xml:lang="en-US">Federal research and development credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" xlink:to="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Net Deferred Tax Assets and Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Capitalized research expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Capitalized research and development costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_DeferredTaxAssetsLeaseLiability" xlink:href="abp-20250930.xsd#abp_DeferredTaxAssetsLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_DeferredTaxAssetsLeaseLiability_lbl" xml:lang="en-US">Lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeferredTaxAssetsLeaseLiability" xlink:to="abp_DeferredTaxAssetsLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_lbl" xml:lang="en-US">Settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of stock options, forfeited/expired/cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Number of shares, vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Vested shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: Accumulated Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: amount representing interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_DeferredTaxLiabilitiesRightofuseAsset" xlink:href="abp-20250930.xsd#abp_DeferredTaxLiabilitiesRightofuseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="abp_DeferredTaxLiabilitiesRightofuseAsset_lbl" xml:lang="en-US">Right-of-use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeferredTaxLiabilitiesRightofuseAsset" xlink:to="abp_DeferredTaxLiabilitiesRightofuseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="abp_StockOptionsMember" xlink:href="abp-20250930.xsd#abp_StockOptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_StockOptionsMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockOptionsMember" xlink:to="abp_StockOptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_UnvestedRestrictedStockUnitsMember" xlink:href="abp-20250930.xsd#abp_UnvestedRestrictedStockUnitsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_UnvestedRestrictedStockUnitsMember_lbl" xml:lang="en-US">Unvested restricted stock units [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_UnvestedRestrictedStockUnitsMember" xlink:to="abp_UnvestedRestrictedStockUnitsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CommonStockOfACABNetOfRedemptionsMember" xlink:href="abp-20250930.xsd#abp_CommonStockOfACABNetOfRedemptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_CommonStockOfACABNetOfRedemptionsMember_lbl" xml:lang="en-US">Common stock of ACAB, net of redemptions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommonStockOfACABNetOfRedemptionsMember" xlink:to="abp_CommonStockOfACABNetOfRedemptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember" xlink:href="abp-20250930.xsd#abp_ACABFounderSharesLessOfForfeituresAndTransfersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember_lbl" xml:lang="en-US">ACAB Founder Shares, less of forfeitures and transfers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember" xlink:to="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedToPIPEInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToPIPEInvestorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NewAbproSharesIssuedToPIPEInvestorsMember_lbl" xml:lang="en-US">New Abpro shares issued to PIPE investors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesIssuedToPIPEInvestorsMember" xlink:to="abp_NewAbproSharesIssuedToPIPEInvestorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedToServiceProvidersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToServiceProvidersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NewAbproSharesIssuedToServiceProvidersMember_lbl" xml:lang="en-US">New Abpro shares issued to service providers [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesIssuedToServiceProvidersMember" xlink:to="abp_NewAbproSharesIssuedToServiceProvidersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember_lbl" xml:lang="en-US">New Abpro shares issued in Merger to Legacy Abpro stockholders [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" xlink:to="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesTransferredToInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesTransferredToInvestorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NewAbproSharesTransferredToInvestorsMember_lbl" xml:lang="en-US">New Abpro shares transferred to investors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesTransferredToInvestorsMember" xlink:to="abp_NewAbproSharesTransferredToInvestorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember_lbl" xml:lang="en-US">New Abpro shares issued to settle the promissory note with executive [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" xlink:to="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementAssetMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ForwardPurchaseAgreementAssetMember_lbl" xml:lang="en-US">Forward purchase agreement asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreementAssetMember" xlink:to="abp_ForwardPurchaseAgreementAssetMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_ForwardPurchaseAgreementAssetMember_lbl0" xml:lang="en-US">Forward Purchase Agreement asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreementAssetMember" xlink:to="abp_ForwardPurchaseAgreementAssetMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAPutRightsAssetMember" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAssetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SEPAPutRightsAssetMember_lbl" xml:lang="en-US">SEPA put rights asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPAPutRightsAssetMember" xlink:to="abp_SEPAPutRightsAssetMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_SEPAPutRightsAssetMember_lbl0" xml:lang="en-US">SEPA Put Rights Asset [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPAPutRightsAssetMember" xlink:to="abp_SEPAPutRightsAssetMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_EmbeddedDerivativeLiabilityMember" xlink:href="abp-20250930.xsd#abp_EmbeddedDerivativeLiabilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_EmbeddedDerivativeLiabilityMember_lbl" xml:lang="en-US">Embedded derivative liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EmbeddedDerivativeLiabilityMember" xlink:to="abp_EmbeddedDerivativeLiabilityMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_EmbeddedDerivativeLiabilityMember_lbl0" xml:lang="en-US">Embedded Derivative Liability [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EmbeddedDerivativeLiabilityMember" xlink:to="abp_EmbeddedDerivativeLiabilityMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Level [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl" xml:lang="en-US">Stock price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Risk-free interest rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Expected term (in years) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl0" xml:lang="en-US">Expected term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl1" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Expected volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Expected dividend yield [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl" xml:lang="en-US">Exercise price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl0" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_NumberOfSharesMember" xlink:href="abp-20250930.xsd#abp_NumberOfSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NumberOfSharesMember_lbl" xml:lang="en-US">Number of shares under each advance notice [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfSharesMember" xlink:to="abp_NumberOfSharesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_NumberOfSharesMember_lbl0" xml:lang="en-US">Number of shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfSharesMember" xlink:to="abp_NumberOfSharesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ForwardPurchaseAgreementMember_lbl" xml:lang="en-US">Forward Purchase Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreementMember" xlink:to="abp_ForwardPurchaseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_BlackAndScholesModelMember" xlink:href="abp-20250930.xsd#abp_BlackAndScholesModelMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_BlackAndScholesModelMember_lbl" xml:lang="en-US">Black and Scholes Model [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_BlackAndScholesModelMember" xlink:to="abp_BlackAndScholesModelMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_WarrantsToPurchaseCommonStockMember" xlink:href="abp-20250930.xsd#abp_WarrantsToPurchaseCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_WarrantsToPurchaseCommonStockMember_lbl" xml:lang="en-US">Warrants To Purchase Common Stock Outstanding [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WarrantsToPurchaseCommonStockMember" xlink:to="abp_WarrantsToPurchaseCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Unit Activity [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl0" xml:lang="en-US">RSUs [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl1" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_ConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConvertibleNotesMember_lbl" xml:lang="en-US">Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleNotesMember" xlink:to="abp_ConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AbproHoldingsIncMember" xlink:href="abp-20250930.xsd#abp_AbproHoldingsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AbproHoldingsIncMember_lbl" xml:lang="en-US">Abpro Holdings Inc [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AbproHoldingsIncMember" xlink:to="abp_AbproHoldingsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_RestatementAdjustmentMember_lbl" xml:lang="en-US">Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer hardware and software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_EquipmentUnderFinanceLeasesMember" xlink:href="abp-20250930.xsd#abp_EquipmentUnderFinanceLeasesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_EquipmentUnderFinanceLeasesMember_lbl" xml:lang="en-US">Equipment under finance leases [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EquipmentUnderFinanceLeasesMember" xlink:to="abp_EquipmentUnderFinanceLeasesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_LegacyAbproCommonStockWarrantsMember" xlink:href="abp-20250930.xsd#abp_LegacyAbproCommonStockWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_LegacyAbproCommonStockWarrantsMember_lbl" xml:lang="en-US">Legacy Abpro Common Stock Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LegacyAbproCommonStockWarrantsMember" xlink:to="abp_LegacyAbproCommonStockWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PrivateWarrantsMember" xlink:href="abp-20250930.xsd#abp_PrivateWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PrivateWarrantsMember_lbl" xml:lang="en-US">Private Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PrivateWarrantsMember" xlink:to="abp_PrivateWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PublicWarrantsMember" xlink:href="abp-20250930.xsd#abp_PublicWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PublicWarrantsMember_lbl" xml:lang="en-US">Public Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PublicWarrantsMember" xlink:to="abp_PublicWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option Valuation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringCostAndReserveAxis_lbl" xml:lang="en-US">Restructuring Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_RestructuringCostAndReserveAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl" xml:lang="en-US">Investment, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtAxis_lbl" xml:lang="en-US">Extinguishment of Debt [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl" xml:lang="en-US">Supplier [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_DebtInstrumentInterestRateTermAxis" xlink:href="abp-20250930.xsd#abp_DebtInstrumentInterestRateTermAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_DebtInstrumentInterestRateTermAxis_lbl" xml:lang="en-US">Debt Instrument, Interest Rate Term [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DebtInstrumentInterestRateTermAxis" xlink:to="abp_DebtInstrumentInterestRateTermAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_WarrantsExercisableDateAxis" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_WarrantsExercisableDateAxis_lbl" xml:lang="en-US">Warrants Exercisable Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WarrantsExercisableDateAxis" xlink:to="abp_WarrantsExercisableDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Combination [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title and Position [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PledgingPurposeAxis_lbl" xml:lang="en-US">Pledging Purpose [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US">Tax Period [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Estimated useful life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ReverseStockSplitSharesOfIssued" xlink:href="abp-20250930.xsd#abp_ReverseStockSplitSharesOfIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ReverseStockSplitSharesOfIssued_lbl" xml:lang="en-US">Shares of issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReverseStockSplitSharesOfIssued" xlink:to="abp_ReverseStockSplitSharesOfIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ReverseStockSpllitSharesOfOutstanding" xlink:href="abp-20250930.xsd#abp_ReverseStockSpllitSharesOfOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ReverseStockSpllitSharesOfOutstanding_lbl" xml:lang="en-US">Shares of outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReverseStockSpllitSharesOfOutstanding" xlink:to="abp_ReverseStockSpllitSharesOfOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SecurityBidPricePerShare" xlink:href="abp-20250930.xsd#abp_SecurityBidPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SecurityBidPricePerShare_lbl" xml:lang="en-US">Security bid price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SecurityBidPricePerShare" xlink:to="abp_SecurityBidPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Market value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayable_lbl" xml:lang="en-US">Funding amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NotesPayable_lbl0" xml:lang="en-US">Outstanding principal balances under the promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl0" xml:lang="en-US">Principal amount of promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xml:lang="en-US">Converted in common shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Number of shares, converted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Converted shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl1" xml:lang="en-US">Shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl1"/>
    <loc xlink:type="locator" xlink:label="abp_InstallmentsAmount" xlink:href="abp-20250930.xsd#abp_InstallmentsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_InstallmentsAmount_lbl" xml:lang="en-US">Installments amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_InstallmentsAmount" xlink:to="abp_InstallmentsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AccrueInterestPercentage" xlink:href="abp-20250930.xsd#abp_AccrueInterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AccrueInterestPercentage_lbl" xml:lang="en-US">Accrue interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccrueInterestPercentage" xlink:to="abp_AccrueInterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repaid balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl0" xml:lang="en-US">Repayment of amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl" xml:lang="en-US">Transaction cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl0" xml:lang="en-US">Transaction costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Issuance cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0" xml:lang="en-US">Issuance costs (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl1" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilities_lbl" xml:lang="en-US">Net liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilities_lbl0" xml:lang="en-US">Liabilities net (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LegalFees_lbl" xml:lang="en-US">Legal fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LegalFees_lbl0" xml:lang="en-US">Legal fees (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Issuance discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl0" xml:lang="en-US">Debt instrument, repayment date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreement" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ForwardPurchaseAgreement_lbl" xml:lang="en-US">Forward purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreement" xlink:to="abp_ForwardPurchaseAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue_lbl" xml:lang="en-US">Shares of forward purchase agreement (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue_lbl0" xml:lang="en-US">Seller purchased shares from third parties (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl" xml:lang="en-US">Termination obligation aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GainLossOnContractTermination_lbl0" xml:lang="en-US">Notice of termination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_EarlyTerminationResetPricePerShare" xlink:href="abp-20250930.xsd#abp_EarlyTerminationResetPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_EarlyTerminationResetPricePerShare_lbl" xml:lang="en-US">Early termination reset price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EarlyTerminationResetPricePerShare" xlink:to="abp_EarlyTerminationResetPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherReceivables_lbl" xml:lang="en-US">Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl" xml:lang="en-US">Company&#8217;s operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl" xml:lang="en-US">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Ownership interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl" xml:lang="en-US">Redemption price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Recognized income tax percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US">Unrecognized tax benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl" xml:lang="en-US">Converted into shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_AdditionSharesOfCommonStock" xlink:href="abp-20250930.xsd#abp_AdditionSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AdditionSharesOfCommonStock_lbl" xml:lang="en-US">Additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdditionSharesOfCommonStock" xlink:to="abp_AdditionSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Total consideration (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AggregatePurchasePrice" xlink:href="abp-20250930.xsd#abp_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AggregatePurchasePrice" xlink:to="abp_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AggregateIncentiveShare" xlink:href="abp-20250930.xsd#abp_AggregateIncentiveShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AggregateIncentiveShare_lbl" xml:lang="en-US">Incentive shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AggregateIncentiveShare" xlink:to="abp_AggregateIncentiveShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl" xml:lang="en-US">Forfeited number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_RemainingSharesIssued" xlink:href="abp-20250930.xsd#abp_RemainingSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_RemainingSharesIssued_lbl" xml:lang="en-US">Remaining shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RemainingSharesIssued" xlink:to="abp_RemainingSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl1" xml:lang="en-US">Accrued amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">Tax payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Income tax payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_EarnoutShare" xlink:href="abp-20250930.xsd#abp_EarnoutShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_EarnoutShare_lbl" xml:lang="en-US">Earnout shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EarnoutShare" xlink:to="abp_EarnoutShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_TradingDays" xlink:href="abp-20250930.xsd#abp_TradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_TradingDays_lbl" xml:lang="en-US">Trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TradingDays" xlink:to="abp_TradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NumberOfConsecutiveTradingDays" xlink:href="abp-20250930.xsd#abp_NumberOfConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NumberOfConsecutiveTradingDays_lbl" xml:lang="en-US">Consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfConsecutiveTradingDays" xlink:to="abp_NumberOfConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Exceeds per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl" xml:lang="en-US">Derivative feature estimated amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl0" xml:lang="en-US">Derivative of fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share price upon closing of merger (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharePrice_lbl1" xml:lang="en-US">Floor price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="abp_EstimatedFuturePricePerShare" xlink:href="abp-20250930.xsd#abp_EstimatedFuturePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_EstimatedFuturePricePerShare_lbl" xml:lang="en-US">Estimated future price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EstimatedFuturePricePerShare" xlink:to="abp_EstimatedFuturePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AgreementInitialTerm" xlink:href="abp-20250930.xsd#abp_AgreementInitialTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AgreementInitialTerm_lbl" xml:lang="en-US">Agreement initial term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AgreementInitialTerm" xlink:to="abp_AgreementInitialTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MilestonePayments" xlink:href="abp-20250930.xsd#abp_MilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MilestonePayments_lbl" xml:lang="en-US">Milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePayments" xlink:to="abp_MilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NonRefundablePayments" xlink:href="abp-20250930.xsd#abp_NonRefundablePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NonRefundablePayments_lbl" xml:lang="en-US">Aggregate non-refundable payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NonRefundablePayments" xlink:to="abp_NonRefundablePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xml:lang="en-US">Royalties amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_OriginalCelltrionAgreement" xlink:href="abp-20250930.xsd#abp_OriginalCelltrionAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_OriginalCelltrionAgreement_lbl" xml:lang="en-US">Original celltrion agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OriginalCelltrionAgreement" xlink:to="abp_OriginalCelltrionAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfOriginalCelltrionAgreement" xlink:href="abp-20250930.xsd#abp_PercentageOfOriginalCelltrionAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfOriginalCelltrionAgreement_lbl" xml:lang="en-US">Original celltrion agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfOriginalCelltrionAgreement" xlink:to="abp_PercentageOfOriginalCelltrionAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfAmendedCelltrionAgreement" xlink:href="abp-20250930.xsd#abp_PercentageOfAmendedCelltrionAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfAmendedCelltrionAgreement_lbl" xml:lang="en-US">Amended celltrion agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfAmendedCelltrionAgreement" xlink:to="abp_PercentageOfAmendedCelltrionAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfReimbursement" xlink:href="abp-20250930.xsd#abp_PercentageOfReimbursement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfReimbursement_lbl" xml:lang="en-US">Percentage of reimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfReimbursement" xlink:to="abp_PercentageOfReimbursement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xml:lang="en-US">Guaranteed annual minimum royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl" xml:lang="en-US">Royalty payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyIncomeNonoperating" xlink:to="us-gaap_RoyaltyIncomeNonoperating_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNet_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl" xml:lang="en-US">Performance obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ClinicalDevelopmentMilestones" xlink:href="abp-20250930.xsd#abp_ClinicalDevelopmentMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ClinicalDevelopmentMilestones_lbl" xml:lang="en-US">Clinical development milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ClinicalDevelopmentMilestones" xlink:to="abp_ClinicalDevelopmentMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_RegulatoryEvents" xlink:href="abp-20250930.xsd#abp_RegulatoryEvents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_RegulatoryEvents_lbl" xml:lang="en-US">Regulatory events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RegulatoryEvents" xlink:to="abp_RegulatoryEvents_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CommercialSales" xlink:href="abp-20250930.xsd#abp_CommercialSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_CommercialSales_lbl" xml:lang="en-US">Commercial sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommercialSales" xlink:to="abp_CommercialSales_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MilestonePaymentsCommercialMilestones" xlink:href="abp-20250930.xsd#abp_MilestonePaymentsCommercialMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MilestonePaymentsCommercialMilestones_lbl" xml:lang="en-US">Milestone payments commercial milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePaymentsCommercialMilestones" xlink:to="abp_MilestonePaymentsCommercialMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PaymentForExtensionRoyalities" xlink:href="abp-20250930.xsd#abp_PaymentForExtensionRoyalities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PaymentForExtensionRoyalities_lbl" xml:lang="en-US">Extension royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PaymentForExtensionRoyalities" xlink:to="abp_PaymentForExtensionRoyalities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued extension royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_DevelopmentMilestones" xlink:href="abp-20250930.xsd#abp_DevelopmentMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_DevelopmentMilestones_lbl" xml:lang="en-US">Development milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DevelopmentMilestones" xlink:to="abp_DevelopmentMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AnnualSalesMilestonePayments" xlink:href="abp-20250930.xsd#abp_AnnualSalesMilestonePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AnnualSalesMilestonePayments_lbl" xml:lang="en-US">Annual sales milestone payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AnnualSalesMilestonePayments" xlink:to="abp_AnnualSalesMilestonePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NetProfitsFromLicensedProductSales" xlink:href="abp-20250930.xsd#abp_NetProfitsFromLicensedProductSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NetProfitsFromLicensedProductSales_lbl" xml:lang="en-US">Net profits from licensed product sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NetProfitsFromLicensedProductSales" xlink:to="abp_NetProfitsFromLicensedProductSales_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PaymentOfDevelopmentMilestones" xlink:href="abp-20250930.xsd#abp_PaymentOfDevelopmentMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PaymentOfDevelopmentMilestones_lbl" xml:lang="en-US">Payment of development milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PaymentOfDevelopmentMilestones" xlink:to="abp_PaymentOfDevelopmentMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AccruedToAmount" xlink:href="abp-20250930.xsd#abp_AccruedToAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AccruedToAmount_lbl" xml:lang="en-US">Accrued amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedToAmount" xlink:to="abp_AccruedToAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents" xlink:href="abp-20250930.xsd#abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents_lbl" xml:lang="en-US">Milestone payment upon achieving</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents" xlink:to="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MilestonePaymentOnNetSales" xlink:href="abp-20250930.xsd#abp_MilestonePaymentOnNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MilestonePaymentOnNetSales_lbl" xml:lang="en-US">Milestone payment on net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePaymentOnNetSales" xlink:to="abp_MilestonePaymentOnNetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PatentCostsReimbursements" xlink:href="abp-20250930.xsd#abp_PatentCostsReimbursements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PatentCostsReimbursements_lbl" xml:lang="en-US">Patent costs reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PatentCostsReimbursements" xlink:to="abp_PatentCostsReimbursements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentMilestones"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones_lbl" xml:lang="en-US">Net sales of licensed products milestone payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:to="us-gaap_LongTermPurchaseCommitmentMilestones_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl" xml:lang="en-US">Settlement payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_BusinessDays" xlink:href="abp-20250930.xsd#abp_BusinessDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_BusinessDays_lbl" xml:lang="en-US">Business days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_BusinessDays" xlink:to="abp_BusinessDays_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MonthlyInstallmentPayments" xlink:href="abp-20250930.xsd#abp_MonthlyInstallmentPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MonthlyInstallmentPayments_lbl" xml:lang="en-US">Monthly installment payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MonthlyInstallmentPayments" xlink:to="abp_MonthlyInstallmentPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US">Endorsement on motion for default judgment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AdditionalAccruedInterest" xlink:href="abp-20250930.xsd#abp_AdditionalAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AdditionalAccruedInterest_lbl" xml:lang="en-US">Additional accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdditionalAccruedInterest" xlink:to="abp_AdditionalAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SettlementLiabilitiesCurrent_lbl" xml:lang="en-US">Outstanding settlement agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementLiabilitiesCurrent" xlink:to="us-gaap_SettlementLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalFees_lbl" xml:lang="en-US">Professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DemandDepositAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DemandDepositAccounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DemandDepositAccounts_lbl" xml:lang="en-US">Demand for payment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DemandDepositAccounts" xlink:to="us-gaap_DemandDepositAccounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Shares issues price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsTotalCostToInvestors"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors_lbl" xml:lang="en-US">Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsTotalCostToInvestors" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl" xml:lang="en-US">Redemption price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ExciseTaxLiability" xlink:href="abp-20250930.xsd#abp_ExciseTaxLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ExciseTaxLiability_lbl" xml:lang="en-US">Excise tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExciseTaxLiability" xlink:to="abp_ExciseTaxLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl" xml:lang="en-US">Shares redeemed percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage" xlink:href="abp-20250930.xsd#abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage_lbl" xml:lang="en-US">Excise tax generally of the fair market value percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage" xlink:to="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate_lbl" xml:lang="en-US">Estimated interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate" xlink:to="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfUnderpaymentPenaltyPerMonth" xlink:href="abp-20250930.xsd#abp_PercentageOfUnderpaymentPenaltyPerMonth"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfUnderpaymentPenaltyPerMonth_lbl" xml:lang="en-US">Percentage of underpayment penalty per month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfUnderpaymentPenaltyPerMonth" xlink:to="abp_PercentageOfUnderpaymentPenaltyPerMonth_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfLiabilityTotal" xlink:href="abp-20250930.xsd#abp_PercentageOfLiabilityTotal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfLiabilityTotal_lbl" xml:lang="en-US">Percentage of total liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfLiabilityTotal" xlink:to="abp_PercentageOfLiabilityTotal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExciseAndSalesTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExciseAndSalesTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ExciseAndSalesTaxes_lbl" xml:lang="en-US">Excise taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExciseAndSalesTaxes" xlink:to="us-gaap_ExciseAndSalesTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationInterestExpense_lbl" xml:lang="en-US">Interest and penalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ExcessTaxes" xlink:href="abp-20250930.xsd#abp_ExcessTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ExcessTaxes_lbl" xml:lang="en-US">Excess taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExcessTaxes" xlink:to="abp_ExcessTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl" xml:lang="en-US">Estimate of interest and penalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyExcessExpenseReimbursable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl" xml:lang="en-US">Company recorded excess</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl" xml:lang="en-US">Penalties and interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForRent_lbl" xml:lang="en-US">Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PaymentOfRentAndMaintenanceExpense" xlink:href="abp-20250930.xsd#abp_PaymentOfRentAndMaintenanceExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PaymentOfRentAndMaintenanceExpense_lbl" xml:lang="en-US">Rent and maintenance expenses to landlord</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PaymentOfRentAndMaintenanceExpense" xlink:to="abp_PaymentOfRentAndMaintenanceExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_lbl" xml:lang="en-US">Additional interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForFees_lbl" xml:lang="en-US">Payment to CRO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettlementAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SettlementAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SettlementAssetsCurrent_lbl" xml:lang="en-US">Settlement agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementAssetsCurrent" xlink:to="us-gaap_SettlementAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquityShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquityShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquityShares_lbl" xml:lang="en-US">Maximum up to common stock shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityShares" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquityShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidRoyalties_lbl" xml:lang="en-US">Prepayment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRoyalties" xlink:to="us-gaap_PrepaidRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_DerivativeChangeInFairValue" xlink:href="abp-20250930.xsd#abp_DerivativeChangeInFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_DerivativeChangeInFairValue_lbl" xml:lang="en-US">Derivative change in fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DerivativeChangeInFairValue" xlink:to="abp_DerivativeChangeInFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl" xml:lang="en-US">Initial price per recycled shares (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:to="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardContractInitialResetPricePerShare" xlink:href="abp-20250930.xsd#abp_ForwardContractInitialResetPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ForwardContractInitialResetPricePerShare_lbl" xml:lang="en-US">Initial reset price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardContractInitialResetPricePerShare" xlink:to="abp_ForwardContractInitialResetPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardContractBaseResetPricePerShare" xlink:href="abp-20250930.xsd#abp_ForwardContractBaseResetPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ForwardContractBaseResetPricePerShare_lbl" xml:lang="en-US">Base reset price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardContractBaseResetPricePerShare" xlink:to="abp_ForwardContractBaseResetPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" xlink:href="abp-20250930.xsd#abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare_lbl" xml:lang="en-US">Number of trading days used for calculating VWAP price of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" xlink:to="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_VolumeWeightedAveragePrice" xlink:href="abp-20250930.xsd#abp_VolumeWeightedAveragePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_VolumeWeightedAveragePrice_lbl" xml:lang="en-US">Volume weighted average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VolumeWeightedAveragePrice" xlink:to="abp_VolumeWeightedAveragePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_VolumeWeightedAveragePrice_lbl0" xml:lang="en-US">Volume-weighted-average price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VolumeWeightedAveragePrice" xlink:to="abp_VolumeWeightedAveragePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" xlink:href="abp-20250930.xsd#abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount_lbl" xml:lang="en-US">VWAP price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" xlink:to="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_lbl" xml:lang="en-US">Settlement amount under forward purchase agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Amount to be received under promissory note agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest accrued on promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement" xlink:href="abp-20250930.xsd#abp_ConversionOfConsiderationUnderPromissoryNoteAgreement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement_lbl" xml:lang="en-US">Conversion of consideration under promissory note agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement" xlink:to="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_IncentiveSharesReceivedBySubsidiary" xlink:href="abp-20250930.xsd#abp_IncentiveSharesReceivedBySubsidiary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_IncentiveSharesReceivedBySubsidiary_lbl" xml:lang="en-US">Incentive shares received by subsidiary (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IncentiveSharesReceivedBySubsidiary" xlink:to="abp_IncentiveSharesReceivedBySubsidiary_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Weekly installments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl" xml:lang="en-US">Common stock, shares issued upon conversion of promissory note (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AdditionalInterestExpense" xlink:href="abp-20250930.xsd#abp_AdditionalInterestExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AdditionalInterestExpense_lbl" xml:lang="en-US">Additional interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdditionalInterestExpense" xlink:to="abp_AdditionalInterestExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRepaidPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepaidPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRepaidPrincipal_lbl" xml:lang="en-US">Debt instrument repaid upon cancellation of agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepaidPrincipal" xlink:to="us-gaap_DebtInstrumentRepaidPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseDebt_lbl" xml:lang="en-US">Interest expense on promissory notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPayableCurrent_lbl" xml:lang="en-US">Accrued interest on promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ExcessOfCommonStockPercentage" xlink:href="abp-20250930.xsd#abp_ExcessOfCommonStockPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ExcessOfCommonStockPercentage_lbl" xml:lang="en-US">Percentage of excess of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExcessOfCommonStockPercentage" xlink:to="abp_ExcessOfCommonStockPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebt_lbl" xml:lang="en-US">Convertible promissory note</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Original issuance discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfVolumeWeightedAveragePrice" xlink:href="abp-20250930.xsd#abp_PercentageOfVolumeWeightedAveragePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfVolumeWeightedAveragePrice_lbl" xml:lang="en-US">Percentage of volume weighted average price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfVolumeWeightedAveragePrice" xlink:to="abp_PercentageOfVolumeWeightedAveragePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleThresholdConsecutiveTradingDays" xlink:href="abp-20250930.xsd#abp_ConvertibleThresholdConsecutiveTradingDays"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConvertibleThresholdConsecutiveTradingDays_lbl" xml:lang="en-US">Convertible threshold trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleThresholdConsecutiveTradingDays" xlink:to="abp_ConvertibleThresholdConsecutiveTradingDays_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfClosingPrice" xlink:href="abp-20250930.xsd#abp_PercentageOfClosingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfClosingPrice_lbl" xml:lang="en-US">Percentage of closing price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfClosingPrice" xlink:to="abp_PercentageOfClosingPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FloorPrice" xlink:href="abp-20250930.xsd#abp_FloorPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_FloorPrice_lbl" xml:lang="en-US">Floor Price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FloorPrice" xlink:to="abp_FloorPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Fixed price reset (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Conversion price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfCommonStock" xlink:href="abp-20250930.xsd#abp_PercentageOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfCommonStock_lbl" xml:lang="en-US">Percentage of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfCommonStock" xlink:to="abp_PercentageOfCommonStock_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_PercentageOfCommonStock_lbl0" xml:lang="en-US">Rate of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfCommonStock" xlink:to="abp_PercentageOfCommonStock_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfAmortizationPrincipalAmount" xlink:href="abp-20250930.xsd#abp_PercentageOfAmortizationPrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfAmortizationPrincipalAmount_lbl" xml:lang="en-US">Percentage of amortization principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfAmortizationPrincipalAmount" xlink:to="abp_PercentageOfAmortizationPrincipalAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ChangeInFairValueEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueEmbeddedDerivativeLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ChangeInFairValueEmbeddedDerivativeLiability_lbl" xml:lang="en-US">Change in fair value of embedded derivative liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueEmbeddedDerivativeLiability" xlink:to="abp_ChangeInFairValueEmbeddedDerivativeLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other (expense) income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl" xml:lang="en-US">Interest expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromPreviousAcquisition"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl" xml:lang="en-US">Gross purchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfCommonStockOutstanding" xlink:href="abp-20250930.xsd#abp_PercentageOfCommonStockOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfCommonStockOutstanding_lbl" xml:lang="en-US">Percentage of common stock outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfCommonStockOutstanding" xlink:to="abp_PercentageOfCommonStockOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfAdvanceNotice" xlink:href="abp-20250930.xsd#abp_PercentageOfAdvanceNotice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfAdvanceNotice_lbl" xml:lang="en-US">Percentage of advance notice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfAdvanceNotice" xlink:to="abp_PercentageOfAdvanceNotice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl" xml:lang="en-US">Commitment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl" xml:lang="en-US">Commitment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeAverageFloorPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAverageFloorPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeAverageFloorPrice_lbl" xml:lang="en-US">Floor price was adjusted (in Dollars per Item)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAverageFloorPrice" xlink:to="us-gaap_DerivativeAverageFloorPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl" xml:lang="en-US">Consecutive trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl" xml:lang="en-US">Common Stock convertible price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_WarrantsExercisableTerm" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_WarrantsExercisableTerm_lbl" xml:lang="en-US">Warrants exercisable term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WarrantsExercisableTerm" xlink:to="abp_WarrantsExercisableTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:href="abp-20250930.xsd#abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US">Redemption price per public warrant .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" xlink:href="abp-20250930.xsd#abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger_lbl" xml:lang="en-US">Stock price trigger for redemption of public warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" xlink:to="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:href="abp-20250930.xsd#abp_NumberOfTradingDaysForDeterminingTheSharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NumberOfTradingDaysForDeterminingTheSharePrice_lbl" xml:lang="en-US">Number of trading days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:to="abp_NumberOfTradingDaysForDeterminingTheSharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PeriodAfterWhichTheWarrantsAreExercisable" xlink:href="abp-20250930.xsd#abp_PeriodAfterWhichTheWarrantsAreExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PeriodAfterWhichTheWarrantsAreExercisable_lbl" xml:lang="en-US">Number of trading day period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PeriodAfterWhichTheWarrantsAreExercisable" xlink:to="abp_PeriodAfterWhichTheWarrantsAreExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PerShareRedemptionsTriggerPrice" xlink:href="abp-20250930.xsd#abp_PerShareRedemptionsTriggerPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PerShareRedemptionsTriggerPrice_lbl" xml:lang="en-US">Redemption trigger price of per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PerShareRedemptionsTriggerPrice" xlink:to="abp_PerShareRedemptionsTriggerPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xml:lang="en-US">Percentage of total equity proceeds and interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PercentageOfMarketValueAndNewlyIssuedPrice" xlink:href="abp-20250930.xsd#abp_PercentageOfMarketValueAndNewlyIssuedPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PercentageOfMarketValueAndNewlyIssuedPrice_lbl" xml:lang="en-US">Percentage of market value and newly issued price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfMarketValueAndNewlyIssuedPrice" xlink:to="abp_PercentageOfMarketValueAndNewlyIssuedPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl" xml:lang="en-US">Number of redemption trigger price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Fair value of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xml:lang="en-US">Exercise price adjustment (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_DesignatedShares" xlink:href="abp-20250930.xsd#abp_DesignatedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_DesignatedShares_lbl" xml:lang="en-US">Designated shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DesignatedShares" xlink:to="abp_DesignatedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Available for issuance under the plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Contractual term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl" xml:lang="en-US">Fair value of common stock (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vested term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Fair value total (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation related to unvested stock option (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Recognized over weighted-average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-average term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation related to unvested restricted stock (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xml:lang="en-US">Employer contributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Agreement amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_UnpaidAmount" xlink:href="abp-20250930.xsd#abp_UnpaidAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_UnpaidAmount_lbl" xml:lang="en-US">Unpaid amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_UnpaidAmount" xlink:to="abp_UnpaidAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl" xml:lang="en-US">Deferred wages</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForMergerRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_lbl" xml:lang="en-US">Payment in merger agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMergerRelatedCosts" xlink:to="us-gaap_PaymentsForMergerRelatedCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AnnualBaseFee" xlink:href="abp-20250930.xsd#abp_AnnualBaseFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AnnualBaseFee_lbl" xml:lang="en-US">Annual base fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AnnualBaseFee" xlink:to="abp_AnnualBaseFee_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Accrued interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceOfSharesPercentage" xlink:href="abp-20250930.xsd#abp_IssuanceOfSharesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_IssuanceOfSharesPercentage_lbl" xml:lang="en-US">Percentage of issuance shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfSharesPercentage" xlink:to="abp_IssuanceOfSharesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Conversion option (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Letter of credit amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_InterestBearingLiabilitiesAverageRatePaid" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_InterestBearingLiabilitiesAverageRatePaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_InterestBearingLiabilitiesAverageRatePaid_lbl" xml:lang="en-US">Increase bears interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_InterestBearingLiabilitiesAverageRatePaid" xlink:to="srt_InterestBearingLiabilitiesAverageRatePaid_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_LetterOfCreditExtendedPeriod" xlink:href="abp-20250930.xsd#abp_LetterOfCreditExtendedPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_LetterOfCreditExtendedPeriod_lbl" xml:lang="en-US">Letter of credit extended period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LetterOfCreditExtendedPeriod" xlink:to="abp_LetterOfCreditExtendedPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl" xml:lang="en-US">Capitalized value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationDeductions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationDeductions_lbl" xml:lang="en-US">Amortization deductions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationDeductions" xlink:to="us-gaap_IncomeTaxReconciliationDeductions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Percentage of future taxable income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CarryforwardsTerm" xlink:href="abp-20250930.xsd#abp_CarryforwardsTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_CarryforwardsTerm_lbl" xml:lang="en-US">Carryforwards term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CarryforwardsTerm" xlink:to="abp_CarryforwardsTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FederalAndStateResearchAndDevelopmentCredits" xlink:href="abp-20250930.xsd#abp_FederalAndStateResearchAndDevelopmentCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_FederalAndStateResearchAndDevelopmentCredits_lbl" xml:lang="en-US">Federal and state research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FederalAndStateResearchAndDevelopmentCredits" xlink:to="abp_FederalAndStateResearchAndDevelopmentCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl" xml:lang="en-US">Percentage of ownership</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US">Unaudited Interim Condensed Consolidated Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NoncontrollingInterestPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_NoncontrollingInterestPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NoncontrollingInterestPolicyTextBlock_lbl" xml:lang="en-US">Non-controlling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NoncontrollingInterestPolicyTextBlock" xlink:to="abp_NoncontrollingInterestPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl" xml:lang="en-US">Recently Adopted Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_EmergingGrowthCompanyPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_EmergingGrowthCompanyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_EmergingGrowthCompanyPolicyTextBlock_lbl" xml:lang="en-US">Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EmergingGrowthCompanyPolicyTextBlock" xlink:to="abp_EmergingGrowthCompanyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PatentsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_PatentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PatentsPolicyTextBlock_lbl" xml:lang="en-US">Patents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PatentsPolicyTextBlock" xlink:to="abp_PatentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-lived Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertiblePreferredStockPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_ConvertiblePreferredStockPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConvertiblePreferredStockPolicyTextBlock_lbl" xml:lang="en-US">Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertiblePreferredStockPolicyTextBlock" xlink:to="abp_ConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ContingentEarnoutPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_ContingentEarnoutPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ContingentEarnoutPolicyTextBlock_lbl" xml:lang="en-US">Contingent Earnout Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ContingentEarnoutPolicyTextBlock" xlink:to="abp_ContingentEarnoutPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements and Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_lbl" xml:lang="en-US">Restatement of Previously Issued Financial Statements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" xlink:to="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_LabEquipmentMember" xlink:href="abp-20250930.xsd#abp_LabEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_LabEquipmentMember_lbl" xml:lang="en-US">Lab equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LabEquipmentMember" xlink:to="abp_LabEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ReverseStockSplitMember" xlink:href="abp-20250930.xsd#abp_ReverseStockSplitMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ReverseStockSplitMember_lbl" xml:lang="en-US">Reverse Stock Split [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReverseStockSplitMember" xlink:to="abp_ReverseStockSplitMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MarketValueOfPubliclyHeldSharesMember" xlink:href="abp-20250930.xsd#abp_MarketValueOfPubliclyHeldSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MarketValueOfPubliclyHeldSharesMember_lbl" xml:lang="en-US">MVPHS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MarketValueOfPubliclyHeldSharesMember" xlink:to="abp_MarketValueOfPubliclyHeldSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MarketValueOfListedSecuritiesMember" xlink:href="abp-20250930.xsd#abp_MarketValueOfListedSecuritiesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MarketValueOfListedSecuritiesMember_lbl" xml:lang="en-US">MVLS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MarketValueOfListedSecuritiesMember" xlink:to="abp_MarketValueOfListedSecuritiesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SecondConvertibleNoteMember" xlink:href="abp-20250930.xsd#abp_SecondConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SecondConvertibleNoteMember_lbl" xml:lang="en-US">Second Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SecondConvertibleNoteMember" xlink:to="abp_SecondConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PIPEFinancingMember" xlink:href="abp-20250930.xsd#abp_PIPEFinancingMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PIPEFinancingMember_lbl" xml:lang="en-US">PIPE Financing [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PIPEFinancingMember" xlink:to="abp_PIPEFinancingMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PromissoryNoteMember_lbl" xml:lang="en-US">Promissory Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteMember" xlink:to="abp_PromissoryNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertibleNoteDiscountMember" xlink:href="abp-20250930.xsd#abp_ConvertibleNoteDiscountMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConvertibleNoteDiscountMember_lbl" xml:lang="en-US">Convertible Note Discount [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleNoteDiscountMember" xlink:to="abp_ConvertibleNoteDiscountMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractTerminationMember_lbl" xml:lang="en-US">Early Termination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractTerminationMember_lbl0" xml:lang="en-US">Contract Termination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MabwellShanghaiBioscienceCoLtdMember" xlink:href="abp-20250930.xsd#abp_MabwellShanghaiBioscienceCoLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MabwellShanghaiBioscienceCoLtdMember_lbl" xml:lang="en-US">Mabwell (Shanghai) Bioscience Co., Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MabwellShanghaiBioscienceCoLtdMember" xlink:to="abp_MabwellShanghaiBioscienceCoLtdMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_MabwellShanghaiBioscienceCoLtdMember_lbl0" xml:lang="en-US">Mabwell (Shanghai) Bioscience Co Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MabwellShanghaiBioscienceCoLtdMember" xlink:to="abp_MabwellShanghaiBioscienceCoLtdMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_AbMedMember" xlink:href="abp-20250930.xsd#abp_AbMedMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AbMedMember_lbl" xml:lang="en-US">AbMed [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AbMedMember" xlink:to="abp_AbMedMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Share [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ContingentEarnoutSharesMember" xlink:href="abp-20250930.xsd#abp_ContingentEarnoutSharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ContingentEarnoutSharesMember_lbl" xml:lang="en-US">Contingent Earnout Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ContingentEarnoutSharesMember" xlink:to="abp_ContingentEarnoutSharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesACommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesACommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SeriesACommonStockMember_lbl" xml:lang="en-US">Series A Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesACommonStockMember" xlink:to="abp_SeriesACommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SeriesBCommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesBCommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SeriesBCommonStockMember_lbl" xml:lang="en-US">Series B Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesBCommonStockMember" xlink:to="abp_SeriesBCommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PIPESharesMember" xlink:href="abp-20250930.xsd#abp_PIPESharesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PIPESharesMember_lbl" xml:lang="en-US">PIPE Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PIPESharesMember" xlink:to="abp_PIPESharesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AbproBioInternationalIncMember" xlink:href="abp-20250930.xsd#abp_AbproBioInternationalIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AbproBioInternationalIncMember_lbl" xml:lang="en-US">Abpro Bio International, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AbproBioInternationalIncMember" xlink:to="abp_AbproBioInternationalIncMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_AbproBioInternationalIncMember_lbl0" xml:lang="en-US">ABI [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AbproBioInternationalIncMember" xlink:to="abp_AbproBioInternationalIncMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteAgreementMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PromissoryNoteAgreementMember_lbl" xml:lang="en-US">Promissory Note Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteAgreementMember" xlink:to="abp_PromissoryNoteAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ABIMember" xlink:href="abp-20250930.xsd#abp_ABIMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ABIMember_lbl" xml:lang="en-US">ABI [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ABIMember" xlink:to="abp_ABIMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CelltrionIncMember" xlink:href="abp-20250930.xsd#abp_CelltrionIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_CelltrionIncMember_lbl" xml:lang="en-US">Celltrion, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CelltrionIncMember" xlink:to="abp_CelltrionIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SponsorMember" xlink:href="abp-20250930.xsd#abp_SponsorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SponsorMember_lbl" xml:lang="en-US">Sponsor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SponsorMember" xlink:to="abp_SponsorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ACABMember" xlink:href="abp-20250930.xsd#abp_ACABMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ACABMember_lbl" xml:lang="en-US">ACAB [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ACABMember" xlink:to="abp_ACABMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_InvestmentAdvisorMember" xlink:href="abp-20250930.xsd#abp_InvestmentAdvisorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_InvestmentAdvisorMember_lbl" xml:lang="en-US">Investment Advisor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_InvestmentAdvisorMember" xlink:to="abp_InvestmentAdvisorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_LegacyAbproMember" xlink:href="abp-20250930.xsd#abp_LegacyAbproMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_LegacyAbproMember_lbl" xml:lang="en-US">Legacy Abpro [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LegacyAbproMember" xlink:to="abp_LegacyAbproMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FirstSharesTargetMember" xlink:href="abp-20250930.xsd#abp_FirstSharesTargetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_FirstSharesTargetMember_lbl" xml:lang="en-US">First Shares Target [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FirstSharesTargetMember" xlink:to="abp_FirstSharesTargetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SecondShareTargetMember" xlink:href="abp-20250930.xsd#abp_SecondShareTargetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SecondShareTargetMember_lbl" xml:lang="en-US">Second Share Target [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SecondShareTargetMember" xlink:to="abp_SecondShareTargetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ThirdShareTargetMember" xlink:href="abp-20250930.xsd#abp_ThirdShareTargetMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ThirdShareTargetMember_lbl" xml:lang="en-US">Third Share Target [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ThirdShareTargetMember" xlink:to="abp_ThirdShareTargetMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ABCDMember" xlink:href="abp-20250930.xsd#abp_ABCDMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ABCDMember_lbl" xml:lang="en-US">ABCD [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ABCDMember" xlink:to="abp_ABCDMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleDebtMember_lbl" xml:lang="en-US">Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MonteCarloSimulationMember" xlink:href="abp-20250930.xsd#abp_MonteCarloSimulationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MonteCarloSimulationMember_lbl" xml:lang="en-US">Monte Carlo Simulation [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MonteCarloSimulationMember" xlink:to="abp_MonteCarloSimulationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FirstConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_FirstConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_FirstConvertibleNotesMember_lbl" xml:lang="en-US">First Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FirstConvertibleNotesMember" xlink:to="abp_FirstConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SecondConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_SecondConvertibleNotesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SecondConvertibleNotesMember_lbl" xml:lang="en-US">Second Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SecondConvertibleNotesMember" xlink:to="abp_SecondConvertibleNotesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl" xml:lang="en-US">Expected volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl0" xml:lang="en-US">Measurement Input, Option Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_NJCTTQCollaborationAgreementMember" xlink:href="abp-20250930.xsd#abp_NJCTTQCollaborationAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NJCTTQCollaborationAgreementMember_lbl" xml:lang="en-US">NJCTTQ Collaboration Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NJCTTQCollaborationAgreementMember" xlink:to="abp_NJCTTQCollaborationAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ABP201CollaborationAndLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_ABP201CollaborationAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ABP201CollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US">ABP-201 Collaboration and License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ABP201CollaborationAndLicenseAgreementMember" xlink:to="abp_ABP201CollaborationAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CelltrionCollaborationAndLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_CelltrionCollaborationAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_CelltrionCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US">Celltrion Collaboration and License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CelltrionCollaborationAndLicenseAgreementMember" xlink:to="abp_CelltrionCollaborationAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FirstMilestoneMember" xlink:href="abp-20250930.xsd#abp_FirstMilestoneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_FirstMilestoneMember_lbl" xml:lang="en-US">First Milestone [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FirstMilestoneMember" xlink:to="abp_FirstMilestoneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember_lbl" xml:lang="en-US">ABP-100 Collaboration and License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember" xlink:to="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntellectualPropertyMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US">Intellectual Property [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MedImmuneLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_MedImmuneLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MedImmuneLicenseAgreementMember_lbl" xml:lang="en-US">MedImmune License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MedImmuneLicenseAgreementMember" xlink:to="abp_MedImmuneLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NCILicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_NCILicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NCILicenseAgreementMember_lbl" xml:lang="en-US">NCI License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NCILicenseAgreementMember" xlink:to="abp_NCILicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MSKLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_MSKLicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_MSKLicenseAgreementMember_lbl" xml:lang="en-US">MSK License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MSKLicenseAgreementMember" xlink:to="abp_MSKLicenseAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_OtherAccruedExpensesAndAccountsPayableMember" xlink:href="abp-20250930.xsd#abp_OtherAccruedExpensesAndAccountsPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_OtherAccruedExpensesAndAccountsPayableMember_lbl" xml:lang="en-US">Other Accrued Expenses and Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OtherAccruedExpensesAndAccountsPayableMember" xlink:to="abp_OtherAccruedExpensesAndAccountsPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_OtherAccruedExpensesMember" xlink:href="abp-20250930.xsd#abp_OtherAccruedExpensesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_OtherAccruedExpensesMember_lbl" xml:lang="en-US">Other Accrued Expenses [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OtherAccruedExpensesMember" xlink:to="abp_OtherAccruedExpensesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_VAZYMELicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_VAZYMELicenseAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_VAZYMELicenseAgreementMember_lbl" xml:lang="en-US">VAZYME License Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VAZYMELicenseAgreementMember" xlink:to="abp_VAZYMELicenseAgreementMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_VAZYMELicenseAgreementMember_lbl0" xml:lang="en-US">VAZYME License agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VAZYMELicenseAgreementMember" xlink:to="abp_VAZYMELicenseAgreementMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableMember_lbl" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_VendorsMember" xlink:href="abp-20250930.xsd#abp_VendorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_VendorsMember_lbl" xml:lang="en-US">Vendor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VendorsMember" xlink:to="abp_VendorsMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="abp_VendorsMember_lbl0" xml:lang="en-US">Vendors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VendorsMember" xlink:to="abp_VendorsMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_SettlementAgreementMember" xlink:href="abp-20250930.xsd#abp_SettlementAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SettlementAgreementMember_lbl" xml:lang="en-US">Settlement Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SettlementAgreementMember" xlink:to="abp_SettlementAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CROVendorMember" xlink:href="abp-20250930.xsd#abp_CROVendorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_CROVendorMember_lbl" xml:lang="en-US">CRO Vendor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CROVendorMember" xlink:to="abp_CROVendorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NonRedemptionAgreementsMember" xlink:href="abp-20250930.xsd#abp_NonRedemptionAgreementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NonRedemptionAgreementsMember_lbl" xml:lang="en-US">Non-Redemption Agreements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NonRedemptionAgreementsMember" xlink:to="abp_NonRedemptionAgreementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NotePayableMember" xlink:href="abp-20250930.xsd#abp_NotePayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NotePayableMember_lbl" xml:lang="en-US">Note Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NotePayableMember" xlink:to="abp_NotePayableMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteWithABIMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteWithABIMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PromissoryNoteWithABIMember_lbl" xml:lang="en-US">Promissory Note with ABI [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteWithABIMember" xlink:to="abp_PromissoryNoteWithABIMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FundingDateToMaturityDateMember" xlink:href="abp-20250930.xsd#abp_FundingDateToMaturityDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_FundingDateToMaturityDateMember_lbl" xml:lang="en-US">Until Maturity Date [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FundingDateToMaturityDateMember" xlink:to="abp_FundingDateToMaturityDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AfterMaturityDateMember" xlink:href="abp-20250930.xsd#abp_AfterMaturityDateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AfterMaturityDateMember_lbl" xml:lang="en-US">After Maturity Date [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AfterMaturityDateMember" xlink:to="abp_AfterMaturityDateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_YearTwoThousandTwentyFourABIPromissoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember_lbl" xml:lang="en-US">2024 ABI Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember" xlink:to="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNotesWithExecutiveAndDirectorMember" xlink:href="abp-20250930.xsd#abp_PromissoryNotesWithExecutiveAndDirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PromissoryNotesWithExecutiveAndDirectorMember_lbl" xml:lang="en-US">Promissory Notes with Executive and Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNotesWithExecutiveAndDirectorMember" xlink:to="abp_PromissoryNotesWithExecutiveAndDirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ExecutiveOfficerMember_lbl" xml:lang="en-US">Executive [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ExecutiveOfficerMember_lbl0" xml:lang="en-US">Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_DirectorMember_lbl" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_IssuanceDateOfWarrantsMember" xlink:href="abp-20250930.xsd#abp_IssuanceDateOfWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_IssuanceDateOfWarrantsMember_lbl" xml:lang="en-US">Issuance Date [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceDateOfWarrantsMember" xlink:to="abp_IssuanceDateOfWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:href="abp-20250930.xsd#abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember_lbl" xml:lang="en-US">One Year Anniversary of Issuance Date [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:to="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:href="abp-20250930.xsd#abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember_lbl" xml:lang="en-US">Two Year Anniversary of Issuance Date [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:to="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PromissoryNoteWithACABExecutiveMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteWithACABExecutiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PromissoryNoteWithACABExecutiveMember_lbl" xml:lang="en-US">Promissory Note with ACAB Executive [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteWithACABExecutiveMember" xlink:to="abp_PromissoryNoteWithACABExecutiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ExecutiveMember" xlink:href="abp-20250930.xsd#abp_ExecutiveMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ExecutiveMember_lbl" xml:lang="en-US">Executive [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExecutiveMember" xlink:to="abp_ExecutiveMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ConvertiblePromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_ConvertiblePromissoryNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ConvertiblePromissoryNoteMember_lbl" xml:lang="en-US">Convertible Promissory Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertiblePromissoryNoteMember" xlink:to="abp_ConvertiblePromissoryNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FloorPriceEventMember" xlink:href="abp-20250930.xsd#abp_FloorPriceEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_FloorPriceEventMember_lbl" xml:lang="en-US">Floor Price Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FloorPriceEventMember" xlink:to="abp_FloorPriceEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ExchangeCapEventMember" xlink:href="abp-20250930.xsd#abp_ExchangeCapEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ExchangeCapEventMember_lbl" xml:lang="en-US">Exchange Cap Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExchangeCapEventMember" xlink:to="abp_ExchangeCapEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_RegistrationEventMember" xlink:href="abp-20250930.xsd#abp_RegistrationEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_RegistrationEventMember_lbl" xml:lang="en-US">Registration Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RegistrationEventMember" xlink:to="abp_RegistrationEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FirstConvertibleNoteMember" xlink:href="abp-20250930.xsd#abp_FirstConvertibleNoteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_FirstConvertibleNoteMember_lbl" xml:lang="en-US">First Convertible Note [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FirstConvertibleNoteMember" xlink:to="abp_FirstConvertibleNoteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SEPAMember" xlink:href="abp-20250930.xsd#abp_SEPAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SEPAMember_lbl" xml:lang="en-US">SEPA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPAMember" xlink:to="abp_SEPAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_YAIIPNLtdMember" xlink:href="abp-20250930.xsd#abp_YAIIPNLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_YAIIPNLtdMember_lbl" xml:lang="en-US">YA II PN, Ltd. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_YAIIPNLtdMember" xlink:to="abp_YAIIPNLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_RedemptionTriggerMember" xlink:href="abp-20250930.xsd#abp_RedemptionTriggerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_RedemptionTriggerMember_lbl" xml:lang="en-US">Redemption Trigger [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RedemptionTriggerMember" xlink:to="abp_RedemptionTriggerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PrivatePlacementWarrantsMember" xlink:href="abp-20250930.xsd#abp_PrivatePlacementWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PrivatePlacementWarrantsMember_lbl" xml:lang="en-US">Private Placement Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PrivatePlacementWarrantsMember" xlink:to="abp_PrivatePlacementWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Business Combination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ExecutiveWarrantsMember" xlink:href="abp-20250930.xsd#abp_ExecutiveWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_ExecutiveWarrantsMember_lbl" xml:lang="en-US">Executive Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExecutiveWarrantsMember" xlink:to="abp_ExecutiveWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_TwoZeroTwoFourEquityIncentivePlanMember" xlink:href="abp-20250930.xsd#abp_TwoZeroTwoFourEquityIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_TwoZeroTwoFourEquityIncentivePlanMember_lbl" xml:lang="en-US">2024 Equity Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TwoZeroTwoFourEquityIncentivePlanMember" xlink:to="abp_TwoZeroTwoFourEquityIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_TwoZeroOneFourStockIncentivePlanMember" xlink:href="abp-20250930.xsd#abp_TwoZeroOneFourStockIncentivePlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_TwoZeroOneFourStockIncentivePlanMember_lbl" xml:lang="en-US">2014 Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TwoZeroOneFourStockIncentivePlanMember" xlink:to="abp_TwoZeroOneFourStockIncentivePlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl1" xml:lang="en-US">Stock option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl" xml:lang="en-US">Board of Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl0" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_ChiefExecutiveOfficerMember_lbl" xml:lang="en-US">Chief Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SeparatePromissoryNoteAgreementMember" xlink:href="abp-20250930.xsd#abp_SeparatePromissoryNoteAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_SeparatePromissoryNoteAgreementMember_lbl" xml:lang="en-US">Separate Promissory Note Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeparatePromissoryNoteAgreementMember" xlink:to="abp_SeparatePromissoryNoteAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NewConsultingAgreementMember" xlink:href="abp-20250930.xsd#abp_NewConsultingAgreementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_NewConsultingAgreementMember_lbl" xml:lang="en-US">New Consulting Agreement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewConsultingAgreementMember" xlink:to="abp_NewConsultingAgreementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_AdvanceNoticeToYAMember" xlink:href="abp-20250930.xsd#abp_AdvanceNoticeToYAMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_AdvanceNoticeToYAMember_lbl" xml:lang="en-US">Advance Notice to YA [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdvanceNoticeToYAMember" xlink:to="abp_AdvanceNoticeToYAMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_RothCapitalPartnersMember" xlink:href="abp-20250930.xsd#abp_RothCapitalPartnersMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_RothCapitalPartnersMember_lbl" xml:lang="en-US">Roth Capital Partners [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RothCapitalPartnersMember" xlink:to="abp_RothCapitalPartnersMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_TaxYear2037Member" xlink:href="abp-20250930.xsd#abp_TaxYear2037Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_TaxYear2037Member_lbl" xml:lang="en-US">Tax Year 2037 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TaxYear2037Member" xlink:to="abp_TaxYear2037Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DomesticCountryMember_lbl" xml:lang="en-US">Federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_PostApportionedMassachusettsMember" xlink:href="abp-20250930.xsd#abp_PostApportionedMassachusettsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="abp_PostApportionedMassachusettsMember_lbl" xml:lang="en-US">Post-Apportioned Massachusetts [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PostApportionedMassachusettsMember" xlink:to="abp_PostApportionedMassachusettsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementDomain_lbl" xml:lang="en-US">Revision of Prior Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related and Nonrelated Parties [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_StockholdersEquityTablesTable" xlink:href="abp-20250930.xsd#abp_StockholdersEquityTablesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StockholdersEquityTablesTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Tables) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockholdersEquityTablesTable" xlink:to="abp_StockholdersEquityTablesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_StockholdersEquityTablesLineItems" xlink:href="abp-20250930.xsd#abp_StockholdersEquityTablesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StockholdersEquityTablesLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Tables) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockholdersEquityTablesLineItems" xlink:to="abp_StockholdersEquityTablesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Schedule of Diluted Net Loss Per Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MergerScheduleofCommonStockOutstandingDetailsTable" xlink:href="abp-20250930.xsd#abp_MergerScheduleofCommonStockOutstandingDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MergerScheduleofCommonStockOutstandingDetailsTable_lbl" xml:lang="en-US">Merger - Schedule of Common Stock Outstanding (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="abp_MergerScheduleofCommonStockOutstandingDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Schedule of Common Stock Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Schedule of Company&#8217;s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesFairValueLineItems_lbl" xml:lang="en-US">Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativesFairValueLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:href="abp-20250930.xsd#abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable_lbl" xml:lang="en-US">Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:to="abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Schedule of Warrants to Purchase Common Stock Outstanding [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable_lbl" xml:lang="en-US">Share-Based Compensation - Schedule of Company&#8217;s Restricted Stock Unit Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:to="abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Schedule of Company&#8217;s Restricted Stock Unit Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Schedule of Recorded Stock-Based Compensation Expense [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl0" xml:lang="en-US">Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ConsolidatedEntitiesDomain_lbl" xml:lang="en-US">Consolidated Entities [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ConsolidatedEntitiesDomain" xlink:to="srt_ConsolidatedEntitiesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementTable_lbl" xml:lang="en-US">Condensed Balance Sheet Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl" xml:lang="en-US">Schedule of Balance Sheet [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Schedule of Property and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativesFairValueLineItems_lbl0" xml:lang="en-US">Schedule of Fair Value of the Company&apos;s Position Under the Forward Purchase Agreement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativesFairValueLineItems_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl0" xml:lang="en-US">Schedule of Common Stock Warrant Activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable_lbl" xml:lang="en-US">Share-Based Compensation - Schedule of Company&#8217;s Stock Option Activity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" xlink:to="abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xml:lang="en-US">Derivative Contract [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable_lbl" xml:lang="en-US">Share-Based Compensation - Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" xlink:to="abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" xlink:href="abp-20250930.xsd#abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable_lbl" xml:lang="en-US">Income Taxes - Schedule of Net Deferred Tax Assets and Liabilities (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" xlink:to="abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" xlink:href="abp-20250930.xsd#abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies - Schedule of Depreciation on Property and Equipment Estimated Useful Lives (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfRestructuringDomain_lbl" xml:lang="en-US">Type of Restructuring [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_TypeOfRestructuringDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:href="abp-20250930.xsd#abp_OrganizationandDescriptionoftheBusinessDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_OrganizationandDescriptionoftheBusinessDetailsTable_lbl" xml:lang="en-US">Organization and Description of the Business (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="abp_OrganizationandDescriptionoftheBusinessDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Organization and Description of the Business [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_EquityMethodInvesteeNameDomain_lbl" xml:lang="en-US">Investment, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EquityMethodInvesteeNameDomain" xlink:to="srt_EquityMethodInvesteeNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="abp-20250930.xsd#abp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="abp_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MergerDetailsTable" xlink:href="abp-20250930.xsd#abp_MergerDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MergerDetailsTable_lbl" xml:lang="en-US">Merger (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MergerDetailsTable" xlink:to="abp_MergerDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_MergerLineItems" xlink:href="abp-20250930.xsd#abp_MergerLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MergerLineItems_lbl" xml:lang="en-US">Merger [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MergerLineItems" xlink:to="abp_MergerLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_FairValueMeasurementsDetailsTable" xlink:href="abp-20250930.xsd#abp_FairValueMeasurementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FairValueMeasurementsDetailsTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FairValueMeasurementsDetailsTable" xlink:to="abp_FairValueMeasurementsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl0" xml:lang="en-US">Fair Value Measurements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_LicenseandCollaborationAgreementsDetailsTable" xlink:href="abp-20250930.xsd#abp_LicenseandCollaborationAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_LicenseandCollaborationAgreementsDetailsTable_lbl" xml:lang="en-US">License and Collaboration Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LicenseandCollaborationAgreementsDetailsTable" xlink:to="abp_LicenseandCollaborationAgreementsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl0" xml:lang="en-US">License and Collaboration Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl" xml:lang="en-US">Extinguishment of Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:href="abp-20250930.xsd#abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable_lbl" xml:lang="en-US">Commitments under Research and Collaboration Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl1" xml:lang="en-US">Commitments under Research and Collaboration Agreements [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl" xml:lang="en-US">Supplier [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_CommitmentsandContingenciesDetailsTable" xlink:href="abp-20250930.xsd#abp_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommitmentsandContingenciesDetailsTable" xlink:to="abp_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherCommitmentsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ForwardPurchaseAgreementDetailsTable" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ForwardPurchaseAgreementDetailsTable_lbl" xml:lang="en-US">Forward Purchase Agreement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreementDetailsTable" xlink:to="abp_ForwardPurchaseAgreementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US">Forward Purchase Agreement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_WarrantsExercisableDateDomainDomain" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableDateDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_WarrantsExercisableDateDomainDomain_lbl" xml:lang="en-US">WarrantsExercisableDateDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WarrantsExercisableDateDomainDomain" xlink:to="abp_WarrantsExercisableDateDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_DebtInstrumentInterestRateTermDomainDomain" xlink:href="abp-20250930.xsd#abp_DebtInstrumentInterestRateTermDomainDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_DebtInstrumentInterestRateTermDomainDomain_lbl" xml:lang="en-US">DebtInstrumentInterestRateTermDomain [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DebtInstrumentInterestRateTermDomainDomain" xlink:to="abp_DebtInstrumentInterestRateTermDomainDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_NotesPayableDetailsTable" xlink:href="abp-20250930.xsd#abp_NotesPayableDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NotesPayableDetailsTable_lbl" xml:lang="en-US">Notes Payable (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NotesPayableDetailsTable" xlink:to="abp_NotesPayableDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Notes Payable [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_StandbyEquityPurchaseAgreementDetailsTable" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StandbyEquityPurchaseAgreementDetailsTable_lbl" xml:lang="en-US">Standby Equity Purchase Agreement (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StandbyEquityPurchaseAgreementDetailsTable" xlink:to="abp_StandbyEquityPurchaseAgreementDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_StandbyEquityPurchaseAgreementLineItems" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StandbyEquityPurchaseAgreementLineItems_lbl" xml:lang="en-US">Standby Equity Purchase Agreement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StandbyEquityPurchaseAgreementLineItems" xlink:to="abp_StandbyEquityPurchaseAgreementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Combination [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_StockholdersEquityDetailsTable" xlink:href="abp-20250930.xsd#abp_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&#8217; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockholdersEquityDetailsTable" xlink:to="abp_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Stockholders&#8217; Equity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Title and Position [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ShareBasedCompensationDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ShareBasedCompensationDetailsTable_lbl" xml:lang="en-US">Share-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationDetailsTable" xlink:to="abp_ShareBasedCompensationDetailsTable_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1" xml:lang="en-US">Share-Based Compensation [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl1"/>
    <loc xlink:type="locator" xlink:label="abp_RelatedPartiesDetailsTable" xlink:href="abp-20250930.xsd#abp_RelatedPartiesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_RelatedPartiesDetailsTable_lbl" xml:lang="en-US">Related Parties (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RelatedPartiesDetailsTable" xlink:to="abp_RelatedPartiesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Parties [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_SubsequentEventsDetailsTable" xlink:href="abp-20250930.xsd#abp_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SubsequentEventsDetailsTable" xlink:to="abp_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Events [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PledgingPurposeDomain_lbl" xml:lang="en-US">Pledging Purpose [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PledgingPurposeDomain" xlink:to="us-gaap_PledgingPurposeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_LeasesDetailsTable" xlink:href="abp-20250930.xsd#abp_LeasesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_LeasesDetailsTable_lbl" xml:lang="en-US">Leases (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LeasesDetailsTable" xlink:to="abp_LeasesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xml:lang="en-US">Leases [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US">Tax Period [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_IncomeTaxesDetailsTable" xlink:href="abp-20250930.xsd#abp_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IncomeTaxesDetailsTable" xlink:to="abp_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxContingencyLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxContingencyLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ACABLiabilitiesAssumedInTheMerger_lbl0" xml:lang="en-US">The value represents ACAB liabilities assumed in the Merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ACABLiabilitiesAssumedInTheMerger" xlink:to="abp_ACABLiabilitiesAssumedInTheMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AccrueInterestPercentage_lbl0" xml:lang="en-US">Accrue interest percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccrueInterestPercentage" xlink:to="abp_AccrueInterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AccruedBODCompensation_lbl1" xml:lang="en-US">Represents the amount of BOD compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedBODCompensation" xlink:to="abp_AccruedBODCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AccruedInterest_lbl0" xml:lang="en-US">Represents the amount of accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedInterest" xlink:to="abp_AccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AccruedLicenseFees_lbl0" xml:lang="en-US">Represents the amount of accrued license fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedLicenseFees" xlink:to="abp_AccruedLicenseFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AccruedToAmount_lbl0" xml:lang="en-US">The amount of accrued to related party amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedToAmount" xlink:to="abp_AccruedToAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AdditionSharesOfCommonStock_lbl0" xml:lang="en-US">Number of addition shares of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdditionSharesOfCommonStock" xlink:to="abp_AdditionSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AdditionalAccruedInterest_lbl0" xml:lang="en-US">Amount of additional accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdditionalAccruedInterest" xlink:to="abp_AdditionalAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AdditionalInterestExpense_lbl0" xml:lang="en-US">Additional interest expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdditionalInterestExpense" xlink:to="abp_AdditionalInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AggregateIncentiveShare_lbl0" xml:lang="en-US">Number of aggregate incentive shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AggregateIncentiveShare" xlink:to="abp_AggregateIncentiveShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AggregatePurchasePrice_lbl0" xml:lang="en-US">The amount of aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AggregatePurchasePrice" xlink:to="abp_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AgreementInitialTerm_lbl0" xml:lang="en-US">Agreement initial term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AgreementInitialTerm" xlink:to="abp_AgreementInitialTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AnnualBaseFee_lbl0" xml:lang="en-US">Represents the annual base fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AnnualBaseFee" xlink:to="abp_AnnualBaseFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_AnnualSalesMilestonePayments_lbl0" xml:lang="en-US">Annual sales milestone payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AnnualSalesMilestonePayments" xlink:to="abp_AnnualSalesMilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_BusinessDays_lbl0" xml:lang="en-US">Business days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_BusinessDays" xlink:to="abp_BusinessDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_CarryforwardsTerm_lbl0" xml:lang="en-US">Carryforwards term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CarryforwardsTerm" xlink:to="abp_CarryforwardsTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_CashTransferredToEscrow_lbl0" xml:lang="en-US">The value represents to cash transferred into escrow pursuant to forward purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CashTransferredToEscrow" xlink:to="abp_CashTransferredToEscrow_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ChangeInFairValueEmbeddedDerivativeLiability_lbl0" xml:lang="en-US">The value represents change in fair value of embedded derivative liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueEmbeddedDerivativeLiability" xlink:to="abp_ChangeInFairValueEmbeddedDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ChangeInFairValueOfEmbeddedDerivativeLiability_lbl0" xml:lang="en-US">The value represents change in fair value of embedded derivative liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfEmbeddedDerivativeLiability" xlink:to="abp_ChangeInFairValueOfEmbeddedDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset_lbl0" xml:lang="en-US">The value represents of change in fair value of forward purchase agreement asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset" xlink:to="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset_lbl0" xml:lang="en-US">The value of change in fair value of forward purchase agreement asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset" xlink:to="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ChangeInFairValueOfSEPAPutRightAsset_lbl0" xml:lang="en-US">The value represents change in fair value of SEPA put rights asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfSEPAPutRightAsset" xlink:to="abp_ChangeInFairValueOfSEPAPutRightAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ChangeInFairValueOfSEPAPutRightsAsset_lbl0" xml:lang="en-US">The value represents change in fair value of SEPA put rights asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfSEPAPutRightsAsset" xlink:to="abp_ChangeInFairValueOfSEPAPutRightsAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ChangeInFairValueOnEmbeddedDerivativeLiability_lbl0" xml:lang="en-US">The value represents change in fair value of embedded derivative liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOnEmbeddedDerivativeLiability" xlink:to="abp_ChangeInFairValueOnEmbeddedDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger_lbl0" xml:lang="en-US">Stock price trigger for redemption of public warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" xlink:to="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl0" xml:lang="en-US">Redemption price per public warrant .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ClinicalDevelopmentMilestones_lbl0" xml:lang="en-US">Represent the clinical development milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ClinicalDevelopmentMilestones" xlink:to="abp_ClinicalDevelopmentMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_CommercialSales_lbl0" xml:lang="en-US">Represent the commercial sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommercialSales" xlink:to="abp_CommercialSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability_lbl0" xml:lang="en-US">It represents common stock issued in settlement of convertible notes and embedded derivative liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" xlink:to="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger_lbl0" xml:lang="en-US">The number of shares in common stock warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger" xlink:to="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ContingentEarnoutPolicyTextBlock_lbl0" xml:lang="en-US">Contingent Earnout.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ContingentEarnoutPolicyTextBlock" xlink:to="abp_ContingentEarnoutPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement_lbl0" xml:lang="en-US">Conversion of consideration under promissory note agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement" xlink:to="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro_lbl0" xml:lang="en-US">The value represents conversion of notes payable-related parties into common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" xlink:to="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro_lbl0" xml:lang="en-US">The value represents conversion of pre-merger preferred stock of abpro into common stock of new abpro.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" xlink:to="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ConvertibleNotes_lbl0" xml:lang="en-US">Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle, if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleNotes" xlink:to="abp_ConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ConvertiblePreferredStockPolicyTextBlock_lbl0" xml:lang="en-US">Convertible Preferred Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertiblePreferredStockPolicyTextBlock" xlink:to="abp_ConvertiblePreferredStockPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ConvertibleThresholdConsecutiveTradingDays_lbl0" xml:lang="en-US">Threshold number of specified trading days in consecutive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleThresholdConsecutiveTradingDays" xlink:to="abp_ConvertibleThresholdConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_DeemedDividendResultingFromTheWarrantDownRound_lbl0" xml:lang="en-US">Deemed dividend resulting from the warrant down round.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeemedDividendResultingFromTheWarrantDownRound" xlink:to="abp_DeemedDividendResultingFromTheWarrantDownRound_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_DeferredOfferingCostsIncludedInAccountsPayable_lbl0" xml:lang="en-US">Represent the amount of deferred offering costs included in accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeferredOfferingCostsIncludedInAccountsPayable" xlink:to="abp_DeferredOfferingCostsIncludedInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_DeferredTaxAssetsLeaseLiability_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset lease liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeferredTaxAssetsLeaseLiability" xlink:to="abp_DeferredTaxAssetsLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_DeferredTaxLiabilitiesRightofuseAsset_lbl0" xml:lang="en-US">Amount of deferred tax liabilities right-of-use asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeferredTaxLiabilitiesRightofuseAsset" xlink:to="abp_DeferredTaxLiabilitiesRightofuseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_DerivativeChangeInFairValue_lbl0" xml:lang="en-US">Derivative change in fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DerivativeChangeInFairValue" xlink:to="abp_DerivativeChangeInFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_DesignatedShares_lbl0" xml:lang="en-US">The number of shares in designated.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DesignatedShares" xlink:to="abp_DesignatedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_DevelopmentMilestones_lbl0" xml:lang="en-US">Development milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DevelopmentMilestones" xlink:to="abp_DevelopmentMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_EarlyTerminationResetPricePerShare_lbl0" xml:lang="en-US">Early termination reset price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EarlyTerminationResetPricePerShare" xlink:to="abp_EarlyTerminationResetPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_EarnoutShare_lbl0" xml:lang="en-US">Earnout share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EarnoutShare" xlink:to="abp_EarnoutShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit_lbl0" xml:lang="en-US">The amount of federal research and development credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" xlink:to="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_EmergingGrowthCompanyPolicyTextBlock_lbl0" xml:lang="en-US">Emerging growth company .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EmergingGrowthCompanyPolicyTextBlock" xlink:to="abp_EmergingGrowthCompanyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_EstimatedFuturePricePerShare_lbl0" xml:lang="en-US">Estimated future price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EstimatedFuturePricePerShare" xlink:to="abp_EstimatedFuturePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ExcessOfCommonStockPercentage_lbl0" xml:lang="en-US">Percentage of excess common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExcessOfCommonStockPercentage" xlink:to="abp_ExcessOfCommonStockPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ExcessTaxes_lbl0" xml:lang="en-US">Excess taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExcessTaxes" xlink:to="abp_ExcessTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage_lbl0" xml:lang="en-US">Excise tax generally of the fair market value percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage" xlink:to="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ExciseTaxLiability_lbl0" xml:lang="en-US">Excise tax liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExciseTaxLiability" xlink:to="abp_ExciseTaxLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ExpiredAtTheMerger_lbl0" xml:lang="en-US">The number of shares in expired the merger.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExpiredAtTheMerger" xlink:to="abp_ExpiredAtTheMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_FederalAndStateResearchAndDevelopmentCredits_lbl0" xml:lang="en-US">The amount of federal and state research and development credits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FederalAndStateResearchAndDevelopmentCredits" xlink:to="abp_FederalAndStateResearchAndDevelopmentCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_FloorPrice_lbl0" xml:lang="en-US">The floor price. A payment or receipt is triggered if the market rate falls below the floor rate on the contract.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FloorPrice" xlink:to="abp_FloorPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ForwardContractBaseResetPricePerShare_lbl0" xml:lang="en-US">Forward contract, base reset price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardContractBaseResetPricePerShare" xlink:to="abp_ForwardContractBaseResetPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ForwardContractInitialResetPricePerShare_lbl0" xml:lang="en-US">Forward contract, initial reset price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardContractInitialResetPricePerShare" xlink:to="abp_ForwardContractInitialResetPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ForwardPurchaseAgreement_lbl0" xml:lang="en-US">The amount of forward purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreement" xlink:to="abp_ForwardPurchaseAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ForwardPurchaseAgreementAsset_lbl0" xml:lang="en-US">The amount of forward purchase agreement asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreementAsset" xlink:to="abp_ForwardPurchaseAgreementAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_IncentiveSharesReceivedBySubsidiary_lbl0" xml:lang="en-US">Incentive shares received by subsidiary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IncentiveSharesReceivedBySubsidiary" xlink:to="abp_IncentiveSharesReceivedBySubsidiary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_InstallmentsAmount_lbl0" xml:lang="en-US">The amount of installments amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_InstallmentsAmount" xlink:to="abp_InstallmentsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses_lbl0" xml:lang="en-US">Issuance costs for Advance Shares included in accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" xlink:to="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_IssuanceOfCommonStockInPIPEFinancing_lbl0" xml:lang="en-US">Number of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfCommonStockInPIPEFinancing" xlink:to="abp_IssuanceOfCommonStockInPIPEFinancing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_IssuanceOfCommonStockInThePIPEFinancing_lbl0" xml:lang="en-US">issuance of common stock in pipe financing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfCommonStockInThePIPEFinancing" xlink:to="abp_IssuanceOfCommonStockInThePIPEFinancing_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_IssuanceOfCommonStockInTransactionCost_lbl0" xml:lang="en-US">Issuance of common stock in transaction costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfCommonStockInTransactionCost" xlink:to="abp_IssuanceOfCommonStockInTransactionCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_IssuanceOfSharesPercentage_lbl0" xml:lang="en-US">Percentage of issuance shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfSharesPercentage" xlink:to="abp_IssuanceOfSharesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_LetterOfCreditExtendedPeriod_lbl0" xml:lang="en-US">Letter of credit extended period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LetterOfCreditExtendedPeriod" xlink:to="abp_LetterOfCreditExtendedPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_LossOnSettlementOfConvertibleNotes_lbl0" xml:lang="en-US">The value represents loss on settlement of convertible notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LossOnSettlementOfConvertibleNotes" xlink:to="abp_LossOnSettlementOfConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_LossOnSettlementsOfConvertibleNotes_lbl0" xml:lang="en-US">The value represents loss on settlement of convertible notes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LossOnSettlementsOfConvertibleNotes" xlink:to="abp_LossOnSettlementsOfConvertibleNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_MilestonePaymentOnNetSales_lbl0" xml:lang="en-US">Represents milestone payment based on net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePaymentOnNetSales" xlink:to="abp_MilestonePaymentOnNetSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_MilestonePayments_lbl0" xml:lang="en-US">Represent the milestone payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePayments" xlink:to="abp_MilestonePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_MilestonePaymentsCommercialMilestones_lbl0" xml:lang="en-US">Milestone payments commercial milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePaymentsCommercialMilestones" xlink:to="abp_MilestonePaymentsCommercialMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents_lbl0" xml:lang="en-US">Represents milestone payments upon achieving research and development and commercialization events.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents" xlink:to="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_MonthlyInstallmentPayments_lbl0" xml:lang="en-US">Monthly installment payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MonthlyInstallmentPayments" xlink:to="abp_MonthlyInstallmentPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_NetProceedsFromTheMerger_lbl0" xml:lang="en-US">Cash received from collaborators during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NetProceedsFromTheMerger" xlink:to="abp_NetProceedsFromTheMerger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_NetProfitsFromLicensedProductSales_lbl0" xml:lang="en-US">Net profits from licensed product sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NetProfitsFromLicensedProductSales" xlink:to="abp_NetProfitsFromLicensedProductSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_NonRefundablePayments_lbl0" xml:lang="en-US">The amount of non-refundable payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NonRefundablePayments" xlink:to="abp_NonRefundablePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_NoncontrollingInterestPolicyTextBlock_lbl0" xml:lang="en-US">Non-controlling Interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NoncontrollingInterestPolicyTextBlock" xlink:to="abp_NoncontrollingInterestPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_NumberOfConsecutiveTradingDays_lbl0" xml:lang="en-US">Represent the number of consecutive trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfConsecutiveTradingDays" xlink:to="abp_NumberOfConsecutiveTradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare_lbl0" xml:lang="en-US">Number of days used for calculating volume weighted average price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" xlink:to="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_NumberOfTradingDaysForDeterminingTheSharePrice_lbl0" xml:lang="en-US">Number of trading days for determining the share price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:to="abp_NumberOfTradingDaysForDeterminingTheSharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_OfferingCostsIncludedInAccountsPayable_lbl0" xml:lang="en-US">The value represents offering costs included in accounts payable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OfferingCostsIncludedInAccountsPayable" xlink:to="abp_OfferingCostsIncludedInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_OriginalCelltrionAgreement_lbl0" xml:lang="en-US">Original celltrion agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OriginalCelltrionAgreement" xlink:to="abp_OriginalCelltrionAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PatentCostsReimbursements_lbl0" xml:lang="en-US">related to the patent costs reimbursements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PatentCostsReimbursements" xlink:to="abp_PatentCostsReimbursements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PatentsNet_lbl0" xml:lang="en-US">The amount of patents, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PatentsNet" xlink:to="abp_PatentsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PatentsPolicyTextBlock_lbl0" xml:lang="en-US">Patents.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PatentsPolicyTextBlock" xlink:to="abp_PatentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PaymentForExtensionRoyalities_lbl0" xml:lang="en-US">The company is liable for extension royalties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PaymentForExtensionRoyalities" xlink:to="abp_PaymentForExtensionRoyalities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PaymentOfDevelopmentMilestones_lbl0" xml:lang="en-US">The amount of payment of development milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PaymentOfDevelopmentMilestones" xlink:to="abp_PaymentOfDevelopmentMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PaymentOfRentAndMaintenanceExpense_lbl0" xml:lang="en-US">It represents rent and maintenance expenses to landlord.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PaymentOfRentAndMaintenanceExpense" xlink:to="abp_PaymentOfRentAndMaintenanceExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PerShareRedemptionsTriggerPrice_lbl0" xml:lang="en-US">The number of per share in trigger price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PerShareRedemptionsTriggerPrice" xlink:to="abp_PerShareRedemptionsTriggerPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfAdvanceNotice_lbl0" xml:lang="en-US">The percentage of advance notice.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfAdvanceNotice" xlink:to="abp_PercentageOfAdvanceNotice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfAmendedCelltrionAgreement_lbl0" xml:lang="en-US">Percentage of amended celltrion agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfAmendedCelltrionAgreement" xlink:to="abp_PercentageOfAmendedCelltrionAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfAmortizationPrincipalAmount_lbl0" xml:lang="en-US">Percentage of amortization principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfAmortizationPrincipalAmount" xlink:to="abp_PercentageOfAmortizationPrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfClosingPrice_lbl0" xml:lang="en-US">Percentage of Closing Price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfClosingPrice" xlink:to="abp_PercentageOfClosingPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfCommonStock_lbl1" xml:lang="en-US">Percentage of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfCommonStock" xlink:to="abp_PercentageOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfCommonStockOutstanding_lbl0" xml:lang="en-US">Percentage of Common Stock Outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfCommonStockOutstanding" xlink:to="abp_PercentageOfCommonStockOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfLiabilityTotal_lbl0" xml:lang="en-US">Percentage of total liability.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfLiabilityTotal" xlink:to="abp_PercentageOfLiabilityTotal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfMarketValueAndNewlyIssuedPrice_lbl0" xml:lang="en-US">Percentage of market value and newly issued price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfMarketValueAndNewlyIssuedPrice" xlink:to="abp_PercentageOfMarketValueAndNewlyIssuedPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfOriginalCelltrionAgreement_lbl0" xml:lang="en-US">Percentage of original celltrion agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfOriginalCelltrionAgreement" xlink:to="abp_PercentageOfOriginalCelltrionAgreement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfReimbursement_lbl0" xml:lang="en-US">Percentage of reimbursement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfReimbursement" xlink:to="abp_PercentageOfReimbursement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfUnderpaymentPenaltyPerMonth_lbl0" xml:lang="en-US">Percentage of underpayment penalty per month.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfUnderpaymentPenaltyPerMonth" xlink:to="abp_PercentageOfUnderpaymentPenaltyPerMonth_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PercentageOfVolumeWeightedAveragePrice_lbl0" xml:lang="en-US">Percentage of volume weighted average price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfVolumeWeightedAveragePrice" xlink:to="abp_PercentageOfVolumeWeightedAveragePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PeriodAfterWhichTheWarrantsAreExercisable_lbl0" xml:lang="en-US">Period after which the warrants are exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PeriodAfterWhichTheWarrantsAreExercisable" xlink:to="abp_PeriodAfterWhichTheWarrantsAreExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl0" xml:lang="en-US">The policy disclosure of recently adopted accounting pronouncements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense_lbl0" xml:lang="en-US">Represent the amount of reclassification of residual value guarantees under finance lease to accrued expense.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" xlink:to="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_RegulatoryEvents_lbl0" xml:lang="en-US">Represent the regulatory events.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RegulatoryEvents" xlink:to="abp_RegulatoryEvents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_RemainingSharesIssued_lbl0" xml:lang="en-US">Remaining shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RemainingSharesIssued" xlink:to="abp_RemainingSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for restatement of previously issued financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" xlink:to="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ReverseStockSplitSharesOfIssued_lbl0" xml:lang="en-US">Reverse stock split shares of issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReverseStockSplitSharesOfIssued" xlink:to="abp_ReverseStockSplitSharesOfIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ReverseStockSpllitSharesOfOutstanding_lbl0" xml:lang="en-US">Reverse stock spllit shares of outstanding.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReverseStockSpllitSharesOfOutstanding" xlink:to="abp_ReverseStockSpllitSharesOfOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SEPACommitmentFeePaidInCommonStockShares_lbl0" xml:lang="en-US">The value of SEPA commitment fee paid in common stock shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPACommitmentFeePaidInCommonStockShares" xlink:to="abp_SEPACommitmentFeePaidInCommonStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SEPAPutRightsAsset_lbl0" xml:lang="en-US">The amount of SEPA put rights asset.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPAPutRightsAsset" xlink:to="abp_SEPAPutRightsAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of property plant and equipment depreciation over the estimated useful lives.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SecurityBidPricePerShare_lbl0" xml:lang="en-US">Represent the amount of security bid price per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SecurityBidPricePerShare" xlink:to="abp_SecurityBidPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties_lbl0" xml:lang="en-US">The value represents settlement of bonus accrual through notes payable - related parties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties" xlink:to="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl0" xml:lang="en-US">Share based compensation arrangement by share based payment award fair value assumptions fair value of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards exercised, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards Forfeited,Expiration, and Cancelled, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">Weighted average remaining contractual term for option awards granted, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount_lbl0" xml:lang="en-US">Share price after deducting from volume weighted average price upon calculation of settlement amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" xlink:to="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted- Average Remaining Vesting Period, forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted- Average Remaining Vesting Period, granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Weighted- Average Remaining Vesting Period, vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_StandbyEquityPurchaseAgreementTextBlock_lbl0" xml:lang="en-US">The entire disclosure for standby equity purchase agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StandbyEquityPurchaseAgreementTextBlock" xlink:to="abp_StandbyEquityPurchaseAgreementTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl0" xml:lang="en-US">Number of shares issued under the merger, net of transaction costs and acquired liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:to="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl0" xml:lang="en-US">Represents the value of stock issued under the merger, net of transaction costs and acquired liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:to="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_TradingDays_lbl0" xml:lang="en-US">Trading days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TradingDays" xlink:to="abp_TradingDays_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for unaudited interim condensed consolidated financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_UnpaidAmount_lbl0" xml:lang="en-US">Unpaid amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_UnpaidAmount" xlink:to="abp_UnpaidAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_VolumeWeightedAveragePrice_lbl1" xml:lang="en-US">Volume weighted average price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VolumeWeightedAveragePrice" xlink:to="abp_VolumeWeightedAveragePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_WarrantsExercisableTerm_lbl0" xml:lang="en-US">Warrants exercisable term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WarrantsExercisableTerm" xlink:to="abp_WarrantsExercisableTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PrivatePlacementWarrantsMember_lbl0" xml:lang="en-US">Private placement warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PrivatePlacementWarrantsMember" xlink:to="abp_PrivatePlacementWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PromissoryNoteAgreementMember_lbl0" xml:lang="en-US">Promissory note agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteAgreementMember" xlink:to="abp_PromissoryNoteAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PromissoryNoteMember_lbl0" xml:lang="en-US">Promissory note .</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteMember" xlink:to="abp_PromissoryNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_PublicWarrantsMember_lbl0" xml:lang="en-US">Public warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PublicWarrantsMember" xlink:to="abp_PublicWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SeriesACommonStockMember_lbl0" xml:lang="en-US">Series A Common Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesACommonStockMember" xlink:to="abp_SeriesACommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SeriesBCommonStockMember_lbl0" xml:lang="en-US">Series B Common Stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesBCommonStockMember" xlink:to="abp_SeriesBCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="abp_SponsorMember_lbl0" xml:lang="en-US">Sponsor.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SponsorMember" xlink:to="abp_SponsorMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_lbl" xml:lang="en-US">Shorter of useful life or lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember" xlink:to="us-gaap_UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ChiefExecutiveOfficerMember_lbl0" xml:lang="en-US">Chief Executive Officer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ChiefExecutiveOfficerMember" xlink:to="srt_ChiefExecutiveOfficerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl0" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MedImmuneLicenseAgreementMember_lbl0" xml:lang="en-US">Med Immune License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MedImmuneLicenseAgreementMember" xlink:to="abp_MedImmuneLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativesPolicyTextBlock_lbl0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesPolicyTextBlock" xlink:to="us-gaap_DerivativesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement_lbl1" xml:lang="en-US">Conversion Of Consideration Under Promissory Note Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement" xlink:to="abp_ConversionOfConsiderationUnderPromissoryNoteAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl0" xml:lang="en-US">Features of Convertible Preferred Stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl0" xml:lang="en-US">Accrued Professional Fees, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PublicWarrantsMember_lbl1" xml:lang="en-US">Public Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PublicWarrantsMember" xlink:to="abp_PublicWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FirstConvertibleNoteMember_lbl0" xml:lang="en-US">First Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FirstConvertibleNoteMember" xlink:to="abp_FirstConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl0" xml:lang="en-US">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MabwellShanghaiBioscienceCoLtdMember_lbl1" xml:lang="en-US">Mabwell Shanghai Bioscience Co Ltd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MabwellShanghaiBioscienceCoLtdMember" xlink:to="abp_MabwellShanghaiBioscienceCoLtdMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Finance Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1" xml:lang="en-US">Business Combination, Transaction Cost, Excluding Separately Recognized Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_DeferredOfferingCostsIncludedInAccountsPayable_lbl1" xml:lang="en-US">Deferred Offering Costs Included In Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeferredOfferingCostsIncludedInAccountsPayable" xlink:to="abp_DeferredOfferingCostsIncludedInAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount_lbl1" xml:lang="en-US">Share Price After Deducting From Volume Weighted Average Price Upon Calculation Of Settlement Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" xlink:to="abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesCPreferredStockMember_lbl0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesCPreferredStockMember" xlink:to="us-gaap_SeriesCPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger_lbl1" xml:lang="en-US">Class Of Warrant Or Right Redemption Of Warrants Or Rights Stock Price Trigger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" xlink:to="abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl1" xml:lang="en-US">Stock Issued During Period Shares Merger Net Of Transaction Costs And Acquired Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:to="abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PromissoryNoteWithABIMember_lbl0" xml:lang="en-US">Promissory Note With ABIMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteWithABIMember" xlink:to="abp_PromissoryNoteWithABIMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SEPAMember_lbl0" xml:lang="en-US">SEPAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPAMember" xlink:to="abp_SEPAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CROVendorMember_lbl0" xml:lang="en-US">CROVendor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CROVendorMember" xlink:to="abp_CROVendorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_VolumeWeightedAveragePrice_lbl2" xml:lang="en-US">Volume Weighted Average Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VolumeWeightedAveragePrice" xlink:to="abp_VolumeWeightedAveragePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_DesignatedShares_lbl1" xml:lang="en-US">Designated Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DesignatedShares" xlink:to="abp_DesignatedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl0" xml:lang="en-US">Investment Income, Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_RegulatoryEvents_lbl1" xml:lang="en-US">Regulatory Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RegulatoryEvents" xlink:to="abp_RegulatoryEvents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl0" xml:lang="en-US">Other Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl0" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AggregateIncentiveShare_lbl1" xml:lang="en-US">Aggregate Incentive Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AggregateIncentiveShare" xlink:to="abp_AggregateIncentiveShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AdditionSharesOfCommonStock_lbl1" xml:lang="en-US">Addition Shares Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdditionSharesOfCommonStock" xlink:to="abp_AdditionSharesOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl1" xml:lang="en-US">Liabilities, Fair Value Adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl1" xml:lang="en-US">Liabilities, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NonRedemptionAgreementsMember_lbl0" xml:lang="en-US">Non Redemption Agreements Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NonRedemptionAgreementsMember" xlink:to="abp_NonRedemptionAgreementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl0" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MarketValueOfPubliclyHeldSharesMember_lbl0" xml:lang="en-US">Market Value Of Publicly Held Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MarketValueOfPubliclyHeldSharesMember" xlink:to="abp_MarketValueOfPubliclyHeldSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0" xml:lang="en-US">Common Stock, Convertible, Conversion Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FirstSharesTargetMember_lbl0" xml:lang="en-US">First Shares Target Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FirstSharesTargetMember" xlink:to="abp_FirstSharesTargetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PatentsPolicyTextBlock_lbl1" xml:lang="en-US">Patents Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PatentsPolicyTextBlock" xlink:to="abp_PatentsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonMember_lbl0" xml:lang="en-US">Treasury Stock, Common [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonMember" xlink:to="us-gaap_TreasuryStockCommonMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_TradingDays_lbl1" xml:lang="en-US">Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TradingDays" xlink:to="abp_TradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SeriesBConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series BConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesBConvertiblePreferredStockMember" xlink:to="abp_SeriesBConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage_lbl1" xml:lang="en-US">Excise Tax Generally Of The Fair Market Value Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage" xlink:to="abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SeriesCConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series CConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesCConvertiblePreferredStockMember" xlink:to="abp_SeriesCConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl1" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0" xml:lang="en-US">Accounts Receivable [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PIPESharesMember_lbl0" xml:lang="en-US">PIPEShares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PIPESharesMember" xlink:to="abp_PIPESharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl1" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses_lbl1" xml:lang="en-US">Issuance Costs For Advance Shares Included In Accrued Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" xlink:to="abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl1" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncome_lbl1" xml:lang="en-US">Other Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncome" xlink:to="us-gaap_OtherIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl0" xml:lang="en-US">Accrued Salaries, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset_lbl1" xml:lang="en-US">Change In Fair Value Of Forward Purchase Agreement Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset" xlink:to="abp_ChangeInFairValueOfForwardPurchaseAgreementAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NoncontrollingInterestPolicyTextBlock_lbl1" xml:lang="en-US">Noncontrolling Interest Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NoncontrollingInterestPolicyTextBlock" xlink:to="abp_NoncontrollingInterestPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl0" xml:lang="en-US">Amendment Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NewConsultingAgreementMember_lbl0" xml:lang="en-US">New Consulting Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewConsultingAgreementMember" xlink:to="abp_NewConsultingAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl0" xml:lang="en-US">Finance Lease, Principal Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ForwardPurchaseAgreementAsset_lbl1" xml:lang="en-US">Forward Purchase Agreement Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreementAsset" xlink:to="abp_ForwardPurchaseAgreementAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MonthlyInstallmentPayments_lbl1" xml:lang="en-US">Monthly Installment Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MonthlyInstallmentPayments" xlink:to="abp_MonthlyInstallmentPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl0" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FirstConvertibleNotesMember_lbl0" xml:lang="en-US">First Convertible Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FirstConvertibleNotesMember" xlink:to="abp_FirstConvertibleNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MilestonePaymentsCommercialMilestones_lbl1" xml:lang="en-US">Milestone Payments Commercial Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePaymentsCommercialMilestones" xlink:to="abp_MilestonePaymentsCommercialMilestones_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt_lbl2" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRelatedPartyDebt" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CarryforwardsTerm_lbl1" xml:lang="en-US">Carryforwards Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CarryforwardsTerm" xlink:to="abp_CarryforwardsTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SeriesDConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series DConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesDConvertiblePreferredStockMember" xlink:to="abp_SeriesDConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation_lbl0" xml:lang="en-US">Salary and Wage, Excluding Cost of Good and Service Sold</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensation" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_OriginalCelltrionAgreement_lbl1" xml:lang="en-US">Original Celltrion Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OriginalCelltrionAgreement" xlink:to="abp_OriginalCelltrionAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue_lbl1" xml:lang="en-US">Forward Contract Indexed to Equity, Settlement, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_RegistrationEventMember_lbl0" xml:lang="en-US">Registration Event Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RegistrationEventMember" xlink:to="abp_RegistrationEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PostApportionedMassachusettsMember_lbl0" xml:lang="en-US">Post Apportioned Massachusetts Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PostApportionedMassachusettsMember" xlink:to="abp_PostApportionedMassachusettsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebtMember_lbl0" xml:lang="en-US">Convertible Debt [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtMember" xlink:to="us-gaap_ConvertibleDebtMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CashTransferredToEscrow_lbl1" xml:lang="en-US">Cash Transferred To Escrow</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CashTransferredToEscrow" xlink:to="abp_CashTransferredToEscrow_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ExchangeCapEventMember_lbl0" xml:lang="en-US">Exchange Cap Event Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExchangeCapEventMember" xlink:to="abp_ExchangeCapEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Granted Outstanding Weighted Average Remaining Contractual Term2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MonteCarloSimulationMember_lbl0" xml:lang="en-US">Monte Carlo Simulation Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MonteCarloSimulationMember" xlink:to="abp_MonteCarloSimulationMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_BusinessDays_lbl1" xml:lang="en-US">Business Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_BusinessDays" xlink:to="abp_BusinessDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ACABMember_lbl0" xml:lang="en-US">ACABMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ACABMember" xlink:to="abp_ACABMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation Federal Research And Development Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" xlink:to="abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl1" xml:lang="en-US">Class Of Warrant Or Right Redemption Price Of Warrants Or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NonRefundablePayments_lbl1" xml:lang="en-US">Non Refundable Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NonRefundablePayments" xlink:to="abp_NonRefundablePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Equity, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ForwardContractInitialResetPricePerShare_lbl1" xml:lang="en-US">Forward Contract Initial Reset Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardContractInitialResetPricePerShare" xlink:to="abp_ForwardContractInitialResetPricePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Assumptions Of The Stock Options Granted To Employees Directors And Nonemployees Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract" xlink:to="abp_ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SeriesEConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series EConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesEConvertiblePreferredStockMember" xlink:to="abp_SeriesEConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl1" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ACABLiabilitiesAssumedInTheMerger_lbl1" xml:lang="en-US">ACABLiabilities Assumed In The Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ACABLiabilitiesAssumedInTheMerger" xlink:to="abp_ACABLiabilitiesAssumedInTheMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ParentMember_lbl0" xml:lang="en-US">Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ParentMember" xlink:to="us-gaap_ParentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PrivateWarrantsMember_lbl0" xml:lang="en-US">Private Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PrivateWarrantsMember" xlink:to="abp_PrivateWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NJCTTQCollaborationAgreementMember_lbl0" xml:lang="en-US">NJCTTQCollaboration Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NJCTTQCollaborationAgreementMember" xlink:to="abp_NJCTTQCollaborationAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfCommonStockWarrantActivityAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCommonStockWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfCommonStockWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule Of Common Stock Warrant Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfCommonStockWarrantActivityAbstract" xlink:to="abp_ScheduleOfCommonStockWarrantActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_LegacyAbproMember_lbl0" xml:lang="en-US">Legacy Abpro Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LegacyAbproMember" xlink:to="abp_LegacyAbproMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_BlackAndScholesModelMember_lbl0" xml:lang="en-US">Black And Scholes Model Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_BlackAndScholesModelMember" xlink:to="abp_BlackAndScholesModelMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl0" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_lbl0" xml:lang="en-US">Payments for Merger Related Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMergerRelatedCosts" xlink:to="us-gaap_PaymentsForMergerRelatedCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ABIMember_lbl0" xml:lang="en-US">ABIMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ABIMember" xlink:to="abp_ABIMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NCILicenseAgreementMember_lbl0" xml:lang="en-US">NCILicense Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NCILicenseAgreementMember" xlink:to="abp_NCILicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_OtherAccruedExpensesMember_lbl0" xml:lang="en-US">Other Accrued Expenses Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OtherAccruedExpensesMember" xlink:to="abp_OtherAccruedExpensesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CelltrionIncMember_lbl0" xml:lang="en-US">Celltrion Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CelltrionIncMember" xlink:to="abp_CelltrionIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl0" xml:lang="en-US">Investment Company, Reimbursable Excess Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AbproHoldingsIncMember_lbl0" xml:lang="en-US">Abpro Holdings Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AbproHoldingsIncMember" xlink:to="abp_AbproHoldingsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfCompanySRestrictedStockUnitActivityAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCompanySRestrictedStockUnitActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfCompanySRestrictedStockUnitActivityAbstract_lbl" xml:lang="en-US">Schedule Of Company SRestricted Stock Unit Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfCompanySRestrictedStockUnitActivityAbstract" xlink:to="abp_ScheduleOfCompanySRestrictedStockUnitActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl2" xml:lang="en-US">Previously Reported [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset_lbl1" xml:lang="en-US">Change In Fair Value Of Forward Puchase Agreement Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset" xlink:to="abp_ChangeInFairValueOfForwardPuchaseAgreementAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AccrueInterestPercentage_lbl1" xml:lang="en-US">Accrue Interest Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccrueInterestPercentage" xlink:to="abp_AccrueInterestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PromissoryNoteMember_lbl1" xml:lang="en-US">Promissory Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteMember" xlink:to="abp_PromissoryNoteMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfDilutedNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="abp_ScheduleOfDilutedNetLossPerShareAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl3" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PaymentOfDevelopmentMilestones_lbl1" xml:lang="en-US">Payment Of Development Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PaymentOfDevelopmentMilestones" xlink:to="abp_PaymentOfDevelopmentMilestones_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl0" xml:lang="en-US">Finance Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl0" xml:lang="en-US">Finance Lease, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_DerivativeChangeInFairValue_lbl1" xml:lang="en-US">Derivative Change In Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DerivativeChangeInFairValue" xlink:to="abp_DerivativeChangeInFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl1" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ExciseAndSalesTaxes_lbl0" xml:lang="en-US">Excise and Sales Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ExciseAndSalesTaxes" xlink:to="us-gaap_ExciseAndSalesTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PatentCostsReimbursements_lbl1" xml:lang="en-US">Patent Costs Reimbursements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PatentCostsReimbursements" xlink:to="abp_PatentCostsReimbursements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NumberOfTradingDaysForDeterminingTheSharePrice_lbl1" xml:lang="en-US">Number Of Trading Days For Determining The Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfTradingDaysForDeterminingTheSharePrice" xlink:to="abp_NumberOfTradingDaysForDeterminingTheSharePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember_lbl0" xml:lang="en-US">ACABFounder Shares Less Of Forfeitures And Transfers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember" xlink:to="abp_ACABFounderSharesLessOfForfeituresAndTransfersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl0" xml:lang="en-US">Other Nonoperating Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl1" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AnnualBaseFee_lbl1" xml:lang="en-US">Annual Base Fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AnnualBaseFee" xlink:to="abp_AnnualBaseFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NewAbproSharesTransferredToInvestorsMember_lbl0" xml:lang="en-US">New Abpro Shares Transferred To Investors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesTransferredToInvestorsMember" xlink:to="abp_NewAbproSharesTransferredToInvestorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PatentsNet_lbl1" xml:lang="en-US">Patents Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PatentsNet" xlink:to="abp_PatentsNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_WarrantsExercisableDateAxis_lbl0" xml:lang="en-US">Warrants Exercisable Date Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WarrantsExercisableDateAxis" xlink:to="abp_WarrantsExercisableDateAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl2" xml:lang="en-US">Repayments of Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivables_lbl0" xml:lang="en-US">Other Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivables" xlink:to="us-gaap_OtherReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfOriginalCelltrionAgreement_lbl1" xml:lang="en-US">Percentage Of Original Celltrion Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfOriginalCelltrionAgreement" xlink:to="abp_PercentageOfOriginalCelltrionAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ChangeInFairValueEmbeddedDerivativeLiability_lbl1" xml:lang="en-US">Change In Fair Value Embedded Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueEmbeddedDerivativeLiability" xlink:to="abp_ChangeInFairValueEmbeddedDerivativeLiability_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl0" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl0" xml:lang="en-US">Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesDPreferredStockMember_lbl0" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesDPreferredStockMember" xlink:to="us-gaap_SeriesDPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_TwoZeroTwoFourEquityIncentivePlanMember_lbl0" xml:lang="en-US">Two Zero Two Four Equity Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TwoZeroTwoFourEquityIncentivePlanMember" xlink:to="abp_TwoZeroTwoFourEquityIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SeparatePromissoryNoteAgreementMember_lbl0" xml:lang="en-US">Separate Promissory Note Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeparatePromissoryNoteAgreementMember" xlink:to="abp_SeparatePromissoryNoteAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SecondConvertibleNotesMember_lbl0" xml:lang="en-US">Second Convertible Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SecondConvertibleNotesMember" xlink:to="abp_SecondConvertibleNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl0" xml:lang="en-US">Temporary Equity, Redemption Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidRoyalties_lbl0" xml:lang="en-US">Prepaid Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidRoyalties" xlink:to="us-gaap_PrepaidRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl1" xml:lang="en-US">Unaudited Interim Condensed Consolidated Financial Statements Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:to="abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties_lbl1" xml:lang="en-US">Settlement Of Bonus Accrual Through Notes Payable Related Parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties" xlink:to="abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl3" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesEPreferredStockMember_lbl0" xml:lang="en-US">Series E Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesEPreferredStockMember" xlink:to="us-gaap_SeriesEPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_InterestBearingLiabilitiesAverageRatePaid_lbl0" xml:lang="en-US">Interest-Bearing Liabilities, Average Rate Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_InterestBearingLiabilitiesAverageRatePaid" xlink:to="srt_InterestBearingLiabilitiesAverageRatePaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember_lbl0" xml:lang="en-US">Year Two Thousand Twenty Four ABIPromissory Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember" xlink:to="abp_YearTwoThousandTwentyFourABIPromissoryNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FloorPrice_lbl1" xml:lang="en-US">Floor Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FloorPrice" xlink:to="abp_FloorPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ForwardContractBaseResetPricePerShare_lbl1" xml:lang="en-US">Forward Contract Base Reset Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardContractBaseResetPricePerShare" xlink:to="abp_ForwardContractBaseResetPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl2" xml:lang="en-US">Assets, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NewAbproSharesIssuedToServiceProvidersMember_lbl0" xml:lang="en-US">New Abpro Shares Issued To Service Providers Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesIssuedToServiceProvidersMember" xlink:to="abp_NewAbproSharesIssuedToServiceProvidersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_lbl1" xml:lang="en-US">Restatement Of Previously Issued Financial Statements Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" xlink:to="abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FloorPriceEventMember_lbl0" xml:lang="en-US">Floor Price Event Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FloorPriceEventMember" xlink:to="abp_FloorPriceEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountIssued1" xlink:to="us-gaap_ConversionOfStockAmountIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl2" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConvertiblePreferredStocksMember_lbl0" xml:lang="en-US">Convertible Preferred Stocks Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertiblePreferredStocksMember" xlink:to="abp_ConvertiblePreferredStocksMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl2" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AnnualSalesMilestonePayments_lbl1" xml:lang="en-US">Annual Sales Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AnnualSalesMilestonePayments" xlink:to="abp_AnnualSalesMilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Stock Price Trigger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember_lbl0" xml:lang="en-US">One Year Anniversary Of Issuance Date Of Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:to="abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ReverseStockSpllitSharesOfOutstanding_lbl1" xml:lang="en-US">Reverse Stock Spllit Shares Of Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReverseStockSpllitSharesOfOutstanding" xlink:to="abp_ReverseStockSpllitSharesOfOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal_lbl1" xml:lang="en-US">Debt Instrument, Issued, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuedPrincipal" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConvertibleNotesMember_lbl0" xml:lang="en-US">Convertible Notes Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleNotesMember" xlink:to="abp_ConvertibleNotesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_LetterOfCreditExtendedPeriod_lbl1" xml:lang="en-US">Letter Of Credit Extended Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LetterOfCreditExtendedPeriod" xlink:to="abp_LetterOfCreditExtendedPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0" xml:lang="en-US">Repayments of Related Party Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DemandDepositAccounts_lbl0" xml:lang="en-US">Demand Deposit Accounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DemandDepositAccounts" xlink:to="us-gaap_DemandDepositAccounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl0" xml:lang="en-US">Interest Expense, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl2" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl0" xml:lang="en-US">Payments for (Proceeds from) Previous Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract_lbl0" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl1" xml:lang="en-US">Stock Issued During Period Value Merger Net Of Transaction Costs And Acquired Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:to="abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ContingentEarnoutSharesMember_lbl0" xml:lang="en-US">Contingent Earnout Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ContingentEarnoutSharesMember" xlink:to="abp_ContingentEarnoutSharesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_LossOnSettlementsOfConvertibleNotes_lbl1" xml:lang="en-US">Loss On Settlements Of Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LossOnSettlementsOfConvertibleNotes" xlink:to="abp_LossOnSettlementsOfConvertibleNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NumberOfConsecutiveTradingDays_lbl1" xml:lang="en-US">Number Of Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfConsecutiveTradingDays" xlink:to="abp_NumberOfConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConvertibleNotes_lbl1" xml:lang="en-US">Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleNotes" xlink:to="abp_ConvertibleNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Employee Stock Ownership Plan Dividend, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ChangeInFairValueOfSEPAPutRightAsset_lbl1" xml:lang="en-US">Change In Fair Value Of SEPAPut Right Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfSEPAPutRightAsset" xlink:to="abp_ChangeInFairValueOfSEPAPutRightAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementAssetsCurrent_lbl0" xml:lang="en-US">Settlement Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementAssetsCurrent" xlink:to="us-gaap_SettlementAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NetProfitsFromLicensedProductSales_lbl1" xml:lang="en-US">Net Profits From Licensed Product Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NetProfitsFromLicensedProductSales" xlink:to="abp_NetProfitsFromLicensedProductSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRent_lbl0" xml:lang="en-US">Payments for Rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRent" xlink:to="us-gaap_PaymentsForRent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SettlementAgreementMember_lbl0" xml:lang="en-US">Settlement Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SettlementAgreementMember" xlink:to="abp_SettlementAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue_lbl0" xml:lang="en-US">Stock Repurchased During Period, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ForwardPurchaseAgreementMember_lbl0" xml:lang="en-US">Forward Purchase Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreementMember" xlink:to="abp_ForwardPurchaseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl0" xml:lang="en-US">Repayments of Lines of Credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_lbl0" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl0" xml:lang="en-US">Interest Expense, Operating and Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro_lbl1" xml:lang="en-US">Conversion Of Premerger Preferred Stock Of Abpro Into Common Stock Of New Abpro</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" xlink:to="abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_InvestmentAdvisorMember_lbl0" xml:lang="en-US">Investment Advisor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_InvestmentAdvisorMember" xlink:to="abp_InvestmentAdvisorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl1" xml:lang="en-US">Proceeds from Issuance of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AgreementInitialTerm_lbl1" xml:lang="en-US">Agreement Initial Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AgreementInitialTerm" xlink:to="abp_AgreementInitialTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_DeemedDividendResultingFromTheWarrantDownRound_lbl1" xml:lang="en-US">Deemed Dividend Resulting From The Warrant Down Round</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeemedDividendResultingFromTheWarrantDownRound" xlink:to="abp_DeemedDividendResultingFromTheWarrantDownRound_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0" xml:lang="en-US">Equity Method Investment, Ownership Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfCommonStockOutstanding_lbl1" xml:lang="en-US">Percentage Of Common Stock Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfCommonStockOutstanding" xlink:to="abp_PercentageOfCommonStockOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ExciseTaxLiability_lbl1" xml:lang="en-US">Excise Tax Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExciseTaxLiability" xlink:to="abp_ExciseTaxLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfVolumeWeightedAveragePrice_lbl1" xml:lang="en-US">Percentage Of Volume Weighted Average Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfVolumeWeightedAveragePrice" xlink:to="abp_PercentageOfVolumeWeightedAveragePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConvertibleThresholdConsecutiveTradingDays_lbl1" xml:lang="en-US">Convertible Threshold Consecutive Trading Days</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleThresholdConsecutiveTradingDays" xlink:to="abp_ConvertibleThresholdConsecutiveTradingDays_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense_lbl1" xml:lang="en-US">Reclassification Of Residual Value Guarantees Under Finance Lease To Accrued Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" xlink:to="abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AbproBioInternationalIncMember_lbl1" xml:lang="en-US">Abpro Bio International Inc Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AbproBioInternationalIncMember" xlink:to="abp_AbproBioInternationalIncMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_DeferredTaxAssetsLeaseLiability_lbl1" xml:lang="en-US">Deferred Tax Assets Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeferredTaxAssetsLeaseLiability" xlink:to="abp_DeferredTaxAssetsLeaseLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AdvanceNoticeToYAMember_lbl0" xml:lang="en-US">Advance Notice To YAMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdvanceNoticeToYAMember" xlink:to="abp_AdvanceNoticeToYAMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_lbl1" xml:lang="en-US">Stock Repurchased During Period, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_RemainingSharesIssued_lbl1" xml:lang="en-US">Remaining Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RemainingSharesIssued" xlink:to="abp_RemainingSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ReverseStockSplitMember_lbl0" xml:lang="en-US">Reverse Stock Split Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReverseStockSplitMember" xlink:to="abp_ReverseStockSplitMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ChangeInFairValueOfSEPAPutRightsAsset_lbl1" xml:lang="en-US">Change In Fair Value Of SEPAPut Rights Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfSEPAPutRightsAsset" xlink:to="abp_ChangeInFairValueOfSEPAPutRightsAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SEPAPutRightsAssetMember_lbl1" xml:lang="en-US">SEPAPut Rights Asset Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPAPutRightsAssetMember" xlink:to="abp_SEPAPutRightsAssetMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_InstallmentsAmount_lbl1" xml:lang="en-US">Installments Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_InstallmentsAmount" xlink:to="abp_InstallmentsAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPayableCurrent_lbl0" xml:lang="en-US">Interest Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl0" xml:lang="en-US">Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ThirdShareTargetMember_lbl0" xml:lang="en-US">Third Share Target Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ThirdShareTargetMember" xlink:to="abp_ThirdShareTargetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationDeductions_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationDeductions" xlink:to="us-gaap_IncomeTaxReconciliationDeductions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl2" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PerShareRedemptionsTriggerPrice_lbl1" xml:lang="en-US">Per Share Redemptions Trigger Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PerShareRedemptionsTriggerPrice" xlink:to="abp_PerShareRedemptionsTriggerPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SponsorMember_lbl1" xml:lang="en-US">Sponsor Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SponsorMember" xlink:to="abp_SponsorMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ExcessTaxes_lbl1" xml:lang="en-US">Excess Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExcessTaxes" xlink:to="abp_ExcessTaxes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro_lbl1" xml:lang="en-US">Conversion Of Notes Payablerelated Parties Into Common Stock Of New Abpro</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" xlink:to="abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_lbl0" xml:lang="en-US">Forward Contract Indexed to Equity, Settlement, Cash, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfUnderpaymentPenaltyPerMonth_lbl1" xml:lang="en-US">Percentage Of Underpayment Penalty Per Month</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfUnderpaymentPenaltyPerMonth" xlink:to="abp_PercentageOfUnderpaymentPenaltyPerMonth_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AccruedLicenseFees_lbl1" xml:lang="en-US">Accrued License Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedLicenseFees" xlink:to="abp_AccruedLicenseFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRepaidPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Repaid, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRepaidPrincipal" xlink:to="us-gaap_DebtInstrumentRepaidPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl2" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet_lbl1" xml:lang="en-US">Derivative, Fair Value, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl1" xml:lang="en-US">Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractTerminationMember_lbl1" xml:lang="en-US">Contract Termination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractTerminationMember" xlink:to="us-gaap_ContractTerminationMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl2" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate_lbl0" xml:lang="en-US">Servicing Assets and Servicing Liabilities at Fair Value, Assumptions Used to Estimate Fair Value, Discount Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate" xlink:to="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConvertiblePromissoryNoteMember_lbl0" xml:lang="en-US">Convertible Promissory Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertiblePromissoryNoteMember" xlink:to="abp_ConvertiblePromissoryNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquityShares_lbl0" xml:lang="en-US">Forward Contract Indexed to Issuer&apos;s Equity, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityShares" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquityShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConvertibleNoteDiscountMember_lbl0" xml:lang="en-US">Convertible Note Discount Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertibleNoteDiscountMember" xlink:to="abp_ConvertibleNoteDiscountMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SeriesARedeemableConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series ARedeemable Convertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="abp_SeriesARedeemableConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl1" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare_lbl1" xml:lang="en-US">Number Of Days Used For Calculating Volume Weighted Average Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" xlink:to="abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForRoyalties_lbl0" xml:lang="en-US">Payments for Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl0" xml:lang="en-US">Accrued Liabilities, Fair Value Disclosure</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CollaborationRevenueMember_lbl0" xml:lang="en-US">Collaboration Revenue Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CollaborationRevenueMember" xlink:to="abp_CollaborationRevenueMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_LabEquipmentMember_lbl0" xml:lang="en-US">Lab Equipment Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LabEquipmentMember" xlink:to="abp_LabEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ReverseStockSplitSharesOfIssued_lbl1" xml:lang="en-US">Reverse Stock Split Shares Of Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ReverseStockSplitSharesOfIssued" xlink:to="abp_ReverseStockSplitSharesOfIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfCommonStock_lbl2" xml:lang="en-US">Percentage Of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfCommonStock" xlink:to="abp_PercentageOfCommonStock_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PeriodAfterWhichTheWarrantsAreExercisable_lbl1" xml:lang="en-US">Period After Which The Warrants Are Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PeriodAfterWhichTheWarrantsAreExercisable" xlink:to="abp_PeriodAfterWhichTheWarrantsAreExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones_lbl0" xml:lang="en-US">Long-Term Purchase Commitment, Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:to="us-gaap_LongTermPurchaseCommitmentMilestones_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExercisePriceMember_lbl1" xml:lang="en-US">Measurement Input, Exercise Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_IssuanceOfCommonStockInThePIPEFinancing_lbl1" xml:lang="en-US">Issuance Of Common Stock In The PIPEFinancing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfCommonStockInThePIPEFinancing" xlink:to="abp_IssuanceOfCommonStockInThePIPEFinancing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAbstract_lbl1" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_RevenueAbstract_lbl0" xml:lang="en-US">Revenue Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RevenueAbstract" xlink:to="abp_RevenueAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AccruedToAmount_lbl1" xml:lang="en-US">Accrued To Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedToAmount" xlink:to="abp_AccruedToAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl2" xml:lang="en-US">Sales and Excise Tax Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnContractTermination_lbl1" xml:lang="en-US">Gain (Loss) on Contract Termination</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnContractTermination" xlink:to="us-gaap_GainLossOnContractTermination_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ExcessOfCommonStockPercentage_lbl1" xml:lang="en-US">Excess Of Common Stock Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExcessOfCommonStockPercentage" xlink:to="abp_ExcessOfCommonStockPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_BoardOfDirectorsChairmanMember_lbl1" xml:lang="en-US">Board of Directors Chairman [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_BoardOfDirectorsChairmanMember" xlink:to="srt_BoardOfDirectorsChairmanMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfPropertyAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfPropertyAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule Of Property And Equipment Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="abp_ScheduleOfPropertyAndEquipmentAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PIPEFinancingMember_lbl0" xml:lang="en-US">PIPEFinancing Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PIPEFinancingMember" xlink:to="abp_PIPEFinancingMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_VAZYMELicenseAgreementMember_lbl1" xml:lang="en-US">VAZYMELicense Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VAZYMELicenseAgreementMember" xlink:to="abp_VAZYMELicenseAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyMember_lbl1" xml:lang="en-US">Related Party [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput_lbl0" xml:lang="en-US">Derivative Liability, Measurement Input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl0" xml:lang="en-US">Forecast [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesFPreferredStockMember_lbl0" xml:lang="en-US">Series F Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesFPreferredStockMember" xlink:to="us-gaap_SeriesFPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_DeferredTaxLiabilitiesRightofuseAsset_lbl1" xml:lang="en-US">Deferred Tax Liabilities Rightofuse Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DeferredTaxLiabilitiesRightofuseAsset" xlink:to="abp_DeferredTaxLiabilitiesRightofuseAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ABP201CollaborationAndLicenseAgreementMember_lbl0" xml:lang="en-US">ABP201 Collaboration And License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ABP201CollaborationAndLicenseAgreementMember" xlink:to="abp_ABP201CollaborationAndLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_RedemptionTriggerMember_lbl0" xml:lang="en-US">Redemption Trigger Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RedemptionTriggerMember" xlink:to="abp_RedemptionTriggerMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ConvertiblePreferredStockPolicyTextBlock_lbl1" xml:lang="en-US">Convertible Preferred Stock Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ConvertiblePreferredStockPolicyTextBlock" xlink:to="abp_ConvertiblePreferredStockPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_WeightedAverageDiscountRateAbstract_lbl0" xml:lang="en-US">Weighted Average Discount Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WeightedAverageDiscountRateAbstract" xlink:to="abp_WeightedAverageDiscountRateAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilities_lbl1" xml:lang="en-US">Other Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForFees_lbl0" xml:lang="en-US">Payments for Other Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl1" xml:lang="en-US">Repayments of Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl2" xml:lang="en-US">Accrued Income Taxes, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl2"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule Of Company SAssets And Liabilities That Are Measured At Fair Value On ARecurring Basis Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="abp_ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_YAIIPNLtdMember_lbl0" xml:lang="en-US">YAIIPNLtd Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_YAIIPNLtdMember" xlink:to="abp_YAIIPNLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MSKLicenseAgreementMember_lbl0" xml:lang="en-US">MSKLicense Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MSKLicenseAgreementMember" xlink:to="abp_MSKLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonValue_lbl0" xml:lang="en-US">Treasury Stock, Common, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonValue" xlink:to="us-gaap_TreasuryStockCommonValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_UnvestedRestrictedStockUnitsMember_lbl0" xml:lang="en-US">Unvested Restricted Stock Units Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_UnvestedRestrictedStockUnitsMember" xlink:to="abp_UnvestedRestrictedStockUnitsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl0" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl0" xml:lang="en-US">Accrued Royalties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FundingDateToMaturityDateMember_lbl0" xml:lang="en-US">Funding Date To Maturity Date Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FundingDateToMaturityDateMember" xlink:to="abp_FundingDateToMaturityDateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl0" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Taxes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl0" xml:lang="en-US">Restricted Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl2" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PaymentForExtensionRoyalities_lbl1" xml:lang="en-US">Payment For Extension Royalities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PaymentForExtensionRoyalities" xlink:to="abp_PaymentForExtensionRoyalities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SecurityBidPricePerShare_lbl1" xml:lang="en-US">Security Bid Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SecurityBidPricePerShare" xlink:to="abp_SecurityBidPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NewAbproSharesIssuedToPIPEInvestorsMember_lbl0" xml:lang="en-US">New Abpro Shares Issued To PIPEInvestors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesIssuedToPIPEInvestorsMember" xlink:to="abp_NewAbproSharesIssuedToPIPEInvestorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CommercialSales_lbl1" xml:lang="en-US">Commercial Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommercialSales" xlink:to="abp_CommercialSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Forfeited Outstanding Weighted Average Remaining Contractual Term2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyMember_lbl0" xml:lang="en-US">Royalty [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl1" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_IssuanceOfCommonStockInTransactionCost_lbl1" xml:lang="en-US">Issuance Of Common Stock In Transaction Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfCommonStockInTransactionCost" xlink:to="abp_IssuanceOfCommonStockInTransactionCost_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SEPACommitmentFeePaidInCommonStockShares_lbl1" xml:lang="en-US">SEPACommitment Fee Paid In Common Stock Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPACommitmentFeePaidInCommonStockShares" xlink:to="abp_SEPACommitmentFeePaidInCommonStockShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl0" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_IssuanceOfCommonStockInPIPEFinancing_lbl1" xml:lang="en-US">Issuance Of Common Stock In PIPEFinancing</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfCommonStockInPIPEFinancing" xlink:to="abp_IssuanceOfCommonStockInPIPEFinancing_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_EstimatedFuturePricePerShare_lbl1" xml:lang="en-US">Estimated Future Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EstimatedFuturePricePerShare" xlink:to="abp_EstimatedFuturePricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract_lbl0" xml:lang="en-US">Liabilities Convertible Preferred Stock And Stockholders Deficit Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract" xlink:to="abp_LiabilitiesConvertiblePreferredStockAndStockholdersDeficitAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AbMedMember_lbl0" xml:lang="en-US">Ab Med Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AbMedMember" xlink:to="abp_AbMedMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_OfferingCostsIncludedInAccountsPayable_lbl1" xml:lang="en-US">Offering Costs Included In Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OfferingCostsIncludedInAccountsPayable" xlink:to="abp_OfferingCostsIncludedInAccountsPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl0" xml:lang="en-US">Temporary Equity, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_LossOnSettlementOfConvertibleNotes_lbl1" xml:lang="en-US">Loss On Settlement Of Convertible Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LossOnSettlementOfConvertibleNotes" xlink:to="abp_LossOnSettlementOfConvertibleNotes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_UnpaidAmount_lbl1" xml:lang="en-US">Unpaid Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_UnpaidAmount" xlink:to="abp_UnpaidAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember_lbl0" xml:lang="en-US">New Abpro Shares Issued To Settle The Promissory Note With Executive Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" xlink:to="abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability_lbl1" xml:lang="en-US">Common Stock Issued In Settlement Of Convertible Notes And Embedded Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" xlink:to="abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_IssuanceOfSharesPercentage_lbl1" xml:lang="en-US">Issuance Of Shares Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceOfSharesPercentage" xlink:to="abp_IssuanceOfSharesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_RothCapitalPartnersMember_lbl0" xml:lang="en-US">Roth Capital Partners Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RothCapitalPartnersMember" xlink:to="abp_RothCapitalPartnersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl1" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl0" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0" xml:lang="en-US">Asset Acquisition, Consideration Transferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0" xml:lang="en-US">Condensed Cash Flow Statement [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_TaxYear2037Member_lbl0" xml:lang="en-US">Tax Year2037 Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TaxYear2037Member" xlink:to="abp_TaxYear2037Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_OtherAccruedExpensesAndAccountsPayableMember_lbl0" xml:lang="en-US">Other Accrued Expenses And Accounts Payable Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_OtherAccruedExpensesAndAccountsPayableMember" xlink:to="abp_OtherAccruedExpensesAndAccountsPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0" xml:lang="en-US">Debt Instrument, Increase, Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForLegalSettlements_lbl0" xml:lang="en-US">Payments for Legal Settlements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLegalSettlements" xlink:to="us-gaap_PaymentsForLegalSettlements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeFixedInterestRate_lbl0" xml:lang="en-US">Derivative, Fixed Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFixedInterestRate" xlink:to="us-gaap_DerivativeFixedInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember_lbl0" xml:lang="en-US">Two Year Anniversary Of Issuance Date Of Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:to="abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger_lbl1" xml:lang="en-US">Common Stock Warrants Of Legacy ACABAcquired In Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger" xlink:to="abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfMarketValueAndNewlyIssuedPrice_lbl1" xml:lang="en-US">Percentage Of Market Value And Newly Issued Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfMarketValueAndNewlyIssuedPrice" xlink:to="abp_PercentageOfMarketValueAndNewlyIssuedPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AdditionalInterestExpense_lbl1" xml:lang="en-US">Additional Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdditionalInterestExpense" xlink:to="abp_AdditionalInterestExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_DirectorMember_lbl0" xml:lang="en-US">Director [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl0" xml:lang="en-US">Security Deposit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl0" xml:lang="en-US">Defined Contribution Plan, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember_lbl0" xml:lang="en-US">New Abpro Shares Issued In Merger To Legacy Abpro Stockholders Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" xlink:to="abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Equity [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_WeightedAverageRemainingLeaseTermInYearsAbstract_lbl0" xml:lang="en-US">Weighted Average Remaining Lease Term In Years Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WeightedAverageRemainingLeaseTermInYearsAbstract" xlink:to="abp_WeightedAverageRemainingLeaseTermInYearsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PromissoryNoteWithACABExecutiveMember_lbl0" xml:lang="en-US">Promissory Note With ACABExecutive Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteWithACABExecutiveMember" xlink:to="abp_PromissoryNoteWithACABExecutiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl0" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl0" xml:lang="en-US">Embedded Derivative, Fair Value of Embedded Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember_lbl0" xml:lang="en-US">ABPOne Hundred Zero Zero Collaboration And License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember" xlink:to="abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl0" xml:lang="en-US">Forward Contract Indexed to Equity, Settlement, Share, Fair Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:to="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ContingentEarnoutPolicyTextBlock_lbl1" xml:lang="en-US">Contingent Earnout Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ContingentEarnoutPolicyTextBlock" xlink:to="abp_ContingentEarnoutPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfClosingPrice_lbl1" xml:lang="en-US">Percentage Of Closing Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfClosingPrice" xlink:to="abp_PercentageOfClosingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl2" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsDisclosureTextBlock" xlink:to="us-gaap_CommitmentsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesIssued1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleDebt_lbl0" xml:lang="en-US">Convertible Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebt" xlink:to="us-gaap_ConvertibleDebt_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfEffectiveIncomeTaxRateAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfEffectiveIncomeTaxRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfEffectiveIncomeTaxRateAbstract_lbl" xml:lang="en-US">Schedule Of Effective Income Tax Rate Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfEffectiveIncomeTaxRateAbstract" xlink:to="abp_ScheduleOfEffectiveIncomeTaxRateAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_DevelopmentMilestones_lbl1" xml:lang="en-US">Development Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DevelopmentMilestones" xlink:to="abp_DevelopmentMilestones_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SecondShareTargetMember_lbl0" xml:lang="en-US">Second Share Target Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SecondShareTargetMember" xlink:to="abp_SecondShareTargetMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterest_lbl0" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterest" xlink:to="us-gaap_MinorityInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl0" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AdditionalAccruedInterest_lbl1" xml:lang="en-US">Additional Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AdditionalAccruedInterest" xlink:to="abp_AdditionalAccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Net Deferred Tax Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="abp_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SeriesBCommonStockMember_lbl1" xml:lang="en-US">Series BCommon Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesBCommonStockMember" xlink:to="abp_SeriesBCommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ForwardPurchaseAgreement_lbl1" xml:lang="en-US">Forward Purchase Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreement" xlink:to="abp_ForwardPurchaseAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ResearchAndDevelopmentServicesMember_lbl0" xml:lang="en-US">Research And Development Services Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ResearchAndDevelopmentServicesMember" xlink:to="abp_ResearchAndDevelopmentServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl0" xml:lang="en-US">Restricted Cash, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_DebtInstrumentInterestRateTermAxis_lbl0" xml:lang="en-US">Debt Instrument Interest Rate Term Axis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_DebtInstrumentInterestRateTermAxis" xlink:to="abp_DebtInstrumentInterestRateTermAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementLiabilitiesCurrent_lbl0" xml:lang="en-US">Settlement Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementLiabilitiesCurrent" xlink:to="us-gaap_SettlementLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl0" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfBalanceSheetAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfBalanceSheetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfBalanceSheetAbstract_lbl" xml:lang="en-US">Schedule Of Balance Sheet Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfBalanceSheetAbstract" xlink:to="abp_ScheduleOfBalanceSheetAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNet_lbl0" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNet" xlink:to="us-gaap_AccountsReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncontrollingInterestMember_lbl0" xml:lang="en-US">Noncontrolling Interest [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncontrollingInterestMember" xlink:to="us-gaap_NoncontrollingInterestMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl0" xml:lang="en-US">Operating Lease, Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl0" xml:lang="en-US">Intellectual Property [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract_lbl" xml:lang="en-US">Schedule Of Fair Value Of The Company SPosition Under The Forward Purchase Agreement Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract" xlink:to="abp_ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_LegacyAbproCommonStockWarrantsMember_lbl0" xml:lang="en-US">Legacy Abpro Common Stock Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_LegacyAbproCommonStockWarrantsMember" xlink:to="abp_LegacyAbproCommonStockWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl0" xml:lang="en-US">Restricted Cash, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputSharePriceMember_lbl0" xml:lang="en-US">Measurement Input, Share Price [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_WarrantsExercisableTerm_lbl1" xml:lang="en-US">Warrants Exercisable Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WarrantsExercisableTerm" xlink:to="abp_WarrantsExercisableTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyIncomeNonoperating_lbl0" xml:lang="en-US">Royalty Income, Nonoperating</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyIncomeNonoperating" xlink:to="us-gaap_RoyaltyIncomeNonoperating_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_lbl0" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_VendorsMember_lbl1" xml:lang="en-US">Vendors Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_VendorsMember" xlink:to="abp_VendorsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfReimbursement_lbl1" xml:lang="en-US">Percentage Of Reimbursement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfReimbursement" xlink:to="abp_PercentageOfReimbursement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalFees_lbl0" xml:lang="en-US">Professional Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalFees" xlink:to="us-gaap_ProfessionalFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ChangeInFairValueOnEmbeddedDerivativeLiability_lbl1" xml:lang="en-US">Change In Fair Value On Embedded Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOnEmbeddedDerivativeLiability" xlink:to="abp_ChangeInFairValueOnEmbeddedDerivativeLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SEPAPutRightsAsset_lbl1" xml:lang="en-US">SEPAPut Rights Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SEPAPutRightsAsset" xlink:to="abp_SEPAPutRightsAsset_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl2" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_EmbeddedDerivativeLiabilityMember_lbl1" xml:lang="en-US">Embedded Derivative Liability Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EmbeddedDerivativeLiabilityMember" xlink:to="abp_EmbeddedDerivativeLiabilityMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl0" xml:lang="en-US">Revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SeriesFConvertiblePreferredStockMember_lbl0" xml:lang="en-US">Series FConvertible Preferred Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesFConvertiblePreferredStockMember" xlink:to="abp_SeriesFConvertiblePreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_WarrantsToPurchaseCommonStockMember_lbl0" xml:lang="en-US">Warrants To Purchase Common Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_WarrantsToPurchaseCommonStockMember" xlink:to="abp_WarrantsToPurchaseCommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PaymentOfRentAndMaintenanceExpense_lbl1" xml:lang="en-US">Payment Of Rent And Maintenance Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PaymentOfRentAndMaintenanceExpense" xlink:to="abp_PaymentOfRentAndMaintenanceExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RestatementAdjustmentMember_lbl0" xml:lang="en-US">Revision of Prior Period, Adjustment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfRecordedStockBasedCompensationExpenseAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfRecordedStockBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfRecordedStockBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule Of Recorded Stock Based Compensation Expense Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfRecordedStockBasedCompensationExpenseAbstract" xlink:to="abp_ScheduleOfRecordedStockBasedCompensationExpenseAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CommonStockOfACABNetOfRedemptionsMember_lbl0" xml:lang="en-US">Common Stock Of ACABNet Of Redemptions Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CommonStockOfACABNetOfRedemptionsMember" xlink:to="abp_CommonStockOfACABNetOfRedemptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MilestonePayments_lbl1" xml:lang="en-US">Milestone Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePayments" xlink:to="abp_MilestonePayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl1" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_EquipmentUnderFinanceLeasesMember_lbl0" xml:lang="en-US">Equipment Under Finance Leases Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EquipmentUnderFinanceLeasesMember" xlink:to="abp_EquipmentUnderFinanceLeasesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayable_lbl1" xml:lang="en-US">Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayable" xlink:to="us-gaap_NotesPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRemainingPerformanceObligation_lbl0" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRemainingPerformanceObligation" xlink:to="us-gaap_RevenueRemainingPerformanceObligation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl0" xml:lang="en-US">Restricted Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MarketValueOfListedSecuritiesMember_lbl0" xml:lang="en-US">Market Value Of Listed Securities Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MarketValueOfListedSecuritiesMember" xlink:to="abp_MarketValueOfListedSecuritiesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NetProceedsFromTheMerger_lbl1" xml:lang="en-US">Net Proceeds From The Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NetProceedsFromTheMerger" xlink:to="abp_NetProceedsFromTheMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NotePayableMember_lbl0" xml:lang="en-US">Note Payable Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NotePayableMember" xlink:to="abp_NotePayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SecondConvertibleNoteMember_lbl0" xml:lang="en-US">Second Convertible Note Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SecondConvertibleNoteMember" xlink:to="abp_SecondConvertibleNoteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule Of Changes In The Fair Value Of Level3 Financial Assets And Liabilities Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract" xlink:to="abp_ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AggregatePurchasePrice_lbl1" xml:lang="en-US">Aggregate Purchase Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AggregatePurchasePrice" xlink:to="abp_AggregatePurchasePrice_lbl1"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Warrants To Purchase Common Stock Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract" xlink:to="abp_ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ChangeInFairValueOfEmbeddedDerivativeLiability_lbl1" xml:lang="en-US">Change In Fair Value Of Embedded Derivative Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ChangeInFairValueOfEmbeddedDerivativeLiability" xlink:to="abp_ChangeInFairValueOfEmbeddedDerivativeLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_NumberOfSharesMember_lbl1" xml:lang="en-US">Number Of Shares Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_NumberOfSharesMember" xlink:to="abp_NumberOfSharesMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PrivatePlacementWarrantsMember_lbl1" xml:lang="en-US">Private Placement Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PrivatePlacementWarrantsMember" xlink:to="abp_PrivatePlacementWarrantsMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0" xml:lang="en-US">Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MilestonePaymentOnNetSales_lbl1" xml:lang="en-US">Milestone Payment On Net Sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePaymentOnNetSales" xlink:to="abp_MilestonePaymentOnNetSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ExpiredAtTheMerger_lbl1" xml:lang="en-US">Expired At The Merger</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExpiredAtTheMerger" xlink:to="abp_ExpiredAtTheMerger_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfAdvanceNotice_lbl1" xml:lang="en-US">Percentage Of Advance Notice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfAdvanceNotice" xlink:to="abp_PercentageOfAdvanceNotice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl1" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl0" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_EarlyTerminationResetPricePerShare_lbl1" xml:lang="en-US">Early Termination Reset Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EarlyTerminationResetPricePerShare" xlink:to="abp_EarlyTerminationResetPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl4" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl4"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AccruedBODCompensation_lbl2" xml:lang="en-US">Accrued BODCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedBODCompensation" xlink:to="abp_AccruedBODCompensation_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2_lbl1" xml:lang="en-US">Sharebased Compensation Arrangement By Sharebased Payment Award Vested Outstanding Weighted Average Remaining Contractual Term2</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors_lbl0" xml:lang="en-US">Capital Units, Cost to Investors</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalUnitsTotalCostToInvestors" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl0" xml:lang="en-US">Deferred Tax Assets, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationInterestExpense_lbl0" xml:lang="en-US">Income Tax Examination, Interest Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationInterestExpense" xlink:to="us-gaap_IncomeTaxExaminationInterestExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ExecutiveOfficerMember_lbl1" xml:lang="en-US">Executive Officer [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember_lbl1" xml:lang="en-US">Measurement Input, Option Volatility [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ABCDMember_lbl0" xml:lang="en-US">ABCDMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ABCDMember" xlink:to="abp_ABCDMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare_lbl0" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DomesticCountryMember_lbl0" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_SeriesACommonStockMember_lbl1" xml:lang="en-US">Series ACommon Stock Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_SeriesACommonStockMember" xlink:to="abp_SeriesACommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LegalFees_lbl1" xml:lang="en-US">Legal Fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StockOptionsMember_lbl0" xml:lang="en-US">Stock Options Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StockOptionsMember" xlink:to="abp_StockOptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract_lbl" xml:lang="en-US">Schedule Of Diluted Net Loss Per Share Of Common Stock Attributable To Common Stockholders Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract" xlink:to="abp_ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfCompanySStockOptionActivityAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCompanySStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfCompanySStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule Of Company SStock Option Activity Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfCompanySStockOptionActivityAbstract" xlink:to="abp_ScheduleOfCompanySStockOptionActivityAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents_lbl1" xml:lang="en-US">Milestone Payments Upon Achieving RDAnd Commercialization Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents" xlink:to="abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PromissoryNoteAgreementMember_lbl1" xml:lang="en-US">Promissory Note Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNoteAgreementMember" xlink:to="abp_PromissoryNoteAgreementMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PromissoryNotesWithExecutiveAndDirectorMember_lbl0" xml:lang="en-US">Promissory Notes With Executive And Director Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PromissoryNotesWithExecutiveAndDirectorMember" xlink:to="abp_PromissoryNotesWithExecutiveAndDirectorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_StandbyEquityPurchaseAgreementTextBlock_lbl1" xml:lang="en-US">Standby Equity Purchase Agreement Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_StandbyEquityPurchaseAgreementTextBlock" xlink:to="abp_StandbyEquityPurchaseAgreementTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_EarnoutShare_lbl1" xml:lang="en-US">Earnout Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EarnoutShare" xlink:to="abp_EarnoutShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeAverageFloorPrice_lbl0" xml:lang="en-US">Derivative, Average Floor Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAverageFloorPrice" xlink:to="us-gaap_DerivativeAverageFloorPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables_lbl0" xml:lang="en-US">Increase (Decrease) in Notes Receivables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl2" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm_lbl1" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Expirations And Cancelled In Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xlink:to="abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfAmendedCelltrionAgreement_lbl1" xml:lang="en-US">Percentage Of Amended Celltrion Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfAmendedCelltrionAgreement" xlink:to="abp_PercentageOfAmendedCelltrionAgreement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableMember_lbl0" xml:lang="en-US">Accounts Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableMember" xlink:to="us-gaap_AccountsPayableMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockCommonShares_lbl2" xml:lang="en-US">Treasury Stock, Common, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockCommonShares" xlink:to="us-gaap_TreasuryStockCommonShares_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AfterMaturityDateMember_lbl0" xml:lang="en-US">After Maturity Date Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AfterMaturityDateMember" xlink:to="abp_AfterMaturityDateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl2" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ExecutiveWarrantsMember_lbl0" xml:lang="en-US">Executive Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExecutiveWarrantsMember" xlink:to="abp_ExecutiveWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="abp_ScheduleOfCommonStockOutstandingAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCommonStockOutstandingAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfCommonStockOutstandingAbstract_lbl" xml:lang="en-US">Schedule Of Common Stock Outstanding Abstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfCommonStockOutstandingAbstract" xlink:to="abp_ScheduleOfCommonStockOutstandingAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl0" xml:lang="en-US">Lessee, Finance Lease, Description [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_TwoZeroOneFourStockIncentivePlanMember_lbl0" xml:lang="en-US">Two Zero One Four Stock Incentive Plan Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_TwoZeroOneFourStockIncentivePlanMember" xlink:to="abp_TwoZeroOneFourStockIncentivePlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_IncentiveSharesReceivedBySubsidiary_lbl1" xml:lang="en-US">Incentive Shares Received By Subsidiary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IncentiveSharesReceivedBySubsidiary" xlink:to="abp_IncentiveSharesReceivedBySubsidiary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl1" xml:lang="en-US">Fair Value, Option, Changes in Fair Value, Gain (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_IssuanceDateOfWarrantsMember_lbl0" xml:lang="en-US">Issuance Date Of Warrants Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_IssuanceDateOfWarrantsMember" xlink:to="abp_IssuanceDateOfWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Business Combination, Series of Individually Immaterial Business Combinations [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl0" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl1" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl1" xml:lang="en-US">Recently Adopted Accounting Pronouncements Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:to="abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LetterOfCreditMember_lbl0" xml:lang="en-US">Letter of Credit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LetterOfCreditMember" xlink:to="us-gaap_LetterOfCreditMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl2" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfLiabilityTotal_lbl1" xml:lang="en-US">Percentage Of Liability Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfLiabilityTotal" xlink:to="abp_PercentageOfLiabilityTotal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl0" xml:lang="en-US">Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ClinicalDevelopmentMilestones_lbl1" xml:lang="en-US">Clinical Development Milestones</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ClinicalDevelopmentMilestones" xlink:to="abp_ClinicalDevelopmentMilestones_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_PercentageOfAmortizationPrincipalAmount_lbl1" xml:lang="en-US">Percentage Of Amortization Principal Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_PercentageOfAmortizationPrincipalAmount" xlink:to="abp_PercentageOfAmortizationPrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_CelltrionCollaborationAndLicenseAgreementMember_lbl0" xml:lang="en-US">Celltrion Collaboration And License Agreement Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_CelltrionCollaborationAndLicenseAgreementMember" xlink:to="abp_CelltrionCollaborationAndLicenseAgreementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseDebt_lbl0" xml:lang="en-US">Interest Expense, Debt</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_AccruedInterest_lbl1" xml:lang="en-US">Accrued Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_AccruedInterest" xlink:to="abp_AccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FederalAndStateResearchAndDevelopmentCredits_lbl1" xml:lang="en-US">Federal And State Research And Development Credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FederalAndStateResearchAndDevelopmentCredits" xlink:to="abp_FederalAndStateResearchAndDevelopmentCredits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl1" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_EmergingGrowthCompanyPolicyTextBlock_lbl1" xml:lang="en-US">Emerging Growth Company Policy Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_EmergingGrowthCompanyPolicyTextBlock" xlink:to="abp_EmergingGrowthCompanyPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ForwardPurchaseAgreementAssetMember_lbl1" xml:lang="en-US">Forward Purchase Agreement Asset Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ForwardPurchaseAgreementAssetMember" xlink:to="abp_ForwardPurchaseAgreementAssetMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ExecutiveMember_lbl0" xml:lang="en-US">Executive Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ExecutiveMember" xlink:to="abp_ExecutiveMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl0" xml:lang="en-US">Income Taxes Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_FirstMilestoneMember_lbl0" xml:lang="en-US">First Milestone Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_FirstMilestoneMember" xlink:to="abp_FirstMilestoneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl1" xml:lang="en-US">Schedule Of Depreciation On Property And Equipment Estimated Useful Lives Table Text Block</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl0" xml:lang="en-US">Investment Income, Amortization of Discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl0" xml:lang="en-US">Proceeds from Other Equity</label>
<!-- [WMV6][o3R/86zhDJXATaq+CpT8tohHPRj2qKXzwmHBCbFbhiqFbQK3bKcevK8q9dyYuFeo6NgLdSMXW098wHajkqcvs4DYk6k0t0RrQYlz4DOmT1d1U+k+SD+nSHQKDO9HDru5xu2OPYJNhdk9zr9uGDfPq8pFMTAei58dyVBa+tmfZB0z4X9ijfP7EEk0xjgLbKMx3ft6W7wWMV8pCO9jVh7tCShddi3PzHWWapgRp797B40duVtCRuelYuz/ryTkeYW9LWCxTbnv7ZdPa1srbMZ6q38ybPUI8xm9EbWprJPV1IVuzR/ayxiRABIwVLebBNbmWlJyp0Qc56JqBgEWgk5eUbe/RoulD+mB1g==] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl0"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>30
<FILENAME>abp-20250930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Fri Nov 28 18:01:32 UTC 2025 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedBalanceSheet" roleURI="http://www.abpro.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedIncomeStatement" roleURI="http://www.abpro.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareholdersEquityType2or3" roleURI="http://www.abpro.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.abpro.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ConsolidatedCashFlow" roleURI="http://www.abpro.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_OrganizationandDescriptionoftheBusiness" roleURI="http://www.abpro.com/role/OrganizationandDescriptionoftheBusiness"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SummaryofSignificantAccountingPolicies" roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_Merger" roleURI="http://www.abpro.com/role/Merger"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_AccruedExpenses" roleURI="http://www.abpro.com/role/AccruedExpenses"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_FairValueMeasurements" roleURI="http://www.abpro.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_LicenseandCollaborationAgreements" roleURI="http://www.abpro.com/role/LicenseandCollaborationAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_CommitmentsunderResearchandCollaborationAgreements" roleURI="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreements"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_CommitmentsandContingencies" roleURI="http://www.abpro.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ForwardPurchaseAgreement" roleURI="http://www.abpro.com/role/ForwardPurchaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_NotesPayable" roleURI="http://www.abpro.com/role/NotesPayable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StandbyEquityPurchaseAgreement" roleURI="http://www.abpro.com/role/StandbyEquityPurchaseAgreement"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StockholdersEquity" roleURI="http://www.abpro.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareBasedCompensation" roleURI="http://www.abpro.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_EmployeeBenefitPlan" roleURI="http://www.abpro.com/role/EmployeeBenefitPlan"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_RelatedParties" roleURI="http://www.abpro.com/role/RelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SubsequentEvents" roleURI="http://www.abpro.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_PropertyandEquipment" roleURI="http://www.abpro.com/role/PropertyandEquipment"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_Leases" roleURI="http://www.abpro.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_IncomeTaxes" roleURI="http://www.abpro.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_AccountingPoliciesByPolicy" roleURI="http://www.abpro.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_MergerTables" roleURI="http://www.abpro.com/role/MergerTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_AccruedExpensesTables" roleURI="http://www.abpro.com/role/AccruedExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_FairValueMeasurementsTables" roleURI="http://www.abpro.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StockholdersEquityTables" roleURI="http://www.abpro.com/role/StockholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareBasedCompensationTables" roleURI="http://www.abpro.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_PropertyandEquipmentTables" roleURI="http://www.abpro.com/role/PropertyandEquipmentTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_LeasesTables" roleURI="http://www.abpro.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_IncomeTaxesTables" roleURI="http://www.abpro.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofDilutedNetLossPerShareTable" roleURI="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCommonStockOutstandingTable" roleURI="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofAccruedExpensesTable" roleURI="http://www.abpro.com/role/ScheduleofAccruedExpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable" roleURI="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable" roleURI="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable" roleURI="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofWarrantstoPurchaseCommonStockOutstandingTable" roleURI="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysStockOptionActivityTable" roleURI="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysRestrictedStockUnitActivityTable" roleURI="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofRecordedStockBasedCompensationExpenseTable" roleURI="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofConsolidatedStatementsofCashFlowsTable" roleURI="http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable" roleURI="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofBalanceSheetTable" roleURI="http://www.abpro.com/role/ScheduleofBalanceSheetTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCommonStockOutstandingTable0" roleURI="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofPropertyandEquipmentTable" roleURI="http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofAccruedExpensesTable0" roleURI="http://www.abpro.com/role/ScheduleofAccruedExpensesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0" roleURI="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0" roleURI="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0" roleURI="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofLeaseExpenseTable" roleURI="http://www.abpro.com/role/ScheduleofLeaseExpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofFutureMinimumPaymentsTable" roleURI="http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCommonStockWarrantActivityTable" roleURI="http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0" roleURI="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysStockOptionActivityTable0" roleURI="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable" roleURI="http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofCompanysRestrictedStockUnitActivityTable0" roleURI="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofRecordedStockBasedCompensationExpenseTable0" roleURI="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofIncomeLossBeforeProvisionTable" roleURI="http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofEffectiveIncomeTaxRateTable" roleURI="http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ScheduleofNetDeferredTaxAssetsandLiabilitiesTable" roleURI="http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives" roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_OrganizationandDescriptionoftheBusinessDetails" roleURI="http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_MergerDetails" roleURI="http://www.abpro.com/role/MergerDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_FairValueMeasurementsDetails" roleURI="http://www.abpro.com/role/FairValueMeasurementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_LicenseandCollaborationAgreementsDetails" roleURI="http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_CommitmentsunderResearchandCollaborationAgreementsDetails" roleURI="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_CommitmentsandContingenciesDetails" roleURI="http://www.abpro.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ForwardPurchaseAgreementDetails" roleURI="http://www.abpro.com/role/ForwardPurchaseAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_NotesPayableDetails" roleURI="http://www.abpro.com/role/NotesPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StandbyEquityPurchaseAgreementDetails" roleURI="http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_StockholdersEquityDetails" roleURI="http://www.abpro.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_ShareBasedCompensationDetails" roleURI="http://www.abpro.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_EmployeeBenefitPlanDetails" roleURI="http://www.abpro.com/role/EmployeeBenefitPlanDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_RelatedPartiesDetails" roleURI="http://www.abpro.com/role/RelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_SubsequentEventsDetails" roleURI="http://www.abpro.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_PropertyandEquipmentDetails" roleURI="http://www.abpro.com/role/PropertyandEquipmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_LeasesDetails" roleURI="http://www.abpro.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#abp_r_IncomeTaxesDetails" roleURI="http://www.abpro.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="abp-20250930.xsd#DocumentAndEntityInformation" roleURI="http://www.abpro.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:role="http://www.abpro.com/role/ConsolidatedBalanceSheet" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesFConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesFConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesFConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesEConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesEConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesEConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesDConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesDConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesDConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesCConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesCConvertiblePreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesARedeemableConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DeferredOfferingCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="ForwardPurchaseAgreementAsset" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecurityDeposit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SecurityDeposit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentsNet" xlink:href="abp-20250930.xsd#abp_PatentsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="PatentsNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SEPAPutRightsAsset" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="SEPAPutRightsAsset" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotes" xlink:href="abp-20250930.xsd#abp_ConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="ConvertibleNotes" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FeaturesOfConvertiblePreferredStockAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FeaturesOfConvertiblePreferredStockAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_TreasuryStockCommonValue" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesFConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesFConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesFConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesEConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesEConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesEConvertiblePreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesDConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesDConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesDConvertiblePreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesCConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesCConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesCConvertiblePreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesBConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBConvertiblePreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesARedeemableConvertiblePreferredStockMember" xlink:href="abp-20250930.xsd#abp_SeriesARedeemableConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesARedeemableConvertiblePreferredStockMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ConsolidatedIncomeStatement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentServicesMember" xlink:href="abp-20250930.xsd#abp_ResearchAndDevelopmentServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ResearchAndDevelopmentServicesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CollaborationRevenueMember" xlink:href="abp-20250930.xsd#abp_CollaborationRevenueMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="CollaborationRevenueMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="RevenueAbstract" xlink:href="abp-20250930.xsd#abp_RevenueAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="RevenueAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNonoperatingIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncome" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfForwardPuchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfForwardPuchaseAgreementAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfForwardPuchaseAgreementAsset" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfSEPAPutRightsAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfSEPAPutRightsAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfSEPAPutRightsAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfEmbeddedDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="ChangeInFairValueOfEmbeddedDerivativeLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossOnSettlementOfConvertibleNotes" xlink:href="abp-20250930.xsd#abp_LossOnSettlementOfConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="LossOnSettlementOfConvertibleNotes" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividendResultingFromTheWarrantDownRound" xlink:href="abp-20250930.xsd#abp_DeemedDividendResultingFromTheWarrantDownRound"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="DeemedDividendResultingFromTheWarrantDownRound" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ShareholdersEquityType2or3" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStocksMember" xlink:href="abp-20250930.xsd#abp_ConvertiblePreferredStocksMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="ConvertiblePreferredStocksMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockCommonMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_ParentMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_NoncontrollingInterestMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="7.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesCPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesCPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesCPreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesDPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesDPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesDPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesEPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesEPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesEPreferredStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesFPreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesFPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesFPreferredStockMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="6.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:href="abp-20250930.xsd#abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" xlink:href="abp-20250930.xsd#abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInThePIPEFinancing" xlink:href="abp-20250930.xsd#abp_IssuanceOfCommonStockInThePIPEFinancing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInThePIPEFinancing" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInPIPEFinancing" xlink:href="abp-20250930.xsd#abp_IssuanceOfCommonStockInPIPEFinancing"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInPIPEFinancing" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_StockRepurchasedDuringPeriodValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockRepurchasedDuringPeriodShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_StockRepurchasedDuringPeriodShares_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockCommonShares_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockCommonShares_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ShareholdersEquityType2or3_Parentheticals" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInTransactionCost" xlink:href="abp-20250930.xsd#abp_IssuanceOfCommonStockInTransactionCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="IssuanceOfCommonStockInTransactionCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ConsolidatedCashFlow" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LossOnSettlementsOfConvertibleNotes" xlink:href="abp-20250930.xsd#abp_LossOnSettlementsOfConvertibleNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="LossOnSettlementsOfConvertibleNotes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherIncome" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfForwardPurchaseAgreementAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfForwardPurchaseAgreementAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfForwardPurchaseAgreementAsset" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOfSEPAPutRightAsset" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOfSEPAPutRightAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOfSEPAPutRightAsset" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueOnEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueOnEmbeddedDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ChangeInFairValueOnEmbeddedDerivativeLiability" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInNotesReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInNotesReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInNotesReceivables" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromOtherEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceedsFromTheMerger" xlink:href="abp-20250930.xsd#abp_NetProceedsFromTheMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetProceedsFromTheMerger" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashTransferredToEscrow" xlink:href="abp-20250930.xsd#abp_CashTransferredToEscrow"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="CashTransferredToEscrow" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfRelatedPartyDebt" order="9.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingCostsIncludedInAccountsPayable" xlink:href="abp-20250930.xsd#abp_OfferingCostsIncludedInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="OfferingCostsIncludedInAccountsPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" xlink:href="abp-20250930.xsd#abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_ConversionOfStockAmountIssued1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredOfferingCostsIncludedInAccountsPayable" xlink:href="abp-20250930.xsd#abp_DeferredOfferingCostsIncludedInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DeferredOfferingCostsIncludedInAccountsPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" xlink:href="abp-20250930.xsd#abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SettlementOfBonusAccrualThroughNotesPayableRelatedParties" xlink:href="abp-20250930.xsd#abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="SettlementOfBonusAccrualThroughNotesPayableRelatedParties" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ACABLiabilitiesAssumedInTheMerger" xlink:href="abp-20250930.xsd#abp_ACABLiabilitiesAssumedInTheMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ACABLiabilitiesAssumedInTheMerger" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" xlink:href="abp-20250930.xsd#abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" xlink:href="abp-20250930.xsd#abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SEPACommitmentFeePaidInCommonStockShares" xlink:href="abp-20250930.xsd#abp_SEPACommitmentFeePaidInCommonStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="SEPACommitmentFeePaidInCommonStockShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_Cash" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/OrganizationandDescriptionoftheBusiness" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/Merger" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/AccruedExpenses" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/FairValueMeasurements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/LicenseandCollaborationAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralizedAgreementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralizedAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralizedAgreementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreements" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAbstract" xlink:to="us-gaap_CommitmentsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/CommitmentsandContingencies" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ForwardPurchaseAgreement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/NotesPayable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/StandbyEquityPurchaseAgreement" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="StandbyEquityPurchaseAgreementAbstract" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="StandbyEquityPurchaseAgreementTextBlock" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementAbstract" xlink:to="StandbyEquityPurchaseAgreementTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/StockholdersEquity" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ShareBasedCompensation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/RelatedParties" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/SubsequentEvents" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/PropertyandEquipment" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/Leases" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/IncomeTaxes" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/AccountingPoliciesByPolicy" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NoncontrollingInterestPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_NoncontrollingInterestPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="NoncontrollingInterestPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RecentlyAdoptedAccountingPronouncementsPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmergingGrowthCompanyPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_EmergingGrowthCompanyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="EmergingGrowthCompanyPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_PatentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PatentsPolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePreferredStockPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_ConvertiblePreferredStockPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConvertiblePreferredStockPolicyTextBlock" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_ContingentEarnoutPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContingentEarnoutPolicyTextBlock" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" xlink:href="abp-20250930.xsd#abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:href="abp-20250930.xsd#abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="srt_ScheduleOfCondensedBalanceSheetTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/MergerTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/AccruedExpensesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/StockholdersEquityTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityTablesTable" xlink:href="abp-20250930.xsd#abp_StockholdersEquityTablesTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityTablesLineItems" xlink:href="abp-20250930.xsd#abp_StockholdersEquityTablesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="StockholdersEquityTablesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityTablesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityTablesTable" xlink:to="StockholdersEquityTablesLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityTablesLineItems" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/LeasesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/IncomeTaxesTables" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfDilutedNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="abp-20250930.xsd#abp_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="StockOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnvestedRestrictedStockUnitsMember" xlink:href="abp-20250930.xsd#abp_UnvestedRestrictedStockUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="UnvestedRestrictedStockUnitsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockOutstandingAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCommonStockOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="MergerScheduleofCommonStockOutstandingDetailsTable" xlink:href="abp-20250930.xsd#abp_MergerScheduleofCommonStockOutstandingDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockOutstandingAbstract" xlink:to="MergerScheduleofCommonStockOutstandingDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockOfACABNetOfRedemptionsMember" xlink:href="abp-20250930.xsd#abp_CommonStockOfACABNetOfRedemptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="CommonStockOfACABNetOfRedemptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ACABFounderSharesLessOfForfeituresAndTransfersMember" xlink:href="abp-20250930.xsd#abp_ACABFounderSharesLessOfForfeituresAndTransfersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="ACABFounderSharesLessOfForfeituresAndTransfersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesIssuedToPIPEInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToPIPEInvestorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesIssuedToPIPEInvestorsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesIssuedToServiceProvidersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToServiceProvidersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesIssuedToServiceProvidersMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesTransferredToInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesTransferredToInvestorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesTransferredToInvestorsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofAccruedExpensesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedLicenseFees" xlink:href="abp-20250930.xsd#abp_AccruedLicenseFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedLicenseFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterest" xlink:href="abp-20250930.xsd#abp_AccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedBODCompensation" xlink:href="abp-20250930.xsd#abp_AccruedBODCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="AccruedBODCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreementAssetMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="ForwardPurchaseAgreementAssetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SEPAPutRightsAssetMember" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="SEPAPutRightsAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmbeddedDerivativeLiabilityMember" xlink:href="abp-20250930.xsd#abp_EmbeddedDerivativeLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="EmbeddedDerivativeLiabilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesMember" xlink:href="abp-20250930.xsd#abp_NumberOfSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="NumberOfSharesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreementMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ForwardPurchaseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BlackAndScholesModelMember" xlink:href="abp-20250930.xsd#abp_BlackAndScholesModelMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BlackAndScholesModelMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DerivativesFairValueLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:href="abp-20250930.xsd#abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract" xlink:to="FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreementAssetMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="ForwardPurchaseAgreementAssetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SEPAPutRightsAssetMember" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="SEPAPutRightsAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EmbeddedDerivativeLiabilityMember" xlink:href="abp-20250930.xsd#abp_EmbeddedDerivativeLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="EmbeddedDerivativeLiabilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability_0" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseCommonStockMember" xlink:href="abp-20250930.xsd#abp_WarrantsToPurchaseCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="WarrantsToPurchaseCommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySRestrictedStockUnitActivityAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCompanySRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySRestrictedStockUnitActivityAbstract" xlink:to="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="abp-20250930.xsd#abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="abp-20250930.xsd#abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="abp-20250930.xsd#abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRecordedStockBasedCompensationExpenseAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfRecordedStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRecordedStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertiblePreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionsMember" xlink:href="abp-20250930.xsd#abp_StockOptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="StockOptionsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_ConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="ConvertibleNotesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnvestedRestrictedStockUnitsMember" xlink:href="abp-20250930.xsd#abp_UnvestedRestrictedStockUnitsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="UnvestedRestrictedStockUnitsMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofBalanceSheetTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfBalanceSheetAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfBalanceSheetAbstract"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementTable"/>
    <loc xlink:type="locator" xlink:label="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CondensedBalanceSheetStatementsCaptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBalanceSheetAbstract" xlink:to="srt_CondensedBalanceSheetStatementTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAdjustmentMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAdjustmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAdjustmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_ConsolidatedEntitiesAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="AbproHoldingsIncMember" xlink:href="abp-20250930.xsd#abp_AbproHoldingsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ConsolidatedEntitiesAxis" xlink:to="AbproHoldingsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementTable" xlink:to="srt_CondensedBalanceSheetStatementsCaptionsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_Liabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedBalanceSheetStatementsCaptionsLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockOutstandingAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCommonStockOutstandingAbstract"/>
    <loc xlink:type="locator" xlink:label="MergerScheduleofCommonStockOutstandingDetailsTable" xlink:href="abp-20250930.xsd#abp_MergerScheduleofCommonStockOutstandingDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockOutstandingAbstract" xlink:to="MergerScheduleofCommonStockOutstandingDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CommonStockOfACABNetOfRedemptionsMember" xlink:href="abp-20250930.xsd#abp_CommonStockOfACABNetOfRedemptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="CommonStockOfACABNetOfRedemptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ACABFounderSharesLessOfForfeituresAndTransfersMember" xlink:href="abp-20250930.xsd#abp_ACABFounderSharesLessOfForfeituresAndTransfersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="ACABFounderSharesLessOfForfeituresAndTransfersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesIssuedToPIPEInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToPIPEInvestorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesIssuedToPIPEInvestorsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesIssuedToServiceProvidersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToServiceProvidersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesIssuedToServiceProvidersMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesTransferredToInvestorsMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesTransferredToInvestorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesTransferredToInvestorsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" xlink:href="abp-20250930.xsd#abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerScheduleofCommonStockOutstandingDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfPropertyAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_EquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EquipmentUnderFinanceLeasesMember" xlink:href="abp-20250930.xsd#abp_EquipmentUnderFinanceLeasesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="EquipmentUnderFinanceLeasesMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofAccruedExpensesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedSalariesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedSalariesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedLicenseFees" xlink:href="abp-20250930.xsd#abp_AccruedLicenseFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="AccruedLicenseFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedInterest" xlink:href="abp-20250930.xsd#abp_AccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="AccruedInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedBODCompensation" xlink:href="abp-20250930.xsd#abp_AccruedBODCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="AccruedBODCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreementAssetMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="ForwardPurchaseAgreementAssetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SEPAPutRightsAssetMember" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="SEPAPutRightsAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmbeddedDerivativeLiabilityMember" xlink:href="abp-20250930.xsd#abp_EmbeddedDerivativeLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="EmbeddedDerivativeLiabilityMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfSharesMember" xlink:href="abp-20250930.xsd#abp_NumberOfSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="NumberOfSharesMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreementMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ForwardPurchaseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BlackAndScholesModelMember" xlink:href="abp-20250930.xsd#abp_BlackAndScholesModelMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="BlackAndScholesModelMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_DerivativesFairValueLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativesFairValueLineItems" xlink:to="us-gaap_DerivativeLiabilityMeasurementInput" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:href="abp-20250930.xsd#abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract" xlink:to="FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreementAssetMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="ForwardPurchaseAgreementAssetMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EmbeddedDerivativeLiabilityMember" xlink:href="abp-20250930.xsd#abp_EmbeddedDerivativeLiabilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="EmbeddedDerivativeLiabilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SEPAPutRightsAssetMember" xlink:href="abp-20250930.xsd#abp_SEPAPutRightsAssetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="SEPAPutRightsAssetMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionChangesInFairValueGainLoss1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOptionChangesInFairValueGainLoss1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueOptionChangesInFairValueGainLoss1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueNetAssetLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueNetAssetLiability_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofLeaseExpenseTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LesseeFinanceLeaseDescriptionAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_FinanceLeaseInterestExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseLiability" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCommonStockWarrantActivityAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCommonStockWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCommonStockWarrantActivityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LegacyAbproCommonStockWarrantsMember" xlink:href="abp-20250930.xsd#abp_LegacyAbproCommonStockWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="LegacyAbproCommonStockWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivateWarrantsMember" xlink:href="abp-20250930.xsd#abp_PrivateWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrivateWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicWarrantsMember" xlink:href="abp-20250930.xsd#abp_PublicWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PublicWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ExpiredAtTheMerger" xlink:href="abp-20250930.xsd#abp_ExpiredAtTheMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="ExpiredAtTheMerger" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsOfLegacyACABAcquiredInMerger" xlink:href="abp-20250930.xsd#abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="CommonStockWarrantsOfLegacyACABAcquiredInMerger" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_0" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySStockOptionActivityAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCompanySStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySStockOptionActivityAbstract" xlink:to="ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract" xlink:to="ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_StockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfCompanySRestrictedStockUnitActivityAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfCompanySRestrictedStockUnitActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfCompanySRestrictedStockUnitActivityAbstract" xlink:to="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfRecordedStockBasedCompensationExpenseAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfRecordedStockBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRecordedStockBasedCompensationExpenseAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfEffectiveIncomeTaxRateAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfEffectiveIncomeTaxRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveIncomeTaxRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTable" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" xlink:href="abp-20250930.xsd#abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="abp-20250930.xsd#abp_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" xlink:href="abp-20250930.xsd#abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" xlink:to="srt_StatementScenarioAxis" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGrossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsLeaseLiability" xlink:href="abp-20250930.xsd#abp_DeferredTaxAssetsLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="DeferredTaxAssetsLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxLiabilitiesRightofuseAsset" xlink:href="abp-20250930.xsd#abp_DeferredTaxLiabilitiesRightofuseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesRightofuseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" xlink:href="abp-20250930.xsd#abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LabEquipmentMember" xlink:href="abp-20250930.xsd#abp_LabEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LabEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationandDescriptionoftheBusinessDetailsTable" xlink:href="abp-20250930.xsd#abp_OrganizationandDescriptionoftheBusinessDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationandDescriptionoftheBusinessDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MarketValueOfPubliclyHeldSharesMember" xlink:href="abp-20250930.xsd#abp_MarketValueOfPubliclyHeldSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MarketValueOfPubliclyHeldSharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MarketValueOfListedSecuritiesMember" xlink:href="abp-20250930.xsd#abp_MarketValueOfListedSecuritiesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MarketValueOfListedSecuritiesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSplitMember" xlink:href="abp-20250930.xsd#abp_ReverseStockSplitMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="ReverseStockSplitMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_ContractTerminationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SecondConvertibleNoteMember" xlink:href="abp-20250930.xsd#abp_SecondConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SecondConvertibleNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PIPEFinancingMember" xlink:href="abp-20250930.xsd#abp_PIPEFinancingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PIPEFinancingMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNoteMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNoteDiscountMember" xlink:href="abp-20250930.xsd#abp_ConvertibleNoteDiscountMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNoteDiscountMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="srt_StatementScenarioAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationandDescriptionoftheBusinessDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSplitSharesOfIssued" xlink:href="abp-20250930.xsd#abp_ReverseStockSplitSharesOfIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ReverseStockSplitSharesOfIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReverseStockSpllitSharesOfOutstanding" xlink:href="abp-20250930.xsd#abp_ReverseStockSpllitSharesOfOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ReverseStockSpllitSharesOfOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProfitLoss" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="SecurityBidPricePerShare" xlink:href="abp-20250930.xsd#abp_SecurityBidPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="SecurityBidPricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Cash" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NotesPayable" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InstallmentsAmount" xlink:href="abp-20250930.xsd#abp_InstallmentsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="InstallmentsAmount" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccrueInterestPercentage" xlink:href="abp-20250930.xsd#abp_AccrueInterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AccrueInterestPercentage" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherLiabilities" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LegalFees" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFixedInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFixedInterestRate" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreement" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ForwardPurchaseAgreement" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_GainLossOnContractTermination" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarlyTerminationResetPricePerShare" xlink:href="abp-20250930.xsd#abp_EarlyTerminationResetPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="EarlyTerminationResetPricePerShare" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="abp-20250930.xsd#abp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="srt_EquityMethodInvesteeNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AbMedMember" xlink:href="abp-20250930.xsd#abp_AbMedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="AbMedMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ContingentEarnoutSharesMember" xlink:href="abp-20250930.xsd#abp_ContingentEarnoutSharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="ContingentEarnoutSharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MabwellShanghaiBioscienceCoLtdMember" xlink:href="abp-20250930.xsd#abp_MabwellShanghaiBioscienceCoLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="MabwellShanghaiBioscienceCoLtdMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivables"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OtherReceivables" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_OtherIncome" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PreferredStockRedemptionPricePerShare" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/MergerDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="MergerDetailsTable" xlink:href="abp-20250930.xsd#abp_MergerDetailsTable"/>
    <loc xlink:type="locator" xlink:label="MergerLineItems" xlink:href="abp-20250930.xsd#abp_MergerLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="MergerDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_PreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesACommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesACommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesACommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeriesBCommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesBCommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesBCommonStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PIPESharesMember" xlink:href="abp-20250930.xsd#abp_PIPESharesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="PIPESharesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AbproBioInternationalIncMember" xlink:href="abp-20250930.xsd#abp_AbproBioInternationalIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AbproBioInternationalIncMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ABIMember" xlink:href="abp-20250930.xsd#abp_ABIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ABIMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CelltrionIncMember" xlink:href="abp-20250930.xsd#abp_CelltrionIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="CelltrionIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SponsorMember" xlink:href="abp-20250930.xsd#abp_SponsorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SponsorMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ACABMember" xlink:href="abp-20250930.xsd#abp_ACABMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ACABMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PIPEFinancingMember" xlink:href="abp-20250930.xsd#abp_PIPEFinancingMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="PIPEFinancingMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="InvestmentAdvisorMember" xlink:href="abp-20250930.xsd#abp_InvestmentAdvisorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="InvestmentAdvisorMember" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LegacyAbproMember" xlink:href="abp-20250930.xsd#abp_LegacyAbproMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LegacyAbproMember" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ABCDMember" xlink:href="abp-20250930.xsd#abp_ABCDMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ABCDMember" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstSharesTargetMember" xlink:href="abp-20250930.xsd#abp_FirstSharesTargetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="FirstSharesTargetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondShareTargetMember" xlink:href="abp-20250930.xsd#abp_SecondShareTargetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="SecondShareTargetMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ThirdShareTargetMember" xlink:href="abp-20250930.xsd#abp_ThirdShareTargetMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="ThirdShareTargetMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteAgreementMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="PromissoryNoteAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerDetailsTable" xlink:to="MergerLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionSharesOfCommonStock" xlink:href="abp-20250930.xsd#abp_AdditionSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="AdditionSharesOfCommonStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="abp-20250930.xsd#abp_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="AggregatePurchasePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_Cash" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIncentiveShare" xlink:href="abp-20250930.xsd#abp_AggregateIncentiveShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="AggregateIncentiveShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_RepaymentsOfDebt" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RemainingSharesIssued" xlink:href="abp-20250930.xsd#abp_RemainingSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="RemainingSharesIssued" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="13.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_OtherLiabilities" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_Liabilities" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxesPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_TaxesPayableCurrentAndNoncurrent" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_IncomeTaxesPaid" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="EarnoutShare" xlink:href="abp-20250930.xsd#abp_EarnoutShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="EarnoutShare" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TradingDays" xlink:href="abp-20250930.xsd#abp_TradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="TradingDays" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfConsecutiveTradingDays" xlink:href="abp-20250930.xsd#abp_NumberOfConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="NumberOfConsecutiveTradingDays" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LegalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_LegalFees" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent" order="27.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MergerLineItems" xlink:to="us-gaap_AccruedIncomeTaxesCurrent" order="28.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsTable" xlink:href="abp-20250930.xsd#abp_FairValueMeasurementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="FairValueMeasurementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebtMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MonteCarloSimulationMember" xlink:href="abp-20250930.xsd#abp_MonteCarloSimulationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MonteCarloSimulationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_FirstConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="FirstConvertibleNotesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_SecondConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="SecondConvertibleNotesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EstimatedFuturePricePerShare" xlink:href="abp-20250930.xsd#abp_EstimatedFuturePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="EstimatedFuturePricePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CollateralizedAgreementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollateralizedAgreementsAbstract"/>
    <loc xlink:type="locator" xlink:label="LicenseandCollaborationAgreementsDetailsTable" xlink:href="abp-20250930.xsd#abp_LicenseandCollaborationAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollateralizedAgreementsAbstract" xlink:to="LicenseandCollaborationAgreementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandCollaborationAgreementsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ABIMember" xlink:href="abp-20250930.xsd#abp_ABIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ABIMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NJCTTQCollaborationAgreementMember" xlink:href="abp-20250930.xsd#abp_NJCTTQCollaborationAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="NJCTTQCollaborationAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ABP201CollaborationAndLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_ABP201CollaborationAndLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ABP201CollaborationAndLicenseAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CelltrionCollaborationAndLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_CelltrionCollaborationAndLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="CelltrionCollaborationAndLicenseAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandCollaborationAgreementsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstMilestoneMember" xlink:href="abp-20250930.xsd#abp_FirstMilestoneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="FirstMilestoneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember_0" xlink:href="abp-20250930.xsd#abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntellectualPropertyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IntellectualPropertyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementInitialTerm" xlink:href="abp-20250930.xsd#abp_AgreementInitialTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AgreementInitialTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="abp-20250930.xsd#abp_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRefundablePayments" xlink:href="abp-20250930.xsd#abp_NonRefundablePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NonRefundablePayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OriginalCelltrionAgreement" xlink:href="abp-20250930.xsd#abp_OriginalCelltrionAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="OriginalCelltrionAgreement" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOriginalCelltrionAgreement" xlink:href="abp-20250930.xsd#abp_PercentageOfOriginalCelltrionAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfOriginalCelltrionAgreement" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAmendedCelltrionAgreement" xlink:href="abp-20250930.xsd#abp_PercentageOfAmendedCelltrionAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfAmendedCelltrionAgreement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfReimbursement" xlink:href="abp-20250930.xsd#abp_PercentageOfReimbursement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PercentageOfReimbursement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RoyaltyIncomeNonoperating" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsReceivableNet" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligation" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:href="abp-20250930.xsd#abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAbstract" xlink:to="CommitmentsunderResearchandCollaborationAgreementsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_ExtinguishmentOfDebtAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExtinguishmentOfDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExtinguishmentOfDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_ExtinguishmentOfDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="OtherAccruedExpensesAndAccountsPayableMember" xlink:href="abp-20250930.xsd#abp_OtherAccruedExpensesAndAccountsPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="OtherAccruedExpensesAndAccountsPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherAccruedExpensesMember" xlink:href="abp-20250930.xsd#abp_OtherAccruedExpensesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="OtherAccruedExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ExtinguishmentOfDebtAxis" xlink:to="us-gaap_AccountsPayableMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MedImmuneLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_MedImmuneLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MedImmuneLicenseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NCILicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_NCILicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="NCILicenseAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MSKLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_MSKLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MSKLicenseAgreementMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VAZYMELicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_VAZYMELicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="VAZYMELicenseAgreementMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsunderResearchandCollaborationAgreementsDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePayments" xlink:href="abp-20250930.xsd#abp_MilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePayments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalDevelopmentMilestones" xlink:href="abp-20250930.xsd#abp_ClinicalDevelopmentMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="ClinicalDevelopmentMilestones" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegulatoryEvents" xlink:href="abp-20250930.xsd#abp_RegulatoryEvents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="RegulatoryEvents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommercialSales" xlink:href="abp-20250930.xsd#abp_CommercialSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="CommercialSales" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsCommercialMilestones" xlink:href="abp-20250930.xsd#abp_MilestonePaymentsCommercialMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePaymentsCommercialMilestones" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentForExtensionRoyalities" xlink:href="abp-20250930.xsd#abp_PaymentForExtensionRoyalities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PaymentForExtensionRoyalities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrentAndNoncurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DevelopmentMilestones" xlink:href="abp-20250930.xsd#abp_DevelopmentMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="DevelopmentMilestones" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualSalesMilestonePayments" xlink:href="abp-20250930.xsd#abp_AnnualSalesMilestonePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AnnualSalesMilestonePayments" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProfitsFromLicensedProductSales" xlink:href="abp-20250930.xsd#abp_NetProfitsFromLicensedProductSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="NetProfitsFromLicensedProductSales" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfDevelopmentMilestones" xlink:href="abp-20250930.xsd#abp_PaymentOfDevelopmentMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PaymentOfDevelopmentMilestones" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedToAmount" xlink:href="abp-20250930.xsd#abp_AccruedToAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="AccruedToAmount" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentsUponAchievingRDAndCommercializationEvents" xlink:href="abp-20250930.xsd#abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePaymentsUponAchievingRDAndCommercializationEvents" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestonePaymentOnNetSales" xlink:href="abp-20250930.xsd#abp_MilestonePaymentOnNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="MilestonePaymentOnNetSales" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedRoyaltiesCurrent" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentCostsReimbursements" xlink:href="abp-20250930.xsd#abp_PatentCostsReimbursements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="PatentCostsReimbursements" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LongTermPurchaseCommitmentMilestones" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermPurchaseCommitmentMilestones"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentMilestones" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_OtherIncome" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="abp-20250930.xsd#abp_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesACommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesACommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesACommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="VendorsMember" xlink:href="abp-20250930.xsd#abp_VendorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="VendorsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CROVendorMember" xlink:href="abp-20250930.xsd#abp_CROVendorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:to="CROVendorMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SettlementAgreementMember" xlink:href="abp-20250930.xsd#abp_SettlementAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SettlementAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MSKLicenseAgreementMember" xlink:href="abp-20250930.xsd#abp_MSKLicenseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="MSKLicenseAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRedemptionAgreementsMember" xlink:href="abp-20250930.xsd#abp_NonRedemptionAgreementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="NonRedemptionAgreementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForLegalSettlements" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BusinessDays" xlink:href="abp-20250930.xsd#abp_BusinessDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="BusinessDays" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MonthlyInstallmentPayments" xlink:href="abp-20250930.xsd#abp_MonthlyInstallmentPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="MonthlyInstallmentPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalAccruedInterest" xlink:href="abp-20250930.xsd#abp_AdditionalAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="AdditionalAccruedInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SettlementLiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_GainLossOnContractTermination" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfessionalFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ProfessionalFees" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DemandDepositAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DemandDepositAccounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DemandDepositAccounts" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalUnitsTotalCostToInvestors" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalUnitsTotalCostToInvestors"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CapitalUnitsTotalCostToInvestors" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityRedemptionPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TemporaryEquityRedemptionPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_TemporaryEquityRedemptionPricePerShare" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExciseTaxLiability" xlink:href="abp-20250930.xsd#abp_ExciseTaxLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ExciseTaxLiability" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExciseTaxGenerallyOfTheFairMarketValuePercentage" xlink:href="abp-20250930.xsd#abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ExciseTaxGenerallyOfTheFairMarketValuePercentage" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfUnderpaymentPenaltyPerMonth" xlink:href="abp-20250930.xsd#abp_PercentageOfUnderpaymentPenaltyPerMonth"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PercentageOfUnderpaymentPenaltyPerMonth" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfLiabilityTotal" xlink:href="abp-20250930.xsd#abp_PercentageOfLiabilityTotal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PercentageOfLiabilityTotal" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ExciseAndSalesTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExciseAndSalesTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ExciseAndSalesTaxes" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncomeTaxExaminationInterestExpense" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExcessTaxes" xlink:href="abp-20250930.xsd#abp_ExcessTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="ExcessTaxes" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentCompanyExcessExpenseReimbursable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentCompanyExcessExpenseReimbursable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_InvestmentCompanyExcessExpenseReimbursable" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForRent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForRent" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PaymentOfRentAndMaintenanceExpense" xlink:href="abp-20250930.xsd#abp_PaymentOfRentAndMaintenanceExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="PaymentOfRentAndMaintenanceExpense" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_PaymentsForFees" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SettlementAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SettlementAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_SettlementAssetsCurrent" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ForwardPurchaseAgreementDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreementDetailsTable" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="ForwardPurchaseAgreementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForwardPurchaseAgreementDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForwardPurchaseAgreementDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForwardPurchaseAgreementDetailsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ContractTerminationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractTerminationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_ContractTerminationMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForwardPurchaseAgreementDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ForwardPurchaseAgreementMember" xlink:href="abp-20250930.xsd#abp_ForwardPurchaseAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="ForwardPurchaseAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ForwardPurchaseAgreementDetailsTable" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquityShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquityShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquityShares" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_PrepaidRoyalties" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_GainLossOnContractTermination" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="DerivativeChangeInFairValue" xlink:href="abp-20250930.xsd#abp_DerivativeChangeInFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="DerivativeChangeInFairValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForwardContractInitialResetPricePerShare" xlink:href="abp-20250930.xsd#abp_ForwardContractInitialResetPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="ForwardContractInitialResetPricePerShare" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForwardContractBaseResetPricePerShare" xlink:href="abp-20250930.xsd#abp_ForwardContractBaseResetPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="ForwardContractBaseResetPricePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" xlink:href="abp-20250930.xsd#abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePrice" xlink:href="abp-20250930.xsd#abp_VolumeWeightedAveragePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="VolumeWeightedAveragePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" xlink:href="abp-20250930.xsd#abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EarlyTerminationResetPricePerShare" xlink:href="abp-20250930.xsd#abp_EarlyTerminationResetPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ForwardContractIndexedToIssuersEquityLineItems" xlink:to="EarlyTerminationResetPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/NotesPayableDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="NotesPayableDetailsTable" xlink:href="abp-20250930.xsd#abp_NotesPayableDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="NotesPayableDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="srt_RestatementAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_ScenarioPreviouslyReportedMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisableDateAxis" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="WarrantsExercisableDateAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisableDateDomainDomain" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableDateDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsExercisableDateAxis" xlink:to="WarrantsExercisableDateDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="IssuanceDateOfWarrantsMember" xlink:href="abp-20250930.xsd#abp_IssuanceDateOfWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsExercisableDateAxis" xlink:to="IssuanceDateOfWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OneYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:href="abp-20250930.xsd#abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsExercisableDateAxis" xlink:to="OneYearAnniversaryOfIssuanceDateOfWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoYearAnniversaryOfIssuanceDateOfWarrantsMember" xlink:href="abp-20250930.xsd#abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsExercisableDateAxis" xlink:to="TwoYearAnniversaryOfIssuanceDateOfWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AbproBioInternationalIncMember" xlink:href="abp-20250930.xsd#abp_AbproBioInternationalIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AbproBioInternationalIncMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ExecutiveOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_DirectorMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExecutiveMember" xlink:href="abp-20250930.xsd#abp_ExecutiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ExecutiveMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentInterestRateTermAxis" xlink:href="abp-20250930.xsd#abp_DebtInstrumentInterestRateTermAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="DebtInstrumentInterestRateTermAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DebtInstrumentInterestRateTermDomainDomain" xlink:href="abp-20250930.xsd#abp_DebtInstrumentInterestRateTermDomainDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentInterestRateTermAxis" xlink:to="DebtInstrumentInterestRateTermDomainDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FundingDateToMaturityDateMember" xlink:href="abp-20250930.xsd#abp_FundingDateToMaturityDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentInterestRateTermAxis" xlink:to="FundingDateToMaturityDateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AfterMaturityDateMember" xlink:href="abp-20250930.xsd#abp_AfterMaturityDateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentInterestRateTermAxis" xlink:to="AfterMaturityDateMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExercisePriceMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputOptionVolatilityMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NotePayableMember" xlink:href="abp-20250930.xsd#abp_NotePayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="NotePayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteWithABIMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteWithABIMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNoteWithABIMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YearTwoThousandTwentyFourABIPromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_YearTwoThousandTwentyFourABIPromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="YearTwoThousandTwentyFourABIPromissoryNoteMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNotesWithExecutiveAndDirectorMember" xlink:href="abp-20250930.xsd#abp_PromissoryNotesWithExecutiveAndDirectorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNotesWithExecutiveAndDirectorMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteWithACABExecutiveMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteWithACABExecutiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNoteWithACABExecutiveMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPaidNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_SharePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfConsiderationUnderPromissoryNoteAgreement" xlink:href="abp-20250930.xsd#abp_ConversionOfConsiderationUnderPromissoryNoteAgreement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ConversionOfConsiderationUnderPromissoryNoteAgreement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_Cash" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncentiveSharesReceivedBySubsidiary" xlink:href="abp-20250930.xsd#abp_IncentiveSharesReceivedBySubsidiary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="IncentiveSharesReceivedBySubsidiary" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromNotesPayable" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RepaymentsOfNotesPayable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_NotesPayable" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpense" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIssuedPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIssuedPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuedPrincipal" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="18.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalInterestExpense" xlink:href="abp-20250930.xsd#abp_AdditionalInterestExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="AdditionalInterestExpense" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRepaidPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRepaidPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentRepaidPrincipal" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestPayableCurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="StandbyEquityPurchaseAgreementAbstract" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementAbstract"/>
    <loc xlink:type="locator" xlink:label="StandbyEquityPurchaseAgreementDetailsTable" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StandbyEquityPurchaseAgreementLineItems" xlink:href="abp-20250930.xsd#abp_StandbyEquityPurchaseAgreementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementAbstract" xlink:to="StandbyEquityPurchaseAgreementDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExchangeCapEventMember" xlink:href="abp-20250930.xsd#abp_ExchangeCapEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="ExchangeCapEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SEPAMember" xlink:href="abp-20250930.xsd#abp_SEPAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="SEPAMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="YAIIPNLtdMember" xlink:href="abp-20250930.xsd#abp_YAIIPNLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="YAIIPNLtdMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="FirstConvertibleNoteMember" xlink:href="abp-20250930.xsd#abp_FirstConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="FirstConvertibleNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecondConvertibleNoteMember" xlink:href="abp-20250930.xsd#abp_SecondConvertibleNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="SecondConvertibleNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ConvertibleNotesMember" xlink:href="abp-20250930.xsd#abp_ConvertibleNotesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertibleNotesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertiblePromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_ConvertiblePromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="ConvertiblePromissoryNoteMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FloorPriceEventMember" xlink:href="abp-20250930.xsd#abp_FloorPriceEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="FloorPriceEventMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RegistrationEventMember" xlink:href="abp-20250930.xsd#abp_RegistrationEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="RegistrationEventMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementDetailsTable" xlink:to="StandbyEquityPurchaseAgreementLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExcessOfCommonStockPercentage" xlink:href="abp-20250930.xsd#abp_ExcessOfCommonStockPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="ExcessOfCommonStockPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_ConvertibleDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfVolumeWeightedAveragePrice" xlink:href="abp-20250930.xsd#abp_PercentageOfVolumeWeightedAveragePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="PercentageOfVolumeWeightedAveragePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleThresholdConsecutiveTradingDays" xlink:href="abp-20250930.xsd#abp_ConvertibleThresholdConsecutiveTradingDays"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="ConvertibleThresholdConsecutiveTradingDays" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_SharePrice" order="11.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfClosingPrice" xlink:href="abp-20250930.xsd#abp_PercentageOfClosingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="PercentageOfClosingPrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FloorPrice" xlink:href="abp-20250930.xsd#abp_FloorPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="FloorPrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VolumeWeightedAveragePrice" xlink:href="abp-20250930.xsd#abp_VolumeWeightedAveragePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="VolumeWeightedAveragePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonStock" xlink:href="abp-20250930.xsd#abp_PercentageOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="PercentageOfCommonStock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAmortizationPrincipalAmount" xlink:href="abp-20250930.xsd#abp_PercentageOfAmortizationPrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="PercentageOfAmortizationPrincipalAmount" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeFairValueOfDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeNet" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChangeInFairValueEmbeddedDerivativeLiability" xlink:href="abp-20250930.xsd#abp_ChangeInFairValueEmbeddedDerivativeLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="ChangeInFairValueEmbeddedDerivativeLiability" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_OtherExpenses" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentIncomeAmortizationOfDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeAmortizationOfDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_InvestmentIncomeAmortizationOfDiscount" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForProceedsFromPreviousAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromPreviousAcquisition"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_PaymentsForProceedsFromPreviousAcquisition" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonStockOutstanding" xlink:href="abp-20250930.xsd#abp_PercentageOfCommonStockOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="PercentageOfCommonStockOutstanding" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfAdvanceNotice" xlink:href="abp-20250930.xsd#abp_PercentageOfAdvanceNotice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="PercentageOfAdvanceNotice" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeeAmount" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeAverageFloorPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeAverageFloorPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DerivativeAverageFloorPrice" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StandbyEquityPurchaseAgreementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/StockholdersEquityDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="abp-20250930.xsd#abp_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeriesACommonStockMember" xlink:href="abp-20250930.xsd#abp_SeriesACommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="SeriesACommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LegacyAbproCommonStockWarrantsMember" xlink:href="abp-20250930.xsd#abp_LegacyAbproCommonStockWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="LegacyAbproCommonStockWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RedemptionTriggerMember" xlink:href="abp-20250930.xsd#abp_RedemptionTriggerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RedemptionTriggerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicWarrantsMember" xlink:href="abp-20250930.xsd#abp_PublicWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PublicWarrantsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrivatePlacementWarrantsMember" xlink:href="abp-20250930.xsd#abp_PrivatePlacementWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="PrivatePlacementWarrantsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExecutiveWarrantsMember" xlink:href="abp-20250930.xsd#abp_ExecutiveWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="ExecutiveWarrantsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsExercisableTerm" xlink:href="abp-20250930.xsd#abp_WarrantsExercisableTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="WarrantsExercisableTerm" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" xlink:href="abp-20250930.xsd#abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" xlink:href="abp-20250930.xsd#abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfTradingDaysForDeterminingTheSharePrice" xlink:href="abp-20250930.xsd#abp_NumberOfTradingDaysForDeterminingTheSharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="NumberOfTradingDaysForDeterminingTheSharePrice" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PeriodAfterWhichTheWarrantsAreExercisable" xlink:href="abp-20250930.xsd#abp_PeriodAfterWhichTheWarrantsAreExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PeriodAfterWhichTheWarrantsAreExercisable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PerShareRedemptionsTriggerPrice" xlink:href="abp-20250930.xsd#abp_PerShareRedemptionsTriggerPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PerShareRedemptionsTriggerPrice" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="PercentageOfMarketValueAndNewlyIssuedPrice" xlink:href="abp-20250930.xsd#abp_PercentageOfMarketValueAndNewlyIssuedPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="PercentageOfMarketValueAndNewlyIssuedPrice" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleStockPriceTrigger"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleStockPriceTrigger" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="22.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DesignatedShares" xlink:href="abp-20250930.xsd#abp_DesignatedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="DesignatedShares" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/ShareBasedCompensationDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsTable" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoZeroTwoFourEquityIncentivePlanMember" xlink:href="abp-20250930.xsd#abp_TwoZeroTwoFourEquityIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoZeroTwoFourEquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoZeroOneFourStockIncentivePlanMember" xlink:href="abp-20250930.xsd#abp_TwoZeroOneFourStockIncentivePlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="TwoZeroOneFourStockIncentivePlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfCommonStock" xlink:href="abp-20250930.xsd#abp_PercentageOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="PercentageOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" xlink:href="abp-20250930.xsd#abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AccruedLiabilitiesFairValueDisclosure" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/RelatedPartiesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartiesDetailsTable" xlink:href="abp-20250930.xsd#abp_RelatedPartiesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartiesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ChiefExecutiveOfficerMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="srt_ChiefExecutiveOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="us-gaap_AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="SeparatePromissoryNoteAgreementMember" xlink:href="abp-20250930.xsd#abp_SeparatePromissoryNoteAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="SeparatePromissoryNoteAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NewConsultingAgreementMember" xlink:href="abp-20250930.xsd#abp_NewConsultingAgreementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="NewConsultingAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExecutiveMember" xlink:href="abp-20250930.xsd#abp_ExecutiveMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="ExecutiveMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_BoardOfDirectorsChairmanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="PromissoryNoteMember" xlink:href="abp-20250930.xsd#abp_PromissoryNoteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="PromissoryNoteMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartiesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnpaidAmount" xlink:href="abp-20250930.xsd#abp_UnpaidAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="UnpaidAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromRelatedPartyDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromRelatedPartyDebt"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ProceedsFromRelatedPartyDebt" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SalariesWagesAndOfficersCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalariesWagesAndOfficersCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SalariesWagesAndOfficersCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_SeveranceCosts1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForMergerRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForMergerRelatedCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PaymentsForMergerRelatedCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualBaseFee" xlink:href="abp-20250930.xsd#abp_AnnualBaseFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="AnnualBaseFee" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/SubsequentEventsDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="abp-20250930.xsd#abp_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="RothCapitalPartnersMember" xlink:href="abp-20250930.xsd#abp_RothCapitalPartnersMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="RothCapitalPartnersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AdvanceNoticeToYAMember" xlink:href="abp-20250930.xsd#abp_AdvanceNoticeToYAMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="AdvanceNoticeToYAMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="srt_StatementScenarioAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventLineItems" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfSharesPercentage" xlink:href="abp-20250930.xsd#abp_IssuanceOfSharesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="IssuanceOfSharesPercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/PropertyandEquipmentDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/LeasesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="LeasesDetailsTable" xlink:href="abp-20250930.xsd#abp_LeasesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="LeasesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_PledgingPurposeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PledgingPurposeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_PledgingPurposeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PledgingPurposeAxis" xlink:to="us-gaap_LetterOfCreditMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesDetailsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLinesOfCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_RepaymentsOfLinesOfCredit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_InterestBearingLiabilitiesAverageRatePaid" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_InterestBearingLiabilitiesAverageRatePaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="srt_InterestBearingLiabilitiesAverageRatePaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LetterOfCreditExtendedPeriod" xlink:href="abp-20250930.xsd#abp_LetterOfCreditExtendedPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="LetterOfCreditExtendedPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/IncomeTaxesDetails" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="abp-20250930.xsd#abp_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_TaxPeriodAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxPeriodDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TaxYear2037Member" xlink:href="abp-20250930.xsd#abp_TaxYear2037Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="TaxYear2037Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PostApportionedMassachusettsMember" xlink:href="abp-20250930.xsd#abp_PostApportionedMassachusettsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="PostApportionedMassachusettsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxContingencyLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationDeductions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_IncomeTaxReconciliationDeductions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CarryforwardsTerm" xlink:href="abp-20250930.xsd#abp_CarryforwardsTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="CarryforwardsTerm" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FederalAndStateResearchAndDevelopmentCredits" xlink:href="abp-20250930.xsd#abp_FederalAndStateResearchAndDevelopmentCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="FederalAndStateResearchAndDevelopmentCredits" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxContingencyLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:role="http://www.abpro.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="abp-20250930.xsd#abp_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentDescription" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
<!-- [WMV6][0h3AYtNyinJGVdejdpiarnbF0zCZ9aCJABCsJCf/j408yOXtZgrEuadUzo4Btxp4pupP2e4GpTr3jZX3oe6R5agLD6EW6N5++2ReVdLQqow+PwddxNWB99XUgBL6W5M9b5slXKibANfTzovZXfxkRWRG3jVLeW1Q9gMI1l6Pc5k/3bkAxf2KAPUSaRlFVZQ2eD/eAnH2pjjFiSbXkllT9lv1+v+0OTZZGob21rxzojIrjv4tRLVySyu0KuuojtVGJFpuNPvxsK3qcYoAkPZRytcngA6jAeNTEvJETs5ldhQQu7Z7aMN3fH5UhLxkAdHsFsno8OORfAdxjzaYkPEiJh+psdoYKswm] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>124
<FILENAME>0001213900-25-116002-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-116002-xbrl.zip
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M>S&0[/$7O0UA;S@*Y99BHY;W,B)HFLG)9^N(F)"@=)4D'M>,L7>&^:URD3J
M?1G-X-H=9Y./V!"QTN1@J(2'\=,,N3-6+QW+-H&9B68#U>9@E02+@5E+#TU$
MQ Z+5X?/=*7-!!NT ^\2WJ;/XMBWR]1 581X4S0-^ W6JG<3G\*Q54*D3'-<
MRNYHJR6A!UN/3H/4Z57I+5??5-N\ISJI>6 BI9,@_\JOI1*D *G29]?! B!O
M:P'B#Q1&DT,I3V0B+CYP$3B#VW!4/TR\3!ZE8A?$FH/?(O8ACO6V5.Z4,!7N
M/+[\\.'L3V(];E%\H0*::BJ)]*.VLJD"G"K_! Q#D71$3%MQ*<QCND5 L\%*
M5>*3ZH=,%EU+N21#J#H)8-;Y<A+']%!;\F2402F=X7&N9V:8BF<D53F?;;ZZ
M4HL,A<6M"DUHWZ''?P*1R:N'YO&]T%[!&->"E9FMDC@3RPA4H93;(9WNR07D
MWH,G#G/) )&QH=WI60*UMT8JC4KH# [V]O.Y$X+T7<;5";@E]-2 JB:Y'\"?
MH\!CBN,+))C_[[F,P,;(50/2;7?.L,BG$5MGYR)6(/, &&MVQ"8MG4!"[1B)
M32 K+UVQ!JVA3*=@QA?0LP-L!HDB]=AX07 '8;&8Q3EM>421:PD)2G!R'K!J
M/V.?^[&I5;240:DO&V8.$$?X<]L.0B2HY/8!]ZY?@%!D)>?FA!UD2%!)R>CX
MP/W*K5UWAGFN">Q!WPI*%, 4UZNO^A_9+A(3*T@HHI$>/*99PIZ%25 7K3*!
M4MJ6+?JL I \@U>6?O[P0A#9H004P-29"=* E0DW"2ZAN ZX.EVSA#0SE.JH
MRSB%09C-B6P+>2IL9J&D/ ;^!%&1Q=X6HA38S(FRAD55H-1IXE95!B1Y]4F(
ML'445<,SIBU[#<,^TBK0*7)%R$,4K:!,CT]^;2!]\TI<GCE#XI9W?+1@!VE:
M?*H;$2+6M L6XB#+#GJJ0:G3(B1A]980D$<C??$@+9<Z7.U"7T E%:(S1&A8
M4/-64*( IKB^7U')#L:HD"E/FGB]58HQ>T@I0I*^ZL +QX;=") IM$-+R5#)
MI\GJRHD]JK8:DS:W1>G^G7A[TPZ*#!#6?5S-:L)T-$5!',@;PA&VSOVF0R>7
MQ!Y3@U2DV6M[-XA:XL&2H9)'9R11-YSF=;2Y';2HH$D).@?CE3UJ!1D5@.3@
MX12X2^&CSSA.K.**$43YM,E4MXT< TOF8OBKE2Y>.2[I,SE@? M]?\@W.C.
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M] !5C!'1&G#@ U=\MDH#:L!)7Z6(J]E(BK$?69)"UA):5-B4PF9=0)8L"LL
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MD\N7$<C4<G_;8D12=P;G0$RL_P-02P,$%     @ Q'%\6[CG%+/W$@  9/D
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M)=;7<+RRUM((O46U5$ H8-T,1Y/@U40 E7$ZDDNL'1\&Z(@%+Y+W"@6),NW
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M2#_^@>./R=_OJR G:;DA91P&23&(W>.Q<+B_I?MN2QY+^N\MI6;-\?'WE$L
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M?'#P.R8Y<XU[(D&L'H52ZO4%\RGX2L;<AA+*[V!#RF2*U^GPE(V^IU-BN"(
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M9D II=:B!>\UJ=_G";_5K_(X#>-75KNK9@88+C6M&6D\C=!:M& R4#47@GV
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M7&QJ/A&>>/7TYF%M6,BO!0X^5.8TNHZ;-8>, _P0XA.",]IA)N)KP9,[06"
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MXXT(:[,<_P9MV6%S/J53'G4N\]:RTY A=$8\Q-G1F5%G.G1RET$:DB29EGD
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M[N)72<E+:6<A0PCY,'(Z$^B3JE^[6@PQJS,+":*DHJ@H>2X+J%VH6H@LTD&
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MX-TKZ^..)\KUW@' &U7RNGD7])B-&&F2%D$-Y;[*]L7N\"?->\N"U3; >BX
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M!SF)KM,R[E6Q8K^&ON"[<O$N-^]@:-IX Y0&F'L_(UN5]Z2LPU2"-"08"\.
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M#3.J;U/)Z2AT1*B^GJNMHY6*MJHOJ%US?%CR W+/#5)UHX',^$PDP;->3)$
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MTU(JB"Z$CMW\X>Z2/"2_.NDA;B^TECX)%-"M1@V7J1.(3XX>)U;G@<P:>B)
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M/@?2K <N\M,!6*(>O3@3!(1!;\%+0B\T4+Y!MV2G+= MVW!'?@*/P) (@F(
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MGD(O88^?T 9CM(N2F")PN1?*8^'JNLP.<S&/>\PCXOH$E^7VF@:X5W,U;@K
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ME_S0#SITA-J>0I\XS,0^<#GJ3Y#]O?SZ&<=UBF\V*])]G*0U34)]C]=UP3*
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M^QWB%&AI@I>D3/J%O8-& 4X"D#CLSWY&K1<$)T,G^HJ,\SS/JB2KD^RI>6]
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MI&J@UH;)55UD+&\HV7FNDJ\L@^@LUHB$D.\Z(3 KT.UEVX#9'9NFR3(L#K4
M!V\]Y4/W&DV@QY,P8\U 'E>P/,*<0ER*Q"KDH.VZ*^TWRXH^[CV ]^&(!>AY
M?/2(</OE,E8M()D^+D1CLXT*I956:S*;\P("HA*BB@_ "YS:GGV-GJ,B_A(U
MBJ7,-Q7[81&04<AP6/X)'KRUI<"J+=*TI-=;FER8V2+SF HR2O[=%1)NP'0<
M30N4])HLQ*^I(<9AR4WYZ"V\$1TJ/].8S*LDH]&8C(Z^8T+=A]^D32IVH%#S
M;E?B\:D;WA*EK.D"<GMIRZI+":0U$Y;Q%+TDR;T[]?;"71L\6MWX#:K280G4
M-KWDV;I%OOPCR41V+9BT9\5""]VRE%78&#SB=G[1(N0!@$?S[4(JOBEGOA4]
M/$0;6=>/:;(V%[6HF<](*Q$#D)C9I\M:\K)I[^0,#=$^/*I756X6\W3<OW^C
M=,2#-),4_[!7@'L9IB@HJ+X!*AZI9=C&!7ZLKK.R*FKF2?V:E(ZQ(2 PP^DW
ME2!CS $ #?HA.GR)_H-^&]QW!DMH6(-=.$CKLRT+%*K755TDV=-Y7E:KC!88
MQ,4+G@$D*FJ.MQ@96A2LR"(JVU;H@7!VC)Y0T6%J&8[BPQ2CG[ /U8\E_JVF
MD20OY'_H-,T )HB*9[4#L %M2]W7B'V^% PI1#;8ER0#MKJRO6\O^.[7.(N*
M)-<%B^*R5MRO)WB #$# :#X9[4:>KV:EPF@O9>&!63P'NE\_X[A.\<V&NE!H
MYIGJ.8]Y61X6C3;Z+<:?HJVV2E&A9 IYY_8O"*4)7 *(.S1^A^BG CO(-_8<
M(*&#Z-0)L]_^KI(LJ?"'Y(66.:O(E-.P)I;VOSS;?XS^*R_.TZ@L9]@232A[
MWB8-6(-B$5@/)ZP+=.B#5X,HT>,>L6X0ZV<A1KT%% 8WY(:39GT,H'MZ$B=1
ML;^/Z)IA9\^9;#8Q'?=WZ"JC3<@'M#N3KV@V!^Y56 :VE#([-MK@ =O>KM\_
MYT5%DQ728^E<9KZ0AL>3HI !""?TVQ.6F))^_4YHW@>"BTQ6 ZB X[7?$B^_
M5N2@62?E,]U[;S:TZQFP I)Q?2<JPPO$!)ATJ_\Y53+,/S7"3(A8'874!D$[
MLE%/B.1BF6C.HA+'/^=Y3&N\?\HSO-VE^1[CIAHR+^@9K:FK]&Q_7^]V:8*+
M6731)&:\G!;<\ JZ+_@G(4^I;I$QU'R3I\SBCF[HTNTG<:=*>(QBX8V=1B>>
M*^RI.=)SS[\[RM_/LSZ'@Y^9R-K;/LW9L"F_VEXA-JGR(G)$N"#]:@)'UMKW
MJQ<)+ZJ\&KTFZ((E3PUJHVO*Y3AS!C1PZW/=65TF&28GQ/5O9&M.J-*:85N$
MJ'AV,0!L0,F9FJ]IY-!CDC77PXLXV2FDUM^R9&.V1LTMF2@3#ZL!5 9=>[6'
M^I2A4!+R$^ *#8 "D13ZHA\-R,+W_I!4U!MPG;%DXG64.G*JB_OU>/4B9  0
M._N6Q;W?YGP)A;Z$D8JE]7##0[1.[9&232>^C8IJW[-R9XD#@"EY50H21L (
M -8"L2:HUV897AX-&0[C .3CMT32;8KCIR1[NJV+75[.LX^,*?AT\@CH@YL*
M_Q(UGR[AZ"R1SW"'$0]R@COG(?IZBXLDCV? Q+!OS\;G@#BTT41?$?]H(8:F
M4!I]!(Q'96U47F?K?(M)AZNZ>LZ+I-K/  & B-<]1<P#> E//T84&?^G+I(R
M3L2;20!PR 761XEDQ+8;2)'O,-F3J(U+8],.CVM*O*G3#\D&N]Y0-"@&>.>K
MP1;X_(&W?(=86V;?=JW?(=X>T0[";D7ZDAYL39KS$B#;F"9KPD*$995LF7E9
M<_&D _&\00%-R"RF0>$"E^LB82'T-QOJ:+W\6N&LI%$4EUF]Q07S^OC7))I\
MA7@^[HQ[/;7T3J*7WC%?_SO4HX?^XT +]8@%MZ2<@]%P+1G(Q"JAUAU^H<AA
M82/WNS3A1<W+F\UU6=8XUKAH4/7@]R&A@ALPO(,5<\DW*&&?L;*^_)??A;QJ
MT)1.>]V@,WB+B\RC;GO]]I*;FR,%Z,?WY9065TK<Y+TT[R+PA 6.7&0 ?"0S
M8:5J[O&ZIF>(LR1F5;_( 93UKX$<L*GGNV^(#P@>S>?H,8F;VGM$W_/240PE
M%WF:1D5Y^&TPP*B$TV)$.@/6)1[S#.\_1L6ON+JJL[A<5>=14>P)VN@#3]<G
M0A4UW\G;%/R M4=H _1"/PE<R%%/>H-J@!I#M@]*9)E&;Z,]O6YWC)U!U_X?
M2??)@YG]^"84;?,ZJT(^/1.)H0^"T6#\5_T]9D%T=N\7<"$Z/%LGNRA%CU%*
M\\"T91BK9UI<-=\2\S$O]K00(RZ#NE],)]^^/N]1!!2S-&_;>7*\_.2TO-=N
MD;(#9R]I('2T0@,=<+7$![]4%PTZ3)D6)5^BQ7TL#6K*P^OX;<CGU-9Y3WOF
M";W+),^:U-[T!5.7MH#-X?L9%KT6V0!N?%W>Y)G=<8S(86#-,UWQPK(A-VY3
M.1^C3WM"[)-_M@2:!T_\G-I1<XU -;TP"4$57&E6DGY'D-?"4.CW"I(:5%/"
MPR2A.A/BW&K7V)NT.!/M3P<%47:NIE9/T'["[DWS2>G4I3+7*S&FQ9>HS-B]
M2C)O2S3O+4[FU'-$MX H35FZ5;X):#C^!(V\ID$=TP?C/0X?CBU[S\X\>*I;
M-QXP+LLLIJOUNJAQ^_CE%A,)9%7TI./9!9MZ]NQ"?$!%-]CGQ&IK7C#MN@:A
M'+@J&71U660#M37([O NVC,P\0>BCNVO4?>^7;3'#( QQ+LHB5O?4.B3/224
M89RP8&!!:F:(.!$7[FN^HQMN<VCO7:4$N4"9.N.32F((7@K1Q&\W&_:+ L>7
M694,HL#IGST\%=/B(L"9W9)5*/:W]U)@3;X+B;^)4%"\/].>I "Q>1/8%2F9
M8Z&68A6SE$>$ 80\+;YOC7%<7I%A40WX"5<\0H5NFG/H)@V"WJ\.U#Q!!XWF
MFZ&R"10:IRG'HY@WG8&'N4/08TZD,09B =7%6Q.3[S+P>ER)G#3D2WJQPUJ'
M-LSGE(AU_?>;ZAD7'Y+H,4G)1H!=Z^!1][Z/<,<,0,YQ@I/T\%5(:PZ22!\4
MPE$%.;^).!$IRMXGB*QV0%.^HNF>='BC]6#2*^Q\N1WZ]6[9=*0EU7U2M,&#
MB_40 A_-_;!*6'\48:R1 0_"M=1-)6AP+'MB)X4BB-,NL136,>2#=AV!)"/L
M/SQ0GSG5X2).RO5Q=%+XX!<-,4LB8533X02*'Z.*Q4?3-$^S0F] R+<Q!;,"
M1BOS3U!,OED4J$0"@T$T&FH06TO.DVBG8+GWDE[NO:)SHQ]+Y+6+9)(]=H%9
ME;;D!5\E7UER[DYG.%_-,*40.P?(#7CAW5Q]%HO CU)L0P#)1VOQ1NXJ+[Y$
M17Q+)/,<E7CU5&!62$/C"AQLZOD*'.(#>FC /T>[YGL4M0U"78&K9-!>@4L'
M:GL%WG1ZGF=5$:V)?HHQ@=9#S@)PBY*7I;C'594R6JN4R")C&"QYE,VJNHJ2
M8HX'3TY9\VUJN&1>^8IS V(:>A$<0-G-@;1!<0K7,Q[$1G(]"I%5=8_3%!<=
M6KH@32HO5#TG%$E1P5Q=8OC\@1Z->9]@SOT<)=F'O"QOLI8?FD*A20KK6,O*
M:7EWPTG9@6(9#E^@_#%-GO@_HR>B!9]H\N60@8U&,NTC4CT38=Q[2KY$*N=3
M7M%GY&2OJ@X?OS6!&+L%J55W&17IOM<1+7M9F28:T.C$LU6NY@BJ/T(;]E%"
MSOPENP4URD/@VXC7%V-KSFO.D*UAS^Y\[O :DR/C8SK/Q6B_^R 7HST&P-C6
M[HOPUW0"<8RNZ8Z'-*'L+7ZBILH=WN5%Q>KJQMO;(M\D%=5B'W%4U@7^:_[E
M,S$!>_F:' /%EHL $9:6K(*/)+>[*-O_XS_\^8?W__POY)RV:[)>!;V=GPB*
M07F:"=-E7>%-0/.0<9RE(%]E<9LW_:;XN<CKW4U!9+%-JJ:DIH^D>_/QZ=TB
MGVTH8/8A1@]U!-^A\YN+C[3N3DL4"5+DYP5BE)N""<J\? M9>T[!JUJ=[L0V
MX7 KKG][\R4C0'Q.=K-=@>O3]6W*:',&K)CNR^YA5V!7G[&(!Y7[C&;#WCRZ
M);#"18%C]F3T#L=XR_8GR=G+04BW#DW_]VA:?($6=OOU@G/%60E]&,:J.T.6
M\1B7FPU>4W]BE[V<WNN1TP 95)(F3/6V!P3^J^SINL+;LED0KK7E5':\VRE3
M.88/D/E3EOS.DIVPY/A5]#7PPUG7F!FH7Q?3.,$\^)P5W8P3XF<XP^1$X=I]
M 5$)D1 %X 7 8_]K!L7'YONPWE2%V/H(DXW7OF(\5<L\:]1%7= B,:Q.2#\3
M!$\0\3ESCR9#XK[M2S/V-'(^5?EQNJ<@QRDKD0_.2.838V]OGJ=16=YLFMJ:
M-\5=\O1<\:1&-YLF/VU"R$9IBN.S?5N#L_G0-62G<A,D<]0TGC7S2M%_?>%-
M0\>'.8+,(%>.@SD,DHIJ.M^B>\FN8*\T@?X?HG\>/)\VS[03Q\S-U"9F/V<9
MIYCZU;C=E+7VG79?P@N4<Z=I$:6C3=,OM#0%T67<48S4VE1;E26N!F_WLS*)
M&^\B>[3/3]J.=SQML@%NGG1Y@P)@\HJ@:]UOM)P'BJ;B[JLLHWFQ*5:_:F.$
MVJA:YL_1T4GBAM[5D9 -2!-U 5%=H"CWV"WA%9Y:&IUB@L=L5>"CZ^\ZHPZ,
MY 7KAMU +;WF^@.8@ L\\H^6L!G))WXD;\$ )SB:I(<_]K]G-#B67N/CK&0:
MYRHO-CBIG&]-DU@)$2@Q@5_X60;_.\J.SF-!HR4<8$3;X: S<39[W!W>1DE&
MB'$R!A721.U\UT43\ !ZZIMOVX,\/].%+80FF?I#_2IHC)9723Q79MQ+^'!>
M$RN)U>K[1!CF/[@VK_6(AO ;Z;$F39D:(_R5+DDP94$(P]I(S .S6G]"0OAZ
M]-D3N71:@8G2X03RX_F05(#4X_K,B5);M7(*7_')AWALTH^W5!ZBKUW1(P^:
M7$G.?WR*BB7(+T)OZGFKQ23;U15F'V9:P[<T%KIK?DHA<7VR.>X]P&'EB 7X
M7-S%=BP,,8"$^@ 1C='FJ' 9%5E>5P;/C@Z?^W9]]8G#;XGH)^UY0/5DR/_Y
M0#3?O?=!P_%9.;<>BHB6 +R(]J6&0/M?^SWH]2C#&:M9,<.8?!(HOA68T%9B
MQV.P> W87L=11S=>U]39929!10>^0D_4K,!A)NW'J (D[EOD>D)I4: Q[ EO
MNJ(4-T5NYHQ3!LGX?WT"< )I_*\LV:S!.]$PH4L*,0Y\AK(9"/,$7,:2,.$$
M^9Z7J#1[P_N:13,A1V27Y:E-*$%+;K2__(1=G_<T" 8H4:OB"5  AV_0!M,4
M:QCALDJV-'&BH'1MV*1?"OD"N;]D$Q*JAJT.<^($?YVX:!XCTOJH-/P;$Y"U
M5F!Z11"<,'VK/W0<XB:QHPZ]!J7*E6\<02\"1],_V >&HPA02&;(@7 /9CLN
MWX'K'2T0D^8EM:[)NMOBXHELO\LZ']M,_:G#4ZN>#WQ(7^3GODKSO'@=IH_!
M3+^W<T=<MGOQ54WW9N,\-[+F7J-N9)Q 9Y/.#MFP-N&TFJXD.E>4:K"V!3C;
M-(7765(E44JSX6B@0-C,IV=#Q  8<]=F8DSXMRRU4;@:J[(I/P1< <.S"_[^
MF*3$!,\S?-M4$-00\;B-;_?RB ,H17C['6H+)(9:T> \MW(5#\E*CW^B^:HV
M=1;3FQ(#N8K;^74U"WE0ALQF>792=,W&P@[AEY0)H7-'@J.U/(FT?5SEQ5V^
MC](9JBX)200XG8CX@(+/VK\O()Y!)J%!3@-H>#97AS=%\I1D47J.T[0JDCPS
MR24N:>Q7-\",0+E7F@9HW;80)!0/H!O4XF@5A&+(%I=8AQ0M-YM)L-#LR*OA
MK\?3)+1XAHJ9N%K8&,R#Y>F@3V%%.HMQ/!E%<#^^[4LMKB"KA'^_-)UC)# 1
MCN3S8&6H]KN_P\GVL28RL0#.L*W/PR;(!0".P_?4M5?T6X0[=BK%((+#>+3V
M%^=W^ 5G-6ZR^="'%=UIB*<:&W[PN_,W/A8,!+!XS;D$'V.P[] AU4M8WZ:]
M_/L6L^7TV&8[Y5;Y_N<ZHB_Q,<U)0K,S,J-]Q8X9KD&J)NC]*EC-$P#!KD6,
MHBRC:4.W299LZRTJVM-.X*M@??D.0*@W(1.>1C84>%3IISQK4A=G3_/ 34 G
MA.J#F)&>^/>M)RCT-9E29@(( 6.U55>K-2N^61Y2F+L/5A'3\)U12\@%_(",
M?4NWPN;CT%B1"NKH?0LP3GM+K$D>6&+"\/,JBR_(EIGF.[J&+OD;.\>0T2#H
M?5-3\P3:5;P-2WX='UJA$A<OR7H950XT9"NH>Z":C"D;6FN6-2]MR2ECDQ=;
M6C/XIBL8-)?!+Z7I_RV5%E_PV;+]ME=I*;0592)<H36OG D+)^@Y^46RCM(>
MF+NS@LY-F;R]YVH^4F:@2/ZFS4!+;;M6?PKF[]223.N/4(_<+B7#4YW2O^TO
M7S1O3D=-?"=B&)('MZ?V,X1?CN]'O2=?$$_R(>^"8$@V*YT<OW"Q3J*4QH-K
MK>VC%C[=B4>TX>(US5>HC$+53I),;K<\!:-Q%*5RZ-I(;^OU$SR:1<25=H0+
M6A_@<=#HX;S+1K(#HV' *;&[>."]7N5%4T4ES]BI.QG'2X@O'Z3M/>__4F;
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MQGZ#P6!&M$!3T2\%9[. $!'+0H0*P7@M'4+<[*!ZC\96$_/#^>6WB(+WHY2
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M8VI+%FK+NPC\6L,"!GUHFL[5A">N>!<EA]QFKC>YX^[]/W$=,@ ^ ,+ >[%
M3US%4AD^<16,S#91?Y&\1%7R@L^?R:S@ZZP+6]$XU<E:^T[M(^$%?#'8MD!K
MUH28S#R:D(41!LWBKY3*(9>_?-C.=[-& 74;*%-%'<V9'HQ,9,:_RW(:P^ E
M,CGTD)/=X4E<@=?[=8KC_B:XM->+;H"DLT4:3*Y%GK,1528,6D*TDKR5$NI-
M[:Y\9J3194H!SH(V.'ZUN2A@V@BS5;=&DV2W)1^1.(OH1=-TD ']^-ZFM;B"
M4O.1CRWQ%19><AD"V)),C=7SND_U]A$7-QN:-Y!&*A-RYU&ZIN4HD^SI;WE:
M;_$O.'EZKG"\>L%%](1-(3>9A.]*+A/YA3+3LFY93&D1L61+-)<DJFE^6IJ?
M8GV@@?[VR^JV03/YGF_C(0O . ))5Q[&Q0S;W%K!76O@6-+8;Z 9S @ /=X
M?6E:H(@WT7R.[!UN:BFU0%+,A&-#29+60LV,**<%;W'2RN7$3"ZO5"JG5BN7
MK7O6QVI#%L<%IOF\B;*@]:5@>K3P1Z=9\NQF<YQ^4F/9ST79MXTUTS@@E7/8
MP;3M,<^ GAE2[6J8<]YGOI4XD$P)YQES*)7G4?G<>^D6Y-)"BS'OU_7N>->X
M76,@X&_:J/E(":-=4PU G+MS05X>>YB97XIHS[>S'!97$5GK@NW%<6Z*'IG
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M(J#SM^5FM3C;GTTM5Q8"BL#!HP%0FNP@=2C2&=BX#2A^PEX.Q9C@3E3Z/SA
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M/;UB'%^3Y4$^S::1SC<FO1;97NL=N8O?LO)0YT<6DSI+=N*I.P0M0'HBL(9
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M4FW;F>?C.:'3@D80: LJPSC$[-(%?,9::K<9QDK$O%ZM/F95S9\W-E!9WMW
MT<T,^DUK@- %_,%HX9]DX^-KOQ8.")Z;,/55GFCV&%US(N]U,\,J5&H@S!E_
M+#9D*;RW<*"?YJ?&U)/WFY>L\F*]9F+HLUT-AH;W=+"-]>'/>3,/!/,-F'J=
M^*O+J^L)CHMV<%"-N]U6Z[>XNE["53TF9N>[Z*'@7]Q/2ONZQD_G>5E2[Q$Z
MIT,)A6M:WQ)R.HRL&N3_:##UL\P^ET6#KY(J+Q^SUT.NS>!3?N.&R8%#]K6
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MC,II(9]H5  8O7+MV.5XXS1D[[GA5"CZZ4SD=%L7^*^'(JUP^N^X*N&_.>]
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MQ&N$CPRVL*(+"S9A[-DV[&'-!,K]$7PP(R3/!WOK'K ?ULAP. 9_H%:3N'V
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MUFKVT=?T I5@0<U+TB#P6;5' /FW=/62KSL9'@GQG^5"B[A!$ST/;_TJBSQ
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M8D>L"Z93,XTA-U#XA\E&0E\9P39[2LBX+00%8]R@%&)4^6_V924\87E9/'^
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MK>/T%)*%OD5/*VZD:;3V+10T\BMD-+& 45!.5MES5B3Y%<[SAAA>A34&5,Q
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MC/CL[R.[!>WXJ?CE2I5 )I674>QL_(;OI#W%UG4S; /57R!*[DM^!*T_R7.
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M+2[0W0%.$5K=O]^R-(:3?4;Z*'WRL],_X(?[@)\S>+:D(:=OUD<M>3CKWKF
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M-&CP0B[5B/[H-D/2;E'K;,Y&,Z41-R]# A=9X ^C'\N*&?6\T@"->M;;V+P
MQJZLN%NCK;70C^V.9'4;<%*;X58B!*JFMKJ\M00^B0$Q5<86B)'+J ]^N&"&
MJ]M/V1:\A:X&=CO!8%>'MZQU:(P,:C.^(;/JI1:!PF%K)GV_4:*8$]NIH<=C
M2'L;QL&BMD1>_VVQM60GMN4+R- %)$./(1_26(=;T);&4#V;AN25K_ND.-Z\
M;W%=MUEOV>O3H:I!$=>1O5L!\24@J;";A]B*JBY1,6Y-=X155^A4<@4-P5)V
MKQHG=5P.DSI8"%-79+"FW_[F)2GXF_RO!&=X$F%1XBY]PK1)/4\\J6?83PS@
MN. %+*1:D#5BYVA#@!%A%Q>(P8.R@L>MQ[6, Y%=:4H'97G 8VGD&8"X$89<
MGI=?(6%Q4NYS.QVU\^/VP;"BIV*W,U6"::341_?7,H=,L-IZ0S/WHQBNN:9#
M*_E*#$8:OP'/P&Y)WT]>%7TU2-X;1GMH?9FGG_3J,#M%=]Y1L$WL".& ])_U
MR/?F?T^^_9[10%-Z?"!72I7!^O3]Y$N1G?R>YKQN*&O%"SJW]S58#4G+\<<V
M6-#\TA;SH6TJXY4O;I/H&,@I4%<- 1(7"5&/[BO\EI6'.C\^8"CO@]/N>E!7
M;Q7CD9@0MY*."S(RA]R1#UBZU="0;]8^AK9.#L'=#-,0'_D@?.@6,$J1>J#:
M7GUMO7MM<"(=+W4M;&?$BTC4H##2,8VH!E/I[PG@65V7U1&B:LS!T=U86K$]
MOC:O GY(9SV"@:N >>80F'('EA$/.B%W8!(M O-'G;K,?7VL;:B^.B=/"$\&
M">%MW37>3O6/45O5J"_(#BBKN.=,J6"]&*_++75L;<C*6D\1'X-@4)3K80BI
M3%LU%J<:8]=9?B ZVAUN/I5U+=(@O>PORU*!GI)=X7$PLO@"B*R 8(DN 59E
M5T4SJ]Q8.+:D'.@3UI4%A?W@/W!&OR4YN*$[*P]^08Z3_@^DD0#O7U2W(QEV
M@6BQPVXT+7,I[&8V @[FP0][$ZY8-UVHF].VTXWL>CJ)7LI+]W0&!'R#Y\XL
M"!MLKQA[/QOA=X3O6[J'U8UL@JNK1I1&BJL# 0*K2'(75!&YJ56*!BU@V_%1
M2]*K$%!]*P9,(])<6(N6&F #RK?6L>)-/C(/!@C9.*'$/Y2S]QK3Y*OL#8^<
M*+K3J)N"5)ZFF&>1 9OA061%/+ >,>BZQA.!S*Z+<;<YT6!05=X_KA$]QLIB
M0NO($/ %_^9]F]70H_"1J M04%N?L\V&LJ9 ,!C1T5&#.A30JTBN13)H!->V
M@J/P&K,_;PO1)_(!;S'Y3HVQ6VP.^D[,_AZB:MJ>F]T*D3\&%R15#'(G3E!%
MMJ$!9#5 P2+&L+$N&9O 8LY1?TI,7ZL.C;'>:L0W(.59,Z3U;E,E$,D!I5T_
MEM4U)DK$*ZU:#,5HP"JF1:*T9>)82R4H"<36H45LX8D(24NQ>D'4>T!7BY?(
M/ GI(?-\2!:O*;70!Z%.25NDLO^4XM2!NM608:$+U!4$5;TGQ8D@FX"VZF3T
MH%NXJ+*KU>5'<DJGW$=5?\)0:9+(W0YGS:&B;3A$2PA+'+ZT%N^ AF U_J8K
MUJ-I>^V*T5/V? @P>D[T)F)8[?WV=4^,!^K8J*ZS>E_62;[>?2J+YT]$!E,6
MZ,C>$*Q)MMU:" YCOAJDW,)Z'^B";4RHPPM,)&7'@R)*Y<>;LO'#UEU"#]N0
MPB[X[0(*[FVI+W?@VEA,J*"*4R8:!"^Q12A8BLKIK+ZS.<=)'L\+9L<N'J]&
M0T5Y(\81(GM]FG+PD/VYV[.<%N#;)FM(8"G">_4]6B+W! [/#.W!$$,F@M8H
MTNNBUX>*@&C..S(K[X@M,<H46I;2+N,Y35L?4RA@<%Y1$*F!S_\CUD?DT4$(
M1B$R+&I"MPSO2%\>(Q.RN9QO6+]<-K<6^5J#;YW^\IH(2\]-?Z;,CO;@9R!U
M67J*TY\.00"9YA%D,5K;V3CAK@Z>61@"OV+2X#[:F#N5CS 6@@Q*F59$:: C
MF]D_W%F:'[Y@.:.QQ<B&GY+Q;D0)=\+?X:\T]8UY$'I=.%DJ=&GSOY 5>-DQ
M[GT9M"!MEXE=&L$=U9&+="*1PK&/>=[K.WV^ Q\!,6\1>VFW8*J?#CH$0A]2
M<R;;J6IIG]$ TV58JJN7+\]/,B.59[UCI[$VJ">-UN!?>?0C6-D3"6+(A1X?
M)4=MZ(>*"Q+%F&_><;7-:#40T+=6[YDV!*(M.2W-87HQS(KXR&O 97A66]$.
M'174EFHUFCQRZ=I6@V0Z6/0(H#X&ZJ ?%9:!K\DO-5[O;NHF>R7\ULHXM!LM
M=Z@=M^ 7F#Y"*KJK4 Y:'T7V!TF17^ROM>B_]Y.STTQ:0_RC;EL8+LEM9D#6
M[CFS4BKPER.:')&[ZXT H59*[DIJ11 +'O2/>E,V22[_'B)K[LKF=]Q !\[G
M(ON3:"S4</Q85OQ',.ZG4Q[5& 1"N80M(6P2'7&#NEU%(V%:,5/:.:[\A"6R
M2@ACL#FH!_\![WEQT?5.#C[5E4#HQL.5T(N_C1KWJ<-#Q50SS@$O ^H9ZN(9
M+;V1I(%+>*:5P-&^SXYP"QFLV09!K7?K*GO."O)5BKJ-;6T$K7NEG0T!1V(^
MZDI5MBM$\WNY(3ARS$P@RY*>4>I37.?<LNE"'7V?4.H9WU $4"--;9&NG/GH
M[^74F9O]P:K@#O-L;EZ?<)KBM$O%Z26E.9>V$>L@*3,I:F+>5&R'!]-T2LF*
MDE-&??=:0VP_EI$Y[@BM3JD'RM2$-)0LNZ1^HK3A"_X+)-O_"\Z;6OR$IM_3
MU/MI>P;5_9Q TJ7?B[F@!LJS_SG9E_6_BH*P?XAEXOHCI_"[_ZSG2J& 5^4#
M?L/% 4N&0YM+_!DW+V7:'T",#7VQ$SI0-O@NN@1KQ%:#%/S>L#]QY&B<Z010
M6P%^9 SZB9+K+B-6"L]]@G=EZG%SC*JFL^$#[>8OM7Z-&Z(J/DXA45A'=MMH
MQ?R4TPY;2@+K &ZE7T2%6MC+BSX:77N\F5TO^,U,B8_^S<R ?B@%=_.U_'=<
ME>2/CV1-49X<3$Q(1"+T-_.$S$,P'\%?8(6NE#Q?@W9YBAUCXHCE4*>=1)RP
MW47Q5^G$K,J"_'7++*U)5PR-$FH70OV5EGK93$5>]0'Z$7!Z%3 I(;I\Q:U"
M>B8K1;=+X-<5#1@:6X2-1IU)HK Z(EVE%JX-,MZU. =+X'S$^Z0B$/1+;3HV
MK1*3T;"ZJ*F%5?!R;"X8#L_Q"60)V F8&"9%.BP>8F,1S)'?C/D;3MR.Z294
MQKRPH1W0%M_@UWU9)=61W>T/.,4LLHRZ&D6I/JWR(V9SI0=,;;$ \PIWE0SC
MFMQN>*J.M2D4"MQ:LB)?=98^E,<DAZZUVFZ2;!QJ!T8VSX9PJZBNQBW@Z]N7
M(CFD&>U$U!!3Y95\KRFD]<*'6Q/-*(7^E:P@6);D[:VGRFI6N<3;Y1%?'[4;
M('D'U&[1J0<U&FFCT>R*F<@T/"-GI7ZP%ARX:7+N;;TLBT--ZZHG^>:E*@_/
M+_)+/>]_>I]40KB5L=CM@O"&2Y=$?$W$%QU4$!--8OG",9MQ^!)C?%V>1-70
M1W*YRVB56UV56"CQR_7][V#<]Y UNLT/M)K/?5FQ!]NFJ;*G0T-YVI2TM  D
MRY9YSE+=619FU("5#E7U^=TG1."8($-1<-_"Z9&C@PP8J1\'K"0(&1Q!G7TW
M'K[.FP7[.I7XZ'V=!O1#W%#0.D<<')=$-C(HQL*>HR%Y@>?F@XU(]"Y]V3ZV
MP >^ I*6N.A**U ;FBP3RTZ>A*O,,0\BA=(N?B?@;+Z6FY?R4),C:O.5?,]'
M\,JN+F]UC454+(1UJ+-:K(384LQYW5M,UUHEM"XQ%?6A"N%'NI#GX^&IQG\_
MP G]!FJLU6O=34!L!OIC(:YI+2K*@]&,=S"OX<>\+"MCY44Z(F9*0A_,H80/
M$0AH*/.>7:*8"\2W@?+1C-PC2K+RYF9B-BO60>?K_4>AJ>Z"X(@A[E0):Z&P
MVFMMC-IU5F_SLCY4VH!Y4;1."MWK)L5^GM!BHSIM+*@'.VWZ6?LLX6]3\@P-
M<A]!)N_DX@:\+,6&_( MA-J58K\]3\%W^!U-IU502_-LZ3741."AP?,E3[$%
M#4E4JU=X$(ZI/P2AJ#(B*!PK ][.T$2G#0'M.J:R#\G??2TM"ZY)J:\L/X<F
MNJT#GT@G4F5X2,U"Y-"Y*B?4]ON5?0)%*JI/;$KXT?22?TYYH:=6 V/04K=>
M6X&D*>F/9ZD1^4U6B9R/A4J[;C'012FGVC:^:PN:,X__)GD'WQ%<#>1$R#-*
ME0TX^>T&O^@6"'4,VIKP_"&!K,M\;OV5T1]T;75U@Q@R>P)=E%)V,ITC.!BH
MH\.LVTN^!N;=B:W *Z'7NR!&*,8OZNU;P?"7BK]@G;M6\3C=DFZ]@%+$\])2
M>UN<@V4QFH%!60^>;,6,*:8%:C4=J>")2$039IBB%E"\=F ZO%0,=:%$V%R+
M>4NNS92+[5U&3YEV_2V=#U:RSGI,.#(Q7(SR3.>=HPYLO+Z0140ON8@BA8B*
MVTM<7K?%MV!!1># **0IA@"$5,)&%P!SW_*89WX'J!X;E+<A]W"WLV,>>5;,
MG.Y#-3DB-/WP$4*1!28JF]6T4L[F)2D65Q&^3<5K8645NE%#H)VW7OPW=?_.
MS<)9K^OSR%=0&U1=3%U^P_I85ORA0?^\8R@WSY82U4)IT3NQ7%P7SR3,E6+C
M0;N [RE2VDX_G,_R7BLG+ TB&A5-_X*7O;%@-51@W*@0]CY;BSY:M#U[K]*.
MLB1=VSB,MZ8?UQZ*=*IK$%%]+$:<PY*?/7-A"HA.+Z6_-+[[\%4$3PSF!!TQ
M,B0BL&L:XBHN^I N<#ZSZ%W-$RVN#N2+9T7VE)U/11=O/OP"\0EQW9EJ))21
M0@9T0RH2HK#YJD@?0"[DKFK"LE.946U1=WCT9#/[+YU+>,*T(:=BC!M!0H5D
ML\9=CTF.Z[;T$M=DM8\&O"D9G225JA+38D5$F% 9WOYVM)=0CYSJ(]2]MZFR
MYV>]:F8N2,ZT</88QQ>*JF&[XZOZ?J92*VP_==Z[*'EGD9K$PJM*HN37ZF0F
M?8%YT>,I>6<MER'%[@-?"^GRO"*K$5.Q5W/7AX)A]<0[W%PE]0L/W4POCU]J
MR/+E45+%\PK>\3-3.CM,%\&M*3B OH,E4%9\C]I5$%_F*&=70L!O">5NP&3F
MJK-<(3Y*(1]7:JCX/966H>[%=8$AY8;<$QGX/9/JN-Z!Z0Y:+KAFUCMQCYN-
M9K(.HNE*TDH0;BC68OXX\H-6WXE;!60JWL.+U8]N 2Y;%N0(,+&+XG&?$SN3
M^636.TD'T\>+TLG\-F73A5\?RI-W*\0+"75 ;QSXZ4R3L*?LH&LO=9N1VYV<
M"OLD=^[,PN9=H'9F]#O2@)5=W5&2(=#7,ZW*D;6\44P/H:&TD:6H42 ?[2?<
M-+A:[ZZ(*I0U-^\-+E+1L$0G^VP.G$5L%A+31NV[ Q/>A,R0_';$@U9Y[IJ4
M2(4YCO!-ZFLPR,U9Y&(F1P3S8K[\FO!1G3UV_$-?":\):/_[LLX:X>#2V\2O
MS#RBHT6!S#JVRTB)@_K@UR(;O!(DJR; 2V_<E44IG/:V(@NB\@A-Y&IGQ?6A
M&M!1\<&*?01O:G<I&5RGRE+6$;VD^N(B"JP"!Y+TD_@M95T&A0L4=(Y?M,!0
MR46/:^!S13A</T+0?;G%.*T_$IQ$]MEJ^_=#5M.N -JR@.*JA>B![\0B""CS
M?9O1AZ2%XI:;<L97Q;>IU IY+&G3TN4*NLIG-E-FOJ:&\))R]$W%A!V)$K!8
MK3HNA4+W&5?/N+K#S7JW(6=Q3<#CN<#P4$6%BVCD4B$A;4BN-N2'\Y?MA*"(
M'#%5I,UH2C?Y6HG2)O:3:S/%,QQGI=O0X#D#4T(KY<QC?_62$&A5B<%J[9R_
M</!IKOV,8[YKJ#$TO6*8:!(T>T3[:+9Y(5M!2R6H2HJW!\A )+(&3K_KY%AK
MHUS,+X[MJDA:%O%U$2R\S =(&S4FO4>ZD3;D-4TC< "BV]=]5;ZQ3'ZSLMM.
M0?*<I73),2"D8I45_V =">D;WC/HX$E5E ?N<[=Z5/DDQ&>)YX<%>%;UZ"@<
MK#;<@QZ-5^7K:UD,ZEDJ6T#2@;H2GG$^@!'P*K'78!A*V*&"[KKH:B#7Z]W0
MR:YU:9.I:$UHWDVF_NWAVT(\U[8=MY&'VY4< 4/"[PX@%A00Q4VEXPZ;Q1EB
MON5#E^LRXC/DB OV@5TCY\L\^5A6.\S*TIN?D\+E+K4@=>E+WVC1@.G45WKH
M0C,_H-KC=.P;SO?XS\:V!^/PJ:HNI6.N<7K8LK1Q422.UG3[6N"J?LGVT CO
M.H,8K"+5/JFY5NVY0.UVY!#@^W'%J=V1]104>U[ A[_MQ3#&J-PW-R55G_>9
MV!4R@VS8)GR]>[RY7]T?&AK13AV?VF];U4B=J!!\ 1;JSV)>%]-!78'>Z!1P
M)LFW5$F(EYB !!*F)(4H=B=M>H'8MG%?UN8FXJQWOIE3H=76UJIACQ^6)"NI
M.9!X"!IG6<7AN1H1)>=,.(=QQ:<X^\^;HJ&MW9XS>%PJFKOD55N6@(U%W6 $
MHR.Y,G3 R[0V(QC24(;RY] 6B+Z]?LJVM*,7^1%<US2=2&LLTW+P="J"N4A,
M1GPVRZ>*J>G:D1M9SH[D".[0RQIJ_ZQHDTKF;MR:\C&Z*32GIC<IZN5C0$;G
MZC/B'E+[D"(6'@RW0"^(XR%ZBNT :DLHQD/_J%]T[2U5$3%)7Y7<Q.>KMZ6N
M"#>P!61/>[1VN.>G\B@4(!1C [:R;G4CU_;5G49H:%@=K1&DM4>U$=_ VO@@
M=83'L8*S@=9Q3[G')7G6*HKC=!H1UPNK7+#"^"GJ%EK0L[X)7_L[OIU:P:LQ
M/> ]6?,%/OY1I)"Y ),T<UB%:5 $+%:])1-N2J/+C2#A8NMXLZ1[#I#C<2=Z
M1XEIQD,O4M,H#4K#H\^% ('//SE]Y5-60$XC2RMRR]VA4^ O;%)LEX06&]7W
M84$]J#TVJ <D7EMYFFF79&J+%1Y54N+OSU!EDZ?ARO5AKK/\ *,7$T0\E0XJ
MOOK1,G 9+:%YWN'FFIS(;PD\=E#G6%O>ZS-.(!(Z71</>'NHX/ F6FU6?RG*
MIQI7;^#'O"WV!*'^NX@4-J$]4UM3XH(&&7<@,"<C^JZ%XGLDX$#$W&@A0124
M"R0#@Q@THX<N":#8!T0@NJO$,BC+PTKS(/W+/>&MJ\X''B5-^ML2$N!4#%5B
M'<QLE(L-WU>$]Q &WZ_2N-[1GGH$SE(R;]<[T6S/'%I JS.SIE]L\5&+;O)+
MUIL0=N@Y).!7;>O"V-GL)]%('<DP ]E#?Z'B&;UW;H@7V5%%(3BHF&<ES\NO
M4)CD]'@'_JJ=%6A<NJE&[8ZHW7()?0I/)YSZZ)B''0%?=6YI1T3JMDG?LKJL
MS%9;-QSQ\0NPUC0X#+]Q(ZH!2RNT4M*EQ5ESAJ2/4$X25&<*Q?R>%#@9OQ0M
M#<(>I'):J:C9M-Z)8@^JV[27<=O5M"(66:_4191G'"TRRA<="^J!/1>:HLA2
M:(&*&_IZT..XBN44A3:$5KB0(?#3<DY^4E;,O.D>9B8<8KTE>N]FBSS3)F"L
M?H^>2+# =1],E?KEIL>BUU(:,  .UXIX^*4U1% 22>NQ]R!U,*.S]5C?%EF3
MF?M.=6YZ/CAF%7<=\$/53X]@X-NM][I=I"+"^1(7>)<U$-I<.QRCTC=&^R*+
M,'.^# TOKS4G:9Q 'F>D-9$]$XD6J"S@-0A5*H+1'W!]R.'*!DUJ\X)Y:9_K
M\FOQ0.Q=;;816Z5-!T#M.BQ8CJPD*J0B6 O1Q6+%ADQ#>?@=^A L:#H)S2+Z
MC)N7,NW,Q2[UP!HUP-.^V JH6^)"3OY0A Q$R?AP15;U34ZD5$"/1K=U+_S'
MH<QM-W,8B:4L<1O^JK.C-OS@7(D1U)20JK9P>\;V_BG-:.TY]>MFC$H,6G14
M'XX-^8!?RLT[*)N;Y+W7>DCU9;"1U/T4O=&2&O*AX.MP"^CGZQK<KXHF2^%-
MGEB"C_ "2-E/0,P/*4[A]@,5Y]!0#6>]@^(0Y,NLR<=+;82><J.,3>4[@?=)
MW@MUFR&Q&_-72?O!)+$CW$T\@O6/#7W[75 MHOGIJ336SL2U4(G&\HG_:YD?
M7H=-J=J>R?8KD,T?]_'JMZZ.>@WJ431=A3;"A"\K;JF8Y)(N/J7R5*Q'6Q=<
MU6^S[E0*%_GX@+=Y4M?9+MOR0X"8-%EZ2'(:$?++(0%[!N/Z2Y'B2FX4MRE7
MVVUUP*D49:#NO-#? ;Y*L0=/&NAV070;U.O"AS8EXEN)^(R84C ?Q892,C<O
MPCG?('C@,BMIW$E!84_RVV)KKLC$(C3(--2;!Z_UD=NHF/$9>>8<L ^H$H^>
MZ,>M.=V:5M7\\U.IR\%=-D:<QCX:!Q*$=,KTG\+\NY..W@BG]B>-_G#HUZ#4
MCWZ!*ZFVCV+43]&Z>WGK!5KW=90 9G>5*Y^<I%>IY3PVGD@ %=]GH6DX96J5
MOL&5?%<VT,:P_'UECD3BPQ$;#VJ.F!'MXE,C,+KQ3'B&=$^<K=26Y%W4G3:0
MG@T^KP-[B]-&M(>KQ-9+H##<#!+D]'Z('ON^*#XJ/2I+ C!.;1A#RAZ+ C"7
ME#<D,;+ID=-[[/AIPR(<J!*L0R(7&;8WB]?0V^7B/.#Y5VQXO/:'"MC'%K(6
MP:!OK**J&Z[>R VH/AWN2OJF2+YG. CJ3=DDN?Q[4%[(#?H[;B#4^KG(_L1I
MMQ*;-#PM/)5$VK^) =->*>^B*2U;^H+V;P!5!!UQ@SJ0EA#J'HW>RF?CN,P/
MZ$D8-!?-+.G0HQ:KV2@/.OB9HD1@?*H8\ SE1S=7(*Q/K\I8#\HRAG>?NZ X
M\IR[TR5@*YX1!&9/IXH/T<O^ZY 8<L",;# ?,^C029ZSXECT1M)16QXYO+S"
MDWD,]Y# .LP"G#Q=9;Z;=]JCB'8@ZXI+&\H/WKRC;D;4NM\F)&1:VY$-&D(D
MDG2)O@9A"I9BFVV&,A^NJK49,1FYCX1*;3*A&U)WA\N^..B+"8K?1PTW%D"H
M"-E'(*R/^TM1M>KJ)GGGX<M:6LK#Z;N2F!#9V->@H:*V$>.PQ/^%[%TE.?2.
M2U^)%0PA=Q ]8*EMP*?1,/O^Q-%K>@166)!2L<2)#@'-I,U+5C'C;0/]XBQ6
M$AW- ]38^/@5\M08#/44$YYAOP0I#/@^J=85*_%&S0,1NN;2!NH"&KNCLA*%
M\)C=U,8/+J<YE Y)U=?A3)N@RH[<?UYJALG4W;K7(%-_,>>L7"&L(7<>%1XJ
M6NU+^GE<S6@"QNI;?B+!%E&UHVM\,6L3DI$1MYQR&QW&:J77B4S13L^A&UW5
MC[Y_8K(9%\/'@L@'I.[-P GE<'XC<0 _X!3S0K^;*GNF=7K,$<U<89 F(CYS
M 9',)IR&2H03"4+8@Y(W $HE9<7S+U7YM7D!+WU2'&W>#SX'L4F(SXK>A$&)
MB\8)HD<[H"=UGL8IT!+-\?G\?,71.4AM 0!(GIP2AO'-U4KWYL'(Q1Q)"L)5
M4M\3*.5J34H)9(/BFX,]:$>\&J,2,.)+4T&55XL=%5*=MQAM5&UG(N8J+<B+
M>"%]L_TB[LPSGVWY!^]<Y5[,$\=SY*A8$TXJ+CD0(> 'UR\@.52>E0UA^K4X
M+S3A17&JBNF043'"AGK@"+Q[6I@7W^?)UJ$V/1^-VN%+Z7FN1D--?SW"H5)1
M;]ZWN*Z) :^/;V1#$!T3.:%<@#J\LT=8A#S45]LM]5D]X"W.:)WH.]Q87CO%
M'-1-ND#)KB%7=%MGE#:<8F7Q$71E7TSW01/"*CFW$RB</287$:;]D/ES;=6Y
M(S-R"IY6MYDNC/HK([[T-U&QV8,RPT]R%D('U -X@Q!A1MT6*7['Z::D%V)5
MLSAWJ8%2SG,AWW!]E=0OJZ8-X+)U4Q%;(+X'(O+ EI?K]9.OG2RK< W'*=X_
M&W54!\3<M \H-N0D8SYP.*%9O0EH:G@@Y@7/Z2/6Y.HMR7(0_HT0=M"U($>>
M8 ==!K8ZF8$.$?P=X3O8X7M1&D1L@KI=4+L-DDX8::<+VCEB&_,U?"9RJ81H
M5DY$JH5%\]YY:YQ[7"1Y<R2__DP0>7&K!B(O@/@*],&7KA%3>W-$4^%.=Z=.
MV&*[Y.31J@/D=[%?UPD(RI>B%NQ @=^\<,/_U]VW/L=M(_O^*[AUJD[%M9,3
M)]F\ZM[S8?1*E-B65I+M3;9.;5$S&(GQB%1(CBWEK[]HO B2#1 <C1J3\R&Q
M+!--=(, ^OEKW7WWA/L-#8.!H1]E\&S*3W8X\_[7Z>.-\ +J>E.@L5:^%(9E
ML<COLW6T2TF-FS$[,O'7&^1JW*F$BH'4J=3BM</,Q-UTMC+ [;*HVQ>,[D+6
MPUC5)JI<M?CUDD#*6WR</=S=$2<4TLUCFD$YY1?M+]_X*U+:AV:LU](K<9/1
M,8[PW1,G!^K2][ZWWAO7[!:'IVT8&A.I\'!'[+92=U<?ZW+\>AX"?2:^+KR\
M>-Q1(<9)E<CY\O>-@N6MK\KY<IDK<*5S<7N=%H?9?=YD:SQX[&+27W!A(==Y
M8THV54Q%%UZ&4@[GYZ>',QR8P2VN-16TPKZJ).B.]$Q".:WSCM0N"B)1HE\4
MY2I2Y](IGPSD%.0*^RL<Y+?>+6<$&II)DU'GX0:UE,*LDYX3-JNT3;C,&MY-
MNIPW)WP)A0.0$;UIRNJQ\[!/XXQ/6,T:IM_ ["OZ@V8&.CWU4N] 8MA'L;.%
M(+WJW?/)S)5W'&97)3@&A(H.L/_+@\>W,MG(PI+-@6=Y5X[!@+?O B^D?1ES
M/)G@G10O8^9M  [T&;R0Y<4+IS&I?NGC_O1(?@Y!CEXH.UTP2@U>7F,P%PE1
M."^6]C>.[N4X[\5S&YTR"]Q<E<=UD]^)'6.? +@T"(>8;81"A9B7&)!'J MK
M?^F\6AYHCNWFO)_)SQ$",WH*G0?--.2)ES;[YIF%C-HN%.M*W,Q7(A>+S727
MU[4XKR%@&4X_<4&=VW$R\CO(;TR'XHQQA =J1P1 >5NY'U&A<I-T@$8% B<T
MHE"MEQ2XW-Y<(K'\87MOFFQ(5537O>=\4Z9))9[#Y3H[W2W5[<^9VL?98V?,
MN8ER3[F#XN+I%KYM:K*"(O.?V7U9_]^Z35T8H-SM;Z*"%^]NLN2H,Y?D5P6G
ML[DRXZ\I>3=9U24U.D^0G< =Y>.=KM2!5W#Z0GT7OY-('^X%ZF;4AI=&T6$.
M(=95*CI9QLG7:RK;_27<3FR$YLK8U3I-W4A]#HYQLXURD:)>0GT79ROQIRQR
MTE'"(,"_>;H7*$T6RD9XP(-P7F8)TY%LT4SV**TU<2,>9NO%9BW="OZF/&.X
M%+H Z6PEN]PH^_H$P@@M\7 O(P2W@O@(?*IH^D?B;D1-JN2_*8O2N)B4+VH$
MG,<=8#,9]9@7J;>FEQML>XZP3FMKZ48 XHNY*!^S-1S97B-+/RN#=O;IQ,85
M,G_4JO+R22KN*WYW7U99]>CJ_^$B,3ND9Q\-JL22R#_ $+8,H_Q3Z@0F"'W$
MU9^GA0[HVR"+K37P8PWJ./9GAL@+Z&7?AK+:ZHVDJ2036,66;;*D:$/+PSR,
MCC]8M44)%% -DU$<<."60NI+)HK-N#P5KWQ(@XG2ZS]6WR8?VIOT('?*J*B'
M/-'NA6[_)PE%?+82.J%%?XYJEB7'?5ZN/A<C!V#8>] ;J\<7MA(1@B!K_+D6
M?RLKW8])8I*..=N<$4P/28P0[^=BZ&,+\TM5D?PJNP8UXWZ\!%P\R>RC"*H(
MM:R',^_+V,<;*1+VY5VV7A]LZKS@M1_&3L% R6>9>3B),N29N"O:(&]DCN%!
MEP6=Y+L::U,S["IA,%I6:<V%"*[Z7WB4$-)TIBSK^C"KJL>5BO%X/WWG6A5#
M6&?,_MRG?6["ERG..S' QP5O,K$QEZ8+^UBW%?5TV_A^3P ^<#8P^8<8IMP#
M6\./82D\%WG]X:3BW.#=FYP=;VW&TUH#.C:=,PG0=>L/#.;!;.> ;C96JM*/
MYY0S]I$1+2Z5^N<6_#K($-YZN4[YLPNKD4KC]C#0ORB#?!*9.*K"8 ZP,^]O
M\\7MU2U_G\&'T]3SBFO00>,>\A2?"P),4F"2!!,TF"$BMCEG#IG$]>=QO"(+
M-45(]*Z8T8QLE0:+Y;\E\\4$DY\1KM(C, XJ]H*X'1/Q%[NX'/L$OXBSC2W;
M%G(C#>*\*HL;*.4YU[U,X=#-98[]ZWPMKKJR\,?08.SG,)B9T:P=/F,M@;1K
M&,,BFO@1+1IBB^$US\#)#3,Y+>XWC<'!E6'P<!V:,Y3)L3.+6ZSS"1!S(L&:
M1;"(+5FT9$CWV(_"W*G!V!0[OCA^ --SD]>W,$NH)[_VUA;#0(-P)!2X[E X
M-3L)P2G:^(QQABU2I#CH<D@-VD)'Y3PMA$IS?GI^?)(7XA\#I?86@:*G:@,.
M..A]'2*I].]('OMJWB31D ,-S8LE_ '.XX_96C92=/0C'P21S$>4/S@#]T41
M#+.%;:<809!Z>PMA.X\HWR8*9)Y+E\#;FS#FN!WP0WS=FPS(J^Q!&0'G%:1<
M-8_G0J:-6'H;//$#&^D<4*A'-D%H0V7&)!V;I7N_#^#9L1QC&V*JO%*D[MJY
M_5B5_G 3NFYR1'(@*HR-J,5P&*9RGNF4D:LRW$#8),]<E>G;!_>FW#^64(Z(
MCZ5+<=% 1OSQ VC88GV'+5XQUZ0<I@X;.5!^VX'NMDD\UF'64']SC#2(5P@4
M;="SSPH$M"/2YL" 2U*'^X)\^2R.$4%08BJ;"(-CK9Z7ZWSQJ/Y_Q1^:@[7V
M>J-5B&WPQR$A[G$YG/U+_PETF"245J6-YA=;NHG"(BP)4>CZ'<.HC5Z,= WH
M6XKMP(1W3I"A_@T4P3V)T5%7S;\/2N@)M3K**[YHRJH^O!4?S5TV LDD1TDG
MBAG'S,#$3K!QGMS5B)5 =VN471;$WS,Q$/G,+Q>W?+E9\[.54:-=#;IO-]U6
M?"7'??[5RZ^^>?G#UR__ZZ%>_L<$0E1*8=QT0'28$J,'PT8VP]G<-: 0TY:Z
M-'72PMF"U'BQ4**!N\ZFD0XX[J.)TTR1:0_BJ#[.R%PV[^:__?KZ6(,USV\J
MWNNZ@YV=G3',#MJ#;-,0-WW9CW-.J!6ZG9_#PN]VQ!Y<54ERO_ISQU0Y'X>T
M-04M?J\I(7GL1XW\[A@SU!;8/,[8(*26VCR*X!#WU$0*ADRONQ0;,ZOR\J04
M:DU6C^2]FZ>2[@C_M/LJ6X@YVAWQ2BCRG'=+3-I/(&LVE?CS2K8'&;-,%:D9
M&]3@./NE*=DU9^<26-]09_^2]/?&9-U")&@&P;:2I7;E2122DRUP6DX&B"S[
M<!\%^$%]=V/L4]DDCK/<J6^4Y5[E:N.4>P6!/L"AZL*OM./35K]%<]C7TR:(
MA2YI8'YP_M7++SOE8<)2\BN3: ZBI,&Z%7)@1NZC9CV%X4&\8K*P""/62Z[2
MO*^J_.:&5^$E:Q]G^OD]6!H/#\-@=H!5TOXB]T+GR:WW'=>UVV?2*]3M7'#-
MN<\/U87A10M#G./^!ITXM-H@BK ?T*T!+OO?^S3ID&=U7#<M8,&H9BU[4[7/
M"X5Y3U1E#Q_X/@FPG 1EP\+GZ#"MN)3>")9'NQ3+/ $,-2@AE$:0%VPYXF5
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MY0!-UR7/-/WD75*>+IK^JN]*V%3;<W[]FH_ W<ZOF7BFGQ!%O%+.//LB'[!
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M,MOFU)I:TH2AB9QCZ[J5\$@!Z@%+P^D=+RR#.E_J="V9#ZVBO]X(*XQG#@$
M,G%(,(=&ZAR;6%ZQA9PF)](-BD'\UBIO1K#__C9?W/9A?1U7H%>C\>,JR]0I
MB8G^"8@C0,JN1S>IEO,DT:#JSPZ$3;&_H2V<V]FX6 )"CE3;3M;EI\M&S!CN
ME[B>,W:\TF^! K,DPAUG2'?Z=ER[Z_P4N1&I66"VBAOE5YY57[W\^KNPB0CW
MK7DR><_GP:S[UKB'+3K7DZJ45)>Q1I6":[J7_A$6N:XWU:U<#!7IB>QGQR3V
M6T_A=I H,UE2I)?BO&CR9;Z63O$6YO[X027TJ/X5X'I0];&KXZP"-(#:9#F&
MDP5<XFYO 4/>- RQ+X![U+RBS06=#=(-TJA%NQ 5JC/M;@V2=7HTS:7TEV[T
M]>A&CV;\S!X(AD1*O2B*1VQ))PB'THJQ?4'CU!FGU>F(\I)@;3R\8*L19#M-
M=M!)6;WB-]FZC3:-)P=!1TLYR(GF)6[&$6 GE!ODY9YR,V!(F8?B[[DJQQ32
MAJ200.<4#V2IHL$Z1%*;])&\XD?9!#&1WC\F 'N2/[2'*J!Z^)?,#)DQ.:CU
MH\&PY BQ7H;P=1GAGRH8>O6I!&-D7A0Y@!AGU>/9R@1JP>"W7H"1&*F@(TTP
MYE""0+4-6DM_RMFJ]:.DM0JF\CTPXK:2&U$6DY,88?TT*SBS%X_SP_F!]/!5
M\-6]YM6-/WC4R4:QZR;64)%B+BU(4U'4TN)43F [D$X2+S4ZJ[U-ESA;*?P!
M62T(C9;XI_6CRH"QR8THTJNE (NHD1DD$6FW2S(FZZB?ADK=!2::V?XJ3A43
MW0+.ETOI5<_6YKC7+@6O!6X'M%>='I(0.<#+1G\E1O@E<B2"K_-([-M%4U;A
M*\P\E3@Z/IQPWW6+L4/J=VJU%Z?J6>RPG_CRIH,2, &2R4E;=,O?(5ZJR;*6
M;@Q*4UHM<+I@PFKBMH(F_2Z\ ?X)WT$P+R)BW?<I)R)RE:>+C=!2PU.A(C&@
M?!EC23,>HCA"PZ+QHB '1AE "/>AP]X62UXYO0KA8ZL[-3$74&+CQ'%U1<T4
M4.&Q&JI #\A9KP2*R>F,E4WYD:537P5[LBK8=[PG4TMP0;FP#@:V18,YG4,_
MC[*8-TV57V\:Z6LNH5<>S+I<KZ$[GN/Z_QKYTDWU>0L0I8DRERIK2M:ENQ?1
MDMV(!OW<=BATVJ]%M[@\XO=EG7O#8;:1IWXNZ>76FS.Z'AA;Q/;#*B_@]"G4
MNNO3!8(\@.E\4X10/_5@YHZ6NN)L3SJ%C;/F\=3'RH3*-XQ5Z!GOUU6I/6/R
M 6>';U<':;V'4!%IW(OJ.1>7*'W-S1-DTO>//%F\B:].**J;8-AI;#O4;-N+
M^\[#3]R5%A0&8<Z<3_F24710NTX+B%N,MD0.:-J2E-2Q8=M*:D.@L 1;<RKK
M_?VXG>@(3?%7O*XYMV"<<EZV?M5$YX_\UK@:/W- 376.B"4R ^7T6H'9)U5C
M8EG%$T:FB(GT$ 4/@0*T6*_+3S)6V O0']Z"475:M'EAV$I:.LP2FK%A3D.;
MF<4^.^+JIQ?#A+P$ZSM5$-@Z;R=,PH#= ,$ PHB1@!$H%$1G_!XH0U$<#@)T
M\6(ASN[RN6&?Z+,.)M_MD[MZ.R=U.M?TJ[S);Y3ORJ:BJ:TN$8$ 3D0F<,NV
M%WZ,5$/$2<RS7<DU(;@65<:[I)5V_2:QC5Z0T^66H!@3$/94^K1$6!<WN458
MKP_XJJS:9E"0;RU4LK):YD56/9XV_*[V>Y%0; U5N/D9O/2%R6PW[VVAW6NA
M',&;G79<@+TTYLY+5]?Y+$+$OJEG7S/B\NXA4HS%YSY;C<#(H-;O$)YGYB"S
MR]J)* 2?%%W<MI0%]IT\3:Z$AO3\X/RLX#]MBJ50*'_C50G_'8HO,[LNU1<M
M+L%7^0(26N8W%>?C2":*)-,T&1!4_^N0E;E8FC"SE).7M3U!'H/$H*>*EO0V
M.E$YTB9Z=5HL^0-<D1J5U]Z@THUG/V8721[[%C15&[9DFBYH&A;%V-%'="V5
M<V(@:/M)0#R>)![LB-B%P!T7>=F5@_A[UI259[%MZ>O92K>TR=;GI:J&[_N-
M;BN^4C*LA1"E %=9?2VEJ.D):7[US1=\W=3F-Y_#;_[KH5[^QZ17$FK5,?,!
M(6.1,%LM+:XS.YB9T>Q?9GQB"VC**G?=OI&BH35<K:O+E*AZBW:MX\\\F5*M
M&$P;$[F'-]+\&ELICX/3.CD2M>D2%5>B%YT:8\CN$0K![J2#[K0=R9Q0850V
MSXU8-ZCQ+3<8JA%>96'&,3V0#4"?4CKYQOCJ:W=Q<J ](6-# F_$)*\^\?5'
M_EIP<>L]2*=%4F:J,DKHO(D=1UM*X2E!%ERBQ,:\&V&/:G#524Z8>=M;I4HK
MQ%CQ)OKY^2;#3G9K<@[70F$J;B84*ND1^U22Y#(QB&\$F:7/V?"!JRMXY%JB
M4CA0R2V&Q5/0Z%OB8 JXB-4M_>2:RY.DXTT+>:*\27'Q%*2%VQ-M4U5<QG?
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M'TJ+3-9.%OO^A\S0UN++R(]%)CKGU:JL[F23Z.MU?B-/V9%(U\Q!E'+&LY;
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M!#L2R$721IVYP#4V[#\[,MJNNJ_^XOO7HACX.W]#PZ#^>IW$6S,QRV(Y/WE
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M6-A6G7ZR33I6T4"^T(\BX$*BWNB>J9?3I.<1K /AG)U).K M"HA5X(R@4RK
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MV\Q\2<ER?9UF=.MEX#/!CA9'=7;UF'=,%L 6^3I<^A)Y>4 SWNV1K4/Y&,F
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M="*';'B]D5F>V7K(GXR0CLSS^HUAY$%W0($/$DSI]#9 :O8W)@Q&UC(+,;0
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M1"H>^\2YG<_8(1#L>ZRY1EZ&7II6AM"E-G;@(-E:8%WLD@]I&F03$2<9Z (
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MS8MW$=DA019?;U_#>$=(>D43XC--Y..;[^.(U#\?:&]F5OHBPG&Y?A+B^"3
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M0[.C2);9>1453Y0\FX)&!2D<G5LR.//C2 _-D(ZR0XWS<W8;\0WQ<\"!U10
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MY+U7D<++/.%D@GX[&8!VRDH\2.E:%@RB<H+7$A-A*"\DP2W;[)9CR&[^3L1
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M;))<H<:YJ9ZL$S5(W9KM$'$G/1\J8_ OXY1WA6KTE%1SGV3?GN19W$.JFGL
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MV2^.8V?3IK;K.$F;FYL;1:)M);+D)>4D[J\_4O*+9),228&FE/K+73>)"!(
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M\D#@,6O57@1.V'-FR  &1VYH2]A\TMLV5UR1XXEMR1@!V-@9W&I4F*>"/'$
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M0)13M'R *$I)BH=P/=$J^M2M13R-L&^D=Z2 2$,LYCYS  IU8&1ET$YRR-3
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M\C3[[S_:E\/??K,24=*^>*9:!Q;"%09P_WS-Z-\Y!+'_^C]02P,$%     @
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M:,?AX#OC_12'[T8*:-R-X$5D4*=9B+TU3/::7E\ O:Y2JD>QIZSA31J?O?+
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M[<<?S-5YT@RVUA'C31'C6M-''P\/T("D<LM3_]T^2$;0UN#^''W8]\^&_\+
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M@_]K&PO9\R5*(20]Z&UO/ND--EO'2-IUKJS+<]?%F[?];*OW9+#==K/*>])
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MGS$6:V6<FU-RI&PP0EA+*JU%%SM:<!^H2D!.%_EE=; &K+-I?$7>\QJG5_3
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M);DHBG#:2#F7@&,[( B47-O1B"FTLH([(-P[/O@9^$#'_*G7S3& ):5O>\S
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M!+J?TP_+1'!7:#"+M3B 7_"!*&LN"--PZ,ZRT',!5@[5:?9W?0O9J9Y7&2A
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MSK_9E%!=A(,0GU($YFB2DT#-<P6OL^]4M=0_^E1KRD&D>T OPB=DN$?5DM$
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MZ*!KKRHYKML@T0\9CUE'Y(%"?\9<1<KK8J1%L]2N*407#$*@$'38I[A%.5F
MW$K]-GG)5%W4LE&LNWSY?4E.Z7;<K2/^@W;FN)4'WS#Z8S)FBF>1LXBKN(!A
MZJN!9HZ:Z5.XY92$J1[L*4^-]29D8='9?6$IVL; @!&1B[C2&6%+BBI^/#5,
MT,+H'#>,&$R>"FON<B^;B:2RP^1>GEM,[)WRZ'9LZ%0SW#J;3>SKH?)'WGDC
M<5>WF[H<4CO\C/U4S$Y2)W1[6@^*VR]%0$!) <;!R=70=OT2A--BUW\=PY;-
MI@6/W9X9-94?:1\W(ZI=6ADNE 5B9H1\3.#(2M7:G- PAM/,VDNE1+8+RQ/B
M_ 270_BQE\-J>CG(/7")R*50=F9_U_WS&#ZO7>P3IC!<7=^<CE!._91HM<A;
M"MV);#GA.RC_01:/MP'S]DT(.,6GY)*S[C"K+T_95"S_L BTH]:@QRI&KXT^
M+C%+Z=W"] SN"7T]G+2<[I "S$2',\*X74<FR 3 ="DIWE6Q8 8P$OQ-F,HS
MN;AF, 8/4>2.0?G:Q-UWK/C'GN@&!$7;N7$8$?%<^$29LDT5^+LIV<F( :S#
MMMIP=[)<-/F*QO'%D.^E6%+M>_VRW5>PE90 O6?XP\/MZLMS/'7;U>?QBA](
M*3?.Y 9X< [TX;4)31B34/&E3XY<-(KU9E5N:AQB;M:%]O:6?]D.8)[7&IQR
MTF0)[#+]'LR#-/BF-$2U_LVI.;3;Z"Q2ENY;FF^; 9KB<S4(T %VFKC0'7G\
M^IS"V4[PE?Z"1O?(!;'%$71#4?'!AJ#<D'2[X67B37RB%(\ F/!@ _@I>= S
MB$1G$:5_JI0FD7 A,H8^^#[03]OFKH.QQ#Z5+ECW^O;N4BJ9$TCGF][3R+*]
MYGL;T/@FD<;"^Q80) /(^#A?/&,S$FBH*J09<*0K](#J^YJ3>Q=)/!. UA&G
M<_K)%/<<?\!(X?T;+K70_>]H9[V+,IJH6>&%D*=+"*R8'D9?EWIUX]*LX^;6
M!CM]W_BAP^CO[H55UA*,V4-2$ED>T0<?S+>9C'QJC7CRZOU1JZ?U6]?S]JRM
M[PGOG[%J_PRYR'^Z)N:;@#Y^_=$5]+$(^OCU%?2QN'_?<J+Y*[&$RKM(E8_N
M+O[W/YS=L0B:XY!NWKQ,"$>1H^G[JAM&O_-2Y"9$GEK7)W"W4;MZ:*=Z!-=,
M,@_ADYJ<5#"04]PN%Q7UC972U C]1#+\CJQ\1UL;. H.RTFQ!0A7/$&0V]0*
MU+KB'.V<\@A] =HFM!X&)Y@F]-"4%Z22QUY>H\U$(TK\$I$PIPB)M]X1;GNG
MG+N%N12E-Q'\-Q;SD*R#R3T5PI3\>%\U4#!]O&\/(N5'[CV@L>PY3V25QBHZ
MQ(]_. XC#NU+AV,>]Z[- 7_V D!.TY<\4:.233S+18*X"@U#55IJ+X5EF@5^
MQI#&#;#<W:\9 Z7, ZI!7AW^ZXCJAD/$!\DWC&;F(IT%7B.LN0]Q?U9V7&WN
MY 92GX &-@9%^F&0]*.\KI..3X0:/T %_ W@R'GB0B?<DQ#[]@/A"+[F-W"H
MD>2FC974Q4+.*R_W!8[F6(+N.;J^C*% .#J6DTM4DPH1D"S#XDV3,6"D-T""
MV[_&W-"3/:98L>TL/'6_L5Z!=0H;PJYUW6P0ZJ,2KK7!T4#HM'#Z,Y/U6Z9H
MDYQGNQ_W&,,R2I,&A\,T0:6RDW@],-4^M7012@@F22K][9V)2  =T?;CD8RQ
M+=3J95TA.86:LFY=_*(EKAV(NV[GS0BU=IPH!F,=0=)AO6M&NNVF91U&$NUD
M=KT2=8Y<TL#0]2VVJ?6^JX[1DY=&$?=5/O/J)WM':3*>ZWBEXR^0F\D(L%?K
M^*$%-EJ2H6NS[F8'2!'65J:CS=K=YXF H@FD$FQ8EH+49A(B"WL )&O47Y\Z
M1Z^XDG_ZEW\WN^I>R_TB+<; ;!OD=YEWEJ]:4]VIC^D29U8]>>NO_1[<<Y^-
M^]HEPN'FZ@1GX(ZA'R@Q2N8BY;/FUBGUB<8GW-?K6I;))*]OPZ<.J68'=^K]
M*J-A-K(XACR%]HC+45NL:,=I:GRFXI!LHU!24\>P9XPF9B=P,W#I/PXZWI\.
MGI:Z>%T+*:A#.GH?7'C9@&:4?LPH]V%]&K+RF905"0<R="TKVG"N>P9RXPK@
M/!#$T*(,87!0IR4A"3N73L.+76: <^?854@[#UX?O&*[HAZ,D?N#=T!S?+4E
MUMM= '.\"K;EVSI>GQ#5$I-YF:2/(S)0^ -<._"^J9;A6HKX;<Y.L0\;MFJ$
M[*K*79CHU^ZHJ#[(*704?YF5R8)+;8C-WHU+5JSTQZ@5D$=: 3 AG!/Z07_I
MLC?N<S)9N_)!O*2L))W3G5S@4W02;(4#$1CFW+,UK>O6NU'^;H+86.UF3 #H
M)A/#U2,8$AOBT^(!Z@#"=9*X>X;V/DZ2$ BD6'5^]XQ9_F3-#-5S&QP=V;CD
M,H_Y>I/OJ9N%K3^B6@J&#D&(W,LZQE-,&3^4?ZA71PF/+4Z'%1*G,(_FDC,G
M4D*GI^MNH:3(I7\-U4L0/XWDAWUID2O@*!4]]PM&F:ST9;2Q1=^,@3,J?]0^
MM*_'(<[0:B94110EI7+J)_D9U#?'/S1S3P:=^%N$BYD,R:D>$C/0Y _K:%X(
MH)-(?)1^RZYXJD5SGO"Q[+;5-F%FW"63]3(G3=L1!(?@P(L%*-T/8VF&-]J>
MX^S@?!\B^QHQ0LI0BRE 2J![:X&YW"CN0K>T23[X*_1+)D%0OU,X'0_'TSZN
M^SFDSGA<>)X"(FFL$TY$%Q%V<R] 1<X&>%;4L=B*S](>\J&P&!BUU8V%S=VU
M(X?0\3"7U)\BGK;GY!:>!QQ/[F)C)@>]Z3RHTEY(R 70+A/TD(WO).,4F@?G
MT]E.(JL[$;1T-$?II%.<SPQ2:?:R1 JF+Z0$4 YJ 26]S(Q5K"4?EBSS8F.O
M>#/VE_[NL#.*;@+)\OTT,#%]]'M!SO3VBWAO5)/^^%J37JQ)_^9:DWY?]S@R
M5]].TA#JV$C$XC#3@0IE=YQ[?3[15T;O55\N6+'!;T_#1C3&)&5N"KM:IPP7
M:E 3=3J&7#-WZ!AW?"UP\Q"^.F6);ITN)AWKBR P\P*4ZED=3MU?YPC,EY 2
MU3_=J@L$LH7FRHU(=E0W<IUP"S4IS:/-,KKK#9T+>SYCY_K'66?!8HJ"P9'>
MJ:(<0!9$\WU+6A3E!M5^;F@GV0WCWXJ_I;8M)O]=G[65^ '%E2#T7+Y%9ZP_
M_V0.0 O3'_K^GXD-"_$(@VPWM'E$^[?!HGKY/Z6A+UCR>)746+'7"K%))>R3
M,ZB<&YU9O$NPAHF#.3IM3Q\0?QA^0,M-^&%JS,IPX3J"4#5D1@__P4G..Q[6
MGC#4TCZ3Z< ( UWO=*7S/I\85O2L06U4T/-U3-H1AQC4GN<)GS47DW?F!)-.
M?-8:CTA*&%CQ=\!51?W2\ZPS\_JG;7=LE<V7FN"9/PY8>F&/"Y]F,BHTL8LB
M"$JIGKTQA !:T<9!HUKZ( 10E%H\+@MM%9:AG]VE6:9O364-IVS%PJU*7B#K
MF;$NV_>2R9P A#C9DWW%)//#V9*T?G*N9X[ONNRYW\, U1/4>0X=4-:&4>O#
M#"7J"I2HZ-IDB%7)&2Z!TX]?;'/?MAQ,5LU=R;AR9QE,[CK?F<MOYK.775 %
M4I1T9 X'3V$^!DPY*D/FGY$Y[BJ[/(7RM60\?4K.5N,85;RTN+F"8WF>*FGS
MXY%C-+IDIAW!9<LKOGU>,3M7)G:(H9R7](+E?$K4^@NGAYK#D&;;(C.15=\X
M&UW9K#&A2-2SBJ"A= G\8=(UCB?I<-1<MSY=((9QEZU/<5 -[[?[F@0<&C5R
M: +JI7C5\\FA;C[VI)N'&D07H2+*)C+=I15:)/-[Z36P083>@*MZW$-26L?+
MTQOE4=KZ-,T,9FO9>0O?^\&[+9:YFG@NP>WF&0/!2:U3(S<?GZZ1&UPE)Y@V
MW_3(/JG7Q4%=,%VK996NC%"HJT YX^0LRAC9=TUU-E;H786_,2".O0M, @&L
M^#B:X0 ]6R:(O.3O79BUW%3W5?5:73[_6OSS,K_72I<F/#^%]LJ* F-$%I<1
M!/NE%CM]&^D<QN<9*F#Y<4$>Y_H,Y9[+M"9SDPO%P+$V=2[,@<)L#G.ZM#^"
ME88$GLIMOR.4ZDF$ U^[]NGX+$<22W S(<]6U234?  BM/VG6@!INZW/;)H"
M#'K!,F'46.Q5WW+LV1R2WE4YX4D\=8,L*UV'9S8DI6N-:Y@#;<.X'TZ<RQ9:
M[8Q*FX-.AC*>)[T"\A@:B#PHY+"'/MHBI>E-F>.K%7["LH#<;5?SMLZ$XJ C
MDFZYSF7?K +I@&3=<YO'YBWS%([^K<0U27(H 1O2:'C+G[U':L]/H4Z&%WAB
M?.%Y-X=QS8,BG D!15GMH>V*=*J=24@D<T\,%_Y&<'7U!'&W:\;*Z]0N#A$+
M_T@?YDWJ3L9/X X+5>Q:XJL3<"S)<B!^2SC9= \XX4FNH26HY^BB(C4"39S)
MRFV)E:)>"Z.'_65\#<FLCDTXZ4DX[**>]!3XBN-&":<I-0R T(:7 H*$B?#X
M-F)&.W2,P+:YY=H3I1YE2[H$%KX-?\OX'$;Q(UM:WID2[8KHG*% IB.<V0%&
MWQ7W[5E4G^;QML%#+MP:<S5T$F-@+-782JXR&:1$\Y=3@I"Y-ZI2$M C]]_4
MODA=G+Z@$7 = L,ET2%]=^>7^RBTSW;"@G"SG3!:^SCY-3<9!9%]INUGI(/Q
M^<.9R0]\QF.L7M Y;_ (O<@5=9U3;M\DB[GD:57*^[@J3!!S:*V3.('YNOHP
M3KFXQ>-5HS:@*@9[M3"$E/MS/XC)?0#]:4^P:^@<2HRJ ^">>H7@%LDW&=W3
M87I/<^*8Z%=EHC^-7D/\^3=#NWG]/MR;[\/M.1O#0. 34J6+]:C40.4R*F>?
M^S TA/&FHG$C$S(:0>_'O0EDG?E.9*@+>O\9,<C])\)YD-3DB=N!@UAZWJEQ
MN0P<AJEMFD<L9M]JW^>J<#XNS[XH\5QML-W0"G&[^AP0'^'[3JF)E+&P8UD"
M^5S=$3]R(AV%N#A#)((RI!#1Q4E(11/K5L9<6JQ0OP:V*QY*BGYH!^QH82M&
M*>@''N/QC#^+K]YONOK()J-=0_.U07J-A>M9))"^ZC9D;]7,3 /R79DMT]?C
MV3=C2'M#;*OR+HW(Y!P<A7Y]7R% D78B;S;MGA)Z"72O;&$LZI[:"H$<I85F
MFFEEXTI?Q[Z9ED)W+;%\P7_ *;"7ZEE.TNBW4  ;3T'.]>4W7I^S5\1X:9Z2
MA7<*.&VQ)MGRSBFZ6:[/\D&6V.$7-<JY5.6=,0)&5LY#YYH$@9TJ;KYY+-,%
ME$W>%Q02VPD*^+S@M@GF1V[#>"KSF9P[4BXY!ZFV^(9Q+?M!2J.(K:KNOCSV
MW"^5[YB$M@T@[$\=9!<-DD*!1Z!.C2\S]4OXJ"5\S'D*(G]OA7\^U]1*.?.?
M0B(K")%"=2.+\?TSSRAET16_R5LM\D2[=)\)TI%-]E3 ;O)8S7ACNZ24TC/*
MQL]A^'AZ5CZ43JHWPER]N&*N%C%7_W[%7/T\=CR^_(LWP9$(6> 8BGFQS/6#
MA6&$Q4%9HUR6F_QR<2/XTF9J(L,4S^C)U:Y@YD#?@O;YP4,,/R*1[GJHKS P
MX3E)J9I$4[*/T]UORF,5:FK4H^NY>FCW#[@!N3L^]?YP D1*!_NSR#-PTJZ+
M@5L+YE_V&*H?!,6R*E1P64PA#&A.<;E)("=U>8G^*67",_Z#*;GGB&-@W;7E
M%L02$CLZ/H%$!=R2$L'T T82J#%J*HR0' V )-SD+O]4( RAB+C]2BI;2!%3
M7^'JJR6,..7N7%:*<O;D4S@*>GZS,=1_U(TJM;TG&$5(_._IXQH6>]NKO:1Y
M$!R0RH5X_5Y&'@UDU10P[_.AT0,6RDO1R.D=MH>-08#(L\U3;GIR(_F#.H1/
M#4 ?8R54R>JG0(OL91-_!7!11N%"V^*9DX]S5770M$8E8&#'L77%OS)'^XS[
M;T8% * R1-WQ^693SYLV'^2GQH=SRK6#,*U8(5Q>G\.HATO9A*V$NY:0<^78
M\EBV)47PDIW@3UN1%R27;W*5A!G>$>8<86#?!8NQ^*(),60]?:-)RBNJ<9O^
M5*^30U2$^ A4Y&/ %*E,R5RNT=3.W(1KOY.7@')4MO?Y:BOAKWVC3+F.#WQ3
M6;J0VPJJI$\*Z=9/(]LWONI?'=RDUPJX*H"5OEU'U>.?L]W#I-S^H;L'7^"R
MQPG)^'""MO]3ME#0E*@F[,[.A,] OL@#RVA=,W@DD#[9H8,,GB))_QKO(J@H
MO/@#\99_]!%W!4B^9.F/658-VT(L<#FDG -M87Q,,:?&)LOR7WFEY!3_9Y_?
MLK?AU8RQF)40@7G;]]6CN2\HA_3W-$KR@+ZOZ5:/>_+CWZ\.<7'O>QM]);(
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M1SX_V<OJ(NFP^.;0;C2F0@-$.W[[.%)2Z#%_5]!.<!E,S_X:B7KTQWI0_)6
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M*&=TH=X3M.N@>^8<CUUO33K54*E&;+P7$L5+W5!" JZD'>3;U6>R(^B)N$3
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MSZSP/3#ZO"N.M,ZB*TFX7@%'JS;NS!9]O"=X6#82I\2:5#=%?D+.?<T=R_4
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MG;))A3T79EK:P"T!#$\=9CBKL(B^]-0"AUD+C.TRN:V7+@1]@\F=D+]S]F9
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M9U0P_6IAB#R !6JYW,7,C;O.V\RP>GK;2-@W$N?JD*I,>R18':T+IK4(N"#
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M388#J]#/<Q]"MB1'&B>H%=+ES[5G%A&"!R),J6'?Z[H/K6A-&TQV-W"J6E(
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MSDD\#L<B<_B'0Y:.,SH/)O7?A![5.FF :G3.G)DSC&K +?,):=:C?KU/^A6
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M3$E!ES&3&$W@(;.)FR'V[::Y.(G)D]@8C=UAI.>YT*$AYM_RJX[*U91!8>F
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M/<+CV#N=L??*CQ@I3M#-4!E+AC[7;0F17J["S+FA511:>(4)HQQD8V>PKBB
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MB)@PRJ9 E7#/E<:A6>ZBCH1\C!V'J \!^HF$D4]G!B=S5O,H3I^Z..6ASD[
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M!25E*=>!:O >85ET1[[MN]3,"62JXZ5QAHN-,ZC"G $I)&*1;9"P 93A$,X
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M#RV6,PJQ_H0P2,WEKZUX-&LVM?S'5WE3UEY44*]-*;:+IM 0L?"SF,](L\T
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M*QL93T"UPOF7M4RET\ +WV@&GO?0_)BX5P[.,UTX\IH*9O6_NR+ICH#TB+"
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M.:Q$\&%R\]&M5)S[-<;!@UR9W?T!1V+M-X3, IUPPNO^4'5OE3-MD8D"]&I
M9ZR!Y,NI!;1+]>?LP<\/-7O;(L>=:"U%F&$64( AHBP2O/;ZF(MLW?ALC2(#
M=*W#]A,1Q.AY^LV&'%W?!WGEXN3)I4Q-,IA .4OV#^G]00U8-%?BD$+-MQ2
M68IKAT&D=E$R/O,LIZ^Q#[><ND5(61&I05NL ]H]679@-2]$_X_=YMZ?",QX
M<UG[N7Y4KQ[UY,*1=<R&;CZU ";D,F^$!P<Z&_J@9^JJ[;$J2?:#03QF 8>Z
MHWSO"'SJQ9@<*RRBLE C^J/-[BAP15P@(O&(9OI!X5&:R.77ZNEF<ZZ5E3$M
M":9>B7B"V (C(YY ,4-'"M/HNW)5DC+HNQ]@"PK>1PBR>3.% E<1%$/,;>V@
M!R#QMZ&YE<,,*(<2G0)0ME;-]#P5A0)1I+ :*4-/RT[O1/WAXC>\WDMBFVN-
MJ@LE)Y& 3F:_1W_$*-??)W)$7:X?"\%"@2+$"Q>2$\MH)&B:P^VD*%>IM4+U
M#I?KM."T7!+!B)_#FJLIY"[B>^+@;XHY);[>B;%7&GO$9D0^ A?P(]"%"K"V
M/CV TK1:SL9^PR3FG!A@(5\Q<U.Q#U42O'Q0)AQ\L$FL+$EBQ8(LOSW^>'KR
MA/-J\J19",>ZD/E84X2:40[3&71OM_K14(-;C6G_\?&SYR?/DC0SG9)+FAI!
M#W&4&'EGLH'PKZ6RYQ!S9]U<Y%7Y+REU=4TAQ![Z4>"8I,+6A\$A/#L-T)1E
MOK>F9_8D?/6(X/027"X2M#UWD@Q<E+C.S*A;PEBJ%$A39!>EM:\5*;XL-MO8
MUT"F-<!2Q.N(7>5IAC8$>/HA_C)R7PY$PK'.95,KW9$(4UC"O-Z.%'JHL5 _
MMC*F,2@"M"TN0P"KIP^<F,P;U(9Z]ZR>B?>?P&FL((<LA\*(DAHP/([SZ*A*
MC&[0-14:DS%,':33VU("S3^5'YLO",[(IG>]X980<4KU*25E<74TK/#&)QH+
MLZ B"H6\Z;W@DTA)-5DEWK&)Q*C^,R3^A0XI5+I=43!>%M:\P4GV/4YY21ZM
M<[&*TY3UO! M@:W.Y;YM[:UYQGMAVOQPW66Q#E4=;XAMF/S)!D4V6T("[N!%
M2,ZT*'['&-@[Y4J>'7,E4[F2IZ?'7,G'*N,&O21*.N!D4ZYF+@9P8YE22\IE
MN#L#<6&H'>^3!DS#,LDG\GKP?F48IO&)ELTA-:&D"([6;H*,0>N18^2?3MNF
MWJ:(6T'J"IE(,&#(BJ]QI/D#^23[GZW8.<PJYFT7NHJS:F4[@9Z>2>IA#&6.
MD>.P7_M9TYJ3B=J\03D<,[0H3'>]=U5Q44N.S!*WI;[F"%VN0!B4Q]>0MH^1
M&[:&3P2T+3ON/A'GTQ'-"Q&_#1'@DY#O]U<&_FFY.*'J9*A^VE']DY1UWX8]
M _90PCCPBVCOI$*;F2^FJ0-2O@#+^!,X _K4CY\4I*2?@V=D&R5>YM%'8#J/
M-;JIR4$3OJ*:]QSP'UB]<[\/V=&0Z%.?AQ1 (0E3"45\XHZ(@@RXL8]"N7\$
M&VL$,LM3Y9*5\TMSZ=TG38ZPTIJDE*&OD5]>[X>5>I-/-,"\5A,_!$0([$+1
MM:V65IZ2>))VT/A%HY,F&O8U=:A</L;#3X6M'_'LRYT!1!IT?5]AP2L$#A5Q
M?^0/<$9'&CL\W 6';YQN6=N<%,DL011&AC<*R-/H$(4A*CBSR,W9)7(T7,F[
M"!9AIYCGF38BWA1Y%5CPTR?Z>>[+T\V=5W8*RL[Q8W:5R\NZEN#2CTF@GP5W
MX;]N$4P9B6 8%*GE.IY0,3=J%V>TRP?7*A^!;OFV:VC)*,TPTV0 L3Y*G#A,
M/QK"4)Y#6P%87ER["MAWG9B;-LS<4ME5JD/Z!THV<J"<N//X28Q9$YU(VX=$
M 6D]B5,]@!FU&&[B#A>2:]8AS/)]XEY6[:[(E\A$<H^&^*XZL)E]0<U(7@LY
MDHAI:#(^+!/,PR1L*>83R#H((]^M<]H#+NF?,;R'8.S5;,E')D_#2D:+ECWM
MC@37R+KPFHA9+N%(YF-DR%&B=*^+\-*CV]'F3#^*_?C!3_ED9]35NF=OD53J
M%'-D.:A;"JZB]$O]NZF*6(7LJ](?4 1$X/3H>@7]Z?BXT1(<Q(XIPGO3"&8\
MUF3Q)S2!'%ZI0@A'EY8 D_U!8)# P^+O(H%?B%TRC"E(W3T2OU["D+=FR7R:
M^"\T8$P:.\G:,FT6>44F29L)L B=,)9]EN'89*?FY2I2\@;\!$D1+)!?J(6_
M-[%*4+$D<ZS=OZK_I#,)SW?7. W57=?-.SY\F.\>O2Y"C(7*;(B0BG *O&M#
M2$A6B@W8KIA8-38"N*>4%*IJSPUNOD'E2%=$.K632"$^7>$\YJ9N@="6^\=C
M';._^L/&'\S!<KM1[+*!V+E;B1V0G_X)L^$CT+!E38B*T<<HAF!7R]'([95:
MF,XRW3-G(U+"?B8$F=HZX)%W:=[1NVA/F/"('K/:R !E=@KR(. @C&X7-[5=
MI,<?^EG93:> *,.D$E>BXW#O1NEE@'JA9!:W<T'FMD-V=IY7[Z(Z8 O$,KKP
M7L8[$\21:4/9E*HW\[+*):SC3XUZE59PYA1MRRLE#0TCCLL#KC?DZ=QUJ'(*
M2I_;J-25I +Y,R[.:B2&<9+%$%54_@/2K]WEY.%)0 A8/@?I) 3#+];5S5X3
MQTR"G^/%5QB@Y]YU*A#S)"QE9(N%.KCDUA'^?A2N,AJ!RP8E/A:C8B#MB%S*
MQG",<W$MN]"_)^S(>W0J3AIE$Q(*[\@4<Z3F,VJ-=1-&KX7;M"&<EOXB#72+
M14URLB[])EH"*5RS&O#;IA;3C'IL1LS&CS9Y?2=+"J"40!H%?7Y=]-R6&\-U
M2CO#]7H0XRB_A0D$9*.! )ZR<=_?M-*B5.+8>-7I<.J7IJ,OV_$22&;.#\&<
MV^S6$&<Y0)WM8J0JP0,8 . PO",E[VDQ"J SC&-KJ31JT91SJK;U4U%64.$Z
MR09.') #CJI&%:LP%5BY[WO\;GB!+XYX@4F\P.,C7N"3V0NAQ\Q._?<8VJL1
M?BK%<.!6>6X0:;J62!*RP,:O_N;U>4CF2=OM"V\IM3$PU.NJ+B3.9)N=9!*0
M3"*\3-RT(/ _._M[O?^J6Z]#!\1@"Z:#^>U]R(\.H?"JREXM=C6MWY-3T"1]
MA@F&1BB6+O"PT7RQ&_"/\Y0+D.V3?YP#]4EM70109O(EW9;^^<>GI]G&RX7!
MPJ<I GO7<TH+>17Q/8"41%"\)I!WY"<6/H^(A%UV(73%H^!R3L9T<L"4G4\Y
MSI]\_L@_&Z4L%?#CY!UKP9!_VR]M,(T=#Y>.*@G&H?:D7*$4AVQ"%KVFV% !
M:((E5$J3UU[$O3%-+27]_;R+1\4M,4UB0W8_,+/>#\;YX*(E;LN,2JB0'WKS
MS8M0NR24?).4S(?)IX%C'&-0ADDAD^%X,J0^YU\/%<SJQ<Y+*B(.(??'[-3,
MH!$<;8*J6$CSH86<C40X<V^TKC$2GFTIL1W,MQ?1P93[S[AY)J2+)OVED*QE
M^EJ$PN%RNYY0RO1(85804%)$M$>,L:8PWS@3]]ZV>I-?!7ZG)%(@A.1]45S5
ME-AATDEON6^%2J>_7("5+XL5DB,2^J+-_)!A/5&".1ND-2,CFY&0W-RT=KUW
M 6#4E%)HJKVV!3&LU)G1^4"<(D05)O>7%\#>H11C$:EV+*E6<S\;_5'2[0L.
MRWC>/>TAJ_)KJ=^[$";+Z"06IDGOO/D]IS!NEG#R5F?<]<#/;64 RU-O:Y@/
M4FYTTU&&;]TG\933^GYO&=-I/!ZM<!)=+*O@-46+7;^:?BIUCQU:%(TM:ES"
MK$3??-.^USVX A*4;L11'B%HU>H)<!_B>,+9.;;F\7GET!J-DB-&Z8QI3A&
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M,_M]1*#"L9AV"!J/1JEU<;=HU'U9>XLQ-P7YNR+?\+IA)N=-G2]-"S"'LP
MX)ADJF!H6FPG-IJT23SD=T7;DFS"?=U%O"WM;U9,E_4U"5.L;Y)DDI8:AT<;
M1#.GTNFLZR +M/C[W[Q-Q4>PS-.T:Y.+[OJ+CDK6^GVM^K6V$J=[P\0**[SB
M@('7/'2KG4$[URV#O8O-=HTCS!8.4]I16EMK.Q08AEH:\OYVN4[S63_!\<%T
MN27WI?T5JY8!WE=W\:=N>:%S58\*AP4?IZ( >+@1AKB9 UE8B-U$0 RS0(OA
M[O;T4-/FB((=K;8<S*DK-W7\+D0$S)XG:YD;H72HAXE=;&F_OQS"HF?9M@@<
M:"5YKP'8XW@ (Z_$%"=@!B2W+MAN>\I.68;'F7"8$5?"KFLJ<9"YZH%Z='-;
MT]$Y!DB&MX#C\J;@!JSWMLK.]'A2UF4MNJMNYG29C30U3Y%B=G]\F!UR*,?[
M_)CCG<SQGAUSO+].\/!_>58N_\\?\O__]/09 1#RO[P7O<W2 #/LQ:OOOGOY
M]NTW7V??_/?_O'S[C^S;E]^??__BY??_E;U7:^6C.ZYNGPHE-]'[H=\PBO&U
MQO@BA^P#\03)K \$@)(\'<F=7AL*H)!@L)%%39_.3D_QOPDO>33G9%H1LZJ-
M&8&V0&TKH)W&/QI&C\8]5M=+5]PAR1%P6YH[T82)"<9*UQHZ4^IM;+IQS4$Y
MOE]5:PB#_ .=-=PIJ8X?R;*\!"#4JU\$G *V.=YN&':]3GKA3J-!&6H6&B#W
M0]!)HO:710/]=#V?/7OV=';Z^-FA.+6SD?V9EKZ/M5;FP"%-<!2\V6_FH7YT
MRB!";0<[TZE]GZ;X:&+?\$J,9NB\ZU]RNC!EC#*83[,U<8L0Y(R%IU'81S>O
M.,Y$O=7ZRUKB!$RJ+102^JN:-R)IB&#QTD6,@C(,>:'6S<V=JM''9205$SA<
M[88PC!3\!GG"83HU16YDBJ;TFP:'TI5E<#1B>I?V+F/Z4-22\5+#ZKI5V5 P
M/7;G9I!)S%_39V>?"?9$X"F!Q<WDK72X1.Y1HAL,!VG#F^:&]S'FG5D&W0/.
MKJD^)=VI\4E!,82#:1[P#Z %:0B_4RF#&<LR[C9R#\FZZZWND8(@GRJF\R1P
MSGU3.=?73^X=R,&J7_S\60A))Q!B.7YSHOY\Q"%%;VD\$BHZE$ H=1WI>43)
M8X][]O]DW;[C^[YNXJJ!$6:(F-"N!U2M ($NO2/XOS^>OTX@%NCJ^- :"(0#
M,'Q[,Z>D\[DV6J&W&(X=WFL(R%, #A3'BP[*Q3+XS;+!+:<F9*;!&!-N,+>*
M6CBV@Y>MT([C??[A+0>92IH+6RQ/'J]0#MKWEUU-LW=5K[M-X<]DTC>T:?US
MR.V8KO\(!,)Z9GQ__N;K\_^FM6D*BF9P1N2K=5U3!/PB^_O)ZQ-=#:_C.Z^D
MPV@NJ?(KUM8X;SQU6Y)AYMI5K6M$>3)M'9H):0*)\7Y&U%D-W2.%H%T%AL @
M=P 89"T&2BP@)3'Z[2'$#RHYKO*F++@AR!3 QS%)X%AUF;(>J]DZ7A4Q0!7-
MDBUUN)#I_['WYLUM7,F^X/_U*2K\Y!=DW"*; %?9W1U!D9*M:RV\HMR>GHF)
M%P7@@"BK4(6NA13\Z5]N9ZD-!"3NQ,2\OC(!5)TE3YY<?OE+/0ZVKF4L-KSK
MA,]\A[17*KM,'46E:A$Y#&WMWS.2-GV[2,K!/8:>S>)*$DK$J"Y S'JY.!_;
M[5S K^HI5I.>Q9)0W)IPC-@)XM;'2V,8QL.20^:N$WPNO/*]W8W1IKX"W-X,
M[/AA#A^^,]K:12-R6L8R851G-+7-9AX8#3([2AICED^BF1VG7QLGE<-@W+6:
M(G:SPY<IQ2]G7 F:.=G'RA)M%/;:?67&X'TT8WAG//-G:C]5HMQ&.BFL(%6;
M-25'/D7&D<6YAG)5&BL3% :%M^:-$:A1?64.=5U&ZB1]"2(E $C2CY[#+L;Z
M5UMI%.NGUB"U>FL<CT!&L8$C7,^HRG0.Z8GL;?5E*T7/85CKZ'E7]'QW'3U_
M$/*])$B%NG6/Q/ @;>#$(IRJ!==?[X(VZ6!")O>@*3CE*G6*R=FX;BT*TAGC
M\ @#C$$\ZE/FEE*,E>ES;,W2%[O[&%JV';NZ?J+#.2^#ESO[-!7YSK,S^0V>
M#FU^*O,Q12^>:0H6:KY2KJJ-\+TU5#X^=LI$HQSK<F+08G]@W(UH'#Y3\*[S
MV1+BOU2)T,(G@KN,A%C'=!T1*B>"7E,-4Q7P,&Y\73I>XR<<=AJ25TIT$1FW
MMXJM_\=6ERXP\F3\IG:H]ES-5&S%O)*V8+P=G0N),I*7A:%!-,1D;9X[L.;8
M2,MK'93U3D.L96FOB=&<?+1]O>#@:"_8WWG9I:8<"[BMZM[8ZR?AS#!2()X'
M8]&[NP?!X>YNQZ-1J$MF'4'BQR@M\WCNLF]P0.QK-"VG6F%IA/M0#'[)H&BZ
M-H8;D^^M,<9UT'+4S/\P6-A$W<5V!X^5WLS.;09>R+8.^QCJFL[:!91]C8'&
M_J5BD'*VQ<)1%R\05\?5PD6UH(R!A8#E$!(I*[LQWHM>_R7V]=A@ ]GH#AO=
M(]>%ND3 'P0P_7$L+M-)G%+U&T4,R8N#39<H(\:CZ.O;<%-L^M%TJD:,?I%"
M/]WMS\BCC_+XL\\-&OB%>E:+7ZS5RK@>#.Q^:^T4;!*>U/##2/-TBEM)L]16
M:+IUFF6 L7 ?H2#D%2?OW/G]L?S>>';>Q\1?@(^?,);G.J0]U7!I*#WGHIOO
M;(/3>]\,I_?7</I%+FP=>>RH+>X/8NMO&]Q E41PY+ \<H9.U[)VEOGP47?#
M9U]UP=Z+O3U3:UVC0O)J<2"=K'L3IS#@,TN4VYB;4Q!(<,;J'#FD0LF$!G5*
M"T#;6Z[B[&:DK'5/'X6-:1/17Q+$(NL$;DO&J1IZ-_&*ZET]#!.)&6J B(W
MVETZ-S!Z[KO#]]5Z?[IXH'0.4)/;9U'^A?MPZZH/H\%M@8,IEPVE4Y=;_K0@
M]$^G,U?\$L,T1UY"BL1/TOC0'9 WBN+2M)]RVAI0(A_CZ=HPK'1"J#>:V(;5
MDF:VXJM2LUK,X>LVGM$_/\&P_#><@4#,N[:6GI=?2(E1V((I42" 5D1=3;EZ
M3(ABT!F7+L.$S0"-752G"><8'9 4V+>SN45E&,1$B*2]DV@ %DUO9[M_=$]W
M\>VNN*X2D2RLFQ'[O7J%W6I3F2I?RZV\P,SP=M[Q4,_)'W7<H\'@>-^ P0D<
MB-7-@'"\*ER189BADRVK)LN=6)J%:C;Q.QI4X,)W:MZM%?20(GQ>$^C5A<CI
M0/4TP0QI4H<J7(?R(3?J]E-5C\3Z7RWUT5NG/CI3'WOKU,=#/ MT,YU4\):O
M0TO[],SN*@>-ZR!,"]U@M,8,)A0<%)V#U\=SO\)?UJ#TT*S5U^6*(J/&F^CT
M:M^=.H#6M#=UF$9K-P+'BK& L4%7Y6"(?[KG/6<"YZ&*XQGR92<7__AAYX=O
M'<!"=?8SN-"C8H+/V_G1:-Q\%B*:$+_Q]6<X(T6F7X[=16!E8RU/\.R.ZF?O
M[\5(_TK>P6+VMW^V?=*'CZI/BM68ENCEP>%+6*-BY/ZN]96T]=@@+1Q2"SQ$
M^)A*/NDN;_('M023Y]!0<YNS2NQ2/-!*;H$'!7M69* D:,]D'V^] =I:0+Y9
M0+K(S1>6LVP@VHNX#A)B IO6:/3;']J&_:^\R$1 '-8P82*D&$8:UZD@O;9@
MR2:Z&&C@4B)*ERTXU(J=13>VGL$4'H%6UG4#+:.G.EU6]QX(5**8T)N!NB!8
MB5P-EHAME Y+7@R3CK##<1%PG'RUFAM?Q_!>OIO= JTK%5\J]FP\\6RZ<R3.
M,\U5[Y^[A1>4L5F?YD=VFBV>7<0?) &!&U@.9"J#!"PP!1%@[0WBZC4O!8,(
M-;B"H)Z_=P -1I+-^6$TWT"UCP$[%^DAT)OX=SIK>@>B]_>!D;ZV$-): K]3
M AVM:7*7^!=N/L\")-'1H1@<KA 1R:]54W2#F%P'Y:$:P7-\NI,),<VKNBAL
M34PD<P;K<7::<F?<.1B>;#I(Y9)3R=(I9\LJW&7X;'DY/Q";JJD+ DKSM*5R
M S^+PRM>!%>CFX8B=AVM@;_6QX_M-"1IA01CR#V;D%Z8Y5F*-J@G#;;MIAH+
M^&U1%H1B\=]KM?RQ+!!YZ+^F;R$@@Z2-ZK+;*[DV*R>07\VZ?Z"[EI;PDK50
M/4*A0NDIT6U'.$K@:!#L:*6+YVB2 7=@X:]2.1R2WOQ9)FSF.2)"EC)<](CQ
M"33]05 IND I349IEEL5C7W%J+G3!6),$K0-$!-?%I,T$^6)][S"#"5,(8MR
M9'&CLGVT\.'IE,^B$\#Q<J0-TM9(S'#_>E?OG$G6QKH*R?2'KQ(T.:;(6LH?
MFY0O*)S%^-I_RK00((K.90CHA,%*WH:8"KB@_TZS+_);[5X%_H=_G[_VCZ>P
MND-<;0?K]4N<#D"(N6C6$ ?*AR=2]L&?;K)\BN%1'Z]I^[.D(6*P&P3I:I_>
M&;A\PVAF1M T0PP0A/BSR)KW+%JH(PIHRLHNHQ1/CYU/'1HG1AI[ 7(&E:SJ
MME^W_PR7@BZVH9A!O=J< @#2M!3VGZQ$S9B5*1B.Z4FMNQ6.2 )"ER1 YJT+
M6FGI]<#6Y_^QG7]&V!@S.H0#0QA1O$<L8DDNFK]0VY>%7R8<*_),L.4*&UR5
M"<8U,SQ1'2JEC8K8H>C(5_,H?D:ML):X1R9Q<#4H6!57;VI<#@,+JIL<6%WG
M.6:4S?C@G\XU/!3-,^Y<2CXP4='KG X'&D$%QBJ$U^S[GT7EGR+2V7DV/&5F
M".))7-LB?"8IA3&\[?L3PQL(T:R4;.^OD^V=R?;]=;+];B67(&R?+?&!2^YS
MN\"UA]9K[/>$>EZJ,(LCS''(FN EG=NV3O4")8?MPOP";WL8&=T@\5P;>OS@
MG'0UA3E@J6\O6_T]T(SUO?S-GF 'LB^![W?!^YS^;I[\J,ZRM;;3'JL\5,GT
ML%&*M9)L(YTZ PIS3#!=4[.^IMJTQU39.*C.>_0B[[C_39RG+12(5A-;!)/M
MX$=8(XIXYQ01!!<^C)%TF^J!J(1O8W^S4L8GX"JQA]LXZ"J=_QC+E"D/(T!(
M NJ4K=616+SIAAX$?S%7A:W"?'9EZ]+>C;;6:77P[V,*#C5W=C#WIR414^E]
M(68V;.+X044$9,#V\,2!P$_.L<+$YY!5DH_YS$69=J90 $B4=$%CC7*UAKM.
M4M[ZO&X]"2IDFHXBG4J^"C6/"WX+F5*I1YC#WT_A:K R\B(C[ 4:'#@OJGB$
M8?.O065.O-LK++\KZTR_!XS_<^Q*LW4.=PRA8:A8[];-P@<G^]4./AQN+-KX
MJDP8U+;WX29(IK?/HCX^#!BRC\#" N*/%LB]SE/P",!FA1LDRB<J]T)B1>+7
MS-*< 3EMD8CN6GH9 JS"C-BV!$,EA[.%'JG9XY6;*3?B'*U-.'$P]2]B",YT
MV>. +YTOIXF9IGW@\11M7&->K?=36Y6]F1MW'Z:8,!,(4$DU!4A"&8NV^NB!
MO+1/X&R_EO8+8\O$355[R[3K\J1IP[E;HOC\M,(QB&"'\+7 #]/,H _+#G)&
M@_[F]B!.47@GW+!929UXE<XQ]#RF,&/:@@&1H6'$#RTIM$'Y]'?L?&,HSAO)
MZ7;?Q3/V6@"79LK+T"*;CDV-1F="9%/E- \KI:E<#.5U,\LO.1>Q3"_ ,DC$
M/I4@_TQE&.DUBKB@NEK6[M3;&Z,(@<<D([;Y:H6<MXWM$DN^N*Y6 _MAKR9@
M\3 )+-@ZN%?G3>IPVYVH)E;>W7?Y]6M=?KU:E]\6?.Z#ZNK[X+3,VS&;!9C;
MO**R?DU_X-$B+>R?T,XP(W<Z)K7@ 6%;0V;WSI7*8[>[%N<;P("F N3"$T+%
M&N$8,Y%5SF^U4Y]TX<9&24X5BX@(:0K2:,V3:=Y,)U/LKCCZ@B!JY!.VG\O(
M.$&WJ,,D:RM:&%276401;ON@6%VJF'Y7J8I'!AA<NR$UQNTLGK?/ :=SF$Y-
MZ7Q4:2(EW8VV38/RO#Z@T.@("7E>8LZB<;K4W*RGU[V055:!,;AKF55D(U51
MW*%92V;_D;9FRC=[CZ7F9MC$(R=IT4@K*J\^!&ZH,=((-U!CFHHSK# C-#@F
MVMN#(#AI[ S"I>[4_/TC.#<IQXC#=N)D4?-313<GWA6)U=A4SR(]L'1O%MRB
M:?A%H5- =0RXV]$0E[6FT10W?T$@%/UKBS)[:N0YC4<T81[O!EY#S '%7"QT
M8VH*TR>B!K^''71WG;7KS-H=K+-V#T*^E[GF7REK*59#R9[#V<8%$:A:V?J]
MID6$5GS+D299,Y(4Y3@N43^"\TL,4[H1@FO&YJUVK!/A< !C9])BX8R+BS;:
MV04W V&+K.9;*K5CV)Y("(E ?4;P]'FEO6_SLG#U_X+I.W="+9K?M@6>NP76
MLKBF4S#_/@NCO$(<[;>U#'X:VGU9[AN-G;)B:/O2=%NS-E[&V%Z;<:"+'+;O
M$MRF"RNJ=*-36,F)7@3$>S@KC$/G*_".TFDTI,N6N=NQEQO8!#GC%JE3SJ)G
M6M9 L@35"*S?&(DF+R8+Q+3[<>E5PH_T<+8$RZ9^/E4CKB)!]59<P2)E8:CX
MKYN1J?/UP$B#FR]6&?O$28$J6]:D2!'FZJ98JB!<HDTQW=OTYM\Z08CN8;AD
M.\6CNVFG^/OY:__C&__LT\>3UZ]/S^\0=/$@CO^QA4I619+Y D735H]_G121
M<9XZWB2*F2H#KIBSM<34TQ\.5%D@Q6XQ@%#N5)M$._&=;<^0M\JUJA]BNBUN
M[U@*Q2X*1HXOFXXN]*@O:E&\@ZD5G<X'[-5=<]J_N1&"XV6EV1?0H,@UU])M
M+,H]NPE-GK<&R]M9'%(R[A1KNZ,!^<<8.-;4N.!AJRON-)0T]GBLR\2C! M"
MPUN*Q#\ $I75TK+:R^5FS&Z+"D];/D9*JP'G;^A'X1]?9Y[1T1#[C+FJYAYY
MRD(04LQ=:#1E2X?4<0I&G]L6GT[6ET.ZN3YR\.MT2+GF5,PF_J7NHU5I$&(G
MO^U56HMK>S!3Q%K2Z"!O@M"V@7QNNW@_M'OJY=W<4^^//_WV^K/_]L.;CY_>
M'W]^^_&##__RL1LP_//\\\>3W_SC#Z?^Z=M_O3U]_>'4._OX[NW)OY_N?<:K
MPB[16ZN6GNZ$.VC-\EF8Z-=M?5%J]I-?9*7ZX9\?VWIZ@7WHG94#< W]/Y@@
M)J<\%;)D6R[CMG(J1X/E\^D@C0WA^O$KTU</7V'_^L<?@?[ ZI1XCIH,LT0?
MX*"3(=YW*;8UP?WAOF_L[S%J$E @;4XOZ -<@B>ZZ23EIQ'BJ&!ISU+8N/ES
M$W%-.XG7&D5@J'PUS"?>2!:&:L=:LWI82$$6W"R<ZXZY^%/?_I1# =78KS9J
M:]38^(H,R[U+ 42H,$NHTYZG#4%]F5>*[=R;'7OL)D0:;[* C1%2]P$S0#T8
MO,IEF.YMR4?B51IFHWN_&V_I^ELI+KVWCDMWQJ4/UW'I&[7^>CMW9?U]./[E
M]?O7'SX+\/8<#+WSD]_/S]$01+L/OO#NW^=OS_V/;[PW;S\<?SAY>_P.S,,/
MIV\_Z^]\>GW^^[O/^)6_#[*__=/[>/;Z$YF2^"?_P^L_?+BT/WV\S\*3/ALU
MM\OAO(IY%5&$U +I4/.6.4);N4UL$L;SG)A>D#D\^HMSP!5<C 9V<)C4J8<F
M[<'\#-P3E? ^E(<.VNZ) ,PTN%7@/^;LK=$E.(:1F1CK4#C^.)2/WQE;[$R4
MCM!=I BB[@7-=T_;_/S*_.3Y+:,2*AP:-IIUMK\KPB)-^Y80<347BN''Z)3R
M<)U%L,]V6.>L4\K4$& $5"C9[(^<V(1G* X7A35XZET3EK$3ZKI] FZ\I>F,
M&ZI]3PSB4V6II]'ZU36HAJ?TE73*->V*:L,S7<M@GE=PVV_Y<9I^X5"Q62^+
M9'.;D\!61VI,VP.'(^0L.B5\KBCEC\35(,'"E"0(A$!@%F99?6;!*9#.P^E1
M$M!6VN>:OL@B%+R'U%J9XN32]-PCWIQ<6D(Q3,/E#W&2,[((C.6+A'Q,,.-Z
M,5K6HA:@QX;+*4:S^#PZ'*E>_37<#4":((=$'=@J25_G]GU_<P,Q-K@2STVK
M!B5<)_4F#&X'!ME[S_&DWL@,W\D,S\T,P>Z1A@7N(WXV!!B?PN0+LXF/_(\D
MN&^3$:@[^,%I6(2VT\-]:=D'DP8#/2_ECI9\ +Z"!&>8@,VTRL;?.E\1*S\/
M;$>(W,B'B<6F>B?-F3=^L7QPI>I_ 2&J_04.F?X3%5S(GX5W+W!=<(%GPY&C
M?O($!J,!$I\]D7S\"KXU]PA_FPRW36=EA/[ !8.MR3'2MI:+SO#*6W8'CY,$
M5=TG(@T%=>N]P7:;O9VMW\S-.P<O$>F7X,"?JB&'/'9[%/+8JS0D T.O\C@T
MQ#1_?\#Q5-(V%,9Q>^\)[->]3;W6V]0=4MXQIET2!OA'GR\ EI<3"4A+]VNZ
ML"@K&TV%,558*Q%BH%\#OK'RJ*A3O^Q<S0IYVPZO@,U=R"J\_CJ+X2X!33;'
M^@3=P: M+Z&-@R6[VWA;I"=S6-Y8FJ_[&"7[F%V$2?17:*R9<]CB(04"MC!O
ME6'&&6'5!I4;ZH,M.V(HN,5,^I:]:>DTA & PNDS.O95EJ7<#''Q*UJ-J<#7
M/07Q)=S9ID2"T AYB0IZ1.YT^)2\OD;UX0O&.*0A ^$(2H&;7S*=#]I@.!)]
MAU%A HK" !SFBRPM$Z=9FAE5X'&9<#X,8V.DPATO=&;4.#2-JPU\)5G!:L[-
M2551KE<2."(;;O'9\5KMR!8S>L%AWC4B*N+WWIA$YLB<5JW-8\>\?J-'X)U4
M3.M/8D7!5SX:TUJ6F'#GN"VH=(JJN6AL5"* FF58)V5703([?/KPF/E]7_I?
MG;BB:D;EF!TU!O%FKM!ADW97,[/'KB8$UA1#Q*4VDW6^RQ.IU\>=I4,/]UJQ
MKTB%I4RW$DB-)@D593#W!HU2:[CHX0+':8ZZ040SEWQN.E2CDKNP91RLM*35
M+$<-[:]S;M5W@=".S-&G9C-")7FEPB_H(#"<-RI$ R?LC?%8*'EF5\&H9C+V
MC9%"._<6IN^_/#8U8>[5\[2CZM?'F<,IGW%R 5+"_>"M1#1 4Y4TM C3BPMU
M>,/G9D5J?19'^(0%SCDE) Y8'4>\CO5WH"WJVI_X0F744V[?23&)&;(OCNR+
MW?>(5U+==K^2J6W$*8Q@>34771_M=C7:;&O=6#H8_[C,$BRJM.LH/GB2@J>;
M7(!@DR-.WA_&XY]D%[7N-!!8,Q_A=%]&ZNJ.^6$>Q/%<Y+=XKM\2U(UJT:NN
M.8W'(_0'$5Q\PTF2QNG%W,3.)BH<_:<$!YXJU4!B7Y49%F$7&(%['^8Y6(-E
MK@HTJ$9*?$2N(;M4<3K#@ +RFVQQRD<N\B(:I",ZA5DX4R787-Q9>DJ,D734
MD'^,+@HPQB)N^8YW>(ZP)S:YXFBLMEQF1;B.$(LHL2S3X0-5$-@!%CLL0],)
MI@1>&>M!8>E#2;V;\4IA6T$5&%7 RPXO%(8LJ03V37$!"Q*UXOG&4 >X +#N
M-LX1(CP2WQ)-IV62;J7)D!8X\-+9!+1;/.7UEN@2V>YEKJ=R5X?Z0<CTJSE5
M-V7A!07'Z$XQR^^=$@W.6UQ%\()ZAWOLW;_'$L#WX>#S>RM62^V4L&E8,<5*
MZVBFJ*B)[%PM#P$1*F $1"= X[G'MDI&,%K8T3@<I#K02W)ZP7"!V20$O3\D
M$1=4$X:<PXRJE(0C&W[T1#>Z+5UY9R]:E!?=7SXO>EW&LYKTZ\J</J*\Z-$Z
M+_K-A^D>U"8&;8JK%&DWR?,:E</"&R+8'<U4>/[QJ[.MWDZ??6SX=W\'/*XQ
MW)KHMZ&:)?XQYWXN5)&%EV&,]Z-1JFS 4EG)9_S\5=3\C",J@RBA"A,/1^64
MR,+\E+[&^2/$]F.SHHB1^7F$Z2PL<N'O;INA4V\ (;BA0),@I$-M'=@P'%T0
M?C[/T:&#08R)]FF(J/X,+7^B1,&W?2;.LMS1XEO\6OQP4L(.^6J&498IE\]<
M80]6BIT1E'.&_^C3>OSZ^I.$!\%OQYI^;+]J)A[QHN[25T].X?]^WL(WXPOU
M@P@13CY5E$0%IWRL#66684ST\KJH$R,':/S0^_^+E9%?E%-,YWAD\@CA=IK-
M)O3HD>Y1LJT%H;ZR@YC8%N(T'?F7Z%W'OA, (CXC7(_H+\3=3N&HZ:^9=?0J
MZW@9YHRJ1<9]L(?BJ+Z8M"S_>OW+&^&/A=LZG:41_GR+E_?XPR];?;M"M77!
M29B5T*_SQ'XRS-YS(H"Q2W*E0'@NE"Y\A</'PQPIYQQL_ '?.GY_NDDOQ_ "
M\R%P@EA<S 5'3YH/":C7-2Y #)Q%$GE@LIXLKV8K73EBWW8:DMDJ0D%C,]AK
MC^4'@[#P+K(Y"@R7L!MNCI/@NXB.$&S0,3ZOO],_T YXI*46$6(=#\*%Q\"H
M!?8S7LP;EWR<W?8S3]>^(5?TO8*]S)ZC(_J11>DD3G/F>L9^'L<GQZ\\C)5@
M0I;\0?B*SNBC8S;068-ZE4F%JZ'U%\>Z>1>3H5'P%HGSZHD9'D5 ACIOCW]>
M#K;]L]H;%[\DT,>P.L&-:),>[S,O/Z<+DY#I9#3FM^JB>^BBFT@UCFHC@J?8
MH6&E_X7N(\;N(#SLG;K II><*.7/W#]A().2/F5VR3150]/84M,'X/,WN,^.
M)>\*O&I80$OPX)]N\C0@WT9CE6T472CIW)XE'*H>V#K:ZQ:V^OY/BIJC>)^4
M@$8E!>7&*>#6HN*?"YZIDDI+WD>>0%!=G0$\#9D*D-F#R':IN-#$1TS!E<0*
MMG6AI_S9MH& 59URK+BU3T<-'0Z?&3QW;T]2>\])*U3H-'0ZT!!B>);;M,)@
M"JO>Z_6#_M[A@A;"N.AG;\]>ZQ01(<C@1L1$!.?]+##'R*L^O7725*]68 WO
M>]'K;?=U[=RVWP!"(.9J%-12%)A-*."6UP<E'.'R"'O^D&? B1%,.F2Z@X,;
M+6;RFFKP.R7>IYJ@F]::G_!;J !R10P?%*-8XN@]44G4=S%H$+P=3FV0+[_S
MB_G!T9<OJ(Q)_(]@AY.J.G!*3W0/RWJSV%,0URN4W7,L_2Y$B5(^%/3L"5(N
M4XZ>#M,QIH>X#2\+;^USN!/MC5UOS8R!:XT7['JN@PAAWY,5OI-L+/S]G\!2
MG6U/MU$OZ[E*UG&?DL9RP$+L KP%)VFKF$19 2/H_;2[LTE5#G@W<3.>? 8&
M;26J+G>7Z*AS_-R.J]I[I3I%X[4V63!;GDEI6=U4R:NV#S9/JA3*2RH5YXE$
MXIC:FBKV.?2P*J7]CB@P(&7_CE.?#[:^M25IKBT69X<";'\(!V)WQ]EOAX:P
MDX: LN35O@!#4MU*S$#D0]OH;78]C-[F-<C$\-#"U[A&B"\-N2%FX.LR99?A
M%-D&F\4?9VS/A8;1C8:F7]NY"JZ<;H.I"Y=?B)UR*[0-D]2Y1YG$P>W9)W E
M0[JJ6D8SL/PT0I(:.@P6\B6"&URJ))Y3450>#9BGL6.\/JD?GFC;*,+$Q7#H
M,0GE(UWC+:QWC/#A<GS48Q1C0RM45,$#JQA_4%?2FTHKA-9S5E282[JH1)P3
M0KN+^21$@.!&QDB:,"J'NA'142_H,4>^?AS"&U#;?M44D_W@<&<_V#GH>?R-
MA8RE5"$:S_4LZGJZ<GIYM#-+@GFERU%IV()=K=J5X/1*/7N:84%I*D$7^H;
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M^01?AC<-27NWE+ [Y-J"4KPRQ?.HM='EBI(M<=_68K@6PV7$4'S)P#5\T?!
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M%_?^]L%A\[Z]A[ONX>"05DJI'*Q3*ITIE9?KE,H#/A+T@H^@'RXC=75;KW@
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M%"?2GNC0.47$G?2E:0E)>5&Y<C Z;OQG;.3C#Z-L6 I#!:)MMA#B6WL_CZY
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M [FSF#GI]<<1'?6@"<ZP(,4_9L.G96NFT4R34MH@IC2'-!^+9K[@P>">6=X
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MA6'LV]$/6 42DFW"XBMW.Z'8LYJ&<7$R)IHGF'N>7_,^1QI:M5*&=9.CL!/
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M)*F338;BNV<(*<P%$YX;#F 0WPK_F1&XD8M0QW.ZE"J'=#69SD%VUSU0A,]
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M5MO&M$%*I7E-YFSLTF"R^U861CM 233A.V:"M6XTPI=PW9Q.:"41]BTQ*5.
M ERZTQF8N&5@.@2+EB_R"4]D'5E 0,,/9AI%\E^R;#9ITMR)8#&,:DY3,*\!
M/,_-!F%FKN1SU3?I!7LNL(PN\]>)[U;FG)\JR(JN3UI&FC-K!8><+(61#!.F
MW.\H<>PWGSSI]%C2*J!W41:NV3(*E0:EX5+7/Y((*KUE;]"GX$T!L%BU/C!X
M8@3/PCW);PF)AR)7"6S\A8D3.*RCZT?8LC1"69,@+5B<,G>B'%?HZ\V;\0S6
M4Z]J]FI;S1;8A;**K\XL7\LZ%1,O[+W\;ULZL#>KIR$0\%&S"%*_@_BYSW=/
M7)T+:S85#NC??E4S^ZTO-NMII5FNO3W@-J!6[RT774!4&R,[G0IW1-#1JHWG
MG($A!P"'I"7OJZ;DS*R'<JN!4_(.-AW<Q1ED8.HB(EO(F>M)BM\S,Q,=]E,4
M-C TY,NUX;TN$]H<?](:')'70 MYGF&1NIS:UBLFKHIWI1VJ2L.16Q^(-V-!
M4W3P.4LX?_CU^?OA UIBQ\/]Q_NRPGX[?#W\[<EC^0>W2_UR>+C[].%^IU6K
M90BQFOE,%8),2R RCZK+:F_;;J>3>237'TO&TLM/MJD">$=Q>SR2_L@+PGIK
MS>FC<$_.UC0CX_$IXAJVC#B_1#V2N"7-YI</0'G76"_SY%,V;^;M=>/HG6'H
M:0_RQ3YQ'<_J16Z\\C*;7'@XZ4FLRA#AX_:4V_'1BX/AT?/A_L,'@0]>IFA7
M=626<KJ&*TJ]KEG&"?\&!Z)0>Y)U/(<EU:<"T7M3=M99E'#R%L[#3[Y,+]^
MPN8IA-!;E<(D:/BV^DM ,YZI&!46A\Y1,#5NNKKI8>=:A<N!-_"Z0B!<"KS2
M;B$PD'&D>__/^^'CA\/=07QT^&I(Z_B7XX</!_%_O3XZ'N[R-R)>*T&<DI:C
MT=Y]O@-ZM<+=S7KOM%"@D8+W^,T;V=>Y C@<7X)[B]%(7V+ZZ30;<7.ABR N
M93^04U?.45YQYTGGI)>T?L?P:AF#?FG^URSJ]><Z-6>U%P)DN:#L''(FB'O>
M+1FXPM^:VT5VLB_)KYTMF-H7W4(KI*)*;H!XKNWFE_*,S&G;IA_H<@N8=QT\
MK*]X1S=>"5@G+)*YA9M]KAP.W]6.RA:ZP<4PWAM55HLH\:?]"F5&]VA9134$
M9XN<@F))+S)F6 PM8Z9+#1/U;6?U]_LUZ?=#3?I'.P^_FJP^SXFM5UI%M&6Y
MP'0#HM:W:)?V'S$0Z0R\<?A]ITEYQEX]!VGQP7C<U,BG3 LP#"GW>DV[V/'U
M[<;-R?WYF\O\Z<$%EV#PJZ.?&KY[J7P)"7PH3U'>=N*1JY8Q.R63N%'9FN<O
MXE<'AQ_HX>A9$BT>,_\@-^7C2O]%L7$QK<^9:Z"*_]W@1NQ (CD(2Y.3.]<4
MX*/#T<D\=11U CMZ].KU/<&=M Y;O@7YXP,]7<61YMP;N\"[.S_NQB]_/(X9
M.Q)O[>[L#'9V=N33>-/\KRI-.5L79$'NJ0T<-Z/$O9J 40HGU#Z%]N2"(GJM
MU=NJ:9&T1WC>?M*F<ME+NLTQG-R?9\7>]@[R.G5!\RI8+N9!L(6R';_A2 *9
MPZHOT&#YCU,E?G"D6:IBI/D"=F/I\EL4Z@_-28\E%($O^TDL=]>EO==")25Z
M=>0E(\NGQEN!2^PHPFIR">CI:+KF*2@S#N!P%FB3=D-9)>LR9C10!M0)"/M>
M/' )YJ2<\W0R)H@'8^=+I%?<OLE=?BM<U./"Q]E(.G/E03RJ*$C]6<X.R@_*
MH^%(SAPC5I#8FZUZB/V.@$7&V,&5I$-I"3"NI6H6:9DG"(TKEYAH98@MOM\#
MV8<:J[;O7/G1B3%<7>N%1W_)&+<DTK_G]XLZS@FMT(G(D%B!!>%<=U3A?ED7
MW]F*M5C8EGX0*7(%H.DZX1A(Y#SNP,/?X@CN'M9Q)_OJWI!XQ6UKLF92.MM^
MS6-$ZQ_C;1 7]$!8VV1JM/.8?&K"*KGB JY,*]FS:89B2U 7T ]'[0J#*Z5=
MZ2'6OXMO/7R]'DYB?X.36(N3>+S!2=SQO<#Y#/97@U8E;J^)PBP'61\D$0,L
MN>9J.77K)(919#'XICAZJMQD60\KRK6,M<-KMAD\5?E/*!TMYZ'TL'&:GV5E
MD<]-],EPKIHT<7#7@5)"LEF>DX=W(I< E$%%\2[K!O"I15:*=(5)QK!_MHK+
MET^A[/D4BB;W5C)AT=K72"NJ9+V\56>J<[YU Y>>(],82'M\&Y; T ,Z,M_A
M6\JJK$NF/.1DROT[GR2YYF,_^DH>.\P-[6ENZ,?/B(>[9;FA]5F,R&<Q6IF)
M&\Q$;,>'70M%UX@0?XZE[[<5\Y$)G#7X_>Z/#QFN4U7),AXUL(LF+1MV=25Q
MQ=D=AGRIT.\G)(/HZ!V.$@GR<0D\H0U\;%8U O)IP+BG@2*B& ?U9O@HWGK/
M2@8OX@_<*EO=?YX5++::WM/04)[!0#+=BZ.&?I2<O,L^6;/MUAM(L::?[FU_
M\55R"YPK.R[;]6VN[T9>8HYE%V,(7#2);\INYQ;6Q9Q2COU$_HM(^PI:!N&\
MX*WFV=BB_+"XEE@)Q*!OJK)HY[F<QTG;NW,,M++FP/[;L%9WJX["OJ1D->M,
M6+!;0MDN6G7MAF?961')D+?CES[R#TMT+4T^^LX$)99BX=R_-C9T-?"W$N$L
MD;XX^F$L5?[#HT/+Z:!K/SG%(],U?G[S3DIKHOREE4ZY6IN5^TZUTP@5HP-5
M!]/HYVT#L^82-S-P4K >;$K/I!Z=]]"U,QD[74D+!N].<13LWM];X7$/TU,7
M,+EG!E(-&G1;4 =!XT2K[.5A+KHH%V@NY*Z^4-W]SBU;3-C>SBYOVQ='+WDO
M_BNMH0>T6;*BWA*0>:\3<:$9''0Z_/M4=9-ZA=6 TZ]5_,^7/[\28I+??AYJ
M4(C7@O*#+FT* )=<(6=P8M6,\B2GP'_&S-):4D'#/%]!2/H+P4PR_CSY R=#
M5:!WE+$*N&6X[O'OW4</!_+#DZ=BY?D?>[O;\8N&P6$(4-<T\0]LU-$ENC%<
M8-(1^(<VR!MDH^GS35:=(D]0*YWY>FT52XY(2T:GP35R#:Y\5YEO/[\9CXA/
M7'5G16(Z@](5<+5_!*Y:AZ7"-1-S.4@5*VA-,6*L3!8#4ZHHTWG!(O8,^FX_
MM3P=:\@O-UGDZV61'VZRR&NSR$\V6>0[OA>.-;F''#%;;Z!WBW,R/A$9_RJ;
M9$D)K.?H"$5T<DC4JY**&6@*Q!&%[0U/>8]T:]-ZM!4CPY.AXQ=L\R\R\NMS
M&"W4Q#2P'O&(&50X0N]&,DIK84<0TRZ(_#.4;F=B>.-D)%MH)FE).F0_ H>1
M382:18XN"#':049W'&A?CA"[1*,9HABZ;E:II68(JK6@:9,9.G*X.6W;G@/V
MW,-SD1% CK7S2)X%)!#IMI$F@FFS9XC:SR<QJ/![T5@3%<Y9>1C<PM(A^F?@
MDYO9B9*.40S:+.2@P/'K)FPZ8Q:O2IN%ZM.FXM.S*)D)!1E\(=Z2R!8'VTQG
M:5N.(799S)&F*U*\S%Z-PZ- .1J'5F<)<,69YNHE[05YKC<-;I!57LQ#:.XF
M$=X^!*DH!DV0^4F9=&.2+C)+Y(BHI4F:C4^3LAYTCTG@,00/39YX'98]DOPD
M0[4!T'ANGU*;'+Z,,"@CCXVO2)'&$H]?4B@NX6]5L^;EGT(?P3Y%ZXW2JV)B
MG=5JB5OA>CNH;8]/1?J%-M:8XFR=\1J5>I,XX]H'34S1&- 5PB*M>_(3K<R^
M:Z*#"E %N9Q@^"[WWUZ.M(3EP;W^/!=KY.^1KF=V+M-).D\ZK6@-O;\39<K@
MN):OI7HWBS(C,[=L=T\&W'ET&UEO.=<X> '^JT.XXO"C#BF K16\7,T]VA7P
M9YUNVXO"QY=6+2^[\Q5>SHZ$YYLL6SS^S/G[ST',9\R13J&6CC,YV32RO:.:
MJ]?)C,Y RH@^*=J1?/C,V/)KKC$I(Z=#U3$HUHT!!,PL9849_CX=)04=IGUA
M"ZRG.U-@0OF8[YHO/3"'"7(P,^!V8A$Y0Z#*ERU49%F8+LG<?8!A8QX?^"&2
MX'&=\-S%,DI3EZR42$QWN(P11'^^*US8B,C[-5UE,5=D?;-<I,XT!PJ,*B"H
MDV$Q'8ZE:YF;OBIWMJ$27Z9*]0F,(3)2&4"FW)4X8YE2'Q27R8EVF">U!O(2
M<[.P#T[.S@6C:<,>C Z/#;7B9M&W9,QHOK^7G]>:WH%R%#( ?54Z#GJW!V=)
MQ>QG/>/O&WODNW#M)'<JI7Y_3<5C8GTU%7[S_J3&R^P\0;IQ1K[@K/\JMAC/
MU;W\UH/@YU*NPCS)]#.GK5N%T=I)%-'Q/>GOUYW>G\Z0;C:!^(GH('WW-UIC
MIZ9))CXN;4D*&$ZY))><.)XL&4"DMYBAAX"U?_4SUHT^X+N$_H$;\G;\KLRX
MT8;_[KQ'7@OZT .WOMS70OI!7=2<J#TBM_D$2GJ+]"19T$;.1A2Q3[)F[I_Y
MGI0VVRMRVWT5VRC#2G_UXF#HYKUWKIW5Q'SO['_S"_9 G42:+\V/6AE9K4<D
MBZDAGU@\?EJF^^ $F>.H45/X]L^F!)7"%OV'_D!6LX)6<GL!SU$?J%4<[?6L
M.<OPU@'<A\ C,.H4*:1UD:,+N?^K49#&;^VQ3/3F.#.9C);5O-A&0X27[/.B
MEW3&O&HX0#@2(=37>85=P(6$_@UG3FU"$T&A5:0*JM4IRRQ/.ZNL43U![ ?C
MHF.'G$:X.V T4/QT_P?;^8ZN3I9X;5$,UPO5\^X=%K\9G9JJ1Z&PHC=!.PD*
M!'>OMG&Q3[BI<K@A> ?'W!)D_F4/1+RDI!R'%($WC^N\ C./K"YX]'+;+/55
M_0&79GJ>BL/J5G$4' 3*6T-#8=J=0GF)*$BU6G=?.#UP[IYW*C5JC"6^U0J
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MO"FYKBNY/MW9E%SO^%Z /<31)A#=(>N<HX)(/GN13<BORE/R/"J.=:TCB.E
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M\WF3I_^HF@4>]/$^/2A^1KC'AR]]\ @'_U$RX@\='P4?6-"!*U3R=1%I"S/
MHV4!EOQLD;*("MQ5W*48TK$BHA_J#H48)QP]P Z*3$DJ,B<G#&;,F5)?W >G
M(2\J)U#SO1G!A<^R#?!^=G<V2_P[FPIIY.PNZ<CCCG]^=_B %R8462WZ\H6&
M5J_@:;I(Z@+6A'W,<5*"'PQN)701#P\'04^]==]R<D2Y#%663T9E[5-,6ID!
MG)Z)RO2,X=@\+B@7'QZ:F*P.LLB]"I8IS0YHCV0H=7"AI!+X/)L]7M!">SV>
M%:)BB_J'M9&4&?EK)6L:-"RH3CM%+6:@^<<?Y0W"?_F(7D@@*'F4C/6-L1>'
MT[16QL<35WK2%EV_$2FVY3(P?S84MD'M)7SD <TEDQQDW-E,'B;>" _#W2(1
MZ04>2"!&C#$!X8K#+2_@:C,54J$]G?![JZ8\RY2BC5^>NJXB'ZEA+EX6T-VC
M5'@5/"..UHQ<8Y!YNU!G1CG=:64P@RD35)$/ANR8 $;3!H-B*6I$, SQH1#=
MUB4<_D@O'A(\8# ">I6^YB3 40N##O,0LQMO2'%?Z&_R.9E&5+$0B_"PY.F_
M2:S.WN[7HSGH\[T,N9&%Q5%N4B>;;*LT#7( KRUZ#-DK4^D8CP+--PE<A?2#
M2[5HDN,#0:VMKP*K'605,C) 0Z'-1\SN;*7RF3#Q!X7F"XE^L3L9H]>JCTO:
M?:S\B:*WUI)D"TO+?3<T;;9_I4I*TA*]ZFI;,13?#J0>::MH;V?O<8>M\L-O
M'YB:9&()1-"O@,XB..9" U<Y1I(.;TG)S<'?[^YM/W6M]2,P*#S8N7N<D#R+
M#V_([[H5FT>?\%)W:CQ+T(46[S[9WKNJ6]461*/E^P:=Z8@J!%FB:L,6P$F.
M3@<3-*%'/5Y4:SB O+6UU[QC19]=[UL9IP1]Z (+H->.6GO_,!P <P6-9TTE
MI[7WB(*1&<EQ8JQ^FOED@4G.(GH&\Z;,N;4,UBSTE20?G]< Y#&1).P"MRPE
MXP:-)4Y -0.O2DUN09"MQ.!/RR+'8'@>Q.?Y!B ANSL[FSS=VCS=@TV>[HO9
MYDL]V;V-)WNK'_)O1_'L/?@[W_AM #K=AG5P*WRM=][+!S;#O!UTQ%>11B+F
M=S! 1 6=U_DFK#DNV%0!P!9@!JB6.2(AG/*A%+6D=*5:C;0P>7IYQ8U&+%'-
MSA+_5?T<KVC=<P%TG"].17F%&Z\@"Y(WTA"MSA=SS_&+AA/E?*[64UO\9;$0
M8WWU$Q%300X13QCO@#Q@Z/L-XA&Y.2A<R]_HR3B)/4EI1%7MT+#)FB?G+SFW
MB9_40R'$%8W:V%KMCYYE=0TEL/D"0!?$.,BHGZ?@=APPSW@-*=&M*69G3&-I
MY@O1E0!G'E,SI/,%+LF0;HC!PS?\B*XLD[*?.A X!WIHD$._?E?IGE[XI"SF
MY"E6R;D;F,%6V)$TR,@6DU6,BGL!>*0WB'78(#<W/(D@(Y!%PFW0=2I3=NW
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M81D;8U+*/@GU$V\P5HJ.QL6,]D9A:$/M9P1C[B(I:U',<<P+ GZF>Y/C@(U
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MNM_*"U;NYDEV0I[@ EPIPA [2A2#DT,ZF15=>(7:)M%=)!,-4'%[MD6="9W
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M[E'QLDX[CL;3B>"EM_FCC_GTXP1T3P(>5(%U1X+8BG!L)(D#[ $QYI3+LVD
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M=N^D'4,&Q_/6Q1"^9&/S:4;;40\PU&:.Z'Y4;?]D#'?E66*[9>=5HW/JNG;
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MWXGI520_5X]=Y-P+D5Q:=#-4\J;1HV :/1F,5@C<OEG$,X@RQN3!:Q^J=_^
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M>@B:"W&Z<)B"4)3^:72Z@]N,Y:KN4.B9=!O+^X;@Q'HNE4IZNY0C<XV52MU
MD3SE+D[B?W<@8+,U7'O),*[8$3B@13:O[Y4]OS63?H$L]/TV84/YYBTF+'7*
M]3(V*.2B&?H(ZWM[>[EE!+<\.CYZ84\3&ZP35D5K:Z^8$GMXD?C]T ZA.=O?
MZ=V05*%G'(,;1?Z--BX/<7)(=L-$-U7\%CZD/<B@%6@-C,\<WAOW6-G8/J2K
M%2F:VI@6M>42V_P>-;H2=NYU5)+:0$FSM CRB/ .Y6E>5\)E YJTFBKPK!MX
M9#P9@9"DAN;"0O\Q1 PSZ0@N+?5WZOK)12%+/O04_B[V=9E88FJ\^#O8PY2>
MKA( #-5I+8@RD\[2I%L]0<93_="I 9-6Z/)V(G(E<$<),=ZZ#7TQ.G<I5K>#
M.<4FRG?:XOWH75VU#,OR<UV=P4;_U!$47ZGMD +;6\ZC6<?X0S@478)I0$!"
MVZ++1L._E4)U_GX2OS3X'6X-G\4?:D)>60ME%7]JEM=+C[+)V5I'>$_2'+GG
MGAB\#9H8A&QA5G?$[@";V=BN<#$?+-MX=^:U,B7"9\#")I.<%C\Q9766Q._2
MMH6-?%'-Q5>A]N.=XYUX0OQZ2MD68?RT0D$YJRK:NVZ5,,P;X9>1W=,V>KN%
MLE#U6O@!!$QG8;(Y D-1*;0&?X#X_1ID=ZLF$W;IM#^Y=ZZC155DN-SXS<Z+
MG2.R[S_QW!L?VI\-4CRWU5GIF?5'V(!$27YB"3B9+JJ*!GE>6!+9-/[;#BA,
M.P[JOAR\Z5_3,_EZQ+KCQ<8R:/B,WPU.I,B(W=8+P_D/O([@<:V8A&Z<>K.(
MWK*.N!_*TQG;3SU!,3?D3^ \WB-V,'+&=F/W0GJ"*3 9&WS)H 8UO]BSI-$?
MMZ3XNO&J?6WK!T#D2JXLL"1YFR;-U/M#!D_"T(/=R944_!A>+_C956G#B@*^
M@@?S[Q4HI7+[8&<B:[;CCOL2XSESN_<<Y<5&M_N)/D:P(9]9]FDZG2(&(_Z^
M!(?.#KQF@0H-'V3K?ODF(>IYVO$1J92?^R%B\IF0ZW-QH<_2+DQM2T*;0W C
M<"\B1+548O8\G9=5DTM\:Y'<AW9;G]%&,LNT:3VVS\P0,2JIE%]@G2FLSE,K
M.;U<C8PP+(-MIGDXCL 6WI7?+:S6>UTNTHM=9CA*@A5O45<LG%X\'7U1P'1.
M:/Q5 J5[JN(N-\/P;)QAV#[#L#?.,-SUTT &W^\)N0)[;R\]8/1I-&]+&E<3
MHY%_ZQ<UD6*\@0=I/$R'ALUEHT'J4PS:-6N<H T(#:>';M(:9%/'"?L/)__S
MJ #_'#XV![\[%B)35;O1T6EIBOAG^%/"-L2QECW9R $_)5)YYBA-L3N=0!;\
M[1 3(2A^%M?2(BIHO*O!,VY&WD8T"FEH8O$-&?HCCH_35=X2&PEZP8U,N8DE
M3W'8=Q<>J"C0M4":;PKPX$\(>87\9!L;AG$6IS>M9U97\#W:JF/8/[#Q9?3:
M>MOQB[3\J$BVZI,C ",;UW^ CU!UIQ@C_5J5F0!(?J@@VF\KY8C1O;&6==[E
M&2=KP5\BE[Y.$>$Z7D X59N,#*4\%N' 9#@94!. A>S(@!#Z<KVE0/'2M\1*
M* 4"$O^#$,UIYIE0*1.[%_#^";(; MI(_ZKRY&<G6)XT[.T=CUCC*WN>6-+J
M_#_PJ?,SN/[5= ?]C'C:A(S(N"AV$=PF:):V6"/K >;KIQZNBCB%$X>EHMG;
MSX=:D81:-^>4W$P1\G.:EQJY1.G&?:W[!\MGR7#M[#RMZU\]LF'\T,4%%=]5
M_;;<C1=Z+/I,X-F]?.CF&F9A_+6_&_GQUV,_88J ">TYQ3LM/*$BW%@(<]?L
M'FX\"9],?#.;CQ3I(UWL,>CZG-][MM$.OV7IP1?]?7#K\J1DNKT2:FN+0<Z7
MM@%L)_*H[ @0TM_?GKP\^F^0^>>/GS_??=BW;\\5I8&"6V\9&EJ5\='."U9<
M4GJBGH-I559+S-K1]5[48:)* /@UN66E[9>T/L5-L5+'.:@-98<K&%)T\&8_
M6]N5K0D_-Z5]W)BV2_"3!"B%H#]Y/^ +JEB1:KXF#,^VAGHW/[)W=<KV)T[W
MO_>8;N[C-"CCY2%*GM0_?.J?)F+V(;2Q@CWJI0'J@=G/;]M><B,3'1-,B@>#
M=O=':A""T1;?25?-9F W"(TVJNHY.)#(,>(P>%AF)!WJ4MH$1<:[";JX 6^4
M/-H9RA,[%TA9C P0\%>$<=%+;(_I/C +!2*^1$CPA9>="#!LZ*GD/C<R@<DW
M&+WYW1B>@P]FNC$%=5!PYX0^D&"^N)C-?RKD.HB6QC!^O@"TUUC4R67C+.Y:
M02&4$MO<^U08A*?I%,),VG^N]W&/%X$<)I$5(GR/F&S/E/8/"7 ,(KPU#:Y#
M.B_M/UZSGZ/]F E?6Z4-)(1 L>CKG D%[=>TZ7QNF&\(+OX(0U*"Q6IVH@_A
M/#QJT\:2MPE?A4[;RZ*NBXW^<B_W=G4"WU^^2YT/\#6B'SQC&1<9&5#^F(*=
MT9DQ]X&G EQQ].5+Q*9$U2, 14U;33]BQ1;$_(>;;3X>Y?(.R^6F8'J-/HAN
MR^4G7TJ;+6+ZY'-BBA<<1744U2^?MNC+*F5-5$Q/NH\7$=.GGQ'3D:3WNQ^/
M6O:;-G8J\G=*^"0)F9B @24[D1-3(WE'!(;)V4$B967NJ(J_Z_PL_ZW!YTI]
M:_0&X1:FX.XRF]^UZ9LV9S0_^H1214E:9.JG#NG#1+S4>R@//6EA\CJ\DOUN
M7ON+1[\PZXIUI OS[FHH$,J;W@8$H9*C6"):40&:G\49Q.IK82@3PC!R-!TG
M%?,QE&V-759!G/+M!^H6Z>,U2"LB_F-2[+X%ZT<-19Y$9R@B!1'SLBJC$SR:
MPD,CI2!)!/Z6-EGZ;X(.3C-*$2D$J1*<=86+I_G35(R;84-ERA#&EDB6D,&%
M -W+]B++LGTO[4[TU@K[@A+'.,(!:^* 6UD#\7<2LV%^6N)RXG\MB8E2:2#X
M4EZ?C@=CS.=1;(-QD*^@4R)^,HK-X8XUG-=3!#=N;/G,L7 B-7#CTQ72I>'?
M@E8NJ5<K>6%FE=($LG6ZK1!HEAE\NXF8WX\9\V;<FJ5HT-ZFV<M94EE\V2MJ
MX$PL93B9O,U4G7 ;2 5-F.'X.XCO#B$UZ*<(E XC%P>,X-1)FFA^N5KEI9>9
MR9NF\UJDAN:*&"B>@)UGIC:NH1=664]SYOSP'C3R<>&G:5VOE:"A);+RS42/
M$[1[GTMYA99Y [J/R2=).H8\(]O'E0;'U,]U-"*;?J;O' 4AL,6VRNKY9A'V
MU?V+N:K#%Q\,HPW=,+C1R:MCNHD<JU]E,>_I,SY,LU-"WOF,?$I&ZI#0]!QK
M0N2![";_(E+>ZK,W]V]'71V<8H+3DX3^AK0A.KC?2"Z8=G!WFF_+VQ9#*B6S
M %7'+H+W-^T:QY)6R3?>.IG@?XT@HJ<=0D1C^:HZ^^;]@LLUV3T?F^RV-]GM
MCTUVMUS8M5KU5NL;J*W>Y\W'^^8&ORT5Q#W^:) !MYPJIJU73-#X,2^9X<G5
MA;0CHH:]\SOT5DPKX%=]L@H>@'B3+&-R;-TH<O'(0O8NY)1RA+Q+H+/)7[:7
M0 HA=*8;X5-I,61TR],'$M.&+5*+FD9L7,F+O$,(G0L3- WH!Q6L7I<8V27U
M2F=,^I-ER/Y.SX$N H8)EK<G)R3[E1!-ICAZ1<&'+I>L*Q$:3[$BEL2;K\ Z
M=05$[QBY5F4.%EL-&U52&G::M5Y'6VH^K2J*!-3;Z)E1OH&-I0/?D<BBR2_)
MI$%%C".1 DRIT.BZSJR'2[Z+Q^P6K,,-=,&;6S4D1-YKI]6TZ4>F<N9GM/3C
M&+0C [2[6!(Y-A$L3V)-TL(T,X$TT8.3L6<F$^&]F*QE_HM6Q]MG"5"\!>5"
MGH)KDH+JT Y&U"RK"W9\T^S*%T29V&-R#]VKMUV]Q9GA/:'K\S)YB7(KC22K
MWO>C59&B+V6W@=L:JWF=+AM>X)H7EZY@K5/*U5YPG9=RJICA7I?K\C5P$JA>
M+4&X]]7^B^S7I'G9<J!81#<7\,W[;9,?CX?UT4WV2^[?EB#/94],@ZGGO%EP
MZQL=WLAW^;<=.YZBO)2L\_$0ZX($]S3)=%;C'TM,0V*UGACF,#T<61859UET
M*I4UB&E<*L [IOZ)Q%>O=/9#<1XV#JZ\;@]91.-6X3TQFHG3-"_H+I5VRV'7
M.':4:\8#=$JM*5G;?VJU_YF9-'E+%8.SL[.=%/^X,ZV4:,]V"3'OH)II<#NX
MTR#4>H&>0BVX?1,HYDQQBMLTC]Y^*L"K.9JV-G7E?1,C4Y?7\I)5-Y8:V??Z
MC&\':(._HB.R=U;;W/32;HN*^>"R&/%PBB+" Q74A)->[T)8(B;"P U4 5(]
MV.^:YK6O8!:IR^,J]:3Q<EMN;=' VJQC>>%,JB:;)NM$ (0,YQLY23IT'D.%
M%''BR3N)Z..Y'53MW-/!^"UXD4>/#AY,'C[('X9D=E3:P9.>>,1R;B_"IOR>
M\L=A6%AWFDFM"HMRK:BE+&5@"\^/;7"@@Y\OW^S'DF?M/\%F$JVN<WRG$27F
M\UXN/O'B"O,IY5?+M<3>A?G)K-IMIM6**WG>$(DFP5(:@^%-R&M!2"!SQI8C
M,@19X_KU!H7%=NXI8V$:"\LNJ&AJXMN!E8NYVAH=^%(&NI<"./@8C[)$N*L=
M5^VP=K+AC9=@2*F.22RYA& %-Z>5R<R.FHN!6.?>I[Z]=E DJEQ5C4I%U'_C
MN928&W08Y@/!X48':=\KIQ=@7Z=']9UX-:/:D#,AWE7.--5%I-&>)?=E6:XX
M"#"&+KY%DGHBM!.?X*S\# /B@?4/A<2L2,S8F#AVU6Q? 38G-!8^2)IOI0#H
M9\G08GDBR6S;-C5BQ5_R$BR4;F9,53B)J#UP@S;)_UX"MX7[KFH$K$BMNXWG
M:ZYEI8M?"*[D930F:V]]=.@'KG)>$@&O>?I0>>-3*05O1A*J#>3Z$I&YK>3"
M+L[YTK.UG[$M?<4@A:8'L)2P *6<WD&E>FAYE[G9]369CJKCMJL.'%,TU#+%
MJ&J>TVYE/I3!BTB853T8[K([2.DSS ,RJSWI$-]/3KMVP65FLL@\JI+R!(:G
MFUPN+LW@'*?3-3?]87^+S8NX',HHZJ.H;XJZ5SZPDN]Y]K[[QY**316;6K=9
MPRE8<EN$?%J=Q:$[A$U'%SA&U/;C\9 KP['7R-2_,=>=!JTZ!:)47"'$/W!@
MT4SA%4NN3G6U>A#(9-Q-;6&-MN VG*0_?N7+M1CL[XXM!MM;# [&%H/1"GRS
M5B 9, &7=H0&C(93S>2KU(* Z<<2FFA(PN*QW[9V?J7X-NCJ4=YOB[Q/37ZJ
M\NZDGQV#QCG[EQ%K[]A03@'+8P.2K/Z*Y"("2%].= U&LT.9 ,DB4/FLH'-)
M_2L6(5+&T_6+W"7$V09!K"*<WY^/CMYYGM#$F-+KLMQ0 35LNHO%9:LZSE12
M]X>_%KQ.X3>6V+6Y'E#[.\R'S$Q=4Q'C\F] \@64#^'LY1+9#O#1;8FW6BZ[
MTBY^8MHS?-HO\4*S8%/XP1OR3CVON3#XLK%;O9DN3(:5$MBEKDPSE&J#NA8!
MC EV;510HX+ZHK#L\M)+&4L>$Y/)+JD2#>8;&2**^P P+FH1CEQJDF_L4JRF
M>BFKE9SF$7@+:P20 ,'_R5[^&*(IUV;PGN9]Z"-O;5^YEC:#?.O*IP^8Y84,
M.&[JRR-^O/>JT<OX)U!^L+V/_DZW_&_[S ,?^>_Q+(YG<>,L)@0AI.U*0H4C
M$U"4P"-CME[)-) SMM;0R=\0_ N+U]JD0\;#_P(/GDJ9"]WKA'"7X98$?-R0
MWVO21HRJ_9LBP&A/'I7D4CJ <HYK:96:@\G)1YLSRKE;P5>W,N@+>:.]FSIZ
M.- +:$A</RJWH'BNI?-=EZ9=5%F#S%ZS1Y.TH"/0++#IH&GK#LFDPF:R2G@U
MO/OR6#=>>,0;&4_/'_'8;-"!)X7*,]2U305DDY&>SLO3JJ#X,ZPD<]2":6OX
M&\4/>:K-$*.J'H5-5Z#8#D&3E:VG;$$P3>0/S@FW?Z!Q#\:E#A-\>),0Y/CR
M9@!4?\-M#L:[%HW#8 PN74Q=HSC;#&M&O74<"(R2/TK^<&"<KLC1Q9]P+*E.
MRR:=AJF=4,$RX'O&LUR&,$&Q2 YJMG7M<HH-&D:>W"&#]W(Y+6EU?8T5S\/=
M0QI6M.WJ\0F$FC9>=1>B(I34*2OR_4<!'P5<5^#'E^PS9.2]:GQ)J>L5IF&-
M%JF#O"K-FV S6)H3Q#]ENCFAZLNRULK]!E"G^IT&=R7TVED$26&[#"Y\:D9H
MUM(]6I7K)8UF=I-E+GH>%F"$>).N1E=.+2\ _ AG+@ D^7>'A'!529+IK:FJ
M!_+IXQD:S]"FD=ATD#:C4#^-_V6%@*IK<017''T%^<$BT.# IE: >)+,0F6E
M+G)0Q*QR:Q.HK74\]$;>O"906R"EDY89/6/8PA)TF&&,7M7<><W-E-(G+LNE
M*_ L':<")',D>//N4/M:!^&].AWJTZ(:59B(<L0]*&'O^&?^8H6OG@H(9FC[
M_4%>!L+[BDO<X>0<S;W 39==,2?_0,I/SE4^<E\]L5^EIN+$HJD@)8 TS;LL
M@W3P80"'RQO5U*BFADV]RK :^@4[FQ@+6;-)S>F(]%#[MO0+BM7W"P3RTBUN
M>V.+V_86M\.QQ>U62OEE9H2=98M>$?_O.#3<QR48&-^-PN%?QT[#;&!2$N]/
MJSD'AJF6O9%=*OP1,GKNYG?!49&$PM,'V<,'CQ]NIA4BG>]M^@YBM5K@U)-@
MLGY^YE=!"%Z7R#IF@7IZ,Z\.[D;19DP6\HP[=XWU%D2M%A@7?+XR5RH*R]L:
M\OYXS=D5+N@VG)G;-^E_["-AC /_GQ_X#Q!W0B"-FYK[CW2)?V# ?^M!/F=X
M?PN,"E."7!:QX!QL1U1E*=%RV\A0GR7 Q(1#S\@!3R:/#OS@*QK&#^ V)+A9
M,^OW!DZ'T49X@QRPR3;H)II.9\3MG(= \/\C'UM+0_89(3IAV,ZI9]!7\C:"
MYX=X.Z\9I(6 @Y4G!S]<I->&67EK3^K6B>]()KZWB=:5#7Z/T?)MCY9=4H]@
MXL+AY'/*GMPA97\[#@2,PG5AL "AE=9RHP%]WZ62<FRYW($8-5F>4?UP%E ,
M*I!6$S]P^=8M0OIP%,91&#]7XYY7:2%X_@3KC;UJ#O)?>J+/TX*<G=Y$UO>M
M;>)+^3D7=#,KVR_<R(<";0W'JE#L#477<YA]FT^82/]YVYYS?B[\>'&!1[K9
M8%/ D5Y]<"FI;I8B(+8N*@RQU^-Q'8^KM1WV@%(;55JD=8Z?GU1EIQW:VMCG
M"2(A/A3%P*FY?N$:1>QVB]@VBQ (U"J=?DSGXH:4<&VG5VU'$S5LN,Q>^)VA
MSW/L:AHIBH[>\RB>EYU6\P#=R9!3FZF5, =_H^9:G&X[>.#$4AC*2'#MUR[F
M]/1N>WW22_\%T6@ODAYY!++1CO)^M^1=ZB:UP3R5*;.4@SYI: L[J$.%'4"_
MHT"/2G44LF$AL]*5.XHF9;<PC&6N)(RU;7F2SP5"-S@L:UFK1@$<!?!S3B<)
MW!DUP"W33'O@J15P(_2F&(ATFU9_<2Z5K\F77-78>R]-@H%DWP99O'9PK?VQ
M\VA[Y]'CL?-HU*-W7(]^WELLJG+^B)N"2CQ4FWXC,P?Y</H.@(=(<MD;"'*S
M_^[R=OUHDB*DCUP _IJ SIX:$()4&#;/L#T[,]BW[O5!2Z,SSE9QTP/^4IH6
MWL'%XB/A^JI3KV6!RB'^?:F&HDT!$U.:6=Z.CN]X7K;E4PDH%UL%:)BZ!E%"
MYAKXJOYRFC8+T.-KAU,CT;[^W3\V^&<5NK2NT47F[Z&<;OK$FWG90'['%,(H
MY&,*812RNR-D8PIA%, QA3#*XBB+8Q@VAF'C>1G#L#$,N^]"OHD48>$*:"#$
MPT"L2H]JQ('.#W0).MJKU:K*R]8="XMB/RK:408W>\^7/I&F<"L';33'/:Y.
M$+M/ZS@D=1-<9_&&/:PJ?T1JE+]1_G0%B,&BX90/FFWG:@:'3E$?NH:KXWYG
MZZ9:E&OW158%/7=,O1>A A\%>!1@JT!)LHIU?W+!S@WZIMG.(3CLLOZGD%&W
ME>[![4DSS%9@\J'"D*J?+I,K2'NBO<4( 32*;K "2GRUG(O ,&O6U10Y*8JE
M]M,NZ+6&G]E@2\Z7+(S=2H##/ R*_G1S+Z5 *!(F0VY*I'KH&+$*9Y4;%>)!
M-:PV O3T_8(4.A>FX;>*&^PEUW2L#<S1SX2C1NIG1&_X/'I#:?<Q"AO!YVX?
MKQ34P4$C.%B$:"LLPK4".D2IMST>G .MN0P%\#,;=PX(0GPQ$(3H%H,@W':L
ML8.QXV][Q]^3L>/OEDCY11$\8D'P"%50]!D5='7 'OQ?7/1(MO'-N,T]7(;S
M.QN090;19GGBUJ5D";7-FN4Q*AO%RV;$",I\MB;0.G5_Z >0E;K+VT'!\X!
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MD>LWA-<SB.TA;/XU__$W"U'WTN'BR29MQ]VZNAGU[_KLHE=R@U>%X!V0H/F
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MMA5&-ZE<-$J+,L)]YH7NR2]=,! 6-Z,@!@&=S!3A",+UP7C LG.Q#&6:!$O
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MR=G.H/>F=VJ&-F(421<PN5I,X'<%E*]#CZ"C2EG33+C.8[^YFP>EUUI$OJ7
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M>!?*,F_\5.94=W<LH(+T4K'4D1C[!8*-3M>]-/MZ\#2>L&=G<-3S:(_-CX-
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M_S8I/OHZ2V\8+9!$_[>@Q%6^1 @!HM6QQQN+D[W0JY2:&QIQM3KR%'L,B8C
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M8F];V16S&NE0ZM"5VOFNWX:/8R(+BWQM]W/#\8NV-KU;NH6QP&I"!T).H15
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M/LE[/8^8V\14;9]B!IZB!%H.A_;(*T-&RGW\SWY\LG<<[Y\\&BHV=B3%(=G
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MA'NCIRV%ZE%$5$-&>X^V+K81NVB9'D.Q=8<)# Z:))G9<S::)1IEO'!>>S/
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M'<S*7^(S,F; 4,8(H8JJN_9;R]YU/*5._B3HX(56E7GJ"9GH6.Q*Z1!]2ZQ
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M"1=*$ ^;Y5>.>94FZ]\*K27"29>R>AR"R'X/7BA0^\%_YPWE'O,,!"BX7A>
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M54UYCU%8/J L-YOHABT;#WP'GXELS>ZE-GI*T_#TEA,:)@B5RKN9EM3:54)
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M//?1O\.;S[W?J (6VO4<)?$[O7 LV$+D#X@#EF*Q\6JB$"2<2N#UQ9[K+/F
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MF69,$8'440A$U;DQ]IUE1/'T!&O;/WH5DPKD85WW>J;Z:&O^/FE%*@Z>A,$
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M?QMHZD/_]OJ7GX?Y"7/TLFX?^W>]_J!WI]*_!H^?'^ZZ+_0?@Q?ZGR^]_LM
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M8'ZO:-5V1:N7J\CO*?-[O5Q!?B\<O]>U2AEHTT%^3Y??ZUJGWD&&+QS#PY2
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M)S(=*A2[!=4X=F>6)X57/4$U.+ELU8Z?'51YPB&5B>G0L8G*+A]+Q0["5:F
M?BD4P*K0+P3%-OJMYRRN/$K;_2<KMLQ&%TU,7G0OGK,V[-G#,!L"=UZ+JW)$
MYKP09,XVQL>B3:"ZY9-U@ 4R.$@V=,<Q#K:'W[W\(]Q=^!^E+/X_1A0?08Y2
MEUQ)/?S#T+>SO] ^>>N$;F#GNRI\^#'V$I2>\ \ZFZ]6['R83)SQBA-O+G#:
M7:/7W4GP\N7D%_;A[!PT6V!GN?8S#$'<N[I>PTNZJI"!YJDY<NY=WT=?"0L*
MZ8R.1NZF1NZ^[E@]L[># O3BHC8P\N@]'0ICG1\V8W5/+@>]/3OE^ZE]*,KD
M[MH2V<$N^BO*XB5O6_/"P%--.TA&GK/:L?SG*E>EZB6;W9368=^4\Y/+3K<V
M0B9_VNT="^ C-^6YJ;\WL[D>/_5.+EO=M27O=OCI6!MY@*&8(T$.PCY8M,B[
M9#;C>C'+H\'H7A E(6'AR"*8>,&3Z?HL<% TH=D M_R4_AJ'EA_Q=3]64![O
MP@%(['46=PW*%BUA$Z?D[.O0J@R-P\BA2A+= H6^U)PL?-$'5_^YVO2_JI/:
ML*/P&D>%,) 74$6UA?R,0GL3BA0)FP-]@[;#J##W_;4.9&#+84H'G&:< 4=^
M#$)!3*;EM2"E&K<@9H_5="PN3BZ?;<['@1YF;3C@_H9]'HXB_YB933ZFBGWX
M8 "N.=9(PCW&ZQXYX:,[/M[EBGA!X,/Q1?!,@7X>3G'JUS71KU7GWIXWFZ!-
MZH=B?_*+^S)GHFQ!$U^5W$]0N=D.)F-BQ]@=>0ZXG;&8\^I,1XZ-*MIV0O<1
M'-/'ZLDH!\D=SZNCM=XE?(^O_3M%96QMHFA,Y9;8)U00^+VB;^D@BFH1T,+.
MYQ>=5SB\<1="8+!!^\Y7H[WE?-I<H5?>'C^(&:P[88+6SU  =J#>,XI)R8 W
M@O_(I<FX,*O./SUOMD$.]E_"_-,M*/2OSMBSHLB=P!OI6$!_@Q/HVHGE";/\
M/K%""\X*]#B\VPES)6%QD/>X7P*;UK[@^VMP=:"4>^8+GF?0F\E7P9[_0.[\
M33'G'\B;>G75MR ;P*AW^3O@![6>JT_,,0-Z@$F.(T$./@,ZC$!)S8(005!/
M;OP 5F;\X,"MMA+;)614 -+ C_A?A*JS\-<CRR/-%3TX3GS,?A[OP6%+ZZL]
M5IWLWB38%'%73Y]W3RX[[<'/'=)8\WPVQK#5.Z'S5Y7'7*O?QJ(Z,_F5(^C]
M.01+%E99CX$12[GGDN CFSRW?%N'4?H(NJU=<79XY0[;Z#ZT!"K^+8@MCY==
M58?+?[4B<P9_</R8H\QH_V?,^R-T?3]FV4Z!Z^?-P;$0XD5QTV$70IPW+PZH
M$.*O,28I*#A]:1B&B"IO.KLMN[PQ2LQPA07.Y'KVM)QO(-@QA3B%#\PQPR@@
M!2'\V@?)'SOWH>6!G@EC(YB@'HAJ1()$QR?X8A3#+ZC[UMG![+GJ".1Z_M?I
MJ?G1=3S[%_/6NH<+>^?\*W% ]<':>N>_FA0:AW^;IZ?BJR1F^,M:ZH,7>1H'
M\.96&SE9_$;R=P]_M\PH.RD0R,<K[M6B4Y$P:A&TK&;)JIHH93^>ZF20!/C5
M_#:?P=:'H35RQ[^:7T">,)&^!$B-<_U+?Y7?(CK13#A)H2J*C4+'^GXZ<D"(
MP7-G1'Q]N;V2Y2)E=1IIK)$>=>7+]?7B/M(SW19W;B ,Z'\L$JB3?S;1E?_O
MOUJ7N[TUY2-!A^]NO]Z8O]]\>G_]Y;>[AGG]Y>J,IW\^TV6NF%1Z\^W#G?GM
MQKRZ^?+^PY>[#^_Q7W<WGZ[?#[_!#Q^OOPR_7%T//QEWW^ 7GS]\^79W ,M^
MPPC"B"WK((G #H?G.C_&#M[Z!Y:^MC%S0O$3B%7K[2&L7(G^':VF\LWRJI2]
ME*V++\D4'C@N ,3P9]=/''L(9M$_;\)[RW?_3=G.*Z6SX <P=F[9Y1&9T(]2
MB=TI'?9>E8-]@S>\\X+Q]]-Q\Y_XAG^"9>^ 231#/PU7G#.VMOW>U,YJ#SH]
M[)1,Y@T<H.<).^I_G\#N5SZ.)]>.'_"CS;\HY00>JF?-(I#)\E_J3R"ZL-<;
M'M^/7T^6.+\@Q(M>K7AANSO[D9.5E,>*W'\[O'+DC<N6D#M%(W_Y=_4S(-_W
M/9Q8Z,XD- .]W'=)Y/I.%.7?DC<CC=VQ^G^[BMO=2\GQQFY?J)-F^Z^MKP"W
M\+ZL0/LSB6)W,E^8[QS-PL#\/?#PTL!#K_WQ&;&'"R(Z2D:1:[M6Z,+[C#?(
M(O_U'X-VN_GK%1O-]%/KU[>F"V:S.7+!?AX_^($7W,]-85>#BV8CP (LXSB
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M)]H-G:CF@Q49H1.'@25OIV7C6>-*/$]>$USQ+)05$,HIALUYM&A8V-C)-.*
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M0"9<WX:UA',M3MXP1V"%HDWFN5.7]7,C@U48,=0"''S0].283 -,%W#G3=L
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M/T(F2,_H5&7+#'BD&L!^9GX !\!TRVU*V)<-#RXC&&7'HF0\=J)HDL#ZP#_
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MW 7:@ T,=*=E"V,!?1ZY$A98 TJA6,\#+Q',0$+ ">??'(DJ(# [YU&6BGX
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MT)W^%-6MR6LO+1H<] ]FK=V3RXM6H]/I+2\AE(!N44!$#VL0]@^%]3(9,MA
MAE3LF3SJXI87"I3SI6=S<1@+[9U<]@9EHY7R@A#5)LYU(.")E.I'T;8,A9?/
MD?+XB]T"ZVH/,VGWRP=KG9GO$S*>T $1T'\UY]V5B5^>[?$(II:T]0IV(/JF
M(XQ/3J3-B:!03^8RE#L;"&@/ERN"18EC:6.SU988*B6E!4"WLGZ1^C>I->'3
M)/Z5,ST"]?,HIZKG^X" T>L!-SC>W)!E&-07+8<N9BAR116%&*V;A?16PIQ
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MN9B14L4>R]IK-<F?B7QP? 4'+J'1'OA*-U#]*BVDG/Y&!?TQ1T_HUC.E+@E
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M.Q;'[S%R04=2"3.LQ]E]0A:VNONMBS]RSO.&3+;!.8.3RT&OMAH[O'X*VVA
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M_DV/#].18V.O*%NE]E3>:GXT0;;!BE6V_D;>5']];^IU4FY=W7^QG1:@:QL
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M*%SHV+-64'AY,]!"4#C?U47$=ZID20DL] CL7&;:Z!/J%E@WA@6_QA;M5G9
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MTP_^+);=A&D#&;>F?6#BJI<EKB)"GBU2BY.+XQH%$X)I.PO_,\X8?R>WT;J
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M#YI@ES)H("';95YN+*ATRJ2S&F>0F$>!)80.,:7<6;@97CY#T=JJTYU)130
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MHHO1_FM%^Y"*[ZF*17/4 )6;&5W-^J$7=Q3'^F7MFGDGG8;S?8U,((N8^!'
M'! '=!:AB('9>&E!. N+4QT#,F@Y'ALK'%0%J #\7XC%P:9N0]B8N#V\TH^^
M3I];.>KMRJ06H#O\@0;KKL1K;RS+GS@S[!S?>()&'UJ5%:F%"Z+2!#=J\8%W
M+)M $U/IM['=VE+Y*N$O_%/N,M5!BQA^QK@5[\U.BA 2O: JWPF?N'!PDZK^
MZ<.U$,URB.%V&2"!!,JA/(L3+HU%!@"CI:S!0 ??]B+=&3PE(M6J95Z*7KM,
M#\JOD)'XS25ZW[]SKG] )F-M^Z]P0AM,8AA &%E5KQDJ_,+R+DB!H (.O0LU
M-VO9YRU0-IP[*\IUUS#N,US9Q0!OPW@U<0Z**G',G*J84=DOLV7R_T;LV+OY
M%3&+;4"LP,*ID'C: ,)BT 4(BU8_7D>N1<M<PF7/89I%Z154P&36O>CIQ]5H
MX)/+6YB<0[Q8N.F3]0OY@0)BE,$JT?*FL!_%XFFYL(FI(J;!1QJ\@^0G4^HS
MN?:/OC8]Y!!N==NK+H(@1-OH=N.!'E7S@*%YIHUU-5NLVZM09_1/+@<JZQ<N
M%]9QRB-Z#CD7EA+ :44"./_S*,&>T>0 >/I03KAPP?U3S>33+4+N)5D4KD9U
M8'D>&!Q.M]6'*N=_X&1Y?6HM%DMS!K$5Y-B-:?MNSU:O\-763R*!-G47"W/I
M6S_K_%_B3X2($)6!L_CQRPG.N%]Y_*T8_R"\Q0]GY2Y/6(9H->-?8B_L])8_
M(J<&BS[W[?]:=.7DK\^7[0[AK>=+<7JK6>R!V>R@>K!,>>9YL/'JT?>1_^?A
M1O^.)-]B+64ME,:S<@7_L"_E -<]1D<ACH9TI 66SY];J4Y\.MTG' #HTLJ?
M,&JU[7H:#RV&JBU_LU[,Z8<^>2:25?C#'(*;3DA#JX?\!URU!:N>=(@.7KK,
MFS;7JU?7P\+VD"4I9LIG6)+=XAI6J@*A6G4BUI);K0Y.+GM8+:>LF-,2_#Q$
MV,JSNQ)]KX+IRVT0P +;QJ#3,CH]A8(--K@4EXR5\RFYXPKN).(66S0'*_&"
MH0<([H8F&,./,09< $!ETA\"E.J4^Q[4^++?!36L[),O:3_7(C__$OOYU29O
MOXK]_.L&/]>^QGY^O<G;KT.%Q>S#FTV><",6H(&^Y;%"7?P*4A2^:O!CY,'L
M.8V+0UT<<O,=BPH!X9K\;GDO"(FY6,#]PH+>Q0>/[, )RJ43:8<(WFS0A(Q=
MX>%JS@!H++C2L-GP]0U7O2/@'2^D3&@W#G?BD?^2Q4)4:(2[GQ&J;$H-Q^"!
M*"MD#:71>E^VHZ"3"5#^#)ZKMX,LM<6!T>B3((H"%78_$-MB\<'X(5TNA]R>
MVV\W1?6.=&1!U@Z3=K<,!6XS#/K!Z.2R==$:Q"6U(0)EM+!::MUD 2<&*0].
M-+G!,UID0EPG ((\)XX4\0MLXDK%O"<I!UMOWZD>=83]IHXPI8ZPW]01[A=H
MK4#4H$-%4*%XP_:HD^(9H@X#<=@XAKE-$>;YA8*NW"S0DMT[A/24IC+-+,#C
M0 C0=U='G4-_AOK_%\D@H+6.<G\09"Z2W^3.-6&O!%YE1H!V7,)]K,C!PH'<
M20YDLG^%],G?)[%SSWC8 L<QV35.2($VWD"X#$E8WA,IK/+ PRJ2-ZU%O6F8
MN#"+^ML3/OX+?6U1-(@)+NP#:Y_QODY?==.)L8%E07-]9A.3<>5Z?B BV*5;
M?6BB9S9'D*-=QI2NY@X.VSGOX 9 _.5V<F]Z=QX.EJ#ID&*SEH< 8WI8*^ZB
M_])JQ1.RBF%N)D_!1F4CILL1!!/[[7P:N4 'R 480^)3VOZK>@X%\X2UP!/F
MDQJ"7#"?]?#*'HVM!N8,2N5P;A#YE;N@!3XX[\)>T,^GXC8RUYBK0T1 T/_E
M4L!/F,%%GBG_T=#XITMQ:WT68UU@I9@!]"#*T5Z:*U34M'#/7!BT20!:)R%@
M@)VN'LU3B\IW'J9UH 6/O &1M6TV8R'8C7^A/='&#?A_A;4/K3;\K^6Y>>ZS
MJD,OZT+W,A@_+2^[_=7U3R[A\7E8/&!L)H2D>,]FI7T[TJR)9K<,LK%U$SMQ
M%7^:GF<Z'&3CDYOZ- =$W.#7+"[2@@+154X!T&L/2AB@X!C<S=EIW7E85U/D
MJ@TR!$&O/:S!*H=8%:FT/A2S=201<+\FFFRJ<ZZF/E+D0R+?IS"GR/IA>5/;
MQWAJZO2I]DC9PX&( G('!W_!=?#@)\M["V\-ZI([L5X-!CLDRFG8&'<T4:\F
M7X1C><OFVK(MW4&)'RHW6IL#/Z/QXO]M.G3,.9U$WF%01391;T2AV5ZQ+4?:
M5OBY\XU/G!DM^)+./$Z!,9UJJ']8IN?'*!%4%$FIU<8+BC1CX$%"2\.S*(#E
M\01LD=$0MU5.L49G^3'NIZTVD2L2\,JK^1U:)V2 (!@EC36YU!B*_%(\EC;N
M:V#[22-R@J*_I+DR9-7?+0'&*&<Y>;EE4!T<&G@C;V@5O_6 P+."F4%!0@1V
M"7->7:SP7[.Y2^S5GH5.FXY (^ ?1A!P!*P0^84_Q]9'@$$*".7'D%-D2EQH
MWUS]G1$-2?T<DDA!>B+SR*-H3"$:Q4ACBK>R$THA*1[P>_1DQ:0BNA_HQS*@
M3G-!^VZ)D\&Z?ZF?0'[WMI3/VP_.>V&^\TI#C<XG)_]!M@%C?J<2(B9_C\X@
M(-@?WKF8;\1#6#P D ^=6*VZ"C_7D%S'5P^7MF5%'=P&A77_Z_\=#X;CU*<5
MJ*HCWNT[N5X,"Q&[Y="#_N4 JNEJP3V9O%,)WU3',R7Y11J2GJ/!85"LUUSI
M44"5TQL&<[ R0/S99W]7%X$GQMA&+8BQ=16!SB6.WL-GQV]!<P<:"1I^*MI,
M(#F#F:S=%O;(\Q+E,!(? YM$DX=S-"[C!68Z2P,YWR7/U8UXKA# -24SC5I(
MOX 4;P1W([A5BGY.G0M$>H3_H#8V#.* SCG37U$8'B';J9/&2DQ#[@+"+/AT
MN!:%)\S2 ^.MZ(&X"J Y&-C!$P4;VE GM$\N^SW(O*BU OY$IX<,:!(4J8!A
M([#&H>6".(0&^Z^9#3E$9^9#1[GKO9@.0[7$#U@I&?](^'X+^R_KC&';?J1'
M;#HM9<0F,B+]&^9R[N82H,>-ZWUE$_8@7/-J81P?21<F2>?DLA,?DQX:C0X>
M+W255;%4VOPT 2'X)P2WR,I$G,FSI!A;>)4P"B>VRG,9/(?-CPN!E-"!PJF"
M%G-!#D.^A*:ZT,YIA54X,@#'33-H"D'/XPAAN>V'1O8%#*XS+A;SY:$__)O[
MG8:H@_[P^"\HIAAGSTSDW5ZG."H0,DZP I^M@+'21M</)M ,QQ?#^/7#1/T<
M>D,M"#2$,&4O:F^D[;YZ:4Z#>:]L5%*4PSW1,:"%0:OBR, B &3CB'+!:)@[
MQ?G/ -IKKR!JMG:"<=4T> -*@@:)Z&LP'D0APZ2 $&$V#94/@[M;+.2J9QHB
MBL2/FN //6;YN,A56_BJT \2.#@[@[S6,5]H1#8(^")NH)!2;' J'@:74K34
M'6H&P/[DC*%Z(<2D7=UW(2EA<L$&LS,P^/AL^K9O,*F&<ZS%C;9##*N;'+^1
M=^RS=U(K!6,6BHK]?/%B+70S@->?K4!F0JDW0T*>VMYT_0:I#8HMRZ&0XX/A
MPUH?H:ZB:CYJ"1C:&[8WP'>#3GG$M?BG^TZ>[1EH9A$&"1$*19\1OMURL#AD
MF\@!]7 +EG#G-7P@WO(PE2_TB:B"A^$7-K@P;-/X0ID%<2IM,'$7^HUQ8@K+
M'33AVYWFGCLE&N^KRNJ.^EFYYTZ9YL6J5@D=C(.V,1C$(5?BOL ]XE)90MP9
M-.$<^10!R$ 0H&O)+;^(I!276\RQCCY&@\?()BF*5"Y+=92E-*GET1%%@7('
M 2Q!S7[@5UZMA6@"LEEBF4,[>.C547R9)3@'*X%0#M56EG^A,9VCW"Q_M$]L
M#*P\6XEY H7>9JA?!5)'>Y:MF"CT)JW@"DCVS%#ON2+C0\*@(( 14*DX#QDC
MH1Y]/H.FSR>ESV?0]/GL!2^\4'O/'K9&W'W>@FB FW7ZXRQ<'0 V "\&T*1N
MQ:39"QZ#KSQ?V,Y?4$\IO"H##45FJ^H<]X:(ZJ7KTXD*JGX8J6+)9'VZ,#V>
M;(?6)[!HHB>/UI/_,)>BYEL((@K(%B0'!=G!P$2QNNP1P&,.!QGQP2C13Y%:
M8N95%E$TCJ5.HW/4%7EQW1F@;9$'A55=2DL"QGL-@<(E >R&YV\QP^1Q"=X'
M^B$V6!USJ->F8Z'%6"'S+^KW0&OLE ]Y_-!O7.JX,]QVV<((/U67GPH1*N'E
M&[KH7PZM[DR30V/?<*@2/4>*ZAO@ )Q^G$6:N=EL)CY#)QC#$PP*\2PH\[80
MX#;G4)I>IU><$;_ L$G"\>3TGFU:U/ZXLI;2>"HJC6[9-,%;!_]$C*$ ?SLG
MX/9H='*I&($HIMA01"@J#C1.) 9\PF<9HJ>!D!3?37N!IA2' 9ZOV0B7X.:K
MQKF0F[!<6+S07WSS%#S#4&34/S,T'+?T7WJ,W]W%^@V\'+#HH2B?>,*@;WC\
M-92GB%X&==Y"&O>[YZ#Z."NHSL/5?,Z?IH"##S*%,YS@Q<<LR!$A2GWHD1"4
MQQN U*/F-;M:OYO>7^1,T%@3Z!CO6/0%<8&L^'&_^)U0^G LTF\EY/K;FPGN
M<2M1<&M"<!OA"LD0@P4A%@[T(.(KITQ^.I:)=P9NZ1FO@N. Y/G!:8LA\M/3
MP\.;.#,4DY*VRRDQQM  UH[CM J1002KN0H*\>A+-7RK2%[%1710U)B!HM<J
MP40(Q"L P"5 B9(IP7$G3TI03O"P! QE'U[CF9];M&PXI )DV@Z_ &SH*$7%
M*/E%S^*74#+LJ_ON$,N:*!O]ACR,+$$DPYKX(3H(BGQ@%NT0U94QJC1.42WZ
M6$B$ @5$(S%REG$&K\N1:BQ8%%9IJG$,J<9V[V*LN-:<','UCN=7M4([+S[:
MIL*=]Q.3K&'<(<7%S*[XZXSJL,7!R>5XK#I;FD5*GFV1A&P<W -->0^"N\3<
M'N0(#Z\>8E?SR5@L,R35Q4>G870&K?-VZ[S3/V_+8^7GQ%MPL'TU&'/A4^PI
MUI(+;PG>.J<7OA&2D1IY/%(&E1XY$]/'C*"$H/YLK=XMED*/,X245,<J$(S!
M"YL\FJH40TTH#P8&)81PV*K .7S!16!8\_QQ"J79/L_*+MG@HS=W9BU"Z)3*
M%9"O!5W6^&@&L<UF9L+,EC6[;#_KI^999(Y).'*T4=M_@>C,%Y ]<$J6X^.2
M)T @FJ3^\A%\A0UZGL!@%C$K9!+L).0X;"@WH &Q>]&+RPW*QI*G</I\!AUU
MUA2N)W%5R8H!@)V0*0]P6B<4RLHWV'9+Q*);^)?8P0-AJ+SFWXB(6:5E_!,A
MT/0LN%D?$# N1)N],A*ES5>VBTTH0_Q[-55F9[IG^W^=SZ&4C(=9-(\&3 Z*
M=1[(-F[(+GBD*C]YQJT63%AN*48'LXG;EG2Y%O8\1IN$L,U8&;:!AE,E)9ZS
M*?&\":- SVL[O%$Z2CH:Z*%[P498J@QLAG(HIB DZQHZ31NDMVB9Y9I&BVJ:
M'.-.RLS%J92=_F1QO@D-\T4O7Q[\^W$+9HFTC/90-38%RN$HV,^",I;2+DL=
M6>%'9E:(4&AH:(76#*T(FU[I JU;8E!11=4?XU;WY+)CM+J]!,4O8PV$K")^
M+;4HHBM'"PY]R"#W*!0M]QU$K)4VZ,_X,)FF$3ZRB#M'O[&>/<0W&!J)LT^R
MV*T,'EQ5[-8C[#8RNMWXV"/M^@<?WBF<RU/?LA@L6:N64:]42(E^QC"-Z:LU
M6R^LN[DZ)1\-_"N':PQ;@WUDYY]"WA1+)$*JG/(4XEX]0]Y4B EY-%[8O<H!
M:'3$#=PIS5NJ)J\-.KEHU0MMYMJH<4OJML)>*IJ(A <N9@5:P,B&X!/T:)(>
MJZH_VNQ5U2WZ +;/3<;S@Z! 5;MF!K*BYZ6Y!#5G@6UL7\4.==U_57M^X-#]
M^[\$O^A,[P7EE5"*6@US9)6Z_J*7)B6MV$K8K7)KBI=6QU2'3DX>?*;YLB,D
MZ^Y(>44> %X1%-#\9L^+*#QB+Y)UO6!"#&Q+U_M9]UZ>3SNMGM'ICHQ.OW^F
M;/,?]'X*+W=AS5<%B!C ;"K/B9NV/^WA?*1W1S=:F.]ROW4<>2OVDJ:]-L.G
M[Y2:0U.55]^'K',2?&4A!JCP; Z0U_Y6:S:K6XWC&&(@4-*BJ/D]9O;C3XYR
M%V_?V?AUJ>&L;B=WCFD3>-1Q:PB9HFZL))BAI2;A&T2_K]4E+K2+1<0@;@)L
M35_#L@J>&9O)I=_$<; X\BX=)A$/M?$HJ]P.=5C=?YM,2 [:GN[F<BKO@98?
M7;G^RH]E\H)(;-ZYR25?(P=\1Y!"K@>,U/:G*7>W-4T9:'V.Q-;E\]C?+.6:
MH^9#5I?-FX8A,]#8_9VX>@O3:7#T$^;U*$FF <E"5=[X-?A49$,Y6GL VZQ(
MB^J3A%2)D:>4IEL"=Z!P[0/O&F)#>GA;U8WK_0J**[>S 8#RHZ[1&<:K:.C>
MHQV@&LM8XR2R4#>7: 0,BE+%>7"(>=O/V<L2H6JQ[@1I\%;>DB*8'Y;2B9")
M$A-N) O2>EB-25NG:*V.((T\(8HPIXR^#T]#>$8PWV3(,?$-9-.!C"Y&?A\9
M5M)EU?SP1GIE(,/H?6==)>::V+,F:AM ])-*B,@WV4Q3<68(*P?S;) &I^99
MK@M2H-&Q_%&VB6I/Z4%2G:2B!5!+3*]*A*9$Z+;Y,Y8>^0-^"0\.:]&>SW0S
MFWVD;EUU?ZX6[\]M1LB6@Y88-M 2*= 2PP9:8L\C9*MRJ_A@V>K<M#U0\@^5
M;1$&KW/T%S"!-, P@II+HM^(JF0"?,E04XF]\NWQS@=8 VZ Q[]QB]]@"&=+
MD.JV&8 6(O:JOR)B=L5'Y<4_T4!!D6^NG?AWEY:'FA#NDPE&G2_-E(._H'Y@
M?P&D/$(E'$=OO2T7[H?%1M:1?8H/$-GS?Z^)(H_5M6E(E>S"MOX>K-D[2G0T
M7?U;AX*W_@JP"WD-V3;AQI'14G21\A,-P$9B6 #Q.FG6*9/=J-8MT6M<+;DB
ME<_X1_!N1)7T9F'@=N?D<J#J?3.X'1C,+,T<GMOKEIA>5I9,4KR4>DVY>0KZ
MD@=*+#?]X?$//S+,1YAH5Z^V-=>#"LR[^=R>DBNM\(NH+Q"2/#J_IX!]*4C\
M'9J\H9]PO5C0\;)!MVZ?/@67%/P8/8ZKZSOQ4XH[3$UY:/XC]CZK1F<C.$W'
M@>E//G@6A/-_-SWR8=>07C&5DJE@J/+K$MX #M6%Q=A^>E%G=[C)G+#"S1:,
M#_YE09/MQ)F)1@L7/I+8(W*%1'V(E$..-V>T>R>7@,>O'$A&R1:7+XP\(7L?
M V@(+JKNW9 P;\/8F\)WP<-'V)0ZEO?NIZXV0;3[O,R;1O3QLM +DA'2Q^X/
MZ=B"AL@<O9:AQFAU Z46;J!4!1@V:,7)[VQ7VH4C/E,[[OD4$.3!+WIQ%[[:
M)LI63?K@RK10CMO0J=ZIN(6R "/5K(%RW![F::#4!$Y5_@;*NK!-B?;)]NCD
MLGLQ5L3(%.V33-MGMT^J,:_VV#S9'I]<]B]B0U/EYLE/I"Q3DE+M'FLI:W)2
M2E,BD4*1%%2;1ME%"BK:TP<&A&C2"^+.4D(*P18!5<2CD![HN>)\4,\FFV#&
MMX]Y*Y.U\O+GX),9(KSCBED7+(K T.FYER![)&WND4P@*4"_OO2L[[:[]A<?
MXB<8H8AU&>&;18Y-!NZC.0]#8Z!R !9HS7)E#48'&8CHM,!I'!BC_B@Q%&&P
M])DT5X7U$U-\:^).3E=A @*=?6L%1 !><.0_3?AP T-_7J]H_.@=&KD]=&#@
MV_1LHF-\;2_"45*/8/?L@C&[PB\-!Z "+W7UL61Y)'0Z819OA@>XT:3HPL>*
M_P^</<*Q]$S#.J+3/KF$[NLD)TY-B+"X($L_MW^<O]HS8J3\K-/_/9^3DSP'
M6,/+E<MD&(*K!Q2,T$R&8V&Y:LFM0W?RS?QAOZW?DKQQ+>R-$R^SZB,HX81O
M[FUWPB?52?.V/Y$BSU,^(3@U&GM&">9KO+L<HA%"79'K_=WT0.HG7G.EVB#O
M]5E@8[JPYW,F IBO:WO^*AI@$KRM!;Q]M*&2C)HD?=]%253$L5M:1YLOW>?(
MV1NN5""X=;;S"5@PQ/E^@K(6=<W@H+^O)G'B[;Q)=R=:)"7+?<UD&]'I4 H:
M;/)_II2MA:!J^L"/I5WM&R]K^<>S]_=+/2)*CJYY;3]$#MK4D<B\81?_X^C[
M!>M'\J!Y&/]3,EKI![%>PZT?Q/:;&5-A=>28P"I:@]CI937TE._<J;(%,:/S
MJZRN+-P\5JI#<6^)] Z,U>V,C:XBV!PJ7DQL]JJ^@6SG_);4AKB5)L,2+885
M<DD,C*\HI.JXTSNY[+<OND5Z$H^ =\K(JK383V\'4)=5!'ZZ+>2 9 +U+P(%
M$ZF WAIC%->W?[[:*RO3A_B5!F\BIUZ8]2KCM^JD5&N?VJQ,C+^?5&R8@V2%
M:'^TIUZQ;O++E$R6T4]0@+%!R_R1,D2INH!254B1\\VI8D(:IM])HP5TA>52
M,'O3*FHO+@?*T&&H&*FG)#77!O4>R:\-0/ZP\^)S7,N\I.ND.J8-Z=)(U]X;
MZ2JQ0U-C4VD+NG&]N44>,_O[-:UI^?L5U*PL%C&Q4O@597&#=@A,M9&5=%I?
MXYB=ZAIZR[%@GM44"=,IMZD\1#0A8Z28AK)9>'234SQK6*^F!GI9OJO09!^=
M7/9;%]TX\,'V^#+UB#\;<^96K:EV>;IJW<Z9;2O3$EUM+_W\(RF7>*]*3D;+
M>$T!-B-/U&?N^GEA;9O+DMY43@*V#S/- N.@.QUCT$U)LZ2S0F?+,JT^K+81
M*N0.N.P(DC3=%FK43KSPN>&^K0NZ_;;D5)+D:;>ZHS2B]7(G>;;#6%MUM#-X
MDUU++(\S5W(57Z/VCT/M2R>\F=KOMG%\NM'N#1K!VZC]G#Q6H=KO8&W&J#$Z
M/ZO:3V:K'! :1.T/!O57^PE(V8EXSK4%&_LLZ]D,!'#4@ "F@ ".&A# ;8!/
MIZ, 5@K6U]EBSU+BCA^"MD/:$_('M!U^KN:R@ 9( J0 [4G.ZC1KM\;#FG::
M!?VD6M!/JC<M9[5K.:NDTV:SIIGRZSB <8D)G4%;V41#CB)AN..<4DHC0_2%
M[OS3\AN6>2)4SJ<E@7IXZ8'?LD-O&&W&H%9*3@!ZHVYY0]**2,I D.B::$G5
M9^I2_L/YCBC <HLRG][!AOT<7;-RL2Q%KS?82S:,#GFZ=8B#N<98QAW F3V]
MF@X+-G]SV1ENF"7KGEP.\Q?['5?_Z$Y[CR.<LZ,,5WZ^J1@HO]L[N>R-5$CY
MGX*UMM6:W-\P?;45GMF\GL67 WCM<6KI:@M0:7,EMIJFY?JTK_;Z^RD3R636
M<&]K;KW83QQR\;EZ5ROAAKHHNZV.ANDVS<Z9VJN=O]VY2.$%$[,EZRT[Z0V?
MG8O!T?4\TR$P!\%?B4]*[QNLK7ZBI-]8/T$#8:^S#5D3[1(\,#8X1+T4YH&J
M]=)H0T_L2!53[L:Z;OIK1YUV)WAOT[G^Z3HTCTT#B1/?6 G!#)EQ;@^IZ6#?
M<P=[3;6?U-U>L>KKM394?4TS^YZ:V5-A#//HW,-H:<^9@\ML7JNGA54T,=*O
MIUXLF%+KM8\S=)B4+=L:)]1%/VTK1=;K- '#\@'#VJ>[NJU4Y=;)W<>US88M
MK2YUYSM?Q%><=(SU_.0DTP8=:Z"(C8R1[KW6'N;S;2G(V.NJ@XQT^!0S5Q0S
M&>D,/1R=1V?OX3!T?'YL<#.._'/<%1\\S8;'O[H+8F[Z;#15_!B:F69D$7>.
M?C==N3COOD/G21C*QI1GES")1@@9#"LSUZM7U[/_"R2'X8H^3$"<XJBP# 9O
M[X'!J07&FHG\R7?37H 8(YXC*N'<#-T#Q%JCI9@(37GZU/5T<[GTW!]D^3AL
M,(,8G0,F1I\HGY;1Z\6KOR@QR-T3LSC)ON39FE,VEC4TN?WZQ_05UJX]P$[.
M@!6)+R,N^(<E+KGB5J.7<Z'?L/?0H?,P7R]#*.M4*$M<KQ,6!V=UIJ5/A.\1
M\28=WGEWH].;+!;N%'H-U<<(@Y<=/S (NV&#,'P0 S@(Q5Q4V'[6'GHUV</P
MY'+0CN_!@*:X)1V N_C ";Y4[D^E%^$\;?(F\EULWV1*@'P@22E@23H,$:?E
M@M+Q@)?8;_W8C[7(CRDG9M&S7X:>=$F_V>8SC*JW+5]X!D'#:CYRCHB@,EIM
MA>[-PQ2#>FQB?'+9'?<46TBX_KBWV(BD, O58RYE+<92GN.-U>4KJ[,[>ZS-
MQ-=L]"I9Y'=[:B6H4"K6R+_NY@]$%[PX( .HZ8N=X<JVXB[&(.O05LSU%Y64
MYU3'RO)2X_(RW%%<0Y.X%EW$FIZG8XO")&PAYK&=9AFQ7-$P,]AEP\P3VF>_
M4[/L&LTR;'+%984D^W'U*.V9[-_ &*X?U2&T]$ENV4[;TC: +3S8^[-K@B9U
ML34$;3BT'@3=,8?N47A7=C ;Y2 K@6+9RM)W!"/3D'T/9,][S?(5DT2O(G.#
M^IT->^$>+-\RO>DKAEYFUG=KX2XAT%QM0V7":FO=K]L9UR2TVH<BM@/LHCW,
M0R\5_ZWPT*&(J-V<^HY.O53 O,)3[\"HDN;4=W3JPYJ<>O?D<K"'4R]CD;!.
MDRR/H(!']JOE6![D]XA!8L[>;,?V5S#M[/M&:$?EV+?V==7%.+[7[]2$XWM$
MSHURL_P!5.5_&@ZJ2<U$OT^,XE9NL[CAH/IP4%W<J@&46+2[A:?#-#RT/QZJ
MBY<&7?A&;[#G8:G;#2WQ-</"?M9;%^U.WW;B:XZ;>AD#9IZPC"NIQB$G 3<>
M8I/KBASP&*5.7:[&"$R\XQF]=?1\4Y<0R)@8=NWC&9IU['S3J@?;#%IHS?6/
M9\CJL3-.IR;1MP%$VHU^-W>P?7OCU,"&:_KS(HN8)!2+8\^'9^GOT*8BM^QD
MMGV48;Q<!<BB81C;=7PT=.6_0Q'R-W?U;VL5E"=C13?KULO'MQW"MV-%@P"A
MUMKQQ(/#G193\FJY4V+-40=H5X:+"]!-7#?MWR$;Q!Z+*?O%,RU09@]WB:>A
MF_H[GW1BTL98;8G5UE(WF;J_MSO.W=^[-<K3PO ;UV,?P??:85)W 96V%[V3
M.BS3O] WYM#,_HW1<7 H=-MUXB@(Z1RJ8L[88*W2#*I7SZ!JU$K6I"=:D?YP
MB(*52'F_,,6D4#IF]@%ZZ*39H8SDFR-9PA$ C.U%-X%S)<F>.+"SIN,QBS>3
MA#I%G!F_+E\LQYK;*SP.97](OPW](14U-*BZ%E3=#44:&E;N,K$^J--;_HA0
M'<L'?<*:=.70=739[EW0[J%D<S3[.%4/YM36&;EUH'?T55%;Z+-:/D]23^LK
MZ!"]UVJ?_G5&Q-O*]K!%6%\2^NDF;P'6B/@S%PO=(N^P@5$M1F^BI22<@S+-
MM6_F+*N)LE0(ZBMA"P=$*)%J]O.:BTA02($JRJ=^!B>7\?A3CO[),BYMA<L?
MGEQVXW$0Z* EBYF^PF%.I=?XAA9NM65("L AQ4^_M_GIEPDD54@^B#\J.MNS
MC[^48UKA!L: 51#W2HLQ0%35RS SM5;TVYR#O;,9V_48YCW./\P[.YN79]QW
MO)^VQL.\Q\TP[^U=YO)F.YOL?6]ZJX\GCQCI5!SZ 2:!VFH'8(K/8K7WMV2U
M,]KK0'P;!CDV]GH>>WU*CICXZ/K2<]]LWW>]#\#! 0RL %!.0\ LZX<U78/:
M]FD?1H#2E B4\TALN&_D:61?#186Q<+ZWZ:S!AB%=A^)U J;KJA"$*]LY6K@
M-+T0,QA]*, V^FYZMKOV023YZP7,@M1]&D C"R2G,*-V'1A?\%#Q8X,BGIGZ
M&SV@A,GP7P" "_[XE1_MA7[G:&+%N.!N\H+)"QQ"-VEUP?(YY)KN$X$I>(<L
M[-6>ONK^>FEYOC5C.%_!SV8F16\3BP"248 =Z=EDZX#C9COX[5G@14 $B3D-
M,<26S=T-3>ULVLYT[0$-,@*F_3(^1X)FF;RY:T#2FTN?Y3+<AZW,\J4R'D;E
MRVV?7*H@2*-NQQH"E^1T '.$\T=E?B4_Z*S<3;],9+QRRG54E,L#T-0?UVD;
MB/(8CY1$H;O4#$"3'\2@?=T T F.?NTL37NFF[AL%#3I1"M2> S#I/[ ]U#J
MY*-'+^O^[FPE$+T?J8H+(Q\T%@"U "9+SR;>Y4@E8L+Z/VJ41?6IZ01&&012
MB%*UR#_1%B '"D+-0,-AO80_9]SW09F0XKWG3BUKYM^0%<MW_ZOUG).- %]0
M61L#YLQ\C89H2)0G*'<M3E5&ETR)-VCOE0)8ISM6C"K1Y^29N*/@N-6"KC&X
M2UPW)^M^$?N:T'Q)44X92'"0$\9#"K^-G-**_">>G.DM;&I[G]IG^!'')V7F
M.$4MU4 ;G=KD*]_<[Y2I.RUNL3[)+"#L=EP6;./=?+$8@J1GH>+BG@#57^1%
M63>@3._5H[D@#HKE_PG+F#BSN_F<N":>+R<S\]T$"(MWU%%EB2J=7L/CE,<#
MHK13V%QC3IIO078>XH9I_'X*3P >Z[1^>12_F/!?X%_:OYQ=Z/=K#V"95SR4
MCY#:G*D5OS2T6+)&7I-TO;*8M4R;EU@8@BVV\_'E.($OUTM7D([\B^U=DLM/
M:E($CB^-J9"]$8&PMOU7^&"QT%PHS@D>Y.O/UNK=LIR(,H#?2D1MK@6]%L(L
M@ N1D"<T.<-I.1BN3%<8 \>&05)4TC,C ?DO%_N-B,_>'RJ@:MG%>R1<2&S%
M!+#[\+UD$-F"$_?-,A0A$.)CZ\6'WNGS0(N-9^!8]#A8&$L98:*W@6A!^8KP
MHQ87Y-6VYOJUN#A,1>FG3-!=7=]QP0;R3PL^)H\2+XT)P4B< /'#V25(9ZA0
M$<*&R.Q0GG6+KZ)&,2T1I*5<Y)3P3P%C9>"LCY+G =&- #@U#]=!P1LU+2"8
M8OUG;2[(?_HK(K&HE"(;_1T!>[IHC@\,\9]PK$,#ST/^:,1 LPF+BNAD LUQ
M,@-DO6;R:Z2X',0,5?%-[9G'-Z70]7+IVLZ*Q1W)*^G2"($6"V)#0?4:=3_(
M?Y*SF5)1:\WGY/?<N LBC\]$IJRAQDU_]^S5RI(-2L:5FI(KX;WDXI+?^^3D
M/\@6/GRV;.(#VN1/_('$#20,"]^T;-0-2_ Q*/7X8]]MLEIAFEJ"FES'FXY#
MUJA!%: ^MZP\FG:P.9]",&&";X+"SALK<>Y0F \[)Y?=EGKZ@0&B&I-DY$B>
M[7-"S[\6'R'.N]#_8'Y11-XE<5/TYNKN,Y%9K+93>S/_HN3C1@GE=92WP/HK
M%(GPA;EI>R "_[)6^G?(7TLO%H:ZA1-0P-NPH%C4Y^8Y>SV1=G,\)/)QN\-C
MD^Y<(Q(/9Q90E\-9>>Y")\8$6<]I/.J?M%,NI,B?;7CS=W=!&)@8[(2$$@_#
M^]TUN67FFK 'X3RR4B+$?0WB""^N"W6NIN\Z%_$LZD&5;)0 ^EX_^YAX7UW#
M&2048HX^44IWL*64;D!IG9)Z^TG=79NU&18LGYS35B:>Z)R2#-$]+&YB7.$,
M)#0TJ%E!S8W<-D67R/*.,1PJ8GK104NL9%X8J^8+D5L@AW6'2-3EFFAY4%=+
MJ#W/H[!&E1M66)64;E?%E!D@R"@ TECPCAS[9/8=C?1O5*T3Q?+O22[[_?'Z
M?E*QS5XSUA<QC6%QWA_OC_<A*](VB-[?.>\/RPQWJX[W!S!V>Q>LOUV[8X]5
MH9O63HY;^6LG\U1&"H,BL<+RD&HGNZVF=K(2[M:DU?[#Q#L__Y]6NPWL:EYN
MQ=SG[!%'AGFG$']8_[=T/0P;WQ(1LX3$H+/2'JP7VZ=)GOLU<>VF^H3(%_#<
MB6]T8WMO? #1-KV5/,OGU*Y^-6PM-A*$?!+%Q1'V^!,+(X(.$*,M68@B7AL&
M_S%Y7GJN_D_R74).\O);9WKQ\S8$H715JN;_Y\N[I>U@V)XZT#?$$W:F-I%B
MCRNBA-\"QV,K;Z_!P?]IZ:\FI!'6,YO'PD -HZG%.CA0WD.$0'LV%ZB=_5?+
M6B6R 7(..'#VS,:L8"BA)(7F('[*2DAC13CXD*#HD'?=AI;CBT."1[A+RS-I
MHPE\#;U=\,&7'D^2LMY<A_V+,3J/MD$P96JO\.]3TW_5YS"U2DR6Q)94^)>C
ML_(*=D$TOC9:/,LB\O)"];G@*VG)I^"]2]TP 8E47P^2;K>$7=<>V2ZR+OVA
M^(5,$[)Q'^M'3=MCLPTAM@D]WAX\G)5/^9%'Z$O7M^5DEHA99IX4%QGDR>O%
MRH>\B@V'(TX&OP$?Y2(PS0" #0NQ,QK##$0X,8K)>I<+0O,7BLFZ^("_0Y67
M"(G]X0!;:WB=*<.BI6A>')RH>K#$T<(^@."?4%Y-?'UF^].U[],SQHJ7#K]T
MJHM#<\XAF::\CFKN[G+N[N _9%X-L2H*T6?(/7GTG+#5G[@SH#*A_)IXK?Q=
M5&!@+9.KK,8FTHKF\L(%'&P?T:FB=!C?5AAZJV?.7G#]MB0^KHW4-_7?S161
M3CJQW8C1 23ZU87_?^42M>,YQ\W;3[GX%#A-0TY;0J6/A^.*_?4;K8TS5R&1
MS?)!")M@86V@_N(RM0X$Q?K8^(5JIUXH5'IR(XDH@X>@Q<+U@2]]&PP%&S,=
M())15<&7'8AO0 )65@%0/Q71$KATQX+MS6:HC\@J6#$@)&B 3@MK1?M'(0DB
M30>!-!WQ"' >+^$LS[1Q2<0D69F$%N1!@!=%[N6SNUXIKR =+OM!+W&,?)H@
MW^^F8[Z(A##^%-:#^1T/F3@8%OR&O W5';Z+J" SRY]Z]K-,>)K.4Q[\S*5S
MZ)WI8CVS--3(./Z:_AG/_@TP.)CZ#4H'R28)M5A>BM!C[;#6G]7'X>G!+R@L
M0! SX_WHA8*?P!# 0LS:@O(/F[*LEM#B\R8X]4*_6WN17T%BD# J42OD<[B
MW+[DKE'T<<H5B7'KQ$#5T*4@5Y"X&+!24U]2+UPRX>;$"X=KPOUT$?5C#CL7
M,I+C?D?L>A^YG/JEI]3"HP:0?R;*.>ZO)G=?N-&,E94FUD;^9VU[ H?'#L(%
M]-W,)(XH9E5L\H^+QPM];LUP%H!O$0&(LZCUA?D>N,[F<DFV@9E ;TT,55P'
MV>]ZP02=*)43OX=O\$'U\'XP'!#RBCT2]W5 MW833Y1(U=D:89+ P:'\DQ 7
MUK!!$4&6& TI88CX=,E]"?[*3IR*QW>+ 9(08A)M YX%/2=X%1RZ^XP=D33/
MC><&NI553**R>'^UL/@BT>L"-IM[M+9"N%JR^6>(9\S6&/RFYA[YO[E'%A(N
MZ"#7$H2^S+=@ !@0;:7EOF1/EO-"KO8,T%78K@PL]L!=,1\,*P] A?(J @2>
M"FZQAS$T++0G)@&4EJ!/+<[!@!=%KQ C%WD7QO9%TRB\,^_[]&="5=@CMZV7
M:V\)9T@>PL015GO%)!(MQ2&6A ,22RWUM$VVC5Q&_@F^\KLE9*'C$LMA^LI?
M?XQW[TZ^;FA>B/M!/6UW:LW6'HUNF&#?^>A5>;;_EY_(Z/Q,U$9DZB4PY"L:
M70+<9*J]D.57>.-Q*1?Z(YR4]&6Q'>N'^89X9 ;PCTGHX*] 7]ED*=9W>X8)
M 4^X'8'GQ5N>>1N_*-U1;>M"DTB)=EZP *@-8FX?,_3C@8PUZ$\,4)$#LN=$
M=X Q2T[I#>,76+8*I69"EV/#S[M%3&7RO\$K\'2 U2'@P^) IAS342X>5/6S
MM;"M[TQ>2F*8T!2H1"@G"<=G88M)$:D#NB#PY+_[?]?_=!=S_7^9;\M?@H*L
M^XNK ]L)C^5"8SAZA6K/!LZ3G!AUT"#$<6#;_.+Z*W F?Y]LX^FLBT=4(5L_
MP'L5RLF#2GXT,""4[!/S;L44$:$X+]EAL:,^=^NT-AZ&RVIH1:4JN3NBU&%
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MI&@TG_5S#N#@O)"7F/ZQ%S>4$2=WG%*_ :&0F'?S/WPK;UB1\&3[Y++7WE7
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MGBU/[[8-O=/J]/![Y!]=0R<_7EI3J)-9?/RB+VRR^IF)Q*$V@ 4=3.09Z09
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MPCF6_F_+]'S]FGBSLW\\>W^_U,(@Z+F<_-@KP^3(Z\G7@-"=Z@D-!=+5T/%
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MQZ4 E-;QGPCH:\UTDSP?<.PI<^GN>N6OB!* "-0Y>4>"3MBAY;U!V"+#_-Y
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M\6>9^;.2GQ5_EID_*_E9\6>9^;.2GQ5_EID_*_E9\6>9^;.2GQ5_GC1_5@5
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M.!$QV3N[&%B#024E?THV;=5/A$W[9Q>]CM49Y!:G>Q=@58Q\<M=]JU',=3\
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M9NMHC<%YK..0MS"DWZ+RCZRZCU,0Z]>^5R-+SA$Y"">O\1,78GX%K&HKB8(
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MJY_MNB%K)>I'\]F91(\X7OT7)?3#N8T5[/C$CX\XGY66$(R=WNE_QV'D3%_
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M:P(#9Q&,//-A/!ZS,)S&,#^XXM&HE4<#[F &YQ,&1DF;=B#AAAE@4 !UTB1
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MXAAU90Y]KRTZS1H8>,_ZVD@/A;O@D^$G]ISWU=W P+AOSIBZ%P38$-@/16\
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MJZ;%8T/RY\DNCA&C.8@<=$3. ^GV%(]A*E_BS*(-1V J >!%3W-/I.I/FQH
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M_9YA @?-IYFR"V16OS!84L1-&>LA@553;JHH*$*'!ZE3H;ED]CL+6;^RQ)L
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M%]\2>SS)1A3QS^-(_:@E7+7+??/0:V@E7FZ^>QP877TH5$WZ)(A%_SP"KC&
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M"%?,)'K$4>J_J.?"N8U)';CF'Q_/4+'Z+0KD6PDF:6R[<N5<83L3ZE<T422
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M<SK[W#B[Z/2M?G-?"7H\4N=6:_LKU=HR"?^5=MD?E*W),"2.D4V"/>'>'=S
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ME___!!OCG-"XO!,1WCMH"?K^^@,UD)$SKUXPH\%6].E=E?BM7P=^:V_:Y/<
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M[SP&Z3W^)?%=7W8+&3,-N6UD[CGX?6PV22BM*)0/MOV< 7P:XDI#9O&(G(A
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M__:]Y0Z"9 86V#@89E[RL;DI%5C4XDE2DP8\8*LDO.;*\%K-^8<WPZ._C>9
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M0>G.X#7X8:!")MF?G8)?F*LVP5I4]:S\PD!:A"-ZJ4@ &&'DZV$:B0VV\=_
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M)7D9VA###_C;9<3:I&AC6\1"+[1VUNJ6TDORK!K/;=8:(JAL,@'&!:<#*Q>
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M*.;OI[>G."5[ZO/'U,EH";7/5F^;D<3IKU=B.>\Y/:+9\1?8UO;._P8+N/'
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M5IM7X2T8C\$H\.+ K\C#K:/S?K%K,44CQ%/-$99(!#4.1]B[)32TV51I7DP
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M'=Y_"*)Y,D$@VV"*L[01[*6>SJ807&.'=32FAX&=P'^2H T%J09_$Y\.[QK
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MUH#99/5DQ@MP":;S61GN<J>VFRQO[RI] 3IMD'L-2X9**U4S-?TBE%EIKD)
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M8O5EB,>23)\L!Y.TVILD+5=GG*X-/U@)/;*)B[7Z.A$P4FNW;=E4$P3RP41
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M/;:7;+9Q )MM(6K>.CA%[97;M]BV&X4^<2#:]]@S*$$>83WCY$BQW II-0^
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M=LCIBA\OF8C:O0X*<WPPF<CS\F0[%AKX3 EF<K2!T,C%P<S)OEK38EJ@M/\
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M+LO6VON@:I&I'V!DPE+(INH:MDNW,\3+@\1APPSTDD2D+IX9?[8%Z.9:].T
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MED0"65EYGP_,6[V6[_WB..&59U.E]-Q#EII=C*[I]PQ>@$:29&;D%[<F"]0
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MDD#K(. [FJ12B0!:;YE X"K/@%71FAG;V?27RAW&^^6.*R#7D9#+S:D>7>B
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M14R487<H;*-BDF'7L( DWC O,E%IY>%1YE> ,"[,VV'NFR&\ $L.!MSWQK(
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M0<P+<'R:;VO+Z;A>3$6.6!;)G5=>_C; J8MP2R,<(.7Q\9^R*M<V*6&-Q7P
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M $+(.9EN(*K\T'.6P/%M5.#7V"]D:"CU#Z)=)%U63,Y[XK@)4. 5XY0]#+_
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M^KMW&;X_YWQ"?LU&.MJ0Q->YM\[CZ*E/)1LJX2*Q=<B=C-YDX3;C*)ZB<FG
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M-VV@?[:"L35P8B(&4-L7X+Y']L4<[+=(6O7(?BNKIL-C4>6>@S6AKX$U6?4
MANJ[8;_VW.Y[LJVK.9,+V;\^N3YH.3"R/:[Z>/%=>89K[S7#:0GVR' JP]7T
M#+=3([6FL5%GY4M6RC-DB5J\C'^Z4M[LK)<WU[Q;Y<B;,WFS_FZ48;>4+9JL
MLZO7BJ:E)-DB9S2* HH)S<E7B]0:'77>'O'5098:U:O=3A?8JMOM=7I-M6]=
M- :R 7M^4##L:Z-MY2+HU-U*\Y\@YIWN]JL=N_URW7[M8[??L=MO'M6A[(Q?
MM1;1EM0=9K??%!V3&MX*NJ5HU) 0^-P0RMEMT<CR@ K 6;)"'-5Z-?AW[(8N
MJ2ATH"[,V]LE[;I-:JVC-;<Q:^X@R^SJ#?A/(^4D-9K9=>5473?58Q)9MEYF
M!M$*W:7&:E-B&8@/E\7FX:85<\Q!SNVJMQKM3AUT4P]T4TWU?ZY];^B"21OQ
M"?D ]=WW:]%\?A\X$\NUD31?K<!FT\&M :LFR12F=;2CO#(E*8*C_GF%*NO^
M6\7\^OUF#H9:@7<E 9Y'4<UDF,-FBH,LP:JW:IUFZX/=JP);-%2F^.9[YP^.
M[8P+1GY+$FK-HGGZ+5'@(_S+M4S](/^O]]MA@7D&.KQS%CC,B5FM:JW70;U0
M;S=3\QS!,O%LH$*A"'(SNC-&%"M^R$]R+..Z",60S04I2F*N2HA5<DCSR"%E
M.:3W3CBD7F*(\ YSQPI<_2-WS+_MH7I(W#%CPE6CJHZX A>#G%",K=X'_M@-
M0S]X R**G)Q!Q2M>FW.XV-4M#[IZYW1]4(NXY,+&1JO::1%=-WJU=H_3=6I!
M71)J^N9?F+R%>B:E\XPWTP>M.6V:E5 YAZ YQ\+&=T[B*YIFLQ+";'<:34:8
MK2K?))HES%66>TT9:T,#.*IR*:DN=IH9:X@?^.3ZU\XHC,-T?=><<=75<0,[
MAL(,,RN[WC,SM ]K[V)BQG2JW08S8YJU6HVXJBVX"E=YI#;O#$&T4P=M/*95
MH9P6E8UQ2.F??X+'[#T1C:(F0+M=URM;WMAIKY#NDWKIZM'6*4-H]=JATG[>
MA*_7TAH%:Z)<V[4"I&V^!5>XOZ5KHQ"!1U-]^>SQ*FFZ<5'3;XU>V+BAE<[M
M5K5.=-18IV7"6QW_\$=#OJU6)IKN+ZX+5/D"ZXXW0B-K'/#=76EU#]!,7;]J
M7%/>LTRGA*C_J176_^S;(G*%:.=81([2=11CU[#K26':NJB='0E\/03>!*%X
ML 1^'BK$_2?K?T!UKA)Y]_XK*&7<0A1%?N !42?DZ[-9IR$<THKBP*$24V$1
MN!Y8SN '@KI'=Y,;&?J-QP64OX*REW>F_S';]WC]MQ69 "L#Z]8#&G#,__?I
MX:OYW?KI>_[X31F=]CAX=L:6>>.#_P74L);ZIW=("-=77_>,$*ZMT2 >,>'P
MU?5^]#%!79(LCA20IX";SU_VC )NG"$ICB,!K(0 OEY]VC,"^&KUG='<=W_4
M"24)XO[A\YX1Q#T;;+284CC212FZ:.X:35S[@"#F3E!6"2N47^#6P2DROX!K
M;9X.L6TOXC-[7(6$:'<W/,^"WZ0\;"#_LSTBE_WQK\$C/5SW&N-'YT/'64\
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MQY8-7[7,B1]&YPY\C(4R+76N"=DS^M*(CUMG^)7@N%:,89<PS(M*&'(#/YP
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M&TY&UALJ1\_!!/?/C\^.!;!<FJ9!/[FV[7CB)_C4MW@,2!Y042A@\ %'UP]
M>[CV?Y^P#Q-AGL.O/&N,KW#<CV+S!=;7@:%^7OMP]9</J>==RA=\"5A1;?H-
MM?P;:N(-5G_R\8L?O%J!?<_+XN6B\*LP=*(3,_9<]J XM$_,GZ'[T7-'8*40
M5PA0Q)LOD9'F!J<NP(G#\R?+FGR\#_P)R)*W^Y$%<'CVYW_'[@1A^K8(1'/#
MT\C"<P?04(O(5YP1]8!U'W?#WP%7"Z)H;HB:TR'Z*EI ^1[>C=Q:*PO3U6
MC[=OO8$_=KY;/YUPD^"T59J^]CU21B"7O_F1$\X-P=RO[V2Q\7G<=^#/]@WP
MZ(N%\>\OEAO\ R>%W0WS?Y17N BRY@>WFP676A\B*A( A@/\(7$YWL!=.?+J
M>6AZVX-&)QVK>7G$>^P>(W_P@^YP]32MP4NMMA5(=#C)R6B\(M]; HSYL9&3
MRVN&08>'G"3^CG,#X^"-H&  ;9! <D)XN^"TL^#<<'*]XWUZUWX8K9J%6QI
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M5[_'!]09/_G^^ST^H$[1YQOY]_> 6H,K/Q1@?P^H-=7RHP;N W_H1EC,M/)
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M;0%HG9F4GY.Q8T#K3)_\<(T= UIGSN0G<NP8T#H3)3^W8\> UID=;7U<8'>
MUID2[;GJ8#</M-8\:,]5&+L%H+7K%W9=(VHQO<&(KU8EMS<8\=6JU_8&([Y:
M5=G98,17J_8Z&XSX:E58?F;'&@'0J:/\T(XU J!3+?FI'6L$0*<F\F,[U@B
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MNMUU^#>A9OXO2^)TL=.G.)!-M*E;?=O(K<(P9#@:+"]7%[1Q %=]P= Y9%.
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M<@VVP.JHZH+4 QS!:I;P<!2Z'L'*A' OD!.*)UB!+O:5L;M??&%)JTTU @H
MSO'X7%YF%JP4!A9.H:L3K@XU=X@W061QAUX\GI\\O"=BJ*]U^N_EVX&TP.H[
M\1%D'Q"1EWWG9-P3F^V>3BQGC!>^%1R'+"ADKE_5FV*H U9,$KGXRT"@H^K4
M PK%KDX-/Y1I=6H+K.RE>">'SP.GNN5X*_T3C51]$K"B;R]]#DV//[&YL>^K
MP\ABT9FLDJL]MI1ASA9?Q]\&*TXJ2PF:=V#%U.36[_YUB=B=7HRLF=>ZJ%4
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M$2RA$SBEIK$A%7LO1&(?S8$P7Y'':<)#05$@9FXP-C1]3FW=T"Q?237.Q@;
M"XA"XN0BM3CLC4==]XLQ3JF)BKC27_/MV!6X,1C+0"?Q(7)P9:_2A\R+K(ND
M3HV,,^_F2<(<NVO GZ^2UCN1O@;]=V3%+,Z+$=K1*H$D&&\O1TR0[)$ELP'P
M':-PW8&7*S"5LB9QAL E(1'W5<0(TE@"X]=KH5>4[-J[%+'K0C\,OTYG61$\
M9._)=N]%&1U6WSD:,I.LN,.!UD6Y>93=>\+UESZKOC.G4)Q;V("Q/![*)97C
MH'!9UN0][T],!_/+0-'EP2.:5U+,#");GOY=+#X^9,;5 J6Z)9AD4:QYC\2>
M IP5(P[JEG4C\=-6XR-,^9%:6+1T6'S1#]+C9^GGQ8/0L!6$LJ4'DS0E$-+"
MK3I&&2_,$W#08K"E>XM-N1:97[4!VAJ7-HP:FJ*A?$B0U>+GRG-IL;C^%U_J
M?20@<?@W4V^.JZK"BS1AO50<*[=]2)"M](DYA1J*='@G'IYVYBV0!Q*[+F#8
MS9DUC+Y]L230QLQXW0OAFHFT_<&'C.KX2,[?@HCL$/GF,03#^8_##7 HT*V<
M#@Q<"$V:D^&8L_89&**ZHIM+[S.][!=X\K9[:]^VQ@7.(J3=[62>^FI5#Y3,
M<DD7C\D/-H7;TRC>Y%?@!;872'RQ+Y<!D^$$C''T7J[,JK,BJ54:7;'DJ8'@
M:@\44_3R0E,<[#REJ0EH>I?0LW7/!!-8M%ZN\DF![0,\\][+0J2X]FB;>= T
ML4$.@'_:5/"M\41:Z2?4+0 SF6%T;[,ON-PS,#?#F.W'?AJBDQ]<0VGU\W4L
MW9Z'=BV7 J4DO<<"=9D,ZG'$HQDPX;\319TQ417 3YNW0,GOFXYS@6_;@+6<
MB692P:$1!YVI0W4-Z6L2X-;JW[N=,[P)M/02*_H^#LJ0JL#K!,+_V8ZH13$D
M\ET::AU@GL"/!,+>/B-MI^>#KSZA T-6CES+S7(4GVS<T'QP5M?*73_5//VE
MXIGTYQ4NEB_G@;)LS?#4OT/GN06MFG,*INB49HT5;7F6T5/&(*H3$0C<B]'+
M*:CXGO>!7 8F.3=1:\<B/!8;<CRXPEUQ/"+!+\;67Q2Y*TXE*+!VVJ-++=1H
M_]6,7?4#D7M<3E5>>_MFQO+'*='2IWEV,FY]5P.$_ZBJ]HJ=/!$VDKH?TKYT
M=PB-^S.HJOW8Z92HHM,I&!$&N*A=ZF(:KYE7]N-6#4+3O2UK6U6_>LYA#YHU
M;4Q&.!9];_TZ^4V0]AH]>?Z)5&FL^H*+1RQV"9P!7H1''&FQ267JI/L+W69K
M+J5/_@A=7P7TNQ$-XNT9R%. J?((SA%P38D(349#=^2*#5^?M#S\#U7]Q$IK
M'(DG[W72;_3)PQ;Y*UG/)3FU">SSX-/M0+".;@_6 V6]! F\&JC3B=>A4I/H
MZD'3*RIS*G\<S+<174[?E0^^BAP4Z=A*-J&_DNMV+DKX%0)1X(U8/%8F"<,-
M @T;>L+FM[^E7=%SWW#;-E6V.K4B:7O?YI@6-(8[ JJ4-1(!?P;\843'JS6\
M*FAF=)05/R53\$VD_6^"'^I&IDDO0MP4>@?1,-EC A3-JV12)<"ECD:J*LLH
M39P.35&O_T02MF$0A3WIX7YA#*\S)[VNLQI?+,AA?+5SM0N+_AW-^O9C[H(D
MZYW!EF5=O$'0"236<&)$(]8#NX?BDB+:X'0N1>N-+?),FN3^=-U_KYY_DYX-
M^2B:W0Z1N;,K[C!]&6FE"'&Z$W,GX'^> "+XG_\'4$L#!!0    ( ,1Q?%OS
M;3FP1*\  *.X   -    :6UA9V5?,# R+FIP9\R[>512;=@OC&FIF9+S+)65
ME1E-:BI!DYKY&&6#I2F5E9H9328I0FK. PU/^90IVF1ERF-.I00J"I493DEJ
MRE0YY]ZEN)/MYM Y9[WO.=_W_?&M<]8ZZ\"ZUX+%#=S7=5_7;]B#ZK-*@EJX
MR\O'"Z6AH8$ZJGZB5'VH[7_>_6\]_OS(_^YO:*CJ488Z&OIS+#4UEJ#F&&IH
M&FJHFE 8%$IC[G^;@/KO#XTYFEISYVGKZ,[74T^H6HB:HZ&I.4=+<^Y<+2WU
MI_'JSU%:AG.-%J_;.L]X[S'M)>=-UB?<*-*QWU;>8.K?#BS=</Q"HNY\,W,+
M2ZMERQU6K%RUT=G%=9.;^_8=GE[>.WUV[=M_X&# H<.!H2=.G@H+CSA]\5+T
MY1C*E=BD:\DIJ6GI&3=O_7W[3NX_=^\]>/CH\9/BI\^>OZRHK*JN>?6ZMI'7
MU,P7O'WWOJ.SZU.WZ'-/KU0F__KM^^#0\ CX\]?DE&(:^CWS)RX-E.9_A/[_
M&9>A.JXY6EJ:6MI_XM*8$_-G@J'6W,7KYAEMW:M][+SQDO4).B;;;A25-^C:
M;_ '3(]?:)]OMG2C=!GX)[3_&MG_O\ 2_Y<B^X_ _C.N7M0"30WUYFD:H@@H
M!%GQ( /U?]-P-(O?_5Z7)MS\@TD^YPW']H<X?-]N.-$W&G3@]PU0I#@)'99/
M])DKCD&9,F*/O+[ Y>,-\ O5!RPK!6H\0>-LXLYV&J8F@2YU!;45&EI>&R_@
MC!"'ZU=#3UPS.^"O,4/VI&G .$B@#(?WM7,T*"ZC>V:+8?L7A^'5L]=PELJM
MD!PQ.5@NR??GR0U>R[%VX?2JA/8J;AI&:U_CS/?.!T.A?&0%<)<\E[+2A9!@
M47%]=5 DLV8PX9+%LG*0,>XLCYPPH7@KJBK! 9:,D%R _A1-T(!($OIX#V N
M=6UD6D#6GFTTO3ITUL"JV2QG<0[&!*<OW8,C8?A$B_!U4 =V#O1N#TI#.>Q)
M6PNOZ5:A(AE6,+EM8ZDQGXGA2KW#-17E(KP95">+X3&A;2+9(0"?J31%)P=B
MQA?>F^:1YE-8V]H"9*XYA--T/<KBOVCS068.U53B"382LJUCLG)O0K]!7T4=
M% ,R!*[&HV*3(.]J*$A>U])'2E6A#*+S/20JU+6\K;/_L*_(&9"?>1"HW4 P
MIP0("FP)AI6V.O1&/\RXK82;Q5D -@"B!$$"-502$"I?B_Y2Z_C[+5..'F==
MD1(,Q-2-('%\&:@MG5=<BGQP5:$,D6604AJ6C5C"WFU5!#NJQ6QA-#=CQB%1
M#JA08T6RB?3U5 \5*CGU,=+BY)"!<P+B^-L;UU-^-0TL(%E17.M!J(Y/TYDF
M:%&$BN*N:(N-W&S$9;9(A9)NPJ.AX#!)L(-T>DQ9BDD0F^&PI;"9U6 ST1+V
M)RV$38#KT!50!_:T<\>[ L497.D"D)GX,0GX .G5/X9/.B113V@H-50H77(*
M0;J,K)<=XTDV)CZB-_I&2<N?1X0VU1186=6WTVN\4C2N0Y=&<];)G ]N7VE(
M'G";W(7$T8Q@!ZB_<-2=WB2&ME$C+LJSXPZI4(FGAVKN>:?A;88$/'>#7*D*
ME1*+ J5MDUCHH!PQ5:%2J?8RXGB]"@6D#R(+[VP2)NW64!8K+$!",V$A%%P,
ME<C1O=9-'%>F5-!0ZBTK8(!U4@TH2BK4A"]WFP>KT\4J@IU +2:::JM>O5WB
MS,P9LC[E.,F"@FDH*82.4AP$\[#F_QY%=]Q;\>#J_/_3 P[K4*$D3Y P/L$:
MWE 'D!N3JP$A@Q!)F)<7KZE(%.&(H,=V]9R3\?8R,RZ+^A?T&"C>!JWJ@-VA
M*[)48!=T@L+DV3F!N9D2D,Y@8XTHYLU#-LW*=:2[,ZEC<R4$X],#B^M #)^4
M?2\W88ID0ST!O7X$X[$ _2^ >PWO@+07H*$&"<8NTMVLHHCJ@C&:^DY$PQ?
M+[2%@" ##I9-Z#@H?JYND=MX+=0L[Z235:B>F6!J>* H;8IKX'NVM_1.C:Q/
MK G[=7(,(SC+VSBZ->..I9 S?B4ELQ$Q WB4&[0%WB548L,-0]C\@=\&_1$C
M(K:3+BG"ZW=QED?BK;@ *QU>*3F$Q>E$4;>#>CRZ$<<:ZE-BCT!SE7YPG"@Z
MV[S!;C$4_?U?LC[R<:Q(CX)'W9O("$",=X#B:ZF)UMQ/A*/81*L)=7EJBUCX
M1:-XVSKHEHR(.=T;/%#ZX+0O_3F4JE@C4J&.Z5_<N?J21AV/"(0%=^.VE3]_
M42+/NHE[8H<.V4)OV Q;E@P$4Y($*I0EW@/V CWY18_G@>9I#)[^AGT]#VA"
M.H9[ZHW>[AY *15=H[HO)J>**TDY[!V'VP]!4JKKBNUS5*C&I?5V"8]I8A6J
MXOO#HP[E] S7P.IG,I(6%,KCS"/H<)8?AGW!BQ1E0Z\*Q8#1I9!] U%:)&,N
MI)";Q&BJH5QLY)"NL?\0/%=VH/%W>$D7A:&X#\UEP=90%&@01S>F]*G;9=R!
MPC$ L(DO$%-*9Q-M*?0/9W$;[%TV6KL("D0LR$8P%XW;+">;4F188\H>'&U^
M&\[KQ/QD+0X:3%*X?'HQA=&&/2'S9U K#0N=Y"R,0 P^G65?E(CG1MR;=PO(
MDS*:)ZZ]_] K'I."2;Q  $Q-X;B,#EB"N2G4PU*M(^NASGHND/P%\MFCL-.:
MS:KRLU:<G[U#,Z,P9+GI5%<P5'&6#=2D7V)E$A9$46V?GJ8#!0Z)[#@)UJ9&
M8=Z$2<4[ =5OU*&80F1930Z\IH-2TJB[SB^*>LZ\$>^>;;5V 3J16<-L8)A1
M/:"MYV5^V&!@!V<],,C#C&<[>$/G0<<]@#<O&"L39#D+452'=BJYC*&/T8<)
M:JAF-<4N+;!0OPAK)AI#RZZ2[-#:1:V1_2I4@Z\*=<K1,6K;3*0*E:&8<4F6
M8DRH6[F@[BP3O[XF1<!#:XS2/^,]H )G+N2U'Y/*U'/NT,ZA[KU]*&BN*<_F
M6X08V(U)Y9AUL E2,IJZ'^JFVA?W42VJH1M2Q[R)% $1ZA9KXL('<(#78WD^
M"3']@E_2=N+6D>L.6<1&)4-[NTR%TAFZ0=FV,Z,Q8_94L0JEI4)!QU[ ;MUX
MRR,4IH#^V3UWK 4<5 34UE9Q@*M=J5>Y$4YDSVXXJC0=G;P;YRM-*.)S]+<D
M-5S7748 DG?-,4>U0WG*,-@).N_:C$:3A*7#M+50-# H2VUR/ !R$_#+*0[U
M TX='&-;'>AKN-TFHGH+D %UBO96]>O>9:]4,YSEW;WW")K%6=[7J,?+IPNT
M9E]PC.%=$)/0R%Q @KKE30LIM^3:*2]8SO049!TPD1@M-*;.!], \^;->MO!
M[AHIQ,;*-E]LQ#N<NK=7>OC;Z@<'MO$:!];^I$6 #K"QME0[$[X">O"M6 R\
M@QE4\Y :"W17/#[<!V,ZI_0)/K,/Y=OE+(AE++T"Y<IT<4XN-ZP@ XPYA=<L
ME.KX4ES64N<S4#.$1G$%^BH5\R>/$,\'Q# (E; U:*PHA)(>'NX?"$_:V>5,
M[BWA=T"_!'HOS # JXV]0;8Y@I%XX^2'\TONYC7_%;I&0W' 9.^6N?_'1D :
M]3+T3DKL$4LFFC$Y=INL<N'%:G+":<OH:1QL=?L8T[\KCV>GTXX)[.[;T:&)
M7M>T2W/!USD6M_YYBU+,.'YEY' KQ3S6U< ;'3"U8%'!16"?7"@XBG-[1(]0
MH9JUE9LB0C1%;.HAV_A=T(U<_HPUM&YG__?*&W?\.9$4I%1YN3B%8R$$ _CT
ME]/CZZ0$O2-0KD2<S+:-*N'6V_H>@.[*B#E<(]@#R&NP\DXTYW$K S*Z=B$K
MP>J4Q[B#5)LBXC]EQ=.K-&:PGK08@3(6\MHY 3M& 3%R )(^43,!WF@ ^;B]
MD38?8V[<U#O!"R;+/B:79)_G+,$DI$HGU6)JX^:+S=XR"E1+-:_;EEM?$ M!
MS9+N&6])&)\T'Z9!I$)J$%!57?$D8D;=KID;?5LQS8'[(I#E:CF40=67^]'K
M\9N RS4/77,KFD),H 1)Z46>?Z'7XLKMY?>O_D3%S?[/64\,@4\"90E@7;T8
M-;&DRSL'%P/4R%C-^7;?]<SI!C7)B E%+D4G4+?<XU3;H*&=!F_ NH:32PXQ
M8]5XOG51?::!QL2E@,&0$F4<- ]K.#1@ - ;Z=ET,S9)1DS'5)(;\\UY)(-)
M[-RR1\[TGJ#@]DOHC%AD(HUD"*^4"L?6L2)C-](,CKG]:O%8OZ/,\#DTJ)AL
MA\U9E-3&>[ECP\H]Q!<4M"0WA1".S;@\8*>&.(*Q:R-Q#F7T,/2Z*%R3WVN6
M#!:Q?<H@!EVMB6R,I<SDE7+2;9,SIZA\C9G-ZJT(H:D[6><%'/1P*#! W=@4
MAG16F(77HV[HYH9CT)2X7?2D&>VFB5ZL#V!,70*<K2B)Y"PCIM^34]BP/W0H
MJ!F/!L*R<*82$3B8W"E 7(![3TUG[/_?96SZNS]>>5Z="+O3O79,]9[(<]X
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M)>K>.R5%9R\!8Y)V/8=^8.99?NU_31B? GB\.]R%ZG6E<5!0#U G\[XJY"V
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MK#>'R%(2;!*)Z/X"%:/$V?R-1)O35O2>Z'TGI2U8T^!1O%5GU?>V\GK182"
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M;+$20EH5\5K(QC=@?_&X]2/(5Z9"\8(W\'L'KVZ,BJ]$HZD;VJ;$"Z'<1B;
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M?CTZ\[>(HP$.\AF]>.4N=X=T*@$T;YXA->FM/Z-"R=6YZ/V1.9O$)(\>03"
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M<JG3^(=\1M!+D6F,.X<JLZ5/0[G:L'I=3%!]/I%P$>V 2)QE,H61AP6=G.7
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MK&DK!T*4-M[=%?%QG@J#\<)OK+"I3F-ER)SE/>-SZ>]RY\?&S%B\&:>FDBN
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M.+*-1H5!3:@;M%@\RK7N3AOXMWJ]#NX=3O?^G7#FTR%M8L+_7SM@!Q[KQ-0
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M/<?:P#J&>4<%%?9$K(.P>2PMCI>&<H98$"7YBW2E[-:/C).#5S*P"%>_%35
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MW@,MUK=)N2M&K<L$/O#JQ\?H5HGR82@L@6@FI2Z#[3R[&):CIIM ,K([J@3
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MS='K$N6&UM?!]_;=*3*I4[_<,=V48:\QLF<50#/7I[YW1G33Y?ZU<+UB.]"
M"K>\H#O#J\(+ OS!J$G+7T\_'&2]YO\@]^"15WP5KGA"V$C+^^MDF<G'R[0%
M.K[AX9RKH?%6(<W !KNXF8GXC5XIP.'NV=!+(K:/:&)K+=!DZI,T[>WEW\U.
MSGT<?#3SQ87JT(:>X7_P)R*N'4Z\_H=Z./4&M8S2S!ZSZP^3_X5%S33BNG )
M)5E4.9D1F1DFH:;:V;F8/KE>4)JL\Z81:" -K%^^^630E2S/ W.+,5A>"EF@
MZ0KG$%]2BNMP#3^#XRUA:OGJWL^SKWRXAA-O_RN19PR:R)8O08KA;T'*1##Q
M&&1Y1V/.LT'A(/.V[,!4@;L .ZV<O.'69SG[D^#\#+7_@_3$@+62#9S#Z]*<
M&R)@=IVHC,^L##.@4[LNEO)>88DX6*IM/I19,/1@K0IW(YFB"<?G>[IY?OJV
M3^KL/%&=A.QY#/<WUI!O<IR!L*=#IC-W6<5#PBI.^I>M\M=DI\UN6N9GQES8
M@\[R*/3?;I(V##0%K"<$0V3FAAF*/GQ[8E*(A9RTV:D1>^IS$;BO]305/NB
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M#;8/0ZC@/=H%ZD(3CO$]+1:8N\'-OU\JRB2M@O,@LV:6.L-I2(4K&VS6UF\
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MBKL(":J+$>4Q[&^CF\'F(XA+;9$V,T61,T*P"Y[!50T3LQ@\_6'U;S!Z5%?
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M966FYBDU*Q$JCYIUS)-=-$VI+"^1::F)2I"16MXH/67'CG',S,R22M"3-T1
MNAE>4E)3!%(S-#=YV^D&AF9F_6;-6O/'K)EWK_>/O=]WO6M_WN?V?50?54/
M\KW>OMZ AH8&<%S] *I^P//GV_]K_#SD_WN&AJH9,%@"I )!FAIK@$4&&IH&
M&BHN@ ( C<7_L0'XSZ&Q2%-KL39BB<Y27?4&YG)@D8:FYB(MS<6+M;34JY?4
MZX"6P6+#U9MW:1L=.(%8<]YX2]K-DB4VNY^S30(ZP+7.)R]<T5EJ:F9N8;EN
MO>T&NXTNKEO=MFW?X?FKE[?/'M^]!P\=/A(8=#0X_-3IB,BHZ#/Q"8D7DPC)
M*92KZ1F9UZYGY1?\<>MVX9T_B^Z7/BA[6/ZHXO&+:@:SIO:?EW4M'"ZOE?_J
M]9O.K@_=/<*/O7UBB?3S\,CHE[&O\N]3TS.S<]"/^9]<&H#FO]#_1RX#-=<B
M+2U-+<1/+HU%23\W&&@M7KU9VW#7 <2)\T9KMJ0M,=Y]L^0Y6\?&.0 T.7FA
M8ZGI6A?Q.OE/M'\G^]^!7?D_D?T+[+^X^H!EFAIJXVD: %A ^4\95"[?WS^;
M!64ON,FL;;L=$UE&!&HSUE2Y5%:ZIR,-M>BH!<G^B^$3$BHA$:1>:["H@G!*
MP\AD8MA3>9+X:EI>]PW";>K";_ )!N2D G0$U]%>D@.57\GF#-;54MX]>W"4
MLTN<J[M/R(KR2Q7[P.OK-J6#,-+H%($8%6:!X/UITUHWEX&$5V^+0,SLOV3Y
M?NI03??ZYS6% 0S&!X?QF9"[O\>.&QT]%5USI?3<_MS2U>*C-79O\I"VY? J
MZ/3?O8+P$@C18NG8.'"OXG12S ,HU:?S;72?##EQ8^\C*QQT30I=K'O^X%-
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M9BBYCGKG!L]HR^U&/IHATTTZ'RG?C[G+A;8$/5@5NZ>I66-=SK4G['JJW,:
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M;OH&%$0MH@RG6* (:AI[@1+RS50#W!6EO,.@1L-)"/E\Y7_@U$6?T%Z/'C8
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M6[%.]FT],PR[7?$SWZ/2\#$LI*)X%PKZ:3E')1DE2ZHSAOBZ?8OET.RKU7*
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MM1 VW+.DY9Q0P'17(GQ],+H#@-.I)V6(^RA"K>(?X)GH4^9-:/PL9!OJ [>
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M*6(\EI#A(2B_"A+!A4Y/4E(W]+ &DKC%)?:*7N!IB9:Z)0U YC5"QO2PFBA
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MW3C?H=-Y$^C@.DAQ0S@.K.TQG!R%!LKPZ[+<[FZB>Q-W>#4>%\G"S$+H>M*
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M:2M7#!Y&?0,.#H+C0J1"5\3QWHKNU)QH(;7.R8)@59?Q/\1WW]0."#H6XHW
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MG-^0'.A> 2 VDT&0)3KK^8.Q+ ^V\7L]'6;[I-Y/44M_]3YGH:^\ED3E '7
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M/OU7H6+@C],/&&:04ZYV61BGP7BK+34KA3LYY1#''SH;(]0Z0/]YD<45C3-
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M.LLGR+U/MRK$.1,,K%*<A=8'PPMU;L9P:KMT,:JEXB).0B^@B/2<PM-1PRC
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M]35!)0@SM VW*RN'XC">D#B-,7U6' S)4MD.ZM"0C%T)=-7Q*>O6LQLJ;8V
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M#10RXOZJAI<VYLAXYCA3+?K2UB3[# WHS:S/,:T7IQ6RN!+,$GKJ=_4R:VD
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M\@F^[\(V?"(ITB]?CCI[_4@(E[*7R._][#^ZY$=TA.'<5FA"D&7$9VL'$W9
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M4]TF+\;F%#^:B>F:85_CK2";?J<]%Z39%(XE^*Z!\Z1J8 $\(:BU;"WWIJX
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M?1..B,,9&/WG ;C_?C.893C;: [>V&2N*79 C05NEH&AX:S9AD9&LV=C[U[
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M6T;I6:BK4/>0GW2@ZWY<?78NK9EP*6(ZH\AXLS'=HJS) ZI"%V04K;XJ4EG
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MI[Q[^JD\^-:SFP]V]"\9*V#M[Z,=.$/%R.KX!$>/F^/-X% (\$,M@^G1CH1
MAE*'[FOJ!)?IDL[Q)/[LN A\SJ1_,KJT?G#<%JQ3Z7&7!"O!MB972=3B#J_=
M/&>JBM"GE*HF3(,T4CO7EM:977J<T1S=$[;*&DQH$RM2*2ZR)J(S<#(*X+8,
M$+L/8HUDI'0Z>5OT_OS'M'.0*\>3-_M/*4 2L\%KP(<;&.[/@5O!<I4H]_&)
MZJZ)Q]&UV@W$S\-=J*OHXGAD2VDYG!C446-*,M\W7._4\&ZPCT%]>E*/JV*K
M8WDS!9B;ZQ:=D<")OQUYZ]'F$[*TM-5]]]F\QY7]M7&MM$"(V9KOF;>TR,05
MZO&Z/?YW9X_+) $UL8)>-$69PNE\])6G(I(M>?)6X/L(V0SOO6<Z:*H*"=_\
M;G(%DE@\//=WAZ4L-^=%C 5$D[^<;%OJ"3FEN.UJD1T&GMNN?!L(H_)V?J/2
M6,^1^&_1>ES:7J;_.W*"-@I.EX$'TE7L=);AN]4U*>6A,F0990/U?80YIW$]
M1FQG  6Z\M#W9X?D4XNQ3SJ7#5&O\%\^ZS)+DYPVO&Q2YKAT[!T_WK?T1BU-
MR'\^4V=^Y/3O@M)@A\=CMWNK>BCRT800NXTHM?/Q'@L][B$Q$'ET_EO7A[DK
M[E[\C^'F$%N6%=7R8?\@-%R47C=':*V[(SI%RQ15/:;X.:]T=N^NI"R,&.:!
M!5&Q+,([#*[LJB"*\(7 5/DZL47J;(_AWR7RGM=W79%E9G7B@7E^@UDT;EMZ
M-@>Q>6/P]>^J<[0I)S3M3V_'EV/_8@(,Y4Y[RGI,)D9.BR?'&]\DTK/9EFSE
M75[U_'C**G!0RL8Q74%Y+G/=&?Z\89\B-X8#<@!T;>;GG?_ (G:'BS&%V7^G
M3D(S1=9S)5$.4)WD!L3/8:T$ A9LUTQ?X<(! C?7?-Y'_B6Z-3N^S;:,,[6-
M? $JV/TGB-GR727 1G0^T7:8.AM="@=I'&(4SE/]R2V%*EV!P(NY$DI1360@
M05IW0*,"X'#UAXU(M/.*5>18)=$:\'J G]R@F>!$X>#P>_G1:E(3 0\;!C][
M'N+0UN1,A5CYRHI5HWM6B;VXX_D7NJ3YE55;7STH6Y>PLG%>^* [>_H-[*AZ
MO75"\C.@V07A+Q/RDA*L).@<# 1J>); 39E#07;-:P"0;@&7<N8#1V6M*N]V
M[^?D%#7)%+Y_!@P=^ARHZ09Y^5;'>)?];!O=$QNC_.45B)-:YRCE63")L2IV
MVH C9)N*.)6PCR/[.I$DR#, )%T6NB)A[1@\5F+8T4*W 1+5!6.#$!DH;^9]
M60ZGJX]@LO2XTE-#-7J'D:P]G%PRY'!A,@Q=W8DN9))@"X65T#K6-LJC6[#Q
M(=,+Y".+>4^IL@N,K>U3"@*<PW(%4IJ*W",)T_?!5H(U+(!?,^UHJ?C+3*)R
MT<*+K"<P:5H(NVBWQCDPI/'$N3"GF6>&KAX 2E0?\S4\:SAQBS,>&LQA4HOA
M](.02$J# VK&+U"635 <VYEQ.V"^.(:C2U>?B?R+\P*430]B#72*U<FN^G?Z
MMH;]/EZ% 94/LO(=M68-<AA$6YOJEY= )-6+1<3WLDUT"VHF.50S80X\_%QJ
M![>VO'H5L!3W^BNF-+J4)%-DC>X.Q9@P!UXG<=_:)QVPA4F8$5L8Z_,@*7@\
M5$PAZ"I95L#H 7E2OZDTUUN/LP!N-O&>RB4MT)_.:\_2[>(/+1'<9!X:P&2K
M424<H")9 Q.JH":Z,RHG5LDRR50EWV#D+'YZB>XA:RT2#-/ +O5+5"Z_>1"^
M>9?7@ZT*+4/HBF'?MCW\K)T3>%@FOA>SZ-:@=UN.]+!'2N],W%1R\H'>Z6]%
M \%%)SY0UYR\&^);^IR7(FSP?A>?X$/QT%UC1XL,6%V\N2PO9BS$;:8183UN
MOZ[PY%2P(I?W1)Z-&&E(&2+;20P^8OQ6R*NI1K#B(#2'3./9F,V##Q(SG0F8
MQFLCPX260=E1_&1E*SJ7JN;.'L9+B/-0>V0%1,E7+@?;LH3F<+**EE/30)/2
M:XB_DXWN;%=R>^A1W_><4<M\TX/P;F:BDCT/[K;'Y]OXR NBD<4YMASR<<(]
M/4[LB"Y'K&"I=O4H)CTQFCE&-$-?"><_A=Y4*$66PT4+JNF6R#JXLM[G2CIJ
M0T]%$C#M,,2XY$PLT,9;BC@+E%M;!?/W?B-E$XU9*_MZ$,MZ.=,I*8&:_0DU
MI\<O/G4FQ?"0;<1W>(6_R,YWWF]0+S_QW; O9<\5KC)[9)^#6_5IY/"?[W]<
MWMV@73HQ>CCZ7#>C:7WER7A&2-_9L(B*7B'*_L6#BRQ(G,Y\.T'FXV-Y)@C+
MG>3%@P,Q;6J.^,+7[@-'I[.@3\\&#/U<Q_2X8C8#V=JOI<+7)*/0@<8AQ0)T
M=5V>P+I.)K2#7@'V;)455)=.)EZF*N\J:DC3>X4/S;(XR25LR5QF:'3Y =8;
MJA737]< %: 6.L,F.M@F_0$BYN30LX]*9SYEM$+#IY6EZ,"FHO6FR@F[S$],
M)S!4-K/U#^7-E1BW37;<0;;!&Y*G-[9=4I@%.-N!MNG40U?V!T 6B3Q+],WY
MP0T@.Z]G\]-C/A^K?*7NNYT(^VO3#\*G[]=>AQ1- ]Y5U2_@$O#]2C.P58VF
M7L3\W-4,RM(W:<DK7%L>$7*"F0P#Y C3J1TH*QRA@KM(O072)0=H=@%W808-
M1/.G)YR M*_3+/CFHUC4"):I=+;JCR_XK+89Y_P[\.\O(8+J(\N8&?J%0H%W
MW107F5%-F+L^ O]@]7Y8V08'/HYDBP/TN-CA^^Y8VYD-L>;6U0@A_[*6B:=H
M&]N*G/ (?3,CS"QG1NP"6\5N=X K=>,;[P!543 1"I:@Z[&YWP&DXB)3>D:1
M*]1!A/8!GF*6F0(N 'ET02?+M>< D*[JKXH3KM,5?SDBLF9:WJ]?(U).P*MN
MI-XM^.(H\1AR7A2@N6U=BM7P0\[OB+_ZJH;A*"BR@"Z"+&[31&:!O)9.Q.1-
M1JOJTK-W:X0>BHCWV/0[X=@R]\OEKODBY:/"3VE)W7+DAX S%.\. ^>5">4:
MD@%<? OP8BZ#TH&U\OLZ__,L'WSM"V</[0E6"]O,BYU:I\?5^5XFLXO1EX7?
M0&(6:Q':25F G><D$@3'D%,JZ[(Q@=R2(21"CL#-31"!PUH27R89&YC/MF-+
M8I+:@U)I7")JY84,Z:Y0CW/[OH,L1W63!X<6N<,A6M+(87X-MY?0G '$-\V@
M-[PVGW&/5]'3R#\$Y:1"T0'J^V!V'MGZUC^:0K2,&M>?*'$VUMT0K@6X,J+Q
M&G8,PQCV574_K("YRH&"DAATV5O*LEB'Y=SGDXN+XQ7@;UE'<C=7G?)X\B$Y
M+QN-$BD+B\QA M0V704':#<S+; ^7XB*N^L9E]IR:&/96@HS&9:IZ1R%C3P*
M3YW'<HNA6Y"#5,2LI0L37%34=&[4S40NPZSY5F"&6.!P+6XZ8N#5ZUA^/)7N
MTM3T\T!H[J\MZ\O++I0T=(VG*$*XO:^CU2(I#W9U&*+B6 N9[G7U("5=U3:/
M^=.[RBFNL\]-B*$.*^?#(CJ(/J-8P];D#6J^%3,:E@2E)1/G>L*;;"&\E&CH
MMA**.'=!EB%2WBUDYTSI<? 6%YBHR4^6]7Y-]>)SA!9@@81]B6@FB)W6X[+.
M*PV27C,.R 7!2CUN'L9[@4WL]T4.=-,Y4!HLH3L#88QLU <J2 O*HXNCLB&V
M]'RI8IP*:O;0#8&J_6!M>JR26AO7&YYUX*?.,<>M':)8$7%4ICWY"#[, :ZI
MDB5MICQXQQ<,^8["Z5*7QFPQ7]V-587LRT56VWDZLDHTC[D*3@5;I1$_0T$Y
MY#6G,/2DC77I<28J^+AV >OE^4\U=>C6TVJB-;(%?JAA+\" (B-(C'H??8&Z
ML8TTJ!O5LBXO0>-XZNN+A-JO_2\^:6=.<N-6+OWMY*_;W?;'_!K,V"D;#L_"
M (M8)<I;C;5$*]$&X-(P)<'N$MK#)7M!8E[U:U]U[.* #J;5W;JLMEQF@#KF
M56W;/,)<U[QE(<YT!V YR1Z>MUK:)W#4;F<2H;H<Q.DNG*(N2%\CV*5QM]W[
M3K!!F:X)<9"V?)7^T,T,*!G]3,BLE#;O(+LNSZF4:O9"?EN9MAHJ@3NKGNA8
MQOF!FN<@2Z4L[!FE6R$7_+DY9T(V]ZFIN0P!L1Q."8=XTP47(:AL^CT\ 1UD
MKN[ ?=]__&Y+D -:/Z8%2$66#UB#)8 7+!='?,/>!(&_@3JQK(5<E\N.=HIH
M"X#;0#7)#J@+C!>9CXAL!/03-Q6[X0(M#7&%25K/^-&*4:%?KP_6_ >@F^H;
M&<Q$%6,NACY"$Z@@76"H!J1P8",;_)WG8$@MO?;@=1YNTYOU;TK@O$.#R$9Y
MX#SAF6-?41:O4_1'OR-V,I49<YANXAU"^Y%J2?(.)F3RYNEQT43+& P(!69@
M@2Q;S>!2K)"5<$=%3+[:0X\S-96R;9@;E%Q'YD^0*%,N_I=IJU3@@&):&OG8
M2PW-GEN*6K'%FU&O <S\$QX+#BM_)Y][P*1U9C[L9&X$%2U$([*'DI[K\ G#
M%I.!3"47CN!9(#\,V$%?LP0'0$T@),LE6ZFY>"S(@P->"8:HU9V@5/)AI48)
M$OK]W#[RTH@.9!+4UVCC[ /FU46XU]Y^#)>+*<O^?*OQ)&63SRD;CB,>&L:<
MY7Q5WVM/J="5;0+SMKU#O##^Q,<5ZG&9T7Z.LECV1]R].X22XVGVPFG/T2ZN
M+!?Y0_<,M8VM)W+(!MK-L85S7B2R55S+99^>Q!ZOB ]6]:<T.QM?(*AEDMOQ
M41U4U1*.I'<BAQRJ)F0&@V[BJ!70#WDC+!(0W_CHN:5OANC J$3H/>2\"O*5
M*NQCB^:(M/C\MHRIC1,&_8XACKL<DB]/KHZ/,GG7-CUT_$*1"]JR<9^U.>[(
M/0:.>.4LO>H#1H4<) #$IR*^"4I>Y@PA)V0B:RH^H 1PD;I(9CYR-!,9V2V%
MMOF0&CM6XJI=@?RLNX7\1-[[%\4+GF,,;H 4R/*M]:_9V\"SW') T<2S%,27
M],;V%EU7809^&1B41EY/CG\1#/I4%:.=$1]SPR/=507.JV$.R)\> -^0OW.B
M+3^O 'O(6?@GT!/>Y$W,<[:!0@8S:MH6 H-A##PPW=J$+:5@2WE4W$SEO1O.
ML^75(1?.K!#$UV&:SL0!?<.K)31B_I'MB.Q=$T"M"L_!/!SYFKA595:TYK.[
MRW1Z^CC1#-E-<8H+/ET,F,IXU8-Y7B\> PDUBE2'Z:H[\(0LR@?T"03H34O9
MTJVL]SQ3A* *56-2M0USMUGKR [DR$W$(]\W>ISS*X91FW:!FYJ:$_&I 8/(
MA4R3)W(!6^U9.HRZ0>&I9]B7J,;(YD^O[QA=8*,VQ+% [7K@:,O <K" $^B:
MSTP&.U+!:]L= .&;V]!&::^P"JQ_U88%8(9L5.6?JZ'-ZS$EX7U*U FFC><'
M\]BJW<BJ]K_@=*S1X>UGS 86ZIY13*PIUF VIYUHP0P&5SJ;@R2.H:^8:DZF
M:S>/G'7&\QI1P@O(%7'C&P#TEN1"OI24[;P.YMXGY/&@P][]IIB>*;L+I'P$
MOUYJ:V+T=!V$J"T3UFS)43UN03CBWF8%.,IX8"8F"IGQ&NH^D#\6H#W<=EB5
ML$JS^:W %TM$="K9(_KX/9BC+DLG6]V/(3J?<;=2.:<6,VD@Y3D( "(M>SH9
MWDF-IJ:BKB!-HN 0H0B@2XN#!V5"_/<?35PV.0^J)GIMU:P_6;/CZ_GY:Q9;
MP2\DW0,N3ZO>B50+_X1L*J #+:(G-*Z@X=C0UO77I.A\.$7[ Q(/OO($0B5V
M?G.<F!$^P1KJ5:JR-(SW=%JD/1;K,"A^S9@6/L=4\B6 H&JY><2+UQ,T?1YD
MCQ/O#T791C*TR8TR-5_"RXL3S7NB"JRX72:)6HNIR#^20'3CLGWA/):<.F>*
MT>,I.;_U^@4U*0M=#3=H1+/B%*8('FR' UNBO$%YT^L],>5W@,'I.OB><!%$
MS&"K</!?S UW 5=)\^^P +.<9+*YT.?8<78ZVP(!P.064I]C"TJ$FZ'0IK/=
M"@NR1^PTR0RN4O&RO=C9SLN[)E\;L_]: &BD_R [Y3+B%V]8VN(B-%G*L[+Z
MX_#:_+(4!2049G>#@T8?D4VW_DS>)8_<_<V?IT"#IC#PG#T&\<=+-8R>D;XH
M79T ?Q<F:%9 9\L/E[SG1-I*"XM>*/>]R2HDYI,9Q7!*$VL-*+\HV*[NOG9@
M/]E=E;/?HB5CR?-D?BO <F=N  <*IMGPCNHV^(X>%Q-"BA!HEQ4]98E5;$.
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M87QV;55%/.ITSKN1%GWB\.4&.]UY\^/XM]^O*7BL;5V_G#ABT$)=K<<5;9B
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M5TVU0U_3;?6XFJ36\6#4O7D8I#?3:O9K4*NV]/.?DOI-U6>SQU6D;PYK?S'
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MIWP%,7*]=@-\WG88.@!LL916>)(ZGOKD-IS_*Z2#S&U:O@U)Z3^EME-3\V'
MIJ65-_V+&A[L[*.$')=-MFIWXK=DN@VX:I[JSX*?F-0#R>?787$5A&DXI".I
M8@_P)V;GR0$Q<(%*P:IIR<NAMJXS'+J+]C_&9Q@Z&H<TP_GC^ &1U]J#T\GT
MJ\6![HH:&?HD;Z(I!'\E.CV Q^R&A!<'Z;Y"M$(V@R-R$D0SYS *,P<_G1I\
M_'O[=<$)CM2IRQN:]W2:N1I5^H7G/UBXS*$6=&-K_LSO 9K4<X4Z>WRR4'8G
M1BOGHMV7:P*Y=4\YF>B*D'OD^M)9)OC;->44=!ID\M=AJ4O"0+\WP-AC@;H)
MJ%_W[XG[DOK^&^5<KI>P\4]H=@S3Y.NVE5\;"#D;-8NDF@I;8=<?7@)<,EY<
M^8F#'D!YJ^9?"0%'EJARELLI5?X<-.XSWNOX[&3#"C+I-._%](H-]7GD[0 U
MK@GB]G=W1TG1^(4XE"M.7(>-9Y-I).;J69'<0-TZ+-G%T4OD CD)=@+8%+Q_
MI;C=]/Y<'L;!_A04&U8L(VW3S*E[D<%AY]K<02<;I5VS?I^1VF#FVEE);?2*
M#F)ZA:_)GT<"ZS#5MO?7Q(>#AIO'EE."HNM)'B$#:QZ4M3,KB.].G\VVZ8V@
M3VX[],Y2WO_=TDZ8H]VCA\>/1VU/S6^6&2=K3=F?VK33\7^-TUJSEQV?5,L^
M/.X2VJI5;V.W9WG!B2,-RK;O(%BUN0\Q";T5SBHW)_N^TAXK85;_3?1Y?SRR
M1IN].W+/*QO9F@U2?\P%/.@0,I6H"\Y< *0)[EWM7 O&83 G=NC3Q-BO-G<_
M5AYU2R!WZ/$S0H- IMW2VQ=H7DX##XHT!/\:F<LIG7*((3K*?4I^;E?6RE\+
M6ER'14%ADKZDM%9 #RN$(MR'\!H^+7<8!J^'OG]>0BJY8387"(+\6&J,K$)H
MIDU3ONFR1[./*]!1';/V2';J-=O"^D9ZE7\E*2(($K*QM0O)(HPOWU*6/8;H
MI0?Q>:K0$T)INSN-UE$@0,C9%S_7B?TV@-<(K2MI:I*TD**V"%X=FNVF=N@;
M5IY0WI%[85!-Z#XPKX/0]Q3IUH+!M.>$D5/I; D4'8%8@J"QXG'>CA$YMQ+@
M)1A<L/94: I0*'A+<P\@@N) ;>_AIK21X%#:H=I>>,HL2G$&[:]VH[Q(^\TS
M1&]!(DI;9 G2%;Y"R$Z4*FA<D8LJJ))-,_?HU\F0,W0.;^PWMGO W^\:6&MT
MAW/LC,J9*DWSB*V&AS2;GVS/@$D?^!'[X*WEW07L^QS183F_UD=343R6;*4Z
MF[0=B@;U!$./QPM@/,L?B>&C(1AP.4ORD6]G(D./(&3E,LK+H&S9-9.N\;%*
MX#7.[&#;%.HPZ)UJ7'NX^_ET]6\S'3:9V\/?ZQK,.$YT&Z";CS<[M8MW0MV@
MN@.HG5:)8Z  EP0J0\]^/,V#'Y)(]'B!X]K&$ZTEZ],&0E19"Z?P!7 *&!&_
MI%66/A<4YE8]= 4F?OY%< Y,O?XC-LYNXX]=,@]HD(PDU0- ?1-:4I"'?PC^
MV>'9D&@A!WHOL,:T/3QND5@A0HQ\4EU:T)N#ISB+[\+_^I;0\8IUX(FFUNFU
M9C3NORJN9I("WL%NF7*OSY.OY2-347LY1'C55TAGG%%4,ATVE2\/%> %<C(N
M.$1*&:@;WHQA-9:DC\_H>:F>X@Q%GC.[!@4#@>[Y6I+:1K$'&]H,17L@YBH:
M0ERN@YI]36-I"Y2H'ZE$:_YH2)O+3SD-(ZHFT2/>&6A%RQ+EA*XTY!PU\?>R
M*4?S4%\(DHX(B2@.4.M>Z@IX\J7"= A(#\H=G.%@,9"IY9.<8Y'G0[)\@C[^
M,S^T@KWTVZ6>4],?]HT7RS#O53W;\&_>+5+'L<S4.#NG3U$)-S6M-MV\KML*
M]G2Z[^X-/ITO%7KWO,VMRH<5I\5*<5*3[!TGWU'ODW1$6FM%9+\9<V226!:*
M$/#42%UB@^IJ#MT0/!E\<\G!OBW7]8=;O\6E(W]]P08T&E2K%)8$D'1[^5Y:
M[8T1CP2C^N$.IBYY9W3'$90Q,^BM0'\#1^B[S!S';I@A;<T4M/22$"-3O!V,
M@X2&<?? *!]"/#OWR'+C1Y0Z<*]QYX6I3_4K^;1*J$: V.&.3A"IOU3/Z]$3
M2,S2,9?&^N5F>O]4V=KE9&$^PM-TJ8Y;H/?;:=7N3F/$16?NS%MO1"+J>--:
MAH7UZM^=I=,^_*',51<"VJKYK<DZ#$32/M>%R!"*K$)V=VS9[[";:"M\*GW*
MUS/!OTHY*6CWJ57T./Q!W>FBD?=YUX)#[X2V'K@:<_OXZ5TG]\8=>W1_S:R7
M'$C^LA]^EQLR^ZL4DF[G,#?-BW=,YT[$CX^088&YV7F2,(?G#ZR:U((WVJ8C
M53R:Y8QM'9S).[U>D'2Q.P-SCUTP?NJ#R5X M 1^;<VV?$;CU*HV(46"AKOI
M\$K(_@)$&\=N)A2Q<AL245K,5C+T.!%*4:%5?@U :8#I<5?^>JV>$N-W"KR-
M:RQY=++WW\!Z!U4;GXQKE1HASQD-@P=X9$@%I15'/--V)!BWAZ]WUGMBZ/OM
M.N?5%_W]^*ILSEQ/VIAYKTX?=]=?K];2&D<?'B_-#TVM.K7W2=G>A_)Z4^G0
M/C(%7W9CK11U^,_%SO$%=2B]A;3]<U45(V1.+KK51//@P-)PT+?M3"ZX -)2
MM9T/^A38#O0R":VXG]+CG6U(KOER2=YE,+]Y?$&!H+7L#*"2!7 UHC4TX@,;
M"#8NV$Q GU4K7BIH>S-OC'Q-2'$!#0,F:[]^'3EZV?SWT=:0$2IE'=:0T[HP
M3&GI(QX ;&>GA'*R++24$?P_'W6YD-QV>5R7;G4P/>6O==B5:89T32\-62NZ
M!$:DX4_R.<9=<MH8Z.SL@:=7FWKW<:J,'- 7IMX?'_/$#BWW5KE\+ZKA=G5C
M29UY@D[5*^ 7ZW^N9 T*1L9&[+07B@)*,ETX>3CL;^'>T$=/PM]I',NWW&S;
MO__NAZBC%GYQ9A+^C(ERX<LDH\<K2(>K ^JH\B)=**R<4'JNK\[!R:Z:(B@I
M+R.$"7A)1&^C&\"/UG58XI@VI;7M#$I[:FO59"WT^SQXVS\[7S,FNO7V"*.\
M$*KJ$R/T!B7=O9!,>T"[6F[/5]??RRJ=;"<:"T81?$VF7ZD=V!#X'MW:DQ*U
MN;;JJ7W+F"P0[G,QCXU50'[O7TRAK3J,M+_HY$MJO=L*"W!:T1_9>>KA"=F,
M6V<N=X[IW-U\\E,T7D W[.!IDK:(CC3T'X3209\63?EX%_J;ZL_?.43'$FY5
M$3FX>NT9E][XM.5)2__?-2D%R'>15Q7_Y;JRR&8D"S!GSD/H2K01ZTL.5JX(
MQVZ?86QKY[3+H3$@AD5--</GM*OSDLDJ(G@8D&N);D49 9\>HUN1JI!3*P\N
MWM\9NH%X^O6;6AFQ0H'B5&Z&[_0ZK/8.U2<4C-J-#T+Q'+%RA.CQA=3P'KG)
MHVX0KI.D MHFBP\2X#9Y[+'-IU^->1 =H%(!#A[?D(\&0RCY*A@YXJG$P;R+
M@Q9(_ESP4?@7#:QXFR/@W,^N?$;P8XG18-9H=GJ0 +G;\E-\*1$U*-+@X[IO
M^INIIG!LH)P* MH#+'F$UQVXUH"AY-YH[*_/>;EKR.:I!+KLK^#?W!^:-.TZ
MX/BNM,3YLMQN+1WU^.WRY\]OU6;^6P>9 DS'0;J+A ;A4/ J.QN8&ML#ZK""
M;DQP,9IVSXBFT2_KRF5YFP@Y;BG>H')]P3@OH:"N@+7FTZJY^]?%W?1(P&P=
MQD;M3G?DC _BB]9D1>I#]-."@@0RW,):,'=XAN5]:%"DRI^A[O)?>;&!Y]AO
M81M0*AL4<NY-39=M27UZN8WGW,3)XQ7* P^EYHPNF,F+Q77_RUEA_T$ %Y"I
M/UK<C<84^\)'(SQ36,YJY'9J4F/98)V#*2M?%JC*9QS.:3%C-$=0IW/_7OF4
MYP,BK#[370QR^)<&:#/Z.FVF(54Y?0:"1.S@"H"\C]C 4"'ZI.V%LL8M9=I[
M8#@]_%#XEV"+D9 \$].JT+7RDEG$B+3-6_V@Y9>QPQ,^>Q&)8QI0Y7A[(SA6
MSD?OGD:I 9Q$(^QVT9'>/OR0A6&YN\APH&X4V9IKFB12R?#TIJMPR6V2OKD.
M4T8=(YAZ64M<9'NWX;DZM>*AXC"Y&*EUF*R/X/![XX[FHDG-O2 EGJ2>YFT-
M.E.*9VJ0[=; 6)H@ 1A+%ZRI66[XJ4]NQRJ*+43[^T0G2TKTE_1566ICF<1>
M*/4,JX^$)+<:B#6A'N=!VBBB8VQ_BM>0:.LKT=$!&B*9I/I9?-3S*V';M\YR
MUP#2KKZEC4!E P5IL2DT-%(GSMC>JFQF.22F_._,#3\B/D119[56+Q!4YCLO
M]ANGA;%7E)<JL_- =4?(07B]&7H/(CH:46]]A<CMHAO,=5A""Y)^<-S.&*XZ
M_ 6'.@8@X\/U9G#,G?:X8 ^Q0J6B'B UU>B[#FM-B;%JO6/6$X=?ATF[#O<$
M")BR@2B5H3FJZ%@A0>944R.(3K"PBD&FU'6C7?,G>/S?LPG\?W([N#,N'(NC
M#%VK,L\>C8D'4]L@F1;N?-8X3\Y*..63V<[<@=</7H:K$PR]:D%4*>HQ/)ZQ
MC>C2:Z!_\P@M)44_4'@92@.=C?OQO!V6]-S?24MKI^],VE5Z#XM\M<1]J UF
M-A0PNK4ZP-1[+R"3A/9;4"^AC6.4"5@^IG5S7QU9EF@.4.]K0]12%-,WHDAT
M$?!.$]B3-P]SH2!:D%([6MF:1F_\D6!-F\C4H9 #?4JG-3>""9T4JO[B#%H%
MRFEI/.!L.I23@SH.+5"YQ'#P[Y62V''[10I[>0P&-8 R JR$,#6)MB#J_DVJ
MOE$H-3#*)/W BG/1+AF.]WY(25"@00CK^$F0Z2 I#@23]N/4Q,]"ZK JKKQ(
MKDT3GYD^9@$\ :M*&E'%^AUY@AXN@K_(4*I]G>/VU"?F^,]VO*6*\=E/H*3?
M]-PW-;/MR);<V[BUF*7.VH&*YU[JYP9F:3'J_)Y4TG&(:M<;_-7]?<FC\BG$
M=A3<N*V[< KAHS:?*TF;Q:C7+G$$P&'#*6;6G+OANAY.P-\2!7?#L<F\D5R+
MWU@X S[-@$/-JQ8!#+E^$:Y<QDPU@6A/!O+&&3F(A!=,9G76(GDGRX_?>WN%
MWIOJY2'DL>1,^<K+E4+$'BSAFOHZ3&FZP>SY8]'ITFGL\$KI[$SQ%\(GH4/=
M7XWMR\7%4)=0)]7F:1G7SJB/EO#1V5MMT,7>'OPTGQG%[?&Z.+PT IJ];ARX
M[\[P]6V"BOJ=&?.EZ2*G!L@0D!5H5H: IL)FZMQE(.KG)EIFBR9\[86%]7CZ
M?;0LW3"B- V) 8(I -ENX'HO/>+9^]MS_Q5$MZD@66['[K/[3F@VC:_#8GF;
MET+NB7<W 6A6FI4U@$D2(]VG\A7J!A>92OZ-6918?,AFHCV(O2=2LOQ4]K*>
M&?V<.R61%6Y^"?"=L2V9<5'HWKYB4[J_QAG=<L88GL@P!K2+5U5%FR4)ZH3?
MS3<&'>H:<K$=!<.=UC^)&L73_1K>P@X$?!WFCZY)WS'B^D/M^U).&J.O48.U
MMV$@ZXM^3.0XDJLD4'E;2#2AIPA\)UXP#H*E;3%&QDMCF5'&EEKL?+FU#"J^
M1W[83N-)2M64/55T:M"QKN,K<?0OOKJCHNW^!S<WD);Z&YK+S_-4;19%F+)/
MU[FNYLPX,].@DR$5X8[]#K0_AC\6E(D[H(A]X%A%_IZW_0F='3R$?T7NY67J
M'G=\_N,2\9#[<P+V_,#YLA_^^>H%?O?>0;Y;);XQ\-)GHR/$H[=6#+U#$<HD
M>='A6F"AO?4EY"[N_*L61'>8SPA?V N2R+5$#7ZEWC(@?O]YT:-;]9)]$P+>
MM0[;@J3$0>HLDO.]N>?0+?B&7S?QB+JEGK0"13^@I+9<LJY# ZU[.AQPK)#;
MC:J)]G)28DVB XAZ5/P]O&3K :=UF*_.\@UR0_:R7LQVN^68\V&>O#24J>A\
M72V4MQVEYR&;#@]$JX8/#FAVL1ZEN!TQ#AFI/=M[Y>VCNM9EM_N0:5OL_L<9
MU_3G[NBN>M=<G\KB1IG0YE<+U._10ZL'J9'FS<@ VQXO^IHI2AJRC 0H0@2;
MMP$1SU337X==)R>0]@Q5U(%\9/(ZK(Z<;$Q.1N\(EY.?R[L D8, )'8@,;8(
M(K-=HJ(":EH%*@;Y&GI2:9ZO$&6,W:(M9B$)%IL$^JI\>FX%8RM$ 48N]B]9
MFK>"TRXK^N-0V.IQ*+-=\WC-X^>#CK.T41]^(FT=MM6Y$5T3-&\M?G40+'D\
M 2.NPY:3ZD!;-C-9;-'/#/S/3G862.RE7\]V0K;=7!5I,^F3A"/PF/N-VWKV
MI D*=HAB:AOHF>=][YDT+N?N=Y]Q/J^^&CCAZ1OE@%B^WV]Q&3 (LF]!*RW9
M8Q))NR0Y3A2V.C?DZX)RQ9_2BKP@J^6/D OP@]55PO-RPV5'O,:,(^">DDR9
MD_!YR-D9?03[X714YO/7OVZOZ0S_0NN/#/5X$--?"92/.,N?Z,CKT[O$=;8S
M_I3U8K$IN-L_8V$^0Z0*998$1"UGC:-AV@\E-<?;%&0\W<Z]!H79T''PK<1
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MD#B%+""S)5^]UWAA>&$Y%FA@SYVLFU/Y$K@B8>#)QM+X^467 ;Q1IJL71J#
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MBE4(CRT4 .%R.' !"@-E!.$D31H8-$\%X]DN*]B4G!8T?.^@;[JM"Y!SKU)
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ME\/B-MPS*MA#O 3-"3$4[,Y9D3&^0F0"#0)-@H)4VD*2A)Q%F'(/^F]G[P/
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M,=3980Z'VCH=[G.Y*A?QTY&V3VS+R\;%_3%D"M3K<S<ALA9G\,NAWO#W"#L
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MZY0:?7UJ"BJ5*15LZM3Q;-]00EJ]>_T3,JTZM]A 5,*._20QL*SK;(52,>G
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ML+)%Q45H#@XE5?_G"Q67$#T'BJ#RJL#MA% ;AS;/^*=%7 A[$6CU+J>C8">
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M)T.!L9F>J40YYH#0I!1R<(*>351A.R[.T+A25?4HF8!>6]"IE:3:T-S$%N(
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M/?X?H39D4AGHHSMH:N/?NB&V@^Y;':".8[/0*"6"KVO=H#5J_#(PV?&_G25
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MMKM@ZFR6K//$^B&N:\/;'A_5&[6#>XU-T)_<4&V8VN[6&@U/X;6^,(J"T([
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M1TW0R*>DTN FV$(F[FXMH-SC39 ";46T.XC>&E&6SO_8*#-\().UN8ALD_^
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MO9G?$!8]45KB(A^M"9]>GUO#T.P!?-GY^TGD%-;AYP6U[J_8,%TEG$9:&(*
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MFE?'0CE=E*S+\].%V/Y&)1:L^ES<)ZI"6OVUUS#B]'9CWO#W<).DKF0@\8/
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M8?-.QC_L(XKG*:.AS:L<1N7N'?#\ C NM77#V\[S;_LV#'P9>>9U9FQ#7'B
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MT'ZA 1/[_D+HX)@GA<=0VG](84R-Y;WSF(J%("=Q[#,:]\Z1A*]1WQ-PSV;
M],E>(DB_U'A=B@A?T#9$ZHV]!I@_K6HB4E47J#Z(7>T,J:]'-1<K#EVB5I M
M&GO"7 MGL@*&8<YRF+4QAEE[E= :_ 5HE"<IL:!FGC%4W=ZAO!$5GY)E;SRK
M_:3<<K?DT1#,0R5=7$!'[JAZ>@QN%&P\A8$XG% YLI>2YAJLAG$"I-43YVH+
M3K#\0:ZU/"O^5TT M4GHU^"C-/S>ARB6U!WY_B$:IDCO,AYA7SRO?TX8WQ?6
M (J-<SAMNS^T?WK>$AX2!LB:LU!&+_(GG@P%5]-6Y TMTL+5G\#9#]0,\,LO
MI+EALH!'?/A#C67G69(7\BGO1N%XP72B(Z<L_R+?7AM7K22# 2=B[13"  )V
M$*X[ZRE/'6J-5D\!CG,I#IA$2Y3K##*:&6LP0QM>"68 XOF7Y(P).N#9%J@/
M-EYAFW^"2Y2 \^4P(?(4D:1S%[%M*#;NGDPM Z3IANK3N=Y:$01(99=HR(%:
M<BDZ;]90))P2VC*$_/5G9BRVL:.[YM_<(+YK;R<VW6'S*LCQ63B_K:HUXF2?
M";+8+UV(MY_7V<0K>QXBR9^IM?E1TIG-#TW0$P88ENSVLE?-:JS'T3")^HE(
M$R'[&6,^(B5YZ;IAH5GJ7,.Q!EFU,<2\)655#P_>,/CPN2L;!&;&%#!D:U:(
MTMMAPKD:M>V,[\A@V6IXR23.S4;*E5SR=E<)XX G[T+%"];&:9\>MTNQ?':]
ML<1;14;QTE$;$[1+S/[4!IRWI7QO"B*-USX/?XB&XG#EP^:T/C<+34Y:(VT+
M7A9L)[.+(B-H^6-S>?^ (HF"-=PTJ7,#Q5"CXR+S[' T!;#R8H&OII>Q(]MW
M?7VI9&A$9SS(2@CF29N3[O^H9G*6(KU/D@-/BO7,:9],EAE<2"[MB&7W\\Q(
M7PU&K:,=!)&@V31^.%</ WY/7D,^W(P4SNHW1O?O_O)9L>'.*Y_0KJX#7IR7
MW74][]^^_7#XF8TGW*&Z&CGA![$AK+2'CJ;-=D?N.N<Y-9+=R(OM'>P0\PXN
MB_X"AS=7> ".K3!>+.R3C.,OK2E'[F(]44>UV=$RU(JV)QD[B'L%:J2U<?A.
M2O_H,NE:23-Q%96).;$GH0?Y^;0MH(S5SFIL(M]";H+Z?,<,C5!J>=W]ZB7"
MR6C5RC)NF_UWKTW0/EX&DX'#J=X)&T(5#Q=?-2SCK^D,:=9;Z)L3AYE1!VWG
MZ<07,9T)S/U+USO0%9LY6? X(5.P&O19@E+G%F/PY;PT0?NS@[3M)5K7,'@'
MX:YG'*>L0==]3BKJ"E'C)HAZAN&G2%TE[3Q\BT?G&Q]<7.BG&NH6J R!@I^-
MCZ13^/F&F"K5* R8W:+3@!5S, =4MNPC,K;"%^?5MB\A.GI<C&7#HL*P.A(E
M@M%JC/0"C=-!/6V?2XB2'I)BVKX1<)F]0C5_&\^V3H,RZK37O=MX#FBUSU40
MC;515T 1>]%VHFXNF0<@#0AW?[BK/E@Q)*8<SNLGE.1R%M ->1 Q7QR[]VI[
M.S^I"FYC^^!(<M_CN!"ZJKY,,HD_;%PJ%0:(VZ )NE%.C^^.U9TSG'"Y>,Z3
M[4*#-/8,'M'K=:]/#_=<YMC7YR2/4?ZLRQGJ8T+TQM_EX;>^!GR(ZP'!G1$
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M9$2(FBZ.2<5T6STLS,JL/CLN2!(N/!EHBP+PK6&47\F?+4D8!@<VJ$UO$_3
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MP:\B3#L[[63M/%^*MJ\W]E<OAR77 N9ZQ;Y>JG^?[-5/I-(;?\'^L9Q! L$
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MMLG2=5"<.I+J6SM!*G!.'F%:2L+S62H%-VT$F,V*J-/<"/;Y^#Y7#LXW,O!
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MTPA<P19AQ\)&+B6MU *$\KDJOG*ZUETU*LC8_[(>M:\:IU[ K(DJ, 7]E5S
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MUO7$'2(<NMY9-_DI !L!Z*W6>]?_WK!/=<EHR\"G3I#>?@44\QO!;H.'H+S
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MP);Z;YK=:1BDVK3X\>RG#1.D$%[<>!^ZEL@L$VQ]1'FLHL.VIG/!AQ&?$^[
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M=OT)_IH*19:#?ZC1]WR:>[!3D5R&[DI(ZW0]Z%O=50/"*0G(*EA\2_@#W1"
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M"U^'953'?WE81%^M]_]=9#-",\9. SD2#YW5F04_*J^?0TKDFJF[X%R$U>1
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M >1)>V%C-^!T,?L#ZM]UZ+OY@O=?QI):"_F6HWFXCZ^,"I@/&^QE0VLAVP=
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MK*^O@_98'/_X4/$_CA'\7Z[&^!Q+5))L*C^8,^6847>253:1,4TY>QR0H7:
MB^18:I-L\S3_X< CS2S\QQ%.FZ9\+BR9IKS_]?$#PF.:\BT3NVNYKSPI'+?I
M)^\6F7]]8!-E[W\:6":UN KO<Z>N"-_*(-XT)7&:8EI.WK?_?VTSC4V2#.?^
M0E P3?GLA/\TA9LT)^_#>T84<;7NY"I=9.,T15M4.TU)K9)8JCQ+5UB_D#WY
M,_'+:4HZ1Y33_DUL]O&KT6CU#LL[1)]Y<70;$:>+?<3W^W=+>^CO5WW?I>?E
M;_#=/N>$^'\<&YY^^M]02P,$%     @ Q'%\6Y,@V?/A^   ;P,!  T   !I
M;6%G95\P,3 N:G!GI+MY5!/IMS8:!$% #*-A3%00%(2TRJ 8$A45%2'." A1
M40%IC!,2L4R0*<Q1::6%EHB(J#2D$1#%F  AT(X!42(@))6T@@)-E0.6I!)N
M^3MG?>>?N]8]ZWYAO5FKJ*I=M=^]][.?YTW5]-MI)<Y\\X9-&W!Z>GJX?=@?
M;GH %_ASZ__J\]/(_ZT-O>D6G,4LW(\9]OIZ"W S+/3T+?2FVW$D'$YOYG\=
M@/OOC]X,?8.9AD:SC$U,L0,:S7$S]/3U9QCHSYQI8(#M/8?MQQE8S+2<OW2-
MH=6V_48+CELO.W^Q?);SVKI6F^W=D,OR R?2C$WF$FSM[!>ZNBU:[.[MX^NW
M8J5_X+KU&X(V;MJ\8^>NW6%[PB-B#AXZ'!L7?^3DJ:33R:PS*>D9F5G<[)S<
M2T6_7;Y2_/O5DAL5-RMO5=V^<_=>?4/C_:8'#YO;).W2CLZ_GSQ]U?/Z3:_\
M;5\_J%+_\_[#\,C'3_#G+U^_37Y'?DS]]$L/I_]_7/]_]<L"\VN&@8&^@=%/
MO_1F)/\\P,)@YOREAI9KMAGM/VZU8-GY6=9K+Y;7M1H[+]\.V1PXT6TRU\4;
M7 C_=.T_GOWO'$O[_^79_W'L?_SJQ\W6U\."IV^!H^%TND4W<G$_!YHN%\=Q
M!CCMU$7:1N$F*"Q8^T<27U_WA&,3!G[G4FU9\E:%E8.*(2TO9\LXLZ@K1W/%
MU@WX[ F0;S8J\J#96$FHQGMT>%9CX*+D^1$A0SE0PB2"[((#5?B,4X_(YD?,
M]L,= \KWT[BV\84HOC:^N?#J76"/MBQI&M<?MJ8;B%7'J!93EI3-@Y,E,ORG
MX=;C'0ORKYG0C?;?&OSP6>>FS6'[?F(OT58G"FTTNSY.XTQ%UKI>=@#3'EW?
MY2U.K=J!-)7'1RA:Q5S.K,9!0LLT;F[21 X>I,]Y%$<TY3V!'<6S  8Y@Q3I
MZ1C[Q.LW2N(TSD "A3Y23N/R=6;(275-$$A&7=TF8T@&Z'IPT.53BF ,OJ-[
M&FW&T&=9[>W:(%;I:T4"L+)(@O]@6P<Z)<80]QU?A!MME"'NA#%YPDVW[#$C
MJ<!Z9'>T]1N1*TL6!A5+0I+;_<,DO/0(0KXP29F!=*N3X]0A5J BC]!*](9I
M:;$%A^"J/-3A>K!Z(10.;=XL26CG0]M)?5_6OJ8P;PY\Y-L"@?CSU(7Q)$-2
M.]$*8=9\$MG"C Y/%L*)[M816%;M. FH,&==%OK4CNC<-GVFV(O,F3["(V_C
M!CY,\$C0)E)6F3^\NUB &'Y1%G.=&[1E(EO=<[D]O8/>%PLVC1-%-I!16T%"
M%%&_5S>KJ=WL# >,1@,9^-&IX<R#T[B,<N"X4D#80''_C+CX9>ZB"UB:25S3
M&]$<E(%LNL&2M59L1/B:M5AXOYPCJ9);F(9 %+*)57,3.2NYB"Z'.]NN)0J7
M .O!.Z7KPBQ9P5*=&?SK4C<NO_7DZ@-Q(_IBF(Y:+U=R,T\Q#:+?L9:K;U6J
M\'9(D)3JVXSLOXE:PX65L$=+M 'D^@ P5O/M$76+1@_ZSA4N5FUAQ=6]&UI^
MD8?.<^LXNX8J@4TG:Y$ )2,CV@CI(=;=009:IW%62?P9>X#YC"Q_ZATUW0((
M?T/U,.A%\3=9A'5=!RZB:X%MX#W=HI"K@<JO3+NGGZH_ZPY^(D$;\&:^%R&)
MQJV38RR,5//T$(**)W$84!1.X^Z)N)K5P/(NE*SFYY0,2Z^9;D(60DV=?,M<
ME,3(]->)JY&8EB.Z93 OXR:TB3@+?D==:GSQNUB*[_,1KH<8DQPD04FS;Y+P
M"+IG.E>$H9I(U_D6MT2;OQ'Z5"&E8')&DABW;DK1)L,'@7@S3IN?2FR6T#_,
M=8-D&:36O!FCLFG<K/G0A>S-J8X;'D[C9I(0TLV/*4M+6QD-OC6J:SLD(G^8
MEZ>S9W&4_'P?>@[?!%@,"?;R6G14F"?%&_QKR4J6B BPR;W%8?!QN BGTZ/;
M_\JC^L1BQEP>/M;>]$2MJC[19M/ LD9ZOO_AO%AXW^"GT4?*#TU8 ?U#N_\[
M<B6I1X!%?OE[GL6'7P8V8>GB))2ZKG6I56_5YHKCO>'=E7""A']_U_VK\$ G
MQPS= 16I!'F4( TU3K< VO7]?)+8D97729TYC<L,4]*0/4,6-/RWB4RCCN;O
M68"I6Q[E$)SM/_H/\I7U9(-ZN)F)6JX"SUWNN ;6JV46>X$%/80MW1S0I/G^
MA4_#+?T$U.J;6%F64,ZWF\8Q<935@!<-=*<NH5H;;-)<+Y!<P!_NGL8I;T[C
MZA.'"E2)G)U_(8^4SI4(K4UA+O1+A*U 4CZP4D7.H>K#G05?:7HL0CBR"_Q@
MIF(2-ZEDV=$N$".S6/)+.X5)SJ<D@W%5T#Z&37O",Y2)S=IRJ/<:3 "G<:E+
MJ&;H4>BF;C&4/.Y7C3S;C7 A;H?_[G*(OQNQPH 'Q_KB_R'#)B@;6$7C L>O
MLR[1+5D[.CSM=H"_K2?^6M46'0MI=,96E<@JR=2M-. ,E"YA+^)*.$9_BAR0
M425I+ 9B*@79*$TE.$^R$^K!PRUB2]V2A&:C;#02FV/1?$ZVPI1B#<2"?"08
M<%(R[7]'0QU:$UPN(.*VZ#=JYMM8=:PTD;D:3FY7]-=&Q71,-M/&\<H)RTWQ
MT+:OO*S3G-GBN(DLW0QH3KU2D,F>S<CQ4/%F<-J64/3+D3^14BEU.5S'F3NJ
M<PM76SRS1[;H"QNF<6GY@'7N1%M_]"T@OB9"6ZJ<R&*[  >@B3:!'3Z--!L]
M"\L"(=\F)=T0&>WTJM*9+U>IU7P]\P?P?B@,=1/94ZFE;9LRCU8HOZ/6^DI>
M!R,G@B#!&W_DS/6^#V?5P8&2:#U8ED=U&(UV1.+5"FO4K+>0"T>VZF;#90\6
MV$_CLH4>7ES5C*?<82(1#G6@VAPKTS-"K5:UEW"XWY@9.B=MN9EX#(9I[?P9
ME$1X /PVW-9SFS4L%2U&')3\C#*#0Q!=BJ7C4S:)%:L2<*FS6#:4XV \Q4Y-
MF F$#LV$J](CI?MY0F"E-EL-6?/O:=N) 0]>=X[UP&&394AI/ _OM *IX\3K
MPZQG-]0ZRQG]..@"4I5A8E>9:!QF<?0=SD?DK1LD&;(-6$WM&"AFD"S='B*)
MX,1LI$<=E(M:*!-/=D8;(E8@W4&<39#TRZ4<\Y%N C2-XU;QUO2BVSS&8I2"
MF2/W6,.=RUC!+:5>#OG:"^)X<8ZB(;F#-F 5+!<NT1DA3 T59=(,J8[Q_GR)
MP)9ULKWD69R(U-7X^&Q'Q' AL$:U4>BC.G2F41G6)B) ],S2UB$+CNE2F)_/
M 3TW<'G:Z^+]/'O@$,P<7XB!3G&' -FM,.8DR&:P8D'>N(<R@9^Y%)&W3RFR
M*+3R407^VXM(,+8P4DJUI..0H@[.G,9>2);W'@Y+UWF1BV^P8CJHQAM=URZ<
M^J(,:LDCI=ES.Q<K>U\V)L+%:G$.>[E#Y#6RAA+'&! 90Z3SH;D5_X[NQZ?M
MRA O*4SJ\@7JF+@I=NZBZS/^-T-<1LL30SOYV8K9;"]VU]#<]$X,OVTZT<7T
M_M@6AC[%6;,,R9)TE-#'/>#J+?(&1H9H7B*SE;BL2+4)>LU><!A^V0Q85V$U
MB\X'&\SO$9<SNMZS5P([L50_C:Y',L2-S-3(R:N0(DNDQW[+MVBD9Y-L*-:T
M6#&RB>JZ)S[ENX2$ Q;*O]+TT9URG4M3%L7?03)DO%7D2INU!UG9^#SUM,<%
M_*%>L?(&!JRG\-; %NB]B N+]SY #L%;T-FOCWXE9TZ-?AQ:@F#1?WN"GZ8P
M::^D@0$(5WM>,%+FVG8#64JQI 2IEZI=\EIUOYB/!V)P-!,)IF5^Q3H!?PXG
MCF./W!J5#@5 8=DB<U:P4I#?2,NEZL%!;2\<ULJ!,S<01>!;RE*P&^--"2D&
MZ=1?#L$5HSH[HA[#EF<SGT*LT!C%KH53H2"I-JB-9.XP^?BU.%&0.;3B#;
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M?"PJ 1S.TCDCBBCD(BGS/;*%<KC>  I&/NR)V;T/3T&.8S>BAU2>Q+K'4Z0
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MP_1<3+<X<[(CR(5 ""D+V/T$*_RS2"KMO/ U<8\N3>.[J57?$9HS]'-E1GM
M_ ?= 9F#3^-8^_#.$VDPL5)%UT>/]E*VP?I*6AXE\,PTSH8V*9B43WXO%-DE
ME*WXA],F@:JR&UOAP%;B8AGJRE[N/XW3XOG&E$/J-9K%&F<TM%?GAB[H(700
MC+;!\G2?<SO JL)O^XQ0^C<R_G(4H6/=\8LJA=E]KNI80!+\]D#S7PCG[KY7
M;9\N-2HNUSQ*^?C]5R#(<I@V@ :6#-M6/EOR[\V[#ZH7OG!]-W;YTJ/$D2O-
M20^_K5R[RX&R:.7HDQ::^O64''1#Y])440H>6Q\9GF0C=.8=A-<Q%5VCC(I5
MI7:13X6L"L686);W;@QUQD92AIH$K**V(V7S3)H)N?0L@\(O+/\-LQ?0K3NX
MWQPFKR+7:E$WA*SB$Y"CII&\N2')-Q&_UHX1K\JJCSIW^.7C<@0?V)LT<;D8
MPUR3T?[7[(4PUZ3#<\[VC0=NB2U/\0QD,%\UAZ?Q9>E+(ZY@W&B6=#A3Y\9^
M13)_\%H8<OUC3(1N2-<A3Q)-X^PX<32+$2 %6:ZSY#C&D* LDJUP-W&/T$G<
MK!H;>O5X<N+T?LG#^VZ+7BY[KC:V'MJTW>?,P2+A]9Y,54_HRZ4ITH%SWK$M
MXGK^6.E=]@N^)=L9JR);MDQ%S^]W4F2*+)%5;6QCHW;.OM??)@SCB %RBITR
M=74B1T7*,WQ8CL08&)+>KMA'F87/[_P*:Q:@<WJIIH!?,Y-0RD0B2!8^-1X=
M) O=DU/RJ</7[OQ\U\9^3H'RA?'3%<PY2+ DQ34/Y#^J>T^W0)Z4^,%;KGZ6
M]3U2\MNJ:85\&Y$KXM="=&AZ"/W+ YD9DQSS.5?D.C^Y\,P-K,<P;!J+8=&C
M1U*BRQR?B9DL1D>9*V>N.)]72 E0,0U8D!&4\HO612O[UY]3_ZV3,QH='7)I
MW^=:YMV%$PQV\=&IAFO?4B8>4;_S4(:*9AX3NO+9AYVO=_Y:!N?FQKN^WM[X
M>L=8[7ARQ<84QQ3[B, NK=E99FSBV/AH#USW@P<.#\C>/Y1%KXV>Y^JP?V5T
MV<WQ@.,OE_;TE"7\J-7>XQQ.]&@I6P3+V@0V<?QX9"%\=V*'"#EYU[(B]*_7
MC:K^#XW0F\;K&+D?F@>)L[N%VY3I#?.A$TCBSGM(8,<63N7.K2Y>1TUG%SU5
MV]G]N[13H&_;N5+@AUR#ODLX-FP24@PJ<D]I5T6^HFRK^!3A,WY+4/'1_DKI
ME[2'B82]2R[M(S4G+[C@\NZ7/VF_P!Z2/^O;]S[RE*@JGY3\<SDF(B_]#WMA
M^>+U?=55BQ:[/?_>%\FX#N9K#_Y^U?TW]1^';#X^M0$]?)ZM>)T7TO#C&O6T
MZEUTK^BNHH,W%JA9A3*U%VE'.'U<=<UG.FP$LJL2X#?"0 &R)*ZJO62"2S$(
M:I'E^E.;E!P+5EY;BS?',NF:D72SSFH#=6D2<97I9:(IK1^?IIO/8JC\,K]R
M[%B!D?=[A33!VYJAHKOAC_PO/=W0,<.Y*=( 1*F?:F=<D# 9/]?=+'2MR$HE
M/I]F1/'#JH*7S=;O9]UZIC9JX?P_;+UY7!)M]#=,65J9DOLN=9O99E1N9025
MF:D9=5N9FE)9J9%1J4F&4*F1*RUW65J2EEFY4*[E BHN=XOADI):LE7N.5.*
MDP[#.]V?]_<\S^=YWS_F(\AG9JZYSO><\_U>G.LPOT>-:7) U<J1T*W00"X=
MYZ;&W$,QFDCPR,4:< RA7>CGWU#_Q0IM6KC 733N!DDE9I!+C^ H+R5 A].$
MQ?I#;H?*05P#JS=PY\?R-.M?7K6NZ7>8RP<S791RJOFR^6_ 4&&K22#%O-B4
M!MA=G?>.U1!"B;[Q[55-OL9"8_O\=Z9/JR5A.UP=OQ3G<K^$R'["6:O^'<@B
M/ A<_L#3QX-R?K_="L>,6P_**#=)IT8:B6L9AP!2O6#>(8C7/-785SZN=+Z1
M-W2@Z!F410%7YY!>EE&P@]7W)EOC+KW]:_VEX7S, B5P;M:D&:^.TLM2Q"6*
M&LE).'WX"#'OK(S%#E[:Q5\(_P7D%3TZF?D X>6.I$GC&&&QJ_3[%T.)8*"<
MF-IOLE_K)+1J&]"0FXA.QK_8_47B=Q.;[[Z[W>Q)00]BQ4E/4N!2%5G(LF*^
M$5@PU\)_0UE@C/P:41]@I0M.;B;79R^9.<][/,QW%I?;TW:(^:[X*Q,>;8R=
M.Q)E('"8LY#5L!M9;U?_$*<!&:Z_I2!I,>7,>@%&(#L"335(]'>P:1$ 23J$
M ZZHDM];.31EN[9%Y@R&N,\]R&IP 7BGJPIW[F$<8S@:-?+U0>98T";EWR]+
MH7 9;AXCO*.,DD*Q)#K#OAV3!2+=X>Z01J861%55%UG%M-C4F^/@Y-^0+T!Q
M$Q/P:HRVNT!>"F8HM1)A'37&@19/,*-49.JFY=$O[D99YR8+'Y==G:>0EKSP
M@.,%X;UQZ?<Q\YZ^^O1*X_PLRXE=+T_"E/5 @4X6E'@;/+^>G+'TG_RWO=_N
M?^OV>I>I3'O]>HRZ)OB$9+1'E/[9/1LX1?<U_"=\Z[;[-J8_FPUSYFU;FVI2
M_?C(Z>.F,SQJ$Z7,<M:$H37;ZLQ9;W=F^]!+J.5>Z_"!6\%#4\YGO;K%)L9I
M86O&SOA<JZ_76,KY1ZI1R<UCF;(J*'4BZQ&2]I*NL7&&1Z0"U]/G![K =MF8
MZNINQO;>JWD/[[0A*]),<MH(6^4O'X5)#$T0/5]N:E.-X[H[0#0KO-FFWD"U
MU90T\(OW7M 7([6M_4/JJ>"O^I^!$*VY'PLX/RNDM_Z8*$?Q@+KC51B;.U*M
M^<KJ1AEN$?WXM7V@UPJ[!NQ;>AWD6]]2S\?K'1<YUJO^=B%'4U4?6C=W2"Y&
M?%2Y-.@ZUI_Q,W;;\'[]T_WY5A\59C-OQQP?/\E8?RZEW=\+[CY'_IF%S+.?
M^7O$+T"0)CCNX^O+#01:*]E.I!2*KH.X(?;HB+EUO"+-3'.MHX'<_J([N$;V
M!F1?8^PINFZ('5Z1M.]M^NZUFV>-2(@#.? EWO?G(]):01V6P\**X+]Z8X3<
MI"G6;(;#G^]YVK@+3HFNBAIY!O#JB+B:R$(JN[(1;T2/.01X)#'"@<HF=C,)
MN,>[M V-"B%H*$DG6,SXSC@RPE]#3=*4&W*')^$"/1A7Y)$#C>_J&"_-IPPO
M56-.#P:O;S?+7L^W FEL9RC9:4OCSGY;(.2>10,O/34#WR1;_U1VMNA=AG<E
M*\;;OF]F57%6&&=3T^[E;Z"6E-+=-F_.7?NZYT/>^Z&M[EMW(Q/_'#%MNKCC
M-7?UT:Q;M,!*Y>ROE[-?38LMY%S#0:9N.[Y<9##<Z\)VC%C?&?V#]URRAOND
M9_:FTH%O&$Y5#$9SLP[9B'[+&V"Q&5OE>#U*X% O-C'J@7= UV3@]=F?ALR7
M79_NKRRL.#<O[<*IJ%6O-.[[_=*>B65^G.(; L=P9:&-9)U>J%)^O@"TJZM@
MS68:GJRDHRC0XZ0Y6EW<UCZQ*W1&HS'8"/C!1HF@1QK\MZ<:DRS*A]]D+R3Y
MWSI&K^G?O<&II+;WXFC&A][BI N/U9CE[TMKEOD6VQ<4<4\4BN5E2)&0^:G?
MDE0>*N3U-@AE&4E.>'.HKTF-*1^&EP+L>LF"Y<! 4KD.WJV;:$"M&H"7]7[G
M^\W$(/H"W9&3_0N >HH6+]Z#PUA/B$9'D03<6S&]&:6V^6K,E:@17$GPY>>,
MW5!^2"ZO66(2;O\H:,AXRL.W@V](Q\T<'BF0?C'P7V )L9OF#*8I#NBOIJGB
M99>,1 D=9&-F+-+(+:ML'-=@S(9D,T'T%-D F[\6/HS#D4Z0>T0-UJM> U?S
M\W5<#H"=])BM8&'FLD0I28<N; H^BN:/#IHAO1':[0S&I+$J#^W4GG<)N2(X
MAN>XLL>< )MZBODD2Z</6A4,.M ?H1P[8?3'9 -*&&MT%%:L.F1Q^UTH14C4
M!Y>NS)QB3^;RS4%*XB,P-.'8/=D_JZO]^;1U,H8Q]IKMZJ#L"-UCO6?#'6\K
M:R[</-_=2GE4+MA=1W_6](JO><@AH?6XY:V-9V^Q:TW"'!5:0#GVG'U3^"8J
M_;6=\OH@\<J=Z^>TVOX6[P4OHS+3.O=P+/8M_PB4!P1Z0QQJP1O-9Q<>!=&Y
M.R(,FI>-NY/UPK,7 Z_6&*5?,PLAV@(5#0PC^3&+J](.#WG38K_.B;TQ7U*\
M [W/=TC.2R[_M@&UY!&<40NPG(&741)(%L@*AI,J%W:2LZZ9>PA%E[(7H7@2
M[X5HBO&$,6"FCK]1S'KIU[B\%ROD&4&1S?WSM%\4!B\".9<I4:?Y:X.JU9A9
M?-U !AVZ(,7VY@XC(]NA6I#GU\D*UW@^G+D6M)I*)#@H)%?SA8@6%)H;-M!H
MT] [)UL7<BB 7!I^0ID;M:&6YMCYX.>7=^@%[TBG>>:0T!-J?T2A7]QO;24
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MKT0'A>SK=FH]9T$;2[MXL,NI0%2"_=.6\BD>&59C!CB%[QE[*,/#33)SI.=
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M7S,KGFM$M*-?%"*;H1 %2\^0/&KTA8<U:)'?,UH*7/*[X?9D 2+V6R(/TO8
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M1=FO#@6T9A$>'!4K+T(&2))2]%M+C3D-[X8F58X^Z#/-L39K\:54<E_.J31
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M&3)V_\%_;HZJ7%6-,II\.V0''MJ)QF-4EOI]$  B 4I>*ECE?U:0Z#$S9,2
M"Y%9Y345,S&P;2!C?*R(.ZS&?#V&)N L5!QS@6160Z@:8R2Z_:=.3D1Q_[\:
M<AG](C5)>D-DE'J+\7E#E$5/H!1JI,+G8+BU.8IT;QFNF93D_6SX].,G-XN
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MD)#XY=(5UU]J#*>-,0OD7<T22HP9E-PA8"A[";"NK+H$3*&'-F8;@J1TIS(
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M\V;#G)<8E4)R78UA#[#J;4F#*B)*565N!6K,K\W!+T$M9'ZB&C/G!U2J(!O
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MM09<%+JS/:9=QHPV-AUWN:(0\'U=)]S[2OR>QT6\K?)V';U;A\,H##1G_UE
M/1*#AD@PRT/@38NG;N3/":.OJ<Y(RN,@HG'5' ,Z1M-:0#WD(X*CT;G&!=["
M647OE"(23%3DQVK/UP8MNR\^GGSR:3BVJJ=7$8"N5KQOY8QZH@./)RZ@T.]_
M%TY)>M^\\*5<GI/J9L5R=!#Q 112E=]6U('J+'G1,X;**%&34U,E'+<B? T
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ML9?%!H,^6=KX@EIYWLP 08_2TM:(M^K"&\*Z8*(P16TN%581C0!SV966V#V
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MPJS$HN_Y9L/&74C'O&/@FR&5T75I2*F4P-!8L\'\[+>%$L)"E2YPZ, P'20
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MP[_!0A)7BM>0V]VWD;;!B@"H>N2_>?!F3!8QB@PA. $*MO](UJ2;D@,'@KU
M<KI]Q#GJ+$8C3>U.W N5KF$35@"97\I2D42('4@<<H-E&R8;FIJ9H&8@5TIV
M\GEK-A4E<$68T>* TK>;!QK7Z1IV_55EH?TB_WSP#^/-*E_QHUP17B%Q+HEW
M2G#2>\1+WV@9)%N"^5'P[\K+D?'54P..&_L;*[LQT+KAVRXE:M:-[DY[, #*
M"@R3:2K#;N!J6=OXB@$%@.#U875W<%*RE:9,&FG)RF=X5A&:.WBKPS7*/>O?
M"/38F *)RX,SF\^E;XN>3EIGOE35-I-:>CGY/O7=3T5Y?#EY<M+<-)Z+"5U0
MDO1)XA3E[RKK"S6 <6)-R2'I/R0W.1!-&F,]):57PZ3>;JH1+5%]'B%)&O@]
MHDD3*L"8P K^O.E%R^IBP3^[OA"S/3^W!\TLS .*0DLDQ^#S<*I^HE0&["9>
M152!CPNE=ET8G9-2*B,V90*735V+>?II)6.C?N7ZL0<PF;,MZ4#%ZNJ+?*8^
MJUR"V,UKIN%Z6?76 &G[1QF;9SQ'YM-)3M+6,+0A4J5Q_J/H+;\@[^WCVY V
MU#)M?N0/G;:D<N&O2?C:A;C<@?^)I)-L0#Y%3D4:,Y'$:/QJ;R$RF]<8V-F;
M[VHC,7>]SAH,[!BW'Z)/V9^]Y+RR3ALY'^;6H6G;.TM2*Y-4MRV8O5+#!0%!
MF\L67!;*5LF!R9\557H9-=$B8],,64TM+GAJB70O<K&Y*"GVZY0HB!BV?;:M
MVM#_K>VZ9'X8IH<ZIX#!Y0?A"@C'*>:R\2/!1^ZU\33M[PWW.]CD'0ZR(["Z
M+IS)RFO7!NU+=+78LC7Z9@_#*B\(GQT[N &K9U%"9Q6%)RY**#'F@G=CV7%Y
M:FF'WG-OU1O6F\Z?O=?T>,OXZ'?*]XE@B)K.L-5&KX<"L^@G1$.-!798%/7'
MFTV>3 /0\&&?)%R!8SH=B"R4_P,XRY1>@O/^L/*'E_:;WM"K<:6W) >P8.LQ
MJ&2HZ^6$=1BGU&'HQS6\ T8GIJ6KF6AW(\[LX>N[:I89AKVFA&U,XQB9:DLS
M%X6H@PO;@QJ;?$IK!/5)Q_OF7^T>>=3ZP*5[(_8%/[! UGAR/F8GKF%4)*$,
M8X0KS\H!OV^R08H;#:R?:R9;*^Y'7%)12;9G/9N7Z+D++=D8K>\\=46MS1W
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MK?WC6 C:>33 *>+-$B_0*5\."! P!+D+,5V]^3E0:]>-::0^(Y[/&IEHDYE
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M$ J#B_B3Q!?.S$R8UP#<*'KFS5UVVP/PDJGF\3LGP,<A:9^]MW6"+WV1B=/
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MLL*I4SZ^8]U!UP%;KBV8CHV:*8.3MHW-:UHF+]7N&5CSN$BLG; )#,GEV6]
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MQ&AKR3.D,9L.M2XA,BU%VI^N^?)166G&\N5K?FU*DW.$?4/FRZJA>=#?^MY
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M>Z@[]U'WF_J%WMYG;%'QXAOX0NJ+[_?/RR',OWK08/ 4"Z; WR=XO#0P$K.
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MUU#M^NRHVI_05V8TQ8./'F>C11:QAAQ7 ]LB[+W&/]@GLC+60O5_I^I%@N%
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M&.V ;;%L@6EC DQS/3BRHZ253$9.%=8L8+<_XDJ"XG76M3>N'XI\(6ORBF_
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MK2@NXLGS.30&\NMVO.Q-?$N:\!7>E&>.%P/0=VO)R;JJH#.P=@3P2D=@E<"
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M9#;@L>.4;I[43$(3XB!X#=0C)4#\\GTG33#4Z^6@;8^JI"N7AZ(8V0#WFVJ
M]$KP6!C8J;O/PBWO^H-(O;R[5]0.?P[<FX]KVJV#(.-0P(U)U!@-R":?#U]!
M #>3J.)@B5K/G/,.<9Q8.U&4*"H4H4M$M-DH[L_%QIB[78EP_5B2Y9\RJ%;L
M3>JGU9"[D)E%Y [<>DA1.-^)5"&U7X#=@-\=SOOXWTMX'ZX(NXQV0MQRR(-=
M9/8D+L1F-PL).V*>JPR[:JO_(__OUZ*E8I\A5C1YU)?/ZJ1EH% KB/,QUTJW
M U\FVO"01XNE$&U$,"6:/R9:0P6FWPO.] 9 6/;1GE@A2V93Q!F!LML>9M05
MKD>#\=F/JQ5G[U15AG/L:0F/IY=R[]RM&!U38BP:[EV,%WOH:\ Q3]X<7[?O
MU->&@)V*)J$NG!_ZE83H*K. XLMSG8/:]K-&CG5=>_:]V?#DZ-K+;[H?D3<U
MKB :Z-T]&>.RR_4D.6G(VX3X/".9D17$:88^,1A80>22C(D(;*V$5085N ]O
MZB_V!**SF1:+-$6-QUU]TU?N9QW0Q]V]62"N <NZR'H2%+G-F9)-#J6N[11P
M<Z\HMJ$1XP3D_E<>'IG?!X/[ZO8E)%3XXST-T\NJ3DRZ'AFTM;0X%S]8_V:X
M?S?_$P+9.U-9>75UT/<?WQTCPVXI?2_ZMG5V;C?BETDYL=MX0XV32#&7]-H2
M$D&WQ4<EO:PZU*R^^ RT)8;SRW?(*1'X@4]>6NXJ!M&BI$&2(DP$DAIJA:^U
M#X):MX4H!8ML=A,]C9'0X$%6@LK8B4<#\ <J#J7=#;PE23T!GUM^^17BBGVA
M:!25J5D')8C5B6N@!('CAS5HBG]<!%<+CJTF:@XE+!\7^@Q^+8Y)M]W9<L#
M/QM3U-]80#%_E_M<9AG1AT^36$O5[MK?1D=L)&3&ZDAR\=3W7D&D4Z $(=D
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MC2/DN@1D9E/#HQ ><M4D>-)#]Q48W1Q<P7SRY'.:O<00 !W21NX<RY=9TCA
MDH&#I:)53G098BI+!IEZ== >(6LT0%0.&0,C4A>E$5^ET>70F(+9L">!][<K
MWB^W/N/!.;23XV7GJM>SF9;&DPZ<L2^(MMV(N-D5A#:+5QFD";D+>G2AB %>
M8P<URT@#TBB'#I##:=G,=<,M%O1)K-*B:K!G7WUDL7Q?0NX9P\B.@BD'K\>-
M05OTY#0:BJKW\7('9<26!TC;B">E@V-!CFT26ZB2CT[EUM*[:!P-=\B01U:
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M*SAJ+TWLW*.?&]IE[B,I)"5RFW4"EC*,U9+H0(TG>UOV 0S!CEDT4"D*#SS
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M6)#J<(@>QNK%&$Z.S5G5GRE'U8[_.*:+OJ:3E\C7AM?K2U0_2O^?'(Y^(/G
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MU9X8<<)5XL,MD9\V C^><N[:KS7#^#^4/ZQ4[2U9@Q,K$XI%!1!5[ P3H:O
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MZW(4S];E[I9-%[)57C]LJ3]] I*2I;*!)7&=HBN\E18>DJ1_'2Z8;YKG(WY
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M!8+&C%@*VOCD=@2SGS,\.U(2(; E:\+5)#T2.> STR^- Q1G6/\ ;W'SO4Z
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M!H$'N&4^ T$=X\J,<Y.1=@2B@UMQE^-XRB\'X+MKGY:?/G&&V$Y(8L9V0-5
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MD!S:AOB&87'Z>?>_[QN6K,7TGSOZ$W]BOB5@/?FO7@%'DX4#H+3&9NHA1N*
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M(4SP*RN++T>9"/(8OB&K&S>)8K\"$VGNKN/."OL44(E<04-HK,5^UJNZ0/_
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M9B[T_=P_0_N\$6PW/PV+,3B7L/?MX0I)%ZO'!XBS:@*1\ </S9?^..[8Y?@
M(KA^$/((EG'@W[?7.PJ<$U@^8?T_YOAW#1R%96WX_LK4^J77=WT_!4VM4=-7
M>G8QZ/RE/1W6JM^I9:KSINE$P%AK:_AC1^FETZ+?<HCWW,DW&P??)_WL#GP=
ML*!\8L 5KGOB\:4]@C6*SK'^4R\#._S[TTZ9YIA?1%A#CIV+*C@X;[Q7Z+/T
MP8!<*\B;];T[_AQX0Y&_W6V@?3Z-(EW[WYE#:DEIQ5?+!_JN2D3NLDB W$HX
MOD<_7_#8P0)J[!<J>M[HQ[2X>\^IWC?6![P#%80>%'\['/N@Y4CH3NVK]XO2
M4T8V_Q/(E[@O(PVQ@_QW0#/RG)!@BO"*Y5GM V\S+SVFG*.:"W2?9N_.M888
MWPZ8:PA[?/I1X7U1XOV9).KJA:3?#4$;YZ0A)Q[OMM.$[$L?P0=-KQ<7/%;U
M8:A?[TX:7/BD+OWNSLU5-:\'$*& $[-O6[K_F[0[GE!K,* ]=%B];7?H1[%C
MA8+S\_O%5>7E*GX%\40.,4B*H!1; GP20G6/< ;J\XZRB)WX'6A2-Q;Z(<(!
MWCDGUN+/:%7LRC,>/]B:<KTZ^.\?YN$UQS33BH>WLZ>3>P_7O!%OX>JS5J@#
M*6:7(JAS0IB;8! =)>\3N^C'D_N*0>0C%9BIW^YGU^1<K!E1R]9[I[_CBI+S
M#DTSFN6AIE3F+L#X_%BUV8ERS!WP5C&Z9))I,-%B6(:Q!"BQ1+&W2R^&4)4!
M#1*&#<-&H]=\1K_]A*B< !#)L)NH;UHT8BP/@OXR8 >$K?X-!()Z<&(!/'FN
M.Y Q0XSD>A%63DSW>*%HN<ANK7<X)7&5ON7T;TBA2PJ5J3^FSQS\8F&Z]7_[
MP$V@V,^S>'N-J[BAH X5IK 2A)W>ABC5FZ8>0,KN6*"$&\5X%H!^;B+)QN1+
M>P+JATM?J7^H1XJ\E!W]G'K 8?Z8T%I)+;U5I"O;<JR!&6'SM=Y+-H[C[#H6
M/"5JM,"Y5+LGU7DDH$H[EB[TXLSW$7%MHY_!JWKWUDW=(CZ9+A*8*'_>L%>0
M]T/E/OL[GWX->#V\U^\?6I3<,8A/;>I_!O_MP#'$R'S%(?'?\#2C')8T@2G'
MT'MB<>Q?D7?^3R)@*>OR6A=V[U8^Y@AU3<4O3PIP3N:&!8J.LP?B*UO,:67:
M>MF_J',Z+[H^3Z>92&T0N!(IOZ_6;Z7SZ9*G@_>H!].!($8<A;"#;W:/BHII
M=-1Y$$DW1<G8E\$>8R3H6O&ZU0V(':#?L&/L>*><<5WK]%A"S>S^IP5Q-=";
M%SYC+!G)7WK"$E#/,F_;'XUJ.)#^^S^>S"G'AY";5V?MGPFH/?D:LG/QA(O"
M'P5*_QK9#2=^8\IW<CJ;E^]?XGYC5]ZLO GJI<75MG,B$L]@DB=).U<\M,8Q
MEE4V5>ZNU:_R?2:=LL*\E)L+W-&=7XEL,LO]\1YB:E^M[I/('[1WQQ9@T,3.
M[NL]F@>(H3_I.2M5DRA"T")052E5AWR4XPZ]VY+:@P./AKZ>Q)/G)IRFU&)K
MP?DD\4//0Z B99>%.QPK.ZX".X\IG=@)Y("79R=4W3(;ZQ]^^:CSL[_X==;"
MR2D4^U6'6M"O_%/S8AF;_PJ1J^^ )Y+>?<O9NXO0H[L'@OL([YSX,\5SP!Y"
M#UC7@U&<FQ@OX/R$"^;,D#9/&*V+DT8CR;S_/@#^I5TZ%K^O(7',M1T>UD&H
MK?PR9/@->-!;A*M$8$E#<L7#CZB+:XL7]_?K7]=5[LN/<D[$_G*N&_NRY ++
M-F_)T(P9U?C9X&L\WN2]@N-*?CK/^\37B"E+!]]<">*<Y$_#S0,^+0ZTF(N/
M;Q;4%6Q#0EPR[E<&;;D90_+0\XQJ(<00*5,/U-!IRT+R/T,(N*J@,Y\=FRZT
M^H%Q?56O.*-:XWU='+E-UMWBAWV6=YIWTT[)"U\&+(Y_GE[8#&<Y%1C@Q9"N
MK[1WE625&5D>/?-KYQ%!?R^U6^^/"@F-T]!UDL4Y/X+2 B[=& ]O^,FLGB36
MV?1[7[(W?.$I([U:)9TVBKJ3-K3Q[9<YU&2L@JXGW?_,4-1QPK<H[\J%03&=
M"]IV/HSF@UOYCF\=QDY/.U^XJ4GX!650/-&W1[ZAPVSJ,3]$W&3OY05IV*?G
M,9M_J,T_Z3U9G4*2?N&DI\0*=4"\;9J=,ABMQ/_=^%/3JZW<.$5\!7IS+&_8
MT5/!(\Z)=]-NL7'1VY!WVY"H>M'#W])<9W%/5;19*A65]@=/B:@F2\%/G.RR
M;WD84Z,/9'%E3+N:V!\XZLN;63$A\O5XV<4\&!@16+S"_AXS\SH<__3/VKZ5
MQ5D7ETL(Z[%UV?<"+^P5:K(>I(G/P.2KKISGSTL&!F<?[^F6*H.!@/ITD5U4
MV;@+)-;%5T?W[6.FP7-',-5S^KMB,('\J=!F87.HA DH)?Q+Z7\I(^ :S2']
M8W^];$[/I-F#N'N_[B)F^A2W;N=6/:<\8E]/ZW11RVS2D:/=P; /\_$-L3#_
MB$135ACO\E  QN-6QU1W1]'ZA:R?GGV:>&0HV">I[)KTCNC_U(]=];=,.DK'
M@1JK8=D&B(:LKE1]YXL @FE,6,[>)Q*#O(Y!Y8/>/;N/OZ%)/G+Z?<WN>6A1
M5<O' YG]%<+4EOKA &;.AMPF-OWAG7;J\=Y]OJJ!,R\R@D8[)GNDYT#-QXE.
MK UF!UWQKHXWCG-FT0-:WR3*R<)W806 +SE54E.8RZ:UJ);*U9GK"W@3^V6D
MM;^)7M]L*?9\6G>S.DZMF:3Z"49]0P)<X1-G>,*]%>+"7#>@IUM<"LW[.8AW
M&,1HT43>&XC:/3[)@26A\GG==S65BIJ;J,Y]L!H25PG*,>.-F,PE8IQ9412$
M\#;DSLS.3H6VEW/[6N08.&5[&'E.UF['VGB(NZ5GK8.*N<BJVM)0Y[C&.N'7
MZH67AIQB%H<=#DIQSG,MQO[U,$'LPRBS%-N)LN?&'AF3FVZ$)S6*'3?KAWJ@
MCBXX8&F5"]%14:\3N(M;KTC4Y&U(S5H[0I![!@ST!\;;$<H6^\%"\F96@IEX
M >8B$!M/QTM@3F6RN/W.G29Z"84-_LZ7 >YQ+&"4'Z;^Z^2L&*VI957]GHK<
MWN)2BSSVZ_%0M\F-7R1X\^R+VF2[DZ6*=JY]4["K?U"E^9Q3P#:$/;*5WJ:U
M-$:<$\?YZD6V:41^WZGFA)# Z!+O9/1>0066=QQGF'_U?J-YP S_=%T92L::
ML42_).)*_!I_9E]/X=B/5OYT6@O(_2!XW.V&1\"WN>/^)T5_E\EKD&#!VQ#P
MX!I7,HZ.CZY?F4&P3P-AL8;O8Y@-7XJI#@@*;^_HY=-,?/K%L<-$IVM:M8VW
MX >?/[,XS\KB*G[G*/GDG1AG6DAA$%N$-N&>4HW<L)MY.T 60^OES6M#[RBT
M$=T)JSN29?;[;LJ:2:V_/#>4>'%2LWC<MBWNXU?[E7(7@Z)1?/580^J4ZLU/
MIQKO-'*LGCS?[]RJ+-1_SYMA_F7V1SDZ0),W%+G#3972%/LUZ-G<A+JQ +[U
M._>5TNI?[)H,MQ.CR%]_5[%#DVV%VQ 151J4*X-@9P*(V#]KRNA/77G2++F4
M$%$8Q1A>?GT9-F'B4%)>@/@4$H)^=T'L6[6L9;/B:4W#]8O)G'_=FT)Y4/")
M&J#)E4:Q<6!-YF9C(<JWE'L#U-)-:WK=9=_SZE%8P<OL+U:X[R7? TC&!"?T
M]\1>9BBGBDM27%\.N1W<T,R+^Z,505C,OELLEH4KZT)%!(KGLFT9:2[G\.]Y
MW"UZJ>JNYN"!DA]1]>!&E](."PI]O]ANVUNOI9)H*<)"D0\/DU[.03%G^:$K
MLC[U@)]]!0:ZE8151>?0Q')OT47M'0%$TKK>[F6%DL<=]NK%;37O)OP<;;75
M]Z55/D]7!1Y,;.#Y J4#3J*6YDFU 0&M+&/>GAF6HIM]\I&?3 )6%'/Y:XNE
MX-O-6\=K:ENN_W3[C)K-.-KW^1S5 1N1Z45RZG8O#JN:W$@GA841O:?GFW_R
M-GC>ZT+6.%-9'' _+*K%_+]&D+$-$03YEH_D*I&>WEYTY\J06$ZY$LIVS5^_
MATREG+MR4E[P1ZM0)PX('."GKQM-Z0XL(<H:E'NL*?'5%7IJ!^FIBE1D?]RU
M]TUX^^<"2I'NH[BGK_>EOC\U,.NG]=N3ML&56> )Y[*N_L6*;#5:[%B6E-J&
MJ!!G#6L&%P:4!"K,XQD6I7GBQ8\>T0B3.ZF$U'PI4(0!ZYR3*97?AD1'=/-D
MQH2%E%+K5J +J:X0=OK_]NQ>Y_[XUU,:8T['2?PK6P_S2H9US-7I=>$FB<Z(
M"1&&(1DOVG9D.=SH.6WE@'./BD(<)WQVP7TXQ/YDR)V8'\3KF>(&;BU/B[0:
M<04G[[K<ENI2>V"CN3;DHR[9\^"QTE\;[6/H[NDRAOS\^!,DM&ZNZU$8.QI
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M)W;"A#"VB-BF+QD$-),PD. ))E>X)B9C>Z[6U;M9CU8SM2]_]#]MP1SY5U.
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M!WTW#=0S'P\<__;9/F 'JH1O,AOB(:H<*_<=9U!DV<Q1N[&3(Y<!>,DB3L3
M(!BNB"CI:< IP^-*.CZUZ)0" :OSEUKA\KXI&6&TFZ2:T0_^'[L1U!327!98
MA7N&(26SA&'I=+A^SR:M&'#4D3!/:;]JWX0NLZ]8CCG"Q& OHNG/E9"Z>\G=
MLX>:I"!'OCS\'MCZ1]L8L],4:=XK@H,^=$J0G<-"8XN8 _$MUV <G26T) $M
M 7AYL#+*YZ34N*(L'#LODVZ@"(0YCJSJXR'R?A&E+HLJHV80CXB%<6>HCX32
MH2C+'EX.>F? ED;Z !RZYR2:CEL>83FR0X!6FF<<!=ZCF@Q57LS;/\X]\1X
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MMXG8,":^J/+&--#F8&W0GRDWMZ_6?=X]FG'0X*[[S^>U5SGWIO;,^0N@?H%
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M,/C0_@XD<A>![A_F<5KXF07+\[IMH<]2D83RLE[F.?NS,2.^0N+-@6<49J+
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M@3^,<VW*'8J^32?K75US'39JMD_>!DEJ594;][]K77^D^V#FQ:,C,BA-7LM
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M!!">37I^&=(8*FIMSIKKIA0U?:[8\T@ "&)NSI&[#<1@U?QOZN(L: )*#8D
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M*T5WV(ID%BWD*0%!HC$%CI( [H(M@_#"HS;!JO&"4>E=O<I"MH[F-=TK<2!
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M3J)S[RPN-MBN06?!#M':<PPJ*M"=_\;;  OW45+=+_P[(MW&;J)-":&LO:8
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MIT/,SMB_9RC<)]=TH@=AC6DD*GB)E*!P..]3#7 9N<.X2@N@:JA4F)[7ZAB
MI+!L9]47CD'=WQVL#_G>>%OG\7OKP(M9\UI-/BN)%Z2[3GV>??3F?I20O%G+
M?Z/WI<..O@>B9C$-66<!_!N4"+V_#RSHBY% W5+);#&,=K,?LH&^7@4_-)"\
ML=*"$G$HAKIKOOY9M7V8/.YJ,9C_%<I/QE%_,D^R;@/X2I88$$;?[$*K KC"
MP3"!_CB$EHIOP,:Z%>9!-[G2&BX+UQ*)BLZLRKW%'LZ>/GG^]H'[D3.P]A<<
M)@_C8E]^Z?P_[]6^;S^Z(;.%AA(C0S]O4T\S$ED]B*SUDZC)GCP[]VE*8?MH
M?=0EJ-VVO*H#H:#K9D$??$X66N9?FKJ1#K=33;9IR#;XEVE[R5CAUI/J]+_@
M.2+#DF[3SX^=Z3[/?M,F^9[E%;.U9IO5Y;3[?/5A"!S<T%!:#%VMG1$XL>1>
MSY3_A]!UG%!NLO 7Z]EW!]():<Q9+Z*#*;_*:>!/, 46'P66O*N[T!U"3C&S
MWG#5K*K_V5<:4$C2?R=CDXCG%PY W_\X5KUQTNIA_^!U*37>-3B!'_#> ]W\
M.+799E+HL>9V_>G8=F2[DF/SI-[$T0V1+@X\K+7NZI9M)^)GZL&,.>E0E?J%
M(S3$<.)Q^OW^IVVZD&3$S9.-2=XCP64HBX=/0@_$ND9:3]R]2CCELG'SP+_
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M(WE5)R?#W6-NVB8L.">CM7)L2$V=/'U)3GMXN$6()2;*,*9#.JGV2PLYS N
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M;BHY3$YPQFC5+V;A@.+38_$W3CL)OSGC@_CSS/*'-.[7<^QVVA]S1ST>5AE
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MM>IBZ#_9S;$OI#K9LB<G1E'V2C)7[3$M+]S+3?$N1?U_$P!02P,$%     @
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M\-V[#!K&;YKY&:S5G@=4UXA3X15_<.?!,L^?4)_:$KXHL5=QXJ]V;_-G2QX
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MCX\4??.=4KFAXK0.]_3[X^(?J$U5*>UW%VY-_9J66T/5E!FL=?L'I=^81YZ
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MDA)N#@*YZ'+&[A;R>FC9PVH)RQA,9>0H[G'O#";)SEN'0NP6]V-,5^BDKYG
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MJGQC%6<>;+N5"ON2B8Q<N%"1\5R',^]*5WG1EC->P&/-_<Y@9,IFRL;Z19I
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MM443_!13IGTW:ER30UJKT+(P<NH&B3/8A4K9W%G6C<6K_H0&4CZ0K1SELA[
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MQ?I8C[$,L);01Y>O IJQZK0H="B+HH ^R=L7W7Q+49BVCSKG[7KU36F9AAR
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MLG@?R"H-XO@@_ PZ#8F4<NG.:Y55 Y'RQ?3M78ZHB+Y#8,-AS4%H6?Y93_D
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M+"Q"JS1,&S\D4+L19D<'ZT&,6KBPKZB/0-C9=@E_G!0"UITB>'5.U^)QTI5
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MITYBBWV/-"-GLF9Q :-[:):VO++^T"<=@P*/D]*6S_R-$TS-$JGDS-O,T_0
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M<?!*A0X=%?[!1!>-#LS7CI->5XR<JGZ)VT=0 ] "9*V<:X=&P.\Z6K]A61:
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MZ6 B\>\)Y"WI5G54:V)E0#9H!FH<T=W:6EI]X>I6^I82MD!:N*S-U9B64G7
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MXCXIX^&]&C3WQAP)/NWX=,R;:6F8OE%..WR%Y892]:TI;4MD]0KT'-,'XE@
MM"4Z[21Q5EJV:)SD=^8L+<B?B";H92D$6_.!.Y7Q!!SD^U]'*7ZP+)'/N(TF
MU!I+D0C_3UGJ.AZP7O.R!AJ90)D,',M55%.R?A1,@T_S)K@F,>2D[WOW.7VD
M_>-<OO^V&\MZ]-85S"O?V!6;K<)GWS>JZ*N2$55!_*;@14$H^ZN;P.>NVJ
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M!+38=YK]DPK_*L,74\;HI2:O)$8ZYW>*I89"K#Y04%]LL1 M>6(8MCFJQAP
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MXP44O?)0;#X;7<ER-/M114]'R(IY91'QWAAS%P'J4H57L 7H9?UZUCQT\Y_
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M#0DS>8;LHQ#OA%C"'3B=+9VK8=I=Z8Y'52!ZTW2>@90ES+?YG@VK\0G)PW,
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M8\JSQ_P;2_$9KH\?.0\<;TE-P>TC::*3/<P)U0QA3/3188?5FE/9//TTX])
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M"B&5L;EX+9R;Q0Q#,@VR%,RSJ(MMAFTI#0T%$N1<*^+39Y#/R3K9"0$35VI
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MX[L'#Y[6;[QP)'J#RZY;CLW$/UO<;P?;AQ/"'B7]0]KNA+1?'?^K.D*N3U$
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MQ_"L#K9)+^HH9IXG7^"G=0Q;_BZ8_J@4W$, !86V'9\.3L+6H3L%-*!;SG)
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MB+8;-XI($)MQXHH-\?P]O>)@,R1VM<#_D;_]Y@6"@:^B1\-%G6N@[ZFK &&
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M4>%XI!T+U$YG^):#QX;:(=R>HRH'_Z?_^O]P ?[#ZG_#JO)51BD:I^0@H93
M!8+Y&L$"P:$W 4NVYJ +A'\" [VX=B\\_1=02P,$%     @ Q'%\6^EH/SUE
MT@$ '=X!  T   !I;6%G95\P,3,N:G!GO+MG5%-;V"T<!$1J5#H(44%0$9$F
M2DG$0A$Q*@H(0E2DBZB 1 R)B!!ZCJ)R1"5*51&0KI2$'LNAET@0TE0Z[*T0
M-J1].>_WCGO'N-_[W7''O6/<).M'QEY967,]SS/7G"L[XF]B%FSC<2=7)YB4
ME!3LHN0)$X_!COS[[O_H\>\@_Z=C2(E;8)LV2,VNTY:6V@Y;MTE*>I.4N .&
M@,&D9/_?#K#_?$BMDY:172^W05Y!4=*A=B-LG92T]#H9:5E9&1G)U7C)=9C,
M)MG-V\P=UZN>OB2W_8::1<*#5QL,#E>VJI_I!PPM+]^\)Z^@H:FEK;/#R'CG
MKMU6UOMM#ART/7+TF).SB^MQC[/G/+V\S_L$7 D,"@X)#8N*CKD5B[T=EW@_
M*9F8DIKV,/O1XR<Y?S_-S2\H+"HN>?WF;55U36U=_8>/#6WM'9U=M$^?OPP,
M#@V/T+^-,M@<[H^?OR:GIF? WW^6EGDKT.K:O[BD8-+_#?I_B6N3!-<Z&1EI
M&;E_<4FMB_VWPR89V6WFZS<[GI:[=$-UNT7"!K7##UY5MLH;6)X!U"_?[%?0
M,+1B[P#_A?8?R/[7@-W[WT+VWX#]=UP,F)*TE"1XTIM@*)A(M#,_#?:_TDQ^
MF_&^0[?%,-EK(+,C4CF,\!XUK\>WPZE#ER+8094@/@%\QJ84<94)I\$*7G$A
MH<XJPCMT+^H]W=GV\J,=OG$?SVU=1_#;^1+.J6")8?.F8IB< BY42$&%(;YI
M'A:6HP*Z+6GD*OI]@2IG41VBGX)VTUH9OYYQW2U=AQY$8P>=;(&M,R%ECTUT
M?G\[=Y7@0GB_F$RXQB0R59J\0B43DX?& %_.9(<?IO,+10J$M\&52Q+M49'L
MZN(N3=>AI>9(MSZE-6XX@B%[[FCF]GDY65]$%NJ]IN!=F>33R4L(.;R\$":&
MW8]B+[(S?C7T0@=$8MB92C&,Z$D(GK&IV_Y'I' ,N/SESYSFP&$_R]>6>YXI
MW$Y#3RB9CR9TP@@GZ#:>=4_$L-#&AN0OPVJ13VX;U*=:]C556>1'T0R56"IH
MZV=G!F$U1FNCQU8T9,NW'_M[_M-&\^M&>_9],=A[_KK7UA\B(T)K)SWG%@IP
M1HQI3*(;FZH;:H'Z>_<FO">L+-X@D4#>\4]9%2]*Y+2"MF3?BX*6)3//J0=S
M4J@L,@8X+)1NH=B"<NT5&MA>3NP<F^V.ZLK3'S(:M';7^>,/G7LY?68F _Q4
MY=)Q?,ZF.O!;G8KY(00][S$8Q?8OX/#%,%@H4U4@_P8[Z:9D9@\/YIJJG@(=
M$@-"Y8ZY9M4WZ6O;U^UN*5=;BA;#U"G:OM (G#@H. '8ZSM\J%/U@71F.WTV
M@ON!&XGY5K-EJ19X]FFCF^OFNP@9:,B4+MA,XX6)8??"1)\)LM1PS+<.+)TM
M-^\%]'+I[0Y2(KOS6&YGG!B6:1_Y&OKCY1(S']DEYTWWBWEQ:?GI,_\4=47]
M#8A=L%@RX-D+&=#F/O+W$EK-<>'\()S#1RB%<)6<F I0.3]I\\YO!(? F,4.
MM"[$] .1Q))91E:-[P7S#>/+#]X9[G[[5NJ4UCTU:?YAZI"5<'?/+TF4&ZLJ
M!^?Z\]9XO+-I.X>=W#X;)IU6VQ+XG 7#LNC/(5VN7!LU-4?G"9EEEDJ XZ+B
M"R?YGKUMR'W]]L=,LS=&"8LT2/99?QN$*GV0N?AC7?CJ"6$=S@-$B11,^"<(
MK48$5JZ/I&XTL(IL!(T\ZMPFAM62Y\/C6667,7 HA^/Y/$_U,&Y[S&N >_3Q
M4K-KT08<S?;UC_<^*%8I&7#%C,Z*Y#_R]UT@M#H26,]M8U-1@8M98EA54"6+
MI.4OAK69<,GJ3"B64W%/L],6^: L).] __*+",X(PZ7VQ(^[WI6,)@68J'FA
MUL'L9(;R<5$;;25RJR;COCEB[P[3/8G=-QZE.H9N47[]LOKQZ5QNDR8HW8+8
M:,4O\V#_&Q%S;N;V@=DK#>0DZS+CCEO[9ASL/Y*//#SU4/KYPJ7&U^QPZ(<D
MLHW*:-ZDL +%2O Q]#<"">UD9=&(:,/(,@)!4@BWK2>:!0/!'1A%K)L/F'._
MYXUTL4='G%/!6RQ.X\Q,P]-6MK<8YDZN) E4>WF^PKO1BRD^QG-4@(<AQCEW
M=&/<1NQ]BUPYI@'^@V.G^Y>8<V4F?&-^Q/<"BQ]?#LC^R1N26JD,A#UL@36F
M&L/V'@QXN$_._J'YK#^J&!< '2F%\@E$!J*S@NA3D57F741/BL"%OIS1-ZK%
MST1?&<FJ;=R:K% B_?Z'%P<CV&+)=Q1<A,[SC7#&D G@UME :B>E(.K,Y@V
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MPM5:M1TWX*G+?Y65P6[* [_#_UY[K=Z=UNF\X?&/6E^,KYE7?-,+2K"G[Y.
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M\Q\JM3Q,2R2TQWAN'K0Y,R@P!H\<!S7G5CC=3O-7KTZ"?[Z-0XA30]Z7O$Z
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M.E:U>E>:1D&%/1'#Y'$QZ\D1G/AKOF;?2"+Y(HY'>)D U:_J0NW#&PF\B2Y
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MRZ\<.4^5F^_"/UU%2N%V4H4/!'HLE/*4XJMV\*M(@?IF:M\418$Z;-H4'%B
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MAV_.N:T_U;D9)O]]X6? T5/K?P7!5";7494DB<R4);1:B@Z$QTT4<18S_64
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M]CQ^13S9%S,.I^DCAILN3B!"!"B;]$U+L4DO/2^2JWFI7/)=LAIR"W[HH<
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MU'SWE4/M2HS!:9^X;V^)MFX<>*B+-/J/D<$LM&SI6@.\9#_:$G*PY]NWB*0
MJ]RM#-O@\))-O9U;4%>30>1QR=8BCT>B_)E.*]9$_/',ZE&.581J(V891E2*
MK.WB#54SHN,M)2O+18:<OI!AN6>+\9KPP-%B@-%FLM#T\IMOR,_]4)&H28N+
MW@#KC%J]S>J/+_&1DG]*(7^0T5XO _&Y/G)W2O-AE051-1O06XUYJ;B.XG8)
MIK@W"-1YBD[@"7'H0.-.>$;CT2+Z&@T[9)IN^N7E9?)83WWXW4781<IJ:'\0
M;8@O":"1\.6D;4 LEYX58H:V@3++AI6O("P7O?4\S:=_-CKAQY2QIM06M=*4
MJ8GVO3"Q>M#LDNU\KO04O2:^[;6$9@I--5/6D*TGZ<SZZ=RG"D]@YLU0!.)B
MMI2B2^[L9O!\#7R D8]9E/I&#/AGA^1R]>VLAD;K??L>7LJFM[*3UQU_5=9\
MV#Q1M?5V3/B_LZ,11A&MY<%E97_)FO)\Z?LDY%,O&OU-%#W'>@(5W>GCE;^"
M96AOJ%:;LY2]37':N&82X<285LKC27K*4@52''6^D]&(0G()@MO-9#/%(?!"
MX<9;5J]ZYLK=_25P"^+M[T[^:/-X#VU/[< WC!3Z*K8U'F>.P;O1DMG+!Q5J
M53*0-2K_P5Q 4EU_W8SZ6/"L2TPWF\CS4H-[%GL5\$4_$5!55*B7$:HZDKSQ
MVC'20?8?Q(L8R0V28,&@%8=D9?KY0\&5"G/(&Q@. KUFKLI-B&_:5'K]\^8X
M>:P_+@6G[6Y;/(4V  +2[2_N[FW<+0I&(TVP!+LO](EMT"V;O/ 7)?P.A:=\
M-VD_U%E,?I<SCC%J]!-15I,'<+4N;70J>TM?<4]F<LYC4GQ/XZ8SS\<#2],)
MNDX>R+8?D76C6^.BT![1PYUBI=-Q\P_'.96+, ;'3W1X5D*;IDN+I0Q!0*OS
MZ#8@E\M9@FK'#,W*6H PA<TOP;FO]W,SW35#GS):9W"\8W@[)><)T3C>AIOG
M7WDY^<<B3&R=?OS5:+3+MCR.&1,YY-9,=E$^)J\G<GCD+?U.=&,BMIE>#Z>Z
MVXB,Z-R:$?I-UPLW8M3CAC8FWOXSFJ,/%0?B-_ ; ^TM'3K$482#F7W/[-'7
M>F9SI&%)&%$!QDBU<?Q!7AF5C2:90!RYH>(4WQ%K$E$#Y;8BVM-)#E<CGRS"
M".Z]F_OG[N>+96^>?YX8/$/:+>XRB#037XOY.Q3 IBKVD@TIS1CT5I)7?XRI
MXB@0*XG-XIQF"/[ &H6_CQ7/:N$+M]6\!JP?DWQ,/M2[@.J$NPC3949BC"O8
MZ8RJ2:UG@_)CQV 8LD)/ZHMJ8Z\&*%G1;6F^J-911*_[T;.@SSKN-.);CD5E
M,6E?]HA6XKWR#6?_U7=(^[XP^(VN,##V[Z:$F=%NYV4.Y%,J51\PAN1-)-A=
M68N?S@ K5(0QG+RF,A_X/G=>2YFAV@ATMN545M]?(W=;Z7VDYK[3PLE=*PR/
M_C\?9+KP=VL$1\!_BV-ZM<YF8FK;;Y-6@&4M&#.*6+\!Q-YV#Y)Z L.\46VP
M/J'1I00*$1Y["=JUW4<7,(@N/%=C>NF^9X'OM!>V).^O/^+=_C5(]3'$5)E+
M=E;L2E"MQI1.C#KUJ#8%EK6BDA#*P:1YCH%B"4!-5?@]F\RKYW%@D ^6F2SU
M[B7Y%4W9E7:50>FGZM3^GL[+6_V?+_I2\<)\Y9OA(-OQ0RX#=T:;/T[A9QZ
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MH$ZW%L(VS76!O(4T^+3.]DT8<[7RN+%M2 X0!XR4V0"$I,8SNA7Q0)@X;"9
M[JW8U<TDP"-#D /N>E):>H@UW^P@,)O&0JW!W^F0C#B;:[0']C^ZT4O(/S5
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M=3"*]+!N#V$GM+B.+70&COD-S-BO[K0?J)#8XE7;(I OYV=&<\2S*3]4W1C
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M>*!8[LD+U,A@L7K/YK<U5#>5CAX(,<U(D/FH-!TV#28W;I-[*=;03B+U&MV
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MY.H"$M8[+M_<:X5LPVF@8XFUKHLA[+W:\6?!^&C6\BBQG7H@IAZV'W1N#&-
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M0R;=7C(ZT\:,ZA&;SY),*+<>T\ ^13@@@:^TK\?OA_;<,6=E-*N.'O\I69B
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M#;4==QP+!PM)X F%X3^DW0%Q@G5DA:O]-)FKRQYW*AYI4]>XB[J2WY%N_ZL
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MF;YS*%$OG?^7G[$)N4V+055O=61C#SO&9&<M@R8/'A'HZ3#C6U%*5_#7>*=
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M=B;(HY]TIV3FLT)G7J-<:J.7IW$Q@G_%!J]ZE,W?JL2WV>"#%E4#M*P A73
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M7> 3UMSB!NREX?#%1-Z$&K?T!3+9.!_1ENN?&$Z$C@6H&ZZ4I)GVWZ^[2'%
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MAC,2SX.9/>?> \)?-1$J3?YLF(HM^N5E$'^NP<O#>4AKTQ-?0J"@X)\0$)P
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MZ+76 \4YZC;7.:<-/F8\HZ7%W5NBRAI9T"R^&Q79VD?7M[5P,8P^-SSX([!
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M^2,=J^.C02M6Y[+@[=Y+&?2_UB0\,FL:=QG?=MR8("O8]VT=<JU/VJV-U9?
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MJ_RO*Z&K<S022IL[U<T '*"I!6I@#_<41W7^%#](<%*8P1:+2O9=@3.7RJK
M20*+':B-8%'7ZM\,/AL:;]!LM_<FZ-]-7XKW;!J[8CQP_(^AT;'Q8;&->,*0
MPSKP==UPO=[:8 N7VH&SH(GTB.GJ>@LF;/3V"90@9$!D32:M0V2DLKCZ)YL&
MKS<-U#Z2*BX=!'WL4KJIJ:Q^'NS=E?NH:($+N H0F<0DL@HFDHU.W0W\^L#M
MZ7Z$/0#Z^O"B\]Y;VG+RT@^$.#)L3R;U^.*/!#1FMMW5;3NBJFCQY&@<*[*;
M% _3B""F1,&H2&5;MJ8_,S$C A5/4=ICNNH2R&)HS&S64;<LN+:/3):=_E?$
M+NI!^+4V+[N_/QRP?KG3C?6BZ-&HL<@/C0TY/^H6&AS';^ \IA& /3I=M$OX
M$N&'I+OR",(FW"[1-\16A!],;2YW'1)OG$J2#-"2!YS['D0X2%X"R*2R3Z73
M%\]4LCV35J(CT8H+JM7IAINO'0I&=JY#@#-0.0R#M;JPFR4C,L7T4,DZ8 \?
MY2ZB,[;@=F'\;6OJ!D6;L9<&PH7'PN]6+H_U';-T+3Y.#^K6J2_\RMO7YG8?
M5;WIW@&UV!S]!KWL\=4[:9/)D 6YS.-'IX.[?E,"D ]48+!:XFC05.<M3T'8
ML+5&$$JU=G&C84LW,1+X&Y']#=6)?G5#\2F^7O'I*-H([?KW=FDS96%+V.Q\
MDZ'U<E.ER?)\\+SV>/ ORE_M)=<N&& 'IR,X>AU]HV,<U07M_]5U3^?F=,-J
MH)TD.<$E$,\B@"X%.X%(JMWIG'*Y_*A@BGR D;UU)=OP3@?^*GU\O)="K9_W
MZ [2LJZN$\9A;5GKD+$:=ME"&'.1H%Z0 TSQDH#0=!:);L:[-6RI_'*6#NLH
M!D@)*RB9 +_NCNICP\;:)6UO/M(9C[::9_XL!<Q<9W;]7/AHF&D:E_7^RJ&Q
M$>W;/WW$ESS5M+Z>F><9MN4-\_<5BS<</:W6$1>-0]U>9KVK)DTC$?[1E(&>
MX^':(2,,C4 *?6D:MRM0W$-8QCIDBP#Q&BLG?(Y@%L-@(AE1MX?P5YTB""L#
M/=M%>[F1]RP/L^_JA$2VP63)^[P/<?7BEC?^^>6EN^:<_8<:N)<X6AB&^D\0
M*59U0=/6"+%J\NLAW$.IBO;@OA*UUB'7%Z30LE@%D%O<"R4(CF/U[A;KY"0W
M:W.WT3J=O%#8$]^P3H'70E?D%AQG[1.Y$JH/MIW&(ZL.&@L/=L6<%2T8+"\<
MT$BWO? ^4-GPI?VER,:[I0;:-G5N/X,3(C=([$PXF7<9FF?IQ;^.Z]52 H\P
M^^AR%\&:$CL S8:G"?284"G,G[.Q?SS[5QC;,8D=VM0)K9J:Z#/Q0\U1#4EQ
M,UGD?@V;'09S6FXQH>Z>&LD-1P)U:Y\,9>?TTX=G@N$C*0Y[YT>\Z;_)_A\9
MU22!DD77.D02?P.F**(C5"A!*!BNGZ+6C :4<9LQC?@=T^K^";6O#/6X#W!Z
M;P<MCQ3/9.:AH6 0[6/"1XQ?KPLS:%4]GW\97WP,43T&?2D*$9EL5]@L??O>
MY[T[[\F^O;@C[-M/2 QWN&)DQ##GY=&3_YOV^G\)A/^?"WJ*,3:<$KI\3&,0
MD-%(N-D-69GNOA==\%B"C5>W-@;E>%C0DX-,(VZ/B Z1;"V0_/9[A:*(>JCW
MM++V[5@@/33K>G%O]*M95]>M[H&\.Y_VKN8TF X#VCU&D@+N^(R6E;#6,M"7
M_Y]H6'UO?:-\_& N:7Z1#P\:N$O>!IXJO'Q?-Y6-3%K3\J9V$)577A6[<*4*
M7^OPB"_:##PB2IZ';6HBX83O+>]0ZO06T$6BK_6NL!!0B:\]'H!2M(:/CMF)
M$CD(NG2'2YDK&,),]SAWU[412C6$S4\8#R\#OY=FR;N QN9K#L<.3Z)J^[KE
MS7C1H V;D.1:W_L:O'\1!L5 J:SV7C8CB:R[;08G!RSD*7U0GW/A'P@RZX_;
M:6[S>.2(^9B--FGFL@[U^QFQ/*@_G/(G?WQ?1,Y22<3=8Q;>G^B\EB>,7\_=
M.XY^XG@C'W\ZH1]M&]YRJ:[:+LPSM,'Z%N@0#$B*TXA+.4,94]1!A\?AU'$=
ME)H*E#(^0(.?VH(X#FBN=ISFJML =RT#H[<FGB5_ 'V#7V&R7+\9EJ5=UJCT
M1-H?_?*0W<+GC AV%O(/"XP'+'U?8[5 0^XZA$-S[[G[ J-TN1I8H"18*G+@
M,*]>(8'5<@QU,8?O/=(>17[5WX-(*:[-V%BO#Q]M/ZK]5Q>\-F'%_=W +??@
MVJ8>K$,EK$.VX;3',*F=^I*U:&Y/%T[-O!D/9(%)IIL8L3=,8E"H+-:_DPIQ
M>7ORW*O:J_*O!X^M+$@Z<:^!P:T3L!1;KG2ZY2TF3!+TT#@^>V4X@K$C8,T[
MY]"E+7?^2_JHIAI(_RS1&6.%E)O[I780W?'W>5$F_> EUJ;MQ2^+:=-CF78!
M RG17O5A5X_6N]VXXYQEL_]&6;#=W/7A]+&)IB;7#T+'=4C;'L0U H&LP<5W
MP\%]?0O=$65>HE%$O;U;'^+!<K?K@$@6JTOK:4@4J4_3M"T#P[8[C<89A%XX
MG0/YU.K#;_FYQ4=OH\_[H]HSS]>B5ZI.L09A/H#>@_E0V4]A4G'%-D>D?DA2
MU?^;[]#:_$@V_WN/9O'/*W= /6UI,D9OKE7D+(A+12H3,J/HM^U*2HKVV^ 4
M'8+K*^O'\)2KE!_8'\[B?*4J0M=/_3%;ATC;8(P\UR'?@YEZ&>'OPRU(VP1&
MPG=D!=0TFMUB;HBF_K$N"7X34&\:M9+^\99I\K'W--N4Y=7SZ&%3A;1-8G<B
MEDPP@;*3[;N!E7';5B)@L])0H/],FV\VWQ"X=<.<K;NV@</'3;FF.W:]]LE6
M@QGB4O!M;69.V+O@)A;A.T&,U(051A*CEI*$C008G*X\II6"_9D%@3XPQRJH
M7YH5Z7!Q)(M4E$+@VG3M!P?#@SIY3H,%,IW%83M\9=;@P"KO%1C"/RWJ&<9O
MQVK?0B2R@ @60.Q ;0$KK_9;.@&T+JUMU0E]W=YJW%I53TZ#IYQF0V/HRS>/
M?KA9NCYL&ON<@8N#[O16V:\7H]+<<*?:&S]5Q[,\/;3J22YO^O,7UD,0*,7Q
M;H*?@!J1W M+5?[) 'R-XR.N''-DWK\24_I%U$/>4 ,@8]<A-=B0-]VE,VMD
M4NE8[>LP]C[MP5'Z=,)UY-.'$D&BKBL/N+'(&U-9B^"4'NFRK.BJ2$X0]*T"
MSZR"*5*8A=;Z )(0CAJ5Y(RT]6T2?8')D(UGHVQ:ZC,:?SUY$WAAIL!\9/GC
M+R];1P":NK)@]*N'BCO4DB)G0OO]XL,@.T.&'2EZN>O,=RF%M))3B:==3I\L
MC"O?3_]X*<'%*6&CZ:V4J2^DHL!Y4E$]742Y^WMRP+6_=&6TC/$2W? #=T4,
MVXOKD*O0K:(QA&2SZ3I$UO(\$8H/I-SS-AL@&XF5X+&-AF0"9U$^?PD3>:E-
MHZ(923CXRRFI^J\?F[S]W^XT)F4KUGC8!)F(J#>;?\(_#FKPJ@!38@EXA-,=
MVZS,\K0@;#EN_,VFH<-0:FEI3<.3+[=</SA9-U Q$?RLHZ+?Z\R+D>53MS(D
M=OE+OEHL6(>DXW>A &>2PJRUNCC_/L3:MPP5N(AM!58)M&/CY;WM?VWRA,LA
MV6CIN9N>3=CJ'75R&AK/BA[4G%!YM716\?H6'*/]!U&Z\[+MSNR7/R\VIC-T
MJV\-F8761WF/C;GBGW-NX(X<8$WEE4[M7;'S&C5KC@CMZ>EQ6D2#!U#=C%%]
M7K,P"R<K&L=+BW:)\7F,;RJ&+4K,+W3M]EMT3:4N%_RF9G\.45:7 O#9(['H
MBPX71QQI6*^K+*CB3/]X=UCA#]3,C7K:N;7T490G=Z0-)8L]W@@T=#%B<U<H
M[<@,NN%SG YXBDMC"2OTW]@KTV4,PQ>53I3=53?+L)1@OW]+WC.PXN:;U.55
M&UX[EBORM-;%!'?FD+>"]\5O:!B<+MC#I<2&-ANRTW=_Q[=;<.%4WBHZ6BJ1
MS0_-2?>/]B^=PVT?FH)&EWH?F/_.IOB+W](C1NT;D,_DI0+Z'9%F4#9T$^C)
M]V?]89#';9W 8,//F&@/H*8V_G(P0MK2J70"H^_$^?IDS[>(0,60"#L=_/AD
MZ]R#/Y=']O<BHAT#7UVZ\"OUHHO]L_TG71I=+PZ%5N%TDMAV?J!-GJ\=+;?!
M4I.CRQXY,GDGN]*JJ,Q^'#9 FH?S??KX]J#G92"G@P@-)$L(BW'RC!.LOG2&
M_'P5%FC,_U+$-V-#8\_U4IQ -"?=_)A)NM%?YZ^YZ@X*[BZ_55,H_^$N^UA!
M]-Y)OM(KA*QQ"X8$5*P[5ZJ!;R9P "/XMS%20XR+H+T)*5YD&:ARZQ ZB5C-
MJ\&F<F4'%B[8Y77 Y H0H#M.\]J.7N7L(M]0=?O\2N%^$-^QAD@UUI3KF( -
M7ATR1BH&UN<.I[\Z+D$X/X"^FL(><)M4L[M6L+\H6_6T_@&C1I63.T2V'<_@
M/!<3ED^%QJ]4EVJ'AN#RJM[@>H+/LJ/&5TK#H8*U"Z^5 W7G?V>3GHS^SE\>
MYT5:R.Y7?;$&G;3W5ER6^+^_8OQ?%P]'6-I N<'DS*#DQ$%Y7+1I%E$+GT_G
MAK6N259CYNP&KH#)P,"O[T8F#021UJP=!R[I406Q,)%;V,,XW3B6_S;HB(JL
M><S$)<4,1L]SKBC*.6RG4<>WZDDU=W>WK;+53V[>NI]P\=26)9FUD4>YD^]O
MC!VHO-=EFZL<>"DQQE_VX5#P\)E;V$KK7L2'LK48/NP!?K/U+C>!)^@ S+']
M"KYD3Q@#^ 3!J9WZG^H&2<8TJ_F+"Y\2W!;9V=(9#ID&K,(KU>4Z48?V'K(Z
MLRMM+>Y1VZHP> H>2]\!6G%]>"^$.=4A\V0H]LIPLR?3WMK'!;3GOD 0!#KH
MT,K:'FA"76]DIX?.\T>):>D;)HPM'KY:@VL/$K%,8M7=3ZN+O_5%5YM#6'9B
M+]F7I";[@(73SX^Z_.WQL9RZ_(#/9FF>A':21OG*..S;,Q=M/DKBB?[,CN*%
MZMJ+J[DME5-HQ $\@%R';/\$4'E$X2N$7Q[;L-F*NW>&4F?6GG?QY'\C.!U/
MO#SV6G_XV];-ZY!J2YNK+\'XPG.689B7;+N3SR30HX5JU(B_;T_;TDC3""&&
M-(7GV*; F(0.QF@-KRK6):6;6=91CI;!VCZ+W(>,9:A+Y3,).W_,5AQ]CHEV
M:P3*4NPM[M[$M^^_&Z:_-]2;\O+HP1?O$_8S<]6N/K/\.)ER*3R<B7:Y>.K@
MF8VQ)S,ECI%6[:<#V?Z"_PB;P"#,Z/Y? L2FDZ26+P.Q-PF(YA_X.^21@^F!
M+_U_[O3*;B:9Y1A^\ R=ZVVJ5&ZH$4/12&1]^19-:QSQ!(?&MSGB@TE;<51&
M-3Q59 IJ4#W0J2+M<9#P[ZL]+'Y"<_"73"&2J\0FI8;W28-!?U"-=Y1,$\N\
M9ZM1/SHS57:HY2G&SJV=C(*5>5-$C8(__U@9U]W-FQ,^;KX%;.OI6-62XH86
M5F#LQ:98P3)T&!_T#BCK("5.Z TTHY@.8>>KG1D1Q1.SYL[UCUZUOCD[&J2Z
M^S'D_V#L/8.:>J-PWR *2HN*@'25IM*D2S$1%1 1HJA4(0HBA @H-4!(5*27
MB @H($&J2(ETJ0%"$1&1&JDA0>DED;8AA</_W#MSYYYS9^[Y\'[=F?WNO9[U
M>][LM19REQGPCPU^#U&ARX9CI\NQ!YI5T$(,?/M^"MB_#O0)\156N/&VZ OF
M=0!\!7CXD74>OQ76'Y @US>(#J83[E410PE'4>Z7GS*6MLBC0P&B7 .Z!U=8
M%63H- &C#NS#)RZ6HTOO8XG(;B'8+QKUZ5TTGT2C8_3P:=E$"-A3]IB1+8.O
MJS6DTN,.*F/&)]J],M5)R8+162Q\'U&3)1LL/_@1?#&ZXC7V7N.Y:5E A=!)
MB88>8D&95SVA!Z"/?5[MDY2193Z00</M>TYWBN021(5!7-%Q^WCE01W]6HA0
M^0,5])%IK.@I*#W)[J;2L(K=RI>Z,1Y( +UO69_IS^F0H'10(O$5N.5UYG',
M$!:$D6.9,7#MN B( ONC>S6=V Y__@]8OVU04)2->HL36@PB'F7)92^-Q=?W
MXI-#>7+J;V2<K!%K992?N)#FD[+94!DF4^.D3K!$)R2OPQ6)A"4G6&; VOB5
MF:U-.B_KF,7,:EWN_*YM_-__QN?!IM6E.J@O0K).I+5/"=&[$C>:KCK1<SS-
M12;[(C;9^@_(C8:7VL(JVBQOV' ][21>@4ZG<&7,[)-?J+?5&G#6K/UH/)>^
M4AM&Y+RM..4?M5.K+EC<V1,?1WP('6NXO[_SPK?1]C/@*.@QSAE.+Z4ZG17&
MSC:"40E"'E"^QA.[,L79J$PGQ!Y(D*7\<>&78Q)UO-2%9$K?RGAV?'(Q,,F;
M6,_]E)!/?*@^&D<K; %'PVOQT1P%4FYKWKY%K2Z,PVB@];V4[#F_LWQXD%/2
M@U4?=)T"+\Z\6@A*PCZ.\)@F=6*L0;/-[IHHLU?FILSYE"F.;> :Q;G0=I,=
M(F/(#$*'L0MP*]Q,70X)7J&7T*B^_XZD=1'!J&V:;+MLXI0"/8JE.+('.@(1
M9>DEFU=GK9'2^8ULMILU&6G1FS8#54QD!U,TPR?J75<\K@_/BR!6];6H RI3
M:33B&)F&C>+H_689[6^V._H.V4B'D4S""%;1%2MG]BV\'^W,DO.I\'9GB?+T
ML#.D#@?'TE\5L9,1)7'!PIWF'_0PJ9P)V0KBRJ$9: *<"_J$\GMQJ<47T[^/
MG)'O9_ \4-):K%[MF \)GP#EXYSN*A@#BJE;Y31'C3F4N^/ FO8?\I. H.KZ
MF-7+CY(2T,/TKJUK[";.!<XD'3-,K,%%-?.C@J@%1.9IM"4[LPP#1BLQ C_2
MGM%I,,FE7=1M=FF88'/^C*79_>@E:^3N;K2J]K=!,U&;WS76!1*)@@^/5]A4
M_D6@MX?]E^L7283-/1!X@M70OQ_*>R!1B ;+<&@/Y.D(!LY'[7.A$2I=C@83
M9AFQ7[(LZ(1;#*'W12@SBS=_4+9M^](,4; HP!]S8%UF*&TYR.-R8YX<=WPG
M D>XRL[#._J L^!.> *^LFLYC+'4@J\B[V^Q$KQ%-I'")\_8;O>)VP.)0,M9
M;@S3'IJ_YCNU9G&6%G"OU,@ALCSWJKQ#^QN@6O0VG\-H26J</$,EL["-\AO'
MX8,S%5D::5LP0)ENP3FR!V(0J)U)SXKG\8>QGKCXFIHM[/%F*4#/>M@MC=2/
M&J<N =ZKV&@'<OB "T>VWN M#ZOKY)!=]KA35"<%4,*OO)C&C4EN!;$+(6(H
MV2U7=CW:F,[<0N"F>1,XDIA?-:FR?$:J^Z)[XBH-MK+4%X_G5RW9:+)H&Q.H
M9T]SOC?^RAFX<PNI8!M:(6X9>-X.ZD?M5UZN"6KPM!VW5'V44FTJ54$V#^MC
M$;4ZL6ZX<>C6"W9IU1X(.$M8#LW#C#:#@4V?_6<<2*>TXU]A:\S"(8=-IC_8
M.&FUC^Q^1U62QO;U?A*C+ L&"BPMJQ#347:#;0Z][&+]2'>W#O0QO?!F0Q0W
M1_ O.W63N0>*Q=/KU%D6S.N<'H.Y%LJ!Q6:I?O2Y')9.LCE0IU.0,>TX:6'F
M8^A4/5*=CVSHM?F3D6\VWI JMZ6U9<:.V /Y9(#'A;>JV-E$3VV -P>%W'K/
M3MW OW(&]V.XP\&1D&,P:D.3A46_D1@RE^)H[PS$=DI#[WJYP$2BO8+N>YO4
M"JZ#I>AS+&$2A^]8&;95MUF80Y(]UBR+%OO%,F-J<P;@!XS,Z>M=D), W@];
MB+X.F$W[Q%JCR)TR"L,EJU6_ID08]Q)3*>[E]&XQY:>+!_7LY6NK(TFEPQ\V
MFQ-*&YS&>[RJO.[/7BKL)(I IPN@Y>HK.DSQ^RPL.P\BC>F''R8^P<5O40XT
M.M+[K@.P N  .-Q9F<PR+%IR@!"F?8XMI-U9JI]*>^R_!SI76GU78,H1TB]Y
M )M32ES1FX.G8NFW9$<=:905008OYPB3!H^L<9#:A2\/,UU0AC/P=IL1';$!
M]_#6,7#DYB79V\E7!.>DK1=O?ZK/TWK98?HKCQM>E$$F;T"ISM^$_O>^\/_?
M:^$^. %][^$TGA=%[*R//8/ \-.WJFF&VW)(<[=LCTJDI.9E^=2$Y[S/O_N&
MD$.3%J$:SJZ,JZU'T18 DL%/[5UI'PLK3&P4HT%YG2C9C]]\%_0S'_;'U9;Q
M+$BC__H6KS]X\2M6. YY=WAX>7!@D0DAGR!\7VGZT/1D!?C-\2:Z#(^@3>C6
M@S.\L6(K$"-VKI$CS0?'@=:Y05P\L4<#F!ELOO:7FG+TM<A3OXR@'AU/1\9,
MOERYXX41V4>5/1#R'M#+M'; _* (!L2LJ3:+DYY1BY<:KCRJ^-5H7X9X3<09
M/:J]L!:I/ END\@G1*)E[/N7 PC'D8-JY*I: MDG#B/Y'Z%P>F0K2K#@4LX!
MEM9_<^XA8AY3X@"4VI=H,-?N*.C3!M$G&QE_6G ^1!<JI&^WBHHR4#GK[5.G
MAQ[W__TRL"G\!^56IF:55_M0"M>];_[&MQSI8OM"!K-C<='SM!8Y\H M7;9%
MHK8#%^WP'EF*I<$Z^^(E$@DS/C$076+CY=Y+I!/TM2@CC3Q1I"5$^:%$A'(L
MFQ"I\>XFY2+56:8MKZCM9UY-O-?CG7QZESM#>[L.:-8[W_D@U2O39?7/Q%MA
MZ^:R^S7-I9XU-C7%'ZD.5DD/<Q;& F/R[3H*$0XJHJ*I6Z]?V_SL/'7P=1=N
M!Y%4;T>>O;H]!$)NK',.[S#U)C$#Q%KW*'00]E$MG(_XB/\<YPQ0P$C*@(UP
MU)=J0LKBZ+5ML2 -_7Z5V1%T\*7Z\O2!;<N!Q^G:S'N5T-F?452"%/H*HR^\
M61!]AMY+B>=HL&XV?!EH/$1%/F763M6H-\()YA)?!UG@CR\?,0KR0_]4BHP_
ME(OE+&.G\?CRJ'T\>@@=[6K#\FP<><0 QWM/P4313HQ!A^@U-)9AZ/2XGN'<
MT%13%>()UQYI%J\-G'Q(78$,?#O:; ?%SLB*/_C'*F3;]GPV63?M'7RK]+U9
MG.CK.SR:WS0>./KN*:^@2[EX[D]&K>>V;3_RLRVRX -F9@PM$#@O^\!H N%0
M4)DW=>P%?OG#_4SAT1=/O)X\^",EL3;P]*3P\UB[9HU_)>AOV&ENA;H98OXS
MY]OT_WIOW<X#6?<Y^C-4H^7XVNC!!OVF<F#BW8X?&<9C[UY3@XOK5]9&M:4#
M=R<B0BV%[S=> 0M0'F4@;@E!GKC!T(Q>[ &7<HLCF6S+JKI\_W$+6O+JP&+5
M!">#A'Q941D8HNK<ET,N9&FP-EB\(ZL<-?1M]N<]$*+W8<3/7(;?3&$<6G"Z
M9U8?B8V <E<[6;1B^'YM%,BJ-B667TJMI1UQ@B7/+8D)E:YK0$4XY"PEAEA;
M7[RS CNK\139P'L_ QY2&8!( 8[WTBQ<#XP!9.I:;-4D-\V$DVEZJ+F4MA:.
MD:^O)Q)=N.!\I%F]-''E+=EE#= >*!(&Z/F':WGNZE:63LE\'DO-+5W<S?HT
M_=QT=-SZ051N%@^RA^@) R-"B"M1>Z"#?QJ::A.#-[#1T).KRP[WU5-[Z5@;
M+@SZP1=YT%,[=^D.#"Z25*R:UA VX-U/Q#3L@1S0Q?U$VYW*)7RT+!]+;@;^
M"J( G%-+<9=]N4DX9#D=ZJ3=J4JK&K1*7'"3>?=%L*8G^\>3CHI,.=TTOH*G
M.<V%^^$<QKI#;E;&=%$.-9K0@BVW$_R;>+;W<VF"FB*T$=^!%]QL<F_%R']-
M"_I!T"%'N-<]8-IU&5G/(#_ZR,$V8\&@KP=#O<6E[H$!18-N=WK43%GXUDM5
M-)0)9V$&-_+F'PY6XX\:?ZZ_L"2N'O;I0"'O]G=H@C&CLO1"PH8-N0!7;[,P
ML>4+WQ[WIDQMAHD17#?*7$JK>*1F7AMO=LOVX7\2^:#3M?C*D>H9;&368781
M^MP#\F[A\A<?(O715:3P^TWU<.PQ=?\5,><DN02+!B#(OG\#*_WQUK60:Q(3
M*E?,3\M^;?]T\#CO[?%X(3/J@M,<B7@0X:Q%QR?2&&IXGU*4>]>(4EO0KBK[
ML]-".B5";M 4][G#2(SOJL*/H/K/YY@5\KW5[Z1&6&+O:/\R]T#G?W[Q23$N
M-$2L=G1TPV$QI@Z0&J<[!D M^%7'7_4#PQF6\L/I7N;*A64K4&79N=DW9F=,
M5*S>F!B8*33&MKZYF\RCE)"F?*;9=*#AQ25-9 =O)_OJE@'0-4V(VXIY!HZ(
M2I!G^%MX_GC9UZZ<DP&-YDB]FXYF*3."VFR$$0,.=795% D4EC3VEYRJGO^6
M\YPSCBWOBR8^ ./2]D"'=;2'RC#<J/';PSK@T62:<XY"AOFP-G]\]R?6V1%"
MIG<E TL:E66>Z9A+4=/I [OLMJJIWWWQW]?$^^Y<-2JBT;AL?BPHN@K+CQIO
MR5(>JOIP8T#PZ@T&3PR"MG(&=@RA9?ST,!)[W$[Q8\Y4G37QD1OBL/4A;-#<
M5Y;8R:?^?O$%MQ/L.C6?S>*J&ETR"3+>_CNYVH.VCI=P?Y:%N*7?/I.OR+S[
M:*'G_3G?[JM3OG\][S?6-.9PU%*A^REE*4L Z*4OF3*$TK0=*,\Y"L#YJ:WQ
MWG'5@B+JF@3BBOG'=!$5J?&%^OBMT;GC;0NOY[\3_SMIE6OT*EXBEK.C2(*8
M11K3EIW>+(^^S/[@5M^0UMO<V(\1]UR2)8UO9RAMUQ+!!/0Y/]_2=9-GVDE?
MK5^!.XFOB(?V>=IG5&OK%=#-E&3Q 4[4-1R%"R+KX2P)#-.56@:!D<$6_,E&
M/;H?+;\S/TRZ.>(3JL@;?6D&)H12[EHK!B['_*D=62XY56ESN*)-=NN_H<S=
M=$D:OD7VE3.T#A@O_#U/%(9HH!\SW#L)HBA'DR%L[0;ND ,R-<0F+0=EH@.4
M4B52<_-00:1=U:G*, &UM-IMVUO*ANZRO5*V67_M)@I.T))[J3HA,<Z+>G'W
MOV\U?W >J=EB0R,J5/K.]2H8W:W+'DI_ SP9].R%.-VQ(<.T-MJ?\@[$<AT\
M8' L:4/;ME4I9_A)_8[<VI78LP7_KV.RZR%2(1(.X*L;N[=XJ7,K_1_W0&WE
M[$JH.S0A]4L)1 98HZJ?X/R$&#7@5HD)1MHZ\&@\/Z%,@;LGX4$H5!SP%98[
M^WBD:M[E1](K2712%G!PNW,F AKW%.S70LC; TWG0WEU^N*P%;SM\T;BB#GT
M5<"Y7JP3'WEAO+ATE$%L8SO(2JB^]<U)?4BS0%HT\=V6N9FT>.>3]:@(@TC:
M XDOX(^A#TT393V\A6)F<'P(9Z4JE\7.DP%A4IY/KQQ^(NSVM*Q2J!R\^=P6
MB&-:H'4XO3,">-P%#4_[[_&>WS4"+15D@S]=["AD]0;7NFXF<OW((%D<0C8T
M2:]1KJ7L+N5<;98'P%>!7#JSDRAD9"+1FXU:;ZN/>J7SJ3[ZP7!517%15ZN@
M9E_Y?8',ER6&MJ.R=$M"7'IA1]\HM*6F6?-=-\-PFKU*H)O1@J>,QG'B+)4A
M*/7$UR&W^V+7&)8%^ +@W;?%@TM%.M_%$MJC9H^-2V5=,-6'Y-;X]>6[<3ID
MSOJ\@M:L=1#"MV]^01ENY=%5:SO7#F2?=HFBX=N(RX0#+)N!_@KNGL] R$RK
MP6Y;R0#TMT[<\T@MY43L: /M;86WUH]&O4Y+7_>$ZE[YY"(1_]Q@^=FJ?K7'
M5=5O8%:0GCNM)2XC3O6$>\78.1_\ZMEYP]"0V]=/RN@=,.,]&+ 'DO7\;SR.
M,KMU\%Y!NLZXY27MWZSX^V#CNP65P@%/@F8*_#)G9)T;_6P]RH*B8*'(W3W0
M>/:#7E>-OK[DE:P]T-5Q:-%*\BVL*W1[#W1[9655.:]E0_9U+O<OS)4Z;,53
M;/>.9&CP#@8ZZTO\78$-O<1[>S >3-Z<J>8U2692OF5-0ONP^0&.MK^P^Q*+
MVVG)]=B0G6/M@3+Y>IARW+\Q4Q@X;B>3LF6(F[G$ALI,=?W+C[OY]D'J*3^V
M,>O"Q>6GP9W*'R=&F43"( L+=S6O:X+VR<[LXJ["F+*'QO\)M]/@XX&;\+\<
M-[L<_05RF:]F6,C<HKD\WJ')1&0\BF0FD&ZU2*%C"74G(T[<=KK\?S0"*"/M
M15+R-_'_JS3ZCZO^R<T5YWLS\.A 9^$WT@8CO=4)+A[#@^:))K8UILPWL*="
MO^7\MAVN?&Y'E\#,WU(/3OP]6:RW=D/#QGP/I&61/>!S+2/L30-++<3[3F:Q
MT"4P]#[!JI"AH[9Y_D=)B=@I:B2W^CW7S'/2ZX--Z$%P!U%TW,I[$RRP(+95
MJ+2<;KG<4_(\A*$O&L4M3ZWK-*0U)-RAI;VH@G(O4DY43X9TF=+5HZI4X<[D
MZJ:'S=V(;(3#@?+AN:':$W<";U!=WI80:CV+7+C^M-+H7T<O4J7N?QC.?3S>
ME))3-M5@#XGQ%M)T[+S!II'3_N6N8SE\R@S>MBDAH)4)OH]^6$G>]\O/LZ2!
MRAGUN"F=?5O#@RKNW J)2N#( %8!^X**' ?S+=27Y0OE-"N-P-MU[U@>#/%S
M!D+ZD&F_>6>CNGP 17(7!3BW!^I:$\7\GCI!A/V>:W4^^ZM1E;Y-RN('>JB"
M9LY '$.N+4O"RYX*5):@7#IW#[.XL44])2;Y*#/+K^D6G]#0@O%%B<QCSJ^+
MIU@6_[7M Y;:910;L:.Y6VCZ2 .=)O[*P3V!HP7@;.D_*VE+U\<3@HSIF"AA
M"F),U_1:R,J8I\IA'V5OT&[7_ZP*:D3=V7K-:(IJZ4O@<&%?[(L1RT)A# 6Y
M:'29HP0$S8R6.GH5)%%[?:_5-M8PI*>Z'X>WU?XL?5K^W6ONW4>1K9-&#3&^
M)XWF>#[?J1_P-OC4K;B:;G5.=2,P=+Z*=*'EH8;=O8C.JUFJ4V.CQ8C/":F[
M4[;-7?68%@K])NXE]HM,4C$0;ISF".0S>CIK7H\!<S,^\5[3&>VU]?XJ6;:1
M1NI/&G+I71&EHS&#VOQRX@UW-3W%#GU1WCPAJOPKD?>6V2V#Q EZ6%>U.CF1
M2W\:1RC4GZ'/YDT7S?T%)7Z=:PZ^>&HZT<QAI]%43CRNP^BQII6?5\U$W8?)
MK<HPY]ANA5_Q$%G!2)**VO'S1V/[Y4<:X'<;[)=VLV ,?A(Y_2<>63+OHD5
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M"@$(M8^Q' FG*2ONY ZI.#V*>+?F]9YW)P]XOP?B648_'91OQ%-]5@RI:S*
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M:XUPUN0U?!6"MJZ8.5]6<53D+?Y!/_8/?_YZ)L+F419T;L H.=%@7UX4&V_
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M,/5>&U"LNURW>/MSILLJ02_T;'%W34HM<NC;ESW0_9\5)>>MS'^J6]J\@5G
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M#FMI'>"<9.B-YX[H0 _+27>.MP?61_SP_!;[ [*VL,82)G*.(*>A+\;ZPO=
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M\M-L7;&5$G.L+@,^$!<MN/TYUMB)JO4?&:+Y5GBQ>;2HQ]"%K1(,%%&E<LU
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MZ#2P+;6A/[JX<N$QS6M2W$)<X=VH,ICRB_L.?5))*^!7B?LDO?1_6FL@O:-
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MT'9A[REFL]Y;#R_YY3C@D\+#P[G''1MOG/\3[)%%<KF?TS6IBOBXX+OLY6M
M0^'3<$1!*?< [_@O4S,")A34\&+Z!K>M9T7BHY<#Q;;_@$I.^!C&RW%271>N
M-I6J_JPZ^[@7=KGDNW8F[P&HP8YG(-IP5-46@3X_!2O*LP&/T<4T*/5N^1\7
M-OZ[BQ%;_691*^A&^+79!<7(\CA^[ORI+]ZU5^9-,G8<<D-M:/(+21XXB&#
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MF1_.'],*ZTD0J*+QG/N@ =M*L!?*E(@/76_K])/&!/7AO'OV";HE;?-',4:
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MMW^^F%06?_AUT.UOFQ#_@>?F5@)9!;&1+-!NRS4^ XL D3;LX=YF(5".?&9
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MVCWII&M_<'<G03#NC,THX"$ E4@VGJ)XXJ^W0WUR"T[\?GU34<(J0L+G8VF
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MX-VX;>0OY^_9.C@44QWB+MQ_G.[K&]R:FEDU9?X%0-R<@);&#2,E,\!HK5>
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M"JHG=9NA>:FS<JT#@A^B+[>SD*X\'>R1!4%)8/Y9I&"/D1V$_'08;YI&50F
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MWM^=8_*V'IX6G6<>%AAFQ=S]3FO#0J;#LVYR'%1!VHS4:@YG)<5:^H9703*
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M_)[*-_@M,I*QEVQFR#J#>6_O 5N_Y8>,L-V*;30/@-!!4*4%@DI4"R'7;27
MSG,S#8+=H=A2R*'M.)FWFA9?2;U!$C69<2(8NDW.,L[J;41=*LX##$AN.CC
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M17E.N894585^/PE#]16PC6+08%.1#6D52V/?)O!/$*=2@=U.]Y5A8,/.A>,
M.W6>E#&$R9I' A@6X.:"\L!^Q%^B$]?%[G&BKX2W=]'MJ%->AU6%W/4 ,Z-I
M/RT F H"%C.:5H\:LMJ+,&".RV)Z4]Q&I.<,66;U=R&F0G,+,-5>3S*_;*_8
M1ML?J-@^@:NM8E:$A 9&FN>5GU&B:L-;.3?%&DT>E8SH'?;P!O/%U,Z6$:WV
M8P?^])7;ZU(?W%DY1')%JNHSR\3N9,M6B\2F>,H33,:H)?102JZK[7%<6T<"
M:I6H"Q2F^&5Z\XNO2,^W.P#U7N!1T]6T\,K]5^O)V] #SHQZYG3!XZDB)T"<
MX^9()0N"> *VYB2BJ2-5S6<K(UU"LTLC/ 44^47SH?';U/-M#I!34V2Q=>X<
M1HM:W9Y/W5++IT6]>*9#SX5"0(<6)<H,KUI,VP?%5[+UJ;AV8_9EH+^2?/[Y
MQ+NGD>WW?>Q*3I\:N$O[=M(LB](A"^%MH*]CM*YIL@2M.I0H4WR8C,UBZ]?Z
MSF:'ZD)O 2@XJM [\WD4W1#@"#VDO4B"\.@7T$;-@0)XG1=-3^K'0D/;ID8W
M;^^8],0-[\$=-K]X]^R3"WKD\ 4WERL.;#H!<ZA+O<_PF/M*HZ#3/_Q^G!K)
MV^.0-_H#M@&GVDE&!$D%\@F.F!H@,>'O\3F:R7TK+?=,+&%$1254TPY=['C]
M")?+ W+&0]<@<2 JYR0QQZ+C?(>Y.'W;"NN<%M1RWB/>-IJ%K!/:_*P>2K'.
MH9O1MM7W:Q=TD'GI<E^S7G<WG6XG)2I)?MH>M/C'98EZM[93"QHDIAYRWT /
MR+WK\_Y+T&P;#K+Q2F^6V]KLA78#JFUQYB&+:9=@@JS1IOM)9,/"@RK(.L3E
MZ\L2)>HR?  ATN_UJ8IU#]!6[8C5IEY 7KASH6JSZH)=%ORI0,:>29.2F(6,
MK'EBDC]2R-QGX(@HI\E*.OP>(V#L3'DX3GD80=>TDCEGL]O0[=SU^:<!<3*>
M^.=-O-VH*^"<HD*!]NU>$B.I$#AZP_7I.B4J_0*@4[M ,8F*,RE((+#FTLQG
MTY) E:[82C7RZ":57QDO%G&&$B[JO$0J0YHZU5%U[FL6/')?)IIY=]41&%"\
MYYK7.0<45N8^&!&Q:D)\#KTTUZF5J3R<LL9N0&.W A/=>&)>7#XB>#N=SW?<
MG255SV;3MT&S? <H7^YS\Y*;!?4OB.7?S4J?GF74'E>BCG31<E6<^GR\L6O<
MK,'505,^:XY37V-2@@6O<*;OM^C<Q)TXYF6(.N9%6USR8?#G"I"<D;5N^4\*
MO+N,%FXMT)8L\<R'[@$(8;.$[HI_S7L^P3P@-Y>B4?SM5_4C[NBN.P&M01RF
M$A4=6//.DG 8[.2?)=^0D2Q#H(+V2BM.YAQ&VY4L;TFP2RIA\%]CS44D_FUD
M'%X8W1S&,*V'-V2; 9&:>:HR]10D&5LU ?^*V#HTRM*>".[FFIY5@5#"DJ!P
MM$S:N'P(C@!7P$-SJ8@CLP7.XG55D!7<4T_M5.A[6Q1\*<;T'K3Y3I%^P@''
M]NQ8"N1"SPC3,Y7#.&VHE!HWS(^66^(?G(QQYZ+-O^-TPGZGIF_#*?2.'S ?
MRQ3HHU/<NU).(2XQ.\J ;. AG1WL]*Y?61.-%04@%^FN)4#Y!V0JRR_B(%8D
M=HNUYTEMMJUZ,.KR6MRC.P%CI85,V- EXI3'0\4_/ZG15@'HZ7JN0[YB4]78
MDL&IM[9I:KI':1DE$=AM[BMOC+6X=N8M%F$:<#5V!=+#A(ZZH;^Z*ZMHF.6*
MF.;X0R$F'A?[=_Y&\HBD[?W9<\?UUC&58Q9GWJC,)?[7G(8!GT_@] F21[D5
MT+LC39"]Q*HL,M0:'.'<G'5D3-]8MF_GFIG[,SE4JU,BW&E())G5AU8VC9R%
M[7=@-* W8WMM?J%K'T#G[$=/5AK]./F<AD2+Y#MOY;:>Q&I(%2@4MRY4RM.!
MT?+EETJ4)C;V) +_NT(WKK\3_H6A4: MLS1I ?=C4@/-;6E0%Y+>S"L46D Z
MJP-CB8RK_;"KW"(-.@EP)"26 L?*8FC1'$H3G_<&]^*1D*VQ%79R66QG9"8,
M(Y&"9B6E83+&:;:2&C7 R#).3[X5M;SO$6^[&YJ&7#8Y963*&S-D(F$DTZS/
M1I]_[L2&UZEZ]SDN,XYUX<V*/TTE#$ #P2V^,DX&IY*EE@8P<EY*$'7, JBN
M"CT"= @^7TQWI0]71R4/'UJ^8WLX_8^H2_,W#I\7-KC=?QZ%W:KH *PS-+IJ
M_T5@[*"YYEX+!7CP!@G49I_CJ-^X-RQ"=:XJ"^X!E*@.UG"%?=IT+''0QLOE
M[OM[!<C:W'L6#0:WUKG$WGLRY)W^\VUW30!HM=]_YPZ- FJN\ZX3/_P4^LL8
M#3AR^64M+CO(A-ET8\EY@'I-RLL*X/?[AVZN!M=/)K!28Z]*Q'IDA4L__-\*
M*5%( %KC9GGMT7BH"1#TQST$1VW-?U7XB^*F%Q B&N7]@^D>VOSH]Y7_@P__
MDYWAR#!P%*?\9,RP0"L!5V7Y-N\\9LBM0R1DG:^ 4D[T<;7A#<N/I]UV(+@M
MI$H4EERD!9T$CRFL$'_![,!E/$7#&Z:D;&,J03)$)5BW>LHOBS77<^9>D][;
MW2\>@ E(=:I/07Z"(D.P]L/#>/ 8LXUEP4ICO\HK6%CV$Y*J)\#1M$H&A7IC
MX2#.T&E6!ZI?P@BQIF"U_0Q.,L,#;D*_)PNPJ]?B>M+*X!N(=6I<-J\\YH4R
M_%_>0P- U];O-$\H43:[8B)T:W\3FB%CZ405.A5DT[;$+F#T(=K4+MRPB]6%
MFY/PL\N_FEYIT56)FFW?B\FDFP#Q@\)\9&H*N9N7_'^])DFDM+CH85OJ\]"7
MUJR:>PY92\OX##UX*]2,L,%3I-A..PI57T+JQ7416@K;M"JM3O35(\O9#?EP
MM*-K^X!QT)/\V:D&&+:&-TY)2K,%HVLHJI!U*WA/<[$6N5UO]\FKOF\TDN4;
M_T(E("/3;M0CU-MC:G:V<_Y#U-U_%2=\BA1LUIIKXC(EJOQ[N20 -LQ?B(%&
MI&)3,ANX&P3;876@?!DE_3!2P,PA84K3'EETO%]7>JI%8)<C 0/=;V</TW%6
MP:==]'^E7Y X$<[:EX_^C.,V*U&VM@./O>K_N?LSHHIG7S0V/MIC>/-7X@_"
M8XL#1S7'OL\K[OZXL>3&:/5PY&0?ATDI0O%JV =08%1H)_I@$XEOI;TWR,DS
M$7)-NO_<F2W?P<5!,807AM]6U$G*++P-5:N73!4B%\Z,#6B-Q*!9Q_O1!C[0
M1G +WD3:62N^U$=XE5,(6I_N1O0[4P4W4#ICK9_(WR[U/%K;-MZ[F.#8G[D0
M;<FR;=\ 'GF[>?3]X]C+68N]G,9%]I.;9U3&MWNM_:0ZN=(VD!]0%+%>^.=5
MB,'^1GZ'-^*,3G$W0[SSB2[_GH+"A86AV26J9-;+2#9005/AU#?JR;3)IZUR
M;FJ\,:N8S1&KPUM #C]:BC$*A0J.]'H-]+T7I=8R@:]/3 U:^@UW_IORW?GT
M&?:=BW\AMH2[YB5 KP<;!?<"7#[WI1> /@+_N((@Q<L**NO8.CH*7H=2HBY!
M27\,/&W9H*^YP>CXW\6J$W]O?I1W,V!Y]L=(8&^HQVJN#]QTYNJ/<+?7<[M^
M^E^NK@B,B,N^2K7;OZM&O;^/T[FT^^CCEY,ZF$,I6? ;<+9M=I#-Y]6KL^6S
MAF*H;EBN7@"LA6SI;VAASR(;&&F=N83Z_TR.E?MJ3?0&:G'.>553LRI&A=2N
M?TO5N^ 0\>$&$EWHC;-KE\7RK<-N3#S)FHWGWOL>/K[\^,LSY^Q:+;.R.I<]
M=:S'I*"@[$-1)-#%!5C[PE0RGKIR-GF[R+)[UTP1XP'=#K)>:(->*U':!>#(
M93=+VCDH:0F1 'X=1%*B5G%[6[$KNN=MC[SSQT_]_%"':^,:\ITS/OS5^&O<
MPZ'2,P$3C%9>;H-]^Q1)MY:5#E.DASWY#>410QWYH*H@5]KL_[8%OS6QQS3<
M[+*ICFL>JSSVP'!LV6'1D?[51RR,+,WK1!-34!F#<.+&9T,==[=:_XBF\2?,
M)PGQDRHXZ?RLQX?K\6T8$QQZA*JN4<'MIX7)1QQ:"W+LXA[L<7J/(UWH^PX'
M$UY>+=KAT#'3-QG[XP%RTU8R"O\=.]4/XBW<@4K "^P\A5K[D_+(1XR+)!SD
M&3NC]H"BT->3*5$&5X0*_6M(IY=EP[CO9VZED)XXJIS+VER\(DOR"&2FE8HH
ML$VT;(_Q5)MY6,&P$U%G.&H(L>/THFNU;!^+/X[.G?M[CQ;<2OZ$R5"BZDS2
M*^:K):3T@"%&-CXD/DR1=E\$ZE16I;N7!0'._%F,O+V(T*6QH3Y;B^HJ&;]X
M"1H_?Y/L)YH7#SE+K=-Y$?9H^C]#G S%>Y AI&/Z:)%2'D9K3[!B$]:\^TA3
MX(<:DP@":"4RW7F$\7*-KO?*N)^\-@HF@NL,%"13*'/O0L([?)^/1"S$%X[>
M>C+IK$0-K"+4'6$^Q$%/YTMR9H<M+K_9O>X*0PL?#13(,1V8H44I3S@\T72
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MI@?A6K!Z *H/2<@K1B?K1@V +RQI^T<GJY(IL8-=\M/2WU0^K5GA?DF?.$!
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M>"4,#.L1?\U^9"M&)OO?#.;>XEV@S(Z\I4Z[Q[#W/7374[UHKX_4Z&[)SA=
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M)Z#0Z_1.*A@ S"A.< 5!A_ONP2*S,.CP4^2GH682?>EG<) XE;U:!21-\E,
M3!Y5#57YBW2XK50+LGU)!.I4C/K=ZE_S]T9_/R7PQYJJ7?!]%3>1IS_*KSVD
M $R&Z16>39JWN_:!7!'5L.>.#VI!M$QIDVJ,SP8PRA0DO%FSM)\YG?7GGKRI
M-?'^S3J<E< &F06V8R+BCBE34+.->)T&GUB[RHECUX8N@C]4:J,J^7.>)#^*
MP9L0+>81W* M259])"E2SUY@57+@8^;LQ[NV#1XOZUR/TK$([=CQIT3C_+XC
M\W/8&W7YYC 9?R@:9J@\&\L\7#+*4$_$ZGW$>R@.^X-H#9/<WK3GY(VXL.XY
M9Z=7XV$,]5*)1S5,Q)67 $1HB+T4*:9>CHVS-1A*%%R=+;8OEWYYQWI<%X!:
M]R>AYI'!$2ELGW"ET#XKE.CW0:B84]V&6+E11Y\5AT$/DMW;G5,S6?MJX"LT
MX]?EJ"4NI3V\ ;QZ;G?8K/>C%-M>>.^[\?7ML5E,TQQ"1_]FL(,W<_";VX["
MQ>UL_!6#-&GD4;!E]*[J]JA[Q_6*$19_U[AP&V;\-Q&#.NU]SE*V0Y(J*(6\
M^9"<-H6]$EI6Q#HCRE_YGNRCO<_GF3G$&C3'B$6!L4$:&[]%.ZZ_'W[D]T=<
MF/8OX8D:4H;0GGJ<.'THS*!38/%Q@&Y5:Q@N)UG#Y6*A23K\KF=,M$9OK8G\
M@D)B ?\]#$.$3&]J5IS)^9F#JNL44_ISP6(X2.E1)]>86"K>]B?^J#NL' MX
M"A'*E'A3C_OW>3,CFU;IW?TC>Z,-P<XI9>F0[73P3WK6<O;)+C(#E#7F3^VH
MG<>0VT>';X6H34Q[^$DG:H$!L47HD><9\K?&ZY:&LM>/5*\"&FE"1US_Z=NX
M^.@-LU(>#GG8N:>TE)1\ZAGL.9L7>7*,=/))3BHO_/#=*^]^??1X%#[S[DFC
M L&0&3Z9LY(]]T.,9#8<U[2='0[?GTGPT1:1#<J"!SQR;Q$*BEE;^8D3;XWM
MEL!)HK"E1A)M5HW]GB"'"U.%7AQ;](T.-YMM"1FW>#N+9;T!2L\T-QTN75C!
M*5$RTX@SRZA/D<!'K/* GE6J-6="I(C['3UG)C*/LF@V2$]B'V-C"+-*CM/^
M4G)[PA4_Q<9,PRA@&MG_P7 ^M4W@&F4^T$> SG(?P^<#A>]W-7#F22LLWK5^
M%:8)XJV(EG#P9JMXN9]/?Q5,TGCEV(NKQ\2RS)XU@CJHIB4.ZLLK+;W\")]J
M%Z%>W29M)!AU_3S9_=6$8?KP+3'978>#_>S-[W&5*FWIT(V.L0>WAG_F9S9I
M@XR?1=>465^<C!NZP4?ME=C@?NJ<0CU*(K /2IE %&D.Z\P.;:' :3".,Z="
M$X$XW<JOT2:5#5=_J\-,[C5DDXKL^SV==-YH=&VT,I&J, %/,YIK3\\VY=3!
M%^22F8AM9VP>!F"1W$P.[D/MT2/D%86?/@.-LY1;AQI,,PJ';Q$3TT2-CP56
M"]@;5!O 0G]G9![J$ <I*[8Z^#!-T+=GET'/-*JJ9H<@&IRCTKKJ<'L[*#9#
M50+3=L2[;RIH7?G8HU*A-0?.49]7ZG S/9Z6P2>ILT:8-M[#5UP673GX83!8
MA\- ; 8K5QF?UL0WE[&N'HA>(MUJ1TN)C0_1!-3?PF>ZK:%STE2AQFNCA1]Y
M9E/F 0KGC4L-[*L6/XE-:Q3^+ L;CCOV?%B&:.9\&)^YUT4[Z!+S+.!!'HE&
M$FYC*&W28IE&L,N^]W)M@6#%H'2XL']S324H3D*B2_9'/*@0&&,B)+J@I)J%
M3WN6\/9-/]->0.T"3@ I@EG:0O%(42D2I7U4*<RTQM)0C/!BG'=5(@4_(+,@
MNS^!#R10E5O(4\!=S8*%SIS-Q@K<%M#PN'8A5"7"ZR%KW[,7/&2)1-6<*D >
M?825UQCD>9 XHMV_L>W-C-5O4MZ=OJ?O9?#'R>&1&^?1]G2R#O=,RQU='?I1
M_'GX8NV$!/Q:O<9C<+ 3?/J.X\3BJ_LHT^#K8(V\3E"J82 ;/R!'P0/8]X?:
MU(TU?+914.O'X$N;*-%G0J&?#8>4!]D'IBQA+U;@9U^GS 7%B>P9Y$,JF;75
MF@=IFMGLF?#+1XBMMI:SBGT"O@ Y*S%4HN&/YSO#3$@P'M1>NUK!,QP,EJI[
M9_^@ZGFF'0(E:IM4FU!IEP=$3[9O?K6[@ON27:P]\^%'/+ZI)[;E>MG@+4[Y
MO3#7DZ.DI=(=G6-36C@[;3<;O/>\*^'XB $C9 KD+/) \5!:ZLB$T+CG\Z#T
M1L^>'M[(]QVI[WXMN?ORX+:U1\6[+N$IVCOD$"Q8IE0'95>0")_9.]HG/OLU
M3:;FJ,Z/.J+FG[?H<-N8LQFO"R,G!>EL'P65A)J[25+>/)I?'GGRSY4^^45*
M:0,U&7"H)5(3**L0+S"HF3@MM"^JJHIC"5]0O'5NRK=!.]KOT#>>;:O\$MF:
M-+Y0'F#A>W3_'.F]R!Z/W+M1U9RKA?MZ!JL];AY;^B/'96LE^J[SA-N(J_EV
MDTPK$YEKW^E>PV/G!B/U)'(02"G[88\W"HGT=A>FQK2N<7TG$0F[@_=W5&A7
M;9P[T+-RX)OMU+FO<]8ES%A2$'=]#L(SHMA^OHE]W3C6]LMQBAH=S@L^O_%L
M*&WMU0UV>@F[7QFD"O_^L3WS0.'CXY<7]=1K]*VF?+F%;Y2D<F9UC,0(\2R]
MQF "+_H>$+Z_NYMUQK^SOH,;2$S9-4[8=WK5NW-?U'03E!#UK#>/J _[!UIW
MM;QK/X'XW-L7G[5MS_5@]\:$S.+@+ORKFHPNV3GKB&,31HOT_J&)B&D[!JU[
M3(0BV7032I=&LU&*=71R^$;OT/Q[IZ<_=LNY8/#._S/EY(K$5=5/@$9]^=CH
M&+R5JC #<S'4$B-.1/!BI!"\,C&L?9G3+::>)_2^Y*\K3%@^,O+X1VO(>>/9
MT2,GHJ,IKZ.B&,>G\XX8>.&B#^A=2*H\]^W7S8Q/_^O4)3!X/%#J3H1=9FDG
M,"U-)UAV5A =8/H(,)-/L4<XSLW5V[4\?[5UAIQK/T!PQ##@&'6Z)+WVC(IK
M!7]DE3>(6XI;BIKD&.];1>3@QP(Y4Y%-(#.SEHB-XD/P*55H2(/0PFUL.MRJ
MY*6,D!V@%[#-IFCW2A)\S.&\+[7\6XXJ2;/I"-O.>;U4X,PS!D1>*ZBVXHP,
MIRK,+W"4;.USSDJ&3%^PA+V\#?$!Q^5E7WFJ,5/66#/%$<Z%/.6Y+4#6@ECZ
M- 9G:KL;?3K0G S'JFS 7Q2B]!/7DE69V&R3IDKU$M\(T"H@"6K9C1K#GS L
M,(9IRK6@1VF< F_&_;VA9-2CJ.K"R&<KGW,+3NY2FL1<Z[G@-_7(U@<=_P@S
MZ>!^V@R6O=*YB=_=+\J?EQL<RF8%*'/ZD]Z5JHA)%",X_(BL-PS75KNVK 2N
M@ZH4]JPDY=PV=RE-GQ72.*SL'[<4<;Q=N#/X2>P(K6%4D79J(SYD.>"[!L /
M^Q(E9VN@7:C1'E-!U^0F^ .SF)LBG,YG!VHO@\"&]Q6?]>I[QA*!8POA,LBG
MP5L.,WEFG'8_Y<*7FO77X6! L6)>C+YCO?SPLX6P$.OY3:M"'(1$]@7YZ(J3
M$F3Q,AM'>2<1?Q6Z#30_5ZE+#KL_XUC'_%I+U7L]55C$^Q^+P(K^YQH?/;!?
MR4O7X1@.?NJU,.D49%DOL'I_8@+(H)8;LS=#XB:\S7"?(2P[1E=+0!RX:C/H
M)Y)-XZ;8-^4O!O\AZ$/..?FTV:PU!=#%.N6FH(9% IOU0'\>:CJ@PUTMUUX'
M1OHJJ=K]DQ/ (6$5'\E++=+ACI:J W2XKBJ82A?G(@X8^SI':);H<-UUQX')
M\HDAW#L=+FDS]=_O0!1/XX&Q1*EG_2RX#/O %W2X:W<YG^GJTQ1LO'=V\WMX
ML-M5E.:LOJG#E8<3)\O94^B9,G ?\=<6@]$/.ER$HTJB77,+ASZDRB_ROC_!
MCV+]=CAM%.N(1]N$R4;HF [WG[Z!PYK)[,;<8!.U@:AQHLX$)DS:&#VEC>BT
MOI"/J$2',^#SBQ-[6F0*?(+KF.NW)\^6^H)AR9QCCBFXIZL/GIMRY8W]"U"2
M0[97-K^@&\!\4?Y"#<E&^-&NZ^JC^#0R;EOJN\VK6XSG0&]Q<=?^*TN<0MZ,
M%S9]%G?J/93\0E,?M_OJS\HJB2\?L<%Z#D;;-([QW-$UGN%W/HX.R[PDYY!:
M.+98AVO8MA2A*O$P+9:?-'GQ29\E=/*.'(JFY-X_#H#7%[XLR+$_(-V8HK@.
MOO('OS/$]7WV7MQ&GQLT!VK.^H=]>-Q/C$LYK;<>/'W$L/O %=.X! NT$R)E
M3.35T(Q8S3%RH*KR\I-O2P4.)[@SA-]J9T\/)=MC.N&W*/UQFL6X>E77Q%()
M=92NV3/S(N<U-#?JG@[W2J]3=-/+>R$@#WVWX8];)W_O:V.:)=+AS.9^(&\
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MFL:FVLTYS;H:\6Y%99S%O@CF-+W)!85"$S<B[!6"&E[@LUZR[74XX^+@]K+
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M98JTY;-CO77NC?RE-;!8(1DAPFOMF_3]D4WLE6N=X/8+]9]P3M%>AR8C-/N
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M.HS1##/AU&OR!;IP+A%REF[!?YHWAQ80[2TB.GSP\_9:^,EM[573[8._H]L
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M]=N/(37".0^P#>#2 ,@V*S+0@V=*-%!N 5H#(0RW")G+I5G"82(&[%4W?#T
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M$A&XC=0K/6Q;BJM(P+,R%4J?*K&+WG,U3NTFPT@""E*H9_EBS:2O\$;30BA
MY-&^%'2>LA<">O<O@"=L,[%APG]D-LH5 2+F8!$FB6W"D,8V00X/0(F72Q$=
MRN0*=!Q]/^+6,W1( I ^%H/,GG%3W[MY! >.M@)P(:6\G8-@;1A!XLT1?JJ
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M/0 R,O49[!C.U2YS'G12'AR=IEQ7;GPN^+'$PW:IN(F.?\.O!XZ<HIQ+,5M
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M;S(9.FJ :@KYCO$VB7^=DH@SA6G 7:@TY,[@>>/0([GJ].MEY.O%?4&>4CX
M,P'-H[(V8%]Q.G]>2Z9%EI=[$?Z:9YCFQQ(_H'P_CC60NC&70DEB[+TY'BC4
M3&A_QWQVVO2Y2T5M3<K52P--3=_NO&KRJ%MG^A$_^3F*IWN:37[@)LM<VM&*
M2JN# #MZP>K>*GYS*Q!]@;5(W/^BAE9<4_=*V]?3(>!>3^PWH#,*S.N[8<.E
M0">)-[HWF4#U)O^*5^,5_M::>H=J#PO?@*UWXR:=[5<G^.+MZEQ-FU4E5*;
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MN6NG:D#CSKMY%0\'I2-?FWCA!::X(V$]+8BHT%5[WO?1.2XV\N/XU5%MZW=
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M1ZLR3^[>ST\GQI\*JB8HP$PC[Z_;7;=YA05TTP#?2I9722$]<.7W&5M.HB^
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MLV='"63W*+]DSI9$I5A-'<REMX]%*H2QATPO;RP*6UOD_B,I0#;C0\E0P#J
MN3^7 W]67UN-8EV09YJ.>O+BKV=GN%]\CK*4C\Y-X1[0BS:6H!]'H$VS*NES
M4RK9]8$-7K9/0IN#Q2O5K&--!E5#_!,WGSS!YJ :Z_:_9R-85%1&^V[,=)]8
M^%CS2>RZQ.&'ZYJHGF=]3R%KT'>U)CVJ"GF<*[6Q2G!Z2EF$V%[R$S^5JQ6<
M)9_^2FK%?5@LDQ+S+RLC0]]A')(IBZ$;F"-0>"\Y!&?[K\ZC, Z_WGI(_/?Z
M<F'< WZ+.Z#_:\!XD -[\_3L=EZR<V /6!J(O993#818MN-]"AC#X\O-S@9W
MQZ$-3^(/38SC##M%BB[%!=;):\:]NN)MJ,^T1Q=89# !790ALL4$L1.K--9N
M&E+ J3WMW$)8MO?G%-\U%S4V?<3S+RKG14+$>-J7P3UV$+?>$6B-'F([!!&!
M>F)>0AJ^%Q6OX@0U[V.%LJT(^E5/T/[NY3/VH>%KP3ZIW'OU17<R,BWO=*F=
M_-Q_/:P,(T1%=W-'@V\2E<QXD',+QS6=YEP%A)$-=[R.><%C,BMQ*45PL;(Z
M^.D?MNAA_7*![.]L0>;OU/B9_I[!4<Q'IEY"^0;FUS'GUIK!4FC^%;!@I%'K
M:"F?T_JL' -/V+%K'/X&L;WA&>Q3^'D4-?R-Z?QG@0UM/GIYV!D 8TVIC2I&
M9BP>ZO4=(%XK.PL.V7P<5]+) )\=WW56=,JS4&_M]T-O"+=#*^C%=^\KZ@\G
M_"$%Y-4?@3:HI<[#H64T;N#AR=\]JVE.=W,%\9)9<"5WM[&R.'A-KN&3,9,O
MC*<G(2_:%"Z^KDC>6*3()G-70]E13%)AK&U9^]T6Q_.Y5EEH44\FH;VUN Y>
MWRA:O?C)V\HZPV.+8T!Q3=^(9]M"1URH!Q>GS0'D8^73N@ZB)@L@D2C;T/D9
MGS^.G/H#9I\G,DWQ37>2[[F*U&+*Q&6L"%E: 1=&ZRZ^3>SE]A1G(ZR[6,V/
MQ&#/4"YX,7>%"8VAI+!7J">/0'$H77#B0X&X=?#Y2<V""L_@K*FVT#+[VXE6
MF[Z/6'12HNP6V;4<PMDO%QY'_L[-_!-Q?V$<P$@/5M;4GW:S2J^Z)4:Y;?O,
M&D4 VW(HB"O^-51R<SSU1D-RRP]4I>'%"-$(IM#+[LQ:OB.3X<RC.ZMS98N;
ML!R7"_\A%F,$#*9*Q[8K!(:2'U/-(IN&76^-MRL(1<N+VN994/9J_8*X4GS\
M+T]-VV6HQO=\M39[[9=-EW2*"8SYI4A<J4'MAU*8Y\,J#^;'L?PTC7'6MJK:
MSQCED>BG^&6'\8P;\35K+=!'?[?]U3*.0.:&109,%]H-B4R2IYCFH=S0^0)(
M0TN?G#'A+N7W<ASF<<=X.V>I%"DIUDMDRA.L';M$J?2,4W:E)SP9;YSRL_D+
MLB+SG+?^^<*N%4WC#]ES?V<'FUW7EASU\S8Q'U?:Y.[-.@)%N3=3&(VD:V4E
M*P??@B\UE+TORFF'0E\OV@?D3,LV/?V]\#.LFH ]@1+%LZ:IO*<,=66YTR0C
M3;UY[%9L5*3O>G-^RU(@?*U4XCR3X'+I$U?W+7OC+WV5T6W'.EM>T\ZK]M#=
M%Y)?+E.\^W(Q)4.%Z(=3\28ASN@;ZV?M;CQLA$NYW3"Z>N-FV'.[E_GB^Q&T
M)_FT6Y3-Y/CV*Q78NGPOFW[RD$6<^*U):9=IOQEK&QUN%AZ0]I3 BF3^$0@Z
ME/RU_? X]<(U92@#70P($#J?*.61>Y92FZJ4S+U:(9LV/0U?";P"S\DR>)JJ
MFQ+_W'?<==0#5!CW7_*OTS5&F>Z@%JF$O3@@\% ;CH5,AITWJ8Z'\GD6&1"2
MDDN&RV.;E/&[XG9W0AH@4^?3[CT'VS!+^IS^XC02A6O$=(\DO%GY")@X3UA9
M4MW2:]9=P'A_'/NZB/@$([-DS=5@HBQZRQ!7G]CNT/GCJ?['UK6$/%DY4*B>
M[DKPSN8@C97+;#[L;63^R+$6K2-0SI65L+=,5%C?'.D(-!_3B1.Q!R3) 6TU
M*P?]-87P, F\>[;)6P.4?X>5#5Y.R$#LO<N2\R6]FDKN#5.6&;A[+]]*D6,\
M.@N>1['$3!%MJ+*YG/7)9!!5TS9,JBG>^#-EN-53B+D;+*8M\[YQOK4*_903
M?>L;0^#Z:>W)%_1FO_ ;8:U4[F[YJ%D%XB(5$:<- 4QZU3>"-8!@+9C]V%/$
MK@::Z_OT+WQ^^]LO*:NI=>U!8MXWKB=F^R;*L$[O^0#,#P5^=Y1U;<<$-!]$
M?2_P+9<""X]-;WI7&C18>F4WP)<=S_)ZO.M3<BPXS<W[LI%I :M$;],^C60_
M1K8:LA'-&;$P)X"T[6;<'$7!N&(]9P6Q!)1]";+(D5*[CMMTFPCTH@(PFS'R
MG;';:$K*I3Q$)+V&2;N  MO+!F#424X>I(;5Q(;_3&#7<G^SBP@5G'8MG6Q
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M=7"XF%[2D:5$N.-3$/ASY+!;*#_@5YWPX C93*#"T-K,G'N<W6J4#ATI4?P
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M]^(,XO;D+I)Q#L5II\S)^M59FQ6V*1]W]Y_CF^?#$K/<6D;]#M@O__V'!--
MAN21;!?9\UJU!6G<$@%L##ZS>&8)O^\@X9T3V-C\$W'J1 &REB=!C[+55/5S
MC:.8M$)R*ZB<=6DUNMI7MLK;-J1P[5G8]C>#N?^#KW-Q9\)___]*I<@IIQ"K
MB,JI<BJG=7)*+)'3L$H.LUAR6LQ6*6<6BC="<IA#+(>1XW).DL/8F)A-R&'9
MP@PS/Y_O'_#[#^[K==WW\_EX7J^3P %&TAJD1;9\"*VY;U6->8115T>NJV!
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M%\ :M<Y[V ZE?;N 5TXV>_"/\Y-/3L 1*@DEUU2ZO(ELF902"X1/^42?RG
M=ONZ_UWOE/%"[U#-6>,!Z5CB2$&$>Y,*)Y16L,FLP.>O2?O.9JJJ:73-G"F<
M4>CQ*MMX3_!S;?F49[U3LLSOSSMH>@)93L][P3^//8B+UL/+<+6O(41NT%.>
M33=A8Z:.IX'C;10ZPFUC"J>$32XMDJ_7P \I1-2W?FG(M29>^=1V0K =^F)E
M.H][UJ(''.LY8Y%@[*5:S@+19PNXVIU)(E,%13E.]T:;&^3Y4]3A&YQ >E.<
MLGTTB/7?3TDQ<>4)4R6>)S>GC&? LIE_W7H0V?C/1==?#0Q?.=::1$_0JX^\
M> M.WK))ZO^)WTGY4ETHC[H[)1TJN%(#O,35P;4,, O8,5U9Y'RV*$AF$7H$
M)0V+R%\,%X8!1=<X"0XC^R-?WE#I?Z;RL,?Z7U"Z?> G)O5AAE*KK*+\<8_'
M;@Y>*HR=T::ZTI+)IE9.I-WOAT%'E;OZIJKS]-[-EE'2MVFV[EM-A B=]0,G
M_N_4O>;I-> U7BGL_4=_MZC:1SZ" LIA:DJ9QGD>:^( XZ/B3R_+;0U3?D)K
MM;'\LR@#KC^&07S-!S3MM;>1C=.MNGK6ZT3YG%^4+%1C5N&&4'!L@+:4BL6I
M]!\OFU[%]/U^CB1B>9$XE!:W8=N*=WT4/TO2'1!"]Q,/&5L$E;7FZ..]BBK3
M&!CLF:\U=>D*Y:,:^<[ZRZ&_CSX;6%[9L^I#7 6V/7U$?B.!KX5TNLEV2X7F
M@*\G6+--$X/+WUU.JDB%6R_@3TVL)EFH7AQT/7IT&F7!VL"V&B-C.-U<?X,.
M=T@;^B2;MCS#FJ#SL:;U#.P1:&2QIODN8$:O,G/&T5"K%!W,5/Q+0&%\@.H0
M6M&OBZ3F0:O-)L[YG52,W\ X?/H54/@UN07^5&\'XMP*%88;FD7'S]N?-#M3
M2WWE)!O[[=ZMMV>_/;DF[4$1&D;&?"<Y^FV-;ZJ%,FM<E]#S!=>1:B_?R5 X
M^$NUCRMZ/X:UQF_A,RHVM?>4O,U"28Q[SFG/I\6X 1A1/V+-:%X'5@II;\]]
MGB[?TF&)<MO2(C(BS4*>/?[P^D'U2+/:]';8?IJOP2U1@WW0PE;0_[U3UD<[
MRM,L1Q(AW&PM7*%O*-G)L*4[@4Z3\,MP_+:QI^FO^;TR.=*-+W_+[ (LKSP^
M$3PP3TQ R_%_K:(G0$+-%H@9&R32<8*.3_BX)TM[0WIFW;K)"((7H2XY7?1+
MM"%S"?[@=AGFR8S ?SC'RP_56W>JT1*\2#9^N8\==9UMP5/96D]#[J4+^PC_
M&ZXLYJ^[9A_ ._B@$H4(DW JO3+X2=.GVEW <GMC0UN*BIJ:\URFJKKD8:<V
M1UROM-SE[]:9A2W,^H!_Q(TL6.&G<CIG'!3BN^8_X1]1OPL0\%QH$>/\8^T)
M&L"9NS$MU@&*QTCP3,I[(W;B&!CIL1LLS-<@""PL_'4B-9:-PZI4UXR>Y)-)
M6>-K?8>+1N3"SG>.3T"3,CQ$V;:$O9X"$MD;<6LB-SJADL8/Z#H5ON&8U\']
MMVCM3J&N_)?&:KBV0K_<\S+4Y *ZO^8'SS+X,9AC5G"O3%%KVZ=*U09,'>@A
M:!S+*([;UN&)?JZWT38;G&4Q*XDB\V.Z-O9=KIH#L80<'P\B>:V*X1YA/ZP[
MZ:$WDN9DJ8DR.5 >F0-Z(N38#&T#'0!-EX/^=Z\1EWN!FT)G"G=,Z>ZD(%#B
MZ(YRGBN;_':K?WF^+1R%LVKT%YJP9\N\J\2TM[>,:NT"JFK+#P>_@,\!:[(=
MX=UEHT_>50E)E=F8^:6^RZZ.^/*O>,UI2+UN?327)CI76WTO:]LUN,RJK5WK
MD[(F:</S9W%Z)9^9LR,VB8T"B2IS?:;[_&7N$1#B?I>*JQC;VY+J11MQA./^
MS/F(T/]2-=:VX7 XQ/+:OPJFOS^]WG(Z6A?Z^.O7 P)<S"U>V$Y#L_;>FMIP
MB=N7D7U?\ZKG<*R,:6*7__4E<)H5.^\U[UF9XMUYJV&"E?]Z#O#6:#.$COR$
MTM'"%[?Y!_J7N$/ ^JH8S1<1!?[+P)J1/-:=@4,\<:XG'9RP!6I#Q!&EFJ],
MTT3^3!FSNPO8PIV&WOD,K+0K+,N]JW\N'X[CNCEWE?27_J+="-)+33CWZOP/
M%U&%]%[?U%L[QZ"I%M][5V_=C>BMQ[#U^<Q0T"U?_%?B^ Q?Z-FV+R]XYPO(
M%S/&P(SUM6/$F'R &=[&H LCS>U@Z.6]XMVN4U(=UE446#:01$H_'D)Y*:YM
MU4<K36WQ_,B&(7V7J_?%+8.F/X*$,=,5NX!:P381T-XD5],ZM:.!-3V=PB!Y
MWZE3(R&(@]P59ZPKI=8&9&/U%W4I:S[>6 <.\_+2PI7JADFJG#^#$%,)F A@
M.C)C=SH_-CM-TWAJZ5 QGF(^RIK80#$.I!,/(R,LV1F)BOX5>]Z0H-NBI:GC
MSC:KR_&]JVZIEP0%-X\P-1A)I^&0,45/(;.(.W_."JP2^4(7MT]S!SBTG4Q4
MV#:(JS 3DX#>CXSINKNP(9.KQIKMFLQIH7'0%46+DG]:->H^9U$<1GA&(2)O
M4\ [V%)GM[X3J<I-W?V-\\NT;35DP;3/<L$T:#RF"W/".(0-<685QQ4N;.Q%
M3,M_?H:3$V.+IS<K:I<<4Q"U_2?,#Y9-^LDG<3[4]7C^^!:*_R/3R5_<8=""
M(QF'-4DKXI9JI0>B1@:_)>I7JVL=[CBK?$#<_'#W816)7\?$I)X%,TE_Q;1B
MYL_T+$>RY;\/7//7YB2S?^(98*&!$C^T4C-%^:VS5>G$0E9=1GX=[AA< :&)
M,MK!-3U:T@UO:QJE_KE-<MT%>#&Y:APPNSB%H5[AV0E40H55P,)L9B"7C<^=
M^-='+QPR!HN6%[B._U)8*,P-JZMMJ6ZJC^O0N/2G2O>:S8_7Q*OZ)__$7[ZW
M7?"W.%3;-B&M-MCMO:?N\<'UFY=/13N<N#0#?VI8>4C,[D7RVWV;B;N SZU5
ML$+3>(QO7NQ\AY/A8_V:<2ZZSYK%[$HNH:YP.)F,2/6^!G_5[QN6[/T5_9.$
MW!Q)&]]C<H>O?VR)Z,BKR4A$ :<'Q+@0"^Y064^Y[Q8N-D1=,\*.-=FR5E59
M3U=E[>Q$ORMV\QM6B(BPN8-IMSL #IR=\*@?SX]3MBE@XK4NM+V"?9&Y/^'T
MQ(<^=N*1+!"9#&GU_?>1:M^']931R):%RS[\>VOF0%/J#\N^BQI/K73W;4[(
M+H>%"48%\($3J #VFJDXUHZD'1PG8R3!F)1K/A52\HL+\V1?:=KVZE22&IW[
M/%J1\DE.^^.@9KV,3@#H0QUYXD'=ZJ1:P\VK%-\7MW^4[$OYUJ9Z6\:DVO;"
M98.;@2]>R ,N/I>^>OQ.5&+H57%,]?ZUXS@ X"M@WR   (RY!?!-DKY>=KKD
MJY#4P7VV#H!#A\24!_^=NW[2_87#2<!!H?W/ 0!_@>, P*'+ -&1Q;/[<MTP
M!G])<]NT\[PQ]ZBP$W13#TS,[$+7?MWC[2?;-"X41'M/=0:V^>SK770.,%X%
M?WPN*3"(=JBUNPHTY"Y-S[_FP6;R#G)Q=\@HN^)%):F6W$6*%4FO"L?%.$OZ
M*3MD;T?<:HAG0&8S[&M2S>%&V3=4,W7)3P,([QC&VMT#241YM!(RO<^")?L5
M*,6S)_D,.ME]H:P99!W_%""W?B&XX60M))^3_]N9>4#P]-,GEP#;![KD?GK>
M2(EZZW%M\@WR-ZJ_C;\:_K[DIGO7/8>J/O$/ 2:7QDZ\#TS+ G#+IV,2FJUF
MQ+!0A16>V310FBLT!XHA'OKTH89]IC_I1\:@")21AO%;V#^8GF!N\7"_![ N
M3J!*^+T8H>?:5*O7,.X?R!>4G-85>/12#RMO>NVEBV?0L4M^(*FQ*STBB1@Q
M4YQ <M0T!HMH/<4S'FYV"6*X"W;=I4TN'L["1S.3DM,=-6WHR1<?:ZWX:,1G
M0P)/AEQV_" 6^O3J\<M+_"=7]%9]NLLGF.!K6'IE3(1F'8%]:W@78)5FEWF_
M(:&#+Q,M8WJ1?9.3^C)FV=' T1 ^GE*%T(M4S+S1\W1TQ2GCXEA;B.;HCXMM
M4J81S</'IPDU5\-NK::E/9>K:=+\*O>;TK&1=TP7> #IV4.L!2?XSXZL@R06
M9--!HLTJU;K4W[F"5?#-X**J8=I_?XT#45H\&[S-4>OS%B:YV<'#%@43*FZT
MOT3FT[!;?W_^)8_"0NNM<0_H%'*@^A%@O(VV(W6I>*I1 MVW!]7:TR:._I+M
MKMAH EX4I<2JQ8BA+I9QP1V-X!A_$,$8CLS58!?]2(&%&;S))K]"WG3[]7G[
M9M+1:,? ?V1$UW'^9>0,YR47]H%W@9O!R!/F:;)^&(YF=&_3Q,9AE#H=/_#
MZS5LO9]$;91;9JL[FO&UHC7SN +G EYFYR7_$C*MFU83DM.=1H];0\0!Q5$8
MMJA^;82+%RGX3X4V/8I_#/*E,'EJ=FU'TLI:1*;K]_$1K<=*%_J3RK<TZ=^:
MY::MW06^"CA4&4[R#%_WY]12A+;JZD-?@6(#7 JC>AO>UD@^_>MA 3CB4I75
M(?#^?/_<?TTJ(P5*C[)L&E286H]RJ)&/F<4]I5"QV+Z+8.&SYTQ:_JA.IB<%
MF;5,8?VU*D?[6P2_A@-?!S?UF1PZO(S0.Z@95O9+EQI=$%(N_?5+<W-.84-C
MG:"*F4:_?!I!^JKJ%QO0]+(X4NPV*[JEPIHAO*,$^SW8;.55O MHOU(&2_WU
MD_JV6$YW'._]_)NER^V Z!"HEOOW3NP'V>]N]YF7 3, ; !@8=/>*D9ET]+J
MBMK]WC.AOU.;4_.TP"SV<(M8A3O,"%>15H?MRZZY18;C\)G]ZGK]ZJ%-]1X9
M]1X]\QEQQBX5OM!:M>4]GLI3_(-6'N'=*%%+=+K!SHVBET<0A99</6**816F
M!0SK=X=FOFX,'CD\LISP/4U&$W=2JY,?;6Z59-GV;8D"NFX>N*/>;FPA%NO$
M@'9,,(TZG%PK8_P%XXAUZWW/UKX\YAFI%AS3\,<@-,<:FD,<]GGT.Y<]/P0
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M'S\UH'$QVOC]'J\&=7GLWZFLY)_O+^=ZSCA%::#E=P&(A;""-M?<A!*KP%W
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M@_)["LNU\N@Y IT9^I)8T2B 9@ED8E$^L2A$3O[JAH%"*X=[@PZ,RW"U^5G
MQEERGP6Q):V1P+85^L[^[F%W^>[Y#GFS6A+T^\;6;U9D>2>GL2T=<DZBZ+.,
M]<FTWC$4KBWWR$X!HAE1M.@!8N6U&;D+=X8[;(EU2\5TK/JY4N*9]VO8P3)/
M?%>T*K023AADA+E&C@Y#78 @\)=T?7,7+2<P3<+^T$Q?@>/X>/GZU,(6P>MC
MU>C14)?7;WW6A9I[>VAW85-+3$U_B@4<%C0+'<-P^KGN;"?Z :CL.BV)"*@=
M$.<F.)*#W2$.0UJ?&(/!_CH=C7T+3Q;D#T4=6%+,*?ID+V+MTO1E5#D9TG\+
M7OY\V#7 @\+(8 9M"W AG!=<A6FQ6& M(8FRAU.N?DS65EN L5F)LU\NVFP"
MS- 4V#;H0"MM7SVQ-_N$+PWN13^>[Z>!N1V<9T.H,ZSR&UQ%EL4TI3U'87JN
MM-)]C'>#&X3('T?Z7$W[2AT?*:;\S-E)"/.6=,E=+J1D2!2 @W_P/3]?KASN
MX81SG\V8.-%!7: $FI"I GP7H(26\]6_\"?7V%0N.H(F[+<Z]B+<6#$R!''F
M=RCK]6'QVR5"50I@Y4Y\^H,J1^>XIYHC#W\IMZSTR1[FC%9LF43)93Y4TF1\
M7LK2GG0CI]GYD=U^;:MNN0=D_5K%2O&'0?N,3Q4CTYP2.'FLT4]*"BP>=72R
MA=-4O-1A2_JTMMU_=WAE^QCY,L$=S#R",!W>>*/7#J, 9#??<O'+>VIU4)@K
MS<9/<]ZQM6_NE*"EN!V6N4MNU=D0MDA,;.OQ'_]@6VD6I9IS>95CV>62W@5]
M6/TRJ?O*!^=:?Y#XQUUL9FCQX0.QM4 A*!+#$(MNEJ7WNTS<2IUWHLQ48]WJ
MFH9Y#FERM1';5A6$\0?;YGE> =5FI6Y=%[WJOF\.Q(-\W 7HQ*\V"+K%<B]K
M@J[V0K?E%L,;NA_*?>R,E'3%.F?ID2EWA]>NZ"XPM1\1LAB;?S5<O)Y-N^1D
M1EM<ZBW5<.TZ3[ARUV.EMK2O..Y?Z;_E"@*MM)])ZJBCM$30T@V:6LB4\*U%
M%'%F@'N>MMS/VN"\YFJS!+I ,JV*;HLT62=[=Y ]BXQC ,47MIS&B;]/A"0Y
MFHAV]UEN7P.DA84!@O):KX *<L6Y^=.(6,^[F/W(@8XIG?IAF5][9MY_7=%F
M69[5K;M":/,=",Z#_=..%\AAR!F^[EU=$GMI>HC]GBABJL)SYWJQ9CI!BL8'
M/RP$CG%[C77@ST+HBJ'N)C9+2*A#P^N5"G_-PCF]ZB^Q%JOB]_Z[\&]E/Q?.
M*1SB7Z8A8SJIX+85KI/IJ<:FF"[YE9@/3:1F.[SOUD4RD;[_WN>F4>\Z0NMK
MPAG#5TTW4X.:T[+62NZ$3:Y/-M7BBW=0XS\C!R9(V+[5GB6/:^P;76AU5MAK
MT?IIO @HV?CF5O<+W#@R&%H4VQR_X6#M[KAUI/B-NMO$0O7DI/"E6^40]3?2
MUF+W=P&@>>D]0S ]#@,=6^9=1)1R$SKY<FD=IJJ?V6:O6N5&[P_-Y\YUN:A%
M,^>2[77O]NB6&UI],?S6]JZC)63?IC*[<H932D8?X/]2DN+"618,=.8,^ 1R
M!]^LR=!A"]+3">6Q!.!!GNZ7>R]I':;*S:,K_F3=YL$'43>&U\WBYJ*/':GZ
MXK*-?P&4PDQ_  F92J(46!O)K8?^8"0)<<97Z%CA7[^6,!*UNX"CW';%IT"Q
MUO+R/"D%3D-CO&^J0O3;1:I'^FR IO#OP_V1ZM,#8V!ZV$MC)]FXX($3J$<C
MZ\(F039D!M:57>,!>P-=V(M5,3QP0 K5>>'-S70#P^2DHSK4@Y;>PTJ+W\WT
MJ;99;P)!BJV2_)]*0+9W(E$6K<NS944.=&$DN3V=5)D\8/PC4K-Q2& !C,9Z
MDV!=-(S#WJB2^>SB ;NXY-K)AFS^@^FW*6-.-=Y#_MMQFIR;XI6V!$]1)@9F
M)R,]);P;3I/+[RE,!%!AU)[7W%7.JYU64TV4+1O4Y@[DF(T:"T^#1&&.AE-X
MMM *0S0U5YY]N]A$=<Y:4ZQ;-F\<+3L:G%8R.0#3CRM&II)<@TDK#UH:/]\(
MKX/*H"E*\CMEILI[E2NW8CFVW'RV&&30&%J\0/:T9&N_T&,&=,^WF>HWLUIQ
M87L<^4I)F*T,=]1W"G-]5C7,[X656(B^2/CS_:MUWN@8_P*ZQ^,4-Y(!?"Y#
M5/0<7F,*(95;R7]Y-D&%2X-F8G'K(G['F<W0B .TQPY-5;EM=O<HRS\XWULA
MR_)Y!WC6VUI<U6V&8"?Q",^O>?0^.[0ELIA;X,#&)^2L)1EX6$\&.6R?R4DO
MDLF ^=(>U(T2+KSYH%D\\>-9]-P/)6-S21'MN"8<A\#TJ:2T3FJ.K/U;[I-X
MV=1Q_5+XY)?B91*$N@6GY&-980Q!K.DQI#8=^IQ)?*0=_\9]*=R_6=):NU/[
M9>OC_SU^?G"$&OUEON=B2V%XLSZ;ZOJ,NPNP?JDH*'3*F13+/;/MRQ^C2:"U
M>1B6+!8TG8.1YBLA#>AAL3-#QOO8^W<!/4IBI _<F(>@6E?W@.\K71FY0-94
MO8RFQK>T-B?^Z9L&(@UU$E@K-C"9^ @LCZR#QA[C#U-=CYQAN:G^[&"89OO0
M^W,%V?XQ<;I?/*B3P^8)3J,R4\(ES\^%<1IDKC,<!\KZMKW0/YS2<Y7#N /3
MW(I:U?JAD/\H#L)G7HS6*N38GOE\KU[$J%9F]7A=S,1.GE&(N3U,Y5.J=1_X
M>T].7&>DMZWKJO[?OQ,M$Z0*PG#/=U!M/7-FVY%W86\89QB";1BN&K@;DUB?
M:\SVB/KPB^N/"IK^HZ<IT+&U5FT6P3#J5V]WC8G7>T?X+$%M_.7G&.Z8_C&R
MP^$J;\<E</LJRN$S90TJY([N TIUX_#<H'ML*4EL["[@$-":@!#9!=R/K+F=
M;:=DY)2\\)M\RMT =9!PKX9\/-'YAS1:DA>ZD[6F+?#'0X0;P7:R8:OF3*\<
M3K)Y#+F;!F7'_S%TJ7IFPXS^MIZI!D(\?TF.-KN:'3MV<?5G-AO',>(V;'MP
M V;:\^10-A4\;U(P5S<"+,I%KT(0^SVZZ"V79IRK&]+EUD@?^T*T,F<2FO3?
M+D)RMZCK]YII8C2Y:W+0&BRS9=L%Y1(U<X HC9G.V04<;Q6"H'39K47T78!H
M7SGJ&LO\/<J+#@?,=;C$(JF[@ YL$&?D3*[_/@+\T->+BX5T\(+%J^;KQC;T
M),G.E(X2%XN*/UN.99I:A?7/:LDC#CH+]:JJU(#:4/_Z><U55/5%@60G1EY[
MA=B,X"LO%B9NI=D,-ZXWF<-SXA\?F6/Q2Z785<('#+#*?2=\<MC*'W/&ODY$
M);'@TW-1+'B'/=>BHW$^87W2=,4IPPD^<'PI$/F2<T3+N";01[J]S/)DSJ?"
M8YUB;Y=7YO:[E A,>J?<50U]\/G<R>B)AN?3 6J)*2-O!.\^T8%F9_5T#235
M\!RXZ@Q%'XX_6W-VG1C5JJU5 /_ L^1ZI[^Q"/SDZ^@:N+J>)[[@ <TK6E@(
M$VHZO;@+\,^L51WISOMO%W"-T&\H@K@U4EO>$%"AJ2=LM'UDEI!E'?$E_WP?
M)_O* R^D]]5.C11Z1C)2FC4ZSY.<H"OA2JC0*>3$S,WV'MO!-:[6:?;.6_%>
M6,'T@L]RX!^TB_L%5]?B]UU!OO7R_Q'&.>5)TTKJ='#B+J ._8Z!2-Y(SZLB
M%,WE,+1C4Y$Q'35+T.,H,?I$%,Z,KBC;89LFW%=:H:=H;4U"Z1W(H(WE41L5
M"!-']!Y_6T1K[GS$^&"I<,Z?F.D5;.%.%N\<Z[NV&!=GS<W'!'DR$*^Q#+"X
M,TU#TA1;"7%&IJBVC.HVJ5]^_*F([3262[*+YK9[ILR);-6SLZ?GV[5%49=(
M/'O&P#&4V5#S*1:VP\-$/PWI9)^[?2]2N=OQZ4+63B+YSD)C.=SP;7K8T_&%
MN[I/P0B,9L$$\YTX+HXGS\W<ED+_I,;$@NC'N#3\4F-&G&:PM<VCI?"I&L9V
MI!+%&IY9FY!T?;;VM;S($.*8.?77[!P,]PC>\K<VB+%>&^G1B.<B5I5DY>([
M'JX[D:R;_E!RULDT;,HX5[E+28\%C?V9A?'"Q_%/<Z-*?,/D*XMF!L118*Z$
M'O.WH3$5C35-VRDS?AH\*6.%6)F)JW57HAY6)NEH#%F5:!O+?LV;D.0TLITZ
ML+'\2]R!7<"!->X[5O)&FX<^NS6N .G7PYAOG^CK1W0HR;]- G7*/.'B[K**
M=OH\\KMC1%\7+6YYX_XE&=F-6@':Z$BB)T*<=X<H;]"#D()[G*X?D67L]_W'
M;9\S4:5R:%U@MH*^D*Y*],+CF*CYT9"=,_N2^]I)"DE/U3<1R^O6F'R^&NK1
M3F;K25Q4L")\YDQQ5$0A$F_%]GE]:DBOJFC1H)$6<X/P]D[19"TY(^MQ^V80
M(CSIP"N+UPK[]@^Y^-97#T7V@;\B$ZU'W<=;*ID5'"="Y9JCNPDXR_02?XQ8
M/Q"%UN#M8^'::5PU3))QR)XRBC8\P_'NLN_U=.;M6\Q0.EIMD 7-"%2JHN/%
M/;AAUSO#,KX"Y:?^G'+]=3IEEM&"[0+5XI@WA)$;-UDQRTXS?0-R2)^V]$8^
MUJL<Y<G5R)(>_5ML;+8+./Q;=0XH'UF,.0\6F<+ 5',;TWHYY2'^XW;NV.=$
MV"Y@W*C-]1+2R8P[6NB7/N@G7S']CJ#>_]#W9U69U:>? 2OD?BMK]9QKCS^*
MG-K6%99N?F G[:1V8P<'>M3&@$JA[$AH7=\J&A)GP_K[^I-^?NF4U0?K(E_7
M8J+BZY\9#\XTP)^M !U&92)BWPA'29>@1$QG^H^8VG+MMA]@VNY6FHJTS4 3
MH2Q;FIAOJY9URUV3&Y8Q,_.O4"#E'O_R'>QMI&[2==BZU[9MNMG0?M*C5W*'
MGG8W1 PH8=I<0Q 31M/X!#U@S+$]AH5\9A'C:E?BH8>:KY2AM$>Q<7I]24:.
M:==''G#?:<>;MCTR[JL0^;CM75I RSL]XYVQ6@/$_>__#4^.V4BSNEK'0#Q-
M$@4N@BSF7APQ-CF!/E3%UFA<SVVBPW-LA^>Z?B85+PZJOD=\_$* O]=XK%8=
M-[Z_7/L72!0<4]EZ GF.IQP948IT7&W+D@JW+4#^:RTPB)X9OA>\E)UR[E(?
M)DCAH=5[N1-[L>*M_!Q'NVE[%R"FMX1[<V*@ Q2W%8/=!=#/F)YBR<:CY?RF
M)"@S@SY#(3M!'>$_G(105W!+<(8(R('5C?\$<]J"55/\F6X[93=EA\Z&3.4O
M3<4H5SXU3#;<P+]IE4'W@D31DLB_,PS$*P(X5C9KF2J,]-(=.(;,G5OI8/LN
MGSSD')Q!HFZ96)FU-&/\MJ^^FZFO3_P<?[A])V*"M; +6.(3DX)?S.5>YB;1
MQ:(Y6=X%,YJ!P48V"/=AWKG"WB<J_[G!PU]XD^Y#-7C#[L$][.?[?E[FH_]B
M?$%"7!#_2/VVVS4ZZ!@7TIDG :*'HYY]&>;):1%+,(\C\]RY"V5GYNI/I#<2
MBI;#R%33\A"\!4)DZWB 9H;M=,\)3PYE!IW$-K)7$H?&F"JQQ.(^/0Y1]+P[
M$HQ7I-Y IF=MP?I!+P@MEZS_*Y:I@2F=//C[2U1?NKK K$J"DAFJG+7T_P(!
M%/[KX._M)71USPG\1/!G[/3?##Q-XDA\6:]X=T[0+N[_ +5U76_&>FZIX_AU
M66ZU=Q8ZI<6MYJ/B2R2S5;'_ (21#IP7[!P)PW^SXJTO>6C:=FM[I:W5F]_U
M0;:[VU/&/@__ ,%$)K3X1?">'Q7X-\(>#KB_\(^'UGCT/Q/KGBZWLM4?38K]
M]*_LSP[IOB3Q-HMW)%;Z@TB^(X&=C$0[L-Q/R5K/_!1KQ+\;/VFOB5^SCK_Q
M&L/AO\!+KP];W6H:WH_@#QI/X]DT^VT?1[_6-$\-#4;;3-<@UC4+V]N8+C4Y
M],%FFBW,PTEAJ-@ GZ;?$'P%^TEJL^AZ9X.\#_! :/\ #CXE7/B/X5IJEC?_
M -G:)X:M]#?2_#5Q#:Z9K=G<3^(;7[7KO]I::D?]G.);=98S:A=2'MUWX3^(
MEM\.=;\6>'O"WPIN/VF;NQM=.?7F\,Z=_9.HZ;I>MMJ&DZ;?WQOOM%M8KX<D
ME:WMI=<%O#J4SW**)6=CZ;JX-)V2UOUBK7OO=.WGOKHKW/0H9AA'A7S9;4YF
MFKN]^J3N[]=;Z)Z+6Q^3O[8/QE_9ZL/V1/BF^G>(?#>C^'/#>@Z5%;>*?B?\
M0-"3['=:=XATRUEAT7P+;'9H&IR:I)-#))J&E:)/*\TBR.YD<-]J?L>?$W]E
M#P1\#_A9J&F?&OX=WMWXF\!>#[DZ^^LV<=YK8U'PW%=6UCI\:N;6WM(]+5'B
MM-(5(52)6$051GTK0?@7XD\=:9\1?AY\?OAO\(=9^"7Q#N_%%YJ_P_BT&765
MO-2U/6-$U&Q;6)+O5KFWU=K]8M393H\5NVB:O#]HC,<X#UN^-OAK\0--U/PU
MX<^%/@OX56WP_P#ASX$MY_A3I=WHVR'P-\2M+@72M( M;34O#ULW@5/"4GV%
M+:%?-2\OCA,V2*OFVBFY*,4WIS**4K7[I)Z]==CL_MS$_P!BK)US1BI.?*G[
MK3^RUVBM4DE[U^IR>@?\%)OV)O$OQV\1?LYZ-\=_#][\6/"/A^P\2:_I_P!B
MUJ+28=(==/S-_P )2=-71[S<UUIY*VLENN94+'+$#9^,_P#P4<_8U_9_^&GB
M'XL?$SX]>#U\)>&@%U,>%7O_ !5JWG'5_P"PC8:?I>BP7-[J5U_;1%IL%M#(
MI!CZ+EO>M)_9X^"VD?%76?CYIGPF\%:9\:/$VCP^'_%'Q+M?#UK'XMUK3$2W
M)M;N\2(W%[9B2VM@D4\\BHEM!@'R(R.7L/@;X2\5_#7QA\-/C1X$^'?CWPKX
ML\8^+=3U/P_J7AZWUGP9K^D:AXOU'Q%X?&JVE_%<Q'4-(M@BW<LT1*:I&MQO
M$P5B]]]?77\SPSS;P5_P4-_8P\:>#?"GCK2?VE/AO:Z%XTT;2=7T)_$>MOHN
MMW&G^([(:CHTFH:)JB6-YI>HS19(L;FUADVAACE >*\'?\%2_P!AKX@?'_Q-
M^S5X3_:"T+4OBAX.\+6GBK6=/DM=5LO#_P#9CBRQ/!XONK./1]4+M>V <:7)
M,%%QRQ+\>A?&+X1^,/L/PK\+? _P/\'+#PS\+[BRU?1M U_1H;'2_#>HZ)>Z
M-8Z ?#NGZ%JVFVVEZ?%X8/BFVM8Y()XH;Z.R,:(\:$>FZO\  [P#IWB#QQ\7
M_ 'PZ^'VE_M!^)_"5YH<WQ)F\)63ZSJ>HVNGP-I]IK&JK -2O]&>2VMV6TN[
MJ6W;[-;$*SPH0 >C>"/'GA?Q]H*^(/"'B;1_$_AV2XN[--;T34GO;-]1LKH6
MNHVMQ>LD7V6_MM1!MS8-"K@!AY:C<B^FX/J?T_PKX5_9O\(_''P-K_C72?BA
MX?\ A5H7@36=3UKQAIJ^ TO;?4+_ ,8>(-:U/5_$5]K7]HZI="U6:2..;3OL
MVWR=C20MN69;#[HR/?\ [['_ ,50!RGB/^W+C1M3LO#U[%I^M7>D7W]AZK=1
MF6&UU,+NA6[MV#JP0E>61]H5OD8C:?@_X'?LS+=^,T_:#_:(TSP1K'Q[DMI=
M!N)]-TRTN_#=W=^&;Q6\,>/9FU"">XM_&5KI.C6-E8ZAHI\-6EK%:ZC=MX<T
M?7=2O=.L/T<V(>J+U+?='WFZGIU/<]3WJN]E9R'+VELYW(V6@C)W1S?:4;E?
MO)<#SU/42_O!\_- 'RW\>?A'+\7] \/:=IOQ!\8?#O4O#7C'3_%&E:_X1N;Z
M/=?6_FZ#+IFL0VTL,FL:!##K-U=I:7+O:Z;KL&G7^J17VC6NJZ#<^X^"? 7A
M+X=>'[?PQX+\.Z5X=T>(7EPL&G6-I9)=ZGJ4IN=2U&_CLXH4GO\ 4KDFZOKN
M13+<S.\DK,Q&.W%O H0+#$HCV^6!&@"; 0FW ^78"0N,;03C%2[5&3M&3R>!
MD_7CDT >*K\'_AP/B2WQ;3PK9#XC'1#X;G\7!]2\VXT,R6EW]EEMA<_V+*/(
ML;*W&NR69U?RK.UMQ.%MHD3V$PPN0R+#O">6&V*6$?0IN(W;<X^7@9[9//S3
M^T#\.O'/Q-\'VNA^"/%H\+ZI_P )'I5Y?Q+JOB7PS9^)M'L_MXN= NO$?@R\
MTSQCX<=UN-,U"6\L+^ 7&H:3:>'92=-U:]CD^6M4^!G[;JSZJ^F?M@6^D0P:
MEXNA\-6J>%M)?3Y4UG4M&L/"MGJ,&KZ#=ZG*G@_1(]>TNPTV3Q%)=Z_JDD&N
M:EXEEN/-;3 =WW?WL_3F.TM(D\J*&UCC$LD_EQP0H@GEE,\LVQ5"B62=C-))
MC>\S&1B7.:E,:<N1'YA# R%%W$$+N!.-W(C4L#UV*#]T8_+U_@1^W9>:O>RW
MO[6!TSPY-XE\ :AI&@V.BZ/+JH\-:?I+:=XV\-SZI>>"])E6]UB]DU*]@O3,
M\FINEA)9/X>D@5AR>E_LT_M]6WAWP/X3O/VNXKR'0HM$?Q/K#P7,6O:SJOA[
MQYIVKRZ8+T^%/M=SH.J>&;*S\)ZCJK2R7MU)<:G>3/()YF8$?K>RQ,,,0R@@
MX8 @$'@X(P"#G!]:#&C'D1D_*W*(3\OW#TS\O\)[=L5^;'P]^#G[:^B>*_"N
MK>,/VJ[?Q#X5\.ZG-!KOAR+POI MO%6^_L$BM[W67T W5K%%93WN@_V1:$W;
M:EI%GJI\3?;=6U72].\W\9_LT?MG^/-)L+>T_:RUWP&;+QM-?WUEI5W)=K;?
M\4Q)I&F/;W.CZ;:^(HK?7]=U74O%DGAKQ'?7>CZ9;W>A6*P@Z5:I& ?K<BP\
M(H4A 0%(^Z",$*I P"." .GXU(8XR5)C0E?NDHN5^8-\IQQ\P#<8^8 ]0*^3
MOV4? _Q6^&/PHL?!_P 6O&U[X\\3:/JTVG0>(]4U&ZU'5+VUMM/TJT:YU+4;
MZ>:XNG\5ZM;ZEXET_P Z1VTFRUJWTN(1I:)&/K2@" 6MLK,RV\ 9\[F$,89L
MN\IW$+DYDDDD.2<O([GYF8F>BB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/0@$?D: &K%&ARL:*0JJ"J*#M0$*N0 =JAF"CH 3@#)I]%% '__94$L#!!0
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M&Z/O\W+UI 6/NB^7_?I'-]9IFV5CL"7,11O>$DG-DFG #:!@ ;8;FQ'1);,
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ML[O# A*H]7JY\NO[C4NAP>Q9I<BRZWTKZ<UR6 FG)HC:2T<D,T;MR<10/M[
M'TP3X#,#NHR\Q'\9XWI@8E2;R8L)[,2N?N^L;&69=4C>%C>)3Q[<X'78!ZX?
M)_M7VU9),A1WE4_1@9H8".67D"L*00PF.-GM;\>-.M.EK;T2BS#==DL8Z?O%
M276P<0> 34M!#RBH2GEV0DR1_HNZ"OYEC2- <@8]BIK-47GNB-2*"G*:R$+I
MQIV4OJF.'!UOH5H]^XG1(QSUU 1OJ'.DZ2:72P*\I.2X#_9PXOXZ.L2H5:0Z
MB1<P!;061#D',0C8SF*L>$4__56]NQFKS1K,RKF]A6\W;FDKLS^$A6E6[*,\
MJC^@UME(JF.3YS Y"%M0+1V]&==F"A3ETK97$B[!E4.C3,DY#4CU*%>C=$>,
M%A0G,:DAI'5I\KK89V/4?Q/#QC< I-PO)%SAI=MI?)88.2*'\:JRVS2)JX$$
M!E6?\/<H5,6':W@\#<1"[,/U9/_/\XTQ^*#ASWN5MJ\LV)2:FO9J\T@'K"6@
M%0RELY"PR&+2]4TU-(=G$A1TGQ\3T>GITV^VO_6S1.>Y!-,W%S,Z&*G,S"%#
M?A]B\K\HE:H=C=^&+YW\;^)7K..H!L](Y"3 7D]&@MA.;&Y R0H@OI#7V!]'
M@I,ZO6N.4[0)]XC1H^+4FGPMC-8'7AEJ8[;)I00"YQ)DQ'K?IF;=;8$1]T-_
M03.NHHT[[3/$8N6N<0<P]=6-"6;0IEM7>?<UD;L&\A;[V?4;4+X\LYI$'YTR
M<N<M"-<=M@IN:PO/NZ5QA7*>0!3>GAQU9V5S!V,:A*W(O:X-)86QHS<>GGEV
M+L>I]+'CZ_#2(N,0WO5S 2J\;+5/).6Y7N,1283T\4F0E./8JS.M=@PZ-1R0
M&)"I4#H_C!]:8Y5C%A;R(1[;K^6#.*57<-M'-9E)?8 VD\/>)4HK,<*_7+:L
MU [KW?=?'M9:<G8@ J0RX1E(C=&_AP;GW/>S611MVB5'\_#CP._R&@*V?12=
MPX/F=@T3T4*^XQDH0\!1@?+OK43E/(J)OYR*/1[P+CYL71_->RD0YVHD+LF_
M2)6X0#:/-TZMG35]>$UR'*QMCNN$G=II+]G8LVI;3)7I3.:G;X]UKXB57RH2
M]7G(0P[;@=56[ H6=%\.Z]E]T;2(@1RA>[]Y/8"/.UDY[=PNK1V=Y?_-J__F
M0Q!<4FC^?N.2UA6?-E_$'LM"3<RQD%68_"L!#.AY9FH-%@Y!;\ $\HTKTZ@(
MJ@!&HGQZ#6[/Q)E)_<;?M8:*Z=Y3_<1[_2M1 SY8_O5XV=SMR=:$/LB-E_6K
M=4D?LN97=9-71X7O&W2BF$ %?DLQ'(F='&9"JB(Q'^!&^S'@85(?HQ97\?+!
M[0M'N,@GM.U<<LJQQ/F,F0RB=\QEOH9"$</'X-=+MH!66[=AOD0PL[:)_MQT
MRS.%/,6ND!P&NO%=1)>7=DM<P:QTE%LY(9QA5+)=]G9HCKHB6F8^%+>F5+)/
MUM%';W(:V"O\#EU8%G]SFW7I6BJIXS@F"GY##JL+Z/3/0MA(2ZID/>!R.F@)
M102V*/0*MP=$2O9^RJ6&_[ LM&!N^[IM(=7-8]OSK7D,S"<._8/^F[*%&K,G
MSA36^5MX>OS5K[XW2:?.7N@\%1PS4''8VX0Z/I"Q:[ J=J[P?I#[\)V(7X4&
M7=#6X+%>=2AHZ0AL.B'(N? * 3/]S^A>=?C)MRK?_RJ/MWBV6P^TN@5[-_<O
MUB#Y]V;MG^9?>?)EJI%MU#0X-A8<)(>QO@VQE78(2I*@U5(M+;--%2=5ZUT*
M_-5NR6&(2B%*<\18)<)DXR6WTV(G,$)$77(B;I$^06M/([705M LDZ))PUR.
MJ\22.CT>$VX2+OO)!LB!?@1-O >;SK_+!AP/IX-[7TW<]#CGH@C;U^B:*-4E
M-RB 5YA%)IZ\#-#;BZTS1FBX:J+/4)R[WQQ]6;Y:6&@HZOR9P[QO&JXF:R16
M*"0R3=N5L K:)CH=T"D2MV"QS7\Y;]$U>3\F?A"+FAQR?_P)^4IK^O.SQ7U<
MR&<S?,W>U LY2&CML&QT8E]=2\,;,.Q&T?3H8&KY:1-EP[MMDRR+E1\#FYL"
M*G'%QZ@J?TV]*J*>>. 2GAR75@Z(XF#-UV_&G_%!KK?+4*DD&*L42^2PS_0(
MTDC;@#FI8[2*A=?I4&7GU+?8_]*@YBXZWWM"(#'E,*"ZMS-?S<OMKB&H)K$@
MD&4Z%'UU>/[I$\0D9-[1$/NJW0J+0\V@= :X%G7=?^@2 $3<H!T67*WNU2&0
M.\(4SC.=<5CQL*'[31GARZ;46<+5SI+5RSQXEPX0ML1B- AC:R3KN+-FRE-*
MH$4[)EK6BS4C^(IF+C\;=:)*+(.V3BO56WUJ7A63J<F[_3OD9&,&^J3JO_2C
ME=-!84^C\$D5G.!IT[BAHC';WR)[3'WLTK=MX)L0AS6\E]U>R8>8/[S?-F)?
ML:_%:>KMNL/F)^3-NZ^:##.J&\#;BM"FG*EB<N:<)H[1/)/Z/EH!MM;:=>YJ
M?:C>E=G3BCG3]%4?Z H*0,POOS+"[>WU/FU6Q+W]$KL88+:3#C]G1W2+JXAJ
MLQP<\QR27*P1)G:P QB#AEA#=&O9#/!]B^T64J<[KW>+9Q=/'?6/TN*R,YGK
M:;\NDEE?28M9PI#N.OZ,)A3=*3@,(K/K8XS\&QKMKCZ;7FPK/-'HN3KS[!HE
MZY]*.2:K-WQ'YFW"G)C)O#3NX_XW#VT[?8Q=Y=?<\HH&7E<80[?(1(O)@__V
ML1D]':%8+'@P](UBZBQFV/J;_R(V%.)> D:_,KB4K%%2EX8Q+50@A^ET@=@]
MLJ[A[M:D\G\!69$T._8?HF9Y9+)I2J1G^#)&U,HO@HWJL,7NP6,#\]MB)EZU
M-31?F_X8-F(6?+-SUG^,D2>P*7BG(MAF2]]B7(S-);H]Q4:;[B^LF6J^4_XH
M5$,3NZ]N2%567A5MNZ4NX(#L-*&=-YOY_32L&KQ3M:0E0;%I/GQ[_1Z^'';=
M<+&;_@SZLS@]"9%]/GN5C+N=-1W/*??EPS6=B=MY)_2A=8?6]L4 _9<8G=DV
M31!RR1(ZS#VOX'!UHRP4"?3L:FZE9[(9*\>=003YV82O*SO;21QQ%/B"'$MC
MNOZL*^+4_]ZXM(<!2WKXWY^C7 G(0UL0@MNKRZG9,[_K>T5"^HM1G<<XUWL\
M@PO[,VND.1W;SYIG>IS8,\=Q1F(_RV'Y,.)!KN96&69T1OR@9>?NMBJ (0ZF
MU6/.LH^G&K:"X ,C-O$@GZZY9<U*"K1;8LW]\0Y][M(#J-&_2<C'9%$4_@/X
M0F]0^]*4U"(SH/]JD=:)D9!GDV )+_B)::3S%(URO3K^8I-,ES).ZK6'2L4!
M8__"#N[6AWW=^,?G^R)EB@WV$,<$_OI0P#X(!'P9[,7?&3AJ=)LI5.*89#4;
M(/LT9-](5E*6YI<;+BQ%_!.N=L?RUESN/Z@;< P9"OB![Z*GA>E#,TO!1 Q4
M&"$.M>]"JL1B5T]B-5"!=UH/"EI-:)@:87%W7?EZQ632=J@I<D?Z41VS^!DH
MT'-CX/&IC%*/-Y<M;^?B:L9;.5?/J4W7&/ X\+8UH5#GZ"+KZ "6,>X$-!6%
M*Q96_>LXV6'W4& 9L]@Y3*>6<)D)W:(A^9L?^YB\OS;V""T(3%%@4TI[&AUO
M:I<A>_H,&SPUFOPP\OR,_::V4/0'_Y ?=W\8F1WX[0ZF=BN!_E T=610EDME
MP"6VL4$B-29^12CT2L"[U_RZ&4QYX5+S^%MD,4<<'L5 NHC[ "%TCERD1.RV
M)+Y!F<YBH'#ZR%59=M.U1"E5YJ'\1\A6R, CN!OD:3TJA^$HHPE'KRU.'.AO
M4 !&ODJNXXT]QJHUWGL2M9^#&(O/JH4N/&7'+E\:DP133)Z>0N.7-:69MOV@
M]O:.S';(5@-($7[I&)30.6[63US'6\)FRF&OP+JZ/I2R(KF'W7_(0;@*<63H
M^"JX=5>("@;<)<"G^R6G_I<;"D/R_1?L22LQOQY(%*0SV-OI*OYIJ>7V=X[Z
M@9.;2!=I5"=_0ZJ)9'!<VZH6",_%9(RC\#D(??"LU+U!%,#4C5S5C,@0I /L
MW/L[V)^;.NEZ6L[/PR<6B$'=#8S^GS]])LO&\#&'&YO&?JI-KS.8U:I8V@F1
M.N,3\WN[W#$AD >^8K+G26BH9$=CJ MC_[+\4N+E1Q0#P@&'N17$$VV;>S^-
M:Z@5*,*OS%[B"M7Q[-Q8'"WBX3)"2Z>I,)H^@K;HLU]>48G--SKN:J&_42UP
ML];.DIH49SWR$)C0'S45]_?Q\#AIL\UTLLM0K!R6,VX"J+B:=WU$6 &<'-I>
MI_#G42L:7?&I\V2MR<0OIMM#/VH0.#O-!##=^,)-C^%GJ624'^C ^XAM2.B0
MPV AD( 1/^XRE*Q#/.V*26<'#N@Q_[9#+!ZB<:3?XX,V4:^6R[LH3>/O@[TW
M;6N9]2XJ@5B-&&DH/61P[ **SD^X;D\TX]G(87I3;8;#M,"$,S6$L$&9S@S<
MUOMH6R@^I!^%"O6T2$%M:QXCY+<KI0?9I)\YCYL=9)'JJW+0#D1C:(8K#1!?
MA=YQ-=$S7#H9*].%:Q.W%S 3PV9^>3Q:;PK/1J$^4)^8<B3K5KW^(M-2[*MH
MO]+[W20@*_D:@<3'9*)./A4&6>54MPZ7\G!4Z$&@_^/HQ>"ZE/@K,7Q[K3+A
MJ/*6#M E,Y!_RN*'%_^*_>AM;5*$_PW.F[,6/#5RJM5@X&<?19>ZA,J0BJMW
M>7V9#$T\D?IA\R,M!K=7<HN:3A'O)VK*897N*ULOT<A<MN06_?_R6HIIN;+^
MX]0]S+P3R&3X@J2:VSM*$5"9^*R2[9 .4,[K9?@;$9H.21_1O)\IO!@?FT5K
M]?>%G"HF\Q^U-0C\KNX>^:D#SXI[A_)=H1I@:GF_?PQG>Y(]O$5KPY_'Q2UC
MM:WV=;(FN/_]=U"-(#=TTSJ7,!@4SC]\Y7G;I*)!)$=!EUUQ!\O@=[;&PC,^
M[KJ]WG_!W#N3?16Y@O#"97!\'V:6)8>98P0A$^DHNS("AM&<D"EQ.^TH0OHV
M&,;?>>C\Y/>E)()*G-J8=76-6?242\5<2V/1[!]E'H7,>05/0;L1?2 /T($9
M=H:<G:PYO7BGB<?1CCI6_!KT&-KK(M;I=WJHP7RYEM1ISW="K$,"_T*>7>#"
M<\Y&WI=$5#(&]&?L,L0:KS(RA1LV8[KR-PW52S="KT0:@IH5V_V5A$PXA?F,
MU6%[06&OO;9C5[ 'VY4>) A#['-+!\X K.R8^9<Q4O+EQ]%W$BJ%I8-FWC$"
MU.G,5?[$DNU=>YD5E9N&V1&#'\*^N0?<7<UAV&?+#*&7O%R2"2&,+YOQ?MTV
M-'<U^$.+7A529 </2=((/*!T3L2NCS!16Q7P(V2+\M G->RLC!0D69+#KL42
MC?IE*K)/=\+4!B3;<;R6JU1C:")4QFH8=GKHCQP+XD6^DXV[O086)[-*M :V
MW&9* _FD;)D1L'L\*X*?O_-W)TF/(\W=HU$N;,Z\$[<N;ZL5M2:RS9Q0;][Q
M8H!PEV'FHI+EU2[D!9..CIVY*OTMAR4_9&@W-5&FKZH20P&<W^M7TJ=TW%AN
M6G<E91G>#O/=X3/!(:RO62A;!RJLU<=5$S(=1R A;3L2W 4W5^2I" '&6%KP
MDR%<I(#4/)D6Z2R)<3B933^Q9/U0C$G%C-'/*-H&DR F2]:@UXQ)ZQ1D^M>-
M_H+TXJ)"7R(DQZZZQ"@ZP$BF_?Y$TE,%E8J3R7].G)IV/C#M7.0<@'1J':H.
M"B4]OKGC')A*N5]0D+)_SS^KV#FR3Z"9?:H<MI*V,&]S/[<W*\QX^/R,T]6:
M\".?S\^')GB%X@*QHH>Q66<B3DEN&FG>?JVR-$_X^^NO'&9ISV5);U.52-/(
MTD-#O#/?Y3 W23OUN2+G=OXGL;W:#2J4Y;!_RM!OI]G&UNJIB\G]BKG.%21%
M.VE0TK'F*0TN:4O>9!.BZG;8:@'ZL;;WZG#,KL&Q)/<=-F\KH5N\[+9_CDNV
M%@N.**!3CO;/AYYZ_YF ZV+M;QN,]>K#-(7&#?+HT.Z=#.F;LFN68."E.%KA
M>>7%WUX.M\AA0[-6=5<P$B<CQE7[%].DLW)8AAV8GDN+LMC?#A9U[M^\@OA@
M=5Y"A]J#^R)J)?TFTJ]?H<$+BC*KKG?P5OCXC(^FB)S:J+\D \Q+IWR+8V!F
M%O=1<U@3MS=;.6P8TQ3'T2/X(Q!8. EO?<,[8S7TD> 60EK]A)7N@ZX _PI8
MK)DLCF$L7(7H!&U_2O0"6CE9L3T1 :!J59K,<IIRXC,[=*W[:EP;4HV!!(]Q
M"5$>[P#?[2"+["WY)TVY4P[C5ISBXS4EIOWGSJ-\+C^9IALTG*D#;A0"(\F6
M46TV1Z$H$";TH/,+05_"%5KC[O^4J;.4=K::2KA)O4:,N0.D4VKFE$!VN_3J
M4;;,,7E -[I-BTW4CVD@91[+K2!<F^E8O%%!JNL(EUFOHVWG8PV>?.(:!'Y^
MH9+?$4)^B9N *]3[3Q@]BKPHA9SDL">^ ?US__%A[I1RR5T#X:P;+^!7!?#!
M0]%UJ;)^9/UPT46^+\4\E.#6?B>@L2BH#>5T\AE!L%L9N^:"OR2W30UP5OL(
M-[;4H0R:+@AYJ*DXT%[\J&W;6K9 +:-^JY(<]LB['9EN^@7=WMA(L@CJBSE(
M*9Z>Y_C:^]+;$;W],N^7PL%LQY:EWY2S]2YI; O+)9+Z/_';%@.ZZ75TQGU[
M(XD6A!/ #0@%?))D'=H1R+PGL-<QPUZGZ-)<*C=54VT(:2'6._M0^U%.CV:?
M4PJ7^Z].J65,8?,2*6+OSID<UU+N5(D*Z#ZSOR76_9PL1(<%'4/^FC\;.Y/*
M67GN8D]5*FJ3FDS= A4QZ)XD[(S^TDUO;9*VCLF4)@]<"HP8+D@XG'=XNGA_
M0..BDU%E:^,&[R6T!'/-TS&1TH4+OWV<G$\W.7 I44+73L'P<;/6LI5K^")K
M\66 S;"[[ -@R&T67Z.Q.O6Y#!R_-Y^B.V_GYH]6&W:$ZZ@4>(!&V9)@7NM%
MVI'B]4!OT=JGRP[LF5 6]UQ9G8I.@F$GIGHGL+;)GT=_ISTF6# FCC9]KO5C
M=V%3D7\T@.$FOH,<MJZJW;T>X;V_=?'&EE"3#+.3K</\N2$WMV]NDX*K"Y(B
MO&?6+*7Z[*VNGT\G-OO4!@:.7-J[\F]S2.W!1"=@>NR<N'?9=#@3H05T-[CG
M#-*;4&Z/<9@1NQ3;[H9RKPD?8V/F.18*_B#)IH_2))#:6.PK-HDI+8:W7-B,
MOHL,6PY'-U"M\:S%@#/(3!L)9G&?OY'^YY>7H@*WOZL8V>Y3,5FP5QJ37-5%
M;V#]8O'PHQ1>/6(9&) [WZO^):JXL:B&A(MRN:Y?:)E:$YD.U\*]]\$0#5;'
M_).TB-"2/I H<_U'*/Z0R3,")>1S\NK)1.-7BI(YD77RM_IK$[ [S["=&H;G
M_SVQJ)8IV1>;%<AFK#EFK_::L=9ALX@4A<PH,8:> KT'@)GKLK73]%6.2]66
MKUI!S:KL@#U>@WL^3+DR_=< XM<93>=O'#JN[?S;K&2/&8^2<@:R4-"Q]W7B
MQ2>$@G;QJ#/YB@!N%CV^F4%(ZQPUBPSZW8;RH)(Z=W )"5UA9OT. M5-!A(D
MM5GWT9U:5^,(Z5/;T.*0FKBI.)S3^2+I.9?[$[VK7JGA?Z4O#+Z"&A+H]BX!
M8E%U5.A7X*&:&"<M1NGQ<TMKB1&@=4[MN4\/N2V<E9" __MV^5) J*O NQ2'
MXX$\YXO\R;$031Y='^]OXOIB[+4QN[_M'\E*Z. 5TI,PCN3@4)L9(>OH9R=<
M2T^@9#?WSM#RRC8=8(7K./$J3PXSI(H5E,F# K@D@W;_3T]YDGWP:^3;XY<?
M)W^2P^HP:9*=G#&2\:;YA[Z^S0-$AP2>O2'Q<'_]8-5T;YE0A@S5"\5K5640
M??C*?"H<E_A[1H-0W8,U@3_,['281&JC5TJ,/_\8MI_'7S=J@PT[!2_8XIV.
M@>1K6D^<W)7W EJOJ7*8P4R6) S3)-E(62G1Y+]E<?[0T"K74?K$NLE63K5D
M)',T?O!WGTBF2C0%_!EF=#WA. QLJQ"$(KN=D_5?TER*NW.?1MVQ[C#=8JH[
M&;X#6-SDG=50O_VK3Z@:8T^*84]2#':M@C+@7'HZ &4QD7!:0#7A.C*[,=FX
ME=;RNKD_SMWF@(S5'V8P/!?E"(<KLAUT+R3$ET_2[>&W9*XH4X?WK*:$'OI?
MWVK^UU">]1?/L>M[57R7-A-8S''+9F B,Y;ZG]\_ ;>GK\T<#[62P_:IS@O*
M<:Z(E$]QL];9<^[P+K/@SCP#(IJ>8!M,!2=^K>/BL\>W@-Y,S6 ^OMO/60[K
M=OE0'3H5Y)]3CX-K'G\Y$+LBQ=5:8G%:*M+<[WOGG9OXQ3OL6(#?F^$UD/*I
M<0S8E()IP$1BE283-U&Y^9;3]T#GQKCYOOVM<IB14<<78$G;%X8ZZS#8L>\U
M:_R%'/84Z2EYHCQ;)R8"Z24KI96DR%ZU4>@^R[0U,Q4@BT_4#^")B@K1C[4I
M'1:GR&$WL1)+-(+,R%2R&L8 F;[\WA57KI><1#@8[25Y50N0*M(JF>FL^,&2
M$]V"9_WKE=^7"=$':2LH_&B!6 _N:2=?L);IV*NM.GWELASV=LQ^Y+-"7B+"
M_"]JOBPV(]7OA\EA7KW8D(2W[>)W^DH_208H[%4N14WHVEUH4%M*#<EW\0;N
M%";4:_IV!8GK$*F/IBP?<.':.->-IP4_MJF<T/ENBDEKX*@2FKCL+$>ZEC#9
M&J!GHEP$'S#&!,DW@NT&$-TB3:6:1P3WYJA=-V,F;P+5AR7[6)UMNC8/B1?2
M?CR?R1K?T@8)!35FP0J!C1<R$M44VBSR%;9:_5[R^IP++858>/;UF6N_[LV0
MF2,AGY2S:GBRQ"'+S -YMD\.&XE-1'^+"ZV?7'(+@1?*G".#/@9YE8(N[<Y-
M). E2I5'U^5$&=Z)KSJ$MA]LJFWY3TRN*T?=:J.56/_Y1C.M4?=7ASH$A'NY
MOGI76+_LE[RG.?7>[20-:*Q[$5W-Z\UF<A0.\HRB9[6C-'@]01\;W]16YCS/
M-ZG00FWGI^^0P=_?!A]T]UK-(V/"@KY,'VLR#.C3N(^[)<95XVX<+3)?,7FY
MPWC;>2T"==40>A6$$.P<<)3#U"+C9>IO@)<GN5)LAW,$(Y&2_N[6+2./TWEK
M@+^_O_3P4.05A'JEG]W*U8<6NPUX;=7B^\>2#B79XQ1^^(#[$/7<';Z-R423
MD8O-+5R'76J)&F:?3D^0Q;T;B>'DL(:%F&K)V=< 1]2QY$:T@NX#SX1,BC;1
M Z@3Z "<;OA*@@>)9S*8BD"R][^L?4APR:$I-<FTDQ(8JUWR%MB*^H[P99A#
M3Y@GQ>RR9/_SO8,DRA&UGP$9\SV;X-#ZOTR%/(Q^^]98P2==2XP"$K*<<!P3
MCB8S,NAGR_/(1PZ$X)U8Z+:V)ZG3FB_&P[-60CLQ_KC9<O_!?9RFWIR?I-40
M$Q>$[W#?^D?0H;P'"5R+1I@,-U3V6\0.<_@VJ7P/OJ7>.<6.<.A,#CSD<9-0
M?3DY=U"9C\FX-$89\Q37+:&V4V0& ;]:Q/\QZ[^;>"*."^NVUHRV+G'7]E[)
MNF0#A6&W)T,[@]&N #E/*'H/^?.VI<A&Z T7,A->OU&P[\6ES;DM1\$[=7R'
M$QUM[C?W9U%UT<CJ$Z0N.]XISV5MSG'?^'\:_IZ!Z1\\'L1<GK15!F\*F2I)
MNH<5^89H[F19F@L[MJ\6N=_@?<Y<OI@P.-.GI<>'YV6EH"R>1K_R<@H]W9!Y
MB_=-M?!@PXP>;L YAR?2?S$AVXC1UC$FSIG=,*4E=,C4\4K$O9!G1<C7H&A7
M<147?V.T-[OA)$O\-Z>!8T)<PW;J.?']IL^EO3=A'4>5+[S[TSO2=)2=;!-%
M@DO"!4C]:9*V8C<MBT).!LDJBWU<9YC?8A((:<%CO-Y54#!C%^3+".H'.F%T
M5-L_4*&1)F_'T'S<7P8O22!59C4A-H#KGH^;]$M\R[Y,QJ?M4!3\[)(?^U.&
M]-7HL!RFV92#V%WDV7=/"3SO$OGT#^7!(3DL3@X[.]/2.C<TD]0P)C/6RNH.
M6]&'_@?R[D*L /VN31>KY<W%A#/0:^L_J8H+:Z/L2J>G\BXN-75L:]^HKK9:
M,@(TB2VE13(XM)75KDBB2$ VL;O/Z)AS5A=:>P"%YY\U'7X1UQ2*9R+6*.93
MQ4S\?.V8F>_VK\^8JF[WT'1::^; :-3/#D-N0>_YS=[LQ81:--P82IQEI'4=
M"$OCS4:)/_C61>^ I<TJI16,J9V__/>%S;V?F&/$&KIORWQPF'@A 5[=E/!>
ME"2J\A[[N!"$3R$ISY%&FWAJ-QRI&6'+^FDG*R1KH?>.,<$^P'!^Q?0=).@*
M^3Y*T4I_F4?JQ CP9F4(3TT2,_]V37,;K]#_SO[-6UCNH/0*E5S$8S$Q!K)^
MK*9LFT_M5*)]&M&&ZX\@V,BT<^^CH#L0]'4RJ%\1<);OV#AJF)V75GCRVK:N
M)/)K?>YL?;S[ME[\7IS>?.U4U(^))P\-$/>GII[]^9U\2L9"K^MC=<-'Y; .
MMNFGB@2!ICW_5JOL+:UU>-[.<R? T(QS-%=OJ+E*RKQ+"*4$3W0FV\3MU@I6
M68^OE,-PN(ZJY ]R6+V=$!L<U3W&4V,.+YWAY')XS5]N<7L2U&1Z\4APO_97
MLMZR> &*3PL6AP]690F0HG B*DG0$_^;S?]YOSRZ&5WWF'26$/;AJ*D)6Q&6
M;=%K(=92'#S+J4<3X6_?:>:5)8>M=3!4:LN45FC^HL#:G#O.&#Z]?"G9 %J(
ML8MM<3>4PP[:*SKV_"O80?Y6U/;9BR\(]__:)LRH?CS5[!6'74[ZGD^T5.3;
MRUPL:2%U,G2)71MP2V(JA]UV 0ID[WI3Z7.LTH#: TIA:I$!3(YYW-5KRE-R
MF!;:/"K1J6)$@RS"7P^:')X766B2YY,1@,LULYG3YA<,/JA2B515R K-#A>0
MC%<XD\V)WJ#7"_UPM;U]='Y:7T.%\5O$1F#FFJ._WHGPA\3892GNT]?7EU?(
M834P:MAN2RQ0#)%__<+P[P*M4T:O3UL$@RZ?O&Y^W:26(?[QHJ9A;/6S.R9(
M/53<U4="!!SPRBG%N212R)OF;2RJ1XZ3(J-*] <&)X;C'N)L+U6_%GW0-GZP
MV2UGO@:^KZEOKCK)];VMQ_D5RJ@ER@^1A)4[G^=L8\3>7^.&_=WT\1MG8O1'
MKMU6EG>Z1T5@\)084OLU')]R>DFT$MUVC>Z".3=C,)5L" TN60C;-H+K@9D,
M$B]\_9!HTV!@VV!#]Z?T6"<;WI^59'4HO2JGB%EB=Y +==ZR<)M 5C4L#"V%
M!'Z=INACSGQ0%I 1A*-.F#R;\'*D\F3/4R?QTQ>X&\5B!5]J6'1&E1*(D:8Z
M"P6=B$V'S#Z<UN1?&EAR]GVUE+><P!+K0"0!5@_79CV$MB1>:/R,.EH=W3PT
M5)4E\2R/"@J0[&_XEA!XP3$"&"V[F]E,=,L\\:>]5K8E.)5/-X,;!4L?$%U(
M7#EL5$W<T%\SCS42'HBZ*$'4]9\GXOE88ZC@D.M)X&PK=>.D@B%IKKG2%*)/
MC= 2KMZ42S-]OG+&?W53/LJ$!^^+)'TFE\J.@C,=DHZE \E#[8P8O+C:/M6J
MYX;:6)9D3?/"!,(2/+ML;C5AFX!Z38O$<P1SE7\5KR]+V88TA*H] >L,B0=_
M1G]\+'(< 522GT%%S,2*]J,W&#Y]<SE.-?AC%JEW"R]P$U8OVQ,$E8O/0.!%
MD,2U[KA*'A'N4W 6G<%J;S/MCR/G)-N^&I*X<&LTCO7-Q?4[U?L9%X+6Y'DY
M#-IC<4'(<\2K;=[(8D6&KVLKA42;TW@1.7-?4OR\F<(J@K)WKU1%$O>\*K7^
MW(/4O_,O;R>I=^.,Q(' SRP>9H3%3<[B]=COZZ_/]<\85W4>3O2[.SCWO3NC
M[.;1'6_/LDQ,SEC&PC0+VZJ3FP9$L<$R7YGY"_1>$/NK\'$TMJ&I0P[+-Z7>
M0)V\#-)](!]PUZ3,N<4U0&(1K^8Y+%$MBTQ<#VSOS>S-TB >!MN&)KK=G "C
M;CD,N"\"<Q:I7M"]9Y&+*0"):;>.YB3 W4&.&)7-(%0A,MGV'.#<9*W!7P8+
M "C7CQ"8,:>JNF0:_M"^WH//*=!;^PP99T6R&UG2BEZ&%!Y%HPC6G1SM9"W)
M?@"3_WS>C+**<+^]S;I__A9/W)MSX]_8B%6.YZHCL+#;*:JJ_5ZB1_U8/3/K
MZTT;]_:L:VP]5UB_=$>ZDSWXNKBH&Z,RB3 ?G._5GV;MHK/G+CZ?0B LI\.L
MZ(-%UC++1$2*?XY3_Y\_NNY=-WYOP>H%0DWB?T&2B T4'<[J,,6GRV$1]\FI
M)+U?<AB_VE+B2Q]:7L=U'IZ_51:9;!E>NA5*)]KV9CY8)M-&6%VRL%2=D</"
ML2EH-0@+1/"Z\WDU\*.-@/@^[]O:WVR9;GNO@*P=;7N:O?REP._TGN6-!Q]B
M.\9-UWNGE9L==QZ*E,X&UBG<2R8%PA/]6*,DGB_Q%&OQ8#L2N$>T^+KE]6Q>
MB@?WIO]^POI35^C?W'\D7!56A2:Y+B0Q^FD.XV/S2W0[^N&I9^O-ER>MK[V)
MV8KAENH0P@]#5WCF&MT)Q78-+\"/R=9U@RB/"(&F]][/#:GEA*(=_7LGPQ!]
M/V-(,AU_;5PR CP!5)=13+K*"-DFQ+4=M)-J=5"O.!\ZN.0>76($!?); YCQ
M!0H/O*:2%)Y6#K&8%- WD@Y:%H4HMOH7:XD_I;-8*Z<6*NI^OZZH>[E38(*;
M+KROF75-$<)QKFK9\YQ5D8GL;.*FN).\&FQ ?VR+R'^G*U?V=ACSHB$9N1NO
M[V5P6N=]V0E+KZ,V/UBW^-1,#)R8=+&*0^ H;'<&*B"I,BR*,V*$7@O\)C]M
M3>EW>BWQ*)/#3J%?:+U; VIE/8:N;[XQ$K?3_/5&)0%%F1BCH!%SR0GI8R=_
M-4(=H\1VL*:!E.EJ_FTB*RX?R8PW37Y:!CF2SDT^FJS]<CI$F>YV]\(SI1MM
M7=2T>7N3$,E6T$A$%GS9=,Y6#N-I 1R&W[GQZ&:ONJ=3SV*QF6?H_+A2*,D_
M^^X&ZU-0V-:]-[LN/3?K(YWNS;],)$(F7/CU)A=3ISXPOZ2< ,^:(QM')8;I
M'9<Q50-87\#U:_Z],VZ$ROM7"5<@W++(&;)[EB^'A;80Z1_CT=2RZUO5#E\7
MOKX^/_NW?>SE59?NI(2V5I##>HV2PSXJ#ERA6(CP!<7#2H>N)%67Q8(YY/LV
M0VE1FSW!(C W$- L''YSA2_L-2:>@.Y?P2M.P.?.B>R(=J"_P)N)U('4@ET%
MDT@@KX"?KQ22B=6_\ZT<2DG9=>E5 Q2:J"X61IQA*Q)&RE6J"-&)22&9W8W%
MK"22R!*+N'XIAM%P7H)(\0::>)__D7*4"8$^4V_[U[JW3*2--;424^4PU340
M& -8B^/9U*K^37%UH'93)\XCJCK?\8O+C5AWHN:)DI2UDU*U[18_>:F+-N)(
M\#3:&=( "KI?!IIC9+KX++3R<$8)1M 3]TW#L^##W()GW@E*2UHWCGF0--8C
M/*,_$Q%3,SE3%=8:A[YV)=E:LQ/H,0VIJUG?957R[*'TQ]7:IV&N]3,Q]G,'
MNAW&+"= 64D#8"WJ>69,@P-RV-Y74$"9Y."P$R=7IOQJ(#8_;'#7VO;)8K;$
MTNPR=142VDMZB>$9O!51YS&$Q1D&58?HS6Y;1[PP0/.OA1(. KVIM/"*R##M
M@5CZ"I>L..ROFLL=Z&5@G^OP:]E&\#C[/>D\1<L-OH+@\5"G,3/>RSAL"V!8
M %;Q4P?F@_,CEI1Y=B4%"6>)&+Y[!.,<,:%6:!&RR_[19MMQ?4"64\JMNS2^
M=BSOMN_'Y*;KC&#U\HF _HK'A0KUE4ZP^.B&^2/ C8&8*^XA^(EQUE#0#N1(
M8K(MJ<XA0@Y#/#C+2LN0P^#X<\-#1^I3/&)4D+/MJH*Q>(Q6,NUHL]A@(2#Y
MZ-^1Y*I'U#-)OZC",Z3NB8^8>G*[?Q:FWB757F(".OLE(N'?1MQ:?Y/Y?E@&
M963IR):S^ZA9R(MKCA#N;-C,M.K;9H!/7D'<.IBL,R99M^3ULDRRZ0W"J#^C
MD)WC5'6YHK*IS.H6MVLXCJ,]@T"">T9X!WGD!WM&%](M]RW=/RR^!LQT4G4D
MV]B/((; C:1$0(SWQK_DC]&-R:I3S;K/!/$--<+O!&S4PAX%NY3N_=$V^?7X
MGO%E@!85:-FM6$'Q<.DSR&IZICWQTZUG<.WIYK1HFU*A#,F.5<<T/<PE0WL:
M1$COKTH:U@^6C"X_TSJ:\U%6_^+IIF ;-[O6<W1N6]Z4>&:ZI14QO) HJ_KH
MC%PFAYW!+(]VB![E=!]CGZ_Y5%CZ;0IA"W64:]H%UOL1K7+Y2,A+002&28D8
M0P(I=%CB8YU)//2*;*Q[VN9[=?/2\G( R4M@#K4-TZP%/=$#/Q4-=.P5'32Z
MAMI=1B@X9/IH@*A:^E8.&PL2I_+Y*$_>2X#:86?R]7>6Y[%"'ZWR9?@O=)Y*
MD'MOACTQ'$0N8<*:O?KKZ_CNJ\W@O_PS\[FHR!Q%)T\F$:F9F>H@7F*U^H%X
M8VLL4H5H4.K-Z]41ECB#1T<A)&N4VE7.1VI'RW0'T2-/\E7GK-#;,$ NI%C,
M$OT^_7/ AP4=R-4=SEB5WI0FT6_3$\Y_G7!(UGD'V'!%O^MXO9J2 $ D&2W\
M&N0^5$GE<S*%U<Y5W I3/9M\74O0JH5O::%KGS,>N'SYC%W*L<6ZW>QZJG:4
M>+$V)Z%*Z.I5%8FWG8_9!,:9N\YIHX7>;R[FK<YT[UB3JLP?D6D0T9\=2:N@
M&Q_XXJ8K7-%&X3X@(LW>EN@+?(1BYKK JA1R*DUK] ,ASB@$;0#E<F-6>8DV
M@&F;\<O>$H/BRXTXKR+:,7K'"9O,1!&![/../9O<\1UM:_IIWF563V)K](+8
MJ MQ#W7J[>&II9,6S# 72Y=T9G@4\#S:N/:XLF)97)$+(CF,C 2>!\[G6[T7
M^K]ZW=;8]/IS[Y>YW,-Q!4D9;S<^TMVS6JNJR8J.GN.,N(FC:8,T]]KCA%?<
MXQ3=R,7^(5*C3)%&3@M'2VC$;2B#<AN(Q$ "^>;71S< :Z% "_P*EQOWB,O7
M(NSAQ_[S+Q&52<B!7WU?*/7OQAH&"0['.')"R 93L.D-I9E_YD//4>"I-1_>
MS%\*[3C4_(O20KX0V8X&6D##HI,;FEII#8%I4>GJOX]<I.*L=_<'W_:>L;3<
MK!PO*'G\^K-LX-52P)?D?IQ8#GLIK?OUVHU>=_G&W6[,/O$8UCR*_C*K(VF+
M)+RJMVHZL9(BH$,>9LSX1*K83K$3LU+C>I1#^SR^/3J]4+*VWS^'>-KD*,(O
MVOOKLP,W%/FK8UN;JGH>!R@D'I<-H.W1#LU#\)Q8DLAP"%P#>PV\:[<(_&">
M?H-6LD)MW*A97%"Y6Z6YLJHJ"@@-M2NLZ/HV.M6Y=&A[Z#,?Y9\;">M>>*-B
M#%HF/.4P=SHHD!DL3%7+VI$J#3Z_SF;ZK_[B61DV79Q9A"L?)V#V&=I1GX:>
M,@XOX F?AY]:^\[Z;HDM6@</>;#1RP%J.LUHE8(%.M!ML*GFIHP&-SW^&(ZD
M\6V:7<YH+*Z]272BDLX+JVN%62']WEG.0LZL*M!F3)2M5)R42=1_;(F_">][
MK[#ZF&WT<PM$BIGL[4X2Y/7;CRURYWKB<-6A@B/6ELJEDW3@)6TU,GJCU0[P
M%G(L-;CCD'88W7,-[>4?J(3#N<5V[Q!"%VR^4T:MN3/9,GLL<?/+Z\&:;@R9
M,5AYC^\7--W++'$$(G+JI0>$IJMJ:B ;+)1<SHSBJP <B768@>4[WHHT D#H
MMXPB6EF@R$SX%QMN%G/&C)#%A^=L0N%PM5#)K&B4+K$8MS ]7QRWICPR: 7^
M%Q[R_K;G3+_%P@TM3X?P"T=@P]")F:M+8<G#=QK_[CX?TV::_#':_/S<*R\0
M7#C"1\)9SH<O; =MQVTN>(5'9GU;2J:[M<$(#ON@I"4?6;_,#!B:R3U??Q^?
MCGFU.#G1A;""'O)W#UY[!XK4^T^#?[,M@4[HRO$\%E"!6L,MZQC>03Q7MX=2
MYEC2VR_;MXQ6S8^GXWF],$(+T\6UXE..]![O6Q 4W1CO]VS:4-7QWW5S,:N]
MFT)O[5FG?>O.)V/1^\0:XA!H^AYN3F!W(#70/;BX1S:DSCY05-N'X0>4XOXA
M&.T>7K;&6J9+R?:6Z>Y:2#" 2/PS=@\:4&YU_G7^OZ,6Q,I,#/<A70O]CV2+
M]"YJ32DQ",P&Z4SSP\P2%.B2@_(0.U09#L5Q3 @IHK?;V.HJ)\=0#V)^^$B5
M//[(MDO(_H/%/(D>E[R2Z [\:,J@Z?!ZC#J3D?4J@5%H9)UI_/W3;MQ-R_W-
MU1JWUWZ4PSZ0&(N?^3@I3A\,G:D<F\)%UOLV^6^V/;A;_UOA6&/QW+P4!L1$
M,$HVTB JEVH:)9:9A:HQ9-K@3*93? MM&)[M2> $ EI-="^-1T].PB5KS$Y[
M%QY_>&+AQ+F=[B^S+"S0"\+!)KPP[/ 3R2&%RP7-.CFK?OM+CB"VOAQR>FBY
MZISKV:S\GKR()^W?PZTM4.P:MC-R,^-4[9VIT9[S@[C+4;L/!%7>D?Z5)%**
M$<JTUQ392G.PN,/,.[X>6L<K]*T.[CDDAS'%QX?FG/R,0K^!FD-*G1]+B?HF
M\4\*NE,(39W:;']^;PZFZ6A1MA.$TEERAY#,$F/$VB$[FCO?IM<X\GH<?95S
MO6 WVVP74N?41O^L[IL? W6:[KFHO#LZ1]8DK@9MD?^CL3</A^J/_[]'UK*,
MI1 Q2E%)E"V,F4I1^4@EV6(J%9HT+61BS%A"MJ:5/L18DK)-92O;8 :?/GUD
M-R%FJ^R<$\9AMGOZWO=]7??]NW[7?=U_O*_+,L8Y[_-Z/Y_/QYGW^WVJLU*)
MUM.W0X9&8KX^"C??,HG:!F;FEE[S\PF0%6B= &OC;?%7CP(YT@![YR59>[-+
M ^=U.AZ)/V-E.KQIX!(Q0MQ5WYUNPQIYRG]-@^**_2%<.YWC/=L208'[X@7'
MP69*@;HTZ_C(^[229"84(Q-1.,N@CI\^^$;>TIEF/0AK6VPW1Q:<&1VG5XRT
MA@$L_B6]?0.=";0J7/4'HA,%>BR!75 $C0" *8'5'4192F"I+?\ACS]"*HRK
MR,[[P<Q::"'VY1S(F2>X9Y[8PFP\(%:NJ=$)_DMGA"K5==6"D")?0;TZ20-;
MOV^_@OQYT=".EI61U;*.JYU2.M[8J _,<X?,,F3;]%!O0>>.=0>+/$[Q&(:*
MP-XDME8<]_;X ="DMY$J-'*ZZ:8.WR6!Q<<0#(#@5MJP&;LN@8!PZOKZ%,NA
M5YP?#QC//4J-B(GVCKD3>.7&W<?43!@O%FYJLQ)P.T\?&$_F!.P>/0+\>EX2
MDGVTD/(AU,_]R=1(U$2^C+/:K;P#1K))E9696Q<LG! LIEAI"R*U1J,((IT9
M;"17&^SO/MUDR[IF'_;IP->3KJ;?+L<->#\0*GU@2JU8 FN1)MDF,O^*!"8T
MCO+M(^Q$_S#(?W1(KV/#(\)!^LV@YY?_&?UR ^,*Q5GK9?&)]YFUM>^^2V"A
M,WZ#8SVRLX%Z/2U[OGR7)K&O25:M, T_!-S_&&H#(&K.*O.#'G;TM5^?LW'?
M0YZ=X11IEJJME[VS%;;.V7+Z5O?7&,RFE"YB'?],3;VO65CA<(1K89D$]N%W
MA7]F[OQ28.C8:BC-L^?B;T*12D!]Q-IB_^B[R=!_T7=NS8E)B Z:-=)+<$QX
M,)F_! 4!;JUK>"9*=T:L.KC0&!$1)GHDGYQ2C9GCRIC2][#Q/I-1&E<,]\B3
MZMH>?%Q'.T9_JGY@!OM09&<8'12+_DR-S-I0?RTW3[ \]\O%4?;!EYN]^(KI
M0V>/^^<\G_U1.7(7ZSHSSGK)>E_3]5^>C8C:F"+<>LN&VNE^KF]DIHU)&]$+
MX[^I/^(;=DN:'$W N\C#>4;!.XX0-;R-%('+@0Z&^_??0J@C9027\='LDLX,
M3^Y*!SD)9080T/)"DHTX$P6?P6C2JO4%!OL14L( )NX+/;F:!'M1C9[%_7_6
M<P<,K=-:#2T\-I;$-VY>MFCQ2&@V@ZYPT2G-5J"-./G6&\(QT)0_]Y.<N(S1
MOX8R&%C6=J]GI4M@[R)^(^TY% U\J>^V1:05!W]%(__FN!48;1D^2[IFA;.8
M98'CRJ.LV9D@(*V3%MKP$7Q=!\SZF JWUD]KH^Q[#N/)]"O'MD,9=G(RJ9<S
M/3^U1?X_;]OB<*MQDUXSSW^0_G?W<B]'D1<EL!E$+NR>17M%%&F#T!$D/:A^
MC[M3-D74'QBE9]Z7Y7=OO&F]8\LR:INX_<>-3GOV&\<\.2"&'"^$<S#R/B=O
M[$%:<+K,Z.>NLA>KG/N>'K%G!^/_LI0M, J.Q\/3+ TP/I 7.]%>"A )7%LI
MZ'I>XYT*,.5<(AN0KBN<DI7E!BBWHO1-WQINE8W5;EHQ6K+/7Y?0\RO[U<L?
M)(JXYE;SSL&DQT73>NGK1GY-^ME]"SNVN6E@-"BD%+Y]/D+NH? "\)%'W7'8
MSM]Q7C!F:9^[#C['TH(2&)X71D.S2N@.]ATN8^I/*_,^H<'3N?D_%O-ETZ_6
MSP7[O.L)_R+R]LP-FPT?=7+A_YZ56LN37=^/==XL?I\'S:6N*G*9&<U;I+".
M:4&HX3NY^X!Q:D3YM?C^$RB+H? QCW8:N(/Y6RV1 TI@FQ0(1T4IK:W+_^A2
M/2FN(+P][2IJ5U4#0(F]D252;B.%&#.(>_H/K8YV<'0<U.(Y688;O_L"B@_W
M_8W4NUD0?!_GUG37NZ&IEAEMF#Q87I3:'OW^KEM$(?9HS5B6T* +$<<R)!H0
M>PTUI80>P#W$Q2F/SCCDI8G>XEY=6PO1RWS ,8 Q3VENM#2^_3(SX#\KC)EX
ML&Z=Q8@CWSH99?#BO/#L@+@3&Q/^F7OPL )3_[ %:-PF&^I9\,3U/N%2[$_=
M]5IMAYL_0\' 4PZKS4 )C^%T)@CM.>:R<^9X:\J&4(>3?[^^\L ^9."-D\,/
M2[&FW1:HKA.=D+<=R@+A')>ZX,@B_Q I>^^>L8M,*<,SZ>.V/>GD*A\'A-#X
M<2:S,U7HX)IT!0UDXNVW!OP^-FZ90>*HDUQ5Q;/--:,E977TB@5<Y^E+J++E
MDF6/I/&92-*5@+'0P='^.S/=M;XJ=.30C[A^8P0G+_]1M!Z4S)$K.2UZ(X%A
M7\SN-1(<31;NFC,@?KY3<. S8/>@YM4BZ3WAP/:S8]1U7=P4I+]16//EMS)
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M4)QQYP1HDOPV5/^8F-D7D6M\JB^N.^S\/DSG3>/8XT[$BU"RX)9P':!#1EH
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MOS(N&@Q1BQN:FOQ60XF4<\(] *-9'8 G$,S+OH]<"S3JMX[9UWBTS._#GVW
MVK=+8&'8^F]GE)- UP>CON#6W8<3=JGL=W'R%XHC?N;MA*K8%HJAV1GB"IZ%
MTA3]KRI!&)-/3;'.L(-%/>G<OM*"N7GTI@0&IX72$B0P=>'Z?+R8WAFH5-N[
M_.70O32:3@AK\H#NUN:+>;==E=-7*NVOZF+*/XYW!Y#8A/1 O2+WWQY2U(B)
M^CW:+38P["V;/K=FF'6G;)Q2-1I:Z_=\KE?7&)8IA^BT[_Y-)8MWA-PA> !)
M-&!/^ZV&3O&6 2;/Y6TQYA;'0P5B6V'K;>^_8N/3VJ\AZ$1EL\S=%;PGOJ?@
M.JO![>312(YY-Z-"EJT33PCB(#3QM [=)KUW()R?%6^M_K82>X\9T8X&TAVU
M\FN1^Z16<4GSU<Z#.N9+E7%<"2Q>+ OD2F CJ%V0L6UM]NL:KH?Z=+-E[\,2
MTEN>V#3[:]UG>T6Y"-[/B8J;HB#EU/:F$:8_>D:LZ-GT$RJON/+BOW,9K[G9
M#34+.MN%<[0K)03:L!FG+I$()W935!JW<GQH5=5QG HK/^6(NS+B7N8#9DT3
M@_U[Y$N<T-2T9TBU+DT8(57KH-;^4#V#4N%.*<1'\!K<,.IC8UIOI_6R^..Q
M_MX] QH2V$:!*7_W99+&=YD6SPF6LM@$0G#1;=V)MAC@Q10-B/6#].F95YGT
MK+G2:QC-97>M8^(VIG68EG./+?0"(D")&\-QD%O5SZ+K7V]6H*P.O1%_)ZD2
M-[=?X53 /?[L/,'-F=O6SPBT--0#VR4PX4EKC3IGR+<:_Y(GT(%!5:9DK<O2
MNMK1[?%. KLB)8_0X3+6YPJ;WS0/5#+YQ9[ *^F9%EKA+U]2&%2JO__E+%?L
MWLZI%K;,I+SY1N^HX2B+SW^V96A9=>2J50"+G$W,M$:OTFM1=R Z3S\TVS19
MB*9B3T]E8]*0IPM">/1ZPW2;]P4'@!7A#DULO5WB9= 1)X$]ZDR.CV_;:MK*
M>M\]R^&1]:&GQZ!NL$W5\TB/-4(U% ,7;Q*:-GSH[<@D*!;,$-'BUEXDKA"1
M)-;PY"QLN ZXI@BUN+%W>!:;)XT[74-0&X#@!)I78QA ;T%HS(6++#K%FKW(
M@(O%UXI\^\QM9O:]23,XK1PV^,@J5FD[[\#Y"YJ6^Z:>D?QF5N,@,X$;\8L>
MHK-[A-5NAU"KMD#@3?DI/>$9^_]=Z1 ;B3NDW8J6LI($!B21+LR4'.Y.:O0G
M0T?A#ZW1*EL@9T-K!W@J4O53LM DC,WJ;7+E7^A%<_(:@P W>O;SN7+Q3D #
M.%G%;?)C'B%IX1O.>"A,$N7<(SOJ^R;EL&)CU.:>);1J7:J<B[>[IOKMWF>8
M?&0TJ-."4*E&0R>(VR!F6QZL)W/2U\"_?63H.:?+3'#\!3G'FVFX\\/==ZH9
M+;M,G6IR.E";],_BR2Y2U1CQD?7L/_8U71!QAYXQ?FKSRR>MB@M;CKSR=C'6
M2&5PC!.;*L*J[V+&CX>+(B^?"N-6BGY1L3-A#:RPN]+H)%P3Y="NS&%<!RY
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MLOGA!9\!:ABJOPC?$SJDY]LQIF.6)#N8#%/X:HG-A!( @7B#+-?M4PY' NN
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MQ+.J,/0%78(V= 6@\LO FF[A5ND1/</?X6(24=L);H:FAKN8-K5_EE+M39;
M-@CQ:,YC$)Z(E":ZC4N$&^"PF02VZ:UHC4H16X=0-B%/<^;T.J5*]$!H5XBM
ME7K?$+5\_%IB)OT4\#7U2R4VRN%$'@+TEEK"^A.5:9R_=:XN0$=LI.3UP1)_
MUO;;]9.FJA,2F"QS;>$FVHZ@*% FZ$!=/+2BN)>X&\()G(4F4!SP!/1($)J5
M"2]"3]]DD%"J/1&\\@P<5X'@R>%C-/"CYX%.X9D\"^#:T_S8DH5-+&#B/DZ\
M%RHZ!22GH#:+!_TLXL2V$%J@X_,!#&[W2 ^B8]9_@ZPZTRKD<>KO @A0=:[&
M+>Y_"E<Q4.%&TC\_%X;R=*4BF=!:+H%==P=U^)&#1IYOTS!JE8^E< 6Y]-@^
MKCNZQR/9-26^S-CZ(_C85! :JS(MT\ Q0/ YM:!ML]AJJ'G]],UKQ"V@.S-I
MP;K!/"R<LAY?B(8.6N/633+L,1J?.0M:]=!H.VK_=7MIY1T(VHT,L$A ZB?M
MX+X_7J$Y4Q=,['1!:*6VS222['#^PR4SD.%.R@=X+%%&B (46TER/H1(4#N7
M2]*=;EOHJ%=DD'5#.]LNV#-E9[(1]"&@))%_3$>L\6:1(W^!NOCF>NF-*=([
M7"O) ,^27K"Y3?<*"/X (L,:KAA:M]*L6 ]5\%3=!(YGF-;V&Z;TQ#5<%:A*
MK E7SKW0\=IB$^2^4J?QJ-Q[=&NUJ(%4AYM'UZ&O7N3@:J]^[1>8<C'\%^C1
M[;F=M[Y:3;L<,UJIO!N@Q5]-]JSY^.>S!/[-3^\2Z%$5CSY(O[O3X7 ' Y6'
MT, =0^M5_@V7 W4=G^TSPEY7M_Q+33[K(K&<&EFQ$ED?22IM^DJ>(PPMZ(B*
ML6]--SY?/H?E!*:$3]9$%J!G2]BDE#JTOE"#=X!H,XKW/XN#CLY6SHMM"6X!
M5J?ZEA<4YH:6,Y11.^POC<Q7TT OBL[/)JM4@*Q#;,>HTH+AL7<-%2#7U\2>
MYKUHX''-W'@%FYR.UEQB:?G,XJ"3F!O)4G';E02LI.H[2P_;%V0O/(-B93^W
MQUCEX^_P!579[&MY]J(\FYU[EQ.DSF9$VDQ^%QJS=#&OZ= __W03L5VHK7@=
M\8:ME:QI*TB?VTE'R$%^W9W$'<U]YJ,N;A+8EFE#69R>U/*_9=OJT_/,@:^>
M=-(W'/N#UT%%W,,ZR\OZ>_9J7,K<NS9LT<8:2J8<JBL;&ZM=8'JO5E%PD$G)
M["J/G$I3(87>6\:-Z+>(30!:0F)&<L(>(E)XHK\:6)M/XZKS H9R&.;@+H(S
M0F@R\G4(H*8W;MO\Q7C;\S.BY%D:#Z<[E;<?=(VM)"H+8X"\N%(MGJ.%NM '
M)#&Z'ZP%WP?9M'4ASJU^VC6\W_^%RW)5M<2:5XT[3$T#O[]!<ZLQBC$L-IU[
MD;V@[,R-"Y6.\V/ KR=(MSLABOQ;H!W_1$9$LFD<]5Z)[O:\%T:I"]C2+Q\$
M6:N*WM,2F"7U"V6D<H3I#6+2JE?%"L)PL+G@#C!S K@(DN@&WNUB_:>>?80[
MY?$\%R;!07N?:=(.^5>70;_=R>'@OQ9Q\?^B3[_)A[?15(G_2F *J ,^^&VD
M=%(5?$[O*J0E'5_80%6TNK0B+@^@1M_BC8\"2GHF*850 J,XW 2\?'_ULD6"
MF^IZ];<WQ^$ "1X-*'-V=#.\P #F["VPWZ^_QB.QWGVX;T$:NYZZ 5^3N;DZ
M+DSAK7+R7+>Z)6@)FAW[S+D8EQ2F>"U_;Y'4=GO<MJ@?G!B8,,RU$M]9P&S
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MIHW>JLZ(,O#VA_3J^[&&FZ3GA%IHR]3[K6^P1XJB1YJE['$_%I]X%G80.(4
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MZ.M O!4CSZF_T?->,83S[D%NBW#FFHA93.L N. *//GF,%#)L<J4-771#_C
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M6FA22]4 ^C-R22,_G;*4.*>5M!'[".>7RO@<M@,<FHYJR87Z#E'DM4J:!5-
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MI_2*7YVL 3HMQAB7P=-@8O#\:_VB?0BW\'2T:GC%Z$KR2C5?&43;];Z"FQ-
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MZ"+FL_I&A94$E_*G<O_J5!._M#K&O99XX'KT%1(1U3D$EIX#52(GL(X!#L;
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MTA9F"!^ [Z?K\JAHK!JYE00VA!#RFR!W3;22)N$M>6X?J@.59MH,-.0%#<[
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MQIF&0MC(HAR\1"@^O$F8E=-'78,^-B]FK8N[$VURU&)+:.E4AZJ:E[ +^,8
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M[+V=I7PF*V< 6IK>3%T+R[%%##LD_=RY,6,T$IAFV.*D_X?61^NJ\C(Z&8"
M:_C&(5#9YKIMV_,/L866XE%9643/86)L%Q8)_KGQ%:A::/0G?_(P3Q_F$3)
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M=DDI7PJ0EAP%-=IU:&(A]W ?+6+:3;*;*,;%QKVEG_5'83=-,+(:]L$<VO8
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M_GC]7#R'>FN>@22_OR.H:-=2TD@Z%=)B^ G_$\XQJ]IT.P;*+11-4'T._P,
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M-C[^YG^V_']O V$C)_V?^T8)&[\.?=2S/K;/T//.?^\V0=OU7U!+ P04
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M1-SC(TWG\(Y0$RD=,M?;L$:;&)-']!1]6TF(!.*0C 7A"*VA=Z$,&U_%6MC
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M, -Q6LEM BH*KFW/>+Q@=N*W _K7)#B([ (FH-6P 5#7M;80,WE3V>1(_:L
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ME;Q G#'_MDN-CRVYTONL=(;S3\]_W-<4I*E/TE$0&AJN!*GH##4Q4V1*BS<
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M._NY['%X%I6$,H-@>?90G<L1Y0GHH%T;1JL.6R%>\VRB[>(&A6QX+SM,_\(
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MFLK'6?GER)^._7<N(P0L[0>D-1F0/VLC?*!A5JWZC62X6-\DYY+&:@0GMQH
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MN3, H,05.[N]+;^2T-)%BT2YQWZ_U-"[S>H;8QCWW/B)NC^HYJQ\*:F&UVP
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MD]?TJ6Q/;:(P@'*Y?"'Z7$DA_]HOHRY )0&*2+(E&=W6XJXY!2^UVMQ^)\2
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MG\6*]4/T1&&PA"M4_G%PF)66,6?*PPNYKWM/9E^OS]X(C2.DROZQO=%)36C
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M#IJ?/<0SZ&Z>$P+56!$CO1CTG#D5C2=/M[\T)[_H8+'_'#4IL3F<5]@W[7T
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M9[LC6HOLTM@%7-R(1AKAF-T4K<@QLV'N7VSAU94:="RAN77:9;S!L3DZ-+2
M5'AM];::\PYOU(?U)B:LT("O=,"U PUCY7$*4HN+"QKZA+W\60.5@AU!"^%\
MQ9WKRI6K)#5F]$JW7 8-L:^&>AN)Y8]T@3V<)RF$)NR]9YE&73WO%8*X#<B5
ME].O5OP9BHU5WS;)U,>U5ZP1J(H^G<5KZZB@Q)5/:K"S,-U9C-HC:R7B=%(=
MNT;O("VN1 =<.H+^+7C7K-JN]'!>1*\>F70G8,51@H-CN&,/NT+Y>HF#!YP=
MGJ+QWUG<BO!PE2A#Z9>II.L'NZE"IG33C0H,C0DDB\<L$">ZK-3\%;;3F:(
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MQPF).W,?'[7B8P_H"@IAN2W!H4#6: Y4">B '\;"%U+M>5:?#M@/Q3_>R,_
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M,$7@[& SD,O>XM^VIDTZ[D2C79KI)H22:&6 +PYAV5(2WCOVRO.'UXT;^4&
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M(N4&FS4*%6]<X[%UM%CG4$418AJ7LBV6%2G^<,%Y5P%T6/:#%DL06]I^G%2
M#CR@(8D'&DLI2'&5&;_*Y:$?RW2;H8(4Z_V[& D7ZU6F4 O8F\P/(6;=<I/"
M9.K24ZO/@@8VZ(+)\RY$^!'M3)JNO<YVLQ=UU%%7K0BG&]M%T3;#U4FR:&=F
M%OV /"ET<^U!]JF2#J[2$J (NB-FQ*-E[,4$SNQ,GP^W;%V\QT5#J9(V$S3=
M:]AFZ",AN#WLN]MN."KM=T[&031V+_SSM:*,(C:[83#A?I%0\=!,!W";TK8C
MUG$?$BK/W+MV@,/JE,/;#9?+=]51AN3--M4EC8\?=YN%]=78J-IHDX-%RJVI
M]UBJ"JH#;)GX((CQD@W2I[)X!#:GI89? 164?99!?YPJP8T)O;:%\^$Z1D$D
M%ZCV0?ZJ)6F/T3<HWBC=!G>Q36 9=\A7K]*_(D5/;1V-3[>/<U[-WF)]:=W1
MY)KRI?/)<]&RV%=__'%M3,(3NO>'$3%(J,<7): IQTG2X(-/(?ZR-$U[!^I^
M+X%&\[$MNX@KYYSH'92CB[(KNZ?-H7[TSV(Q5"O3;@OFQ2$"7NC-H9,;M_95
M,='Y9.Q!N)KP+ **!2$DI8B)=?X@='/"O;%*>>CM6ZB2@.\>-(RLW2.?86./
M3[,@I<',-L-7SY%5#T\*C_/B7N7#^]KJ2]TC3@MNK)M<L5)@N5[3$5U+*.G*
M[<+V=F';3;HZTHR//Z:3&RG8;$<' 6Z( ?F%1&:=B90V\Q4!]^I*[9]"50Y*
M7]<SW>W!9M/+P?9)@A>]4[]65OZ>0MY2J0/Z=P=0/M%TP.)'1$^[6L\1-N)%
M>3)S@.@EZP*\R'(KI" D5J7O&\EN1$#,RX-;+,G&<XV$;S36\U@/%G;TYAQM
MIE>GS<U=QXP]VDFW* Q54BZ?.QJT,S27X71WX%/#"LGUMPL?D6+]-O2?@0(H
MZ%)DF%S,C=TT! [X7):H*H:<]W,Q8R?7\EKA"; E>0>_2CX3,W[DW4F>_%$>
M1UW!^D5XRX]<;%MJ6J"$#-] A1IV>@1:6;-VS2?7+RM<SGO-RCLVF.B5FHR)
M_^BE,/8,%U/6EK44.]%N59^MKZ>M2J&(?E-7$P-*UP'O7-B>.N"H5X50*MZ'
M?"HC8=O">)H)76FOP]_^.BWI-U&[8K/>XWO,E7S-0LXDG#-?P!OJ&P&ZR0@Q
M^/E1G@(F?4""^\J1@YR/HN7?;*H8A<0Z/MRIC/RI RBU>"IT&!QQ%59 FH4I
M-/SOZO^V\X]W$SY;,.+:5R'7+&B&\+^'(G#C0A E/"C8#4._%KYR-J]W5-%'
M-=;#[X0CEM9$0+[Z82D8<*V%GO.PM.R>CSH@H$,!X5G>DZ _Y?!><,2NI4]C
MCJW4 =DWZ1)>CS]A6(,UME#3>93PK8_O1-._AF,FA+@^I\%KB$R%.MME/_D[
M!,.0IC![)$-4#;TUK.:#;_D?MW 2.=4@_%2H<,=;Y' I6* #%#NAJLL-D"(8
M.JK2N.$S:#T40B16A6D3>8JQSV[8(&'[%W+.RGX)>KP$Z(0J_B0=<))NPO:!
MVQ"!R,*VS2,GE[T%SA1\?,PHGU1;0)Z9%KYUOLD;)/#20,7\]-3H=HA_E[",
MB\V&M*#@MK1#H%^(F*CS!S5T"MWJ.VX,51& 3WH'CQT%VAJ.+23#OZ3CH"JR
M^L-85=G8'Z<)\$6$Q^T?5[/FTV_A>H8Z6SF,W6 FR-4>I6$Z(&OE&>%LZFR_
MSG Z?(A.DJ/[:SJVPC6/";N3!%OT<=?E/)U?/W@)E>D HY7F-SC*>>EQ1>V3
MWIAH:$@DOMV^FJFQ]G/4 ?6S7]$;; )^"1=!I\C)0GBS<.1?DAX^L9[,!'#T
M5?D"KY_2GO<(M!^&H@NU1J3F>I6\2N-#3X!FA2KH7/F+3SS$2A0!8?M+U./1
M%GQFS!SR7W=?SH?'?4_1+ADKA":"<PEX5 >,54+K@(:/R%2AHS" 9RH/M@20
M2;?(!>3>7%B%KTJN!IQMX%!U9"-G$<M2A-NX0TFD0P3!,92_G3K"_5;KV0T[
M6UF>$"28"+#99:T,[TS7LV5I/HL;^JMMY.GF0B<3?/#UF??US+UEX)(#J RA
M[4<NY<)6_Q)J'W,<V >+"''+0^W/$V9'("8UW=R*NBD(X6 L'#'@FT-5JU<[
MDDL]SJRY+NW2PV8?&@&?<<4 "?M$-N JG9GW2+\B-8$;[$9XB*3:OKD\![:<
MBU,Y3<*9O=)>,AP$!;!9*.DI9@^#V*5\;;[V)=4,)41ME4OZ9JE?TT^A!]CV
M@MY_))T0ML]5BG \J]DPRL#JO7@>D%*(&)89E755?\>[;O=]?ODZDW.^J9 @
MM+#DV[AWQ&O(FRS=Z=S<@A/R];D.D,AUP*$HO1^]]$BHDO#R[>KRU5!3::=P
M]&\6IWQFC/\/'ZD,O I*A)E1A.V<&)U(+I+5$)2R?RC+OPA2YM>2F/>T>O[T
M1X@ N^'LV6T.M547MY[?+93-UCKI@'6TZ3H@]H*P_4<YD1--)N!H"AHCG,P8
M3L7';GO<O(.Z$$BSE\!^AG(J-E=0 @OP;09\S X<+.%^.FV-735]""Z"3HY]
MWB%IQ+6C"AK5(%(\*WVAH)*4*._?1UT*?1U1\K0;[3C#! 3/!W^0^?HZH+M/
M0KP5*T$XD4ID_=N]*$\'^'<D@(-#])^R.A#?,9?HC:>7#MCQ]TAQ$K^?=DJ0
M(I,>X5X@IH -@]HDW)0(Y\^"GFX"]J^=!8=ZH.L"E6D%U$]ED?_!"!W0^4NF
M#LO6 6\<R:-J\(WL';JY* 2WTP&9;[K@:5KIAB'>#ZMS8QO&TE_POSVEL/C?
MG/E$ZHG6 <OFC1V[!GWU5&\@HGR-<FKJ__65@,9:_8J861_M0[#G(IOH_A<;
MNN!OR)\RLL6^1ZL#C@4K!-K]6\OO_YO"TQ]]7]_CN]TU(-24PB)D_;[KF1<)
MF<S5LKGXW:Q_N!E<)@SHXYJ.2GJ(-<G8"P(Z@"DPBLH1_84WH($:UU^MYO#&
M8<SC<LWE^_PDT9C,GGXW\'>>WDE;7^9EMFFD0I@D?+%8*ZGB-7=7+E2I_X8M
M!.KB7CTD'Y\-7F*.LYP/?AVEQCO3E!CK0MMMIZU3TWWNGI?VE,''=( O:@I+
M?+CJU=I,-J<D^U(U :%$#QD#;7S#;JXFZ$[C(&TBD2CO:RY,J:F=N0VXX3-_
M>LL!]. C%JAB]EQ^\@W_H /F<4@KI;UKVFPHZ Y\,:?>5>5UJ<\'7V[1[!3$
MAV^A%>09JYN-Q2U[\QH_)/%O#G50U'<_AD+O2Q*^:9J3_!)GYC[]7G8W97?)
MQ4-,TGCY2QU0G$SKH_S&A1"]CH+:_#V3(Y(;'=.X-KU!3$640<%O0O]^@!7=
M<H=/D9''A&G+L@C0Q>]"!#1Z89Y$+B);H2U\V(LWLD80#ZGMV11B,9,5S?C9
MCEX4\AYE&J2A1X1A24_+=YS5 7G?K^13AF_C)&V!EK#P,7^81VO<V!R-LX\K
MMIP<UP022W.2\?K2I@USNOZX:]!6<UHQ!7/#IQ/H>:,,GH:_[4N !F&;%D(M
M7YNO T2[, X5PNJDX]++0&6XX)PDN]./D#AZDXG,\4,)MCHZ7 V.LDP.D$:<
M;X$BSS(=\%TI=)DGP[>_PG2  UEJ"#'YL*M@9#7Y(C0THI)J=V*;Z6*+?_?;
M@X-$U-YP7:X#3/&F73#+DY!JE^@W01.001]Q$";I /5&=.PVD1L=)(2AY!MY
M:!#*C!JG(=#[[0>,24BORTJZUGGJ?]O@2_S4\#*+/C3<I^W$HL0IIS-?GPXH
M[XK7]FCSS\H3N.J3VL*PLOVC[>R9Q&+%G"[C7^H%"Y]GC3U>YTBIEJ/N7X-8
M<Z27(,44\Q>N^SYYV/3U-1&95;,,__@2'/B#8^H_#_IP^][@H. ">*)/#_M7
MHOI/;;[S:4K\U<=P*H%?,>%=Y7/@OKAD<<0K,XAW=B5),OJS++<H'E+^!1(A
M%7[P\T*J]<YWV9OV61U3T2'.&X*.CT/Y3.TU7IQP-"[(MWM4OD('G.&BA#IY
MN G7OH?:?6_]%G@0]%VQ3 =X?T,%ZD\$""1"E4N%/:>U!/(,N=F=(</[W,TU
MD3Y:WKK'F(6"$B\/1IN4!#E.H8E),\F&*-E7$A-6!Q8-59'4EK:50/3PJ1W/
M\H3_KBT0WN>[CF$FZ(D[6FZ.^BN?AR$YXGO!Y#EYGU+AND'2I&[4TK[QU"88
MUOO=VWYE!FM"]YEIT/$ ?EL.AW\DKX_V:27S0V[8>9Y&^!'J#/PHA._W0+\J
MP#])V X"OR9URX5MMR/T8:D8:J&-/31D7D$W,!1<Y9@^@KU$E)E0E5M;DC'5
M0';^<V'A3L8KR8=33[*MIJ[/9:L(3_Y"@R?Q\2EO"19GZ8"??N67B&G?%RS\
MJ@,(D GQ,59(8\N--?97J7-XJ"L^H4O>3#=<L1WV*^.C+I.!N;_77WT)G-*K
M^SD;K_KX5'W;(JU7,T0$VG&?ABWG.GX16G"X> SV'XY:*?K097T8WT/X'S)X
M- J9Q#9_#+VA'.B?KZ%AVR5#.#L0.^4<, QALYJ/@"'?][>V#83";A5_=\LT
M3/JG,])O=SNJ:+_%LDHS<>- <$1%.JE Y=H >IS6 82$J\<#*<VL ,J03]R^
MF]IO@@>R[^FCG,#U-N<C\$=CY5)M?&'_47)^H/8&A9"C20R4AA*HOIBI=-7R
MRI<2W"2)M]$\(R: 0Z3%-<Y'2+VME&"Z+#N! E1V8+>%E\EJZC]Y9#E?0*JL
MYBQ5F>=T.G5"(Y?%?1D8S?XR^*V?OU[0\4 C==,F"=M[H$"R9A7? !I:"VLA
M ON+95@*K9K)) 5_58^=M'0)2H,(J?U<CJ5Q>PAA&R!3\/"L%$,HA%PL_^=2
MC6E!G]8Y* SA[UA\8NV+8NQ(@U\*X\U07?-(WT_6VK&T3Q"*0.T2U_Y">C8$
M[R"/;-#2\;>R>!TP.*+HPL2">@&ZV!2[FR4@)KY#+!QEU]I@O6VI.N#I*P^!
MLD_;YSF2*")P2=:3XX6 VN6N@REE>K70\J5^L;_ VR;:(T5^B?VNPQ<*=F]9
M_<_IEAWLS6.6A(Y7.A;WVWW^[V=4WR.]@?YW41I!LH#PA['\A41['NW^IRCM
MB1R;V8'O=H)?XQ5R2V@H$!U] OVOJ_ZS=(V$S4K%/=QP?=NQ$[,($=UU!XT^
MP(</]*X^#D[&@:_0GW0T_CM>+S<( 17S/@^=5N1Z^AD^9''-MB;F!>*+%B,W
MOAWMB(WQD&*SDG$/VG^T)"+,9U<*&CM6Q^:S^3$V#QV7F32]0YRQ3YM5.H%
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MKXM8K^"P%G;-+ Z3AQQ3S?'M,NDR^VS4BFD+<BZQ- -#&/%M;&C_L>&9;SQ
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MBVIC>EV1UM;-\!)Q:_+*4R8IZ7XA%I!0Q-5D=,LI24Q?5=TM&O=CP41K9\Z
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MPK76F?HKP.0CU_Q6"W9S2ST\"+ O$9=BF4= ;&;P';ZQI%4@I=U>:Q;7;J#
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MT>,W.:904OMT6XU9T&1KYOCM!G0L!]X9AW8-[^_\),IS'C#M\;MX[;T(E6[
MYGO,Q2B*T(Y3'-NMVG!KZ,J*'R&)'V6QK( NIZ'?L+++5H)>+%\SWH#%-E<F
M!3"MZU_!*U/U A#R60K$7QJ>WDH:V(_U9(N@DZU&MPY> KMW8KU1!MAZ@8#I
M@.8P$BAYN.6;C>WGI\L\G\"78[1VML>0L%[#9^Q-2D)*HR:5#33'3[6HJ-UC
M%A:0CY_19YUA+L5] Q$L$(K7.;<*+.%-82<51DN,E0][#/BA[,)^Q<"LZ8(\
M[4M=2R9^WHR(9@W-F,6JQ=<A!JNM+I:\6M]2A^V=/SG4(0Z;BW8*UC#FRVI%
M03OD<15O"J#Y]=T/EN_Y,]JL^]@RM6#C/?,M+\U7A:S72<UYVAO2AOB"1:]P
M&B%RWL*+,<Y()\:2-S7P4_5I[/V=\%8T4\^\Y<XODKA">MV=\_\$R.P'7+T)
M.1<-[9[&O,HB.%%T''4+&7 X1)I#T"5>O_-V4*--"PX&)S%3) !?;?X$H[;P
M+!AQV.J(VA[&UGMTQ>C)29[RK)/O;EVXQ1.0)IB9$.O,F2VT6 $ZM1KWP9;8
M@ /7)N^/^P.R3FB*^Z-MJO92JU;UV<9L/$+WXJ2VJK1,5 UI=H$P+<MMZ".U
MM<FY$$]#A!:@;FB3?U,<*LK;R<]B.!/WJ4K/\Y*M4"^?-#6^7 EY:F-+SV$4
M>;C^W!CMJ-$%/+]%;TNRT[$+RFSZRQ,$VO!9D)Z-.5$546.R'X5H'O!6/*-E
M7S?:6=N;_G7#?N6D2*=6<"BP"TC139'R8[T"+Z*-Z8R@>Z BTBU$<!\4[# ^
M[_05KGQ9<#-A_ML?GYCL7;](Y?TD:H45VX'I"4XB%/D4R1D/P<+'!;CG@$UG
MRO*3^^J[CKVL^'6*="3A?$Z@3R'UV"^D[U>LV5U\^3"^!B.W"8O8=>KV(^C@
M!8D5-*$4UH8*")&0U.+,,\%/H!4A6$"ZKWO0II=\_14UGH1^%N^#33$!$IK'
MTMUCH9?!<R*^S>$D[72CAEG/]?)+?P:JVBE4XSM-O7,+Q?'#OEC_;C@(X3A_
M*&F(=22,5U\:/FG5$F53>R.I::Q=D!$;V!&>)7&=?G7NVZ2S7G):T8!SG-Y3
M^\=@2V7[IHN\D]PYW#^DLR56X%\]1:$BMXH. +D^ON SS15(]V#F]^^#DI'\
MWU[V.6=Z'E'FX&N^?&S,E2(NZ(>BV7]\\V[8[H:U*(L]0^R)\K[I_#2Z=# 6
M8U;=2'0KR:@3.$$WL106591.BU'[59FV-O4TR0+4A.NOF"*A%\ *\(OTQXN_
MK#P=-D7:NG,S:<Z@Q!%MS(;M#IZX \+EUUA9=?U5$;M?C_D^I7_==>K=NOKD
MPR_K'QS]R_?[>X=^:C:_G%_[L"CREUEOS\YQ).W<_#\-$_#O%,DL% QB%4AJ
M#I,"I;:RS,46V'.$K0RW.\HS,R[%5V$I@L*2W=CQ2OV[.43&GE,^;)R[W/E\
M:,'IX3)7C@-T7Q;>.''LH^C18P'P&L0=GN\$JZN/LER);/##Q_[V"/^S905:
MUDPPH&P=6 .N(K39_O4WA@F'L)+K>7QQJ*YS<@-!1SGE"4PGX*WCK5JI%9H.
M,5U3T0/<( (8G@E&R'F,KQ"-2W1T+U2QO;O^*5.UO^MS\_:@9K]7/ZKV=-1G
M5@V=??CG3TOWLM=H+Y;G^E0\O3%#>GFL+[6=Y3;=SEU0M@38G9A<"VJ#@71R
M+;X5T\C[67803R%9A7F-_"N"5V#O&QPA[_$"50[NJ>-E$BFL%AT.[A!_P_P*
M]B+N0ME^M47? OD9=JA_^B"T%E-N 'W; *.K;GLTVP7Z1R5WXM(QLX>6?8/X
M_!D;;OA4[S%;EE?5=-YDD<FB"Q;?4DIYASB]'+GFD5KF;BKS'[^V^(D>JPA-
MU*O<^B,;QZN;JAXD2>9WBIVN_=WP([@6SA^P%;"9+JA7-K[M$)L,&&<V;IKW
MF'6,UO<<X8P\101D81YS(>:5X07*S^DX9"BT?< #I-S'MW:)*;HT2FO?P%/#
M4WV:LWS84T"!MKEH%/W^2W\_Y1^C9QXUM+(]C:]IM?3STJ3PG&ML.=NC_^_N
M.A4-HBB_['U]^^;'Q<H]:$B]H:&7FE%JI3!ZA"7)_K99Z2%=<./,BI],\ EN
M&ZVVL8W55Z&_4Z2C$VK2EA&*!;?29L/3;><28*B#L8VY$%[]"CYWHV@6<-9Q
M1O285$'<<6H^)=?H?5=]79\J4UD(R; +RLZ(D#/)TT?P35OK#8?4\Y$Q:W!2
M[K18)6MR*D"JYE)*MG7XIGEO[VYM#YA5M^72!B5&.ENFG*/N^+]*O\7NQE:Q
MJ6WHF'(U'.CFC"^;@PKR!.F4W.ER-TI\4?!FW@AE5%ZJ>1/*[GU_Z)\LDY^\
MF%6;23POEI4T7E1(Q-N>%Z?E^M V5J9D+M@0I[<*"V[E><#<ACB%U%JR^F/L
M["XIPAX.',O@FH-)168;C<P[&IY5.7D.X65(O.<00B'K!%1U8;3,1OG9'0FW
M'HJU[5SF2[.)W'!GZ$O,P[K:VKJECDL%_R5VE"8^A/^XPKAT<=8,*9_AC:BL
MH@^\ >Q-W8R@PR>J/C;]]:*Z)-[C9Y_/'-LD>G52DZ1CD*Y+3BG8^K@4R0MI
MM2Q+7T^[Q$)W"_LX;3P2PQ/5M*BG2":#H!>]/Y[GL19LT#_G6$"3T2A;,8[Y
M-Y9_U0&[HM))LKRZ;XJ4B^]7LI>ZL2T>QI#/7*Q]3%O':UT[1=*6G=5DUW\P
MKL YZ+\'H@M8-8 E$]KC?H92C!Y+S XO!D71@$+N6FA>!4Q')Q3AV;%S428?
M"9\IR +H&3,\Q:,'._*7H1H3G6=0,)]^>0.3WID,;^4@/!>(T\YU=PY.?0/O
M1O2&QIO#2WMGNFA,RV=;63]9RPZ[8>.EN#8JS:Y;'G[@:</C)P\[ZM*V[Q<3
MR:-_QVO_A/0-;CX73&Q:CA_N-[8LVJIA/X\894WN "7C'4"$JMMICTK:I7D>
M*SI2PJT_G#X;T<*S 9QH5*VD9$F\CZA[ZZ54[DN6[9^H*$?B@SN!1\I-J+2(
MZ04:9=S5:$0Z;G<#NFKBK6L5#/M(5ABN20]1L@CZ/2JXP$)(72,^QXD,'Z[D
MV5[?V]QY*DZWS@P^IFW,C(@NK*N0&UT.W)M_Z:?SJ9ZVOVLM)EVX+ZZQ1TI0
MAU8-V3?2^FG#%1ZR4(*.EK[]$8J32;PPASOU^E+GEAJ"1.51Y)<QSZ3EVC'K
MII^1D(./RR]WC_Z_52;YOPT*R7"3:9M(HS&MX0W [U[LVZ%DO<CFZ#XW5NZR
M!NL(&==SZ2@R17)+2'=T5#.\I@N<VF]2<E2N!YXL%_H9BGF'63F\1P+Y,,T:
M!,D&J)WP[GL?HC8 @:YJYD<M&%0>>X(Y%_KQ1L7/WX.*V(CK%]L*D+F_&C2]
MOCM,V%?8]=,=F\=:I?5"):=W4%>99RW%/8VDIZ]/A>=?N5(B0L8<0;/L(R67
M,;N)5@0SI>CEH570;IW+6V<9EXYFKL#(>5>W'U\LW9UP@^()TE!UJV8V''!0
M.T;^8)_0%WL]T>72E='Z($/PCL,[OKRLKWI;@CD]$:T-'P "Q;%_?O&LB5]K
M#6H1Z]TZ+SD[UV-6AWAW%12P#V-E,;:7)QB7H:/_=8M#RX]^>7FE<ZCO9?8#
M^/<BJ]E7/F[I4\QJ9<?>/,^:*8U3O8G0\=JN\\APO.$)8Z<(TD2@F1\E+BC_
M/!P=?__#%,F^3F4U%-@>GLGUAG=U+$23<"Y!D,;LAH)UWZ*B-A89_,%GNAS!
M&@LCSE$&^OX?L_22UN<Y/ALD3H;A/$#'(G3^EV^"DE8CI1/?>0L. ?$ZJSG)
MGKHM)BG2[,#V1Y[4"U+TOH+7_^/\96-3I#E6AR]MO#$Y*/]B4XPD4\/1]_RX
MY.ECX3??? @\?*.O(? 'K'[#0O2,5K^&5/.L^DH^Z5>&[0M']$6F64OKS,]O
MS7D[9NF_1/S)&1%.MQ@$D:@5H2<<<+;..R@F/E("*N\GT2Q'ZXKB([IARAU\
M%6EX@-PI3D)K-X1;0M$*[B*T),_OQ8D2Q8!/N"OT6S;:3Z.NV$49'B44VY]J
MW)&."$8/ZDK/C:=@[!$5\7RL\WXG] BJ4NR3V#<%&,D=IX1S%WC#89A:UDTD
M<2A.Y\P7+_[B$(![,I=N41^7W"?T365F?IW@R_/-)-AJ<@FWC6EB^-GW76P,
MTSUH/\C3'?%2Q"[H>O"Y:K7<C7NMJ3M)^$9C);82@>MM#_%%:/_PGZ &GX]L
M=9#1T!(CMO?PG@3CE__;#OS_E^&M%?8)QQ^_EL9S"M@U+/E]RLP/DN69XX\,
MY9160B\T]X1<)U()<_I/2+.^N/J#I9VYY.,IK[![&^/*J F"L:-X_G3W&ZY*
M6*=ND[H8%30GWA$B,YLJC4L(]9SH!.IUX9;P!FP,]TZCLZ?K&49!!?*_0L0,
M/]TC2T)?G-]@FKAFML)I'FTG]Q6M03KR;M)]R.C\FI= R]L!KVO L@=J*@%]
M>R,Z5B@.TX7;6IMN%<2J%W8Q'*;WO+G+L23HG$SB$<%S!5<92SI!".U::LC5
M&="$@@>6#HZ8H"5?@]0JH!_/1PW5E[" UB\\A<IDF$E%-85BSAT-[M-3G]WQ
M+;C^X)F6,QNJ,-JR^2+1[XPU\%X=AB1X/OGWX)F"T.+_I)/?<=MIC?&C21AY
M/-YP+T6:<S8@0^*%V]>#9ZB@G5:KEK/Z(W2ILN!J0-$]@N AKB_*&G754F:#
M]>"<PE-QULYC+?H$/3-=0+*5R+Z%[7_,/>8Q'XLW6GA-1D!)2&,+Q9+[7#/;
M2('(.DHZZTC,=NU3@8+&E]:SVEEF4 GBE?=Y+.\L(=^?GFR5K"&^:$).X(IJ
M=-UD(,T>>HTA A>P#CYR8 79?,5ZUK?7C99V:+3LBW(TK0H_ 'Y%2V3L6;PC
M(GO<M7,Y'HD\9>O"<^$M?>PV=@[3'!O/^?)W+M.=1B%X&79R^"_< N%E/0(O
MPYW!)N6\P1?+%PWB<XJ-%I-Q:'$HT)^9#!GJ@*S80"*=L6R,SK# ?$%Q./C=
M-^S<@2E2=F(U-!L/9.=Q/3!+D+JQYYVZC4DIRK6NNY)<]5\MYF6TR)N,.OI%
M/4K!G+>]YCI )3HST6@Z$;/O#55<2F)@52<ZF,Y=_E%:TSA")&LZ"0RV,M=T
MX$%(!>&19+XX0A=F%<.T,F5&T7-BP^ZMWGM,JKTF;7!6" 1ESH8'1B\H%>&?
MY\X#SXV629-T[FN6/=,&1"@S%1Y4< +EC!\'R[&3R%>>!SS<"N'UH$BG M^4
MM)E=WKOW[9*E&RQ-)O,F PC6:#)%.JK*46$\+5F1Q*9!,_KWO6;XG?S5_U(5
MQ-G5R0A'/F]6GXJ)7X]-D?CBKW0"F^&[D4X[=3]?=/IV_\%'4Z1UD)?1LG+2
M! ]Y+5F46$8Q5,!!U>&H$I%>(#2#Y$\H2!=R]4X,3@?[^B9PKS)_=+KQ^T$X
M"./)RYP#%]=UT[)W0:K$HFTFSWQYWW%ZBW65(X!U7 6VT1EK;P]P.W@-RE'J
MY 8XH+FK^A9F4UH)XG3E1(2,F]=4W6E3YMITA6>_R6[9:SF\^"_<'0W%[8.,
MEN&IU?U'I8X/&,Y5@+_=<'%:./1.1 +^?>,KC;UQ(<4#&AP7@&2]E *\H]%0
MF<H.G*9G:VHGY.4ZZ]3-!Q%.MH<=>O*G?<5*"Y]WA2:32I0P]0MB"HW@.4T1
MB9M.;@?[/LH1EKP"*U$&-DAO W5K8*P0?9*W#VL0/ "3<J9#@8))C4EA(7/W
MH?U;HO;]TQ*1\%H"@T%"J*4!^HG)-9!4SQLYHV=9X-^IN>[X44,IDY#ZLE@_
ME-=&F?VQR>DZIM+Q<CXY]GP6F"=):"@O3[\7'6@P>J'LO'PA.>RQ^\=+CZ33
M/5@(/[K&:[CPI!)?(04T'2V'1Q&?T(8#SP>:&DM0/;D[;?T;^'2FKD1&IY;.
MI8&0WO"<O]"Q=/$)Y#?&WLN<6:!9L73HP9S<_Z1R&KI5T,^)>F2X>QBC9.->
MR+I0_>D:XN'_Z_F4YMW&JQ<HQOJ"%5E&PB".I\*2E(EZ3OZT;EC%V-(52O 4
M"BL/=W>K06$7MBF8'V>3?9[%*S9:FDTN"$VJ>$9K3_/73 :/E[(>F57=DM"P
M5]=*1:-S;HHU_3PKOU)W\2K)@@;UQ)TJ;U"L2,<I<[?!<41>^3[[QA&,J@+>
M])%4?7C.%*GN0O/D6OA[U/D"@X>&:P/:*!<:KD44U7$*/2Q09C,BF)$8-3E%
MDAV^.:Q"M0$$W%CIEKOR"_%P]#+C.[N93^(\-Y'?LV2BWNOK02\Q*2\-OXI/
MH"+%%Z\B7CPKW6U?)294E-FF>>TCHCX)8?5/D70B^0G4@=U5_RZ+GLL(@>G:
MM)-M$O\=$'/^'L_39C^P*%+M97;CE0(B!9U$#N?DH8-(@&R*Y,*5L>IXT]&N
MR6QB*854.!(<%.&'P?V;4 ;==)@U4] V9@/5ZM@C;>C0?T7$\XJR_L3R]J5!
M6_*CY@V93'KQB#O<;"@0S]?1^&P;R2H<1@79DN70=.V$^M+=6SKKPO/*YJ,!
M6?6T@JC )*-9&*]]#$6AN);M.KF;T%S4=H8Q1_>AQ54PT^1+)OLYK6V*!!8K
M1YO/89Q6CP6 <IL(TQ.Z^=HITAO]9HRO%-K@1[&RTMN:#[P9..T&2%6>I8\Z
M3RX;'G##>+*Q/JNXH4 M^$K'LX""6]\O^_7GQ=KPSVO_]UMD_].6V<[)5&,'
MS8YW6-@;J@\8=4:?(X4T%W$X>E+F5J+P5O'5@3TU2'D58*\_S'&[/QSES&?L
M^SC@BG;VB+_^;<%":ZO$8TOBQI^>B)W7<8KEG-"GS*Y_YZ.)[$@QT'9W?"Y=
M-6+>3?]4=8A94)V@:IF_Q6;6#HHJZ_#"%22\!RO!'9OE\>-9!H'$ ?;O\.4X
MX4Q#.2N>E2>MGVACY?=5YD:O[^;.Y+XL(Z-\_F<1!6AB]D3,9Q#@G,+P_6//
M,L]3/SZZN9J>K*6!I:(1*VSW>G!5QS+E=I5Y/"$0JE5C2CC?"U!P#V3*N0'H
MC@ZFZ['33/\NZO2!HVN +U_O]4S'L:(Y;7RYT3G18Q[+?XKTK0HL*B'DT$J(
M.OXZLYTU1^Q<!<>JF;8?-343(Y[ZY-T>B[HD;MR77//P7#*R'K/A$RGCN6.P
MCD4=$NC9LP?;6J3\C#'Y,=YEB36O=<D4Z?ASGBU^H$?B"Z\$+-TX-H$[5$D/
MO6!O!ZV37\-'@.$6O!V4EL,[4,T%5L/GWM,@6$$C2SS PP]1SR&JC&UY".5D
M,2GST _9"U=N?6@Z$2 7HGOH;^@*MKED"7RX6YI01?L&G$2/Z^6Q;J#HC$XZ
M"_\:#<]G?'4/],YAD)L1?A[##V'E'3?ZF/&0Z>6!)-G7C&,1J>F,MN B43;!
M&79RWC3J]T@M1KBN\.EN>.M=_!B1="YP72$KN5Q&LZ^3.DR_=.V3P3BA%Y*A
MS&"U>$79(I2<BWLC#\#/HH+0K)T;*Q9;WF"W4VQXK706IS0""<VOQK?>A;;U
MLZ>/*1N?">N4(ZK)=?@^\*X*/G>N=G*--03TB. "+^'%.?E]7=5)9+# O(F%
MD-'&Z7?I5W#,>-^:SXS[_@M9YSQR=;I.,A9Q88IT9(K4OT"N)8_D(2KBDLP[
M*LAGN=8+>L=:F3X\\T3N,M2KC9TQB 0GL>9(U@BM[?2:0J[#S!%L WKVUYA[
MOR0[FGR:R&5I;P]8O)HB)6IZ31%^Z^A)6=E"L C3**0-FFPF'0]^704?1JJV
MM\0N-ER G0U/14-]"Z!TAI=K KXI!='3'0*W2.>]?5LCVHY*\3DE1@M,KZ+
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M['> K'P&I5#1W+U*#2X"(>80G3A-'FO&ZN55O/1EDG>S80NBMUF<)U0 VL<
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MO9W,%WB1\_II,R?\$KD"*9571HJ%\\@E9NBDX^7NY'@1]T<@B36MXD>NQ4=
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M\IC5*G<=6H+^A;$/VUJ#,HO0D/37)J! :YW[]4KE5666+'U0W,--90QLHEN
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MQDSV%I F.(P]W92]# L#^CEN@\M=]G0T>4;B6?QDZD>L^:;2_6IMY))WI\B
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M%O&OD=MP:WPO "?@5^&6VQWC5Y4!8=O"E;&@\7F85Z^LY,O#80;JF\PFYX[
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M4M@=E?9[@3GS^]T@Q69\6Z\(QK;0B,TP&.J_#"T;$992U#]@43?A2Q$EXA[
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MG?MRQ>+7.TI,'M3#%>9*;PYD/;:FXGS B D(HN#O/EF20UB1SU'P[X_*0,(
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MKNV<P >ZTPW2?_"L6%11#'36'5+:&)&GJN."4.KY^04I0N.=0,(]#T($\7E
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M2 R/RO5N44<]4,V^G][UD5@<PN\-)JQY_PC[V5KF8K;X@1*DO<2[(/EK+;=
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M;WW 2A2MK(8GLD\8A-VA^PCE"=C.?+9C$I;7L5(FG&SP%[!\%=:<>" *=)
M(KDF$4(F:DBIQS;B"]0\9E3@*2""S]E7[%6M;%J3G)N28;S;:K/$=*4$F-?^
MSP\E%K>B5U CW&%TZ>K-MBLL=#JDND0-@J_ 3BD^TG_!H3JVF?)-*\6,19-7
M\X?N?7!FD%G,0,Q>1HEW:W_2G85E5V7:MBFDDT-B^LZO\E)</Z86Z$]!/](7
MT>_=X[PG9B96NEIN;@]-9Y[MS2?:B-2#N8(RMA=6BC+*6FRYV=5YE"%R!<.$
M)9;O9?V:@\^D[P!D)MAU>,N'L#JBIMV82U!AY"&JOJH(/_B^[HA3F'KS\'ID
MWDCZ\)!+RIW@&!;C\X6137VIOU_,RES:S_(;.N!J><;6#%E<T# ?I^:U!P;X
M&ZZIUI VH%\*Y\3)2G?TKO&.9?LJ;$S]D \'_-=$[S1NWIH\UT8:/2SL7Y)J
M-;25.2GHZ[ ;)7EFP_VB1MPA*G>7?TAR2MNB9?4<$_O0I6?:DMU7(Z_\4;]9
M\2A\,?JTWF[.5>R@[E7E1>C+(PPT\366/^ID_.:#K NU(3RC_!.7].H=5V/O
MBQ[3SAR%GKS^1*G<(# W.//;PF?/<^WGYB!O9)[EH=S4,BQ"7M+*]D2]>?C)
MJ[5G+I)5RW3$'K'E@</P*0UI4??_!JI?R%BP;U(QA__@_K63,F_?BI;AI.N@
MJ((L&AT%LXH9K-!"\626M-+XJ_]WH<+7O"BA \M1+)(=1"7Q[(7)LF>"\4LW
MQ%5%/(9N8[9Q/\S0*1#RYLI?NP&8)K99":<=RC1\-A6>R+'[]LLI!9=\ZY3J
MF-/,=G,'!=D(V__5_XN&-(7E]Q;9.^'2K-./3PXS_EOUZ1;LCB'_Z1?'WJ?3
MR]#%-*3T-AE3LA:="KO5_7<HLXK <L] NM-Y\F5QH+CZ(]#<BA>):K*.[AIT
MHEA>0 3Z[B87' 6!F5LV0+G$-__O(U"0VQQ]N&XQTDF,H:"WR;^7>*GH^$KT
M@.2\XW<:>YJ<-CF0]0H^@V^3Y?*G81$;D;1XIT"KFE'=,PUKZ@:,Y7/%2;B=
MAJ3W_@_%?6[59E9->?LB]'JI8K-Y^9_M^K;D0+^A<#0M!0A?PL1>:,3:KB%M
M:Y2*S-.%HE=M^Y]@4[*7[T&$*VM+5LKS,FVVVXY'_-.0RLN/7FN?F9EZ?$-B
M.8<FO27<+RWX/[2]:5036=<V'$2-@A 9!&1(5%14!)11(28H MJ(J*@H"%%Q
M !'2-B EA!2#$.:TVHHCP0%1$:(-2,N00!)(.X* 1$$SJJ"(5+6 )53"5[GO
MYUOK?;I]WG4_/]X?<9&85)TZ^]K7OJ[DU#Y]K]<JPL+]MQ(7AL^-)5.A_C;*
MO&ZWP'")2%]=>5W;17W_1C>^X8F2&;!V)XZK/H"'9B%QH7 U86["/<WCX^>N
M:4#<$9_-#^ T2#QV'[&'\S5&9=V3N >8XWDHP6<3LJD*;>O__&S8.U[.]7MN
MF?[VW_CZ0O[/\36[/5.>>D9\&7RV5WO7SNW,D%JY-J!8HN$U4QEF)1*ECG9!
MHZ+4@>>$;OY]$L=V/-'S:,U$0>0]._+8&.'O>#C)?,&O_I;#='WKD%7%OQGM
MJ0_$B'K=OE2/T2W\E;9W8DH,8$G:N_"8"5V1U!3JSW$U,2^*V!"\#P8S+U)-
MQ/+\'%"QTACQ.@V^CA'?#U ,_2046SI(N8H*O@GR7/(3'!##=(=\AT4?7>DD
M)*4Y$%,\L5I/I=VX2< Q1.3(G@WDB-NJ.= P:R%]&K+</W- ,Q_J_]Q?.M@C
MM>I&]<OZ!BTK3_&JNUS;=9 GHOT3<:<J8QKTD!1AN6;9W.!FS?Q]BE)0X0H#
MT'A<7O!O<7X&D6/4\RTN41?GW#*X\UI*FHW@VY*C/8M8=Y',M1)7;_):Q0==
M413#2+67X2R#=S^$OJ8;9]S5^:^(W(#P+<,V"-A:8M;-",!G.#8ZW R5?3*?
M6?:I_A9LTR]21]>^U=^#<"H&8Q4W:+.1?!'/YB46.Q+5X^2!DX-2NY]G_'6:
MU_ZOK,AW326-'7DYRB5$)P=E.!A\RPO;?K^3\AJJ;@N-NW3B=A0^PO)#7GU/
MDR)=48@7E9AIA)(D8-\5\F'SL1F">]NL>O\."N],I03-HA# U[3.2=RH'CR4
MXH<O1;,8=#@8H[17B;1,C;^08T"J16F=0X[PX3/I<CZQ?^'HNU&+-M\4_(^K
MX8<46::D][VX4%4<D9Y R@$M&ETP4C7^&!B],#!%D:JK*$]GN&L,%V]H/D<U
M!5@MEEY(<Z"^D)HQ.FR$K%BYK3IDWR1.#R^O4YNP#4&YT23.$G:(H+Z.#WH
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MH<0KPT.VB96/H#,A1'<DON*3U++3;<T>-$C2>%A.)<9(G9'RNZ!@0R5F;PA
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M^?BR(C7F/Z*K5D=45Y'R+(16TM]F5G@0RYT\J3GRL"*:%MOI+G-*1ZWD5,)
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M:I.A_NT%VOWZ*J3FI>.$]P'>1(-)G+Y,P!E9PHC%R)6!M&O;8_'B>^8CA[E
MOJB7Q[VAZ;AX@+($'KN@FG"#OK6PV1IKF)BE*M17U*-V/:/M0^T$Y(!]5,0R
MY&=7PJSRK((#%1C+;%7Y_FKORB.HIW'S350VTGR8KL3^=(H=(KO$PNR?$(\;
M^H4'1X9<?#H3@EYC?BQ*36LS/%U]5((&5@W6B[/?;[BPM=&N%$C>@6O XV""
M(6 K(,[6]@JV .)4JIV7H/X6V4=,M*7$3*Q!F6)TD:ZB'%UVK#*F7I9#7K71
M7B&8B14"[SC;3 N*LW9?^3ZL4AHSG"5Q;E<2$%N5$;SF^7T%UZ27%H'.1+[?
MBJY0TJ><P62AW^^NOM"?NGLMYO9N?M&4.47\Z"CU"#V/2,D7?(O0@>J$:N>O
M2LM/3'.(Q6*L5=J$;8-MV$7BYH7(L-5@KZ58848S!,Z0H/RK;VY;<@R0+YLX
M<]CX1=A,HQN1T>L VQ]BM_9Q]&B%/SV1?TLC1Z8J J[$"#W/9:HX>99^?'53
M)>#P=F4-D#/0YT&ZL+LL7S,;)<R8A_>!-.WRX?2:%(-E,B&)6/OB)I(OT"RN
M?>G&QMC<HF\;<2$4E#$2.#,L"HF;>[(HD6LRN_T^&EF)7-\7,M7F#U#A+U0&
M304RG'",>$^Q\/X=C^PO02U![ OW+?O'H*.ZBM*?,JL&5^_?'" ?LFC'*_A%
M_#F)3?AF9R#.AKJ-W]#9Z"*G&@U2YC>%>PE#9:)AZ_K[<(Q[ON*[!4<?26GY
M!;E"7IZ7JT0H#L@1U[]^\GM:3QC2A?TC8'Z+DP&2'P!]RZ[DS0<*J_20@)T]
MB?"MZ(N.N3!MO<0U_""Z5G%ROSFM8\3)>.&I5=X!"[/*V!0'W&C02;YUXU+\
MR=&[0)AJ'PFJT7A&?N97][<%BU%'.C$M" TKVOA.]]'" U\&UOAKS/E9U($M
M2-\D+N<[S)G$77D9\Z.NQK=^F(2YP,0NR$ZDWXX?3!J>V 2D;(46/QC_<"95
M0<O@6-3\57^SJ<R&,!&8L"9>49S;?<.[<6O#DE\-8D2!'I?FGVI_\_(ODE@=
MV7;1E\W:"QT6><GT "&M"_6_C@0(>"2H_V2BC4\KT^O8#1N3G1(WMI&_,FH$
M([G9=F&P4V$.JSTQ*E!<$+P?\&F;9ZVIO(/:]]0.T5I#^S&Y$^6B-$C9B.$X
M;&(WTXC!Z*H-Q =H7G6$;\8L]PS,<O\&I+)S7 ,)K0[*+80G5^,(Z5\3B=-@
MF9#+JL>\1;T=BTEYX]!3>R<FI+X\AS>3D=I=N\8G6%(+#E720R1N/4A\C8M7
MP8J^4SECE\]171AKD6^PK*7$%4YB+?BCNRIQL(%J+-N].V:,2>AD$.1!^H/4
M&KS *8NDQSAX;;!",8QL?$QB\=PEY"#527@W?)*N5.-%\#TH PC6S'XPX2('
M"]Q *P;E ?_EL<2['TOFP^V9;A5/*B/])1K9'<"D+6(>Y%YWUX8NY%ECN37:
M/'RM5!^[N*2LS;IMD8_>-)M1_Q&RK3\BL*8/>3BDSA\95M"1<"F5HS&B%^ZF
MZFD,7T_B'DU''L>SYS*22".;3[3HWL3/2WS?=/A'L!F8Q/T509DWB7L]7]LX
M[':Q.'EL&0ZB(Q$:4TSY^*CH&MM_4>P.%7'12Z8^(-P%.W*K 'O5U>[&\!N
ME="RZ7U="Y4=&K80U$</*@DV@-7.CC&$YFG8H*"9(%T[86]XY9+=UW<ZK_8-
M_C:-F<S8A+"T&_2ZJ,LJ72=QEN&!Y5$</=[4&(YA3067 *Q;68I<5X(B?CY1
MMR>ATF2GX/<GROOR2D,SS%VNQ*:*=I*\"U_P92%=1ZS\TU2W"GH[W,(G&$S%
M&-D);@_F=S!.W&%X5_>X!65PB*-K@D)AZ4-Y94KSN+2NR@PY^J1!8_0V?C?T
M:NHTW>CO:;-04Z(Y8C-+8O(ZBE_SX$KJ3? 0-ZTVAII%(_F50UV;.\)$_KXO
M*&8D)&23*X&0KJ)9 7O3=(@&$JN6N92I%(/MCR&Q:#COXF>I06>8DLG3K**:
MU7)FD::6LRASCX34L[(;C6!/$K*YEIXG=>Y(T%%D:.8BQQ/H!K;H4K8@@%3@
M]JB1L%"S'.Y. X+Q0IHES^Y3[S>!C3$]K]CS8%W;6Z=FS 4QR]1G(-E$@)QW
MO>HC2'1[%M_2.U>[2<;)>'LE27> /^LLTYY@CO U"R,6!WVW&?L#-\X1\(V8
MUHB)0$."P"QT#EP="&%I5'/%PZ_S*%_A@P('JKL2#L[0.00]Z&]^'__(H>9[
M;JU_V(\ 5SR6 OM5J*B9)/U&&C=B;5+%H'0:-%9;<>1!0Z@P/#JA=/H?Y7H[
M&!L64A9LN2-:GF=Q^6"3,HVR#@YIO6+?&N&,>%R++K%!KM[<$\[8MB6.$0QE
M*D.R1YJIBE $S=9(87RVN3#M%$?9:V%S_>?EK<D2$89^"Z8!^#J</8G;42[2
M6Z*K&K8$XL>8R"U&JIR-F26C!-JT=@58R/."W<\<()^X!MBVFEF6%VD,8O@S
MJ773\]!8HA5RNPJYWE)BUQ*O(B!^C8E&S@MN7![.HDQA-DMGPHL+E5Q]X*NB
M[1(7B?C67-Y<LH!D3#9SH^K8I3=&<I'T!-K4P<,<P@!E.=TZIL0$KF_;!72U
M)&,J8_["6WNOCUKFX;[3%3)1T.L&Q5C6[:AD$J99LWHNIDH*R*DJ+_X#Q@8(
MB*Q@;(?Y.4S[P:>O8;,I=3D,^MV: ^_NV>%N!4=@W(>1@)RN-N.>Y"/'&JTF
M<<_FI,PQU5'Q(;X&DXDOCB"8)V19M?#1%UO_IS?_11=Q"CGXX7U0T"N*(\/Q
M80PM1S.UL7["B<W #,6\]J'3T]?"9MX?SV3C5[<FLU#,#*;S1T)YQIA\;H/H
MDSC7'9^W;\%C:EJ *71M<]H*A9/&FHX-X*NO___N[=N'F6ZH;G=EW'(Z<R5C
MT</[];7NQ<=92FKFO>VJ;#IFMHLS@+EQ.F].<..NI5')BAHUQ[6=L&L@<RP+
M.99XZVSG78;/;0X16+6X0?$KQ7@@^4M!KS.2^9[B" T+*@D";G'BUBJ@X [K
M#&&02F"N9I"JV6UM$RJ"H(]6R_"#=PQ=K8>_9>;RNC9NFH87[;+5*5)NGZ53
M^_M/ZL.^.&#X!Y>S'?S!A42T^N*8\:URZJLW8?GVP_E4P]I!H[O(D8'00<U*
M)/I6^9A_!B<B%M_RS&I@KP=KKV7/ U+K*BPM56U[Z]#%/ \XV6O^>)\&*]#-
MLG$'VDP04@$>D[B+R\:6+=$5@PH0Q13JM9=0\23.T",3_'Z-:X94P]7RL6N8
M&9K.@0,4<>5C0?E2LZ:'9M(U4")RK^OX(-)C2%[[%U<O8-K^F?ONQ>K3#K[P
M)GK]"!FD?R(HY/Y6;Y(M,MQ*J_9@E]53%B!"2"D#3Y*#Y!5GJY%RN=IU\055
M8:2POJ?6XG75Z?H/DSC=@?8/[L?C'+[Z;=BL*_09 SH2@_0_=3([*7-[6%EN
M'%/D>7M MV8%ZN$95Z;B6)<7/6]2A?_B)BY6NA<K.47W2HQ!/<3EL60+*#!I
M$$@)NYC?KJ61DWXP+]0?3,G^:VF4]<AN;%HTE_:IXD&8KD@LK4?*5$^>!-4
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M68T3ZCB<0X*/\@PQ;ZS8@1*I&'-F?57-(Z [0:(G!SE,Z$Z.[S#!!OW/>">
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MOW,_HDJYB2[OIBPXT@&0)M9)Q*'<C,^QKAR+0<OBC,VWM8M[T7G)'NA.&53
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MKI)F#B3Y(30E>SH0SM@M;_M%>^^D-[P+"BE(HW3]_T&@_-]R@><59(RF9OK
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M3XP9+%EG5J?TGPD+*[AI$:Z;A+^R&S-BXL:Z6T>F'5>:A5R\20:(GUF DF)
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M,I[A!)JGI#QY-@TC7@[SX=Q"=4FFH:G60#>S,N5@,IM&;^/H$9Q+A_&UC%.
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MZ:E8XWM 19U<6I0NDGE\Y"O;-S37DQ);FUM>="9TX[F!NMD3I$V/_D3>NND
M&Y'SMY=1/_'_'(1>0?<='Z/$$BC1TAT>&IM,91ASUOA/(ZQXT9M"QJRON;UY
M&?CY=K/6&J?K(?*7C_=*T1J7S0.BK9-$QC'1+T?'0F*CVSM*EQ\NE^--6L5?
MM37/%5;4KJ',<"DCVQ[4;S]S>],Y>[E/^8;+Q2AS'EV>< 3,215I5(S UQ"<
MT?*-P*S0Z@W*/29/,XR-?F-QE?<]F[G&73&P?1UJ*^K<=_R^O7MK49[WE@**
M0+TV70\>TVH,#N)2R>1RSU_]3&W9>\^G?#QO(IS%;&GO(1?SG(8#&X[+!)*D
MH"ZZUE<\QK%GI!V]!5B!"0?KAZJ;'$+T[EK:6^K&^?:AK');.6JP4],;NOG'
M-8J ^_4FO8G4?RJREH(3/N>;5]4-S,RY7OO!.=@[-QI.-2?8_(S2W4W!7AII
M&!X@,N\EPI8( 85K=IP^#K.C\YT[)&^V'^S(XB[C& MR3+1YWQS]9]XI[\I^
MRT]0DWV/TVTV?P(6\9EVG]":<T[G^&[O0]K(SNX-^&SF"DR^[+)DP?>9BK?C
M8XX,$2Q+L2'[I)=B6A=GR4Z[UIGD;^KI%!GZ18Q60/XQ%2Y9RSI\(P96AW 4
MC&%4G8]&J@=?;Z2,($Z_02Q&3TTD,01^VNB%_1=M?I&:+JW?*K-)>:P70;*P
MM:VFO>TW-8TH+U=\^*+KW>M?50<UE0NB.TX!<M)RKRRD^O[3#,7K <$9K"5S
MX4K%#:^]OX8Z>X!&*03SBV$7+\MC0R5E-1 09R89;'.8WKSU_!&Y#3?.!5#/
MY.8_?C$EI)P?O%P>;2Q_<V_8C6!<#QDK:!%D=Q?']LA]HB@VH_&!_*=U0AN]
MC,C(\&+\ 5KX\ZG&%SG"B,<5T-EI'V%20=B!#/C/M>#9GB=,L8*B#BT??O>P
M0MP56UMZV@(&($%R'8C5?8+QD5<%F)_T&OS)_L-]EG8>;<21@@O3+P_>E-JI
M-+3Y;8Q&A''=($J-.SVJXUDY2$ 6A5HAKF<VUCZ,+@K13FWNOUX;=>TQX\X>
MZ^^1B<_OKX/$.':5,+H*<$XNJ0?:!^DIIA;Q.W\S8KU$!K'6PDNWBUH38*S/
MF1]OZ=T<VPC,MINOO?"ZX#B$;92'Q2VT$^\DZ$*^,26MY9.YCXIDBWC=ZE#.
MC%6!JI<]$5[8IQF4V-G1:/VH);GUP]I,CSE.!A!FXW[;,MR\C?WH!8Y/U)U*
MV$"KKJJ22$*]5X5A-N*DBC"WZU21QT>^JZIKL^&'$TTWI-)G6DE\;%M64*>/
M7-(OD4WVM%A?DD-$4K3O.V-GND-)F%@9;1NN=;7>+,DLJ>C]IRL$ PNV=JG+
MW1?QUQ=X])LX2W]I/TJ+6*=^B&"F(U8I]UHR<-:^D_Q/IJZ&$&D.V*W ,N_#
MY(K_Q0)'"LS/7O* Y+S!1W1N_XO0W AJ 20!3<71U\,_EQ)**_ L?V#+M+:^
M"8:W&5@0;8U%BC+%&DZ>K5X&8A6D%O6V[0IL#>$\0,HD'!'@E((;S4HDW(GT
MN3PN5NFNUU+41( 5.-Y6?N'F36-UT.A6]$.I-]?5&M),RE<;GZ;B;3]TBPRT
MC8:;.<O4U4-[!CAA\>P,>28>6AH+(KYK:N;D2J291FBL$6-V Y[2O@MO'^HT
M]'YL:M&=5+ULM.0>\$"!>"'PNF47/ORLM'5W/>P/9I_<WHN@S7JQ!L3@&XDV
MZQD#LY)[N-^9_478P=?=BH_QI$OP3G?^'[=1FGFZ;'KR&=7K;Q1DI3%2?'-V
M1DOC)I^T 9%Y^6AY>?'C,N(SGQ!MRLC<:!@OGP[Z5_T.%#O.R/F=W+7GP/B/
M\0AL*E'!@J( +5H!5S(.  MD-9YU:E1G[UQ0O[EE>+C%OH7I=9AHO:2M"9O[
M'ATA'*O<:_#S[/M==N:M;-Q-PCG>C'2'#X(4)2B"&(Q\K:'+CZ:/?HXJZ24)
M5:+/W?Q8$&:Z*7"K3/?^K3"E0%>H]<441O476MN9-ZL24B=<1!>5#4_57<?W
MS5;/*$#K5#6?\D8Z=[ZVRM259D(?@%>=/0^[6@LF<J-'VV?R<\+#(J-#P\TJ
MPDWMMSGO.UOT4&M_A]LNS?RPYP7PM!58."=CS  R7L),H>V \72"+3=N%CK#
MD4;IQ@G<-7PG6&/: #&%< ,L:<E? W8T5%0TU#&"Q"ITI; Q_;LYEXT+N$?7
M(_^B ""1;2+!W4 F43YK!99$K,+P/$,"6\K@,V.6=#:KD[XFI0HH(ZL%,?Y
M-[A9<.9WPG;"^0TB/Z#S#EQTG+ACN0*J$ZS ),H3R*M+I04&X5[AB2?!F%LH
M[:&ZH,/^J*EF&[ XB6NW=M?0L$:.6-4TTGGMV8KELJ(KH]B](9PZXL_PER-?
M D*PFC1$9,GDN"N]ZEUC;TWIVGX)"?>"B+QE><]>!SQ>0!29(I.9EP\Y<.EZ
M$*Y3+BC1#W43N<UZ9E(P(981?Z:HH+P$R%OYZT"Y+$QP]RT,'!4GR9&.NR1_
MH*X=FU;2XO-KU, ?W%+'&)*$U#5WZ,@ "8Q;(V^XH6&/^-,*K,XZ2T*S<8*:
M[G9,JJ2\H=1>!NO)]:-">/ :[TFT+C%ES#8&JD?A -^ WFB.FAPH2P<H]@ V
M$75:<);1AC8]+,*/W#M]6K#DVR&A%)UM\49<UDVT!3ZH;0&IWJQ+<(#(0!)/
MDG$U&/C$(OI1+0:H$6^;P*ROAB/0V8(.H"Z[@)HJ.J"&D!I^L-<I<_T(O!7.
M)O.L9W1>$LZ_A:)#<*_-&7 $1&EU";;$R4[9E*37Q,-]P8W)5%MH*_X!1+'/
M$*N:RTRKD"&7+0!)M(VG<'_OJTOV<$F.BS=X@' 'R!L@\F73!/"D9C3HSL1!
MACA)0(4T=9,6C_2FO$S8#<6)-0Q'+VB 9LXD.>'X'0S_P=HUJ/7\AT3M6SPG
MN5[1[J4P_ @3P9$78>'DBAKS%#UM:,>2(^'"<M%<%K%E3/$@00ZP]F'1Y NG
M8Y6:)')_S 3XG+"3<,A?O ZW#NKLT(.#I$21-#^1@CXP%RXGWF +[)GUAM0*
MK254;&-POCXT&KZ-3')M)S'"=TW8Y#>!+IW$#2C;9SMPZA^6::C3H'2K]K=K
ME/5P3>O;.EC@4_Z^I7W@M1<75F",5GI0=^KZ0&"Z4Z(*1:$$S&L\XS04".KU
M,ZV(BC7FTB)+,0/JIXK6]Q+KHBOYI_4V2S)(O!DR\#Z$5M/;O5WJPUFF,OP=
M/6@W:"U6SV$\X62R6#ZD]G"O-I^ .@&]UGO2YEP_S;6<*ARK>[8SV"&4FHRI
M)?(04K"3%FKZL _URXI8XX1/V&KK9'K(;$H6Z-XJ1DIHM @3(I"H8"OV2/NC
M7+?'KS@EB?.L7MDWKS0_3N@9906""B::>ZC&Y(=;%_^+TT @/*.Q,XEFS<NS
MEFCVWHKY)D4C9NZYOIRC;_V=3[T%K1HO .+;[#V9X7N:ZPE6%:4IXJ\MTG?'
M. $>H"$<!E?R#1 =>N)6 W3D".!KICUS8E^P)Q?#2>E16*T)=^ZEK_:G,$"V
M6;KZFW\^RKSO6',3GTE_BVOSC_-M &\O8C,L7)83?GL,B1PEO+WMT(=B[%3L
M#^D56,3$M[?[QW>J[]!LM3N,8\[*B:0!(P:%-"8%/5$JE!2*":C)[6VE>*C)
MYLZ3Y:)"_%ZF]C]DG3"E2(E0780B'8=0+(SQ&^P#V>/YCA@&;FW U_AT.#M'
M4%X)DC-$)YY]&6%#C#/B?CKH?*L[U4*7>+ G]:M QO(^0^IPSZG$P_KQV%*1
M,4#,$ID&\KHUVU_CZYPZ7MRX&,DW#3PE[I7S!R[1N:[1T*>&'$:LL)&R>V0%
MIE;<]FKS4^D/"1L)6R"#TE T9DADQ^O">6A74/E$!2@3>CU[1ML;,Q)67B<T
MN^V"OQP1(FV>KH'A[75]?/_R+NFAG^*U(H/^:*E7DP'K>N9&#]^)=D%-LO_J
M%!D,?X,YZVWHB16([0]4W@SUWT"4%J'!37K2))\E\U14W T^!3EI$U"*/SZ6
M/!1U0 *LYYO6GDU?_)'V'0J1O3+R\&!$Y,05B,Z(G+;6TTLZ76,S_U)V^DBW
MZ)A]IYQ6ZW3K!Z&QO>J$SS82R2+>VK%_\\8A;:>'Q<%"JU&KD,6=-UPZ[0*O
M-7]+O.(:-;BZX>L$[Y@FL<["P[2=,YS081EO4CLC<-IWO#WU3\*/]4;?I7'O
M;_2#7KQ/5G4V!2 II;VF/+..A1]"+!TZ$[+M\=-@Z/>!M6^V[OR&OM*9#)M/
M-T[L(83SD*I^[$D?=$/(RRGK!*T^5%!8<(/-+>!S$^6G?Z!2PY<56/09T==_
M"H X]O_RWND8B!HQ/=\V[D*_[3>YX)GR^1=K.?N.DJW@UL\]U_9156D IXTH
M-]TL"Y0UJ_1:3*_ =*=SW^4_Q+V8F+*87G8X("GF&9V\Z *#4WX8(2M-_8TM
MS<?Z3[E!A"V+@D#KA;"/#YK37!5KR,+N.U&7FJT:W_1+JC-M372_X,'60P[F
M*4JW*O[0+A(K+_[SE/!D5S1.DV#$BJ;>9C]J>-4RIC\H!6(83\)JARRZG,5&
MN3N#I7UL-J]S.)P+ $,<M<[OI6'W-U\Y2(+-V]FV!FCTUMB6QQSMM>BR/3/0
MN7B]-#P8<?R= +/W[+U[/Z_L;IF*LP%-C03F#(J*W\2;X(#=O99:-<LF83Z.
M>26?<-6=?3K^7L=CSJ[ SDZP^R^^T9#BAL-B$2GS,T8=-I82:+"+#WD5HEV@
M>/&UC^AC?,F%?S1?[O]LOV^30O+)&["IB7^Q-BHW.8BG/2:/3=\1*6,^4!^(
M0N _9X'$(<92#*-9K==BQOSH"BS-[D4%67.CMEMR(76#,OHZ%'DHO#V]"N_,
M*$,H0ZX'ESRK0+FV,>UW U%Y8;Z^_LY'@>NO!"ZE5M4&)_2T>YQ&P[Q;Q+I?
MI#6_$8J,##J;#:>(5=<KRX(12(0YP7:Y\L6DLP\PV)WZQ+._QA1SA"5+DSJY
M>R$EJ4)Y_?MPY5]<!5BLT4UG!D453V3H60-FV25?)Q9BK6;E.&=&=NK %:=#
MKUB8[2Z<V*K92F8<V[+]M?W93&.V\;BYC,@5,B\)[F0DP 97]X1)8#M8;#A$
MY.D!O^Z5WBJ9]$$*99NH,[U6.7^3-P6[?]D;]E[]5CW<&8A)M\!JXR-=P8U9
M9B_L4HK+AG)LBK,J\'$GV#>)GPR8QLC4GM]Y%8@K^P/4[TI-#/S;CIEQL05
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MD([P6$[!(::0<XM_=$QA?*OW[L[TZ4XIGHAEGJ9";1;LP)^,0Z*!A[:#OSA
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M"\HKC>DQ<HO-5$[AT ]0_C^LJE!%[[\!4$L#!!0    ( ,1Q?%OP%LA=VZ(
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MVZ5>PZJ:%(R/(W8Z6:0^PT&01L[HV5>C4\SA))XYGECR6_JM&N0])B4= _$
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M&1V^;Q[7AZP#/>9)B-V+?^3SXXA)^).R8MT23:G$EUA#S?A#'J-@/LOV-_
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MXAEN4B7<:^K2K6Q3[0,K]11\O[94?$1!\DB^<#$UDW:!Y\H.8C>^#N2>:RO
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M_$D^57C/'\E!O?XAX@V!D/)>8I[!N&<51CY@%EMNZ>F.8E !N1@.66DM:>>
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M9B;DMNVR??CP\=L&S-W8$!OV3Y(QL9V((J7*$.I$:\B=[]EBHPMM9'GUTBV
M>$%[&@')V^O9A*OBD*,"8MW VFP?WDNYSA:N,1<A<[ \R_.C-PGJIAOWJ$S;
MI\%K"0Z@7(F2%[!Z>%U6H"4#B/A1'L^=9FJ$&AQ^%J4\9!OT>)KLLAPUXY.
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MY]9>D2'6OG[?-=XET9H6K8-^ 8HLYEKA/(Z-9 5JOAW"F(85Z#5$6/#:*((
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MQU^_&I@7/T>%50Y8YA[I$RHHIKB-HE30&C<^SJ(?GC!+R39#_WD])_?PJ;J
MJ?QWE^KWHN[VC_>*1N;$M1B\]"$I))44@E6:-);SE^1K(+916<ABZ ]I$YR
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M9%I-SIU0HL&@))J&-VET$#44;KK9(]C_F7"E\$,ERZQOL7(/;N7R;*T%XWR
MS+N4@;\4Q203E_45BT\R_/-LU"8&]?O)$E.E1UL;<>NGER;8^C+$5SO^ZC5]
MNQT9^H#G#8(QEI\+4%+HVS!-9PJI,VJH0[V')J_4C%H<PG[^R'R7E7_HW/7X
M ^OOLYU4GAS=KXWXWR0%J \L%12W>J:@@*-=27(5.K_7171^B+X3=&3A5L_@
M#D$/^-BT8KXPV79^$%Z/1(7C5FFQ..K!4.CO:&OX2M92WV9**W$[< _?@B>X
M*N[@OR!^W@9AAD1TR/.%"XALTB$96$GLN3J S4UTI!CS 8QL&72XAF]O)^/
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M2<W7Y92+MQ.V79_ \]^]AJ+3<5[#;,F'Z@OTV9+)GNEWG/M!P*\+5F=?[XE
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M/3UP%R@X.97C<"$W^@G<<Y6 !D89#\Z43B[5-'"#"O%0N$-G;>$'OKXKDS>
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M7%98G-JLR&^1/B 8Z6;ZM\2M?DA.L:3<JD:JL"?]E#IKS[R4(2Y &5[@8(/
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MH+$"\!BVGMAB&>X_T/?.-F1C&.N.;!%6:U?Z/UAMWF\G,0NX8K(5^CN2-\M
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M4J"<<P$#90W@1)[,&%XEK &.JRWH'10<<IH&(?%4:**=9[95VJ'A<$9$=)O
M'3KT1.ECYXSL7.YGE"<N\T(VSNY-8FZ<*V6$W!@K6PYMDK)373H=E;'%"5(1
M"RH#G"*^3#W12$-",7H:[H<40%QQ8?DC_&) VE;F :G]_MI=_ FGD] [6F8)
M35^H!O)VPX>J*D=GCA2D*_'&ADL_#@U45#B[)#5W3=L%@U.#!Q(N!KQ?D78[
M]&4(UO,K]].[63?&1@0+CBZZ4IQX7%60)O85BBF62,[NX>T:?S@1W3.)Q]%8
M;R*U9[%^%*,$7T(6$6_E'P<QL[./?^..ZV%<-#!BP?@%B815$M+ZN5(WOC-S
M68)-,9N8#MZ&O83@0EC89A@@];5A[0,&VWP[FLJ1 E."";(E:::/Z0[Q\J+;
MF&M<GO"-.QVMM^+&VT!\P<S(.8:'W"@5EXU35"B7W43#>@6XCS.#66J?Q ^\
M%Q4) AWD&E05#4V_29U =CLX[E=2;5$W>%=<.\D+VMZ@=#_F*FU?AWA+YIH^
M=<ZN00B*)G8-(=70:0M7F=627@5(I<VUYR]*?R$128::][3=DVZV+37;B2T1
M3LO91+RM__,RDTN!=@^MYC$,K4GV&>*R. 4= VQLL]G5=#P*<1==IV35?%X?
M^:#\@\M-%]QX,>.NWO#6;7$B1F7&J4"+[V=FCS/V(=^AL5^A(#;)WMY;%-]!
M'CI1M@!NK*X@"4&>'2/TZ8&YLH:>/SFB"1-T-S1$6PS%*8^FUZI^)'H$B*O=
MNJPQITX6))-PS&X2N8]( .66B4/%'92W15&OB6'@6#3%M#0@%,*)GZ3V)?C^
M(U246J@NV,?UX-CXO[\3+50\\RU5)!?X*(N/F<:S0;7V%PN(K5EQ5^]6GF'B
MM+?,IY]Q4&D;(L='1[U[%Y'0516!A'<(W-7O>HC&#NN<<HI$,FNU.$PSG?OP
M,:@($(H=G+]<(!H3;35KOG .]%O$W*=^Z^LMYF4/E5V& BCUS5"X)A2/16C1
MB-/L5B24'SO$:^L:<FFS>?4G[S-<EU?^YT8RZ."B)&NS?U((K9 ND6PEY%38
M+E$^[?R-V8MO?#]R;MD@TYIA#KUZH)+GVES^ECM)U@6R$X:$V20;.3#;NH5&
M-A?8!%6CQ#2.*:%#XVMIG?!AIB7),OBW<TA&1ZPNQ5IXKA+Z;6[G[%HD3BK3
M1TXPUL +OG4,954E5QO&!_V)L*N1 #')ZV%OPYSCEL&I9,N],/;T3:HA<I:R
M&,B+&&1XR1SW-N7IY,;T915NQ7S#Z44">:'0YXR#RO%=M+*E#;TIU1H5SAUX
MF7C"YO.=YFWJ-P,Z!8\+%L7NBM\=OY >\?:/I:<,_X/:@52NO#%HW%N%>\L3
M";0$4+QH'H-LBX?EXF27=E7DX%LAJ/N@3Q[5_8YA44>K51(6.YU.U9!P[DQ7
M%A&K[#)[JL92[5CM/I:%N83<:]&3.H\)5@"Y76Z,>E8CY(ZA)3E*N<%8X_*N
M"$@MO.5V]S:U8G_NQQEB!LW%6,>HI]5GAR4&?UWX@--&, 6*).'DABIIM&U,
MB#*($^<[V)XG-$8" E\S5R'A(+>PGHNC.;;%>@VH3)_>U3]/7 :U\7>K/*"U
M1>+#C..JM0)C!_VY^'OMA%6$55H9SQQ:I\B</F;#H=,;6"8(3:1>V]/ ,@(X
MP:\;A#A:\_:[-VDVI-H$STWN4;U3#8[1O:GI=G=D]FNMMRL7LE?L/_^=_6D.
MBOYQTE3@\ ;!MKT&KLQCMCWBGX],*EO3+Q<S'7W#;9S8DYSQIEQO.@X)$_FZ
MG0%9.N.+?H.R,L"G^NXWXB8WF6/"7\AMF%JH+S+K?98,NG-VO4[E9:K7/X#)
M&?S=X&Q1)7#EZ<95.2JZ3NEAZ3]X(TU TS)&,H6[LLY$H'$*N?'ZQZXZ77<2
MR@VJ0US2;*/37*SV] X-]45%1T<O&C[@=1ZS(C]9ZRCE6-GOP?UU)V?3 KQ7
M26>CMUMZB2Q/W/YT\/<-3XEV#D>96<W.F.^L-NJC)A&7+;0BLF"6:$EQ5.PC
M.&!':+PXUMYR(Q&7J&HMN#$F-ZW?9))18*9TRN-ON.Z=Q3^NS&YLRE=V$]?:
MK=Y#F%ID$?Z*_?(+$1Q15?G,Q%5I=JVYUO?,V6/,Y[$^<^4-/&P7"/[X3=1T
MI:*-N0RJRG:;K'7?@X36-/ZYZD\%:^BUHCB_E;0"FNB@G!,LL]'F&KI<18\I
M_BEJ2W/4JYO')**>2+1"F'F=,11^FN%3E3 ##$RUM+Q<T72]X+WZ25UC0^VZ
M_K>1MP^F;/N6M>Y2#]$'7-HC 1-^<_@0B+% IJ"N:<SUUZHF,<X$C>]))J:7
M)S:NJ4#BE2>'BT-A[W'#6V."]=V,/Q0^Y(0GEJ(Q<#>,%1/>?AH])1?AD)^?
MNL#<-B89#W$7R*%KCLSV'C_KHV^'HX+^?AM 3S(ZXC\<A;DU<L>Z[9#"B'T?
MLZ?R/ZW5^5]&+!D. P>*X'CP6Y[ &BG\)KX>6Z0B&WT4V/2E4G7';(19C)"X
MRK%M<7]XQ*0%[DHVV^L?)[YPYY 8>'F@-FV11N#O9JV9SZX('Q5>J)4#S>IA
MB=QRRIXF.>$M\VU(CIY=\<'W5<.-FMH;"4/?#T):2*5;1@4C&!XYAZX.;S<!
M5'MA,KKT8_;3SAG'_XMNQZ.DT[SIT'G,-&'ZY'33FU3")U9CW"QY-DR]KRS^
M</R1\=)O)\J-KN2B47AH)RX;;\@W4_*RN;8HN8+&M(2:I-PA*6C?6=7.,4QJ
M/E*9>DO]G+D8F5#5TB,#X6_B'55J4QZ.X?Q5ZSQI\!#FTUO5PLE9.N*,:YL+
MVR.$YII$A,*X#B^N2?U$UAZ292_JK3'VIA^;!VJ&NJ3IV.C^20](GL/8<R"O
MO7/6E_'KQ5WN;C\#N_9IHNF]M<;8CPV']FY>* LN>3:/"6JVI'ZP>JXZH>MT
M^NB[[7Y+XZ^C]= @:A&D8/*.5[RA(K;*CKR:CU$#EQ-3*V/> !M_3<,9T$X]
M@[X _=PML$?-$&[Z\QNNZ(#FX4=$3FKC"X^=H76LMD@BGG":$:ITH6<*2'W\
M$)!UMLP)Z4P\$-[N8 \-"#S6F/D/1@<>(JV&XW/J35F-*KV7^7Y[%C9=-=B'
M?W1ISYYK'M\:EW@W&:=?IY4$TDK"7O6^*!7P[51O'TB2NK'/K[ ><44E5$Y4
MD_2=D6$(!2YKB:_BF'YH]%Y3A5#WPELS;HWYZA3 3M&]"]T*8%,RN_ES$_04
M*/]^6&8X<'^S,;+[YDS=_WM$XS\=VK#[]-FY_!\-)B/G&@3+T=4(&>0UH8%S
M''2Q@GNVS.4!WF"R<^L\1M4.O%9];E)U[C-DE%9(2 [(W1L<6Z1"POKB\Q"Y
MAO/!YCQ$_IC'+(IA*^/SCW@0+(!'OW0?X0?#"L3_:X>,B"0J*=IO$D^-SC62
MP5TC 2KQ=ZA\8!X35\97B=2K/F+SJR=/JN0Y3,=8:@2 ;X5HIRPZFF66#^O[
MZQ_4?KC6C^\H:6BKI0WALOA1#&U-J!0>JP??U_!4-=:0AR1B#%\_FZ3GLNH[
MZPI8H'X7KI02TSU),4?B@^"8KO8NJR2:$F\.. 8.IJP<;) Z.$+%6?,8T $.
MSZZWQXGA2^?=2$OQVL;2=H>U\#T,8^D0&35W#$.>J#CGN$9,3Z!Y1*(V1$P4
M!'/@XE=)[#J(60+6ZDNH%B1K];"O0^9-0T-<7C!LC!0*'UVEF_UN!2SB'W[^
M0CE-M9;!@^T\Y*?T_J[<U GV##N/W#0"W>A>XYGLKO06Q;A(]/>7)\QCFMH1
MLRV#GG<7<(WQ>@A'2G[X"'AV6BQ8VXT&N08JBR2?Y'\P(F&>9"62<:P:T!;)
MS:EBM4$O'\L@.AVDU7"RF"ZO*P:)Z77 5W]8P"^SA>.S  1H7JT)L*OQ-AK%
M3E;B##L4O*=63"(CU;>QX"#Y=%W=X<^,0# /9P5<9;@@%T">WFBLE6'MV,RK
M)QK:QF4SGLK%,CM.@(GN 0WZZ"6N8.$KGCI"*?L<+LP2$$LEZXP;B4R!UR>?
MW%DL9=7C<]7+@)]G]\!G8&L'G4$/.BX(G-,/+"AFGBZS\'5!:&J3RJ%[RPTB
M*K2I\>&+%"V=M)T0);,!;Q%IZ$UMAF1%J35#,;\/^#Y*=&YN76$ [GW<IOKG
MR-NZZ?]YYI*+<IPZW8(XEE,!V<!L&$R=/GFFAL%*NT.C06,==\$Y %UM(E4E
MF[79?$,="T!A=NP*Z':CWC-P0N\O[!Z.^* %YQQZ\'VZ=@7R+:"OGFZ0-.C^
MD616U*']Z3J!C28?8I@I0^:V9>VL:,Q3FI8M5\MW+[PZR,28FH8L\-ODG_O5
MBKD460ZF(&N(,>"+,_>B/PK?*%]$]I2,C]WP>G=T=)CRDN@F=%^@NT-.?K=&
M8Y SSRC2LF^3H:O(KV^3)],IDO!<V?+>:T+0MOMOM73 LW%E$\=0O!DK9B=A
M_ M.+RS'[;C)__BU0V#\^K>FQWUH./C$2S829--9V?\/[U;BR([>73KJ0=O*
MW>HV'^GUD]JHG[(R3R(S+OM'?S4Q"'R1-UNZ=&S/%>[0S [O&1(F>:_S\\C)
MM:F7A]W^VO_(*KGKL7;W:AZA1[V<01I<=+^72 7MMR3MB<KB'?#@F"3ZLH?K
M'[_QJJYQ>\E=HU_Z]T&_OXSZ#2R?"^R8W2Q]YDK 18.:9O5DLP^GO#,:YFPC
M84%1FK(VOKTY'OWU6=UP@@T^_UVXV#VH(B'6Q>'P^<_KGN;5K6PJ<(18A8;2
M<Y>T6P4ND<RG,J.^<;4]P%8(1103A!4&CW \>5:1,H36)@WI1G>J2O%^W0)G
MY/7>GM0OPF$Y= 6@J=((!:\&AA6OE8>^-UHD\[01^O0ZWXX+50@.##]=VY"<
M)NWX_&IF6*&NOAV\7\7!X1V0D5EZ[,"4T,@W(=81ZAG@TY=KMLZ.Y2[*"1/C
M9PL%SGJRAFK$17%)O1RN%683 V[\E>3@T^NI<2<.]G_"9T][\.R\V0-^'JO@
MQ?AAF3/^#0 '/?V$S6K,;+^B\" CAS00_C/J^. ^O*:+DYQL^GQRK%%N1@Q2
MW*CFZ!(*!]N<.IJ_-&5JS-,^#6W7<G--@;B7#AX=? ;]_MDW&&CBK&SQW'4!
M+B'6'B$K66Q?D\?= E>G'/XF6%O"-(;BLQOP.;$^&BVZIAK'!L$5PM,[Y?XP
M[IQ.=BS9#+FYDF0$G>THA#MZFV?8F4236=.DY@'N+2!:,=)^H(\8 L(5)<>A
M^L0.NA8RMN4K^4'JB0'^)NL(_L[RAQT,@G/6Y52AD1BZ=.$@,Z.5:O#OMF*6
M'V:L>HYX#M]-#1G?^E7D*":;$'\K\QJ8Y&F/V:@S;\QC]K< Q6I3-I(NG#TN
M<= [.'3:"CUT]\F*$Y_XRS0$EP)MDI7"[J)O KM&R^L=5USYT<=55?TI[](D
M448:4ZV7XC<D:U&NLAG)#F)CT>6C(>=?^6<\.;\!VV\<+=IOOC:Z?<UX;:VD
MLK;V,=XY?]]JC-;IBH7?OA=28GZ&A'KH0>2X,ME)8O->F#NY,8V.!3@2DC5L
MF]3\BE-5@ V#R/F,S8K0HV/L8S8_DO[SVJ)DVOOLXC$J>[Y@'91^>;S_\DAV
M?4C:;(S=6/&58M^Z_-J#X)'- SHC87-GC^I>S@X[OTW[.F8B@4?(4&+/'OE<
M^\F5'P=6U_K_G?A[9%34QYF C^'R88YCPC8+  \5E5J&+^[YEQMFD=9V1S'7
M@60'Q(O5]M#?0W?[/GO.4BSVUE65#WEGUX];JHWIEHA^ZXQ\6M&S?L@N0XPW
M]U@:<I\\%OG@;+GVZ"F7-H8)+ *%8@[N@\-/$"L_)9IG -Q"Z&KC>8S),T9S
M[#5EA:K ;BQ*;W1-C?,\Y@APIKLE")1/W=&553ZP&4&J5=SV">P[JN86\H)R
M5AH,!8F[LFUNU[FI^HD;*S6^22^5943@A$<7![IV\I!XM5FH]2U(QO@GV#K<
M]-YCS(QS[M=QQPZ9$6S<\*/HKL37J]'-(YT@?D&O3&K>5<,@U,;/VD8Z6^\=
MW7YF^F?SK'?H@7O;N% I0OY1").+A*">FM!_FB3]<9#W1T4WU#'M";E1_?GX
MJY-Q)YF36J.[PDN:"E%;CZ'D9B!/U.3M6U9[9[29C(:F<"8UQB6A<C"BI_[W
M5YE3?2\>B4I;SQ\M+WUKBOX"^=L"1_B4JC:ZUX5[M'#?1S'+D4.B[6$WJN<Q
MM+%DCI$;"W3O?A<IIRW6^NOY!LS4C$L7)Y^(7]G0.2[,]:"5N 3<:7C__O;=
MRJ=70BNN]#?D/^26[-OMK7W!1ADTI'O^(=X6\4H.FUTE[W"P?=P7*)_>T%O+
M"+SE53EW>X-::N.E^ZYP[7;40(7UT!J]%-XI-!&0 1PHX8?PDHXFV13(Q3AM
MAE<#I,ZH'I5#%X)5++N//07Z6W;R &[[*"F<:G+XXK8HZN) #UC<H]W"@3GC
M:1"M5>T,"\\1@^^-?7-8BAP_"5;C3!-D>$@S\R!F*MT6".A0;^SVZ#3QP!MN
M''M($,D7 &,2$B%B^ 5T*B$__L75=DQZ9N#O,UY/;H_-;"VM2S0K" KM=TUY
M%_US\UY\PX>A 9OE6M9MOP9CJYX-VDW]]WEUU&<.]-(+8_(J1%GSOVP3\^_N
M)-'(Q+0=')2'^JCF,9B/9 OB!@&FF<Z)ZFH?7X%Z:*@1=(0X.?.8A,XX\:GI
M)TZ%GB"\4@4/9C&<!1ZPE$W$@1P#(*0-H9ILJ=F-$JPVS6/RR0?)%HP :+"=
M@-L+C/A!98^@,9',%Z)DHX$*GB$B#^T+RN0?NSEZW:OA)F!-#(!QDG5 BNYD
MNBY1X.RPWG4&ET7<K\@A.JYL[@G$ &&L-A(:L*H6_-Z LT4=NH\D,_1!KGY2
M'/BMM2"^+>IRW5W%0:2I K #<-%X4WXL0[L<N,/8>1Q^8,V@.N6+?S>G8(.4
M[=O5M?.8A3#T?B*/'ZC<Y/RU+2!HD&G_H^6M-?29=Q,]T#LYH9T4A<U(P6$^
M=T\2M% :Q,I$-X'3W2D!RFTB9 O0U4Y:/_"R&WG?G7]I![8&X4Z'P=@<#UKZ
MGF$EJ30-)H<BE@IRQA*662J%;4.Z>^=V]4V 3Y/Y# @?6+J ??!O=Z 1]-=/
M9-!PO<XSNM[6VJ^6&ODJ2GWEF6J=CTMBC08.,\+A^,U(BDRO9XI&QR8,Q>=X
MCKLRN^8Q2]2+<%C#X[&PRT_07V7+D-O$7676,#6?#.I3/YG9?BH^F=<6B$GE
M/J)\2M,$ 0P_)!T>5*Y\<A_.8B<J=_.[&[+Z)WDF'P1.R6FJAZSV>"Y['F-S
M"[$N?Z&4&S*.#?)W*C5F@;L(>4[6?5&+7"$L>&AMPK?O%\TNVGQ+(Z<!7UPV
MJG5<Q='7./?4'H_2Z ZY+BZ'Z%F'.S/D)KQ1=T&5; #DM3.=?B1&1:3>4.X$
MZ<@O%@Q;U2:LB+GAF;/YI1TZBX2HF4N;D^C1AY.^7>=2:T\-MP:UE=G ';50
M4U ?&EJ> 6%!I]8"[<B>U-NPWOJFS&(P":E*V.,\]/7&BGO72"7LZ9/P"G)]
MX#Q&8J+*TU94\^QXDF(H'%TVCX%_Q>6\@.+]$2-[1JKF;<RB-4PA)!O5[QAI
M9T'LF@+EUQ:U&>5\D&8_?5U2.JO]#A &09*N?.)F&KB)KN$G+-\;\AJ,Z&7X
M5"9I0!]=IPAUG*Z'UH_98//#8YW\26L@^;CE+:#T]+'E0G;<9MMKML^+)<+[
M[ (T<I:$C(%&I7!<6ZS!(&D9^FL?/U0Y.Z&-.M"-&)X/>[O:4A"K9N_3? /2
M<E9[L +(/^65H:QP=? L.ED@S5VVF[X0N7OYY]7:L:^G]9OX2(X2;PE4B*F&
M4UTX&M?"DX*/!M*"D8"YR]5CC3;?QG5(&VGKT)T#PV+FFKP?[?'6\ KP(H'^
MCY9J H.B?[?M]5=Z1?85N@VJ%U>N[F6!!@*D1%$;))KF&C%<P*PG9.P!!^]!
MSU!+A?2,8.'8*;<FI19L)>6A=B1[B("ND(+[H?..'<QEH;(-AF#"1?]<S.1<
MN'KQE"*9IFQA_-+T&(HMJ1D"QL+@RY62)E&R>5+4B:X<^4-JH<>:I;0#?YP#
MXD7"1R5(S.*71P2^B]82G8H5#'W-5IR".6QB8JJ2:XG27Q-C6&0.GZ#2GVTA
ML_%080EX VF9W@8;=YS!9\M%)#P9SDM8@.P-4O02-_,!>R%HQGFYNER;,H\Y
M>X3Z7:A[" X24PR12^B&'H:W8KASU:"(:\HW =-9(E^C/&@>XV\C2F#A!)[(
MSQ0D(EGC:H4!R_AA2J$U0K"9R'D&^3QW+3UR8=82*!MPA\9VPSJY<EP51![W
M!DM":@G^OB>*%00D9@;?3EX$L-J&C#*59!.@2>*P$AKU]2[@_U(EEJTM.BR'
M U8[Z%!U,U>7&U6!3I\NJ#@+T8@!TFJDJ$-HY.992Q'%.CVR%.@BFVN1DV(J
M=!$9:=/H*;JI9AZ33),M0PJ4;4H<!MA)6I*0K.C2<S:NV6T_C6SW8A 6JMM.
M97+;2_!95+,?/8]S3/$%(3 W@M^"_,X";0?W,MQ).K[+NHF;E?@E=RCC7X@[
MA9VSTB.M?ZPTUQJ)HJ-FHFA(R5@'39Q1NP#'1;'&D+>$FB$W2RW0P64&A/AV
MH<Y/<-,A/:^W]DP58,7GF]CL7 UGO*5'?L=H<",P7"IZ"07ELT!C*+_B!B1%
MS?KKT['ML7:P)8?OHXS!BD@$NG5,0A/5,/MU0T4=^LM<"=-U[#KQNCN0GPD-
M9J)!D'<4Q#O#7W>_*H-D1),;$HUL I$=51V+S+4N_Z%1B@_\UP*+)+*!V@3]
M&<*?/NPIQ_!$Z7M9[27) 2+?K&(>BJ&?B?4>T,FY@6Z%?N>:(C5U;.4)>-W!
M!'784I@YU74K07@_/#-E(OL;V;QV@K&*L4]H0N&$BY?(C5+H2' )OKZ+0_(9
MB_(9['[:ZIW%/RPTR#CPV,9JQ0)#\QV+*(O5XB\ 67I=6O"9D0QNVK89=@R!
M.1E9UQ2>O6C(73/86RI<8L<(&Z3D^"%GE.:#_"29'43->0K]8>("1B"WM\02
ME'+4+&M,:C,BT7_#=!]KEF8*G#[.Q#94HQ[(-; 3)Q;HI.],%1;.P-@H"(LZ
MTW- HHN24""'BH 57"L=*!*RS/H.GS#A+]_IAZ\L,^LYPE\#IFO[/^GWQ!G+
M1GVW7ZN(!?)VZS47-L]LO:@UX'D1\R+8+?*+Y/J>9ZX1<<+_DG\[__;_ %!+
M P04    " #$<7Q;XZ2,@]SY  !:!@$ #0   &EM86=E7S R,2YJ<&>L^PE4
M$W<<]PL'6<(BA'V'J"BHB*B N,2,2P67:E14"BBIH@(BIJT@48<,BQ!6HZ66
MBDI45*R"J0)2$1-( K%U 42)0"69I!45D!F7^)=,DCO>]Y[G?=[WW'/N<]_[
MPID#FF'X+[_?]_OY,A/3"Y.:XK@N:FT4Q<S,C/(]^4DQ#5)6??W7_Z./KQ?Y
M?WH-,U,;Q<G:S&=2@KG9-,HD)S-S)S.3G$*G4,PL_U\G4/Z/#[-)YA:65E1K
M&UL[\H0F1\HD,W/S21;FEI86%N2KV>3K% LG2^>I\U=8N6S>19WVH^N"W%,7
MK0-6WFIWV]*#30_;_5.>C:V[AZ>7]XS H)FS9H='+(Q<M'C)JF]61T6O6;LN
M9NNV[;'?Q<4G[=F[+SDE=?^AC,S#6=PC1_./%Q3RBXI+?J[XY?2OE;^=J;I4
M<_G*U=IKOU^_W=#8=*?YS[LM4IF\HU/QX*^_G_8^>]ZG?-$_@&JT__[W:OCU
MF[?X^P\?/^D^@R\37^=E1C'_'U/_/YV7$SFO2186YA;4K_,RFY3U]00G"\NI
M\ZV<5VRF[OK19=J"7&O7E:<NWFJW"0C;@KGM_JG'UGUZ.#H#_SJU_WUF_VL3
MR_O_:6;_8V+_[WD-4":;FY&;9^Y$@2A&X\Q+)929(H40S#91QDKQ2-UJC#7Z
MX0H<>":#Y6]\BC0&5F _/U0L1*C$7ORSO-K\:6_[T%3<ZFX=EZY.SCFDX92J
MG.!OPV<2H6JA??"NR\HG*X_LBOW@TV&B8#$FRB!=CMBU>F5A 5IV6SJ'#<),
M% M@N 1QV"=4CJRV+E]D'[&?DV.B>'5)<[%=8@]X.1YY'-Z&N<C3#?R;B)2[
M)]G?";^@R/T,'!<NAVY,!&OH^>P[;%EH:?RX5& >/P@^RX1.S)G$G%YQR)LE
MH45,-W@WILIMHMO3J5P[N?\4$^5X@*:VB.E;*S51Z$*[R!/AVWY$61ZW4J=;
M_F$^KC^:8TMPP&E].K$!K#51+&V !%L.SP!O\ :TD*\/)*C@S!4NHHXF?YP*
ME)LQ1 !GX6%:)?_3?4[G$AFHE Y-\Z:6--+-P+&'*R?]WKTG^,.]<<-)T=F/
M73EB&D:N+17WT?W<\&>?!%T&+F(-J$#*<D[8,=0 TN$03)@ <C5TVL+R2SG;
M(GIO$IN5JQCE'YP=_?ZE4HP91A^C"KICHG0^]M%YY@ 317O_YD6\6>>'J\8L
M<1^C5X4N&=C@29V?C8QN*,63L+DP$C]4H'U%SCM)-N1-?LF*LXV5EICA%[ 7
M4^K*Z(AV>&Q8'P=<-(H.(=_?SG"1-SU5Y23VY"E4#52Y*)?=,%XBV0-1P: "
M:6Q6"$IJM=9*P@-G18-L5#I$J>C8P@UH9[KOPX1EA(]ZW!(J\BKE>$)7O6F$
M<ZEZ/&^41S51I'5 I=\$NS]'DL?SAF8 <[6)X@A'X%VR'Z^G"2='2+R#!)GU
M/IT/-5"A<1[;<0$X8UY^*<QGYM^<A\KG"%6R5V)!3 $7M:)R)^Y#A9@)*O
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M99QIHMB KO:9.9=+_+]A'7A.;M=O_I:X(H<Y!0X'M_1;C ,FBC=AHX7RQ0'
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M*!KJ8WPDM&;LQ=.V@C&\4L&;AWU(8=]F*<S0K_?T[XKIA _^?4^LG'2H7Y:
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M "^%[I;2/0%)+C.*LBR*@G$B;CR&=$@6\E?2 \A&,$9=&*BXE2VW1LM+Z4:
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M?BWP6H<H4SOY)$:?H+HC)[$C?6@QY%<^2GHQW"Z!#H59?:#K2 \)^I(W$K%
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M^^"B*@^/3HI.BK'8/KS5/:7)EH#_W+3^XYQ8(\:@U9QQ/="MB;,(L88$RG.
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MJHGAWUL!YC5X3=YBWS[9\B\U&VG'\1\W4HM.,RJ'DBY.Q\^C-HCD9O:F=,<
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M[Q;KOP221/,H$]@#M&<)-!\8@@57-7QA'H6CX;P )%/QVEQ>F::8-( "6RE
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MYE$K&%T<@(P9Z% 4B*A7?E;F ^*#/?R%]/WJ.PQ=9DN"-"YI5Q<#"U&;D77
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ML-0:_SDR/5G:\Y612/=_ 2[37+B7X+1U*-TS^I>/=HSWJX*#@B"RRD[?GW>
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M(4]S8=%R4I7/U3IFRQ8^]D00269E!"ZWC;=:7,D&BF1G4BMH@:W!."%W8?3
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MLU?>P>E,XW,&UM1?\U$_X=F#ANS,8C?@.<"8A'8*9/96K<W% NX_B"-C(=U
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MLP3""[O<T@CN,@D:8@9>IVUN>3P<J1S.<-NP+ T[I;)%6@4+F>&:%*A)U];
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M@Y1$.\F?\-4"$@(83PLW5^-1:>%C>E W--P:T+!+A*U-)!M(,QI*#SX*U&P
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M@^I?;E ZVSIB[T&5*)B*-A'O3RV*/R6&BQPE [K6C'C-#O8,K]-\/Y$J#"9
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M2&WI,=M,]'/>K%Q7]BAW@[>HH[5)&Z0E8'2AEP:&8SPLU<&>P!LYLKC00M8
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M,)J!,JA-)WECS]OVN<1\2GFREAONJTWN/<7I2M7SMK]WQ5A70=S=>ER#'KB
M_8W%K9;??CU=+.4L]-\AGQIPH#&/DW Y=)KD)9A=#3E+?GRQSF]B\0]KN?6O
M7_5-P_?&(6[F]K\CG!"O]MR<.%9HN5Q_%]]RN$](["N?\1);3'F(:9_R"K;O
M(@Q]0. NT2D7X3!Q)3:4,FS)TZ)9T1$3K&K:] )(=68"8TD.YQU.%9%61^_
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MN1Z(=$AEF(>U2WS !L-&U R.R!;OO<E[2W^@:GKJ%!WDU"SM;2^$Y.7-. #
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MX:L]9-)0+;NG. JO.S6*H(ILS#^!Z11 <>:&P@/-D"DKUM5X59P*>S4^[DN
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MFIIR!Z2NZQ(':TXM$R?JV%,YWS%;XD2<5=+F(/P<,0X3FT8J*5FHM>8F$OV
M$[*2/V/1'<'CA&MIU#X%;T$-S,A$=^D*HQ2;WOB/F'/8<IJ7^$'','/S6W;M
ML$58<<SA\H0!\_"4[+>YK@%_?5YY(.@'--Z\-D90EY5:&>M'R03LE:J>//1
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MC@D/LL_0*__GJ?I8S_\#4$L#!!0    ( ,1Q?%MPGR8)T\,   W.   -
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M:#'V/.?230ENK/TC. !1)DRE@0M*99QCR_M)%\\JF<9'UJ3]0O,Z8B8X:8Y
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MA5D7.RMG0X$<1TQM=FSH:OOV,YT8&\H:^*"?&=5Z9SX>_K?/\7.,_E>Z<F,
M1C<5_H$OJL:"#-Y*:7$LDB=:W..#Y_<J!]WZ2.:KSY#'\?BNV37?1Y9<E6W:
MVM+Q7%M>!9^ ;L48/^C?4CE5:TOX=:W&<O.P5+$WQC="UZBE#ZI8G9_TLTL3
ML5=-^R-*DA/L\+L/]7-7"PY#N17^:>2,IC^.1&\+J:(VQ-GRFWJ 4LHVS18I
M 5_[X!V*J%@EZY:9YQ.KV>O)-X$3P,U%CRIOWHVVYGJ =+DM=NO=""#:%728
MG"1#W@_78BL1\Y*J?.2+XSG&9R:6:?QJ]B:6@(=7Q*VPLR*%VF]Y"- F=]7F
MMRI9]D04)KZJW_:F)N!#]0>_GR*GN_<G^/BO;Z[P_/W)M4B?_5!WIB'F,)($
M=3J:*H!9E^7DN HO;(2H<,J;92-2Q*/\U$10G7PLQLZM;75)?BP;HFU^3\D)
MZ,CG*8MMG?^&?IMO1_)@@:Q3H8,&U.9=2&/=J=Z!+QC2P!\>(O6E;/#X8KTE
M!I45I N</B:$OFPM0;:/N="BP,K.(TU1U'S->PU[1&OU3;V9AP+89Q_&?/^%
M"H+28$]F*'3G%"8*!FN2R&M:ES9Z+Y-P99".$]F$)P.%6B:(F2D(@_ T+Q5Y
MO/D2D*I*L,?F':^^1$DV++#&GW3A^?3MGZ;0\[R%9U]["9R%S_C-K;=:"WUN
M!;(6\EHI+4AQ6 -4JRF"=65\/UA7&3-$&Z%(RD)*(6=D9S73=. %AYV*RHJ8
MZ+'>["\R6Z&U"NK>WYX_1'.$2+=CN+W O]\FQ^!V<L'H2*^IWQK-\T0C\:\#
M)ZG\4IXU-PUI3(:WE4[ZM KD8?Z+0#]VVO07MOSW_-5ZS< C/:-KKY[,#BG=
MAGE*F[AQPFW$<L>9=$Q6=F(X^.GDMU1=19Z>YX8TWH3O+C057MKX<1WI_0..
M 5_U7=TYU^Q<3N$UOV&>36KDJ\ @3?#2DI'O]H1E(TE2; 72;39  ]0 FXH\
MTQ?P"SI(2Z4ZNC '3N)YL@I%\>?[0Z6YMM4X/QX+++XI&> S0'E3X+AM?+#L
M2XZ;Q&NR^OV_27L(T2MS#-*XC602SI:3B.YL&Q$$9J"MI?RZ.L*C$&UM&J)Y
M4$I\:=TI^6FLM:FKJJS>4Q>?F= >HA,M$*WBS/WA,LIBE&)[[('PL>]9T5)&
M681P83NO6*&326MZ!\P& 6#S&V*3\N3!HCFX<S4>A*H'SJ(2.Z%@&7Z\]!JH
MXK^IMZ\&UAMP>=DIOS][@B3QV#4ALO%HRQ4K@>U9C^#B$><7(B>0E'M)%LD0
M+4T&9JM-I9;*45P:"-=I.^DZ7H,T\&//J);3EX&C^H%W[A#MCXQ&P\_(.SZE
M!WFD5T6!$IY(-N%A![3V;?0/O#S*<5Y$L-62SLFF.Y;3Y#"J3E:(:62K&LTT
M)NE9()(S')>95BOP-_\>T_$"_^P)>.E<;+A"+-3#7@^35*?^R2[<#Q8L.$54
M3 ^<C>\7KA+R;UO.4[-6\>]2NH/?7:67#=A3R;D.IF)Q+>))EK/I\=.^FHZ"
M0?/"U/UZ8B8F.3QR@F!X\GXJ5PO=L2><:;=_QW=>-\S0[Z:2'L'*'XN7BB@/
M.7RFI0[1G8=N"XRUYJDL)0M,9"LA"KSO*(Q9YF4@,0(;'/BJDQR$[NRZH)<4
M*.C^+92C+VH745UFIRWFK-:SG,$?J5VZP"F+OBU?,WWKMG@I&,<NX;B:IU%A
M[X)UM=KA)!<HE8@C(< ?ZBN.X5(TB1C_75Z,WM%K'2$_41S^"MG<7S%Z,Y5L
M6\KA\QJY$^8MMK9:#Q8/L_H>_K^ZX121!<SF)01BR8/3M'D)]H!MWDX^BYTF
MU4O=AFA-MUY_J8Y!ZU0RF[0VCLPE.6IC>?/4<]?4!L%P4%K)G7+RLL"E88WJ
MUN-_R"\Q[UH'^JGH84 WKR/;M37L@7PS-R5P"BXH&J)1^T*??<< =UG/K\'X
M15QZPD>!)>?<S;Q*H)V/<RK&XMY%]**09SO&7&C:,IMKC4=.MJJ-:R2=1%3(
MN:]$-F]$6;B JB&9W)GL$#MCF8V#15V: D423!.W5CB#W13?PQ[!"+U_OR:[
M)L!;'>I=0(SY^!*<7KAVS2BOM/0RW_DTB$GMGX!*^D/Y6&K:%&! J2>0SH>-
M/</ +?R)_D_PU& M"J_!RRY@3U%UCFB^%;;H:#6#)CS==%/APEGU5\_XP^R?
MZ7GI]&^^HAA'Z8<\Y:F24W=ST+?+*1UV<<>I14>N)%BU!<3]%/79."I ^%7V
M:81%$:SM7M+(OT5O/BWMGFQR!&K,8% ;)YM30:*AO*6U.U+O752##"@\/YZ"
M\KA3D\7# 4LGL68X)\ZG? N'7=W/QPYZX06[*[=N@FS_':(M$G3TZF$5JQBY
MD]0D/:3UY#*$IW51I?7+4%T(+U\\N;VPB+,$7=CV):8M>.4-ZNT2L)$CG]"6
MO@QJ7L"9,2+U::#FO[I?&3?[SA^F3?A?OV"(MM)2#&]/2S1=:4/2 GCH9>EN
M,P_PFQ L1RC0/\:]BQ==W8RN>YEA]/SLV4:1SFB^_>]',MX*!5S7).4MUC_3
MHCH\E\<=FCKZT[],+TQ2O\N.EG0W^L_O>P=C)EC_QVI&L,A!,"ZIE SAX5]5
M_%MURF51>NZE:JK8>#?^&6S9Q[75$#_9&FZD(@[JHD2P^>9<3JX(&I/363SB
M@+]YH[@1OAUC1'4!UFBY,1S+Y(%C.JWM#F,UB&CK#QW,S6#8[Q!<#'!USKD)
MZ"JN!S[[X-KUDM]6G-N\;[CKP>__,5R3,_>?)8\F7DO1Q!X_?J_^I9&5N6/?
M I95S4XO>-!E+O>B0WO%1\>EOWSJ[O;MB(MU/'V&OLF91N<<U8S@T;Q\/:R^
MR7 9:1]"M9#9<E'L1(P"3GB>28!IRSA6F'^3'U\Y>!!.P[U+:K0C ;UA?V#)
MJ?'YYY(5'L0\_0)PYI259/'\P^1TI]P;D2ZJ5E0+QGXEW#6-VCOL$CBQU8'\
MJ\?])4DC5KRI9]\0+<+F5=PW0$8X<(><KN' ,B$2B]>5QJF4>MZA=UC=H<].
MKA=2. FB^IE8X-+OB+'9G"FBP#%72$S"OJH974O6X>,+=8@[L?@5U^>#=Z [
M]OR.(7X1Q?&Q9)&>X9*L-'N'Q[_G*TF']A._TB<\XFX2]YYC%,J#Q(W\VX)F
M"C_$K3U.H!0K7HI#!8JMS_A-7=H!*O4/I6Y"]7()6E&MB_<.?\%Q2R0;\+'+
M]%[8\YSS?5>J6IC-C8>_J0Z\%S/UY80[TS01J,VK"*ZEAA*Q\-(W< J23X[#
MJHH("/_IJ4H<C/6<ZY+F%% ;>[>V,CEP/']$:C^Z\K\6T4HT.M<K(MPA_+0^
MQNAH7B2,-#59*L3V1)CE5V()'J;C-1O=5:=:FWE=Y5%XV;%+@*^3FAC$6&;$
MBUH98PGZS[+],4>C7SK.Q3?N62P?5<8:/J5B!?W?#[7/@I;)7WTN?KNJO6N(
MMJKA5LW#!U 7^^+N)G.@LLS.9N1AVB=6J8+.]1-E@;4&"<5"WIR) H.D0.L:
M'(Y*?<#R_P;7O0JV9/[$['T9R&?<%N:O.?;WGP<KV%;9'J(W:"L8KQE8B4+N
MY#,N&Y,U!K"C<=X A1:K&Y$[XC\X?'SL1V1$_=3J@(S:M^Y1;_7K D=OL+U?
MG<N)Y<2/B@K[:;:&WQ;[SV#&V:"EO[4\^3Y$X[WZ-V1,^X-EE]YH.Y9]H+D=
M.N?^$,I8&SUW3N.H%?2_Q Q+&9P$%2(U=2JDV[&)/Z+FK;^I!"AU1G8CWXW+
M/"MH"3U^1]_JV!>-MIV"3!X58Q#'OD*N/;8ZN,(;NS@-1@/GKTO[J[</\A.&
M*<5SL*K#(B?]@4F:#5A=:7#::B5W_(M!&OE<PV'K \8L8\2_7+_+=T.PK2C[
ME\W_G7WXY$N,>^.VM'G/WF'A@IU.[]\T/YT8QV4/VV]5]G-WH<C6QCHNZO5
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M=0[;.E):%?C:"IBQ(1IIMY+25F= -,[D@<<Z;<>=!D?#6<=U\7L7^JD/D>.
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M&O8[W\=3-\)NQ-[JU(-S</^JLL\\=XF7YU8<*450YLDWN38_,UK@PPG^F&1
MJY-1.M!XTNQ-/N'?90X8$+VD*ZM)VX'42=1(:2RWTB#KDC3)0]]\>2:4E9%>
MR8',S97L8B@R<P3''\JM3](5X),\\)-X7#3S(YOPC#&E@M,WD,9%< J_3%I;
M-7 )-Y,._F:?CPJ'&MD(PNV.I5P^,36R&;HE/B\?@0T28T.UQ 0M QRC/"2"
M'4F6L_&Y J^DQH09F8%SMXW=B67VU2BP-%9C*=+(=^*.)*(L]Q4".%#(UD45
M!Y\5F Y@_\IP[\8N20'7[4/7C,"$HG. I4*<.6O1G#\N'Y;I5S-.Q"T\>"30
M-ZZ?T369M+N%*?5:]>!AN*:W$>E"3#<L)7*FN,V/301):YC$+*2L1L( J?J>
MWQ[,:/NU/]3K/GIU>9%^X_CW>$3YGN[%\Y_3:.0*A:Y*3K/\+AY-9<5=D<CH
MXNL4%-F4(K7.=W2M7=*EEC,B"$\TY3UJ_SQ8W&,#XFX"MOYKV1=9I[FE:WR.
M?C2ZCV+BU:K8P *1K[X$J-2Z5^AF'3R2G;UAI 7]'U^9Y\L95&MA:R 01%6!
MAG(:.*1C# S1KA)C0*7N(L7Q689'::+=FU%!@%"I;U<8JMT7X*V'8II[Q@O
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MQK*,6AW2J32I\:062N[P_44L5)K7OMP1:$TLRI#Q1]XL-O#H#/\^V$T4IS^
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M(?> G7Q^&0P6Y&QSO"<HJ3N(-.X1CQ2WGLHTSC+/(0Z '.PIZ<##3NNE^>*
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MLV_TY^ENLP[53^MR+6\PHK^()C+SWAU?>?9*\7PHO_P[W )Y4XL7PKH'%4[
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M,18^GF 7X%*PE*VPSU4VT]7'S0:&N'LY^!/]KH5[2[0FEH:MEQH7$BJ^5QW
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M;%M\/6;[P#5/8I]X"^QLR5Y\C;$]*B!8_NAVY#MBZ*SM,:(1LF,RWA'_,"W
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M$G:EN7+[ XI7+$I8JIMK^'=.GZA"TR6)Q#Y5[\.VD\@4@%XJNE-^[MWT2Q?
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M\J \:>Y8FR**>J2#:B0%4I@&,?T8A58PG"^^B-U3L$[ =I5.[8&"T@U7GMT
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M\\!%.(I_(#O'E&HGY2ZAL!I#;-):A64-VAL!39Z:MA/@B">4,)Z 8_%?"V%
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MJ3Y)4M=3ZWL8B=G5CR?M[I\EZB^EO)$L79.K\[6F[\#.#,A4:6CI$G8#3MC
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MI27#*(TK9(QF1B\+67Q9L5,9"EO)1/I4.SA7$DD4BT%1EG(]Q5[E3R#H42-
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M-Z1%[4*V44\\-L?HTWJ9KS"ID_'LO_J.PCSPO6]71=>\0/[>R].N=?Z]ELO
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MYW03((+U+HU[S@ZVKAF[(65H4U=QX):9%2*3F @<_GAP "56&LL'Y@\5R5_
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MOTO0'_JSP&IK2\;]F- 0Z-'HC%_]A9*^X8 [S*=G<)8]W!=LS["(BW8M].=
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MS1#P\,OBD3AJ33@B''NN[+#DNH#K%9R$W:!(V>[>"ME^GK !H]L01L,U_/R
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M.TOJ<[B+N7NK;%?P SRV55; S0=P@W!.I*(^FU#;=IH.D(<:JJLRU$([X*>
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M5$ZDG?LGWPF4K>G#=ME@M!9UL_SUP9QI#%X)B$02-#K=/>C8Q.LDS1WP1>O
MU,X!ZW&S=PA-Q<L]789N5PH+Z$'HH HNQ&<)#*$TGL-_7/YV8%  QWWI*15R
M*VA .+=ZXB;YZ;=-S8?@&"A_R%U7TNB&?&3EX/-!J3:0&XU.M5"M,$H-0M!O
MRU\@5@5G_ *TX:#_)MRR3M84[8K(LK*P^4S568LTQ7BY[=X+XWI2G0"S-U%X
MC"T38C;(<-L[4'8J1;L!"*2X!8B\C2T'IQY@FWIJA3/C+G%20M-]F%;CZ$IB
M,0(;1&[(.LZ)!4-=I'6_A@@NP _KQPA_8$P&\XEW.T2&V3^7Z4G5@HQC-#WI
M")0/NV*SM"&\#I%K+^X:I&+W!RBS"A([R% +/^<:152R@&G)R9/.'C&4X@$L
M\X=H>HF9UXQ;3#=.P^[120@WWZE=BIT%D]J#</,\? 'F"6 "*<22B?YJS474
M3THKH,RI[^6ZW?6[P/6J*C\/_S99SI?Z?^5<WS.G)B3)O67?Z_QC,O.;E 0(
M<_74VD5PF&W1BXJ5'>,%"826O=[FI="3!AQ;ZEG5Y'S'5JCZ57D$A<*/ D-A
M^"*F 2=9>@[I;7F +RYJR^>N%M9C<R)OM:>$:8.(!=D-'Q3W#^X 3&5",BV?
M167,YAX $6(W^AQD2A,%=C[ ]J!_ '+&6[1X]TM"RNM)DM)GMJN6/+#:]M-Y
M> GWK'8:WCL@EG2 E;&2,X1^M*B,T;Q$.S(3A?W77G&>--_DAG?/]$7"UZ(0
MMGWO,A*9D+@M\XX/;AI\W$9+A0\Q!Y]H;'4W8<(_#;HK/<:*3VAWB+Y=.JX&
M,[44+ 'X*>6Y<DNNG5I N&DGGOV(R& >80]&']$R$_4D,MRR5M&L9(,[G'!R
MSH&!P/8FZCV>#]%5(EY;"5E7+"+C?3@%3<H3+>.X:"Z@'R\C'8IZR41ZB6%/
MXT;TE(K9:AF?^ ZRJ(&F_4&(\<8T*<_%?]$ARL+3NWOL/=EH;/H!@8+Y6H*;
M2Z \/2F>!99XM%('/%14J2!#3WID,E9Y&W\N6HC DHX"L55DT] J8)4H-QD=
MH/*Y<PBER_7A$J[=S#&7-V?DJ+)(>8CMM&3(AQ)V(?2 \$<?",QGCK_5KL3_
MHOX6*[-T5![*0RLT&;KK\#%YCK@NJ94P_.N;<$9GS2/Z,O392 P+"4NEGQ#>
M!PDLU#$#5IJ]///=26\A1V#8^GKZ%LI2(O1XWENX[@6?*.;?^W!WKAGT:")'
M?/0Z]/HZ,5OU5 8]$G5I'O+M3GP:J=C7E_@VJ?F:IIY86BF,,A- IP]DF358
MW5Q"0TD_^>67(5<.DW1[J,AN0;J8RK/BO>)9@1@E<P#2Q.INT:E:9^Y^71G/
M>H1: S=_0LJE(B^$G$6(I[H,M%AYZMG0TF\RT5_DCK?M/)+O<^': I?S7P6X
MF04:J_*3R8&'R=@=M$A-S4VD.6-,4("\KQ4[ O&NNBZ?\> ]KPC]2^M[]61I
M6JW-FJTW9Q2&O^AV'T8^*1S'J.AUU??P3#I++08>]>,0(E9]NR6TCSE 4\C2
M1 MX7=3Z88PVV8<OYOX #JK(AC0)-8,Q'27G<*/JE7I2;F1X[QM.>2N/AL!I
M8;&9V:2J=SJB!E*#,1M0J?4CVB- ?)"5"CG3%_E=P#TP?W#D-,L11'R8".IA
MK>^UJJT:+83JN'XJZDP0-QZR;]JCT/#K)Y<;V&XU>7_9?ML:X_^9XZRXL)&L
M9&539J#P>7I,Z7O1'"0H'PNXSXEI8U!ZSG;53E@F#*R/X\WNG+PS[\:C.-N9
M\RX',(V/.S^=FTOZ1,UDS>!1N;, K"1G"BRX'K<X'DT4P\[N#0@_@[XZOO[[
MEZ>O3#6\]U^X=,7-HX"Z;)5DFC<_]+_<W_Z?.1!! 4S%+?#V:#-"A16@<E5L
M.FZ',>I[/K<3;D'L>+@LN"NSXL&3!05E/S?_LT9RN"C3K,UPF1-1TW!<QWD]
MJ4:<D4C.%I-$BSD6:H_T)8GE2&M'-F:H2O&41AP4Y'P^[S1R9*<F[NN_2VMO
M'\O=LYQ \M;'Z])OX [?*!>S!G)4HCD%6'<P Z28SPU'39K@VO*Q<?3DAT$E
MG"URXB2HHC.4<(9H%6S#2=N#K'B,GMVNO 8$$FB>R)KEL+ALR]HHJ3?U+YH!
M3P;7ST;$A8F"'):QB($%@K5JZN"$A.J*+\7(J*Q->)[GK",,;SP[8U3[G;!E
M#_8#P>03.10RL!UR1OAM-^R:1!Y(6,O?*#\M*Q^;=7,,'?6<MM#PZR%4QN=2
M$6$S@P;XJ(O4GYU!MU#0K Z7+$3YN9,)#^^^;R!GUJRF:ME1?;X_Q^[<YFSF
MO-'\19C+]']W:KT"?OBMQVMVSY+8VH:'KXX:C]]X^^L;FH^N]*?4-1XYCI<*
M&V,N0I=@/@MAPF!A$(%OL9\1FI1%0*T+%/?\!E.S4%<FLN?:(;0L<7P[^7L]
M*3,:M*H%.2*HCTO8$8O(/:ACF]",FF\*Q;*M.7:*[9PJ;_3"%#"1EAC',@S0
M-$X;\Q%TR,U1=:R>6+U%*-RTVD(57:ZB??/VIT7=T!$]*5N.\+E!O70"*$UI
M,G:NGC2]AGS^#^T"SIN6+C+9(Y.^MA3; 8!@AIGQ=BG#8?G][TYO)8_\FXL?
M$[.%_4+<?'.B-HR3IF*-)?\*BJ/ ]KL17(KNX0-L=0H:PO4NYU1H!+KK@RSP
M WS(O31A:&Z(V J.(V=^Q2^H]C3PIQ.D%*NP_S3K]LEVU4#LF#%QIM8(<]Q
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M&XV[EIPJ\2Y<->89*G;@S>?] =4PI1T#U0J3MAO;MX"CRE]%KB/X-$2,+;&
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M3M"IZ# "V]NZB+*;0P@[IU&Y;:/EMT>CS#.X1]4D\N# %Q?-2CWIQS U7QL
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MHT4V<2</^'19KZE[TC548B>,('8S]<D"=<-C$AE_X:$(BW ]UY_;5Q)+'<9
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MPK=;\.CN::XA7-@TAU@:)4S+7]&IMJ%R]W39HU*X)K2_9&+F4LNK^]>!PF;
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M[JB-UQIC*5\^/\[7)X<_']T!#V3"?@JBT"-F4\]W*:P#;R#8SIXZ0QQ%NZ]
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M/>RB_@MYHZJ-EI!=D>X4%>>"#V:_O ZIZ 0D1,V&3I7K("I%MU-"#32D=1-
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M@)1Z3?'ZV6Y7V3'(W,(W(^LE2>/E)S80]_\?-%__WUZA3RGZ'A.5B&J:IGF
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METR-^LHO?/-(FI[G?V:;C"/$;).EBIT=Y?/Z-N"BHILAEP>#YJTXI8.\FP[
M%!.%[X_D@)Q.C!//@FRQH"!%I1Y')J8W <[-,.TB4P?=WHN&WDW@-'CF\'2A
M&@G-Z1N=S7=Q.8"L%9@?@:NS>4F8;_T5Z5:\SBT&)\_9+X*NY:MSU,E-,*$4
M#E'?S^\D+VP:H%/%G#G#;TIWN/I[[>SY)H(2VN?XFV\P=?3,?K#-=>NAMI,^
M]6_4M< AR,'8CN^G?5T; [Y90VD"#D/>X^]Z&WJMD-HA-0L);#X0?=TB9=DS
M=TS;83E?&*7:<M#ER_[3N#3.;%X)#%]:X7O@^9?BKTU#DTE?4\^F+?WRQQ1+
M>HL\ :>>U;B/S.#8,S@KG@=T%DS)Y;%4;,=XYAR(?W7-I3/*H1W.\:GE99K6
M>[&#!KEN:G=&0N?%YVX7O&\K*?#VO]NO>#C<);&O3*\&]D,S. D]L]P.EIY'
MC_/)]U^-ZY?)\SY_8X^U#;OIK6S%E!0-"20MRR(XR[^<<4DBV!NM#!V@##)K
MN:+GSX].1@W]H%]_J^'D:9]I!YI;GS\]ZS\V/'U*XYF&OS/URX'J"^C&1+#-
M83JBO'O7JT-]H9I%?4&-VMY7I;J+[Q[7R]H]UUYA_N2Y6Q8O*%'99DB%39NN
M5E5WW!DT;DWP#^]Y';]]WHA)Z:-_'GU?Y\RYRHEP<D_X-M$W,03[_CW[T/>_
MZ#!T/7=TBIC=6%,6(0Z_55;UT2:/++OSJ3F_.FPE8_WIWZK72=T,#?7K2TIW
M]#?6'I8L"-DN:'IU;^4KS=4O+\9HK]?JZ&2Z+WT1L,[IR,GE$>$U-6\^)J=Q
M@N609=QQV;#@V;],^QG<DQP%:]H:]9[!W3K"W<1J8>'?NW?_MS^<D&O-6:8G
M9G"_8;97''K=YRUEI.U0CLQ0'CCR:D0TFME'2[G51DNX>KLR[Z/OIO^YZ.-3
M%K*,SB;KH5Y($L3JY#3ZC(F@%/7OD*0-3A$.F[3TDU<A"4$"B"*,=!=O8W.1
MEY'QU&RYC>#^@=4<3U'4GFB)3HFY:O'K(7Z_YB]OBAF2J<!W=,]GA((G$"]P
MP@I=#Q$+/,A6;+-8IB,]FZM*Q&^5T3H:8IF$(9LL+A(S?3  #IQWX=_5\U?K
M;OVAF=WX\Y)T5E7F#E*RM$0&32G-K>XA'00.U7R,LH!2))Z6#&)GR?$&A9R(
M,/?(J!WRP<WJT_!/=*,6HL63*@G%?91O[V2>H68+NR_PC2#:V,2TKQR9$$_9
MGG.&1\Z335$*-!1?,E!?O8/+&)$,!F15,>@=4T1T<?EBF)WK/6&.5"8*UQ1)
MHE;#K/T4T <^3NMLU%$O (HAL[3=M'SBP_6"^H=].L@X2+VO*?E&*]R,Z<KL
M8XCANT__.LV/S+L=^=CMG<MBW1BMHY?ZEVE#-0==$]K1/3:#0\*)T"WR&RSN
MAO,;M#976?\&3?_ 3 A;PVF]F/+^+JK7S,]4RL9+U:-?[^1S+@Y;M3;0[FMR
MQAQ.:*YI=9;'Z9>^=UT]]Y_4?^O7.^%C/LS@7 T'FMZE<M K$P:L-^N1ZS.X
M.\7"[=^W?VFC:K=/9E+&_D)WS>!>=8%+=BS@8Y#![ZG,6Y[^?_<$__]S_6A6
MYP\<ZJ7$L J'EY3(1"6U@APM'MTE,[BFNN =HBC<[F';,>Q\]"7PV^]W8%TD
M_A<';D'8W2<+5\]_ZOJ=<H4"!7I83&[J(='/NHE:V?K_##-LP:RL*V72,5.X
M6.V;8.H!;(03I!8?,B5R6[XW,+L/M]U67+Y>!NQP883$_#&(P*U/9U=337*G
M[DP'O)7'"1KDDOPG:S066JT<Q(O=A_Q=) ZO4@VSN-WH0NW"Y)=H(K<Y%UT!
M^($#Z^BV6&JRI!C^./$[!?0\/\<2%FB-VB!W%9;9;%#F2Z8SNIQL"?'K,8N>
MPM2%CUU2+*!W,/5EI^IKT(.P64XEXM$T@RNDV18?V RI]B,12I8C)7N>5-'M
MB&2*^7-,56Y0)>-I.J5R^X]@!<]+!'>K^3ZV<GH$)Y=B_/SFXZ9Y:R R#B7[
MV9U:M '_VP:=G3XE:,SL[DY]%TTMTX*Q66535?L<\A1&K9]=0U.+[S>^**IC
M%+6W:(NGO;7/F'K(5P7US?3F =)&)=4(84<BA7"T&#-_Z$H@+&^!- ?=SC>
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MW%)NA&F44091NK6*(>L4G(R=+2G*&DQ1[]$4?/[N2#1'5F)64(6!0 5BSH6
M)'6,*.DY<O!8 U2L[(".MY0[0?),U =L2^F,;H<9"9)J(=D:8F=V7,J%?CZQ
MA6]!GZW>> L)E-KBH4!EC&B:/NC6R?>'4@I((568U#-D&J%[D4FHC+QXMBZ,
M9^1>0RG1$/57SN!, '_8-MO6PDT\D9>KF-!?;@#]/+PN\ _WM.;IQ4C^K@&^
M+F(KD@GTM2M1W5;D1-P-="D/B8 C0E^2XI3/37GXRM@I E%:0LP%#H'<_&$'
M7]WV:.0OOB?LQVBZ[AI4*FF]O@O?C9D.Q453GYR5)#^,_*Q/.8RQA(VVAN#A
M"4P GR+,DZ%&P_-TM39!^Y!G)/^ZT>U,_ZM['#,P(><V.ED\)KW%H.Q$"J>/
MQ3'GR^J:'(UI@^ZBZ- (KN4HT^O5&.]G>0.EW7.\=F$39SXCL[-@\1YC@<C9
M\_(+Q1S'WZ8K^13$^HY<#H1H[HL';:JO:TI5S5F)'A'[' +HF[3/Y#CX'GML
MQ^D=@S;;"R\;_1O]^ ^#D'3\???V[RPKQ@'@)(3/GL$UG_)+.ZNU%G0N:-DP
ML.9*?ZBO7$CZW)O?X 09S$DW, C 3?X-^=-"'^2KI"*-E]:5%DLQ9?X4]>^'
MJ9<?'SE@-Q?566.2/7&G';@_]^T;,V4[X<=_?R1KW?&!X/FRZ8WW64?'FJN/
M>B;(TIJTAFW]WS#','=D.CE@[/932< _E]<]Q4W\_Q'?"$4-(=44(2?CMP.;
MP6XC1B'?'?@9B8#F_(MNDGWGZ*%K(6T1W"T))XHT*6&P1%"1#;OE?,,C@4V/
M>Z^9A79RP9O"QOR%B+MV;ASX-E0Q*?4<;%:?Z6?:(_@.'X(9--O.R!XYU@>R
M))Q"BNT:@1'ZTX#6%4W#S!_;@#&&1B R.$44M0#)FL'-4[6'NXE1QB\\N\N(
MEU1KEXXX-V?]3GS3[<AP[Q"8\]RX##>E82:Z'M85DMWJM6+8\SR0<#V.L!@:
M$-QZFNT;T%PQ*J2:C5YX_LCWB9W!WNYEW>90L#H9<9E>C\2/=LCG,/'H3X@_
MZ-@6,7UR5"0PX9E6(FX[>?U>134)0>"'O=Z:4];MY9LB\Q./@3_I_!.%^D$&
ME1X@'PH]WV2."9.3R)NM(UG?\B>0NQ<WP-GV=MP+I3B6,"ASG=N"5Z%9J*4E
M_B*K"2G=F[B%)7R*'-)F4QYLZ&F #$'M./'=DZ?TTA5F*1;;=O^K.4-S1JUQ
MZ&\:;GUEY(<JK4VUR$5=I,GES&=UIB.LLE]-C5?K;\:2Y1,,&#?2,2E[(.;?
MW3K?OUO]\C+G/O$J!]J-OT"Q)OE,>VA[!T,S?SWE;Y'FWLZTXS? 1ZLO?B_S
M$XN"9;S84PM2CF>3UEVGHBZIKBU>V'<X'>;D=/J'KMH-"I1XYL_@[L=DH40E
MMX"P8IHJ9ADBDUL;>]:DDWZ50]6KZCX0X0,LX<89G/7Z)[^ =#TD0LA<!=&W
M*E02QA?:$%?-0W[<U?;.X.938FC9?#/HHL#[ICSKUT8VLK4T%*[.)>V]&<L:
M:GG_^/IHN=';AJ@97%[2 ;@%D0OOGN881-N_H/Y#J=<OEB30WRA9]DAS1XD\
MAY>VOG^-?S1X@TG PCSYMAR)V8*O9+B%0L=RE+907BS99;"^\? JC&"-D-;+
M'4#LA,KGHVAD'>T.=9&P6E-KG_3X;]MS38WJR_F8PGD9-!7?7=')8,T[$TE>
M(]E3$+^S)XN88/?JW>7313?'77[I7#(1M#O.+[+F+<"==F1V-@OPE"-TMM96
M=@^@@X)<3%L!9^Y^T.HZ5*3YC9&7]21G5B"VX3W]Z^G([09L2)MSH3<0'5W\
MB B=R^(RX-E*JH[:+D&]YD59W1L&6\Q?!!$SDZG6\8.UM^IK\2:C6E>M1);-
M"V@%OV+_[Y-^ AQ/.@"U)DYG\-Q5G#F,?QA?A>G-K5H186VF2I*OQ.?>#T,>
M#'4,XG-)OU0QXKNE=K[7X*C6VM'9S3S?[_GDDB*DJ,O4^RPP??-U,])VG1^%
M:7?@D(XB(!#3$):@AG-A)>"=HJ+,09J%5Z,6OIRWMAK4!-)ZC_3((GLO2/HA
MF?HA.CZ-!/S(>';W]5\ALR/O^'5KT(V_+N\(F Q-"?))J"V??/SOH=N'3CZ]
M@^[P=O\TC,JMAX9:*28411EA.2P=CTN"4Y0<\?G(0-$POB^9DC-0<Y>1(V$N
MT0X3%OZ>\)*QSI/-"U3V .2(@)XW7:O']5&'E!F<<*]JFWR".Y@#/A=D"8ZR
MS='=2)*F6L%U1,V1D#O  8@!U95WW<3N_$7!,N _+DSH8!"L?CL=??"'+/M7
M;E9E7:AVKFQZ>93V*4>'[,8(GU1ZR\7&:4E2@25WQ>6) +)#7Z.+HC A$C)/
MM%@+$_.WT:P\S_5UKFC_/>OB][_3F9-IJY+9YS?O>'6J5!.43)FCN?@UJ,<3
M]XJ[YGG,UN6GRBPC=84'%]Q(EW8YZV\*&C3<Z4HUS@_[F7!TV=&YW)0?I>\2
MWWPNYA7%M:UL]OOJI%%2P!"#/WZ]7.AM=:7*V/OOJF.E;T^^J7X_@<H @J92
MZX.F:+(%L>P+?!<D(@F6A4-I(#106#6(I) =ZE\VM<4EOV6,IMID]# "IY.!
M77(H%X_\W-'#\\30,HGN*K<<^8Q_(Q*GUI5"Q>U3[R9$?O1,YGI8GN%-18)F
M*XUQ]#Z6?$ZN97Q(8&.,0IUM")3/>K\-#D3W$2&,;84;2&:K%)C??X)TC0G>
ML!1'BS,H,<3YZ'H(GY6,S^Q)&)1>?':ZW+OA)2_FUFV9=VW*9@<^NXJ1H@PN
MY%:LS OVR>\]K?1R+.MLX0QV@V;78;IZ,U(+O=>LH9LSRD?!YEQV]O<(FMFH
M0U*<=FGOJ2#*_>]ECIND^>@VTJ:;>_#+]QNOHBR7=GT+%1^E.P(K7.#%-UM/
M-.Y]JSKU63[8L"^50(Z\=NS17U1UN7?3SLD]3;O"A]'B?ZG!\LN3T]U2SYP9
MG#G*9$7/[FIUX!NC[BY*R6.P'BH51<UM\945 L$5Z$\],SCE69@FB=FL=_R)
M+)5  ;U[=%S600>GO90^%TB)<*#:+"=,<TN?.P;#Y=3LJ5+&BZ]BLM- XX0)
MQS3AC,-[]CFI=CG%!DG8@A'Q'^A*@B?!F[!JF^K)MA[/WS%]YLDT0_+!&-1R
M5)W]&+Z2-7"-I=*! \,:FUI?)M=Z[JI_^8V6'521)1& W_7S;S6<>_):[[;T
MS_[IS; +V)RI]<8\*%5$<7S]3SS9#'Y?> >)$5^]6AQ(]1F,>OA;^_R3P2;Z
M"Y**<IQ,&TP"]KU;47/IY%?7]Z7O3_R6=^7Q[IU/_UZ6%#DX^3#GIJ8A3PB;
M,/*-^(1]54=4C+;'X2?B1I.[$N):=C!MF!)!0W4ZYB]?)ZD "T:WB&5'TD^(
M4Y7%O_SZ\_T!@$0!CW)%.W MHQO6:8<IQK;IJG5P!;SLR)*]"6.TH5#%SZF!
M8W+56\=VL@5_8&(-T? I2#\?O:%QP)MF]<%M_P! K@9OP1@\:;G>W7CDUM93
M$+#1_J3A.2MQE^([W1AV0RU5'0XIJ&6^F&+&-$:FI5I<:0CT!&E2^A^>$*>^
MOWD+:=[;\^T0=W3*M57!QB.90K)MN\-RQ@%KJ!ROQN?H'!"'I:4I.,:,*C5=
M<^5;=P;'DNG\4;99R-1[Q?.H L[ C1QXX^OE@2L&=1G]P$9G&I:<E^M TG.E
MXBZWS'<[=(5"JJ-/(6\/R:%\+<6Y*\J&[ORLI+CQCT//[9.^+)4\?[R>5G(<
MJ%O=&P[O_/CM,*-K[8%?M$W*IG/O2F\U9EYNB.O+:8V[??NI;^*:\5N%3.L.
MS-P.GNO6SFU6%JYEZ7UB.D'2+.U2CCU#V+VO;0!8K]P(IM$[6@SX4H(SP=QA
M!I?SM8YMV>RR<(/60;,&V3P=C/ZL*:<<IAL= /9 S86E89 @@S^4>-?O8=GM
M&=Q1HLV#Z ,#0!K84ZO$ST-.%)]D'&1T1N@__!Q6QF!;()N5,1(JXAI0!GU5
ML"44#(O[(5EFXVSA724MR[N,3H5>7%?XZV[S53=#?>$#@.^XTAO)^?JX2#3'
M?ZS%B@7=OQ:8MPF1CM/,4 K\3%Y?@MK FBK@..:\1SI*CN??BVNYWIOL58>,
M;NUB$,,=9&(+TGJEIYFNR7XX-"_%I]!Q*SP/^>REXB([> N([ L@^^Z[D\^M
M_FEH?'Q@3]U <?YO[]MNIBVXVEJ=QN1H%UTAJ8/U2Z&R)473M.^7_I[W4U%2
MXQ)"[*T?)87_T%J4@[LN%B#-8DS?O/74VA6)HT@RP%U%M!EEKGZ%[H X8U.U
M _FW'O=[3Q@^H31%1/20"4BPZ,CM'S(1<S<B71%JDL1^X#V#0Y:Z99^:>$/3
M.D3\#+FVU;FA+B4[JS >C.2J!>JD>-_W#==C@RO9#AP\QS0[*/F&Z,KRTP_[
M[7ZPO 7QQ!R6G2MFG8XPW(*Q1!A2&<'HCH1MKIPYH^#B$4K'U#6R#=T R10;
M*H_E5#+T$C%N.,\XI:LZNGM[IA*XNVRWG $LTOS%MT>C-'\ "Z ()2=CG.^$
MTNA9P];U\$@.2_DKL.-Z?#BQJS(AN)*1U3?-$M4C!6>ZRX9-Z7;N%_K_R;(_
M^MII!C?M<1B^Q/99SE[YLH5EN[QX[;CKC\2S'HZA?S%9X$-WJW++G(3 R<\U
M\55_I/WQ1^+68?/MYOTW%QSN_S%X7!ZL[90W61&;I$)C5OYOR"95!R6^__L.
MJSA;WWK8!3^V2=='+4-=^%9O'UUJM%K7T36?,;UUP?;+%0K"V:]] WQ_31YY
M/L)2%(_U0IQV+?&1K6<R6.NRO_]S#BI 2J->&CRNO;Q.<F2QV6M[U>_D]ESK
M7>R0[H]1;?A[7RBU;X*6OOE5=O9F0L2.LS\X^&N'?WKTUTOZTOS]V^F7QP6G
M!UT'=TZB5_)%O^-KK3+3#2NL&I_]UQ+2,QJR= W%P+F';(54*4?&W6\PGSOD
M9)-2E'0D-&H-3,L!S%54$T;F7KA:1'%B6$JT)D7M6G\($Y>\]4J;(E!P(5EB
MY"'4T?L@KF+<.3:E4I^&V.=(UI"E(N<<<P'CZD2GP!3UAEC@Q2P%Q2:^F#7H
MFY,/>%QG4#;W8BXSP;=KU8Z35 LD9=IB\ZJ0]X1TSO)U,SB_V8WY47;(-27>
M@-D]O Q)N050!YHX<X 0.* IZ1!T@A+_UET\E5U< ZR&Y3E'+I$2IHD?+-!=
MT-BA[YT_CDC/ ^'B0,\EFS1?I[U'!_B>FG*^#J-D8'K/JUI@/_9Q6'D>R1'C
M,9)R5_XK5C-J#VIHTQ'3=*4]Q>)[NRAB'H"I)_ZJ:W\*"CO^^'F#89_WEYAV
M\[OX?.+#I?TQ?9]7P4/"<UUC ]D=V:68A7\.6<9&%Q];>$'O\MDR>2=MO^PI
M"S<VV*V4C1<6;AK9;<MJ-,SB4EX>WSBMZS/V'#)9>5G'[?R_JDOG@EX8;"#?
MXW:QK8%]FAL+L5 H0IV1_3<9%*%O<7MAL$+*;CK;/?_ <)'RQ*V&#[J2J2<4
MZ-+"?9! [._8/FQ'MB/C06#K([];2Z"<3_[8?'VPH0QM;B?X%!9/^XG(AK.-
M#O>$I+.:F@KI&WJ$=48K4H $*'AJO-MQ7\N7\82]^_*9?]?^<>_*CZ.)QVMK
M:X^5C7]-8)6TM;"B8N1=/6F&7V[>6&#8LUOF?"YOM7_@CVZ$^*3WTJB6]81R
M!1<Z@[M*&YEN4B1]"B_GI,&$Q)5II!VS51^%)=ZRP5J,AMT.0#%"#], G7U/
MM&_T7Z7/*[MAO0+//V)6;0U^F<%))\7$Z15$$]:WYU#>X]'69)DL2N!5WMJ7
MMK=EJORM8>F_'2.J;NFZ%UZ9Y67U!>K.\/_Z- .C1S\(%I_2M_KEY__4$>\_
M=LG+$/S*&J*"G#':371IO]:5D2097OZ*N1(-(IJ@IN"$T2C-D.1S6SZZ3%&6
M$F5:.RH@:!>C3DC"=>34 H-U?W6I5C3G-W%,-M?O"_4>1@U*[)E>S('AP L[
M6^>A@9#!G@5V97J8X/L3,D2#&JY?65SG<_3BY_5=R<\T=P1'"XW5-9 [L!X.
M%;/RR#K0Y^H$U3BQ4\W!-[$,,E7=.HSICL$97 8I25'X&V9*AE<85S!J1(,_
M"DG!H#?$O@@X6>,S@!3%#_NG^6J@]UL;4>4Y3K_YL=P,$]TS.# :,:\U:NBU
M]NXAFP(4E[!H4.U9]I@([R4B/T>8'3"I[#$<O.)4M>K1]]T4W\N9/2,OLQY%
MUNX;W?NIB987^'69XD^2!P6U-9O!;:<:,J!/^VJ4B8-ML@O?DFXNB-!:9[=A
M[JS^.L?L.(8HNM9\ KG90?Y))0&*9G"KC[*V?5E<<VQ?>\1<[=.6OO&UYTW@
M#WM4=BJ]U'/KN)9]O,V5 DD;*\BSUG33:+O6KM?#TS#'N_[6VIN5HTS*0/(5
M[=LT/4:L;W9! [VKA>AA?6UOV@SN>6G7!_(C-,W_S QN-"E"-M74)^P,V.E>
M,LA/2*@M2IU,X[TH"#A1\AZH\4Z4F/][KC]\^=/8QM9?0ONBWO)$H/3<!&IX
M_9/OD2_(\4_#(V+F4MB_XB7)%_"*CKO#D$NBG&&#QK4^%WA[GQ9%GDC71ADX
M^I6Y?.9ZU*T<6[GPW-DRW[.E^YH:^Q/W!E0?Y2A_J?/T*+KT.*S^W\*AR-1X
M=]V_8 ]C,.K:#>3TM'#J?<T=9%(T=8M[+\'V:KE[$Q0W@\LM;ZL;;=$^;&><
M%95;%F; 9@_V!]\Y^K9I^V=@RN :2#/[,$7$TN6^W%NO8VW4K",[7 ?$IC\M
M&WH<<+&B;K6.=$7[2:E.3L16G42/OF9J*[W]WT;V/"1)=%79+6JQR:^,F,%U
M==85WHQ+3;U/>K]UJ_''@JMV'[;NA0_TB,#GA^-&>/49I_)G<-\Z--S2E9EG
MM$)CI;.AG+4X6R>@M^SVV=2ENDI*.E.W!PV<I@PA[ITI4[>:JP_4U43?V_^1
M[((4@6T; )'OQF.P';QA(96R3G_CPN D6K IQBQ64%EG3J[G7$AR[;#^]XE\
M[[((\8:/%0?YW'M(1MG]G:N7)#7JV[NM_Q:_=)3Y?U7V[G$M]O'_^!)-.DRE
MUGF(0FH.'4@VB4K=%4)T&I+*U+B5ALM6TEF&$'775 BIZ$AEJ]8!W5KIO&@G
M=%Q=UXUU:=?6=WW^^O[Q>_Q^O\\?^V-[//:XKKVNU_4\7'N_GN]W<W*98B5@
M]'0B!,.4VO:?!3!J><^"@@&]WE^!; S5PB/8UX]B-DG7_)NWJ:MJ4;M"=U$@
MV53MO6'C2F8,7 ).-A.KXIK8AL V*&"2"%Y'W,#IHH))[)'[F4*)#]?KEEF+
MUGE'V_[%,YLEJPQO9;S-XD\R^BGV6EOZ R=M\'Z0G52P_G-,1NDJ>^LO-X\I
M(=]5Z*M=9*ZBZUDRYE)Z[T@.V2VOCQ5R?_Q[H;>=95G.Y9*=YB71G9,@P5!^
MDWUJ8;I-G1B&60ILJ*A]"^&2@;#(I\@NR'"@/-O/:3;=^7SA&''XN)EF&_'5
M,0QBD>1945BRR%-R44*/F%D1R:PL;R[70V*[D!TOOF"NL4QW-! ?NQN:6X,;
MSC15*\6\IR)RR87O<#)1+]X2#"UR>EPC;LO7@2AO 1/C3TR.[U+JA6"PIECX
MSKU9H0NV9<0^F1C(L9%ANV."M9W7*PDYM>'(XWAM_H/7*+T[^VMC129R/9^N
M:C/7%O^Z:&;1$&_KF8& ZL^9.V,D!1=**N\=>&/PX:3+1MI9W2+Z2[8$+V5>
MVAGU[YU[(S5G('^OF*K(BV\3"Q0?^Z:F!@*?#94<"_2*&7Z//)5GT_ N,C=:
M"VXY;=LGH<2?X]<$AK:3U)&=PLGZ(?NK6W=_1C"" O/ZDC'C#R-UGZF5+6=N
M* )>8&!W9(>@]C!]V8?-,G_I*U@?)UD/;FWGHTM_<^$]L0R]\=4='(5]30]V
M?V^5C3?SXT']@Q?7K^,+N=@7%5MA8A"T8F/HS[5#OL*99&0'A)>&*84&8"8R
MT<+NZB,8C-,T^F:<K<F%$Z036H*JKMBO1KN(MO7F4PZ'MEP_S1OZ,H_:RP_^
M$D$PQQJ7=A:7?@D8PE0'C8>8]%7;N,GCMUOL ><JIWF^/IL'PRTG15'I<YWZ
M_SVQL;CR^.V[D>XKP5]W\N+"'7 8Q4?99!DW?.#[']RJA> O&GH"5\F?*@ G
M&YV*,W_CC+]P'V.,YE'DX&-ES*=C9/&UG'F45#M58W59HC#S>^ABT'!ST_%[
MLV24NY6YXIZ(M'A:J7^3O 4:1E/5I8X'NQIPPF"3HU4#O_)(G)R\_*+"L;G5
M$\*JJ%C7POL=UE$\PU=';DW;2S*Y#ZX.%+/V(:^#J'.#:2?#TN[EY$9[[;WR
M9^^:.G+T2'FQ=NGUBA[W&H;OV_MCA>G_CBV,NA)UZ8)RO_%)(7[(RZW/CKF(
MVC\:)"_ <DC@2Y8552,(8B<A5/L9-6H*9SCVH1U&E^K5$H)3-K]W]56]5JN6
M\]163>L"MQ"<P4PPOY!8,9OJ;";"#[&E5(B1<!;86@R[MC*7L(S@K&:'D*7@
M]&LA=_$@[!\ TE-^1V$\0&+*[\\C:[J ;3FJ!<K/EJJM6[0Q]=@YHCU1\&0>
MI3:/.E/.LVIWH&LX[P!_LRP4'P.8"3%T'>I'KC>8/54L]M6)(%B!;O60:CMK
MBY-:HNP E=QZ?F&*!IR^#58*24U&JUT%W*7[Q.RT_"T0DJ][!Z.V6+Y/GEO%
M3ZLC-N*N.>%:8;L24@:/U(Q+KB%A)78:-E8^X"AB@X-=J_S$E8]L4S')1*&Y
MN:5B^+^4I*;:_Y#7:GZ+X@DIY3>(X9Q"3 :IIB3R\OX>HM@"L+._2-(^,V)J
MG/R47^G>:-_W.W-Z.7EF'8\N7'MXN"'JIW9?N(S V@WKG2_[!/E+6QWG:,RG
MB=! \Z?34?:WZ5+Y-MJ_?-2U"9B VVW4<>+0]$&:_XG&XYABBS>'CUILJ\ES
M(89)S2K0?XB9]!U,_890J$ZL6!8J\G;?_:J?RPGO!GS)15]Y8W--/=K/!8PE
ML'KEO8]*2M8H$D:GW-EFM0O\,+J=^ :G-#A"+&Y9 \4QW=X;LZ>+*#3K90V5
M4%/'5;U>]59FZJ1!BVJ3,VS9<B@YZTQT4#+N(7,)P3R 6M1,4(<?"BEZ9P(>
M+-BI"-(-GGE6*%G *7[3C9!!!F?.EE&HI<$YKW31UYF<^/H7SID+3[_K3J%>
MZ_24,6W =.ZEG0=KTIX4,R]*Z@C%*4<.)S7_>/#OU^WK]S;K'/A[EI?E71US
MK_#>RVS[ZO[V*6G>L^&)BP:S_7X9N>028DU L,XME_?(.0]DR^8;1S*!2AD>
M<5$>JU+HFS1E$V/C.4)?&DD'DR9X#X+71<;-U28,-6 L(O[-7W7WV<5NPSOO
MEYO:NASW?7-FQ/+S+\,H 9M%C*RKL.3NJZ5(;'R01ZA,G-M^8&^9P]2T>KW%
M1O2)#Q+PG83O+H\&ZB-KQ)51Y5[U-"VSLF[%OMG966+>R3.7^^\5!%ZM/\*J
M[BE-S"!5!P>CMFQ52GD?MRG0YV^/]]R<22<E^V/W.?I?4,H [09"_:$)7JOT
MWC-JD8F:*&<?FN.D)Y&]/ 6E;0%*!7TG[K5_;FUZ$ 2'-@=,/WD6S5?6C]EB
M_2GPK][XX_X!&6[!='J:XLCA\\+;0OQ2JMU'G)*?TRL&8FF3].PQ_/&^J>KQ
MXI#<LA]?%%:00>D*]F#=BAR''/UHMG 5%,667CF1$,QSO\9AZ.[0>G.+^@C>
ME[ ]N"F9[L0.(^&HF!:F#OW,5:L]\/-(2.] /2P!N:U8@P[P.V+(T\ZO:T^(
MT<?Q/I:,JI2/A7/V.AK8""%Q/!LZLC'QUS;80 &_:\]P]B^;+(Z>S+/XRXJ3
M;_KZUNIGZH415QI<7Q:]2/@.%[72;-*.Y?7YG[?_4RPDJ@T!]BQ83IRJ!<F-
M!ZD_>J37X& A0S<DDK#=>&$@-]Q\"23>:G9N"8.PJE]^V&4 \%3Y*B0 7RX&
MYWPD\6['?3_O\\^EW!O!I=2V\6#;.K:7>8W9-\.S&7:MIQNX]M\9%;5XJ]:/
MT[D7LLY\6E>R-BKP(JGB^G>?'J[9G\D9[FB(-40;.09LI:S!\D;RSK'PH-;M
MN@4._5VN/5$0RS4:<S*H?/M+[SX.9$S:7(O;=%);3<.<)+)J-R&FL)9V.9_D
MK6U['EI.IIET>Q=FACO1BLLFF8,'U @X<"#C4C#UV=G$K,YS6VB^2C]W;0B@
MP<6@EPM(G^**F? NVEIZ,TF -YS$^L<5_]7KGNP?&*7AVMU6 Q#$G)'5E-1V
M5XOX)B7V6NONCYJ[H68F.K^9E?;DXJ\ MVG)V)SU):6].YK:H4&=K"XM^7[Q
MJLG8[#M&3\;2U54ULFU;$LYNB@O:RBS@/)L[1;-_'A((MLWN[W56$93Z^??Y
MMUS.'$UNV'KI!7SOI4^._3OOJACOP"-.FY?9;;68OAI_(^RD11'Q^8(YXZ;U
MY,CY]U],>@V_J/MC9GUJQ8&]FY:M>_S^-^[!HR7_GUD=#(4&P#<CDC_'>I5&
M,-+9FHU*E9-FA7BDRIF(:J9FIN::)_L6C2HVG'Q,/VL[$+8,-Y;GVU)GF:B=
M>[YLTNEBAO;SDO$<LX=]T6[_4&*]SS&GHDPVCCK]2MJ_P=8LV63QWTQG0*,=
MP6.4GDFQ)MMXG9)$;X,<^:9YU"F]\G !.G[91+M,Y\'TRNM14X\W-1=>[47-
MS2EMH*IJ#S*/NO6_74%I_8T4?S^NGVZ@-)&U$]E.#^K@&:'7\.;8TT01Z0ES
MB"FP0O;]:7>]<]7]K,!?*7%H _G+Y7?LF.IG\FU ]DW ^RG\8K(5.Q#>?&!L
M,4QL'$%WGQY XL17@^",%IH^;I"EVV6TAJY%/1$.D>\NL3CYG[VC-!:JY3Q4
MK%$,\GZDB>916E\C!TA5YK?PMAL1M[J;]CLUI*?AI;'_7CN?VK3DE2_JWN*D
M@RJC\RCP$$-YV!WR9(4C?,$UUZ>FWU;BK!YW&G I&3<W_<R)^)_X6%-"K0@%
M;,5U%(S.7K?U?+3JH2M@+=-6=,[BU*>49<1GA*QZTU.MP=8$T/"G$Z*.8&O1
M+@B37&7FJ#"(OH;.M,-/K:!KB)M#S*'7! >KUK)-CF<IIE2/:/DCJ!BQ+C>!
M0T/ VG3 O3!HC/<X*OQE@%F@I^L\2O<(.H#TX)_E*])69'YL!)ZI^PFD<>8J
M(*,-GZPP?P5ATV(^83DX+=KF"'XH&>N[># 9RF[>$A-%4?J=ZZ?@J*-J* OJ
M:]+?%?>,%E\V!#R/DEY$UK,RPD=9L[7B@C$A9,AXX6Q2:TV39AP:>;?C$KT)
M@>5*4B1?JF;P4J1E\FP$+^#COHZ;+X)OBZ)".5Z"7%^TTKJ[R^\53*8)HJZX
M.W6R141U.-"E"]L2X>QG=&JC"6G=S81O5K^RW1/%>YX_ST,+G^:!C<&V!\4M
M(?@N9*_X*CGBCW\ ]!ZG+U5BOBKLV[8X5*7K;X*S/%>A%DE?$#>^O"OM!/,!
M I8WYI0W,]A@$1E[1?[P^>#XY1_5CR;SG9Q^J.\ UHNV.&\I6E6!VO;-?\R"
MG(]/]YM'8?%"M^-.MQP&")A^E_?]-Z\76XD\VK-%SC#9&?@F^;IJ\!*DH1Y;
M^*N"_ZV4)6H1_M?@8"6_.0UY/R?%Z5^UKZPGL[^4^[J!_HRI:04O!I]B;%ZX
MD=6N9!HM?IIS*&35HL0&"@D<O<[H$H3_^<T<).J-/E#>M"UF6)\>3Z!#Z)L2
MZM,71S]W1K$2LLH0C&VGPWO1/GGJ'QSC9IDV,VUD;Z>_!XE@^C@!TU.AH;64
M 3_S:_V#&_YCG55%L!#\;;)X,WH#P0'./;@UK^3L)["_/:$,@WEN4PAL=[^P
M,&C,U7J[Y%53-G!GO>79>AH.W&'*+><6!P.9Z@0<N2Z/)0D4,5K2A'6=D]9D
M[A+X@F;#^5)JG)"?Y.Q!2)B+Z_101$\3=@ &\FM(H,P+%C?Z\PT:HD28M'E4
M55S25)G$^6@,12>/^%=7$]3?L" ALJQ%>-B#+G1<!AQ1GH(N3O/7/"J]9>!7
M\/G'B%-OASI $1UY\^9D3>& :/3&KR],25(WP:^ ^E#_+IPR>^)N79KA(K</
MRVF':#TD5<)2>$<S83MD_AST\H/O14$FTEN@5::-C;.-2()MR;=B&T\S"J@K
MR,;= RGI#5ZUK>:K*<:%R!.V<#/4/=+Y[8UT"Q!SKI-ZC+?_[L'O9VQM/U("
MVX/G4;EN57M/5""6ZX<-<^NKLP/?O>0%6A/J!NMEX;01?YP*31/&BO#Q"@-R
MOFVWPA+F".^_*FYQE CY6D=AAFM_%=YL97>N"P%_P2J]J'NW4N9EGUXRJX!^
MSBYA9&3[P48"DC%\]B@YCJA334JF+[=G+O^:&7[ 2^)_;,!Y1YF2D5=@DI&
MX5S9"OC$,BV6UB'PA_AN$- JBT:\X;BGB"9\X<DX754I,2\%!B">\(FP,$'F
M0>[1GLP[8P%M:*D#L'4>I2?23BNCAGZW4KC2UG0<?S YZ@NOS\\6EJ<2%S5@
MQ;C$$&Q]8@AA+6@$89'5^=H0+?=Y"!P8W%TM1[L<'A:6*E9:M! '$YMHIUU6
M;HE:7$K=?N_LA^^5]_T,GU\XP]M7]90O*),\K9L)Y7_X3[/$[E/H7>MOW<!
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M+3(P,C4P.3,P7V1E9BYX;6Q02P$"% ,4    " #$<7Q;TZ8P->HQ 0"&'0\
M%               @ 'ZR@  86)P+3(P,C4P.3,P7VQA8BYX;6Q02P$"% ,4
M    " #$<7Q;<;S7:%65  ">/ H %               @ $6_0$ 86)P+3(P
M,C4P.3,P7W!R92YX;6Q02P$"% ,4    " #$<7Q;<@9_+38R!@ =W3D &
M            @ &=D@( 96$P,C8V-3 R+7,Q83%?86)P<F\N:'1M4$L! A0#
M%     @ Q'%\6W!+'6QF @  XP<  !L              ( !"<4( &5A,#(V
M-C4P,C Q97@R,RTQ7V%B<')O+FAT;5!+ 0(4 Q0    ( ,1Q?%N6?0#"?BD
M ,8J   -              "  :C'" !I;6%G95\P,#$N:G!G4$L! A0#%
M  @ Q'%\6_-M.;!$KP  H[@   T              ( !4?$( &EM86=E7S P
M,BYJ<&=02P$"% ,4    " #$<7Q;2> -H"(6  !L%P  #0
M@ ' H D :6UA9V5?,# S+FIP9U!+ 0(4 Q0    ( ,1Q?%N 1Q<>!V$  +5Z
M   -              "  0VW"0!I;6%G95\P,#0N:G!G4$L! A0#%     @
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M2P$"% ,4    " #$<7Q;X$H,-33:   <Z0  #0              @ %G80L
M:6UA9V5?,# Y+FIP9U!+ 0(4 Q0    ( ,1Q?%N3(-GSX?@  &\# 0 -
M          "  <8[# !I;6%G95\P,3 N:G!G4$L! A0#%     @ Q'%\6Y0H
M:U%WQ0$ *L\!  T              ( !TC0- &EM86=E7S Q,2YJ<&=02P$"
M% ,4    " #$<7Q;C_;Y*YW3  #M[@  #0              @ %T^@X :6UA
M9V5?,#$R+FIP9U!+ 0(4 Q0    ( ,1Q?%OI:#\]9=(! !W> 0 -
M      "  3S.#P!I;6%G95\P,3,N:G!G4$L! A0#%     @ Q'%\6PMPLQWJ
M[0  ,OD   T              ( !S* 1 &EM86=E7S Q-"YJ<&=02P$"% ,4
M    " #$<7Q; )#@$M64   4EP  #0              @ 'ACA( :6UA9V5?
M,#$U+FIP9U!+ 0(4 Q0    ( ,1Q?%N.VN&N4'T  *^!   -
M  "  >$C$P!I;6%G95\P,38N:G!G4$L! A0#%     @ Q'%\6SU50 Q#I0
MMZT   T              ( !7*$3 &EM86=E7S Q-RYJ<&=02P$"% ,4
M" #$<7Q;GN?>1R8# 0"$$@$ #0              @ '*1A0 :6UA9V5?,#$X
M+FIP9U!+ 0(4 Q0    ( ,1Q?%N>TKDCBQ,! 'PV 0 -              "
M 1M*%0!I;6%G95\P,3DN:G!G4$L! A0#%     @ Q'%\6_ 6R%W;H@  7*\
M  T              ( !T5T6 &EM86=E7S R,"YJ<&=02P$"% ,4    " #$
M<7Q;XZ2,@]SY  !:!@$ #0              @ '7 !< :6UA9V5?,#(Q+FIP
M9U!+ 0(4 Q0    ( ,1Q?%MPGR8)T\,   W.   -              "  =[Z
M%P!I;6%G95\P,C(N:G!G4$L! A0#%     @ Q'%\6P,7_4/$Y@  D?(   T
M             ( !W+X8 &EM86=E7S R,RYJ<&=02P4&     !X '@ B!P
&RZ49

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>ea0266502-s1a1_abpro_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:abp="http://www.abpro.com/20250930"
  xmlns:compsci="http://compsciresources.com"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="abp-20250930.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesFConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ResearchAndDevelopmentServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesDPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesEPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesFPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ConvertiblePreferredStocksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-16</instant>
        </period>
    </context>
    <context id="c179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">abp:ReverseStockSplitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-04-02</instant>
        </period>
    </context>
    <context id="c183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MarketValueOfPubliclyHeldSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-10</instant>
        </period>
    </context>
    <context id="c184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MarketValueOfListedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:SecondConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-23</startDate>
            <endDate>2025-06-23</endDate>
        </period>
    </context>
    <context id="c186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-01</endDate>
        </period>
    </context>
    <context id="c187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-01</endDate>
        </period>
    </context>
    <context id="c189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-08-01</startDate>
            <endDate>2025-08-31</endDate>
        </period>
    </context>
    <context id="c190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MabwellShanghaiBioscienceCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MabwellShanghaiBioscienceCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abp:AbMedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-11-13</startDate>
            <endDate>2024-11-13</endDate>
        </period>
    </context>
    <context id="c203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-13</startDate>
            <endDate>2024-11-13</endDate>
        </period>
    </context>
    <context id="c204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesBCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPESharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:CelltrionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="c217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="c218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="c219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-11</startDate>
            <endDate>2023-12-11</endDate>
        </period>
    </context>
    <context id="c220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:InvestmentAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ACABMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-02-28</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:CommonStockOfACABNetOfRedemptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:ACABFounderSharesLessOfForfeituresAndTransfersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToPIPEInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesTransferredToInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-01-28</startDate>
            <endDate>2025-01-28</endDate>
        </period>
    </context>
    <context id="c237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FirstConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:SecondConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abp:NumberOfSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abp:NumberOfSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="c283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NJCTTQCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ABP201CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MedImmuneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NCILicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesAndAccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesAndAccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">abp:VendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2023-02-28</startDate>
            <endDate>2023-02-28</endDate>
        </period>
    </context>
    <context id="c312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2023-05-31</startDate>
            <endDate>2023-05-31</endDate>
        </period>
    </context>
    <context id="c313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">abp:CROVendorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="c314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:SettlementAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-06-17</startDate>
            <endDate>2025-06-17</endDate>
        </period>
    </context>
    <context id="c318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-10-22</instant>
        </period>
    </context>
    <context id="c321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-10-23</instant>
        </period>
    </context>
    <context id="c322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NonRedemptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-05</startDate>
            <endDate>2024-11-05</endDate>
        </period>
    </context>
    <context id="c323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NonRedemptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NonRedemptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">abp:VendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-16</startDate>
            <endDate>2024-08-16</endDate>
        </period>
    </context>
    <context id="c326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-08-16</startDate>
            <endDate>2024-08-16</endDate>
        </period>
    </context>
    <context id="c327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-01</endDate>
        </period>
    </context>
    <context id="c328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-11-07</startDate>
            <endDate>2024-11-07</endDate>
        </period>
    </context>
    <context id="c330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-28</instant>
        </period>
    </context>
    <context id="c332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-28</startDate>
            <endDate>2025-01-28</endDate>
        </period>
    </context>
    <context id="c333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:NotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="c336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:NotePayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-18</instant>
        </period>
    </context>
    <context id="c338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:FundingDateToMaturityDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <context id="c339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:AfterMaturityDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <context id="c340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-22</startDate>
            <endDate>2024-08-22</endDate>
        </period>
    </context>
    <context id="c341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-22</instant>
        </period>
    </context>
    <context id="c342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:YearTwoThousandTwentyFourABIPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-07</instant>
        </period>
    </context>
    <context id="c343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:YearTwoThousandTwentyFourABIPromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-07</startDate>
            <endDate>2024-10-07</endDate>
        </period>
    </context>
    <context id="c344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:FundingDateToMaturityDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:AfterMaturityDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:FundingDateToMaturityDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:DebtInstrumentInterestRateTermAxis">abp:AfterMaturityDateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-20</instant>
        </period>
    </context>
    <context id="c365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-20</startDate>
            <endDate>2024-11-20</endDate>
        </period>
    </context>
    <context id="c366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="c369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="c371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:IssuanceDateOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:OneYearAnniversaryOfIssuanceDateOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:TwoYearAnniversaryOfIssuanceDateOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithACABExecutiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-16</instant>
        </period>
    </context>
    <context id="c380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithACABExecutiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-16</startDate>
            <endDate>2024-08-16</endDate>
        </period>
    </context>
    <context id="c381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteWithACABExecutiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-10-30</instant>
        </period>
    </context>
    <context id="c383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="c384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-14</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="c385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="c386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-06-23</instant>
        </period>
    </context>
    <context id="c387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-06-23</startDate>
            <endDate>2025-06-23</endDate>
        </period>
    </context>
    <context id="c388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-23</startDate>
            <endDate>2025-06-23</endDate>
        </period>
    </context>
    <context id="c389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-06-23</startDate>
            <endDate>2025-06-23</endDate>
        </period>
    </context>
    <context id="c390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="c393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-11-12</instant>
        </period>
    </context>
    <context id="c394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-02-12</instant>
        </period>
    </context>
    <context id="c395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-29</instant>
        </period>
    </context>
    <context id="c396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-20</instant>
        </period>
    </context>
    <context id="c397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FloorPriceEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FloorPriceEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExchangeCapEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:RegistrationEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:FirstConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:SecondConvertibleNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:YAIIPNLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SEPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-19</instant>
        </period>
    </context>
    <context id="c419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:RedemptionTriggerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-11-30</instant>
        </period>
    </context>
    <context id="c429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivatePlacementWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:ExecutiveWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:WarrantsToPurchaseCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroTwoFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroTwoFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-31</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="c436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-31</instant>
        </period>
    </context>
    <context id="c437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroOneFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="c442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="c443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:SeparatePromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abp:ExecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-30</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="c463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-11-21</startDate>
            <endDate>2024-11-21</endDate>
        </period>
    </context>
    <context id="c464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-12-24</startDate>
            <endDate>2024-12-24</endDate>
        </period>
    </context>
    <context id="c465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-25</startDate>
            <endDate>2025-07-25</endDate>
        </period>
    </context>
    <context id="c466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-07-25</instant>
        </period>
    </context>
    <context id="c467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:AdvanceNoticeToYAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-01</instant>
        </period>
    </context>
    <context id="c468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:AdvanceNoticeToYAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-01</endDate>
        </period>
    </context>
    <context id="c469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:AdvanceNoticeToYAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-11-07</instant>
        </period>
    </context>
    <context id="c470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:AdvanceNoticeToYAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-11-07</startDate>
            <endDate>2025-11-07</endDate>
        </period>
    </context>
    <context id="c471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2023-10-18</instant>
        </period>
    </context>
    <context id="c474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-04-18</instant>
        </period>
    </context>
    <context id="c476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-18</startDate>
            <endDate>2024-04-18</endDate>
        </period>
    </context>
    <context id="c477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-10-07</instant>
        </period>
    </context>
    <context id="c478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-10-07</startDate>
            <endDate>2024-10-07</endDate>
        </period>
    </context>
    <context id="c479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-14</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="c480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNoteDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="c481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNoteDiscountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="c483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="c484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-28</instant>
        </period>
    </context>
    <context id="c485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-28</startDate>
            <endDate>2025-01-28</endDate>
        </period>
    </context>
    <context id="c486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-02</instant>
        </period>
    </context>
    <context id="c487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-29</instant>
        </period>
    </context>
    <context id="c488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:MabwellShanghaiBioscienceCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:ContingentEarnoutSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">abp:AbMedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abp:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abp:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">abp:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">abp:AbproHoldingsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesBCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:FirstSharesTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:SecondShareTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:ThirdShareTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:FirstSharesTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:SecondShareTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">abp:ThirdShareTargetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPESharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:PromissoryNoteAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:CelltrionIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:SponsorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:InvestmentAdvisorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ABCDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:PIPEFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:CommonStockOfACABNetOfRedemptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:ACABFounderSharesLessOfForfeituresAndTransfersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToPIPEInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToServiceProvidersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesTransferredToInvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abp:EquipmentUnderFinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">abp:EquipmentUnderFinanceLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-14</instant>
        </period>
    </context>
    <context id="c557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-14</startDate>
            <endDate>2024-11-14</endDate>
        </period>
    </context>
    <context id="c558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MonteCarloSimulationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">abp:NumberOfSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:BlackAndScholesModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:ForwardPurchaseAgreementAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:SEPAPutRightsAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">abp:EmbeddedDerivativeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NJCTTQCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NJCTTQCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:ABP201CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:CelltrionCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="c592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">abp:FirstMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MedImmuneLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NCILicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-31</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:MSKLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">us-gaap:AccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesAndAccountsPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ExtinguishmentOfDebtAxis">abp:OtherAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:VAZYMELicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2021-11-19</startDate>
            <endDate>2021-11-19</endDate>
        </period>
    </context>
    <context id="c610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-10-21</instant>
        </period>
    </context>
    <context id="c611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2024-11-20</instant>
        </period>
    </context>
    <context id="c612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">abp:VendorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-23</startDate>
            <endDate>2023-01-23</endDate>
        </period>
    </context>
    <context id="c613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2023-01-30</startDate>
            <endDate>2023-01-30</endDate>
        </period>
    </context>
    <context id="c614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-01-24</startDate>
            <endDate>2024-01-24</endDate>
        </period>
    </context>
    <context id="c615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-05</startDate>
            <endDate>2024-11-05</endDate>
        </period>
    </context>
    <context id="c616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NonRedemptionAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-05</instant>
        </period>
    </context>
    <context id="c617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-07</startDate>
            <endDate>2024-11-07</endDate>
        </period>
    </context>
    <context id="c618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-07</instant>
        </period>
    </context>
    <context id="c619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-11-13</instant>
        </period>
    </context>
    <context id="c620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">abp:ForwardPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:AbproBioInternationalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="c628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-07</startDate>
            <endDate>2025-02-07</endDate>
        </period>
    </context>
    <context id="c630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:IssuanceDateOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:OneYearAnniversaryOfIssuanceDateOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNotesWithExecutiveAndDirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="abp:WarrantsExercisableDateAxis">abp:TwoYearAnniversaryOfIssuanceDateOfWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-07</instant>
        </period>
    </context>
    <context id="c633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2025-02-15</instant>
        </period>
    </context>
    <context id="c637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FloorPriceEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:FloorPriceEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:ExchangeCapEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:RegistrationEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">abp:SeriesACommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:LegacyAbproCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">abp:PrivateWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroTwoFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroTwoFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroOneFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroOneFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">abp:TwoZeroOneFourStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-01</startDate>
            <endDate>2024-11-30</endDate>
        </period>
    </context>
    <context id="c667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-22</instant>
        </period>
    </context>
    <context id="c669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2023-12-31</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NewConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NewConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NewConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">abp:NewConsultingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-13</startDate>
            <endDate>2023-03-13</endDate>
        </period>
    </context>
    <context id="c685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="c686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-03</startDate>
            <endDate>2023-05-03</endDate>
        </period>
    </context>
    <context id="c687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-18</startDate>
            <endDate>2023-10-18</endDate>
        </period>
    </context>
    <context id="c689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">abp:PromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-29</startDate>
            <endDate>2023-12-29</endDate>
        </period>
    </context>
    <context id="c691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">abp:ExecutiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-20</startDate>
            <endDate>2024-11-20</endDate>
        </period>
    </context>
    <context id="c692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">abp:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">abp:PostApportionedMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">abp:PostApportionedMassachusettsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-08</startDate>
            <endDate>2025-04-08</endDate>
        </period>
    </context>
    <context id="c698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-30</startDate>
            <endDate>2025-04-30</endDate>
        </period>
    </context>
    <context id="c699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-04-30</instant>
        </period>
    </context>
    <context id="c700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001893219</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">abp:RothCapitalPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-28</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="usdPeritem">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>compsci:item</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentDescription contextRef="c0" id="ixv-42258">AMENDMENT NO. 1</dei:AmendmentDescription>
    <dei:EntityRegistrantName contextRef="c0" id="ixv-48">Abpro Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0" id="ixv-58">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFilerCategory contextRef="c0" id="ixv-42259">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0" id="ixv-42260">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0" id="ixv-42261">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0" id="ixv-42262">false</dei:EntityExTransitionPeriod>
    <us-gaap:Cash contextRef="c1" decimals="-3" id="ixv-42263" unitRef="usd">328000</us-gaap:Cash>
    <us-gaap:Cash contextRef="c2" decimals="-3" id="ixv-42264" unitRef="usd">2850000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c1" decimals="-3" id="ixv-42265" unitRef="usd">271000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c2" decimals="-3" id="ixv-42266" unitRef="usd">271000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c1" decimals="-3" id="ixv-42267" unitRef="usd">611000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" id="ixv-42268" unitRef="usd">358000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <abp:ForwardPurchaseAgreementAsset contextRef="c2" decimals="-3" id="ixv-42269" unitRef="usd">155000</abp:ForwardPurchaseAgreementAsset>
    <us-gaap:RestrictedCashCurrent contextRef="c1" decimals="-3" id="ixv-42270" unitRef="usd">15000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c2" decimals="-3" id="ixv-42271" unitRef="usd">142000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent contextRef="c1" decimals="-3" id="ixv-42272" unitRef="usd">1225000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-42273" unitRef="usd">3776000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-42274" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-42275" unitRef="usd">418000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:SecurityDeposit contextRef="c1" decimals="-3" id="ixv-42276" unitRef="usd">66000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="c2" decimals="-3" id="ixv-42277" unitRef="usd">66000</us-gaap:SecurityDeposit>
    <abp:PatentsNet contextRef="c1" decimals="-3" id="ixv-42278" unitRef="usd">169000</abp:PatentsNet>
    <abp:PatentsNet contextRef="c2" decimals="-3" id="ixv-42279" unitRef="usd">176000</abp:PatentsNet>
    <abp:SEPAPutRightsAsset contextRef="c1" decimals="-3" id="ixv-42280" unitRef="usd">243000</abp:SEPAPutRightsAsset>
    <abp:SEPAPutRightsAsset contextRef="c2" decimals="-3" id="ixv-42281" unitRef="usd">188000</abp:SEPAPutRightsAsset>
    <us-gaap:Assets contextRef="c1" decimals="-3" id="ixv-42282" unitRef="usd">1703000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-42283" unitRef="usd">4661000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c1" decimals="-3" id="ixv-42284" unitRef="usd">4724000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" id="ixv-42285" unitRef="usd">3936000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-42286" unitRef="usd">8026000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-42287" unitRef="usd">7496000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c1" decimals="-3" id="ixv-42288" unitRef="usd">4401000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c2" decimals="-3" id="ixv-42289" unitRef="usd">4401000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-42290" unitRef="usd">456000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="-3" id="ixv-42291" unitRef="usd">366000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c3" decimals="-3" id="ixv-42292" unitRef="usd">147000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c4" decimals="-3" id="ixv-42293" unitRef="usd">147000</us-gaap:NotesPayableCurrent>
    <abp:ConvertibleNotes contextRef="c2" decimals="-3" id="ixv-42294" unitRef="usd">2725000</abp:ConvertibleNotes>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="c2" decimals="-3" id="ixv-42295" unitRef="usd">80000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:LiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-42296" unitRef="usd">17298000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-42297" unitRef="usd">19607000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="4"
      id="ixv-42298"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-42299"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-42300"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-42301"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-42302"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-42303"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-42304"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-42305"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="4"
      id="ixv-42306"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-42307"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-42308"
      unitRef="shares">110000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-42309"
      unitRef="shares">110000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c1"
      decimals="INF"
      id="ixv-42310"
      unitRef="shares">2672222</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-42311"
      unitRef="shares">1727192</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c1"
      decimals="INF"
      id="ixv-42312"
      unitRef="shares">2672222</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-42313"
      unitRef="shares">1694414</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c1"
      decimals="INF"
      id="ixv-42314"
      unitRef="shares">32778</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c2"
      decimals="INF"
      id="ixv-42315"
      unitRef="shares">32778</us-gaap:TreasuryStockCommonShares>
    <us-gaap:AdditionalPaidInCapital contextRef="c1" decimals="-3" id="ixv-42316" unitRef="usd">108487000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" id="ixv-42317" unitRef="usd">100608000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-42318" unitRef="usd">-124631000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-42319" unitRef="usd">-116103000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c1" decimals="-3" id="ixv-42320" unitRef="usd">-16144000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-42321" unitRef="usd">-15495000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c1" decimals="-3" id="ixv-42322" unitRef="usd">549000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c2" decimals="-3" id="ixv-42323" unitRef="usd">549000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="-3" id="ixv-42324" unitRef="usd">-15595000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="-3" id="ixv-42325" unitRef="usd">-14946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c1" decimals="-3" id="ixv-42326" unitRef="usd">1703000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-42327" unitRef="usd">4661000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c22" decimals="-3" id="ixv-42328" unitRef="usd">183000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c24" decimals="-3" id="ixv-42329" unitRef="usd">183000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c25" decimals="-3" id="ixv-42330" unitRef="usd">243000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c26" decimals="-3" id="ixv-42331" unitRef="usd">642000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" id="ixv-42332" unitRef="usd">881000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c27" decimals="-3" id="ixv-42333" unitRef="usd">2469000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c25" decimals="-3" id="ixv-42334" unitRef="usd">1093000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c26" decimals="-3" id="ixv-42335" unitRef="usd">1472000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" id="ixv-42336" unitRef="usd">5674000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c27" decimals="-3" id="ixv-42337" unitRef="usd">4864000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c25" decimals="-3" id="ixv-42338" unitRef="usd">1336000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c26" decimals="-3" id="ixv-42339" unitRef="usd">2114000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c0" decimals="-3" id="ixv-42340" unitRef="usd">6555000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c27" decimals="-3" id="ixv-42341" unitRef="usd">7333000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c25" decimals="-3" id="ixv-42342" unitRef="usd">-1336000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c26" decimals="-3" id="ixv-42343" unitRef="usd">-1931000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" id="ixv-42344" unitRef="usd">-6555000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c27" decimals="-3" id="ixv-42345" unitRef="usd">-7150000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome contextRef="c0" decimals="-3" id="ixv-42346" unitRef="usd">200000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="c27" decimals="-3" id="ixv-42347" unitRef="usd">3556000</us-gaap:OtherNonoperatingIncome>
    <abp:ChangeInFairValueOfForwardPuchaseAgreementAsset contextRef="c0" decimals="-3" id="ixv-42348" unitRef="usd">-23000</abp:ChangeInFairValueOfForwardPuchaseAgreementAsset>
    <abp:ChangeInFairValueOfSEPAPutRightsAsset contextRef="c25" decimals="-3" id="ixv-42349" unitRef="usd">230000</abp:ChangeInFairValueOfSEPAPutRightsAsset>
    <abp:ChangeInFairValueOfSEPAPutRightsAsset contextRef="c0" decimals="-3" id="ixv-42350" unitRef="usd">55000</abp:ChangeInFairValueOfSEPAPutRightsAsset>
    <abp:ChangeInFairValueOfEmbeddedDerivativeLiability contextRef="c25" decimals="-3" id="ixv-42351" unitRef="usd">-150000</abp:ChangeInFairValueOfEmbeddedDerivativeLiability>
    <abp:ChangeInFairValueOfEmbeddedDerivativeLiability contextRef="c0" decimals="-3" id="ixv-42352" unitRef="usd">-773000</abp:ChangeInFairValueOfEmbeddedDerivativeLiability>
    <abp:LossOnSettlementOfConvertibleNotes contextRef="c25" decimals="-3" id="ixv-42353" unitRef="usd">214000</abp:LossOnSettlementOfConvertibleNotes>
    <abp:LossOnSettlementOfConvertibleNotes contextRef="c0" decimals="-3" id="ixv-42354" unitRef="usd">358000</abp:LossOnSettlementOfConvertibleNotes>
    <us-gaap:InvestmentIncomeInterest contextRef="c25" decimals="-3" id="ixv-42355" unitRef="usd">6000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c26" decimals="-3" id="ixv-42356" unitRef="usd">2000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c0" decimals="-3" id="ixv-42357" unitRef="usd">30000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c27" decimals="-3" id="ixv-42358" unitRef="usd">3000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c25" decimals="-3" id="ixv-42359" unitRef="usd">193000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c26" decimals="-3" id="ixv-42360" unitRef="usd">164000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c0" decimals="-3" id="ixv-42361" unitRef="usd">1104000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c27" decimals="-3" id="ixv-42362" unitRef="usd">306000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:NonoperatingIncomeExpense contextRef="c25" decimals="-3" id="ixv-42363" unitRef="usd">-321000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c26" decimals="-3" id="ixv-42364" unitRef="usd">-162000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" id="ixv-42365" unitRef="usd">-1973000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c27" decimals="-3" id="ixv-42366" unitRef="usd">3253000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss contextRef="c25" decimals="-3" id="ixv-42367" unitRef="usd">-1657000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c26" decimals="-3" id="ixv-42368" unitRef="usd">-2093000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-3" id="ixv-42369" unitRef="usd">-8528000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c27" decimals="-3" id="ixv-42370" unitRef="usd">-3897000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c25"
      decimals="2"
      id="ixv-42371"
      unitRef="usdPershares">-0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c25"
      decimals="2"
      id="ixv-42372"
      unitRef="usdPershares">-0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c26"
      decimals="2"
      id="ixv-42373"
      unitRef="usdPershares">-3.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c26"
      decimals="2"
      id="ixv-42374"
      unitRef="usdPershares">-3.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c0"
      decimals="2"
      id="ixv-42375"
      unitRef="usdPershares">-4.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c0"
      decimals="2"
      id="ixv-42376"
      unitRef="usdPershares">-4.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c27"
      decimals="2"
      id="ixv-42377"
      unitRef="usdPershares">-6.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c27"
      decimals="2"
      id="ixv-42378"
      unitRef="usdPershares">-6.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c25"
      decimals="INF"
      id="ixv-42379"
      unitRef="shares">2613889</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c25"
      decimals="INF"
      id="ixv-42380"
      unitRef="shares">2613889</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c26"
      decimals="INF"
      id="ixv-42381"
      unitRef="shares">640606</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c26"
      decimals="INF"
      id="ixv-42382"
      unitRef="shares">640606</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c0"
      decimals="INF"
      id="ixv-42383"
      unitRef="shares">2069965</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c0"
      decimals="INF"
      id="ixv-42384"
      unitRef="shares">2069965</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c27"
      decimals="INF"
      id="ixv-42385"
      unitRef="shares">639996</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c27"
      decimals="INF"
      id="ixv-42386"
      unitRef="shares">639996</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c43"
      decimals="INF"
      id="ixv-42387"
      unitRef="shares">1727192</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c44"
      decimals="INF"
      id="ixv-42388"
      unitRef="shares">-32778</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c45" decimals="-3" id="ixv-42389" unitRef="usd">100608000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c46" decimals="-3" id="ixv-42390" unitRef="usd">-116103000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c47" decimals="-3" id="ixv-42391" unitRef="usd">-15495000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="-3" id="ixv-42392" unitRef="usd">549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="-3" id="ixv-42393" unitRef="usd">-14946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="c56"
      decimals="INF"
      id="ixv-42394"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c58" decimals="-3" id="ixv-42395" unitRef="usd">714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c60" decimals="-3" id="ixv-42396" unitRef="usd">714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="c62" decimals="-3" id="ixv-42397" unitRef="usd">714000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c58" decimals="-3" id="ixv-42398" unitRef="usd">308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c60" decimals="-3" id="ixv-42399" unitRef="usd">308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c62" decimals="-3" id="ixv-42400" unitRef="usd">308000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss contextRef="c59" decimals="-3" id="ixv-42401" unitRef="usd">-3887000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c60" decimals="-3" id="ixv-42402" unitRef="usd">-3887000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c62" decimals="-3" id="ixv-42403" unitRef="usd">-3887000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c63"
      decimals="INF"
      id="ixv-42404"
      unitRef="shares">1732192</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c64"
      decimals="INF"
      id="ixv-42405"
      unitRef="shares">-32778</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c65" decimals="-3" id="ixv-42406" unitRef="usd">101630000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c66" decimals="-3" id="ixv-42407" unitRef="usd">-119990000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c67" decimals="-3" id="ixv-42408" unitRef="usd">-18360000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c68" decimals="-3" id="ixv-42409" unitRef="usd">549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c69" decimals="-3" id="ixv-42410" unitRef="usd">-17811000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c79" decimals="-3" id="ixv-42411" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c81" decimals="-3" id="ixv-42412" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c83" decimals="-3" id="ixv-42413" unitRef="usd">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c77"
      decimals="INF"
      id="ixv-42414"
      unitRef="shares">513981</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c79" decimals="-3" id="ixv-42415" unitRef="usd">3694000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c81" decimals="-3" id="ixv-42416" unitRef="usd">3694000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c83" decimals="-3" id="ixv-42417" unitRef="usd">3694000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ProfitLoss contextRef="c80" decimals="-3" id="ixv-42418" unitRef="usd">-2984000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c81" decimals="-3" id="ixv-42419" unitRef="usd">-2984000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c83" decimals="-3" id="ixv-42420" unitRef="usd">-2984000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c91"
      decimals="INF"
      id="ixv-42421"
      unitRef="shares">2246173</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c92"
      decimals="INF"
      id="ixv-42422"
      unitRef="shares">-32778</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c93" decimals="-3" id="ixv-42423" unitRef="usd">105478000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c94" decimals="-3" id="ixv-42424" unitRef="usd">-122974000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c95" decimals="-3" id="ixv-42425" unitRef="usd">-17496000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c96" decimals="-3" id="ixv-42426" unitRef="usd">549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c97" decimals="-3" id="ixv-42427" unitRef="usd">-16947000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c104"
      decimals="-3"
      id="ixv-42428"
      unitRef="usd">78000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c106"
      decimals="-3"
      id="ixv-42429"
      unitRef="usd">78000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c25" decimals="-3" id="ixv-42430" unitRef="usd">78000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c102"
      decimals="INF"
      id="ixv-42431"
      unitRef="shares">367491</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c104"
      decimals="-3"
      id="ixv-42432"
      unitRef="usd">2243000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c106"
      decimals="-3"
      id="ixv-42433"
      unitRef="usd">2243000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c25" decimals="-3" id="ixv-42434" unitRef="usd">2243000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c102"
      decimals="INF"
      id="ixv-42435"
      unitRef="shares">91336</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c104"
      decimals="-3"
      id="ixv-42436"
      unitRef="usd">688000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c106"
      decimals="-3"
      id="ixv-42437"
      unitRef="usd">688000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c25" decimals="-3" id="ixv-42438" unitRef="usd">688000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c102"
      decimals="INF"
      id="ixv-42439"
      unitRef="shares">32778</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c103"
      decimals="INF"
      id="ixv-42440"
      unitRef="shares">32778</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ProfitLoss
      contextRef="c105"
      decimals="-3"
      id="ixv-42441"
      unitRef="usd">-1657000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c106"
      decimals="-3"
      id="ixv-42442"
      unitRef="usd">-1657000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c25" decimals="-3" id="ixv-42443" unitRef="usd">-1657000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c118"
      decimals="INF"
      id="ixv-42444"
      unitRef="shares">2672222</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c120"
      decimals="-3"
      id="ixv-42445"
      unitRef="usd">108487000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c121"
      decimals="-3"
      id="ixv-42446"
      unitRef="usd">-124631000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c122"
      decimals="-3"
      id="ixv-42447"
      unitRef="usd">-16144000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c123"
      decimals="-3"
      id="ixv-42448"
      unitRef="usd">549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c1" decimals="-3" id="ixv-42449" unitRef="usd">-15595000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-3" id="ixv-42450" unitRef="usd">-8528000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c27" decimals="-3" id="ixv-42451" unitRef="usd">-3897000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c0" decimals="-3" id="ixv-42452" unitRef="usd">18000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c27" decimals="-3" id="ixv-42453" unitRef="usd">67000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" id="ixv-42454" unitRef="usd">1158000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c27" decimals="-3" id="ixv-42455" unitRef="usd">1531000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c0" decimals="-3" id="ixv-42456" unitRef="usd">418000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c27" decimals="-3" id="ixv-42457" unitRef="usd">408000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OtherNoncashExpense contextRef="c0" decimals="-3" id="ixv-42458" unitRef="usd">854000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense contextRef="c27" decimals="-3" id="ixv-42459" unitRef="usd">53000</us-gaap:OtherNoncashExpense>
    <abp:LossOnSettlementsOfConvertibleNotes contextRef="c0" decimals="-3" id="ixv-42460" unitRef="usd">358000</abp:LossOnSettlementsOfConvertibleNotes>
    <us-gaap:OtherIncome contextRef="c0" decimals="-3" id="ixv-42461" unitRef="usd">200000</us-gaap:OtherIncome>
    <us-gaap:OtherIncome contextRef="c27" decimals="-3" id="ixv-42462" unitRef="usd">3556000</us-gaap:OtherIncome>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c0" decimals="-3" id="ixv-42463" unitRef="usd">160000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <abp:ChangeInFairValueOfForwardPurchaseAgreementAsset contextRef="c0" decimals="-3" id="ixv-42464" unitRef="usd">-23000</abp:ChangeInFairValueOfForwardPurchaseAgreementAsset>
    <abp:ChangeInFairValueOfSEPAPutRightAsset contextRef="c0" decimals="-3" id="ixv-42465" unitRef="usd">55000</abp:ChangeInFairValueOfSEPAPutRightAsset>
    <abp:ChangeInFairValueOnEmbeddedDerivativeLiability contextRef="c0" decimals="-3" id="ixv-42466" unitRef="usd">-773000</abp:ChangeInFairValueOnEmbeddedDerivativeLiability>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c27" decimals="-3" id="ixv-42467" unitRef="usd">183000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" id="ixv-42468" unitRef="usd">257000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c27" decimals="-3" id="ixv-42469" unitRef="usd">93000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c0" decimals="-3" id="ixv-42470" unitRef="usd">787000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c27" decimals="-3" id="ixv-42471" unitRef="usd">325000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c0" decimals="-3" id="ixv-42472" unitRef="usd">-73000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c27" decimals="-3" id="ixv-42473" unitRef="usd">551000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c0" decimals="-3" id="ixv-42474" unitRef="usd">-366000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" id="ixv-42475" unitRef="usd">-456000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c27" decimals="-3" id="ixv-42476" unitRef="usd">-421000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" id="ixv-42477" unitRef="usd">-5386000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c27" decimals="-3" id="ixv-42478" unitRef="usd">-5215000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c0" decimals="-3" id="ixv-42479" unitRef="usd">26000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" id="ixv-42480" unitRef="usd">26000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c0" decimals="-3" id="ixv-42481" unitRef="usd">132000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c0" decimals="-3" id="ixv-42482" unitRef="usd">1840000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt contextRef="c27" decimals="-3" id="ixv-42483" unitRef="usd">4877000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromNotesPayable contextRef="c0" decimals="-3" id="ixv-42484" unitRef="usd">553000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="c0" decimals="-3" id="ixv-42485" unitRef="usd">553000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromOtherEquity contextRef="c0" decimals="-3" id="ixv-42486" unitRef="usd">739000</us-gaap:ProceedsFromOtherEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c27" decimals="-3" id="ixv-42487" unitRef="usd">365000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c27" decimals="-3" id="ixv-42488" unitRef="usd">17000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" id="ixv-42489" unitRef="usd">2711000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c27" decimals="-3" id="ixv-42490" unitRef="usd">4495000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" id="ixv-42491" unitRef="usd">-2649000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c27" decimals="-3" id="ixv-42492" unitRef="usd">-720000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-42493" unitRef="usd">2992000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-42494" unitRef="usd">861000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-42495" unitRef="usd">343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c177"
      decimals="-3"
      id="ixv-42496"
      unitRef="usd">141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" id="ixv-42497" unitRef="usd">21000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c27" decimals="-3" id="ixv-42498" unitRef="usd">1000</us-gaap:InterestPaidNet>
    <abp:IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses contextRef="c0" decimals="-3" id="ixv-42499" unitRef="usd">51000</abp:IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses>
    <us-gaap:ConversionOfStockAmountIssued1 contextRef="c0" decimals="-3" id="ixv-42500" unitRef="usd">161000</us-gaap:ConversionOfStockAmountIssued1>
    <abp:CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability contextRef="c0" decimals="-3" id="ixv-42501" unitRef="usd">5937000</abp:CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability>
    <abp:DeferredOfferingCostsIncludedInAccountsPayable contextRef="c27" decimals="-3" id="ixv-42502" unitRef="usd">575000</abp:DeferredOfferingCostsIncludedInAccountsPayable>
    <abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense contextRef="c27" decimals="-3" id="ixv-42503" unitRef="usd">113000</abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense>
    <us-gaap:Cash contextRef="c1" decimals="-3" id="ixv-42504" unitRef="usd">328000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="c177"
      decimals="-3"
      id="ixv-42505"
      unitRef="usd">1000</us-gaap:Cash>
    <us-gaap:RestrictedCash contextRef="c1" decimals="-3" id="ixv-42506" unitRef="usd">15000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="c177"
      decimals="-3"
      id="ixv-42507"
      unitRef="usd">140000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c1" decimals="-3" id="ixv-42508" unitRef="usd">343000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c177"
      decimals="-3"
      id="ixv-42509"
      unitRef="usd">141000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0" id="ixv-28366">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Organization and Description of the Business&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Abpro Holdings, Inc. and its subsidiaries,
(the &#x201c;Company&#x201d;) is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives
of patients with severe and life-threatening diseases. The Company is focused on the development of novel antibodies using its proprietary
discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology and infectious disease.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 13, 2024 (the &#x201c;Closing Date&#x201d;),
Atlantic Coastal Acquisition Corp. II (&#x201c;ACAB&#x201d;) consummated a merger (the &#x201c;Merger&#x201d;) pursuant to the terms of the
Merger Agreement, dated as of December 11, 2023 (the &#x201c;Merger Agreement&#x201d;) by and among Abpro Corporation (&#x201c;Legacy Abpro&#x201d;),
ACAB, and Abpro Merger Sub Corp., a Delaware corporation (&#x201c;Merger Sub&#x201d;) and wholly owned subsidiary of ACAB prior to the
Closing Date. Pursuant to the Merger Agreement, on the Closing Date, (i) ACAB changed its name to &#x201c;Abpro Holdings, Inc.&#x201d;
(&#x201c;New Abpro&#x201d;), and (ii)&#160;Merger Sub merged with and into Legacy Abpro, with Legacy Abpro as the surviving company in
the Merger (such transactions, the &#x201c;Merger,&#x201d; and, collectively with the other transactions described in the Merger Agreement,
the &#x201c;Reverse Recapitalization&#x201d;). Shares of the New Abpro common stock commenced trading on the Nasdaq Global Market on November
14, 2024.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;After giving effect to the Merger, Legacy
Abpro became a wholly owned subsidiary of the Company. The Merger was accounted for as a reverse recapitalization in accordance with
U.S. GAAP, and under this method of accounting, ACAB was treated as the acquired company for financial reporting purposes and Legacy
Abpro was treated as the acquirer. Operations prior to the Merger are those of Legacy Abpro. Unless otherwise noted, the Company has
retroactively adjusted all common and preferred share and related price information to give effect to the Exchange Ratio as set forth
in the Merger Agreement (see Note 3). The &#x201c;Company&#x201d; refers to Abpro Holdings, Inc. and its subsidiaries, including Abpro
Corporation, prior to and subsequent to the Merger. Legacy Abpro is the accounting acquirer in the Merger and, as such, the condensed
consolidated financial statements for the three months and nine months ended September 30, 2024 present operations of Legacy Abpro prior
to the Merger Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Refer to Note 3 &#x2014; Merger for further
details of the Merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 16 , 2025, the Company filed with
the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the &#x201c;Certificate
of Amendment&#x201d;), which became effective on October 31, 2025 (the &#x201c;Effective Time&#x201d;), to effect a one-for-thirty (1:30)
reverse stock split (the &#x201c;Reverse Stock Split&#x201d;), of the shares of the Company&#x2019;s common stock, par value $0.0001 per
share. The Reverse Stock Split was approved by the Company&#x2019;s stockholders at the 2025 annual meeting of the stockholders on October
10, 2025. The Company&#x2019;s common stock began trading on a reverse stock split-adjusted basis upon market opening on November 3, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As a result of the Reverse Stock Split, every
30 shares of issued and outstanding common stock will be automatically combined into one (1) issued and outstanding share of common stock,
without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split. Instead, stockholders
who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly divisible by the
Reverse Stock Split ratio will be entitled to receive an additional fraction of a share of common stock to round up to the next whole
share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;All of the Company&#x2019;s historical share
and per share information related to issued and outstanding common stock, restricted stock units, and options and warrants exercisable
for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1:30 reverse stock split.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of more advanced
or effective therapies, dependence on key executives, protection of and dependence on proprietary technology, compliance with government
regulations and ability to secure additional capital to fund operations. Programs currently under development will require significant
additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization.
These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting
capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will
realize significant revenue from product sales.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is required to evaluate whether
there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern
within one year after the date that the condensed consolidated financial statements are issued. Through September 30, 2025, the Company
has funded its operations mainly through equity and debt financings, including the proceeds from the issuance of shares under SEPA (see
Notes 11 and 16), as well as from the Merger and the PIPE Financing (see Note 3), and to a lesser extent, payments received in connection
with collaboration and license agreements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of September&#160;30, 2025 and December&#160;31,
2024, the Company had an accumulated deficit of $124,631 and $116,103, respectively. The Company&#x2019;s net loss was $1,657 and $8,528
for the three and nine months ended September&#160;30, 2025, respectively. Substantially all of the Company&#x2019;s net losses resulted
from costs incurred in connection with the Company&#x2019;s research and development programs and from general and administrative costs
associated with the Company&#x2019;s operations. The Company expects to incur substantial operating losses and negative cash flows from
operations for the foreseeable future as the Company advances its product candidates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On April 2, 2025, the Company received written
notice (the &#x201c;Notice&#x201d;) from the Listing Qualifications Department staff (the &#x201c;Staff&#x201d;) of the Nasdaq Stock Market
(&#x201c;Nasdaq&#x201d;) notifying the Company that, based on the closing bid price of the Company&#x2019;s common stock for the last 30
consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq
Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the &#x201c;Minimum
Bid Price Requirement&#x201d;), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement
exists if the deficiency continues for a period of 30 consecutive business days. &#160;Pursuant to the Nasdaq Listing Rules, the Company
has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. The
letter stated that the Company had 180 calendar days, or until September 29, 2025, to regain compliance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On April 10, 2025, the Company received two
letters from the Staff of Nasdaq. One letter (the &#x201c;MVPHS Notice&#x201d;) indicated that based upon Nasdaq&#x2019;s review of the
Company&#x2019;s Market Value of Publicly Held Shares (&#x201c;MVPHS&#x201d;) for the last 30 consecutive business days prior to the date
of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities
to maintain a minimum MVPHS of $15,000,000 (the &#x201c;MVPHS Requirement&#x201d;). The second letter notified the Company that from February
20, 2025, to April 9, 2025, the Company&#x2019;s Market Value of Listed Securities (&#x201c;MVLS&#x201d;) was below the minimum of $50 million
required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the &#x201c;MVLS Requirement&#x201d;).
Each letter stated that the Company had 180 calendar days, or until October 7, 2025, to regain compliance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On September 30, 2025, the Company received
a letter from Nasdaq notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement during the compliance
period. Accordingly, the Company timely requested a hearing before the appeal panel (the &#x201c;Panel&#x201d;), which stayed the suspension
of the Company&#x2019;s securities with Nasdaq pending the Panel&#x2019;s decision or any extension of time provided by the Panel to regain
compliance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 14, 2025, the Company received
a letter (the &#x201c;Notice&#x201d;) from Nasdaq notifying the Company that it had not regained compliance with either the MVPHS Requirement
or the MVLS Requirement during the compliance period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Hearing was held on October 30, 2025.
During the Hearing, the Company presented its plans to regain compliance with the Minimum Bid Price Requirement, the MVPHS Requirement
and the MVLS Requirement. On November 10, 2025, the Company received a decision letter from the Panel granting the Company&#x2019;s request
for continued listing on The Nasdaq Stock Market, subject to the Company&#x2019;s strict adherence to certain interim deadlines and conditions.
The Panel will maintain jurisdiction over the Company&#x2019;s listing through March 30, 2026, and may reconsider the terms of the exception
or delist the Company if it fails to meet any of the imposed deadlines or becomes deficient with any listing rule during this period.
There can be no assurance that the Company will be able to meet the conditions imposed by the Panel or regain and maintain compliance
with Nasdaq&#x2019;s listing requirements. Failure to do so may result in the delisting of the Company&#x2019;s securities from Nasdaq.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 23, 2025, the Company received net
proceeds of $1,840 from the Second Convertible Note pursuant to the SEPA (see Note 11).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In July and August 2025, the Company issued
three Advance Notices to YA (see Note 11) in accordance with the terms of the SEPA, under which YA purchased from the Company 91,336
common stock shares, raising $688 in total net proceeds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of September&#160;30, 2025, the Company
had cash of $328. Due to its current liabilities, the cash available to the Company will not be sufficient to allow the Company to operate
for at least 12 months from the date these financial statements are available for issuance. The future viability of the Company is largely
dependent on its ability to raise additional capital to finance its operations. The Company expects to seek additional funding through
equity and debt financings, collaboration agreements and research grants. Although the Company has been successful in raising capital
in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company,
if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development
programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accordingly, based on the considerations discussed
above, management has concluded there is substantial doubt as to the Company&#x2019;s ability to continue as a going concern within one
year after the date the condensed consolidated financial statements are issued. The Company plans to continue to fundraise, as well as
seek alternate revenues from collaboration and license agreements. If adequate funds are not available, the Company may be required to
initiate steps to slow cash burn, extending the cash runway until financing can be secured. The condensed consolidated financial statements
do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might result
from the outcome of this uncertainty.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c178"
      decimals="4"
      id="ixv-42510"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <abp:ReverseStockSplitSharesOfIssued
      contextRef="c0"
      decimals="0"
      id="ixv-42511"
      unitRef="shares">30</abp:ReverseStockSplitSharesOfIssued>
    <abp:ReverseStockSpllitSharesOfOutstanding
      contextRef="c0"
      decimals="0"
      id="ixv-42512"
      unitRef="shares">30</abp:ReverseStockSpllitSharesOfOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c179"
      decimals="0"
      id="ixv-42513"
      unitRef="shares">1</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c179"
      decimals="0"
      id="ixv-42514"
      unitRef="shares">1</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c1" decimals="-3" id="ixv-42515" unitRef="usd">-124631000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-42516" unitRef="usd">-116103000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:ProfitLoss
      contextRef="c180"
      decimals="-3"
      id="ixv-42517"
      unitRef="usd">-1657000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c181"
      decimals="-3"
      id="ixv-42518"
      unitRef="usd">-8528000</us-gaap:ProfitLoss>
    <abp:SecurityBidPricePerShare
      contextRef="c182"
      decimals="2"
      id="ixv-42519"
      unitRef="usdPershares">1</abp:SecurityBidPricePerShare>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="c183"
      decimals="-3"
      id="ixv-42520"
      unitRef="usd">15000000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="c184"
      decimals="-6"
      id="ixv-42521"
      unitRef="usd">50000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c185"
      decimals="-3"
      id="ixv-42522"
      unitRef="usd">1840000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c186"
      decimals="0"
      id="ixv-42523"
      unitRef="shares">91336</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c187"
      decimals="0"
      id="ixv-42524"
      unitRef="shares">91336</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c188"
      decimals="-3"
      id="ixv-42525"
      unitRef="usd">688000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c189"
      decimals="-3"
      id="ixv-42526"
      unitRef="usd">688000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:Cash contextRef="c1" decimals="-3" id="ixv-42527" unitRef="usd">328000</us-gaap:Cash>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0" id="ixv-28511">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Summary of Significant Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). The accompanying condensed
consolidated financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation
(&#x201c;AbMed&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts
have been reclassified to conform to the current period presentation with no material impact on the condensed consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The preparation of condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported
in the condensed consolidated financial statements and accompanying notes. Significant estimates in these condensed consolidated financial
statements include stock-based compensation expense, the fair value of derivative instruments, the fair value of options and warrants,
pre-clinical&#160;and clinical accrued expenses, the valuation and realizability of deferred tax assets, and the ability to continue
as a going concern. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates
on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making
estimates, actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2022, the Company received an invoice
from Mabwell (Shanghai) Bioscience Co., Ltd. (&#x201c;Mabwell&#x201d;) for approximately $3,500 in connection with the manufacturing of
certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based on the information available
at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its validity. The Company continued to
dispute the amount and its contractual basis because the parties had neither finalized nor executed a clinical trial manufacturing agreement.
In July 2024, the Company received communication from Mabwell that they will not be pursuing the collection of the originally invoiced
amount. Accordingly, during the quarter ended March 31, 2024, the Company reversed the liability and recognized $3,500 of other income.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Unaudited Interim Condensed Consolidated
Financial Statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The accompanying interim condensed consolidated
financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared
on the same basis as the audited financial statements, and in management&#x2019;s opinion, include all adjustments, consisting of only
normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of September&#160;30, 2025
and its results of operations for the three months and nine months ended September&#160;30, 2025 and 2024, and cash flows for the nine
months ended September&#160;30, 2025 and 2024. The results of operations for the three months and nine months ended September&#160;30,
2025 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2025 or any other period. The
December&#160;31, 2024 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not
include all disclosures from the annual financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Certain information and footnote disclosures
normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant
to the rules and regulations of the SEC. Accordingly, these condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements for the year ended December&#160;31, 2024 and the related notes included in the Company&#x2019;s
Annual Report on Form 10-K, filed with the SEC on April 15, 2025 (the &#x201c;Annual Report&#x201d;), which provides a more complete discussion
of the Company&#x2019;s accounting policies and certain other information. There have been no significant changes to the significant accounting
policies disclosed in Note 2 of the audited consolidated financial statements as of and for the year ended December&#160;31, 2024 included
in the Company&#x2019;s Annual Report.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC Topic No. 280, Segment Reporting (&#x201c;ASC
280&#x201d;), establishes standards for the way that public business enterprises report information about operating segments in their
annual consolidated financial statements and requires that those enterprises report selected information about operating segments in
interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and
major customers. The Company&#x2019;s business segments are based on the organization structure used by the chief operating decision maker
(&#x201c;CODM&#x201d;) for making operating and investment decisions and for assessing performance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In accordance with ASC 280, the Company has
determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in the
areas of immuno-oncology, ophthalmology and infectious disease. The financial results of the Company&#x2019;s operations are managed and
reported to the &lt;span style="-sec-ix-hidden: hidden-fact-405"&gt;Chief Executive Officer&lt;/span&gt;, who is considered the Company&#x2019;s CODM, on a consolidated basis. The CODM assesses performance
and allocates resources based on the Company&#x2019;s consolidated statements of operations, and key components and processes of the Company&#x2019;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development expenses, general and administrative
expenses, and interest expenses, which are each separately presented on the Company&#x2019;s condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Non-controlling Interest&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company holds an 82% ownership interest
in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not owned by
the Company and is reported as a component in stockholders&#x2019; equity on the condensed consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $2.00
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling
interest holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the
nine month periods ending September 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company follows the two-class method to
compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 12), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#x2019;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#x2019;s outstanding common
stock for all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic net loss per share attributable to common
stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock outstanding
during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion of such
shares would be anti-dilutive. As the Company has incurred losses for the three and nine months ended September 30, 2025 and 2024, basic
and diluted net loss per share were the same all periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share, because their effect was anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-404"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;662,921&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;990,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,159&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;222,635&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;345,164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;16,667&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,292&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,229,302&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,013,536&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2023, the&#160;Financial Accounting
Standards Board&#160;(&#x201c;FASB&#x201d;) issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted.
The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these unaudited
condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 4, 2024, the FASB issued&#160;ASU
2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the
same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting
periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.
The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Management does not believe that any additional
recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#x2019;s
financial statements.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0" id="ixv-28523">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). The accompanying condensed
consolidated financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation
(&#x201c;AbMed&#x201d;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts
have been reclassified to conform to the current period presentation with no material impact on the condensed consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0" id="ixv-28535">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The preparation of condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported
in the condensed consolidated financial statements and accompanying notes. Significant estimates in these condensed consolidated financial
statements include stock-based compensation expense, the fair value of derivative instruments, the fair value of options and warrants,
pre-clinical&#160;and clinical accrued expenses, the valuation and realizability of deferred tax assets, and the ability to continue
as a going concern. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates
on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making
estimates, actual results could differ materially from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2022, the Company received an invoice
from Mabwell (Shanghai) Bioscience Co., Ltd. (&#x201c;Mabwell&#x201d;) for approximately $3,500 in connection with the manufacturing of
certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based on the information available
at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its validity. The Company continued to
dispute the amount and its contractual basis because the parties had neither finalized nor executed a clinical trial manufacturing agreement.
In July 2024, the Company received communication from Mabwell that they will not be pursuing the collection of the originally invoiced
amount. Accordingly, during the quarter ended March 31, 2024, the Company reversed the liability and recognized $3,500 of other income.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:OtherReceivables
      contextRef="c190"
      decimals="-3"
      id="ixv-42528"
      unitRef="usd">3500000</us-gaap:OtherReceivables>
    <us-gaap:OtherIncome
      contextRef="c191"
      decimals="-3"
      id="ixv-42529"
      unitRef="usd">3500000</us-gaap:OtherIncome>
    <abp:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock contextRef="c0" id="ixv-28568">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Unaudited Interim Condensed Consolidated
Financial Statements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The accompanying interim condensed consolidated
financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared
on the same basis as the audited financial statements, and in management&#x2019;s opinion, include all adjustments, consisting of only
normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of September&#160;30, 2025
and its results of operations for the three months and nine months ended September&#160;30, 2025 and 2024, and cash flows for the nine
months ended September&#160;30, 2025 and 2024. The results of operations for the three months and nine months ended September&#160;30,
2025 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2025 or any other period. The
December&#160;31, 2024 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not
include all disclosures from the annual financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Certain information and footnote disclosures
normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant
to the rules and regulations of the SEC. Accordingly, these condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements for the year ended December&#160;31, 2024 and the related notes included in the Company&#x2019;s
Annual Report on Form 10-K, filed with the SEC on April 15, 2025 (the &#x201c;Annual Report&#x201d;), which provides a more complete discussion
of the Company&#x2019;s accounting policies and certain other information. There have been no significant changes to the significant accounting
policies disclosed in Note 2 of the audited consolidated financial statements as of and for the year ended December&#160;31, 2024 included
in the Company&#x2019;s Annual Report.&lt;/span&gt;&lt;/p&gt;</abp:UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c0" id="ixv-28584">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ASC Topic No. 280, Segment Reporting (&#x201c;ASC
280&#x201d;), establishes standards for the way that public business enterprises report information about operating segments in their
annual consolidated financial statements and requires that those enterprises report selected information about operating segments in
interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and
major customers. The Company&#x2019;s business segments are based on the organization structure used by the chief operating decision maker
(&#x201c;CODM&#x201d;) for making operating and investment decisions and for assessing performance.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In accordance with ASC 280, the Company has
determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in the
areas of immuno-oncology, ophthalmology and infectious disease. The financial results of the Company&#x2019;s operations are managed and
reported to the &lt;span style="-sec-ix-hidden: hidden-fact-405"&gt;Chief Executive Officer&lt;/span&gt;, who is considered the Company&#x2019;s CODM, on a consolidated basis. The CODM assesses performance
and allocates resources based on the Company&#x2019;s consolidated statements of operations, and key components and processes of the Company&#x2019;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development expenses, general and administrative
expenses, and interest expenses, which are each separately presented on the Company&#x2019;s condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription contextRef="c0" id="ixv-28598">The financial results of the Company&#x2019;s operations are managed and
reported to the Chief Executive Officer, who is considered the Company&#x2019;s CODM, on a consolidated basis</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <abp:NoncontrollingInterestPolicyTextBlock contextRef="c0" id="ixv-28618">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Non-controlling Interest&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company holds an 82% ownership interest
in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not owned by
the Company and is reported as a component in stockholders&#x2019; equity on the condensed consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $2.00
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling
interest holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the
nine month periods ending September 30, 2025 and 2024.&lt;/span&gt;&lt;/p&gt;</abp:NoncontrollingInterestPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c192"
      decimals="2"
      id="ixv-42530"
      unitRef="pure">0.82</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="c193"
      decimals="2"
      id="ixv-42531"
      unitRef="usdPershares">2</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0" id="ixv-28630">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company follows the two-class method to
compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 12), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#x2019;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#x2019;s outstanding common
stock for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Basic net loss per share attributable to common
stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock outstanding
during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion of such
shares would be anti-dilutive. As the Company has incurred losses for the three and nine months ended September 30, 2025 and 2024, basic
and diluted net loss per share were the same all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share, because their effect was anti-dilutive:&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-404"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;662,921&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;990,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,159&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;222,635&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;345,164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;16,667&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,292&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,229,302&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,013,536&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c0" id="ixv-28646">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share, because their effect was anti-dilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-404"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;662,921&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;990,000&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4,159&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;222,635&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;345,164&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;16,667&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,292&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,229,302&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,013,536&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c195"
      decimals="INF"
      id="ixv-42532"
      unitRef="shares">662921</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c196"
      decimals="INF"
      id="ixv-42533"
      unitRef="shares">990000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c197"
      decimals="INF"
      id="ixv-42534"
      unitRef="shares">4159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c198"
      decimals="INF"
      id="ixv-42535"
      unitRef="shares">222635</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c199"
      decimals="INF"
      id="ixv-42536"
      unitRef="shares">345164</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c200"
      decimals="INF"
      id="ixv-42537"
      unitRef="shares">16667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c201"
      decimals="INF"
      id="ixv-42538"
      unitRef="shares">1292</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c0"
      decimals="INF"
      id="ixv-42539"
      unitRef="shares">1229302</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c27"
      decimals="INF"
      id="ixv-42540"
      unitRef="shares">1013536</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <abp:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock contextRef="c0" id="ixv-28776">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2023, the&#160;Financial Accounting
Standards Board&#160;(&#x201c;FASB&#x201d;) issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted.
The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these unaudited
condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</abp:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0" id="ixv-28803">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 4, 2024, the FASB issued&#160;ASU
2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the
same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting
periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.
The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Management does not believe that any additional
recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#x2019;s
financial statements.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c0" id="ixv-28821">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Merger&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 13, 2024, Merger Sub, a wholly-owned
subsidiary of ACAB, merged with Legacy Abpro, with Legacy Abpro surviving as a wholly-owned subsidiary of ACAB. At the effective time
of the Merger:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;each outstanding share of Legacy Abpro common stock was converted into approximately&#160;0.068&#160;shares of the Company&#x2019;s common stock;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;each outstanding share of preferred stock of Legacy Abpro was converted into the aggregate number of shares of New Abpro&#x2019;s common stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately&#160;0.068; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;each outstanding option or warrant to purchase Legacy Abpro common stock was converted into an option or warrant, as applicable, to purchase a number of shares of the Company&#x2019;s common stock equal to the number of shares of Legacy Abpro common stock subject to such option or warrant multiplied by approximately&#160;0.068, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately&#160;0.068; in each case, rounded down to the nearest whole share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition, at the Closing Date, 6,744,550&#160;shares
of Series A common stock and 1 share of Series B common stock of ACAB, on a pre-split basis, automatically converted into shares of the
Company&#x2019;s common stock, on a&#160;one-for-one&#160;basis.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Former holders of the Legacy Abpro common
stock and Legacy Abpro preferred stock are eligible to receive up to 483,333 additional shares of the Company&#x2019;s common stock (&#x201c;Contingent
Earnout Shares&#x201d;) if, within five calendar years after the closing of the Merger, the volume weighted average price of shares of
the Company&#x2019;s Common Stock on Nasdaq, or any other national securities exchange on which the shares of the Company&#x2019;s Common
Stock are then traded (&#x201c;VWAP&#x201d;) meets or exceeds three-tier target prices defined in the agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the Closing Date, the Company issued an
aggregate of&#160;112,247 shares of the Company&#x2019;s common stock (the &#x201c;PIPE Shares&#x201d;) in a private placement for the total
consideration of $11,225 (the &#x201c;PIPE Financing&#x201d;). Out of the total PIPE Shares, 20,749 shares were issued to Abpro Bio International,
Inc. (&#x201c;ABI&#x201d;), a significant investor in Legacy Abpro&#x2019;s Series E and F convertible preferred stock, pursuant to the
terms of a subscription agreement dated August 22, 2024 with ABI (the &#x201c;Abpro Bio Subscription Agreement&#x201d;) for an aggregate
purchase price of $6,225, of which $4,225 was used to repay the balance due by Legacy Abpro to ABI under the promissory note agreement
(see Note 10) and the remainder of $2,000 in cash. In addition, pursuant to the Abpro Bio Subscription Agreement, ABI received an aggregate
of 41,498 shares of New Abpro common stock reserved for use in the PIPE Financing or to obtain capital for ACAB or the surviving company,
as defined in the Merger Agreement (the &#x201c;Incentive Shares&#x201d;). The Company also issued 16,667 common stock shares of New Abpro
to Celltrion, Inc., a company organized and existing under the laws of South Korea (&#x201c;Celltrion&#x201d;), pursuant to the terms of
a subscription agreement dated August 22, 2024 with Celltrion (&#x201c;Celltrion&#x201d;) (the &#x201c;Celltrion Subscription Agreement&#x201d;,
together with the &#x201c;Abpro Bio Subscription Agreement&#x201d;, collectively the &#x201c;PIPE Subscription Agreements&#x201d;) for an
aggregate purchase price of $5,000. In addition, Celltrion received an aggregate of 33,333 Incentive Shares.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Pursuant to the terms of the Merger Agreement,
at the Closing Date, ACAB&#x2019;s sponsor, Atlantic Coastal Management II LLC (the &#x201c;Sponsor&#x201d;) received 20,020 shares of New
Abpro common stock in lieu of repayment of $2,000 of Unpaid SPAC Expenses (as defined in the Merger Agreement) owed to the Sponsor as
a result of advances made by the Sponsor to ACAB. This settlement was related to the ACAB liabilities incurred prior to the Merger and
had no financial impact on the Company&#x2019;s December 31, 2024 consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the Closing, and in accordance with the
Sponsor Letter Agreement entered into on December&#160;11, 2023, as amended, the Sponsor transferred 32,778 common shares to Legacy Abpro
and 32,778 shares to ABI, and 32,215 shares were forfeited. The shares transferred to ABI for no consideration were accounted for as
a recapitalization with no impact on the December 31, 2024 consolidated financial statements. The Sponsor also transferred&#160;6,667
shares to one of ACAB&#x2019;s financial advisors for the services provided prior to the Closing Date. The shares transferred to Legacy
Abpro were deemed to be repurchased by the Company for no consideration and included in treasury stock as of the Closing Date. These
treasury stock shares were retired on September 24, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition, at the Closing, the Company issued
36,095 common stock shares to various service providers, of which 1,095 shares were issued to an investment advisor in the PIPE Financing
and the remaining 35,000 shares of common stock were issued in settlement of ACAB&#x2019;s liabilities for the services provided by various
legal and investment advisors prior to the Closing Date. The issuance of these shares, related to the services provided to ACAB prior
to the Merger which were expensed on the books of ACAB, had no financial impact on the Company&#x2019;s December 31, 2024 consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The number of shares of the Company&#x2019;s
common stock outstanding immediately following the consummation of the Merger was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Common stock of ACAB, net of redemptions&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ACAB Founder Shares, less of forfeitures and transfers&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;126,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares issued to PIPE investors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;112,247&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares issued to service providers&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;42,762&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares issued in Merger to Legacy Abpro stockholders&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,304,107&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares transferred to investors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;72,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares issued to settle the promissory note with executive&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total shares of common stock outstanding immediately after
    Merger&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,684,510&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Merger was accounted for as a reverse
recapitalization in accordance with U.S. GAAP. Under this method of accounting, ACAB is treated as the acquired company for financial
reporting purposes and Legacy Abpro is treated as the acquirer. This determination is primarily based on the fact that subsequent to
the Merger, the Legacy Abpro stockholders hold a majority of the voting rights of the combined company, Legacy Abpro comprises all of
the ongoing operations of the combined company, Legacy Abpro comprises a majority of the carryover governing body of the combined company,
and Legacy Abpro&#x2019;s senior management comprises all of the senior management of the combined company. Accordingly, for accounting
purposes, the Merger was treated as the equivalent of Legacy Abpro issuing shares for the net assets of ACAB, accompanied by a recapitalization.
The net assets of ACAB were stated at historical costs. No goodwill or other intangible assets were recorded. Operations prior to the
Merger are those of Legacy Abpro.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company received $5,700 in proceeds from
the Merger and related PIPE Financing, net of ACAB transaction costs settled at the Closing. The Company incurred $2,100 in transaction
costs and $900 in issuance costs related to the PIPE Financing, consisting of banking, legal, investment advisory and other professional
fees, of which were recorded as a reduction of proceeds to additional paid-in capital. At the Closing Date, Legacy Abpro assumed $6,600
of net liabilities, including tax liabilities and legal fees, of ACAB. As of September 30, 2025, the ACAB liabilities were $5,300, of
which $900 was included in accrued expenses and $4,400 in excise tax payable. As of December 31, 2024, the ACAB liabilities were $5,800,
of which $1,000 was included in accrued expenses, $4,400 in excise tax payable and $400 in income tax payable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In February 2025, the Company issued 5,000
shares of common stock to Roth Capital Partners (&#x201c;Roth&#x201d;) as an additional payment for the services provided under the engagement
letter dated July 17, 2024 between Roth and ACAB, which provided for an adjustment to their fees in shares based on the trading price
of the Company&#x2019;s common stock. The issuance had zero impact on the September 30, 2025 condensed consolidated financial statements
as the fees to Roth were deemed to be related to the Merger and were recorded as a both an increase and reduction to additional paid-in
capital.&lt;/span&gt;&lt;/p&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c202"
      decimals="3"
      id="ixv-42541"
      unitRef="shares">0.068</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c203"
      decimals="3"
      id="ixv-42542"
      unitRef="shares">0.068</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c204"
      decimals="3"
      id="ixv-42543"
      unitRef="shares">0.068</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c203"
      decimals="INF"
      id="ixv-42544"
      unitRef="shares">0.068</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c205"
      decimals="0"
      id="ixv-42545"
      unitRef="shares">6744550</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c206"
      decimals="0"
      id="ixv-42546"
      unitRef="shares">1</us-gaap:ConversionOfStockSharesConverted1>
    <abp:AdditionSharesOfCommonStock
      contextRef="c0"
      decimals="0"
      id="ixv-42547"
      unitRef="shares">483333</abp:AdditionSharesOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c207"
      decimals="0"
      id="ixv-42548"
      unitRef="shares">112247</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="c208"
      decimals="-3"
      id="ixv-42549"
      unitRef="usd">11225000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c209"
      decimals="0"
      id="ixv-42550"
      unitRef="shares">20749</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abp:AggregatePurchasePrice
      contextRef="c207"
      decimals="-3"
      id="ixv-42551"
      unitRef="usd">6225000</abp:AggregatePurchasePrice>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c210"
      decimals="-3"
      id="ixv-42552"
      unitRef="usd">4225000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:Cash
      contextRef="c211"
      decimals="-3"
      id="ixv-42553"
      unitRef="usd">2000000</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c212"
      decimals="0"
      id="ixv-42554"
      unitRef="shares">41498</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c213"
      decimals="0"
      id="ixv-42555"
      unitRef="shares">16667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abp:AggregatePurchasePrice contextRef="c0" decimals="-3" id="ixv-42556" unitRef="usd">5000000</abp:AggregatePurchasePrice>
    <abp:AggregateIncentiveShare
      contextRef="c0"
      decimals="0"
      id="ixv-42557"
      unitRef="shares">33333</abp:AggregateIncentiveShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c214"
      decimals="0"
      id="ixv-42558"
      unitRef="shares">20020</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RepaymentsOfDebt
      contextRef="c215"
      decimals="-3"
      id="ixv-42559"
      unitRef="usd">2000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c216"
      decimals="0"
      id="ixv-42560"
      unitRef="shares">32778</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c217"
      decimals="0"
      id="ixv-42561"
      unitRef="shares">32778</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="c218"
      decimals="0"
      id="ixv-42562"
      unitRef="shares">32215</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c219"
      decimals="0"
      id="ixv-42563"
      unitRef="shares">6667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c220"
      decimals="0"
      id="ixv-42564"
      unitRef="shares">36095</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c221"
      decimals="0"
      id="ixv-42565"
      unitRef="shares">1095</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abp:RemainingSharesIssued
      contextRef="c222"
      decimals="0"
      id="ixv-42566"
      unitRef="shares">35000</abp:RemainingSharesIssued>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="c0" id="ixv-28906">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The number of shares of the Company&#x2019;s
common stock outstanding immediately following the consummation of the Merger was as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Common stock of ACAB, net of redemptions&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;ACAB Founder Shares, less of forfeitures and transfers&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;126,076&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares issued to PIPE investors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;112,247&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares issued to service providers&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;42,762&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares issued in Merger to Legacy Abpro stockholders&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,304,107&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares transferred to investors&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;72,285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;New Abpro shares issued to settle the promissory note with executive&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;20,000&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total shares of common stock outstanding immediately after
    Merger&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,684,510&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c229"
      decimals="INF"
      id="ixv-42567"
      unitRef="shares">7033</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c230"
      decimals="INF"
      id="ixv-42568"
      unitRef="shares">126076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c231"
      decimals="INF"
      id="ixv-42569"
      unitRef="shares">112247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c232"
      decimals="INF"
      id="ixv-42570"
      unitRef="shares">42762</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c233"
      decimals="INF"
      id="ixv-42571"
      unitRef="shares">1304107</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c234"
      decimals="INF"
      id="ixv-42572"
      unitRef="shares">72285</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c235"
      decimals="INF"
      id="ixv-42573"
      unitRef="shares">20000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c118"
      decimals="INF"
      id="ixv-42574"
      unitRef="shares">1684510</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c220"
      decimals="-3"
      id="ixv-42575"
      unitRef="usd">5700000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="c223"
      decimals="-3"
      id="ixv-42576"
      unitRef="usd">2100000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c220"
      decimals="-3"
      id="ixv-42577"
      unitRef="usd">900000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:OtherLiabilities
      contextRef="c224"
      decimals="-3"
      id="ixv-42578"
      unitRef="usd">6600000</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities
      contextRef="c225"
      decimals="-3"
      id="ixv-42579"
      unitRef="usd">5300000</us-gaap:Liabilities>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="c225"
      decimals="-3"
      id="ixv-42580"
      unitRef="usd">900000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="c225"
      decimals="-3"
      id="ixv-42581"
      unitRef="usd">4400000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:Liabilities
      contextRef="c226"
      decimals="-3"
      id="ixv-42582"
      unitRef="usd">5800000</us-gaap:Liabilities>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="c226"
      decimals="-3"
      id="ixv-42583"
      unitRef="usd">1000000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:TaxesPayableCurrentAndNoncurrent
      contextRef="c226"
      decimals="-3"
      id="ixv-42584"
      unitRef="usd">4400000</us-gaap:TaxesPayableCurrentAndNoncurrent>
    <us-gaap:IncomeTaxesPaid
      contextRef="c227"
      decimals="-3"
      id="ixv-42585"
      unitRef="usd">400000</us-gaap:IncomeTaxesPaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c228"
      decimals="0"
      id="ixv-42586"
      unitRef="shares">5000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0" id="ixv-29041">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued salaries and wages&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,549&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,273&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued license fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;273&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Board of Directors compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;242&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;865&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,496&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c0" id="ixv-29052">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued expenses consisted of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued salaries and wages&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2,033&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,549&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,121&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,273&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued license fees&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3,300&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Accrued interest&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;273&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;267&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Board of Directors compensation&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;285&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;242&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,014&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;865&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,026&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;7,496&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="c1" decimals="-3" id="ixv-42587" unitRef="usd">2033000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c2" decimals="-3" id="ixv-42588" unitRef="usd">1549000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c1" decimals="-3" id="ixv-42589" unitRef="usd">1121000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c2" decimals="-3" id="ixv-42590" unitRef="usd">1273000</us-gaap:AccruedProfessionalFeesCurrent>
    <abp:AccruedLicenseFees contextRef="c1" decimals="-3" id="ixv-42591" unitRef="usd">3300000</abp:AccruedLicenseFees>
    <abp:AccruedLicenseFees contextRef="c2" decimals="-3" id="ixv-42592" unitRef="usd">3300000</abp:AccruedLicenseFees>
    <abp:AccruedInterest contextRef="c1" decimals="-3" id="ixv-42593" unitRef="usd">273000</abp:AccruedInterest>
    <abp:AccruedInterest contextRef="c2" decimals="-3" id="ixv-42594" unitRef="usd">267000</abp:AccruedInterest>
    <abp:AccruedBODCompensation contextRef="c1" decimals="-3" id="ixv-42595" unitRef="usd">285000</abp:AccruedBODCompensation>
    <abp:AccruedBODCompensation contextRef="c2" decimals="-3" id="ixv-42596" unitRef="usd">242000</abp:AccruedBODCompensation>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-42597" unitRef="usd">1014000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-42598" unitRef="usd">865000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c1" decimals="-3" id="ixv-42599" unitRef="usd">8026000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-42600" unitRef="usd">7496000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0" id="ixv-29225">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Fair Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table presents information about
the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025 and December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company&#x2019;s utilized to determine such fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 65%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forward purchase agreement asset (Note 9)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-406"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;155&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;SEPA put rights asset (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Embedded derivative liability (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-407"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Forward Purchase Agreement was fully settled
on January 28, 2025 for $132 cash received by the Company. The fair value of the Company&#x2019;s position under the Forward Purchase
Agreement was calculated as of December 31, 2024 by multiplying the number of shares under the Forward Purchase Agreement by the market
price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;53.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair value of the SEPA put rights asset
was estimated as the sum of the fair values of the put rights under each assumed advance notice over the term of the SEPA. The number
of shares under each advance notice was based on the historical trading volumes of the Company&#x2019;s stock taking into account the
beneficial ownership and daily volume limitations. The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;53.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;3.7 &#x2013; 4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;0.1 - 1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;1 - 2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;93-99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of shares under each advance notice&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;26,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,883&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair value of the embedded derivative
feature was $0 as of September 30, 2025 and estimated to be $80 as of December 31, 2024, based on the difference between the fair value
of the convertible note with these embedded features and the fair value without each one of these embedded features. As of December 31,
2024, the assumptions incorporated into the valuation model included the stock price of $53.70, the estimated future price per share
of $61.80 (derived using Monte Carlo Simulation), the expected volatility of 99%, the risk-free rate of 4.18% and the term of 0.9 years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair values of the Embedded Derivative
Liability associated with the conversion of the First and Second Convertible Notes (see Note 11) of $703 and $243, respectively, were
based on the difference between the fair value of the common stock shares issued upon conversion and the outstanding note balance at
the conversion date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The changes in the fair value of Level 3 financial
assets and liabilities for the nine months ended September 30, 2025 are as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forward&lt;br/&gt; Purchase&lt;br/&gt; Agreement&lt;br/&gt;
    Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;SEPA&lt;br/&gt; Put Rights&lt;br/&gt; Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Embedded&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Derivative&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Fair value as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;155&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Initial measurement at the issuance date (see Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-408"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-409"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Settlement&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(132&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-410"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(946&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;773&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Fair value as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-411"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-412"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="c0" id="ixv-29236">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following table presents information about
the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025 and December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company&#x2019;s utilized to determine such fair value:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Level&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 65%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forward purchase agreement asset (Note 9)&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 9%; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-406"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;155&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;SEPA put rights asset (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Embedded derivative liability (Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-407"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c245"
      decimals="-3"
      id="ixv-42601"
      unitRef="usd">155000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c246"
      decimals="-3"
      id="ixv-42602"
      unitRef="usd">243000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c247"
      decimals="-3"
      id="ixv-42603"
      unitRef="usd">188000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c249"
      decimals="-3"
      id="ixv-42604"
      unitRef="usd">80000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c236"
      decimals="-3"
      id="ixv-42605"
      unitRef="usd">132000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c0" id="ixv-42606">The fair value of the Company&#x2019;s position under the Forward Purchase
Agreement was calculated as of December 31, 2024 by multiplying the number of shares under the Forward Purchase Agreement by the market
price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;53.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;98&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Stock price&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.72&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;53.70&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;3.7 &#x2013; 4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;6.45&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;0.1 - 1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;1 - 2&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;100&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#160;93-99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of shares under each advance notice&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;26,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,883&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c250"
      decimals="2"
      id="ixv-42607"
      unitRef="pure">53.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c251"
      decimals="1"
      id="ixv-42608"
      unitRef="pure">4.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c252"
      decimals="1"
      id="ixv-42609"
      unitRef="pure">0.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c253"
      decimals="0"
      id="ixv-42610"
      unitRef="pure">98</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c254"
      decimals="0"
      id="ixv-42611"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c255"
      decimals="2"
      id="ixv-42613"
      unitRef="pure">6.72</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c256"
      decimals="2"
      id="ixv-42614"
      unitRef="pure">53.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c257"
      decimals="1"
      id="ixv-42615"
      unitRef="pure">3.7</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c258"
      decimals="1"
      id="ixv-42616"
      unitRef="pure">4.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c259"
      decimals="1"
      id="ixv-42617"
      unitRef="pure">4.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c260"
      decimals="2"
      id="ixv-42618"
      unitRef="pure">6.45</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c261"
      decimals="2"
      id="ixv-42619"
      unitRef="pure">51.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c262"
      decimals="1"
      id="ixv-42620"
      unitRef="pure">0.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c263"
      decimals="1"
      id="ixv-42621"
      unitRef="pure">1.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c264"
      decimals="0"
      id="ixv-42622"
      unitRef="pure">1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c265"
      decimals="0"
      id="ixv-42623"
      unitRef="pure">2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c266"
      decimals="0"
      id="ixv-42624"
      unitRef="pure">100</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c267"
      decimals="0"
      id="ixv-42625"
      unitRef="pure">93</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c268"
      decimals="0"
      id="ixv-42626"
      unitRef="pure">99</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c269"
      decimals="0"
      id="ixv-42627"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c270"
      decimals="0"
      id="ixv-42628"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c271"
      decimals="0"
      id="ixv-42629"
      unitRef="pure">26667</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c272"
      decimals="0"
      id="ixv-42630"
      unitRef="pure">1883</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c237"
      decimals="-3"
      id="ixv-42631"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c238"
      decimals="-3"
      id="ixv-42632"
      unitRef="usd">80000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:SharePrice
      contextRef="c239"
      decimals="2"
      id="ixv-42633"
      unitRef="usdPershares">53.7</us-gaap:SharePrice>
    <abp:EstimatedFuturePricePerShare
      contextRef="c240"
      decimals="2"
      id="ixv-42634"
      unitRef="usdPershares">61.8</abp:EstimatedFuturePricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c241"
      decimals="2"
      id="ixv-42635"
      unitRef="pure">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c241"
      decimals="4"
      id="ixv-42636"
      unitRef="pure">0.0418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c241" id="ixv-42637">P0Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="c242"
      decimals="-3"
      id="ixv-42638"
      unitRef="usd">703000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="c243"
      decimals="-3"
      id="ixv-42639"
      unitRef="usd">243000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0" id="ixv-29685">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The changes in the fair value of Level 3 financial
assets and liabilities for the nine months ended September 30, 2025 are as follows:&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forward&lt;br/&gt; Purchase&lt;br/&gt; Agreement&lt;br/&gt;
    Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;SEPA&lt;br/&gt; Put Rights&lt;br/&gt; Asset&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Embedded&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Derivative&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;Liabilities&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Fair value as of January 1, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;155&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;188&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;80&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Initial measurement at the issuance date (see Note 11)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-408"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-409"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;93&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Settlement&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(132&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-410"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(946&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(23&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;55&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;773&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Fair value as of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-411"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;243&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-412"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c273"
      decimals="-3"
      id="ixv-42640"
      unitRef="usd">155000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c274"
      decimals="-3"
      id="ixv-42641"
      unitRef="usd">188000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c275"
      decimals="-3"
      id="ixv-42642"
      unitRef="usd">80000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c278"
      decimals="-3"
      id="ixv-42643"
      unitRef="usd">93000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
      contextRef="c276"
      decimals="-3"
      id="ixv-42644"
      unitRef="usd">132000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
      contextRef="c278"
      decimals="-3"
      id="ixv-42645"
      unitRef="usd">946000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="c276"
      decimals="-3"
      id="ixv-42646"
      unitRef="usd">23000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="c277"
      decimals="-3"
      id="ixv-42647"
      unitRef="usd">-55000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="c278"
      decimals="-3"
      id="ixv-42648"
      unitRef="usd">-773000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c280"
      decimals="-3"
      id="ixv-42649"
      unitRef="usd">243000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c0" id="ixv-29893">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;License and Collaboration Agreements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;NJCTTQ Collaboration Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In January 2019, the Company entered into
a collaboration agreement with Nanjing Chia Tai Tianquing Pharmaceutical Co., Ltd. (&#x201c;NJCTTQ&#x201d;) to research, develop and commercialize
two anti-Claudin 18.2 lead antibodies (the &#x201c;NJCTTQ agreement&#x201d;). Under the NJCTTQ agreement, the Company granted a non-exclusive,
non-sublicensable research license and an exclusive, sublicensable license to NJCTTQ within the People&#x2019;s Republic of China and
Thailand (the &#x201c;NJCTTQ Territory&#x201d;). The initial term of this agreement was 5 years, which could be automatically renewed for
another 5 years. If no collaboration project reached the clinical stage within the first 5 years of the NJCTTQ agreement, then this agreement
would not have been renewed. The agreement expired in January 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company was eligible to receive up to
an aggregate of $405,000 of non-refundable milestone payments from NJCTTQ upon achieving certain development, regulatory approval, and
commercialization and sales milestones for each unique licensed antibody or product in NJCTTQ Territory. The Company agreed to pay NJCTTQ
up to an aggregate of $5,000 in nonrefundable amounts upon achieving of a regulatory milestone in the Company&#x2019;s territory, which
includes all other countries other than the NJCTTQ Territory. No milestones have been reached through the expiration of this agreement
in January 2024, no products were sold by NJCTTQ, and no related revenue amounts have been recorded in the condensed consolidated financial
statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company and NJCTTQ agreed to pay reciprocal
royalties, with each of them paying the other party low single-digit royalties, tiered based on net sales per calendar year in its territory.
The agreement remains unrenewed as of September 30, 2025 after the expiration of its initial term. However, notwithstanding the agreement&#x2019;s
expiration, the low single-digit royalties and the $5,000 regulatory milestone payable to NJCTTQ based on commercial approval in the
Company&#x2019;s territory, as described above, will continue to apply. Through September 30, 2025, no products were sold by NJCTTQ or
the Company under the NJCTTQ agreement and no regulatory milestones were achieved by the Company in the Company&#x2019;s territory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;ABP-201 Collaboration and License Agreement
&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In January 2020, the Company&#x2019;s consolidated
subsidiary, AbMed, entered into a collaboration and license agreement with ABI (the &#x201c;ABP-201 Agreement&#x201d;), pursuant to which
the Company granted to ABI an exclusive, royalty-bearing, license under specified patent rights to make, use and sell certain of its
proprietary ANG-2/VEGF-HIRK bispecific antibodies within the licensed territory comprising People&#x2019;s Republic of China, Japan, South
Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States. Unless earlier terminated in accordance with its terms,
the agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the ABP-201 agreement, ABI agreed to
use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within
specified territories and timeframes. ABI is committed to pay the Company up to $56,500 in milestone payments upon achieving certain
research and development events, up to $485,000 in milestone payments based on annual net sales per each licensed product, and a double-digit
percentage royalty in the low teens, tiered based on cumulative net sales by ABI, its affiliates or sublicensees beginning with the first
commercial sale of a licensed product in its territory. No milestones have been reached through September 30, 2025, no products were
sold by ABI, and no related revenue amounts have been recorded in the condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Celltrion Collaboration and License
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In September 2022, the Company entered into
an exclusive collaboration and license agreement with Celltrion, as amended in October 2024 in connection with the execution of the Celltrion
Subscription Agreement (the &#x201c;Amended Celltrion Agreement&#x201d;). Under the Amended Celltrion Agreement, the Company granted to
Celltrion a worldwide exclusive license under specified patent rights to develop, make, have made, import, export, use, have used, sell
and have sold certain of its proprietary ABP-102 bispecific antibodies. The License Agreement also provides that the Company is to perform
certain preclinical in vitro studies. The License Agreement will remain in effect for so long as ABP-102 is being developed or commercialized
anywhere in the world. Celltrion may terminate the license agreement at any time by providing&#160;six months prior written notice to
the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Celltrion is committed to pay the Company
up to $10,000 under the Original Celltrion Agreement and $6,000 under the Amended Celltrion Agreement in milestone payments upon granting
the license and achieving certain research and development events, and up to $1,750,000 in milestone payments based on annual net sales
per each licensed product. The proceeds from commercialization are subject to a 50/50 profit split. Amounts that may be paid by third-party
collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization partners, are also subject
to a 50/50 split. Following commercial approval of ABP-102, the Company has agreed to reimburse Celltrion 87.5% under the Original Celltrion
Agreement and 250% under the Amended Celltrion Agreement of its direct and certain indirect costs and expenses incurred through first
commercial sale. Under the Original Celltrion Agreement, Celltrion is entitled to offset amounts otherwise due to us under the agreement
until our share of these costs has been paid back; provided that the Company is entitled to a minimum 25% (or 50% under the Amended Celltrion
Agreement) of profit from commercial sales and from third-party collaborators regardless of the amount of unreimbursed development costs
outstanding (and then 50% once the reimbursement has been made in full).&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The first milestone of $2,000 was achieved
upon granting the license at the collaboration effective date, as defined in the Celltrion Agreement, in December 2022, received in January
2023 and recognized in revenue prior to December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the three and nine months ended September
30, 2025 and 2024, the Company recognized &lt;span style="-sec-ix-hidden: hidden-fact-413"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-414"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-415"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-416"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; revenue in connection with this arrangement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Milestone Payments.&#160;&lt;/i&gt;The Company
is entitled to development milestones under the Celltrion Agreement and certain regulatory milestone payments which are paid upon receipt
of regulatory approvals.&#160;Except for the first milestone of $2,000 achieved in 2022, &lt;span style="-sec-ix-hidden: hidden-fact-417"&gt;no&lt;/span&gt;&#160;other milestone payments were earned
through September 30, 2025. The Company evaluated whether the remaining milestones are considered probable of being reached and determined
that their achievement is highly dependent on factors outside of the Company&#x2019;s control. Therefore, these payments have been fully
constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achievement of each milestone and any related constraint, and if necessary, adjust its estimate of the overall transaction
price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect the reported amount of collaboration
revenues in the period of adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Profit Splits. &lt;/i&gt;As the license is deemed
to be the predominant item to which profit splits relate, the Company will recognize revenue when the related sales or third-party collaborator
income occur.&#160;No&#160;profit split revenue has been recognized from inception through September 30, 2025.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <abp:AgreementInitialTerm contextRef="c282" id="ixv-42650">P5Y</abp:AgreementInitialTerm>
    <abp:MilestonePayments
      contextRef="c283"
      decimals="-3"
      id="ixv-42651"
      unitRef="usd">405000000</abp:MilestonePayments>
    <abp:NonRefundablePayments
      contextRef="c283"
      decimals="-3"
      id="ixv-42652"
      unitRef="usd">5000000</abp:NonRefundablePayments>
    <us-gaap:PaymentsForRoyalties
      contextRef="c283"
      decimals="-3"
      id="ixv-42653"
      unitRef="usd">5000000</us-gaap:PaymentsForRoyalties>
    <abp:MilestonePayments
      contextRef="c284"
      decimals="-3"
      id="ixv-42654"
      unitRef="usd">56500000</abp:MilestonePayments>
    <abp:MilestonePayments
      contextRef="c212"
      decimals="-3"
      id="ixv-42655"
      unitRef="usd">485000000</abp:MilestonePayments>
    <abp:OriginalCelltrionAgreement
      contextRef="c285"
      decimals="-3"
      id="ixv-42656"
      unitRef="usd">10000000</abp:OriginalCelltrionAgreement>
    <abp:OriginalCelltrionAgreement
      contextRef="c286"
      decimals="-3"
      id="ixv-42657"
      unitRef="usd">6000000</abp:OriginalCelltrionAgreement>
    <abp:MilestonePayments
      contextRef="c285"
      decimals="-3"
      id="ixv-42658"
      unitRef="usd">1750000000</abp:MilestonePayments>
    <abp:PercentageOfOriginalCelltrionAgreement contextRef="c0" decimals="3" id="ixv-42659" unitRef="pure">0.875</abp:PercentageOfOriginalCelltrionAgreement>
    <abp:PercentageOfAmendedCelltrionAgreement contextRef="c0" decimals="2" id="ixv-42660" unitRef="pure">2.50</abp:PercentageOfAmendedCelltrionAgreement>
    <abp:PercentageOfAmendedCelltrionAgreement
      contextRef="c287"
      decimals="2"
      id="ixv-42661"
      unitRef="pure">0.25</abp:PercentageOfAmendedCelltrionAgreement>
    <abp:PercentageOfAmendedCelltrionAgreement
      contextRef="c181"
      decimals="2"
      id="ixv-42662"
      unitRef="pure">0.50</abp:PercentageOfAmendedCelltrionAgreement>
    <abp:PercentageOfReimbursement
      contextRef="c285"
      decimals="2"
      id="ixv-42663"
      unitRef="pure">0.50</abp:PercentageOfReimbursement>
    <abp:MilestonePayments
      contextRef="c288"
      decimals="-3"
      id="ixv-42664"
      unitRef="usd">2000000</abp:MilestonePayments>
    <abp:MilestonePayments
      contextRef="c289"
      decimals="-3"
      id="ixv-42665"
      unitRef="usd">2000000</abp:MilestonePayments>
    <abp:MilestonePayments
      contextRef="c290"
      decimals="-3"
      id="ixv-42666"
      unitRef="usd">2000000</abp:MilestonePayments>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="c0" id="ixv-30006">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Commitments under Research and Collaboration Agreements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;MedImmune License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In August 2016, the Company entered into a
collaboration and license agreement with MedImmune Limited (&#x201c;MedImmune&#x201d;), pursuant to which the Company received from MedImmune
an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license to certain intellectual property rights
relating to the Company&#x2019;s ABP-200 product candidates (the &#x201c;MedImmune License Agreement&#x201d;). The Company agreed to use
commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within specified
timeframes. Unless earlier terminated in accordance with its terms, the MedImmune License Agreement, as amended, remains in effect on
a country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of products
based on the ABP-200 product candidates. The Company is no longer developing ABP-200.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the MedImmune License Agreement, the
Company agreed to pay milestone and royalty payments, including up to $244,000 in milestone payments, which are comprised of $14,000
upon meeting certain clinical development milestones, $80,000 upon achieving certain regulatory events and $150,000 upon meeting certain
worldwide commercial sales thresholds; and tiered high-single to low double-digit percentage royalties based on annualized net sales
of each product commercialized from our collaboration on a country-by-country basis. No milestones have been reached and no products
were sold by the Company through September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;NCI License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In August 2017, the Company entered into a
patent license agreement with the National Cancer Institute (the &#x201c;NCI&#x201d;), a division of the National Institutes of Health
(the &#x201c;NIH&#x201d;), pursuant to which the Company received an exclusive, worldwide license to make, use, sell, offer to sell and
import products covered by the licensed patents in the field of using certain monoclonal antibodies as monospecific or bispecific antibodies
for the treatment of liver cancer (the &#x201c;NCI License Agreement&#x201d;). The license agreement was amended in May 2020 and October
2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the treatment of GPC-3 expressing
liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization was extended. Unless
earlier terminated, the Company&#x2019;s agreement with NCI will expire upon expiration of all licensed patent rights. The Company may
also terminate the agreement as to any licenses in any country or territory upon 60 days written notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Pursuant to the NCI agreement and amendments,
the Company agreed to pay low single-digit royalties based on net sales of licensed products as well as milestone payments of up to $3,995
due upon achievement of clinical and regulatory milestones, and up to $12,000 milestone payments due upon achievement of commercial milestones.
No milestones have been reached and no products were sold by the Company through September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company also has to pay the guaranteed
annual minimum royalties of $25 starting on the effective date of the agreement (which annual minimum royalties may be credited against
the running royalties on net sales of any licensed products or services). During each of the three months ended September 30, 2025 and
2024, the Company incurred $6, in minimum royalty payments, included in research and development expenses. During each of the nine months
ended September 30, 2025 and 2024, the Company incurred $19, in minimum royalty payments, included in research and development expenses.
Under the amendment entered into in March 2020, the Company is also liable for the extension royalties of $225 payable under this agreement
which were rescheduled to become due in several installments starting in March 2022. As of both September 30, 2025 and December 31, 2024,
the accrued extension royalties were $200, included in accrued expenses on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company also agreed to reimburse patent
costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights. During
the three and nine months ended September 30, 2025 and 2024, the Company did not incur any expenses related to the patent costs reimbursements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Mabwell License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In October 2020, the Company entered into
an exclusive collaboration and license agreement with Mabwell (the &#x201c;Mabwell License Agreement&#x201d;). The agreement was amended
in November 2020. Under the Mabwell license agreement, the Company received a non-exclusive, royalty-free research purpose license as
well as an exclusive commercial license within certain territories, as defined in the agreement, to Mabwell&#x2019;s series of anti-SARS-CoV-2
monoclonal antibodies. Under the agreement, the Company is responsible for conducting at its sole expense, research and preclinical,
clinical and other developments of any licensed products and bears all development costs and expenses related to obtaining or maintenance
of marketing authorizations of licensed products in its territories. Mabwell is obligated, at the Company&#x2019;s request, to supply
the Licensed Antibodies to the Company for clinical trial purpose at costs plus margin as defined in the agreement. The parties agreed
to undertake certain joint clinical research and development activities with a portion of the costs contributed by Mabwell. Unless earlier
terminated, the Mabwell License Agreement will expire on the occurrence of the last to expire royalty term, which is the later of a)
the expiration of the last to expire valid claim of the patent rights and b) ten years from the first commercial sale of such Licensed
Product, and determined on jurisdiction-by-jurisdiction basis. Either party may terminate the agreement in the event of any uncured material
breach by the other party.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The agreement provides for development milestones
of up to $32,500 and annual sales milestone payments of up to $50,000 payable by the Company to Mabwell. The agreement also provides
for a profit sharing, with Mabwell sharing 50% of the net profits from the licensed product sales in certain territories as defined in
the agreement. The Company will also make tiered royalty payments in the mid to high single digits on net sales of commercial products
in the licensed territory.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the three and nine months ended September
30, 2025 and 2024, development activities under the Mabwell collaboration agreement were immaterial to the condensed consolidated financial
statements. No milestones have been reached and no products were sold under the Mabwell License Agreement through September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2025, the Company received a draft
of a termination agreement from Mabwell which outlines Mabwell&#x2019;s claim for the total payment of $3,300 under certain development
milestones asserting that these development milestones were achieved by the Company during 2021. The Company does not believe that a
liability under the milestone related provisions invoked by Mabwell was triggered and is planning to engage in discussion with Mabwell
about the validity of their claim. This liability of $3,300 is included in accrued expenses in the condensed consolidated financial statements
as of September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;MSK License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2017, the Company entered into an
exclusive license agreement with Memorial Sloan Kettering Cancer Center (the &#x201c;MSK License Agreement&#x201d;), pursuant to which
the Company received an exclusive, royalty-bearing, worldwide license under specified patent rights to make, use and sell certain of
MSK&#x2019;s proprietary Her2-huOKT3 bispecific antibodies. The agreement was amended on March 31, 2017, March 31, 2018, and January 1,
2020. Unless earlier terminated in accordance with its terms, the agreement was to remain in effect on a country-by-country basis until
the expiration of the last royalty term in such country as to be determined by the launch of products based on MSK antibodies. On September
19, 2023, MSK License Agreement was terminated by MSK due to the Company&#x2019;s failure to make the payments for the patent costs reimbursements
discussed below.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the MSK License Agreement, as amended,
the Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific
antibodies within specified territories and timeframes. The Company was committed to pay MSK up to $10,500 in milestone payments upon
achieving certain research and development and commercialization events or within a certain number of months of the effective date, up
to $30,000 in milestone payments based on net sales, and tiered mid-single-digit percentage royalties based on annualized net sales of
each product commercialized from the collaboration with guaranteed annual minimum royalties between $20 and $30 depending on certain
development events. During the three and nine months ended September 30, 2025 and 2024, the Company did not incur any minimum royalties
or any milestone payments under this agreement. As of both September 30, 2025 and December 31, 2024, the accrued minimum royalty and
milestone payments were $790, included in accounts payable in the condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company also agreed to reimburse patent
costs for all documented out of pocket costs associated with the preparation, filing, prosecution and maintenance of patent rights in
the license territory. During the three and nine months ended September 30, 2025 and 2024, the Company did not incur any patent reimbursement
costs. As of both September 30, 2025 and December 31, 2024, the liabilities for the patent costs reimbursements were $273, included in
accrued expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of both September 30, 2025 and December
31, 2024, the accrued liabilities for the unpaid interest on the outstanding minimum royalty and milestone payments due to MSK were $169,
included in accrued expenses. The company has ceased accruing further interest as a result of the termination of the MSK License Agreement.
See Note 8 for discussion of the June 2023 demand letter.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;VAZYME License agreement &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In April 2021, the Company entered into a
License Agreement with VAZYME Biotech Co., Ltd (&#x201c;VAZYME&#x201d;) (the &#x201c;VAZYME License Agreement&#x201d;), pursuant to which
the Company was granted an exclusive, perpetual, royalty-bearing, worldwide license under specified patent rights to research, develop
and commercialize VAZYME proprietary anti-SARS-CoV-2 monoclonal antibodies. Unless earlier terminated in accordance with its terms, the
agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the VAZYME License Agreement, the Company
agreed to use commercially reasonable efforts to reach certain research and development, and commercialization milestones for such antibodies.
The Company also agreed to pay $200 to VAZYME at the effective date of the agreement. The Company is committed to pay VAZYME up to $11,100
in milestone payments upon achieving certain research and development events, up to $70,000 in milestone payments based on annual net
sales, and tiered low single-digit percentage royalties based on annualized net sales of each product commercialized from the collaboration.
No milestones in the VAZYME License Agreement have been reached through September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In December 2021, the Company entered into
a Cooperation Agreement with Chengdu Bio-Innovate Pharmaceutical Technology Co., Ltd (&#x201c;Bio-Innovate&#x201d;) and a three-way sharing
agreement with VAZYME and Bio-Innovate (&#x201c;the Company&#x201d;, &#x201c;VAZYME&#x201d; and &#x201c;Bio-Innovate&#x201d;, collectively
&#x201c;all parties&#x201d;), pursuant to which the Company entrusted Bio-Innovate to perform certain preclinical testing and all parties
agreed that VAZYME will ship the agreed antibodies to Bio-Innovate rather than the Company to fulfill the requirements under the VAZYME
License Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For the three and nine months Ended September
30, 2025 and 2024, the Company did not incur any expenses related to the VAZYME License Agreement. As of both September 30, 2025 and
December 31, 2024, the accrued liabilities under this agreement were $200, included in accounts payable in the condensed consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <abp:MilestonePayments
      contextRef="c292"
      decimals="-3"
      id="ixv-42667"
      unitRef="usd">244000000</abp:MilestonePayments>
    <abp:ClinicalDevelopmentMilestones contextRef="c0" decimals="-3" id="ixv-42668" unitRef="usd">14000000</abp:ClinicalDevelopmentMilestones>
    <abp:RegulatoryEvents contextRef="c0" decimals="-3" id="ixv-42669" unitRef="usd">80000000</abp:RegulatoryEvents>
    <abp:CommercialSales contextRef="c0" decimals="-3" id="ixv-42670" unitRef="usd">150000000</abp:CommercialSales>
    <abp:MilestonePayments
      contextRef="c293"
      decimals="-3"
      id="ixv-42671"
      unitRef="usd">3995000</abp:MilestonePayments>
    <abp:MilestonePaymentsCommercialMilestones contextRef="c0" decimals="-3" id="ixv-42672" unitRef="usd">12000000</abp:MilestonePaymentsCommercialMilestones>
    <us-gaap:PaymentsForRoyalties
      contextRef="c293"
      decimals="-3"
      id="ixv-42673"
      unitRef="usd">25000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c294"
      decimals="-3"
      id="ixv-42674"
      unitRef="usd">6000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c295"
      decimals="-3"
      id="ixv-42675"
      unitRef="usd">6000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c296"
      decimals="-3"
      id="ixv-42676"
      unitRef="usd">19000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c297"
      decimals="-3"
      id="ixv-42677"
      unitRef="usd">19000</us-gaap:PaymentsForRoyalties>
    <abp:PaymentForExtensionRoyalities
      contextRef="c298"
      decimals="-3"
      id="ixv-42678"
      unitRef="usd">225000</abp:PaymentForExtensionRoyalities>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c1" decimals="-3" id="ixv-42679" unitRef="usd">200000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c2" decimals="-3" id="ixv-42680" unitRef="usd">200000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <abp:DevelopmentMilestones contextRef="c0" decimals="-3" id="ixv-42681" unitRef="usd">32500000</abp:DevelopmentMilestones>
    <abp:AnnualSalesMilestonePayments contextRef="c0" decimals="-3" id="ixv-42682" unitRef="usd">50000000</abp:AnnualSalesMilestonePayments>
    <abp:NetProfitsFromLicensedProductSales contextRef="c0" decimals="2" id="ixv-42683" unitRef="pure">0.50</abp:NetProfitsFromLicensedProductSales>
    <abp:PaymentOfDevelopmentMilestones contextRef="c62" decimals="-3" id="ixv-42684" unitRef="usd">3300000</abp:PaymentOfDevelopmentMilestones>
    <abp:AccruedToAmount contextRef="c0" decimals="-3" id="ixv-42685" unitRef="usd">3300000</abp:AccruedToAmount>
    <abp:AccruedToAmount contextRef="c34" decimals="-3" id="ixv-42686" unitRef="usd">3300000</abp:AccruedToAmount>
    <abp:MilestonePaymentsUponAchievingRDAndCommercializationEvents
      contextRef="c299"
      decimals="-3"
      id="ixv-42687"
      unitRef="usd">10500000</abp:MilestonePaymentsUponAchievingRDAndCommercializationEvents>
    <abp:MilestonePaymentOnNetSales
      contextRef="c299"
      decimals="-3"
      id="ixv-42688"
      unitRef="usd">30000000</abp:MilestonePaymentOnNetSales>
    <us-gaap:PaymentsForRoyalties
      contextRef="c287"
      decimals="-3"
      id="ixv-42689"
      unitRef="usd">20000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c181"
      decimals="-3"
      id="ixv-42690"
      unitRef="usd">30000</us-gaap:PaymentsForRoyalties>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="c300"
      decimals="-3"
      id="ixv-42691"
      unitRef="usd">790000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="c301"
      decimals="-3"
      id="ixv-42692"
      unitRef="usd">790000</us-gaap:AccruedRoyaltiesCurrent>
    <abp:PatentCostsReimbursements
      contextRef="c302"
      decimals="-3"
      id="ixv-42693"
      unitRef="usd">273000</abp:PatentCostsReimbursements>
    <abp:PatentCostsReimbursements
      contextRef="c303"
      decimals="-3"
      id="ixv-42694"
      unitRef="usd">273000</abp:PatentCostsReimbursements>
    <abp:PatentCostsReimbursements
      contextRef="c304"
      decimals="-3"
      id="ixv-42695"
      unitRef="usd">169000</abp:PatentCostsReimbursements>
    <abp:PatentCostsReimbursements
      contextRef="c305"
      decimals="-3"
      id="ixv-42696"
      unitRef="usd">169000</abp:PatentCostsReimbursements>
    <abp:MilestonePayments
      contextRef="c306"
      decimals="-3"
      id="ixv-42697"
      unitRef="usd">200000</abp:MilestonePayments>
    <abp:MilestonePayments contextRef="c0" decimals="-3" id="ixv-42698" unitRef="usd">11100000</abp:MilestonePayments>
    <abp:MilestonePayments
      contextRef="c296"
      decimals="-3"
      id="ixv-42699"
      unitRef="usd">70000000</abp:MilestonePayments>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="c307"
      decimals="-3"
      id="ixv-42700"
      unitRef="usd">200000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="c308"
      decimals="-3"
      id="ixv-42701"
      unitRef="usd">200000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0" id="ixv-30166">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Commitments and Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Litigation and other matters&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company, from time to time, is subject
to legal proceedings and claims that arise in the ordinary course of business. Resolution of any such matter could have a material adverse
effect on the results of operations and financial condition. The Company considers all claims on a periodic basis and based on known
facts assesses whether potential losses are considered reasonably possible, probable and estimable. Based upon this assessment, the Company
then evaluates disclosure requirements and whether to accrue for such claims in its consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company records a provision for contingent
liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On September 12, 2023, a contract research
organization (&#x201c;CRO&#x201d;) vendor filed a lawsuit against the Company based on the Company&#x2019;s failure to make certain installments
pursuant to a settlement agreement entered into with this vendor on January 23, 2023. Under the settlement agreement, the Company agreed
to pay a total of $1,644 to the vendor, with $600 due 5 business days after the settlement effective date and ten monthly installments,
approximately $104 each, starting in February 2023. The Company made the upfront payment and the first four monthly installments for
a total of $1,016 but failed to make the monthly installment payments due after May 2023. On January 24, 2024, the Company received endorsement
on motion for default judgment which requested the Company to pay approximately $700 to the CRO vendor. During the three and nine months
ended September 30, 2025, the Company accrued an additional $21 and $63 in interest, respectively, included in interest expense. As of
September 30, 2025 and December 31, 2024, the outstanding balance under this settlement agreement was $848 and $785, respectively. These
amounts were included in accounts payable and accrued expenses in the condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition to the lawsuit from a CRO vendor
above, the Company accrued $325 as of both September 30, 2025 and December 31, 2024 related to disputed invoices with vendors.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In June 2023, the Company received a notice
of breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded payments totaling $1,230 for
the services performed under the MSK License Agreement (see Note 7). The corresponding liability is included in accrued expenses in the
condensed consolidated financial statements as of both September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The MedImmune License Agreement (see Note
7) provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement (December 2022). These
target dates were not met, which gives MedImmune (now AstraZeneca) a termination right. The Company does not expect a material impact
on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with the development
of ABP-200, which the Company is no longer developing. The Company believes that it does not need the intellectual property licensed
under that agreement for the development and eventual commercialization of ABP-201 or any of its other programs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 17, 2025, the Company received a complaint
from a former director asserting that the Company owes the former director a total of $748 for consulting fees, bonuses, and for unpaid
promissory note principal and interest. The principal and interest on the promissory note were $176 and $9, respectively, as of September
30, 2025 and December 31, 2024 (see Note 10). The remaining liability of $560 was included in accrued expenses in the condensed consolidated
financial statements as of September 30, 2025. On November 10, 2025, the Suffolk Superior Court in Massachusetts issued a preliminary
injunction prohibiting the transfer of the Company&#x2019;s assets outside the ordinary course of business. At this stage, the Company
is unable to evaluate the likelihood of an unfavorable outcome or provide an estimate of the amount or range of potential loss, beyond
the amount already accrued above.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 22, 2025, the Company received
a demand for payment from Integral Molecular, Inc. in the amount of approximately $182. The Company is currently in negotiations to settle
this claim.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 23, 2025, the Company received
a demand for payment from Brookline Capital Markets, a division of Arcadia Securities LLC, in the amount of $140. The Company is currently
in negotiations to settle this claim.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Non-Redemption&#160;Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 5, 2024, Legacy Abpro and ACAB
entered into a&#160;non-redemption&#160;agreement (the&#160;&#x201c;Non-Redemption&#160;Agreement&#x201d;), with Sandia Investment Management
LP on behalf of certain funds, investors, entities or accounts for which it or its affiliates acts as manager, sponsor or advisor (the
&#x201c;NRA Investors&#x201d;). Pursuant to such&#160;Non-Redemption&#160;Agreement, each NRA Investor agreed to rescind or reverse any
previously submitted redemption demand of the common stock of the Company held or to be acquired by such NRA Investor (the &#x201c;NRA
Investor Shares&#x201d;) up to 4,145 shares of common stock in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the Closing Date, the NRA Investors reversed
redemption demands with respect to 11,043 Series A Common stock shares (pre-split) of ACAB. Pursuant to the Non-Redemption Agreement,
upon consummation of the Merger, the Company had to pay to the NRA Investors a payment equal to the number of NRA Investor Shares multiplied
by the redemption price, minus the number of NRA Investor Shares multiplied by $9.00 (pre-split). As of September 30, 2025 and December
31, 2024, the Company owed NRA Investors $26, based on the redemption price of $340.80 at the Closing Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Excise Tax Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;At the Closing Date, the Company assumed the
excise tax liability of $4,330, as adjusted, as discussed further below, from ACAB related to the redemptions of shares in 2023 and calculated
as 1% of the shares redeemed during fiscal year 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On August 16, 2022, the Inflation Reduction
Act of 2022 (the &#x201c;IR Act&#x201d;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1%
excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly
traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself,
not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the
shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are
permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same
taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#x201c;Treasury&#x201d;)
has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the second quarter of 2024, the Treasury
and Internal Revenue Service (&#x201c;IRS&#x201d;) issued final regulations with respect to the timing and payment of the excise tax. Pursuant
to those regulations, the Company would need to file a return and remit payment for any liability incurred during the period from January
1, 2023 to December 31, 2023 on or before October 31, 2024. The Company has filed the excise tax return and has engaged with the IRS
in determining a payment plan for the balance.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company is unable to pay its obligation
in full, and, as such, it is subject to additional interest and penalties which are currently estimated at 8% interest per annum and
a 0.5% underpayment penalty per month or portion of a month up to 25% of the total liability for any amount that is unpaid from November
1, 2024 until paid in full.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In March 2025, the Company received the letter
from the IRS, requesting to set up a meeting with the Company to discuss the unsettled tax matters of ACAB and referencing $4,401 amount
owed in relation to the 2023 excise taxes, of which $210 was in interest and penalties (the &#x201c;IRS Letter&#x201d;). The Company believes
that the excise tax liability in the IRS Letter is overstated as compared to the amounts in ACAB&#x2019;s filed tax return for the year
ended December 31, 2023. Pending further discussions with the IRS, the Company recorded the excess of $1,268 over the Company&#x2019;s
estimate of $3,133 (inclusive of interest and penalties) as the additional excise tax liability assumed from ACAB at the Closing Date.
As of September 30, 2025, the Company recorded the excess of $946 over the Company&#x2019;s estimate of $3,455 (inclusive of interest
and penalties) as the additional excise tax liability. As a result, management has not accrued any further interest or penalties on this
amount.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="c309"
      decimals="-3"
      id="ixv-42702"
      unitRef="usd">1644000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="c310"
      decimals="-3"
      id="ixv-42703"
      unitRef="usd">600000</us-gaap:PaymentsForLegalSettlements>
    <abp:BusinessDays contextRef="c311" id="ixv-42704">P5D</abp:BusinessDays>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="c311"
      decimals="-3"
      id="ixv-42705"
      unitRef="usd">104000</us-gaap:PaymentsForLegalSettlements>
    <abp:MonthlyInstallmentPayments
      contextRef="c312"
      decimals="-3"
      id="ixv-42706"
      unitRef="usd">1016000</abp:MonthlyInstallmentPayments>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="c313"
      decimals="-3"
      id="ixv-42707"
      unitRef="usd">700000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <abp:AdditionalAccruedInterest contextRef="c25" decimals="-3" id="ixv-42708" unitRef="usd">21000</abp:AdditionalAccruedInterest>
    <abp:AdditionalAccruedInterest contextRef="c0" decimals="-3" id="ixv-42709" unitRef="usd">63000</abp:AdditionalAccruedInterest>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="c314"
      decimals="-3"
      id="ixv-42710"
      unitRef="usd">848000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="c315"
      decimals="-3"
      id="ixv-42711"
      unitRef="usd">785000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c1" decimals="-3" id="ixv-42712" unitRef="usd">325000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c2" decimals="-3" id="ixv-42713" unitRef="usd">325000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:GainLossOnContractTermination
      contextRef="c316"
      decimals="-3"
      id="ixv-42714"
      unitRef="usd">1230000</us-gaap:GainLossOnContractTermination>
    <us-gaap:ProfessionalFees
      contextRef="c317"
      decimals="-3"
      id="ixv-42715"
      unitRef="usd">748000</us-gaap:ProfessionalFees>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="c318"
      decimals="-3"
      id="ixv-42716"
      unitRef="usd">176000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="c319"
      decimals="-3"
      id="ixv-42717"
      unitRef="usd">9000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent contextRef="c1" decimals="-3" id="ixv-42718" unitRef="usd">560000</us-gaap:OtherAccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:DemandDepositAccounts
      contextRef="c320"
      decimals="-3"
      id="ixv-42719"
      unitRef="usd">182000</us-gaap:DemandDepositAccounts>
    <us-gaap:DemandDepositAccounts
      contextRef="c321"
      decimals="-3"
      id="ixv-42720"
      unitRef="usd">140000</us-gaap:DemandDepositAccounts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c322"
      decimals="0"
      id="ixv-42721"
      unitRef="shares">4145</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c205"
      decimals="0"
      id="ixv-42722"
      unitRef="shares">11043</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c323"
      decimals="2"
      id="ixv-42723"
      unitRef="usdPershares">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CapitalUnitsTotalCostToInvestors
      contextRef="c323"
      decimals="-3"
      id="ixv-42724"
      unitRef="usd">26000</us-gaap:CapitalUnitsTotalCostToInvestors>
    <us-gaap:CapitalUnitsTotalCostToInvestors
      contextRef="c324"
      decimals="-3"
      id="ixv-42725"
      unitRef="usd">26000</us-gaap:CapitalUnitsTotalCostToInvestors>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="c323"
      decimals="2"
      id="ixv-42726"
      unitRef="usdPershares">340.8</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="c324"
      decimals="2"
      id="ixv-42727"
      unitRef="usdPershares">340.8</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <abp:ExciseTaxLiability contextRef="c35" decimals="-3" id="ixv-42728" unitRef="usd">4330000</abp:ExciseTaxLiability>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed contextRef="c35" decimals="2" id="ixv-42729" unitRef="pure">0.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c325"
      decimals="2"
      id="ixv-42730"
      unitRef="pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <abp:ExciseTaxGenerallyOfTheFairMarketValuePercentage
      contextRef="c326"
      decimals="2"
      id="ixv-42731"
      unitRef="pure">0.01</abp:ExciseTaxGenerallyOfTheFairMarketValuePercentage>
    <us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate
      contextRef="c327"
      decimals="2"
      id="ixv-42732"
      unitRef="pure">0.08</us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate>
    <abp:PercentageOfUnderpaymentPenaltyPerMonth
      contextRef="c327"
      decimals="3"
      id="ixv-42733"
      unitRef="pure">0.005</abp:PercentageOfUnderpaymentPenaltyPerMonth>
    <abp:PercentageOfLiabilityTotal
      contextRef="c327"
      decimals="2"
      id="ixv-42734"
      unitRef="pure">0.25</abp:PercentageOfLiabilityTotal>
    <us-gaap:ExciseAndSalesTaxes
      contextRef="c328"
      decimals="-3"
      id="ixv-42735"
      unitRef="usd">4401000</us-gaap:ExciseAndSalesTaxes>
    <us-gaap:IncomeTaxExaminationInterestExpense
      contextRef="c328"
      decimals="-3"
      id="ixv-42736"
      unitRef="usd">210000</us-gaap:IncomeTaxExaminationInterestExpense>
    <abp:ExcessTaxes contextRef="c69" decimals="-3" id="ixv-42737" unitRef="usd">1268000</abp:ExcessTaxes>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="c62" decimals="-3" id="ixv-42738" unitRef="usd">3133000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:InvestmentCompanyExcessExpenseReimbursable contextRef="c0" decimals="-3" id="ixv-42739" unitRef="usd">946000</us-gaap:InvestmentCompanyExcessExpenseReimbursable>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="c1" decimals="-3" id="ixv-42740" unitRef="usd">3455000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c0" id="ixv-30292">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Forward Purchase Agreement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 7, 2024, ACAB and Legacy Abpro
entered into a Confirmation of an OTC Equity Prepaid Forward Transaction (the &#x201c;Forward Purchase Agreement&#x201d; or &#x201c;Transaction&#x201d;)
with YA (the &#x201c;Seller&#x201d;) to which a maximum of up to 16,667 common stock shares were subject to the Transaction. At the Closing
Date, the Seller purchased 3,333 shares from third parties (&#x201c;Recycled Shares&#x201d;), pursuant to the pricing date notice dated
November 12, 2024, and paid approximately $1,100 (the &#x201c;Prepayment Amount&#x201d;) to the redeeming shareholders. Pursuant to the
terms of the Forward Purchase Agreement, at the Closing Date, the Company remitted the Prepayment Amount into an escrow account for the
benefit of the Seller.&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 28, 2025, YA elected to effect
an Optional Early Termination (as described in the Forward Purchase Agreement) with respect to all 3,333 shares subject to the Forward
Purchase Agreement which terminated the agreement as a whole. YA paid the Company the Early Termination Obligation in the aggregate amount
of $132.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Forward Purchase Agreement was accounted
for at fair value as an asset in accordance with the guidance in ASC Topic 815 Derivatives and Hedging (&#x201c;ASC 815&#x201d;), with
subsequent changes in the fair value recorded in profits and losses. The fair value of the Forward Purchase Agreement asset was $494,
$155 and $132 as of November 13, 2024, December 31, 2024 and the settlement date, respectively. The Company recorded losses on the change
in the fair value of $0 and $23 in other (expense) income for the three and nine months ended September 30, 2025, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ForwardContractIndexedToIssuersEquityShares
      contextRef="c329"
      decimals="0"
      id="ixv-42741"
      unitRef="shares">16667</us-gaap:ForwardContractIndexedToIssuersEquityShares>
    <us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue
      contextRef="c330"
      decimals="0"
      id="ixv-42742"
      unitRef="shares">3333</us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue>
    <us-gaap:PrepaidRoyalties
      contextRef="c330"
      decimals="-3"
      id="ixv-42743"
      unitRef="usd">1100000</us-gaap:PrepaidRoyalties>
    <us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue
      contextRef="c331"
      decimals="0"
      id="ixv-42744"
      unitRef="shares">3333</us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue>
    <us-gaap:GainLossOnContractTermination
      contextRef="c332"
      decimals="-3"
      id="ixv-42745"
      unitRef="usd">132000</us-gaap:GainLossOnContractTermination>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c333"
      decimals="-3"
      id="ixv-42746"
      unitRef="usd">494000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c334"
      decimals="-3"
      id="ixv-42747"
      unitRef="usd">155000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c2" decimals="-3" id="ixv-42748" unitRef="usd">132000</us-gaap:AssetsFairValueDisclosure>
    <abp:DerivativeChangeInFairValue contextRef="c25" decimals="-3" id="ixv-42749" unitRef="usd">0</abp:DerivativeChangeInFairValue>
    <abp:DerivativeChangeInFairValue contextRef="c0" decimals="-3" id="ixv-42750" unitRef="usd">23000</abp:DerivativeChangeInFairValue>
    <us-gaap:DebtDisclosureTextBlock contextRef="c0" id="ixv-30318">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Notes Payable&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Note Payable&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In January 2025, the Company entered into
an insurance premium financing agreement and borrowed a total principal amount of $553. The note bore an annual interest rate of 7.74%
and matured in September 2025. The interest expense on the note amounted to $21 for the nine months ended September 30, 2025. The note
was paid in full prior to September 30, 2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&lt;span style="text-decoration:underline"&gt;Notes Payable &#x2013; Related Parties&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Promissory Note with ABI&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 18, 2023, the Company entered into
a promissory note agreement with ABI, a significant investor in the Company, to receive up to $6,000. The promissory note accrued interest
at a rate of 5% per annum on the principal amount of each installment from the installment funding date until the maturity date and at
a rate of 7% per annum after the maturity date if any amounts then remain outstanding. The &#x201c;Maturity Date&#x201d; was defined in
the agreement as the earlier of (i) eighteen months from the funding date and (ii) the successful closing of the Merger. On August 22,
2024, ACAB entered into the Abpro Bio Subscription Agreement (see Note 3) with ABI, pursuant to which ABI purchased 20,749 shares of
the Company&#x2019;s common stock, concurrently with the closing of the Merger at a price of $300.00 per share, for an aggregate purchase
price of $6,225, of which $4,225 was paid through the conversion of the balance due by the Company to ABI under the promissory note agreement
and the remainder of $2,000 in cash. In addition, ABI received an aggregate of 41,498 Incentive Shares.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 7, 2024, the Company entered into
an additional promissory note with ABI (&#x201c;the 2024 ABI Note&#x201d;) to receive up to $1,000 from ABI in weekly installments of $250.
The note accrued 10% interest and had a maturity date 5 business days after receipt of the proceeds under the PIPE Financing (see Note
3). The Company received $1,000 under this note through the Closing Date, and the balance of $1,000 was repaid at the Closing from the
PIPE Financing proceeds.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of both September 30, 2025 and December
31, 2024, the outstanding principal balances under the promissory notes with ABI was $0. During both the three and nine months ended
September 30, 2025, the Company recorded $0 of interest expense on these promissory notes with ABI. During the three and nine months
ended September 30, 2024, the Company recorded $53 and $142, respectively, of interest expense on these promissory notes with ABI. As
of both September 30, 2025 and December 31, 2024, accrued interest totaling $191 was included in accrued expenses in the condensed consolidated
balance sheets.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Promissory Notes with Executive and Director&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On December 29, 2023, the Company issued promissory
notes to one of its executives and one of its directors, in the principal amount of $176 and $124, respectively, for deferred bonuses.
Amounts under the promissory notes plus accrued interest are due and payable on the earlier of (i) the closing of the Merger and (ii)
June 29, 2025. These promissory notes accrued interest at 5% per annum until the maturity date and 7% thereafter. At the Closing Date,
the Company paid $150 towards these promissory notes. As of both September 30, 2025 and December 31, 2024, $150 of principal was outstanding.
Interest expense on these promissory notes totaled $2 and $6 for the three and nine months ended September 30, 2025, respectively, included
in interest expense in the condensed consolidated statement of operations. Interest expense on these promissory notes totaled $4 and
$11 for the three and nine months ended September 30, 2024, respectively, included in interest expense in the condensed consolidated
statement of operations. Accrued interest on these promissory notes totaled $20 and $14 as of September 30, 2025 and December 31, 2024,
respectively, included in accrued expenses in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On April 18, 2024, the Company entered into
a separate promissory note agreement with the same executive to receive, as amended, up to $2,158 in funding. During the year ended December
31, 2024, the Company received $1,997 from the executive under this agreement. These advances accrued interest at 7.5% per annum through
the maturity date and at 9.5% per annum after the maturity date if any amounts then remain outstanding. All advances, plus accrued interest,
were due and payable on the earlier of (i) the closing of the Merger and (ii) November 20, 2024. At the Closing, the outstanding promissory
notes of $1,997 were converted into 20,000 newly issued common stock shares. Accrued interest on these promissory notes totaled $62 as
of both September 30, 2025 and December 31, 2024, respectively, included in accrued expenses in the condensed consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Pursuant to the terms of the promissory note
from April 18, 2024, the Company agreed to cause to be issued to the executive a number of New Abpro stock options or warrants in an
amount equal to the outstanding principal amount of such promissory note, subject to required approval by the New Abpro Board of Directors
(&#x201c;BOD&#x201d;) and Compensation Committee and registration of such securities on Form S-8. On February 7, 2025, the Company issued
28,333 common stock warrants to the executive (the &#x201c;Executive Warrants&#x201d;). The Executive Warrants are exercisable at $99.90
per share and bear an expiration date of February 7, 2035. 14,166 of the Executive Warrants are exercisable on the issuance date, 6,667
warrants become exercisable on the one-year anniversary of the issuance date, and 7,500 warrants become exercisable on the two-year anniversary
of the issuance date. The warrants were fair valued and immediately expensed at the issuance date as an additional interest expense related
to the promissory note. The fair value of the Executive Warrants at the issuance date was determined using the Black-Scholes option pricing
model based on the following assumptions: (a) fair value of common stock of $&lt;span style="-sec-ix-hidden: hidden-fact-418"&gt;32.10&lt;/span&gt;&#160;per share, (b) expected volatility of&#160;90.00%,
(c) dividend yield of&#160;0%, (d) risk-free interest rate of&#160;4.49%, and (e) expected life of&#160;10&#160;years. For the three
and nine months ended September 30, 2025, the Company recognized $0 and $714, respectively, of additional interest expense related to
the Executive Warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Promissory Note with ACAB Executive&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On August 16, 2024, an executive at ACAB agreed
to loan Legacy Abpro $103 under a promissory note (the &#x201c;ACAB Executive Note&#x201d;). The ACAB Executive Note did not accrue interest
and the Company agreed to repay a total of $206 at the earlier of i) November 20, 2024, and ii) the closing of the Merger.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 21, 2024, the ACAB Executive Note
was amended to clarify that it should have been between Legacy Abpro as borrower and ACAB as lender. Pursuant to the Severance Agreement
(see Note 15), the liability to the ACAB executive was cancelled. According to the terms of the amended note, Legacy Abpro was to repay
the principal amount of $103. The amended note did not bear interest and was payable upon demand on or before December 31, 2024. The
note balance has not been repaid and was eliminated in consolidation at September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c335"
      decimals="-3"
      id="ixv-42751"
      unitRef="usd">553000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c336"
      decimals="4"
      id="ixv-42752"
      unitRef="pure">0.0774</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" id="ixv-42753" unitRef="usd">21000</us-gaap:InterestPaidNet>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c337"
      decimals="-3"
      id="ixv-42754"
      unitRef="usd">6000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c338"
      decimals="2"
      id="ixv-42755"
      unitRef="pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c339"
      decimals="2"
      id="ixv-42756"
      unitRef="pure">0.07</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c340"
      decimals="0"
      id="ixv-42757"
      unitRef="shares">20749</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c341"
      decimals="2"
      id="ixv-42758"
      unitRef="usdPershares">300</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c340"
      decimals="-3"
      id="ixv-42759"
      unitRef="usd">6225000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <abp:ConversionOfConsiderationUnderPromissoryNoteAgreement
      contextRef="c340"
      decimals="-3"
      id="ixv-42760"
      unitRef="usd">4225000</abp:ConversionOfConsiderationUnderPromissoryNoteAgreement>
    <us-gaap:Cash
      contextRef="c341"
      decimals="-3"
      id="ixv-42761"
      unitRef="usd">2000000</us-gaap:Cash>
    <abp:IncentiveSharesReceivedBySubsidiary
      contextRef="c340"
      decimals="0"
      id="ixv-42762"
      unitRef="shares">41498</abp:IncentiveSharesReceivedBySubsidiary>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c342"
      decimals="-3"
      id="ixv-42763"
      unitRef="usd">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="c343"
      decimals="-3"
      id="ixv-42764"
      unitRef="usd">250000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c343"
      decimals="2"
      id="ixv-42765"
      unitRef="pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c343"
      decimals="-3"
      id="ixv-42766"
      unitRef="usd">1000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c343"
      decimals="-3"
      id="ixv-42767"
      unitRef="usd">1000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NotesPayable
      contextRef="c344"
      decimals="-3"
      id="ixv-42768"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="c345"
      decimals="-3"
      id="ixv-42769"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:InterestExpense
      contextRef="c346"
      decimals="-3"
      id="ixv-42770"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c209"
      decimals="-3"
      id="ixv-42771"
      unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c347"
      decimals="-3"
      id="ixv-42772"
      unitRef="usd">53000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c348"
      decimals="-3"
      id="ixv-42773"
      unitRef="usd">142000</us-gaap:InterestExpense>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c344"
      decimals="-3"
      id="ixv-42774"
      unitRef="usd">191000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c345"
      decimals="-3"
      id="ixv-42775"
      unitRef="usd">191000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="c349"
      decimals="-3"
      id="ixv-42776"
      unitRef="usd">176000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="c350"
      decimals="-3"
      id="ixv-42777"
      unitRef="usd">124000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c351"
      decimals="2"
      id="ixv-42778"
      unitRef="pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c352"
      decimals="2"
      id="ixv-42779"
      unitRef="pure">0.07</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c353"
      decimals="-3"
      id="ixv-42780"
      unitRef="usd">150000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NotesPayable
      contextRef="c354"
      decimals="-3"
      id="ixv-42781"
      unitRef="usd">150000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="c355"
      decimals="-3"
      id="ixv-42782"
      unitRef="usd">150000</us-gaap:NotesPayable>
    <us-gaap:InterestExpense
      contextRef="c356"
      decimals="-3"
      id="ixv-42783"
      unitRef="usd">2000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c357"
      decimals="-3"
      id="ixv-42784"
      unitRef="usd">6000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c358"
      decimals="-3"
      id="ixv-42785"
      unitRef="usd">4000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="c359"
      decimals="-3"
      id="ixv-42786"
      unitRef="usd">11000</us-gaap:InterestExpense>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c354"
      decimals="-3"
      id="ixv-42787"
      unitRef="usd">20000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c355"
      decimals="-3"
      id="ixv-42788"
      unitRef="usd">14000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c360"
      decimals="-3"
      id="ixv-42789"
      unitRef="usd">2158000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c361"
      decimals="-3"
      id="ixv-42790"
      unitRef="usd">1997000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c362"
      decimals="3"
      id="ixv-42791"
      unitRef="pure">0.075</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c363"
      decimals="3"
      id="ixv-42792"
      unitRef="pure">0.095</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:NotesPayable
      contextRef="c364"
      decimals="-3"
      id="ixv-42793"
      unitRef="usd">1997000</us-gaap:NotesPayable>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c365"
      decimals="0"
      id="ixv-42794"
      unitRef="shares">20000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c366"
      decimals="-3"
      id="ixv-42795"
      unitRef="usd">62000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c367"
      decimals="-3"
      id="ixv-42796"
      unitRef="usd">62000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c368"
      decimals="0"
      id="ixv-42797"
      unitRef="shares">28333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c369"
      decimals="2"
      id="ixv-42798"
      unitRef="usdPershares">99.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="c370" id="ixv-42799">2035-02-07</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c371"
      decimals="0"
      id="ixv-42800"
      unitRef="shares">14166</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c372"
      decimals="0"
      id="ixv-42801"
      unitRef="shares">6667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c373"
      decimals="0"
      id="ixv-42802"
      unitRef="shares">7500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c374"
      decimals="2"
      id="ixv-42803"
      unitRef="pure">32.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c376"
      decimals="2"
      id="ixv-42804"
      unitRef="pure">90</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c377"
      decimals="0"
      id="ixv-42805"
      unitRef="pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c378"
      decimals="2"
      id="ixv-42806"
      unitRef="pure">4.49</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <abp:AdditionalInterestExpense contextRef="c25" decimals="-3" id="ixv-42807" unitRef="usd">0</abp:AdditionalInterestExpense>
    <abp:AdditionalInterestExpense contextRef="c0" decimals="-3" id="ixv-42808" unitRef="usd">714000</abp:AdditionalInterestExpense>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c379"
      decimals="-3"
      id="ixv-42809"
      unitRef="usd">103000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c380"
      decimals="-3"
      id="ixv-42810"
      unitRef="usd">206000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentRepaidPrincipal
      contextRef="c381"
      decimals="-3"
      id="ixv-42811"
      unitRef="usd">103000</us-gaap:DebtInstrumentRepaidPrincipal>
    <abp:StandbyEquityPurchaseAgreementTextBlock contextRef="c0" id="ixv-30406">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Standby Equity Purchase Agreement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October&#160;30, 2024, Legacy Abpro and
ACAB entered into a Standby Equity Purchase Agreement (the &#x201c;SEPA&#x201d;) with YA II PN, Ltd. (&#x201c;YA&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Subject to the satisfaction of the conditions
set forth in the SEPA, YA committed to advance to the Company the aggregate principal amount of up to $5,000 (the&#160;&#x201c;Pre-Paid&#160;Advance&#x201d;),
which shall be evidenced by convertible promissory notes (each a &#x201c;Convertible Note&#x201d;). On November 14, 2024, the Company received
the first Pre-Paid Advance and entered into a Convertible Note (defined below). The second&#160;Pre-Paid&#160;Advance was to be in a
principal amount of $2,000 and advanced on the later of (i)&#160;the second trading day after the initial registration statement filed
pursuant to the Registration Rights Agreement (as defined below) becomes effective and (ii)&#160;the second trading day after the required
shareholder approval to issue shares of the post-combination Company&#x2019;s common stock in excess of 20% of the Company&#x2019;s outstanding
shares pursuant to Nasdaq Rules (the &#x201c;Exchange Cap&#x201d;) has been obtained. At the special meeting of stockholders held on April
8, 2025, the Company obtained stockholder approval for the issuance of shares over the Exchange Cap.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 14, 2024 (the &#x201c;First Convertible
Note Issuance Date&#x201d;), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the &#x201c;First Convertible
Note&#x201d;) with YA for $3,000 and received net proceeds of $2,755, net of the original issuance discount of 8% (the &#x201c;Convertible
Note Discount&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On June 23, 2025 (the &#x201c;Second Convertible
Note Issuance Date&#x201d;), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the &#x201c;Second Convertible
Note&#x201d; and together with the First Convertible Note, the &#x201c;Convertible Notes&#x201d;) with YA for $2,000 and received net proceeds
of $1,840, net of the Convertible Note Discount.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Convertible Notes have a maturity date
of November 13, 2025 (subject to earlier repayments based on Amortization Event described below) and incur interest at a rate of 0% (or
18% upon the occurrence of an uncured Event of Default).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Convertible Notes are convertible at the
option of the holder at any time after the issuance dates based on the conversion price determined as the lower of (i) $345.00 per Common
Share (the &#x201c;Fixed Price&#x201d;), or (ii) 94% of the lowest daily VWAP during the 5 consecutive trading days immediately preceding
the conversion date (the &#x201c;Variable Price&#x201d;), but which Variable Price shall not be lower than the Floor Price then in effect
(the &#x201c;Conversion Feature&#x201d;). The Floor Price at the First Issuance Date was $34.62 per share calculated as 20% of the closing
price of the Company&#x2019;s stock on November 12, 2024. The Floor Price was adjusted downward to $5.70 per share on February 12, 2025
when the initial registration statement was declared effective by the SEC. On April 29, 2025, in accordance with the terms of the Convertible
Promissory Note, the Company reduced the Floor Price down to $4.50 per share. The conversion is subject to the limitations including
beneficial ownership limitation, principal market limitation and monthly conversion limits. If the Company, at any time while the Convertible
Note is outstanding, shall issue any Common Shares (other than pursuant to the SEPA) for no consideration or for a price per share that
is lower than the Fixed Price then in effect, the Fixed Price shall be reduced to equal the lowest price per share of such issuances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On April 20, 2025, the Company entered into
an amendment to SEPA with YA, pursuant to which, the definition of the conversion price was amended to state that the Fixed Price should
be adjusted (downwards only) to equal the VWAP of the Common Shares over the three (3) Trading Days immediately preceding the 20th Trading
Day following the Issuance Date if such price is lower than the initial Fixed Price. As a result, at the amendment date, the Fixed Price
was reset down to $50.40 per share.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Convertible Notes were redeemable at the
option of the Company if the volume-weighted-average price (&#x201c;VWAP&#x201d;) of the Company&#x2019;s Common Stock was less than $345.00
which may be adjusted downward upon payment of stock dividend, stock split or reclassification, or if the Company issued common stock
for no consideration or at a price lower than the then-effective Fixed Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the terms of the Convertible Notes,
the Amortization Event was to be occur if i) the daily VWAP is less than the Floor Price for five trading days during a period of seven
consecutive trading days (a &#x201c;Floor Price Event&#x201d;), (ii) unless the Company has obtained the approval from its stockholders
for the issuance of shares pursuant to the transactions contemplated in the SEPA in excess of the Exchange Cap, the Company has issued
in excess of 99% of the Common Shares available under the Exchange Cap (an &#x201c;Exchange Cap Event&#x201d;), or (iii) any time after
the Effectiveness Deadline (as defined in the Registration Rights Agreement entered into in relation to the SEPA), YA was unable to utilize
a Registration Statement to resell Underlying Shares for a period of 10 consecutive trading days (a &#x201c;Registration Event&#x201d;).
If at any time after the Issuance Date, and from time to time thereafter, an Amortization Event was to occur, then the Company had to
make monthly payments beginning on the 7th trading day after the Amortization Event Date and continuing on the same day of each successive
month. Each monthly payment had to be in an amount equal to the sum of (i) $1,250 of principal in the aggregate among the Convertible
Note (or the outstanding principal if less than such amount) (the &#x201c;Amortization Principal Amount&#x201d;), plus (ii) the payment
premium equal to 5% of the Amortization Principal Amount, and (iii) accrued and unpaid interest hereunder as of each payment date. The
obligation of the Company to make monthly prepayments related to an Amortization Event was to be cease (with respect to any payment that
has not yet come due) if any time after the Amortization Date (A) in the event of a Floor Price Event, on the date that was the 7th consecutive
trading day that the daily VWAP was greater than the Floor Price then in effect, or the date that the Company reduces the Floor Price
in accordance with the terms of this Note, (B) in the event of a Registration Event, the condition or event causing the Registration
Event has been cured or the Holder was able to resell the Common Shares issuable upon conversion of this Note without limitations in
accordance with Rule 144 under the Securities Act, or (C) in the event of an Exchange Cap Event, the date the Company has obtained stockholder
approval to increase the number of Common Shares under the Exchange Cap and/or the Exchange Cap no longer applied, unless a subsequent
Amortization Event occurs. No Amortization Events occurred from the Note Issuance Dates through the date the Convertible Notes were converted
into common stock shares as discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;It was determined, in accordance with ASC
815, that the Conversion Feature is required to be bifurcated due to the adjustments to the settlement amount of this embedded feature
that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares, and should be recorded as
a liability (the &#x201c;Embedded Derivative Liability&#x201d;) at fair value with a corresponding amount recorded as a discount on the
Convertible Notes. The Embedded Derivative Liability is marked to market at each reporting period end with any changes recorded in other
income or expense. The fair value of the Embedded Derivative Liability associated with the First Convertible Note was estimated at $69
at the issuance date based on the difference between the fair value of the convertible note with these embedded features and the fair
value without each one of these embedded features. The fair value of the Embedded Derivative Liability associated with the Second Convertible
Note was estimated at $93 at the issuance date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the second quarter of 2025, the First
Convertible note was fully converted at the option of YA into an aggregate of 513,981 Common stock shares. During the third quarter of
2025, the Second Convertible note was fully converted at the option of YA into an aggregate of 367,491 Common stock shares. At each of
the conversion dates, the Company calculated the fair value of the Embedded Derivative Liability associated with the converted portion
of the Convertible Note based on the difference between the fair value of the common stock shares issued upon conversion and the outstanding
note balance, resulting in the total loss on the change in the fair value of $150 and $773 for the three and nine months ended September
30, 2025. The difference between (a) the carrying amount of the First Convertible Note and the fair value of the related Embedded Derivative
Liability at the conversion date, and (b) the fair value of the shares issued was $144 and was recorded to other (expense) income as
a loss on the settlement of the convertible notes during the second quarter of 2025. The difference between (a) the carrying amount of
the Second Convertible Note and the fair value of the related Embedded Derivative Liability at the conversion date, and (b) the fair
value of the shares issued was $214 and was recorded to other (expense) income as a loss on the settlement of the convertible notes during
the third quarter of 2025.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The total discount resulting from the Convertible
Note Discount and the bifurcation of the Embedded Derivative Liability at the issuance dates was amortized over the terms of the Convertible
Notes through non-cash interest expense using the effective interest method. The non-cash interest expense related to the discount amortization
was $27 and $160 for the three and nine months ended September 30, 2025, respectively, and was included in interest expense in the condensed
consolidated statement of operations.&lt;/span&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i style="-sec-ix-redline:true;-keep: true"&gt;SEPA Put Rights&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the terms of the SEPA, starting at the
Closing Date, the Company has the right, but not the obligation (&#x201c;SEPA Put Rights&#x201d;), to issue shares of its common stock
to YA (&#x201c;Advance Shares&#x201d;, and such issuance and sale, an &#x201c;Advance&#x201d;) and YA shall subscribe for and purchase from
the Company such Advance Shares, through written notice by the Company to YA (&#x201c;Advance Notice&#x201d;), provided (i)&#160;no balance
is outstanding under a Convertible Note, or (ii)&#160;if there is a balance outstanding under a Convertible Note, an Amortization Event
(as defined above), has occurred in accordance with and subject to the terms of the SEPA. The SEPA contemplates purchase by YA of up
to $50,000 in aggregate gross purchase price for newly issued shares of the Company&#x2019;s common stock. If any amount remains outstanding
under a Convertible Note, without the prior written consent of YA, the Company may only (other than with respect to a deemed Advance
Notice pursuant to an Investor Notice (described below)) submit an Advance Notice (A) if an Amortization Event has occurred and the obligation
of the Company to make monthly prepayments under the Convertible Note has not ceased, and (B)&#160;YA pays the aggregate purchase price
owed by the Company from such Advance by offsetting the amount of the Advance Proceeds against an equal amount outstanding under the
subject Convertible Note. Any such sales would be subject to certain limitations, including that YA could not purchase any shares that
would result in it owning more than 4.99% of the Company&#x2019;s common stock, or any shares that, aggregated with any related transaction,
would exceed 19.9% of all shares of common stock outstanding on the date of the SEPA unless shareholder approval was obtained allowing
for issuances in excess of such amount.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;For as long as there was an outstanding balance
under a Convertible Note, YA had the right, but not the obligation, by delivery to the Company of Investor Notices (as defined in the
SEPA), to cause an Advance Notice to be deemed delivered by YA, which triggers the issuance and sale of Advance Shares to YA, subject
to terms and conditions as specified in the SEPA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The purchase price for the Advance Shares
shall be the price per Advance Share obtained by multiplying the Company&#x2019;s stock price (i)&#160;by 96% in respect of an Advance
Notice delivered by the Company with an Option 1 Pricing Period (defined by reference to VWAP on the trading day the Advance Notice is
submitted), (ii) 97% in respect of an Advance Notice with an Option 2 Pricing Period (defined by reference to the lowest daily VWAP on
three consecutive trading days commencing on the Advance Notice Date), or (iii)&#160;in the case of any Advance Notice delivered pursuant
to an Investor Notice, equal to the Conversion Price (as defined in the Convertible Note).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company accounted for the SEPA Put Rights
as an asset at fair value in accordance with the guidance in ASC 815, due to the adjustments to the settlement amount of this derivative
instrument that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares. The fair value
of the SEPA Put Rights was $243 and $188 as of September 30, 2025 and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As consideration for YA&#x2019;s commitment
to purchase shares of common stock, upon execution of the SEPA, the Company engaged to remit YA the commitment fee of $500. In December
2024, the Company issued to YA 9,905 shares of common stock in settlement of the commitment fee obligation. The fair value of the shares
issued to YA was $327 at their issuance date and the difference of $173 was recorded as a gain on extinguishment of accrued liabilities
in the fourth quarter of 2024. The excess of the fair value of the SEPA Put Rights above the commitment fee at the issuance date of $1,051
was included in the change in fair value of SEPA Put Rights in the consolidated statement of operations in the fourth quarter of 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In July and August 2025, the Company issued
three Advance Notices to YA in accordance with the terms of the SEPA, under which YA purchased from the Company 91,336 common stock shares,
raising $688 in total net proceeds.&lt;/span&gt;&lt;/p&gt;</abp:StandbyEquityPurchaseAgreementTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c382"
      decimals="-3"
      id="ixv-42812"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c383"
      decimals="-3"
      id="ixv-42813"
      unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <abp:ExcessOfCommonStockPercentage
      contextRef="c383"
      decimals="2"
      id="ixv-42814"
      unitRef="pure">0.20</abp:ExcessOfCommonStockPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="c383"
      decimals="-3"
      id="ixv-42815"
      unitRef="usd">3000000</us-gaap:ConvertibleDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c384"
      decimals="-3"
      id="ixv-42816"
      unitRef="usd">2755000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c385"
      decimals="2"
      id="ixv-42817"
      unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ConvertibleDebt
      contextRef="c386"
      decimals="-3"
      id="ixv-42818"
      unitRef="usd">2000000</us-gaap:ConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="c387"
      decimals="-3"
      id="ixv-42819"
      unitRef="usd">1840000</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c388" id="ixv-42820">2025-11-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c388"
      decimals="2"
      id="ixv-42821"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c389"
      decimals="2"
      id="ixv-42822"
      unitRef="pure">0.18</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c1"
      decimals="2"
      id="ixv-42823"
      unitRef="usdPershares">345</us-gaap:SaleOfStockPricePerShare>
    <abp:PercentageOfVolumeWeightedAveragePrice
      contextRef="c390"
      decimals="2"
      id="ixv-42824"
      unitRef="pure">0.94</abp:PercentageOfVolumeWeightedAveragePrice>
    <abp:ConvertibleThresholdConsecutiveTradingDays contextRef="c391" id="ixv-42825">P5D</abp:ConvertibleThresholdConsecutiveTradingDays>
    <us-gaap:SharePrice
      contextRef="c392"
      decimals="2"
      id="ixv-42826"
      unitRef="usdPershares">34.62</us-gaap:SharePrice>
    <abp:PercentageOfClosingPrice
      contextRef="c393"
      decimals="2"
      id="ixv-42827"
      unitRef="pure">0.20</abp:PercentageOfClosingPrice>
    <abp:FloorPrice
      contextRef="c394"
      decimals="2"
      id="ixv-42828"
      unitRef="usdPershares">5.7</abp:FloorPrice>
    <abp:FloorPrice
      contextRef="c395"
      decimals="2"
      id="ixv-42829"
      unitRef="usdPershares">4.5</abp:FloorPrice>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c396"
      decimals="2"
      id="ixv-42830"
      unitRef="usdPershares">50.4</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <abp:VolumeWeightedAveragePrice
      contextRef="c397"
      decimals="2"
      id="ixv-42831"
      unitRef="usdPershares">345</abp:VolumeWeightedAveragePrice>
    <abp:ConvertibleThresholdConsecutiveTradingDays contextRef="c398" id="ixv-42832">P5D</abp:ConvertibleThresholdConsecutiveTradingDays>
    <abp:ConvertibleThresholdConsecutiveTradingDays contextRef="c399" id="ixv-42834">P7D</abp:ConvertibleThresholdConsecutiveTradingDays>
    <abp:PercentageOfCommonStock
      contextRef="c400"
      decimals="2"
      id="ixv-42836"
      unitRef="pure">0.99</abp:PercentageOfCommonStock>
    <abp:ConvertibleThresholdConsecutiveTradingDays contextRef="c401" id="ixv-42837">P10D</abp:ConvertibleThresholdConsecutiveTradingDays>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c1" decimals="-3" id="ixv-42838" unitRef="usd">1250000</us-gaap:DebtInstrumentFaceAmount>
    <abp:PercentageOfAmortizationPrincipalAmount contextRef="c0" decimals="2" id="ixv-42839" unitRef="pure">0.05</abp:PercentageOfAmortizationPrincipalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c402"
      decimals="-3"
      id="ixv-42840"
      unitRef="usd">69000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c403"
      decimals="-3"
      id="ixv-42841"
      unitRef="usd">93000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c404"
      decimals="0"
      id="ixv-42842"
      unitRef="shares">513981</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c405"
      decimals="0"
      id="ixv-42843"
      unitRef="shares">367491</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <abp:ChangeInFairValueEmbeddedDerivativeLiability contextRef="c25" decimals="-3" id="ixv-42844" unitRef="usd">-150000</abp:ChangeInFairValueEmbeddedDerivativeLiability>
    <abp:ChangeInFairValueEmbeddedDerivativeLiability
      contextRef="c406"
      decimals="-3"
      id="ixv-42845"
      unitRef="usd">773000</abp:ChangeInFairValueEmbeddedDerivativeLiability>
    <us-gaap:OtherExpenses
      contextRef="c407"
      decimals="-3"
      id="ixv-42846"
      unitRef="usd">144000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c25" decimals="-3" id="ixv-42847" unitRef="usd">214000</us-gaap:OtherExpenses>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="c25" decimals="-3" id="ixv-42848" unitRef="usd">27000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="c0" decimals="-3" id="ixv-42849" unitRef="usd">160000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:PaymentsForProceedsFromPreviousAcquisition contextRef="c0" decimals="-3" id="ixv-42850" unitRef="usd">50000000</us-gaap:PaymentsForProceedsFromPreviousAcquisition>
    <abp:PercentageOfCommonStock contextRef="c1" decimals="4" id="ixv-42851" unitRef="pure">0.0499</abp:PercentageOfCommonStock>
    <abp:PercentageOfCommonStockOutstanding contextRef="c1" decimals="3" id="ixv-42852" unitRef="pure">0.199</abp:PercentageOfCommonStockOutstanding>
    <abp:PercentageOfAdvanceNotice
      contextRef="c287"
      decimals="2"
      id="ixv-42853"
      unitRef="pure">0.96</abp:PercentageOfAdvanceNotice>
    <abp:PercentageOfAdvanceNotice
      contextRef="c181"
      decimals="2"
      id="ixv-42854"
      unitRef="pure">0.97</abp:PercentageOfAdvanceNotice>
    <abp:ConvertibleThresholdConsecutiveTradingDays contextRef="c1" id="ixv-42855">P3D</abp:ConvertibleThresholdConsecutiveTradingDays>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c408"
      decimals="-3"
      id="ixv-42857"
      unitRef="usd">243000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c409"
      decimals="-3"
      id="ixv-42858"
      unitRef="usd">188000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="c0" decimals="-3" id="ixv-42859" unitRef="usd">500000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c410"
      decimals="0"
      id="ixv-42860"
      unitRef="shares">9905</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c411"
      decimals="-3"
      id="ixv-42861"
      unitRef="usd">327000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c412"
      decimals="-3"
      id="ixv-42862"
      unitRef="usd">173000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityCommitmentFeeAmount
      contextRef="c412"
      decimals="-3"
      id="ixv-42863"
      unitRef="usd">1051000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c102"
      decimals="0"
      id="ixv-42864"
      unitRef="shares">91336</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c25" decimals="-3" id="ixv-42865" unitRef="usd">688000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0" id="ixv-30547">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Stockholders&#x2019; Equity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of December 31, 2023, and immediately prior
to the Closing Date, Legacy Abpro&#x2019;s amended and restated articles of incorporation authorized the issuance of up to 40,000,000
shares of common stock and up to 11,620,248 shares of preferred stock. Legacy Abpro&#x2019;s Certificate of Incorporation, as amended,
authorizes the issuance of Series A Redeemable Convertible Preferred Stock (&#x201c;Series A&#x201d;), Series B Convertible Preferred Stock
(&#x201c;Series B&#x201d;), Series C Convertible Preferred Stock (&#x201c;Series C&#x201d;), Series D Convertible Preferred Stock (&#x201c;Series
D&#x201d;), Series E Convertible Preferred Stock (&#x201c;Series E&#x201d;) and Series F Convertible Preferred Stock (&#x201c;Series F&#x201d;),
collectively referred to as &#x201c;Convertible Preferred Stock&#x201d;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In connection with the Merger, all previously
issued and outstanding Convertible Preferred Stock was converted into the aggregate number of shares of New Abpro&#x2019;s common stock
that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately
prior to the effective time, multiplied by the exchange ratio of approximately&#160;0.068, and the remaining amount was reclassified
to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Common and Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In connection with the Closing, the Company&#x2019;s
articles of incorporation were amended to designate two classes of stock; preferred and common stock. The articles of incorporation of
New Abpro authorize 1,000,000 shares of preferred stock and 110,000,000 shares of common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s Amended and Restated Certificate
of Incorporation (and Certificate of Amendment, as referenced in Note 1) provides the Company&#x2019;s board of directors with the authority
to issue up to 1,000,000 shares of $0.0001 par value preferred stock in one or more series and to establish from time to time the number
of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations,
powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions.
There were zero preferred shares outstanding as of September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of both September 30, 2025 and December
31, 2024, there were 500,000 outstanding Public Warrants. The Public Warrants became exercisable 12 months from the closing of ACAB&#x2019;s
Initial Public Offering, which closed on January 19, 2022, and will expire five years from the Closing Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company will not be obligated to deliver
any common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless
a registration statement under the Securities Act covering the issuance of the common stock issuable upon exercise of the Public Warrants
is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration.
No warrant will be exercisable, and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless
common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the
state of residence of the registered holder of the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company may redeem the Public Warrants:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;in whole and not in part;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;at a price of $0.30 per warrant;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;upon not less than 30 days&#x2019; prior written notice of redemption
    given after the warrants become exercisable to each warrant holder; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;if, and only if, the reported last sale price of the Series A common stock equals or exceeds $540.00 per share &#160;(as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three trading days before the Company sends the notice of redemption to the warrant holders (the &#x201c;Redemption Trigger&#x201d;). In November 2024, the Redemption Trigger was adjusted to $179.70, as further described below.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If and when the warrants become redeemable
by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for
sale under all applicable state securities laws.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;If the Company calls the Public Warrants for
redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless
basis,&#x201d; as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of
the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization,
merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of both September 30, 2025 and December
31, 2024, there were 461,667 Private Warrants, The Private Warrants are identical to the Public Warrants, except that the Private Warrants
are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees.
If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will
be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In addition, if (x) the Company were to issue
additional shares of common stock or equity-linked securities, for capital raising purposes in connection with the closing of a Merger
at an issue price or effective issue price of less than $276.00 per share of common stock (with such issue price or effective issue price
to be determined in good faith by the Company&#x2019;s board of directors, and, in the case of any such issuance to the Sponsor or its
affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such issuance)
(the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represented more than 60% of the total equity
proceeds, and interest thereon, available for the funding of a Merger on the date of the completion of a Merger (net of redemptions),
and (z) the volume weighted average trading price of the Company&#x2019;s Series A common stock during the 20 trading day period starting
on the trading day after the day on which the Company completes a Merger (such price, the &#x201c;Market Value&#x201d;) was below $276.00
per share, the exercise price of the warrants would be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market
Value and the Newly Issued Price, and the $540.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal
to 180% of the greater of the Market Value and the Newly Issued Price (the &#x201c;Down Round Feature&#x201d;).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;In November 2024, the &#x201c;Down Round Feature&#x201d;
was triggered and the exercise price of the Public and Private Warrants was adjusted down to $114.90 and the per share Redemption Trigger
was adjusted down to $179.70 based on the Newly Issued Price of $99.90. The Company accounted for the change in fair value of the Public
and Private Warrants triggered by the down round as a deemed dividend under the guidance in ASC 260-10-25-1 related to financial instruments
that include a down round feature.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company valued the deemed dividend as
the difference between the fair value of the warrants before and after the exercise price adjustment. The warrants were valued using
the Black-Scholes option pricing model immediately before and after the modification using the following assumptions: (a) fair value
of common stock of $53.40&#160;per share, (b) expected volatility of&#160;90.00%, (c) dividend yield of&#160;0%, (d) risk-free interest
rate of&#160;4.09%, and (e) expected life of&#160;4.9&#160;years. The increase in the fair value of the warrants resulting from the exercise
price adjustment was $10,177 and was reflected as a deemed dividend in the consolidated statements of operations for the fourth quarter
of 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The 2,034&#160;outstanding common stock warrants
of Legacy Abpro (&#x201c;Legacy Abpro Common Stock Warrants&#x201d;) expired at the Closing Date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On February 7, 2025, the Company issued 28,333
Executive Warrants (see Note 10).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following presents information about warrants
to purchase common stock outstanding as of September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;990,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;114.60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;No warrants
were exercised during the nine months ended September 30, 2025.&lt;/span&gt;&#160;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c413"
      decimals="0"
      id="ixv-42866"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c414"
      decimals="0"
      id="ixv-42867"
      unitRef="shares">11620248</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c415"
      decimals="INF"
      id="ixv-42868"
      unitRef="usdPershares">0.068</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c193"
      decimals="0"
      id="ixv-42869"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c1"
      decimals="0"
      id="ixv-42870"
      unitRef="shares">110000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c1"
      decimals="INF"
      id="ixv-42871"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-42872"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c1"
      decimals="INF"
      id="ixv-42873"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c1"
      decimals="0"
      id="ixv-42874"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-42875"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c416"
      decimals="0"
      id="ixv-42876"
      unitRef="shares">500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c417"
      decimals="0"
      id="ixv-42877"
      unitRef="shares">500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <abp:WarrantsExercisableTerm contextRef="c418" id="ixv-42878">P12M</abp:WarrantsExercisableTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c418" id="ixv-42879">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <abp:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="c416"
      decimals="2"
      id="ixv-42880"
      unitRef="usdPershares">0.3</abp:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <abp:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger
      contextRef="c419"
      decimals="2"
      id="ixv-42881"
      unitRef="usdPershares">540</abp:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger>
    <abp:NumberOfTradingDaysForDeterminingTheSharePrice contextRef="c420" id="ixv-42882">P20D</abp:NumberOfTradingDaysForDeterminingTheSharePrice>
    <abp:PeriodAfterWhichTheWarrantsAreExercisable contextRef="c420" id="ixv-42883">P30D</abp:PeriodAfterWhichTheWarrantsAreExercisable>
    <abp:PerShareRedemptionsTriggerPrice
      contextRef="c421"
      decimals="2"
      id="ixv-42884"
      unitRef="usdPershares">179.7</abp:PerShareRedemptionsTriggerPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c422"
      decimals="0"
      id="ixv-42885"
      unitRef="shares">461667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c423"
      decimals="0"
      id="ixv-42886"
      unitRef="shares">461667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c419"
      decimals="2"
      id="ixv-42887"
      unitRef="usdPershares">276</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="c424"
      decimals="2"
      id="ixv-42888"
      unitRef="pure">0.60</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <abp:NumberOfTradingDaysForDeterminingTheSharePrice contextRef="c420" id="ixv-42889">P20D</abp:NumberOfTradingDaysForDeterminingTheSharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c425"
      decimals="2"
      id="ixv-42890"
      unitRef="usdPershares">276</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <abp:PercentageOfMarketValueAndNewlyIssuedPrice contextRef="c0" decimals="2" id="ixv-42891" unitRef="pure">1.15</abp:PercentageOfMarketValueAndNewlyIssuedPrice>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="c205"
      decimals="2"
      id="ixv-42892"
      unitRef="usdPershares">540</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <abp:PercentageOfMarketValueAndNewlyIssuedPrice
      contextRef="c415"
      decimals="2"
      id="ixv-42893"
      unitRef="pure">1.80</abp:PercentageOfMarketValueAndNewlyIssuedPrice>
    <abp:PerShareRedemptionsTriggerPrice
      contextRef="c426"
      decimals="2"
      id="ixv-42894"
      unitRef="usdPershares">114.9</abp:PerShareRedemptionsTriggerPrice>
    <abp:PerShareRedemptionsTriggerPrice
      contextRef="c427"
      decimals="2"
      id="ixv-42895"
      unitRef="usdPershares">179.7</abp:PerShareRedemptionsTriggerPrice>
    <abp:PerShareRedemptionsTriggerPrice
      contextRef="c428"
      decimals="2"
      id="ixv-42896"
      unitRef="usdPershares">99.9</abp:PerShareRedemptionsTriggerPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-42897"
      unitRef="usdPershares">53.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c429"
      decimals="4"
      id="ixv-42898"
      unitRef="pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c429"
      decimals="2"
      id="ixv-42899"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c429"
      decimals="4"
      id="ixv-42900"
      unitRef="pure">0.0409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c429" id="ixv-42901">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c0" decimals="-3" id="ixv-42902" unitRef="usd">10177000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c430"
      decimals="0"
      id="ixv-42903"
      unitRef="shares">2034</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c431"
      decimals="0"
      id="ixv-42904"
      unitRef="shares">28333</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c415" id="ixv-30706">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The following presents information about warrants
to purchase common stock outstanding as of September 30, 2025:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%; text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;990,000&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;114.60&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 11%; text-align: center; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c432"
      decimals="INF"
      id="ixv-42905"
      unitRef="shares">990000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c432"
      decimals="2"
      id="ixv-42906"
      unitRef="usdPershares">114.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c432" id="ixv-42907">P4Y3M18D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0" id="ixv-30800">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Share-Based Compensation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;2024 Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company&#x2019;s 2024 Equity Incentive
Plan (the &#x201c;2024 Plan&#x201d;) became effective at the Closing Date. As of September 30, 2025,&#160;183,279&#160;shares of common
stock were available for issuance under the 2024 Plan, which is equal to 10% of the number of shares of common stock of the Company following
the Merger. The 2024 Plan provides that on January 1 of each year commencing January 1, 2026 and ending on December 31, 2034, the 2024
Plan reserve will automatically increase in an amount equal to the lesser of (a)&#160;5% of the number of shares of the Company&#x2019;s
common stock outstanding on December&#160;31 of the preceding year and (b) a number of shares of common stock determined by the Company&#x2019;s
board of directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Under the 2024 Plan, the Company can grant
non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock
units, unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees. In July 2025, the Company
granted 8,080 options with the weighted average fair value of the option of $6.90, to the directors and 16,667 RSUs to the Company&#x2019;s
Chief Executive Officer under the 2024 Plan. The stock options granted to directors vest in full in November 2025. The RSUs granted to
the CEO vest in three equal installments on each anniversary of March 3, 2025. The contractual term of the stock options and RSUs is
ten years. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The fair value of the options issued during
the three months ended September 30, 2025 was determined using the Black-Scholes option pricing model based on the following assumptions:
(a) fair value of common stock of $9.45&#160;per share, (b) expected volatility of&#160;92.00%, (c) dividend yield of&#160;0%, (d) risk-free
interest rate of&#160;3.95%, and (e) expected term of&#160;5.2&#160;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;2014 Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The 2014 Stock Incentive Plan (the &#x201c;2014
Plan&#x201d;) of Legacy Abpro was expired as of the Closing Date, in accordance with its original terms. As a result of the expiration,
no further awards may be granted under the 2014 Plan. All awards previously granted and outstanding as of the effective date of the Merger,
which totaled&#160;166,858 options, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise
remain in effect pursuant to their original terms (see Note 3). Stock options granted to employees and directors typically vest over
four years. Stock options granted &lt;span style="-sec-ix-hidden: hidden-fact-425"&gt;to&lt;/span&gt; non-employees typically vest immediately at the grant date. The maximum contractual term of the
stock options is ten years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company granted restricted stock units
(&#x201c;RSUs&#x201d;) to various employees and directors under the 2014 Plan. These RSUs cliff vest on the first anniversary of the grant
date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The summary of the Company&#x2019;s stock option
activity is as follows:&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of&lt;br/&gt; Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;329,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,080&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-419"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-420"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-421"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forfeited/Expired/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(114,840&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-422"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;222,635&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercisable at&#160;&#160;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;180,146&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The summary of the Company&#x2019;s restricted
stock unit activity is as follows:&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vesting&#160;Period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Unvested at December&#160;31,&#160;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;739&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;16,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(142&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-423"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forfeited/Expired/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(597&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-424"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Unvested at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;16,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;During the nine months ended September 30,
2025, 142 RSUs vested in accordance with their terms, but the shares of common stock were not issued to the holders as of September 30,
2025.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 22, 2024, the Company&#x2019;s board
of directors authorized the issuance of 10,000 RSUs (or approximately 20,449 RSUs as adjusted for the Merger closing based on the Exchange
Ratio), that were not yet issued as of September 30, 2025. For the three and nine months ended September 30, 2025, the Company recorded
$208 and $618, respectively, in stock compensation expense related to these authorized RSUs. The total accrued expenses related to these
authorized RSUs were $1,012 and $394 as of September 30, 2025 and December 31, 2024, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b style="-sec-ix-redline:true;-keep: true"&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The summary of the recorded stock-based compensation
expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended &lt;br/&gt;
    September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nine Months Ended &lt;br/&gt;
    September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;404&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,136&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,469&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;286&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;415&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,531&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;As of September 30, 2025, there was approximately
$192 of unrecognized compensation cost related to unvested stock option awards that are expected to be recognized over a weighted-average
period of 0.4 years. As of September 30, 2025, there was approximately $127 of unrecognized compensation related to unvested restricted
stock awards that are expected to be recognized over a weighted-average period of 1.3 years.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c433"
      decimals="0"
      id="ixv-42908"
      unitRef="shares">183279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <abp:PercentageOfCommonStock
      contextRef="c433"
      decimals="2"
      id="ixv-42909"
      unitRef="pure">0.10</abp:PercentageOfCommonStock>
    <abp:PercentageOfCommonStock
      contextRef="c434"
      decimals="2"
      id="ixv-42910"
      unitRef="pure">0.05</abp:PercentageOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c435"
      decimals="0"
      id="ixv-42911"
      unitRef="shares">8080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c435"
      decimals="2"
      id="ixv-42912"
      unitRef="usdPershares">6.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c436"
      decimals="0"
      id="ixv-42913"
      unitRef="shares">16667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c437" id="ixv-42914">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock
      contextRef="c0"
      decimals="2"
      id="ixv-42915"
      unitRef="usdPershares">9.45</abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="4" id="ixv-42916" unitRef="pure">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" id="ixv-42917" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="4" id="ixv-42918" unitRef="pure">0.0395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0" id="ixv-42919">P5Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c438"
      decimals="0"
      id="ixv-42920"
      unitRef="shares">166858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c438" id="ixv-42921">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c438" id="ixv-42922">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0" id="ixv-30865">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The summary of the Company&#x2019;s stock option
activity is as follows:&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number of&lt;br/&gt; Stock Options&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;329,395&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51.30&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;8,080&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-419"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-420"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-421"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forfeited/Expired/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(114,840&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50.39&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-422"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Outstanding at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;222,635&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;50.28&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Exercisable at&#160;&#160;September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;180,146&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;51.85&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-42923"
      unitRef="shares">329395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-42924"
      unitRef="usdPershares">51.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c449" id="ixv-30924">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c0"
      decimals="INF"
      id="ixv-42925"
      unitRef="shares">8080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-42926"
      unitRef="usdPershares">9.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm contextRef="c0" id="ixv-30952">P10Y</abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c0"
      decimals="INF"
      id="ixv-42927"
      unitRef="shares">114840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      decimals="2"
      id="ixv-42928"
      unitRef="usdPershares">50.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-42929"
      unitRef="shares">222635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-42930"
      unitRef="usdPershares">50.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c0" id="ixv-31038">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c1"
      decimals="INF"
      id="ixv-42931"
      unitRef="shares">180146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c1"
      decimals="2"
      id="ixv-42932"
      unitRef="usdPershares">51.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0" id="ixv-31066">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0" id="ixv-31097">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The summary of the Company&#x2019;s restricted
stock unit activity is as follows:&#160;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Weighted-&lt;br/&gt; Average&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Number&#160;of&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Grant Date&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Remaining&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vesting&#160;Period&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Unvested at December&#160;31,&#160;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;739&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48.90&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;16,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.6&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(142&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48.90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-423"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Forfeited/Expired/Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;(597&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;48.90&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-424"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Unvested at September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;16,667&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;9.60&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c446"
      decimals="INF"
      id="ixv-42933"
      unitRef="shares">739</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c446"
      decimals="2"
      id="ixv-42934"
      unitRef="usdPershares">48.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c450" id="ixv-31192">P0Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c451"
      decimals="INF"
      id="ixv-42935"
      unitRef="shares">16667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c451"
      decimals="2"
      id="ixv-42936"
      unitRef="usdPershares">9.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <abp:SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c451" id="ixv-31220">P2Y7M6D</abp:SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c451"
      decimals="INF"
      id="ixv-42937"
      unitRef="shares">142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c451"
      decimals="2"
      id="ixv-42938"
      unitRef="usdPershares">48.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c451"
      decimals="INF"
      id="ixv-42939"
      unitRef="shares">597</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c451"
      decimals="2"
      id="ixv-42940"
      unitRef="usdPershares">48.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c445"
      decimals="INF"
      id="ixv-42941"
      unitRef="shares">16667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c445"
      decimals="2"
      id="ixv-42942"
      unitRef="usdPershares">9.6</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c451" id="ixv-31304">P2Y4M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c440"
      decimals="0"
      id="ixv-42943"
      unitRef="shares">142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c441"
      decimals="0"
      id="ixv-42944"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c442"
      decimals="0"
      id="ixv-42945"
      unitRef="shares">20449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c443"
      decimals="-3"
      id="ixv-42946"
      unitRef="usd">208000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c444"
      decimals="-3"
      id="ixv-42947"
      unitRef="usd">618000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="c445"
      decimals="-3"
      id="ixv-42948"
      unitRef="usd">1012000</us-gaap:AccruedLiabilitiesFairValueDisclosure>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="c446"
      decimals="-3"
      id="ixv-42949"
      unitRef="usd">394000</us-gaap:AccruedLiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0" id="ixv-31324">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The summary of the recorded stock-based compensation
expense is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Three Months Ended &lt;br/&gt;
    September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Nine Months Ended &lt;br/&gt;
    September 30,&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;22&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;62&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;282&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;404&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,136&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,469&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;286&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;415&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,158&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;1,531&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c294"
      decimals="-3"
      id="ixv-42950"
      unitRef="usd">4000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c295"
      decimals="-3"
      id="ixv-42951"
      unitRef="usd">11000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c296"
      decimals="-3"
      id="ixv-42952"
      unitRef="usd">22000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c297"
      decimals="-3"
      id="ixv-42953"
      unitRef="usd">62000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c452"
      decimals="-3"
      id="ixv-42954"
      unitRef="usd">282000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c453"
      decimals="-3"
      id="ixv-42955"
      unitRef="usd">404000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c454"
      decimals="-3"
      id="ixv-42956"
      unitRef="usd">1136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c455"
      decimals="-3"
      id="ixv-42957"
      unitRef="usd">1469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c25" decimals="-3" id="ixv-42958" unitRef="usd">286000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c26" decimals="-3" id="ixv-42959" unitRef="usd">415000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" id="ixv-42960" unitRef="usd">1158000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c27" decimals="-3" id="ixv-42961" unitRef="usd">1531000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c447"
      decimals="-3"
      id="ixv-42962"
      unitRef="usd">192000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c439" id="ixv-42963">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c448"
      decimals="-3"
      id="ixv-42964"
      unitRef="usd">127000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c439" id="ixv-42965">P1Y3M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c0" id="ixv-31514">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Employee Benefit Plan&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has a 401(k) retirement plan available
to all eligible employees. During the three and nine months ended September 30, 2025, the Company made $6 and $35 in matching contributions,
respectively, to the plan. During the three and nine months ended September 30, 2024, the Company made $29 and $101 in matching contributions,
respectively, to the plan.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c25" decimals="-3" id="ixv-42966" unitRef="usd">6000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c0" decimals="-3" id="ixv-42967" unitRef="usd">35000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c26" decimals="-3" id="ixv-42968" unitRef="usd">29000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c27" decimals="-3" id="ixv-42969" unitRef="usd">101000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0" id="ixv-31547">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Related Parties&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;The Company has certain promissory notes outstanding
with executives and directors as of September 30, 2025. See Note 10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On January 15, 2020, the Company entered into
an agreement for various consulting services, as defined in the agreement, with a member of the Company&#x2019;s Board of Directors. On
January 1, 2023, the Company entered into a new consulting agreement with the same director, which superseded the agreement dated in
January 2020. The agreement was terminated during the year ended December 31, 2024. During the three and nine months ended September
30, 2025, the Company incurred $0 under this agreement. During the three and nine months ended September 30, 2024, the Company incurred
$0 and $146, respectively, under this agreement. As of both September 30, 2025 and December 31, 2024, the unpaid amount was $189.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On April 18, 2024, the Company entered into
a promissory note agreement with an executive to receive, as amended, for up to $2,158 in funding. During the year ended December 31,
2024, the Company received $1,997 from the executive under this agreement. See Note 10.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On April 18, 2024, the Company entered into
an agreement with an executive to defer payment of compensation from April 18, 2024 until the earlier of (i) the closing of the Merger
and (ii) November 20, 2024. The executive&#x2019;s deferred wages were repaid in the amount of $221 in November 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 21, 2024, the Company entered
into a severance agreement with an executive (the &#x201c;Severance Agreement&#x201d;). Pursuant to the terms of the Severance Agreement,
the Company made a severance payment of $221 upon execution of the agreement. The Severance Agreement supersedes and extinguishes all
other agreements between the executive and the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On December 24, 2024, the Company made a payment
of $574 to the Sponsor in accordance with the terms of the Merger Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&lt;br/&gt;
On July 25, 2025, in connection with a consulting agreement executed between the Company and the Chief Executive Officer (&#x201c;CEO&#x201d;)(the
&#x201c;CEO Consulting Agreement&#x201d;), the Company issued&#160;16,667&#160;RSUs, which vest in three equal installments on March 3,
2026, March 3, 2027, and March 3, 2028. The term of the CEO Consulting Agreement commenced on March 3, 2025, the date the Company&#x2019;s
board of directors appointed the CEO, and shall remain in full force and effect until terminated by mutual written agreement between
the Company and the CEO, or by sixty days&#x2019; prior written notice by either party. The Company will compensate the CEO with an annual
base fee of $300,000, payable in bi-weekly installments. Under the terms of the CEO Consulting Agreement, the Company is obligated to
make the payment equal to three times the fair market value of the CEO&#x2019;s equity interests in the Company, if within 12 months of
a change of control event (as defined in the CEO Consulting Agreement), the CEO is involuntarily terminated without cause or resigns
for good reason.&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c456"
      decimals="-3"
      id="ixv-42970"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c457"
      decimals="-3"
      id="ixv-42971"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c458"
      decimals="-3"
      id="ixv-42972"
      unitRef="usd">0</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c459"
      decimals="-3"
      id="ixv-42973"
      unitRef="usd">146000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <abp:UnpaidAmount contextRef="c3" decimals="-3" id="ixv-42974" unitRef="usd">189000</abp:UnpaidAmount>
    <abp:UnpaidAmount contextRef="c4" decimals="-3" id="ixv-42975" unitRef="usd">189000</abp:UnpaidAmount>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c460"
      decimals="-3"
      id="ixv-42976"
      unitRef="usd">2158000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c461"
      decimals="-3"
      id="ixv-42977"
      unitRef="usd">1997000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c462"
      decimals="-3"
      id="ixv-42978"
      unitRef="usd">221000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SeveranceCosts1
      contextRef="c463"
      decimals="-3"
      id="ixv-42979"
      unitRef="usd">221000</us-gaap:SeveranceCosts1>
    <us-gaap:PaymentsForMergerRelatedCosts
      contextRef="c464"
      decimals="-3"
      id="ixv-42980"
      unitRef="usd">574000</us-gaap:PaymentsForMergerRelatedCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c465"
      decimals="0"
      id="ixv-42981"
      unitRef="shares">16667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abp:AnnualBaseFee contextRef="c466" decimals="0" id="ixv-42982" unitRef="usd">300000</abp:AnnualBaseFee>
    <us-gaap:SubsequentEventsTextBlock contextRef="c0" id="ixv-31587">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;16.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="-sec-ix-redline:true;font-size: 10pt"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On October 1, 2025, the Company issued 32,778 shares of common
stock with the aggregate net purchase price of $211 under an Advance Notice to YA in accordance with the terms of the SEPA.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="-sec-ix-redline:true;-keep: true"&gt;On November 7, 2025, the Company issued 11,217 shares of common
stock with the aggregate net purchase price of $59 under an Advance Notice to YA in accordance with the terms of the SEPA.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="c467"
      decimals="0"
      id="ixv-42983"
      unitRef="shares">32778</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c468" decimals="0" id="ixv-42984" unitRef="usd">211</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:CommonStockSharesIssued
      contextRef="c469"
      decimals="0"
      id="ixv-42985"
      unitRef="shares">11217</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c470" decimals="0" id="ixv-42986" unitRef="usd">59</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:Cash contextRef="c2" decimals="-3" id="ixv-42987" unitRef="usd">2850000</us-gaap:Cash>
    <us-gaap:Cash contextRef="c5" decimals="-3" id="ixv-42988" unitRef="usd">723000</us-gaap:Cash>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c6" decimals="-3" id="ixv-42989" unitRef="usd">323000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c7" decimals="-3" id="ixv-42990" unitRef="usd">88000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:DeferredOfferingCosts contextRef="c5" decimals="-3" id="ixv-42991" unitRef="usd">878000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c6" decimals="-3" id="ixv-42992" unitRef="usd">306000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c7" decimals="-3" id="ixv-42993" unitRef="usd">208000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <abp:ForwardPurchaseAgreementAsset contextRef="c2" decimals="-3" id="ixv-42994" unitRef="usd">155000</abp:ForwardPurchaseAgreementAsset>
    <us-gaap:RestrictedCashCurrent contextRef="c2" decimals="-3" id="ixv-42995" unitRef="usd">142000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c5" decimals="-3" id="ixv-42996" unitRef="usd">138000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" id="ixv-42997" unitRef="usd">3776000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c5" decimals="-3" id="ixv-42998" unitRef="usd">2035000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-42999" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-43000" unitRef="usd">102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" id="ixv-43001" unitRef="usd">418000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c5" decimals="-3" id="ixv-43002" unitRef="usd">966000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:SecurityDeposit contextRef="c2" decimals="-3" id="ixv-43003" unitRef="usd">66000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="c5" decimals="-3" id="ixv-43004" unitRef="usd">66000</us-gaap:SecurityDeposit>
    <abp:PatentsNet contextRef="c2" decimals="-3" id="ixv-43005" unitRef="usd">176000</abp:PatentsNet>
    <abp:PatentsNet contextRef="c5" decimals="-3" id="ixv-43006" unitRef="usd">186000</abp:PatentsNet>
    <abp:SEPAPutRightsAsset contextRef="c2" decimals="-3" id="ixv-43007" unitRef="usd">188000</abp:SEPAPutRightsAsset>
    <us-gaap:Assets contextRef="c2" decimals="-3" id="ixv-43008" unitRef="usd">4661000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c5" decimals="-3" id="ixv-43009" unitRef="usd">3355000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" id="ixv-43010" unitRef="usd">3936000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c5" decimals="-3" id="ixv-43011" unitRef="usd">7916000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-43012" unitRef="usd">7496000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-43013" unitRef="usd">5381000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c2" decimals="-3" id="ixv-43014" unitRef="usd">4401000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-43015" unitRef="usd">456000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-43016" unitRef="usd">567000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent contextRef="c5" decimals="-3" id="ixv-43017" unitRef="usd">130000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="-3" id="ixv-43018" unitRef="usd">366000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c4" decimals="-3" id="ixv-43019" unitRef="usd">147000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c8" decimals="-3" id="ixv-43020" unitRef="usd">1742000</us-gaap:NotesPayableCurrent>
    <abp:ConvertibleNotes contextRef="c2" decimals="-3" id="ixv-43021" unitRef="usd">2725000</abp:ConvertibleNotes>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability contextRef="c2" decimals="-3" id="ixv-43022" unitRef="usd">80000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-43023" unitRef="usd">19607000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-43024" unitRef="usd">15736000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c5" decimals="-3" id="ixv-43025" unitRef="usd">455000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c2" decimals="-3" id="ixv-43026" unitRef="usd">19607000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c5" decimals="-3" id="ixv-43027" unitRef="usd">16191000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c9"
      decimals="INF"
      id="ixv-43028"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c9"
      decimals="INF"
      id="ixv-43029"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c9"
      decimals="INF"
      id="ixv-43030"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c10"
      decimals="INF"
      id="ixv-43031"
      unitRef="shares">9088398</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c10"
      decimals="INF"
      id="ixv-43032"
      unitRef="shares">1136049</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c10"
      decimals="INF"
      id="ixv-43033"
      unitRef="shares">1136049</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c10" decimals="-3" id="ixv-43034" unitRef="usd">10000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c10" decimals="-3" id="ixv-43035" unitRef="usd">9991000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c12"
      decimals="INF"
      id="ixv-43036"
      unitRef="shares">9008324</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c12"
      decimals="INF"
      id="ixv-43037"
      unitRef="shares">6756246</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c12"
      decimals="INF"
      id="ixv-43038"
      unitRef="shares">6756246</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c12" decimals="-3" id="ixv-43039" unitRef="usd">10000000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c12" decimals="-3" id="ixv-43040" unitRef="usd">29841000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c14"
      decimals="INF"
      id="ixv-43041"
      unitRef="shares">2679397</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c14"
      decimals="INF"
      id="ixv-43042"
      unitRef="shares">2679397</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c14"
      decimals="INF"
      id="ixv-43043"
      unitRef="shares">2679397</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c14" decimals="-3" id="ixv-43044" unitRef="usd">18194000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c14" decimals="-3" id="ixv-43045" unitRef="usd">17622000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c16"
      decimals="INF"
      id="ixv-43046"
      unitRef="shares">4101409</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c16"
      decimals="INF"
      id="ixv-43047"
      unitRef="shares">4101409</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c16"
      decimals="INF"
      id="ixv-43048"
      unitRef="shares">4101409</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c16" decimals="-3" id="ixv-43049" unitRef="usd">15725000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c16" decimals="-3" id="ixv-43050" unitRef="usd">14949000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c18"
      decimals="INF"
      id="ixv-43051"
      unitRef="shares">1281402</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c18"
      decimals="INF"
      id="ixv-43052"
      unitRef="shares">1281402</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c18"
      decimals="INF"
      id="ixv-43053"
      unitRef="shares">1281402</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c18" decimals="-3" id="ixv-43054" unitRef="usd">1798000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c18" decimals="-3" id="ixv-43055" unitRef="usd">1401000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c20"
      decimals="INF"
      id="ixv-43056"
      unitRef="shares">3938098</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c20"
      decimals="INF"
      id="ixv-43057"
      unitRef="shares">3938098</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c20"
      decimals="INF"
      id="ixv-43058"
      unitRef="shares">3938098</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityLiquidationPreference contextRef="c20" decimals="-3" id="ixv-43059" unitRef="usd">1795000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c20" decimals="-3" id="ixv-43060" unitRef="usd">1795000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="c5" decimals="-3" id="ixv-43061" unitRef="usd">75599000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-43062"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c5"
      decimals="4"
      id="ixv-43063"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-43064"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-43065"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c5"
      decimals="4"
      id="ixv-43066"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-43067"
      unitRef="shares">110000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="ixv-43068"
      unitRef="shares">81795590</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="ixv-43069"
      unitRef="shares">1727192</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="ixv-43070"
      unitRef="shares">646044</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-43071"
      unitRef="shares">1694414</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="ixv-43072"
      unitRef="shares">639039</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c2"
      decimals="INF"
      id="ixv-43073"
      unitRef="shares">32778</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c5"
      decimals="INF"
      id="ixv-43074"
      unitRef="shares">7006</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c5" decimals="-3" id="ixv-43075" unitRef="usd">33000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" id="ixv-43076" unitRef="usd">100608000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c5" decimals="-3" id="ixv-43077" unitRef="usd">19920000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-43078" unitRef="usd">-116103000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c5" decimals="-3" id="ixv-43079" unitRef="usd">-108871000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" id="ixv-43080" unitRef="usd">-15495000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" id="ixv-43081" unitRef="usd">-88984000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c2" decimals="-3" id="ixv-43082" unitRef="usd">549000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c5" decimals="-3" id="ixv-43083" unitRef="usd">549000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="-3" id="ixv-43084" unitRef="usd">-14946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="-3" id="ixv-43085" unitRef="usd">-88435000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" id="ixv-43086" unitRef="usd">4661000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c5" decimals="-3" id="ixv-43087" unitRef="usd">3355000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c28" decimals="-3" id="ixv-43088" unitRef="usd">183000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c31" decimals="-3" id="ixv-43089" unitRef="usd">99000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c33" decimals="-3" id="ixv-43090" unitRef="usd">23000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c34" decimals="-3" id="ixv-43091" unitRef="usd">183000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c35" decimals="-3" id="ixv-43092" unitRef="usd">122000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c34" decimals="-3" id="ixv-43093" unitRef="usd">2983000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c35" decimals="-3" id="ixv-43094" unitRef="usd">4266000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c34" decimals="-3" id="ixv-43095" unitRef="usd">7121000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c35" decimals="-3" id="ixv-43096" unitRef="usd">7602000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c34" decimals="-3" id="ixv-43097" unitRef="usd">10104000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c35" decimals="-3" id="ixv-43098" unitRef="usd">11868000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c34" decimals="-3" id="ixv-43099" unitRef="usd">-9921000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c35" decimals="-3" id="ixv-43100" unitRef="usd">-11746000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncome contextRef="c34" decimals="-3" id="ixv-43101" unitRef="usd">3556000</us-gaap:OtherNonoperatingIncome>
    <abp:ChangeInFairValueOfForwardPuchaseAgreementAsset contextRef="c34" decimals="-3" id="ixv-43102" unitRef="usd">-339000</abp:ChangeInFairValueOfForwardPuchaseAgreementAsset>
    <abp:ChangeInFairValueOfSEPAPutRightsAsset contextRef="c34" decimals="-3" id="ixv-43103" unitRef="usd">-312000</abp:ChangeInFairValueOfSEPAPutRightsAsset>
    <abp:ChangeInFairValueOfEmbeddedDerivativeLiability contextRef="c34" decimals="-3" id="ixv-43104" unitRef="usd">-11000</abp:ChangeInFairValueOfEmbeddedDerivativeLiability>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c34" decimals="-3" id="ixv-43105" unitRef="usd">173000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InvestmentIncomeInterest contextRef="c34" decimals="-3" id="ixv-43106" unitRef="usd">9000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c35" decimals="-3" id="ixv-43107" unitRef="usd">63000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating contextRef="c34" decimals="-3" id="ixv-43108" unitRef="usd">387000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating contextRef="c35" decimals="-3" id="ixv-43109" unitRef="usd">23000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:NonoperatingIncomeExpense contextRef="c34" decimals="-3" id="ixv-43110" unitRef="usd">2689000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c35" decimals="-3" id="ixv-43111" unitRef="usd">40000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss contextRef="c34" decimals="-3" id="ixv-43112" unitRef="usd">-7232000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c35" decimals="-3" id="ixv-43113" unitRef="usd">-11706000</us-gaap:ProfitLoss>
    <abp:DeemedDividendResultingFromTheWarrantDownRound contextRef="c34" decimals="-3" id="ixv-43114" unitRef="usd">10177000</abp:DeemedDividendResultingFromTheWarrantDownRound>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic contextRef="c34" decimals="-3" id="ixv-43115" unitRef="usd">-17409000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic contextRef="c35" decimals="-3" id="ixv-43116" unitRef="usd">-11706000</us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c34"
      decimals="2"
      id="ixv-43117"
      unitRef="usdPershares">-22.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c34"
      decimals="2"
      id="ixv-43118"
      unitRef="usdPershares">-22.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c35"
      decimals="2"
      id="ixv-43119"
      unitRef="usdPershares">-18.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c35"
      decimals="2"
      id="ixv-43120"
      unitRef="usdPershares">-18.35</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c34"
      decimals="INF"
      id="ixv-43121"
      unitRef="shares">780332</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c34"
      decimals="INF"
      id="ixv-43122"
      unitRef="shares">780332</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c35"
      decimals="INF"
      id="ixv-43123"
      unitRef="shares">637777</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c35"
      decimals="INF"
      id="ixv-43124"
      unitRef="shares">637777</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="c124"
      decimals="INF"
      id="ixv-43125"
      unitRef="shares">3938098</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c124"
      decimals="-3"
      id="ixv-43126"
      unitRef="usd">1795000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c125"
      decimals="INF"
      id="ixv-43127"
      unitRef="shares">1281402</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c125"
      decimals="-3"
      id="ixv-43128"
      unitRef="usd">1401000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c126"
      decimals="INF"
      id="ixv-43129"
      unitRef="shares">4101409</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c126"
      decimals="-3"
      id="ixv-43130"
      unitRef="usd">14949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c127"
      decimals="INF"
      id="ixv-43131"
      unitRef="shares">2679397</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c127"
      decimals="-3"
      id="ixv-43132"
      unitRef="usd">17622000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c128"
      decimals="INF"
      id="ixv-43133"
      unitRef="shares">6756246</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c128"
      decimals="-3"
      id="ixv-43134"
      unitRef="usd">29841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c129"
      decimals="INF"
      id="ixv-43135"
      unitRef="shares">1136049</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c129"
      decimals="-3"
      id="ixv-43136"
      unitRef="usd">9991000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c130"
      decimals="-3"
      id="ixv-43137"
      unitRef="usd">75599000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c131"
      decimals="INF"
      id="ixv-43138"
      unitRef="shares">646044</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c132"
      decimals="INF"
      id="ixv-43139"
      unitRef="shares">-7006</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c132"
      decimals="-3"
      id="ixv-43140"
      unitRef="usd">-33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c133"
      decimals="-3"
      id="ixv-43141"
      unitRef="usd">19920000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c134"
      decimals="-3"
      id="ixv-43142"
      unitRef="usd">-108871000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c135"
      decimals="-3"
      id="ixv-43143"
      unitRef="usd">-88984000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c136"
      decimals="-3"
      id="ixv-43144"
      unitRef="usd">549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="-3" id="ixv-43145" unitRef="usd">-88435000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c144"
      decimals="INF"
      id="ixv-43146"
      unitRef="shares">2017</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c137"
      decimals="INF"
      id="ixv-43147"
      unitRef="shares">-3938098</abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c137"
      decimals="-3"
      id="ixv-43148"
      unitRef="usd">-1795000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c138"
      decimals="INF"
      id="ixv-43149"
      unitRef="shares">-1281402</abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c138"
      decimals="-3"
      id="ixv-43150"
      unitRef="usd">-1401000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c139"
      decimals="INF"
      id="ixv-43151"
      unitRef="shares">-4101409</abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c139"
      decimals="-3"
      id="ixv-43152"
      unitRef="usd">-14949000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c140"
      decimals="INF"
      id="ixv-43153"
      unitRef="shares">-2679397</abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c140"
      decimals="-3"
      id="ixv-43154"
      unitRef="usd">-17622000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c141"
      decimals="INF"
      id="ixv-43155"
      unitRef="shares">-6756246</abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c141"
      decimals="-3"
      id="ixv-43156"
      unitRef="usd">-29841000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c142"
      decimals="INF"
      id="ixv-43157"
      unitRef="shares">-1136049</abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c142"
      decimals="-3"
      id="ixv-43158"
      unitRef="usd">-9991000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c143"
      decimals="-3"
      id="ixv-43159"
      unitRef="usd">-75599000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c144"
      decimals="INF"
      id="ixv-43160"
      unitRef="shares">955884</abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c145"
      decimals="INF"
      id="ixv-43161"
      unitRef="shares">-25772</abp:StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c145"
      decimals="-3"
      id="ixv-43162"
      unitRef="usd">33000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c146"
      decimals="-3"
      id="ixv-43163"
      unitRef="usd">68073000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c148"
      decimals="-3"
      id="ixv-43164"
      unitRef="usd">68106000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities contextRef="c34" decimals="-3" id="ixv-43165" unitRef="usd">68106000</abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities>
    <abp:IssuanceOfCommonStockInTransactionCost contextRef="c34" decimals="-3" id="ixv-43166" unitRef="usd">863474000</abp:IssuanceOfCommonStockInTransactionCost>
    <abp:IssuanceOfCommonStockInPIPEFinancing
      contextRef="c144"
      decimals="INF"
      id="ixv-43167"
      unitRef="shares">113342</abp:IssuanceOfCommonStockInPIPEFinancing>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c146"
      decimals="-3"
      id="ixv-43168"
      unitRef="usd">10361000</abp:IssuanceOfCommonStockInThePIPEFinancing>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c148"
      decimals="-3"
      id="ixv-43169"
      unitRef="usd">10361000</abp:IssuanceOfCommonStockInThePIPEFinancing>
    <abp:IssuanceOfCommonStockInThePIPEFinancing contextRef="c34" decimals="-3" id="ixv-43170" unitRef="usd">10361000</abp:IssuanceOfCommonStockInThePIPEFinancing>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="c144"
      decimals="INF"
      id="ixv-43171"
      unitRef="shares">9905</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c146"
      decimals="-3"
      id="ixv-43172"
      unitRef="usd">327000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c148"
      decimals="-3"
      id="ixv-43173"
      unitRef="usd">327000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c34" decimals="-3" id="ixv-43174" unitRef="usd">327000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c146"
      decimals="-3"
      id="ixv-43175"
      unitRef="usd">1927000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c148"
      decimals="-3"
      id="ixv-43176"
      unitRef="usd">1927000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c34" decimals="-3" id="ixv-43177" unitRef="usd">1927000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="c147"
      decimals="-3"
      id="ixv-43178"
      unitRef="usd">-7232000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c148"
      decimals="-3"
      id="ixv-43179"
      unitRef="usd">-7232000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c34" decimals="-3" id="ixv-43180" unitRef="usd">-7232000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c43"
      decimals="INF"
      id="ixv-43181"
      unitRef="shares">1727192</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c44"
      decimals="INF"
      id="ixv-43182"
      unitRef="shares">-32778</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c45" decimals="-3" id="ixv-43183" unitRef="usd">100608000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c46" decimals="-3" id="ixv-43184" unitRef="usd">-116103000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c47" decimals="-3" id="ixv-43185" unitRef="usd">-15495000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c48" decimals="-3" id="ixv-43186" unitRef="usd">549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c2" decimals="-3" id="ixv-43187" unitRef="usd">-14946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c150"
      decimals="INF"
      id="ixv-43188"
      unitRef="shares">3938098</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c150"
      decimals="-3"
      id="ixv-43189"
      unitRef="usd">1795000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c151"
      decimals="INF"
      id="ixv-43190"
      unitRef="shares">1281402</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c151"
      decimals="-3"
      id="ixv-43191"
      unitRef="usd">1401000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c152"
      decimals="INF"
      id="ixv-43192"
      unitRef="shares">4101409</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c152"
      decimals="-3"
      id="ixv-43193"
      unitRef="usd">14949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c153"
      decimals="INF"
      id="ixv-43194"
      unitRef="shares">2679397</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c153"
      decimals="-3"
      id="ixv-43195"
      unitRef="usd">17622000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c154"
      decimals="INF"
      id="ixv-43196"
      unitRef="shares">6756246</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c154"
      decimals="-3"
      id="ixv-43197"
      unitRef="usd">29841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c155"
      decimals="INF"
      id="ixv-43198"
      unitRef="shares">1136049</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c155"
      decimals="-3"
      id="ixv-43199"
      unitRef="usd">9991000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c156"
      decimals="-3"
      id="ixv-43200"
      unitRef="usd">75599000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c157"
      decimals="INF"
      id="ixv-43201"
      unitRef="shares">643488</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c158"
      decimals="INF"
      id="ixv-43202"
      unitRef="shares">-7006</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c158"
      decimals="-3"
      id="ixv-43203"
      unitRef="usd">-33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c159"
      decimals="-3"
      id="ixv-43204"
      unitRef="usd">17615000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c160"
      decimals="-3"
      id="ixv-43205"
      unitRef="usd">-97165000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c161"
      decimals="-3"
      id="ixv-43206"
      unitRef="usd">-79583000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c162"
      decimals="-3"
      id="ixv-43207"
      unitRef="usd">549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c163"
      decimals="-3"
      id="ixv-43208"
      unitRef="usd">-79034000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="c171"
      decimals="INF"
      id="ixv-43209"
      unitRef="shares">2556</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c173"
      decimals="-3"
      id="ixv-43210"
      unitRef="usd">2305000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c175"
      decimals="-3"
      id="ixv-43211"
      unitRef="usd">2305000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="c35" decimals="-3" id="ixv-43212" unitRef="usd">2305000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="c174"
      decimals="-3"
      id="ixv-43213"
      unitRef="usd">-11706000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c175"
      decimals="-3"
      id="ixv-43214"
      unitRef="usd">-11706000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c35" decimals="-3" id="ixv-43215" unitRef="usd">-11706000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="c124"
      decimals="INF"
      id="ixv-43216"
      unitRef="shares">3938098</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c124"
      decimals="-3"
      id="ixv-43217"
      unitRef="usd">1795000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c125"
      decimals="INF"
      id="ixv-43218"
      unitRef="shares">1281402</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c125"
      decimals="-3"
      id="ixv-43219"
      unitRef="usd">1401000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c126"
      decimals="INF"
      id="ixv-43220"
      unitRef="shares">4101409</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c126"
      decimals="-3"
      id="ixv-43221"
      unitRef="usd">14949000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c127"
      decimals="INF"
      id="ixv-43222"
      unitRef="shares">2679397</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c127"
      decimals="-3"
      id="ixv-43223"
      unitRef="usd">17622000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c128"
      decimals="INF"
      id="ixv-43224"
      unitRef="shares">6756246</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c128"
      decimals="-3"
      id="ixv-43225"
      unitRef="usd">29841000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c129"
      decimals="INF"
      id="ixv-43226"
      unitRef="shares">1136049</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c129"
      decimals="-3"
      id="ixv-43227"
      unitRef="usd">9991000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c130"
      decimals="-3"
      id="ixv-43228"
      unitRef="usd">75599000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="c131"
      decimals="INF"
      id="ixv-43229"
      unitRef="shares">646044</us-gaap:SharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="c132"
      decimals="INF"
      id="ixv-43230"
      unitRef="shares">-7006</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c132"
      decimals="-3"
      id="ixv-43231"
      unitRef="usd">-33000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c133"
      decimals="-3"
      id="ixv-43232"
      unitRef="usd">19920000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c134"
      decimals="-3"
      id="ixv-43233"
      unitRef="usd">-108871000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c135"
      decimals="-3"
      id="ixv-43234"
      unitRef="usd">-88984000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c136"
      decimals="-3"
      id="ixv-43235"
      unitRef="usd">549000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="-3" id="ixv-43236" unitRef="usd">-88435000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c34" decimals="-3" id="ixv-43237" unitRef="usd">-7232000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c35" decimals="-3" id="ixv-43238" unitRef="usd">-11706000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c34" decimals="-3" id="ixv-43239" unitRef="usd">74000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c35" decimals="-3" id="ixv-43240" unitRef="usd">279000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation contextRef="c34" decimals="-3" id="ixv-43241" unitRef="usd">1927000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c35" decimals="-3" id="ixv-43242" unitRef="usd">2305000</us-gaap:ShareBasedCompensation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c34" decimals="-3" id="ixv-43243" unitRef="usd">548000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c35" decimals="-3" id="ixv-43244" unitRef="usd">513000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OtherIncome contextRef="c34" decimals="-3" id="ixv-43245" unitRef="usd">3556000</us-gaap:OtherIncome>
    <us-gaap:OtherNoncashExpense contextRef="c34" decimals="-3" id="ixv-43246" unitRef="usd">39000</us-gaap:OtherNoncashExpense>
    <abp:ChangeInFairValueOfForwardPurchaseAgreementAsset contextRef="c34" decimals="-3" id="ixv-43247" unitRef="usd">-339000</abp:ChangeInFairValueOfForwardPurchaseAgreementAsset>
    <abp:ChangeInFairValueOfSEPAPutRightAsset contextRef="c34" decimals="-3" id="ixv-43248" unitRef="usd">-312000</abp:ChangeInFairValueOfSEPAPutRightAsset>
    <abp:ChangeInFairValueOnEmbeddedDerivativeLiability contextRef="c34" decimals="-3" id="ixv-43249" unitRef="usd">-11000</abp:ChangeInFairValueOnEmbeddedDerivativeLiability>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c34" decimals="-3" id="ixv-43250" unitRef="usd">173000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c34" decimals="-3" id="ixv-43251" unitRef="usd">235000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c35" decimals="-3" id="ixv-43252" unitRef="usd">-1942000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c34" decimals="-3" id="ixv-43253" unitRef="usd">98000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c35" decimals="-3" id="ixv-43254" unitRef="usd">-84000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInNotesReceivables contextRef="c35" decimals="-3" id="ixv-43255" unitRef="usd">-4000</us-gaap:IncreaseDecreaseInNotesReceivables>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c34" decimals="-3" id="ixv-43256" unitRef="usd">-860000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c35" decimals="-3" id="ixv-43257" unitRef="usd">-743000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c34" decimals="-3" id="ixv-43258" unitRef="usd">383000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c35" decimals="-3" id="ixv-43259" unitRef="usd">484000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c34" decimals="-3" id="ixv-43260" unitRef="usd">57000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c35" decimals="-3" id="ixv-43261" unitRef="usd">-64000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c34" decimals="-3" id="ixv-43262" unitRef="usd">-566000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c35" decimals="-3" id="ixv-43263" unitRef="usd">-500000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c34" decimals="-3" id="ixv-43264" unitRef="usd">-9030000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c35" decimals="-3" id="ixv-43265" unitRef="usd">-7402000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c35" decimals="-3" id="ixv-43266" unitRef="usd">48000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <abp:NetProceedsFromTheMerger contextRef="c34" decimals="-3" id="ixv-43267" unitRef="usd">490000</abp:NetProceedsFromTheMerger>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="c34" decimals="-3" id="ixv-43268" unitRef="usd">10361000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <abp:CashTransferredToEscrow contextRef="c34" decimals="-3" id="ixv-43269" unitRef="usd">1134000</abp:CashTransferredToEscrow>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c34" decimals="-3" id="ixv-43270" unitRef="usd">5883000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt contextRef="c35" decimals="-3" id="ixv-43271" unitRef="usd">1442000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:RepaymentsOfRelatedPartyDebt contextRef="c34" decimals="-3" id="ixv-43272" unitRef="usd">5735000</us-gaap:RepaymentsOfRelatedPartyDebt>
    <us-gaap:ProceedsFromConvertibleDebt contextRef="c34" decimals="-3" id="ixv-43273" unitRef="usd">2755000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c34" decimals="-3" id="ixv-43274" unitRef="usd">1442000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c35" decimals="-3" id="ixv-43275" unitRef="usd">371000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c34" decimals="-3" id="ixv-43276" unitRef="usd">17000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments contextRef="c35" decimals="-3" id="ixv-43277" unitRef="usd">222000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c34" decimals="-3" id="ixv-43278" unitRef="usd">11161000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c35" decimals="-3" id="ixv-43279" unitRef="usd">849000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c34" decimals="-3" id="ixv-43280" unitRef="usd">2131000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c35" decimals="-3" id="ixv-43281" unitRef="usd">-6601000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-43282" unitRef="usd">861000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c163"
      decimals="-3"
      id="ixv-43283"
      unitRef="usd">7462000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-43284" unitRef="usd">2992000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-43285" unitRef="usd">861000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c34" decimals="-3" id="ixv-43286" unitRef="usd">1000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c35" decimals="-3" id="ixv-43287" unitRef="usd">16000</us-gaap:InterestPaidNet>
    <abp:OfferingCostsIncludedInAccountsPayable contextRef="c34" decimals="-3" id="ixv-43288" unitRef="usd">436000</abp:OfferingCostsIncludedInAccountsPayable>
    <abp:OfferingCostsIncludedInAccountsPayable contextRef="c35" decimals="-3" id="ixv-43289" unitRef="usd">507000</abp:OfferingCostsIncludedInAccountsPayable>
    <abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense contextRef="c34" decimals="-3" id="ixv-43290" unitRef="usd">113000</abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense>
    <abp:SettlementOfBonusAccrualThroughNotesPayableRelatedParties contextRef="c35" decimals="-3" id="ixv-43291" unitRef="usd">300000</abp:SettlementOfBonusAccrualThroughNotesPayableRelatedParties>
    <abp:ACABLiabilitiesAssumedInTheMerger contextRef="c34" decimals="-3" id="ixv-43292" unitRef="usd">6585000</abp:ACABLiabilitiesAssumedInTheMerger>
    <abp:ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro contextRef="c34" decimals="-3" id="ixv-43293" unitRef="usd">2000000</abp:ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro>
    <abp:ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro contextRef="c34" decimals="-3" id="ixv-43294" unitRef="usd">75563000</abp:ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro>
    <abp:SEPACommitmentFeePaidInCommonStockShares contextRef="c34" decimals="-3" id="ixv-43295" unitRef="usd">327000</abp:SEPACommitmentFeePaidInCommonStockShares>
    <us-gaap:Cash contextRef="c2" decimals="-3" id="ixv-43296" unitRef="usd">2850000</us-gaap:Cash>
    <us-gaap:Cash contextRef="c5" decimals="-3" id="ixv-43297" unitRef="usd">723000</us-gaap:Cash>
    <us-gaap:RestrictedCash contextRef="c2" decimals="-3" id="ixv-43298" unitRef="usd">142000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash contextRef="c5" decimals="-3" id="ixv-43299" unitRef="usd">138000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-43300" unitRef="usd">2992000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-43301" unitRef="usd">861000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c34" id="ixv-37250">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Organization
and Description of the Business&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Organization&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Abpro Holdings, Inc. and its subsidiaries,
(the &#x201c;Company&#x201d;) is a biotechnology company headquartered in Woburn, Massachusetts, dedicated to developing next-generation
antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. The Company is focused on the development
of novel antibodies using its proprietary discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology
and infectious disease.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 13, 2024 (the &#x201c;Closing
Date&#x201d;), Atlantic Costal Acquisition Corp. II (&#x201c;ACAB&#x201d;) consummated a merger (the &#x201c;Merger&#x201d;) pursuant to the
terms of the Merger Agreement, dated as of December 11, 2023 (the &#x201c;Merger Agreement&#x201d;) by and among Abpro Corporation (&#x201c;Legacy
Abpro&#x201d;), ACAB, and Abpro Merger Sub Corp., a Delaware corporation (&#x201c;Merger Sub&#x201d;) and wholly owned subsidiary of ACAB
prior to the Closing Date. Pursuant to the Merger Agreement, on the Closing Date, (i) ACAB changed its name to &#x201c;Abpro Holdings,
Inc.&#x201d; (&#x201c;New Abpro&#x201d;), and (ii) Merger Sub merged with and into Legacy Abpro, with Legacy Abpro as the surviving company
in the Merger (such transactions, the &#x201c;Merger,&#x201d; and, collectively with the other transactions described in the Merger Agreement,
the &#x201c;Reverse Recapitalization&#x201d;). Shares of the New Abpro common stock commenced trading on the Nasdaq Capital Market on November
14, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;After giving effect to the Merger,
Legacy Abpro became a wholly owned subsidiary of the Company. The Merger is accounted for as a reverse recapitalization in accordance
with U.S. GAAP, and under this method of accounting, ACAB is treated as the acquired company for financial reporting purposes and Legacy
Abpro is treated as the acquirer. Operations prior to the Merger are those of Legacy Abpro. Unless otherwise noted, the Company has retroactively
adjusted all common and preferred share and related price information to give effect to the Exchange Ratio as set forth in the Merger
Agreement. The &#x201c;Company&#x201d; refers to Abpro Holdings, Inc. and its subsidiaries, including Abpro Corporation, prior to and subsequent
to the Merger. As described in Note 3, Legacy Abpro is the accounting acquirer in the Merger and, as such, the consolidated financial
statements present operations of Legacy Abpro prior to the Merger Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Refer to Note 3 - Reverse Recapitalization
for further details of the Merger.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On October 16, 2025, the Company filed
with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the &#x201c;Certificate
of Amendment&#x201d;), which became effective on October 31, 2025 (the &#x201c;Effective Time&#x201d;), to effect a one-for-thirty (1:30)
reverse stock split (the &#x201c;Reverse Stock Split&#x201d;), of the shares of the Company&#x2019;s common stock, par value $0.0001 per
share. The Reverse Stock Split was approved by the Company&#x2019;s stockholders at the 2025 annual meeting of the stockholders on October
10, 2025. The Company&#x2019;s common stock began trading on a reverse stock split-adjusted basis upon market opening on November 3, 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As a result of the Reverse Stock
Split, every 30 shares of issued and outstanding Common Stock will be automatically combined into one (1) issued and outstanding share
of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split.
Instead, stockholders who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly
divisible by the Reverse Stock Split ratio will be entitled to receive an additional fraction of a share of Common Stock to round up to
the next whole share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;All of the Company&#x2019;s historical
share and per share information related to issued and outstanding common stock, restricted stock units, and options and warrants exercisable
for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-30 reverse stock split.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Risks and Uncertainties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company is subject to risks and
uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors
of more advanced or effective therapies, dependence on key executives, protection of and dependence on proprietary technology, compliance
with government regulations and ability to secure additional capital to fund operations. Programs currently under development will require
significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization.
These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting
capabilities. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will
realize significant revenue from product sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company is required to evaluate
whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going
concern within one year after the date that the consolidated financial statements are issued. Through December 31, 2024, the Company has
funded its operations mainly through equity and debt financings, including the proceeds from the Merger and the PIPE Financing (as further
described in Note 3), and to a lesser extent, payments received in connection with collaboration and license agreements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Since inception, the Company has incurred
losses. The Company&#x2019;s net losses totaled $7,232 and $11,706 for the years ended December 31, 2024 and 2023, respectively. The Company
had an accumulated deficit of $116,103 as of December 31, 2024. The Company expects to incur operating losses for the foreseeable future.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On October 18, 2023, the Company entered
into a promissory note agreement with Abpro Bio International, Inc. (&#x201c;ABI&#x201d;), a significant investor in Legacy Abpro&#x2019;s
Series E and F convertible preferred stock (see Note 12), to receive up to $6,000. The Company received $4,225 through the Closing Date,
including $2,786 during the year ended December 31, 2024, in which the aggregate principal amount was converted in common shares at the
Closing Date in connection with the PIPE Financing (see Note 3).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On April 18, 2024, the Company entered
into a promissory note agreement with one of its executives (see Note 12 for terms and conditions) to receive, as amended, up to $2,158
in funding. The Company received $1,997 through the Closing Date. The principal amount of this note was converted into 20,000 common shares at the Closing Date as described in Note 12.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On October 7, 2024, the Company entered
into an additional promissory note with ABI (&#x201c;the 2024 ABI Note&#x201d;) to receive up to $1,000 from ABI in weekly installments
of $250. The note accrued 10% interest and had the maturity date which was 5 business days after receipt of the proceeds under the PIPE
Financing (see Note 3). The Company repaid the $1,000 balance at the Closing out of the proceeds from the PIPE Financing.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company received $5.7 million in
net proceeds from the Merger and related PIPE Financing, net of ACAB transaction costs and liabilities settled at the Closing. The Company
incurred $2.1 million in transaction costs and $0.9 million in issuance costs related to the PIPE Financing, consisting of banking, legal,
investment advisory and other professional fees, of which were recorded as a reduction of proceeds to additional paid-in capital. At the
Closing Date, Legacy Abpro assumed $6.6 million of net liabilities, including tax liabilities and legal fees of ACAB, of which $1.0 million
was included in accrued expenses, $4.4 million in excise tax payable and $0.4 million in income tax payable as of December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 14, 2024, the Company entered
into a Convertible Promissory Note with YA II PN, Ltd. (&#x201c;YA&#x201d;) (see Note 13) for $3,000 and received net proceeds of $2,755,
net of the original issuance discount of 8% (the &#x201c;Convertible Note Discount&#x201d;). The convertible note has a maturity of November
13, 2025 (subject to earlier repayments based on Amortization Event described below), incurs interest at a rate of 0% (or 18% upon the
occurrence of an uncured Event of Default).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;At the Merger Closing Date, the Company
paid approximately $1,100 pursuant to the terms of the Forward Purchase Agreement (see Note 11) with YA. On January 28, 2025, YA elected
to effect an Optional Early Termination with respect to all 3,333 Shares subject to the Forward Purchase Agreement which terminated the
agreement as a whole. YA paid the Company the Early Termination Obligation in the aggregate amount of $132, based on the Reset Price of
$39.60 per share in effect on January 28, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On April 2, 2025, the Company received
written notice (the &#x201c;Notice&#x201d;) from the Listing Qualifications Department of Nasdaq notifying the Company that, based on the
closing bid price of the Company&#x2019;s common stock for the last 30 consecutive business days, the Company no longer complies with the
minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities
to maintain a minimum bid price of $1.00 per share (the &#x201c;Minimum Bid Price Requirement&#x201d;), and Nasdaq Listing Rule 5810(c)(3)(A)
provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business
days. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain
compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company&#x2019;s common stock must
be at least $1.00 per share for a minimum of 10 consecutive business days prior to September 29, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Due to its current liabilities, the
cash available to the Company may not be sufficient to allow the Company to operate for at least 12 months from the date these financial
statements are available for issuance. The future viability of the Company is largely dependent on its ability to raise additional capital
to finance its operations. The Company expects to seek additional funding through equity and debt financings, collaboration agreements
and research grants. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful
in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the
Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization
efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Accordingly, based on the
considerations discussed above, management has concluded there is substantial doubt as to the Company&#x2019;s ability to continue as
a going concern within one year after the date the consolidated financial statements are issued. The Company plans to continue to
fundraise, as well as seek alternate revenues from collaboration and license agreements. If adequate funds are not available, the
Company may be required to initiate steps to slow cash burn, extending the cash runway until financing can be secured. The
consolidated financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and
their classification that might result from the outcome of this uncertainty.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="4"
      id="ixv-43302"
      unitRef="usdPershares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ProfitLoss
      contextRef="c471"
      decimals="-3"
      id="ixv-43303"
      unitRef="usd">-7232000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="c472"
      decimals="-3"
      id="ixv-43304"
      unitRef="usd">-11706000</us-gaap:ProfitLoss>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" id="ixv-43305" unitRef="usd">-116103000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NotesPayable
      contextRef="c473"
      decimals="-3"
      id="ixv-43306"
      unitRef="usd">6000000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="c474"
      decimals="-3"
      id="ixv-43307"
      unitRef="usd">4225000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="c34" decimals="-3" id="ixv-43308" unitRef="usd">2786000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NotesPayable
      contextRef="c475"
      decimals="-3"
      id="ixv-43309"
      unitRef="usd">2158000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="c476"
      decimals="-3"
      id="ixv-43310"
      unitRef="usd">1997000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c476"
      decimals="0"
      id="ixv-43311"
      unitRef="shares">20000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:NotesPayable
      contextRef="c477"
      decimals="-3"
      id="ixv-43312"
      unitRef="usd">1000000</us-gaap:NotesPayable>
    <abp:InstallmentsAmount
      contextRef="c478"
      decimals="-3"
      id="ixv-43313"
      unitRef="usd">250000</abp:InstallmentsAmount>
    <abp:AccrueInterestPercentage
      contextRef="c478"
      decimals="2"
      id="ixv-43314"
      unitRef="pure">0.10</abp:AccrueInterestPercentage>
    <us-gaap:RepaymentsOfDebt
      contextRef="c478"
      decimals="-3"
      id="ixv-43315"
      unitRef="usd">1000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c474"
      decimals="-5"
      id="ixv-43316"
      unitRef="usd">5700000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts contextRef="c2" decimals="-5" id="ixv-43317" unitRef="usd">2100000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c34" decimals="-5" id="ixv-43318" unitRef="usd">900000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:OtherLiabilities contextRef="c2" decimals="-5" id="ixv-43319" unitRef="usd">6600000</us-gaap:OtherLiabilities>
    <us-gaap:LegalFees contextRef="c34" decimals="-5" id="ixv-43320" unitRef="usd">1000000</us-gaap:LegalFees>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c2" decimals="-5" id="ixv-43321" unitRef="usd">4400000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="-5" id="ixv-43322" unitRef="usd">400000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:NotesPayable
      contextRef="c383"
      decimals="-3"
      id="ixv-43323"
      unitRef="usd">3000000</us-gaap:NotesPayable>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c479"
      decimals="-3"
      id="ixv-43324"
      unitRef="usd">2755000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c480"
      decimals="2"
      id="ixv-43325"
      unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c481" id="ixv-43326">2025-11-13</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c482"
      decimals="2"
      id="ixv-43327"
      unitRef="pure">0</us-gaap:DerivativeFixedInterestRate>
    <us-gaap:DerivativeFixedInterestRate
      contextRef="c483"
      decimals="2"
      id="ixv-43328"
      unitRef="pure">0.18</us-gaap:DerivativeFixedInterestRate>
    <abp:ForwardPurchaseAgreement contextRef="c34" decimals="-3" id="ixv-43329" unitRef="usd">1100000</abp:ForwardPurchaseAgreement>
    <us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue
      contextRef="c484"
      decimals="0"
      id="ixv-43330"
      unitRef="shares">3333</us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue>
    <us-gaap:GainLossOnContractTermination
      contextRef="c485"
      decimals="-3"
      id="ixv-43331"
      unitRef="usd">132000</us-gaap:GainLossOnContractTermination>
    <abp:EarlyTerminationResetPricePerShare
      contextRef="c484"
      decimals="2"
      id="ixv-43332"
      unitRef="usdPershares">39.6</abp:EarlyTerminationResetPricePerShare>
    <abp:SecurityBidPricePerShare
      contextRef="c486"
      decimals="2"
      id="ixv-43333"
      unitRef="usdPershares">1</abp:SecurityBidPricePerShare>
    <abp:SecurityBidPricePerShare
      contextRef="c487"
      decimals="2"
      id="ixv-43334"
      unitRef="usdPershares">1</abp:SecurityBidPricePerShare>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c34" id="ixv-37369">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Summary
of Significant Accounting Policies&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). The accompanying consolidated
financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation (&#x201c;AbMed&#x201d;).
All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Emerging Growth Company&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company is an &#x201c;emerging growth
company,&#x201d; as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but
not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section
404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden
parachute payments not previously approved.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the
amounts reported in the consolidated financial statements and accompanying notes. Significant estimates in these consolidated financial
statements include stock-based compensation expense, fair value of common stock, pre-clinical and clinical accrued expenses, valuation
and realizability of deferred tax assets and the ability to continue as a going concern. On an ongoing basis, the Company evaluates its
estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed
to be reasonable. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In March 2022, the Company
received an invoice from Mabwell (Shanghai) Bioscience Co., Ltd. (&#x201c;Mabwell&#x201d;) for approximately $3,500 in connection with
the manufacturing of certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based
on the information available at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its
validity. The Company continued to dispute the amount and its contractual basis because the parties had neither finalized nor
executed a clinical trial manufacturing agreement. In July 2024, the Company received communication from Mabwell that they will not
be pursuing the collection of the originally invoiced amount. Accordingly, during the year ended December 31, 2024, the Company
reversed the liability and recognized approximately $3,500 of other income.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;ASC Topic No. 280, Segment Reporting
(&#x201c;ASC 280&#x201d;), establishes standards for the way that public business enterprises report information about operating segments
in their annual consolidated financial statements and requires that those enterprises report selected information about operating segments
in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas
and major customers. The Company&#x2019;s business segments are based on the organization structure used by the chief operating decision
maker (&#x201c;CODM&#x201d;) for making operating and investment decisions and for assessing performance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In accordance with ASC 280, the Company
has determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in
the areas of immuno-oncology, ophthalmology and infectious disease. The financial results of the Company&#x2019;s operations are managed
and reported to the Chief Executive Officer, who is considered the Company&#x2019;s CODM, on a consolidated basis. The CODM assesses performance
and allocates resources based on the Company&#x2019;s consolidated statements of operations, and key components and processes of the Company&#x2019;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development and general and administrative
expenses, which are each separately presented on the Company&#x2019;s consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On March 3, 2025, the Board removed
Ian Chan as Chief Executive Officer of the Company for cause, and Miles Suk was appointed as Chief Executive Officer of the Company. In
addition, pursuant to Mr. Chan&#x2019;s employment agreement with the Company&#x2019;s wholly-owned subsidiary, Abpro Corporation, Mr. Chan
was notified that he was terminated as Chief Executive Officer and director of Abpro Corporation, effective March 3, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in bank deposit accounts,
which, at times, may exceed federally insured limits. As of December 31, 2024 and 2023, the Company has not experienced a loss on its
accounts for which it exceeds federally insured deposit limits.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The restricted cash balance is related
to a balance provided as collateral associated with the letter of credit for one of the Company&#x2019;s facility leases (see Note 9) and
is reported as a current asset in the consolidated balance sheets. The following tables reconcile cash and restricted cash to amounts
shown in the consolidated statements of cash flows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,850&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;723&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;142&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total cash and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;861&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accounts receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Accounts receivable are stated at the
amount management expects to collect from outstanding balances under its license and collaboration arrangements. The Company applies the
guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 326, &lt;i&gt;Financial Instruments-Credit Losses&lt;/i&gt; (&#x201c;ASC 326&#x201d;),
which requires measurement and recognition of expected credit losses for financial assets. The Company records receivables net of any
allowances for doubtful accounts for current expected credit losses under its license and collaboration arrangements. An allowance for
doubtful accounts is determined based on the financial condition and creditworthiness of customers as well as the economic factors and
trends expected to affect future collections. Any allowance would reduce the accounts receivable to the amount that is expected to be
collected. As of December 31, 2024 and 2023, the Company determined that no allowance for doubtful accounts was required.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Deferred offering costs consist of
legal, accounting, underwriting fees and other costs of Legacy Abpro that are directly related to the Merger. These costs were accounted
for as a reduction of the proceeds received at the Closing Date of the Merger. As of December 31, 2024 and 2023, the Company had deferred
offering costs of &lt;span style="-sec-ix-hidden: hidden-fact-429"&gt;$0&lt;/span&gt; and $878, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Property and equipment are stated at
cost, less accumulated depreciation. Repairs and maintenance charges that do not increase the useful life of the assets are charged to
operations as incurred.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Depreciation on property and equipment
is calculated using the straight-line method over the estimated useful lives as follows:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 77%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&lt;br/&gt;
Useful Life&lt;br/&gt;
(in years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 - 5&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: white"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 - 5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 - 7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: white"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-426"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company accounts for leases in
accordance with ASC Topic 842, &lt;i&gt;Leases &lt;/i&gt;(&#x201c;ASC 842&#x201d;). Under ASC 842, the Company assesses its contracts at inception to
determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly
or implicitly identified asset for a period of time. As a lessee, the Company records a right-of-use asset and a lease liability in its
consolidated balance sheets for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with
classification affecting the pattern of expense recognition in the consolidated statement of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company recognizes operating
lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated balance sheets. ROU assets
represent the Company&#x2019;s right to use an underlying asset during the lease term and lease liabilities represent the
Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at
commencement date based on the net present value of fixed lease payments over the lease term. The Company&#x2019;s lease term
includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. ROU assets also
include any advance lease payments made and are net of any lease incentives. As most of the Company&#x2019;s operating leases do not
provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in
determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would
expect to pay to borrow over a similar term, and on a collateralized basis, an amount equal to the lease payments in a similar
economic environment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company enters into lease agreements
for the use of laboratory and office space, and laboratory equipment, under both operating and finance leases. Operating leases are included
in Right-of-use asset - operating lease, and Operating lease liability - current and Operating lease liability - noncurrent in the consolidated
balance sheets. Finance leases are included in Property and Equipment, net, Finance lease liability - current and Finance lease liability
- noncurrent in the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company incurs costs related to
patent license fees and patent applications. These payments are capitalized when the Company believes that there is a high likelihood
that the patent will be issued and there will be future economic benefit associated with the patent. These costs are amortized from the
date of the patent application on a straight-line basis over the estimated useful life of 20 years, which is the legal life of the patent.
All costs associated with abandoned patents applications are expensed.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company periodically evaluates
its long-lived assets for potential impairment. Potential impairment is assessed when there is evidence that events or changes in circumstances
indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is based on undiscounted expected future
cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market
trends, and product development cycles. An impairment of the carrying value of each asset is assessed when the undiscounted expected future
cash flows derived from the asset are less than its carrying value. The impairment loss would be measured as the excess of the carrying
value of the impaired asset over its fair value. No impairment charges were recorded for the years ended December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company recognizes revenue in accordance
with the guidance of &lt;i&gt;Revenue From Contracts With Customers&lt;/i&gt;, Accounting Standards Codification Topic 606 (&#x201c;ASC 606&#x201d;).
Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements
the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with
a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance
obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;License
and collaboration revenues - &lt;/i&gt;The Company&#x2019;s license and collaboration revenues have been generated primarily through collaborative
research, development, manufacturing and commercialization agreements. The terms of these agreements generally include the license of
intellectual property and associated know-how and the provision of other goods and services. Payments to the Company under these arrangements
typically include one or more of the following: non-refundable, up-front license fees; milestone payments; and royalties on future product
sales.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;License
of Intellectual Property&lt;/i&gt; - If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to
the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation
is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue associated with the bundled performance obligation.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;Milestone
Payments - &lt;/i&gt;At the inception of each arrangement that includes milestone payments based upon the achievement of specified clinical
development, regulatory and/or sales milestones, the Company evaluates whether the milestones are considered probable of being achieved
and estimates the amount to be included in the transaction price. If it is probable that a significant revenue reversal would not occur,
the associated milestone amount is included in the transaction price. Milestone payments that are dependent on factors outside of the
Company&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.
These payments are fully constrained and therefore are not included in the transaction price. At the end of each reporting period, the
Company re-evaluates the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the reported amount
of license and collaboration revenues in the period of adjustment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;Royalties.
&lt;/i&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is
deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales
occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially
satisfied).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s research and development
expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation charges for those individuals involved
in research and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies
and clinical materials. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods
or services to be used in research and development are capitalized until the goods or services are received.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Income taxes are accounted for under
the asset and liability method, as required by FASB ASC Topic 740, &lt;i&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC 740&#x201d;). The Company provides for
federal, and state income taxes currently payable. Deferred tax assets and liabilities are recognized for the future tax consequences
attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases as well as for tax loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted income
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The effect of a change in income tax
rates is recognized as income or expense in the period that includes the enactment date. The Company files income tax returns in the U.S.
federal jurisdiction and various state jurisdictions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company recognizes the effect of
income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured
at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period
in which the change in judgment occurs. The Company recognizes interest and/or penalties related to uncertain tax positions in income
tax expense. There were &lt;span style="-sec-ix-hidden: hidden-fact-430"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-431"&gt;no&lt;/span&gt;&lt;/span&gt; uncertain tax positions as of December 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Share-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company accounts for share-based
payments in accordance with Accounting Standard Codification Topic 718, &lt;i&gt;Compensation-Stock Compensation &lt;/i&gt;(&#x201c;ASC 718&#x201d;).
Under ASC 718, the Company measures, and records compensation expense related to share-based payment awards (to employees and non-employees)
based on the grant date fair value using the Black-Scholes option-pricing model. The Company recognizes forfeitures related to employee
share-based payments when they occur. Forfeited share-based awards are recorded as a reduction to share-based compensation expense.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The determination of the fair value
of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including
expected volatility, expected term, risk-free interest rate and expected dividends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In determining the exercise prices
of options granted, the Company&#x2019;s Board has considered the fair value of the common stock as of the measurement date. As Legacy
Abpro&#x2019;s common stock was not traded prior to the Merger, the fair value of the common stock was determined by the Board at each
award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company&#x2019;s
financial position and historical financial performance, the status of technological developments within the Company&#x2019;s proposed
products, an evaluation or benchmark of the Company&#x2019;s competition, the current business climate in the marketplace, the illiquid
nature of the common stock, arm&#x2019;s length sales of the Company&#x2019;s capital stock, including convertible preferred stock, the
effect of the rights and preferences of the preferred stockholders, and then prospects of a liquidity event, among others.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company does not have sufficient
history of market prices of its common stock, and as such, volatility is estimated using historical volatilities of similar public entities.
The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a
sufficient amount of historical information regarding the volatility of its own stock price becomes available. The expected term of the
awards is estimated based on the simplified method for grants to employees and is based on the contractual term for non-employee awards.
The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield
assumption is based on history and expectation of paying no dividends.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Convertible
Preferred Stock &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company accounts for its convertible preferred stock in accordance with the guidance in ASC Topic 480, &lt;i&gt;Distinguishing Liabilities from
Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;). Preferred stock subject to mandatory redemption (if any) is classified as a liability instrument and
is measured at fair value. Conditionally redeemable common stock (including preferred stock that features redemption rights that are either
within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s
control) is classified as temporary equity (see Note 14).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Derivative
Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
connection with the Merger, the Company assumed the warrants for common stock shares issued by ACAB, which include warrants issued in
the ACAB&#x2019;s initial public offering (&#x201c;Public Warrants&#x201d;) and warrants purchased by the Sponsor (the  &#x201c;Private Warrants&#x201d;)
(see Note 14). &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company accounts for financial instruments as either equity-classified or liability-classified instruments based on an assessment of the
specific terms of the instruments and applicable authoritative guidance in ASC 480 and ASC Topic 815, &lt;i&gt;Derivatives and Hedging &lt;/i&gt;(&#x201c;ASC
815&#x201d;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#x2019;s own stock and whether the holders of the warrants could potentially require &#x201c;net cash settlement&#x201d;
in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Public and Private Warrants were accounted for as equity instruments as they meet all of the requirements for equity classification under
ASC 815 based on current expected terms, which are subject to change. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Contingent Earnout Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In connection with the Reverse Recapitalization
and pursuant to the Merger Agreement, Legacy Abpro equity holders are entitled to receive, as additional merger consideration, up to 483,333
shares of the Company&#x2019;s common stock (the &#x201c;Contingent Earnout Shares&#x201d;), comprised of three separate equal tranches,
for no consideration upon the occurrence of certain triggering events, including a change of control event. It was determined that based
on its provisions, the contingent consideration is indexed to the Company&#x2019;s stock and therefore qualify for the scope exception
from the derivative accounting in ASC 815-10-15-74(a). As a result, the Company elected to recognize the contingent consideration obligation
in accordance with ASC Topic 450, &lt;i&gt;Contingencies &lt;/i&gt;(&#x201c;ASC 450&#x201d;) when the contingency is resolved, and the consideration
is paid or becomes payable. Based on the Company&#x2019;s stock price, no amounts were due under the contingent earnout provisions as of
December 31, 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements and Fair
Value of Financial Instruments &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company categorizes its assets
and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1)
and lowest priority to unobservable inputs (Level 3). The carrying value of cash, accounts receivable, accounts payable, accrued expenses,
excise taxes payable, income taxes payable, and related party loans payable approximate fair value because of the short-term nature of
such instruments.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Level 1 - Inputs are unadjusted quoted
prices in active markets for identical assets or liabilities available at the measurement date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Level 2 - Inputs are unadjusted quoted
prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market
data.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Level 3 - Unobservable inputs based
on the Company&#x2019;s assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In some circumstances, the inputs used
to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement
is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Transfers to/from Levels 1, 2 and 3
are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Non-controlling Interest&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company holds an 82% ownership
interest in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not
owned by the Company and is reported as a component in stockholders&#x2019; equity on the consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $2.00
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling interest
holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the years ended
December 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company follows the two-class method
to compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 14), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#x2019;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#x2019;s outstanding common stock
for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Basic net loss per share attributable
to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock
outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common
stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or
converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion
of such shares would be anti-dilutive. As the Company has incurred losses for the years ended December 31, 2024 and 2023, basic and diluted
net loss per share is the same all periods presented.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders,
because their effect was anti-dilutive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-427"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;324,184&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;961,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-428"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unvested restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;739&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,350,625&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;696,838&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In November 2023, the FASB issued ASU
2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which enhances disclosure
requirements about significant segment expenses that are regularly provided to the chief operating decision maker (the &#x201c;CODM&#x201d;).
ASU 2023-07, among other things, (i) requires a single segment public entity to provide all of the disclosures as required by ASC 280,
(ii) requires a public entity to disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s)
of segment profit or loss in assessing segment performance and deciding how to allocate resources and (iii) provides the ability for a
public entity to elect more than one performance measure. ASU 2023-07 is effective for the fiscal years beginning after December 15, 2023,
and interim periods beginning with the first quarter ending March 31, 2025. Early adoption is permitted, and retrospective adoption is
required for all prior periods presented. The Company has adopted ASU 2023-07 effective December 31, 2024, and concluded that the application
of this guidance did not have any material impact on its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In December 2023, the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The
Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 4, 2024, the FASB issued
ASU 2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the same
tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods
beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company
is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Management does not believe that any
additional recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#x2019;s
financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;Restatement of Previously Issued
Financial Statements&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company identified an error in
the amount of the accrued expenses within the audited balance sheets as of September 30, 2024, December 31, 2023 and 2022 included in
the Company&#x2019;s Form 8-K, filed on November 26, 2024. In accordance with Staff Accounting Bulletin (&#x201c;SAB&#x201d;) No. 99, &lt;i&gt;Materiality&lt;/i&gt;,
and SAB No. 108, &lt;i&gt;Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements&lt;/i&gt;,
the Company evaluated these misstatements, and based on an analysis of quantitative and qualitative factors, determined that the impact
of these misstatements was material to its reporting periods ended December 31, 2023, December 31, 2022 and September 30, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Accordingly, the Company has restated
its consolidated financial statements for the years ended December 31, 2023 and 2022, and its interim reporting period for the nine months
ended September 30, 2024, and has included that restated financial information within this annual report.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The impact of the revision on the Company&#x2019;s
balance sheet as of December 31, 2023 is reflected in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As previously&lt;br/&gt; reported&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As restated&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,081&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,891&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,191&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(105,571&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108,871&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(85,135&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(88,435&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The impact of the revision on the Company&#x2019;s
balance sheet as of December 31, 2022 is reflected in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As previously&lt;br/&gt; reported&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As restated&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,865&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(97,165&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75,734&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(79,034&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The impact of the revision on the Company&#x2019;s
balance sheet as of September 30, 2024 is reflected in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As previously&lt;br/&gt; reported&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As restated&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,745&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,045&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(109,468&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(112,768&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(87,501&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(90,801&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c34" id="ixv-37382">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;). The accompanying consolidated
financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation (&#x201c;AbMed&#x201d;).
All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <abp:EmergingGrowthCompanyPolicyTextBlock contextRef="c34" id="ixv-37392">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Emerging Growth Company&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company is an &#x201c;emerging growth
company,&#x201d; as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but
not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section
404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden
parachute payments not previously approved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company&#x2019;s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.&lt;/p&gt;</abp:EmergingGrowthCompanyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c34" id="ixv-37403">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the
amounts reported in the consolidated financial statements and accompanying notes. Significant estimates in these consolidated financial
statements include stock-based compensation expense, fair value of common stock, pre-clinical and clinical accrued expenses, valuation
and realizability of deferred tax assets and the ability to continue as a going concern. On an ongoing basis, the Company evaluates its
estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed
to be reasonable. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In March 2022, the Company
received an invoice from Mabwell (Shanghai) Bioscience Co., Ltd. (&#x201c;Mabwell&#x201d;) for approximately $3,500 in connection with
the manufacturing of certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based
on the information available at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its
validity. The Company continued to dispute the amount and its contractual basis because the parties had neither finalized nor
executed a clinical trial manufacturing agreement. In July 2024, the Company received communication from Mabwell that they will not
be pursuing the collection of the originally invoiced amount. Accordingly, during the year ended December 31, 2024, the Company
reversed the liability and recognized approximately $3,500 of other income.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:OtherReceivables
      contextRef="c190"
      decimals="-3"
      id="ixv-43335"
      unitRef="usd">3500000</us-gaap:OtherReceivables>
    <us-gaap:OtherIncome
      contextRef="c488"
      decimals="-3"
      id="ixv-43336"
      unitRef="usd">3500000</us-gaap:OtherIncome>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="c34" id="ixv-37431">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Reporting&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;ASC Topic No. 280, Segment Reporting
(&#x201c;ASC 280&#x201d;), establishes standards for the way that public business enterprises report information about operating segments
in their annual consolidated financial statements and requires that those enterprises report selected information about operating segments
in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas
and major customers. The Company&#x2019;s business segments are based on the organization structure used by the chief operating decision
maker (&#x201c;CODM&#x201d;) for making operating and investment decisions and for assessing performance.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In accordance with ASC 280, the Company
has determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in
the areas of immuno-oncology, ophthalmology and infectious disease. The financial results of the Company&#x2019;s operations are managed
and reported to the Chief Executive Officer, who is considered the Company&#x2019;s CODM, on a consolidated basis. The CODM assesses performance
and allocates resources based on the Company&#x2019;s consolidated statements of operations, and key components and processes of the Company&#x2019;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development and general and administrative
expenses, which are each separately presented on the Company&#x2019;s consolidated statements of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On March 3, 2025, the Board removed
Ian Chan as Chief Executive Officer of the Company for cause, and Miles Suk was appointed as Chief Executive Officer of the Company. In
addition, pursuant to Mr. Chan&#x2019;s employment agreement with the Company&#x2019;s wholly-owned subsidiary, Abpro Corporation, Mr. Chan
was notified that he was terminated as Chief Executive Officer and director of Abpro Corporation, effective March 3, 2025.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c34" id="ixv-37447">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in bank deposit accounts,
which, at times, may exceed federally insured limits. As of December 31, 2024 and 2023, the Company has not experienced a loss on its
accounts for which it exceeds federally insured deposit limits.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c34" id="ixv-37474">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Cash&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The restricted cash balance is related
to a balance provided as collateral associated with the letter of credit for one of the Company&#x2019;s facility leases (see Note 9) and
is reported as a current asset in the consolidated balance sheets. The following tables reconcile cash and restricted cash to amounts
shown in the consolidated statements of cash flows:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,850&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;723&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;142&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total cash and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;861&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <srt:ScheduleOfCondensedCashFlowStatementTableTextBlock contextRef="c34" id="ixv-43337">The following tables reconcile cash and restricted cash to amounts
shown in the consolidated statements of cash flows:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cash&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,850&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;723&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;142&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;138&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total cash and restricted cash&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;861&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedCashFlowStatementTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" id="ixv-43338" unitRef="usd">2850000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c5" decimals="-3" id="ixv-43339" unitRef="usd">723000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent contextRef="c2" decimals="-3" id="ixv-43340" unitRef="usd">142000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent contextRef="c5" decimals="-3" id="ixv-43341" unitRef="usd">138000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c2" decimals="-3" id="ixv-43342" unitRef="usd">2992000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c5" decimals="-3" id="ixv-43343" unitRef="usd">861000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c34" id="ixv-37531">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accounts receivable&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Accounts receivable are stated at the
amount management expects to collect from outstanding balances under its license and collaboration arrangements. The Company applies the
guidance in Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 326, &lt;i&gt;Financial Instruments-Credit Losses&lt;/i&gt; (&#x201c;ASC 326&#x201d;),
which requires measurement and recognition of expected credit losses for financial assets. The Company records receivables net of any
allowances for doubtful accounts for current expected credit losses under its license and collaboration arrangements. An allowance for
doubtful accounts is determined based on the financial condition and creditworthiness of customers as well as the economic factors and
trends expected to affect future collections. Any allowance would reduce the accounts receivable to the amount that is expected to be
collected. As of December 31, 2024 and 2023, the Company determined that no allowance for doubtful accounts was required.&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:DeferredChargesPolicyTextBlock contextRef="c34" id="ixv-37540">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Deferred offering costs consist of
legal, accounting, underwriting fees and other costs of Legacy Abpro that are directly related to the Merger. These costs were accounted
for as a reduction of the proceeds received at the Closing Date of the Merger. As of December 31, 2024 and 2023, the Company had deferred
offering costs of &lt;span style="-sec-ix-hidden: hidden-fact-429"&gt;$0&lt;/span&gt; and $878, respectively.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts contextRef="c5" decimals="-3" id="ixv-43344" unitRef="usd">878000</us-gaap:DeferredOfferingCosts>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c34" id="ixv-37551">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Property and equipment are stated at
cost, less accumulated depreciation. Repairs and maintenance charges that do not increase the useful life of the assets are charged to
operations as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Depreciation on property and equipment
is calculated using the straight-line method over the estimated useful lives as follows:&#160;&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 77%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&lt;br/&gt;
Useful Life&lt;br/&gt;
(in years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 - 5&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: white"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 - 5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 - 7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: white"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-426"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <abp:ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock contextRef="c34" id="ixv-37559">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Depreciation on property and equipment
is calculated using the straight-line method over the estimated useful lives as follows:&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 77%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Classification&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: black 1.5pt solid; width: 22%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Estimated&lt;br/&gt;
Useful Life&lt;br/&gt;
(in years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Computer hardware and software&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 - 5&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: white"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3 - 5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: #CCEEFF"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5 - 7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top; background-color: white"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-426"&gt;Shorter of useful life or lease term&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</abp:ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c492" id="ixv-43345">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c493" id="ixv-43346">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c494" id="ixv-43347">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c495" id="ixv-43348">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c496" id="ixv-43349">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c497" id="ixv-43350">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c34" id="ixv-37616">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company accounts for leases in
accordance with ASC Topic 842, &lt;i&gt;Leases &lt;/i&gt;(&#x201c;ASC 842&#x201d;). Under ASC 842, the Company assesses its contracts at inception to
determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly
or implicitly identified asset for a period of time. As a lessee, the Company records a right-of-use asset and a lease liability in its
consolidated balance sheets for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with
classification affecting the pattern of expense recognition in the consolidated statement of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company recognizes operating
lease right-of-use (&#x201c;ROU&#x201d;) assets and operating lease liabilities in the consolidated balance sheets. ROU assets
represent the Company&#x2019;s right to use an underlying asset during the lease term and lease liabilities represent the
Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at
commencement date based on the net present value of fixed lease payments over the lease term. The Company&#x2019;s lease term
includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. ROU assets also
include any advance lease payments made and are net of any lease incentives. As most of the Company&#x2019;s operating leases do not
provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in
determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would
expect to pay to borrow over a similar term, and on a collateralized basis, an amount equal to the lease payments in a similar
economic environment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company enters into lease agreements
for the use of laboratory and office space, and laboratory equipment, under both operating and finance leases. Operating leases are included
in Right-of-use asset - operating lease, and Operating lease liability - current and Operating lease liability - noncurrent in the consolidated
balance sheets. Finance leases are included in Property and Equipment, net, Finance lease liability - current and Finance lease liability
- noncurrent in the consolidated balance sheets.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <abp:PatentsPolicyTextBlock contextRef="c34" id="ixv-37633">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Patents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company incurs costs related to
patent license fees and patent applications. These payments are capitalized when the Company believes that there is a high likelihood
that the patent will be issued and there will be future economic benefit associated with the patent. These costs are amortized from the
date of the patent application on a straight-line basis over the estimated useful life of 20 years, which is the legal life of the patent.
All costs associated with abandoned patents applications are expensed.&lt;/p&gt;</abp:PatentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c489" id="ixv-43351">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c34" id="ixv-37643">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company periodically evaluates
its long-lived assets for potential impairment. Potential impairment is assessed when there is evidence that events or changes in circumstances
indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is based on undiscounted expected future
cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market
trends, and product development cycles. An impairment of the carrying value of each asset is assessed when the undiscounted expected future
cash flows derived from the asset are less than its carrying value. The impairment loss would be measured as the excess of the carrying
value of the impaired asset over its fair value. No impairment charges were recorded for the years ended December 31, 2024 and 2023.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c34" id="ixv-37670">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company recognizes revenue in accordance
with the guidance of &lt;i&gt;Revenue From Contracts With Customers&lt;/i&gt;, Accounting Standards Codification Topic 606 (&#x201c;ASC 606&#x201d;).
Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements
the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with
a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance
obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;License
and collaboration revenues - &lt;/i&gt;The Company&#x2019;s license and collaboration revenues have been generated primarily through collaborative
research, development, manufacturing and commercialization agreements. The terms of these agreements generally include the license of
intellectual property and associated know-how and the provision of other goods and services. Payments to the Company under these arrangements
typically include one or more of the following: non-refundable, up-front license fees; milestone payments; and royalties on future product
sales.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;License
of Intellectual Property&lt;/i&gt; - If a license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to
the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation
is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue associated with the bundled performance obligation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;Milestone
Payments - &lt;/i&gt;At the inception of each arrangement that includes milestone payments based upon the achievement of specified clinical
development, regulatory and/or sales milestones, the Company evaluates whether the milestones are considered probable of being achieved
and estimates the amount to be included in the transaction price. If it is probable that a significant revenue reversal would not occur,
the associated milestone amount is included in the transaction price. Milestone payments that are dependent on factors outside of the
Company&#x2019;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.
These payments are fully constrained and therefore are not included in the transaction price. At the end of each reporting period, the
Company re-evaluates the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the reported amount
of license and collaboration revenues in the period of adjustment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;Royalties.
&lt;/i&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is
deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales
occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially
satisfied).&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c34" id="ixv-37710">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s research and development
expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation charges for those individuals involved
in research and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies
and clinical materials. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods
or services to be used in research and development are capitalized until the goods or services are received.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c34" id="ixv-37720">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Income taxes are accounted for under
the asset and liability method, as required by FASB ASC Topic 740, &lt;i&gt;Income Taxes &lt;/i&gt;(&#x201c;ASC 740&#x201d;). The Company provides for
federal, and state income taxes currently payable. Deferred tax assets and liabilities are recognized for the future tax consequences
attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases as well as for tax loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted income
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The effect of a change in income tax
rates is recognized as income or expense in the period that includes the enactment date. The Company files income tax returns in the U.S.
federal jurisdiction and various state jurisdictions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company recognizes the effect of
income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured
at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period
in which the change in judgment occurs. The Company recognizes interest and/or penalties related to uncertain tax positions in income
tax expense. There were &lt;span style="-sec-ix-hidden: hidden-fact-430"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-431"&gt;no&lt;/span&gt;&lt;/span&gt; uncertain tax positions as of December 31, 2024 and 2023.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent contextRef="c34" decimals="2" id="ixv-43352" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c34" id="ixv-37739">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Share-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company accounts for share-based
payments in accordance with Accounting Standard Codification Topic 718, &lt;i&gt;Compensation-Stock Compensation &lt;/i&gt;(&#x201c;ASC 718&#x201d;).
Under ASC 718, the Company measures, and records compensation expense related to share-based payment awards (to employees and non-employees)
based on the grant date fair value using the Black-Scholes option-pricing model. The Company recognizes forfeitures related to employee
share-based payments when they occur. Forfeited share-based awards are recorded as a reduction to share-based compensation expense.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The determination of the fair value
of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including
expected volatility, expected term, risk-free interest rate and expected dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In determining the exercise prices
of options granted, the Company&#x2019;s Board has considered the fair value of the common stock as of the measurement date. As Legacy
Abpro&#x2019;s common stock was not traded prior to the Merger, the fair value of the common stock was determined by the Board at each
award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company&#x2019;s
financial position and historical financial performance, the status of technological developments within the Company&#x2019;s proposed
products, an evaluation or benchmark of the Company&#x2019;s competition, the current business climate in the marketplace, the illiquid
nature of the common stock, arm&#x2019;s length sales of the Company&#x2019;s capital stock, including convertible preferred stock, the
effect of the rights and preferences of the preferred stockholders, and then prospects of a liquidity event, among others.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company does not have sufficient
history of market prices of its common stock, and as such, volatility is estimated using historical volatilities of similar public entities.
The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a
sufficient amount of historical information regarding the volatility of its own stock price becomes available. The expected term of the
awards is estimated based on the simplified method for grants to employees and is based on the contractual term for non-employee awards.
The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield
assumption is based on history and expectation of paying no dividends.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <abp:ConvertiblePreferredStockPolicyTextBlock contextRef="c34" id="ixv-37772">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Convertible
Preferred Stock &lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company accounts for its convertible preferred stock in accordance with the guidance in ASC Topic 480, &lt;i&gt;Distinguishing Liabilities from
Equity &lt;/i&gt;(&#x201c;ASC 480&#x201d;). Preferred stock subject to mandatory redemption (if any) is classified as a liability instrument and
is measured at fair value. Conditionally redeemable common stock (including preferred stock that features redemption rights that are either
within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#x2019;s
control) is classified as temporary equity (see Note 14).&lt;/span&gt;&lt;/p&gt;</abp:ConvertiblePreferredStockPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock contextRef="c34" id="ixv-37783">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;b&gt;&lt;i&gt;Derivative
Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
connection with the Merger, the Company assumed the warrants for common stock shares issued by ACAB, which include warrants issued in
the ACAB&#x2019;s initial public offering (&#x201c;Public Warrants&#x201d;) and warrants purchased by the Sponsor (the  &#x201c;Private Warrants&#x201d;)
(see Note 14). &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Company accounts for financial instruments as either equity-classified or liability-classified instruments based on an assessment of the
specific terms of the instruments and applicable authoritative guidance in ASC 480 and ASC Topic 815, &lt;i&gt;Derivatives and Hedging &lt;/i&gt;(&#x201c;ASC
815&#x201d;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#x2019;s own stock and whether the holders of the warrants could potentially require &#x201c;net cash settlement&#x201d;
in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
Public and Private Warrants were accounted for as equity instruments as they meet all of the requirements for equity classification under
ASC 815 based on current expected terms, which are subject to change. &lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <abp:ContingentEarnoutPolicyTextBlock contextRef="c34" id="ixv-37804">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Contingent Earnout Shares&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In connection with the Reverse Recapitalization
and pursuant to the Merger Agreement, Legacy Abpro equity holders are entitled to receive, as additional merger consideration, up to 483,333
shares of the Company&#x2019;s common stock (the &#x201c;Contingent Earnout Shares&#x201d;), comprised of three separate equal tranches,
for no consideration upon the occurrence of certain triggering events, including a change of control event. It was determined that based
on its provisions, the contingent consideration is indexed to the Company&#x2019;s stock and therefore qualify for the scope exception
from the derivative accounting in ASC 815-10-15-74(a). As a result, the Company elected to recognize the contingent consideration obligation
in accordance with ASC Topic 450, &lt;i&gt;Contingencies &lt;/i&gt;(&#x201c;ASC 450&#x201d;) when the contingency is resolved, and the consideration
is paid or becomes payable. Based on the Company&#x2019;s stock price, no amounts were due under the contingent earnout provisions as of
December 31, 2024.&lt;/p&gt;</abp:ContingentEarnoutPolicyTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c490"
      decimals="0"
      id="ixv-43353"
      unitRef="shares">483333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c34" id="ixv-37832">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurements and Fair
Value of Financial Instruments &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company categorizes its assets
and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1)
and lowest priority to unobservable inputs (Level 3). The carrying value of cash, accounts receivable, accounts payable, accrued expenses,
excise taxes payable, income taxes payable, and related party loans payable approximate fair value because of the short-term nature of
such instruments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Level 1 - Inputs are unadjusted quoted
prices in active markets for identical assets or liabilities available at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Level 2 - Inputs are unadjusted quoted
prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market
data.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Level 3 - Unobservable inputs based
on the Company&#x2019;s assessment of the assumptions that market participants would use in pricing the asset or liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In some circumstances, the inputs used
to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement
is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Transfers to/from Levels 1, 2 and 3
are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <abp:NoncontrollingInterestPolicyTextBlock contextRef="c34" id="ixv-37857">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Non-controlling Interest&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company holds an 82% ownership
interest in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not
owned by the Company and is reported as a component in stockholders&#x2019; equity on the consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $2.00
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling interest
holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the years ended
December 31, 2024 and 2023.&lt;/p&gt;</abp:NoncontrollingInterestPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="c491"
      decimals="2"
      id="ixv-43354"
      unitRef="pure">0.82</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="c2"
      decimals="2"
      id="ixv-43355"
      unitRef="usdPershares">2</us-gaap:PreferredStockRedemptionPricePerShare>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c34" id="ixv-37867">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company follows the two-class method
to compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 14), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#x2019;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#x2019;s outstanding common stock
for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Basic net loss per share attributable
to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock
outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common
stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or
converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion
of such shares would be anti-dilutive. As the Company has incurred losses for the years ended December 31, 2024 and 2023, basic and diluted
net loss per share is the same all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders,
because their effect was anti-dilutive:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-427"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;324,184&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;961,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-428"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unvested restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;739&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,350,625&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;696,838&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c34" id="ixv-37893">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders,
because their effect was anti-dilutive:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Convertible Preferred Stock&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-427"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;324,184&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;961,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,034&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Stock options&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;329,395&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;369,092&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Convertible Notes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,824&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-428"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Unvested restricted stock units&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;739&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,528&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,350,625&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;696,838&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c500"
      decimals="INF"
      id="ixv-43356"
      unitRef="shares">324184</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c501"
      decimals="INF"
      id="ixv-43357"
      unitRef="shares">961667</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c502"
      decimals="INF"
      id="ixv-43358"
      unitRef="shares">2034</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c503"
      decimals="INF"
      id="ixv-43359"
      unitRef="shares">329395</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c504"
      decimals="INF"
      id="ixv-43360"
      unitRef="shares">369092</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c505"
      decimals="INF"
      id="ixv-43361"
      unitRef="shares">58824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c507"
      decimals="INF"
      id="ixv-43362"
      unitRef="shares">739</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c508"
      decimals="INF"
      id="ixv-43363"
      unitRef="shares">1528</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c34"
      decimals="INF"
      id="ixv-43364"
      unitRef="shares">1350625</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c35"
      decimals="INF"
      id="ixv-43365"
      unitRef="shares">696838</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <abp:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock contextRef="c34" id="ixv-37975">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In November 2023, the FASB issued ASU
2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#x201c;ASU 2023-07&#x201d;), which enhances disclosure
requirements about significant segment expenses that are regularly provided to the chief operating decision maker (the &#x201c;CODM&#x201d;).
ASU 2023-07, among other things, (i) requires a single segment public entity to provide all of the disclosures as required by ASC 280,
(ii) requires a public entity to disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s)
of segment profit or loss in assessing segment performance and deciding how to allocate resources and (iii) provides the ability for a
public entity to elect more than one performance measure. ASU 2023-07 is effective for the fiscal years beginning after December 15, 2023,
and interim periods beginning with the first quarter ending March 31, 2025. Early adoption is permitted, and retrospective adoption is
required for all prior periods presented. The Company has adopted ASU 2023-07 effective December 31, 2024, and concluded that the application
of this guidance did not have any material impact on its consolidated financial statements.&lt;/p&gt;</abp:RecentlyAdoptedAccountingPronouncementsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c34" id="ixv-37985">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In December 2023, the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#x201d;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The
Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 4, 2024, the FASB issued
ASU 2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the same
tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods
beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company
is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Management does not believe that any
additional recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#x2019;s
financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <abp:RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock contextRef="c34" id="ixv-38014">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;Restatement of Previously Issued
Financial Statements&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company identified an error in
the amount of the accrued expenses within the audited balance sheets as of September 30, 2024, December 31, 2023 and 2022 included in
the Company&#x2019;s Form 8-K, filed on November 26, 2024. In accordance with Staff Accounting Bulletin (&#x201c;SAB&#x201d;) No. 99, &lt;i&gt;Materiality&lt;/i&gt;,
and SAB No. 108, &lt;i&gt;Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements&lt;/i&gt;,
the Company evaluated these misstatements, and based on an analysis of quantitative and qualitative factors, determined that the impact
of these misstatements was material to its reporting periods ended December 31, 2023, December 31, 2022 and September 30, 2024.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Accordingly, the Company has restated
its consolidated financial statements for the years ended December 31, 2023 and 2022, and its interim reporting period for the nine months
ended September 30, 2024, and has included that restated financial information within this annual report.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The impact of the revision on the Company&#x2019;s
balance sheet as of December 31, 2023 is reflected in the following table:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As previously&lt;br/&gt; reported&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As restated&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,081&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,891&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,191&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(105,571&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108,871&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(85,135&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(88,435&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The impact of the revision on the Company&#x2019;s
balance sheet as of December 31, 2022 is reflected in the following table:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As previously&lt;br/&gt; reported&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As restated&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,865&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(97,165&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75,734&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(79,034&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The impact of the revision on the Company&#x2019;s
balance sheet as of September 30, 2024 is reflected in the following table:&lt;/p&gt;&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As previously&lt;br/&gt; reported&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As restated&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,745&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,045&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(109,468&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(112,768&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(87,501&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(90,801&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</abp:RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock contextRef="c34" id="ixv-38026">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The impact of the revision on the Company&#x2019;s
balance sheet as of December 31, 2023 is reflected in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As previously&lt;br/&gt; reported&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As restated&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,081&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,381&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12,891&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,191&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(105,571&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(108,871&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(85,135&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(88,435&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The impact of the revision on the Company&#x2019;s
balance sheet as of December 31, 2022 is reflected in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As previously&lt;br/&gt; reported&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As restated&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,897&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5,197&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,987&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,287&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(93,865&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(97,165&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(75,734&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(79,034&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The impact of the revision on the Company&#x2019;s
balance sheet as of September 30, 2024 is reflected in the following table:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As previously&lt;br/&gt; reported&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Adjustment&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;As restated&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Accrued expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,745&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6,045&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15,277&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;18,577&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Accumulated deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(109,468&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(112,768&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Total stockholders&#x2019; deficit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(87,501&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(90,801&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c509"
      decimals="-3"
      id="ixv-43366"
      unitRef="usd">2081000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c510"
      decimals="-3"
      id="ixv-43367"
      unitRef="usd">3300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c511"
      decimals="-3"
      id="ixv-43368"
      unitRef="usd">5381000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="c509"
      decimals="-3"
      id="ixv-43369"
      unitRef="usd">12891000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c510"
      decimals="-3"
      id="ixv-43370"
      unitRef="usd">3300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c511"
      decimals="-3"
      id="ixv-43371"
      unitRef="usd">16191000</us-gaap:Liabilities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c509"
      decimals="-3"
      id="ixv-43372"
      unitRef="usd">-105571000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c510"
      decimals="-3"
      id="ixv-43373"
      unitRef="usd">-3300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c511"
      decimals="-3"
      id="ixv-43374"
      unitRef="usd">-108871000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c509"
      decimals="-3"
      id="ixv-43375"
      unitRef="usd">-85135000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c510"
      decimals="-3"
      id="ixv-43376"
      unitRef="usd">-3300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c511"
      decimals="-3"
      id="ixv-43377"
      unitRef="usd">-88435000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c512"
      decimals="-3"
      id="ixv-43378"
      unitRef="usd">1897000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c513"
      decimals="-3"
      id="ixv-43379"
      unitRef="usd">3300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c514"
      decimals="-3"
      id="ixv-43380"
      unitRef="usd">5197000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="c512"
      decimals="-3"
      id="ixv-43381"
      unitRef="usd">11987000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c513"
      decimals="-3"
      id="ixv-43382"
      unitRef="usd">3300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c514"
      decimals="-3"
      id="ixv-43383"
      unitRef="usd">15287000</us-gaap:Liabilities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c512"
      decimals="-3"
      id="ixv-43384"
      unitRef="usd">-93865000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c513"
      decimals="-3"
      id="ixv-43385"
      unitRef="usd">-3300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c514"
      decimals="-3"
      id="ixv-43386"
      unitRef="usd">-97165000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c512"
      decimals="-3"
      id="ixv-43387"
      unitRef="usd">-75734000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c513"
      decimals="-3"
      id="ixv-43388"
      unitRef="usd">-3300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c514"
      decimals="-3"
      id="ixv-43389"
      unitRef="usd">-79034000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c515"
      decimals="-3"
      id="ixv-43390"
      unitRef="usd">2745000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c516"
      decimals="-3"
      id="ixv-43391"
      unitRef="usd">3300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="c517"
      decimals="-3"
      id="ixv-43392"
      unitRef="usd">6045000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:Liabilities
      contextRef="c515"
      decimals="-3"
      id="ixv-43393"
      unitRef="usd">15277000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c516"
      decimals="-3"
      id="ixv-43394"
      unitRef="usd">3300000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c517"
      decimals="-3"
      id="ixv-43395"
      unitRef="usd">18577000</us-gaap:Liabilities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c515"
      decimals="-3"
      id="ixv-43396"
      unitRef="usd">-109468000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c516"
      decimals="-3"
      id="ixv-43397"
      unitRef="usd">-3300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c517"
      decimals="-3"
      id="ixv-43398"
      unitRef="usd">-112768000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c515"
      decimals="-3"
      id="ixv-43399"
      unitRef="usd">-87501000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c516"
      decimals="-3"
      id="ixv-43400"
      unitRef="usd">-3300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c517"
      decimals="-3"
      id="ixv-43401"
      unitRef="usd">-90801000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c34" id="ixv-38263">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"&gt;&lt;b&gt;Merger&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 13, 2024, Merger Sub, a
wholly-owned subsidiary of ACAB, merged with Legacy Abpro, with Legacy Abpro surviving as a wholly-owned subsidiary of ACAB. At the effective
time of the Merger:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;each outstanding share of Legacy Abpro common stock was converted into approximately 0.068 shares of the Company&#x2019;s common stock;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;each outstanding share of preferred stock of Legacy Abpro was converted into the aggregate number of shares of New Abpro&#x2019;s common stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately 0.068; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;each outstanding option or warrant to purchase Legacy Abpro common stock was converted into an option or warrant, as applicable, to purchase a number of shares of the Company&#x2019;s common stock equal to the number of shares of Legacy Abpro common stock subject to such option or warrant multiplied by approximately 0.068, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately 0.068; in each case, rounded down to the nearest whole share.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In addition, at the Closing Date, 6,744,550
shares of Series A common stock and 1 share of Series B common stock of ACAB automatically converted into shares of the Company&#x2019;s
common stock, on a one-for-one basis (pre-split).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Former holders of the Legacy Abpro
common stock and Legacy Abpro preferred stock are eligible to receive up to 483,333 additional shares of the Company&#x2019;s common stock (&#x201c;Contingent Earnout Shares&#x201d;) if, within five calendar years after the closing of the Merger, the volume weighted
average price of shares of the Company&#x2019;s Common Stock on Nasdaq, or any other national securities exchange on which the shares of
the Company&#x2019;s Common Stock are then traded (&#x201c;VWAP&#x201d;) meets or exceeds three-tier target prices defined in the agreement,
as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;one-third of the total Earnout Shares, if, the VWAP is greater than or equal to $390.00 over any 20 trading days within any consecutive 30 trading day period (the &#x201c;First Share Target&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b)&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-left: 0in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;one-third of the total Earnout Shares, if, the VWAP is greater than or equal to $450.00 over any 20 trading days within any consecutive 30 trading day period (the &#x201c;Second Share Target&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.5in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;one-third of the total Earnout Shares, if, the VWAP is greater than or equal to $540.00 over any 20 trading days within any consecutive 30 trading day period (the &#x201c;Third Share Target&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;If following the Closing, a Change
of Control (as defined in the Merger Agreement) occurs on or before the five year anniversary of the Closing Date, then if (i) the per
share value of the consideration to be received by stockholders in connection with the Change of Control exceeds $390.00 per share and
the First Share Target has not been previously achieved, then the First Share Target will be deemed to have been achieved, (ii) the per
share value of the consideration to be received by stockholders exceeds $450.00 per share and the Second Share Target has not been previously
achieved, then the Second Share Target will be deemed to have been achieved, and (iii) the per share value of the consideration to be
received by stockholders exceeds $540.00 per share and the Third Share Target has not been previously achieved, then the Third Share Target
will be deemed to have been achieved. Any Contingency Consideration that is not deemed to be earned in connection with the Change of Control
shall be forfeited by the stockholders for no consideration.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;At the Closing Date, the Company issued
an aggregate of 112,247 shares of the Company&#x2019;s common stock (the &#x201c;PIPE Shares&#x201d;) in a private placement for the total
consideration of $11,225 (the &#x201c;PIPE Financing&#x201d;). Out of the total PIPE Shares, 20,749 shares were issued to Abpro Bio International,
Inc. (&#x201c;ABI&#x201d;), pursuant to the terms of a subscription agreement dated August 22, 2024 with ABI (the &#x201c;Abpro Bio Subscription
Agreement&#x201d;) for an aggregate purchase price of $6,225, of which $4,225 was used to repay the balance due by Legacy Abpro to ABI
under the promissory note agreement (see Note 8) and the remainder of $2,000 in cash. In addition, pursuant to the Abpro Bio Subscription
Agreement, ABI received an aggregate of 41,498 shares of New Abpro common stock reserved for use in the PIPE Financing or to obtain capital
for ACAB or the surviving company, as defined in the Merger Agreement (the &#x201c;Incentive Shares&#x201d;). The Company also issued 16,667
common stock shares of New Abpro to &lt;span style="background-color: white"&gt;Celltrion, Inc., a company organized and existing under the
laws of South Korea (&#x201c;Celltrion&#x201d;)&lt;/span&gt;, pursuant to the terms of a subscription agreement dated August 22, 2024 with &lt;span style="background-color: white"&gt;Celltrion
(&#x201c;Celltrion&#x201d;) &lt;/span&gt;(the &#x201c;Celltrion Subscription Agreement&#x201d;, together with the &#x201c;Abpro Bio Subscription
Agreement&#x201d;, collectively the &#x201c;PIPE Subscription Agreements&#x201d;) for an aggregate purchase price of $5,000. In addition,
Celltrion received an aggregate of 33,333 Incentive Shares.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Pursuant to the terms of the Merger
Agreement, at the Closing Date, ACAB&#x2019;s sponsor, Atlantic Coastal Management II LLC (the &#x201c;Sponsor&#x201d;) received 20,020 shares
of New Abpro common stock in lieu of repayment of $2,000 of Unpaid SPAC Expenses (as defined in the Merger Agreement) owed to the Sponsor
as a result of advances made by the Sponsor to ACAB. This settlement was related to the ACAB liabilities incurred prior to the Merger
and had no financial impact on the Company&#x2019;s consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;At the Closing, and in accordance with
the Sponsor Letter Agreement entered into on December 11, 2023, as amended, the Sponsor transferred 32,778 common shares to Legacy Abpro
and 32,778 shares to ABI, and 32,215 shares were forfeited. The shares transferred to Legacy Abpro were deemed to be repurchased by the
post-merger Company for no consideration and included in treasury stock as of the Closing Date and December 31, 2024. The shares transferred
to ABI for no consideration were accounted for as a recapitalization with no impact on the consolidated financial statements. The Sponsor
also transferred 6,667 shares to one of ACAB&#x2019;s financial advisors for the services provided prior to the Closing Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In addition, at the Closing, the Company
issued 36,095 common stock shares to various service providers, of which 1,095 shares were issued to an investment advisor in the PIPE
Financing and the remaining 35,000 common stock shares were issued in settlement of ACAB&#x2019;s liabilities for the services provided
by various legal and investment advisors prior to the Closing Date. The issuance of these shares, related to the services provided to
ACAB prior to the Merger which were expensed on the books of ACAB, with no financial impact on the Company&#x2019;s consolidated financial
statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The number of shares of the Company&#x2019;s
common stock outstanding immediately following the consummation of the Merger was:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Common stock of ACAB, net of redemptions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,033&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;ACAB Founder Shares, less of forfeitures and transfers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,076&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;New Abpro shares issued to PIPE investors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;New Abpro shares issued to service providers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,762&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;New Abpro shares issued in Merger to Legacy Abpro stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,304,107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;New Abpro shares transferred to investors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;New Abpro shares issued to settle the promissory note with executive&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Total shares of common stock outstanding immediately after Merger&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,684,510&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Merger was accounted for as a
reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, ACAB is treated as the acquired company for
financial reporting purposes and Legacy Abpro is treated as the acquirer. This determination is primarily based on the fact that
subsequent to the Merger, the Legacy Abpro stockholders hold a majority of the voting rights of the combined company, Legacy Abpro
comprises all of the ongoing operations of the combined company, Legacy Abpro comprises a majority of the carryover governing body
of the combined company, and Legacy Abpro&#x2019;s senior management comprises all of the senior management of the combined company.
Accordingly, for accounting purposes, the Merger was treated as the equivalent of Legacy Abpro issuing shares for the net assets of
ACAB, accompanied by a recapitalization. The net assets of ACAB were stated at historical costs. No goodwill or other intangible
assets were recorded. Operations prior to the Merger are those of Legacy Abpro.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company received $5.7 million in
proceeds from the Merger and related PIPE Financing, net of ACAB transaction costs settled at the Closing. The Company incurred $2.1 million
in transaction costs and $0.9 million in issuance costs related to the PIPE Financing, consisting of banking, legal, investment advisory
and other professional fees, of which were recorded as a reduction of proceeds to additional paid-in capital. At the Closing Date, Legacy
Abpro assumed $6.6 million of net liabilities, including tax liabilities and legal fees, of ACAB, of which $1.0 million was included in
accrued expenses, $4.4 million in excise tax payable and $0.4 million in income tax payable as of December 31, 2024.&lt;/p&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c202"
      decimals="3"
      id="ixv-43402"
      unitRef="shares">0.068</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits
      contextRef="c203"
      decimals="3"
      id="ixv-43403"
      unitRef="shares">0.068</us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c204"
      decimals="3"
      id="ixv-43404"
      unitRef="shares">0.068</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c204"
      decimals="3"
      id="ixv-43405"
      unitRef="usdPershares">0.068</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c518"
      decimals="0"
      id="ixv-43406"
      unitRef="shares">6744550</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c519"
      decimals="0"
      id="ixv-43407"
      unitRef="shares">1</us-gaap:ConversionOfStockSharesConverted1>
    <abp:AdditionSharesOfCommonStock
      contextRef="c34"
      decimals="0"
      id="ixv-43408"
      unitRef="shares">483333</abp:AdditionSharesOfCommonStock>
    <abp:EarnoutShare
      contextRef="c520"
      decimals="2"
      id="ixv-43409"
      unitRef="usdPershares">390</abp:EarnoutShare>
    <abp:TradingDays contextRef="c520" id="ixv-43410">P20D</abp:TradingDays>
    <abp:NumberOfConsecutiveTradingDays contextRef="c520" id="ixv-43411">P30D</abp:NumberOfConsecutiveTradingDays>
    <abp:EarnoutShare
      contextRef="c521"
      decimals="2"
      id="ixv-43412"
      unitRef="usdPershares">450</abp:EarnoutShare>
    <abp:TradingDays contextRef="c521" id="ixv-43413">P20D</abp:TradingDays>
    <abp:NumberOfConsecutiveTradingDays contextRef="c521" id="ixv-43414">P30D</abp:NumberOfConsecutiveTradingDays>
    <abp:EarnoutShare
      contextRef="c522"
      decimals="2"
      id="ixv-43415"
      unitRef="usdPershares">540</abp:EarnoutShare>
    <abp:TradingDays contextRef="c522" id="ixv-43416">P20D</abp:TradingDays>
    <abp:NumberOfConsecutiveTradingDays contextRef="c522" id="ixv-43417">P30D</abp:NumberOfConsecutiveTradingDays>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c523"
      decimals="2"
      id="ixv-43418"
      unitRef="usdPershares">390</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c524"
      decimals="2"
      id="ixv-43419"
      unitRef="usdPershares">450</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c525"
      decimals="2"
      id="ixv-43420"
      unitRef="usdPershares">540</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c526"
      decimals="0"
      id="ixv-43421"
      unitRef="shares">112247</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="c527"
      decimals="-3"
      id="ixv-43422"
      unitRef="usd">11225000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c528"
      decimals="0"
      id="ixv-43423"
      unitRef="shares">20749</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abp:AggregatePurchasePrice
      contextRef="c526"
      decimals="-3"
      id="ixv-43424"
      unitRef="usd">6225000</abp:AggregatePurchasePrice>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c526"
      decimals="-3"
      id="ixv-43425"
      unitRef="usd">4225000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:Cash
      contextRef="c529"
      decimals="-3"
      id="ixv-43426"
      unitRef="usd">2000000</us-gaap:Cash>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c530"
      decimals="0"
      id="ixv-43427"
      unitRef="shares">41498</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c531"
      decimals="0"
      id="ixv-43428"
      unitRef="shares">16667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abp:AggregatePurchasePrice contextRef="c34" decimals="-3" id="ixv-43429" unitRef="usd">5000000</abp:AggregatePurchasePrice>
    <abp:AggregateIncentiveShare
      contextRef="c34"
      decimals="0"
      id="ixv-43430"
      unitRef="shares">33333</abp:AggregateIncentiveShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c532"
      decimals="0"
      id="ixv-43431"
      unitRef="shares">20020</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RepaymentsOfDebt
      contextRef="c533"
      decimals="-3"
      id="ixv-43432"
      unitRef="usd">2000000</us-gaap:RepaymentsOfDebt>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c216"
      decimals="0"
      id="ixv-43433"
      unitRef="shares">32778</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c217"
      decimals="0"
      id="ixv-43434"
      unitRef="shares">32778</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited
      contextRef="c218"
      decimals="0"
      id="ixv-43435"
      unitRef="shares">32215</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c219"
      decimals="0"
      id="ixv-43436"
      unitRef="shares">6667</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c534"
      decimals="0"
      id="ixv-43437"
      unitRef="shares">36095</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c535"
      decimals="0"
      id="ixv-43438"
      unitRef="shares">1095</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <abp:RemainingSharesIssued
      contextRef="c536"
      decimals="0"
      id="ixv-43439"
      unitRef="shares">35000</abp:RemainingSharesIssued>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="c34" id="ixv-38355">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The number of shares of the Company&#x2019;s
common stock outstanding immediately following the consummation of the Merger was:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify"&gt;Common stock of ACAB, net of redemptions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;7,033&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;ACAB Founder Shares, less of forfeitures and transfers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;126,076&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;New Abpro shares issued to PIPE investors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;112,247&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;New Abpro shares issued to service providers&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;42,762&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;New Abpro shares issued in Merger to Legacy Abpro stockholders&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,304,107&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;New Abpro shares transferred to investors&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72,285&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;New Abpro shares issued to settle the promissory note with executive&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: justify; padding-bottom: 4pt"&gt;Total shares of common stock outstanding immediately after Merger&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"&gt;1,684,510&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c539"
      decimals="INF"
      id="ixv-43440"
      unitRef="shares">7033</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c540"
      decimals="INF"
      id="ixv-43441"
      unitRef="shares">126076</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c541"
      decimals="INF"
      id="ixv-43442"
      unitRef="shares">112247</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c542"
      decimals="INF"
      id="ixv-43443"
      unitRef="shares">42762</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c543"
      decimals="INF"
      id="ixv-43444"
      unitRef="shares">1304107</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c544"
      decimals="INF"
      id="ixv-43445"
      unitRef="shares">72285</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c545"
      decimals="INF"
      id="ixv-43446"
      unitRef="shares">20000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c43"
      decimals="INF"
      id="ixv-43447"
      unitRef="shares">1684510</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c534"
      decimals="-5"
      id="ixv-43448"
      unitRef="usd">5700000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts
      contextRef="c537"
      decimals="-5"
      id="ixv-43449"
      unitRef="usd">2100000</us-gaap:BusinessAcquisitionCostOfAcquiredEntityTransactionCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c534"
      decimals="-5"
      id="ixv-43450"
      unitRef="usd">900000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:OtherLiabilities
      contextRef="c538"
      decimals="-5"
      id="ixv-43451"
      unitRef="usd">6600000</us-gaap:OtherLiabilities>
    <us-gaap:LegalFees
      contextRef="c536"
      decimals="-5"
      id="ixv-43452"
      unitRef="usd">1000000</us-gaap:LegalFees>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="c2" decimals="-5" id="ixv-43453" unitRef="usd">4400000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c2" decimals="-5" id="ixv-43454" unitRef="usd">400000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c34" id="ixv-38434">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;4&lt;/b&gt;.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Property
and Equipment&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s property and equipment
include the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware and software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equipment under finance leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Depreciation expense was $65 and $269
for the years ended December 31, 2024 and 2023, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c34" id="ixv-38446">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s property and equipment
include the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Lab equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,097&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer hardware and software&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;15&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;788&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Equipment under finance leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;740&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Property and Equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,693&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: Accumulated Depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,656&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(2,591&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;37&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;102&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c546"
      decimals="-3"
      id="ixv-43455"
      unitRef="usd">53000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c547"
      decimals="-3"
      id="ixv-43456"
      unitRef="usd">53000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c548"
      decimals="-3"
      id="ixv-43457"
      unitRef="usd">1097000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c549"
      decimals="-3"
      id="ixv-43458"
      unitRef="usd">1097000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c550"
      decimals="-3"
      id="ixv-43459"
      unitRef="usd">15000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c551"
      decimals="-3"
      id="ixv-43460"
      unitRef="usd">15000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c498"
      decimals="-3"
      id="ixv-43461"
      unitRef="usd">788000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c552"
      decimals="-3"
      id="ixv-43462"
      unitRef="usd">788000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c553"
      decimals="-3"
      id="ixv-43463"
      unitRef="usd">740000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c554"
      decimals="-3"
      id="ixv-43464"
      unitRef="usd">740000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" id="ixv-43465" unitRef="usd">2693000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c5" decimals="-3" id="ixv-43466" unitRef="usd">2693000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-43467" unitRef="usd">2656000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-43468" unitRef="usd">2591000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" id="ixv-43469" unitRef="usd">37000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c5" decimals="-3" id="ixv-43470" unitRef="usd">102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c34" decimals="-3" id="ixv-43471" unitRef="usd">65000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c35" decimals="-3" id="ixv-43472" unitRef="usd">269000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c34" id="ixv-38549">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Accrued
Expenses&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Accrued expenses consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt; (As&#160;Restated)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued salaries and wages&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,549&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,398&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued license fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-432"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BOD compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-433"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;865&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;590&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,496&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,381&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c34" id="ixv-38560">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Accrued expenses consisted of the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt; (As&#160;Restated)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Accrued salaries and wages&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,549&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1,398&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,273&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Accrued license fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Accrued interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;267&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-432"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;BOD compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;242&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-433"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;865&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;590&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,496&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,381&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent contextRef="c2" decimals="-3" id="ixv-43473" unitRef="usd">1549000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c5" decimals="-3" id="ixv-43474" unitRef="usd">1398000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c2" decimals="-3" id="ixv-43475" unitRef="usd">1273000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c5" decimals="-3" id="ixv-43476" unitRef="usd">93000</us-gaap:AccruedProfessionalFeesCurrent>
    <abp:AccruedLicenseFees contextRef="c2" decimals="-3" id="ixv-43477" unitRef="usd">3300000</abp:AccruedLicenseFees>
    <abp:AccruedLicenseFees contextRef="c5" decimals="-3" id="ixv-43478" unitRef="usd">3300000</abp:AccruedLicenseFees>
    <abp:AccruedInterest contextRef="c2" decimals="-3" id="ixv-43479" unitRef="usd">267000</abp:AccruedInterest>
    <abp:AccruedBODCompensation contextRef="c2" decimals="-3" id="ixv-43480" unitRef="usd">242000</abp:AccruedBODCompensation>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-43481" unitRef="usd">865000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-43482" unitRef="usd">590000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-43483" unitRef="usd">7496000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c5" decimals="-3" id="ixv-43484" unitRef="usd">5381000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c34" id="ixv-38665">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair
Value Measurements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The following table presents information
about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2024, and indicates
the fair value hierarchy of the valuation inputs the Company&#x2019;s utilized to determine such fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Forward purchase agreement asset (Note 11)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;155&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;SEPA put rights asset (Note 13)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Embedded derivative liability (Note 13)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;There were no assets or liabilities
measured at fair value on a recurring basis as of December 31, 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The fair value of the Company&#x2019;s
position under the Forward Purchase Agreement was calculated by multiplying the number of shares under the Forward Purchase Agreement
by the market price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;November&#160;13,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;173.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The fair value of the SEPA Put Rights
was estimated as the sum of the fair values of the put rights under each assumed advance notice over the term of the SEPA. The number
of shares under each advance notice was based on the historical trading volumes of the Company&#x2019;s stock taking into account various
beneficial ownership and daily volume limitations. The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;November 13,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;173.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;82-90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;93-99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Number of shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The fair value of the Embedded
Derivative Feature was estimated at $69 at the issuance date based on the difference between the fair value of the convertible note
with these embedded features and the fair value without each one of these embedded features. The assumptions incorporated into the
valuation model as of November 13, 2024, the issuance date of the Convertible Note included the stock price of $173.10, the
estimated future price per share of $130.80 (derived using Monte Carlo Simulation), the expected volatility of 90%, the risk-free
rate of 4.31% and the term of 1 year. As of December 31, 2024 the assumptions incorporated into the valuation model included the
stock price of $53.70, the estimated future price per share of $61.80 (derived using Monte Carlo Simulation), the expected
volatility of 99%, the risk-free rate of 4.18% and the term of 0.9 years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The changes in the fair value of Level
3 financial assets and liabilities for the year ended December 31, 2024 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Forward&lt;br/&gt;
Purchase&lt;br/&gt;
Agreement&lt;br/&gt;
asset&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SEPA&lt;br/&gt;
Put Rights&lt;br/&gt;
Asset&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Embedded &lt;br/&gt;
Derivative Liability&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 67%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value as of January 1, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-434; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-435; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Initial measurement at the issuance date&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;494&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,551&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;69&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(339&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,363&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;155&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;188&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock contextRef="c34" id="ixv-38676">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The following table presents information
about the Company&#x2019;s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2024, and indicates
the fair value hierarchy of the valuation inputs the Company&#x2019;s utilized to determine such fair value:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Level&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Forward purchase agreement asset (Note 11)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;3&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;155&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;SEPA put rights asset (Note 13)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;188&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Embedded derivative liability (Note 13)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;80&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c245"
      decimals="-3"
      id="ixv-43485"
      unitRef="usd">155000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c247"
      decimals="-3"
      id="ixv-43486"
      unitRef="usd">188000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c249"
      decimals="-3"
      id="ixv-43487"
      unitRef="usd">80000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c34" id="ixv-38749">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The fair value of the Company&#x2019;s
position under the Forward Purchase Agreement was calculated by multiplying the number of shares under the Forward Purchase Agreement
by the market price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;November&#160;13,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;December&#160;31,&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Stock price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;173.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.6&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.4&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.3&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.1&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;90&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;98&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;November 13,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;December 31,&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2024&lt;/td&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Stock price&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;173.10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;53.70&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.3&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.2&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Exercise price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;166.20&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;51.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;82-90&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;93-99&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Number of shares&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;5,500&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,883&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c562"
      decimals="2"
      id="ixv-43488"
      unitRef="pure">173.1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c250"
      decimals="2"
      id="ixv-43489"
      unitRef="pure">53.7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c563"
      decimals="1"
      id="ixv-43490"
      unitRef="pure">4.6</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c251"
      decimals="1"
      id="ixv-43491"
      unitRef="pure">4.4</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c564"
      decimals="1"
      id="ixv-43492"
      unitRef="pure">0.3</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c252"
      decimals="1"
      id="ixv-43493"
      unitRef="pure">0.1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c565"
      decimals="0"
      id="ixv-43494"
      unitRef="pure">90</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c253"
      decimals="0"
      id="ixv-43495"
      unitRef="pure">98</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c566"
      decimals="0"
      id="ixv-43496"
      unitRef="pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c254"
      decimals="0"
      id="ixv-43497"
      unitRef="pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c567"
      decimals="2"
      id="ixv-43499"
      unitRef="pure">173.1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c256"
      decimals="2"
      id="ixv-43500"
      unitRef="pure">53.7</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c568"
      decimals="1"
      id="ixv-43501"
      unitRef="pure">4.3</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c259"
      decimals="1"
      id="ixv-43502"
      unitRef="pure">4.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c569"
      decimals="2"
      id="ixv-43503"
      unitRef="pure">166.2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c261"
      decimals="2"
      id="ixv-43504"
      unitRef="pure">51.6</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c570"
      decimals="0"
      id="ixv-43505"
      unitRef="pure">1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c571"
      decimals="0"
      id="ixv-43506"
      unitRef="pure">2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c264"
      decimals="0"
      id="ixv-43507"
      unitRef="pure">1</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c265"
      decimals="0"
      id="ixv-43508"
      unitRef="pure">2</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c572"
      decimals="0"
      id="ixv-43509"
      unitRef="pure">82</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c573"
      decimals="0"
      id="ixv-43510"
      unitRef="pure">90</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c267"
      decimals="0"
      id="ixv-43511"
      unitRef="pure">93</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c268"
      decimals="0"
      id="ixv-43512"
      unitRef="pure">99</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c574"
      decimals="0"
      id="ixv-43513"
      unitRef="pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c270"
      decimals="0"
      id="ixv-43514"
      unitRef="pure">0</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c575"
      decimals="0"
      id="ixv-43515"
      unitRef="pure">5500</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="c272"
      decimals="0"
      id="ixv-43516"
      unitRef="pure">1883</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c555"
      decimals="-3"
      id="ixv-43517"
      unitRef="usd">69000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:SharePrice
      contextRef="c556"
      decimals="2"
      id="ixv-43518"
      unitRef="usdPershares">173.1</us-gaap:SharePrice>
    <abp:EstimatedFuturePricePerShare
      contextRef="c556"
      decimals="2"
      id="ixv-43519"
      unitRef="usdPershares">130.8</abp:EstimatedFuturePricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c557"
      decimals="2"
      id="ixv-43520"
      unitRef="pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c557"
      decimals="4"
      id="ixv-43521"
      unitRef="pure">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c557" id="ixv-43522">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="c239"
      decimals="2"
      id="ixv-43523"
      unitRef="usdPershares">53.7</us-gaap:SharePrice>
    <abp:EstimatedFuturePricePerShare
      contextRef="c558"
      decimals="2"
      id="ixv-43524"
      unitRef="usdPershares">61.8</abp:EstimatedFuturePricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c559"
      decimals="2"
      id="ixv-43525"
      unitRef="pure">0.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c560"
      decimals="4"
      id="ixv-43526"
      unitRef="pure">0.0418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c561" id="ixv-43527">P0Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c34" id="ixv-38932">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The changes in the fair value of Level
3 financial assets and liabilities for the year ended December 31, 2024 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Forward&lt;br/&gt;
Purchase&lt;br/&gt;
Agreement&lt;br/&gt;
asset&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;SEPA&lt;br/&gt;
Put Rights&lt;br/&gt;
Asset&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Embedded &lt;br/&gt;
Derivative Liability&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="width: 67%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value as of January 1, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-434; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 8%; text-align: right"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-435; font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;-&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Initial measurement at the issuance date&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;494&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1,551&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;69&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(339&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;(1,363&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: white"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value as of December 31, 2024&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;155&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;188&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 4.5pt double; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;80&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c578"
      decimals="-3"
      id="ixv-43528"
      unitRef="usd">494000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c579"
      decimals="-3"
      id="ixv-43529"
      unitRef="usd">1551000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c580"
      decimals="-3"
      id="ixv-43530"
      unitRef="usd">69000</us-gaap:LiabilitiesFairValueAdjustment>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="c578"
      decimals="-3"
      id="ixv-43531"
      unitRef="usd">-339000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="c579"
      decimals="-3"
      id="ixv-43532"
      unitRef="usd">-1363000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="c580"
      decimals="-3"
      id="ixv-43533"
      unitRef="usd">11000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c273"
      decimals="-3"
      id="ixv-43534"
      unitRef="usd">155000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c274"
      decimals="-3"
      id="ixv-43535"
      unitRef="usd">188000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c275"
      decimals="-3"
      id="ixv-43536"
      unitRef="usd">80000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c34" id="ixv-39056">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;License
and Collaboration Agreements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;NJCTTQ Collaboration Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In January 2019, the Company entered
into a collaboration agreement with Nanjing Chia Tai Tianquing Pharmaceutical Co., Ltd. (&#x201c;NJCTTQ&#x201d;) to research, develop and
commercialize two anti-Claudin 18.2 lead antibodies (the &#x201c;NJCTTQ agreement&#x201d;). Under the NJCTTQ agreement, the Company granted
a non-exclusive, non-sublicensable research license and an exclusive, sublicensable license to NJCTTQ within the People&#x2019;s Republic
of China and Thailand (the &#x201c;NJCTTQ Territory&#x201d;). The initial term of this agreement was 5 years, which could be automatically
renewed for another 5 years. If no collaboration project reached the clinical stage within the first 5 years of the NJCTTQ agreement,
then this agreement would not have been renewed. The agreement expired in January 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company was eligible to receive
up to an aggregate of $405,000 of non-refundable milestone payments from NJCTTQ upon achieving certain development, regulatory approval,
and commercialization and sales milestones for each unique licensed antibody or product in NJCTTQ Territory. The Company agreed to pay
NJCTTQ up to an aggregate of $5,000 in nonrefundable amounts upon achieving of a regulatory milestone in the Company&#x2019;s territory,
which includes all other countries other than the NJCTTQ Territory. No &lt;span style="background-color: white"&gt;milestones have been reached
through the expiration of this agreement in January 2024, no products were sold by NJCTTQ, and no related revenue amounts have been recorded
in the accompanying consolidated financial statements. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company and NJCTTQ agreed to pay
reciprocal royalties, with each of them paying the other party low single-digit royalties, tiered based on net sales per calendar year
in its territory. &lt;span style="background-color: white"&gt;The agreement remains unrenewed as of December 31, 2024 after the expiration of
its initial term. However, notwithstanding the agreement&#x2019;s expiration, the low single-digit royalties and the $5,000&#160;&lt;/span&gt;regulatory
&lt;span style="background-color: white"&gt;milestone payable to NJCTTQ based on commercial approval in &lt;/span&gt;the Company&#x2019;s &lt;span style="background-color: white"&gt;territory,
as described above, will continue to apply.&lt;/span&gt; Through &lt;span style="background-color: white"&gt;December 31, 2024&lt;/span&gt;, &lt;span style="background-color: white"&gt;no
products were sold by NJCTTQ or the Company under the NJCTTQ agreement and no regulatory milestones were achieved by the Company in the
Company&#x2019;s territory.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;ABP-100 Collaboration and License
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In December 2019, the Company
entered into an exclusive collaboration and license agreement with a related party, ABI (the &#x201c;ABP-100 agreement&#x201d;). Under
the ABP-100 agreement, the Company granted ABI the license to develop and commercialize products and services based on the
Company&#x2019;s Her2-hu-OKT3 bispecific antibody (&#x201c;ABP-100&#x201d;) within the territories of People&#x2019;s Republic of China,
Japan, South Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States, as defined in the agreement. Unless
earlier terminated, the ABP-100 agreement, will expire upon the satisfaction of all obligations under the agreement following the
expiration of the last royalty payment obligation. Either party may terminate the agreement in the event of any uncured material
breach by the other party. The license granted under the ABP-100 agreement was a sub-license from Memorial Sloan Kettering Cancer
Center (&#x201c;MSK&#x201d;) pursuant to MSK License Agreement (see Note 6). This agreement was terminated due to the termination of
the MSK License Agreement in September 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Under the ABP-100 agreement, ABI agreed
to use commercially reasonable efforts to reach certain development and commercial milestones for at least one licensed product or licensed
service within specified timeframes. ABI is committed to pay the Company running royalties on net sales of any licensed products or services
from the mid-single digit percentages to the low double-digit percentage, and the guaranteed annual minimum royalties of $30 starting
on the first anniversary of the effective date of the agreement (which annual minimum royalties may be credited against the running royalties
on net sales of any licensed products or services). Through the termination of this agreement in September 2023, &lt;span style="background-color: white"&gt;no
products were sold by ABI under the ABP-100 agreement.&lt;/span&gt; During the years ended December 31, 2024 and 2023, the Company earned &lt;span style="-sec-ix-hidden: hidden-fact-436"&gt;$0&lt;/span&gt;
and $23 in minimum royalty payments, included in royalty revenue. As of both December 31, 2024 and 2023, the accounts receivable were
$53, associated with the minimum royalties &lt;span style="background-color: white"&gt;under this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In addition to the royalty payments,
the Company could receive up to $498,000 in milestone payments per licensed product or licensed service upon the achievement of specified
research and development and sales milestone events. No milestones have been reached through the termination of this agreement in September
2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company was also entitled to research
funding fees for costs incurred by the Company for certain sponsored research activities and the reimbursement of 60% of the costs of
certain product development directed activities, as outlined in the agreement. During the years ended December 31, 2024 and 2023, the
Company did not earn any research funding fees.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Further, the Company was to be reimbursed
for patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights
in the license territory. The Company did not receive any reimbursements of patent costs during the years ended December 31, 2024 and
2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;ABP-201 Collaboration and License
Agreement &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In January 2020, the Company&#x2019;s
consolidated subsidiary, AbMed, entered into a collaboration and license agreement with ABI (the &#x201c;ABP-201 Agreement&#x201d;), pursuant
to which the Company granted to ABI an exclusive, royalty-bearing, license under specified patent rights to make, use and sell certain
of its proprietary ANG-2/VEGF-HIRK bispecific antibodies within the licensed territory comprising People&#x2019;s Republic of China, Japan,
South Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States. Unless earlier terminated in accordance with
its terms, the agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Under the ABP-201 agreement, ABI agreed
to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within
specified territories and timeframes. ABI is committed to pay the Company up to $56,500 in milestone payments upon achieving certain research
and development events, up to $485,000 in milestone payments based on annual net sales per each licensed product, and a double-digit percentage
royalty in the low teens, tiered based on cumulative net sales by ABI, its affiliates or sublicensees beginning with the first commercial
sale of a licensed product in its territory. No &lt;span style="background-color: white"&gt;milestones have been reached through December 31,
2024, no products were sold by ABI, and no related revenue amounts have been recorded in the accompanying consolidated financial statements.
&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Celltrion Collaboration and License
Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
September 2022, the Company entered into an exclusive collaboration and license agreement with Celltrion (the &#x201c;Original Celltrion
Agreement&#x201d;). The Company and Celltrion entered into an amendment to the agreement in October 2024 in connection with the execution
of the Celltrion Subscription Agreement (the &#x201c;Amended Celltrion Agreement&#x201d;). The amendment is subject to termination by the
Company or Celltrion if (i) the share purchase under the Celltrion Subscription Agreement is not completed, or (ii) the Celltrion Subscription
Agreement is terminated pursuant to Section 7 of the Celltrion Subscription Agreement. Under the Amended Celltrion Agreement, the Company
granted to Celltrion a worldwide exclusive license under specified patent rights to develop, make, have made, import, export, use, have
used, sell and have sold certain of its proprietary ABP-102 bispecific antibodies. The License Agreement also provides that the Company
is to perform certain preclinical in vitro studies. The License Agreement will remain in effect for so long as ABP-102 is being developed
or commercialized anywhere in the world. Celltrion may terminate the license agreement at any time by providing six months prior written
notice to the Company. &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;Celltrion
is committed to pay the Company up to $10,000 under the Original Celltrion Agreement and $6,000 under the Amended Celltrion Agreement
in milestone payments upon granting the license and achieving certain research and development events, up to $1,750,000 in milestone payments
based on annual net sales per each licensed product. The proceeds from commercialization are subject to a 50/50 profit split. Amounts
that may be paid by third-party collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization
partners, are also subject to a 50/50 split. Following commercial approval of ABP-102, the Company has agreed to reimburse Celltrion 87.5%
under the Original Celltrion Agreement and 250% under the Amended Celltrion Agreement of its direct and certain indirect costs and expenses
incurred through first commercial sale. Under the Original Celltrion Agreement, Celltrion is entitled to offset amounts otherwise due
to us under the agreement until our share of these costs has been paid back; provided that the Company is entitled to a minimum 25% (or
50% under the Amended Celltrion Agreement) of profit from commercial sales and from third-party collaborators regardless of the amount
of unreimbursed development costs outstanding (and then 50% once the reimbursement has been made in full).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;The
first milestone of $2,000 was achieved upon granting the license at the collaboration effective date, as defined in the Celltrion Agreement,
in December 2022 and received in January 2023. During the year ended December 31, 2022, the Company allocated $64 to the initial obligation
to perform in vitro testing for the research and development services and the remaining $1,936 to the license of the Company&#x2019;s intellectual
property, bundled with the associated know-how.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s initial obligation
to &lt;span style="background-color: white"&gt;perform in vitro testing for the research and development services&lt;/span&gt; represents a distinct
performance obligation. The revenue for this performance obligation was be recognized on a straight-line based over the term of the studies.
During the years ended December 31, 2024 and 2023, the Company recognized $0 and $64, respectively, in connection with this performance
obligation, included in collaboration revenue.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Milestone
Payments. &lt;/i&gt;The Company is entitled to development milestones under the Celltrion Agreement and certain regulatory milestone payments
which are paid upon receipt of regulatory approvals. Except for the first milestone of $2,000 achieved in 2022, no other milestone payments
were earned through December 31, 2024. The Company evaluated whether the remaining milestones are considered probable of being reached
and determined that their achievement is highly dependent on factors outside of the Company&#x2019;s control. Therefore, these payments
have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company
will re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust its estimate of
the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect the reported amount
of collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;&lt;i&gt;Profit
Splits.&lt;/i&gt; As the license is deemed to be the predominant item to which profit splits relate, the Company will recognize revenue when
the related sales or third-party collaborator income occur. No profit split revenue has been recognized from inception through December
31, 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <abp:NonRefundablePayments
      contextRef="c581"
      decimals="-3"
      id="ixv-43537"
      unitRef="usd">405000000</abp:NonRefundablePayments>
    <abp:NonRefundablePayments
      contextRef="c582"
      decimals="-3"
      id="ixv-43538"
      unitRef="usd">5000000</abp:NonRefundablePayments>
    <us-gaap:PaymentsForRoyalties
      contextRef="c582"
      decimals="-3"
      id="ixv-43539"
      unitRef="usd">5000000</us-gaap:PaymentsForRoyalties>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="c583"
      decimals="-3"
      id="ixv-43540"
      unitRef="usd">30000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="c585"
      decimals="-3"
      id="ixv-43541"
      unitRef="usd">23000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:AccountsReceivableNet contextRef="c5" decimals="-3" id="ixv-43542" unitRef="usd">53000</us-gaap:AccountsReceivableNet>
    <us-gaap:PaymentsForRoyalties
      contextRef="c586"
      decimals="-3"
      id="ixv-43543"
      unitRef="usd">498000000</us-gaap:PaymentsForRoyalties>
    <abp:PercentageOfReimbursement contextRef="c34" decimals="2" id="ixv-43544" unitRef="pure">0.60</abp:PercentageOfReimbursement>
    <abp:MilestonePayments
      contextRef="c587"
      decimals="-3"
      id="ixv-43545"
      unitRef="usd">56500000</abp:MilestonePayments>
    <abp:MilestonePayments
      contextRef="c530"
      decimals="-3"
      id="ixv-43546"
      unitRef="usd">485000000</abp:MilestonePayments>
    <abp:OriginalCelltrionAgreement
      contextRef="c588"
      decimals="-3"
      id="ixv-43547"
      unitRef="usd">10000000</abp:OriginalCelltrionAgreement>
    <abp:OriginalCelltrionAgreement
      contextRef="c589"
      decimals="-3"
      id="ixv-43548"
      unitRef="usd">6000000</abp:OriginalCelltrionAgreement>
    <abp:MilestonePayments
      contextRef="c588"
      decimals="-3"
      id="ixv-43549"
      unitRef="usd">1750000000</abp:MilestonePayments>
    <abp:PercentageOfOriginalCelltrionAgreement contextRef="c34" decimals="3" id="ixv-43550" unitRef="pure">0.875</abp:PercentageOfOriginalCelltrionAgreement>
    <abp:PercentageOfAmendedCelltrionAgreement contextRef="c34" decimals="2" id="ixv-43551" unitRef="pure">2.50</abp:PercentageOfAmendedCelltrionAgreement>
    <abp:PercentageOfAmendedCelltrionAgreement
      contextRef="c471"
      decimals="2"
      id="ixv-43552"
      unitRef="pure">0.25</abp:PercentageOfAmendedCelltrionAgreement>
    <abp:PercentageOfAmendedCelltrionAgreement
      contextRef="c590"
      decimals="2"
      id="ixv-43553"
      unitRef="pure">0.50</abp:PercentageOfAmendedCelltrionAgreement>
    <abp:PercentageOfReimbursement
      contextRef="c588"
      decimals="2"
      id="ixv-43554"
      unitRef="pure">0.50</abp:PercentageOfReimbursement>
    <abp:MilestonePayments
      contextRef="c591"
      decimals="-3"
      id="ixv-43555"
      unitRef="usd">2000000</abp:MilestonePayments>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c592"
      decimals="-3"
      id="ixv-43556"
      unitRef="usd">64000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="c593"
      decimals="-3"
      id="ixv-43557"
      unitRef="usd">1936000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c2" decimals="-3" id="ixv-43558" unitRef="usd">0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c5" decimals="-3" id="ixv-43559" unitRef="usd">64000</us-gaap:RevenueRemainingPerformanceObligation>
    <abp:MilestonePayments
      contextRef="c594"
      decimals="-3"
      id="ixv-43560"
      unitRef="usd">2000000</abp:MilestonePayments>
    <us-gaap:CommitmentsDisclosureTextBlock contextRef="c34" id="ixv-39189">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Commitments
under Research and Collaboration Agreements&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;MedImmune License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In August 2016, the Company entered
into a collaboration and license agreement with MedImmune Limited (&#x201c;MedImmune&#x201d;), pursuant to which the Company received from
MedImmune an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license to certain intellectual property
rights relating to the Company&#x2019;s ABP-200 product candidates (the &#x201c;MedImmune License Agreement&#x201d;). The Company agreed
to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within
specified timeframes. Unless earlier terminated in accordance with its terms, the MedImmune License Agreement, as amended, remains in
effect on a country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of
products based on the ABP-200 product candidates. The Company is no longer developing ABP-200.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Under the MedImmune License Agreement,
the Company agreed to pay milestone and royalty payments, including up to $244,000 in milestone payments, which are comprised of $14,000
upon meeting certain clinical development milestones, $80,000 upon achieving certain regulatory events and $150,000 upon meeting certain
worldwide commercial sales thresholds; and tiered high-single to low double-digit percentage royalties based on annualized net sales of
each product commercialized from our collaboration on a country-by-country basis. No milestones have been reached and no products were
sold by the Company through December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;NCI License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In August 2017, the Company entered
into a patent license agreement with the National Cancer Institute (the &#x201c;NCI&#x201d;), a division of the National Institutes of Health
(the &#x201c;NIH&#x201d;), pursuant to which the Company received an exclusive, worldwide license to make, use, sell, offer to sell and
import products covered by the licensed patents in the field of using certain monoclonal antibodies as monospecific or bispecific antibodies
for the treatment of liver cancer (the &#x201c;NCI License Agreement&#x201d;). The license agreement was amended in May 2020 and October
2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the treatment of GPC-3 expressing
liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization was extended. Unless
earlier terminated, the Company&#x2019;s agreement with NCI will expire upon expiration of all licensed patent rights. The Company may
also terminate the agreement as to any licenses in any country or territory upon 60 days written notice.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Pursuant to the NCI agreement and amendments,
the Company agreed to pay low single-digit royalties based on net sales of licensed products as well as milestone payments of up to $3,995
due upon achievement of clinical and regulatory milestones, and up to $12,000 milestone payments due upon achievement of commercial milestones.
No milestones have been reached and no products were sold by the Company through December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company also has to pay the guaranteed
annual minimum royalties of $25 starting on the effective date of the agreement (which annual minimum royalties may be credited against
the running royalties on net sales of any licensed products or services). During each of the years ended December 31, 2024 and 2023, the
Company incurred $25, in minimum royalty payments, included in research and development expenses. Under the amendment entered into in
March 2020, the Company is also liable for the extension royalties of $225 payable under this agreement which were rescheduled to become
due in several installments starting in March 2022. As of both December 31, 2024 and 2023, the accrued extension royalties were $200,
included in accrued expenses and accounts payable on the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company also agreed to reimburse
patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights.
During both the years ended December 31, 2024 and 2023, the Company did not incur any expenses related to the patent costs reimbursements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Mabwell License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In October 2020, the Company entered
into an exclusive collaboration and license agreement with Mabwell (the &#x201c;Mabwell License Agreement&#x201d;). The agreement was amended
in November 2020. Under the Mabwell license agreement, the Company received a non-exclusive, royalty-free research purpose license as
well as an exclusive commercial license within certain territories, as defined in the agreement, to Mabwell&#x2019;s series of anti-SARS-CoV-2
monoclonal antibodies. Under the agreement, the Company is responsible for conducting at its sole expense, research and preclinical, clinical
and other developments of any licensed products and bears all development costs and expenses related to obtaining or maintenance of marketing
authorizations of licensed products in its territories. Mabwell is obligated, at the Company&#x2019;s request, to supply the Licensed Antibodies
to the Company for clinical trial purpose at costs plus margin as defined in the agreement. The parties agreed to undertake certain joint
clinical research and development activities with a portion of the costs contributed by Mabwell. Unless earlier terminated, the Mabwell
License Agreement will expire on the occurrence of the last to expire royalty term, which is the later of a) the expiration of the last
to expire valid claim of the patent rights and b) ten years from the first commercial sale of such Licensed Product, and determined on
jurisdiction-by-jurisdiction basis. Either party may terminate the agreement in the event of any uncured material breach by the other
party.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The agreement provides for development
milestones of up to $32,500 and annual sales milestone payments of up to $50,000 payable by the Company to Mabwell. The agreement also
provides for a profit sharing, with Mabwell sharing 50% of the net profits from the licensed product sales in certain territories as defined
in the agreement. The Company will also make tiered royalty payments in the mid to high single digits on net sales of commercial products
in the licensed territory.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;During the years ended December 31,
2024 and 2023, development activities under the Mabwell collaboration agreement were immaterial to the consolidated financial statements.
No &lt;span style="background-color: white"&gt;milestones have been reached and &lt;/span&gt;no products were sold under &lt;span style="background-color: white"&gt;the
&lt;/span&gt;Mabwell License Agreement &lt;span style="background-color: white"&gt;through December 31, 2024. As discussed in Note 2 to these consolidated
financial statements, the Company recognized other income of $3,556 during the year ended December 31, 2024 associated with the reversal
of the estimated liability associated with a disputed invoice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="background-color: white"&gt;In
March 2025, the Company received a draft of a termination agreement from Mabwell which outlines Mabwell&#x2019;s claim for the total payment
of $3,300 under certain development milestones asserting that these development milestones were achieved by the Company during 2021. The
Company does not believe that a liability under the milestone related provisions invoked by Mabwell was triggered and is planning to engage
in discussion with Mabwell about the validity of their claim. The Company accrued $3,300 expense related to this claim in the consolidated
financial statements as of December 31, 2024 through debit to accumulated deficit. The Company also restated the accrued expenses in the
consolidated financial statements as of September 30, 2024, December 31, 2023 and 2022 included in the Company&#x2019;s Form 8-K, filed
on November 26, 2024 (see Note 2).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;MSK License Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In March 2017, the Company
entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (the &#x201c;MSK License Agreement&#x201d;),
pursuant to which the Company received an exclusive, royalty-bearing, worldwide license under specified patent rights to make, use
and sell certain of MSK&#x2019;s proprietary Her2-huOKT3 bispecific antibodies. The agreement was amended on March 31, 2017, on March
31, 2018, and January 1, 2020. Unless earlier terminated in accordance with its terms, the agreement was to remain in effect on a
country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of products
based on MSK antibodies. On September 19, 2023, MSK License Agreement was terminated by MSK due to the Company&#x2019;s failure to
make the payments for the patent costs reimbursements discussed below.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Under the MSK License Agreement, as
amended, the Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such
bispecific antibodies within specified territories and timeframes. The Company was committed to pay MSK up to $10,500 in milestone payments
upon achieving certain research and development and commercialization events or within a certain number of months of the effective date,
up to $30,000 in milestone payments based on net sales, and tiered mid-single-digit percentage royalties based on annualized net sales
of each product commercialized from the collaboration with guaranteed annual minimum royalties between $20 and $30 depending on certain
development events. During the years ended December 31, 2024 and 2023, the Company incurred $0 and $20 in minimum royalties, included
in research and development expenses. During the years ended December 31, 2024 and 2023, the Company did not incur any milestone payments
under this agreement. As of both December 31, 2024 and 2023, the accrued minimum royalty and milestone payments were $790, included in
accounts payable in the consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company also agreed to reimburse
patent costs for all documented out of pocket costs associated with the preparation, filing, prosecution and maintenance of patent rights
in the license territory. During the years ended December 31, 2024 and 2023, the Company expensed $0 and $49 respectively, related to
the patent costs reimbursements, included in general and administrative expenses. As of both December 31, 2024 and 2023, the liabilities
for the patent costs reimbursements were $273, included in other accrued expenses and accounts payable.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As of both December 31, 2024 and 2023,
the accrued liabilities for the unpaid interest on the outstanding minimum royalty and milestone payments due to MSK were $169, included
in other accrued expenses. See Note 10 for discussion of the June 2023 demand letter.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;VAZYME License agreement &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In April 2021, the Company entered
into a License Agreement with VAZYME Biotech Co., Ltd (&#x201c;VAZYME&#x201d;) (the &#x201c;VAZYME License Agreement&#x201d;), pursuant to
which the Company was granted an exclusive, perpetual, royalty-bearing, worldwide license under specified patent rights to research, develop
and commercialize VAZYME proprietary anti-SARS-CoV-2 monoclonal antibodies. Unless earlier terminated in accordance with its terms, the
agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Under the VAZYME License Agreement,
the Company agreed to use commercially reasonable efforts to reach certain research and development, and commercialization milestones
for such antibodies. The Company also agreed to pay $200 to VAZYME at the effective date of the agreement. The Company is committed to
pay VAZYME up to $11,100 in milestone payments upon achieving certain research and development events, up to $70,000 in milestone payments
based on annual net sales, and tiered low single-digit percentage royalties based on annualized net sales of each product commercialized
from the collaboration. No &lt;span style="background-color: white"&gt;milestones in the &lt;/span&gt;VAZYME License Agreement &lt;span style="background-color: white"&gt;have
been reached through December 31, 2024.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In December 2021, the Company
entered into a Cooperation Agreement with Chengdu Bio-Innovate Pharmaceutical Technology Co., Ltd (&#x201c;Bio-Innovate&#x201d;) and a
three-way sharing agreement with VAZYME and Bio-Innovate (&#x201c;the Company&#x201d;, &#x201c;VAZYME&#x201d; and
&#x201c;Bio-Innovate&#x201d;, collectively &#x201c;all parties&#x201d;), pursuant to which the Company entrusted Bio-Innovate to perform
certain preclinical testing and all parties agreed that VAZYME will ship the agreed antibodies to Bio-Innovate rather than the
Company to fulfill the requirements under the VAZYME License Agreement.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;For the years ended December 31, 2024 and 2023, the Company
did not incur any expenses related to the VAZYME License Agreement. As of both December 31, 2024 and 2023, the accrued liabilities
under this agreement were $200, included in accounts payable in the consolidated financial statements.&lt;/p&gt;</us-gaap:CommitmentsDisclosureTextBlock>
    <abp:MilestonePayments
      contextRef="c595"
      decimals="-3"
      id="ixv-43561"
      unitRef="usd">244000000</abp:MilestonePayments>
    <abp:ClinicalDevelopmentMilestones contextRef="c34" decimals="-3" id="ixv-43562" unitRef="usd">14000000</abp:ClinicalDevelopmentMilestones>
    <abp:RegulatoryEvents contextRef="c34" decimals="-3" id="ixv-43563" unitRef="usd">80000000</abp:RegulatoryEvents>
    <abp:CommercialSales contextRef="c34" decimals="-3" id="ixv-43564" unitRef="usd">150000000</abp:CommercialSales>
    <us-gaap:LongTermPurchaseCommitmentMilestones contextRef="c34" id="ixv-43565">$3,995</us-gaap:LongTermPurchaseCommitmentMilestones>
    <abp:MilestonePaymentsCommercialMilestones contextRef="c34" decimals="-3" id="ixv-43566" unitRef="usd">12000000</abp:MilestonePaymentsCommercialMilestones>
    <us-gaap:PaymentsForRoyalties
      contextRef="c596"
      decimals="-3"
      id="ixv-43567"
      unitRef="usd">25000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c597"
      decimals="-3"
      id="ixv-43568"
      unitRef="usd">25000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c598"
      decimals="-3"
      id="ixv-43569"
      unitRef="usd">25000</us-gaap:PaymentsForRoyalties>
    <abp:PaymentForExtensionRoyalities contextRef="c34" decimals="-3" id="ixv-43570" unitRef="usd">225000</abp:PaymentForExtensionRoyalities>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c2" decimals="-3" id="ixv-43571" unitRef="usd">200000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <us-gaap:AccruedRoyaltiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-43572" unitRef="usd">200000</us-gaap:AccruedRoyaltiesCurrentAndNoncurrent>
    <abp:DevelopmentMilestones contextRef="c34" decimals="-3" id="ixv-43573" unitRef="usd">32500000</abp:DevelopmentMilestones>
    <abp:AnnualSalesMilestonePayments contextRef="c34" decimals="-3" id="ixv-43574" unitRef="usd">50000000</abp:AnnualSalesMilestonePayments>
    <abp:NetProfitsFromLicensedProductSales contextRef="c34" decimals="2" id="ixv-43575" unitRef="pure">0.50</abp:NetProfitsFromLicensedProductSales>
    <us-gaap:OtherIncome contextRef="c34" decimals="-3" id="ixv-43576" unitRef="usd">3556000</us-gaap:OtherIncome>
    <abp:PaymentOfDevelopmentMilestones
      contextRef="c599"
      decimals="-3"
      id="ixv-43577"
      unitRef="usd">3300000</abp:PaymentOfDevelopmentMilestones>
    <abp:AccruedToAmount contextRef="c34" decimals="-3" id="ixv-43578" unitRef="usd">3300000</abp:AccruedToAmount>
    <abp:MilestonePaymentsUponAchievingRDAndCommercializationEvents
      contextRef="c600"
      decimals="-3"
      id="ixv-43579"
      unitRef="usd">10500000</abp:MilestonePaymentsUponAchievingRDAndCommercializationEvents>
    <abp:MilestonePaymentOnNetSales
      contextRef="c600"
      decimals="-3"
      id="ixv-43580"
      unitRef="usd">30000000</abp:MilestonePaymentOnNetSales>
    <us-gaap:PaymentsForRoyalties
      contextRef="c471"
      decimals="-3"
      id="ixv-43581"
      unitRef="usd">20000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c590"
      decimals="-3"
      id="ixv-43582"
      unitRef="usd">30000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c601"
      decimals="-3"
      id="ixv-43583"
      unitRef="usd">0</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties
      contextRef="c602"
      decimals="-3"
      id="ixv-43584"
      unitRef="usd">20000</us-gaap:PaymentsForRoyalties>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="c301"
      decimals="-3"
      id="ixv-43585"
      unitRef="usd">790000</us-gaap:AccruedRoyaltiesCurrent>
    <abp:MilestonePayments
      contextRef="c603"
      decimals="-3"
      id="ixv-43586"
      unitRef="usd">790000</abp:MilestonePayments>
    <abp:PatentCostsReimbursements contextRef="c34" decimals="-3" id="ixv-43587" unitRef="usd">0</abp:PatentCostsReimbursements>
    <abp:PatentCostsReimbursements contextRef="c35" decimals="-3" id="ixv-43588" unitRef="usd">49000</abp:PatentCostsReimbursements>
    <abp:PatentCostsReimbursements
      contextRef="c303"
      decimals="-3"
      id="ixv-43589"
      unitRef="usd">273000</abp:PatentCostsReimbursements>
    <abp:PatentCostsReimbursements
      contextRef="c604"
      decimals="-3"
      id="ixv-43590"
      unitRef="usd">273000</abp:PatentCostsReimbursements>
    <abp:PatentCostsReimbursements
      contextRef="c605"
      decimals="-3"
      id="ixv-43591"
      unitRef="usd">169000</abp:PatentCostsReimbursements>
    <abp:MilestonePayments
      contextRef="c606"
      decimals="-3"
      id="ixv-43592"
      unitRef="usd">200000</abp:MilestonePayments>
    <abp:MilestonePayments contextRef="c34" decimals="-3" id="ixv-43593" unitRef="usd">11100000</abp:MilestonePayments>
    <abp:MilestonePayments
      contextRef="c597"
      decimals="-3"
      id="ixv-43594"
      unitRef="usd">70000000</abp:MilestonePayments>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="c308"
      decimals="-3"
      id="ixv-43595"
      unitRef="usd">200000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="c607"
      decimals="-3"
      id="ixv-43596"
      unitRef="usd">200000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c34" id="ixv-39312">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Leases&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s leases are for
office and laboratory spaces, classified as operating leases, and laboratory equipment, classified as finance leases.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 19, 2021, in connection
with its laboratory and office space in Woburn, MA, the Company provided to the landlord a standby letter of credit in the amount of $131
(the &#x201c;LOC&#x201d;), which serves as security for the Company&#x2019;s performance of its obligations under the lease and bears interest
at a per annum rate of the U.S. prime rate plus 1%, with the minimum interest rate no less than 4.25%. The letter of credit is automatically
extended without a written amendment for a period of one year, for each and every future expiration date, unless the Company elects not
to extend this letter of credit through November 30, 2025.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The components of lease expense were
as follows as of and for the years ended December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;594&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;594&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9.25pt"&gt;Amortization of ROU assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;638&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;850&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The total cash paid for amounts included
in the measurement of lease liabilities for the years ended December 31, 2024 and 2023 included the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flows from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Lease term and discount rate were as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted-average remaining lease term &lt;i&gt;(in years)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: justify; padding-left: 9.25pt"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.66&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.66&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company had the following future minimum payments due
under its operating lease agreements as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating&lt;br/&gt;
 Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;465&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Obligations under lease liability, noncurrent&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-437"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company had no future minimum payments
due under finance lease agreements as of December 31, 2024.&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:RepaymentsOfLinesOfCredit
      contextRef="c608"
      decimals="-3"
      id="ixv-43597"
      unitRef="usd">131000</us-gaap:RepaymentsOfLinesOfCredit>
    <srt:InterestBearingLiabilitiesAverageRatePaid
      contextRef="c609"
      decimals="2"
      id="ixv-43598"
      unitRef="pure">0.01</srt:InterestBearingLiabilitiesAverageRatePaid>
    <abp:LetterOfCreditExtendedPeriod contextRef="c608" id="ixv-43599">P1Y</abp:LetterOfCreditExtendedPeriod>
    <us-gaap:LeaseCostTableTextBlock contextRef="c34" id="ixv-39327">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The components of lease expense were
as follows as of and for the years ended December 31, 2024 and 2023:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;594&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;594&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Finance lease costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 9.25pt"&gt;Amortization of ROU assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;43&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt"&gt;Interest on lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;16&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;638&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;850&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The total cash paid for amounts included
in the measurement of lease liabilities for the years ended December 31, 2024 and 2023 included the following:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Operating cash flows from operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;566&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Financing cash flows from finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;222&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Lease term and discount rate were as
follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Weighted-average remaining lease term &lt;i&gt;(in years)&lt;/i&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 76%; text-align: justify; padding-left: 9.25pt"&gt;Operating leases&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.73&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.25&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;Weighted-average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Operating leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.66&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.66&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Finance leases&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.50&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c34" decimals="-3" id="ixv-43600" unitRef="usd">594000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c35" decimals="-3" id="ixv-43601" unitRef="usd">594000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c34" decimals="-3" id="ixv-43602" unitRef="usd">43000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization contextRef="c35" decimals="-3" id="ixv-43603" unitRef="usd">240000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c34" decimals="-3" id="ixv-43604" unitRef="usd">1000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense contextRef="c35" decimals="-3" id="ixv-43605" unitRef="usd">16000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost contextRef="c34" decimals="-3" id="ixv-43606" unitRef="usd">638000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c35" decimals="-3" id="ixv-43607" unitRef="usd">850000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c34" decimals="-3" id="ixv-43608" unitRef="usd">566000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c35" decimals="-3" id="ixv-43609" unitRef="usd">500000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseLiability contextRef="c2" decimals="-3" id="ixv-43610" unitRef="usd">130000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability contextRef="c5" decimals="-3" id="ixv-43611" unitRef="usd">222000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-43612">P0Y8M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-43613">P1Y8M23D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2" id="ixv-43614">P0Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c5" id="ixv-43615">P0Y3M</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="4" id="ixv-43616" unitRef="pure">0.0666</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="4" id="ixv-43617" unitRef="pure">0.0666</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="4" id="ixv-43618" unitRef="pure">0.065</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent contextRef="c5" decimals="4" id="ixv-43619" unitRef="pure">0.065</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c34" id="ixv-39526">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company had the following future minimum payments due
under its operating lease agreements as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;For the year ended December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating&lt;br/&gt;
 Leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: justify; padding-bottom: 1.5pt"&gt;2025&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;465&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Total future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;465&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: amount representing interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Present value of future minimum lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;456&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less: current maturities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(456&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Obligations under lease liability, noncurrent&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-437"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c2" decimals="-3" id="ixv-43620" unitRef="usd">465000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="-3" id="ixv-43621" unitRef="usd">465000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="-3" id="ixv-43622" unitRef="usd">9000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="-3" id="ixv-43623" unitRef="usd">456000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" id="ixv-43624" unitRef="usd">456000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c34" id="ixv-39578">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;10&lt;/b&gt;.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Commitments
and Contingencies&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company, from time to time, is
subject to legal proceedings and claims that arise in the ordinary course of business. Resolution of any such matter could have a material
adverse effect on the results of operations and financial condition. The Company considers all claims on a periodic basis and based on
known facts assesses whether potential losses are considered reasonably possible, probable and estimable. Based upon this assessment,
the Company then evaluates disclosure requirements and whether to accrue for such claims in its consolidated financial statements.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company records a provision for
a contingent liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On August 12, 2024, the Company&#x2019;s
landlord filed a court summons for eviction based on the Company&#x2019;s failure to make payments pursuant to one of its lease agreements.
According to the summons, the landlord was claiming the full amount of rental payments over the term of the lease. As of September 30,
2024, the Company owed $186 to the landlord in late rent. On October 21, 2024, the Company paid the landlord $100 for late rent and maintenance
expenses. A court date was scheduled for November 14, 2024, and was subsequently postponed to November 21, 2024. On November 20, 2024,
the Company paid the landlord $115 and on November 25, 2024, the court summons for eviction was dismissed by the landlord. As of December
31, 2024, no amounts were due to the landlord for past due rent.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On September 12, 2023, a contract research
organization (&#x201c;CRO&#x201d;) vendor filed a lawsuit against the Company based on the Company&#x2019;s failure to make certain installments
pursuant to a settlement agreement entered into with this vendor on January 23, 2023. Under the settlement agreement, the Company agreed
to pay a total of $1,644 to the vendor, with $600 due 5 business days after the settlement effective date and ten monthly installments,
approximately $104 each, starting in February 2023. The Company made the upfront payment and the first four monthly installments for a
total of $1,016 but failed to make the monthly installment payments due after May 2023. On January 24, 2024, the Company received the
endorsement on motion for default judgment which requested the Company to pay approximately $700 to the CRO vendor. During the year ended
December 31, 2024, the Company accrued an additional $83 in interest, included in the interest expense. During the year ended December
31, 2024, the Company made an $11 payment to CRO. As of December 31, 2024 and 2023, the outstanding balance under this settlement agreement
was $785 and $751, respectively. These amounts were included in accounts payable and accrued expenses in the consolidated financial statements
as of December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In addition to the lawsuit from a CRO
vendor above, the Company accrued $325 and $379 as of December 31, 2024 and 2023, respectively, related to disputed invoices with vendors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In June 2023, the Company received
a notice of breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded payments totaling $1,230
for the services performed under the MSK License Agreement (see Note 8). The corresponding liability is included in accounts payable and
accrued expenses in the consolidated financial statements as of both December 31, 2024 and 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The MedImmune License Agreement (see
Note 8) provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement (December 2022). These
target dates were not met, which gives MedImmune (now AstraZeneca) a termination right. The Company does not expect a material impact
on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with the development
of ABP-200, which the Company is no longer developing. The Company believes that it does not need the intellectual property licensed under
that agreement for the development and eventual commercialization of ABP-201 or any of its other programs.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Non-Redemption Agreement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 5, 2024, Legacy Abpro and
ACAB entered into a non-redemption agreement (the &#x201c;Non-Redemption Agreement&#x201d;), with Sandia Investment Management LP on behalf
of certain funds, investors, entities or accounts for which it or its affiliates acts as manager, sponsor or advisor (the &#x201c;NRA Investors&#x201d;).
Pursuant to such Non-Redemption Agreement, each NRA Investor agreed to rescind or reverse any previously submitted redemption demand of
the common stock of the Company held or to be acquired by such NRA Investor (the &#x201c;NRA Investor Shares&#x201d;) up to 4,145 shares
of common stock in the aggregate.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;At the Closing Date, the NRA Investors
reversed redemption demands with respect to 11,043 Series A Common stock shares of ACAB. Pursuant to the Non-Redemption Agreement, upon
consummation of the Merger, the Company had to pay to the NRA Investors a payment equal to the number of NRA Investor Shares multiplied
by the redemption price, minus the number of NRA Investor Shares multiplied by $9.00 (pre-split). At the Closing Date, the Company owed
to NRA Investors $26, based on the redemption price of $340.80 at the Closing Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Excise Tax Liability&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;At the Closing Date, the Company assumed
the excise tax liability of $4,330, as adjusted as discussed further below, from ACAB related to the redemptions of shares in 2023 and
calculated as 1% of the shares redeemed during fiscal year 2023.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On August 16, 2022, the Inflation Reduction
Act of 2022 (the &#x201c;IR Act&#x201d;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1%
excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly
traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not
its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares
repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted
to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable
year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#x201c;Treasury&#x201d;) has been
given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;During the second quarter of
2024, the IRS issued final regulations with respect to the timing and payment of the excise tax. Pursuant to those regulations, the
Company would need to file a return and remit payment for any liability incurred during the period from January 1, 2023 to December
31, 2023 on or before October 31, 2024. The Company has filed the excise tax return and has engaged with the IRS in determining a
payment plan for the balance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company is unable to pay its obligation
in full, and, as such, it will be subject to additional interest and penalties which are currently estimated at 8% interest per annum
and a 0.5% underpayment penalty per month or portion of a month up to 25% of the total liability for any amount that is unpaid from November
1, 2024 until paid in full. The Company accrued $71 in penalties and interest through December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In March 2025, the Company received
the letter from the Internal Revenue Service of the United States Department of Treasury (the &#x201c;IRS&#x201d;), setting up the meeting
with the Company to discuss the unsettled tax matters of ACAB and referencing $4,401 amount owed in relation to the 2023 excise taxes,
of which $210 in interest and penalties. The Company believes that the excise tax liability in the IRS Letter is overstated as compared
to the amounts in ACAB&#x2019;s filed tax return for the year ended December 31, 2023, and is planning to request further information from
the IRS to reconcile the amounts reported to the Company&#x2019;s records. Pending further discussions with the IRS, the Company recorded
the excess of $1,268 over the Company&#x2019;s estimate as the additional excise tax liability assumed from ACAB in the consolidated financial
statements as of December 31, 2024.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:PaymentsForRent contextRef="c34" decimals="-3" id="ixv-43625" unitRef="usd">186000</us-gaap:PaymentsForRent>
    <abp:PaymentOfRentAndMaintenanceExpense
      contextRef="c610"
      decimals="-3"
      id="ixv-43626"
      unitRef="usd">100000</abp:PaymentOfRentAndMaintenanceExpense>
    <abp:PaymentOfRentAndMaintenanceExpense
      contextRef="c611"
      decimals="-3"
      id="ixv-43627"
      unitRef="usd">115000</abp:PaymentOfRentAndMaintenanceExpense>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="c612"
      decimals="-3"
      id="ixv-43628"
      unitRef="usd">1644000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="c613"
      decimals="-3"
      id="ixv-43629"
      unitRef="usd">600000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="c311"
      decimals="-3"
      id="ixv-43630"
      unitRef="usd">104000</us-gaap:PaymentsForLegalSettlements>
    <abp:MonthlyInstallmentPayments
      contextRef="c312"
      decimals="-3"
      id="ixv-43631"
      unitRef="usd">1016000</abp:MonthlyInstallmentPayments>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="c313"
      decimals="-3"
      id="ixv-43632"
      unitRef="usd">700000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="c614"
      decimals="-3"
      id="ixv-43633"
      unitRef="usd">83000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsForFees contextRef="c34" decimals="-3" id="ixv-43634" unitRef="usd">11000</us-gaap:PaymentsForFees>
    <us-gaap:SettlementLiabilitiesCurrent contextRef="c2" decimals="-3" id="ixv-43635" unitRef="usd">785000</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementAssetsCurrent contextRef="c5" decimals="-3" id="ixv-43636" unitRef="usd">751000</us-gaap:SettlementAssetsCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c2" decimals="-3" id="ixv-43637" unitRef="usd">325000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c5" decimals="-3" id="ixv-43638" unitRef="usd">379000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:GainLossOnContractTermination
      contextRef="c600"
      decimals="-3"
      id="ixv-43639"
      unitRef="usd">1230000</us-gaap:GainLossOnContractTermination>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c322"
      decimals="0"
      id="ixv-43640"
      unitRef="shares">4145</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c615"
      decimals="0"
      id="ixv-43641"
      unitRef="shares">11043</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c616"
      decimals="2"
      id="ixv-43642"
      unitRef="usdPershares">9</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CapitalUnitsTotalCostToInvestors
      contextRef="c616"
      decimals="-3"
      id="ixv-43643"
      unitRef="usd">26000</us-gaap:CapitalUnitsTotalCostToInvestors>
    <us-gaap:TemporaryEquityRedemptionPricePerShare
      contextRef="c616"
      decimals="2"
      id="ixv-43644"
      unitRef="usdPershares">340.8</us-gaap:TemporaryEquityRedemptionPricePerShare>
    <abp:ExciseTaxLiability contextRef="c34" decimals="-3" id="ixv-43645" unitRef="usd">4330000</abp:ExciseTaxLiability>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed contextRef="c34" decimals="2" id="ixv-43646" unitRef="pure">0.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c325"
      decimals="2"
      id="ixv-43647"
      unitRef="pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <abp:ExciseTaxGenerallyOfTheFairMarketValuePercentage
      contextRef="c326"
      decimals="2"
      id="ixv-43648"
      unitRef="pure">0.01</abp:ExciseTaxGenerallyOfTheFairMarketValuePercentage>
    <us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate contextRef="c34" decimals="2" id="ixv-43649" unitRef="pure">0.08</us-gaap:ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate>
    <abp:PercentageOfUnderpaymentPenaltyPerMonth contextRef="c34" decimals="3" id="ixv-43650" unitRef="pure">0.005</abp:PercentageOfUnderpaymentPenaltyPerMonth>
    <abp:PercentageOfLiabilityTotal contextRef="c34" decimals="2" id="ixv-43651" unitRef="pure">0.25</abp:PercentageOfLiabilityTotal>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued contextRef="c2" decimals="-3" id="ixv-43652" unitRef="usd">71000</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:ExciseAndSalesTaxes
      contextRef="c599"
      decimals="-3"
      id="ixv-43653"
      unitRef="usd">4401000</us-gaap:ExciseAndSalesTaxes>
    <us-gaap:IncomeTaxExaminationInterestExpense
      contextRef="c599"
      decimals="-3"
      id="ixv-43654"
      unitRef="usd">210000</us-gaap:IncomeTaxExaminationInterestExpense>
    <us-gaap:ExciseAndSalesTaxes contextRef="c34" decimals="-3" id="ixv-43655" unitRef="usd">1268000</us-gaap:ExciseAndSalesTaxes>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c34" id="ixv-39665">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Forward
Purchase Agreement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 7, 2024, ACAB and Legacy Abpro entered into a Confirmation
of an OTC Equity Prepaid Forward Transaction (the &#x201c;Forward Purchase Agreement&#x201d; or &#x201c;Transaction&#x201d;) with YA (the
&#x201c;Seller&#x201d;) to which a maximum of up to 16,667 common stock shares will be subject. At the Closing Date, the Seller purchased
3,333 shares from third parties (&#x201c;Recycled Shares&#x201d;), pursuant to the pricing date notice dated November 12, 2024 and paid
approximately $1.1 million (the &#x201c;Prepayment Amount&#x201d;) equal to $340.80 per Recycled Share (the &#x201c;Initial Price&#x201d;)
to the redeeming shareholders. Pursuant to the terms of the Forward Purchase Agreement, at the Closing Date, the Company remitted the
Prepayment Amount into an escrow account for the benefit of the Seller.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The number of Recycled Shares subject
to the Forward Purchase Agreement was also subject to reduction following a termination of the Forward Purchase Agreement with respect
to such shares as described under &#x201c;Optional Early Termination&#x201d; as discussed below. The contract was to settle based on the
settlement terms discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;Optional Early Termination&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;From time to time and on any date following
the Closing Date (any such date, an &#x201c;OET Date&#x201d;) and subject to the terms and conditions in the Forward Purchase Agreement
(&#x201c;Optional Early Termination&#x201d;), the Seller may, in its absolute discretion, terminate the Transaction in whole or in part
by providing written notice to the Company (the &#x201c;OET Notice&#x201d;), by no later than the next payment date following the OET Date,
(which will specify the quantity by which the Number of Shares will be reduced (such quantity, the &#x201c;Terminated Shares&#x201d;)).
The effect of an OET Notice would be to reduce the Number of Shares by the number of Terminated Shares specified in such OET Notice with
effect as of the related OET Date. As of each OET Date, the Company would be entitled to an amount from the Seller, and the Seller would
pay to the Company an amount, equal to the product of (x) the number of Terminated Shares and (y) the reset price in respect of such OET
Date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The reset price (the &#x201c;Reset Price&#x201d;)
was initially $300.00. The Reset Price was subject to reset on a weekly basis commencing with the first full week following the Closing
Date, to be the lowest of (a) the then current Reset Price, (b) $300.00 and (c) the VWAP price of the shares of the last 3 trading days
in such week; provided, that in the event of a dilutive offering by the Company, the Reset Price will also be reduced to equal the effective
price per share in such dilutive offering immediately upon the occurrence of such dilutive offering.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;Settlement &lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On the Cash Settlement Payment Date,
which is the tenth local business day immediately following the Valuation Date (defined below), the Seller had to remit to the Company
a cash amount (the &#x201c;Settlement Amount&#x201d;) equal to (i) the Number of Shares as of the Valuation Date, multiplied by (ii) the
difference of (a) the volume weighted daily VWAP price over the Valuation Period, less (b) $15.00, and the Seller will not otherwise be
required to return to the Counterparty any of the Prepayment Amount. In the event that the difference of (a) the volume weighted daily
VWAP Price over the Valuation Period, less (b) $15.00, is equal to or less than $0, then the Settlement Amount shall be $0. The &#x201c;Valuation
Date&#x201d; is the earliest to occur of (a) the date that is 3 months after the Closing Date and (b) the date specified by the Seller
in a written notice to be delivered to the Company at the Seller&#x2019;s discretion (which Valuation Date will not be earlier than the
day such notice is effective) after the occurrence of any of (x) a VWAP Trigger Event, (y) a Delisting Event or (z) unless otherwise specified
therein, upon any Additional Termination Event (defined below). Each of the following was to constitute an Additional Termination Event;
(a) The Merger Agreement is terminated pursuant to its terms prior to the closing of the Merger; and (b) If it is, or, as a consequence
of a change in law, regulation or interpretation, it becomes or will become, unlawful for the Seller to perform any of its obligations
contemplated by the Transaction.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Forward Purchase Agreement was
accounted for at fair value as an asset in accordance with the guidance in ASC 815, with subsequent changes in the fair value recorded
in profits and losses. The fair value of the Forward Purchase Agreement asset was $494 and $155 as of November 13, 2024 and December 31,
2024, respectively. The loss on the change in the fair value of $339 was recorded in other (expense) income during the year ended December
31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On January 28, 2025, YA elected to
effect an Optional Early Termination with respect to all 3,333 Shares subject to the Forward Purchase Agreement which terminated the agreement
as a whole. YA paid the Company the Early Termination Obligation in the aggregate amount of $132, based on the Reset Price of $39.60 in
effect on January 28, 2025.&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ForwardContractIndexedToIssuersEquityShares
      contextRef="c617"
      decimals="0"
      id="ixv-43656"
      unitRef="shares">16667</us-gaap:ForwardContractIndexedToIssuersEquityShares>
    <us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue
      contextRef="c618"
      decimals="0"
      id="ixv-43657"
      unitRef="shares">3333</us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue>
    <us-gaap:PrepaidRoyalties
      contextRef="c618"
      decimals="-5"
      id="ixv-43658"
      unitRef="usd">1100000</us-gaap:PrepaidRoyalties>
    <us-gaap:ForwardContractIndexedToEquitySettlementShareFairValuePerShare
      contextRef="c618"
      decimals="2"
      id="ixv-43659"
      unitRef="usdPershares">340.8</us-gaap:ForwardContractIndexedToEquitySettlementShareFairValuePerShare>
    <abp:ForwardContractInitialResetPricePerShare
      contextRef="c34"
      decimals="2"
      id="ixv-43660"
      unitRef="usdPershares">300</abp:ForwardContractInitialResetPricePerShare>
    <abp:ForwardContractBaseResetPricePerShare
      contextRef="c34"
      decimals="2"
      id="ixv-43661"
      unitRef="usdPershares">300</abp:ForwardContractBaseResetPricePerShare>
    <abp:NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare contextRef="c34" id="ixv-43662">P3D</abp:NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare>
    <abp:VolumeWeightedAveragePrice
      contextRef="c2"
      decimals="2"
      id="ixv-43663"
      unitRef="usdPershares">15</abp:VolumeWeightedAveragePrice>
    <abp:SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount
      contextRef="c34"
      decimals="-3"
      id="ixv-43664"
      unitRef="usdPershares">0</abp:SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount>
    <us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue contextRef="c2" decimals="-3" id="ixv-43665" unitRef="usd">0</us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c619"
      decimals="-3"
      id="ixv-43666"
      unitRef="usd">494000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c620"
      decimals="-3"
      id="ixv-43667"
      unitRef="usd">155000</us-gaap:AssetsFairValueDisclosure>
    <abp:DerivativeChangeInFairValue contextRef="c34" decimals="-3" id="ixv-43668" unitRef="usd">339000</abp:DerivativeChangeInFairValue>
    <us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue
      contextRef="c484"
      decimals="0"
      id="ixv-43669"
      unitRef="shares">3333</us-gaap:ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue>
    <us-gaap:GainLossOnContractTermination
      contextRef="c485"
      decimals="-3"
      id="ixv-43670"
      unitRef="usd">132000</us-gaap:GainLossOnContractTermination>
    <abp:EarlyTerminationResetPricePerShare
      contextRef="c484"
      decimals="2"
      id="ixv-43671"
      unitRef="usdPershares">39.6</abp:EarlyTerminationResetPricePerShare>
    <us-gaap:DebtDisclosureTextBlock contextRef="c34" id="ixv-39717">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Notes
Payable - Related Parties&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;Promissory Note with ABI&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On October 18, 2023, the Company entered
into a promissory note agreement with ABI, a significant investor in the Company, to receive up to $6,000. The promissory note accrues
interest at a rate of 5% per annum on the principal amount of each installment from the installment funding date until the maturity date
and at a rate of 7% per annum after the maturity date if any amounts then remain outstanding. The &#x201c;Maturity Date&#x201d; is defined
in the agreement as the earlier of (i) eighteen months from the funding date and (ii) the successful closing of the Merger. On August
22, 2024, ACAB entered into the Abpro Bio Subscription Agreement (see Note 3) with ABI, pursuant to which ABI purchased 20,749 shares of the Company&#x2019;s common stock, concurrently with the closing of the Merger at a price of $300.00 per share, for an aggregate
purchase price of $6,225, of which $4,225 was paid through the conversion of the balance due by the Company to ABI under the promissory
note agreement and the remainder of $2,000 in cash. In addition, ABI received an aggregate of 41,498 Incentive Shares.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On October 7, 2024, the Company entered
into an additional promissory note with ABI (&#x201c;the 2024 ABI Note&#x201d;) to receive up to $1,000 from ABI in weekly installments
of $250. The note accrued 10% interest and had a maturity date 5 business days after receipt of the proceeds under the PIPE Financing
(see Note 3). The Company received $1,000 under this note through the Closing Date, and the balance of $1,000 was repaid at the Closing
from the PIPE Financing proceeds.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As of December 31, 2024 and 2023,
the outstanding principal balances under the promissory notes with ABI was $0 and $1,442, respectively. During the years ended
December 31, 2024 and 2023, the Company recorded $186 and $5, respectively, of interest expense on these promissory notes with ABI.
As of December 31, 2024 and 2023, accrued interest totaling $191 and $5, respectively, is included in accrued expenses in the
consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;Promissory Notes with Executive
and Director&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On December 29, 2023, the Company issued
promissory notes to one of its executives and one of its directors, in the principal amount of $176 and $124, respectively, for deferred
bonuses. Amounts under the promissory notes plus accrued interest are due and payable on the earlier of (i) the closing of the Merger
and (ii) June 29, 2025. These promissory notes accrue interest at 5% per annum until the maturity date and 7% thereafter. At the Closing
Date, the Company paid $150 towards these promissory notes. As of December 31, 2024 and 2023, $147 and $300, respectively, of principal
was outstanding. Accrued interest on these promissory notes totaled $14 and $0 as of December 31, 2024 and 2023, respectively, included
in accrued expenses in the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;On April 18, 2024, the Company entered
into a separate promissory note agreement with the same executive to receive, as amended, up to $2,158 in funding. During the year ended
December 31, 2024, the Company received $1,997 from the executive under this agreement. These advances accrued interest at 7.5% per annum
through the maturity date and at 9.5% per annum after the maturity date if any amounts then remain outstanding. All advances, plus accrued
interest, were due and payable on the earlier of (i) the closing of the Merger and (ii) November 20, 2024. At the Closing, the outstanding
promissory notes of $1,997 were converted into 20,000 newly issued common stock shares. Accrued interest on these promissory notes totaled
$62 and $0 as of December 31, 2024 and 2023, respectively, included in accrued expenses in the consolidated balance sheets.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;Pursuant to the terms of the promissory
note, the Company agreed to cause to be issued to the executive a number of New Abpro stock options or warrants in an amount equal to
the outstanding principal amount of such promissory note, subject to required approval by the New Abpro Board of Directors and Compensation
Committee and registration of such securities on Form S-8. On February 7, 2025, the Company issued 28,333 common stock warrants to an
executive. The warrants are exercisable at $99.90 per share and bear an expiration date of February 7, 2035. The warrants are exercisable
as follows: 14,166 warrants are exercisable on the issuance date, 6,667 warrants become exercisable on the one-year anniversary of the
issuance date, and 7,500 warrants become exercisable on the two-year anniversary of the issuance date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"&gt;&lt;i&gt;Promissory Note with ACAB Executive&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On August 16, 2024, an executive at
ACAB agreed to loan Legacy Abpro $103 under a promissory note (the &#x201c;ACAB Executive Note&#x201d;). The ACAB Executive Note did not
accrue interest and the Company agreed to repay a total of $206 at the earlier of i) November 20, 2024, and ii) the closing of the Merger.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 21, 2024, the ACAB Executive
Note was amended to clarify that it should have been for the benefit of ACAB. Pursuant to the Severance Agreement (see Note 17), the liability
to the ACAB executive was cancelled. According to the terms of the amended note, Legacy Abpro was to repay the principal amount of $103.
The note did not bear interest and was payable upon demand on or before December 31, 2024. The note balance was eliminated in consolidation
at the Closing Date and December 31, 2024.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c337"
      decimals="-3"
      id="ixv-43672"
      unitRef="usd">6000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c338"
      decimals="2"
      id="ixv-43673"
      unitRef="pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c339"
      decimals="2"
      id="ixv-43674"
      unitRef="pure">0.07</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c340"
      decimals="0"
      id="ixv-43675"
      unitRef="shares">20749</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="c341"
      decimals="2"
      id="ixv-43676"
      unitRef="usdPershares">300</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c340"
      decimals="-3"
      id="ixv-43677"
      unitRef="usd">6225000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <abp:ConversionOfConsiderationUnderPromissoryNoteAgreement
      contextRef="c340"
      decimals="-3"
      id="ixv-43678"
      unitRef="usd">4225000</abp:ConversionOfConsiderationUnderPromissoryNoteAgreement>
    <us-gaap:Cash
      contextRef="c341"
      decimals="-3"
      id="ixv-43679"
      unitRef="usd">2000000</us-gaap:Cash>
    <abp:IncentiveSharesReceivedBySubsidiary
      contextRef="c340"
      decimals="0"
      id="ixv-43680"
      unitRef="shares">41498</abp:IncentiveSharesReceivedBySubsidiary>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c342"
      decimals="-3"
      id="ixv-43681"
      unitRef="usd">1000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="c343"
      decimals="-3"
      id="ixv-43682"
      unitRef="usd">250000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c343"
      decimals="2"
      id="ixv-43683"
      unitRef="pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c343"
      decimals="-3"
      id="ixv-43684"
      unitRef="usd">1000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c343"
      decimals="-3"
      id="ixv-43685"
      unitRef="usd">1000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NotesPayable
      contextRef="c345"
      decimals="-3"
      id="ixv-43686"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="c621"
      decimals="-3"
      id="ixv-43687"
      unitRef="usd">1442000</us-gaap:NotesPayable>
    <us-gaap:InterestExpenseDebt
      contextRef="c528"
      decimals="-3"
      id="ixv-43688"
      unitRef="usd">186000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="c622"
      decimals="-3"
      id="ixv-43689"
      unitRef="usd">5000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestPayableCurrent
      contextRef="c345"
      decimals="-3"
      id="ixv-43690"
      unitRef="usd">191000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c621"
      decimals="-3"
      id="ixv-43691"
      unitRef="usd">5000</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="c349"
      decimals="-3"
      id="ixv-43692"
      unitRef="usd">176000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentIssuedPrincipal
      contextRef="c350"
      decimals="-3"
      id="ixv-43693"
      unitRef="usd">124000</us-gaap:DebtInstrumentIssuedPrincipal>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c351"
      decimals="2"
      id="ixv-43694"
      unitRef="pure">0.05</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c352"
      decimals="2"
      id="ixv-43695"
      unitRef="pure">0.07</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c353"
      decimals="-3"
      id="ixv-43696"
      unitRef="usd">150000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NotesPayable
      contextRef="c623"
      decimals="-3"
      id="ixv-43697"
      unitRef="usd">147000</us-gaap:NotesPayable>
    <us-gaap:NotesPayable
      contextRef="c624"
      decimals="-3"
      id="ixv-43698"
      unitRef="usd">300000</us-gaap:NotesPayable>
    <us-gaap:InterestPayableCurrent
      contextRef="c355"
      decimals="-3"
      id="ixv-43699"
      unitRef="usd">14000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c624"
      decimals="-3"
      id="ixv-43700"
      unitRef="usd">0</us-gaap:InterestPayableCurrent>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c360"
      decimals="-3"
      id="ixv-43701"
      unitRef="usd">2158000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c361"
      decimals="-3"
      id="ixv-43702"
      unitRef="usd">1997000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c362"
      decimals="3"
      id="ixv-43703"
      unitRef="pure">0.075</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c363"
      decimals="3"
      id="ixv-43704"
      unitRef="pure">0.095</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:NotesPayable
      contextRef="c367"
      decimals="-3"
      id="ixv-43705"
      unitRef="usd">1997000</us-gaap:NotesPayable>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="c625"
      decimals="0"
      id="ixv-43706"
      unitRef="shares">20000</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:InterestPayableCurrent
      contextRef="c367"
      decimals="-3"
      id="ixv-43707"
      unitRef="usd">62000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c626"
      decimals="-3"
      id="ixv-43708"
      unitRef="usd">0</us-gaap:InterestPayableCurrent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c627"
      decimals="-3"
      id="ixv-43709"
      unitRef="shares">28333000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c628"
      decimals="2"
      id="ixv-43710"
      unitRef="usdPershares">99.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="c629" id="ixv-43711">2035-02-07</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c630"
      decimals="0"
      id="ixv-43712"
      unitRef="shares">14166</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c631"
      decimals="0"
      id="ixv-43713"
      unitRef="shares">6667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c632"
      decimals="0"
      id="ixv-43714"
      unitRef="shares">7500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c379"
      decimals="-3"
      id="ixv-43715"
      unitRef="usd">103000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c380"
      decimals="-3"
      id="ixv-43716"
      unitRef="usd">206000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentMaturityDate contextRef="c380" id="ixv-43717">2024-11-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentRepaidPrincipal
      contextRef="c381"
      decimals="-3"
      id="ixv-43718"
      unitRef="usd">103000</us-gaap:DebtInstrumentRepaidPrincipal>
    <abp:StandbyEquityPurchaseAgreementTextBlock contextRef="c34" id="ixv-39786">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Standby
Equity Purchase Agreement&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;Convertible Notes&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On October 30, 2024, Legacy Abpro and
ACAB entered into a Standby Equity Purchase Agreement (the &#x201c;SEPA&#x201d;) with YA II PN, Ltd. (&#x201c;YA&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Subject to the satisfaction of the
conditions set forth in the SEPA, YA committed to advance to the Company the aggregate principal amount of up to $5,000 (the &#x201c;Pre-Paid
Advance&#x201d;), which shall be evidenced by convertible promissory notes (each a &#x201c;Convertible Note&#x201d;). On November 14, 2024,
the Company received the first Pre-Paid Advance and entered into a Convertible Note (defined below). The second Pre-Paid Advance shall
be in a principal amount of $2,000 and advanced on the later of (i) the second trading day after the initial registration statement filed
pursuant to the Registration Rights Agreement (as defined below) becomes effective and (ii) the second trading day after the required
shareholder approval to issue shares of the post-combination Company&#x2019;s common stock in excess of 20% of the Company&#x2019;s outstanding
shares pursuant to Nasdaq Rules (the &#x201c;Exchange Cap&#x201d;) has been obtained. At the special meeting of stockholders held on April
8, 2025, the Company obtained stockholder approval for the issuance of shares over the Exchange Cap.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 14, 2024 (the &#x201c;Issuance
Date&#x201d;), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the &#x201c;Convertible Note&#x201d;) with YA
for $3,000 and received net proceeds of $2,755, net of the original issuance discount of 8% (the &#x201c;Convertible Note Discount&#x201d;).
The Convertible Note has a maturity of November 13, 2025 (subject to earlier repayments based on Amortization Event described below),
incurs interest at a rate of 0% (or 18% upon the occurrence of an uncured Event of Default).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Convertible Notes are convertible
at the option of the holder at any time after the Issuance Date based on the conversion price determined as the lower of (i) $345.00 per
Common Share (the &#x201c;Fixed Price&#x201d;), or (ii) 94% of the lowest daily VWAP during the 5 consecutive trading days immediately preceding
the conversion date (the &#x201c;Variable Price&#x201d;), but which Variable Price shall not be lower than the Floor Price then in effect
(the &#x201c;Conversion Feature&#x201d;). The Floor Price at the Issuance Date was $34.62 per share calculated as 20% of the closing price
of the Company&#x2019;s stock on November 12, 2024. The Floor Price was adjusted downward to $5.70 on February 12, 2025 when the initial
registration statement was declared effective by the SEC. The conversion is subject to the limitations including beneficial ownership
limitation, principal market limitation and monthly conversion limits. If the Company, at any time while the Convertible Note is outstanding,
shall issue any Common Shares (other than pursuant to the SEPA) for no consideration or for a price per share that is lower than the Fixed
Price then in effect, the Fixed Price shall be reduced to equal the lowest price per share of such issuances.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Convertible Note is redeemable
at the option of the Company if the volume-weighted-average price (&#x201c;VWAP&#x201d;) of the Company&#x2019;s Common Stock is less than
$345.00 which may be adjusted downward upon payment of stock dividend, stock split or reclassification, or if the Company issues common
stock for no consideration or at a price lower than the then-effective Fixed Price.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Under the terms of the Convertible
Notes, the Amortization Event occurs if i) the daily VWAP is less than the Floor Price for &lt;span style="-sec-ix-hidden: hidden-fact-438"&gt;five&lt;/span&gt; trading days during a period of &lt;span style="-sec-ix-hidden: hidden-fact-439"&gt;seven&lt;/span&gt;
consecutive trading days (a &#x201c;Floor Price Event&#x201d;), (ii) unless the Company has obtained the approval from its stockholders
for the issuance of shares pursuant to the transactions contemplated in the SEPA in excess of the Exchange Cap, the Company has issued
in excess of 99% of the Common Shares available under the Exchange Cap (an &#x201c;Exchange Cap Event&#x201d;), or (iii) any time after
the Effectiveness Deadline (as defined in the Registration Rights Agreement entered into in relation to the SEPA), YA is unable to utilize
a Registration Statement to resell Underlying Shares for a period of 10 consecutive trading days (a &#x201c;Registration Event&#x201d;).
If at any time after the Issuance Date, and from time to time thereafter, an Amortization Event occurs, then the Company shall make monthly
payments beginning on the 7th trading day after the Amortization Event Date and continuing on the same day of each successive month. Each
monthly payment shall be in an amount equal to the sum of (i) $1,250 of principal in the aggregate among the Convertible Note (or the
outstanding principal if less than such amount) (the &#x201c;Amortization Principal Amount&#x201d;), plus (ii) the payment premium equal
to 5% of the Amortization Principal Amount, and (iii) accrued and unpaid interest hereunder as of each payment date. The obligation of
the Company to make monthly prepayments related to an Amortization Event shall cease (with respect to any payment that has not yet come
due) if any time after the Amortization Date (A) in the event of a Floor Price Event, on the date that is the 7th consecutive trading
day that the daily VWAP is greater than the Floor Price then in effect, or the date that the Company reduces the Floor Price in accordance
with the terms of this Note, (B) in the event of a Registration Event, the condition or event causing the Registration Event has been
cured or the Holder is able to resell the Common Shares issuable upon conversion of this Note without limitations in accordance with Rule
144 under the Securities Act, or (C) in the event of an Exchange Cap Event, the date the Company has obtained stockholder approval to
increase the number of Common Shares under the Exchange Cap and/or the Exchange Cap no longer applies, unless a subsequent Amortization
Event occurs. No Amortization Event occurred through December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;It was determined, in accordance with
ASC 815, that the Conversion Feature is required to be bifurcated due to the adjustments to the settlement amount of this embedded feature
that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares, and should be recorded as a
liability (the &#x201c;Embedded Derivative Liability&#x201d;) at fair value with a corresponding amount recorded as a discount on the Convertible
Notes. The Embedded Derivative Liability is marked to market at each reporting period end with any changes recorded in other income or
expense. The fair value of the Embedded Derivative Liability was estimated at $69 at the issuance date based on the difference between
the fair value of the convertible note with these embedded features and the fair value without each one of these embedded features.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The increase in the fair value of the
Embedded Derivative Liability was $11, between the issuance date and December 31, 2024, and was included in other (expense) income in
the consolidated statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The total discount resulting from the
Convertible Note Discount and the bifurcation of the Embedded Derivative Liability at the Issuance Date was amortized over the term of
the Convertible Notes through non-cash interest expense using the effective interest method. The non-cash interest expense related to
the discount amortization was $39 for the year ended December 31, 2024 and is included within interest expense in the consolidated statement
of operations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;i&gt;SEPA Put Rights&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Under the terms of the SEPA, starting
at the Closing Date, the Company has the right, but not the obligation (&#x201c;SEPA Put Rights&#x201d;), to issue shares of its common
stock to YA (&#x201c;Advance Shares&#x201d;, and such issuance and sale, an &#x201c;Advance&#x201d;) and YA shall subscribe for and purchase
from the Company such Advance Shares, through written notice by the Company to YA (&#x201c;Advance Notice&#x201d;), provided (i) no balance
is outstanding under a Convertible Note, or (ii) if there is a balance outstanding under a Convertible Note, an Amortization Event (as
defined above), has occurred in accordance with and subject to the terms of the SEPA. The SEPA contemplates purchase by YA of up to $50
million in aggregate gross purchase price for newly issued shares of the Company&#x2019;s common stock. If any amount remains outstanding
under a Convertible Note, without the prior written consent of YA, the Company may only (other than with respect to a deemed Advance Notice
pursuant to an Investor Notice (described below)) submit an Advance Notice (A) if an Amortization Event has occurred and the obligation
of the Company to make monthly prepayments under the Convertible Note has not ceased, and (B) YA pays the aggregate purchase price owed
by the Company from such Advance by offsetting the amount of the Advance Proceeds against an equal amount outstanding under the subject
Convertible Note. Any such sales would be subject to certain limitations, including that YA could not purchase any shares that would result
in it owning more than 4.99% of the Company&#x2019;s common stock, or any shares that, aggregated with any related transaction, would exceed
19.9% of all shares of common stock outstanding on the date of the SEPA unless shareholder approval was obtained allowing for issuances
in excess of such amount.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;For as long as there is an outstanding
balance under a Convertible Note, YA has the right, but not the obligation, by delivery to the Company of Investor Notices (as defined
in the SEPA), to cause an Advance Notice to be deemed delivered by YA, which triggers the issuance and sale of Advance Shares to YA, subject
to terms and conditions as specified in the SEPA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The purchase price for the Advance
Shares shall be the price per Advance Share obtained by multiplying the Company&#x2019;s stock price (i) by 96% in respect of an Advance
Notice delivered by the Company with an Option 1 Pricing Period (defined by reference to VWAP on the trading day the Advance Notice is
submitted), (ii) 97% in respect of an Advance Notice with an Option 2 Pricing Period (defined by reference to the lowest daily VWAP on
&lt;span style="-sec-ix-hidden: hidden-fact-440"&gt;three&lt;/span&gt; consecutive trading days commencing on the Advance Notice Date), or (iii) in the case of any Advance Notice delivered pursuant to
an Investor Notice, equal to the Conversion Price (as defined in the Convertible Note).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company accounted for the SEPA
Put Rights as an asset at fair value in accordance with the guidance in ASC 815, due to the adjustments to the settlement amount of this
derivative instrument that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares. The fair
value of the SEPA Put Rights was $1,551 and $188 as of the Closing Date and December 31, 2024, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As consideration for YA&#x2019;s commitment
to purchase shares of common stock, upon execution of the SEPA, the Company engaged to remit YA the commitment fee of $500,000. In December
2024, the Company issued to YA 9,905 shares of common stock in settlement of the commitment fee obligation. The fair value of the shares
issued to YA was $327 at their issuance date and the difference of $173 was recorded as a Gain on extinguishment of accrued liabilities.
The excess of the fair value of the SEPA Put Rights above the commitment fee at the issuance date was included in the change in fair value
of SEPA put rights in the consolidated statement of operations for the year ended December 31, 2024.&lt;/p&gt;</abp:StandbyEquityPurchaseAgreementTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c382"
      decimals="-3"
      id="ixv-43719"
      unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="c383"
      decimals="-3"
      id="ixv-43720"
      unitRef="usd">2000000</us-gaap:DebtInstrumentFaceAmount>
    <abp:ExcessOfCommonStockPercentage
      contextRef="c383"
      decimals="2"
      id="ixv-43721"
      unitRef="pure">0.20</abp:ExcessOfCommonStockPercentage>
    <us-gaap:ConvertibleDebt
      contextRef="c383"
      decimals="-3"
      id="ixv-43722"
      unitRef="usd">3000000</us-gaap:ConvertibleDebt>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="c384"
      decimals="-3"
      id="ixv-43723"
      unitRef="usd">2755000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c385"
      decimals="2"
      id="ixv-43724"
      unitRef="pure">0.08</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c633"
      decimals="2"
      id="ixv-43725"
      unitRef="pure">0</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="c634"
      decimals="2"
      id="ixv-43726"
      unitRef="pure">0.18</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c2"
      decimals="2"
      id="ixv-43727"
      unitRef="usdPershares">345</us-gaap:SaleOfStockPricePerShare>
    <abp:PercentageOfVolumeWeightedAveragePrice
      contextRef="c633"
      decimals="2"
      id="ixv-43728"
      unitRef="pure">0.94</abp:PercentageOfVolumeWeightedAveragePrice>
    <abp:ConvertibleThresholdConsecutiveTradingDays contextRef="c635" id="ixv-43729">P5Y</abp:ConvertibleThresholdConsecutiveTradingDays>
    <us-gaap:SharePrice
      contextRef="c635"
      decimals="2"
      id="ixv-43730"
      unitRef="usdPershares">34.62</us-gaap:SharePrice>
    <abp:PercentageOfClosingPrice contextRef="c2" decimals="2" id="ixv-43731" unitRef="pure">0.20</abp:PercentageOfClosingPrice>
    <us-gaap:DerivativeAverageFloorPrice
      contextRef="c636"
      decimals="2"
      id="ixv-43732"
      unitRef="usdPeritem">5.7</us-gaap:DerivativeAverageFloorPrice>
    <abp:VolumeWeightedAveragePrice
      contextRef="c637"
      decimals="2"
      id="ixv-43733"
      unitRef="usdPershares">345</abp:VolumeWeightedAveragePrice>
    <abp:PercentageOfCommonStock
      contextRef="c640"
      decimals="2"
      id="ixv-43734"
      unitRef="pure">0.99</abp:PercentageOfCommonStock>
    <us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
      contextRef="c641"
      decimals="0"
      id="ixv-43735"
      unitRef="pure">10</us-gaap:DebtInstrumentConvertibleThresholdConsecutiveTradingDays1>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c2" decimals="-3" id="ixv-43736" unitRef="usd">1250000</us-gaap:DebtInstrumentFaceAmount>
    <abp:PercentageOfAmortizationPrincipalAmount contextRef="c34" decimals="2" id="ixv-43737" unitRef="pure">0.05</abp:PercentageOfAmortizationPrincipalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c635"
      decimals="-3"
      id="ixv-43738"
      unitRef="usd">69000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c642"
      decimals="-3"
      id="ixv-43739"
      unitRef="usd">11000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:InvestmentIncomeAmortizationOfDiscount contextRef="c34" decimals="-3" id="ixv-43740" unitRef="usd">39000</us-gaap:InvestmentIncomeAmortizationOfDiscount>
    <us-gaap:PaymentsForProceedsFromPreviousAcquisition contextRef="c34" decimals="-6" id="ixv-43741" unitRef="usd">50000000</us-gaap:PaymentsForProceedsFromPreviousAcquisition>
    <abp:PercentageOfCommonStock contextRef="c2" decimals="4" id="ixv-43742" unitRef="pure">0.0499</abp:PercentageOfCommonStock>
    <abp:PercentageOfCommonStockOutstanding contextRef="c2" decimals="3" id="ixv-43743" unitRef="pure">0.199</abp:PercentageOfCommonStockOutstanding>
    <abp:PercentageOfAdvanceNotice
      contextRef="c471"
      decimals="2"
      id="ixv-43744"
      unitRef="pure">0.96</abp:PercentageOfAdvanceNotice>
    <abp:PercentageOfAdvanceNotice
      contextRef="c590"
      decimals="2"
      id="ixv-43745"
      unitRef="pure">0.97</abp:PercentageOfAdvanceNotice>
    <us-gaap:DerivativeFairValueOfDerivativeNet contextRef="c2" decimals="-3" id="ixv-43746" unitRef="usd">1551000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DerivativeFairValueOfDerivativeNet
      contextRef="c409"
      decimals="-3"
      id="ixv-43747"
      unitRef="usd">188000</us-gaap:DerivativeFairValueOfDerivativeNet>
    <us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts contextRef="c34" decimals="-3" id="ixv-43748" unitRef="usd">500000000</us-gaap:DebtRelatedCommitmentFeesAndDebtIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c411"
      decimals="-3"
      id="ixv-43749"
      unitRef="usd">327000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c412"
      decimals="-3"
      id="ixv-43750"
      unitRef="usd">173000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c34" id="ixv-39867">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Stockholders&#x2019;
Equity&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As of December 31, 2023, and immediately
prior to the Closing Date, Legacy Abpro&#x2019;s amended and restated articles of incorporation authorized the issuance of up to 40,000,000
shares of common stock and up to 11,620,248 shares of preferred stock. Legacy Abpro&lt;span style="background-color: white"&gt;&#x2019;s Certificate
of Incorporation, as amended, authorizes the issuance of Series A Redeemable Convertible Preferred Stock (&#x201c;Series A&#x201d;), Series
B Convertible Preferred Stock (&#x201c;Series B&#x201d;), Series C Convertible Preferred Stock (&#x201c;Series C&#x201d;), Series D Convertible
Preferred Stock (&#x201c;Series D&#x201d;), Series E Convertible Preferred Stock (&#x201c;Series E&#x201d;) and Series F Convertible Preferred
Stock (&#x201c;Series F&#x201d;), collectively referred to as &#x201c;Convertible Preferred Stock&#x201d;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In connection with the Merger, all
previously issued and outstanding Convertible Preferred Stock was converted into the aggregate number of shares of New Abpro&#x2019;s common
stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately
prior to the effective time, multiplied by approximately 0.068, and the remaining amount was reclassified to additional paid-in capital.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Common and Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In connection with the Closing, the
Company&#x2019;s articles of incorporation were amended to designate two classes of stock; preferred and common stock. The articles of
incorporation of New Abpro authorize 1,000,000 shares of preferred stock and 110,000,000 shares of common stock.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s Amended and Restated
Certificate of Incorporation provides the Company&#x2019;s board of directors with the authority to issue up to 1,000,000 shares of $0.0001
par value preferred stock in one more series and to establish from time to time the number of shares to be included in each such series,
by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating,
optional, special and other rights shall be stated and expressed in such resolutions. There were zero preferred shares outstanding as
of December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;As of December 31, 2024, there were
500,000 outstanding Public Warrants. The Public Warrants became exercisable 12 months from the closing of ACAB&#x2019;s Initial Public
Offering, which closed on January 19, 2022, and will expire five years from the Closing Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company will not be obligated to
deliver any common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise
unless a registration statement under the Securities Act covering the issuance of the common stock issuable upon exercise of the Public
Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect
to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of common stock upon exercise of
a warrant unless common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities
laws of the state of residence of the registered holder of the warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify"&gt;The Company may redeem the Public Warrants:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;in whole and not in part;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;at a price of $0.30 per warrant;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;upon not less than 30 days&#x2019; prior written notice of redemption given after the warrants become exercisable to each warrant holder; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 0.75in"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;if, and only if, the reported last sale price of the Series A common
stock equals or exceeds $540.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like)
for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three trading days before
the Company sends the notice of redemption to the warrant holders (the &#x201c;Redemption Trigger&#x201d;). In November 2024, the Redemption
Trigger was adjusted to $179.70, as further described below.&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;If and when the warrants become redeemable
by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for
sale under all applicable state securities laws.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;If the Company calls the Public Warrants
for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#x201c;cashless
basis,&#x201d; as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of
the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization,
merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As of December 31, 2024, there were
461,667 Private Warrants, The Private Warrants are identical to the Public Warrants, except that the Private Warrants are exercisable
on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private
Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable
by the Company and exercisable by such holders on the same basis as the Public Warrants.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In addition, if (x) the Company were
to issues additional shares of common stock or equity-linked securities, for capital raising purposes in connection with the closing of
a Merger at an issue price or effective issue price of less than $276.00 per share of common stock (with such issue price or effective
issue price to be determined in good faith by the Company&#x2019;s board of directors, and, in the case of any such issuance to the Sponsor
or its affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such
issuance) (the &#x201c;Newly Issued Price&#x201d;), (y) the aggregate gross proceeds from such issuances represented more than 60% of the
total equity proceeds, and interest thereon, available for the funding of a Merger on the date of the completion of a Merger (net of redemptions),
and (z) the volume weighted average trading price of the Company&#x2019;s Series A common stock during the 20 trading day period starting
on the trading day after the day on which the Company completes a Merger (such price, the &#x201c;Market Value&#x201d;) was below $276.00
per share, the exercise price of the warrants would be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market
Value and the Newly Issued Price, and the $540.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal
to 180% of the greater of the Market Value and the Newly Issued Price (the &#x201c;Down Round Feature&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;In November 2024, the &#x201c;Down Round
Feature&#x201d; was triggered and the exercise price of the Public and Private Warrants was adjusted down to $114.90 and the per share
Redemption Trigger was adjusted down to $179.70 based on the Newly Issued Price of $99.90. The Company accounted for the change in fair
value of the Public and Private Warrants triggered by the down round as a deemed dividend under the guidance in ASC 260-10-25-1 related
to financial instruments that include a down round feature.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The Company valued the deemed dividend
as the difference between the fair value of the warrants before and after the exercise price adjustment. The warrants were valued using
the Black-Scholes option pricing model immediately before and after the modification using the following assumptions: (a) fair value of
common stock of $53.40 per share, (b) expected volatility of 90.00%, (c) dividend yield of 0%, (d) risk-free interest rate of 4.09%, and
(e) expected life of 4.9 years. The increase in the fair value of the warrants resulting from the exercise price adjustment was $10,177.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The 2,034 outstanding common stock warrants of Legacy Abpro (&#x201c;Legacy
Abpro Common Stock Warrants&#x201d;) expired at the Merger Date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The following table sets forth the
common stock warrant activity for the year ended December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Legacy&lt;br/&gt; Abpro &lt;br/&gt; Common&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Stock &lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Private&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Public&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-441"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-442"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expired at the Merger&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,034&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-443"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-444"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Common stock warrants of ACAB acquired in Merger&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-445"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;461,667&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-446"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;461,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The following presents information
about warrants to purchase common stock outstanding as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt;
Average &lt;br/&gt; Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average Remaining&lt;br/&gt; Contractual &lt;br/&gt;
Life&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;961,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;114.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; width: 11%"&gt;4.9 years&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-447"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-448"&gt;No&lt;/span&gt;&lt;/span&gt; warrants were issued or exercised
during the years ended December 31, 2024 and 2023.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c414"
      decimals="0"
      id="ixv-43751"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c414"
      decimals="0"
      id="ixv-43752"
      unitRef="shares">11620248</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="c643"
      decimals="INF"
      id="ixv-43753"
      unitRef="usdPershares">0.068</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <abp:DesignatedShares
      contextRef="c35"
      decimals="0"
      id="ixv-43754"
      unitRef="shares">2</abp:DesignatedShares>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ixv-43755"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c2"
      decimals="0"
      id="ixv-43756"
      unitRef="shares">110000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c2"
      decimals="INF"
      id="ixv-43757"
      unitRef="shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-43758"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c2"
      decimals="INF"
      id="ixv-43759"
      unitRef="usdPershares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="0"
      id="ixv-43760"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c417"
      decimals="0"
      id="ixv-43761"
      unitRef="shares">500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <abp:WarrantsExercisableTerm contextRef="c417" id="ixv-43762">P12M</abp:WarrantsExercisableTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c417" id="ixv-43763">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <abp:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="c417"
      decimals="2"
      id="ixv-43764"
      unitRef="usdPershares">0.3</abp:ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights>
    <abp:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger
      contextRef="c644"
      decimals="2"
      id="ixv-43765"
      unitRef="usdPershares">540</abp:ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger>
    <abp:NumberOfTradingDaysForDeterminingTheSharePrice contextRef="c645" id="ixv-43766">P20D</abp:NumberOfTradingDaysForDeterminingTheSharePrice>
    <abp:PeriodAfterWhichTheWarrantsAreExercisable contextRef="c645" id="ixv-43767">P30D</abp:PeriodAfterWhichTheWarrantsAreExercisable>
    <abp:PerShareRedemptionsTriggerPrice
      contextRef="c421"
      decimals="2"
      id="ixv-43768"
      unitRef="usdPershares">179.7</abp:PerShareRedemptionsTriggerPrice>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c423"
      decimals="0"
      id="ixv-43769"
      unitRef="shares">461667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c644"
      decimals="2"
      id="ixv-43770"
      unitRef="usdPershares">276</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="c646"
      decimals="2"
      id="ixv-43771"
      unitRef="pure">0.60</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <abp:NumberOfTradingDaysForDeterminingTheSharePrice contextRef="c645" id="ixv-43772">P20D</abp:NumberOfTradingDaysForDeterminingTheSharePrice>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c647"
      decimals="2"
      id="ixv-43773"
      unitRef="usdPershares">276</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <abp:PercentageOfMarketValueAndNewlyIssuedPrice contextRef="c34" decimals="2" id="ixv-43774" unitRef="pure">1.15</abp:PercentageOfMarketValueAndNewlyIssuedPrice>
    <us-gaap:DebtInstrumentConvertibleStockPriceTrigger
      contextRef="c518"
      decimals="2"
      id="ixv-43775"
      unitRef="usdPershares">540</us-gaap:DebtInstrumentConvertibleStockPriceTrigger>
    <abp:PercentageOfMarketValueAndNewlyIssuedPrice
      contextRef="c643"
      decimals="2"
      id="ixv-43776"
      unitRef="pure">1.80</abp:PercentageOfMarketValueAndNewlyIssuedPrice>
    <abp:PerShareRedemptionsTriggerPrice
      contextRef="c426"
      decimals="2"
      id="ixv-43777"
      unitRef="usdPershares">114.9</abp:PerShareRedemptionsTriggerPrice>
    <abp:PerShareRedemptionsTriggerPrice
      contextRef="c427"
      decimals="2"
      id="ixv-43778"
      unitRef="usdPershares">179.7</abp:PerShareRedemptionsTriggerPrice>
    <abp:PerShareRedemptionsTriggerPrice
      contextRef="c428"
      decimals="2"
      id="ixv-43779"
      unitRef="usdPershares">99.9</abp:PerShareRedemptionsTriggerPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-43780"
      unitRef="usdPershares">53.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c34" decimals="4" id="ixv-43781" unitRef="pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c34" decimals="2" id="ixv-43782" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c34" decimals="4" id="ixv-43783" unitRef="pure">0.0409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c34" id="ixv-43784">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="c34" decimals="-3" id="ixv-43785" unitRef="usd">10177000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c648"
      decimals="0"
      id="ixv-43786"
      unitRef="shares">2034</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c34" id="ixv-39982">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The following table sets forth the
common stock warrant activity for the year ended December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Legacy&lt;br/&gt; Abpro &lt;br/&gt; Common&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Stock &lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Private&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Public&lt;br/&gt; Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Outstanding as of December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,034&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-441"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-442"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Expired at the Merger&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,034&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-443"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-444"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Common stock warrants of ACAB acquired in Merger&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-445"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;461,667&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding as of December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-446"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;461,667&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;500,000&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c651"
      decimals="0"
      id="ixv-43787"
      unitRef="shares">2034</us-gaap:ClassOfWarrantOrRightOutstanding>
    <abp:ExpiredAtTheMerger
      contextRef="c654"
      decimals="0"
      id="ixv-43788"
      unitRef="shares">-2034</abp:ExpiredAtTheMerger>
    <abp:CommonStockWarrantsOfLegacyACABAcquiredInMerger
      contextRef="c655"
      decimals="0"
      id="ixv-43789"
      unitRef="shares">461667</abp:CommonStockWarrantsOfLegacyACABAcquiredInMerger>
    <abp:CommonStockWarrantsOfLegacyACABAcquiredInMerger
      contextRef="c656"
      decimals="0"
      id="ixv-43790"
      unitRef="shares">500000</abp:CommonStockWarrantsOfLegacyACABAcquiredInMerger>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c658"
      decimals="0"
      id="ixv-43791"
      unitRef="shares">461667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c417"
      decimals="0"
      id="ixv-43792"
      unitRef="shares">500000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c643" id="ixv-40091">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The following presents information
about warrants to purchase common stock outstanding as of December 31, 2024:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt;
Average &lt;br/&gt; Exercise &lt;br/&gt;
Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Average Remaining&lt;br/&gt; Contractual &lt;br/&gt;
Life&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;Warrants&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;961,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;114.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right; width: 11%"&gt;4.9 years&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c2"
      decimals="INF"
      id="ixv-43793"
      unitRef="shares">961667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c2"
      decimals="2"
      id="ixv-43794"
      unitRef="usdPershares">114.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="c2" id="ixv-43795">P4Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c34" id="ixv-40129">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Share-Based
Compensation&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2024 Equity Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s 2024 Equity Incentive
Plan (the &#x201c;2024 Plan&#x201d;) became effective at the Closing Date. As of December 31, 2024, 208,026 shares of common stock
were available for issuance under the 2024 Plan, which is equal to 10% of the number of shares of common stock of the Company following
the Merger. The 2024 Plan provides that on January 1 of each year commencing January 1, 2026 and ending on December 31, 2034, the 2024
Plan reserve will automatically increase in an amount equal to the lesser of (a) 5% of the number of shares of the Company&#x2019;s common
stock outstanding on December 31 of the preceding year and (b) a number of shares of common stock determined by the Company&#x2019;s board
of directors.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Under the 2024 Plan, the Company can
grant non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted
stock units, unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees. Through December
31, 2024, the Company has not granted any awards under the 2024 Plan.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;2014 Stock Incentive Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;The 2014 Stock Incentive Plan (the
&#x201c;2014 Plan&#x201d;) of Legacy Abpro was expired as of the Closing Date, in accordance with its original terms. As a result of the
expiration, no further awards may be granted under the 2014 Plan. All awards previously granted and outstanding as of the effective date
of the Merger, which totaled 166,858 options, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement,
but otherwise remain in effect pursuant to their original terms (see Note 3). Stock options granted to employees and directors typically
vest over four years. Stock options granted to non-employees typically vest immediately at the grant date. The maximum contractual term
of the stock options is ten years.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Options&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The summary of the Company&#x2019;s
stock option activity is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average &lt;br/&gt; Remaining&lt;br/&gt; Contractual &lt;br/&gt; Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;369,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-449"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-450"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-451"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-452"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-453"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-454"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited/Expired/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(39,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;30.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-455"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;329,395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;51.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;276,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;51.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock Option Valuation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The assumptions that the Company used
to determine the fair value of the stock options granted to employees, directors and nonemployees were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.53&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.3&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The weighted average grant date fair
value of awards granted during the year ended December 31, 2023, was $127.80 per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;span style="-sec-ix-hidden: hidden-fact-461"&gt;No&lt;/span&gt; stock options were granted during
the year ended December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Units&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company
granted restricted stock units (&#x201c;RSUs&#x201d;) to various employees and directors under the 2014 Plan. These RSUs cliff vest on the
first anniversary of the grant date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock
as of the grant date.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The summary
of the Company&#x2019;s restricted stock unit activity is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;br/&gt; Grant Date &lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;br/&gt; Remaining &lt;br/&gt; Vesting Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,124&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;48.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-456"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-457"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,386&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-458"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-459"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;738&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;48.90&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In November
and December 2024, after the Closing Date, 369 RSUs vested in accordance with their terms, but the shares of New Abpro common stock were
not issued to the holders as of December &lt;span style="-sec-ix-hidden: hidden-fact-460"&gt;31, 2024&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On October
22, 2024, the Company&#x2019;s board of directors authorized the issuance of 10,000 RSUs (or approximately 20,449 RSUs as adjusted for
the Merger closing based on the Exchange Ratio), that were not yet issued as of December 31, 2024. The Company recorded the
fair value of these RSUs, totaling $394, in accrued expenses as of December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The summary of the recorded stock-based
compensation expense is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,855&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,187&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 9.25pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,927&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,305&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As of December 31, 2024, there was
approximately $1,302 of unrecognized compensation cost related to unvested stock option awards that are expected to be recognized over
a weighted-average period of 1.1 years. As of December 31, 2024, there was approximately $31 of unrecognized compensation cost related
to unvested restricted stock awards that are expected to be recognized over a weighted-average period of 0.3 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c659"
      decimals="0"
      id="ixv-43796"
      unitRef="shares">208026</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <abp:PercentageOfCommonStock
      contextRef="c659"
      decimals="2"
      id="ixv-43797"
      unitRef="pure">0.10</abp:PercentageOfCommonStock>
    <abp:PercentageOfCommonStock
      contextRef="c660"
      decimals="2"
      id="ixv-43798"
      unitRef="pure">0.05</abp:PercentageOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c661"
      decimals="0"
      id="ixv-43799"
      unitRef="shares">166858</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c662" id="ixv-43800">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c663" id="ixv-43801">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c34" id="ixv-40164">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The summary of the Company&#x2019;s
stock option activity is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Stock&lt;br/&gt; Options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Exercise &lt;br/&gt; Price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-&lt;br/&gt; Average &lt;br/&gt; Remaining&lt;br/&gt; Contractual &lt;br/&gt; Life&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;369,092&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;49.20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.1&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-449"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-450"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-451"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-452"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-453"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-454"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited/Expired/Cancelled&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(39,698&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;30.90&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-455"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;329,395&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;51.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 4pt"&gt;Exercisable at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;276,060&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;51.30&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5.4&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c5"
      decimals="INF"
      id="ixv-43802"
      unitRef="shares">369092</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c5"
      decimals="2"
      id="ixv-43803"
      unitRef="usdPershares">49.2</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c672" id="ixv-43804">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c34"
      decimals="INF"
      id="ixv-43805"
      unitRef="shares">39698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c34"
      decimals="2"
      id="ixv-43806"
      unitRef="usdPershares">30.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-43807"
      unitRef="shares">329395</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-43808"
      unitRef="usdPershares">51.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c34" id="ixv-43809">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c2"
      decimals="INF"
      id="ixv-43810"
      unitRef="shares">276060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c2"
      decimals="2"
      id="ixv-43811"
      unitRef="usdPershares">51.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c34" id="ixv-43812">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c34" id="ixv-40299">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The assumptions that the Company used
to determine the fair value of the stock options granted to employees, directors and nonemployees were as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Year ended&lt;br/&gt;
December 31,&lt;br/&gt;
2023&lt;/b&gt;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 88%; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.53&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.3&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;71&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c673"
      decimals="4"
      id="ixv-43813"
      unitRef="pure">0.0353</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c673" id="ixv-40327">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c673"
      decimals="2"
      id="ixv-43814"
      unitRef="pure">0.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c673"
      decimals="2"
      id="ixv-43815"
      unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c664"
      decimals="2"
      id="ixv-43816"
      unitRef="usdPershares">127.8</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c34" id="ixv-40362">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The summary
of the Company&#x2019;s restricted stock unit activity is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt; &lt;tr style="vertical-align: bottom"&gt; &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;br/&gt; Grant Date &lt;br/&gt; Fair Value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted-Average&lt;br/&gt; Remaining &lt;br/&gt; Vesting Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="width: 64%"&gt;Outstanding at December 31, 2023&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;3,124&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;48.90&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.2&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-456"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-457"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,386&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;48.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: White"&gt; &lt;td style="padding-bottom: 1.5pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-458"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-459"&gt;&#x2014;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&#x2014;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt; &lt;td style="padding-bottom: 4pt"&gt;Outstanding at December 31, 2024&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;738&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;48.90&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.2&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c674"
      decimals="INF"
      id="ixv-43817"
      unitRef="shares">3124</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c674"
      decimals="2"
      id="ixv-43818"
      unitRef="usdPershares">48.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c675" id="ixv-43819">P1Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c676"
      decimals="INF"
      id="ixv-43820"
      unitRef="shares">2386</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c676"
      decimals="2"
      id="ixv-43821"
      unitRef="usdPershares">48.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c677"
      decimals="INF"
      id="ixv-43822"
      unitRef="shares">738</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c677"
      decimals="2"
      id="ixv-43823"
      unitRef="usdPershares">48.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c676" id="ixv-43824">P0Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c666"
      decimals="0"
      id="ixv-43825"
      unitRef="shares">369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c668"
      decimals="0"
      id="ixv-43826"
      unitRef="shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c442"
      decimals="0"
      id="ixv-43827"
      unitRef="shares">20449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AccruedLiabilitiesFairValueDisclosure
      contextRef="c446"
      decimals="-3"
      id="ixv-43828"
      unitRef="usd">394000</us-gaap:AccruedLiabilitiesFairValueDisclosure>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c34" id="ixv-40468">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The summary of the recorded stock-based
compensation expense is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Research and development&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;118&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,855&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,187&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 9.25pt"&gt;Total stock-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,927&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,305&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c597"
      decimals="-3"
      id="ixv-43829"
      unitRef="usd">72000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c598"
      decimals="-3"
      id="ixv-43830"
      unitRef="usd">118000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c678"
      decimals="-3"
      id="ixv-43831"
      unitRef="usd">1855000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c679"
      decimals="-3"
      id="ixv-43832"
      unitRef="usd">2187000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c34" decimals="-3" id="ixv-43833" unitRef="usd">1927000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c35" decimals="-3" id="ixv-43834" unitRef="usd">2305000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c669"
      decimals="-3"
      id="ixv-43835"
      unitRef="usd">1302000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c665" id="ixv-43836">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c670"
      decimals="-3"
      id="ixv-43837"
      unitRef="usd">31000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c671" id="ixv-43838">P0Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c34" id="ixv-40535">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;16.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Employee
Benefit Plan&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company has a 401(k) retirement
plan available to all eligible employees. During the years ended December 31, 2024 and 2023, the Company made $110 and $136 in matching
contributions, respectively, to the plan.&lt;/p&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c34" decimals="-3" id="ixv-43839" unitRef="usd">110000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c35" decimals="-3" id="ixv-43840" unitRef="usd">136000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c34" id="ixv-40550">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;17.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Related
Parties&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On January 15, 2020, the Company entered
into an agreement for various consulting services, as defined in the agreement, with a member of the Company&#x2019;s Board of Directors.
On January 1, 2023, the Company entered into a new consulting agreement with the same director, which superseded the agreement dated in
January 2020. The agreement was terminated during the years ended December 31, 2024. During the years ended December 31, 2024 and 2023,
the Company incurred $83 and $250 under this agreement, respectively. As of both December 31, 2024 and 2023, the unpaid amount was $21.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On December 1, 2021, the Company entered
into a consulting agreement with a member of the Company&#x2019;s Board of Directors. Under the agreement, the Company is obligated to
pay fees for various consulting services, as defined in the agreement. This agreement was terminated in May 2022. The Company did not
incur any expense under this agreement during the years ended December 31, 2024 and 2023. As of both December 31, 2024 and 2023, the unpaid
balance was $8.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In September 2022, the Company entered
into a collaboration and license agreement with Celltrion, a significant investor in the Company&#x2019;s Series F, as discussed in Note
7. The Company entered into the ABP-100 Agreement and ABP-201 Agreement with ABI, a significant investor in the Company&#x2019;s Series
E and F, described in Note 7.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On March 13, 2023, the Company&#x2019;s
CEO, upon the approval of the Company&#x2019;s Board of Directors, transferred $5,000 from the Company&#x2019;s bank account at First Republic
Bank to his personal bank account as an emergency response to the collapse of First Republic Bank. This amount was recorded as a receivable
from related party as of March 31, 2023. The full amount of $5,000 plus accrued interest of $18 was returned to the Company on May 3,
2023, and the remaining balance of accrued interest was $3 as of December 31, 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On October 18, 2023, the Company issued
a promissory note to ABI in the principal amount of up to $6,000 for expenses incurred in connection with the Merger and for its operating
expenses, as discussed in Note 12.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On December 29, 2023, the Company issued
promissory notes to one of its executives and one of its directors in the principal amount of $176 and $124, respectively, as discussed
in Note 12.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On April 18, 2024, the Company entered
into a separate promissory note agreement with the same executive to receive, as amended, for up to $2,158 in funding. During the year
ended December 31, 2024, the Company received $1,997 from the executive under this agreement. See Note 12.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On April 18, 2024, the Company entered
into an agreement with an executive to defer payment of compensation from April 18, 2024 until the earlier of (i) the closing of the Merger
and (ii) November 20, 2024. The executive&#x2019;s deferred wages were repaid in the amount of $221 November 2024.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On November 21, 2024, the Company entered
into a severance agreement with an executive (the &#x201c;Severance Agreement&#x201d;). Pursuant to the terms of the Severance Agreement,
the Company made a severance payment of $221 upon execution of the agreement. The Severance Agreement supersedes and extinguishes all
other agreements between the executive and the Company.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On December 24, 2024, the Company made
a payment of $574 to the Sponsor in accordance with the terms of the Merger Agreement.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c680"
      decimals="-3"
      id="ixv-43841"
      unitRef="usd">83000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c681"
      decimals="-3"
      id="ixv-43842"
      unitRef="usd">250000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <abp:UnpaidAmount
      contextRef="c682"
      decimals="-3"
      id="ixv-43843"
      unitRef="usd">21000</abp:UnpaidAmount>
    <abp:UnpaidAmount
      contextRef="c683"
      decimals="-3"
      id="ixv-43844"
      unitRef="usd">21000</abp:UnpaidAmount>
    <abp:UnpaidAmount contextRef="c2" decimals="-3" id="ixv-43845" unitRef="usd">8000</abp:UnpaidAmount>
    <abp:UnpaidAmount contextRef="c5" decimals="-3" id="ixv-43846" unitRef="usd">8000</abp:UnpaidAmount>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c684"
      decimals="-3"
      id="ixv-43847"
      unitRef="usd">5000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction
      contextRef="c685"
      decimals="-3"
      id="ixv-43848"
      unitRef="usd">5000000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="c686"
      decimals="-3"
      id="ixv-43849"
      unitRef="usd">18000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="c687"
      decimals="-3"
      id="ixv-43850"
      unitRef="usd">3000</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="c688"
      decimals="-3"
      id="ixv-43851"
      unitRef="usd">6000000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="c689"
      decimals="-3"
      id="ixv-43852"
      unitRef="usd">176000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="c690"
      decimals="-3"
      id="ixv-43853"
      unitRef="usd">124000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c460"
      decimals="-3"
      id="ixv-43854"
      unitRef="usd">2158000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:ProceedsFromRelatedPartyDebt
      contextRef="c461"
      decimals="-3"
      id="ixv-43855"
      unitRef="usd">1997000</us-gaap:ProceedsFromRelatedPartyDebt>
    <us-gaap:SalariesWagesAndOfficersCompensation
      contextRef="c691"
      decimals="-3"
      id="ixv-43856"
      unitRef="usd">221000</us-gaap:SalariesWagesAndOfficersCompensation>
    <us-gaap:SeveranceCosts1
      contextRef="c463"
      decimals="-3"
      id="ixv-43857"
      unitRef="usd">221000</us-gaap:SeveranceCosts1>
    <us-gaap:PaymentsForMergerRelatedCosts
      contextRef="c464"
      decimals="-3"
      id="ixv-43858"
      unitRef="usd">574000</us-gaap:PaymentsForMergerRelatedCosts>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c34" id="ixv-40598">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;18.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Income
Taxes&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The components of income / (loss) before
provision for / (benefit from) income taxes are:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Domestic&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-462"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Loss before Income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(11,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;For the years ended December 31, 2024
and 2023, the Company did not record a current income tax provision.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;A reconciliation of the Company&#x2019;s
effective income tax rate to the U.S. statutory federal income tax rate of 21% for the years ended December 31, 2024 and 2023 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Net loss before tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,706&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Statutory U.S. federal tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Tax computed at federal statutory rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,519&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,458&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State income taxes, net of federal benefit and tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(606&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(825&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Federal research and development credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(290&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(297&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(98&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,540&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-463"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-464"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Significant components of
the Company&#x2019;s net deferred tax assets and liabilities as of December 31, 2024 and 2023 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt; (As Restated)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9.25pt"&gt;Operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21,135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,478&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,691&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Capitalized research expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,547&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;279&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-465"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,387&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(33,274&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,414&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Net deferred income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-466"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-467"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company regularly assesses the
need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative
evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence,
whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of
deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable
earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant
judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on
a jurisdiction-by-jurisdiction basis.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company continues to maintain a
full valuation allowance against its deferred tax assets. During the years ended December 31, 2024 and 2023, management assessed the positive
and negative evidence in its operations, and concluded that it is more likely than not that its deferred tax assets as of December 31,
2024 and 2023 will not be realized given the Company&#x2019;s history of operating losses. The valuation allowance against deferred tax
assets increased by approximately $3,860 and $3,540 during 2024 and 2023, respectively, related to a full valuation allowance recorded
against additional net operating losses and tax credits generated in the year.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;On December 22, 2017, the Tax Cuts
and Jobs Act (the &#x201c;Act&#x201d;) was enacted. Under the Act, research and development expenditures incurred for tax years beginning
after December 31, 2021 must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on if the research
activities are conducted in the U.S. or outside the U.S., respectively. Effective January 1, 2022, the Company has complied with the mandatory
capitalization and amortization of research and experimentation expenditures. For the year ended December 31, 2024, the Company capitalized
$3,215 and received $2,370 of amortization deductions related to such Section 174 expenditures, which on a tax effected basis represent
$2,547 of the deferred tax assets shown in capitalized research and development costs in the components of deferred tax assets and liabilities
table above. For the year ended December 31, 2023, the Company capitalized $4,416 and received $1,850 of amortization deductions related
to such Section 174 expenditures, which on a tax effected basis represent $3,183 of the deferred tax assets shown in capitalized research
and development costs in the components of deferred tax assets and liabilities table above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As of December 31, 2024, the Company
had federal net operating losses of $85,863, which may be available to offset future federal income tax liabilities. As a result of the
Act, for U.S. federal income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely,
but are limited to 80% utilization against future taxable income each year. The Company&#x2019;s federal net operating losses incurred
prior to 2018, $22,999, expire through 2037, while its federal net operating losses incurred in 2018 and onwards, $62,864, can be carried
forward indefinitely.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As of December 31, 2023, the Company
had federal net operating losses of $78,165 (As Restated), which may be available to offset future federal income tax liabilities.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As of December 31, 2024 and 2023, the
Company had post-apportioned Massachusetts net operating losses of $82,240 and $74,656 (As Restated), respectively, that can generally
be carried forward 20 years and will expire at various dates through 2044.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;As of December 31, 2024, the Company
had $1,772 and $877 of federal and state research and development credits, respectively, which will expire at various dates through 2044.
As of December 31, 2023, the Company had $1,483 and $708 of federal and state research and development credits, respectively, which will
expire at various dates through 2043.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Pursuant to Internal Revenue Code Sections
382 and 383, annual use of the Company&#x2019;s net operating losses and other carryforward tax attributes may be limited in the event
a cumulative change in ownership of more than 50% that occurs within a three-year period. The Company has not completed an ownership change
analysis pursuant to IRS Section 382. If ownership changes have occurred or occur in the future, the amount of remaining tax attribute
carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated,
the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The calculation of the Company&#x2019;s
tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The
Company recognizes liabilities for uncertain tax positions based on a two-step process. First, management determines whether it is more
likely than not that the tax positions will be sustained on audit, including resolution of related appeals or litigation processes, based
on their technical merits. Second, management measures the tax benefit of those positions as the largest amount that is more than 50%
likely to be realized upon ultimate settlement with the related tax authority. While the Company believes that it has appropriate support
for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in
determining the adequacy of its provision for income taxes. As of December 31, 2024 and 2023, the Company did not have any uncertain tax
positions.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company&#x2019;s policy is to recognize
interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement
of operations and any accrued interest and penalties on the related tax liability line in the consolidated balance sheet. As of December
31, 2024 and 2023, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company files income tax returns
in the U.S. federal jurisdiction and various state jurisdictions. There are currently no pending income tax examinations. To the extent
the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination
by the Internal Revenue Service and state tax authorities to the extent the tax attributes are utilized in a future period. The Company&#x2019;s
income tax returns since 2021 are subject to examination by the IRS and state tax authorities.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c34" id="ixv-40609">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The components of income / (loss) before
provision for / (benefit from) income taxes are:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Domestic&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,770&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Foreign&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-462"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;64&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Loss before Income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(7,232&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(11,706&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c34" decimals="-3" id="ixv-43859" unitRef="usd">-7232000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c35" decimals="-3" id="ixv-43860" unitRef="usd">-11770000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c35" decimals="-3" id="ixv-43861" unitRef="usd">64000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c34" decimals="-3" id="ixv-43862" unitRef="usd">-7232000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c35" decimals="-3" id="ixv-43863" unitRef="usd">-11706000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c34" id="ixv-40660">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;A reconciliation of the Company&#x2019;s
effective income tax rate to the U.S. statutory federal income tax rate of 21% for the years ended December 31, 2024 and 2023 is as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Net loss before tax&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(7,232&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(11,706&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Statutory U.S. federal tax rate&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;21&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Tax computed at federal statutory rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(1,519&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(2,458&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;State income taxes, net of federal benefit and tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(606&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(825&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Federal research and development credit&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(290&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(297&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(98&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Change in valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;2,513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,540&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Income tax expense&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-463"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-464"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c34" decimals="2" id="ixv-43864" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c35" decimals="2" id="ixv-43865" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c34" decimals="-3" id="ixv-43866" unitRef="usd">-7232000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c35" decimals="-3" id="ixv-43867" unitRef="usd">-11706000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c34" decimals="2" id="ixv-43868" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c35" decimals="2" id="ixv-43869" unitRef="pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c34" decimals="-3" id="ixv-43870" unitRef="usd">-1519000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c35" decimals="-3" id="ixv-43871" unitRef="usd">-2458000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c34" decimals="-3" id="ixv-43872" unitRef="usd">-606000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c35" decimals="-3" id="ixv-43873" unitRef="usd">-825000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <abp:EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit contextRef="c34" decimals="-3" id="ixv-43874" unitRef="usd">-290000</abp:EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit>
    <abp:EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit contextRef="c35" decimals="-3" id="ixv-43875" unitRef="usd">-297000</abp:EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c34" decimals="-3" id="ixv-43876" unitRef="usd">-98000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c35" decimals="-3" id="ixv-43877" unitRef="usd">40000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c34" decimals="-3" id="ixv-43878" unitRef="usd">2513000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c35" decimals="-3" id="ixv-43879" unitRef="usd">3540000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c34" id="ixv-40775">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;Significant components of
the Company&#x2019;s net deferred tax assets and liabilities as of December 31, 2024 and 2023 are as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Years ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2023 &lt;br/&gt; (As Restated)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify; padding-left: 9.25pt"&gt;Operating loss carryforwards&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;23,229&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;21,135&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Tax credits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,478&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,054&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,691&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,154&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Capitalized research expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,547&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,183&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Depreciation and amortization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,823&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;539&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;124&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;279&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 9.25pt"&gt;Accrued expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;314&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;333&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;181&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-465"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33,387&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;29,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Less: Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(33,274&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(29,414&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Total deferred tax assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Deferred tax liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt"&gt;Right-of-use asset&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(113&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(263&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Net deferred income taxes&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-466"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-467"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="-3" id="ixv-43880" unitRef="usd">23229000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c5" decimals="-3" id="ixv-43881" unitRef="usd">21135000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c2" decimals="-3" id="ixv-43882" unitRef="usd">2478000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c5" decimals="-3" id="ixv-43883" unitRef="usd">2054000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c2" decimals="-3" id="ixv-43884" unitRef="usd">2691000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c5" decimals="-3" id="ixv-43885" unitRef="usd">2154000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c2" decimals="-3" id="ixv-43886" unitRef="usd">2547000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c5" decimals="-3" id="ixv-43887" unitRef="usd">3183000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c2" decimals="-3" id="ixv-43888" unitRef="usd">1823000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="c5" decimals="-3" id="ixv-43889" unitRef="usd">539000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <abp:DeferredTaxAssetsLeaseLiability contextRef="c2" decimals="-3" id="ixv-43890" unitRef="usd">124000</abp:DeferredTaxAssetsLeaseLiability>
    <abp:DeferredTaxAssetsLeaseLiability contextRef="c5" decimals="-3" id="ixv-43891" unitRef="usd">279000</abp:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c2" decimals="-3" id="ixv-43892" unitRef="usd">314000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c5" decimals="-3" id="ixv-43893" unitRef="usd">333000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther contextRef="c2" decimals="-3" id="ixv-43894" unitRef="usd">181000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" id="ixv-43895" unitRef="usd">33387000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c5" decimals="-3" id="ixv-43896" unitRef="usd">29677000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" id="ixv-43897" unitRef="usd">33274000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c5" decimals="-3" id="ixv-43898" unitRef="usd">29414000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c2" decimals="-3" id="ixv-43899" unitRef="usd">113000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c5" decimals="-3" id="ixv-43900" unitRef="usd">263000</us-gaap:DeferredTaxAssetsNet>
    <abp:DeferredTaxLiabilitiesRightofuseAsset contextRef="c2" decimals="-3" id="ixv-43901" unitRef="usd">113000</abp:DeferredTaxLiabilitiesRightofuseAsset>
    <abp:DeferredTaxLiabilitiesRightofuseAsset contextRef="c5" decimals="-3" id="ixv-43902" unitRef="usd">263000</abp:DeferredTaxLiabilitiesRightofuseAsset>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c34" decimals="-3" id="ixv-43903" unitRef="usd">3860000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c35" decimals="-3" id="ixv-43904" unitRef="usd">3540000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c2" decimals="-3" id="ixv-43905" unitRef="usd">3215000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:IncomeTaxReconciliationDeductions contextRef="c34" decimals="-3" id="ixv-43906" unitRef="usd">2370000</us-gaap:IncomeTaxReconciliationDeductions>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c2" decimals="-3" id="ixv-43907" unitRef="usd">2547000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts contextRef="c5" decimals="-3" id="ixv-43908" unitRef="usd">4416000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:IncomeTaxReconciliationDeductions contextRef="c35" decimals="-3" id="ixv-43909" unitRef="usd">1850000</us-gaap:IncomeTaxReconciliationDeductions>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c5" decimals="-3" id="ixv-43910" unitRef="usd">3183000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:OperatingLossCarryforwards contextRef="c2" decimals="-3" id="ixv-43911" unitRef="usd">85863000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c34" decimals="2" id="ixv-43912" unitRef="pure">0.80</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c692"
      decimals="-3"
      id="ixv-43913"
      unitRef="usd">22999000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c693"
      decimals="-3"
      id="ixv-43914"
      unitRef="usd">62864000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c694"
      decimals="-3"
      id="ixv-43915"
      unitRef="usd">78165000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c695"
      decimals="-3"
      id="ixv-43916"
      unitRef="usd">82240000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c696"
      decimals="-3"
      id="ixv-43917"
      unitRef="usd">74656000</us-gaap:OperatingLossCarryforwards>
    <abp:CarryforwardsTerm contextRef="c34" id="ixv-43918">P20Y</abp:CarryforwardsTerm>
    <abp:FederalAndStateResearchAndDevelopmentCredits
      contextRef="c597"
      decimals="-3"
      id="ixv-43919"
      unitRef="usd">1772000</abp:FederalAndStateResearchAndDevelopmentCredits>
    <abp:FederalAndStateResearchAndDevelopmentCredits contextRef="c34" decimals="-3" id="ixv-43920" unitRef="usd">877000</abp:FederalAndStateResearchAndDevelopmentCredits>
    <abp:FederalAndStateResearchAndDevelopmentCredits
      contextRef="c598"
      decimals="-3"
      id="ixv-43921"
      unitRef="usd">1483000</abp:FederalAndStateResearchAndDevelopmentCredits>
    <abp:FederalAndStateResearchAndDevelopmentCredits contextRef="c35" decimals="-3" id="ixv-43922" unitRef="usd">708000</abp:FederalAndStateResearchAndDevelopmentCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends contextRef="c34" decimals="2" id="ixv-43923" unitRef="pure">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends>
    <us-gaap:SubsequentEventsTextBlock contextRef="c34" id="ixv-40994">&lt;table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0in"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;19.&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Subsequent
Events&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;The Company evaluated subsequent events
and transactions that occurred after the balance sheet date up to the date that the consolidated financial statements were issued. Based
upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated
financial statements, other than those disclosed in Notes1, 2, 8, 10, 11, 12, and 13 and further below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;At the special meeting of stockholders
held on April 8, 2025, the Company obtained stockholder approval for the issuance of shares over 20% of the Company&#x2019;s outstanding
shares to YA under the SEPA.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In April 2025, YA exercised its conversion
option for the total principal amount of $250,000 of the Convertible Notes. As a result of the exercise, the Company issued to YA 25,998
shares of common stock based on the average conversion price of approximately $9.60.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"&gt;In February 2025, the Company issued
5,000 shares of common stock to Roth Capital Partners (&#x201c;Roth&#x201d;) as an additional payment for the services provided
under the engagement letter dated July 17, 2024 between Roth and ACAB, which provided for an adjustment to their fees in shares based
on the trading price of the Company&#x2019;s common stock.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <abp:IssuanceOfSharesPercentage
      contextRef="c697"
      decimals="2"
      id="ixv-43924"
      unitRef="pure">0.20</abp:IssuanceOfSharesPercentage>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="c698"
      decimals="-3"
      id="ixv-43925"
      unitRef="usd">250000000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="c698"
      decimals="0"
      id="ixv-43926"
      unitRef="shares">25998</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:DebtInstrumentConvertibleConversionPrice1
      contextRef="c699"
      decimals="2"
      id="ixv-43927"
      unitRef="usdPershares">9.6</us-gaap:DebtInstrumentConvertibleConversionPrice1>
    <us-gaap:CommonStockSharesIssued
      contextRef="c700"
      decimals="0"
      id="ixv-43928"
      unitRef="shares">5000</us-gaap:CommonStockSharesIssued>
    <dei:DocumentType contextRef="c0" id="hidden-fact-0">S-1/A</dei:DocumentType>
    <abp:ForwardPurchaseAgreementAsset
      contextRef="c1"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c1"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c1"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c1"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="c1"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ConvertibleNotes
      contextRef="c1"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="c1"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c1"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c1"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c1"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c2"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockCommonValue
      contextRef="c1"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockCommonValue
      contextRef="c2"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="c2"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ForwardPurchaseAgreementAsset
      contextRef="c5"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:SEPAPutRightsAsset
      contextRef="c5"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="c5"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="c2"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="c5"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ConvertibleNotes
      contextRef="c5"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="c5"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c2"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c5"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c9"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c11"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c11"
      decimals="INF"
      id="hidden-fact-29"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c11"
      decimals="INF"
      id="hidden-fact-30"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c11"
      decimals="INF"
      id="hidden-fact-31"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c13"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c13"
      decimals="INF"
      id="hidden-fact-33"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c13"
      decimals="INF"
      id="hidden-fact-34"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c13"
      decimals="INF"
      id="hidden-fact-35"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c15"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c15"
      decimals="INF"
      id="hidden-fact-37"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c15"
      decimals="INF"
      id="hidden-fact-38"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c15"
      decimals="INF"
      id="hidden-fact-39"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c17"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c17"
      decimals="INF"
      id="hidden-fact-41"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c17"
      decimals="INF"
      id="hidden-fact-42"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c17"
      decimals="INF"
      id="hidden-fact-43"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c19"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="c19"
      decimals="INF"
      id="hidden-fact-45"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="c19"
      decimals="INF"
      id="hidden-fact-46"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="c19"
      decimals="INF"
      id="hidden-fact-47"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="c2"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c2"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="c5"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c5"
      decimals="INF"
      id="hidden-fact-51"
      unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c2"
      decimals="INF"
      id="hidden-fact-52"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c5"
      decimals="INF"
      id="hidden-fact-53"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c2"
      decimals="INF"
      id="hidden-fact-54"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c5"
      decimals="INF"
      id="hidden-fact-55"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="c2"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommonStockValue
      contextRef="c5"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockCommonValue
      contextRef="c2"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c21"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c23"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="c25"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="c26"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfForwardPuchaseAgreementAsset
      contextRef="c25"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfForwardPuchaseAgreementAsset
      contextRef="c26"
      id="hidden-fact-64"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfForwardPuchaseAgreementAsset
      contextRef="c27"
      id="hidden-fact-65"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfSEPAPutRightsAsset
      contextRef="c26"
      id="hidden-fact-66"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfSEPAPutRightsAsset
      contextRef="c27"
      id="hidden-fact-67"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfEmbeddedDerivativeLiability
      contextRef="c26"
      id="hidden-fact-68"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfEmbeddedDerivativeLiability
      contextRef="c27"
      id="hidden-fact-69"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:LossOnSettlementOfConvertibleNotes
      contextRef="c26"
      id="hidden-fact-70"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:LossOnSettlementOfConvertibleNotes
      contextRef="c27"
      id="hidden-fact-71"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c29"
      id="hidden-fact-72"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c30"
      id="hidden-fact-73"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="c32"
      id="hidden-fact-74"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="c35"
      id="hidden-fact-75"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfForwardPuchaseAgreementAsset
      contextRef="c35"
      id="hidden-fact-76"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfSEPAPutRightsAsset
      contextRef="c35"
      id="hidden-fact-77"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfEmbeddedDerivativeLiability
      contextRef="c35"
      id="hidden-fact-78"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c35"
      id="hidden-fact-79"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:DeemedDividendResultingFromTheWarrantDownRound
      contextRef="c35"
      id="hidden-fact-80"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c36"
      id="hidden-fact-81"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c36"
      id="hidden-fact-82"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c37"
      id="hidden-fact-83"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c37"
      id="hidden-fact-84"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c38"
      id="hidden-fact-85"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c38"
      id="hidden-fact-86"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c39"
      id="hidden-fact-87"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c39"
      id="hidden-fact-88"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c40"
      id="hidden-fact-89"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c40"
      id="hidden-fact-90"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c41"
      id="hidden-fact-91"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c41"
      id="hidden-fact-92"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c42"
      id="hidden-fact-93"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c43"
      id="hidden-fact-94"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c44"
      id="hidden-fact-95"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c49"
      id="hidden-fact-96"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c50"
      id="hidden-fact-97"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c51"
      id="hidden-fact-98"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c52"
      id="hidden-fact-99"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c53"
      id="hidden-fact-100"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c54"
      id="hidden-fact-101"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c55"
      id="hidden-fact-102"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c56"
      id="hidden-fact-103"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c57"
      id="hidden-fact-104"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c58"
      id="hidden-fact-105"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c59"
      id="hidden-fact-106"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c60"
      id="hidden-fact-107"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c61"
      id="hidden-fact-108"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="c62"
      id="hidden-fact-109"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c49"
      id="hidden-fact-110"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c50"
      id="hidden-fact-111"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c51"
      id="hidden-fact-112"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c52"
      id="hidden-fact-113"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c53"
      id="hidden-fact-114"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c54"
      id="hidden-fact-115"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c55"
      id="hidden-fact-116"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c56"
      id="hidden-fact-117"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c57"
      id="hidden-fact-118"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c59"
      id="hidden-fact-119"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c61"
      id="hidden-fact-120"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c49"
      id="hidden-fact-121"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c50"
      id="hidden-fact-122"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c51"
      id="hidden-fact-123"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c52"
      id="hidden-fact-124"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c53"
      id="hidden-fact-125"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c54"
      id="hidden-fact-126"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c55"
      id="hidden-fact-127"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c56"
      id="hidden-fact-128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c57"
      id="hidden-fact-129"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c59"
      id="hidden-fact-130"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c61"
      id="hidden-fact-131"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c49"
      id="hidden-fact-132"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c50"
      id="hidden-fact-133"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c51"
      id="hidden-fact-134"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c52"
      id="hidden-fact-135"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c53"
      id="hidden-fact-136"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c54"
      id="hidden-fact-137"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c55"
      id="hidden-fact-138"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c56"
      id="hidden-fact-139"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c57"
      id="hidden-fact-140"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c58"
      id="hidden-fact-141"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c61"
      id="hidden-fact-142"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c63"
      id="hidden-fact-143"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c64"
      id="hidden-fact-144"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c70"
      id="hidden-fact-145"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c71"
      id="hidden-fact-146"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c72"
      id="hidden-fact-147"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c73"
      id="hidden-fact-148"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c74"
      id="hidden-fact-149"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c75"
      id="hidden-fact-150"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c76"
      id="hidden-fact-151"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c77"
      id="hidden-fact-152"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c78"
      id="hidden-fact-153"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c80"
      id="hidden-fact-154"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c82"
      id="hidden-fact-155"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c70"
      id="hidden-fact-156"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c71"
      id="hidden-fact-157"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c72"
      id="hidden-fact-158"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c73"
      id="hidden-fact-159"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c74"
      id="hidden-fact-160"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c75"
      id="hidden-fact-161"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c76"
      id="hidden-fact-162"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c77"
      id="hidden-fact-163"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c78"
      id="hidden-fact-164"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c80"
      id="hidden-fact-165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c82"
      id="hidden-fact-166"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c70"
      id="hidden-fact-167"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c71"
      id="hidden-fact-168"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c72"
      id="hidden-fact-169"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c73"
      id="hidden-fact-170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c74"
      id="hidden-fact-171"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c75"
      id="hidden-fact-172"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c76"
      id="hidden-fact-173"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c77"
      id="hidden-fact-174"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c78"
      id="hidden-fact-175"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c79"
      id="hidden-fact-176"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c82"
      id="hidden-fact-177"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c84"
      id="hidden-fact-178"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c84"
      id="hidden-fact-179"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c85"
      id="hidden-fact-180"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c85"
      id="hidden-fact-181"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c86"
      id="hidden-fact-182"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c86"
      id="hidden-fact-183"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c87"
      id="hidden-fact-184"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c87"
      id="hidden-fact-185"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c88"
      id="hidden-fact-186"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c88"
      id="hidden-fact-187"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c89"
      id="hidden-fact-188"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c89"
      id="hidden-fact-189"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c90"
      id="hidden-fact-190"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c91"
      id="hidden-fact-191"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c92"
      id="hidden-fact-192"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c98"
      id="hidden-fact-193"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c99"
      id="hidden-fact-194"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c100"
      id="hidden-fact-195"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c101"
      id="hidden-fact-196"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c102"
      id="hidden-fact-197"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c103"
      id="hidden-fact-198"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c105"
      id="hidden-fact-199"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c107"
      id="hidden-fact-200"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c98"
      id="hidden-fact-201"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c108"
      id="hidden-fact-202"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c109"
      id="hidden-fact-203"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c110"
      id="hidden-fact-204"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c99"
      id="hidden-fact-205"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c100"
      id="hidden-fact-206"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c101"
      id="hidden-fact-207"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c102"
      id="hidden-fact-208"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c103"
      id="hidden-fact-209"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c105"
      id="hidden-fact-210"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="c107"
      id="hidden-fact-211"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c98"
      id="hidden-fact-212"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c108"
      id="hidden-fact-213"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c109"
      id="hidden-fact-214"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c99"
      id="hidden-fact-215"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c100"
      id="hidden-fact-216"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c101"
      id="hidden-fact-217"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c102"
      id="hidden-fact-218"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c103"
      id="hidden-fact-219"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c105"
      id="hidden-fact-220"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c107"
      id="hidden-fact-221"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c98"
      id="hidden-fact-222"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c108"
      id="hidden-fact-223"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c109"
      id="hidden-fact-224"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c110"
      id="hidden-fact-225"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c99"
      id="hidden-fact-226"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c100"
      id="hidden-fact-227"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c101"
      id="hidden-fact-228"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c102"
      id="hidden-fact-229"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c103"
      id="hidden-fact-230"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c104"
      id="hidden-fact-231"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c105"
      id="hidden-fact-232"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c106"
      id="hidden-fact-233"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="c107"
      id="hidden-fact-234"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c98"
      id="hidden-fact-235"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c108"
      id="hidden-fact-236"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c110"
      id="hidden-fact-237"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c99"
      id="hidden-fact-238"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c100"
      id="hidden-fact-239"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c101"
      id="hidden-fact-240"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c102"
      id="hidden-fact-241"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c103"
      id="hidden-fact-242"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c104"
      id="hidden-fact-243"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c107"
      id="hidden-fact-244"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c111"
      id="hidden-fact-245"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c112"
      id="hidden-fact-246"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c113"
      id="hidden-fact-247"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c114"
      id="hidden-fact-248"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c115"
      id="hidden-fact-249"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c116"
      id="hidden-fact-250"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c117"
      id="hidden-fact-251"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c118"
      id="hidden-fact-252"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c119"
      id="hidden-fact-253"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c131"
      id="hidden-fact-254"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c137"
      id="hidden-fact-255"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c138"
      id="hidden-fact-256"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c139"
      id="hidden-fact-257"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c140"
      id="hidden-fact-258"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c141"
      id="hidden-fact-259"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c142"
      id="hidden-fact-260"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c143"
      id="hidden-fact-261"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c144"
      id="hidden-fact-262"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c145"
      id="hidden-fact-263"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c146"
      id="hidden-fact-264"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c147"
      id="hidden-fact-265"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c148"
      id="hidden-fact-266"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c149"
      id="hidden-fact-267"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c34"
      id="hidden-fact-268"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c144"
      id="hidden-fact-269"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c147"
      id="hidden-fact-270"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities
      contextRef="c149"
      id="hidden-fact-271"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c137"
      id="hidden-fact-272"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c138"
      id="hidden-fact-273"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c139"
      id="hidden-fact-274"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c140"
      id="hidden-fact-275"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c141"
      id="hidden-fact-276"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c142"
      id="hidden-fact-277"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c143"
      id="hidden-fact-278"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c144"
      id="hidden-fact-279"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c145"
      id="hidden-fact-280"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c147"
      id="hidden-fact-281"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceOfCommonStockInThePIPEFinancing
      contextRef="c149"
      id="hidden-fact-282"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c137"
      id="hidden-fact-283"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c138"
      id="hidden-fact-284"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c139"
      id="hidden-fact-285"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c140"
      id="hidden-fact-286"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c141"
      id="hidden-fact-287"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c142"
      id="hidden-fact-288"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c143"
      id="hidden-fact-289"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c144"
      id="hidden-fact-290"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c145"
      id="hidden-fact-291"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c147"
      id="hidden-fact-292"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c149"
      id="hidden-fact-293"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c137"
      id="hidden-fact-294"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c138"
      id="hidden-fact-295"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c139"
      id="hidden-fact-296"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c140"
      id="hidden-fact-297"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c141"
      id="hidden-fact-298"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c142"
      id="hidden-fact-299"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c143"
      id="hidden-fact-300"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c144"
      id="hidden-fact-301"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c145"
      id="hidden-fact-302"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c147"
      id="hidden-fact-303"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c149"
      id="hidden-fact-304"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c137"
      id="hidden-fact-305"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c138"
      id="hidden-fact-306"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c139"
      id="hidden-fact-307"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c140"
      id="hidden-fact-308"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c141"
      id="hidden-fact-309"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c142"
      id="hidden-fact-310"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c143"
      id="hidden-fact-311"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c144"
      id="hidden-fact-312"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c145"
      id="hidden-fact-313"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c146"
      id="hidden-fact-314"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c149"
      id="hidden-fact-315"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c36"
      id="hidden-fact-316"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c37"
      id="hidden-fact-317"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c38"
      id="hidden-fact-318"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c39"
      id="hidden-fact-319"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c40"
      id="hidden-fact-320"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c41"
      id="hidden-fact-321"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c42"
      id="hidden-fact-322"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c43"
      id="hidden-fact-323"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c44"
      id="hidden-fact-324"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c157"
      id="hidden-fact-325"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c164"
      id="hidden-fact-326"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c165"
      id="hidden-fact-327"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c166"
      id="hidden-fact-328"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c167"
      id="hidden-fact-329"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c168"
      id="hidden-fact-330"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c169"
      id="hidden-fact-331"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c170"
      id="hidden-fact-332"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c171"
      id="hidden-fact-333"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c172"
      id="hidden-fact-334"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c173"
      id="hidden-fact-335"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c174"
      id="hidden-fact-336"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c175"
      id="hidden-fact-337"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c176"
      id="hidden-fact-338"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="c35"
      id="hidden-fact-339"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c164"
      id="hidden-fact-340"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c165"
      id="hidden-fact-341"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c166"
      id="hidden-fact-342"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c167"
      id="hidden-fact-343"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c168"
      id="hidden-fact-344"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c169"
      id="hidden-fact-345"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c170"
      id="hidden-fact-346"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c171"
      id="hidden-fact-347"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c172"
      id="hidden-fact-348"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c174"
      id="hidden-fact-349"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c176"
      id="hidden-fact-350"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c164"
      id="hidden-fact-351"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c165"
      id="hidden-fact-352"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c166"
      id="hidden-fact-353"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c167"
      id="hidden-fact-354"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c168"
      id="hidden-fact-355"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c169"
      id="hidden-fact-356"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c170"
      id="hidden-fact-357"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c171"
      id="hidden-fact-358"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c172"
      id="hidden-fact-359"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c173"
      id="hidden-fact-360"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="c176"
      id="hidden-fact-361"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c131"
      id="hidden-fact-362"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:LossOnSettlementsOfConvertibleNotes
      contextRef="c27"
      id="hidden-fact-363"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="c27"
      id="hidden-fact-364"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfForwardPurchaseAgreementAsset
      contextRef="c27"
      id="hidden-fact-365"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfSEPAPutRightAsset
      contextRef="c27"
      id="hidden-fact-366"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOnEmbeddedDerivativeLiability
      contextRef="c27"
      id="hidden-fact-367"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c0"
      id="hidden-fact-368"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="c27"
      id="hidden-fact-369"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="c27"
      id="hidden-fact-370"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c27"
      id="hidden-fact-371"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c27"
      id="hidden-fact-372"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c27"
      id="hidden-fact-373"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c27"
      id="hidden-fact-374"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="c27"
      id="hidden-fact-375"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="c0"
      id="hidden-fact-376"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c0"
      id="hidden-fact-377"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses
      contextRef="c27"
      id="hidden-fact-378"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="c27"
      id="hidden-fact-379"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability
      contextRef="c27"
      id="hidden-fact-380"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:DeferredOfferingCostsIncludedInAccountsPayable
      contextRef="c0"
      id="hidden-fact-381"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense
      contextRef="c0"
      id="hidden-fact-382"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherIncome
      contextRef="c35"
      id="hidden-fact-383"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherNoncashExpense
      contextRef="c35"
      id="hidden-fact-384"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfForwardPurchaseAgreementAsset
      contextRef="c35"
      id="hidden-fact-385"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOfSEPAPutRightAsset
      contextRef="c35"
      id="hidden-fact-386"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ChangeInFairValueOnEmbeddedDerivativeLiability
      contextRef="c35"
      id="hidden-fact-387"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c35"
      id="hidden-fact-388"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInNotesReceivables
      contextRef="c34"
      id="hidden-fact-389"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="c35"
      id="hidden-fact-390"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="c34"
      id="hidden-fact-391"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c34"
      id="hidden-fact-392"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:NetProceedsFromTheMerger
      contextRef="c35"
      id="hidden-fact-393"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="c35"
      id="hidden-fact-394"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:CashTransferredToEscrow
      contextRef="c35"
      id="hidden-fact-395"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RepaymentsOfRelatedPartyDebt
      contextRef="c35"
      id="hidden-fact-396"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="c35"
      id="hidden-fact-397"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense
      contextRef="c35"
      id="hidden-fact-398"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:SettlementOfBonusAccrualThroughNotesPayableRelatedParties
      contextRef="c34"
      id="hidden-fact-399"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ACABLiabilitiesAssumedInTheMerger
      contextRef="c35"
      id="hidden-fact-400"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro
      contextRef="c35"
      id="hidden-fact-401"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro
      contextRef="c35"
      id="hidden-fact-402"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:SEPACommitmentFeePaidInCommonStockShares
      contextRef="c35"
      id="hidden-fact-403"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c194"
      id="hidden-fact-404"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration contextRef="c0" id="hidden-fact-405">http://fasb.org/srt/2025#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="c244"
      id="hidden-fact-406"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="c248"
      id="hidden-fact-407"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c276"
      id="hidden-fact-408"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueAdjustment
      contextRef="c277"
      id="hidden-fact-409"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
      contextRef="c277"
      id="hidden-fact-410"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c279"
      id="hidden-fact-411"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c281"
      id="hidden-fact-412"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="c25"
      id="hidden-fact-413"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="c0"
      id="hidden-fact-414"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="c26"
      id="hidden-fact-415"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized
      contextRef="c27"
      id="hidden-fact-416"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:MilestonePayments
      contextRef="c291"
      id="hidden-fact-417"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="c375"
      decimals="0"
      id="hidden-fact-418"
      unitRef="pure">10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c0"
      id="hidden-fact-419"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c0"
      id="hidden-fact-420"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm contextRef="c0" id="hidden-fact-421" xsi:nil="true"/>
    <abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm contextRef="c0" id="hidden-fact-422" xsi:nil="true"/>
    <abp:SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c451" id="hidden-fact-423" xsi:nil="true"/>
    <abp:SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c451" id="hidden-fact-424" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c439"
      id="hidden-fact-425"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration contextRef="c498" id="hidden-fact-426">http://fasb.org/us-gaap/2025#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c499"
      id="hidden-fact-427"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c506"
      id="hidden-fact-428"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:DeferredOfferingCosts
      contextRef="c2"
      id="hidden-fact-429"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c2"
      id="hidden-fact-430"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c5"
      id="hidden-fact-431"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:AccruedInterest
      contextRef="c5"
      id="hidden-fact-432"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:AccruedBODCompensation
      contextRef="c5"
      id="hidden-fact-433"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c576"
      id="hidden-fact-434"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:FairValueNetAssetLiability
      contextRef="c577"
      id="hidden-fact-435"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="c584"
      id="hidden-fact-436"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c2"
      id="hidden-fact-437"
      unitRef="usd"
      xsi:nil="true"/>
    <abp:ConvertibleThresholdConsecutiveTradingDays contextRef="c638" id="hidden-fact-438">P5Y</abp:ConvertibleThresholdConsecutiveTradingDays>
    <abp:ConvertibleThresholdConsecutiveTradingDays contextRef="c639" id="hidden-fact-439">P7Y</abp:ConvertibleThresholdConsecutiveTradingDays>
    <abp:ConvertibleThresholdConsecutiveTradingDays contextRef="c2" id="hidden-fact-440">P3Y</abp:ConvertibleThresholdConsecutiveTradingDays>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c652"
      id="hidden-fact-441"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c653"
      id="hidden-fact-442"
      unitRef="shares"
      xsi:nil="true"/>
    <abp:ExpiredAtTheMerger
      contextRef="c655"
      id="hidden-fact-443"
      unitRef="shares"
      xsi:nil="true"/>
    <abp:ExpiredAtTheMerger
      contextRef="c656"
      id="hidden-fact-444"
      unitRef="shares"
      xsi:nil="true"/>
    <abp:CommonStockWarrantsOfLegacyACABAcquiredInMerger
      contextRef="c654"
      id="hidden-fact-445"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c657"
      id="hidden-fact-446"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c649"
      id="hidden-fact-447"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c650"
      id="hidden-fact-448"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c34"
      id="hidden-fact-449"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c34"
      id="hidden-fact-450"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm contextRef="c34" id="hidden-fact-451" xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c34"
      id="hidden-fact-452"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c34"
      id="hidden-fact-453"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm contextRef="c34" id="hidden-fact-454" xsi:nil="true"/>
    <abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm contextRef="c34" id="hidden-fact-455" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c676"
      id="hidden-fact-456"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c676"
      id="hidden-fact-457"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c676"
      id="hidden-fact-458"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c676"
      id="hidden-fact-459"
      unitRef="usdPershares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c667"
      decimals="0"
      id="hidden-fact-460"
      unitRef="shares">312024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c665"
      id="hidden-fact-461"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="c34"
      id="hidden-fact-462"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c34"
      id="hidden-fact-463"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c35"
      id="hidden-fact-464"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="c5"
      id="hidden-fact-465"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c2"
      id="hidden-fact-466"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c5"
      id="hidden-fact-467"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="c0" id="ixv-44399">0001893219</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c0" id="ixv-44400">true</dei:AmendmentFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001893219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">AMENDMENT NO. 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Abpro Holdings, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">$ 2,850<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">611<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ForwardPurchaseAgreementAsset', window );">Forward purchase agreement asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">155<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">3,776<span></span>
</td>
<td class="nump">2,035<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset - operating lease</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">418<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PatentsNet', window );">Patents, net</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_SEPAPutRightsAsset', window );">SEPA put rights asset</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">188<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
<td class="nump">3,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,724<span></span>
</td>
<td class="nump">3,936<span></span>
</td>
<td class="nump">7,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,026<span></span>
</td>
<td class="nump">7,496<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise taxes payable</a></td>
<td class="nump">4,401<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="nump">567<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConvertibleNotes', window );">Convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,725<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded derivative liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">17,298<span></span>
</td>
<td class="nump">19,607<span></span>
</td>
<td class="nump">15,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,607<span></span>
</td>
<td class="nump">16,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock, $0.001 par value, issuable in series:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75,599<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">108,487<span></span>
</td>
<td class="nump">100,608<span></span>
</td>
<td class="nump">19,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(124,631)<span></span>
</td>
<td class="num">(116,103)<span></span>
</td>
<td class="num">(108,871)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Abpro Holdings, Inc.&#8217;s stockholders&#8217; deficit</a></td>
<td class="num">(16,144)<span></span>
</td>
<td class="num">(15,495)<span></span>
</td>
<td class="num">(88,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(15,595)<span></span>
</td>
<td class="num">(14,946)<span></span>
</td>
<td class="num">(88,435)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="nump">1,703<span></span>
</td>
<td class="nump">4,661<span></span>
</td>
<td class="nump">3,355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable &#8211; related parties</a></td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesFConvertiblePreferredStockMember', window );">Series F Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock, $0.001 par value, issuable in series:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">9,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock, $0.001 par value, issuable in series:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">29,841<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock, $0.001 par value, issuable in series:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,622<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock, $0.001 par value, issuable in series:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">14,949<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock, $0.001 par value, issuable in series:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,401<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable, Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract', window );"><strong>Convertible preferred stock, $0.001 par value, issuable in series:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">323<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">$ 208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle, if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ForwardPurchaseAgreementAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of forward purchase agreement asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ForwardPurchaseAgreementAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PatentsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of patents, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PatentsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_SEPAPutRightsAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of SEPA put rights asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_SEPAPutRightsAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FeaturesOfConvertiblePreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FeaturesOfConvertiblePreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479772/718-30-S55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.E.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesFConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesFConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">110,000,000<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="nump">81,795,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">2,672,222<span></span>
</td>
<td class="nump">1,727,192<span></span>
</td>
<td class="nump">646,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">2,672,222<span></span>
</td>
<td class="nump">1,694,414<span></span>
</td>
<td class="nump">639,039<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares cost</a></td>
<td class="nump">32,778<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
<td class="nump">7,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesFConvertiblePreferredStockMember', window );">Series F Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,088,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,136,049<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,136,049<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,008,324<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,756,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,756,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,679,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,679,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,679,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,101,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,101,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,101,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,725<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,281,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,281,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,281,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,798<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A Redeemable, Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Convertible Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,938,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Convertible Preferred Stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,938,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Convertible Preferred Stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,938,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,795<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesFConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesFConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_RevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 642<span></span>
</td>
<td class="nump">$ 881<span></span>
</td>
<td class="nump">$ 2,469<span></span>
</td>
<td class="nump">2,983<span></span>
</td>
<td class="nump">4,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,093<span></span>
</td>
<td class="nump">1,472<span></span>
</td>
<td class="nump">5,674<span></span>
</td>
<td class="nump">4,864<span></span>
</td>
<td class="nump">7,121<span></span>
</td>
<td class="nump">7,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,336<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
<td class="nump">6,555<span></span>
</td>
<td class="nump">7,333<span></span>
</td>
<td class="nump">10,104<span></span>
</td>
<td class="nump">11,868<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,336)<span></span>
</td>
<td class="num">(1,931)<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
<td class="num">(7,150)<span></span>
</td>
<td class="num">(9,921)<span></span>
</td>
<td class="num">(11,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">3,556<span></span>
</td>
<td class="nump">3,556<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ChangeInFairValueOfForwardPuchaseAgreementAsset', window );">Change in fair value of forward purchase agreement asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(339)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ChangeInFairValueOfSEPAPutRightsAsset', window );">Change in fair value of SEPA put rights asset</a></td>
<td class="nump">230<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(312)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ChangeInFairValueOfEmbeddedDerivativeLiability', window );">Change in fair value of embedded derivative liability</a></td>
<td class="num">(150)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(773)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_LossOnSettlementOfConvertibleNotes', window );">Loss on settlement of convertible notes</a></td>
<td class="num">(214)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(358)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(164)<span></span>
</td>
<td class="num">(1,104)<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="num">(387)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(321)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
<td class="num">(1,973)<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">2,689<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (1,657)<span></span>
</td>
<td class="num">$ (2,093)<span></span>
</td>
<td class="num">$ (8,528)<span></span>
</td>
<td class="num">$ (3,897)<span></span>
</td>
<td class="num">(7,232)<span></span>
</td>
<td class="num">(11,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_DeemedDividendResultingFromTheWarrantDownRound', window );">Deemed dividend resulting from the warrant down round</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,177)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (17,409)<span></span>
</td>
<td class="num">$ (11,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in Dollars per share)</a></td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (3.27)<span></span>
</td>
<td class="num">$ (4.12)<span></span>
</td>
<td class="num">$ (6.09)<span></span>
</td>
<td class="num">$ (22.31)<span></span>
</td>
<td class="num">$ (18.35)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in Dollars per share)</a></td>
<td class="num">$ (0.63)<span></span>
</td>
<td class="num">$ (3.27)<span></span>
</td>
<td class="num">$ (4.12)<span></span>
</td>
<td class="num">$ (6.09)<span></span>
</td>
<td class="num">$ (22.31)<span></span>
</td>
<td class="num">$ (18.35)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted averages shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding - basic (in Shares)</a></td>
<td class="nump">2,613,889<span></span>
</td>
<td class="nump">640,606<span></span>
</td>
<td class="nump">2,069,965<span></span>
</td>
<td class="nump">639,996<span></span>
</td>
<td class="nump">780,332<span></span>
</td>
<td class="nump">637,777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding - diluted (in Shares)</a></td>
<td class="nump">2,613,889<span></span>
</td>
<td class="nump">640,606<span></span>
</td>
<td class="nump">2,069,965<span></span>
</td>
<td class="nump">639,996<span></span>
</td>
<td class="nump">780,332<span></span>
</td>
<td class="nump">637,777<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abp_ResearchAndDevelopmentServicesMember', window );">Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_RevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="nump">$ 183<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abp_CollaborationRevenueMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_RevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_RevenueAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ChangeInFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents change in fair value of embedded derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ChangeInFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ChangeInFairValueOfForwardPuchaseAgreementAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents of change in fair value of forward purchase agreement asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ChangeInFairValueOfForwardPuchaseAgreementAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ChangeInFairValueOfSEPAPutRightsAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents change in fair value of SEPA put rights asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ChangeInFairValueOfSEPAPutRightsAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_DeemedDividendResultingFromTheWarrantDownRound">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend resulting from the warrant down round.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_DeemedDividendResultingFromTheWarrantDownRound</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_LossOnSettlementOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents loss on settlement of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_LossOnSettlementOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abp_ResearchAndDevelopmentServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abp_ResearchAndDevelopmentServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abp_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abp_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series A Redeemable</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series B</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series C</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series D</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series E</div>
</th>
<th class="th">
<div>Convertible Preferred Stock </div>
<div>Series F</div>
</th>
<th class="th"><div>Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total Abpro&#8217;s Stockholders&#8217; Deficit</div></th>
<th class="th"><div>Non-controlling Interest</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 1,795<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">$ 14,949<span></span>
</td>
<td class="nump">$ 17,622<span></span>
</td>
<td class="nump">$ 29,841<span></span>
</td>
<td class="nump">$ 9,991<span></span>
</td>
<td class="nump">$ 75,599<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="nump">$ 17,615<span></span>
</td>
<td class="num">$ (97,165)<span></span>
</td>
<td class="num">$ (79,583)<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
<td class="num">$ (79,034)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="nump">3,938,098<span></span>
</td>
<td class="nump">1,281,402<span></span>
</td>
<td class="nump">4,101,409<span></span>
</td>
<td class="nump">2,679,397<span></span>
</td>
<td class="nump">6,756,246<span></span>
</td>
<td class="nump">1,136,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,305<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,305<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,706)<span></span>
</td>
<td class="num">(11,706)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,706)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,795<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">$ 14,949<span></span>
</td>
<td class="nump">$ 17,622<span></span>
</td>
<td class="nump">$ 29,841<span></span>
</td>
<td class="nump">$ 9,991<span></span>
</td>
<td class="nump">75,599<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="nump">19,920<span></span>
</td>
<td class="num">(108,871)<span></span>
</td>
<td class="num">(88,984)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">$ (88,435)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">3,938,098<span></span>
</td>
<td class="nump">1,281,402<span></span>
</td>
<td class="nump">4,101,409<span></span>
</td>
<td class="nump">2,679,397<span></span>
</td>
<td class="nump">6,756,246<span></span>
</td>
<td class="nump">1,136,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (3,897)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 1,795<span></span>
</td>
<td class="nump">$ 1,401<span></span>
</td>
<td class="nump">$ 14,949<span></span>
</td>
<td class="nump">$ 17,622<span></span>
</td>
<td class="nump">$ 29,841<span></span>
</td>
<td class="nump">$ 9,991<span></span>
</td>
<td class="nump">75,599<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (33)<span></span>
</td>
<td class="nump">19,920<span></span>
</td>
<td class="num">(108,871)<span></span>
</td>
<td class="num">(88,984)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">$ (88,435)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="nump">3,938,098<span></span>
</td>
<td class="nump">1,281,402<span></span>
</td>
<td class="nump">4,101,409<span></span>
</td>
<td class="nump">2,679,397<span></span>
</td>
<td class="nump">6,756,246<span></span>
</td>
<td class="nump">1,136,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">646,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,006)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities', window );">The Merger, net of transaction costs and acquired liabilities</a></td>
<td class="num">$ (1,795)<span></span>
</td>
<td class="num">$ (1,401)<span></span>
</td>
<td class="num">$ (14,949)<span></span>
</td>
<td class="num">$ (17,622)<span></span>
</td>
<td class="num">$ (29,841)<span></span>
</td>
<td class="num">$ (9,991)<span></span>
</td>
<td class="num">(75,599)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">68,073<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68,106<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities', window );">The Merger, net of transaction costs and acquired liabilities (in Shares)</a></td>
<td class="num">(3,938,098)<span></span>
</td>
<td class="num">(1,281,402)<span></span>
</td>
<td class="num">(4,101,409)<span></span>
</td>
<td class="num">(2,679,397)<span></span>
</td>
<td class="num">(6,756,246)<span></span>
</td>
<td class="num">(1,136,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">955,884<span></span>
</td>
<td class="num">(25,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_IssuanceOfCommonStockInThePIPEFinancing', window );">Issuance of common stock in the PIPE Financing, net of transaction costs of $863,474</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,361<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,361<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">10,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_IssuanceOfCommonStockInPIPEFinancing', window );">Issuance of common stock in the PIPE Financing, net of transaction costs of $863,474 (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">SEPA commitment fee paid in shares</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">SEPA commitment fee paid in shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,927<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,927<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,927<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,232)<span></span>
</td>
<td class="num">(7,232)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(7,232)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,608<span></span>
</td>
<td class="num">(116,103)<span></span>
</td>
<td class="num">(15,495)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">$ (14,946)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Common stock issued for services (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued to related party lender</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">714<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,887)<span></span>
</td>
<td class="num">(3,887)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,887)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">101,630<span></span>
</td>
<td class="num">(119,990)<span></span>
</td>
<td class="num">(18,360)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">(17,811)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,732,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,608<span></span>
</td>
<td class="num">(116,103)<span></span>
</td>
<td class="num">(15,495)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">$ (14,946)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible notes (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">105,478<span></span>
</td>
<td class="num">(122,974)<span></span>
</td>
<td class="num">(17,496)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">$ (16,947)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,246,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">100,608<span></span>
</td>
<td class="num">(116,103)<span></span>
</td>
<td class="num">(15,495)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">$ (14,946)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible notes (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,528)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">108,487<span></span>
</td>
<td class="num">(124,631)<span></span>
</td>
<td class="num">(16,144)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">$ (15,595)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,672,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">101,630<span></span>
</td>
<td class="num">(119,990)<span></span>
</td>
<td class="num">(18,360)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">$ (17,811)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,732,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,694<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible notes (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">513,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,984)<span></span>
</td>
<td class="num">(2,984)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,984)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">105,478<span></span>
</td>
<td class="num">(122,974)<span></span>
</td>
<td class="num">(17,496)<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="num">(16,947)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,246,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible notes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,243<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,243<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible notes (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Advance Shares, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Cancellation of Treasury Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Cancellation of Treasury Stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(32,778)<span></span>
</td>
<td class="num">(32,778)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Cancellation of Treasury Stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,657)<span></span>
</td>
<td class="num">(1,657)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(1,657)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2025</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 108,487<span></span>
</td>
<td class="num">$ (124,631)<span></span>
</td>
<td class="num">$ (16,144)<span></span>
</td>
<td class="nump">$ 549<span></span>
</td>
<td class="num">$ (15,595)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,672,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_IssuanceOfCommonStockInPIPEFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_IssuanceOfCommonStockInPIPEFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_IssuanceOfCommonStockInThePIPEFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>issuance of common stock in pipe financing</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_IssuanceOfCommonStockInThePIPEFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under the merger, net of transaction costs and acquired liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of stock issued under the merger, net of transaction costs and acquired liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_IssuanceOfCommonStockInTransactionCost', window );">Issuance of common stock in transaction costs</a></td>
<td class="nump">$ 863,474<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_IssuanceOfCommonStockInTransactionCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock in transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_IssuanceOfCommonStockInTransactionCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (8,528)<span></span>
</td>
<td class="num">$ (3,897)<span></span>
</td>
<td class="num">$ (7,232)<span></span>
</td>
<td class="num">$ (11,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,158<span></span>
</td>
<td class="nump">1,531<span></span>
</td>
<td class="nump">1,927<span></span>
</td>
<td class="nump">2,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">418<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="nump">548<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Non-cash interest expense</a></td>
<td class="nump">854<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_LossOnSettlementsOfConvertibleNotes', window );">Loss on settlement of convertible notes</a></td>
<td class="nump">358<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income (see Note 2)</a></td>
<td class="num">(200)<span></span>
</td>
<td class="num">(3,556)<span></span>
</td>
<td class="num">(3,556)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount</a></td>
<td class="nump">160<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ChangeInFairValueOfForwardPurchaseAgreementAsset', window );">Change in fair value of forward purchase agreement asset</a></td>
<td class="nump">23<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">339<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ChangeInFairValueOfSEPAPutRightAsset', window );">Change in fair value of SEPA put rights asset</a></td>
<td class="num">(55)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">312<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ChangeInFairValueOnEmbeddedDerivativeLiability', window );">Change in fair value of embedded derivative liability</a></td>
<td class="nump">773<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="num">(235)<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(257)<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="nump">84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesReceivables', window );">Note receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">787<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="num">(860)<span></span>
</td>
<td class="num">(743)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(73)<span></span>
</td>
<td class="nump">551<span></span>
</td>
<td class="nump">383<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="num">(366)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(64)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="num">(456)<span></span>
</td>
<td class="num">(421)<span></span>
</td>
<td class="num">(566)<span></span>
</td>
<td class="num">(500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,386)<span></span>
</td>
<td class="num">(5,215)<span></span>
</td>
<td class="num">(9,030)<span></span>
</td>
<td class="num">(7,402)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(48)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sales of property and equipment</a></td>
<td class="nump">26<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">26<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from settlement of Forward Purchase Agreement</a></td>
<td class="nump">132<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from issuances of debt</a></td>
<td class="nump">1,840<span></span>
</td>
<td class="nump">4,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of Note payable</a></td>
<td class="nump">553<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments on Note payable</a></td>
<td class="num">(553)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Issuance of Advance Shares</a></td>
<td class="nump">739<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NetProceedsFromTheMerger', window );">Net proceeds from the Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from PIPE financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,361<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_CashTransferredToEscrow', window );">Cash transferred into escrow pursuant to Forward Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,134)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from issuance of notes payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,883<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfRelatedPartyDebt', window );">Payment of notes payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,735)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of Convertible Notes, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,755<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of offering costs</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(365)<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
<td class="num">(371)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Repayment of finance lease liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(222)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="nump">4,495<span></span>
</td>
<td class="nump">11,161<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net change in cash and restricted cash</a></td>
<td class="num">(2,649)<span></span>
</td>
<td class="num">(720)<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
<td class="num">(6,601)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash - beginning of period</a></td>
<td class="nump">2,992<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="nump">861<span></span>
</td>
<td class="nump">7,462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash - end of period</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="nump">2,992<span></span>
</td>
<td class="nump">861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of cash flow information and non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_OfferingCostsIncludedInAccountsPayable', window );">Offering costs included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">436<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses', window );">Issuance costs for Advance Shares included in accrued expenses</a></td>
<td class="nump">51<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Fair value of common stock issued for services</a></td>
<td class="nump">161<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability', window );">Common stock issued in settlement of convertible notes and embedded derivative liability</a></td>
<td class="nump">5,937<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_DeferredOfferingCostsIncludedInAccountsPayable', window );">Deferred offering costs included in accounts payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense', window );">Reclassification of residual value guarantees under finance lease to accrued expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties', window );">Settlement of bonus accrual through notes payable - related parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ACABLiabilitiesAssumedInTheMerger', window );">ACAB liabilities assumed in the Merger, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,585<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro', window );">Conversion of notes payable-related parties into common stock of New Abpro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro', window );">Conversion of pre-merger preferred stock of Abpro into common stock of New Abpro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,563<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_SEPACommitmentFeePaidInCommonStockShares', window );">SEPA commitment fee paid in common stock shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>As reported within the unaudited condensed consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and restricted cash as presented in the balance sheet</a></td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 2,992<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ACABLiabilitiesAssumedInTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents ACAB liabilities assumed in the Merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ACABLiabilitiesAssumedInTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_CashTransferredToEscrow">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents to cash transferred into escrow pursuant to forward purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_CashTransferredToEscrow</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ChangeInFairValueOfForwardPurchaseAgreementAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of change in fair value of forward purchase agreement asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ChangeInFairValueOfForwardPurchaseAgreementAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ChangeInFairValueOfSEPAPutRightAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents change in fair value of SEPA put rights asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ChangeInFairValueOfSEPAPutRightAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ChangeInFairValueOnEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents change in fair value of embedded derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ChangeInFairValueOnEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents common stock issued in settlement of convertible notes and embedded derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents conversion of notes payable-related parties into common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents conversion of pre-merger preferred stock of abpro into common stock of new abpro.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_DeferredOfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of deferred offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_DeferredOfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance costs for Advance Shares included in accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_LossOnSettlementsOfConvertibleNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents loss on settlement of convertible notes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_LossOnSettlementsOfConvertibleNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_NetProceedsFromTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_NetProceedsFromTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_OfferingCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents offering costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_OfferingCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of reclassification of residual value guarantees under finance lease to accrued expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_SEPACommitmentFeePaidInCommonStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of SEPA commitment fee paid in common stock shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_SEPACommitmentFeePaidInCommonStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents settlement of bonus accrual through notes payable - related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization and Description of the Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Description of the Business</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>1.</b></span></td>
    <td><span style="-sec-ix-redline:true;font-size: 10pt"><b>Organization and Description of the Business</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b style="-sec-ix-redline:true;-keep: true"><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Abpro Holdings, Inc. and its subsidiaries,
(the &#8220;Company&#8221;) is a biotechnology company dedicated to developing next-generation antibody therapeutics to improve the lives
of patients with severe and life-threatening diseases. The Company is focused on the development of novel antibodies using its proprietary
discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology and infectious disease.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 13, 2024 (the &#8220;Closing Date&#8221;),
Atlantic Coastal Acquisition Corp. II (&#8220;ACAB&#8221;) consummated a merger (the &#8220;Merger&#8221;) pursuant to the terms of the
Merger Agreement, dated as of December 11, 2023 (the &#8220;Merger Agreement&#8221;) by and among Abpro Corporation (&#8220;Legacy Abpro&#8221;),
ACAB, and Abpro Merger Sub Corp., a Delaware corporation (&#8220;Merger Sub&#8221;) and wholly owned subsidiary of ACAB prior to the
Closing Date. Pursuant to the Merger Agreement, on the Closing Date, (i) ACAB changed its name to &#8220;Abpro Holdings, Inc.&#8221;
(&#8220;New Abpro&#8221;), and (ii)&#160;Merger Sub merged with and into Legacy Abpro, with Legacy Abpro as the surviving company in
the Merger (such transactions, the &#8220;Merger,&#8221; and, collectively with the other transactions described in the Merger Agreement,
the &#8220;Reverse Recapitalization&#8221;). Shares of the New Abpro common stock commenced trading on the Nasdaq Global Market on November
14, 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">After giving effect to the Merger, Legacy
Abpro became a wholly owned subsidiary of the Company. The Merger was accounted for as a reverse recapitalization in accordance with
U.S. GAAP, and under this method of accounting, ACAB was treated as the acquired company for financial reporting purposes and Legacy
Abpro was treated as the acquirer. Operations prior to the Merger are those of Legacy Abpro. Unless otherwise noted, the Company has
retroactively adjusted all common and preferred share and related price information to give effect to the Exchange Ratio as set forth
in the Merger Agreement (see Note 3). The &#8220;Company&#8221; refers to Abpro Holdings, Inc. and its subsidiaries, including Abpro
Corporation, prior to and subsequent to the Merger. Legacy Abpro is the accounting acquirer in the Merger and, as such, the condensed
consolidated financial statements for the three months and nine months ended September 30, 2024 present operations of Legacy Abpro prior
to the Merger Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Refer to Note 3 &#8212; Merger for further
details of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 16 , 2025, the Company filed with
the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the &#8220;Certificate
of Amendment&#8221;), which became effective on October 31, 2025 (the &#8220;Effective Time&#8221;), to effect a one-for-thirty (1:30)
reverse stock split (the &#8220;Reverse Stock Split&#8221;), of the shares of the Company&#8217;s common stock, par value $0.0001 per
share. The Reverse Stock Split was approved by the Company&#8217;s stockholders at the 2025 annual meeting of the stockholders on October
10, 2025. The Company&#8217;s common stock began trading on a reverse stock split-adjusted basis upon market opening on November 3, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As a result of the Reverse Stock Split, every
30 shares of issued and outstanding common stock will be automatically combined into one (1) issued and outstanding share of common stock,
without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split. Instead, stockholders
who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly divisible by the
Reverse Stock Split ratio will be entitled to receive an additional fraction of a share of common stock to round up to the next whole
share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">All of the Company&#8217;s historical share
and per share information related to issued and outstanding common stock, restricted stock units, and options and warrants exercisable
for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1:30 reverse stock split.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Risks and Uncertainties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of more advanced
or effective therapies, dependence on key executives, protection of and dependence on proprietary technology, compliance with government
regulations and ability to secure additional capital to fund operations. Programs currently under development will require significant
additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization.
These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting
capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will
realize significant revenue from product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is required to evaluate whether
there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern
within one year after the date that the condensed consolidated financial statements are issued. Through September 30, 2025, the Company
has funded its operations mainly through equity and debt financings, including the proceeds from the issuance of shares under SEPA (see
Notes 11 and 16), as well as from the Merger and the PIPE Financing (see Note 3), and to a lesser extent, payments received in connection
with collaboration and license agreements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of September&#160;30, 2025 and December&#160;31,
2024, the Company had an accumulated deficit of $124,631 and $116,103, respectively. The Company&#8217;s net loss was $1,657 and $8,528
for the three and nine months ended September&#160;30, 2025, respectively. Substantially all of the Company&#8217;s net losses resulted
from costs incurred in connection with the Company&#8217;s research and development programs and from general and administrative costs
associated with the Company&#8217;s operations. The Company expects to incur substantial operating losses and negative cash flows from
operations for the foreseeable future as the Company advances its product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 2, 2025, the Company received written
notice (the &#8220;Notice&#8221;) from the Listing Qualifications Department staff (the &#8220;Staff&#8221;) of the Nasdaq Stock Market
(&#8220;Nasdaq&#8221;) notifying the Company that, based on the closing bid price of the Company&#8217;s common stock for the last 30
consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on The Nasdaq
Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities to maintain a minimum bid price of $1.00 per share (the &#8220;Minimum
Bid Price Requirement&#8221;), and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the Minimum Bid Price Requirement
exists if the deficiency continues for a period of 30 consecutive business days. &#160;Pursuant to the Nasdaq Listing Rules, the Company
has been provided an initial compliance period of 180 calendar days to regain compliance with the Minimum Bid Price Requirement. The
letter stated that the Company had 180 calendar days, or until September 29, 2025, to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 10, 2025, the Company received two
letters from the Staff of Nasdaq. One letter (the &#8220;MVPHS Notice&#8221;) indicated that based upon Nasdaq&#8217;s review of the
Company&#8217;s Market Value of Publicly Held Shares (&#8220;MVPHS&#8221;) for the last 30 consecutive business days prior to the date
of the MVPHS Notice, the Company no longer meets the requirements of Nasdaq Listing Rule 5450(b)(2)(C), which requires listed securities
to maintain a minimum MVPHS of $15,000,000 (the &#8220;MVPHS Requirement&#8221;). The second letter notified the Company that from February
20, 2025, to April 9, 2025, the Company&#8217;s Market Value of Listed Securities (&#8220;MVLS&#8221;) was below the minimum of $50 million
required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A) (the &#8220;MVLS Requirement&#8221;).
Each letter stated that the Company had 180 calendar days, or until October 7, 2025, to regain compliance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On September 30, 2025, the Company received
a letter from Nasdaq notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement during the compliance
period. Accordingly, the Company timely requested a hearing before the appeal panel (the &#8220;Panel&#8221;), which stayed the suspension
of the Company&#8217;s securities with Nasdaq pending the Panel&#8217;s decision or any extension of time provided by the Panel to regain
compliance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 14, 2025, the Company received
a letter (the &#8220;Notice&#8221;) from Nasdaq notifying the Company that it had not regained compliance with either the MVPHS Requirement
or the MVLS Requirement during the compliance period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Hearing was held on October 30, 2025.
During the Hearing, the Company presented its plans to regain compliance with the Minimum Bid Price Requirement, the MVPHS Requirement
and the MVLS Requirement. On November 10, 2025, the Company received a decision letter from the Panel granting the Company&#8217;s request
for continued listing on The Nasdaq Stock Market, subject to the Company&#8217;s strict adherence to certain interim deadlines and conditions.
The Panel will maintain jurisdiction over the Company&#8217;s listing through March 30, 2026, and may reconsider the terms of the exception
or delist the Company if it fails to meet any of the imposed deadlines or becomes deficient with any listing rule during this period.
There can be no assurance that the Company will be able to meet the conditions imposed by the Panel or regain and maintain compliance
with Nasdaq&#8217;s listing requirements. Failure to do so may result in the delisting of the Company&#8217;s securities from Nasdaq.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 23, 2025, the Company received net
proceeds of $1,840 from the Second Convertible Note pursuant to the SEPA (see Note 11).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In July and August 2025, the Company issued
three Advance Notices to YA (see Note 11) in accordance with the terms of the SEPA, under which YA purchased from the Company 91,336
common stock shares, raising $688 in total net proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of September&#160;30, 2025, the Company
had cash of $328. Due to its current liabilities, the cash available to the Company will not be sufficient to allow the Company to operate
for at least 12 months from the date these financial statements are available for issuance. The future viability of the Company is largely
dependent on its ability to raise additional capital to finance its operations. The Company expects to seek additional funding through
equity and debt financings, collaboration agreements and research grants. Although the Company has been successful in raising capital
in the past, there is no assurance that it will be successful in obtaining such additional financing on terms acceptable to the Company,
if at all. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate its research and development
programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accordingly, based on the considerations discussed
above, management has concluded there is substantial doubt as to the Company&#8217;s ability to continue as a going concern within one
year after the date the condensed consolidated financial statements are issued. The Company plans to continue to fundraise, as well as
seek alternate revenues from collaboration and license agreements. If adequate funds are not available, the Company may be required to
initiate steps to slow cash burn, extending the cash runway until financing can be secured. The condensed consolidated financial statements
do not include any adjustments with respect to the carrying amounts of assets and liabilities and their classification that might result
from the outcome of this uncertainty.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Organization
and Description of the Business</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Organization</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Abpro Holdings, Inc. and its subsidiaries,
(the &#8220;Company&#8221;) is a biotechnology company headquartered in Woburn, Massachusetts, dedicated to developing next-generation
antibody therapeutics to improve the lives of patients with severe and life-threatening diseases. The Company is focused on the development
of novel antibodies using its proprietary discovery and engineering platforms, primarily in the areas of immuno-oncology, ophthalmology
and infectious disease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 13, 2024 (the &#8220;Closing
Date&#8221;), Atlantic Costal Acquisition Corp. II (&#8220;ACAB&#8221;) consummated a merger (the &#8220;Merger&#8221;) pursuant to the
terms of the Merger Agreement, dated as of December 11, 2023 (the &#8220;Merger Agreement&#8221;) by and among Abpro Corporation (&#8220;Legacy
Abpro&#8221;), ACAB, and Abpro Merger Sub Corp., a Delaware corporation (&#8220;Merger Sub&#8221;) and wholly owned subsidiary of ACAB
prior to the Closing Date. Pursuant to the Merger Agreement, on the Closing Date, (i) ACAB changed its name to &#8220;Abpro Holdings,
Inc.&#8221; (&#8220;New Abpro&#8221;), and (ii) Merger Sub merged with and into Legacy Abpro, with Legacy Abpro as the surviving company
in the Merger (such transactions, the &#8220;Merger,&#8221; and, collectively with the other transactions described in the Merger Agreement,
the &#8220;Reverse Recapitalization&#8221;). Shares of the New Abpro common stock commenced trading on the Nasdaq Capital Market on November
14, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">After giving effect to the Merger,
Legacy Abpro became a wholly owned subsidiary of the Company. The Merger is accounted for as a reverse recapitalization in accordance
with U.S. GAAP, and under this method of accounting, ACAB is treated as the acquired company for financial reporting purposes and Legacy
Abpro is treated as the acquirer. Operations prior to the Merger are those of Legacy Abpro. Unless otherwise noted, the Company has retroactively
adjusted all common and preferred share and related price information to give effect to the Exchange Ratio as set forth in the Merger
Agreement. The &#8220;Company&#8221; refers to Abpro Holdings, Inc. and its subsidiaries, including Abpro Corporation, prior to and subsequent
to the Merger. As described in Note 3, Legacy Abpro is the accounting acquirer in the Merger and, as such, the consolidated financial
statements present operations of Legacy Abpro prior to the Merger Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Refer to Note 3 - Reverse Recapitalization
for further details of the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Reverse Stock Split</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 16, 2025, the Company filed
with the Delaware Secretary of State a Certificate of Amendment to the Certificate of Incorporation of the Company (the &#8220;Certificate
of Amendment&#8221;), which became effective on October 31, 2025 (the &#8220;Effective Time&#8221;), to effect a one-for-thirty (1:30)
reverse stock split (the &#8220;Reverse Stock Split&#8221;), of the shares of the Company&#8217;s common stock, par value $0.0001 per
share. The Reverse Stock Split was approved by the Company&#8217;s stockholders at the 2025 annual meeting of the stockholders on October
10, 2025. The Company&#8217;s common stock began trading on a reverse stock split-adjusted basis upon market opening on November 3, 2025.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As a result of the Reverse Stock
Split, every 30 shares of issued and outstanding Common Stock will be automatically combined into one (1) issued and outstanding share
of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split.
Instead, stockholders who otherwise would have been entitled to receive fractional shares because they held a number of shares not evenly
divisible by the Reverse Stock Split ratio will be entitled to receive an additional fraction of a share of Common Stock to round up to
the next whole share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">All of the Company&#8217;s historical
share and per share information related to issued and outstanding common stock, restricted stock units, and options and warrants exercisable
for common stock in these financial statements have been adjusted, on a retroactive basis, to reflect this 1-for-30 reverse stock split.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Risks and Uncertainties</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company is subject to risks and
uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors
of more advanced or effective therapies, dependence on key executives, protection of and dependence on proprietary technology, compliance
with government regulations and ability to secure additional capital to fund operations. Programs currently under development will require
significant additional research and development efforts, including preclinical and clinical testing and regulatory approval prior to commercialization.
These efforts require significant amounts of additional capital, adequate personnel and infrastructure, and extensive compliance-reporting
capabilities. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will
realize significant revenue from product sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Going Concern</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company is required to evaluate
whether there are conditions or events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going
concern within one year after the date that the consolidated financial statements are issued. Through December 31, 2024, the Company has
funded its operations mainly through equity and debt financings, including the proceeds from the Merger and the PIPE Financing (as further
described in Note 3), and to a lesser extent, payments received in connection with collaboration and license agreements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Since inception, the Company has incurred
losses. The Company&#8217;s net losses totaled $7,232 and $11,706 for the years ended December 31, 2024 and 2023, respectively. The Company
had an accumulated deficit of $116,103 as of December 31, 2024. The Company expects to incur operating losses for the foreseeable future.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 18, 2023, the Company entered
into a promissory note agreement with Abpro Bio International, Inc. (&#8220;ABI&#8221;), a significant investor in Legacy Abpro&#8217;s
Series E and F convertible preferred stock (see Note 12), to receive up to $6,000. The Company received $4,225 through the Closing Date,
including $2,786 during the year ended December 31, 2024, in which the aggregate principal amount was converted in common shares at the
Closing Date in connection with the PIPE Financing (see Note 3).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On April 18, 2024, the Company entered
into a promissory note agreement with one of its executives (see Note 12 for terms and conditions) to receive, as amended, up to $2,158
in funding. The Company received $1,997 through the Closing Date. The principal amount of this note was converted into 20,000 common shares at the Closing Date as described in Note 12.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 7, 2024, the Company entered
into an additional promissory note with ABI (&#8220;the 2024 ABI Note&#8221;) to receive up to $1,000 from ABI in weekly installments
of $250. The note accrued 10% interest and had the maturity date which was 5 business days after receipt of the proceeds under the PIPE
Financing (see Note 3). The Company repaid the $1,000 balance at the Closing out of the proceeds from the PIPE Financing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company received $5.7 million in
net proceeds from the Merger and related PIPE Financing, net of ACAB transaction costs and liabilities settled at the Closing. The Company
incurred $2.1 million in transaction costs and $0.9 million in issuance costs related to the PIPE Financing, consisting of banking, legal,
investment advisory and other professional fees, of which were recorded as a reduction of proceeds to additional paid-in capital. At the
Closing Date, Legacy Abpro assumed $6.6 million of net liabilities, including tax liabilities and legal fees of ACAB, of which $1.0 million
was included in accrued expenses, $4.4 million in excise tax payable and $0.4 million in income tax payable as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 14, 2024, the Company entered
into a Convertible Promissory Note with YA II PN, Ltd. (&#8220;YA&#8221;) (see Note 13) for $3,000 and received net proceeds of $2,755,
net of the original issuance discount of 8% (the &#8220;Convertible Note Discount&#8221;). The convertible note has a maturity of November
13, 2025 (subject to earlier repayments based on Amortization Event described below), incurs interest at a rate of 0% (or 18% upon the
occurrence of an uncured Event of Default).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At the Merger Closing Date, the Company
paid approximately $1,100 pursuant to the terms of the Forward Purchase Agreement (see Note 11) with YA. On January 28, 2025, YA elected
to effect an Optional Early Termination with respect to all 3,333 Shares subject to the Forward Purchase Agreement which terminated the
agreement as a whole. YA paid the Company the Early Termination Obligation in the aggregate amount of $132, based on the Reset Price of
$39.60 per share in effect on January 28, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On April 2, 2025, the Company received
written notice (the &#8220;Notice&#8221;) from the Listing Qualifications Department of Nasdaq notifying the Company that, based on the
closing bid price of the Company&#8217;s common stock for the last 30 consecutive business days, the Company no longer complies with the
minimum bid price requirement for continued listing on The Nasdaq Stock Market LLC. Nasdaq Listing Rule 5450(a)(1) requires listed securities
to maintain a minimum bid price of $1.00 per share (the &#8220;Minimum Bid Price Requirement&#8221;), and Nasdaq Listing Rule 5810(c)(3)(A)
provides that a failure to meet the Minimum Bid Price Requirement exists if the deficiency continues for a period of 30 consecutive business
days. Pursuant to the Nasdaq Listing Rules, the Company has been provided an initial compliance period of 180 calendar days to regain
compliance with the Minimum Bid Price Requirement. To regain compliance, the closing bid price of the Company&#8217;s common stock must
be at least $1.00 per share for a minimum of 10 consecutive business days prior to September 29, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Due to its current liabilities, the
cash available to the Company may not be sufficient to allow the Company to operate for at least 12 months from the date these financial
statements are available for issuance. The future viability of the Company is largely dependent on its ability to raise additional capital
to finance its operations. The Company expects to seek additional funding through equity and debt financings, collaboration agreements
and research grants. Although the Company has been successful in raising capital in the past, there is no assurance that it will be successful
in obtaining such additional financing on terms acceptable to the Company, if at all. If the Company is unable to obtain funding, the
Company could be forced to delay, reduce or eliminate its research and development programs, product portfolio expansion or commercialization
efforts, which could adversely affect its business prospects.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accordingly, based on the
considerations discussed above, management has concluded there is substantial doubt as to the Company&#8217;s ability to continue as
a going concern within one year after the date the consolidated financial statements are issued. The Company plans to continue to
fundraise, as well as seek alternate revenues from collaboration and license agreements. If adequate funds are not available, the
Company may be required to initiate steps to slow cash burn, extending the cash runway until financing can be secured. The
consolidated financial statements do not include any adjustments with respect to the carrying amounts of assets and liabilities and
their classification that might result from the outcome of this uncertainty.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480922/205-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481034/205-10-S45-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>2.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Summary of Significant Accounting Policies</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accompanying condensed
consolidated financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation
(&#8220;AbMed&#8221;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts
have been reclassified to conform to the current period presentation with no material impact on the condensed consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported
in the condensed consolidated financial statements and accompanying notes. Significant estimates in these condensed consolidated financial
statements include stock-based compensation expense, the fair value of derivative instruments, the fair value of options and warrants,
pre-clinical&#160;and clinical accrued expenses, the valuation and realizability of deferred tax assets, and the ability to continue
as a going concern. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates
on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making
estimates, actual results could differ materially from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2022, the Company received an invoice
from Mabwell (Shanghai) Bioscience Co., Ltd. (&#8220;Mabwell&#8221;) for approximately $3,500 in connection with the manufacturing of
certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based on the information available
at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its validity. The Company continued to
dispute the amount and its contractual basis because the parties had neither finalized nor executed a clinical trial manufacturing agreement.
In July 2024, the Company received communication from Mabwell that they will not be pursuing the collection of the originally invoiced
amount. Accordingly, during the quarter ended March 31, 2024, the Company reversed the liability and recognized $3,500 of other income.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Unaudited Interim Condensed Consolidated
Financial Statements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The accompanying interim condensed consolidated
financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared
on the same basis as the audited financial statements, and in management&#8217;s opinion, include all adjustments, consisting of only
normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of September&#160;30, 2025
and its results of operations for the three months and nine months ended September&#160;30, 2025 and 2024, and cash flows for the nine
months ended September&#160;30, 2025 and 2024. The results of operations for the three months and nine months ended September&#160;30,
2025 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2025 or any other period. The
December&#160;31, 2024 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not
include all disclosures from the annual financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Certain information and footnote disclosures
normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant
to the rules and regulations of the SEC. Accordingly, these condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements for the year ended December&#160;31, 2024 and the related notes included in the Company&#8217;s
Annual Report on Form 10-K, filed with the SEC on April 15, 2025 (the &#8220;Annual Report&#8221;), which provides a more complete discussion
of the Company&#8217;s accounting policies and certain other information. There have been no significant changes to the significant accounting
policies disclosed in Note 2 of the audited consolidated financial statements as of and for the year ended December&#160;31, 2024 included
in the Company&#8217;s Annual Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Segment Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC Topic No. 280, Segment Reporting (&#8220;ASC
280&#8221;), establishes standards for the way that public business enterprises report information about operating segments in their
annual consolidated financial statements and requires that those enterprises report selected information about operating segments in
interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and
major customers. The Company&#8217;s business segments are based on the organization structure used by the chief operating decision maker
(&#8220;CODM&#8221;) for making operating and investment decisions and for assessing performance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In accordance with ASC 280, the Company has
determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in the
areas of immuno-oncology, ophthalmology and infectious disease. The financial results of the Company&#8217;s operations are managed and
reported to the <span style="-sec-ix-hidden: hidden-fact-405">Chief Executive Officer</span>, who is considered the Company&#8217;s CODM, on a consolidated basis. The CODM assesses performance
and allocates resources based on the Company&#8217;s consolidated statements of operations, and key components and processes of the Company&#8217;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development expenses, general and administrative
expenses, and interest expenses, which are each separately presented on the Company&#8217;s condensed consolidated statements of operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Non-controlling Interest</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company holds an 82% ownership interest
in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not owned by
the Company and is reported as a component in stockholders&#8217; equity on the condensed consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $2.00
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling
interest holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the
nine month periods ending September 30, 2025 and 2024.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Net Loss Per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company follows the two-class method to
compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 12), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#8217;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#8217;s outstanding common
stock for all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Basic net loss per share attributable to common
stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock outstanding
during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion of such
shares would be anti-dilutive. As the Company has incurred losses for the three and nine months ended September 30, 2025 and 2024, basic
and diluted net loss per share were the same all periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share, because their effect was anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Convertible Preferred Stock</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-404"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">662,921</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">Warrants</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">990,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,159</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock options</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,635</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">345,164</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Unvested restricted stock units</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,667</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,292</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,229,302</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,013,536</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Recently Adopted Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2023, the&#160;Financial Accounting
Standards Board&#160;(&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted.
The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these unaudited
condensed consolidated financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Recently Issued Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 4, 2024, the FASB issued&#160;ASU
2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the
same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting
periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.
The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management does not believe that any additional
recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#8217;s
financial statements.&#160;</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Summary
of Significant Accounting Policies</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Basis of Presentation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accompanying consolidated
financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation (&#8220;AbMed&#8221;).
All intercompany balances and transactions have been eliminated in consolidation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Emerging Growth Company</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company is an &#8220;emerging growth
company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but
not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section
404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden
parachute payments not previously approved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the
amounts reported in the consolidated financial statements and accompanying notes. Significant estimates in these consolidated financial
statements include stock-based compensation expense, fair value of common stock, pre-clinical and clinical accrued expenses, valuation
and realizability of deferred tax assets and the ability to continue as a going concern. On an ongoing basis, the Company evaluates its
estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed
to be reasonable. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In March 2022, the Company
received an invoice from Mabwell (Shanghai) Bioscience Co., Ltd. (&#8220;Mabwell&#8221;) for approximately $3,500 in connection with
the manufacturing of certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based
on the information available at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its
validity. The Company continued to dispute the amount and its contractual basis because the parties had neither finalized nor
executed a clinical trial manufacturing agreement. In July 2024, the Company received communication from Mabwell that they will not
be pursuing the collection of the originally invoiced amount. Accordingly, during the year ended December 31, 2024, the Company
reversed the liability and recognized approximately $3,500 of other income.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Segment Reporting</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">ASC Topic No. 280, Segment Reporting
(&#8220;ASC 280&#8221;), establishes standards for the way that public business enterprises report information about operating segments
in their annual consolidated financial statements and requires that those enterprises report selected information about operating segments
in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas
and major customers. The Company&#8217;s business segments are based on the organization structure used by the chief operating decision
maker (&#8220;CODM&#8221;) for making operating and investment decisions and for assessing performance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In accordance with ASC 280, the Company
has determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in
the areas of immuno-oncology, ophthalmology and infectious disease. The financial results of the Company&#8217;s operations are managed
and reported to the Chief Executive Officer, who is considered the Company&#8217;s CODM, on a consolidated basis. The CODM assesses performance
and allocates resources based on the Company&#8217;s consolidated statements of operations, and key components and processes of the Company&#8217;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development and general and administrative
expenses, which are each separately presented on the Company&#8217;s consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On March 3, 2025, the Board removed
Ian Chan as Chief Executive Officer of the Company for cause, and Miles Suk was appointed as Chief Executive Officer of the Company. In
addition, pursuant to Mr. Chan&#8217;s employment agreement with the Company&#8217;s wholly-owned subsidiary, Abpro Corporation, Mr. Chan
was notified that he was terminated as Chief Executive Officer and director of Abpro Corporation, effective March 3, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Cash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in bank deposit accounts,
which, at times, may exceed federally insured limits. As of December 31, 2024 and 2023, the Company has not experienced a loss on its
accounts for which it exceeds federally insured deposit limits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Restricted Cash</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The restricted cash balance is related
to a balance provided as collateral associated with the letter of credit for one of the Company&#8217;s facility leases (see Note 9) and
is reported as a current asset in the consolidated balance sheets. The following tables reconcile cash and restricted cash to amounts
shown in the consolidated statements of cash flows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,850</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">723</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">142</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total cash and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">861</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Accounts receivable</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accounts receivable are stated at the
amount management expects to collect from outstanding balances under its license and collaboration arrangements. The Company applies the
guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 326, <i>Financial Instruments-Credit Losses</i> (&#8220;ASC 326&#8221;),
which requires measurement and recognition of expected credit losses for financial assets. The Company records receivables net of any
allowances for doubtful accounts for current expected credit losses under its license and collaboration arrangements. An allowance for
doubtful accounts is determined based on the financial condition and creditworthiness of customers as well as the economic factors and
trends expected to affect future collections. Any allowance would reduce the accounts receivable to the amount that is expected to be
collected. As of December 31, 2024 and 2023, the Company determined that no allowance for doubtful accounts was required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Deferred Offering Costs</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Deferred offering costs consist of
legal, accounting, underwriting fees and other costs of Legacy Abpro that are directly related to the Merger. These costs were accounted
for as a reduction of the proceeds received at the Closing Date of the Merger. As of December 31, 2024 and 2023, the Company had deferred
offering costs of <span style="-sec-ix-hidden: hidden-fact-429">$0</span> and $878, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Property and Equipment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Property and equipment are stated at
cost, less accumulated depreciation. Repairs and maintenance charges that do not increase the useful life of the assets are charged to
operations as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Depreciation on property and equipment
is calculated using the straight-line method over the estimated useful lives as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 77%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Useful Life<br/>
(in years)</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer hardware and software</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 5&#160;</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 5</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 - 7</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-426">Shorter of useful life or lease term</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Leases</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company accounts for leases in
accordance with ASC Topic 842, <i>Leases </i>(&#8220;ASC 842&#8221;). Under ASC 842, the Company assesses its contracts at inception to
determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly
or implicitly identified asset for a period of time. As a lessee, the Company records a right-of-use asset and a lease liability in its
consolidated balance sheets for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with
classification affecting the pattern of expense recognition in the consolidated statement of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company recognizes operating
lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets. ROU assets
represent the Company&#8217;s right to use an underlying asset during the lease term and lease liabilities represent the
Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at
commencement date based on the net present value of fixed lease payments over the lease term. The Company&#8217;s lease term
includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. ROU assets also
include any advance lease payments made and are net of any lease incentives. As most of the Company&#8217;s operating leases do not
provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in
determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would
expect to pay to borrow over a similar term, and on a collateralized basis, an amount equal to the lease payments in a similar
economic environment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company enters into lease agreements
for the use of laboratory and office space, and laboratory equipment, under both operating and finance leases. Operating leases are included
in Right-of-use asset - operating lease, and Operating lease liability - current and Operating lease liability - noncurrent in the consolidated
balance sheets. Finance leases are included in Property and Equipment, net, Finance lease liability - current and Finance lease liability
- noncurrent in the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Patents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company incurs costs related to
patent license fees and patent applications. These payments are capitalized when the Company believes that there is a high likelihood
that the patent will be issued and there will be future economic benefit associated with the patent. These costs are amortized from the
date of the patent application on a straight-line basis over the estimated useful life of 20 years, which is the legal life of the patent.
All costs associated with abandoned patents applications are expensed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Impairment of Long-lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company periodically evaluates
its long-lived assets for potential impairment. Potential impairment is assessed when there is evidence that events or changes in circumstances
indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is based on undiscounted expected future
cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market
trends, and product development cycles. An impairment of the carrying value of each asset is assessed when the undiscounted expected future
cash flows derived from the asset are less than its carrying value. The impairment loss would be measured as the excess of the carrying
value of the impaired asset over its fair value. No impairment charges were recorded for the years ended December 31, 2024 and 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Revenue Recognition</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company recognizes revenue in accordance
with the guidance of <i>Revenue From Contracts With Customers</i>, Accounting Standards Codification Topic 606 (&#8220;ASC 606&#8221;).
Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements
the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with
a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance
obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>License
and collaboration revenues - </i>The Company&#8217;s license and collaboration revenues have been generated primarily through collaborative
research, development, manufacturing and commercialization agreements. The terms of these agreements generally include the license of
intellectual property and associated know-how and the provision of other goods and services. Payments to the Company under these arrangements
typically include one or more of the following: non-refundable, up-front license fees; milestone payments; and royalties on future product
sales.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>License
of Intellectual Property</i> - If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to
the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation
is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue associated with the bundled performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Milestone
Payments - </i>At the inception of each arrangement that includes milestone payments based upon the achievement of specified clinical
development, regulatory and/or sales milestones, the Company evaluates whether the milestones are considered probable of being achieved
and estimates the amount to be included in the transaction price. If it is probable that a significant revenue reversal would not occur,
the associated milestone amount is included in the transaction price. Milestone payments that are dependent on factors outside of the
Company&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.
These payments are fully constrained and therefore are not included in the transaction price. At the end of each reporting period, the
Company re-evaluates the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the reported amount
of license and collaboration revenues in the period of adjustment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Royalties.
</i>For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is
deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales
occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially
satisfied).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s research and development
expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation charges for those individuals involved
in research and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies
and clinical materials. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods
or services to be used in research and development are capitalized until the goods or services are received.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Income taxes are accounted for under
the asset and liability method, as required by FASB ASC Topic 740, <i>Income Taxes </i>(&#8220;ASC 740&#8221;). The Company provides for
federal, and state income taxes currently payable. Deferred tax assets and liabilities are recognized for the future tax consequences
attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases as well as for tax loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted income
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The effect of a change in income tax
rates is recognized as income or expense in the period that includes the enactment date. The Company files income tax returns in the U.S.
federal jurisdiction and various state jurisdictions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company recognizes the effect of
income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured
at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period
in which the change in judgment occurs. The Company recognizes interest and/or penalties related to uncertain tax positions in income
tax expense. There were <span style="-sec-ix-hidden: hidden-fact-430"><span style="-sec-ix-hidden: hidden-fact-431">no</span></span> uncertain tax positions as of December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Share-Based Compensation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company accounts for share-based
payments in accordance with Accounting Standard Codification Topic 718, <i>Compensation-Stock Compensation </i>(&#8220;ASC 718&#8221;).
Under ASC 718, the Company measures, and records compensation expense related to share-based payment awards (to employees and non-employees)
based on the grant date fair value using the Black-Scholes option-pricing model. The Company recognizes forfeitures related to employee
share-based payments when they occur. Forfeited share-based awards are recorded as a reduction to share-based compensation expense.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The determination of the fair value
of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including
expected volatility, expected term, risk-free interest rate and expected dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In determining the exercise prices
of options granted, the Company&#8217;s Board has considered the fair value of the common stock as of the measurement date. As Legacy
Abpro&#8217;s common stock was not traded prior to the Merger, the fair value of the common stock was determined by the Board at each
award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company&#8217;s
financial position and historical financial performance, the status of technological developments within the Company&#8217;s proposed
products, an evaluation or benchmark of the Company&#8217;s competition, the current business climate in the marketplace, the illiquid
nature of the common stock, arm&#8217;s length sales of the Company&#8217;s capital stock, including convertible preferred stock, the
effect of the rights and preferences of the preferred stockholders, and then prospects of a liquidity event, among others.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company does not have sufficient
history of market prices of its common stock, and as such, volatility is estimated using historical volatilities of similar public entities.
The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a
sufficient amount of historical information regarding the volatility of its own stock price becomes available. The expected term of the
awards is estimated based on the simplified method for grants to employees and is based on the contractual term for non-employee awards.
The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield
assumption is based on history and expectation of paying no dividends.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="background-color: white"><b><i>Convertible
Preferred Stock </i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
Company accounts for its convertible preferred stock in accordance with the guidance in ASC Topic 480, <i>Distinguishing Liabilities from
Equity </i>(&#8220;ASC 480&#8221;). Preferred stock subject to mandatory redemption (if any) is classified as a liability instrument and
is measured at fair value. Conditionally redeemable common stock (including preferred stock that features redemption rights that are either
within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s
control) is classified as temporary equity (see Note 14).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="background-color: white"><b><i>Derivative
Financial Instruments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">In
connection with the Merger, the Company assumed the warrants for common stock shares issued by ACAB, which include warrants issued in
the ACAB&#8217;s initial public offering (&#8220;Public Warrants&#8221;) and warrants purchased by the Sponsor (the  &#8220;Private Warrants&#8221;)
(see Note 14). </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
Company accounts for financial instruments as either equity-classified or liability-classified instruments based on an assessment of the
specific terms of the instruments and applicable authoritative guidance in ASC 480 and ASC Topic 815, <i>Derivatives and Hedging </i>(&#8220;ASC
815&#8221;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#8217;s own stock and whether the holders of the warrants could potentially require &#8220;net cash settlement&#8221;
in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
Public and Private Warrants were accounted for as equity instruments as they meet all of the requirements for equity classification under
ASC 815 based on current expected terms, which are subject to change. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Contingent Earnout Shares</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In connection with the Reverse Recapitalization
and pursuant to the Merger Agreement, Legacy Abpro equity holders are entitled to receive, as additional merger consideration, up to 483,333
shares of the Company&#8217;s common stock (the &#8220;Contingent Earnout Shares&#8221;), comprised of three separate equal tranches,
for no consideration upon the occurrence of certain triggering events, including a change of control event. It was determined that based
on its provisions, the contingent consideration is indexed to the Company&#8217;s stock and therefore qualify for the scope exception
from the derivative accounting in ASC 815-10-15-74(a). As a result, the Company elected to recognize the contingent consideration obligation
in accordance with ASC Topic 450, <i>Contingencies </i>(&#8220;ASC 450&#8221;) when the contingency is resolved, and the consideration
is paid or becomes payable. Based on the Company&#8217;s stock price, no amounts were due under the contingent earnout provisions as of
December 31, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Fair Value Measurements and Fair
Value of Financial Instruments </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company categorizes its assets
and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1)
and lowest priority to unobservable inputs (Level 3). The carrying value of cash, accounts receivable, accounts payable, accrued expenses,
excise taxes payable, income taxes payable, and related party loans payable approximate fair value because of the short-term nature of
such instruments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Level 1 - Inputs are unadjusted quoted
prices in active markets for identical assets or liabilities available at the measurement date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Level 2 - Inputs are unadjusted quoted
prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market
data.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Level 3 - Unobservable inputs based
on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In some circumstances, the inputs used
to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement
is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Transfers to/from Levels 1, 2 and 3
are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Non-controlling Interest</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company holds an 82% ownership
interest in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not
owned by the Company and is reported as a component in stockholders&#8217; equity on the consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $2.00
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling interest
holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the years ended
December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Net Loss Per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company follows the two-class method
to compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 14), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#8217;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#8217;s outstanding common stock
for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Basic net loss per share attributable
to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock
outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common
stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or
converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion
of such shares would be anti-dilutive. As the Company has incurred losses for the years ended December 31, 2024 and 2023, basic and diluted
net loss per share is the same all periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders,
because their effect was anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Convertible Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-427">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">324,184</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">961,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,034</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369,092</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,824</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-428">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unvested restricted stock units</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">739</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,350,625</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">696,838</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Recently Adopted Accounting Standards</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In November 2023, the FASB issued ASU
2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;), which enhances disclosure
requirements about significant segment expenses that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;).
ASU 2023-07, among other things, (i) requires a single segment public entity to provide all of the disclosures as required by ASC 280,
(ii) requires a public entity to disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s)
of segment profit or loss in assessing segment performance and deciding how to allocate resources and (iii) provides the ability for a
public entity to elect more than one performance measure. ASU 2023-07 is effective for the fiscal years beginning after December 15, 2023,
and interim periods beginning with the first quarter ending March 31, 2025. Early adoption is permitted, and retrospective adoption is
required for all prior periods presented. The Company has adopted ASU 2023-07 effective December 31, 2024, and concluded that the application
of this guidance did not have any material impact on its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Recently Issued Accounting Pronouncements</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In December 2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The
Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 4, 2024, the FASB issued
ASU 2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the same
tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods
beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company
is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Management does not believe that any
additional recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#8217;s
financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b>Restatement of Previously Issued
Financial Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company identified an error in
the amount of the accrued expenses within the audited balance sheets as of September 30, 2024, December 31, 2023 and 2022 included in
the Company&#8217;s Form 8-K, filed on November 26, 2024. In accordance with Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 99, <i>Materiality</i>,
and SAB No. 108, <i>Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</i>,
the Company evaluated these misstatements, and based on an analysis of quantitative and qualitative factors, determined that the impact
of these misstatements was material to its reporting periods ended December 31, 2023, December 31, 2022 and September 30, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accordingly, the Company has restated
its consolidated financial statements for the years ended December 31, 2023 and 2022, and its interim reporting period for the nine months
ended September 30, 2024, and has included that restated financial information within this annual report.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of December 31, 2023 is reflected in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,381</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,191</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(105,571</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108,871</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(85,135</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(88,435</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of December 31, 2022 is reflected in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,897</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,865</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97,165</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75,734</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79,034</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of September 30, 2024 is reflected in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,045</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,277</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,577</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(109,468</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(112,768</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87,501</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(90,801</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Merger</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>3.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Merger</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 13, 2024, Merger Sub, a wholly-owned
subsidiary of ACAB, merged with Legacy Abpro, with Legacy Abpro surviving as a wholly-owned subsidiary of ACAB. At the effective time
of the Merger:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">each outstanding share of Legacy Abpro common stock was converted into approximately&#160;0.068&#160;shares of the Company&#8217;s common stock;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">each outstanding share of preferred stock of Legacy Abpro was converted into the aggregate number of shares of New Abpro&#8217;s common stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately&#160;0.068; and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">each outstanding option or warrant to purchase Legacy Abpro common stock was converted into an option or warrant, as applicable, to purchase a number of shares of the Company&#8217;s common stock equal to the number of shares of Legacy Abpro common stock subject to such option or warrant multiplied by approximately&#160;0.068, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately&#160;0.068; in each case, rounded down to the nearest whole share.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition, at the Closing Date, 6,744,550&#160;shares
of Series A common stock and 1 share of Series B common stock of ACAB, on a pre-split basis, automatically converted into shares of the
Company&#8217;s common stock, on a&#160;one-for-one&#160;basis.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Former holders of the Legacy Abpro common
stock and Legacy Abpro preferred stock are eligible to receive up to 483,333 additional shares of the Company&#8217;s common stock (&#8220;Contingent
Earnout Shares&#8221;) if, within five calendar years after the closing of the Merger, the volume weighted average price of shares of
the Company&#8217;s Common Stock on Nasdaq, or any other national securities exchange on which the shares of the Company&#8217;s Common
Stock are then traded (&#8220;VWAP&#8221;) meets or exceeds three-tier target prices defined in the agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the Closing Date, the Company issued an
aggregate of&#160;112,247 shares of the Company&#8217;s common stock (the &#8220;PIPE Shares&#8221;) in a private placement for the total
consideration of $11,225 (the &#8220;PIPE Financing&#8221;). Out of the total PIPE Shares, 20,749 shares were issued to Abpro Bio International,
Inc. (&#8220;ABI&#8221;), a significant investor in Legacy Abpro&#8217;s Series E and F convertible preferred stock, pursuant to the
terms of a subscription agreement dated August 22, 2024 with ABI (the &#8220;Abpro Bio Subscription Agreement&#8221;) for an aggregate
purchase price of $6,225, of which $4,225 was used to repay the balance due by Legacy Abpro to ABI under the promissory note agreement
(see Note 10) and the remainder of $2,000 in cash. In addition, pursuant to the Abpro Bio Subscription Agreement, ABI received an aggregate
of 41,498 shares of New Abpro common stock reserved for use in the PIPE Financing or to obtain capital for ACAB or the surviving company,
as defined in the Merger Agreement (the &#8220;Incentive Shares&#8221;). The Company also issued 16,667 common stock shares of New Abpro
to Celltrion, Inc., a company organized and existing under the laws of South Korea (&#8220;Celltrion&#8221;), pursuant to the terms of
a subscription agreement dated August 22, 2024 with Celltrion (&#8220;Celltrion&#8221;) (the &#8220;Celltrion Subscription Agreement&#8221;,
together with the &#8220;Abpro Bio Subscription Agreement&#8221;, collectively the &#8220;PIPE Subscription Agreements&#8221;) for an
aggregate purchase price of $5,000. In addition, Celltrion received an aggregate of 33,333 Incentive Shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Pursuant to the terms of the Merger Agreement,
at the Closing Date, ACAB&#8217;s sponsor, Atlantic Coastal Management II LLC (the &#8220;Sponsor&#8221;) received 20,020 shares of New
Abpro common stock in lieu of repayment of $2,000 of Unpaid SPAC Expenses (as defined in the Merger Agreement) owed to the Sponsor as
a result of advances made by the Sponsor to ACAB. This settlement was related to the ACAB liabilities incurred prior to the Merger and
had no financial impact on the Company&#8217;s December 31, 2024 consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the Closing, and in accordance with the
Sponsor Letter Agreement entered into on December&#160;11, 2023, as amended, the Sponsor transferred 32,778 common shares to Legacy Abpro
and 32,778 shares to ABI, and 32,215 shares were forfeited. The shares transferred to ABI for no consideration were accounted for as
a recapitalization with no impact on the December 31, 2024 consolidated financial statements. The Sponsor also transferred&#160;6,667
shares to one of ACAB&#8217;s financial advisors for the services provided prior to the Closing Date. The shares transferred to Legacy
Abpro were deemed to be repurchased by the Company for no consideration and included in treasury stock as of the Closing Date. These
treasury stock shares were retired on September 24, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition, at the Closing, the Company issued
36,095 common stock shares to various service providers, of which 1,095 shares were issued to an investment advisor in the PIPE Financing
and the remaining 35,000 shares of common stock were issued in settlement of ACAB&#8217;s liabilities for the services provided by various
legal and investment advisors prior to the Closing Date. The issuance of these shares, related to the services provided to ACAB prior
to the Merger which were expensed on the books of ACAB, had no financial impact on the Company&#8217;s December 31, 2024 consolidated
financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The number of shares of the Company&#8217;s
common stock outstanding immediately following the consummation of the Merger was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Common stock of ACAB, net of redemptions</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,033</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">ACAB Founder Shares, less of forfeitures and transfers</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">126,076</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares issued to PIPE investors</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">112,247</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares issued to service providers</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">42,762</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares issued in Merger to Legacy Abpro stockholders</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,304,107</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares transferred to investors</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">72,285</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares issued to settle the promissory note with executive</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total shares of common stock outstanding immediately after
    Merger</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,684,510</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Merger was accounted for as a reverse
recapitalization in accordance with U.S. GAAP. Under this method of accounting, ACAB is treated as the acquired company for financial
reporting purposes and Legacy Abpro is treated as the acquirer. This determination is primarily based on the fact that subsequent to
the Merger, the Legacy Abpro stockholders hold a majority of the voting rights of the combined company, Legacy Abpro comprises all of
the ongoing operations of the combined company, Legacy Abpro comprises a majority of the carryover governing body of the combined company,
and Legacy Abpro&#8217;s senior management comprises all of the senior management of the combined company. Accordingly, for accounting
purposes, the Merger was treated as the equivalent of Legacy Abpro issuing shares for the net assets of ACAB, accompanied by a recapitalization.
The net assets of ACAB were stated at historical costs. No goodwill or other intangible assets were recorded. Operations prior to the
Merger are those of Legacy Abpro.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company received $5,700 in proceeds from
the Merger and related PIPE Financing, net of ACAB transaction costs settled at the Closing. The Company incurred $2,100 in transaction
costs and $900 in issuance costs related to the PIPE Financing, consisting of banking, legal, investment advisory and other professional
fees, of which were recorded as a reduction of proceeds to additional paid-in capital. At the Closing Date, Legacy Abpro assumed $6,600
of net liabilities, including tax liabilities and legal fees, of ACAB. As of September 30, 2025, the ACAB liabilities were $5,300, of
which $900 was included in accrued expenses and $4,400 in excise tax payable. As of December 31, 2024, the ACAB liabilities were $5,800,
of which $1,000 was included in accrued expenses, $4,400 in excise tax payable and $400 in income tax payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In February 2025, the Company issued 5,000
shares of common stock to Roth Capital Partners (&#8220;Roth&#8221;) as an additional payment for the services provided under the engagement
letter dated July 17, 2024 between Roth and ACAB, which provided for an adjustment to their fees in shares based on the trading price
of the Company&#8217;s common stock. The issuance had zero impact on the September 30, 2025 condensed consolidated financial statements
as the fees to Roth were deemed to be related to the Merger and were recorded as a both an increase and reduction to additional paid-in
capital.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>3.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b>Merger</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 13, 2024, Merger Sub, a
wholly-owned subsidiary of ACAB, merged with Legacy Abpro, with Legacy Abpro surviving as a wholly-owned subsidiary of ACAB. At the effective
time of the Merger:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each outstanding share of Legacy Abpro common stock was converted into approximately 0.068 shares of the Company&#8217;s common stock;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each outstanding share of preferred stock of Legacy Abpro was converted into the aggregate number of shares of New Abpro&#8217;s common stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately prior to the effective time, multiplied by approximately 0.068; and</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">each outstanding option or warrant to purchase Legacy Abpro common stock was converted into an option or warrant, as applicable, to purchase a number of shares of the Company&#8217;s common stock equal to the number of shares of Legacy Abpro common stock subject to such option or warrant multiplied by approximately 0.068, at an exercise price per share equal to the current exercise price per share for such option or warrant divided by approximately 0.068; in each case, rounded down to the nearest whole share.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In addition, at the Closing Date, 6,744,550
shares of Series A common stock and 1 share of Series B common stock of ACAB automatically converted into shares of the Company&#8217;s
common stock, on a one-for-one basis (pre-split).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Former holders of the Legacy Abpro
common stock and Legacy Abpro preferred stock are eligible to receive up to 483,333 additional shares of the Company&#8217;s common stock (&#8220;Contingent Earnout Shares&#8221;) if, within five calendar years after the closing of the Merger, the volume weighted
average price of shares of the Company&#8217;s Common Stock on Nasdaq, or any other national securities exchange on which the shares of
the Company&#8217;s Common Stock are then traded (&#8220;VWAP&#8221;) meets or exceeds three-tier target prices defined in the agreement,
as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one-third of the total Earnout Shares, if, the VWAP is greater than or equal to $390.00 over any 20 trading days within any consecutive 30 trading day period (the &#8220;First Share Target&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</span></td> <td style="padding-left: 0in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one-third of the total Earnout Shares, if, the VWAP is greater than or equal to $450.00 over any 20 trading days within any consecutive 30 trading day period (the &#8220;Second Share Target&#8221;)</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.5in">&#160;</td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">one-third of the total Earnout Shares, if, the VWAP is greater than or equal to $540.00 over any 20 trading days within any consecutive 30 trading day period (the &#8220;Third Share Target&#8221;).</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">If following the Closing, a Change
of Control (as defined in the Merger Agreement) occurs on or before the five year anniversary of the Closing Date, then if (i) the per
share value of the consideration to be received by stockholders in connection with the Change of Control exceeds $390.00 per share and
the First Share Target has not been previously achieved, then the First Share Target will be deemed to have been achieved, (ii) the per
share value of the consideration to be received by stockholders exceeds $450.00 per share and the Second Share Target has not been previously
achieved, then the Second Share Target will be deemed to have been achieved, and (iii) the per share value of the consideration to be
received by stockholders exceeds $540.00 per share and the Third Share Target has not been previously achieved, then the Third Share Target
will be deemed to have been achieved. Any Contingency Consideration that is not deemed to be earned in connection with the Change of Control
shall be forfeited by the stockholders for no consideration.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At the Closing Date, the Company issued
an aggregate of 112,247 shares of the Company&#8217;s common stock (the &#8220;PIPE Shares&#8221;) in a private placement for the total
consideration of $11,225 (the &#8220;PIPE Financing&#8221;). Out of the total PIPE Shares, 20,749 shares were issued to Abpro Bio International,
Inc. (&#8220;ABI&#8221;), pursuant to the terms of a subscription agreement dated August 22, 2024 with ABI (the &#8220;Abpro Bio Subscription
Agreement&#8221;) for an aggregate purchase price of $6,225, of which $4,225 was used to repay the balance due by Legacy Abpro to ABI
under the promissory note agreement (see Note 8) and the remainder of $2,000 in cash. In addition, pursuant to the Abpro Bio Subscription
Agreement, ABI received an aggregate of 41,498 shares of New Abpro common stock reserved for use in the PIPE Financing or to obtain capital
for ACAB or the surviving company, as defined in the Merger Agreement (the &#8220;Incentive Shares&#8221;). The Company also issued 16,667
common stock shares of New Abpro to <span style="background-color: white">Celltrion, Inc., a company organized and existing under the
laws of South Korea (&#8220;Celltrion&#8221;)</span>, pursuant to the terms of a subscription agreement dated August 22, 2024 with <span style="background-color: white">Celltrion
(&#8220;Celltrion&#8221;) </span>(the &#8220;Celltrion Subscription Agreement&#8221;, together with the &#8220;Abpro Bio Subscription
Agreement&#8221;, collectively the &#8220;PIPE Subscription Agreements&#8221;) for an aggregate purchase price of $5,000. In addition,
Celltrion received an aggregate of 33,333 Incentive Shares.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Pursuant to the terms of the Merger
Agreement, at the Closing Date, ACAB&#8217;s sponsor, Atlantic Coastal Management II LLC (the &#8220;Sponsor&#8221;) received 20,020 shares
of New Abpro common stock in lieu of repayment of $2,000 of Unpaid SPAC Expenses (as defined in the Merger Agreement) owed to the Sponsor
as a result of advances made by the Sponsor to ACAB. This settlement was related to the ACAB liabilities incurred prior to the Merger
and had no financial impact on the Company&#8217;s consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">At the Closing, and in accordance with
the Sponsor Letter Agreement entered into on December 11, 2023, as amended, the Sponsor transferred 32,778 common shares to Legacy Abpro
and 32,778 shares to ABI, and 32,215 shares were forfeited. The shares transferred to Legacy Abpro were deemed to be repurchased by the
post-merger Company for no consideration and included in treasury stock as of the Closing Date and December 31, 2024. The shares transferred
to ABI for no consideration were accounted for as a recapitalization with no impact on the consolidated financial statements. The Sponsor
also transferred 6,667 shares to one of ACAB&#8217;s financial advisors for the services provided prior to the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, at the Closing, the Company
issued 36,095 common stock shares to various service providers, of which 1,095 shares were issued to an investment advisor in the PIPE
Financing and the remaining 35,000 common stock shares were issued in settlement of ACAB&#8217;s liabilities for the services provided
by various legal and investment advisors prior to the Closing Date. The issuance of these shares, related to the services provided to
ACAB prior to the Merger which were expensed on the books of ACAB, with no financial impact on the Company&#8217;s consolidated financial
statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The number of shares of the Company&#8217;s
common stock outstanding immediately following the consummation of the Merger was:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Common stock of ACAB, net of redemptions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,033</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ACAB Founder Shares, less of forfeitures and transfers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,076</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">New Abpro shares issued to PIPE investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,247</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">New Abpro shares issued to service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,762</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">New Abpro shares issued in Merger to Legacy Abpro stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,304,107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">New Abpro shares transferred to investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,285</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">New Abpro shares issued to settle the promissory note with executive</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total shares of common stock outstanding immediately after Merger</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,684,510</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Merger was accounted for as a
reverse recapitalization in accordance with U.S. GAAP. Under this method of accounting, ACAB is treated as the acquired company for
financial reporting purposes and Legacy Abpro is treated as the acquirer. This determination is primarily based on the fact that
subsequent to the Merger, the Legacy Abpro stockholders hold a majority of the voting rights of the combined company, Legacy Abpro
comprises all of the ongoing operations of the combined company, Legacy Abpro comprises a majority of the carryover governing body
of the combined company, and Legacy Abpro&#8217;s senior management comprises all of the senior management of the combined company.
Accordingly, for accounting purposes, the Merger was treated as the equivalent of Legacy Abpro issuing shares for the net assets of
ACAB, accompanied by a recapitalization. The net assets of ACAB were stated at historical costs. No goodwill or other intangible
assets were recorded. Operations prior to the Merger are those of Legacy Abpro.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company received $5.7 million in
proceeds from the Merger and related PIPE Financing, net of ACAB transaction costs settled at the Closing. The Company incurred $2.1 million
in transaction costs and $0.9 million in issuance costs related to the PIPE Financing, consisting of banking, legal, investment advisory
and other professional fees, of which were recorded as a reduction of proceeds to additional paid-in capital. At the Closing Date, Legacy
Abpro assumed $6.6 million of net liabilities, including tax liabilities and legal fees, of ACAB, of which $1.0 million was included in
accrued expenses, $4.4 million in excise tax payable and $0.4 million in income tax payable as of December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>4.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Accrued Expenses</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December 31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued salaries and wages</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,033</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,549</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued professional fees</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,121</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,273</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued license fees</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,300</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,300</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued interest</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">273</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">267</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Board of Directors compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">285</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">242</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Other accrued expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">865</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total accrued expenses</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,026</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,496</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>5.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accrued
Expenses</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accrued expenses consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/> (As&#160;Restated)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued salaries and wages</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,549</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,398</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued license fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-432">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BOD compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">242</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-433">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">865</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">590</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total accrued expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,496</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,381</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>5.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Fair Value Measurements</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table presents information about
the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025 and December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Level</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Assets:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Forward purchase agreement asset (Note 9)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">3</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-406"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;155</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">SEPA put rights asset (Note 11)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">243</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">188</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Liabilities:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Embedded derivative liability (Note 11)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-407"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">80</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Forward Purchase Agreement was fully settled
on January 28, 2025 for $132 cash received by the Company. The fair value of the Company&#8217;s position under the Forward Purchase
Agreement was calculated as of December 31, 2024 by multiplying the number of shares under the Forward Purchase Agreement by the market
price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Stock price</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">53.70</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Risk-free interest rate</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.4</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected term (in years)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.1</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected volatility</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected dividend yield</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair value of the SEPA put rights asset
was estimated as the sum of the fair values of the put rights under each assumed advance notice over the term of the SEPA. The number
of shares under each advance notice was based on the historical trading volumes of the Company&#8217;s stock taking into account the
beneficial ownership and daily volume limitations. The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Stock price</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.72</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">53.70</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Risk-free interest rate</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">3.7 &#8211; 4.1</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.2</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Exercise price</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.45</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">51.60</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected term (in years)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">0.1 - 1.2</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">1 - 2</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected volatility</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">100</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;93-99</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected dividend yield</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Number of shares under each advance notice</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">26,667</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,883</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair value of the embedded derivative
feature was $0 as of September 30, 2025 and estimated to be $80 as of December 31, 2024, based on the difference between the fair value
of the convertible note with these embedded features and the fair value without each one of these embedded features. As of December 31,
2024, the assumptions incorporated into the valuation model included the stock price of $53.70, the estimated future price per share
of $61.80 (derived using Monte Carlo Simulation), the expected volatility of 99%, the risk-free rate of 4.18% and the term of 0.9 years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair values of the Embedded Derivative
Liability associated with the conversion of the First and Second Convertible Notes (see Note 11) of $703 and $243, respectively, were
based on the difference between the fair value of the common stock shares issued upon conversion and the outstanding note balance at
the conversion date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The changes in the fair value of Level 3 financial
assets and liabilities for the nine months ended September 30, 2025 are as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Forward<br/> Purchase<br/> Agreement<br/>
    Asset</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">SEPA<br/> Put Rights<br/> Asset</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Embedded</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Derivative</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Liabilities</b></p></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Fair value as of January 1, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">155</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">188</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">80</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Initial measurement at the issuance date (see Note 11)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-408"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-409"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Settlement</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(132</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-410"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(946</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Change in fair value</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(23</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">55</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">773</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Fair value as of September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-411"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">243</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-412"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value Measurements</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table presents information
about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2024, and indicates
the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Forward purchase agreement asset (Note 11)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;155</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SEPA put rights asset (Note 13)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Embedded derivative liability (Note 13)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">There were no assets or liabilities
measured at fair value on a recurring basis as of December 31, 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The fair value of the Company&#8217;s
position under the Forward Purchase Agreement was calculated by multiplying the number of shares under the Forward Purchase Agreement
by the market price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">November&#160;13,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">173.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The fair value of the SEPA Put Rights
was estimated as the sum of the fair values of the put rights under each assumed advance notice over the term of the SEPA. The number
of shares under each advance notice was based on the historical trading volumes of the Company&#8217;s stock taking into account various
beneficial ownership and daily volume limitations. The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">November 13,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Stock price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">173.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1 to 2 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1 to 2 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">82-90</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">93-99</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Number of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,883</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The fair value of the Embedded
Derivative Feature was estimated at $69 at the issuance date based on the difference between the fair value of the convertible note
with these embedded features and the fair value without each one of these embedded features. The assumptions incorporated into the
valuation model as of November 13, 2024, the issuance date of the Convertible Note included the stock price of $173.10, the
estimated future price per share of $130.80 (derived using Monte Carlo Simulation), the expected volatility of 90%, the risk-free
rate of 4.31% and the term of 1 year. As of December 31, 2024 the assumptions incorporated into the valuation model included the
stock price of $53.70, the estimated future price per share of $61.80 (derived using Monte Carlo Simulation), the expected
volatility of 99%, the risk-free rate of 4.18% and the term of 0.9 years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The changes in the fair value of Level
3 financial assets and liabilities for the year ended December 31, 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward<br/>
Purchase<br/>
Agreement<br/>
asset</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEPA<br/>
Put Rights<br/>
Asset</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Embedded <br/>
Derivative Liability</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 67%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value as of January 1, 2024</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-434; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-435; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial measurement at the issuance date</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">494</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,551</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(339</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,363</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value as of December 31, 2024</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">155</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">188</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralizedAgreementsAbstract', window );"><strong>License and Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">License and Collaboration Agreements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>6.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>License and Collaboration Agreements</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>NJCTTQ Collaboration Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In January 2019, the Company entered into
a collaboration agreement with Nanjing Chia Tai Tianquing Pharmaceutical Co., Ltd. (&#8220;NJCTTQ&#8221;) to research, develop and commercialize
two anti-Claudin 18.2 lead antibodies (the &#8220;NJCTTQ agreement&#8221;). Under the NJCTTQ agreement, the Company granted a non-exclusive,
non-sublicensable research license and an exclusive, sublicensable license to NJCTTQ within the People&#8217;s Republic of China and
Thailand (the &#8220;NJCTTQ Territory&#8221;). The initial term of this agreement was 5 years, which could be automatically renewed for
another 5 years. If no collaboration project reached the clinical stage within the first 5 years of the NJCTTQ agreement, then this agreement
would not have been renewed. The agreement expired in January 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company was eligible to receive up to
an aggregate of $405,000 of non-refundable milestone payments from NJCTTQ upon achieving certain development, regulatory approval, and
commercialization and sales milestones for each unique licensed antibody or product in NJCTTQ Territory. The Company agreed to pay NJCTTQ
up to an aggregate of $5,000 in nonrefundable amounts upon achieving of a regulatory milestone in the Company&#8217;s territory, which
includes all other countries other than the NJCTTQ Territory. No milestones have been reached through the expiration of this agreement
in January 2024, no products were sold by NJCTTQ, and no related revenue amounts have been recorded in the condensed consolidated financial
statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company and NJCTTQ agreed to pay reciprocal
royalties, with each of them paying the other party low single-digit royalties, tiered based on net sales per calendar year in its territory.
The agreement remains unrenewed as of September 30, 2025 after the expiration of its initial term. However, notwithstanding the agreement&#8217;s
expiration, the low single-digit royalties and the $5,000 regulatory milestone payable to NJCTTQ based on commercial approval in the
Company&#8217;s territory, as described above, will continue to apply. Through September 30, 2025, no products were sold by NJCTTQ or
the Company under the NJCTTQ agreement and no regulatory milestones were achieved by the Company in the Company&#8217;s territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>ABP-201 Collaboration and License Agreement
</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In January 2020, the Company&#8217;s consolidated
subsidiary, AbMed, entered into a collaboration and license agreement with ABI (the &#8220;ABP-201 Agreement&#8221;), pursuant to which
the Company granted to ABI an exclusive, royalty-bearing, license under specified patent rights to make, use and sell certain of its
proprietary ANG-2/VEGF-HIRK bispecific antibodies within the licensed territory comprising People&#8217;s Republic of China, Japan, South
Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States. Unless earlier terminated in accordance with its terms,
the agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the ABP-201 agreement, ABI agreed to
use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within
specified territories and timeframes. ABI is committed to pay the Company up to $56,500 in milestone payments upon achieving certain
research and development events, up to $485,000 in milestone payments based on annual net sales per each licensed product, and a double-digit
percentage royalty in the low teens, tiered based on cumulative net sales by ABI, its affiliates or sublicensees beginning with the first
commercial sale of a licensed product in its territory. No milestones have been reached through September 30, 2025, no products were
sold by ABI, and no related revenue amounts have been recorded in the condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true">&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Celltrion Collaboration and License
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In September 2022, the Company entered into
an exclusive collaboration and license agreement with Celltrion, as amended in October 2024 in connection with the execution of the Celltrion
Subscription Agreement (the &#8220;Amended Celltrion Agreement&#8221;). Under the Amended Celltrion Agreement, the Company granted to
Celltrion a worldwide exclusive license under specified patent rights to develop, make, have made, import, export, use, have used, sell
and have sold certain of its proprietary ABP-102 bispecific antibodies. The License Agreement also provides that the Company is to perform
certain preclinical in vitro studies. The License Agreement will remain in effect for so long as ABP-102 is being developed or commercialized
anywhere in the world. Celltrion may terminate the license agreement at any time by providing&#160;six months prior written notice to
the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Celltrion is committed to pay the Company
up to $10,000 under the Original Celltrion Agreement and $6,000 under the Amended Celltrion Agreement in milestone payments upon granting
the license and achieving certain research and development events, and up to $1,750,000 in milestone payments based on annual net sales
per each licensed product. The proceeds from commercialization are subject to a 50/50 profit split. Amounts that may be paid by third-party
collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization partners, are also subject
to a 50/50 split. Following commercial approval of ABP-102, the Company has agreed to reimburse Celltrion 87.5% under the Original Celltrion
Agreement and 250% under the Amended Celltrion Agreement of its direct and certain indirect costs and expenses incurred through first
commercial sale. Under the Original Celltrion Agreement, Celltrion is entitled to offset amounts otherwise due to us under the agreement
until our share of these costs has been paid back; provided that the Company is entitled to a minimum 25% (or 50% under the Amended Celltrion
Agreement) of profit from commercial sales and from third-party collaborators regardless of the amount of unreimbursed development costs
outstanding (and then 50% once the reimbursement has been made in full).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The first milestone of $2,000 was achieved
upon granting the license at the collaboration effective date, as defined in the Celltrion Agreement, in December 2022, received in January
2023 and recognized in revenue prior to December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the three and nine months ended September
30, 2025 and 2024, the Company recognized <span style="-sec-ix-hidden: hidden-fact-413"><span style="-sec-ix-hidden: hidden-fact-414"><span style="-sec-ix-hidden: hidden-fact-415"><span style="-sec-ix-hidden: hidden-fact-416">no</span></span></span></span> revenue in connection with this arrangement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Milestone Payments.&#160;</i>The Company
is entitled to development milestones under the Celltrion Agreement and certain regulatory milestone payments which are paid upon receipt
of regulatory approvals.&#160;Except for the first milestone of $2,000 achieved in 2022, <span style="-sec-ix-hidden: hidden-fact-417">no</span>&#160;other milestone payments were earned
through September 30, 2025. The Company evaluated whether the remaining milestones are considered probable of being reached and determined
that their achievement is highly dependent on factors outside of the Company&#8217;s control. Therefore, these payments have been fully
constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company will re-evaluate
the probability of achievement of each milestone and any related constraint, and if necessary, adjust its estimate of the overall transaction
price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect the reported amount of collaboration
revenues in the period of adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><i>Profit Splits. </i>As the license is deemed
to be the predominant item to which profit splits relate, the Company will recognize revenue when the related sales or third-party collaborator
income occur.&#160;No&#160;profit split revenue has been recognized from inception through September 30, 2025.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>License
and Collaboration Agreements</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>NJCTTQ Collaboration Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In January 2019, the Company entered
into a collaboration agreement with Nanjing Chia Tai Tianquing Pharmaceutical Co., Ltd. (&#8220;NJCTTQ&#8221;) to research, develop and
commercialize two anti-Claudin 18.2 lead antibodies (the &#8220;NJCTTQ agreement&#8221;). Under the NJCTTQ agreement, the Company granted
a non-exclusive, non-sublicensable research license and an exclusive, sublicensable license to NJCTTQ within the People&#8217;s Republic
of China and Thailand (the &#8220;NJCTTQ Territory&#8221;). The initial term of this agreement was 5 years, which could be automatically
renewed for another 5 years. If no collaboration project reached the clinical stage within the first 5 years of the NJCTTQ agreement,
then this agreement would not have been renewed. The agreement expired in January 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company was eligible to receive
up to an aggregate of $405,000 of non-refundable milestone payments from NJCTTQ upon achieving certain development, regulatory approval,
and commercialization and sales milestones for each unique licensed antibody or product in NJCTTQ Territory. The Company agreed to pay
NJCTTQ up to an aggregate of $5,000 in nonrefundable amounts upon achieving of a regulatory milestone in the Company&#8217;s territory,
which includes all other countries other than the NJCTTQ Territory. No <span style="background-color: white">milestones have been reached
through the expiration of this agreement in January 2024, no products were sold by NJCTTQ, and no related revenue amounts have been recorded
in the accompanying consolidated financial statements. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company and NJCTTQ agreed to pay
reciprocal royalties, with each of them paying the other party low single-digit royalties, tiered based on net sales per calendar year
in its territory. <span style="background-color: white">The agreement remains unrenewed as of December 31, 2024 after the expiration of
its initial term. However, notwithstanding the agreement&#8217;s expiration, the low single-digit royalties and the $5,000&#160;</span>regulatory
<span style="background-color: white">milestone payable to NJCTTQ based on commercial approval in </span>the Company&#8217;s <span style="background-color: white">territory,
as described above, will continue to apply.</span> Through <span style="background-color: white">December 31, 2024</span>, <span style="background-color: white">no
products were sold by NJCTTQ or the Company under the NJCTTQ agreement and no regulatory milestones were achieved by the Company in the
Company&#8217;s territory.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>ABP-100 Collaboration and License
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In December 2019, the Company
entered into an exclusive collaboration and license agreement with a related party, ABI (the &#8220;ABP-100 agreement&#8221;). Under
the ABP-100 agreement, the Company granted ABI the license to develop and commercialize products and services based on the
Company&#8217;s Her2-hu-OKT3 bispecific antibody (&#8220;ABP-100&#8221;) within the territories of People&#8217;s Republic of China,
Japan, South Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States, as defined in the agreement. Unless
earlier terminated, the ABP-100 agreement, will expire upon the satisfaction of all obligations under the agreement following the
expiration of the last royalty payment obligation. Either party may terminate the agreement in the event of any uncured material
breach by the other party. The license granted under the ABP-100 agreement was a sub-license from Memorial Sloan Kettering Cancer
Center (&#8220;MSK&#8221;) pursuant to MSK License Agreement (see Note 6). This agreement was terminated due to the termination of
the MSK License Agreement in September 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the ABP-100 agreement, ABI agreed
to use commercially reasonable efforts to reach certain development and commercial milestones for at least one licensed product or licensed
service within specified timeframes. ABI is committed to pay the Company running royalties on net sales of any licensed products or services
from the mid-single digit percentages to the low double-digit percentage, and the guaranteed annual minimum royalties of $30 starting
on the first anniversary of the effective date of the agreement (which annual minimum royalties may be credited against the running royalties
on net sales of any licensed products or services). Through the termination of this agreement in September 2023, <span style="background-color: white">no
products were sold by ABI under the ABP-100 agreement.</span> During the years ended December 31, 2024 and 2023, the Company earned <span style="-sec-ix-hidden: hidden-fact-436">$0</span>
and $23 in minimum royalty payments, included in royalty revenue. As of both December 31, 2024 and 2023, the accounts receivable were
$53, associated with the minimum royalties <span style="background-color: white">under this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In addition to the royalty payments,
the Company could receive up to $498,000 in milestone payments per licensed product or licensed service upon the achievement of specified
research and development and sales milestone events. No milestones have been reached through the termination of this agreement in September
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company was also entitled to research
funding fees for costs incurred by the Company for certain sponsored research activities and the reimbursement of 60% of the costs of
certain product development directed activities, as outlined in the agreement. During the years ended December 31, 2024 and 2023, the
Company did not earn any research funding fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Further, the Company was to be reimbursed
for patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights
in the license territory. The Company did not receive any reimbursements of patent costs during the years ended December 31, 2024 and
2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>ABP-201 Collaboration and License
Agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In January 2020, the Company&#8217;s
consolidated subsidiary, AbMed, entered into a collaboration and license agreement with ABI (the &#8220;ABP-201 Agreement&#8221;), pursuant
to which the Company granted to ABI an exclusive, royalty-bearing, license under specified patent rights to make, use and sell certain
of its proprietary ANG-2/VEGF-HIRK bispecific antibodies within the licensed territory comprising People&#8217;s Republic of China, Japan,
South Korea, Southeast Asia, the Middle East and the Commonwealth of Independent States. Unless earlier terminated in accordance with
its terms, the agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the ABP-201 agreement, ABI agreed
to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within
specified territories and timeframes. ABI is committed to pay the Company up to $56,500 in milestone payments upon achieving certain research
and development events, up to $485,000 in milestone payments based on annual net sales per each licensed product, and a double-digit percentage
royalty in the low teens, tiered based on cumulative net sales by ABI, its affiliates or sublicensees beginning with the first commercial
sale of a licensed product in its territory. No <span style="background-color: white">milestones have been reached through December 31,
2024, no products were sold by ABI, and no related revenue amounts have been recorded in the accompanying consolidated financial statements.
</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Celltrion Collaboration and License
Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">In
September 2022, the Company entered into an exclusive collaboration and license agreement with Celltrion (the &#8220;Original Celltrion
Agreement&#8221;). The Company and Celltrion entered into an amendment to the agreement in October 2024 in connection with the execution
of the Celltrion Subscription Agreement (the &#8220;Amended Celltrion Agreement&#8221;). The amendment is subject to termination by the
Company or Celltrion if (i) the share purchase under the Celltrion Subscription Agreement is not completed, or (ii) the Celltrion Subscription
Agreement is terminated pursuant to Section 7 of the Celltrion Subscription Agreement. Under the Amended Celltrion Agreement, the Company
granted to Celltrion a worldwide exclusive license under specified patent rights to develop, make, have made, import, export, use, have
used, sell and have sold certain of its proprietary ABP-102 bispecific antibodies. The License Agreement also provides that the Company
is to perform certain preclinical in vitro studies. The License Agreement will remain in effect for so long as ABP-102 is being developed
or commercialized anywhere in the world. Celltrion may terminate the license agreement at any time by providing six months prior written
notice to the Company. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">Celltrion
is committed to pay the Company up to $10,000 under the Original Celltrion Agreement and $6,000 under the Amended Celltrion Agreement
in milestone payments upon granting the license and achieving certain research and development events, up to $1,750,000 in milestone payments
based on annual net sales per each licensed product. The proceeds from commercialization are subject to a 50/50 profit split. Amounts
that may be paid by third-party collaborators, for example upfronts, milestones and/or royalty payments from territorial commercialization
partners, are also subject to a 50/50 split. Following commercial approval of ABP-102, the Company has agreed to reimburse Celltrion 87.5%
under the Original Celltrion Agreement and 250% under the Amended Celltrion Agreement of its direct and certain indirect costs and expenses
incurred through first commercial sale. Under the Original Celltrion Agreement, Celltrion is entitled to offset amounts otherwise due
to us under the agreement until our share of these costs has been paid back; provided that the Company is entitled to a minimum 25% (or
50% under the Amended Celltrion Agreement) of profit from commercial sales and from third-party collaborators regardless of the amount
of unreimbursed development costs outstanding (and then 50% once the reimbursement has been made in full).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
first milestone of $2,000 was achieved upon granting the license at the collaboration effective date, as defined in the Celltrion Agreement,
in December 2022 and received in January 2023. During the year ended December 31, 2022, the Company allocated $64 to the initial obligation
to perform in vitro testing for the research and development services and the remaining $1,936 to the license of the Company&#8217;s intellectual
property, bundled with the associated know-how.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s initial obligation
to <span style="background-color: white">perform in vitro testing for the research and development services</span> represents a distinct
performance obligation. The revenue for this performance obligation was be recognized on a straight-line based over the term of the studies.
During the years ended December 31, 2024 and 2023, the Company recognized $0 and $64, respectively, in connection with this performance
obligation, included in collaboration revenue.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white"><i>Milestone
Payments. </i>The Company is entitled to development milestones under the Celltrion Agreement and certain regulatory milestone payments
which are paid upon receipt of regulatory approvals. Except for the first milestone of $2,000 achieved in 2022, no other milestone payments
were earned through December 31, 2024. The Company evaluated whether the remaining milestones are considered probable of being reached
and determined that their achievement is highly dependent on factors outside of the Company&#8217;s control. Therefore, these payments
have been fully constrained and are not included in the transaction price. At the end of each subsequent reporting period, the Company
will re-evaluate the probability of achievement of each milestone and any related constraint, and if necessary, adjust its estimate of
the overall transaction price. Any such adjustments will be recorded on a cumulative catch-up basis, which would affect the reported amount
of collaboration revenues in the period of adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white"><i>Profit
Splits.</i> As the license is deemed to be the predominant item to which profit splits relate, the Company will recognize revenue when
the related sales or third-party collaborator income occur. No profit split revenue has been recognized from inception through December
31, 2024.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralizedAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralizedAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments under Research and Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAbstract', window );"><strong>Commitments Under Research and Collaboration Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsDisclosureTextBlock', window );">Commitments under Research and Collaboration Agreements</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px; text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>7.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Commitments under Research and Collaboration Agreements</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>MedImmune License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In August 2016, the Company entered into a
collaboration and license agreement with MedImmune Limited (&#8220;MedImmune&#8221;), pursuant to which the Company received from MedImmune
an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license to certain intellectual property rights
relating to the Company&#8217;s ABP-200 product candidates (the &#8220;MedImmune License Agreement&#8221;). The Company agreed to use
commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within specified
timeframes. Unless earlier terminated in accordance with its terms, the MedImmune License Agreement, as amended, remains in effect on
a country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of products
based on the ABP-200 product candidates. The Company is no longer developing ABP-200.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the MedImmune License Agreement, the
Company agreed to pay milestone and royalty payments, including up to $244,000 in milestone payments, which are comprised of $14,000
upon meeting certain clinical development milestones, $80,000 upon achieving certain regulatory events and $150,000 upon meeting certain
worldwide commercial sales thresholds; and tiered high-single to low double-digit percentage royalties based on annualized net sales
of each product commercialized from our collaboration on a country-by-country basis. No milestones have been reached and no products
were sold by the Company through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>NCI License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In August 2017, the Company entered into a
patent license agreement with the National Cancer Institute (the &#8220;NCI&#8221;), a division of the National Institutes of Health
(the &#8220;NIH&#8221;), pursuant to which the Company received an exclusive, worldwide license to make, use, sell, offer to sell and
import products covered by the licensed patents in the field of using certain monoclonal antibodies as monospecific or bispecific antibodies
for the treatment of liver cancer (the &#8220;NCI License Agreement&#8221;). The license agreement was amended in May 2020 and October
2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the treatment of GPC-3 expressing
liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization was extended. Unless
earlier terminated, the Company&#8217;s agreement with NCI will expire upon expiration of all licensed patent rights. The Company may
also terminate the agreement as to any licenses in any country or territory upon 60 days written notice.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Pursuant to the NCI agreement and amendments,
the Company agreed to pay low single-digit royalties based on net sales of licensed products as well as milestone payments of up to $3,995
due upon achievement of clinical and regulatory milestones, and up to $12,000 milestone payments due upon achievement of commercial milestones.
No milestones have been reached and no products were sold by the Company through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company also has to pay the guaranteed
annual minimum royalties of $25 starting on the effective date of the agreement (which annual minimum royalties may be credited against
the running royalties on net sales of any licensed products or services). During each of the three months ended September 30, 2025 and
2024, the Company incurred $6, in minimum royalty payments, included in research and development expenses. During each of the nine months
ended September 30, 2025 and 2024, the Company incurred $19, in minimum royalty payments, included in research and development expenses.
Under the amendment entered into in March 2020, the Company is also liable for the extension royalties of $225 payable under this agreement
which were rescheduled to become due in several installments starting in March 2022. As of both September 30, 2025 and December 31, 2024,
the accrued extension royalties were $200, included in accrued expenses on the condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company also agreed to reimburse patent
costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights. During
the three and nine months ended September 30, 2025 and 2024, the Company did not incur any expenses related to the patent costs reimbursements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Mabwell License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In October 2020, the Company entered into
an exclusive collaboration and license agreement with Mabwell (the &#8220;Mabwell License Agreement&#8221;). The agreement was amended
in November 2020. Under the Mabwell license agreement, the Company received a non-exclusive, royalty-free research purpose license as
well as an exclusive commercial license within certain territories, as defined in the agreement, to Mabwell&#8217;s series of anti-SARS-CoV-2
monoclonal antibodies. Under the agreement, the Company is responsible for conducting at its sole expense, research and preclinical,
clinical and other developments of any licensed products and bears all development costs and expenses related to obtaining or maintenance
of marketing authorizations of licensed products in its territories. Mabwell is obligated, at the Company&#8217;s request, to supply
the Licensed Antibodies to the Company for clinical trial purpose at costs plus margin as defined in the agreement. The parties agreed
to undertake certain joint clinical research and development activities with a portion of the costs contributed by Mabwell. Unless earlier
terminated, the Mabwell License Agreement will expire on the occurrence of the last to expire royalty term, which is the later of a)
the expiration of the last to expire valid claim of the patent rights and b) ten years from the first commercial sale of such Licensed
Product, and determined on jurisdiction-by-jurisdiction basis. Either party may terminate the agreement in the event of any uncured material
breach by the other party.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The agreement provides for development milestones
of up to $32,500 and annual sales milestone payments of up to $50,000 payable by the Company to Mabwell. The agreement also provides
for a profit sharing, with Mabwell sharing 50% of the net profits from the licensed product sales in certain territories as defined in
the agreement. The Company will also make tiered royalty payments in the mid to high single digits on net sales of commercial products
in the licensed territory.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the three and nine months ended September
30, 2025 and 2024, development activities under the Mabwell collaboration agreement were immaterial to the condensed consolidated financial
statements. No milestones have been reached and no products were sold under the Mabwell License Agreement through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2025, the Company received a draft
of a termination agreement from Mabwell which outlines Mabwell&#8217;s claim for the total payment of $3,300 under certain development
milestones asserting that these development milestones were achieved by the Company during 2021. The Company does not believe that a
liability under the milestone related provisions invoked by Mabwell was triggered and is planning to engage in discussion with Mabwell
about the validity of their claim. This liability of $3,300 is included in accrued expenses in the condensed consolidated financial statements
as of September 30, 2025 and December 31, 2024.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>MSK License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2017, the Company entered into an
exclusive license agreement with Memorial Sloan Kettering Cancer Center (the &#8220;MSK License Agreement&#8221;), pursuant to which
the Company received an exclusive, royalty-bearing, worldwide license under specified patent rights to make, use and sell certain of
MSK&#8217;s proprietary Her2-huOKT3 bispecific antibodies. The agreement was amended on March 31, 2017, March 31, 2018, and January 1,
2020. Unless earlier terminated in accordance with its terms, the agreement was to remain in effect on a country-by-country basis until
the expiration of the last royalty term in such country as to be determined by the launch of products based on MSK antibodies. On September
19, 2023, MSK License Agreement was terminated by MSK due to the Company&#8217;s failure to make the payments for the patent costs reimbursements
discussed below.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the MSK License Agreement, as amended,
the Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific
antibodies within specified territories and timeframes. The Company was committed to pay MSK up to $10,500 in milestone payments upon
achieving certain research and development and commercialization events or within a certain number of months of the effective date, up
to $30,000 in milestone payments based on net sales, and tiered mid-single-digit percentage royalties based on annualized net sales of
each product commercialized from the collaboration with guaranteed annual minimum royalties between $20 and $30 depending on certain
development events. During the three and nine months ended September 30, 2025 and 2024, the Company did not incur any minimum royalties
or any milestone payments under this agreement. As of both September 30, 2025 and December 31, 2024, the accrued minimum royalty and
milestone payments were $790, included in accounts payable in the condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company also agreed to reimburse patent
costs for all documented out of pocket costs associated with the preparation, filing, prosecution and maintenance of patent rights in
the license territory. During the three and nine months ended September 30, 2025 and 2024, the Company did not incur any patent reimbursement
costs. As of both September 30, 2025 and December 31, 2024, the liabilities for the patent costs reimbursements were $273, included in
accrued expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of both September 30, 2025 and December
31, 2024, the accrued liabilities for the unpaid interest on the outstanding minimum royalty and milestone payments due to MSK were $169,
included in accrued expenses. The company has ceased accruing further interest as a result of the termination of the MSK License Agreement.
See Note 8 for discussion of the June 2023 demand letter.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>VAZYME License agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In April 2021, the Company entered into a
License Agreement with VAZYME Biotech Co., Ltd (&#8220;VAZYME&#8221;) (the &#8220;VAZYME License Agreement&#8221;), pursuant to which
the Company was granted an exclusive, perpetual, royalty-bearing, worldwide license under specified patent rights to research, develop
and commercialize VAZYME proprietary anti-SARS-CoV-2 monoclonal antibodies. Unless earlier terminated in accordance with its terms, the
agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the VAZYME License Agreement, the Company
agreed to use commercially reasonable efforts to reach certain research and development, and commercialization milestones for such antibodies.
The Company also agreed to pay $200 to VAZYME at the effective date of the agreement. The Company is committed to pay VAZYME up to $11,100
in milestone payments upon achieving certain research and development events, up to $70,000 in milestone payments based on annual net
sales, and tiered low single-digit percentage royalties based on annualized net sales of each product commercialized from the collaboration.
No milestones in the VAZYME License Agreement have been reached through September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2021, the Company entered into
a Cooperation Agreement with Chengdu Bio-Innovate Pharmaceutical Technology Co., Ltd (&#8220;Bio-Innovate&#8221;) and a three-way sharing
agreement with VAZYME and Bio-Innovate (&#8220;the Company&#8221;, &#8220;VAZYME&#8221; and &#8220;Bio-Innovate&#8221;, collectively
&#8220;all parties&#8221;), pursuant to which the Company entrusted Bio-Innovate to perform certain preclinical testing and all parties
agreed that VAZYME will ship the agreed antibodies to Bio-Innovate rather than the Company to fulfill the requirements under the VAZYME
License Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For the three and nine months Ended September
30, 2025 and 2024, the Company did not incur any expenses related to the VAZYME License Agreement. As of both September 30, 2025 and
December 31, 2024, the accrued liabilities under this agreement were $200, included in accounts payable in the condensed consolidated
financial statements.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>8.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments
under Research and Collaboration Agreements</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>MedImmune License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In August 2016, the Company entered
into a collaboration and license agreement with MedImmune Limited (&#8220;MedImmune&#8221;), pursuant to which the Company received from
MedImmune an exclusive, worldwide, royalty-bearing, sublicensable (subject to certain conditions) license to certain intellectual property
rights relating to the Company&#8217;s ABP-200 product candidates (the &#8220;MedImmune License Agreement&#8221;). The Company agreed
to use commercially reasonable efforts to reach certain development and commercialization milestones for such bispecific antibodies within
specified timeframes. Unless earlier terminated in accordance with its terms, the MedImmune License Agreement, as amended, remains in
effect on a country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of
products based on the ABP-200 product candidates. The Company is no longer developing ABP-200.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the MedImmune License Agreement,
the Company agreed to pay milestone and royalty payments, including up to $244,000 in milestone payments, which are comprised of $14,000
upon meeting certain clinical development milestones, $80,000 upon achieving certain regulatory events and $150,000 upon meeting certain
worldwide commercial sales thresholds; and tiered high-single to low double-digit percentage royalties based on annualized net sales of
each product commercialized from our collaboration on a country-by-country basis. No milestones have been reached and no products were
sold by the Company through December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>NCI License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In August 2017, the Company entered
into a patent license agreement with the National Cancer Institute (the &#8220;NCI&#8221;), a division of the National Institutes of Health
(the &#8220;NIH&#8221;), pursuant to which the Company received an exclusive, worldwide license to make, use, sell, offer to sell and
import products covered by the licensed patents in the field of using certain monoclonal antibodies as monospecific or bispecific antibodies
for the treatment of liver cancer (the &#8220;NCI License Agreement&#8221;). The license agreement was amended in May 2020 and October
2023 and the field of use was narrowed to the development and commercialization of a bispecific antibody for the treatment of GPC-3 expressing
liver cancer using a particular moiety for targeting GPC3 and the timeline for development and commercialization was extended. Unless
earlier terminated, the Company&#8217;s agreement with NCI will expire upon expiration of all licensed patent rights. The Company may
also terminate the agreement as to any licenses in any country or territory upon 60 days written notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Pursuant to the NCI agreement and amendments,
the Company agreed to pay low single-digit royalties based on net sales of licensed products as well as milestone payments of up to $3,995
due upon achievement of clinical and regulatory milestones, and up to $12,000 milestone payments due upon achievement of commercial milestones.
No milestones have been reached and no products were sold by the Company through December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company also has to pay the guaranteed
annual minimum royalties of $25 starting on the effective date of the agreement (which annual minimum royalties may be credited against
the running royalties on net sales of any licensed products or services). During each of the years ended December 31, 2024 and 2023, the
Company incurred $25, in minimum royalty payments, included in research and development expenses. Under the amendment entered into in
March 2020, the Company is also liable for the extension royalties of $225 payable under this agreement which were rescheduled to become
due in several installments starting in March 2022. As of both December 31, 2024 and 2023, the accrued extension royalties were $200,
included in accrued expenses and accounts payable on the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company also agreed to reimburse
patent costs for all documented out of pocket associated with the preparation, filing, prosecution and maintenance of patent rights.
During both the years ended December 31, 2024 and 2023, the Company did not incur any expenses related to the patent costs reimbursements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Mabwell License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In October 2020, the Company entered
into an exclusive collaboration and license agreement with Mabwell (the &#8220;Mabwell License Agreement&#8221;). The agreement was amended
in November 2020. Under the Mabwell license agreement, the Company received a non-exclusive, royalty-free research purpose license as
well as an exclusive commercial license within certain territories, as defined in the agreement, to Mabwell&#8217;s series of anti-SARS-CoV-2
monoclonal antibodies. Under the agreement, the Company is responsible for conducting at its sole expense, research and preclinical, clinical
and other developments of any licensed products and bears all development costs and expenses related to obtaining or maintenance of marketing
authorizations of licensed products in its territories. Mabwell is obligated, at the Company&#8217;s request, to supply the Licensed Antibodies
to the Company for clinical trial purpose at costs plus margin as defined in the agreement. The parties agreed to undertake certain joint
clinical research and development activities with a portion of the costs contributed by Mabwell. Unless earlier terminated, the Mabwell
License Agreement will expire on the occurrence of the last to expire royalty term, which is the later of a) the expiration of the last
to expire valid claim of the patent rights and b) ten years from the first commercial sale of such Licensed Product, and determined on
jurisdiction-by-jurisdiction basis. Either party may terminate the agreement in the event of any uncured material breach by the other
party.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The agreement provides for development
milestones of up to $32,500 and annual sales milestone payments of up to $50,000 payable by the Company to Mabwell. The agreement also
provides for a profit sharing, with Mabwell sharing 50% of the net profits from the licensed product sales in certain territories as defined
in the agreement. The Company will also make tiered royalty payments in the mid to high single digits on net sales of commercial products
in the licensed territory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">During the years ended December 31,
2024 and 2023, development activities under the Mabwell collaboration agreement were immaterial to the consolidated financial statements.
No <span style="background-color: white">milestones have been reached and </span>no products were sold under <span style="background-color: white">the
</span>Mabwell License Agreement <span style="background-color: white">through December 31, 2024. As discussed in Note 2 to these consolidated
financial statements, the Company recognized other income of $3,556 during the year ended December 31, 2024 associated with the reversal
of the estimated liability associated with a disputed invoice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">In
March 2025, the Company received a draft of a termination agreement from Mabwell which outlines Mabwell&#8217;s claim for the total payment
of $3,300 under certain development milestones asserting that these development milestones were achieved by the Company during 2021. The
Company does not believe that a liability under the milestone related provisions invoked by Mabwell was triggered and is planning to engage
in discussion with Mabwell about the validity of their claim. The Company accrued $3,300 expense related to this claim in the consolidated
financial statements as of December 31, 2024 through debit to accumulated deficit. The Company also restated the accrued expenses in the
consolidated financial statements as of September 30, 2024, December 31, 2023 and 2022 included in the Company&#8217;s Form 8-K, filed
on November 26, 2024 (see Note 2).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>MSK License Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In March 2017, the Company
entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (the &#8220;MSK License Agreement&#8221;),
pursuant to which the Company received an exclusive, royalty-bearing, worldwide license under specified patent rights to make, use
and sell certain of MSK&#8217;s proprietary Her2-huOKT3 bispecific antibodies. The agreement was amended on March 31, 2017, on March
31, 2018, and January 1, 2020. Unless earlier terminated in accordance with its terms, the agreement was to remain in effect on a
country-by-country basis until the expiration of the last royalty term in such country as to be determined by the launch of products
based on MSK antibodies. On September 19, 2023, MSK License Agreement was terminated by MSK due to the Company&#8217;s failure to
make the payments for the patent costs reimbursements discussed below.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the MSK License Agreement, as
amended, the Company agreed to use commercially reasonable efforts to reach certain development and commercialization milestones for such
bispecific antibodies within specified territories and timeframes. The Company was committed to pay MSK up to $10,500 in milestone payments
upon achieving certain research and development and commercialization events or within a certain number of months of the effective date,
up to $30,000 in milestone payments based on net sales, and tiered mid-single-digit percentage royalties based on annualized net sales
of each product commercialized from the collaboration with guaranteed annual minimum royalties between $20 and $30 depending on certain
development events. During the years ended December 31, 2024 and 2023, the Company incurred $0 and $20 in minimum royalties, included
in research and development expenses. During the years ended December 31, 2024 and 2023, the Company did not incur any milestone payments
under this agreement. As of both December 31, 2024 and 2023, the accrued minimum royalty and milestone payments were $790, included in
accounts payable in the consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company also agreed to reimburse
patent costs for all documented out of pocket costs associated with the preparation, filing, prosecution and maintenance of patent rights
in the license territory. During the years ended December 31, 2024 and 2023, the Company expensed $0 and $49 respectively, related to
the patent costs reimbursements, included in general and administrative expenses. As of both December 31, 2024 and 2023, the liabilities
for the patent costs reimbursements were $273, included in other accrued expenses and accounts payable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of both December 31, 2024 and 2023,
the accrued liabilities for the unpaid interest on the outstanding minimum royalty and milestone payments due to MSK were $169, included
in other accrued expenses. See Note 10 for discussion of the June 2023 demand letter.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>VAZYME License agreement </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In April 2021, the Company entered
into a License Agreement with VAZYME Biotech Co., Ltd (&#8220;VAZYME&#8221;) (the &#8220;VAZYME License Agreement&#8221;), pursuant to
which the Company was granted an exclusive, perpetual, royalty-bearing, worldwide license under specified patent rights to research, develop
and commercialize VAZYME proprietary anti-SARS-CoV-2 monoclonal antibodies. Unless earlier terminated in accordance with its terms, the
agreement remains in effect on a country-by-country basis until the expiration of the last royalty term in such country.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the VAZYME License Agreement,
the Company agreed to use commercially reasonable efforts to reach certain research and development, and commercialization milestones
for such antibodies. The Company also agreed to pay $200 to VAZYME at the effective date of the agreement. The Company is committed to
pay VAZYME up to $11,100 in milestone payments upon achieving certain research and development events, up to $70,000 in milestone payments
based on annual net sales, and tiered low single-digit percentage royalties based on annualized net sales of each product commercialized
from the collaboration. No <span style="background-color: white">milestones in the </span>VAZYME License Agreement <span style="background-color: white">have
been reached through December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In December 2021, the Company
entered into a Cooperation Agreement with Chengdu Bio-Innovate Pharmaceutical Technology Co., Ltd (&#8220;Bio-Innovate&#8221;) and a
three-way sharing agreement with VAZYME and Bio-Innovate (&#8220;the Company&#8221;, &#8220;VAZYME&#8221; and
&#8220;Bio-Innovate&#8221;, collectively &#8220;all parties&#8221;), pursuant to which the Company entrusted Bio-Innovate to perform
certain preclinical testing and all parties agreed that VAZYME will ship the agreed antibodies to Bio-Innovate rather than the
Company to fulfill the requirements under the VAZYME License Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">For the years ended December 31, 2024 and 2023, the Company
did not incur any expenses related to the VAZYME License Agreement. As of both December 31, 2024 and 2023, the accrued liabilities
under this agreement were $200, included in accounts payable in the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>8.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Commitments and Contingencies</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Litigation and other matters</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company, from time to time, is subject
to legal proceedings and claims that arise in the ordinary course of business. Resolution of any such matter could have a material adverse
effect on the results of operations and financial condition. The Company considers all claims on a periodic basis and based on known
facts assesses whether potential losses are considered reasonably possible, probable and estimable. Based upon this assessment, the Company
then evaluates disclosure requirements and whether to accrue for such claims in its consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company records a provision for contingent
liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On September 12, 2023, a contract research
organization (&#8220;CRO&#8221;) vendor filed a lawsuit against the Company based on the Company&#8217;s failure to make certain installments
pursuant to a settlement agreement entered into with this vendor on January 23, 2023. Under the settlement agreement, the Company agreed
to pay a total of $1,644 to the vendor, with $600 due 5 business days after the settlement effective date and ten monthly installments,
approximately $104 each, starting in February 2023. The Company made the upfront payment and the first four monthly installments for
a total of $1,016 but failed to make the monthly installment payments due after May 2023. On January 24, 2024, the Company received endorsement
on motion for default judgment which requested the Company to pay approximately $700 to the CRO vendor. During the three and nine months
ended September 30, 2025, the Company accrued an additional $21 and $63 in interest, respectively, included in interest expense. As of
September 30, 2025 and December 31, 2024, the outstanding balance under this settlement agreement was $848 and $785, respectively. These
amounts were included in accounts payable and accrued expenses in the condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition to the lawsuit from a CRO vendor
above, the Company accrued $325 as of both September 30, 2025 and December 31, 2024 related to disputed invoices with vendors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In June 2023, the Company received a notice
of breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded payments totaling $1,230 for
the services performed under the MSK License Agreement (see Note 7). The corresponding liability is included in accrued expenses in the
condensed consolidated financial statements as of both September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The MedImmune License Agreement (see Note
7) provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement (December 2022). These
target dates were not met, which gives MedImmune (now AstraZeneca) a termination right. The Company does not expect a material impact
on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with the development
of ABP-200, which the Company is no longer developing. The Company believes that it does not need the intellectual property licensed
under that agreement for the development and eventual commercialization of ABP-201 or any of its other programs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 17, 2025, the Company received a complaint
from a former director asserting that the Company owes the former director a total of $748 for consulting fees, bonuses, and for unpaid
promissory note principal and interest. The principal and interest on the promissory note were $176 and $9, respectively, as of September
30, 2025 and December 31, 2024 (see Note 10). The remaining liability of $560 was included in accrued expenses in the condensed consolidated
financial statements as of September 30, 2025. On November 10, 2025, the Suffolk Superior Court in Massachusetts issued a preliminary
injunction prohibiting the transfer of the Company&#8217;s assets outside the ordinary course of business. At this stage, the Company
is unable to evaluate the likelihood of an unfavorable outcome or provide an estimate of the amount or range of potential loss, beyond
the amount already accrued above.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 22, 2025, the Company received
a demand for payment from Integral Molecular, Inc. in the amount of approximately $182. The Company is currently in negotiations to settle
this claim.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 23, 2025, the Company received
a demand for payment from Brookline Capital Markets, a division of Arcadia Securities LLC, in the amount of $140. The Company is currently
in negotiations to settle this claim.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Non-Redemption&#160;Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 5, 2024, Legacy Abpro and ACAB
entered into a&#160;non-redemption&#160;agreement (the&#160;&#8220;Non-Redemption&#160;Agreement&#8221;), with Sandia Investment Management
LP on behalf of certain funds, investors, entities or accounts for which it or its affiliates acts as manager, sponsor or advisor (the
&#8220;NRA Investors&#8221;). Pursuant to such&#160;Non-Redemption&#160;Agreement, each NRA Investor agreed to rescind or reverse any
previously submitted redemption demand of the common stock of the Company held or to be acquired by such NRA Investor (the &#8220;NRA
Investor Shares&#8221;) up to 4,145 shares of common stock in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the Closing Date, the NRA Investors reversed
redemption demands with respect to 11,043 Series A Common stock shares (pre-split) of ACAB. Pursuant to the Non-Redemption Agreement,
upon consummation of the Merger, the Company had to pay to the NRA Investors a payment equal to the number of NRA Investor Shares multiplied
by the redemption price, minus the number of NRA Investor Shares multiplied by $9.00 (pre-split). As of September 30, 2025 and December
31, 2024, the Company owed NRA Investors $26, based on the redemption price of $340.80 at the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Excise Tax Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">At the Closing Date, the Company assumed the
excise tax liability of $4,330, as adjusted, as discussed further below, from ACAB related to the redemptions of shares in 2023 and calculated
as 1% of the shares redeemed during fiscal year 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 16, 2022, the Inflation Reduction
Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1%
excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly
traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself,
not its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the
shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are
permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same
taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;)
has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the second quarter of 2024, the Treasury
and Internal Revenue Service (&#8220;IRS&#8221;) issued final regulations with respect to the timing and payment of the excise tax. Pursuant
to those regulations, the Company would need to file a return and remit payment for any liability incurred during the period from January
1, 2023 to December 31, 2023 on or before October 31, 2024. The Company has filed the excise tax return and has engaged with the IRS
in determining a payment plan for the balance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company is unable to pay its obligation
in full, and, as such, it is subject to additional interest and penalties which are currently estimated at 8% interest per annum and
a 0.5% underpayment penalty per month or portion of a month up to 25% of the total liability for any amount that is unpaid from November
1, 2024 until paid in full.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2025, the Company received the letter
from the IRS, requesting to set up a meeting with the Company to discuss the unsettled tax matters of ACAB and referencing $4,401 amount
owed in relation to the 2023 excise taxes, of which $210 was in interest and penalties (the &#8220;IRS Letter&#8221;). The Company believes
that the excise tax liability in the IRS Letter is overstated as compared to the amounts in ACAB&#8217;s filed tax return for the year
ended December 31, 2023. Pending further discussions with the IRS, the Company recorded the excess of $1,268 over the Company&#8217;s
estimate of $3,133 (inclusive of interest and penalties) as the additional excise tax liability assumed from ACAB at the Closing Date.
As of September 30, 2025, the Company recorded the excess of $946 over the Company&#8217;s estimate of $3,455 (inclusive of interest
and penalties) as the additional excise tax liability. As a result, management has not accrued any further interest or penalties on this
amount.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10</b>.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Commitments
and Contingencies</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Litigation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company, from time to time, is
subject to legal proceedings and claims that arise in the ordinary course of business. Resolution of any such matter could have a material
adverse effect on the results of operations and financial condition. The Company considers all claims on a periodic basis and based on
known facts assesses whether potential losses are considered reasonably possible, probable and estimable. Based upon this assessment,
the Company then evaluates disclosure requirements and whether to accrue for such claims in its consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company records a provision for
a contingent liability when it is both probable that a loss has been incurred and the amount of the loss can be reasonably estimated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On August 12, 2024, the Company&#8217;s
landlord filed a court summons for eviction based on the Company&#8217;s failure to make payments pursuant to one of its lease agreements.
According to the summons, the landlord was claiming the full amount of rental payments over the term of the lease. As of September 30,
2024, the Company owed $186 to the landlord in late rent. On October 21, 2024, the Company paid the landlord $100 for late rent and maintenance
expenses. A court date was scheduled for November 14, 2024, and was subsequently postponed to November 21, 2024. On November 20, 2024,
the Company paid the landlord $115 and on November 25, 2024, the court summons for eviction was dismissed by the landlord. As of December
31, 2024, no amounts were due to the landlord for past due rent.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On September 12, 2023, a contract research
organization (&#8220;CRO&#8221;) vendor filed a lawsuit against the Company based on the Company&#8217;s failure to make certain installments
pursuant to a settlement agreement entered into with this vendor on January 23, 2023. Under the settlement agreement, the Company agreed
to pay a total of $1,644 to the vendor, with $600 due 5 business days after the settlement effective date and ten monthly installments,
approximately $104 each, starting in February 2023. The Company made the upfront payment and the first four monthly installments for a
total of $1,016 but failed to make the monthly installment payments due after May 2023. On January 24, 2024, the Company received the
endorsement on motion for default judgment which requested the Company to pay approximately $700 to the CRO vendor. During the year ended
December 31, 2024, the Company accrued an additional $83 in interest, included in the interest expense. During the year ended December
31, 2024, the Company made an $11 payment to CRO. As of December 31, 2024 and 2023, the outstanding balance under this settlement agreement
was $785 and $751, respectively. These amounts were included in accounts payable and accrued expenses in the consolidated financial statements
as of December 31, 2024 and 2023.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In addition to the lawsuit from a CRO
vendor above, the Company accrued $325 and $379 as of December 31, 2024 and 2023, respectively, related to disputed invoices with vendors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In June 2023, the Company received
a notice of breach from MSK followed by a notice of termination in September 2023, pursuant to which MSK demanded payments totaling $1,230
for the services performed under the MSK License Agreement (see Note 8). The corresponding liability is included in accounts payable and
accrued expenses in the consolidated financial statements as of both December 31, 2024 and 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The MedImmune License Agreement (see
Note 8) provides for a research plan with target dates for an IND application (July 2021) and Phase II commencement (December 2022). These
target dates were not met, which gives MedImmune (now AstraZeneca) a termination right. The Company does not expect a material impact
on our business if MedImmune/AstraZeneca terminates this agreement. This license was originally entered into in connection with the development
of ABP-200, which the Company is no longer developing. The Company believes that it does not need the intellectual property licensed under
that agreement for the development and eventual commercialization of ABP-201 or any of its other programs.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Non-Redemption Agreement</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 5, 2024, Legacy Abpro and
ACAB entered into a non-redemption agreement (the &#8220;Non-Redemption Agreement&#8221;), with Sandia Investment Management LP on behalf
of certain funds, investors, entities or accounts for which it or its affiliates acts as manager, sponsor or advisor (the &#8220;NRA Investors&#8221;).
Pursuant to such Non-Redemption Agreement, each NRA Investor agreed to rescind or reverse any previously submitted redemption demand of
the common stock of the Company held or to be acquired by such NRA Investor (the &#8220;NRA Investor Shares&#8221;) up to 4,145 shares
of common stock in the aggregate.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">At the Closing Date, the NRA Investors
reversed redemption demands with respect to 11,043 Series A Common stock shares of ACAB. Pursuant to the Non-Redemption Agreement, upon
consummation of the Merger, the Company had to pay to the NRA Investors a payment equal to the number of NRA Investor Shares multiplied
by the redemption price, minus the number of NRA Investor Shares multiplied by $9.00 (pre-split). At the Closing Date, the Company owed
to NRA Investors $26, based on the redemption price of $340.80 at the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Excise Tax Liability</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">At the Closing Date, the Company assumed
the excise tax liability of $4,330, as adjusted as discussed further below, from ACAB related to the redemptions of shares in 2023 and
calculated as 1% of the shares redeemed during fiscal year 2023.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On August 16, 2022, the Inflation Reduction
Act of 2022 (the &#8220;IR Act&#8221;) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1%
excise tax on certain repurchases of stock by publicly traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly
traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not
its shareholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares
repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted
to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable
year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the &#8220;Treasury&#8221;) has been
given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">During the second quarter of
2024, the IRS issued final regulations with respect to the timing and payment of the excise tax. Pursuant to those regulations, the
Company would need to file a return and remit payment for any liability incurred during the period from January 1, 2023 to December
31, 2023 on or before October 31, 2024. The Company has filed the excise tax return and has engaged with the IRS in determining a
payment plan for the balance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company is unable to pay its obligation
in full, and, as such, it will be subject to additional interest and penalties which are currently estimated at 8% interest per annum
and a 0.5% underpayment penalty per month or portion of a month up to 25% of the total liability for any amount that is unpaid from November
1, 2024 until paid in full. The Company accrued $71 in penalties and interest through December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In March 2025, the Company received
the letter from the Internal Revenue Service of the United States Department of Treasury (the &#8220;IRS&#8221;), setting up the meeting
with the Company to discuss the unsettled tax matters of ACAB and referencing $4,401 amount owed in relation to the 2023 excise taxes,
of which $210 in interest and penalties. The Company believes that the excise tax liability in the IRS Letter is overstated as compared
to the amounts in ACAB&#8217;s filed tax return for the year ended December 31, 2023, and is planning to request further information from
the IRS to reconcile the amounts reported to the Company&#8217;s records. Pending further discussions with the IRS, the Company recorded
the excess of $1,268 over the Company&#8217;s estimate as the additional excise tax liability assumed from ACAB in the consolidated financial
statements as of December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Forward Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Forward Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Forward Purchase Agreement</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>9.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Forward Purchase Agreement</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 7, 2024, ACAB and Legacy Abpro
entered into a Confirmation of an OTC Equity Prepaid Forward Transaction (the &#8220;Forward Purchase Agreement&#8221; or &#8220;Transaction&#8221;)
with YA (the &#8220;Seller&#8221;) to which a maximum of up to 16,667 common stock shares were subject to the Transaction. At the Closing
Date, the Seller purchased 3,333 shares from third parties (&#8220;Recycled Shares&#8221;), pursuant to the pricing date notice dated
November 12, 2024, and paid approximately $1,100 (the &#8220;Prepayment Amount&#8221;) to the redeeming shareholders. Pursuant to the
terms of the Forward Purchase Agreement, at the Closing Date, the Company remitted the Prepayment Amount into an escrow account for the
benefit of the Seller.<i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 28, 2025, YA elected to effect
an Optional Early Termination (as described in the Forward Purchase Agreement) with respect to all 3,333 shares subject to the Forward
Purchase Agreement which terminated the agreement as a whole. YA paid the Company the Early Termination Obligation in the aggregate amount
of $132.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Forward Purchase Agreement was accounted
for at fair value as an asset in accordance with the guidance in ASC Topic 815 Derivatives and Hedging (&#8220;ASC 815&#8221;), with
subsequent changes in the fair value recorded in profits and losses. The fair value of the Forward Purchase Agreement asset was $494,
$155 and $132 as of November 13, 2024, December 31, 2024 and the settlement date, respectively. The Company recorded losses on the change
in the fair value of $0 and $23 in other (expense) income for the three and nine months ended September 30, 2025, respectively.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>11.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward
Purchase Agreement</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 7, 2024, ACAB and Legacy Abpro entered into a Confirmation
of an OTC Equity Prepaid Forward Transaction (the &#8220;Forward Purchase Agreement&#8221; or &#8220;Transaction&#8221;) with YA (the
&#8220;Seller&#8221;) to which a maximum of up to 16,667 common stock shares will be subject. At the Closing Date, the Seller purchased
3,333 shares from third parties (&#8220;Recycled Shares&#8221;), pursuant to the pricing date notice dated November 12, 2024 and paid
approximately $1.1 million (the &#8220;Prepayment Amount&#8221;) equal to $340.80 per Recycled Share (the &#8220;Initial Price&#8221;)
to the redeeming shareholders. Pursuant to the terms of the Forward Purchase Agreement, at the Closing Date, the Company remitted the
Prepayment Amount into an escrow account for the benefit of the Seller.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The number of Recycled Shares subject
to the Forward Purchase Agreement was also subject to reduction following a termination of the Forward Purchase Agreement with respect
to such shares as described under &#8220;Optional Early Termination&#8221; as discussed below. The contract was to settle based on the
settlement terms discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Optional Early Termination</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">From time to time and on any date following
the Closing Date (any such date, an &#8220;OET Date&#8221;) and subject to the terms and conditions in the Forward Purchase Agreement
(&#8220;Optional Early Termination&#8221;), the Seller may, in its absolute discretion, terminate the Transaction in whole or in part
by providing written notice to the Company (the &#8220;OET Notice&#8221;), by no later than the next payment date following the OET Date,
(which will specify the quantity by which the Number of Shares will be reduced (such quantity, the &#8220;Terminated Shares&#8221;)).
The effect of an OET Notice would be to reduce the Number of Shares by the number of Terminated Shares specified in such OET Notice with
effect as of the related OET Date. As of each OET Date, the Company would be entitled to an amount from the Seller, and the Seller would
pay to the Company an amount, equal to the product of (x) the number of Terminated Shares and (y) the reset price in respect of such OET
Date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The reset price (the &#8220;Reset Price&#8221;)
was initially $300.00. The Reset Price was subject to reset on a weekly basis commencing with the first full week following the Closing
Date, to be the lowest of (a) the then current Reset Price, (b) $300.00 and (c) the VWAP price of the shares of the last 3 trading days
in such week; provided, that in the event of a dilutive offering by the Company, the Reset Price will also be reduced to equal the effective
price per share in such dilutive offering immediately upon the occurrence of such dilutive offering.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>Settlement </i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On the Cash Settlement Payment Date,
which is the tenth local business day immediately following the Valuation Date (defined below), the Seller had to remit to the Company
a cash amount (the &#8220;Settlement Amount&#8221;) equal to (i) the Number of Shares as of the Valuation Date, multiplied by (ii) the
difference of (a) the volume weighted daily VWAP price over the Valuation Period, less (b) $15.00, and the Seller will not otherwise be
required to return to the Counterparty any of the Prepayment Amount. In the event that the difference of (a) the volume weighted daily
VWAP Price over the Valuation Period, less (b) $15.00, is equal to or less than $0, then the Settlement Amount shall be $0. The &#8220;Valuation
Date&#8221; is the earliest to occur of (a) the date that is 3 months after the Closing Date and (b) the date specified by the Seller
in a written notice to be delivered to the Company at the Seller&#8217;s discretion (which Valuation Date will not be earlier than the
day such notice is effective) after the occurrence of any of (x) a VWAP Trigger Event, (y) a Delisting Event or (z) unless otherwise specified
therein, upon any Additional Termination Event (defined below). Each of the following was to constitute an Additional Termination Event;
(a) The Merger Agreement is terminated pursuant to its terms prior to the closing of the Merger; and (b) If it is, or, as a consequence
of a change in law, regulation or interpretation, it becomes or will become, unlawful for the Seller to perform any of its obligations
contemplated by the Transaction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Forward Purchase Agreement was
accounted for at fair value as an asset in accordance with the guidance in ASC 815, with subsequent changes in the fair value recorded
in profits and losses. The fair value of the Forward Purchase Agreement asset was $494 and $155 as of November 13, 2024 and December 31,
2024, respectively. The loss on the change in the fair value of $339 was recorded in other (expense) income during the year ended December
31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On January 28, 2025, YA elected to
effect an Optional Early Termination with respect to all 3,333 Shares subject to the Forward Purchase Agreement which terminated the agreement
as a whole. YA paid the Company the Early Termination Obligation in the aggregate amount of $132, based on the Reset Price of $39.60 in
effect on January 28, 2025.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 185<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-185<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 184<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-184<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 181<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-181<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480960/815-15-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 183<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-183<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>10.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Notes Payable</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Note Payable</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In January 2025, the Company entered into
an insurance premium financing agreement and borrowed a total principal amount of $553. The note bore an annual interest rate of 7.74%
and matured in September 2025. The interest expense on the note amounted to $21 for the nine months ended September 30, 2025. The note
was paid in full prior to September 30, 2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true"><span style="text-decoration:underline">Notes Payable &#8211; Related Parties</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">Promissory Note with ABI</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 18, 2023, the Company entered into
a promissory note agreement with ABI, a significant investor in the Company, to receive up to $6,000. The promissory note accrued interest
at a rate of 5% per annum on the principal amount of each installment from the installment funding date until the maturity date and at
a rate of 7% per annum after the maturity date if any amounts then remain outstanding. The &#8220;Maturity Date&#8221; was defined in
the agreement as the earlier of (i) eighteen months from the funding date and (ii) the successful closing of the Merger. On August 22,
2024, ACAB entered into the Abpro Bio Subscription Agreement (see Note 3) with ABI, pursuant to which ABI purchased 20,749 shares of
the Company&#8217;s common stock, concurrently with the closing of the Merger at a price of $300.00 per share, for an aggregate purchase
price of $6,225, of which $4,225 was paid through the conversion of the balance due by the Company to ABI under the promissory note agreement
and the remainder of $2,000 in cash. In addition, ABI received an aggregate of 41,498 Incentive Shares.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 7, 2024, the Company entered into
an additional promissory note with ABI (&#8220;the 2024 ABI Note&#8221;) to receive up to $1,000 from ABI in weekly installments of $250.
The note accrued 10% interest and had a maturity date 5 business days after receipt of the proceeds under the PIPE Financing (see Note
3). The Company received $1,000 under this note through the Closing Date, and the balance of $1,000 was repaid at the Closing from the
PIPE Financing proceeds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of both September 30, 2025 and December
31, 2024, the outstanding principal balances under the promissory notes with ABI was $0. During both the three and nine months ended
September 30, 2025, the Company recorded $0 of interest expense on these promissory notes with ABI. During the three and nine months
ended September 30, 2024, the Company recorded $53 and $142, respectively, of interest expense on these promissory notes with ABI. As
of both September 30, 2025 and December 31, 2024, accrued interest totaling $191 was included in accrued expenses in the condensed consolidated
balance sheets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">Promissory Notes with Executive and Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On December 29, 2023, the Company issued promissory
notes to one of its executives and one of its directors, in the principal amount of $176 and $124, respectively, for deferred bonuses.
Amounts under the promissory notes plus accrued interest are due and payable on the earlier of (i) the closing of the Merger and (ii)
June 29, 2025. These promissory notes accrued interest at 5% per annum until the maturity date and 7% thereafter. At the Closing Date,
the Company paid $150 towards these promissory notes. As of both September 30, 2025 and December 31, 2024, $150 of principal was outstanding.
Interest expense on these promissory notes totaled $2 and $6 for the three and nine months ended September 30, 2025, respectively, included
in interest expense in the condensed consolidated statement of operations. Interest expense on these promissory notes totaled $4 and
$11 for the three and nine months ended September 30, 2024, respectively, included in interest expense in the condensed consolidated
statement of operations. Accrued interest on these promissory notes totaled $20 and $14 as of September 30, 2025 and December 31, 2024,
respectively, included in accrued expenses in the condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 18, 2024, the Company entered into
a separate promissory note agreement with the same executive to receive, as amended, up to $2,158 in funding. During the year ended December
31, 2024, the Company received $1,997 from the executive under this agreement. These advances accrued interest at 7.5% per annum through
the maturity date and at 9.5% per annum after the maturity date if any amounts then remain outstanding. All advances, plus accrued interest,
were due and payable on the earlier of (i) the closing of the Merger and (ii) November 20, 2024. At the Closing, the outstanding promissory
notes of $1,997 were converted into 20,000 newly issued common stock shares. Accrued interest on these promissory notes totaled $62 as
of both September 30, 2025 and December 31, 2024, respectively, included in accrued expenses in the condensed consolidated balance sheets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Pursuant to the terms of the promissory note
from April 18, 2024, the Company agreed to cause to be issued to the executive a number of New Abpro stock options or warrants in an
amount equal to the outstanding principal amount of such promissory note, subject to required approval by the New Abpro Board of Directors
(&#8220;BOD&#8221;) and Compensation Committee and registration of such securities on Form S-8. On February 7, 2025, the Company issued
28,333 common stock warrants to the executive (the &#8220;Executive Warrants&#8221;). The Executive Warrants are exercisable at $99.90
per share and bear an expiration date of February 7, 2035. 14,166 of the Executive Warrants are exercisable on the issuance date, 6,667
warrants become exercisable on the one-year anniversary of the issuance date, and 7,500 warrants become exercisable on the two-year anniversary
of the issuance date. The warrants were fair valued and immediately expensed at the issuance date as an additional interest expense related
to the promissory note. The fair value of the Executive Warrants at the issuance date was determined using the Black-Scholes option pricing
model based on the following assumptions: (a) fair value of common stock of $<span style="-sec-ix-hidden: hidden-fact-418">32.10</span>&#160;per share, (b) expected volatility of&#160;90.00%,
(c) dividend yield of&#160;0%, (d) risk-free interest rate of&#160;4.49%, and (e) expected life of&#160;10&#160;years. For the three
and nine months ended September 30, 2025, the Company recognized $0 and $714, respectively, of additional interest expense related to
the Executive Warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">Promissory Note with ACAB Executive</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On August 16, 2024, an executive at ACAB agreed
to loan Legacy Abpro $103 under a promissory note (the &#8220;ACAB Executive Note&#8221;). The ACAB Executive Note did not accrue interest
and the Company agreed to repay a total of $206 at the earlier of i) November 20, 2024, and ii) the closing of the Merger.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 21, 2024, the ACAB Executive Note
was amended to clarify that it should have been between Legacy Abpro as borrower and ACAB as lender. Pursuant to the Severance Agreement
(see Note 15), the liability to the ACAB executive was cancelled. According to the terms of the amended note, Legacy Abpro was to repay
the principal amount of $103. The amended note did not bear interest and was payable upon demand on or before December 31, 2024. The
note balance has not been repaid and was eliminated in consolidation at September 30, 2025 and December 31, 2024.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>12.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes
Payable - Related Parties</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Promissory Note with ABI</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 18, 2023, the Company entered
into a promissory note agreement with ABI, a significant investor in the Company, to receive up to $6,000. The promissory note accrues
interest at a rate of 5% per annum on the principal amount of each installment from the installment funding date until the maturity date
and at a rate of 7% per annum after the maturity date if any amounts then remain outstanding. The &#8220;Maturity Date&#8221; is defined
in the agreement as the earlier of (i) eighteen months from the funding date and (ii) the successful closing of the Merger. On August
22, 2024, ACAB entered into the Abpro Bio Subscription Agreement (see Note 3) with ABI, pursuant to which ABI purchased 20,749 shares of the Company&#8217;s common stock, concurrently with the closing of the Merger at a price of $300.00 per share, for an aggregate
purchase price of $6,225, of which $4,225 was paid through the conversion of the balance due by the Company to ABI under the promissory
note agreement and the remainder of $2,000 in cash. In addition, ABI received an aggregate of 41,498 Incentive Shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 7, 2024, the Company entered
into an additional promissory note with ABI (&#8220;the 2024 ABI Note&#8221;) to receive up to $1,000 from ABI in weekly installments
of $250. The note accrued 10% interest and had a maturity date 5 business days after receipt of the proceeds under the PIPE Financing
(see Note 3). The Company received $1,000 under this note through the Closing Date, and the balance of $1,000 was repaid at the Closing
from the PIPE Financing proceeds.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024 and 2023,
the outstanding principal balances under the promissory notes with ABI was $0 and $1,442, respectively. During the years ended
December 31, 2024 and 2023, the Company recorded $186 and $5, respectively, of interest expense on these promissory notes with ABI.
As of December 31, 2024 and 2023, accrued interest totaling $191 and $5, respectively, is included in accrued expenses in the
consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Promissory Notes with Executive
and Director</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 29, 2023, the Company issued
promissory notes to one of its executives and one of its directors, in the principal amount of $176 and $124, respectively, for deferred
bonuses. Amounts under the promissory notes plus accrued interest are due and payable on the earlier of (i) the closing of the Merger
and (ii) June 29, 2025. These promissory notes accrue interest at 5% per annum until the maturity date and 7% thereafter. At the Closing
Date, the Company paid $150 towards these promissory notes. As of December 31, 2024 and 2023, $147 and $300, respectively, of principal
was outstanding. Accrued interest on these promissory notes totaled $14 and $0 as of December 31, 2024 and 2023, respectively, included
in accrued expenses in the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">On April 18, 2024, the Company entered
into a separate promissory note agreement with the same executive to receive, as amended, up to $2,158 in funding. During the year ended
December 31, 2024, the Company received $1,997 from the executive under this agreement. These advances accrued interest at 7.5% per annum
through the maturity date and at 9.5% per annum after the maturity date if any amounts then remain outstanding. All advances, plus accrued
interest, were due and payable on the earlier of (i) the closing of the Merger and (ii) November 20, 2024. At the Closing, the outstanding
promissory notes of $1,997 were converted into 20,000 newly issued common stock shares. Accrued interest on these promissory notes totaled
$62 and $0 as of December 31, 2024 and 2023, respectively, included in accrued expenses in the consolidated balance sheets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">Pursuant to the terms of the promissory
note, the Company agreed to cause to be issued to the executive a number of New Abpro stock options or warrants in an amount equal to
the outstanding principal amount of such promissory note, subject to required approval by the New Abpro Board of Directors and Compensation
Committee and registration of such securities on Form S-8. On February 7, 2025, the Company issued 28,333 common stock warrants to an
executive. The warrants are exercisable at $99.90 per share and bear an expiration date of February 7, 2035. The warrants are exercisable
as follows: 14,166 warrants are exercisable on the issuance date, 6,667 warrants become exercisable on the one-year anniversary of the
issuance date, and 7,500 warrants become exercisable on the two-year anniversary of the issuance date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: left"><i>Promissory Note with ACAB Executive</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On August 16, 2024, an executive at
ACAB agreed to loan Legacy Abpro $103 under a promissory note (the &#8220;ACAB Executive Note&#8221;). The ACAB Executive Note did not
accrue interest and the Company agreed to repay a total of $206 at the earlier of i) November 20, 2024, and ii) the closing of the Merger.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 21, 2024, the ACAB Executive
Note was amended to clarify that it should have been for the benefit of ACAB. Pursuant to the Severance Agreement (see Note 17), the liability
to the ACAB executive was cancelled. According to the terms of the amended note, Legacy Abpro was to repay the principal amount of $103.
The note did not bear interest and was payable upon demand on or before December 31, 2024. The note balance was eliminated in consolidation
at the Closing Date and December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Standby Equity Purchase Agreement<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementAbstract', window );"><strong>Standby Equity Purchase Agreement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementTextBlock', window );">Standby Equity Purchase Agreement</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>11.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Standby Equity Purchase Agreement</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October&#160;30, 2024, Legacy Abpro and
ACAB entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd. (&#8220;YA&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Subject to the satisfaction of the conditions
set forth in the SEPA, YA committed to advance to the Company the aggregate principal amount of up to $5,000 (the&#160;&#8220;Pre-Paid&#160;Advance&#8221;),
which shall be evidenced by convertible promissory notes (each a &#8220;Convertible Note&#8221;). On November 14, 2024, the Company received
the first Pre-Paid Advance and entered into a Convertible Note (defined below). The second&#160;Pre-Paid&#160;Advance was to be in a
principal amount of $2,000 and advanced on the later of (i)&#160;the second trading day after the initial registration statement filed
pursuant to the Registration Rights Agreement (as defined below) becomes effective and (ii)&#160;the second trading day after the required
shareholder approval to issue shares of the post-combination Company&#8217;s common stock in excess of 20% of the Company&#8217;s outstanding
shares pursuant to Nasdaq Rules (the &#8220;Exchange Cap&#8221;) has been obtained. At the special meeting of stockholders held on April
8, 2025, the Company obtained stockholder approval for the issuance of shares over the Exchange Cap.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 14, 2024 (the &#8220;First Convertible
Note Issuance Date&#8221;), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the &#8220;First Convertible
Note&#8221;) with YA for $3,000 and received net proceeds of $2,755, net of the original issuance discount of 8% (the &#8220;Convertible
Note Discount&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On June 23, 2025 (the &#8220;Second Convertible
Note Issuance Date&#8221;), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the &#8220;Second Convertible
Note&#8221; and together with the First Convertible Note, the &#8220;Convertible Notes&#8221;) with YA for $2,000 and received net proceeds
of $1,840, net of the Convertible Note Discount.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Convertible Notes have a maturity date
of November 13, 2025 (subject to earlier repayments based on Amortization Event described below) and incur interest at a rate of 0% (or
18% upon the occurrence of an uncured Event of Default).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Convertible Notes are convertible at the
option of the holder at any time after the issuance dates based on the conversion price determined as the lower of (i) $345.00 per Common
Share (the &#8220;Fixed Price&#8221;), or (ii) 94% of the lowest daily VWAP during the 5 consecutive trading days immediately preceding
the conversion date (the &#8220;Variable Price&#8221;), but which Variable Price shall not be lower than the Floor Price then in effect
(the &#8220;Conversion Feature&#8221;). The Floor Price at the First Issuance Date was $34.62 per share calculated as 20% of the closing
price of the Company&#8217;s stock on November 12, 2024. The Floor Price was adjusted downward to $5.70 per share on February 12, 2025
when the initial registration statement was declared effective by the SEC. On April 29, 2025, in accordance with the terms of the Convertible
Promissory Note, the Company reduced the Floor Price down to $4.50 per share. The conversion is subject to the limitations including
beneficial ownership limitation, principal market limitation and monthly conversion limits. If the Company, at any time while the Convertible
Note is outstanding, shall issue any Common Shares (other than pursuant to the SEPA) for no consideration or for a price per share that
is lower than the Fixed Price then in effect, the Fixed Price shall be reduced to equal the lowest price per share of such issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 20, 2025, the Company entered into
an amendment to SEPA with YA, pursuant to which, the definition of the conversion price was amended to state that the Fixed Price should
be adjusted (downwards only) to equal the VWAP of the Common Shares over the three (3) Trading Days immediately preceding the 20th Trading
Day following the Issuance Date if such price is lower than the initial Fixed Price. As a result, at the amendment date, the Fixed Price
was reset down to $50.40 per share.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Convertible Notes were redeemable at the
option of the Company if the volume-weighted-average price (&#8220;VWAP&#8221;) of the Company&#8217;s Common Stock was less than $345.00
which may be adjusted downward upon payment of stock dividend, stock split or reclassification, or if the Company issued common stock
for no consideration or at a price lower than the then-effective Fixed Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the terms of the Convertible Notes,
the Amortization Event was to be occur if i) the daily VWAP is less than the Floor Price for five trading days during a period of seven
consecutive trading days (a &#8220;Floor Price Event&#8221;), (ii) unless the Company has obtained the approval from its stockholders
for the issuance of shares pursuant to the transactions contemplated in the SEPA in excess of the Exchange Cap, the Company has issued
in excess of 99% of the Common Shares available under the Exchange Cap (an &#8220;Exchange Cap Event&#8221;), or (iii) any time after
the Effectiveness Deadline (as defined in the Registration Rights Agreement entered into in relation to the SEPA), YA was unable to utilize
a Registration Statement to resell Underlying Shares for a period of 10 consecutive trading days (a &#8220;Registration Event&#8221;).
If at any time after the Issuance Date, and from time to time thereafter, an Amortization Event was to occur, then the Company had to
make monthly payments beginning on the 7th trading day after the Amortization Event Date and continuing on the same day of each successive
month. Each monthly payment had to be in an amount equal to the sum of (i) $1,250 of principal in the aggregate among the Convertible
Note (or the outstanding principal if less than such amount) (the &#8220;Amortization Principal Amount&#8221;), plus (ii) the payment
premium equal to 5% of the Amortization Principal Amount, and (iii) accrued and unpaid interest hereunder as of each payment date. The
obligation of the Company to make monthly prepayments related to an Amortization Event was to be cease (with respect to any payment that
has not yet come due) if any time after the Amortization Date (A) in the event of a Floor Price Event, on the date that was the 7th consecutive
trading day that the daily VWAP was greater than the Floor Price then in effect, or the date that the Company reduces the Floor Price
in accordance with the terms of this Note, (B) in the event of a Registration Event, the condition or event causing the Registration
Event has been cured or the Holder was able to resell the Common Shares issuable upon conversion of this Note without limitations in
accordance with Rule 144 under the Securities Act, or (C) in the event of an Exchange Cap Event, the date the Company has obtained stockholder
approval to increase the number of Common Shares under the Exchange Cap and/or the Exchange Cap no longer applied, unless a subsequent
Amortization Event occurs. No Amortization Events occurred from the Note Issuance Dates through the date the Convertible Notes were converted
into common stock shares as discussed below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">It was determined, in accordance with ASC
815, that the Conversion Feature is required to be bifurcated due to the adjustments to the settlement amount of this embedded feature
that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares, and should be recorded as
a liability (the &#8220;Embedded Derivative Liability&#8221;) at fair value with a corresponding amount recorded as a discount on the
Convertible Notes. The Embedded Derivative Liability is marked to market at each reporting period end with any changes recorded in other
income or expense. The fair value of the Embedded Derivative Liability associated with the First Convertible Note was estimated at $69
at the issuance date based on the difference between the fair value of the convertible note with these embedded features and the fair
value without each one of these embedded features. The fair value of the Embedded Derivative Liability associated with the Second Convertible
Note was estimated at $93 at the issuance date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the second quarter of 2025, the First
Convertible note was fully converted at the option of YA into an aggregate of 513,981 Common stock shares. During the third quarter of
2025, the Second Convertible note was fully converted at the option of YA into an aggregate of 367,491 Common stock shares. At each of
the conversion dates, the Company calculated the fair value of the Embedded Derivative Liability associated with the converted portion
of the Convertible Note based on the difference between the fair value of the common stock shares issued upon conversion and the outstanding
note balance, resulting in the total loss on the change in the fair value of $150 and $773 for the three and nine months ended September
30, 2025. The difference between (a) the carrying amount of the First Convertible Note and the fair value of the related Embedded Derivative
Liability at the conversion date, and (b) the fair value of the shares issued was $144 and was recorded to other (expense) income as
a loss on the settlement of the convertible notes during the second quarter of 2025. The difference between (a) the carrying amount of
the Second Convertible Note and the fair value of the related Embedded Derivative Liability at the conversion date, and (b) the fair
value of the shares issued was $214 and was recorded to other (expense) income as a loss on the settlement of the convertible notes during
the third quarter of 2025.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The total discount resulting from the Convertible
Note Discount and the bifurcation of the Embedded Derivative Liability at the issuance dates was amortized over the terms of the Convertible
Notes through non-cash interest expense using the effective interest method. The non-cash interest expense related to the discount amortization
was $27 and $160 for the three and nine months ended September 30, 2025, respectively, and was included in interest expense in the condensed
consolidated statement of operations.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i style="-sec-ix-redline:true;-keep: true">SEPA Put Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the terms of the SEPA, starting at the
Closing Date, the Company has the right, but not the obligation (&#8220;SEPA Put Rights&#8221;), to issue shares of its common stock
to YA (&#8220;Advance Shares&#8221;, and such issuance and sale, an &#8220;Advance&#8221;) and YA shall subscribe for and purchase from
the Company such Advance Shares, through written notice by the Company to YA (&#8220;Advance Notice&#8221;), provided (i)&#160;no balance
is outstanding under a Convertible Note, or (ii)&#160;if there is a balance outstanding under a Convertible Note, an Amortization Event
(as defined above), has occurred in accordance with and subject to the terms of the SEPA. The SEPA contemplates purchase by YA of up
to $50,000 in aggregate gross purchase price for newly issued shares of the Company&#8217;s common stock. If any amount remains outstanding
under a Convertible Note, without the prior written consent of YA, the Company may only (other than with respect to a deemed Advance
Notice pursuant to an Investor Notice (described below)) submit an Advance Notice (A) if an Amortization Event has occurred and the obligation
of the Company to make monthly prepayments under the Convertible Note has not ceased, and (B)&#160;YA pays the aggregate purchase price
owed by the Company from such Advance by offsetting the amount of the Advance Proceeds against an equal amount outstanding under the
subject Convertible Note. Any such sales would be subject to certain limitations, including that YA could not purchase any shares that
would result in it owning more than 4.99% of the Company&#8217;s common stock, or any shares that, aggregated with any related transaction,
would exceed 19.9% of all shares of common stock outstanding on the date of the SEPA unless shareholder approval was obtained allowing
for issuances in excess of such amount.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">For as long as there was an outstanding balance
under a Convertible Note, YA had the right, but not the obligation, by delivery to the Company of Investor Notices (as defined in the
SEPA), to cause an Advance Notice to be deemed delivered by YA, which triggers the issuance and sale of Advance Shares to YA, subject
to terms and conditions as specified in the SEPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The purchase price for the Advance Shares
shall be the price per Advance Share obtained by multiplying the Company&#8217;s stock price (i)&#160;by 96% in respect of an Advance
Notice delivered by the Company with an Option 1 Pricing Period (defined by reference to VWAP on the trading day the Advance Notice is
submitted), (ii) 97% in respect of an Advance Notice with an Option 2 Pricing Period (defined by reference to the lowest daily VWAP on
three consecutive trading days commencing on the Advance Notice Date), or (iii)&#160;in the case of any Advance Notice delivered pursuant
to an Investor Notice, equal to the Conversion Price (as defined in the Convertible Note).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company accounted for the SEPA Put Rights
as an asset at fair value in accordance with the guidance in ASC 815, due to the adjustments to the settlement amount of this derivative
instrument that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares. The fair value
of the SEPA Put Rights was $243 and $188 as of September 30, 2025 and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As consideration for YA&#8217;s commitment
to purchase shares of common stock, upon execution of the SEPA, the Company engaged to remit YA the commitment fee of $500. In December
2024, the Company issued to YA 9,905 shares of common stock in settlement of the commitment fee obligation. The fair value of the shares
issued to YA was $327 at their issuance date and the difference of $173 was recorded as a gain on extinguishment of accrued liabilities
in the fourth quarter of 2024. The excess of the fair value of the SEPA Put Rights above the commitment fee at the issuance date of $1,051
was included in the change in fair value of SEPA Put Rights in the consolidated statement of operations in the fourth quarter of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In July and August 2025, the Company issued
three Advance Notices to YA in accordance with the terms of the SEPA, under which YA purchased from the Company 91,336 common stock shares,
raising $688 in total net proceeds.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>13.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Standby
Equity Purchase Agreement</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Convertible Notes</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 30, 2024, Legacy Abpro and
ACAB entered into a Standby Equity Purchase Agreement (the &#8220;SEPA&#8221;) with YA II PN, Ltd. (&#8220;YA&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Subject to the satisfaction of the
conditions set forth in the SEPA, YA committed to advance to the Company the aggregate principal amount of up to $5,000 (the &#8220;Pre-Paid
Advance&#8221;), which shall be evidenced by convertible promissory notes (each a &#8220;Convertible Note&#8221;). On November 14, 2024,
the Company received the first Pre-Paid Advance and entered into a Convertible Note (defined below). The second Pre-Paid Advance shall
be in a principal amount of $2,000 and advanced on the later of (i) the second trading day after the initial registration statement filed
pursuant to the Registration Rights Agreement (as defined below) becomes effective and (ii) the second trading day after the required
shareholder approval to issue shares of the post-combination Company&#8217;s common stock in excess of 20% of the Company&#8217;s outstanding
shares pursuant to Nasdaq Rules (the &#8220;Exchange Cap&#8221;) has been obtained. At the special meeting of stockholders held on April
8, 2025, the Company obtained stockholder approval for the issuance of shares over the Exchange Cap.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 14, 2024 (the &#8220;Issuance
Date&#8221;), pursuant to the SEPA, the Company entered into a Convertible Promissory Note (the &#8220;Convertible Note&#8221;) with YA
for $3,000 and received net proceeds of $2,755, net of the original issuance discount of 8% (the &#8220;Convertible Note Discount&#8221;).
The Convertible Note has a maturity of November 13, 2025 (subject to earlier repayments based on Amortization Event described below),
incurs interest at a rate of 0% (or 18% upon the occurrence of an uncured Event of Default).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Convertible Notes are convertible
at the option of the holder at any time after the Issuance Date based on the conversion price determined as the lower of (i) $345.00 per
Common Share (the &#8220;Fixed Price&#8221;), or (ii) 94% of the lowest daily VWAP during the 5 consecutive trading days immediately preceding
the conversion date (the &#8220;Variable Price&#8221;), but which Variable Price shall not be lower than the Floor Price then in effect
(the &#8220;Conversion Feature&#8221;). The Floor Price at the Issuance Date was $34.62 per share calculated as 20% of the closing price
of the Company&#8217;s stock on November 12, 2024. The Floor Price was adjusted downward to $5.70 on February 12, 2025 when the initial
registration statement was declared effective by the SEC. The conversion is subject to the limitations including beneficial ownership
limitation, principal market limitation and monthly conversion limits. If the Company, at any time while the Convertible Note is outstanding,
shall issue any Common Shares (other than pursuant to the SEPA) for no consideration or for a price per share that is lower than the Fixed
Price then in effect, the Fixed Price shall be reduced to equal the lowest price per share of such issuances.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Convertible Note is redeemable
at the option of the Company if the volume-weighted-average price (&#8220;VWAP&#8221;) of the Company&#8217;s Common Stock is less than
$345.00 which may be adjusted downward upon payment of stock dividend, stock split or reclassification, or if the Company issues common
stock for no consideration or at a price lower than the then-effective Fixed Price.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the terms of the Convertible
Notes, the Amortization Event occurs if i) the daily VWAP is less than the Floor Price for <span style="-sec-ix-hidden: hidden-fact-438">five</span> trading days during a period of <span style="-sec-ix-hidden: hidden-fact-439">seven</span>
consecutive trading days (a &#8220;Floor Price Event&#8221;), (ii) unless the Company has obtained the approval from its stockholders
for the issuance of shares pursuant to the transactions contemplated in the SEPA in excess of the Exchange Cap, the Company has issued
in excess of 99% of the Common Shares available under the Exchange Cap (an &#8220;Exchange Cap Event&#8221;), or (iii) any time after
the Effectiveness Deadline (as defined in the Registration Rights Agreement entered into in relation to the SEPA), YA is unable to utilize
a Registration Statement to resell Underlying Shares for a period of 10 consecutive trading days (a &#8220;Registration Event&#8221;).
If at any time after the Issuance Date, and from time to time thereafter, an Amortization Event occurs, then the Company shall make monthly
payments beginning on the 7th trading day after the Amortization Event Date and continuing on the same day of each successive month. Each
monthly payment shall be in an amount equal to the sum of (i) $1,250 of principal in the aggregate among the Convertible Note (or the
outstanding principal if less than such amount) (the &#8220;Amortization Principal Amount&#8221;), plus (ii) the payment premium equal
to 5% of the Amortization Principal Amount, and (iii) accrued and unpaid interest hereunder as of each payment date. The obligation of
the Company to make monthly prepayments related to an Amortization Event shall cease (with respect to any payment that has not yet come
due) if any time after the Amortization Date (A) in the event of a Floor Price Event, on the date that is the 7th consecutive trading
day that the daily VWAP is greater than the Floor Price then in effect, or the date that the Company reduces the Floor Price in accordance
with the terms of this Note, (B) in the event of a Registration Event, the condition or event causing the Registration Event has been
cured or the Holder is able to resell the Common Shares issuable upon conversion of this Note without limitations in accordance with Rule
144 under the Securities Act, or (C) in the event of an Exchange Cap Event, the date the Company has obtained stockholder approval to
increase the number of Common Shares under the Exchange Cap and/or the Exchange Cap no longer applies, unless a subsequent Amortization
Event occurs. No Amortization Event occurred through December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">It was determined, in accordance with
ASC 815, that the Conversion Feature is required to be bifurcated due to the adjustments to the settlement amount of this embedded feature
that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares, and should be recorded as a
liability (the &#8220;Embedded Derivative Liability&#8221;) at fair value with a corresponding amount recorded as a discount on the Convertible
Notes. The Embedded Derivative Liability is marked to market at each reporting period end with any changes recorded in other income or
expense. The fair value of the Embedded Derivative Liability was estimated at $69 at the issuance date based on the difference between
the fair value of the convertible note with these embedded features and the fair value without each one of these embedded features.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The increase in the fair value of the
Embedded Derivative Liability was $11, between the issuance date and December 31, 2024, and was included in other (expense) income in
the consolidated statements of operations.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The total discount resulting from the
Convertible Note Discount and the bifurcation of the Embedded Derivative Liability at the Issuance Date was amortized over the term of
the Convertible Notes through non-cash interest expense using the effective interest method. The non-cash interest expense related to
the discount amortization was $39 for the year ended December 31, 2024 and is included within interest expense in the consolidated statement
of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>SEPA Put Rights</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the terms of the SEPA, starting
at the Closing Date, the Company has the right, but not the obligation (&#8220;SEPA Put Rights&#8221;), to issue shares of its common
stock to YA (&#8220;Advance Shares&#8221;, and such issuance and sale, an &#8220;Advance&#8221;) and YA shall subscribe for and purchase
from the Company such Advance Shares, through written notice by the Company to YA (&#8220;Advance Notice&#8221;), provided (i) no balance
is outstanding under a Convertible Note, or (ii) if there is a balance outstanding under a Convertible Note, an Amortization Event (as
defined above), has occurred in accordance with and subject to the terms of the SEPA. The SEPA contemplates purchase by YA of up to $50
million in aggregate gross purchase price for newly issued shares of the Company&#8217;s common stock. If any amount remains outstanding
under a Convertible Note, without the prior written consent of YA, the Company may only (other than with respect to a deemed Advance Notice
pursuant to an Investor Notice (described below)) submit an Advance Notice (A) if an Amortization Event has occurred and the obligation
of the Company to make monthly prepayments under the Convertible Note has not ceased, and (B) YA pays the aggregate purchase price owed
by the Company from such Advance by offsetting the amount of the Advance Proceeds against an equal amount outstanding under the subject
Convertible Note. Any such sales would be subject to certain limitations, including that YA could not purchase any shares that would result
in it owning more than 4.99% of the Company&#8217;s common stock, or any shares that, aggregated with any related transaction, would exceed
19.9% of all shares of common stock outstanding on the date of the SEPA unless shareholder approval was obtained allowing for issuances
in excess of such amount.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">For as long as there is an outstanding
balance under a Convertible Note, YA has the right, but not the obligation, by delivery to the Company of Investor Notices (as defined
in the SEPA), to cause an Advance Notice to be deemed delivered by YA, which triggers the issuance and sale of Advance Shares to YA, subject
to terms and conditions as specified in the SEPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The purchase price for the Advance
Shares shall be the price per Advance Share obtained by multiplying the Company&#8217;s stock price (i) by 96% in respect of an Advance
Notice delivered by the Company with an Option 1 Pricing Period (defined by reference to VWAP on the trading day the Advance Notice is
submitted), (ii) 97% in respect of an Advance Notice with an Option 2 Pricing Period (defined by reference to the lowest daily VWAP on
<span style="-sec-ix-hidden: hidden-fact-440">three</span> consecutive trading days commencing on the Advance Notice Date), or (iii) in the case of any Advance Notice delivered pursuant to
an Investor Notice, equal to the Conversion Price (as defined in the Convertible Note).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company accounted for the SEPA
Put Rights as an asset at fair value in accordance with the guidance in ASC 815, due to the adjustments to the settlement amount of this
derivative instrument that are not inputs to the fair value measurement of a fixed-for-fixed forward or option on equity shares. The fair
value of the SEPA Put Rights was $1,551 and $188 as of the Closing Date and December 31, 2024, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As consideration for YA&#8217;s commitment
to purchase shares of common stock, upon execution of the SEPA, the Company engaged to remit YA the commitment fee of $500,000. In December
2024, the Company issued to YA 9,905 shares of common stock in settlement of the commitment fee obligation. The fair value of the shares
issued to YA was $327 at their issuance date and the difference of $173 was recorded as a Gain on extinguishment of accrued liabilities.
The excess of the fair value of the SEPA Put Rights above the commitment fee at the issuance date was included in the change in fair value
of SEPA put rights in the consolidated statement of operations for the year ended December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_StandbyEquityPurchaseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_StandbyEquityPurchaseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_StandbyEquityPurchaseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for standby equity purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_StandbyEquityPurchaseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>12.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Stockholders&#8217; Equity</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Convertible Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of December 31, 2023, and immediately prior
to the Closing Date, Legacy Abpro&#8217;s amended and restated articles of incorporation authorized the issuance of up to 40,000,000
shares of common stock and up to 11,620,248 shares of preferred stock. Legacy Abpro&#8217;s Certificate of Incorporation, as amended,
authorizes the issuance of Series A Redeemable Convertible Preferred Stock (&#8220;Series A&#8221;), Series B Convertible Preferred Stock
(&#8220;Series B&#8221;), Series C Convertible Preferred Stock (&#8220;Series C&#8221;), Series D Convertible Preferred Stock (&#8220;Series
D&#8221;), Series E Convertible Preferred Stock (&#8220;Series E&#8221;) and Series F Convertible Preferred Stock (&#8220;Series F&#8221;),
collectively referred to as &#8220;Convertible Preferred Stock&#8221;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In connection with the Merger, all previously
issued and outstanding Convertible Preferred Stock was converted into the aggregate number of shares of New Abpro&#8217;s common stock
that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately
prior to the effective time, multiplied by the exchange ratio of approximately&#160;0.068, and the remaining amount was reclassified
to additional paid-in capital.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Common and Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In connection with the Closing, the Company&#8217;s
articles of incorporation were amended to designate two classes of stock; preferred and common stock. The articles of incorporation of
New Abpro authorize 1,000,000 shares of preferred stock and 110,000,000 shares of common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s Amended and Restated Certificate
of Incorporation (and Certificate of Amendment, as referenced in Note 1) provides the Company&#8217;s board of directors with the authority
to issue up to 1,000,000 shares of $0.0001 par value preferred stock in one or more series and to establish from time to time the number
of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations,
powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions.
There were zero preferred shares outstanding as of September 30, 2025 and December 31, 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of both September 30, 2025 and December
31, 2024, there were 500,000 outstanding Public Warrants. The Public Warrants became exercisable 12 months from the closing of ACAB&#8217;s
Initial Public Offering, which closed on January 19, 2022, and will expire five years from the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company will not be obligated to deliver
any common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless
a registration statement under the Securities Act covering the issuance of the common stock issuable upon exercise of the Public Warrants
is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration.
No warrant will be exercisable, and the Company will not be obligated to issue shares of common stock upon exercise of a warrant unless
common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the
state of residence of the registered holder of the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company may redeem the Public Warrants:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">in whole and not in part;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">at a price of $0.30 per warrant;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">upon not less than 30 days&#8217; prior written notice of redemption
    given after the warrants become exercisable to each warrant holder; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt">&#9679;</span></td> <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">if, and only if, the reported last sale price of the Series A common stock equals or exceeds $540.00 per share &#160;(as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three trading days before the Company sends the notice of redemption to the warrant holders (the &#8220;Redemption Trigger&#8221;). In November 2024, the Redemption Trigger was adjusted to $179.70, as further described below.</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If and when the warrants become redeemable
by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for
sale under all applicable state securities laws.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">If the Company calls the Public Warrants for
redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless
basis,&#8221; as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of
the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization,
merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of both September 30, 2025 and December
31, 2024, there were 461,667 Private Warrants, The Private Warrants are identical to the Public Warrants, except that the Private Warrants
are exercisable on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees.
If the Private Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will
be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In addition, if (x) the Company were to issue
additional shares of common stock or equity-linked securities, for capital raising purposes in connection with the closing of a Merger
at an issue price or effective issue price of less than $276.00 per share of common stock (with such issue price or effective issue price
to be determined in good faith by the Company&#8217;s board of directors, and, in the case of any such issuance to the Sponsor or its
affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such issuance)
(the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represented more than 60% of the total equity
proceeds, and interest thereon, available for the funding of a Merger on the date of the completion of a Merger (net of redemptions),
and (z) the volume weighted average trading price of the Company&#8217;s Series A common stock during the 20 trading day period starting
on the trading day after the day on which the Company completes a Merger (such price, the &#8220;Market Value&#8221;) was below $276.00
per share, the exercise price of the warrants would be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market
Value and the Newly Issued Price, and the $540.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal
to 180% of the greater of the Market Value and the Newly Issued Price (the &#8220;Down Round Feature&#8221;).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In November 2024, the &#8220;Down Round Feature&#8221;
was triggered and the exercise price of the Public and Private Warrants was adjusted down to $114.90 and the per share Redemption Trigger
was adjusted down to $179.70 based on the Newly Issued Price of $99.90. The Company accounted for the change in fair value of the Public
and Private Warrants triggered by the down round as a deemed dividend under the guidance in ASC 260-10-25-1 related to financial instruments
that include a down round feature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company valued the deemed dividend as
the difference between the fair value of the warrants before and after the exercise price adjustment. The warrants were valued using
the Black-Scholes option pricing model immediately before and after the modification using the following assumptions: (a) fair value
of common stock of $53.40&#160;per share, (b) expected volatility of&#160;90.00%, (c) dividend yield of&#160;0%, (d) risk-free interest
rate of&#160;4.09%, and (e) expected life of&#160;4.9&#160;years. The increase in the fair value of the warrants resulting from the exercise
price adjustment was $10,177 and was reflected as a deemed dividend in the consolidated statements of operations for the fourth quarter
of 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The 2,034&#160;outstanding common stock warrants
of Legacy Abpro (&#8220;Legacy Abpro Common Stock Warrants&#8221;) expired at the Closing Date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On February 7, 2025, the Company issued 28,333
Executive Warrants (see Note 10).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following presents information about warrants
to purchase common stock outstanding as of September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Average</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Remaining</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Contractual Life</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Warrants</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">990,000</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">114.60</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 11%; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">4.3 years</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt">No warrants
were exercised during the nine months ended September 30, 2025.</span>&#160;</p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>14.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stockholders&#8217;
Equity</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Convertible Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2023, and immediately
prior to the Closing Date, Legacy Abpro&#8217;s amended and restated articles of incorporation authorized the issuance of up to 40,000,000
shares of common stock and up to 11,620,248 shares of preferred stock. Legacy Abpro<span style="background-color: white">&#8217;s Certificate
of Incorporation, as amended, authorizes the issuance of Series A Redeemable Convertible Preferred Stock (&#8220;Series A&#8221;), Series
B Convertible Preferred Stock (&#8220;Series B&#8221;), Series C Convertible Preferred Stock (&#8220;Series C&#8221;), Series D Convertible
Preferred Stock (&#8220;Series D&#8221;), Series E Convertible Preferred Stock (&#8220;Series E&#8221;) and Series F Convertible Preferred
Stock (&#8220;Series F&#8221;), collectively referred to as &#8220;Convertible Preferred Stock&#8221;</span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In connection with the Merger, all
previously issued and outstanding Convertible Preferred Stock was converted into the aggregate number of shares of New Abpro&#8217;s common
stock that would be issued upon conversion of the shares of Legacy Abpro preferred stock based on the applicable conversion ratio immediately
prior to the effective time, multiplied by approximately 0.068, and the remaining amount was reclassified to additional paid-in capital.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Common and Preferred Stock</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In connection with the Closing, the
Company&#8217;s articles of incorporation were amended to designate two classes of stock; preferred and common stock. The articles of
incorporation of New Abpro authorize 1,000,000 shares of preferred stock and 110,000,000 shares of common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s Amended and Restated
Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue up to 1,000,000 shares of $0.0001
par value preferred stock in one more series and to establish from time to time the number of shares to be included in each such series,
by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating,
optional, special and other rights shall be stated and expressed in such resolutions. There were zero preferred shares outstanding as
of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Warrants</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">As of December 31, 2024, there were
500,000 outstanding Public Warrants. The Public Warrants became exercisable 12 months from the closing of ACAB&#8217;s Initial Public
Offering, which closed on January 19, 2022, and will expire five years from the Closing Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company will not be obligated to
deliver any common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise
unless a registration statement under the Securities Act covering the issuance of the common stock issuable upon exercise of the Public
Warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect
to registration. No warrant will be exercisable, and the Company will not be obligated to issue shares of common stock upon exercise of
a warrant unless common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities
laws of the state of residence of the registered holder of the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-indent: 0.5in; text-align: justify">The Company may redeem the Public Warrants:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in whole and not in part;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a price of $0.30 per warrant;</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.75in">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon not less than 30 days&#8217; prior written notice of redemption given after the warrants become exercisable to each warrant holder; and</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 0.75in">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td> <td style="text-align: justify; font-size: 10pt">if, and only if, the reported last sale price of the Series A common
stock equals or exceeds $540.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like)
for any 20 trading days within a 30-trading day period commencing once the warrants become exercisable and ending three trading days before
the Company sends the notice of redemption to the warrant holders (the &#8220;Redemption Trigger&#8221;). In November 2024, the Redemption
Trigger was adjusted to $179.70, as further described below.</td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">If and when the warrants become redeemable
by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for
sale under all applicable state securities laws.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">If the Company calls the Public Warrants
for redemption, management will have the option to require all holders that wish to exercise the Public Warrants to do so on a &#8220;cashless
basis,&#8221; as described in the warrant agreement. The exercise price and number of shares of common stock issuable upon exercise of
the warrants may be adjusted in certain circumstances including in the event of a stock dividend, or recapitalization, reorganization,
merger or consolidation. However, except as described below, the warrants will not be adjusted for issuance of common stock at a price
below its exercise price. Additionally, in no event will the Company be required to net cash settle the warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024, there were
461,667 Private Warrants, The Private Warrants are identical to the Public Warrants, except that the Private Warrants are exercisable
on a cashless basis and are non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the Private
Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Warrants will be redeemable
by the Company and exercisable by such holders on the same basis as the Public Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In addition, if (x) the Company were
to issues additional shares of common stock or equity-linked securities, for capital raising purposes in connection with the closing of
a Merger at an issue price or effective issue price of less than $276.00 per share of common stock (with such issue price or effective
issue price to be determined in good faith by the Company&#8217;s board of directors, and, in the case of any such issuance to the Sponsor
or its affiliates, without taking into account any Founder Shares held by the Sponsor or its affiliates, as applicable, prior to such
issuance) (the &#8220;Newly Issued Price&#8221;), (y) the aggregate gross proceeds from such issuances represented more than 60% of the
total equity proceeds, and interest thereon, available for the funding of a Merger on the date of the completion of a Merger (net of redemptions),
and (z) the volume weighted average trading price of the Company&#8217;s Series A common stock during the 20 trading day period starting
on the trading day after the day on which the Company completes a Merger (such price, the &#8220;Market Value&#8221;) was below $276.00
per share, the exercise price of the warrants would be adjusted (to the nearest cent) to be equal to 115% of the greater of the Market
Value and the Newly Issued Price, and the $540.00 per share redemption trigger price will be adjusted (to the nearest cent) to be equal
to 180% of the greater of the Market Value and the Newly Issued Price (the &#8220;Down Round Feature&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In November 2024, the &#8220;Down Round
Feature&#8221; was triggered and the exercise price of the Public and Private Warrants was adjusted down to $114.90 and the per share
Redemption Trigger was adjusted down to $179.70 based on the Newly Issued Price of $99.90. The Company accounted for the change in fair
value of the Public and Private Warrants triggered by the down round as a deemed dividend under the guidance in ASC 260-10-25-1 related
to financial instruments that include a down round feature.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The Company valued the deemed dividend
as the difference between the fair value of the warrants before and after the exercise price adjustment. The warrants were valued using
the Black-Scholes option pricing model immediately before and after the modification using the following assumptions: (a) fair value of
common stock of $53.40 per share, (b) expected volatility of 90.00%, (c) dividend yield of 0%, (d) risk-free interest rate of 4.09%, and
(e) expected life of 4.9 years. The increase in the fair value of the warrants resulting from the exercise price adjustment was $10,177.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The 2,034 outstanding common stock warrants of Legacy Abpro (&#8220;Legacy
Abpro Common Stock Warrants&#8221;) expired at the Merger Date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table sets forth the
common stock warrant activity for the year ended December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Legacy<br/> Abpro <br/> Common</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock <br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Private<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Public<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Outstanding as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-441">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-442">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expired at the Merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,034</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-443">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-444">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Common stock warrants of ACAB acquired in Merger</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-445">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">461,667</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-446">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">461,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">500,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following presents information
about warrants to purchase common stock outstanding as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/>
Average <br/> Exercise <br/>
Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Remaining<br/> Contractual <br/>
Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Warrants</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">961,667</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">114.90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="text-align: right; width: 11%">4.9 years</td></tr> </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="-sec-ix-hidden: hidden-fact-447"><span style="-sec-ix-hidden: hidden-fact-448">No</span></span> warrants were issued or exercised
during the years ended December 31, 2024 and 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>13.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Share-Based Compensation</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>2024 Equity Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company&#8217;s 2024 Equity Incentive
Plan (the &#8220;2024 Plan&#8221;) became effective at the Closing Date. As of September 30, 2025,&#160;183,279&#160;shares of common
stock were available for issuance under the 2024 Plan, which is equal to 10% of the number of shares of common stock of the Company following
the Merger. The 2024 Plan provides that on January 1 of each year commencing January 1, 2026 and ending on December 31, 2034, the 2024
Plan reserve will automatically increase in an amount equal to the lesser of (a)&#160;5% of the number of shares of the Company&#8217;s
common stock outstanding on December&#160;31 of the preceding year and (b) a number of shares of common stock determined by the Company&#8217;s
board of directors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Under the 2024 Plan, the Company can grant
non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted stock
units, unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees. In July 2025, the Company
granted 8,080 options with the weighted average fair value of the option of $6.90, to the directors and 16,667 RSUs to the Company&#8217;s
Chief Executive Officer under the 2024 Plan. The stock options granted to directors vest in full in November 2025. The RSUs granted to
the CEO vest in three equal installments on each anniversary of March 3, 2025. The contractual term of the stock options and RSUs is
ten years. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The fair value of the options issued during
the three months ended September 30, 2025 was determined using the Black-Scholes option pricing model based on the following assumptions:
(a) fair value of common stock of $9.45&#160;per share, (b) expected volatility of&#160;92.00%, (c) dividend yield of&#160;0%, (d) risk-free
interest rate of&#160;3.95%, and (e) expected term of&#160;5.2&#160;years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>2014 Stock Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The 2014 Stock Incentive Plan (the &#8220;2014
Plan&#8221;) of Legacy Abpro was expired as of the Closing Date, in accordance with its original terms. As a result of the expiration,
no further awards may be granted under the 2014 Plan. All awards previously granted and outstanding as of the effective date of the Merger,
which totaled&#160;166,858 options, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement, but otherwise
remain in effect pursuant to their original terms (see Note 3). Stock options granted to employees and directors typically vest over
four years. Stock options granted <span style="-sec-ix-hidden: hidden-fact-425">to</span> non-employees typically vest immediately at the grant date. The maximum contractual term of the
stock options is ten years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company granted restricted stock units
(&#8220;RSUs&#8221;) to various employees and directors under the 2014 Plan. These RSUs cliff vest on the first anniversary of the grant
date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock as of the grant date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160; </i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The summary of the Company&#8217;s stock option
activity is as follows:&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number of<br/> Stock Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average<br/> Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="-sec-ix-redline:true;-keep: true">Outstanding at December 31, 2024</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">329,395</span></p></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51.30</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.4</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,080</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">9.60</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">10</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-419"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-420"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-421"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Forfeited/Expired/Cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(114,840</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50.39</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-422"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,635</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50.28</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable at&#160;&#160;September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">180,146</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51.85</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Restricted Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The summary of the Company&#8217;s restricted
stock unit activity is as follows:&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number&#160;of</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Grant Date</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Remaining</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Fair Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Vesting&#160;Period</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="-sec-ix-redline:true;-keep: true">Unvested at December&#160;31,&#160;2024</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">739</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">48.90</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.2</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,667</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">9.60</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.6</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Vested</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(142</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">48.90</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-423"><span style="-sec-ix-redline:true;-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Forfeited/Expired/Cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(597</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">48.90</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-424"><span style="-sec-ix-redline:true;-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Unvested at September 30, 2025</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,667</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">9.60</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.4</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">During the nine months ended September 30,
2025, 142 RSUs vested in accordance with their terms, but the shares of common stock were not issued to the holders as of September 30,
2025.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On October 22, 2024, the Company&#8217;s board
of directors authorized the issuance of 10,000 RSUs (or approximately 20,449 RSUs as adjusted for the Merger closing based on the Exchange
Ratio), that were not yet issued as of September 30, 2025. For the three and nine months ended September 30, 2025, the Company recorded
$208 and $618, respectively, in stock compensation expense related to these authorized RSUs. The total accrued expenses related to these
authorized RSUs were $1,012 and $394 as of September 30, 2025 and December 31, 2024, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Stock-Based Compensation Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The summary of the recorded stock-based compensation
expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Nine Months Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Research and development</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">22</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">62</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">282</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">404</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,136</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,469</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total stock-based compensation</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">286</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">415</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,158</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,531</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">As of September 30, 2025, there was approximately
$192 of unrecognized compensation cost related to unvested stock option awards that are expected to be recognized over a weighted-average
period of 0.4 years. As of September 30, 2025, there was approximately $127 of unrecognized compensation related to unvested restricted
stock awards that are expected to be recognized over a weighted-average period of 1.3 years.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>15.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Share-Based
Compensation</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>2024 Equity Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s 2024 Equity Incentive
Plan (the &#8220;2024 Plan&#8221;) became effective at the Closing Date. As of December 31, 2024, 208,026 shares of common stock
were available for issuance under the 2024 Plan, which is equal to 10% of the number of shares of common stock of the Company following
the Merger. The 2024 Plan provides that on January 1 of each year commencing January 1, 2026 and ending on December 31, 2034, the 2024
Plan reserve will automatically increase in an amount equal to the lesser of (a) 5% of the number of shares of the Company&#8217;s common
stock outstanding on December 31 of the preceding year and (b) a number of shares of common stock determined by the Company&#8217;s board
of directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Under the 2024 Plan, the Company can
grant non-statutory stock options, or NSOs, incentive stock options, or ISOs, stock appreciation rights, restricted stock, restricted
stock units, unrestricted stock, performance awards and other forms of awards to eligible employees and nonemployees. Through December
31, 2024, the Company has not granted any awards under the 2024 Plan.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>2014 Stock Incentive Plan</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">The 2014 Stock Incentive Plan (the
&#8220;2014 Plan&#8221;) of Legacy Abpro was expired as of the Closing Date, in accordance with its original terms. As a result of the
expiration, no further awards may be granted under the 2014 Plan. All awards previously granted and outstanding as of the effective date
of the Merger, which totaled 166,858 options, were adjusted to reflect the impact of the Merger as set forth in the Merger Agreement,
but otherwise remain in effect pursuant to their original terms (see Note 3). Stock options granted to employees and directors typically
vest over four years. Stock options granted to non-employees typically vest immediately at the grant date. The maximum contractual term
of the stock options is ten years.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Stock Options</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The summary of the Company&#8217;s
stock option activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Stock<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average <br/> Remaining<br/> Contractual <br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at December 31, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">369,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.1</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-449">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-450">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-451">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-452">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-453">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-454">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited/Expired/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(39,698</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">30.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-455">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">329,395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">51.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.4</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">276,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">51.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.4</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Stock Option Valuation</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The assumptions that the Company used
to determine the fair value of the stock options granted to employees, directors and nonemployees were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended<br/>
December 31,<br/>
2023</b></span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.53</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term (in years)</span></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The weighted average grant date fair
value of awards granted during the year ended December 31, 2023, was $127.80 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="-sec-ix-hidden: hidden-fact-461">No</span> stock options were granted during
the year ended December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Restricted Stock Units</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company
granted restricted stock units (&#8220;RSUs&#8221;) to various employees and directors under the 2014 Plan. These RSUs cliff vest on the
first anniversary of the grant date. The fair value of the RSUs is determined based upon the fair value of the underlying common stock
as of the grant date.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The summary
of the Company&#8217;s restricted stock unit activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Grant Date <br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Remaining <br/> Vesting Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at December 31, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,124</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;48.90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.2</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-456">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-457">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,386</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">48.90</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-458">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-459">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">738</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">48.90</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In November
and December 2024, after the Closing Date, 369 RSUs vested in accordance with their terms, but the shares of New Abpro common stock were
not issued to the holders as of December <span style="-sec-ix-hidden: hidden-fact-460">31, 2024</span>.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October
22, 2024, the Company&#8217;s board of directors authorized the issuance of 10,000 RSUs (or approximately 20,449 RSUs as adjusted for
the Merger closing based on the Exchange Ratio), that were not yet issued as of December 31, 2024. The Company recorded the
fair value of these RSUs, totaling $394, in accrued expenses as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Stock-Based Compensation Expense</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The summary of the recorded stock-based
compensation expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,855</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,187</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 9.25pt">Total stock-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,927</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,305</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024, there was
approximately $1,302 of unrecognized compensation cost related to unvested stock option awards that are expected to be recognized over
a weighted-average period of 1.1 years. As of December 31, 2024, there was approximately $31 of unrecognized compensation cost related
to unvested restricted stock awards that are expected to be recognized over a weighted-average period of 0.3 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>14.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Employee Benefit Plan</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has a 401(k) retirement plan available
to all eligible employees. During the three and nine months ended September 30, 2025, the Company made $6 and $35 in matching contributions,
respectively, to the plan. During the three and nine months ended September 30, 2024, the Company made $29 and $101 in matching contributions,
respectively, to the plan.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>16.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Employee
Benefit Plan</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company has a 401(k) retirement
plan available to all eligible employees. During the years ended December 31, 2024 and 2023, the Company made $110 and $136 in matching
contributions, respectively, to the plan.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/712/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/710/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Parties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>15.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Related Parties</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company has certain promissory notes outstanding
with executives and directors as of September 30, 2025. See Note 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On January 15, 2020, the Company entered into
an agreement for various consulting services, as defined in the agreement, with a member of the Company&#8217;s Board of Directors. On
January 1, 2023, the Company entered into a new consulting agreement with the same director, which superseded the agreement dated in
January 2020. The agreement was terminated during the year ended December 31, 2024. During the three and nine months ended September
30, 2025, the Company incurred $0 under this agreement. During the three and nine months ended September 30, 2024, the Company incurred
$0 and $146, respectively, under this agreement. As of both September 30, 2025 and December 31, 2024, the unpaid amount was $189.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 18, 2024, the Company entered into
a promissory note agreement with an executive to receive, as amended, for up to $2,158 in funding. During the year ended December 31,
2024, the Company received $1,997 from the executive under this agreement. See Note 10.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On April 18, 2024, the Company entered into
an agreement with an executive to defer payment of compensation from April 18, 2024 until the earlier of (i) the closing of the Merger
and (ii) November 20, 2024. The executive&#8217;s deferred wages were repaid in the amount of $221 in November 2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 21, 2024, the Company entered
into a severance agreement with an executive (the &#8220;Severance Agreement&#8221;). Pursuant to the terms of the Severance Agreement,
the Company made a severance payment of $221 upon execution of the agreement. The Severance Agreement supersedes and extinguishes all
other agreements between the executive and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On December 24, 2024, the Company made a payment
of $574 to the Sponsor in accordance with the terms of the Merger Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true"><br/>
On July 25, 2025, in connection with a consulting agreement executed between the Company and the Chief Executive Officer (&#8220;CEO&#8221;)(the
&#8220;CEO Consulting Agreement&#8221;), the Company issued&#160;16,667&#160;RSUs, which vest in three equal installments on March 3,
2026, March 3, 2027, and March 3, 2028. The term of the CEO Consulting Agreement commenced on March 3, 2025, the date the Company&#8217;s
board of directors appointed the CEO, and shall remain in full force and effect until terminated by mutual written agreement between
the Company and the CEO, or by sixty days&#8217; prior written notice by either party. The Company will compensate the CEO with an annual
base fee of $300,000, payable in bi-weekly installments. Under the terms of the CEO Consulting Agreement, the Company is obligated to
make the payment equal to three times the fair market value of the CEO&#8217;s equity interests in the Company, if within 12 months of
a change of control event (as defined in the CEO Consulting Agreement), the CEO is involuntarily terminated without cause or resigns
for good reason.&#160;</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>17.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Related
Parties</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On January 15, 2020, the Company entered
into an agreement for various consulting services, as defined in the agreement, with a member of the Company&#8217;s Board of Directors.
On January 1, 2023, the Company entered into a new consulting agreement with the same director, which superseded the agreement dated in
January 2020. The agreement was terminated during the years ended December 31, 2024. During the years ended December 31, 2024 and 2023,
the Company incurred $83 and $250 under this agreement, respectively. As of both December 31, 2024 and 2023, the unpaid amount was $21.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 1, 2021, the Company entered
into a consulting agreement with a member of the Company&#8217;s Board of Directors. Under the agreement, the Company is obligated to
pay fees for various consulting services, as defined in the agreement. This agreement was terminated in May 2022. The Company did not
incur any expense under this agreement during the years ended December 31, 2024 and 2023. As of both December 31, 2024 and 2023, the unpaid
balance was $8.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In September 2022, the Company entered
into a collaboration and license agreement with Celltrion, a significant investor in the Company&#8217;s Series F, as discussed in Note
7. The Company entered into the ABP-100 Agreement and ABP-201 Agreement with ABI, a significant investor in the Company&#8217;s Series
E and F, described in Note 7.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On March 13, 2023, the Company&#8217;s
CEO, upon the approval of the Company&#8217;s Board of Directors, transferred $5,000 from the Company&#8217;s bank account at First Republic
Bank to his personal bank account as an emergency response to the collapse of First Republic Bank. This amount was recorded as a receivable
from related party as of March 31, 2023. The full amount of $5,000 plus accrued interest of $18 was returned to the Company on May 3,
2023, and the remaining balance of accrued interest was $3 as of December 31, 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On October 18, 2023, the Company issued
a promissory note to ABI in the principal amount of up to $6,000 for expenses incurred in connection with the Merger and for its operating
expenses, as discussed in Note 12.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 29, 2023, the Company issued
promissory notes to one of its executives and one of its directors in the principal amount of $176 and $124, respectively, as discussed
in Note 12.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On April 18, 2024, the Company entered
into a separate promissory note agreement with the same executive to receive, as amended, for up to $2,158 in funding. During the year
ended December 31, 2024, the Company received $1,997 from the executive under this agreement. See Note 12.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On April 18, 2024, the Company entered
into an agreement with an executive to defer payment of compensation from April 18, 2024 until the earlier of (i) the closing of the Merger
and (ii) November 20, 2024. The executive&#8217;s deferred wages were repaid in the amount of $221 November 2024.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 21, 2024, the Company entered
into a severance agreement with an executive (the &#8220;Severance Agreement&#8221;). Pursuant to the terms of the Severance Agreement,
the Company made a severance payment of $221 upon execution of the agreement. The Severance Agreement supersedes and extinguishes all
other agreements between the executive and the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 24, 2024, the Company made
a payment of $574 to the Sponsor in accordance with the terms of the Merger Agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: top">
    <td style="width: 24px"><span style="-sec-ix-redline:true;font-size: 10pt"><b>16.</b></span></td>
    <td style="text-align: justify"><span style="-sec-ix-redline:true;font-size: 10pt"><b>Subsequent Events</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">On October 1, 2025, the Company issued 32,778 shares of common
stock with the aggregate net purchase price of $211 under an Advance Notice to YA in accordance with the terms of the SEPA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">On November 7, 2025, the Company issued 11,217 shares of common
stock with the aggregate net purchase price of $59 under an Advance Notice to YA in accordance with the terms of the SEPA.</span></p><span></span>
</td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>19.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Subsequent
Events</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company evaluated subsequent events
and transactions that occurred after the balance sheet date up to the date that the consolidated financial statements were issued. Based
upon this review, the Company did not identify any subsequent events that would have required adjustment or disclosure in the consolidated
financial statements, other than those disclosed in Notes1, 2, 8, 10, 11, 12, and 13 and further below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">At the special meeting of stockholders
held on April 8, 2025, the Company obtained stockholder approval for the issuance of shares over 20% of the Company&#8217;s outstanding
shares to YA under the SEPA.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In April 2025, YA exercised its conversion
option for the total principal amount of $250,000 of the Convertible Notes. As a result of the exercise, the Company issued to YA 25,998
shares of common stock based on the average conversion price of approximately $9.60.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In February 2025, the Company issued
5,000 shares of common stock to Roth Capital Partners (&#8220;Roth&#8221;) as an additional payment for the services provided
under the engagement letter dated July 17, 2024 between Roth and ACAB, which provided for an adjustment to their fees in shares based
on the trading price of the Company&#8217;s common stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>4</b>.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s property and equipment
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer hardware and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">788</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equipment under finance leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,693</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,656</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,591</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Depreciation expense was $65 and $269
for the years ended December 31, 2024 and 2023, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Leases</b></span></td>
</tr></table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s leases are for
office and laboratory spaces, classified as operating leases, and laboratory equipment, classified as finance leases.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 19, 2021, in connection
with its laboratory and office space in Woburn, MA, the Company provided to the landlord a standby letter of credit in the amount of $131
(the &#8220;LOC&#8221;), which serves as security for the Company&#8217;s performance of its obligations under the lease and bears interest
at a per annum rate of the U.S. prime rate plus 1%, with the minimum interest rate no less than 4.25%. The letter of credit is automatically
extended without a written amendment for a period of one year, for each and every future expiration date, unless the Company elects not
to extend this letter of credit through November 30, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The components of lease expense were
as follows as of and for the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">594</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">594</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Amortization of ROU assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">638</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">850</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The total cash paid for amounts included
in the measurement of lease liabilities for the years ended December 31, 2024 and 2023 included the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Lease term and discount rate were as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term <i>(in years)</i></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-left: 9.25pt">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.73</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9.25pt">Finance leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted-average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9.25pt">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.66</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.66</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9.25pt">Finance leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.50</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.50</td><td style="text-align: left">%</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company had the following future minimum payments due
under its operating lease agreements as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">For the year ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating<br/>
 Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-bottom: 1.5pt">2025</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">465</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">465</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">456</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(456</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Obligations under lease liability, noncurrent</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-437">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company had no future minimum payments
due under finance lease agreements as of December 31, 2024.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%; border-spacing: 0px;"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>18.</b></span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></td>
</tr></table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The components of income / (loss) before
provision for / (benefit from) income taxes are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,232</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(11,770</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-462">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss before Income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,232</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,706</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">For the years ended December 31, 2024
and 2023, the Company did not record a current income tax provision.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">A reconciliation of the Company&#8217;s
effective income tax rate to the U.S. statutory federal income tax rate of 21% for the years ended December 31, 2024 and 2023 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Net loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,232</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(11,706</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Statutory U.S. federal tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax computed at federal statutory rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,519</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,458</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State income taxes, net of federal benefit and tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(606</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(825</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Federal research and development credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(290</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(297</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,513</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,540</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-463">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-464">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Significant components of
the Company&#8217;s net deferred tax assets and liabilities as of December 31, 2024 and 2023 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/> (As Restated)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9.25pt">Operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,135</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9.25pt">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,054</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9.25pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,154</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9.25pt">Capitalized research expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,183</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9.25pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">539</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9.25pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">279</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9.25pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-465">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,387</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,677</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,274</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,414</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">113</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">263</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt">Right-of-use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(263</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-466">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-467">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company regularly assesses the
need for a valuation allowance against its deferred tax assets. In making that assessment, the Company considers both positive and negative
evidence related to the likelihood of realization of the deferred tax assets to determine, based on the weight of available evidence,
whether it is more-likely-than-not that some or all of the deferred tax assets will not be realized. In assessing the realizability of
deferred tax assets, the Company considers taxable income in prior carryback years, as permitted under the tax law, forecasted taxable
earnings, tax planning strategies, and the expected timing of the reversal of temporary differences. This determination requires significant
judgment, including assumptions about future taxable income that are based on historical and projected information and is performed on
a jurisdiction-by-jurisdiction basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company continues to maintain a
full valuation allowance against its deferred tax assets. During the years ended December 31, 2024 and 2023, management assessed the positive
and negative evidence in its operations, and concluded that it is more likely than not that its deferred tax assets as of December 31,
2024 and 2023 will not be realized given the Company&#8217;s history of operating losses. The valuation allowance against deferred tax
assets increased by approximately $3,860 and $3,540 during 2024 and 2023, respectively, related to a full valuation allowance recorded
against additional net operating losses and tax credits generated in the year.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On December 22, 2017, the Tax Cuts
and Jobs Act (the &#8220;Act&#8221;) was enacted. Under the Act, research and development expenditures incurred for tax years beginning
after December 31, 2021 must be capitalized and amortized ratably over five or fifteen years for tax purposes, depending on if the research
activities are conducted in the U.S. or outside the U.S., respectively. Effective January 1, 2022, the Company has complied with the mandatory
capitalization and amortization of research and experimentation expenditures. For the year ended December 31, 2024, the Company capitalized
$3,215 and received $2,370 of amortization deductions related to such Section 174 expenditures, which on a tax effected basis represent
$2,547 of the deferred tax assets shown in capitalized research and development costs in the components of deferred tax assets and liabilities
table above. For the year ended December 31, 2023, the Company capitalized $4,416 and received $1,850 of amortization deductions related
to such Section 174 expenditures, which on a tax effected basis represent $3,183 of the deferred tax assets shown in capitalized research
and development costs in the components of deferred tax assets and liabilities table above.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024, the Company
had federal net operating losses of $85,863, which may be available to offset future federal income tax liabilities. As a result of the
Act, for U.S. federal income tax purposes, net operating losses generated after December 31, 2017 can be carried forward indefinitely,
but are limited to 80% utilization against future taxable income each year. The Company&#8217;s federal net operating losses incurred
prior to 2018, $22,999, expire through 2037, while its federal net operating losses incurred in 2018 and onwards, $62,864, can be carried
forward indefinitely.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2023, the Company
had federal net operating losses of $78,165 (As Restated), which may be available to offset future federal income tax liabilities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024 and 2023, the
Company had post-apportioned Massachusetts net operating losses of $82,240 and $74,656 (As Restated), respectively, that can generally
be carried forward 20 years and will expire at various dates through 2044.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">As of December 31, 2024, the Company
had $1,772 and $877 of federal and state research and development credits, respectively, which will expire at various dates through 2044.
As of December 31, 2023, the Company had $1,483 and $708 of federal and state research and development credits, respectively, which will
expire at various dates through 2043.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Pursuant to Internal Revenue Code Sections
382 and 383, annual use of the Company&#8217;s net operating losses and other carryforward tax attributes may be limited in the event
a cumulative change in ownership of more than 50% that occurs within a three-year period. The Company has not completed an ownership change
analysis pursuant to IRS Section 382. If ownership changes have occurred or occur in the future, the amount of remaining tax attribute
carryforwards available to offset taxable income and income tax expense in future years may be restricted or eliminated. If eliminated,
the related asset would be removed from deferred tax assets with a corresponding reduction in the valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The calculation of the Company&#8217;s
tax liabilities involves dealing with uncertainties in the application of complex tax regulations in a multitude of jurisdictions. The
Company recognizes liabilities for uncertain tax positions based on a two-step process. First, management determines whether it is more
likely than not that the tax positions will be sustained on audit, including resolution of related appeals or litigation processes, based
on their technical merits. Second, management measures the tax benefit of those positions as the largest amount that is more than 50%
likely to be realized upon ultimate settlement with the related tax authority. While the Company believes that it has appropriate support
for the positions taken on its tax returns, the Company regularly assesses the potential outcome of examinations by tax authorities in
determining the adequacy of its provision for income taxes. As of December 31, 2024 and 2023, the Company did not have any uncertain tax
positions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s policy is to recognize
interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying consolidated statement
of operations and any accrued interest and penalties on the related tax liability line in the consolidated balance sheet. As of December
31, 2024 and 2023, no accrued interest or penalties are included on the related tax liability line in the consolidated balance sheet.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company files income tax returns
in the U.S. federal jurisdiction and various state jurisdictions. There are currently no pending income tax examinations. To the extent
the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination
by the Internal Revenue Service and state tax authorities to the extent the tax attributes are utilized in a future period. The Company&#8217;s
income tax returns since 2021 are subject to examination by the IRS and state tax authorities.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The condensed consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accompanying condensed
consolidated financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation
(&#8220;AbMed&#8221;). All intercompany balances and transactions have been eliminated in consolidation. Certain prior period amounts
have been reclassified to conform to the current period presentation with no material impact on the condensed consolidated financial
statements.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Basis of Presentation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The consolidated financial statements
have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
and the applicable rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The accompanying consolidated
financial statements include all of the accounts of the Company and its subsidiaries, Abpro Corporation and AbMed Corporation (&#8220;AbMed&#8221;).
All intercompany balances and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The preparation of condensed consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported
in the condensed consolidated financial statements and accompanying notes. Significant estimates in these condensed consolidated financial
statements include stock-based compensation expense, the fair value of derivative instruments, the fair value of options and warrants,
pre-clinical&#160;and clinical accrued expenses, the valuation and realizability of deferred tax assets, and the ability to continue
as a going concern. On an ongoing basis, the Company evaluates its estimates, judgments, and methodologies. The Company bases its estimates
on historical experience and on various other assumptions believed to be reasonable. Due to the inherent uncertainty involved in making
estimates, actual results could differ materially from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In March 2022, the Company received an invoice
from Mabwell (Shanghai) Bioscience Co., Ltd. (&#8220;Mabwell&#8221;) for approximately $3,500 in connection with the manufacturing of
certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based on the information available
at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its validity. The Company continued to
dispute the amount and its contractual basis because the parties had neither finalized nor executed a clinical trial manufacturing agreement.
In July 2024, the Company received communication from Mabwell that they will not be pursuing the collection of the originally invoiced
amount. Accordingly, during the quarter ended March 31, 2024, the Company reversed the liability and recognized $3,500 of other income.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The preparation
of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the
amounts reported in the consolidated financial statements and accompanying notes. Significant estimates in these consolidated financial
statements include stock-based compensation expense, fair value of common stock, pre-clinical and clinical accrued expenses, valuation
and realizability of deferred tax assets and the ability to continue as a going concern. On an ongoing basis, the Company evaluates its
estimates, judgments, and methodologies. The Company bases its estimates on historical experience and on various other assumptions believed
to be reasonable. Due to the inherent uncertainty involved in making estimates, actual results could differ materially from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In March 2022, the Company
received an invoice from Mabwell (Shanghai) Bioscience Co., Ltd. (&#8220;Mabwell&#8221;) for approximately $3,500 in connection with
the manufacturing of certain clinical material for the Company. The Company recorded the estimated amount in accounts payable based
on the information available at the time, and subsequently engaged in discussion with Mabwell about the invoiced amount and its
validity. The Company continued to dispute the amount and its contractual basis because the parties had neither finalized nor
executed a clinical trial manufacturing agreement. In July 2024, the Company received communication from Mabwell that they will not
be pursuing the collection of the originally invoiced amount. Accordingly, during the year ended December 31, 2024, the Company
reversed the liability and recognized approximately $3,500 of other income.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock', window );">Unaudited Interim Condensed Consolidated Financial Statements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Unaudited Interim Condensed Consolidated
Financial Statements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The accompanying interim condensed consolidated
financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared
on the same basis as the audited financial statements, and in management&#8217;s opinion, include all adjustments, consisting of only
normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of September&#160;30, 2025
and its results of operations for the three months and nine months ended September&#160;30, 2025 and 2024, and cash flows for the nine
months ended September&#160;30, 2025 and 2024. The results of operations for the three months and nine months ended September&#160;30,
2025 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2025 or any other period. The
December&#160;31, 2024 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not
include all disclosures from the annual financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Certain information and footnote disclosures
normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant
to the rules and regulations of the SEC. Accordingly, these condensed consolidated financial statements should be read in conjunction
with the audited consolidated financial statements for the year ended December&#160;31, 2024 and the related notes included in the Company&#8217;s
Annual Report on Form 10-K, filed with the SEC on April 15, 2025 (the &#8220;Annual Report&#8221;), which provides a more complete discussion
of the Company&#8217;s accounting policies and certain other information. There have been no significant changes to the significant accounting
policies disclosed in Note 2 of the audited consolidated financial statements as of and for the year ended December&#160;31, 2024 included
in the Company&#8217;s Annual Report.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Segment Reporting</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">ASC Topic No. 280, Segment Reporting (&#8220;ASC
280&#8221;), establishes standards for the way that public business enterprises report information about operating segments in their
annual consolidated financial statements and requires that those enterprises report selected information about operating segments in
interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas and
major customers. The Company&#8217;s business segments are based on the organization structure used by the chief operating decision maker
(&#8220;CODM&#8221;) for making operating and investment decisions and for assessing performance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In accordance with ASC 280, the Company has
determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in the
areas of immuno-oncology, ophthalmology and infectious disease. The financial results of the Company&#8217;s operations are managed and
reported to the <span style="-sec-ix-hidden: hidden-fact-405">Chief Executive Officer</span>, who is considered the Company&#8217;s CODM, on a consolidated basis. The CODM assesses performance
and allocates resources based on the Company&#8217;s consolidated statements of operations, and key components and processes of the Company&#8217;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development expenses, general and administrative
expenses, and interest expenses, which are each separately presented on the Company&#8217;s condensed consolidated statements of operations.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Segment Reporting</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">ASC Topic No. 280, Segment Reporting
(&#8220;ASC 280&#8221;), establishes standards for the way that public business enterprises report information about operating segments
in their annual consolidated financial statements and requires that those enterprises report selected information about operating segments
in interim financial reports. ASC 280 also establishes standards for related disclosures about products and services, geographic areas
and major customers. The Company&#8217;s business segments are based on the organization structure used by the chief operating decision
maker (&#8220;CODM&#8221;) for making operating and investment decisions and for assessing performance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In accordance with ASC 280, the Company
has determined that it operates as a single reportable segment, which is the business of development of novel antibodies, primarily in
the areas of immuno-oncology, ophthalmology and infectious disease. The financial results of the Company&#8217;s operations are managed
and reported to the Chief Executive Officer, who is considered the Company&#8217;s CODM, on a consolidated basis. The CODM assesses performance
and allocates resources based on the Company&#8217;s consolidated statements of operations, and key components and processes of the Company&#8217;s
operations are managed centrally. Segment asset information is not used by the CODM to allocate resources. The Chief Executive Officer
uses operating losses and cash flows from operating activities to evaluate performance of the operating segment assets in deciding how
to allocate the cash resources. Significant expenses presented to the CODM include research and development and general and administrative
expenses, which are each separately presented on the Company&#8217;s consolidated statements of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On March 3, 2025, the Board removed
Ian Chan as Chief Executive Officer of the Company for cause, and Miles Suk was appointed as Chief Executive Officer of the Company. In
addition, pursuant to Mr. Chan&#8217;s employment agreement with the Company&#8217;s wholly-owned subsidiary, Abpro Corporation, Mr. Chan
was notified that he was terminated as Chief Executive Officer and director of Abpro Corporation, effective March 3, 2025.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NoncontrollingInterestPolicyTextBlock', window );">Non-controlling Interest</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Non-controlling Interest</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company holds an 82% ownership interest
in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not owned by
the Company and is reported as a component in stockholders&#8217; equity on the condensed consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $2.00
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling
interest holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the
nine month periods ending September 30, 2025 and 2024.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Non-controlling Interest</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company holds an 82% ownership
interest in its consolidated subsidiary, AbMed. Non-controlling interest represents the portion of net book value in AbMed that is not
owned by the Company and is reported as a component in stockholders&#8217; equity on the consolidated balance sheets. The Company bears
all the operating costs of AbMed. Upon an event of default by the Company or upon a liquidation of AbMed, the non-controlling interest
holder has the right to put its interest in AbMed to the Company. The amount to be paid under the redemption option is equal to $2.00
per share for each preferred share of AbMed stock held by the non-controlling interest holder plus all accrued and unpaid dividends thereon.
The Company has not allocated any losses to the noncontrolling interests given that the preferred shares held by the non-controlling interest
holder have no contractual obligations to share in the losses of AbMed. There were no operating activities in AbMed during the years ended
December 31, 2024 and 2023.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Net Loss Per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The Company follows the two-class method to
compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 12), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#8217;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#8217;s outstanding common
stock for all periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Basic net loss per share attributable to common
stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock outstanding
during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common stockholders
reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into
common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion of such
shares would be anti-dilutive. As the Company has incurred losses for the three and nine months ended September 30, 2025 and 2024, basic
and diluted net loss per share were the same all periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share, because their effect was anti-dilutive:</span></p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Convertible Preferred Stock</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-404"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">662,921</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">Warrants</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">990,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,159</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock options</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,635</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">345,164</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Unvested restricted stock units</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,667</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,292</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,229,302</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,013,536</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Net Loss Per Share</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company follows the two-class method
to compute basic and diluted net loss per share attributable to common stockholders when shares meet the definition of participating securities.
Series A, Series B, Series C, Series D, Series E and Series F preferred stock (see Note 14), which were outstanding prior to the Closing
Date, met the definition of participating securities. The two-class method determines net income (loss) per common share for each class
of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings.
The two-class method requires income available to common stockholders for the period to be allocated between common and participating
securities based upon their respective rights to share in the earnings as if all income for the period had been distributed. During periods
of loss, there is no allocation required under the two-class method due to there being no distributed earnings for the period coupled
with the fact that the Company&#8217;s Series A, Series B, Series C, Series D, Series E and Series F preferred stock do not contain a
contractual right to absorb losses. Thus, all undistributed losses were allocated entirely to the Company&#8217;s outstanding common stock
for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Basic net loss per share attributable
to common stockholders is computed by dividing net loss attributable to common stockholders by the weighted-average number of common stock
outstanding during the period without consideration of potentially dilutive common stock. Diluted net loss per share attributable to common
stockholders reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or
converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company unless the inclusion
of such shares would be anti-dilutive. As the Company has incurred losses for the years ended December 31, 2024 and 2023, basic and diluted
net loss per share is the same all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders,
because their effect was anti-dilutive:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Convertible Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-427">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">324,184</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">961,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,034</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369,092</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,824</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-428">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unvested restricted stock units</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">739</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,350,625</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">696,838</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock', window );">Recently Adopted Accounting Standards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Recently Adopted Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">In December 2023, the&#160;Financial Accounting
Standards Board&#160;(&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted.
The Company adopted this standard on January 1, 2025 and determined that the adoption does not have a material impact on these unaudited
condensed consolidated financial statements.</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Recently Adopted Accounting Standards</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In November 2023, the FASB issued ASU
2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (&#8220;ASU 2023-07&#8221;), which enhances disclosure
requirements about significant segment expenses that are regularly provided to the chief operating decision maker (the &#8220;CODM&#8221;).
ASU 2023-07, among other things, (i) requires a single segment public entity to provide all of the disclosures as required by ASC 280,
(ii) requires a public entity to disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s)
of segment profit or loss in assessing segment performance and deciding how to allocate resources and (iii) provides the ability for a
public entity to elect more than one performance measure. ASU 2023-07 is effective for the fiscal years beginning after December 15, 2023,
and interim periods beginning with the first quarter ending March 31, 2025. Early adoption is permitted, and retrospective adoption is
required for all prior periods presented. The Company has adopted ASU 2023-07 effective December 31, 2024, and concluded that the application
of this guidance did not have any material impact on its consolidated financial statements.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b style="-sec-ix-redline:true;-keep: true"><i>Recently Issued Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">On November 4, 2024, the FASB issued&#160;ASU
2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the
same tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting
periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted.
The Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Management does not believe that any additional
recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#8217;s
financial statements.&#160;</span></p><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Recently Issued Accounting Pronouncements</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In December 2023, the Financial Accounting
Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures,&#8221;
that addresses requests for improved income tax disclosures from investors that use the financial statements to make capital allocation
decisions. Public entities must adopt the new guidance for fiscal years beginning after December 15, 2024. The amendments in this ASU
must be applied on a retrospective basis to all prior periods presented in the financial statements and early adoption is permitted. The
Company is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">On November 4, 2024, the FASB issued
ASU 2024-03, Accounting Standards Update 2024-03, Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic
220-40): Disaggregation of Income Statement Expenses to improve financial reporting by requiring that public business entities disclose
additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods.
The amendments in this ASU do not change or remove current expense disclosure requirements; however, the amendments affect where such
information appears in the notes to financial statements because entities are required to include certain current disclosures in the same
tabular format disclosure as the other disaggregation requirements in the amendments. This ASU is effective for annual reporting periods
beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company
is currently evaluating the potential impact that the adoption of this standard will have on its financial statements.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Management does not believe that any
additional recently issued, but not yet effective, accounting standards, if currently adopted, would have a material impact on the Company&#8217;s
financial statements.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_EmergingGrowthCompanyPolicyTextBlock', window );">Emerging Growth Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Emerging Growth Company</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company is an &#8220;emerging growth
company,&#8221; as defined in Section 2(a) of the Securities Act, as modified by the JOBS Act, and it may take advantage of certain exemptions
from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but
not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section
404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden
parachute payments not previously approved.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Further, Section 102(b)(1) of the JOBS
Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies
(that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that
when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging
growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison
of the Company&#8217;s financial statements with another public company which is neither an emerging growth company nor an emerging growth
company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting
standards used.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Financial instruments that potentially
subject the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in bank deposit accounts,
which, at times, may exceed federally insured limits. As of December 31, 2024 and 2023, the Company has not experienced a loss on its
accounts for which it exceeds federally insured deposit limits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Restricted Cash</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The restricted cash balance is related
to a balance provided as collateral associated with the letter of credit for one of the Company&#8217;s facility leases (see Note 9) and
is reported as a current asset in the consolidated balance sheets. The following tables reconcile cash and restricted cash to amounts
shown in the consolidated statements of cash flows:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,850</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">723</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">142</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total cash and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">861</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Accounts receivable</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accounts receivable are stated at the
amount management expects to collect from outstanding balances under its license and collaboration arrangements. The Company applies the
guidance in Accounting Standards Codification (&#8220;ASC&#8221;) Topic 326, <i>Financial Instruments-Credit Losses</i> (&#8220;ASC 326&#8221;),
which requires measurement and recognition of expected credit losses for financial assets. The Company records receivables net of any
allowances for doubtful accounts for current expected credit losses under its license and collaboration arrangements. An allowance for
doubtful accounts is determined based on the financial condition and creditworthiness of customers as well as the economic factors and
trends expected to affect future collections. Any allowance would reduce the accounts receivable to the amount that is expected to be
collected. As of December 31, 2024 and 2023, the Company determined that no allowance for doubtful accounts was required.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Deferred offering costs consist of
legal, accounting, underwriting fees and other costs of Legacy Abpro that are directly related to the Merger. These costs were accounted
for as a reduction of the proceeds received at the Closing Date of the Merger. As of December 31, 2024 and 2023, the Company had deferred
offering costs of <span style="-sec-ix-hidden: hidden-fact-429">$0</span> and $878, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Property and Equipment</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Property and equipment are stated at
cost, less accumulated depreciation. Repairs and maintenance charges that do not increase the useful life of the assets are charged to
operations as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Depreciation on property and equipment
is calculated using the straight-line method over the estimated useful lives as follows:&#160;</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 77%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Useful Life<br/>
(in years)</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer hardware and software</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 5&#160;</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 5</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 - 7</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-426">Shorter of useful life or lease term</span></span></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Leases</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company accounts for leases in
accordance with ASC Topic 842, <i>Leases </i>(&#8220;ASC 842&#8221;). Under ASC 842, the Company assesses its contracts at inception to
determine whether the contract contains a lease, including evaluation of whether the contract conveys the right to control an explicitly
or implicitly identified asset for a period of time. As a lessee, the Company records a right-of-use asset and a lease liability in its
consolidated balance sheets for all leases with terms longer than 12 months. Leases are classified as either finance or operating, with
classification affecting the pattern of expense recognition in the consolidated statement of operations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company recognizes operating
lease right-of-use (&#8220;ROU&#8221;) assets and operating lease liabilities in the consolidated balance sheets. ROU assets
represent the Company&#8217;s right to use an underlying asset during the lease term and lease liabilities represent the
Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at
commencement date based on the net present value of fixed lease payments over the lease term. The Company&#8217;s lease term
includes options to extend or terminate the lease when it is reasonably certain that it will exercise that option. ROU assets also
include any advance lease payments made and are net of any lease incentives. As most of the Company&#8217;s operating leases do not
provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in
determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would
expect to pay to borrow over a similar term, and on a collateralized basis, an amount equal to the lease payments in a similar
economic environment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company enters into lease agreements
for the use of laboratory and office space, and laboratory equipment, under both operating and finance leases. Operating leases are included
in Right-of-use asset - operating lease, and Operating lease liability - current and Operating lease liability - noncurrent in the consolidated
balance sheets. Finance leases are included in Property and Equipment, net, Finance lease liability - current and Finance lease liability
- noncurrent in the consolidated balance sheets.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PatentsPolicyTextBlock', window );">Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Patents</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company incurs costs related to
patent license fees and patent applications. These payments are capitalized when the Company believes that there is a high likelihood
that the patent will be issued and there will be future economic benefit associated with the patent. These costs are amortized from the
date of the patent application on a straight-line basis over the estimated useful life of 20 years, which is the legal life of the patent.
All costs associated with abandoned patents applications are expensed.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Impairment of Long-lived Assets</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company periodically evaluates
its long-lived assets for potential impairment. Potential impairment is assessed when there is evidence that events or changes in circumstances
indicate that the carrying amount of an asset may not be recovered. Recoverability of these assets is based on undiscounted expected future
cash flows from the assets, considering a number of factors, including past operating results, budgets and economic projections, market
trends, and product development cycles. An impairment of the carrying value of each asset is assessed when the undiscounted expected future
cash flows derived from the asset are less than its carrying value. The impairment loss would be measured as the excess of the carrying
value of the impaired asset over its fair value. No impairment charges were recorded for the years ended December 31, 2024 and 2023.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b><i>Revenue Recognition</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company recognizes revenue in accordance
with the guidance of <i>Revenue From Contracts With Customers</i>, Accounting Standards Codification Topic 606 (&#8220;ASC 606&#8221;).
Under ASC 606, the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects
the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements
the Company determines are within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with
a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction
price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation.
The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within
the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance
obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the
transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>License
and collaboration revenues - </i>The Company&#8217;s license and collaboration revenues have been generated primarily through collaborative
research, development, manufacturing and commercialization agreements. The terms of these agreements generally include the license of
intellectual property and associated know-how and the provision of other goods and services. Payments to the Company under these arrangements
typically include one or more of the following: non-refundable, up-front license fees; milestone payments; and royalties on future product
sales.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>License
of Intellectual Property</i> - If a license to the Company&#8217;s intellectual property is determined to be distinct from the other performance
obligations identified in the arrangement, the Company recognizes revenue allocated to the license when the license is transferred to
the customer and the customer is able to use and benefit from the license. For licenses that are bundled with other promises, the Company
utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation
is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue associated with the bundled performance obligation.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Milestone
Payments - </i>At the inception of each arrangement that includes milestone payments based upon the achievement of specified clinical
development, regulatory and/or sales milestones, the Company evaluates whether the milestones are considered probable of being achieved
and estimates the amount to be included in the transaction price. If it is probable that a significant revenue reversal would not occur,
the associated milestone amount is included in the transaction price. Milestone payments that are dependent on factors outside of the
Company&#8217;s control, such as regulatory approvals, are not considered probable of being achieved until those approvals are received.
These payments are fully constrained and therefore are not included in the transaction price. At the end of each reporting period, the
Company re-evaluates the probability of achievement of each milestone and any related constraint and, if necessary, adjusts its estimate
of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect the reported amount
of license and collaboration revenues in the period of adjustment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><i>Royalties.
</i>For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is
deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales
occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially
satisfied).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Research and Development Expenses</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s research and development
expenses consist primarily of salaries, payroll taxes, employee benefits and stock-based compensation charges for those individuals involved
in research and development efforts, as well as consulting expenses, third-party research and development expenses, laboratory supplies
and clinical materials. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods
or services to be used in research and development are capitalized until the goods or services are received.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Income Taxes</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Income taxes are accounted for under
the asset and liability method, as required by FASB ASC Topic 740, <i>Income Taxes </i>(&#8220;ASC 740&#8221;). The Company provides for
federal, and state income taxes currently payable. Deferred tax assets and liabilities are recognized for the future tax consequences
attributed to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective
tax bases as well as for tax loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted income
tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The effect of a change in income tax
rates is recognized as income or expense in the period that includes the enactment date. The Company files income tax returns in the U.S.
federal jurisdiction and various state jurisdictions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company recognizes the effect of
income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured
at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period
in which the change in judgment occurs. The Company recognizes interest and/or penalties related to uncertain tax positions in income
tax expense. There were <span style="-sec-ix-hidden: hidden-fact-430"><span style="-sec-ix-hidden: hidden-fact-431">no</span></span> uncertain tax positions as of December 31, 2024 and 2023.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Share-Based Compensation</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company accounts for share-based
payments in accordance with Accounting Standard Codification Topic 718, <i>Compensation-Stock Compensation </i>(&#8220;ASC 718&#8221;).
Under ASC 718, the Company measures, and records compensation expense related to share-based payment awards (to employees and non-employees)
based on the grant date fair value using the Black-Scholes option-pricing model. The Company recognizes forfeitures related to employee
share-based payments when they occur. Forfeited share-based awards are recorded as a reduction to share-based compensation expense.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The determination of the fair value
of share-based payment awards utilizing the Black-Scholes model is affected by the stock price and a number of assumptions, including
expected volatility, expected term, risk-free interest rate and expected dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In determining the exercise prices
of options granted, the Company&#8217;s Board has considered the fair value of the common stock as of the measurement date. As Legacy
Abpro&#8217;s common stock was not traded prior to the Merger, the fair value of the common stock was determined by the Board at each
award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the Company&#8217;s
financial position and historical financial performance, the status of technological developments within the Company&#8217;s proposed
products, an evaluation or benchmark of the Company&#8217;s competition, the current business climate in the marketplace, the illiquid
nature of the common stock, arm&#8217;s length sales of the Company&#8217;s capital stock, including convertible preferred stock, the
effect of the rights and preferences of the preferred stockholders, and then prospects of a liquidity event, among others.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company does not have sufficient
history of market prices of its common stock, and as such, volatility is estimated using historical volatilities of similar public entities.
The peer group was developed based on companies in the biotechnology industry. The Company will continue to apply this process until a
sufficient amount of historical information regarding the volatility of its own stock price becomes available. The expected term of the
awards is estimated based on the simplified method for grants to employees and is based on the contractual term for non-employee awards.
The risk-free interest rate assumption is based on observed interest rates appropriate for the terms of the awards. The dividend yield
assumption is based on history and expectation of paying no dividends.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConvertiblePreferredStockPolicyTextBlock', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="background-color: white"><b><i>Convertible
Preferred Stock </i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
Company accounts for its convertible preferred stock in accordance with the guidance in ASC Topic 480, <i>Distinguishing Liabilities from
Equity </i>(&#8220;ASC 480&#8221;). Preferred stock subject to mandatory redemption (if any) is classified as a liability instrument and
is measured at fair value. Conditionally redeemable common stock (including preferred stock that features redemption rights that are either
within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company&#8217;s
control) is classified as temporary equity (see Note 14).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><span style="background-color: white"><b><i>Derivative
Financial Instruments</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">In
connection with the Merger, the Company assumed the warrants for common stock shares issued by ACAB, which include warrants issued in
the ACAB&#8217;s initial public offering (&#8220;Public Warrants&#8221;) and warrants purchased by the Sponsor (the  &#8220;Private Warrants&#8221;)
(see Note 14). </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
Company accounts for financial instruments as either equity-classified or liability-classified instruments based on an assessment of the
specific terms of the instruments and applicable authoritative guidance in ASC 480 and ASC Topic 815, <i>Derivatives and Hedging </i>(&#8220;ASC
815&#8221;). The assessment considers whether the instruments are freestanding financial instruments pursuant to ASC 480, meet the definition
of a liability pursuant to ASC 480, and meet all of the requirements for equity classification under ASC 815, including whether the instruments
are indexed to the Company&#8217;s own stock and whether the holders of the warrants could potentially require &#8220;net cash settlement&#8221;
in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><span style="background-color: white">The
Public and Private Warrants were accounted for as equity instruments as they meet all of the requirements for equity classification under
ASC 815 based on current expected terms, which are subject to change. </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ContingentEarnoutPolicyTextBlock', window );">Contingent Earnout Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Contingent Earnout Shares</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">In connection with the Reverse Recapitalization
and pursuant to the Merger Agreement, Legacy Abpro equity holders are entitled to receive, as additional merger consideration, up to 483,333
shares of the Company&#8217;s common stock (the &#8220;Contingent Earnout Shares&#8221;), comprised of three separate equal tranches,
for no consideration upon the occurrence of certain triggering events, including a change of control event. It was determined that based
on its provisions, the contingent consideration is indexed to the Company&#8217;s stock and therefore qualify for the scope exception
from the derivative accounting in ASC 815-10-15-74(a). As a result, the Company elected to recognize the contingent consideration obligation
in accordance with ASC Topic 450, <i>Contingencies </i>(&#8220;ASC 450&#8221;) when the contingency is resolved, and the consideration
is paid or becomes payable. Based on the Company&#8217;s stock price, no amounts were due under the contingent earnout provisions as of
December 31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements and Fair Value of Financial Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Fair Value Measurements and Fair
Value of Financial Instruments </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company categorizes its assets
and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with GAAP. Fair
value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal
or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.
The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1)
and lowest priority to unobservable inputs (Level 3). The carrying value of cash, accounts receivable, accounts payable, accrued expenses,
excise taxes payable, income taxes payable, and related party loans payable approximate fair value because of the short-term nature of
such instruments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Level 1 - Inputs are unadjusted quoted
prices in active markets for identical assets or liabilities available at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Level 2 - Inputs are unadjusted quoted
prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets
that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market
data.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Level 3 - Unobservable inputs based
on the Company&#8217;s assessment of the assumptions that market participants would use in pricing the asset or liability.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">In some circumstances, the inputs used
to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement
is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Transfers to/from Levels 1, 2 and 3
are recognized at the end of the reporting period in which a change in valuation technique or methodology occurs.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock', window );">Restatement of Previously Issued Financial Statements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify"><b>Restatement of Previously Issued
Financial Statements</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company identified an error in
the amount of the accrued expenses within the audited balance sheets as of September 30, 2024, December 31, 2023 and 2022 included in
the Company&#8217;s Form 8-K, filed on November 26, 2024. In accordance with Staff Accounting Bulletin (&#8220;SAB&#8221;) No. 99, <i>Materiality</i>,
and SAB No. 108, <i>Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements</i>,
the Company evaluated these misstatements, and based on an analysis of quantitative and qualitative factors, determined that the impact
of these misstatements was material to its reporting periods ended December 31, 2023, December 31, 2022 and September 30, 2024.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accordingly, the Company has restated
its consolidated financial statements for the years ended December 31, 2023 and 2022, and its interim reporting period for the nine months
ended September 30, 2024, and has included that restated financial information within this annual report.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of December 31, 2023 is reflected in the following table:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,381</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,191</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(105,571</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108,871</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(85,135</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(88,435</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of December 31, 2022 is reflected in the following table:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,897</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,865</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97,165</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75,734</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79,034</td><td style="text-align: left">)</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of September 30, 2024 is reflected in the following table:</p><table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,045</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,277</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,577</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(109,468</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(112,768</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87,501</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(90,801</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ContingentEarnoutPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Earnout.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ContingentEarnoutPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ConvertiblePreferredStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ConvertiblePreferredStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_EmergingGrowthCompanyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Emerging growth company .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_EmergingGrowthCompanyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_NoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-controlling Interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_NoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PatentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PatentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The policy disclosure of recently adopted accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for restatement of previously issued financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for unaudited interim condensed consolidated financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share, because their effect was anti-dilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Convertible Preferred Stock</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-404"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">662,921</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td><span style="-sec-ix-redline:true;-keep: true">Warrants</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">990,000</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4,159</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Stock options</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,635</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">345,164</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Unvested restricted stock units</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,667</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,292</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,229,302</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,013,536</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table presents the potentially
dilutive shares that were excluded from the computation of diluted net loss per share of common stock attributable to common stockholders,
because their effect was anti-dilutive:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Convertible Preferred Stock</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-427">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">324,184</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">961,667</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,034</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Stock options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">329,395</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">369,092</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Convertible Notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,824</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-428">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Unvested restricted stock units</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">739</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,528</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,350,625</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">696,838</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock', window );">Schedule of Consolidated Statements of Cash Flows</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The following tables reconcile cash and restricted cash to amounts
shown in the consolidated statements of cash flows:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cash</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,850</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">723</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">142</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Total cash and restricted cash</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">861</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Schedule of Depreciation on Property and Equipment Estimated Useful Lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Depreciation on property and equipment
is calculated using the straight-line method over the estimated useful lives as follows:&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; width: 77%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Classification</b></span></td> <td style="width: 1%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; width: 22%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Estimated<br/>
Useful Life<br/>
(in years)</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer hardware and software</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 5&#160;</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lab equipment</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3 - 5</span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5 - 7</span></td></tr> <tr style="vertical-align: top; background-color: white"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td> <td style="text-align: justify">&#160;</td> <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-426">Shorter of useful life or lease term</span></span></td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Schedule of Balance Sheet</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of December 31, 2023 is reflected in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,081</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,381</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12,891</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,191</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(105,571</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(108,871</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(85,135</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(88,435</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of December 31, 2022 is reflected in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,897</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5,197</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,987</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,287</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(93,865</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(97,165</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(75,734</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(79,034</td><td style="text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The impact of the revision on the Company&#8217;s
balance sheet as of September 30, 2024 is reflected in the following table:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As previously<br/> reported</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">As restated</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Accrued expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,745</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,300</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,045</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15,277</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">18,577</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Accumulated deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(109,468</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(112,768</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Total stockholders&#8217; deficit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(87,501</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,300</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(90,801</td><td style="text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of property plant and equipment depreciation over the estimated useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedCashFlowStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>156
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Merger [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Common Stock Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The number of shares of the Company&#8217;s
common stock outstanding immediately following the consummation of the Merger was as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Common stock of ACAB, net of redemptions</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,033</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">ACAB Founder Shares, less of forfeitures and transfers</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">126,076</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares issued to PIPE investors</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">112,247</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares issued to service providers</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">42,762</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares issued in Merger to Legacy Abpro stockholders</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,304,107</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares transferred to investors</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">72,285</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">New Abpro shares issued to settle the promissory note with executive</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">20,000</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total shares of common stock outstanding immediately after
    Merger</span></td><td style="font-weight: bold; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,684,510</span></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The number of shares of the Company&#8217;s
common stock outstanding immediately following the consummation of the Merger was:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify">Common stock of ACAB, net of redemptions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,033</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">ACAB Founder Shares, less of forfeitures and transfers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,076</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">New Abpro shares issued to PIPE investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,247</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">New Abpro shares issued to service providers</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">42,762</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">New Abpro shares issued in Merger to Legacy Abpro stockholders</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,304,107</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">New Abpro shares transferred to investors</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72,285</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">New Abpro shares issued to settle the promissory note with executive</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">Total shares of common stock outstanding immediately after Merger</td><td style="font-weight: bold; padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">1,684,510</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Accrued expenses consisted of the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December 31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued salaries and wages</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">2,033</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,549</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued professional fees</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,121</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,273</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued license fees</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,300</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">3,300</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Accrued interest</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">273</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">267</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">Board of Directors compensation</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">285</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">242</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Other accrued expenses</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,014</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">865</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total accrued expenses</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,026</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">7,496</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Accrued expenses consisted of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/> (As&#160;Restated)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Accrued salaries and wages</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,549</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,398</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,273</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Accrued license fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,300</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Accrued interest</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">267</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-432">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">BOD compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">242</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-433">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">865</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">590</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total accrued expenses</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,496</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5,381</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Schedule of Company&#8217;s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following table presents information about
the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2025 and December
31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Description</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Level</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Assets:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 65%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Forward purchase agreement asset (Note 9)</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 9%; text-align: center"><span style="-sec-ix-redline:true;-keep: true">3</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-406"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;&#160;&#160;&#160;&#160;&#160;&#160;155</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">SEPA put rights asset (Note 11)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">243</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">188</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Liabilities:</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Embedded derivative liability (Note 11)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">3</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-407"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">80</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table presents information
about the Company&#8217;s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2024, and indicates
the fair value hierarchy of the valuation inputs the Company&#8217;s utilized to determine such fair value:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Description</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Level</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Forward purchase agreement asset (Note 11)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">3</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;155</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">SEPA put rights asset (Note 13)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">188</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Embedded derivative liability (Note 13)</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">80</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement</a></td>
<td class="text">The fair value of the Company&#8217;s position under the Forward Purchase
Agreement was calculated as of December 31, 2024 by multiplying the number of shares under the Forward Purchase Agreement by the market
price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Stock price</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">53.70</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Risk-free interest rate</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.4</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected term (in years)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.1</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected volatility</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">98</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected dividend yield</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  </table>The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">September 30,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">December&#160;31,</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Stock price</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.72</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">53.70</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Risk-free interest rate</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">3.7 &#8211; 4.1</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.2</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Exercise price</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">6.45</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">51.60</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected term (in years)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">0.1 - 1.2</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">1 - 2</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected volatility</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">100</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;font-size: 10pt">&#160;93-99</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Expected dividend yield</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">0</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">%</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Number of shares under each advance notice</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">26,667</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,883</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The fair value of the Company&#8217;s
position under the Forward Purchase Agreement was calculated by multiplying the number of shares under the Forward Purchase Agreement
by the market price at the settlement date estimated using a Monte-Carlo simulation incorporating the following assumptions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">November&#160;13,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December&#160;31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Stock price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">173.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.6</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.4</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">90</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">98</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  </table>The fair value of the put rights under each advance notice was estimated using the
Black Scholes model, incorporating the following assumptions:<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">November 13,</td><td style="text-align: center; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">December 31,</td><td style="text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2024</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Stock price</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">173.10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53.70</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.3</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Exercise price</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">166.20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">51.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1 to 2 years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">1 to 2 years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">82-90</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">93-99</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Number of shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,500</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,883</td><td style="text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The changes in the fair value of Level 3 financial
assets and liabilities for the nine months ended September 30, 2025 are as follows:&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Forward<br/> Purchase<br/> Agreement<br/>
    Asset</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">SEPA<br/> Put Rights<br/> Asset</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Embedded</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Derivative</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b style="-sec-ix-redline:true;-keep: true">Liabilities</b></p></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Fair value as of January 1, 2025</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">155</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">188</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">80</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Initial measurement at the issuance date (see Note 11)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-408"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-409"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">93</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">Settlement</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(132</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-410"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(946</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Change in fair value</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(23</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">55</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">773</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Fair value as of September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-411"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">243</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-412"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The changes in the fair value of Level
3 financial assets and liabilities for the year ended December 31, 2024 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Forward<br/>
Purchase<br/>
Agreement<br/>
asset</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEPA<br/>
Put Rights<br/>
Asset</b></span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Embedded <br/>
Derivative Liability</b></span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 67%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value as of January 1, 2024</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-434; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 8%; text-align: right"><span style="-sec-ix-hidden: hidden-fact-435; font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Initial measurement at the issuance date</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">494</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,551</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in fair value</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(339</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,363</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</span></td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value as of December 31, 2024</span></td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">155</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">188</span></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</span></td>
    <td>&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StockholdersEquityTablesLineItems', window );"><strong>Stockholders&#8217; Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants to Purchase Common Stock Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following table sets forth the
common stock warrant activity for the year ended December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Legacy<br/> Abpro <br/> Common</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock <br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Private<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Public<br/> Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Outstanding as of December 31, 2023</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2,034</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-441">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-442">-</div></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Expired at the Merger</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,034</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-443">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-444">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Common stock warrants of ACAB acquired in Merger</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-445">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">461,667</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">500,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding as of December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-446">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">461,667</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">500,000</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StockholdersEquityTablesLineItems', window );"><strong>Stockholders&#8217; Equity (Tables) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Warrants to Purchase Common Stock Outstanding</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The following presents information about warrants
to purchase common stock outstanding as of September 30, 2025:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Average</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Remaining</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Contractual Life</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%; text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Warrants</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">990,000</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">114.60</span></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 11%; text-align: center; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">4.3 years</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The following presents information
about warrants to purchase common stock outstanding as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/>
Average <br/> Exercise <br/>
Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Average Remaining<br/> Contractual <br/>
Life</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Warrants</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">961,667</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">114.90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="text-align: right; width: 11%">4.9 years</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_StockholdersEquityTablesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_StockholdersEquityTablesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Company&#8217;s Stock Option Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The summary of the Company&#8217;s stock option
activity is as follows:&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number of<br/> Stock Options</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average<br/> Exercise Price</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average<br/> Remaining<br/> Contractual<br/> Life</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="-sec-ix-redline:true;-keep: true">Outstanding at December 31, 2024</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="-sec-ix-redline:true;-keep: true">329,395</span></p></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51.30</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">5.4</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">8,080</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">9.60</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">10</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Exercised</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-419"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-420"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-421"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Forfeited/Expired/Cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(114,840</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50.39</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-422"><span style="-sec-ix-redline:true;-keep: true">-</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Outstanding at September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">222,635</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">50.28</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Exercisable at&#160;&#160;September 30, 2025</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">180,146</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">51.85</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4.4</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The summary of the Company&#8217;s
stock option activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Stock<br/> Options</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average<br/> Exercise <br/> Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-<br/> Average <br/> Remaining<br/> Contractual <br/> Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at December 31, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">369,092</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">49.20</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6.1</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-449">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-450">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-451">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercised</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-452">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-453">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-454">-</div></td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited/Expired/Cancelled</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(39,698</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">30.90</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-455">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">329,395</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">51.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.4</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 4pt">Exercisable at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">276,060</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">51.30</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5.4</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of Company&#8217;s Restricted Stock Unit Activity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The summary of the Company&#8217;s restricted
stock unit activity is as follows:&#160;&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Weighted-<br/> Average</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Number&#160;of</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Grant Date</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Remaining</span></td><td style="font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom"> <td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Shares</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Fair Value</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Vesting&#160;Period</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%"><span style="-sec-ix-redline:true;-keep: true">Unvested at December&#160;31,&#160;2024</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">739</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">48.90</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">0.2</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td><span style="-sec-ix-redline:true;-keep: true">Granted</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,667</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">9.60</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.6</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Vested</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">(142</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">48.90</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-423"><span style="-sec-ix-redline:true;-keep: true">&#8212;</span></div></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">Forfeited/Expired/Cancelled</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">(597</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">)</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">48.90</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-424"><span style="-sec-ix-redline:true;-keep: true">&#8212;</span></div></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td><span style="-sec-ix-redline:true;-keep: true">Unvested at September 30, 2025</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">16,667</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">9.60</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td> <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">2.4</span></td><td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr> </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The summary
of the Company&#8217;s restricted stock unit activity is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of<br/> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Grant Date <br/> Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted-Average<br/> Remaining <br/> Vesting Period</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 64%">Outstanding at December 31, 2023</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">3,124</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;48.90</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.2</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Granted</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-456">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-457">&#8212;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Vested</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(2,386</td><td style="text-align: left">)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">48.90</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-458">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-459">&#8212;</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#8212;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt">Outstanding at December 31, 2024</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">738</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">48.90</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td> <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.2</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Recorded Stock-Based Compensation Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">The summary of the recorded stock-based compensation
expense is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Three Months Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">Nine Months Ended <br/>
    September 30,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2025</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="font-weight: bold; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="-sec-ix-redline:true;-keep: true">2024</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: right"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td colspan="2" style="text-align: center"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">Research and development</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">4</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">11</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">22</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="width: 1%"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="width: 9%; text-align: right"><span style="-sec-ix-redline:true;-keep: true">62</span></td><td style="width: 1%; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">General and administrative</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">282</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">404</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,136</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,469</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">Total stock-based compensation</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">286</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">415</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,158</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td><td style="padding-bottom: 4pt"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td>
    <td style="border-bottom: Black 4pt double; text-align: left"><span style="-sec-ix-redline:true;-keep: true">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="-sec-ix-redline:true;-keep: true">1,531</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="-sec-ix-redline:true;-keep: true">&#160;</span></td></tr>
  </table><span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The summary of the recorded stock-based
compensation expense is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Research and development</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">118</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,855</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,187</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 2.5pt; padding-left: 9.25pt">Total stock-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,927</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,305</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The assumptions that the Company used
to determine the fair value of the stock options granted to employees, directors and nonemployees were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td> <td>&#160;</td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Year ended<br/>
December 31,<br/>
2023</b></span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk-free interest rate</span></td> <td style="width: 1%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.53</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected term (in years)</span></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.3</span></td> <td>&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected volatility</span></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">71</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expected dividend yield</span></td> <td>&#160;</td> <td>&#160;</td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company&#8217;s property and equipment
include the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Furniture and fixtures</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">53</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Lab equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,097</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,097</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer hardware and software</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">15</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">788</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">788</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Equipment under finance leases</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">740</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Property and Equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,693</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,693</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Accumulated Depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,656</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,591</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">37</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">102</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The components of lease expense were
as follows as of and for the years ended December 31, 2024 and 2023:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating lease costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">594</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">594</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Finance lease costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9.25pt">Amortization of ROU assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">240</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9.25pt">Interest on lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total lease costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">638</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">850</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The total cash paid for amounts included
in the measurement of lease liabilities for the years ended December 31, 2024 and 2023 included the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating cash flows from operating leases</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">566</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">500</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Financing cash flows from finance leases</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">222</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Lease term and discount rate were as
follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;"> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Weighted-average remaining lease term <i>(in years)</i></span></td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: justify; padding-left: 9.25pt">Operating leases</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.73</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.73</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9.25pt">Finance leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.25</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Weighted-average discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-left: 9.25pt">Operating leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.66</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.66</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-left: 9.25pt">Finance leases</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.50</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6.50</td><td style="text-align: left">%</td></tr> </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The Company had the following future minimum payments due
under its operating lease agreements as of December 31, 2024:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">For the year ended December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating<br/>
 Leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; padding-bottom: 1.5pt">2025</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">465</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Total future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">465</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(9</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Present value of future minimum lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">456</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: current maturities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(456</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Obligations under lease liability, noncurrent</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-437">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income / (Loss) Before Provision</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">The components of income / (loss) before
provision for / (benefit from) income taxes are:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Domestic</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,232</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(11,770</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-462">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">64</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Loss before Income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,232</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,706</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">A reconciliation of the Company&#8217;s
effective income tax rate to the U.S. statutory federal income tax rate of 21% for the years ended December 31, 2024 and 2023 is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Net loss before tax</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(7,232</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(11,706</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Statutory U.S. federal tax rate</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">21</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Tax computed at federal statutory rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(1,519</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,458</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">State income taxes, net of federal benefit and tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(606</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(825</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Federal research and development credit</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(290</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(297</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">Permanent differences</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(98</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">40</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,513</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,540</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 4pt">Income tax expense</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-463">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-464">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Net Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-indent: 0in; text-align: justify">Significant components of
the Company&#8217;s net deferred tax assets and liabilities as of December 31, 2024 and 2023 are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&#160;</p>

<table cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%; border-spacing: 0px;">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2024</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2023 <br/> (As Restated)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9.25pt">Operating loss carryforwards</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">23,229</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">21,135</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9.25pt">Tax credits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,478</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,054</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9.25pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,691</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,154</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9.25pt">Capitalized research expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,547</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,183</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9.25pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,823</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">539</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-left: 9.25pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">124</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">279</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9.25pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">333</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-465">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33,387</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">29,677</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">Less: Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(33,274</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(29,414</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Total deferred tax assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">113</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">263</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Deferred tax liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9.25pt">Right-of-use asset</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(113</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(263</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred income taxes</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-466">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-467">-</div></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of the Business (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Jun. 23, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Jan. 28, 2025</div></th>
<th class="th"><div>Nov. 14, 2024</div></th>
<th class="th"><div>Oct. 07, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 16, 2025</div></th>
<th class="th"><div>Sep. 29, 2025</div></th>
<th class="th"><div>Apr. 10, 2025</div></th>
<th class="th"><div>Apr. 02, 2025</div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
<th class="th"><div>Oct. 18, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ReverseStockSplitSharesOfIssued', window );">Shares of issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ReverseStockSpllitSharesOfOutstanding', window );">Shares of outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727,192<span></span>
</td>
<td class="nump">2,672,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,672,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727,192<span></span>
</td>
<td class="nump">646,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,694,414<span></span>
</td>
<td class="nump">2,672,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,672,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,694,414<span></span>
</td>
<td class="nump">639,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (116,103)<span></span>
</td>
<td class="num">$ (124,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (124,631)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (116,103)<span></span>
</td>
<td class="num">$ (108,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,657)<span></span>
</td>
<td class="num">$ (2,984)<span></span>
</td>
<td class="num">$ (3,887)<span></span>
</td>
<td class="num">$ (2,093)<span></span>
</td>
<td class="num">(8,528)<span></span>
</td>
<td class="num">$ (3,897)<span></span>
</td>
<td class="num">(7,232)<span></span>
</td>
<td class="num">(11,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_SecurityBidPricePerShare', window );">Security bid price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate net purchase price</a></td>
<td class="nump">$ 688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
<td class="nump">723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Converted in common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,786<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_InstallmentsAmount', window );">Installments amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AccrueInterestPercentage', window );">Accrue interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repaid balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Net liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ForwardPurchaseAgreement', window );">Forward purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue', window );">Shares of forward purchase agreement (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_SecurityBidPricePerShare', window );">Security bid price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares, converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_SecondConvertibleNoteMember', window );">Second Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_PIPEFinancingMember', window );">PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares, converted (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_ConvertibleNoteDiscountMember', window );">Convertible Note Discount [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Issuance discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Contract Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue', window );">Shares of forward purchase agreement (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Termination obligation aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,684,510<span></span>
</td>
<td class="nump">1,684,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,684,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,684,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of common stock (in Shares)</a></td>
<td class="nump">91,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,336<span></span>
</td>
<td class="nump">9,905<span></span>
</td>
<td class="nump">91,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate net purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=abp_ReverseStockSplitMember', window );">Reverse Stock Split [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock shares outstanding (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_MarketValueOfPubliclyHeldSharesMember', window );">MVPHS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_MarketValueOfListedSecuritiesMember', window );">MVLS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Market value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Contract Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue', window );">Shares of forward purchase agreement (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Termination obligation aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_EarlyTerminationResetPricePerShare', window );">Early termination reset price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,657)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,232)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Organization and Description of the Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net losses amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11,706)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFixedInterestRate', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AccrueInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrue interest percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AccrueInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_EarlyTerminationResetPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early termination reset price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_EarlyTerminationResetPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ForwardPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of forward purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ForwardPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_InstallmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of installments amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_InstallmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ReverseStockSplitSharesOfIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse stock split shares of issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ReverseStockSplitSharesOfIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ReverseStockSpllitSharesOfOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reverse stock spllit shares of outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ReverseStockSpllitSharesOfOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_SecurityBidPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of security bid price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_SecurityBidPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred to effect business combination. Excludes separately recognized transaction and indirect cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fixed interest rate related to the interest rate derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares as a settlement alternative for each freestanding forward contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -SubTopic 40<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_SecondConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_SecondConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_PIPEFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_PIPEFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_ConvertibleNoteDiscountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_ConvertibleNoteDiscountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=abp_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=abp_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_MarketValueOfPubliclyHeldSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_MarketValueOfPubliclyHeldSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_MarketValueOfListedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_MarketValueOfListedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 3,556<span></span>
</td>
<td class="nump">$ 3,556<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription', window );">Company&#8217;s operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The financial results of the Company&#8217;s operations are managed and
reported to the Chief Executive Officer, who is considered the Company&#8217;s CODM, on a consolidated basis<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration', window );">Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Chief Executive Officer [Member]<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Recognized income tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Additional shares (in Shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_MabwellShanghaiBioscienceCoLtdMember', window );">Mabwell (Shanghai) Bioscience Co Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_ContingentEarnoutSharesMember', window );">Contingent Earnout Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Additional shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abp_AbMedMember', window );">AbMed [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480341/340-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-9<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477123/405-50-65-1<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482477/820-10-65-13<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 51: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 52: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 53: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 54: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 55: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 58: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479845/805-20-65-3<br><br>Reference 59: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 60: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 61: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 62: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 63: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 64: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 65: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 66: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 67: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 68: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 69: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 70: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 71: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 72: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 73: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 74: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 75: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 76: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 77: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 78: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 79: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 80: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 81: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 82: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 83: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 84: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 85: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-6<br><br>Reference 86: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 87: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 88: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 89: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 90: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 91: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 92: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 93: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 94: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 95: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 96: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 97: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-3<br><br>Reference 98: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 99: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 100: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 101: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 102: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 103: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 104: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 105: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br><br>Reference 106: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476151/220-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from parties in nontrade transactions, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-5<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_MabwellShanghaiBioscienceCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_MabwellShanghaiBioscienceCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_ContingentEarnoutSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_ContingentEarnoutSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abp_AbMedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=abp_AbMedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive shares</a></td>
<td class="nump">1,229,302<span></span>
</td>
<td class="nump">1,013,536<span></span>
</td>
<td class="nump">1,350,625<span></span>
</td>
<td class="nump">696,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive shares</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">662,921<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">324,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive shares</a></td>
<td class="nump">990,000<span></span>
</td>
<td class="nump">4,159<span></span>
</td>
<td class="nump">961,667<span></span>
</td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive shares</a></td>
<td class="nump">222,635<span></span>
</td>
<td class="nump">345,164<span></span>
</td>
<td class="nump">329,395<span></span>
</td>
<td class="nump">369,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_UnvestedRestrictedStockUnitsMember', window );">Unvested restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive shares</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
<th class="th"><div>Nov. 05, 2024</div></th>
<th class="th"><div>Oct. 07, 2024</div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Converted into shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AdditionSharesOfCommonStock', window );">Additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">483,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AggregatePurchasePrice', window );">Aggregate purchase price (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repay promissory note (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 2,850<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AggregateIncentiveShare', window );">Incentive shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Forfeited number of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from financing (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Issuance costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Liabilities net (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,607<span></span>
</td>
<td class="nump">16,191<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exceeds per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Excise tax payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income tax payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_PromissoryNoteAgreementMember', window );">Promissory Note Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repay promissory note (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abp_FirstSharesTargetMember', window );">First Shares Target [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_EarnoutShare', window );">Earnout shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_TradingDays', window );">Trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NumberOfConsecutiveTradingDays', window );">Consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exceeds per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abp_SecondShareTargetMember', window );">Second Share Target [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_EarnoutShare', window );">Earnout shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_TradingDays', window );">Trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NumberOfConsecutiveTradingDays', window );">Consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exceeds per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=abp_ThirdShareTargetMember', window );">Third Share Target [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_EarnoutShare', window );">Earnout shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_TradingDays', window );">Trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NumberOfConsecutiveTradingDays', window );">Consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Exceeds per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_PIPESharesMember', window );">PIPE Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AggregatePurchasePrice', window );">Aggregate purchase price (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repay promissory note (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember', window );">Abpro Bio International, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ABIMember', window );">ABI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
<td class="nump">41,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_SponsorMember', window );">Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ACABMember', window );">ACAB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_RemainingSharesIssued', window );">Remaining shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAndNoncurrent', window );">Tax payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income tax payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_PIPEFinancingMember', window );">PIPE Financing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from financing (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts', window );">Transaction costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Issuance costs (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_InvestmentAdvisorMember', window );">Investment Advisor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_LegacyAbproMember', window );">Legacy Abpro [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Liabilities net (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ABCDMember', window );">ABCD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_RemainingSharesIssued', window );">Remaining shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits', window );">Converted into shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember', window );">Series A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,744,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,744,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesBCommonStockMember', window );">Series B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Celltrion, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Sponsor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares of common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MergerLineItems', window );"><strong>Merger [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Total consideration (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AdditionSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of addition shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AdditionSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AggregateIncentiveShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of aggregate incentive shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AggregateIncentiveShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_EarnoutShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnout share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_EarnoutShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_MergerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_MergerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_NumberOfConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the number of consecutive trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_NumberOfConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_RemainingSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_RemainingSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_TradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_TradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction cost incurred to effect business combination. Excludes separately recognized transaction and indirect cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_PromissoryNoteAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_PromissoryNoteAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abp_FirstSharesTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abp_FirstSharesTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abp_SecondShareTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abp_SecondShareTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=abp_ThirdShareTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=abp_ThirdShareTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_PIPESharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_PIPESharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_SponsorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_SponsorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ACABMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ACABMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_PIPEFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_PIPEFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_InvestmentAdvisorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_InvestmentAdvisorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_LegacyAbproMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_LegacyAbproMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ABCDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ABCDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesBCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesBCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_CelltrionIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_CelltrionIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>168
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger - Schedule of Common Stock Outstanding (Details) - Common Stock [Member] - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">1,684,510<span></span>
</td>
<td class="nump">1,684,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock of ACAB, net of redemptions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">7,033<span></span>
</td>
<td class="nump">7,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">ACAB Founder Shares, less of forfeitures and transfers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">126,076<span></span>
</td>
<td class="nump">126,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares issued to PIPE investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">112,247<span></span>
</td>
<td class="nump">112,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares issued to service providers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">42,762<span></span>
</td>
<td class="nump">42,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares issued in Merger to Legacy Abpro stockholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">1,304,107<span></span>
</td>
<td class="nump">1,304,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares transferred to investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">72,285<span></span>
</td>
<td class="nump">72,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares issued to settle the promissory note with executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_CommonStockOfACABNetOfRedemptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_CommonStockOfACABNetOfRedemptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_ACABFounderSharesLessOfForfeituresAndTransfersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_ACABFounderSharesLessOfForfeituresAndTransfersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToPIPEInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToPIPEInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesTransferredToInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesTransferredToInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Schedule of Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and wages</a></td>
<td class="nump">$ 2,033<span></span>
</td>
<td class="nump">$ 1,549<span></span>
</td>
<td class="nump">$ 1,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AccruedLicenseFees', window );">Accrued license fees</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AccruedInterest', window );">Accrued interest</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AccruedBODCompensation', window );">Board of Directors compensation</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,014<span></span>
</td>
<td class="nump">865<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 8,026<span></span>
</td>
<td class="nump">$ 7,496<span></span>
</td>
<td class="nump">$ 5,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AccruedBODCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of BOD compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AccruedBODCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AccruedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AccruedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 14, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Cash received</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative feature estimated amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_FirstConvertibleNotesMember', window );">First Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_SecondConvertibleNotesMember', window );">Second Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_MonteCarloSimulationMember', window );">Monte Carlo Simulation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative feature estimated amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Note [Member] | Monte Carlo Simulation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_EstimatedFuturePricePerShare', window );">Estimated future price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.8<span></span>
</td>
<td class="nump">$ 130.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.18%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative feature estimated amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes Payable [Member] | Monte Carlo Simulation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_EstimatedFuturePricePerShare', window );">Estimated future price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.18%<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative feature estimated amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Expected volatility [Member] | Maximum [Member] | Monte Carlo Simulation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Convertible Notes Payable [Member] | Monte Carlo Simulation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_EstimatedFuturePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated future price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_EstimatedFuturePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_FirstConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_FirstConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_SecondConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_SecondConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_MonteCarloSimulationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_MonteCarloSimulationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Company&#8217;s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details) - Level 3 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember', window );">Forward purchase agreement asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value measured assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember', window );">SEPA put rights asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value measured assets</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember', window );">Embedded derivative liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value measured liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement (Details)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">6.72<span></span>
</td>
<td class="nump">53.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate [Member] | Minimum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate [Member] | Maximum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years) [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years) [Member] | Minimum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (in years) [Member] | Maximum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility [Member] | Minimum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility [Member] | Maximum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Exercise price [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">6.45<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=abp_NumberOfSharesMember', window );">Number of shares under each advance notice [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">26,667<span></span>
</td>
<td class="nump">1,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_ForwardPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_ForwardPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_BlackAndScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_BlackAndScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abp_NumberOfSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abp_NumberOfSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember', window );">Forward Purchase Agreement asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Begining balance</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Initial measurement at the issuance date (see Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements', window );">Settlement</a></td>
<td class="num">(132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember', window );">SEPA Put Rights Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Begining balance</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Initial measurement at the issuance date (see Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements', window );">Settlement</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">1,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Ending balance</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember', window );">Embedded Derivative Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Begining balance</a></td>
<td class="nump">80<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Initial measurement at the issuance date (see Note 11)</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements', window );">Settlement</a></td>
<td class="num">(946)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value</a></td>
<td class="nump">773<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Collaboration Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AgreementInitialTerm', window );">Agreement initial term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfOriginalCelltrionAgreement', window );">Original celltrion agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfAmendedCelltrionAgreement', window );">Amended celltrion agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfReimbursement', window );">Percentage of reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abp_FirstMilestoneMember', window );">First Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember', window );">ABP-100 Collaboration and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_NJCTTQCollaborationAgreementMember', window );">NJCTTQ Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NonRefundablePayments', window );">Aggregate non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_ABP201CollaborationAndLicenseAgreementMember', window );">ABP-201 Collaboration and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_CelltrionCollaborationAndLicenseAgreementMember', window );">Celltrion Collaboration and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_OriginalCelltrionAgreement', window );">Original celltrion agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfReimbursement', window );">Percentage of reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_CelltrionCollaborationAndLicenseAgreementMember', window );">Celltrion Collaboration and License Agreement [Member] | First Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_CelltrionCollaborationAndLicenseAgreementMember', window );">Celltrion Collaboration and License Agreement [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_OriginalCelltrionAgreement', window );">Original celltrion agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember', window );">ABP-100 Collaboration and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Guaranteed annual minimum royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ABIMember', window );">ABI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfAmendedCelltrionAgreement', window );">Amended celltrion agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfAmendedCelltrionAgreement', window );">Amended celltrion agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | NJCTTQ Collaboration Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>License and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NonRefundablePayments', window );">Aggregate non-refundable payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 405,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AgreementInitialTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement initial term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AgreementInitialTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_NonRefundablePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-refundable payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_NonRefundablePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_OriginalCelltrionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original celltrion agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_OriginalCelltrionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfAmendedCelltrionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of amended celltrion agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfAmendedCelltrionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfOriginalCelltrionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of original celltrion agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfOriginalCelltrionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reimbursement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477866/928-440-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abp_FirstMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abp_FirstMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_NJCTTQCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_NJCTTQCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_ABP201CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_ABP201CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_CelltrionCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_CelltrionCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments under Research and Collaboration Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ClinicalDevelopmentMilestones', window );">Clinical development milestones.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_RegulatoryEvents', window );">Regulatory events</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_CommercialSales', window );">Commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePaymentsCommercialMilestones', window );">Milestone payments commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PaymentForExtensionRoyalities', window );">Extension royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent', window );">Accrued extension royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_DevelopmentMilestones', window );">Development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AnnualSalesMilestonePayments', window );">Annual sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NetProfitsFromLicensedProductSales', window );">Net profits from licensed product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PaymentOfDevelopmentMilestones', window );">Payment of development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AccruedToAmount', window );">Accrued amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PatentCostsReimbursements', window );">Patent costs reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="nump">379<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentMilestones', window );">Net sales of licensed products milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$3,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">$ 3,556<span></span>
</td>
<td class="nump">$ 3,556<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_MedImmuneLicenseAgreementMember', window );">MedImmune License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">244,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_NCILicenseAgreementMember', window );">NCI License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_MSKLicenseAgreementMember', window );">MSK License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents', window );">Milestone payment upon achieving</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePaymentOnNetSales', window );">Milestone payment on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_VAZYMELicenseAgreementMember', window );">VAZYME License agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesAndAccountsPayableMember', window );">Other Accrued Expenses and Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PatentCostsReimbursements', window );">Patent costs reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">273<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesMember', window );">Other Accrued Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PatentCostsReimbursements', window );">Patent costs reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_AccountsPayableMember', window );">Accounts Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PaymentOfDevelopmentMilestones', window );">Payment of development milestones</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | NCI License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Commitments under Research and Collaboration Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 498,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AccruedToAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accrued to related party amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AccruedToAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AnnualSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AnnualSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ClinicalDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the clinical development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ClinicalDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_CommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the commercial sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_CommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_DevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_DevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_MilestonePaymentOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payment based on net sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_MilestonePaymentOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_MilestonePaymentsCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_MilestonePaymentsCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payments upon achieving research and development and commercialization events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_NetProfitsFromLicensedProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net profits from licensed product sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_NetProfitsFromLicensedProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PatentCostsReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>related to the patent costs reimbursements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PatentCostsReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PaymentForExtensionRoyalities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The company is liable for extension royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PaymentForExtensionRoyalities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PaymentOfDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payment of development milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PaymentOfDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_RegulatoryEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent the regulatory events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_RegulatoryEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the nature of achievements or target goals that are to be reached by specified dates to maintain the arrangement or extend it, generally without adjustment of the present financial terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue and income classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_MedImmuneLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_MedImmuneLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_NCILicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_NCILicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_MSKLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_MSKLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_VAZYMELicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_VAZYMELicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesAndAccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesAndAccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAxis=us-gaap_AccountsPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAxis=us-gaap_AccountsPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 17, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Nov. 05, 2024</div></th>
<th class="th"><div>Nov. 01, 2024</div></th>
<th class="th"><div>Aug. 16, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
<th class="th"><div>Jan. 24, 2024</div></th>
<th class="th"><div>May 31, 2023</div></th>
<th class="th"><div>Feb. 28, 2023</div></th>
<th class="th"><div>Jan. 30, 2023</div></th>
<th class="th"><div>Jan. 23, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 23, 2025</div></th>
<th class="th"><div>Oct. 22, 2025</div></th>
<th class="th"><div>Nov. 20, 2024</div></th>
<th class="th"><div>Oct. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_BusinessDays', window );">Business days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_MonthlyInstallmentPayments', window );">Monthly installment payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AdditionalAccruedInterest', window );">Additional accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Outstanding settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfessionalFees', window );">Professional fees</a></td>
<td class="nump">$ 748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DemandDepositAccounts', window );">Demand for payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="nump">$ 182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ExciseTaxLiability', window );">Excise tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,330<span></span>
</td>
<td class="nump">$ 4,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Shares redeemed percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">New U.S. federal excise tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage', window );">Excise tax generally of the fair market value percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate', window );">Estimated interest percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfUnderpaymentPenaltyPerMonth', window );">Percentage of underpayment penalty per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfLiabilityTotal', window );">Percentage of total liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExciseAndSalesTaxes', window );">Excise taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationInterestExpense', window );">Interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ExcessTaxes', window );">Excess taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Estimate of interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentCompanyExcessExpenseReimbursable', window );">Company recorded excess</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Penalties and interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,455<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PaymentOfRentAndMaintenanceExpense', window );">Rent and maintenance expenses to landlord</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Additional interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payment to CRO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal amount of promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_SettlementAgreementMember', window );">Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Outstanding settlement agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 848<span></span>
</td>
<td class="nump">785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_MSKLicenseAgreementMember', window );">MSK License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Notice of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=abp_NonRedemptionAgreementsMember', window );">Non-Redemption Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsTotalCostToInvestors', window );">Investors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityRedemptionPricePerShare', window );">Redemption price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExciseAndSalesTaxes', window );">Excise taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationInterestExpense', window );">Interest and penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=abp_VendorsMember', window );">Vendors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">New U.S. federal excise tax percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=abp_CROVendorMember', window );">CRO Vendor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Endorsement on motion for default judgment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember', window );">Series A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate of shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AdditionalAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AdditionalAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_BusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_BusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ExcessTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ExcessTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excise tax generally of the fair market value percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ExciseTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excise tax liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ExciseTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_MonthlyInstallmentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Monthly installment payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_MonthlyInstallmentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PaymentOfRentAndMaintenanceExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents rent and maintenance expenses to landlord.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PaymentOfRentAndMaintenanceExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfLiabilityTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of total liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfLiabilityTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfUnderpaymentPenaltyPerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of underpayment penalty per month.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfUnderpaymentPenaltyPerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsTotalCostToInvestors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost to investors of each class of capital shares or other capital units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsTotalCostToInvestors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DemandDepositAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of money in accounts that may bear interest and that the depositor is entitled to withdraw at any time without prior notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DemandDepositAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExciseAndSalesTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of excise and sales taxes included in sales and revenues, which are then deducted as a cost of sales. Includes excise taxes, which are applied to specific types of transactions or items (such as gasoline or alcohol); and sales, use and value added taxes, which are applied to a broad class of revenue-producing transactions involving a wide range of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExciseAndSalesTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentCompanyExcessExpenseReimbursable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of carryover of excess expense potentially reimbursable to adviser but not recorded as liability by investment company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentCompanyExcessExpenseReimbursable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (k)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discount rate used to estimate the fair value of servicing assets and servicing liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 860<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481229/860-50-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_MSKLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_MSKLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_NonRedemptionAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_NonRedemptionAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=abp_VendorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=abp_VendorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=abp_CROVendorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=abp_CROVendorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Forward Purchase Agreement (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2025</div></th>
<th class="th"><div>Nov. 07, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityLineItems', window );"><strong>Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityShares', window );">Maximum up to common stock shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue', window );">Seller purchased shares from third parties (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Asset fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_DerivativeChangeInFairValue', window );">Derivative change in fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ForwardContractInitialResetPricePerShare', window );">Initial reset price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ForwardContractBaseResetPricePerShare', window );">Base reset price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare', window );">Number of trading days used for calculating VWAP price of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_VolumeWeightedAveragePrice', window );">Volume weighted average price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount', window );">VWAP price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue', window );">Settlement amount under forward purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=abp_ForwardPurchaseAgreementMember', window );">Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityLineItems', window );"><strong>Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityShares', window );">Maximum up to common stock shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue', window );">Seller purchased shares from third parties (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRoyalties', window );">Prepayment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Asset fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare', window );">Initial price per recycled shares (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember', window );">Early Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityLineItems', window );"><strong>Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue', window );">Seller purchased shares from third parties (in Shares)</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Termination obligation aggregate amount</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Early Termination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityLineItems', window );"><strong>Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue', window );">Seller purchased shares from third parties (in Shares)</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Termination obligation aggregate amount</a></td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_EarlyTerminationResetPricePerShare', window );">Early termination reset price per share (in Dollars per share)</a></td>
<td class="nump">$ 39.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityLineItems', window );"><strong>Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Asset fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForwardContractIndexedToIssuersEquityLineItems', window );"><strong>Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Asset fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_DerivativeChangeInFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative change in fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_DerivativeChangeInFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_EarlyTerminationResetPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Early termination reset price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_EarlyTerminationResetPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ForwardContractBaseResetPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forward contract, base reset price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ForwardContractBaseResetPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ForwardContractInitialResetPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Forward contract, initial reset price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ForwardContractInitialResetPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of days used for calculating volume weighted average price per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price after deducting from volume weighted average price upon calculation of settlement amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_VolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_VolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value per share that would be issued upon settlement of forward contract indexed to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount that would be paid upon settlement of forward contract indexed to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -SubTopic 40<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares as a settlement alternative for each freestanding forward contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (d)<br> -SubTopic 40<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForwardContractIndexedToIssuersEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that could be issued to settle forward contract indexed to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForwardContractIndexedToIssuersEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=abp_ForwardPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=abp_ForwardPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 07, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 21, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 20, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 07, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 22, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 29, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 18, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 14, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 13, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 18, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount to be received under promissory note agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price of newly issued shares</a></td>
<td class="nump">$ 688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2,850<span></span>
</td>
<td class="nump">723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Received from promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balances under the promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,496<span></span>
</td>
<td class="nump">8,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,496<span></span>
</td>
<td class="nump">5,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Received from promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,883<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable, price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AdditionalInterestExpense', window );">Additional interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable, price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_NotePayableMember', window );">Note Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount to be received under promissory note agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest accrued on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNotesWithExecutiveAndDirectorMember', window );">Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balances under the promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Measurement Input, Option Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares) | shares</a></td>
<td class="nump">91,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,336<span></span>
</td>
<td class="nump">9,905<span></span>
</td>
<td class="nump">91,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price of newly issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_DebtInstrumentInterestRateTermAxis=abp_FundingDateToMaturityDateMember', window );">Until Maturity Date [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest accrued on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_DebtInstrumentInterestRateTermAxis=abp_AfterMaturityDateMember', window );">After Maturity Date [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest accrued on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember', window );">ABI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balances under the promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">1,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense on promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember', window );">ABI [Member] | Promissory Note with ABI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount to be received under promissory note agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price upon closing of merger (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price of newly issued shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConversionOfConsiderationUnderPromissoryNoteAgreement', window );">Conversion of consideration under promissory note agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_IncentiveSharesReceivedBySubsidiary', window );">Incentive shares received by subsidiary (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember', window );">ABI [Member] | 2024 ABI Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount to be received under promissory note agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest accrued on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Weekly installments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Received from promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember', window );">ABI [Member] | Until Maturity Date [Member] | Promissory Note with ABI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest accrued on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember', window );">ABI [Member] | After Maturity Date [Member] | Promissory Note with ABI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest accrued on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember', window );">Executive [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount to be received under promissory note agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Received from promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balances under the promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal amount of promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Received from promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable, price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  07,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember', window );">Executive [Member] | Promissory Notes with Executive and Director [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember', window );">Executive [Member] | Common Stock [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Common stock, shares issued upon conversion of promissory note (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember', window );">Executive [Member] | Until Maturity Date [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest accrued on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember', window );">Executive [Member] | After Maturity Date [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest accrued on promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember', window );">Director [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIssuedPrincipal', window );">Principal amount of promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ExecutiveMember', window );">Executive [Member] | Promissory Note with ACAB Executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Amount to be received under promissory note agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepaidPrincipal', window );">Debt instrument repaid upon cancellation of agreement.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, repayment date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 20,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Executive [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercisable, price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb.  07,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Executive [Member] | Promissory Notes with Executive and Director [Member] | Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_WarrantsExercisableDateAxis=abp_IssuanceDateOfWarrantsMember', window );">Issuance Date [Member] | Executive [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_WarrantsExercisableDateAxis=abp_IssuanceDateOfWarrantsMember', window );">Issuance Date [Member] | Subsequent Event [Member] | Executive [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_WarrantsExercisableDateAxis=abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember', window );">One Year Anniversary of Issuance Date [Member] | Executive [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_WarrantsExercisableDateAxis=abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember', window );">One Year Anniversary of Issuance Date [Member] | Subsequent Event [Member] | Executive [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_WarrantsExercisableDateAxis=abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember', window );">Two Year Anniversary of Issuance Date [Member] | Executive [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_WarrantsExercisableDateAxis=abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember', window );">Two Year Anniversary of Issuance Date [Member] | Subsequent Event [Member] | Executive [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants exercisable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">Previously Reported [Member] | Promissory Notes with Executive and Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Notes Payable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Outstanding principal balances under the promissory notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AdditionalInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AdditionalInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ConversionOfConsiderationUnderPromissoryNoteAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of consideration under promissory note agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ConversionOfConsiderationUnderPromissoryNoteAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_IncentiveSharesReceivedBySubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Incentive shares received by subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_IncentiveSharesReceivedBySubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIssuedPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIssuedPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepaidPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of principal of debt repaid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepaidPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_NotePayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_NotePayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNotesWithExecutiveAndDirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_PromissoryNotesWithExecutiveAndDirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_DebtInstrumentInterestRateTermAxis=abp_FundingDateToMaturityDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_DebtInstrumentInterestRateTermAxis=abp_FundingDateToMaturityDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_DebtInstrumentInterestRateTermAxis=abp_AfterMaturityDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_DebtInstrumentInterestRateTermAxis=abp_AfterMaturityDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_AbproBioInternationalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNoteWithABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_PromissoryNoteWithABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_YearTwoThousandTwentyFourABIPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_YearTwoThousandTwentyFourABIPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNoteWithACABExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_PromissoryNoteWithACABExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_WarrantsExercisableDateAxis=abp_IssuanceDateOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_WarrantsExercisableDateAxis=abp_IssuanceDateOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_WarrantsExercisableDateAxis=abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_WarrantsExercisableDateAxis=abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_WarrantsExercisableDateAxis=abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_WarrantsExercisableDateAxis=abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Standby Equity Purchase Agreement (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 01, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 23, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 28, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 14, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 29, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 20, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 15, 2025 </div>
<div>$ / item</div>
</th>
<th class="th">
<div>Feb. 12, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Nov. 12, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ExcessOfCommonStockPercentage', window );">Percentage of excess of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebt', window );">Convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Net convertible note discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,840<span></span>
</td>
<td class="nump">$ 4,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConvertibleThresholdConsecutiveTradingDays', window );">Convertible threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfClosingPrice', window );">Percentage of closing price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_FloorPrice', window );">Floor Price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_VolumeWeightedAveragePrice', window );">Volume-weighted-average price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfCommonStock', window );">Percentage of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfAmortizationPrincipalAmount', window );">Percentage of amortization principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ChangeInFairValueEmbeddedDerivativeLiability', window );">Change in fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (150)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other (expense) income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeAmortizationOfDiscount', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromPreviousAcquisition', window );">Gross purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfCommonStockOutstanding', window );">Percentage of common stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts', window );">Commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Fair value of shares issued</a></td>
<td class="nump">$ 688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAverageFloorPrice', window );">Floor price was adjusted (in Dollars per Item) | $ / item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Fixed price reset (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Original issuance discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 13,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfVolumeWeightedAveragePrice', window );">Percentage of volume weighted average price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConvertibleThresholdConsecutiveTradingDays', window );">Convertible threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Floor price per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_FloorPrice', window );">Floor Price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_RegistrationEventMember', window );">Registration Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConvertibleThresholdConsecutiveTradingDays', window );">Convertible threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=abp_FirstConvertibleNoteMember', window );">First Convertible Note [Member] | Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=abp_SecondConvertibleNoteMember', window );">Second Convertible Note [Member] | Convertible Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Common stock issued upon conversion of convertible notes (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">367,491<span></span>
</td>
<td class="nump">513,981<span></span>
</td>
<td class="nump">513,981<span></span>
</td>
<td class="nump">367,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares) | shares</a></td>
<td class="nump">91,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,336<span></span>
</td>
<td class="nump">9,905<span></span>
</td>
<td class="nump">91,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Fair value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ExchangeCapEventMember', window );">Exchange Cap Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfCommonStock', window );">Percentage of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_SEPAMember', window );">SEPA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on extinguishment of accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_YAIIPNLtdMember', window );">YA II PN, Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Fair value of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 327<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfAdvanceNotice', window );">Percentage of advance notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Floor Price Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConvertibleThresholdConsecutiveTradingDays', window );">Convertible threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeNet', window );">Derivative of fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfAdvanceNotice', window );">Percentage of advance notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Floor Price Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ConvertibleThresholdConsecutiveTradingDays', window );">Convertible threshold trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Registration Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1', window );">Consecutive trading days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_StandbyEquityPurchaseAgreementLineItems', window );"><strong>Standby Equity Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_VolumeWeightedAveragePrice', window );">Volume-weighted-average price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ChangeInFairValueEmbeddedDerivativeLiability', window );">Change in fair value of embedded derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ChangeInFairValueEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value represents change in fair value of embedded derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ChangeInFairValueEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ConvertibleThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold number of specified trading days in consecutive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ConvertibleThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ExcessOfCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of excess common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ExcessOfCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_FloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor price. A payment or receipt is triggered if the market rate falls below the floor rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_FloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfAdvanceNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of advance notice.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfAdvanceNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfAmortizationPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of amortization principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfAmortizationPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfClosingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Closing Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfClosingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of Common Stock Outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of volume weighted average price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_StandbyEquityPurchaseAgreementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_StandbyEquityPurchaseAgreementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_VolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Volume weighted average price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_VolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the charge against earnings during the period for commitment fees and debt issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAverageFloorPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average floor rate on a group of price risk derivatives such as floors or collars. A payment or receipt is triggered if the market rate falls below the floor rate on the contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAverageFloorPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of the assets less the liabilities of a derivative or group of derivatives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeAmortizationOfDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion of purchase discount on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeAmortizationOfDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromPreviousAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromPreviousAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_RegistrationEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_RegistrationEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=abp_FirstConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=abp_FirstConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=abp_SecondConvertibleNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=abp_SecondConvertibleNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ExchangeCapEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_ExchangeCapEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_SEPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_SEPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_YAIIPNLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_YAIIPNLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_FloorPriceEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_FloorPriceEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Feb. 07, 2025</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
<th class="th"><div>Jan. 19, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in Shares)</a></td>
<td class="nump">110,000,000<span></span>
</td>
<td class="nump">110,000,000<span></span>
</td>
<td class="nump">81,795,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, Shares Outstanding (in Shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">961,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PerShareRedemptionsTriggerPrice', window );">Redemption trigger price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 99.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Number of exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfMarketValueAndNewlyIssuedPrice', window );">Percentage of market value and newly issued price</a></td>
<td class="nump">115.00%<span></span>
</td>
<td class="nump">115.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Fair value of common stock</a></td>
<td class="nump">$ 53.4<span></span>
</td>
<td class="nump">$ 53.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="nump">4.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Exercise price adjustment (in Dollars)</a></td>
<td class="nump">$ 10,177<span></span>
</td>
<td class="nump">$ 10,177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_DesignatedShares', window );">Designated shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common Stock convertible price</a></td>
<td class="nump">$ 0.068<span></span>
</td>
<td class="nump">$ 0.068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Number of exercise price of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfMarketValueAndNewlyIssuedPrice', window );">Percentage of market value and newly issued price</a></td>
<td class="nump">180.00%<span></span>
</td>
<td class="nump">180.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abp_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in Shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_WarrantsExercisableTerm', window );">Warrants exercisable term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights', window );">Redemption price per public warrant .</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PerShareRedemptionsTriggerPrice', window );">Redemption trigger price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abp_PrivatePlacementWarrantsMember', window );">Private Placement Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in Shares)</a></td>
<td class="nump">461,667<span></span>
</td>
<td class="nump">461,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PerShareRedemptionsTriggerPrice', window );">Redemption trigger price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">179.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abp_ExecutiveWarrantsMember', window );">Executive Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Number of exercise price of warrants</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_LegacyAbproCommonStockWarrantsMember', window );">Legacy Abpro Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,620,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant shares (in Shares)</a></td>
<td class="nump">2,034<span></span>
</td>
<td class="nump">2,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_RedemptionTriggerMember', window );">Redemption Trigger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PerShareRedemptionsTriggerPrice', window );">Redemption trigger price of per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 179.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember', window );">Series A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger', window );">Number of redemption trigger price</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember', window );">Series A Common Stock [Member] | Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger', window );">Stock price trigger for redemption of public warrants.</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_NumberOfTradingDaysForDeterminingTheSharePrice', window );">Number of trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PeriodAfterWhichTheWarrantsAreExercisable', window );">Number of trading day period</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issues price per share</a></td>
<td class="nump">$ 276<span></span>
</td>
<td class="nump">$ 276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember', window );">Series A Common Stock [Member] | Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of total equity proceeds and interest</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Legacy Abpro Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in Shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock price trigger for redemption of public warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redemption price per public warrant .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_DesignatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares in designated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_DesignatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_NumberOfTradingDaysForDeterminingTheSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of trading days for determining the share price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_NumberOfTradingDaysForDeterminingTheSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PerShareRedemptionsTriggerPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of per share in trigger price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PerShareRedemptionsTriggerPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfMarketValueAndNewlyIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of market value and newly issued price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfMarketValueAndNewlyIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PeriodAfterWhichTheWarrantsAreExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period after which the warrants are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PeriodAfterWhichTheWarrantsAreExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_WarrantsExercisableTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercisable term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_WarrantsExercisableTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-9<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abp_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abp_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abp_PrivatePlacementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abp_PrivatePlacementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abp_ExecutiveWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abp_ExecutiveWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_LegacyAbproCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_LegacyAbproCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_RedemptionTriggerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=abp_RedemptionTriggerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_SeriesACommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details) - Warrants To Purchase Common Stock Outstanding [Member]<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Warrants to Purchase Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, Shares | shares</a></td>
<td class="nump">990,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, Weighted-Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 114.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, Average Remaining Contractual Life</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abp_WarrantsToPurchaseCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abp_WarrantsToPurchaseCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Oct. 22, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfCommonStock', window );">Rate of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Granted and outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,395<span></span>
</td>
<td class="nump">369,092<span></span>
</td>
<td class="nump">329,395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,395<span></span>
</td>
<td class="nump">369,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock', window );">Fair value of common stock (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.09%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
<td class="nump">$ 1,531<span></span>
</td>
<td class="nump">$ 1,927<span></span>
</td>
<td class="nump">$ 2,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="nump">8,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant (in Dollars per share)</a></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Granted and outstanding shares</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Fair value total (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation related to unvested stock option (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized over weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted-average term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized over weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation related to unvested restricted stock (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member] | Stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation related to unvested stock option (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member] | Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abp_TwoZeroTwoFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Available for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfCommonStock', window );">Rate of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abp_TwoZeroTwoFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_PercentageOfCommonStock', window );">Rate of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abp_TwoZeroOneFourStockIncentivePlanMember', window );">2014 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Granted and outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vested term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=abp_TwoZeroOneFourStockIncentivePlanMember', window );">2014 Stock Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_PercentageOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_PercentageOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award fair value assumptions fair value of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abp_TwoZeroTwoFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abp_TwoZeroTwoFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=abp_TwoZeroOneFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=abp_TwoZeroOneFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Company&#8217;s Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract', window );"><strong>Schedule of Company&#8217;s Stock Option Activity [Absstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options, outstanding balance</a></td>
<td class="nump">329,395<span></span>
</td>
<td class="nump">369,092<span></span>
</td>
<td class="nump">222,635<span></span>
</td>
<td class="nump">329,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding</a></td>
<td class="nump">$ 51.3<span></span>
</td>
<td class="nump">$ 49.2<span></span>
</td>
<td class="nump">$ 50.28<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life, outstanding</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options, exercisable</a></td>
<td class="nump">276,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,146<span></span>
</td>
<td class="nump">276,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="nump">$ 51.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.85<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,080<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm', window );">Weighted- Average Remaining Contractual Life, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of stock options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm', window );">Weighted- Average Remaining Contractual Life, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of stock options, forfeited/expired/cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,840)<span></span>
</td>
<td class="num">(39,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, forfeited/expired/cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.39<span></span>
</td>
<td class="nump">$ 30.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm', window );">Weighted- Average Remaining Contractual Life, forfeited/expired/cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards Forfeited,Expiration, and Cancelled, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Company&#8217;s Restricted Stock Unit Activity (Details) - Restricted Stock Unit Activity [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Schedule of Company&#8217;s Restricted Stock Unit Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, granted</a></td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Vesting Period, granted</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested</a></td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, vested</a></td>
<td class="nump">$ 48.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Vesting Period, vested</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, Forfeited/Expired/Cancelled</a></td>
<td class="num">(597)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, Forfeited/Expired/Cancelled</a></td>
<td class="nump">$ 48.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Vesting Period, Forfeited/Expired/Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, outstanding</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, outstanding</a></td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining vesting period, outstanding</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Vesting Period, forfeited</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Vesting Period, granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Vesting Period, vested</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Recorded Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
<td class="nump">$ 1,531<span></span>
</td>
<td class="nump">$ 1,927<span></span>
</td>
<td class="nump">$ 2,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Recorded Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Recorded Stock-Based Compensation Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="nump">$ 1,469<span></span>
</td>
<td class="nump">$ 1,855<span></span>
</td>
<td class="nump">$ 2,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>186
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employer contributions</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 25, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Dec. 24, 2024</div></th>
<th class="th"><div>Nov. 30, 2024</div></th>
<th class="th"><div>Nov. 21, 2024</div></th>
<th class="th"><div>Nov. 20, 2024</div></th>
<th class="th"><div>Apr. 18, 2024</div></th>
<th class="th"><div>Dec. 29, 2023</div></th>
<th class="th"><div>Oct. 18, 2023</div></th>
<th class="th"><div>May 03, 2023</div></th>
<th class="th"><div>Mar. 13, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_UnpaidAmount', window );">Unpaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Executive to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,883,000<span></span>
</td>
<td class="nump">1,442,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForMergerRelatedCosts', window );">Payment in merger agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 574,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AnnualBaseFee', window );">Annual base fee</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNoteMember', window );">Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=abp_ExecutiveMember', window );">Executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalariesWagesAndOfficersCompensation', window );">Deferred wages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Advance Shares, net of issuance costs (in Shares)</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 146,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_UnpaidAmount', window );">Unpaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Accrued interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | New Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Agreement amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_UnpaidAmount', window );">Unpaid amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Executive to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,997,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember', window );">Chief Executive Officer [Member] | Separate Promissory Note Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Executive to receive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,158,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Promissory Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Parties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AnnualBaseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the annual base fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AnnualBaseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_UnpaidAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unpaid amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_UnpaidAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the reporting period for charges associated with the mergers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalariesWagesAndOfficersCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalariesWagesAndOfficersCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=abp_ExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=abp_ExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_NewConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_NewConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_SeparatePromissoryNoteAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_SeparatePromissoryNoteAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2025</div></th>
<th class="th"><div>Oct. 01, 2025</div></th>
<th class="th"><div>Jul. 01, 2025</div></th>
<th class="th"><div>Apr. 30, 2025</div></th>
<th class="th"><div>Apr. 08, 2025</div></th>
<th class="th"><div>Aug. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,672,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,727,192<span></span>
</td>
<td class="nump">646,044<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 688,000<span></span>
</td>
<td class="nump">$ 688,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_IssuanceOfSharesPercentage', window );">Percentage of issuance shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion option (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Advance Notice to YA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued shares of common stock</a></td>
<td class="nump">11,217<span></span>
</td>
<td class="nump">32,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Aggregate purchase price (in Dollars)</a></td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Roth Capital Partners [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Events [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Issued shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_IssuanceOfSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of issuance shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_IssuanceOfSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=abp_AdvanceNoticeToYAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=abp_AdvanceNoticeToYAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=abp_RothCapitalPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=abp_RothCapitalPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Consolidated Statements of Cash Flows (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Schedule of Consolidated Statements of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and restricted cash</a></td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 2,992<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 861<span></span>
</td>
<td class="nump">$ 7,462<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477220/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Depreciation on Property and Equipment Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abp_LabEquipmentMember', window );">Lab equipment [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abp_LabEquipmentMember', window );">Lab equipment [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</a></td>
<td class="text">Shorter of useful life or lease term<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abp_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abp_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stockholders, anti-dilutive</a></td>
<td class="nump">1,229,302<span></span>
</td>
<td class="nump">1,013,536<span></span>
</td>
<td class="nump">1,350,625<span></span>
</td>
<td class="nump">696,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stockholders, anti-dilutive</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">662,921<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">324,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stockholders, anti-dilutive</a></td>
<td class="nump">990,000<span></span>
</td>
<td class="nump">4,159<span></span>
</td>
<td class="nump">961,667<span></span>
</td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_StockOptionsMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stockholders, anti-dilutive</a></td>
<td class="nump">222,635<span></span>
</td>
<td class="nump">345,164<span></span>
</td>
<td class="nump">329,395<span></span>
</td>
<td class="nump">369,092<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stockholders, anti-dilutive</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,824<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_UnvestedRestrictedStockUnitsMember', window );">Unvested restricted stock units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stockholders, anti-dilutive</a></td>
<td class="nump">16,667<span></span>
</td>
<td class="nump">1,292<span></span>
</td>
<td class="nump">739<span></span>
</td>
<td class="nump">1,528<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=abp_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Balance Sheet (Details) - Abpro Holdings Inc [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Schedule of Balance Sheet [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">$ 6,045<span></span>
</td>
<td class="nump">$ 5,381<span></span>
</td>
<td class="nump">$ 5,197<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">18,577<span></span>
</td>
<td class="nump">16,191<span></span>
</td>
<td class="nump">15,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(112,768)<span></span>
</td>
<td class="num">(108,871)<span></span>
</td>
<td class="num">(97,165)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(90,801)<span></span>
</td>
<td class="num">(88,435)<span></span>
</td>
<td class="num">(79,034)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember', window );">As previously reported [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Schedule of Balance Sheet [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">2,745<span></span>
</td>
<td class="nump">2,081<span></span>
</td>
<td class="nump">1,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">15,277<span></span>
</td>
<td class="nump">12,891<span></span>
</td>
<td class="nump">11,987<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(109,468)<span></span>
</td>
<td class="num">(105,571)<span></span>
</td>
<td class="num">(93,865)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(87,501)<span></span>
</td>
<td class="num">(85,135)<span></span>
</td>
<td class="num">(75,734)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RestatementAxis=srt_RestatementAdjustmentMember', window );">Adjustment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems', window );"><strong>Schedule of Balance Sheet [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(3,300)<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
<td class="num">(3,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">$ (3,300)<span></span>
</td>
<td class="num">$ (3,300)<span></span>
</td>
<td class="num">$ (3,300)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedBalanceSheetStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 04<br> -Paragraph a<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedBalanceSheetStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=abp_AbproHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=abp_AbproHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger - Schedule of Common Stock Outstanding (Details) - Common Stock [Member] - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">1,684,510<span></span>
</td>
<td class="nump">1,684,510<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock of ACAB, net of redemptions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">7,033<span></span>
</td>
<td class="nump">7,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">ACAB Founder Shares, less of forfeitures and transfers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">126,076<span></span>
</td>
<td class="nump">126,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares issued to PIPE investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">112,247<span></span>
</td>
<td class="nump">112,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares issued to service providers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">42,762<span></span>
</td>
<td class="nump">42,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares issued in Merger to Legacy Abpro stockholders [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">1,304,107<span></span>
</td>
<td class="nump">1,304,107<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares transferred to investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">72,285<span></span>
</td>
<td class="nump">72,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">New Abpro shares issued to settle the promissory note with executive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Schedule of Common Stock Outstanding [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Total shares of common stock outstanding immediately after Merger</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_CommonStockOfACABNetOfRedemptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_CommonStockOfACABNetOfRedemptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_ACABFounderSharesLessOfForfeituresAndTransfersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_ACABFounderSharesLessOfForfeituresAndTransfersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToPIPEInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToPIPEInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesTransferredToInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesTransferredToInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,693<span></span>
</td>
<td class="nump">$ 2,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,656)<span></span>
</td>
<td class="num">(2,591)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">788<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abp_EquipmentUnderFinanceLeasesMember', window );">Equipment under finance leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 740<span></span>
</td>
<td class="nump">$ 740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=abp_EquipmentUnderFinanceLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=abp_EquipmentUnderFinanceLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued salaries and wages</a></td>
<td class="nump">$ 2,033<span></span>
</td>
<td class="nump">$ 1,549<span></span>
</td>
<td class="nump">$ 1,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,121<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AccruedLicenseFees', window );">Accrued license fees</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AccruedInterest', window );">Accrued interest</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_AccruedBODCompensation', window );">BOD compensation</a></td>
<td class="nump">285<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">1,014<span></span>
</td>
<td class="nump">865<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 8,026<span></span>
</td>
<td class="nump">$ 7,496<span></span>
</td>
<td class="nump">$ 5,381<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AccruedBODCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of BOD compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AccruedBODCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_AccruedLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of accrued license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_AccruedLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Company&#8217;s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details) - Level [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember', window );">Forward purchase agreement asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value measured Assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember', window );">SEPA put rights asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Fair value measured Assets</a></td>
<td class="nump">243<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember', window );">Embedded derivative liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Fair value measured Liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Fair Value of the Company&#8217;s Position Under the Forward Purchase Agreement (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">53.7<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Stock price [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">53.7<span></span>
</td>
<td class="nump">173.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term [Member] | Minimum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term [Member] | Maximum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility [Member] | Minimum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility [Member] | Maximum [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield [Member] | Forward Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Expected dividend yield [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember', window );">Exercise price [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">51.6<span></span>
</td>
<td class="nump">166.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=abp_NumberOfSharesMember', window );">Number of shares [Member] | Black and Scholes Model [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Fair value input assumptions</a></td>
<td class="nump">1,883<span></span>
</td>
<td class="nump">5,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_ForwardPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_ForwardPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=abp_BlackAndScholesModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=abp_BlackAndScholesModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=abp_NumberOfSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=abp_NumberOfSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember', window );">Forward purchase agreement asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Begining balance</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Initial measurement at the issuance date</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(339)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember', window );">Embedded derivative liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Begining balance</a></td>
<td class="nump">80<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Initial measurement at the issuance date</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value</a></td>
<td class="num">(773)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Ending balance</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember', window );">SEPA put rights asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Begining balance</a></td>
<td class="nump">188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueAdjustment', window );">Initial measurement at the issuance date</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1', window );">Change in fair value</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Fair value, Ending balance</a></td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionChangesInFairValueGainLoss1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionChangesInFairValueGainLoss1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_ForwardPurchaseAgreementAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_EmbeddedDerivativeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=abp_SEPAPutRightsAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_InterestBearingLiabilitiesAverageRatePaid', window );">Increase bears interest rate</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Leases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Letter of credit amount</a></td>
<td class="nump">$ 131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_LetterOfCreditExtendedPeriod', window );">Letter of credit extended period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_LetterOfCreditExtendedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Letter of credit extended period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_LetterOfCreditExtendedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_InterestBearingLiabilitiesAverageRatePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average rate paid on interest-bearing liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph b<br> -Subparagraph (4)<br> -Publisher SEC<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_InterestBearingLiabilitiesAverageRatePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Schedule of Lease Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 594<span></span>
</td>
<td class="nump">$ 594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract', window );"><strong>Finance lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">638<span></span>
</td>
<td class="nump">850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">566<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing cash flows from finance leases</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, Weighted-average remaining lease term (in years)</a></td>
<td class="text">8 months 23 days<span></span>
</td>
<td class="text">1 year 8 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases, Weighted-average remaining lease term (in years)</a></td>
<td class="text">0 years<span></span>
</td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, Weighted-average discount rate</a></td>
<td class="nump">6.66%<span></span>
</td>
<td class="nump">6.66%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases, Weighted-average discount rate</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Future Minimum Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Schedule of Future Minimum Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current maturities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(456)<span></span>
</td>
<td class="num">$ (567)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Obligations under lease liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 455<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Common Stock Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abp_LegacyAbproCommonStockWarrantsMember', window );">Legacy Abpro Common Stock Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of December 31, 2023</a></td>
<td class="nump">2,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ExpiredAtTheMerger', window );">Expired at the Merger</a></td>
<td class="num">(2,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger', window );">Common stock warrants of ACAB acquired in Merger</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of December 31, 2024</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abp_PrivateWarrantsMember', window );">Private Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ExpiredAtTheMerger', window );">Expired at the Merger</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger', window );">Common stock warrants of ACAB acquired in Merger</a></td>
<td class="nump">461,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of December 31, 2024</a></td>
<td class="nump">461,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=abp_PublicWarrantsMember', window );">Public Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Common Stock Warrant Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of December 31, 2023</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ExpiredAtTheMerger', window );">Expired at the Merger</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger', window );">Common stock warrants of ACAB acquired in Merger</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Outstanding as of December 31, 2024</a></td>
<td class="nump">500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares in common stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ExpiredAtTheMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares in expired the merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ExpiredAtTheMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abp_LegacyAbproCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abp_LegacyAbproCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abp_PrivateWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abp_PrivateWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=abp_PublicWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=abp_PublicWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract', window );"><strong>Schedule of Warrants to Purchase Common Stock Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants, Shares | shares</a></td>
<td class="nump">961,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, Weighted-Average Exercise Price | $ / shares</a></td>
<td class="nump">$ 114.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants, Weighted- Average Remaining Contractual Life</a></td>
<td class="text">4 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsNoteDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsNoteDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Company&#8217;s Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of stock options, outstanding balance</a></td>
<td class="nump">329,395<span></span>
</td>
<td class="nump">369,092<span></span>
</td>
<td class="nump">222,635<span></span>
</td>
<td class="nump">329,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-average exercise price, outstanding</a></td>
<td class="nump">$ 51.3<span></span>
</td>
<td class="nump">$ 49.2<span></span>
</td>
<td class="nump">$ 50.28<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual life, outstanding</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of stock options, exercisable</a></td>
<td class="nump">276,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180,146<span></span>
</td>
<td class="nump">276,060<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercisable</a></td>
<td class="nump">$ 51.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.85<span></span>
</td>
<td class="nump">$ 51.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual life, exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,080<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm', window );">Weighted- Average Remaining Contractual Life, granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of stock options, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm', window );">Weighted- Average Remaining Contractual Life, exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of stock options, forfeited/expired/cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(114,840)<span></span>
</td>
<td class="num">(39,698)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price, forfeited/expired/cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.39<span></span>
</td>
<td class="nump">$ 30.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm', window );">Weighted- Average Remaining Contractual Life, forfeited/expired/cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards Forfeited,Expiration, and Cancelled, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees (Details) - Stock Option Valuation [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.53%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Company&#8217;s Restricted Stock Unit Activity (Details) - Previously Reported [Member] - Restricted Stock Unit Activity [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of shares, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of shares, vested</a></td>
<td class="num">(2,386)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, vested</a></td>
<td class="nump">$ 48.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of shares, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of shares, outstanding</a></td>
<td class="nump">738<span></span>
</td>
<td class="nump">3,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value, outstanding</a></td>
<td class="nump">$ 48.9<span></span>
</td>
<td class="nump">$ 48.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted-average remaining vesting period, outstanding</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">1 year 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 286<span></span>
</td>
<td class="nump">$ 415<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
<td class="nump">$ 1,531<span></span>
</td>
<td class="nump">$ 1,927<span></span>
</td>
<td class="nump">$ 2,305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 282<span></span>
</td>
<td class="nump">$ 404<span></span>
</td>
<td class="nump">$ 1,136<span></span>
</td>
<td class="nump">$ 1,469<span></span>
</td>
<td class="nump">$ 1,855<span></span>
</td>
<td class="nump">$ 2,187<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory federal income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation allowance</a></td>
<td class="nump">$ 3,860<span></span>
</td>
<td class="nump">$ 3,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">Capitalized value</a></td>
<td class="nump">3,215<span></span>
</td>
<td class="nump">4,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDeductions', window );">Amortization deductions</a></td>
<td class="nump">2,370<span></span>
</td>
<td class="nump">1,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development costs</a></td>
<td class="nump">2,547<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 85,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Percentage of future taxable income</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_CarryforwardsTerm', window );">Carryforwards term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_FederalAndStateResearchAndDevelopmentCredits', window );">Federal and state research and development credits</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends', window );">Percentage of ownership</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=abp_PostApportionedMassachusettsMember', window );">Post-Apportioned Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 82,240<span></span>
</td>
<td class="nump">74,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_FederalAndStateResearchAndDevelopmentCredits', window );">Federal and state research and development credits</a></td>
<td class="nump">$ 1,772<span></span>
</td>
<td class="nump">$ 1,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=abp_TaxYear2037Member', window );">Tax Year 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,999<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_CarryforwardsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carryforwards term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_CarryforwardsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_FederalAndStateResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of federal and state research and development credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_FederalAndStateResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=abp_PostApportionedMassachusettsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=abp_PostApportionedMassachusettsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=abp_TaxYear2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=abp_TaxYear2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income / (Loss) Before Provision (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Schedule of Income / (Loss) Before Provision [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (7,232)<span></span>
</td>
<td class="num">$ (11,770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before Income taxes</a></td>
<td class="num">$ (7,232)<span></span>
</td>
<td class="num">$ (11,706)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems', window );"><strong>Schedule of Effective Income Tax Rate [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before tax</a></td>
<td class="num">$ (7,232)<span></span>
</td>
<td class="num">$ (11,706)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory U.S. federal tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax computed at federal statutory rate</a></td>
<td class="num">$ (1,519)<span></span>
</td>
<td class="num">$ (2,458)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal benefit and tax credits</a></td>
<td class="num">(606)<span></span>
</td>
<td class="num">(825)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit', window );">Federal research and development credit</a></td>
<td class="num">(290)<span></span>
</td>
<td class="num">(297)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="num">(98)<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">2,513<span></span>
</td>
<td class="nump">3,540<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of federal research and development credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Net Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 23,229<span></span>
</td>
<td class="nump">$ 21,135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">2,478<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,691<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research expenses</a></td>
<td class="nump">2,547<span></span>
</td>
<td class="nump">3,183<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="nump">1,823<span></span>
</td>
<td class="nump">539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">279<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">314<span></span>
</td>
<td class="nump">333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">181<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">33,387<span></span>
</td>
<td class="nump">29,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(33,274)<span></span>
</td>
<td class="num">(29,414)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_abp_DeferredTaxLiabilitiesRightofuseAsset', window );">Right-of-use asset</a></td>
<td class="num">(113)<span></span>
</td>
<td class="num">(263)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_abp_DeferredTaxLiabilitiesRightofuseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liabilities right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">abp_DeferredTaxLiabilitiesRightofuseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>abp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>701</ContextCount>
  <ElementCount>505</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>169</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Organization and Description of the Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/OrganizationandDescriptionoftheBusiness</Role>
      <ShortName>Organization and Description of the Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/Merger</Role>
      <ShortName>Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - License and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/LicenseandCollaborationAgreements</Role>
      <ShortName>License and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Commitments under Research and Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreements</Role>
      <ShortName>Commitments under Research and Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Forward Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ForwardPurchaseAgreement</Role>
      <ShortName>Forward Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.abpro.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Standby Equity Purchase Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/StandbyEquityPurchaseAgreement</Role>
      <ShortName>Standby Equity Purchase Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996000 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.abpro.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996001 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abpro.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996002 - Disclosure - Merger (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/MergerTables</Role>
      <ShortName>Merger (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abpro.com/role/Merger</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996003 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abpro.com/role/AccruedExpenses</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996004 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abpro.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996005 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abpro.com/role/StockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996006 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abpro.com/role/ShareBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>996007 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abpro.com/role/PropertyandEquipment</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996008 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abpro.com/role/Leases</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996009 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.abpro.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996010 - Disclosure - Organization and Description of the Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails</Role>
      <ShortName>Organization and Description of the Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/OrganizationandDescriptionoftheBusiness</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996011 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996012 - Disclosure - Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996013 - Disclosure - Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/MergerDetails</Role>
      <ShortName>Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/MergerTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996014 - Disclosure - Merger - Schedule of Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable</Role>
      <ShortName>Merger - Schedule of Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996015 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofAccruedExpensesTable</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996016 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996017 - Disclosure - Fair Value Measurements - Schedule of Company???s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable</Role>
      <ShortName>Fair Value Measurements - Schedule of Company???s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996018 - Disclosure - Fair Value Measurements - Schedule of Fair Value of the Company???s Position Under the Forward Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of the Company???s Position Under the Forward Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996019 - Disclosure - Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable</Role>
      <ShortName>Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996020 - Disclosure - License and Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails</Role>
      <ShortName>License and Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/LicenseandCollaborationAgreements</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996021 - Disclosure - Commitments under Research and Collaboration Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails</Role>
      <ShortName>Commitments under Research and Collaboration Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreements</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996022 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/CommitmentsandContingencies</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996023 - Disclosure - Forward Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ForwardPurchaseAgreementDetails</Role>
      <ShortName>Forward Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/ForwardPurchaseAgreement</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996024 - Disclosure - Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.abpro.com/role/NotesPayableDetails</Role>
      <ShortName>Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/NotesPayable</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>996025 - Disclosure - Standby Equity Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails</Role>
      <ShortName>Standby Equity Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/StandbyEquityPurchaseAgreement</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>996026 - Disclosure - Stockholders??? Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/StockholdersEquityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>996027 - Disclosure - Stockholders??? Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable</Role>
      <ShortName>Stockholders??? Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>996028 - Disclosure - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>996029 - Disclosure - Share-Based Compensation - Schedule of Company???s Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable</Role>
      <ShortName>Share-Based Compensation - Schedule of Company???s Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>996030 - Disclosure - Share-Based Compensation - Schedule of Company???s Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable</Role>
      <ShortName>Share-Based Compensation - Schedule of Company???s Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>996031 - Disclosure - Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable</Role>
      <ShortName>Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>996032 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>996033 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/RelatedParties</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>996034 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/SubsequentEvents</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>996035 - Disclosure - Summary of Significant Accounting Policies - Schedule of Consolidated Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Consolidated Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>996036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation on Property and Equipment Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Depreciation on Property and Equipment Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>996037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>996038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofBalanceSheetTable</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>996039 - Disclosure - Merger - Schedule of Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0</Role>
      <ShortName>Merger - Schedule of Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>996040 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/PropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/PropertyandEquipmentTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>996041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable</Role>
      <ShortName>Property and Equipment - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>996042 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofAccruedExpensesTable0</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>996043 - Disclosure - Fair Value Measurements - Schedule of Company???s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0</Role>
      <ShortName>Fair Value Measurements - Schedule of Company???s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>996044 - Disclosure - Fair Value Measurements - Schedule of Fair Value of the Company???s Position Under the Forward Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0</Role>
      <ShortName>Fair Value Measurements - Schedule of Fair Value of the Company???s Position Under the Forward Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>996045 - Disclosure - Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0</Role>
      <ShortName>Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>996046 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/LeasesTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>996047 - Disclosure - Leases - Schedule of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofLeaseExpenseTable</Role>
      <ShortName>Leases - Schedule of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>996048 - Disclosure - Leases - Schedule of Future Minimum Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable</Role>
      <ShortName>Leases - Schedule of Future Minimum Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>996049 - Disclosure - Stockholders??? Equity - Schedule of Common Stock Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable</Role>
      <ShortName>Stockholders??? Equity - Schedule of Common Stock Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>996050 - Disclosure - Stockholders??? Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0</Role>
      <ShortName>Stockholders??? Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>996051 - Disclosure - Share-Based Compensation - Schedule of Company???s Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0</Role>
      <ShortName>Share-Based Compensation - Schedule of Company???s Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>996052 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable</Role>
      <ShortName>Share-Based Compensation - Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>996053 - Disclosure - Share-Based Compensation - Schedule of Company???s Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0</Role>
      <ShortName>Share-Based Compensation - Schedule of Company???s Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>996054 - Disclosure - Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0</Role>
      <ShortName>Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>996055 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.abpro.com/role/IncomeTaxesTables</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>996056 - Disclosure - Income Taxes - Schedule of Income / (Loss) Before Provision (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable</Role>
      <ShortName>Income Taxes - Schedule of Income / (Loss) Before Provision (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>996057 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ea0266502-s1a1_abpro.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>996058 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable</Role>
      <ShortName>Income Taxes - Schedule of Net Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>abp-20250930.xsd</File>
    <File>abp-20250930_cal.xml</File>
    <File>abp-20250930_def.xml</File>
    <File>abp-20250930_lab.xml</File>
    <File>abp-20250930_pre.xml</File>
    <File doctype="S-1/A" isDefinitelyFs="true" isUsgaap="true" original="ea0266502-s1a1_abpro.htm">ea0266502-s1a1_abpro.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image_001.jpg</File>
    <File>image_002.jpg</File>
    <File>image_003.jpg</File>
    <File>image_004.jpg</File>
    <File>image_005.jpg</File>
    <File>image_006.jpg</File>
    <File>image_007.jpg</File>
    <File>image_008.jpg</File>
    <File>image_009.jpg</File>
    <File>image_010.jpg</File>
    <File>image_011.jpg</File>
    <File>image_012.jpg</File>
    <File>image_013.jpg</File>
    <File>image_014.jpg</File>
    <File>image_015.jpg</File>
    <File>image_016.jpg</File>
    <File>image_017.jpg</File>
    <File>image_018.jpg</File>
    <File>image_019.jpg</File>
    <File>image_020.jpg</File>
    <File>image_021.jpg</File>
    <File>image_022.jpg</File>
    <File>image_023.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="1852">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>215
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0266502-s1a1_abpro.htm": {
   "nsprefix": "abp",
   "nsuri": "http://www.abpro.com/20250930",
   "dts": {
    "schema": {
     "local": [
      "abp-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/sic/2025/sic-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "abp-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "abp-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "abp-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "abp-20250930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ea0266502-s1a1_abpro.htm"
     ]
    }
   },
   "keyStandard": 373,
   "keyCustom": 132,
   "axisStandard": 34,
   "axisCustom": 2,
   "memberStandard": 55,
   "memberCustom": 104,
   "hidden": {
    "total": 470,
    "http://fasb.org/us-gaap/2025": 400,
    "http://www.abpro.com/20250930": 67,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 701,
   "entityCount": 1,
   "segmentCount": 169,
   "elementCount": 862,
   "unitCount": 5,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1852,
    "http://xbrl.sec.gov/dei/2025": 10,
    "http://fasb.org/srt/2025": 3
   },
   "report": {
    "R1": {
     "role": "http://www.abpro.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "dei:AmendmentDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.abpro.com/role/ConsolidatedBalanceSheet",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:Cash",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Parentheticals)",
     "shortName": "Condensed Consolidated Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.abpro.com/role/ConsolidatedIncomeStatement",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.abpro.com/role/ShareholdersEquityType2or3",
     "longName": "004 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c150",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c150",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.abpro.com/role/ShareholdersEquityType2or3_Parentheticals",
     "longName": "005 - Statement - Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)",
     "shortName": "Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "abp:IssuanceOfCommonStockInTransactionCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "abp:IssuanceOfCommonStockInTransactionCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.abpro.com/role/ConsolidatedCashFlow",
     "longName": "006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.abpro.com/role/OrganizationandDescriptionoftheBusiness",
     "longName": "007 - Disclosure - Organization and Description of the Business",
     "shortName": "Organization and Description of the Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.abpro.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "008 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.abpro.com/role/Merger",
     "longName": "009 - Disclosure - Merger",
     "shortName": "Merger",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.abpro.com/role/AccruedExpenses",
     "longName": "010 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.abpro.com/role/FairValueMeasurements",
     "longName": "011 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.abpro.com/role/LicenseandCollaborationAgreements",
     "longName": "012 - Disclosure - License and Collaboration Agreements",
     "shortName": "License and Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreements",
     "longName": "013 - Disclosure - Commitments under Research and Collaboration Agreements",
     "shortName": "Commitments under Research and Collaboration Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.abpro.com/role/CommitmentsandContingencies",
     "longName": "014 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.abpro.com/role/ForwardPurchaseAgreement",
     "longName": "015 - Disclosure - Forward Purchase Agreement",
     "shortName": "Forward Purchase Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.abpro.com/role/NotesPayable",
     "longName": "016 - Disclosure - Notes Payable",
     "shortName": "Notes Payable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.abpro.com/role/StandbyEquityPurchaseAgreement",
     "longName": "017 - Disclosure - Standby Equity Purchase Agreement",
     "shortName": "Standby Equity Purchase Agreement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "abp:StandbyEquityPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abp:StandbyEquityPurchaseAgreementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.abpro.com/role/StockholdersEquity",
     "longName": "018 - Disclosure - Stockholders\u2019 Equity",
     "shortName": "Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.abpro.com/role/ShareBasedCompensation",
     "longName": "019 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.abpro.com/role/EmployeeBenefitPlan",
     "longName": "020 - Disclosure - Employee Benefit Plan",
     "shortName": "Employee Benefit Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.abpro.com/role/RelatedParties",
     "longName": "021 - Disclosure - Related Parties",
     "shortName": "Related Parties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.abpro.com/role/SubsequentEvents",
     "longName": "022 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.abpro.com/role/PropertyandEquipment",
     "longName": "023 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.abpro.com/role/Leases",
     "longName": "024 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.abpro.com/role/IncomeTaxes",
     "longName": "025 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.abpro.com/role/AccountingPoliciesByPolicy",
     "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.abpro.com/role/MergerTables",
     "longName": "996002 - Disclosure - Merger (Tables)",
     "shortName": "Merger (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.abpro.com/role/AccruedExpensesTables",
     "longName": "996003 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.abpro.com/role/FairValueMeasurementsTables",
     "longName": "996004 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.abpro.com/role/StockholdersEquityTables",
     "longName": "996005 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.abpro.com/role/ShareBasedCompensationTables",
     "longName": "996006 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.abpro.com/role/PropertyandEquipmentTables",
     "longName": "996007 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.abpro.com/role/LeasesTables",
     "longName": "996008 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.abpro.com/role/IncomeTaxesTables",
     "longName": "996009 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
     "longName": "996010 - Disclosure - Organization and Description of the Business (Details)",
     "shortName": "Organization and Description of the Business (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abp:ReverseStockSplitSharesOfIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "996011 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:OtherIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
     "longName": "996012 - Disclosure - Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.abpro.com/role/MergerDetails",
     "longName": "996013 - Disclosure - Merger (Details)",
     "shortName": "Merger (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c202",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c202",
      "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
     "longName": "996014 - Disclosure - Merger - Schedule of Common Stock Outstanding (Details)",
     "shortName": "Merger - Schedule of Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c118",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R42": {
     "role": "http://www.abpro.com/role/ScheduleofAccruedExpensesTable",
     "longName": "996015 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R43": {
     "role": "http://www.abpro.com/role/FairValueMeasurementsDetails",
     "longName": "996016 - Disclosure - Fair Value Measurements (Details)",
     "shortName": "Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c236",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c236",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
     "longName": "996017 - Disclosure - Fair Value Measurements - Schedule of Company\u2019s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Company\u2019s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c245",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R45": {
     "role": "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
     "longName": "996018 - Disclosure - Fair Value Measurements - Schedule of Fair Value of the Company\u2019s Position Under the Forward Purchase Agreement (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value of the Company\u2019s Position Under the Forward Purchase Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c250",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c250",
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
     "longName": "996019 - Disclosure - Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c273",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c276",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
     "longName": "996020 - Disclosure - License and Collaboration Agreements (Details)",
     "shortName": "License and Collaboration Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c282",
      "name": "abp:AgreementInitialTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c282",
      "name": "abp:AgreementInitialTerm",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
     "longName": "996021 - Disclosure - Commitments under Research and Collaboration Agreements (Details)",
     "shortName": "Commitments under Research and Collaboration Agreements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "abp:MilestonePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abp:ClinicalDevelopmentMilestones",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
     "longName": "996022 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c311",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c311",
      "name": "us-gaap:PaymentsForLegalSettlements",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
     "longName": "996023 - Disclosure - Forward Purchase Agreement (Details)",
     "shortName": "Forward Purchase Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c329",
      "name": "us-gaap:ForwardContractIndexedToIssuersEquityShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c329",
      "name": "us-gaap:ForwardContractIndexedToIssuersEquityShares",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.abpro.com/role/NotesPayableDetails",
     "longName": "996024 - Disclosure - Notes Payable (Details)",
     "shortName": "Notes Payable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c25",
      "name": "abp:AdditionalInterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
     "longName": "996025 - Disclosure - Standby Equity Purchase Agreement (Details)",
     "shortName": "Standby Equity Purchase Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c383",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "abp:StandbyEquityPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c383",
      "name": "abp:ExcessOfCommonStockPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "abp:StandbyEquityPurchaseAgreementTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.abpro.com/role/StockholdersEquityDetails",
     "longName": "996026 - Disclosure - Stockholders\u2019 Equity (Details)",
     "shortName": "Stockholders\u2019 Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c428",
      "name": "abp:PerShareRedemptionsTriggerPrice",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable",
     "longName": "996027 - Disclosure - Stockholders\u2019 Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c432",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c432",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.abpro.com/role/ShareBasedCompensationDetails",
     "longName": "996028 - Disclosure - Share-Based Compensation (Details)",
     "shortName": "Share-Based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "abp:PercentageOfCommonStock",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c0",
      "name": "abp:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock",
      "unitRef": "usdPershares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
     "longName": "996029 - Disclosure - Share-Based Compensation - Schedule of Company\u2019s Stock Option Activity (Details)",
     "shortName": "Share-Based Compensation - Schedule of Company\u2019s Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R57": {
     "role": "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
     "longName": "996030 - Disclosure - Share-Based Compensation - Schedule of Company\u2019s Restricted Stock Unit Activity (Details)",
     "shortName": "Share-Based Compensation - Schedule of Company\u2019s Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c451",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c451",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable",
     "longName": "996031 - Disclosure - Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c25",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R59": {
     "role": "http://www.abpro.com/role/EmployeeBenefitPlanDetails",
     "longName": "996032 - Disclosure - Employee Benefit Plan (Details)",
     "shortName": "Employee Benefit Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c25",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c25",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.abpro.com/role/RelatedPartiesDetails",
     "longName": "996033 - Disclosure - Related Parties (Details)",
     "shortName": "Related Parties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c685",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c685",
      "name": "us-gaap:RelatedPartyTransactionAmountsOfTransaction",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.abpro.com/role/SubsequentEventsDetails",
     "longName": "996034 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c697",
      "name": "abp:IssuanceOfSharesPercentage",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable",
     "longName": "996035 - Disclosure - Summary of Significant Accounting Policies - Schedule of Consolidated Statements of Cash Flows (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Consolidated Statements of Cash Flows (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives",
     "longName": "996036 - Disclosure - Summary of Significant Accounting Policies - Schedule of Depreciation on Property and Equipment Estimated Useful Lives (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Depreciation on Property and Equipment Estimated Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c492",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "abp:ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c492",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "abp:ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable",
     "longName": "996037 - Disclosure - Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c0",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c505",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.abpro.com/role/ScheduleofBalanceSheetTable",
     "longName": "996038 - Disclosure - Summary of Significant Accounting Policies - Schedule of Balance Sheet (Details)",
     "shortName": "Summary of Significant Accounting Policies - Schedule of Balance Sheet (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c517",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c517",
      "name": "us-gaap:AccruedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0",
     "longName": "996039 - Disclosure - Merger - Schedule of Common Stock Outstanding (Details)",
     "shortName": "Merger - Schedule of Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c118",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R67": {
     "role": "http://www.abpro.com/role/PropertyandEquipmentDetails",
     "longName": "996040 - Disclosure - Property and Equipment (Details)",
     "shortName": "Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:Depreciation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable",
     "longName": "996041 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)",
     "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0",
     "longName": "996042 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "shortName": "Accrued Expenses - Schedule of Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c1",
      "name": "us-gaap:AccruedSalariesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0",
     "longName": "996043 - Disclosure - Fair Value Measurements - Schedule of Company\u2019s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Schedule of Company\u2019s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c245",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R71": {
     "role": "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0",
     "longName": "996044 - Disclosure - Fair Value Measurements - Schedule of Fair Value of the Company\u2019s Position Under the Forward Purchase Agreement (Details)",
     "shortName": "Fair Value Measurements - Schedule of Fair Value of the Company\u2019s Position Under the Forward Purchase Agreement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c250",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c250",
      "name": "us-gaap:DerivativeLiabilityMeasurementInput",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0",
     "longName": "996045 - Disclosure - Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)",
     "shortName": "Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c273",
      "name": "us-gaap:FairValueNetAssetLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R73": {
     "role": "http://www.abpro.com/role/LeasesDetails",
     "longName": "996046 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c609",
      "name": "srt:InterestBearingLiabilitiesAverageRatePaid",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c609",
      "name": "srt:InterestBearingLiabilitiesAverageRatePaid",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.abpro.com/role/ScheduleofLeaseExpenseTable",
     "longName": "996047 - Disclosure - Leases - Schedule of Lease Expense (Details)",
     "shortName": "Leases - Schedule of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable",
     "longName": "996048 - Disclosure - Leases - Schedule of Future Minimum Payments (Details)",
     "shortName": "Leases - Schedule of Future Minimum Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable",
     "longName": "996049 - Disclosure - Stockholders\u2019 Equity - Schedule of Common Stock Warrant Activity (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Common Stock Warrant Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c651",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c651",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0",
     "longName": "996050 - Disclosure - Stockholders\u2019 Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)",
     "shortName": "Stockholders\u2019 Equity - Schedule of Warrants to Purchase Common Stock Outstanding (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R78": {
     "role": "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0",
     "longName": "996051 - Disclosure - Share-Based Compensation - Schedule of Company\u2019s Stock Option Activity (Details)",
     "shortName": "Share-Based Compensation - Schedule of Company\u2019s Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R79": {
     "role": "http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable",
     "longName": "996052 - Disclosure - Share-Based Compensation - Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees (Details)",
     "shortName": "Share-Based Compensation - Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c673",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c673",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0",
     "longName": "996053 - Disclosure - Share-Based Compensation - Schedule of Company\u2019s Restricted Stock Unit Activity (Details)",
     "shortName": "Share-Based Compensation - Schedule of Company\u2019s Restricted Stock Unit Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c676",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c676",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0",
     "longName": "996054 - Disclosure - Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Schedule of Recorded Stock-Based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c25",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R82": {
     "role": "http://www.abpro.com/role/IncomeTaxesDetails",
     "longName": "996055 - Disclosure - Income Taxes (Details)",
     "shortName": "Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable",
     "longName": "996056 - Disclosure - Income Taxes - Schedule of Income / (Loss) Before Provision (Details)",
     "shortName": "Income Taxes - Schedule of Income / (Loss) Before Provision (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable",
     "longName": "996057 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c34",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable",
     "longName": "996058 - Disclosure - Income Taxes - Schedule of Net Deferred Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Net Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c2",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0266502-s1a1_abpro.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "abp_ABCDMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ABCDMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ABCD [Member]",
        "label": "ABCDMember"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ABIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ABIMember",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ABI [Member]",
        "label": "ABIMember"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ABP201CollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ABP201CollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ABP-201 Collaboration and License Agreement [Member]",
        "label": "ABP201 Collaboration And License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ABPOneHundredZeroZeroCollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ABP-100 Collaboration and License Agreement [Member]",
        "label": "ABPOne Hundred Zero Zero Collaboration And License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ACABFounderSharesLessOfForfeituresAndTransfersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ACABFounderSharesLessOfForfeituresAndTransfersMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACAB Founder Shares, less of forfeitures and transfers [Member]",
        "label": "ACABFounder Shares Less Of Forfeitures And Transfers Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ACABLiabilitiesAssumedInTheMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ACABLiabilitiesAssumedInTheMerger",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACAB liabilities assumed in the Merger, net",
        "documentation": "The value represents ACAB liabilities assumed in the Merger.",
        "label": "ACABLiabilities Assumed In The Merger"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ACABMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ACABMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACAB [Member]",
        "label": "ACABMember"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AbMedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AbMedMember",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AbMed [Member]",
        "label": "Ab Med Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AbproBioInternationalIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AbproBioInternationalIncMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Abpro Bio International, Inc. [Member]",
        "verboseLabel": "ABI [Member]",
        "label": "Abpro Bio International Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AbproHoldingsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AbproHoldingsIncMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Abpro Holdings Inc [Member]",
        "label": "Abpro Holdings Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r45",
      "r50",
      "r1255"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r1045"
     ]
    },
    "us-gaap_AccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable [Member]",
        "label": "Accounts Payable [Member]",
        "documentation": "Obligations incurred and payable to vendors for goods and services received."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r862",
      "r929",
      "r1058",
      "r1328",
      "r1329"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "abp_AccrueInterestPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AccrueInterestPercentage",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrue interest percentage",
        "documentation": "Accrue interest percentage.",
        "label": "Accrue Interest Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AccruedBODCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AccruedBODCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable",
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors compensation",
        "verboseLabel": "BOD compensation",
        "documentation": "Represents the amount of BOD compensation.",
        "label": "Accrued BODCompensation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "verboseLabel": "Income tax payable",
        "netLabel": "Income tax payable (in Dollars)",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r93"
     ]
    },
    "abp_AccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AccruedInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable",
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "documentation": "Represents the amount of accrued interest.",
        "label": "Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable",
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0",
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total accrued expenses",
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses (in Dollars)",
        "verboseLabel": "Accrued liabilities",
        "netLabel": "Accrued amount",
        "label": "Accrued Liabilities",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value total (in Dollars)",
        "label": "Accrued Liabilities, Fair Value Disclosure",
        "documentation": "Fair value portion of accrued expenses."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r1289",
      "r1290",
      "r1300"
     ]
    },
    "abp_AccruedLicenseFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AccruedLicenseFees",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable",
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued license fees",
        "documentation": "Represents the amount of accrued license fees.",
        "label": "Accrued License Fees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable",
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued royalties",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r941"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued extension royalties",
        "label": "Accrued Royalties",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable",
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued salaries and wages",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r941"
     ]
    },
    "abp_AccruedToAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AccruedToAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued amount",
        "documentation": "The amount of accrued to related party amount.",
        "label": "Accrued To Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated Depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r160",
      "r777"
     ]
    },
    "abp_AdditionSharesOfCommonStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AdditionSharesOfCommonStock",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional shares",
        "documentation": "Number of addition shares of common stock.",
        "label": "Addition Shares Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AdditionalAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AdditionalAccruedInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional accrued interest",
        "documentation": "Amount of additional accrued interest.",
        "label": "Additional Accrued Interest"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AdditionalInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AdditionalInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional interest expense",
        "documentation": "Additional interest expense.",
        "label": "Additional Interest Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r1045",
      "r1362"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r827",
      "r1169",
      "r1170",
      "r1171",
      "r1174",
      "r1287",
      "r1367"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1217",
      "r1225"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued to related party lender",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r26",
      "r82"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AdvanceNoticeToYAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AdvanceNoticeToYAMember",
     "presentation": [
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advance Notice to YA [Member]",
        "label": "Advance Notice To YAMember"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AfterMaturityDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AfterMaturityDateMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After Maturity Date [Member]",
        "label": "After Maturity Date Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AggregateIncentiveShare": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AggregateIncentiveShare",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive shares",
        "documentation": "Number of aggregate incentive shares.",
        "label": "Aggregate Incentive Share"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price (in Dollars)",
        "documentation": "The amount of aggregate purchase price.",
        "label": "Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AgreementInitialTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AgreementInitialTerm",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement initial term",
        "documentation": "Agreement initial term.",
        "label": "Agreement Initial Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total stock-based compensation",
        "verboseLabel": "Stock compensation expense (in Dollars)",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r448",
      "r458"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r974",
      "r975",
      "r1156",
      "r1305"
     ]
    },
    "abp_AnnualBaseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AnnualBaseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual base fee",
        "documentation": "Represents the annual base fee",
        "label": "Annual Base Fee"
       }
      }
     },
     "auth_ref": []
    },
    "abp_AnnualSalesMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "AnnualSalesMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual sales milestone payments",
        "documentation": "Annual sales milestone payments.",
        "label": "Annual Sales Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dilutive shares",
        "verboseLabel": "Common stockholders, anti-dilutive",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Diluted Net Loss Per Share [Line Items]",
        "terseLabel": "Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total consideration (in Dollars)",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r1025",
      "r1277",
      "r1278",
      "r1279"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r104",
      "r162",
      "r196",
      "r200",
      "r201",
      "r241",
      "r250",
      "r265",
      "r266",
      "r277",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r576",
      "r581",
      "r694",
      "r758",
      "r759",
      "r764",
      "r867",
      "r960",
      "r961",
      "r976",
      "r1045",
      "r1052",
      "r1053",
      "r1065",
      "r1211",
      "r1212",
      "r1313"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r168",
      "r196",
      "r200",
      "r201",
      "r277",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r576",
      "r581",
      "r694",
      "r1045",
      "r1211",
      "r1212",
      "r1313"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measured assets",
        "verboseLabel": "Fair value measured Assets",
        "netLabel": "Asset fair value",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r1035"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1159"
     ]
    },
    "abp_BlackAndScholesModelMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "BlackAndScholesModelMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black and Scholes Model [Member]",
        "label": "Black And Scholes Model Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "verboseLabel": "Board of Directors Chairman [Member]",
        "label": "Board of Directors Chairman [Member]",
        "documentation": "Leader of board of directors."
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r810",
      "r985",
      "r986",
      "r1272",
      "r1275",
      "r1276"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r810",
      "r985",
      "r986",
      "r1272",
      "r1275",
      "r1276"
     ]
    },
    "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transaction cost",
        "verboseLabel": "Transaction costs (in Dollars)",
        "label": "Business Combination, Transaction Cost, Excluding Separately Recognized Transaction",
        "documentation": "Amount of transaction cost incurred to effect business combination. Excludes separately recognized transaction and indirect cost."
       }
      }
     },
     "auth_ref": [
      "r1274"
     ]
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of total equity proceeds and interest",
        "label": "Business Combination, Achieved in Stages, Preacquisition Equity Interest in Acquiree, Percentage",
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination."
       }
      }
     },
     "auth_ref": [
      "r991",
      "r992",
      "r993",
      "r997",
      "r1272",
      "r1273"
     ]
    },
    "abp_BusinessDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "BusinessDays",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business days",
        "documentation": "Business days.",
        "label": "Business Days"
       }
      }
     },
     "auth_ref": []
    },
    "abp_CROVendorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CROVendorMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CRO Vendor [Member]",
        "label": "CROVendor Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalUnitsTotalCostToInvestors": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalUnitsTotalCostToInvestors",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investors",
        "label": "Capital Units, Cost to Investors",
        "documentation": "Cost to investors of each class of capital shares or other capital units."
       }
      }
     },
     "auth_ref": []
    },
    "abp_CarryforwardsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CarryforwardsTerm",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carryforwards term",
        "documentation": "Carryforwards term.",
        "label": "Carryforwards Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "verboseLabel": "Cash (in Dollars)",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r768",
      "r839",
      "r860",
      "r1045",
      "r1052",
      "r1053",
      "r1065",
      "r1095"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "As reported within the unaudited condensed consolidated balance sheets:",
        "verboseLabel": "As reported within consolidated balance sheets:",
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r158",
      "r939"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r89"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and restricted cash - beginning of period",
        "periodEndLabel": "Cash and restricted cash - end of period",
        "totalLabel": "Total cash and restricted cash",
        "terseLabel": "Total cash and restricted cash as presented in the balance sheet",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r69",
      "r193"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r69"
     ]
    },
    "abp_CashTransferredToEscrow": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CashTransferredToEscrow",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cash transferred into escrow pursuant to Forward Purchase Agreement",
        "documentation": "The value represents to cash transferred into escrow pursuant to forward purchase agreement.",
        "label": "Cash Transferred To Escrow"
       }
      }
     },
     "auth_ref": []
    },
    "abp_CelltrionCollaborationAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CelltrionCollaborationAndLicenseAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Celltrion Collaboration and License Agreement [Member]",
        "label": "Celltrion Collaboration And License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_CelltrionIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CelltrionIncMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Celltrion, Inc. [Member]",
        "label": "Celltrion Inc Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ChangeInFairValueEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ChangeInFairValueEmbeddedDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of embedded derivative liability",
        "documentation": "The value represents change in fair value of embedded derivative liability.",
        "label": "Change In Fair Value Embedded Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ChangeInFairValueOfEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ChangeInFairValueOfEmbeddedDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of embedded derivative liability",
        "documentation": "The value represents change in fair value of embedded derivative liability.",
        "label": "Change In Fair Value Of Embedded Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ChangeInFairValueOfForwardPuchaseAgreementAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ChangeInFairValueOfForwardPuchaseAgreementAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of forward purchase agreement asset",
        "documentation": "The value represents of change in fair value of forward purchase agreement asset.",
        "label": "Change In Fair Value Of Forward Puchase Agreement Asset"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ChangeInFairValueOfForwardPurchaseAgreementAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ChangeInFairValueOfForwardPurchaseAgreementAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of forward purchase agreement asset",
        "documentation": "The value of change in fair value of forward purchase agreement asset.",
        "label": "Change In Fair Value Of Forward Purchase Agreement Asset"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ChangeInFairValueOfSEPAPutRightAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ChangeInFairValueOfSEPAPutRightAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of SEPA put rights asset",
        "documentation": "The value represents change in fair value of SEPA put rights asset.",
        "label": "Change In Fair Value Of SEPAPut Right Asset"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ChangeInFairValueOfSEPAPutRightsAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ChangeInFairValueOfSEPAPutRightsAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of SEPA put rights asset",
        "documentation": "The value represents change in fair value of SEPA put rights asset.",
        "label": "Change In Fair Value Of SEPAPut Rights Asset"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ChangeInFairValueOnEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ChangeInFairValueOnEmbeddedDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in fair value of embedded derivative liability",
        "documentation": "The value represents change in fair value of embedded derivative liability.",
        "label": "Change In Fair Value On Embedded Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer [Member]",
        "label": "Chief Executive Officer",
        "documentation": "Person with designation of chief executive officer."
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/ShareholdersEquityType2or3",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r164",
      "r165",
      "r166",
      "r196",
      "r201",
      "r233",
      "r234",
      "r235",
      "r237",
      "r243",
      "r244",
      "r277",
      "r315",
      "r317",
      "r318",
      "r319",
      "r322",
      "r323",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r365",
      "r367",
      "r368",
      "r371",
      "r374",
      "r381",
      "r694",
      "r816",
      "r817",
      "r818",
      "r819",
      "r827",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r840",
      "r852",
      "r875",
      "r898",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r1068",
      "r1162",
      "r1164",
      "r1175"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r165",
      "r166",
      "r243",
      "r359",
      "r367",
      "r368",
      "r369",
      "r371",
      "r374",
      "r379",
      "r381",
      "r638",
      "r816",
      "r817",
      "r818",
      "r819",
      "r977",
      "r1068",
      "r1160",
      "r1162"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration date",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable",
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Weighted-Average Exercise Price",
        "verboseLabel": "Exercise price per share (in Dollars per share)",
        "netLabel": "Warrants exercisable, price per share (in Dollars per share)",
        "label": "Number of exercise price of warrants",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r204",
      "r382"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable",
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants to Purchase Common Stock Outstanding [Line Items]",
        "terseLabel": "Schedule of Common Stock Warrant Activity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares of warrant",
        "verboseLabel": "Warrants issued (in Shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable",
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding as of December 31, 2023",
        "periodEndLabel": "Outstanding as of December 31, 2024",
        "terseLabel": "Warrants, Shares",
        "verboseLabel": "Warrants exercisable (in Shares)",
        "netLabel": "Number of warrant shares (in Shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "abp_ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ClassOfWarrantOrRightRedemptionOfWarrantsOrRightsStockPriceTrigger",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price trigger for redemption of public warrants.",
        "documentation": "Stock price trigger for redemption of public warrants.",
        "label": "Class Of Warrant Or Right Redemption Of Warrants Or Rights Stock Price Trigger"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ClassOfWarrantOrRightRedemptionPriceOfWarrantsOrRights",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price per public warrant .",
        "documentation": "Redemption price per public warrant .",
        "label": "Class Of Warrant Or Right Redemption Price Of Warrants Or Rights"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable",
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "abp_ClinicalDevelopmentMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ClinicalDevelopmentMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical development milestones.",
        "documentation": "Represent the clinical development milestones.",
        "label": "Clinical Development Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "abp_CollaborationRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CollaborationRevenueMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration revenue",
        "label": "Collaboration Revenue Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Collaboration Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r572",
      "r573"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of the Business [Line Items]",
        "terseLabel": "License and Collaboration Agreements [Line Items]",
        "verboseLabel": "Commitments under Research and Collaboration Agreements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_CollateralizedAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollateralizedAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Collaboration Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_CommercialSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CommercialSales",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial sales",
        "documentation": "Represent the commercial sales.",
        "label": "Commercial Sales"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 8)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r97",
      "r767",
      "r851"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r307",
      "r308",
      "r930",
      "r1202",
      "r1207"
     ]
    },
    "us-gaap_CommitmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments under Research and Collaboration Agreements",
        "label": "Commitments Disclosure [Text Block]",
        "documentation": "The entire disclosure for significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements. Descriptions may include identification of the specific goods and services, period of time covered, minimum quantities and amounts, and cancellation rights."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "abp_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_CommitmentsunderResearchandCollaborationAgreementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CommitmentsunderResearchandCollaborationAgreementsDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments under Research and Collaboration Agreements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConvertibleConversionPriceIncrease",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock convertible price",
        "label": "Common Stock, Convertible, Conversion Price, Increase",
        "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r382"
     ]
    },
    "abp_CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CommonStockIssuedInSettlementOfConvertibleNotesAndEmbeddedDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued in settlement of convertible notes and embedded derivative liability",
        "documentation": "It represents common stock issued in settlement of convertible notes and embedded derivative liability.",
        "label": "Common Stock Issued In Settlement Of Convertible Notes And Embedded Derivative Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/ShareholdersEquityType2or3",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock [Member]",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056",
      "r1057",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1169",
      "r1170",
      "r1174",
      "r1287",
      "r1360",
      "r1367"
     ]
    },
    "abp_CommonStockOfACABNetOfRedemptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CommonStockOfACABNetOfRedemptionsMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock of ACAB, net of redemptions [Member]",
        "label": "Common Stock Of ACABNet Of Redemptions Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in Dollars per share)",
        "verboseLabel": "Common stock par value (in Dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock, shares authorized (in Shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r852"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "verboseLabel": "Common stock shares issued (in Shares)",
        "netLabel": "Issued shares of common stock",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Total shares of common stock outstanding immediately after Merger",
        "netLabel": "Common stock shares outstanding (in Shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r55",
      "r852",
      "r873",
      "r1367",
      "r1368"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, value",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r358",
      "r364",
      "r770",
      "r1045"
     ]
    },
    "abp_CommonStockWarrantsOfLegacyACABAcquiredInMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "CommonStockWarrantsOfLegacyACABAcquiredInMerger",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock warrants of ACAB acquired in Merger",
        "documentation": "The number of shares in common stock warrants.",
        "label": "Common Stock Warrants Of Legacy ACABAcquired In Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.abpro.com/role/EmployeeBenefitPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plan",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r1221",
      "r1222",
      "r1223",
      "r1224"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer hardware and software [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedBalanceSheetStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedBalanceSheetStatementTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Balance Sheet Statement [Table]",
        "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r197",
      "r208",
      "r761",
      "r1073"
     ]
    },
    "srt_CondensedBalanceSheetStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CondensedBalanceSheetStatementsCaptionsLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Balance Sheet [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r197",
      "r208",
      "r761",
      "r1073"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "documentation": "Information by consolidated entity or group of entities."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r130",
      "r197",
      "r208",
      "r576",
      "r577",
      "r580",
      "r581",
      "r582",
      "r740",
      "r761",
      "r931",
      "r1090",
      "r1091",
      "r1092",
      "r1210",
      "r1213",
      "r1214"
     ]
    },
    "abp_ContingentEarnoutPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ContingentEarnoutPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Earnout Shares",
        "documentation": "Contingent Earnout.",
        "label": "Contingent Earnout Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ContingentEarnoutSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ContingentEarnoutSharesMember",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Earnout Shares [Member]",
        "label": "Contingent Earnout Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractTerminationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractTerminationMember",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early Termination [Member]",
        "verboseLabel": "Contract Termination [Member]",
        "label": "Contract Termination [Member]",
        "documentation": "Termination of a contract associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": [
      "r946",
      "r967",
      "r968",
      "r969",
      "r970"
     ]
    },
    "abp_ConversionOfConsiderationUnderPromissoryNoteAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConversionOfConsiderationUnderPromissoryNoteAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of consideration under promissory note agreement",
        "documentation": "Conversion of consideration under promissory note agreement.",
        "label": "Conversion Of Consideration Under Promissory Note Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConversionOfNotesPayablerelatedPartiesIntoCommonStockOfNewAbpro",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of notes payable-related parties into common stock of New Abpro",
        "documentation": "The value represents conversion of notes payable-related parties into common stock.",
        "label": "Conversion Of Notes Payablerelated Parties Into Common Stock Of New Abpro"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConversionOfPremergerPreferredStockOfAbproIntoCommonStockOfNewAbpro",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of pre-merger preferred stock of Abpro into common stock of New Abpro",
        "documentation": "The value represents conversion of pre-merger preferred stock of abpro into common stock of new abpro.",
        "label": "Conversion Of Premerger Preferred Stock Of Abpro Into Common Stock Of New Abpro"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion option (in Dollars)",
        "label": "Conversion of Stock, Amount Converted",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock issued for services",
        "label": "Conversion of Stock, Amount Issued",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, converted (in Shares)",
        "verboseLabel": "Converted shares of common stock",
        "netLabel": "Shares of common stock",
        "label": "Conversion of Stock, Shares Converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesIssued1",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued upon conversion of promissory note (in Shares)",
        "label": "Conversion of Stock, Shares Issued",
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible promissory note",
        "label": "Convertible Debt",
        "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r96",
      "r1325"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Note [Member]",
        "label": "Convertible Debt [Member]",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r325",
      "r326",
      "r336",
      "r337",
      "r338",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975"
     ]
    },
    "abp_ConvertibleNoteDiscountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConvertibleNoteDiscountMember",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Note Discount [Member]",
        "label": "Convertible Note Discount Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConvertibleNotes",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible notes",
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle, if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConvertibleNotesMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes [Member]",
        "label": "Convertible Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleNotesPayableMember",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Notes Payable [Member]",
        "verboseLabel": "Convertible Note [Member]",
        "label": "Convertible Notes Payable [Member]",
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r92"
     ]
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock [Member]",
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r367",
      "r368",
      "r371",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "abp_ConvertiblePreferredStockPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConvertiblePreferredStockPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "documentation": "Convertible Preferred Stock.",
        "label": "Convertible Preferred Stock Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ConvertiblePreferredStocksMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConvertiblePreferredStocksMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock",
        "label": "Convertible Preferred Stocks Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Promissory Note [Member]",
        "label": "Convertible Promissory Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ConvertibleThresholdConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ConvertibleThresholdConsecutiveTradingDays",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible threshold trading days",
        "documentation": "Threshold number of specified trading days in consecutive.",
        "label": "Convertible Threshold Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted in common shares",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r21"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes Payable",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r196",
      "r199",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r313",
      "r314",
      "r324",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r340",
      "r347",
      "r348",
      "r350",
      "r638",
      "r706"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r44",
      "r45",
      "r92",
      "r96",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r1043",
      "r1160",
      "r1161",
      "r1163",
      "r1168",
      "r1203",
      "r1204",
      "r1205",
      "r1304",
      "r1306",
      "r1323"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed price reset (in Dollars per share)",
        "verboseLabel": "Conversion price (in Dollars per share)",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "documentation": "The price per share of the conversion feature embedded in the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r327"
     ]
    },
    "us-gaap_DebtInstrumentConvertibleStockPriceTrigger": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleStockPriceTrigger",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of redemption trigger price",
        "label": "Debt Instrument, Convertible, Stock Price Trigger",
        "documentation": "Price of the entity's common stock which would be required to be attained for the conversion feature embedded in the debt instrument to become effective."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading days",
        "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days",
        "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount to be received under promissory note agreement",
        "verboseLabel": "Principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r706",
      "r707",
      "r972",
      "r973",
      "r1043"
     ]
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest",
        "label": "Debt Instrument, Increase, Accrued Interest",
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period."
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1163"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest accrued on promissory note",
        "verboseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate During Period",
        "documentation": "The average effective interest rate during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r343",
      "r1304"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original issuance discount rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r351",
      "r706",
      "r707",
      "r1043"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance discount",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r326"
     ]
    },
    "abp_DebtInstrumentInterestRateTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DebtInstrumentInterestRateTermAxis",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Interest Rate Term [Axis]",
        "label": "Debt Instrument Interest Rate Term Axis"
       }
      }
     },
     "auth_ref": []
    },
    "abp_DebtInstrumentInterestRateTermDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DebtInstrumentInterestRateTermDomainDomain",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DebtInstrumentInterestRateTermDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentIssuedPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentIssuedPrincipal",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "verboseLabel": "Principal amount of promissory notes",
        "label": "Debt Instrument, Issued, Principal",
        "documentation": "Amount of principal of debt issued."
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r349",
      "r638",
      "r761",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r1043",
      "r1160",
      "r1161",
      "r1163",
      "r1168",
      "r1304",
      "r1306"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "verboseLabel": "Debt instrument, repayment date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r971",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r331",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r1043",
      "r1160",
      "r1161",
      "r1163",
      "r1168",
      "r1203",
      "r1204",
      "r1205",
      "r1304",
      "r1306",
      "r1323"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weekly installments",
        "label": "Debt Instrument, Periodic Payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r40"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Periodic Payment, Principal",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares redeemed percentage",
        "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentRepaidPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRepaidPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument repaid upon cancellation of agreement.",
        "label": "Debt Instrument, Repaid, Principal",
        "documentation": "Amount of principal of debt repaid."
       }
      }
     },
     "auth_ref": [
      "r819"
     ]
    },
    "us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtRelatedCommitmentFeesAndDebtIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment fee",
        "label": "Debt Related Commitment Fees and Debt Issuance Costs",
        "documentation": "Represents the charge against earnings during the period for commitment fees and debt issuance expenses."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "abp_DeemedDividendResultingFromTheWarrantDownRound": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DeemedDividendResultingFromTheWarrantDownRound",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deemed dividend resulting from the warrant down round",
        "documentation": "Deemed dividend resulting from the warrant down round.",
        "label": "Deemed Dividend Resulting From The Warrant Down Round"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredChargesPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Offering Costs",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges."
       }
      }
     },
     "auth_ref": [
      "r161"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs",
        "verboseLabel": "Deferred offering cost",
        "label": "Deferred Offering Costs",
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1192"
     ]
    },
    "abp_DeferredOfferingCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DeferredOfferingCostsIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred offering costs included in accounts payable",
        "documentation": "Represent the amount of deferred offering costs included in accounts payable.",
        "label": "Deferred Offering Costs Included In Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGrossAbstract",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails",
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research expenses",
        "verboseLabel": "Capitalized research and development costs",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "abp_DeferredTaxAssetsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DeferredTaxAssetsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset lease liability.",
        "label": "Deferred Tax Assets Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred income taxes",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized value",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs."
       }
      }
     },
     "auth_ref": [
      "r1265"
     ]
    },
    "abp_DeferredTaxLiabilitiesRightofuseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DeferredTaxLiabilitiesRightofuseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right-of-use asset",
        "documentation": "Amount of deferred tax liabilities right-of-use asset.",
        "label": "Deferred Tax Liabilities Rightofuse Asset"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/EmployeeBenefitPlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employer contributions",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r403"
     ]
    },
    "us-gaap_DemandDepositAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DemandDepositAccounts",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Demand for payment amount",
        "label": "Demand Deposit Accounts",
        "documentation": "The amount of money in accounts that may bear interest and that the depositor is entitled to withdraw at any time without prior notice."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/PropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r24",
      "r182",
      "r945",
      "r947",
      "r949",
      "r951"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r24"
     ]
    },
    "us-gaap_DerivativeAverageFloorPrice": {
     "xbrltype": "perUnitItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeAverageFloorPrice",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floor price was adjusted (in Dollars per Item)",
        "label": "Derivative, Average Floor Price",
        "documentation": "The average floor rate on a group of price risk derivatives such as floors or collars. A payment or receipt is triggered if the market rate falls below the floor rate on the contract."
       }
      }
     },
     "auth_ref": []
    },
    "abp_DerivativeChangeInFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DerivativeChangeInFairValue",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative change in fair value",
        "documentation": "Derivative change in fair value.",
        "label": "Derivative Change In Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r841",
      "r843",
      "r857",
      "r858",
      "r859",
      "r863",
      "r864",
      "r865",
      "r866",
      "r868",
      "r869",
      "r870",
      "r871",
      "r886",
      "r887",
      "r888",
      "r889",
      "r892",
      "r893",
      "r894",
      "r895",
      "r910",
      "r911",
      "r912",
      "r913",
      "r942",
      "r943",
      "r944",
      "r1030",
      "r1031",
      "r1055",
      "r1057",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1301",
      "r1302"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFairValueOfDerivativeNet",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative feature estimated amount",
        "verboseLabel": "Derivative of fair value",
        "label": "Derivative, Fair Value, Net",
        "documentation": "Fair value of the assets less the liabilities of a derivative or group of derivatives."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_DerivativeFixedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFixedInterestRate",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Derivative, Fixed Interest Rate",
        "documentation": "Fixed interest rate related to the interest rate derivative."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r841",
      "r843",
      "r857",
      "r858",
      "r859",
      "r863",
      "r864",
      "r865",
      "r866",
      "r868",
      "r869",
      "r870",
      "r871",
      "r886",
      "r887",
      "r888",
      "r889",
      "r892",
      "r893",
      "r894",
      "r895",
      "r910",
      "r911",
      "r912",
      "r913",
      "r942",
      "r943",
      "r944",
      "r1030",
      "r1031",
      "r1055",
      "r1057",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1294",
      "r1295",
      "r1296",
      "r1297",
      "r1298",
      "r1299",
      "r1301",
      "r1302"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Forward Purchase Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Purchase Agreement",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r641",
      "r656",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034"
     ]
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilityMeasurementInput",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value input assumptions",
        "label": "Derivative Liability, Measurement Input",
        "documentation": "Value of input used to measure derivative liability."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of the Company\u2019s Position Under the Forward Purchase Agreement [Line Items]",
        "terseLabel": "Schedule of Fair Value of the Company's Position Under the Forward Purchase Agreement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r597",
      "r598",
      "r599",
      "r600",
      "r1031"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Financial Instruments",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r207",
      "r228",
      "r583",
      "r619",
      "r634",
      "r635",
      "r636",
      "r637",
      "r639",
      "r640"
     ]
    },
    "abp_DesignatedShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DesignatedShares",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated shares (in Shares)",
        "documentation": "The number of shares in designated.",
        "label": "Designated Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abp_DevelopmentMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DevelopmentMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development milestones",
        "documentation": "Development milestones.",
        "label": "Development Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Director [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1183",
      "r1361"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r409",
      "r440",
      "r441",
      "r443",
      "r988"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureTextBlockSupplementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_DocumentAndEntityInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "DocumentAndEntityInformationAbstract",
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal [Member]",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r469"
     ]
    },
    "abp_EarlyTerminationResetPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "EarlyTerminationResetPricePerShare",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early termination reset price per share (in Dollars per share)",
        "documentation": "Early termination reset price per share.",
        "label": "Early Termination Reset Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r176",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r225",
      "r230",
      "r233",
      "r235",
      "r236",
      "r237",
      "r240",
      "r356",
      "r446",
      "r509",
      "r571",
      "r667",
      "r668",
      "r757",
      "r782",
      "r953"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share, diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r176",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r225",
      "r233",
      "r235",
      "r236",
      "r237",
      "r240",
      "r356",
      "r446",
      "r509",
      "r571",
      "r667",
      "r668",
      "r757",
      "r782",
      "r953"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r239"
     ]
    },
    "abp_EarnoutShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "EarnoutShare",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnout shares (in Dollars per share)",
        "documentation": "Earnout share.",
        "label": "Earnout Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/IncomeTaxesDetails",
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statutory U.S. federal tax rate",
        "verboseLabel": "New U.S. federal excise tax percentage",
        "netLabel": "U.S. statutory federal income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r203",
      "r469",
      "r495",
      "r990"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsEmployeeStockOwnershipPlanDividends",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of ownership",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Employee Stock Ownership Plan Dividend, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deduction for dividend paid to employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1167",
      "r1257",
      "r1258"
     ]
    },
    "abp_EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "EffectiveIncomeTaxRateReconciliationFederalResearchAndDevelopmentCredit",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal research and development credit",
        "documentation": "The amount of federal research and development credit.",
        "label": "Effective Income Tax Rate Reconciliation Federal Research And Development Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Effective Income Tax Rate [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r990"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future taxable income",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1160",
      "r1167",
      "r1257",
      "r1258"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized income tax percentage",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Percent",
        "documentation": "Percentage of reported income tax benefit (expense) from difference to income tax expense (benefit) computed by applying statutory federal (national) income tax rate to pretax income (loss) from continuing operation, attributable to other reconciling items. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1258"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation [Table]",
        "documentation": "Disclosure of information about income tax rate reconciliation between amount of reported income tax expense (benefit) attributable to continuing operation to amount of income tax expense(benefit) that would result from applying statutory federal (national) tax rate to pretax income (loss) from continuing operation."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470",
      "r990"
     ]
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Embedded derivative liability",
        "label": "Embedded Derivative, Fair Value of Embedded Derivative Liability",
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability."
       }
      }
     },
     "auth_ref": [
      "r1280",
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "abp_EmbeddedDerivativeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "EmbeddedDerivativeLiabilityMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Embedded derivative liability [Member]",
        "verboseLabel": "Embedded Derivative Liability [Member]",
        "label": "Embedded Derivative Liability Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_EmergingGrowthCompanyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "EmergingGrowthCompanyPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Emerging Growth Company",
        "documentation": "Emerging growth company .",
        "label": "Emerging Growth Company Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Recorded Stock-Based Compensation Expense [Line Items]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1253"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recognized over weighted-average period",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation related to unvested restricted stock (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r1254"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation related to unvested stock option (in Dollars)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1254"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option [Member]",
        "verboseLabel": "Share-Based Payment Arrangement, Option [Member]",
        "netLabel": "Stock option [Member]",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Ex Transition Period",
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r1067"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.abpro.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "abp_EquipmentUnderFinanceLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "EquipmentUnderFinanceLeasesMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment under finance leases [Member]",
        "label": "Equipment Under Finance Leases Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/ShareholdersEquityType2or3",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r140",
      "r147",
      "r148",
      "r172",
      "r173",
      "r174",
      "r209",
      "r210",
      "r211",
      "r214",
      "r223",
      "r226",
      "r228",
      "r242",
      "r278",
      "r281",
      "r293",
      "r355",
      "r383",
      "r446",
      "r490",
      "r491",
      "r505",
      "r506",
      "r507",
      "r510",
      "r570",
      "r571",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r666",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r708",
      "r711",
      "r731",
      "r781",
      "r798",
      "r799",
      "r800",
      "r827",
      "r898"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r501",
      "r694",
      "r1070",
      "r1071",
      "r1072",
      "r1266",
      "r1267",
      "r1268",
      "r1269"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r694"
     ]
    },
    "abp_EstimatedFuturePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "EstimatedFuturePricePerShare",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated future price",
        "documentation": "Estimated future price per share.",
        "label": "Estimated Future Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ExcessOfCommonStockPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ExcessOfCommonStockPercentage",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of excess of common stock",
        "documentation": "Percentage of excess common stock.",
        "label": "Excess Of Common Stock Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ExcessTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ExcessTaxes",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess taxes",
        "documentation": "Excess taxes.",
        "label": "Excess Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ExchangeCapEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ExchangeCapEventMember",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Cap Event [Member]",
        "label": "Exchange Cap Event Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExciseAndSalesTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExciseAndSalesTaxes",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excise taxes",
        "label": "Excise and Sales Taxes",
        "documentation": "The amount of excise and sales taxes included in sales and revenues, which are then deducted as a cost of sales. Includes excise taxes, which are applied to specific types of transactions or items (such as gasoline or alcohol); and sales, use and value added taxes, which are applied to a broad class of revenue-producing transactions involving a wide range of goods and services."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "abp_ExciseTaxGenerallyOfTheFairMarketValuePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ExciseTaxGenerallyOfTheFairMarketValuePercentage",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excise tax generally of the fair market value percentage",
        "documentation": "Excise tax generally of the fair market value percentage.",
        "label": "Excise Tax Generally Of The Fair Market Value Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ExciseTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ExciseTaxLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excise tax liability",
        "documentation": "Excise tax liability.",
        "label": "Excise Tax Liability"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ExecutiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ExecutiveMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive [Member]",
        "label": "Executive Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive [Member]",
        "verboseLabel": "Executive Officer [Member]",
        "label": "Executive Officer [Member]",
        "documentation": "Person with designation of executive officer."
       }
      }
     },
     "auth_ref": [
      "r1183"
     ]
    },
    "abp_ExecutiveWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ExecutiveWarrantsMember",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Warrants [Member]",
        "label": "Executive Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ExpiredAtTheMerger": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ExpiredAtTheMerger",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired at the Merger",
        "documentation": "The number of shares in expired the merger.",
        "label": "Expired At The Merger"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ExtinguishmentOfDebtAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExtinguishmentOfDebtAxis",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt [Axis]",
        "documentation": "Information by type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_ExtinguishmentOfDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExtinguishmentOfDebtTypeDomain",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extinguishment of Debt, Type [Domain]",
        "documentation": "Type of debt extinguished."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r671",
      "r684",
      "r1035"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis [Line Items]",
        "terseLabel": "Fair Value Measurements [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r992",
      "r995",
      "r1038"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r992",
      "r995",
      "r1038"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of the Company\u2019s Position Under the Forward Purchase Agreement",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r1038"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r685",
      "r936",
      "r1036",
      "r1042"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r669",
      "r671",
      "r672",
      "r673",
      "r674",
      "r683",
      "r684",
      "r686",
      "r693",
      "r744",
      "r745",
      "r746",
      "r936",
      "r972",
      "r973",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1035",
      "r1038",
      "r1042"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r679",
      "r681",
      "r682",
      "r683",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r756",
      "r1035",
      "r1039"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "verboseLabel": "Level [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r400",
      "r401",
      "r671",
      "r672",
      "r673",
      "r674",
      "r684",
      "r693",
      "r746",
      "r936",
      "r972",
      "r973",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r1035",
      "r1038",
      "r1042"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements and Fair Value of Financial Instruments",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "abp_FairValueMeasurementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FairValueMeasurementsDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FairValueMeasurementsScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements - Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueNetAssetLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetAssetLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, Begining balance",
        "periodEndLabel": "Fair value, Ending balance",
        "label": "Fair Value, Net Asset (Liability)",
        "documentation": "Fair value of asset after deduction of liability."
       }
      }
     },
     "auth_ref": [
      "r1289",
      "r1290"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "documentation": "Disclosure of information about financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r685"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Assets and Liabilities that are Measured at Fair Value on a Recurring Basis",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r675",
      "r680",
      "r685"
     ]
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Settlement",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements",
        "documentation": "Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r678",
      "r685"
     ]
    },
    "us-gaap_FairValueOptionChangesInFairValueGainLoss1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOptionChangesInFairValueGainLoss1",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "negatedLabel": "Change in fair value",
        "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)",
        "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings."
       }
      }
     },
     "auth_ref": [
      "r695",
      "r696",
      "r936",
      "r1042"
     ]
    },
    "us-gaap_FeaturesOfConvertiblePreferredStockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FeaturesOfConvertiblePreferredStockAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, $0.001 par value, issuable in series:",
        "label": "Features of Convertible Preferred Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_FederalAndStateResearchAndDevelopmentCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FederalAndStateResearchAndDevelopmentCredits",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal and state research and development credits",
        "documentation": "The amount of federal and state research and development credits.",
        "label": "Federal And State Research And Development Credits"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest on lease liabilities",
        "label": "Finance Lease, Interest Expense",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r719",
      "r1044"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing cash flows from finance leases",
        "label": "Finance Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r713",
      "r724"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease liability, current",
        "label": "Finance Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repayment of finance lease liabilities",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r715",
      "r721"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of ROU assets",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r714",
      "r719",
      "r1044"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases, Weighted-average discount rate",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r1044"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance leases, Weighted-average remaining lease term (in years)",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r1044"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r753",
      "r754",
      "r810",
      "r934",
      "r938",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r289",
      "r290",
      "r291",
      "r810",
      "r934",
      "r938",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024"
     ]
    },
    "abp_FirstConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FirstConvertibleNoteMember",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Convertible Note [Member]",
        "label": "First Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_FirstConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FirstConvertibleNotesMember",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Convertible Notes [Member]",
        "label": "First Convertible Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_FirstMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FirstMilestoneMember",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Milestone [Member]",
        "label": "First Milestone Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_FirstSharesTargetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FirstSharesTargetMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Shares Target [Member]",
        "label": "First Shares Target Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_FloorPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FloorPrice",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floor Price (in Dollars per share)",
        "documentation": "The floor price. A payment or receipt is triggered if the market rate falls below the floor rate on the contract.",
        "label": "Floor Price"
       }
      }
     },
     "auth_ref": []
    },
    "abp_FloorPriceEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FloorPriceEventMember",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floor Price Event [Member]",
        "label": "Floor Price Event Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ForwardContractBaseResetPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ForwardContractBaseResetPricePerShare",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base reset price per share (in Dollars per share)",
        "documentation": "Forward contract, base reset price per share.",
        "label": "Forward Contract Base Reset Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForwardContractIndexedToEquitySettlementShareFairValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForwardContractIndexedToEquitySettlementShareFairValuePerShare",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial price per recycled shares (in Dollars per share)",
        "label": "Forward Contract Indexed to Equity, Settlement, Share, Fair Value Per Share",
        "documentation": "Fair value per share that would be issued upon settlement of forward contract indexed to equity."
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "us-gaap_ForwardContractIndexedToIssuersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForwardContractIndexedToIssuersEquityLineItems",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forward Purchase Agreement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForwardContractIndexedToIssuersEquitySettlementAlternativesCashAtFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement amount under forward purchase agreement",
        "label": "Forward Contract Indexed to Equity, Settlement, Cash, Amount",
        "documentation": "Amount that would be paid upon settlement of forward contract indexed to equity."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForwardContractIndexedToIssuersEquitySettlementAlternativesSharesAtFairValue",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of forward purchase agreement (in Shares)",
        "verboseLabel": "Seller purchased shares from third parties (in Shares)",
        "label": "Forward Contract Indexed to Equity, Settlement, Number of Shares",
        "documentation": "Number of shares as a settlement alternative for each freestanding forward contract."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ForwardContractIndexedToIssuersEquityShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForwardContractIndexedToIssuersEquityShares",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum up to common stock shares (in Shares)",
        "label": "Forward Contract Indexed to Issuer's Equity, Shares",
        "documentation": "Maximum number of shares that could be issued to settle forward contract indexed to equity."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "abp_ForwardContractInitialResetPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ForwardContractInitialResetPricePerShare",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial reset price per share (in Dollars per share)",
        "documentation": "Forward contract, initial reset price per share.",
        "label": "Forward Contract Initial Reset Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ForwardPurchaseAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ForwardPurchaseAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward purchase agreement",
        "documentation": "The amount of forward purchase agreement.",
        "label": "Forward Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ForwardPurchaseAgreementAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ForwardPurchaseAgreementAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward purchase agreement asset",
        "documentation": "The amount of forward purchase agreement asset.",
        "label": "Forward Purchase Agreement Asset"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ForwardPurchaseAgreementAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ForwardPurchaseAgreementAssetMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward purchase agreement asset [Member]",
        "verboseLabel": "Forward Purchase Agreement asset [Member]",
        "label": "Forward Purchase Agreement Asset Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ForwardPurchaseAgreementDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ForwardPurchaseAgreementDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forward Purchase Agreement (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ForwardPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ForwardPurchaseAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forward Purchase Agreement [Member]",
        "label": "Forward Purchase Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_FundingDateToMaturityDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "FundingDateToMaturityDateMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Until Maturity Date [Member]",
        "label": "Funding Date To Maturity Date Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture and fixtures [Member]",
        "verboseLabel": "Furniture and Fixtures [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnContractTermination",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination obligation aggregate amount",
        "verboseLabel": "Notice of termination",
        "label": "Gain (Loss) on Contract Termination",
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/ConsolidatedIncomeStatement",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on extinguishment of accrued liabilities",
        "negatedLabel": "Gain on extinguishment of accrued liabilities",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r27",
      "r28"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r878"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r76"
     ]
    },
    "abp_IncentiveSharesReceivedBySubsidiary": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "IncentiveSharesReceivedBySubsidiary",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive shares received by subsidiary (in Shares)",
        "documentation": "Incentive shares received by subsidiary.",
        "label": "Incentive Shares Received By Subsidiary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r202",
      "r468"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable",
      "http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before Income taxes",
        "terseLabel": "Net loss before tax",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r100",
      "r103",
      "r758",
      "r760",
      "r779",
      "r948",
      "r950",
      "r952",
      "r956",
      "r960",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofIncomeLossBeforeProvisionTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r202",
      "r468"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Income / (Loss) Before Provision [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/IncomeTaxesDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r300",
      "r304",
      "r595",
      "r601",
      "r618",
      "r620",
      "r676",
      "r680",
      "r685",
      "r695",
      "r696",
      "r697",
      "r793",
      "r795",
      "r883",
      "r934",
      "r936",
      "r992",
      "r994",
      "r1031",
      "r1033",
      "r1037",
      "r1042",
      "r1271",
      "r1273",
      "r1331"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/IncomeTaxesDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r300",
      "r304",
      "r595",
      "r601",
      "r618",
      "r620",
      "r676",
      "r680",
      "r685",
      "r695",
      "r696",
      "r697",
      "r793",
      "r795",
      "r883",
      "r934",
      "r936",
      "r992",
      "r994",
      "r1031",
      "r1033",
      "r1037",
      "r1042",
      "r1271",
      "r1273",
      "r1331"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r469",
      "r470",
      "r478",
      "r487",
      "r990",
      "r1264"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r469",
      "r470",
      "r478",
      "r487",
      "r990",
      "r1264"
     ]
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxContingencyLineItems",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r203",
      "r463",
      "r469",
      "r475",
      "r476",
      "r477",
      "r480",
      "r486",
      "r496",
      "r498",
      "r499",
      "r500",
      "r763",
      "r809",
      "r821",
      "r990"
     ]
    },
    "us-gaap_IncomeTaxExaminationInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest and penalties",
        "label": "Income Tax Examination, Interest Expense",
        "documentation": "The amount of estimated interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1259"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Penalties and interest",
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1259"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimate of interest and penalties",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r1259"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r114",
      "r196",
      "r227",
      "r228",
      "r241",
      "r255",
      "r266",
      "r467",
      "r469",
      "r497",
      "r784",
      "r948",
      "r950",
      "r952",
      "r990"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r465",
      "r466",
      "r480",
      "r481",
      "r485",
      "r489",
      "r815"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r474",
      "r990",
      "r1257"
     ]
    },
    "us-gaap_IncomeTaxReconciliationDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationDeductions",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization deductions",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions."
       }
      }
     },
     "auth_ref": [
      "r1257",
      "r1258"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent differences",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r470",
      "r473",
      "r990",
      "r1257"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax computed at federal statutory rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r990"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal benefit and tax credits",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r990",
      "r1257"
     ]
    },
    "abp_IncomeTaxesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "IncomeTaxesDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax payable (in Dollars)",
        "label": "Income Taxes Paid",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r71",
      "r1157",
      "r1262",
      "r1263"
     ]
    },
    "abp_IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "IncomeTaxesScheduleofNetDeferredTaxAssetsandLiabilitiesDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes - Schedule of Net Deferred Tax Assets and Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes payable",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r751",
      "r1155"
     ]
    },
    "us-gaap_IncreaseDecreaseInNotesReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInNotesReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Note receivable",
        "label": "Increase (Decrease) in Notes Receivables",
        "documentation": "The increase (decrease) during the reporting period of the amounts due from borrowers for outstanding secured or unsecured loans evidenced by a note."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1155"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "abp_InstallmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "InstallmentsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Installments amount",
        "documentation": "The amount of installments amount.",
        "label": "Installments Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntellectualPropertyMember",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intellectual Property [Member]",
        "label": "Intellectual Property [Member]",
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights."
       }
      }
     },
     "auth_ref": [
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200"
     ]
    },
    "srt_InterestBearingLiabilitiesAverageRatePaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "InterestBearingLiabilitiesAverageRatePaid",
     "presentation": [
      "http://www.abpro.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase bears interest rate",
        "label": "Interest-Bearing Liabilities, Average Rate Paid",
        "documentation": "Average rate paid on interest-bearing liabilities."
       }
      }
     },
     "auth_ref": [
      "r1087"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r250",
      "r254",
      "r256",
      "r266",
      "r705",
      "r960",
      "r961",
      "r1364"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense on promissory notes",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r344",
      "r352",
      "r974",
      "r975",
      "r1364"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r948",
      "r952",
      "r1111"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activity",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r190",
      "r191"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued interest on promissory note",
        "label": "Interest Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "abp_InvestmentAdvisorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "InvestmentAdvisorMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Advisor [Member]",
        "label": "Investment Advisor Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentCompanyExcessExpenseReimbursable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentCompanyExcessExpenseReimbursable",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company recorded excess",
        "label": "Investment Company, Reimbursable Excess Expense",
        "documentation": "Amount of carryover of excess expense potentially reimbursable to adviser but not recorded as liability by investment company."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "us-gaap_InvestmentIncomeAmortizationOfDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeAmortizationOfDiscount",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense",
        "label": "Investment Income, Amortization of Discount",
        "documentation": "Amount of accretion of purchase discount on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r253",
      "r266",
      "r960",
      "r1110"
     ]
    },
    "abp_IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "IssuanceCostsForAdvanceSharesIncludedInAccruedExpenses",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance costs for Advance Shares included in accrued expenses",
        "documentation": "Issuance costs for Advance Shares included in accrued expenses.",
        "label": "Issuance Costs For Advance Shares Included In Accrued Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "abp_IssuanceDateOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "IssuanceDateOfWarrantsMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance Date [Member]",
        "label": "Issuance Date Of Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_IssuanceOfCommonStockInPIPEFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "IssuanceOfCommonStockInPIPEFinancing",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in the PIPE Financing, net of transaction costs of $863,474 (in Shares)",
        "documentation": "Number of common stock",
        "label": "Issuance Of Common Stock In PIPEFinancing"
       }
      }
     },
     "auth_ref": []
    },
    "abp_IssuanceOfCommonStockInThePIPEFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "IssuanceOfCommonStockInThePIPEFinancing",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in the PIPE Financing, net of transaction costs of $863,474",
        "documentation": "issuance of common stock in pipe financing",
        "label": "Issuance Of Common Stock In The PIPEFinancing"
       }
      }
     },
     "auth_ref": []
    },
    "abp_IssuanceOfCommonStockInTransactionCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "IssuanceOfCommonStockInTransactionCost",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock in transaction costs",
        "documentation": "Issuance of common stock in transaction costs.",
        "label": "Issuance Of Common Stock In Transaction Cost"
       }
      }
     },
     "auth_ref": []
    },
    "abp_IssuanceOfSharesPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "IssuanceOfSharesPercentage",
     "presentation": [
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of issuance shares",
        "documentation": "Percentage of issuance shares.",
        "label": "Issuance Of Shares Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "abp_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab equipment [Member]",
        "label": "Lab Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease costs",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r1044"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1307"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements [Member]",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r725"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_LeasesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "LeasesDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_LegacyAbproCommonStockWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "LegacyAbproCommonStockWarrantsMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legacy Abpro Common Stock Warrants [Member]",
        "label": "Legacy Abpro Common Stock Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_LegacyAbproMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "LegacyAbproMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legacy Abpro [Member]",
        "label": "Legacy Abpro Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal fees",
        "verboseLabel": "Legal fees (in Dollars)",
        "label": "Legal Fees",
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings."
       }
      }
     },
     "auth_ref": [
      "r1086",
      "r1365",
      "r1366"
     ]
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance lease costs",
        "label": "Lessee, Finance Lease, Description [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1308"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total future minimum lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r1161",
      "r1168",
      "r1323"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r724",
      "r1161",
      "r1168",
      "r1323"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: amount representing interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.abpro.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r710"
     ]
    },
    "abp_LetterOfCreditExtendedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "LetterOfCreditExtendedPeriod",
     "presentation": [
      "http://www.abpro.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of credit extended period",
        "documentation": "Letter of credit extended period.",
        "label": "Letter Of Credit Extended Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.abpro.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit [Member]",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "terseLabel": "Total liabilities",
        "verboseLabel": "Liabilities (in Dollars)",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r44",
      "r45",
      "r46",
      "r49",
      "r50",
      "r51",
      "r52",
      "r196",
      "r200",
      "r201",
      "r277",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r577",
      "r581",
      "r582",
      "r694",
      "r850",
      "r955",
      "r976",
      "r1065",
      "r1211",
      "r1313",
      "r1314"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders\u2019 deficit",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r99",
      "r774",
      "r1045",
      "r1052",
      "r1053",
      "r1160",
      "r1165",
      "r1188",
      "r1303"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r157",
      "r196",
      "r200",
      "r201",
      "r277",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r577",
      "r581",
      "r582",
      "r694",
      "r1045",
      "r1211",
      "r1313",
      "r1314"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial measurement at the issuance date (see Note 11)",
        "verboseLabel": "Initial measurement at the issuance date",
        "label": "Liabilities, Fair Value Adjustment",
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value measured liabilities",
        "verboseLabel": "Fair value measured Liabilities",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r1289"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_LicenseandCollaborationAgreementsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "LicenseandCollaborationAgreementsDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Collaboration Agreements (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityCommitmentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitment fee",
        "label": "Line of Credit Facility, Commitment Fee Amount",
        "documentation": "Amount of the fee for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r48",
      "r314"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Endorsement on motion for default judgment",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermPurchaseCommitmentMilestones": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermPurchaseCommitmentMilestones",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net sales of licensed products milestone payment",
        "label": "Long-Term Purchase Commitment, Milestones",
        "documentation": "Discloses the nature of achievements or target goals that are to be reached by specified dates to maintain the arrangement or extend it, generally without adjustment of the present financial terms of the arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "abp_LossOnSettlementOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "LossOnSettlementOfConvertibleNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on settlement of convertible notes",
        "documentation": "The value represents loss on settlement of convertible notes.",
        "label": "Loss On Settlement Of Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abp_LossOnSettlementsOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "LossOnSettlementsOfConvertibleNotes",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on settlement of convertible notes",
        "documentation": "The value represents loss on settlement of convertible notes.",
        "label": "Loss On Settlements Of Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MSKLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MSKLicenseAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MSK License Agreement [Member]",
        "label": "MSKLicense Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MabwellShanghaiBioscienceCoLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MabwellShanghaiBioscienceCoLtdMember",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mabwell (Shanghai) Bioscience Co., Ltd. [Member]",
        "verboseLabel": "Mabwell (Shanghai) Bioscience Co Ltd [Member]",
        "label": "Mabwell Shanghai Bioscience Co Ltd Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MarketValueOfListedSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MarketValueOfListedSecuritiesMember",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MVLS [Member]",
        "label": "Market Value Of Listed Securities Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MarketValueOfPubliclyHeldSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MarketValueOfPubliclyHeldSharesMember",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MVPHS [Member]",
        "label": "Market Value Of Publicly Held Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r248",
      "r309",
      "r310",
      "r311",
      "r312",
      "r404",
      "r435",
      "r436",
      "r437",
      "r460",
      "r674",
      "r750",
      "r792",
      "r794",
      "r808",
      "r842",
      "r843",
      "r906",
      "r907",
      "r908",
      "r909",
      "r914",
      "r925",
      "r926",
      "r927",
      "r928",
      "r932",
      "r933",
      "r965",
      "r977",
      "r987",
      "r992",
      "r995",
      "r996",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1049",
      "r1215",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320"
     ]
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExercisePriceMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price [Member]",
        "verboseLabel": "Measurement Input, Exercise Price [Member]",
        "label": "Measurement Input, Exercise Price [Member]",
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset."
       }
      }
     },
     "auth_ref": [
      "r1247",
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedDividendRateMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield [Member]",
        "verboseLabel": "Measurement Input, Expected Dividend Rate [Member]",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputExpectedTermMember",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years) [Member]",
        "verboseLabel": "Expected term [Member]",
        "netLabel": "Measurement Input, Expected Term [Member]",
        "label": "Measurement Input, Expected Term [Member]",
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputOptionVolatilityMember",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility [Member]",
        "verboseLabel": "Measurement Input, Option Volatility [Member]",
        "label": "Measurement Input, Option Volatility [Member]",
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputPriceVolatilityMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility [Member]",
        "label": "Measurement Input, Price Volatility [Member]",
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r1038",
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate [Member]",
        "verboseLabel": "Measurement Input, Risk Free Interest Rate [Member]",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss."
       }
      }
     },
     "auth_ref": [
      "r437",
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputSharePriceMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price [Member]",
        "label": "Measurement Input, Share Price [Member]",
        "documentation": "Measurement input using share price of saleable stock."
       }
      }
     },
     "auth_ref": [
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r672",
      "r673",
      "r674",
      "r992",
      "r995",
      "r996",
      "r1038"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r673",
      "r674",
      "r992",
      "r995",
      "r996",
      "r1038"
     ]
    },
    "abp_MedImmuneLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MedImmuneLicenseAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MedImmune License Agreement [Member]",
        "label": "Med Immune License Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MergerDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MergerDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MergerLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MergerLineItems",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MergerScheduleofCommonStockOutstandingDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MergerScheduleofCommonStockOutstandingDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger - Schedule of Common Stock Outstanding (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "presentation": [
      "http://www.abpro.com/role/Merger"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Merger",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r1270"
     ]
    },
    "abp_MilestonePaymentOnNetSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MilestonePaymentOnNetSales",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment on net sales",
        "documentation": "Represents milestone payment based on net sales",
        "label": "Milestone Payment On Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "documentation": "Represent the milestone payment.",
        "label": "Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MilestonePaymentsCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MilestonePaymentsCommercialMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments commercial milestones",
        "documentation": "Milestone payments commercial milestones.",
        "label": "Milestone Payments Commercial Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MilestonePaymentsUponAchievingRDAndCommercializationEvents",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment upon achieving",
        "documentation": "Represents milestone payments upon achieving research and development and commercialization events.",
        "label": "Milestone Payments Upon Achieving RDAnd Commercialization Events"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r248",
      "r309",
      "r310",
      "r311",
      "r312",
      "r404",
      "r435",
      "r436",
      "r437",
      "r460",
      "r674",
      "r750",
      "r792",
      "r794",
      "r808",
      "r842",
      "r843",
      "r906",
      "r907",
      "r908",
      "r909",
      "r914",
      "r925",
      "r926",
      "r927",
      "r928",
      "r932",
      "r933",
      "r965",
      "r977",
      "r987",
      "r992",
      "r995",
      "r996",
      "r1038",
      "r1039",
      "r1040",
      "r1049",
      "r1215",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r98",
      "r196",
      "r200",
      "r201",
      "r277",
      "r315",
      "r317",
      "r318",
      "r319",
      "r322",
      "r323",
      "r773",
      "r854",
      "r1303"
     ]
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Market value",
        "label": "Money Market Funds, at Carrying Value",
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months."
       }
      }
     },
     "auth_ref": []
    },
    "abp_MonteCarloSimulationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MonteCarloSimulationMember",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monte Carlo Simulation [Member]",
        "label": "Monte Carlo Simulation Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_MonthlyInstallmentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "MonthlyInstallmentPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Monthly installment payments",
        "documentation": "Monthly installment payments.",
        "label": "Monthly Installment Payments"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NCILicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NCILicenseAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NCI License Agreement [Member]",
        "label": "NCILicense Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NJCTTQCollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NJCTTQCollaborationAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NJCTTQ Collaboration Agreement [Member]",
        "label": "NJCTTQCollaboration Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Financing Activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Investing Activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r70",
      "r72"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flows from Operating Activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to common stockholders",
        "label": "Net Income (Loss) from Continuing Operations Available to Common Shareholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from continuing operations available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r237"
     ]
    },
    "abp_NetProceedsFromTheMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NetProceedsFromTheMerger",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from the Merger",
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Net Proceeds From The Merger"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NetProfitsFromLicensedProductSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NetProfitsFromLicensedProductSales",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net profits from licensed product sales",
        "documentation": "Net profits from licensed product sales.",
        "label": "Net Profits From Licensed Product Sales"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NewAbproSharesIssuedInMergerToLegacyAbproStockholdersMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Abpro shares issued in Merger to Legacy Abpro stockholders [Member]",
        "label": "New Abpro Shares Issued In Merger To Legacy Abpro Stockholders Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NewAbproSharesIssuedToPIPEInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NewAbproSharesIssuedToPIPEInvestorsMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Abpro shares issued to PIPE investors [Member]",
        "label": "New Abpro Shares Issued To PIPEInvestors Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NewAbproSharesIssuedToServiceProvidersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NewAbproSharesIssuedToServiceProvidersMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Abpro shares issued to service providers [Member]",
        "label": "New Abpro Shares Issued To Service Providers Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NewAbproSharesIssuedToSettleThePromissoryNoteWithExecutiveMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Abpro shares issued to settle the promissory note with executive [Member]",
        "label": "New Abpro Shares Issued To Settle The Promissory Note With Executive Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NewAbproSharesTransferredToInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NewAbproSharesTransferredToInvestorsMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Abpro shares transferred to investors [Member]",
        "label": "New Abpro Shares Transferred To Investors Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r183",
      "r184",
      "r185",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r221",
      "r229",
      "r240",
      "r271",
      "r272",
      "r278",
      "r279",
      "r280",
      "r281",
      "r292",
      "r293",
      "r301",
      "r353",
      "r354",
      "r355",
      "r356",
      "r444",
      "r445",
      "r446",
      "r447",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r547",
      "r548",
      "r549",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r691",
      "r692",
      "r708",
      "r709",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r813"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "abp_NewConsultingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NewConsultingAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Consulting Agreement [Member]",
        "label": "New Consulting Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NonRedemptionAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NonRedemptionAgreementsMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Redemption Agreements [Member]",
        "label": "Non Redemption Agreements Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NonRefundablePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NonRefundablePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate non-refundable payments",
        "documentation": "The amount of non-refundable payments.",
        "label": "Non Refundable Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information and non-cash transactions:",
        "label": "Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r383",
      "r1169",
      "r1170",
      "r1171",
      "r1174",
      "r1367"
     ]
    },
    "abp_NoncontrollingInterestPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NoncontrollingInterestPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling Interest",
        "documentation": "Non-controlling Interest.",
        "label": "Noncontrolling Interest Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income, net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income:",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NotePayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NotePayableMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Note Payable [Member]",
        "label": "Note Payable Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Funding amount",
        "verboseLabel": "Outstanding principal balances under the promissory notes",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r96",
      "r1325",
      "r1326"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable \u2013 related parties",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45"
     ]
    },
    "abp_NotesPayableDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NotesPayableDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NumberOfConsecutiveTradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NumberOfConsecutiveTradingDays",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consecutive trading days",
        "documentation": "Represent the number of consecutive trading days.",
        "label": "Number Of Consecutive Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NumberOfDaysUsedForCalculatingVolumeWeightedAveragePricePerShare",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of trading days used for calculating VWAP price of shares",
        "documentation": "Number of days used for calculating volume weighted average price per share.",
        "label": "Number Of Days Used For Calculating Volume Weighted Average Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NumberOfSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NumberOfSharesMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares under each advance notice [Member]",
        "verboseLabel": "Number of shares [Member]",
        "label": "Number Of Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_NumberOfTradingDaysForDeterminingTheSharePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "NumberOfTradingDaysForDeterminingTheSharePrice",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of trading days",
        "documentation": "Number of trading days for determining the share price.",
        "label": "Number Of Trading Days For Determining The Share Price"
       }
      }
     },
     "auth_ref": []
    },
    "abp_OfferingCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "OfferingCostsIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offering costs included in accounts payable",
        "documentation": "The value represents offering costs included in accounts payable.",
        "label": "Offering Costs Included In Accounts Payable"
       }
      }
     },
     "auth_ref": []
    },
    "abp_OneYearAnniversaryOfIssuanceDateOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "OneYearAnniversaryOfIssuanceDateOfWarrantsMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One Year Anniversary of Issuance Date [Member]",
        "label": "One Year Anniversary Of Issuance Date Of Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r948",
      "r952",
      "r956",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r1044"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Future Minimum Payments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Present value of future minimum lease payments",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, current",
        "negatedLabel": "Less: current maturities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ScheduleofFutureMinimumPaymentsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability, noncurrent",
        "verboseLabel": "Obligations under lease liability, noncurrent",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r716",
      "r721"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use asset - operating lease",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r712"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1156"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r723",
      "r1044"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofLeaseExpenseTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases, Weighted-average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r1044"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.abpro.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r488"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of the Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Description of the Business",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r149",
      "r151",
      "r153",
      "r811",
      "r812"
     ]
    },
    "abp_OrganizationandDescriptionoftheBusinessDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "OrganizationandDescriptionoftheBusinessDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization and Description of the Business (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_OriginalCelltrionAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "OriginalCelltrionAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original celltrion agreement",
        "documentation": "Original celltrion agreement.",
        "label": "Original Celltrion Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "abp_OtherAccruedExpensesAndAccountsPayableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "OtherAccruedExpensesAndAccountsPayableMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Accrued Expenses and Accounts Payable [Member]",
        "label": "Other Accrued Expenses And Accounts Payable Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_OtherAccruedExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "OtherAccruedExpensesMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Accrued Expenses [Member]",
        "label": "Other Accrued Expenses Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable",
      "http://www.abpro.com/role/ScheduleofAccruedExpensesTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued expenses",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Other Accrued Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid classified as other."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_OtherCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments Under Research and Collaboration Agreements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other (expense) income",
        "label": "Other Expenses",
        "documentation": "Amount of expense classified as other."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r1052",
      "r1053"
     ]
    },
    "us-gaap_OtherIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other income (see Note 2)",
        "terseLabel": "Other income",
        "label": "Other Income",
        "documentation": "Amount of revenue and income classified as other."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r876",
      "r915",
      "r916",
      "r917",
      "r1052",
      "r1053"
     ]
    },
    "us-gaap_OtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net liabilities",
        "verboseLabel": "Liabilities net (in Dollars)",
        "label": "Other Liabilities",
        "documentation": "Amount of liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r765",
      "r846",
      "r847",
      "r976",
      "r1052",
      "r1053",
      "r1065",
      "r1326",
      "r1361"
     ]
    },
    "us-gaap_OtherNoncashExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense",
        "label": "Other Noncash Expense",
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "us-gaap_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Other Receivables",
        "documentation": "Amount due from parties in nontrade transactions, classified as other."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r861",
      "r961",
      "r1052",
      "r1053",
      "r1328"
     ]
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development services",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1256"
     ]
    },
    "abp_PIPEFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PIPEFinancingMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Financing [Member]",
        "label": "PIPEFinancing Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PIPESharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PIPESharesMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PIPE Shares [Member]",
        "label": "PIPEShares Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ParentMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Abpro\u2019s Stockholders\u2019 Deficit",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "abp_PatentCostsReimbursements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PatentCostsReimbursements",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patent costs reimbursements",
        "documentation": "related to the patent costs reimbursements.",
        "label": "Patent Costs Reimbursements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents [Member]",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200"
     ]
    },
    "abp_PatentsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PatentsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents, net",
        "documentation": "The amount of patents, net.",
        "label": "Patents Net"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PatentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PatentsPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "documentation": "Patents.",
        "label": "Patents Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PaymentForExtensionRoyalities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PaymentForExtensionRoyalities",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Extension royalties",
        "documentation": "The company is liable for extension royalties.",
        "label": "Payment For Extension Royalities"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PaymentOfDevelopmentMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PaymentOfDevelopmentMilestones",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment of development milestones",
        "documentation": "The amount of payment of development milestones.",
        "label": "Payment Of Development Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PaymentOfRentAndMaintenanceExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PaymentOfRentAndMaintenanceExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent and maintenance expenses to landlord",
        "documentation": "It represents rent and maintenance expenses to landlord.",
        "label": "Payment Of Rent And Maintenance Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForFees",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment to CRO",
        "label": "Payments for Other Fees",
        "documentation": "Amount of cash outflow for fees classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForLegalSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement payment",
        "label": "Payments for Legal Settlements",
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForMergerRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForMergerRelatedCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment in merger agreement",
        "label": "Payments for Merger Related Costs",
        "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForProceedsFromPreviousAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromPreviousAcquisition",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross purchase price",
        "label": "Payments for (Proceeds from) Previous Acquisition",
        "documentation": "The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent",
        "label": "Payments for Rent",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties amount",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of offering costs",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional interest",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "abp_PerShareRedemptionsTriggerPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PerShareRedemptionsTriggerPrice",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption trigger price of per share",
        "documentation": "The number of per share in trigger price.",
        "label": "Per Share Redemptions Trigger Price"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfAdvanceNotice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfAdvanceNotice",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of advance notice",
        "documentation": "The percentage of advance notice.",
        "label": "Percentage Of Advance Notice"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfAmendedCelltrionAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfAmendedCelltrionAgreement",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended celltrion agreement",
        "documentation": "Percentage of amended celltrion agreement.",
        "label": "Percentage Of Amended Celltrion Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfAmortizationPrincipalAmount": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfAmortizationPrincipalAmount",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of amortization principal amount",
        "documentation": "Percentage of amortization principal amount.",
        "label": "Percentage Of Amortization Principal Amount"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfClosingPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfClosingPrice",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of closing price",
        "documentation": "Percentage of Closing Price.",
        "label": "Percentage Of Closing Price"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfCommonStock",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common stock",
        "verboseLabel": "Rate of common stock",
        "documentation": "Percentage of common stock.",
        "label": "Percentage Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfCommonStockOutstanding": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfCommonStockOutstanding",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of common stock outstanding",
        "documentation": "Percentage of Common Stock Outstanding.",
        "label": "Percentage Of Common Stock Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfLiabilityTotal": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfLiabilityTotal",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of total liability",
        "documentation": "Percentage of total liability.",
        "label": "Percentage Of Liability Total"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfMarketValueAndNewlyIssuedPrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfMarketValueAndNewlyIssuedPrice",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of market value and newly issued price",
        "documentation": "Percentage of market value and newly issued price.",
        "label": "Percentage Of Market Value And Newly Issued Price"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfOriginalCelltrionAgreement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfOriginalCelltrionAgreement",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Original celltrion agreement",
        "documentation": "Percentage of original celltrion agreement.",
        "label": "Percentage Of Original Celltrion Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfReimbursement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfReimbursement",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reimbursement",
        "documentation": "Percentage of reimbursement.",
        "label": "Percentage Of Reimbursement"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfUnderpaymentPenaltyPerMonth": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfUnderpaymentPenaltyPerMonth",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of underpayment penalty per month",
        "documentation": "Percentage of underpayment penalty per month.",
        "label": "Percentage Of Underpayment Penalty Per Month"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PercentageOfVolumeWeightedAveragePrice": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PercentageOfVolumeWeightedAveragePrice",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of volume weighted average price",
        "documentation": "Percentage of volume weighted average price.",
        "label": "Percentage Of Volume Weighted Average Price"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PeriodAfterWhichTheWarrantsAreExercisable": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PeriodAfterWhichTheWarrantsAreExercisable",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of trading day period",
        "documentation": "Period after which the warrants are exercisable.",
        "label": "Period After Which The Warrants Are Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252"
     ]
    },
    "us-gaap_PledgingPurposeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PledgingPurposeAxis",
     "presentation": [
      "http://www.abpro.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Axis]",
        "documentation": "Information by pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r198",
      "r748",
      "r1026",
      "r1046",
      "r1075"
     ]
    },
    "us-gaap_PledgingPurposeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PledgingPurposeDomain",
     "presentation": [
      "http://www.abpro.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pledging Purpose [Domain]",
        "documentation": "Pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r198",
      "r748",
      "r1026",
      "r1046",
      "r1075"
     ]
    },
    "abp_PostApportionedMassachusettsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PostApportionedMassachusettsMember",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Post-Apportioned Massachusetts [Member]",
        "label": "Post Apportioned Massachusetts Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Share [Member]",
        "verboseLabel": "Preferred Stock [Member]",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056",
      "r1059",
      "r1060",
      "r1061",
      "r1062",
      "r1360",
      "r1367"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in Dollars per share)",
        "verboseLabel": "Preferred stock, par value",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r367"
     ]
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockRedemptionPricePerShare",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price per share (in Dollars per share)",
        "label": "Preferred Stock, Redemption Price Per Share",
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock, shares authorized (in Shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r852"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r367"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred Stock, Shares Outstanding (in Shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r852",
      "r873",
      "r1367",
      "r1368"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, value",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r358",
      "r363",
      "r769",
      "r1045"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1099"
     ]
    },
    "us-gaap_PrepaidRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidRoyalties",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment amount",
        "label": "Prepaid Royalties",
        "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r940",
      "r966",
      "r1191"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement [Member]",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "abp_PrivatePlacementWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PrivatePlacementWarrantsMember",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement Warrants [Member]",
        "documentation": "Private placement warrants.",
        "label": "Private Placement Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PrivateWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PrivateWarrantsMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Warrants [Member]",
        "label": "Private Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Convertible Notes, net of issuance costs",
        "label": "Proceeds from Convertible Debt",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance cost",
        "verboseLabel": "Issuance costs (in Dollars)",
        "netLabel": "Net proceeds",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r186"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from settlement of Forward Purchase Agreement",
        "verboseLabel": "Cash received",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuances of debt",
        "verboseLabel": "Net convertible note discount",
        "label": "Proceeds from Issuance of Debt",
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt."
       }
      }
     },
     "auth_ref": [
      "r1153"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from PIPE financing",
        "label": "Proceeds from Issuance of Private Placement",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of Note payable",
        "verboseLabel": "Proceeds from received",
        "netLabel": "Proceeds from financing (in Dollars)",
        "label": "Received from promissory note",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Advance Shares",
        "label": "Proceeds from Other Equity",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromRelatedPartyDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of notes payable - related party",
        "verboseLabel": "Received from promissory note",
        "netLabel": "Executive to receive",
        "label": "Proceeds from Related Party Debt",
        "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of property and equipment",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r134",
      "r268",
      "r752",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r937",
      "r947",
      "r950",
      "r952",
      "r978",
      "r979",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1054",
      "r1080",
      "r1094",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1208",
      "r1209",
      "r1330",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r127",
      "r128",
      "r129",
      "r134",
      "r268",
      "r752",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r937",
      "r947",
      "r950",
      "r952",
      "r978",
      "r979",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1054",
      "r1080",
      "r1094",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1208",
      "r1209",
      "r1330",
      "r1332",
      "r1333",
      "r1334",
      "r1335",
      "r1336",
      "r1337",
      "r1338",
      "r1339",
      "r1340",
      "r1341",
      "r1342",
      "r1343",
      "r1344",
      "r1345",
      "r1346",
      "r1347",
      "r1348",
      "r1349",
      "r1350",
      "r1351",
      "r1352",
      "r1353",
      "r1354",
      "r1355",
      "r1356",
      "r1357",
      "r1358",
      "r1359"
     ]
    },
    "us-gaap_ProfessionalFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalFees",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Professional Fees",
        "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer."
       }
      }
     },
     "auth_ref": [
      "r950",
      "r960",
      "r1063",
      "r1365",
      "r1366"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/ConsolidatedIncomeStatement",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net income (loss)",
        "verboseLabel": "Net loss",
        "netLabel": "Net losses amount",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r155",
      "r169",
      "r170",
      "r188",
      "r196",
      "r200",
      "r201",
      "r206",
      "r213",
      "r223",
      "r227",
      "r228",
      "r277",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r356",
      "r446",
      "r509",
      "r571",
      "r575",
      "r578",
      "r579",
      "r668",
      "r694",
      "r758",
      "r760",
      "r780",
      "r826",
      "r874",
      "r896",
      "r897",
      "r1027",
      "r1028",
      "r1064",
      "r1109",
      "r1211"
     ]
    },
    "abp_PromissoryNoteAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PromissoryNoteAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note Agreement [Member]",
        "documentation": "Promissory note agreement.",
        "label": "Promissory Note Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PromissoryNoteMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note [Member]",
        "documentation": "Promissory note .",
        "label": "Promissory Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PromissoryNoteWithABIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PromissoryNoteWithABIMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note with ABI [Member]",
        "label": "Promissory Note With ABIMember"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PromissoryNoteWithACABExecutiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PromissoryNoteWithACABExecutiveMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Note with ACAB Executive [Member]",
        "label": "Promissory Note With ACABExecutive Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_PromissoryNotesWithExecutiveAndDirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PromissoryNotesWithExecutiveAndDirectorMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Promissory Notes with Executive and Director [Member]",
        "label": "Promissory Notes With Executive And Director Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r725"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r110",
      "r112",
      "r113"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r159",
      "r778"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "terseLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r725",
      "r762",
      "r778",
      "r1045"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r110",
      "r112",
      "r776"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.abpro.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r725"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r1201"
     ]
    },
    "abp_PublicWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "PublicWarrantsMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockWarrantActivityTable",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public Warrants [Member]",
        "documentation": "Public warrants.",
        "label": "Public Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r248",
      "r309",
      "r310",
      "r311",
      "r312",
      "r392",
      "r404",
      "r435",
      "r436",
      "r437",
      "r443",
      "r460",
      "r674",
      "r747",
      "r749",
      "r750",
      "r792",
      "r794",
      "r808",
      "r842",
      "r843",
      "r906",
      "r907",
      "r908",
      "r909",
      "r914",
      "r925",
      "r926",
      "r927",
      "r928",
      "r932",
      "r933",
      "r965",
      "r977",
      "r987",
      "r992",
      "r995",
      "r996",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1049",
      "r1057",
      "r1206",
      "r1215",
      "r1292",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r131",
      "r132",
      "r133",
      "r136",
      "r137",
      "r248",
      "r309",
      "r310",
      "r311",
      "r312",
      "r392",
      "r404",
      "r435",
      "r436",
      "r437",
      "r443",
      "r460",
      "r674",
      "r747",
      "r749",
      "r750",
      "r792",
      "r794",
      "r808",
      "r842",
      "r843",
      "r906",
      "r907",
      "r908",
      "r909",
      "r914",
      "r925",
      "r926",
      "r927",
      "r928",
      "r932",
      "r933",
      "r965",
      "r977",
      "r987",
      "r992",
      "r995",
      "r996",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1049",
      "r1057",
      "r1206",
      "r1215",
      "r1292",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320"
     ]
    },
    "abp_RecentlyAdoptedAccountingPronouncementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "RecentlyAdoptedAccountingPronouncementsPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Standards",
        "documentation": "The policy disclosure of recently adopted accounting pronouncements.",
        "label": "Recently Adopted Accounting Pronouncements Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ReclassificationOfResidualValueGuaranteesUnderFinanceLeaseToAccruedExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification of residual value guarantees under finance lease to accrued expense",
        "documentation": "Represent the amount of reclassification of residual value guarantees under finance lease to accrued expense.",
        "label": "Reclassification Of Residual Value Guarantees Under Finance Lease To Accrued Expense"
       }
      }
     },
     "auth_ref": []
    },
    "abp_RedemptionTriggerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "RedemptionTriggerMember",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption Trigger [Member]",
        "label": "Redemption Trigger Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_RegistrationEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "RegistrationEventMember",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Registration Event [Member]",
        "label": "Registration Event Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_RegulatoryEvents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "RegulatoryEvents",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory events",
        "documentation": "Represent the regulatory events.",
        "label": "Regulatory Events"
       }
      }
     },
     "auth_ref": []
    },
    "abp_RelatedPartiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "RelatedPartiesDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r205",
      "r206",
      "r273",
      "r399",
      "r402",
      "r735",
      "r736",
      "r766",
      "r775",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r872",
      "r905",
      "r1363"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "verboseLabel": "Related Party [Member]",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r205",
      "r206",
      "r735",
      "r736",
      "r737",
      "r738",
      "r766",
      "r775",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r872",
      "r905"
     ]
    },
    "us-gaap_RelatedPartyTransactionAmountsOfTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAmountsOfTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Agreement amount",
        "label": "Related Party Transaction, Amounts of Transaction",
        "documentation": "Amount of transactions with related party during the financial reporting period."
       }
      }
     },
     "auth_ref": [
      "r735"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r205",
      "r206",
      "r735",
      "r736",
      "r1312"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r205",
      "r206",
      "r1312"
     ]
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r205",
      "r206",
      "r273",
      "r735",
      "r736",
      "r738",
      "r879",
      "r880",
      "r883"
     ]
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Parties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r205",
      "r206",
      "r273",
      "r399",
      "r402",
      "r735",
      "r736",
      "r766",
      "r775",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r872",
      "r905",
      "r1312",
      "r1363"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/RelatedParties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Parties",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r732",
      "r733",
      "r734",
      "r736",
      "r739",
      "r822",
      "r823",
      "r824",
      "r881",
      "r882",
      "r883",
      "r902",
      "r904"
     ]
    },
    "abp_RemainingSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "RemainingSharesIssued",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining shares issued",
        "documentation": "Remaining shares issued.",
        "label": "Remaining Shares Issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repaid balance",
        "verboseLabel": "Repayment of amount (in Dollars)",
        "label": "Repayments of Debt",
        "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "us-gaap_RepaymentsOfLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of credit amount",
        "label": "Repayments of Lines of Credit",
        "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r1160",
      "r1163"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on Note payable",
        "terseLabel": "Repay promissory note (in Dollars)",
        "verboseLabel": "Repayment of note payable",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_RepaymentsOfRelatedPartyDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfRelatedPartyDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of notes payable - related party",
        "label": "Repayments of Related Party Debt",
        "documentation": "The cash outflow for the payment of a long-term borrowing made from a related party where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Payments for Advances from Affiliates."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r934",
      "r948",
      "r949",
      "r960",
      "r1321"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/IncomeTaxesDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development [Member]",
        "verboseLabel": "Research and Development Expense [Member]",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r461"
     ]
    },
    "abp_ResearchAndDevelopmentServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ResearchAndDevelopmentServicesMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development services",
        "label": "Research And Development Services Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment [Member]",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r225",
      "r226",
      "r240",
      "r666",
      "r667",
      "r709",
      "r1076",
      "r1077",
      "r1078",
      "r1079",
      "r1084",
      "r1085",
      "r1173",
      "r1182"
     ]
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r141",
      "r147",
      "r148",
      "r150",
      "r180",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r218",
      "r219",
      "r220",
      "r221",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r240",
      "r279",
      "r280",
      "r355",
      "r356",
      "r446",
      "r506",
      "r507",
      "r509",
      "r510",
      "r570",
      "r571",
      "r662",
      "r666",
      "r667",
      "r668",
      "r709",
      "r730",
      "r731",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r813",
      "r1182"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r141",
      "r147",
      "r148",
      "r150",
      "r180",
      "r209",
      "r210",
      "r211",
      "r213",
      "r214",
      "r218",
      "r219",
      "r220",
      "r221",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r240",
      "r279",
      "r280",
      "r355",
      "r356",
      "r446",
      "r506",
      "r507",
      "r509",
      "r510",
      "r570",
      "r571",
      "r662",
      "r666",
      "r667",
      "r668",
      "r709",
      "r730",
      "r731",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r813",
      "r1182"
     ]
    },
    "abp_RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "RestatementOfPreviouslyIssuedFinancialStatementsPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement of Previously Issued Financial Statements",
        "documentation": "Disclosure of accounting policy for restatement of previously issued financial statements.",
        "label": "Restatement Of Previously Issued Financial Statements Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1158",
      "r1322",
      "r1327"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1158"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ScheduleofConsolidatedStatementsofCashFlowsTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash, Noncurrent",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r1096",
      "r1158"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock [Member]",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1176",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Unit Activity [Member]",
        "verboseLabel": "RSUs [Member]",
        "netLabel": "Restricted Stock Units (RSUs) [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r181",
      "r302",
      "r303",
      "r305",
      "r306",
      "r949"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r82",
      "r772",
      "r802",
      "r807",
      "r820",
      "r853",
      "r1045"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r147",
      "r148",
      "r209",
      "r210",
      "r211",
      "r214",
      "r223",
      "r226",
      "r228",
      "r278",
      "r281",
      "r293",
      "r355",
      "r446",
      "r490",
      "r491",
      "r505",
      "r506",
      "r507",
      "r510",
      "r570",
      "r571",
      "r644",
      "r647",
      "r648",
      "r651",
      "r666",
      "r708",
      "r711",
      "r798",
      "r800",
      "r827",
      "r1367"
     ]
    },
    "abp_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "RevenueAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue:",
        "label": "Revenue Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r935"
     ]
    },
    "us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRecognitionMilestoneMethodRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Revenue Recognition, Milestone Method, Revenue Recognized",
        "documentation": "The amount of consideration recognized during the period for the milestone or milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance obligation",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total revenues",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r175",
      "r196",
      "r200",
      "r201",
      "r241",
      "r251",
      "r252",
      "r264",
      "r266",
      "r268",
      "r269",
      "r270",
      "r277",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r694",
      "r758",
      "r760",
      "r960",
      "r1029",
      "r1052",
      "r1053",
      "r1211"
     ]
    },
    "abp_ReverseStockSplitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ReverseStockSplitMember",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Split [Member]",
        "label": "Reverse Stock Split Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ReverseStockSplitSharesOfIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ReverseStockSplitSharesOfIssued",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of issued (in Shares)",
        "documentation": "Reverse stock split shares of issued.",
        "label": "Reverse Stock Split Shares Of Issued"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ReverseStockSpllitSharesOfOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ReverseStockSpllitSharesOfOutstanding",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of outstanding (in Shares)",
        "documentation": "Reverse stock spllit shares of outstanding.",
        "label": "Reverse Stock Spllit Shares Of Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "abp_RothCapitalPartnersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "RothCapitalPartnersMember",
     "presentation": [
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Roth Capital Partners [Member]",
        "label": "Roth Capital Partners Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Guaranteed annual minimum royalties",
        "label": "Royalty Guarantees, Commitments, Amount",
        "documentation": "The amount the entity has committed to make for future royalty guarantees."
       }
      }
     },
     "auth_ref": [
      "r755"
     ]
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyIncomeNonoperating",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment",
        "label": "Royalty Income, Nonoperating",
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1219",
      "r1220"
     ]
    },
    "abp_SEPACommitmentFeePaidInCommonStockShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SEPACommitmentFeePaidInCommonStockShares",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA commitment fee paid in common stock shares",
        "documentation": "The value of SEPA commitment fee paid in common stock shares.",
        "label": "SEPACommitment Fee Paid In Common Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SEPAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SEPAMember",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA [Member]",
        "label": "SEPAMember"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SEPAPutRightsAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SEPAPutRightsAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA put rights asset",
        "documentation": "The amount of SEPA put rights asset.",
        "label": "SEPAPut Rights Asset"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SEPAPutRightsAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SEPAPutRightsAssetMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/ScheduleofChangesintheFairValueofLevel3FinancialAssetsandLiabilitiesTable0",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable",
      "http://www.abpro.com/role/ScheduleofCompanysAssetsandLiabilitiesthatareMeasuredatFairValueonaRecurringBasisTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA put rights asset [Member]",
        "verboseLabel": "SEPA Put Rights Asset [Member]",
        "label": "SEPAPut Rights Asset Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalariesWagesAndOfficersCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalariesWagesAndOfficersCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred wages",
        "label": "Salary and Wage, Excluding Cost of Good and Service Sold",
        "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer and officer employees. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exceeds per share (in Dollars per share)",
        "verboseLabel": "Sale of price per share (in Dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesAndExciseTaxPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excise taxes payable",
        "verboseLabel": "Excise tax payable",
        "netLabel": "Excise tax payable (in Dollars)",
        "label": "Sales and Excise Tax Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast [Member]",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r1088"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported",
        "verboseLabel": "As previously reported [Member]",
        "netLabel": "Previously Reported [Member]",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r141",
      "r147",
      "r148",
      "r209",
      "r211",
      "r213",
      "r214",
      "r218",
      "r219",
      "r228",
      "r240",
      "r355",
      "r356",
      "r446",
      "r506",
      "r509",
      "r510",
      "r570",
      "r571",
      "r662",
      "r666",
      "r667",
      "r709",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r813",
      "r1082",
      "r1083",
      "r1084",
      "r1172",
      "r1173",
      "r1182",
      "r1189",
      "r1190",
      "r1288",
      "r1309",
      "r1310"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0",
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable",
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r152",
      "r154",
      "r229",
      "r405",
      "r1069"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Diluted Net Loss Per Share",
        "verboseLabel": "Schedule of Diluted Net Loss Per Share of Common Stock Attributable to Common Stockholders",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "abp_ScheduleOfBalanceSheetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfBalanceSheetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Balance Sheet Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfChangesInTheFairValueOfLevel3FinancialAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Changes In The Fair Value Of Level3 Financial Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfCommonStockOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfCommonStockOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Common Stock Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/MergerTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Common Stock Outstanding",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfCommonStockWarrantActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfCommonStockWarrantActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Common Stock Warrant Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfCompanySAssetsAndLiabilitiesThatAreMeasuredAtFairValueOnARecurringBasisAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SAssets And Liabilities That Are Measured At Fair Value On ARecurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfCompanySRestrictedStockUnitActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfCompanySRestrictedStockUnitActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SRestricted Stock Unit Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfCompanySStockOptionActivityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfCompanySStockOptionActivityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Company SStock Option Activity Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Balance Sheet",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1161",
      "r1168",
      "r1323"
     ]
    },
    "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Consolidated Statements of Cash Flows",
        "label": "Condensed Cash Flow Statement [Table Text Block]",
        "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations."
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1161",
      "r1168",
      "r1323"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Net Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1261"
     ]
    },
    "abp_ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfDepreciationOnPropertyAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Depreciation on Property and Equipment Estimated Useful Lives",
        "documentation": "Tabular disclosure of property plant and equipment depreciation over the estimated useful lives.",
        "label": "Schedule Of Depreciation On Property And Equipment Estimated Useful Lives Table Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfDilutedNetLossPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfDilutedNetLossPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfDilutedNetLossPerShareOfCommonStockAttributableToCommonStockholdersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Diluted Net Loss Per Share Of Common Stock Attributable To Common Stockholders Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfEffectiveIncomeTaxRateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfEffectiveIncomeTaxRateAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Effective Income Tax Rate Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r990",
      "r1257"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable",
      "http://www.abpro.com/role/ScheduleofRecordedStockBasedCompensationExpenseTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Recorded Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r275",
      "r276",
      "r501",
      "r694",
      "r1070",
      "r1071",
      "r1072",
      "r1266",
      "r1267",
      "r1268",
      "r1269"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Changes in the Fair Value of Level 3 Financial Assets and Liabilities",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1289",
      "r1290"
     ]
    },
    "abp_ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfFairValueAssumptionsOfTheStockOptionsGrantedToEmployeesDirectorsAndNonemployeesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Assumptions Of The Stock Options Granted To Employees Directors And Nonemployees Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfFairValueOfTheCompanySPositionUnderTheForwardPurchaseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Fair Value Of The Company SPosition Under The Forward Purchase Agreement Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income / (Loss) Before Provision",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r1160",
      "r1166"
     ]
    },
    "abp_ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfNetDeferredTaxAssetsAndLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Net Deferred Tax Assets And Liabilities Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofPropertyandEquipmentTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r725"
     ]
    },
    "abp_ScheduleOfRecordedStockBasedCompensationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfRecordedStockBasedCompensationExpenseAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Recorded Stock Based Compensation Expense Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Restricted Stock Unit Activity",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company\u2019s Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r9",
      "r83"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Warrants to Purchase Common Stock Outstanding",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "abp_ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ScheduleOfWarrantsToPurchaseCommonStockOutstandingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Warrants To Purchase Common Stock Outstanding Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SecondConvertibleNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SecondConvertibleNoteMember",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Convertible Note [Member]",
        "label": "Second Convertible Note Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SecondConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SecondConvertibleNotesMember",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Convertible Notes [Member]",
        "label": "Second Convertible Notes Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SecondShareTargetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SecondShareTargetMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Second Share Target [Member]",
        "label": "Second Share Target Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SecurityBidPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SecurityBidPricePerShare",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security bid price per share (in Dollars per share)",
        "documentation": "Represent the amount of security bid price per share.",
        "label": "Security Bid Price Per Share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security deposits",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]",
        "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r959",
      "r964"
     ]
    },
    "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company\u2019s operations",
        "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description",
        "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource."
       }
      }
     },
     "auth_ref": [
      "r263",
      "r958",
      "r963"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r267",
      "r269",
      "r957",
      "r958",
      "r962"
     ]
    },
    "abp_SeparatePromissoryNoteAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SeparatePromissoryNoteAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Separate Promissory Note Agreement [Member]",
        "label": "Separate Promissory Note Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SeriesACommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SeriesACommonStockMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Common Stock [Member]",
        "documentation": "Series A Common Stock.",
        "label": "Series ACommon Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Redeemable",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1098",
      "r1216",
      "r1217"
     ]
    },
    "abp_SeriesARedeemableConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Redeemable, Convertible Preferred Stock",
        "label": "Series ARedeemable Convertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SeriesBCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SeriesBCommonStockMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Common Stock [Member]",
        "documentation": "Series B Common Stock.",
        "label": "Series BCommon Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SeriesBConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SeriesBConvertiblePreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B Convertible Preferred Stock",
        "label": "Series BConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesBPreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series B",
        "label": "Series B Preferred Stock [Member]",
        "documentation": "Series B preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1098",
      "r1216",
      "r1217"
     ]
    },
    "abp_SeriesCConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SeriesCConvertiblePreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C Convertible Preferred Stock",
        "label": "Series CConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series C",
        "label": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1098",
      "r1216",
      "r1217"
     ]
    },
    "abp_SeriesDConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SeriesDConvertiblePreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D Convertible Preferred Stock",
        "label": "Series DConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesDPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesDPreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series D",
        "label": "Series D Preferred Stock [Member]",
        "documentation": "Series D preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1098",
      "r1216",
      "r1217"
     ]
    },
    "abp_SeriesEConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SeriesEConvertiblePreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E Convertible Preferred Stock",
        "label": "Series EConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesEPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesEPreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series E",
        "label": "Series E Preferred Stock [Member]",
        "documentation": "Series E preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1098",
      "r1216",
      "r1217"
     ]
    },
    "abp_SeriesFConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SeriesFConvertiblePreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series F Convertible Preferred Stock",
        "label": "Series FConvertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesFPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesFPreferredStockMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series F",
        "label": "Series F Preferred Stock [Member]",
        "documentation": "Series F preferred stock."
       }
      }
     },
     "auth_ref": [
      "r1097",
      "r1098",
      "r1216",
      "r1217"
     ]
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Member]",
        "label": "Business Combination, Series of Individually Immaterial Business Combinations [Member]",
        "documentation": "Series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r1272",
      "r1275",
      "r1276"
     ]
    },
    "us-gaap_ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServicingAssetsAndServicingLiabilitiesAtFairValueAssumptionsUsedToEstimateFairValueDiscountRate",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated interest percentage",
        "label": "Servicing Assets and Servicing Liabilities at Fair Value, Assumptions Used to Estimate Fair Value, Discount Rate",
        "documentation": "Discount rate used to estimate the fair value of servicing assets and servicing liabilities."
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "abp_SettlementAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SettlementAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement Agreement [Member]",
        "label": "Settlement Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SettlementAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SettlementAssetsCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement agreement",
        "label": "Settlement Assets, Current",
        "documentation": "Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SettlementLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding settlement agreement",
        "label": "Settlement Liabilities, Current",
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers."
       }
      }
     },
     "auth_ref": []
    },
    "abp_SettlementOfBonusAccrualThroughNotesPayableRelatedParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SettlementOfBonusAccrualThroughNotesPayableRelatedParties",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of bonus accrual through notes payable - related parties",
        "documentation": "The value represents settlement of bonus accrual through notes payable - related parties.",
        "label": "Settlement Of Bonus Accrual Through Notes Payable Related Parties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance payment",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r988"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, forfeited",
        "negatedLabel": "Number of shares, Forfeited/Expired/Cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value, Forfeited/Expired/Cancelled",
        "verboseLabel": "Weighted-average grant date fair value, forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r427"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares, granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value, granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r425"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of shares, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted-average grant date fair value, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r422",
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining vesting period, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of shares, vested",
        "terseLabel": "Vested shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value, vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r426"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r1247"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "verboseLabel": "Dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "verboseLabel": "Volatility rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r435"
     ]
    },
    "abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueOfCommonStock",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of common stock (in Dollars per share)",
        "documentation": "Share based compensation arrangement by share based payment award fair value assumptions fair value of common stock.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price adjustment (in Dollars)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend",
        "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term."
       }
      }
     },
     "auth_ref": [
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Restricted Stock Unit Activity [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Share-Based Compensation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r443"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available for issuance under the plan",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock options, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r416"
     ]
    },
    "abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Life, exercised",
        "documentation": "Weighted average remaining contractual term for option awards exercised, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Number of stock options, forfeited/expired/cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1232"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, forfeited/expired/cancelled",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1232"
     ]
    },
    "abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresExpirationsAndCancelledInWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Life, forfeited/expired/cancelled",
        "documentation": "Weighted average remaining contractual term for option awards Forfeited,Expiration, and Cancelled, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures Expirations And Cancelled In Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock options, granted",
        "verboseLabel": "Options granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r428"
     ]
    },
    "abp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInWeightedAverageRemainingContractualTerm",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Life, granted",
        "documentation": "Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Weighted Average Remaining Contractual Term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Number of stock options, outstanding balance",
        "terseLabel": "Granted and outstanding shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Weighted-average exercise price, outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, exercised",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r419"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average exercise price, granted",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r418"
     ]
    },
    "abp_ShareBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ShareBasedCompensationDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r406",
      "r413",
      "r432",
      "r433",
      "r434",
      "r435",
      "r438",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456"
     ]
    },
    "abp_ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ShareBasedCompensationScheduleofCompanysRestrictedStockUnitActivityDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation - Schedule of Company\u2019s Restricted Stock Unit Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ShareBasedCompensationScheduleofCompanysStockOptionActivityDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation - Schedule of Company\u2019s Stock Option Activity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ShareBasedCompensationScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation - Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value Assumptions of the Stock Options Granted to Employees, Directors and Nonemployees [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Axis]",
        "documentation": "Information by supplier."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplier [Domain]",
        "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock price",
        "verboseLabel": "Share price upon closing of merger (in Dollars per share)",
        "netLabel": "Floor price per share (in Dollars per share)",
        "label": "Share Price",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "abp_SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SharePriceAfterDeductingFromVolumeWeightedAveragePriceUponCalculationOfSettlementAmount",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VWAP price per share (in Dollars per share)",
        "documentation": "Share price after deducting from volume weighted average price upon calculation of settlement amount.",
        "label": "Share Price After Deducting From Volume Weighted Average Price Upon Calculation Of Settlement Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "verboseLabel": "Term",
        "netLabel": "Expected life",
        "label": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r434"
     ]
    },
    "abp_SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardForfeitedOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Vesting Period, Forfeited/Expired/Cancelled",
        "documentation": "Weighted- Average Remaining Vesting Period, forfeited",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Forfeited Outstanding Weighted Average Remaining Contractual Term2"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardGrantedOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Vesting Period, granted",
        "documentation": "Weighted- Average Remaining Vesting Period, granted",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Granted Outstanding Weighted Average Remaining Contractual Term2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual life, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining contractual life, outstanding",
        "verboseLabel": "Contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "abp_SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardVestedOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysRestrictedStockUnitActivityTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Vesting Period, vested",
        "documentation": "Weighted- Average Remaining Vesting Period, vested",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Vested Outstanding Weighted Average Remaining Contractual Term2"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average term",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per share (in Dollars per share)",
        "verboseLabel": "Shares issues price per share",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeAxis",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Axis]",
        "documentation": "Information by type of short-term debt arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r1203",
      "r1204",
      "r1205"
     ]
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermDebtTypeDomain",
     "presentation": [
      "http://www.abpro.com/role/FairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt, Type [Domain]",
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r1203",
      "r1204",
      "r1205"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r194",
      "r195"
     ]
    },
    "abp_SponsorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SponsorMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sponsor [Member]",
        "documentation": "Sponsor.",
        "label": "Sponsor Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_StandbyEquityPurchaseAgreementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StandbyEquityPurchaseAgreementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Standby Equity Purchase Agreement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_StandbyEquityPurchaseAgreementDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StandbyEquityPurchaseAgreementDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standby Equity Purchase Agreement (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_StandbyEquityPurchaseAgreementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StandbyEquityPurchaseAgreementLineItems",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Standby Equity Purchase Agreement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_StandbyEquityPurchaseAgreementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StandbyEquityPurchaseAgreementTextBlock",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standby Equity Purchase Agreement",
        "documentation": "The entire disclosure for standby equity purchase agreement.",
        "label": "Standby Equity Purchase Agreement Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0",
      "http://www.abpro.com/role/ShareBasedCompensationDetails",
      "http://www.abpro.com/role/ShareholdersEquityType2or3",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r164",
      "r165",
      "r166",
      "r196",
      "r201",
      "r233",
      "r234",
      "r235",
      "r237",
      "r243",
      "r244",
      "r277",
      "r315",
      "r317",
      "r318",
      "r319",
      "r322",
      "r323",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r365",
      "r367",
      "r368",
      "r371",
      "r374",
      "r381",
      "r694",
      "r816",
      "r817",
      "r818",
      "r819",
      "r827",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r840",
      "r852",
      "r875",
      "r898",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r1068",
      "r1162",
      "r1164",
      "r1175"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0",
      "http://www.abpro.com/role/ShareholdersEquityType2or3",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r55",
      "r58",
      "r59",
      "r140",
      "r147",
      "r148",
      "r172",
      "r173",
      "r174",
      "r209",
      "r210",
      "r211",
      "r214",
      "r223",
      "r226",
      "r228",
      "r242",
      "r278",
      "r281",
      "r293",
      "r355",
      "r383",
      "r446",
      "r490",
      "r491",
      "r505",
      "r506",
      "r507",
      "r510",
      "r570",
      "r571",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r666",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r708",
      "r711",
      "r731",
      "r781",
      "r798",
      "r799",
      "r800",
      "r827",
      "r898"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/ConsolidatedIncomeStatement",
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r242",
      "r357",
      "r358",
      "r359",
      "r361",
      "r711",
      "r752",
      "r814",
      "r828",
      "r840",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r852",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r863",
      "r864",
      "r865",
      "r866",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r877",
      "r878",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r898",
      "r950",
      "r952",
      "r1058",
      "r1363"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Consolidated Statements of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0",
      "http://www.abpro.com/role/ScheduleofEffectiveIncomeTaxRateTable",
      "http://www.abpro.com/role/ScheduleofNetDeferredTaxAssetsandLiabilitiesTable",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r152",
      "r154",
      "r229",
      "r405",
      "r1069",
      "r1074"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/ConsolidatedIncomeStatement",
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r242",
      "r273",
      "r357",
      "r358",
      "r359",
      "r361",
      "r711",
      "r752",
      "r814",
      "r828",
      "r840",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r852",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r863",
      "r864",
      "r865",
      "r866",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r877",
      "r878",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r898",
      "r950",
      "r952",
      "r1058",
      "r1363"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharebasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharebasedCompensationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Company\u2019s Stock Option Activity [Absstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued upon conversion of convertible notes (in Shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31",
      "r55",
      "r58",
      "r82",
      "r341"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesConversionOfUnits",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Converted into shares",
        "label": "Stock Issued During Period, Shares, Conversion of Units",
        "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r31",
      "r54",
      "r55",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for services (in Shares)",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "abp_StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesMergerNetOfTransactionCostsAndAcquiredLiabilities",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Merger, net of transaction costs and acquired liabilities (in Shares)",
        "documentation": "Number of shares issued under the merger, net of transaction costs and acquired liabilities.",
        "label": "Stock Issued During Period Shares Merger Net Of Transaction Costs And Acquired Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ShareholdersEquityType2or3",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Advance Shares, net of issuance costs (in Shares)",
        "verboseLabel": "Purchase of common stock (in Shares)",
        "netLabel": "Additional shares (in Shares)",
        "label": "Shares of common shares",
        "totalLabel": "Aggregate of shares (in Shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r55",
      "r82",
      "r816",
      "r898",
      "r919"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA commitment fee paid in shares (in Shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensationForfeited",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited number of shares",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, Forfeited",
        "documentation": "Number of shares (or other type of equity) forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable",
      "http://www.abpro.com/role/ScheduleofCompanysStockOptionActivityTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stock options, exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r55",
      "r82",
      "r419"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued upon conversion of convertible notes",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r55",
      "r58",
      "r59",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued for services",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "abp_StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StockIssuedDuringPeriodValueMergerNetOfTransactionCostsAndAcquiredLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Merger, net of transaction costs and acquired liabilities",
        "documentation": "Represents the value of stock issued under the merger, net of transaction costs and acquired liabilities.",
        "label": "Stock Issued During Period Value Merger Net Of Transaction Costs And Acquired Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/ShareholdersEquityType2or3",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of Advance Shares, net of issuance costs",
        "verboseLabel": "Aggregate net purchase price",
        "netLabel": "Aggregate purchase price of newly issued shares",
        "label": "Fair value of shares issued",
        "totalLabel": "Aggregate purchase price (in Dollars)",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r55",
      "r82",
      "r827",
      "r898",
      "r919",
      "r1064"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEPA commitment fee paid in shares",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting of restricted stock units",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r55",
      "r82"
     ]
    },
    "us-gaap_StockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockOptionMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofFairValueAssumptionsoftheStockOptionsGrantedtoEmployeesDirectorsandNonemployeesTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option Valuation [Member]",
        "label": "Equity Option [Member]",
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)."
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1281"
     ]
    },
    "abp_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options [Member]",
        "label": "Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodShares",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of Treasury Stock (in Shares)",
        "negatedLabel": "Cancellation of Treasury Stock (in Shares)",
        "label": "Stock Repurchased During Period, Shares",
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r55",
      "r82",
      "r819",
      "r898",
      "r921"
     ]
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchasedDuringPeriodValue",
     "crdr": "debit",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancellation of Treasury Stock",
        "label": "Stock Repurchased During Period, Value",
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r54",
      "r55",
      "r82",
      "r827",
      "r898",
      "r921",
      "r1064"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Abpro Holdings, Inc.\u2019s stockholders\u2019 deficit",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r58",
      "r59",
      "r73",
      "r854",
      "r873",
      "r899",
      "r900",
      "r1045",
      "r1065",
      "r1160",
      "r1164",
      "r1165",
      "r1188",
      "r1303",
      "r1367"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 deficit:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet",
      "http://www.abpro.com/role/ScheduleofBalanceSheetTable",
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders\u2019 deficit",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "terseLabel": "Total stockholders\u2019 deficit",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r39",
      "r140",
      "r141",
      "r147",
      "r148",
      "r173",
      "r209",
      "r210",
      "r211",
      "r214",
      "r223",
      "r226",
      "r278",
      "r281",
      "r293",
      "r355",
      "r383",
      "r446",
      "r490",
      "r491",
      "r505",
      "r506",
      "r507",
      "r510",
      "r570",
      "r571",
      "r644",
      "r646",
      "r647",
      "r648",
      "r649",
      "r651",
      "r666",
      "r698",
      "r699",
      "r703",
      "r709",
      "r731",
      "r799",
      "r800",
      "r825",
      "r854",
      "r873",
      "r899",
      "r900",
      "r923",
      "r1052",
      "r1053",
      "r1064",
      "r1160",
      "r1164",
      "r1165",
      "r1188",
      "r1303",
      "r1367"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders\u2019 Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r366",
      "r368",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r380",
      "r383",
      "r638",
      "r657",
      "r901",
      "r903",
      "r924"
     ]
    },
    "abp_StockholdersEquityTablesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StockholdersEquityTablesLineItems",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Tables) [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_StockholdersEquityTablesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "StockholdersEquityTablesTable",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity (Tables) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r742"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Member]",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r742"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r742"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails",
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r704",
      "r742"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SubsequentEventsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SubsequentEventsDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.abpro.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r741",
      "r743"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockLineItems",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofCommonStockOutstandingTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock Outstanding [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "abp_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLivesDetailsTable",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetailsScheduleofDepreciationonPropertyandEquipmentEstimatedUsefulLives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Depreciation on Property and Equipment Estimated Useful Lives (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r1260"
     ]
    },
    "abp_TaxYear2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "TaxYear2037Member",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Year 2037 [Member]",
        "label": "Tax Year2037 Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax payable (in Dollars)",
        "label": "Taxes Payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r93",
      "r1324"
     ]
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible preferred stock, value",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r317",
      "r318",
      "r319",
      "r322",
      "r323",
      "r357",
      "r358",
      "r359",
      "r362",
      "r457",
      "r459",
      "r771"
     ]
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityLiquidationPreference",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidation preference (in Dollars)",
        "label": "Temporary Equity, Liquidation Preference",
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TemporaryEquityRedemptionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquityRedemptionPricePerShare",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption price (in Dollars per share)",
        "label": "Temporary Equity, Redemption Price Per Share",
        "documentation": "Amount to be paid per share that is classified as temporary equity by entity upon redemption. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesAuthorized",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, shares authorized",
        "label": "Temporary Equity, Shares Authorized",
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r359"
     ]
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesIssued",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, shares issued",
        "label": "Temporary Equity, Shares Issued",
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r359"
     ]
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TemporaryEquitySharesOutstanding",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Preferred Stock, shares outstanding",
        "label": "Temporary Equity, Shares Outstanding",
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r359"
     ]
    },
    "abp_ThirdShareTargetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "ThirdShareTargetMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Share Target [Member]",
        "label": "Third Share Target Member"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1183",
      "r1311"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r1185",
      "r1186",
      "r1187"
     ]
    },
    "abp_TradingDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "TradingDays",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading days",
        "documentation": "Trading days.",
        "label": "Trading Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.abpro.com/role/ShareholdersEquityType2or3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "terseLabel": "Treasury stock, shares cost",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.abpro.com/role/ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r58"
     ]
    },
    "abp_TwoYearAnniversaryOfIssuanceDateOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "TwoYearAnniversaryOfIssuanceDateOfWarrantsMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Year Anniversary of Issuance Date [Member]",
        "label": "Two Year Anniversary Of Issuance Date Of Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_TwoZeroOneFourStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "TwoZeroOneFourStockIncentivePlanMember",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014 Stock Incentive Plan [Member]",
        "label": "Two Zero One Four Stock Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_TwoZeroTwoFourEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "TwoZeroTwoFourEquityIncentivePlanMember",
     "presentation": [
      "http://www.abpro.com/role/ShareBasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 Equity Incentive Plan [Member]",
        "label": "Two Zero Two Four Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails",
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/FairValueMeasurementsDetails",
      "http://www.abpro.com/role/LicenseandCollaborationAgreementsDetails",
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/RelatedPartiesDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/OrganizationandDescriptionoftheBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r181",
      "r302",
      "r303",
      "r305",
      "r306",
      "r949"
     ]
    },
    "abp_UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "UnauditedInterimCondensedConsolidatedFinancialStatementsPolicyTextBlock",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unaudited Interim Condensed Consolidated Financial Statements",
        "documentation": "Disclosure of accounting policy for unaudited interim condensed consolidated financial statements.",
        "label": "Unaudited Interim Condensed Consolidated Financial Statements Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "abp_UnpaidAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "UnpaidAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/RelatedPartiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unpaid amount",
        "documentation": "Unpaid amount.",
        "label": "Unpaid Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r464",
      "r479",
      "r989"
     ]
    },
    "abp_UnvestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "UnvestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unvested restricted stock units [Member]",
        "label": "Unvested Restricted Stock Units Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.abpro.com/role/AccountingPoliciesByPolicy"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r109",
      "r245",
      "r246",
      "r247",
      "r248",
      "r758",
      "r760",
      "r954"
     ]
    },
    "abp_VAZYMELicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "VAZYMELicenseAgreementMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsunderResearchandCollaborationAgreementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VAZYME License Agreement [Member]",
        "verboseLabel": "VAZYME License agreement [Member]",
        "label": "VAZYMELicense Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.abpro.com/role/IncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "abp_VendorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "VendorsMember",
     "presentation": [
      "http://www.abpro.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vendor [Member]",
        "verboseLabel": "Vendors [Member]",
        "label": "Vendors Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_VolumeWeightedAveragePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "VolumeWeightedAveragePrice",
     "presentation": [
      "http://www.abpro.com/role/ForwardPurchaseAgreementDetails",
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volume weighted average price (in Dollars per share)",
        "verboseLabel": "Volume-weighted-average price (in Dollars per share)",
        "documentation": "Volume weighted average price.",
        "label": "Volume Weighted Average Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.abpro.com/role/MergerDetails",
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareTable",
      "http://www.abpro.com/role/ScheduleofDilutedNetLossPerShareofCommonStockAttributabletoCommonStockholdersTable",
      "http://www.abpro.com/role/StockholdersEquityDetails",
      "http://www.abpro.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrant [Member]",
        "netLabel": "Common Stock Warrants [Member]",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r1055",
      "r1056",
      "r1059",
      "r1060",
      "r1061",
      "r1062"
     ]
    },
    "us-gaap_WarrantsAndRightsNoteDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsNoteDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Warrants to Purchase Common Stock Outstanding [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails",
      "http://www.abpro.com/role/ScheduleofFairValueoftheCompanysPositionUndertheForwardPurchaseAgreementTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value input assumptions",
        "verboseLabel": "Fair value of common stock",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur."
       }
      }
     },
     "auth_ref": [
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable",
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable0",
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants, Average Remaining Contractual Life",
        "verboseLabel": "Warrants, Weighted- Average Remaining Contractual Life",
        "netLabel": "Warrant term",
        "label": "Warrants and Rights Outstanding, Term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1291",
      "r1292",
      "r1293"
     ]
    },
    "abp_WarrantsExercisableDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "WarrantsExercisableDateAxis",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants Exercisable Date [Axis]",
        "label": "Warrants Exercisable Date Axis"
       }
      }
     },
     "auth_ref": []
    },
    "abp_WarrantsExercisableDateDomainDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "WarrantsExercisableDateDomainDomain",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WarrantsExercisableDateDomain [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "abp_WarrantsExercisableTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "WarrantsExercisableTerm",
     "presentation": [
      "http://www.abpro.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants exercisable term",
        "documentation": "Warrants exercisable term.",
        "label": "Warrants Exercisable Term"
       }
      }
     },
     "auth_ref": []
    },
    "abp_WarrantsToPurchaseCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "WarrantsToPurchaseCommonStockMember",
     "presentation": [
      "http://www.abpro.com/role/ScheduleofWarrantstoPurchaseCommonStockOutstandingTable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants To Purchase Common Stock Outstanding [Member]",
        "label": "Warrants To Purchase Common Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding - diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r237"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted averages shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.abpro.com/role/ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares outstanding - basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r237"
     ]
    },
    "abp_YAIIPNLtdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "YAIIPNLtdMember",
     "presentation": [
      "http://www.abpro.com/role/StandbyEquityPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "YA II PN, Ltd. [Member]",
        "label": "YAIIPNLtd Member"
       }
      }
     },
     "auth_ref": []
    },
    "abp_YearTwoThousandTwentyFourABIPromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.abpro.com/20250930",
     "localname": "YearTwoThousandTwentyFourABIPromissoryNoteMember",
     "presentation": [
      "http://www.abpro.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 ABI Note [Member]",
        "label": "Year Two Thousand Twenty Four ABIPromissory Note Member"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "SubTopic": "40",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481244/470-50-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-5"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477220/954-210-45-5"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481034/205-10-S45-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-3"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-23"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.E.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479772/718-30-S55-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10A"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2AG",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-2AG"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4I"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480960/815-15-50-3"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477866/928-440-50-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-9"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-48"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479908/805-50-55-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "183",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-183"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "185",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-185"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-11"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(4)",
   "Publisher": "SEC"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480341/340-10-S99-1"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/710/tableOfContent"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/712/tableOfContent"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805/tableOfContent"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
